{
  "chapters": [
    {
      "number": 2,
      "name": "CK",
      "topics": []
    },
    {
      "number": 2,
      "name": "SECTION",
      "topics": []
    },
    {
      "number": 4,
      "name": "SECTION",
      "topics": []
    },
    {
      "number": 2,
      "name": "CK unless you present your permit along with an unexpired",
      "topics": []
    },
    {
      "number": 6,
      "name": "SECTION",
      "topics": []
    }
  ],
  "topics": {},
  "high_yield_facts": [
    "â–  Example: A surgeon declines to perform a procedure because they",
    "Iron deficiency (late) Nuclear defects",
    "Lead poisoning Defective DNA synthesis Diamond-Blackfan anemia",
    "Sideroblastic anemia Folate deficiency Liver disease",
    "Anemia of chronic disease Vitamin B 12 deficiency Alcoholism",
    "Defective globin chain Orotic aciduria",
    "Thalassemias Defective DNA repair",
    "Fanconi anemia",
    "Iron deficiency (early)",
    "Anemia of chronic disease",
    "Aplastic anemia Intrinsic Extrinsic",
    "Chronic kidney disease",
    "Membrane defects Autoimmune",
    "Hereditary spherocytosis Microangiopathic",
    "Paroxysmal nocturnal Macroangiopathic",
    "hemoglobinuria Infections",
    "G6PD deficiency",
    "Pyruvate kinase deficiency",
    "Sickle cell anemia",
    "HbC disease",
    "Fasciculus graciLis (Lower body, legs)",
    "Fasciculus cUneatus (Upper body, arms)",
    "White matter  Cervical",
    "TAO LE",
    "MHS VIKAS BHUSHAN",
    "MONA ASCHA",
    "MD ABHISHEK BHARDWAJ",
    "MARINA BOUSHRA",
    "MD DANIEL GRIFFIN",
    "CAROLINE COLEMAN",
    "MD STEPHANIE JONES",
    "KIMBERLY KALLIANOS",
    "NOTICE",
    "TERMS OF USE",
    "THE WORK IS PROVIDED",
    "HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES\nAS TO THE ACCURACY",
    "ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK",
    "INCLUD",
    "ING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE",
    "AND EXPRESSLY\nDISCLAIM ANY WARRANTY",
    "EXPRESS OR IMPLIED",
    "INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANT",
    "ABILITY OR FITNESS FOR A PARTICULAR PURPOSE",
    "DEDICATION",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM\nPREPARATION",
    "SECTION",
    "RATED REVIEW RESOURCES",
    "SECTION",
    "DATABASE OF HIGH",
    "YIELD FACTS",
    "CONTRIBUTING AUTHORS",
    "MD BIRDEM",
    "IMAGE AND ILLUSTRATION TEAM",
    "ASSOCIATE AUTHORS",
    "MS CMH",
    "FACULTY REVIEWERS",
    "NOTE TO CONTRIBUTORS",
    "INTERNSHIP OPPORTUNITIES",
    "PPMM\n\nS E C T I O N",
    "GUIDE TO EFFICIENT EXAM PREPARATION",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION\nINTRODUCTION",
    "KEY FACT",
    "USMLE STEP",
    "COMPUTER",
    "BASED TESTING BASICS\nWHO CAN REGISTER FOR THE EXAM",
    "HOW WILL THE CBT BE STRUCTURED",
    "KEY FACT",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "KEY FACT",
    "TESTING CONDITIONS",
    "WHAT WILL THE CBT BE LIKE",
    "KEY FACT",
    "WHAT DOES THE CBT FORMAT MEAN FOR ME",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION",
    "HOW DO I REGISTER TO TAKE THE EXAMINATION",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "CK\nFEE PAYABLE TO NBME FEE PAYABLE TO ECFMG",
    "US AND CANADA SCHOOLS ONLY",
    "ALL OTHER SCHOOLS",
    "KEY FACT",
    "WHAT IF I NEED TO RESCHEDULE THE EXAMINATION",
    "RESCHEDULING TIME FEES FOR THE US FEES FOR TESTING REGIONS\nBEFORE EXAM DATE AND CANADA TESTING REGION OTHER THAN THE US AND CANADA",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION\nWHAT ABOUT TIME",
    "SECURITY MEASURES",
    "IF I LEAVE DURING THE EXAMINATION",
    "WHAT HAPPENS TO MY SCORE",
    "WHAT TYPES OF QUESTIONS ARE ASKED",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "COMPETENCY RANGE",
    "SYSTEM RANGE",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION\nTABLE",
    "COMPETENCY RANGE",
    "HOW LONG WILL I HAVE TO WAIT BEFORE I GET MY SCORES",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "HOW ARE THE SCORES REPORTED",
    "FOR EXAMINEE USE ONLY",
    "PARTY USERS OF USMLE SCORES\nSHOULD RELY SOLELY ON OFFICIAL TRANSCRIPTS RECEIVED DIRECTLY\nFROM THE EXAMINEE",
    "S USMLE REGISTRATION ENTITY",
    "USMLE ID",
    "TEST DATE",
    "FIGURE",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION",
    "FIGURE",
    "DEFINING YOUR GOAL",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "WHEN TO TAKE THE EXAM",
    "KEY FACT",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION\nHOW WILL THE STEP",
    "CK SCORE AFFECT MY MATCH",
    "STUDY RESOURCES\nQUALITY CONSIDERATIONS",
    "CLINICAL REVIEW BOOKS\nKEY FACT",
    "TEST BANKS\nA",
    "AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION",
    "KEY FACT",
    "TEXTS AND NOTES",
    "COMMERCIAL COURSES",
    "USMLE PUBLICATIONS",
    "DAY CHECKLIST\nTHINGS TO BRING WITH YOU TO THE EXAM",
    "SECTION",
    "GUIDE TO EFFICIENT EXAM PREPARATION",
    "TESTING AGENCIES",
    "AAMM\n\nS E C T I O N",
    "DATABASE OF HIGH",
    "YIELD FACTS",
    "HOW TO USE THE DATABASE",
    "DISCLAIMER",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nCARDIOVASCULAR",
    "YIELD FACTS IN CARDIOVASCULAR\nELECTROCARDIOGRAM\nKEY FACT",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "DEGREES",
    "LAD V L",
    "III II",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "MNEMONIC",
    "V V V V",
    "A B\nFIGURE",
    "KEY FACT",
    "YIELD FACTS IN CARDIOVASCULAR\nMNEMONIC",
    "D ARMS PITS",
    "CARDIAC PHYSICAL EXAM",
    "MNEMONIC",
    "ARMS PITS",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "MC S S",
    "OS\nKEY FACT",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "FIGURE",
    "HYPERTROPHIC\nMANEUVER",
    "MITRAL VALVE PROLAPSE CARDIOMYOPATHY AORTIC STENOSIS AR",
    "KEY FACT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "B\nARRHYTHMIAS",
    "AV\nERP",
    "BRADYARRHYTHMIAS AND CONDUCTION ABNORMALITIES",
    "TACHYARRHYTHMIAS",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "QRS\nPP",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "AVNRT\nAVRT",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "ETIOLOGY SIGNS",
    "SYMPTOMS TREATMENT",
    "KEY FACT",
    "HASBLED",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "CARDIAC LIFE SUPPORT BASICS",
    "ARRHYTHMIA TREATMENT",
    "YIELD FACTS IN CARDIOVASCULAR\nKEY FACT TABLE",
    "UNSYNCHRONIZED CARDIOVERSION",
    "SYNCHRONIZED CARDIOVERSION",
    "DEFIBRILLATION",
    "MNEMONIC",
    "CONGESTIVE HEART FAILURE",
    "CLASSIFICATION",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "SYSTOLIC DYSFUNCTION",
    "HEART FAILURE WITH REDUCED EJECTION DIASTOLIC DYSFUNCTION",
    "HEART FAILURE WITH PRESERVED\nVARIABLE FRACTION",
    "EJECTION FRACTION",
    "SIDED CHF SYMPTOMS RIGHT",
    "SIDED CHF SYMPTOMS",
    "CLASS DESCRIPTION\nI",
    "SYSTOLIC DYSFUNCTION",
    "HEART FAILURE WITH REDUCED EJECTION FRACTION",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "KEY FACT",
    "CO MRA",
    "FIGURE",
    "FIGURE",
    "WET DRY",
    "CONGESTED",
    "NOT CONGESTED",
    "MNEMONIC\nCXR",
    "KEY FACT",
    "CARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "CLASS EXAMPLES ADVERSE EFFECTS",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "NYHA III",
    "NYHA II",
    "KEY FACT",
    "NYHA II",
    "NYHA I",
    "HEART FAILURE WITH PRESERVED EJECTION FRACTION",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "CARDIOMYOPATHY",
    "TYPE\nVARIABLE DILATED HYPERTROPHIC RESTRICTIVE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "A B C\nFIGURE",
    "DILATED CARDIOMYOPATHY\nLV",
    "KEY FACT",
    "KEY FACT",
    "HYPERTROPHIC CARDIOMYOPATHY",
    "YIELD FACTS IN CARDIOVASCULAR\nKEY FACT",
    "KEY FACT",
    "KEY FACT",
    "HOCM\nLV",
    "ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "RESTRICTIVE CARDIOMYOPATHY",
    "YIELD FACTS IN CARDIOVASCULAR\nSECONDARY CARDIOMYOPATHY\nKEY FACT",
    "CONDITION AND ETIOLOGY SIGNS",
    "SYMPTOMS",
    "DIAGNOSIS TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CONDITION AND ETIOLOGY SIGNS",
    "SYMPTOMS",
    "DIAGNOSIS TREATMENT",
    "LVEF\nLVEF",
    "YIELD FACTS IN CARDIOVASCULAR\nOTHER CARDIOMYOPATHIES",
    "CONDITION ETIOLOGY SIGNS",
    "SYMPTOMS",
    "DIAGNOSIS TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CORONARY ARTERY DISEASE",
    "KEY FACT",
    "ANGINA PECTORIS",
    "KEY FACT",
    "YIELD FACTS IN CARDIOVASCULAR\nKEY FACT",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "PRINZMETAL",
    "VARIANT",
    "ANGINA KEY FACT",
    "ACUTE CORONARY SYNDROMES\nA",
    "UNSTABLE ANGINA",
    "SEGMENT ELEVATION MYOCARDIAL INFARCTION",
    "NSTEMI",
    "NSTEMI",
    "KEY FACT\nSTEMI",
    "NSTEMI",
    "NSTEMI",
    "YIELD FACTS IN CARDIOVASCULAR",
    "NSTEMI",
    "NSTEMI",
    "NSTEMI STEMI",
    "RV LV RV LV",
    "ST\nECG",
    "FIGURE",
    "NSTEMI",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "SEGMENT ELEVATION MYOCARDIAL INFARCTION ASA",
    "NSTEMI",
    "NSTEMI",
    "KEY FACT",
    "PPMM\n\nKEY FACT",
    "MB\nMLC",
    "INFARCT LOCATION LEADS WITH ST",
    "SEGMENT ELEVATIONS OR Q WAVES",
    "II\nFIGURE",
    "YIELD FACTS IN CARDIOVASCULAR\nSTEMI",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "KEY FACT",
    "NSTEMI",
    "NSTEMI",
    "KEY FACT",
    "YIELD FACTS IN CARDIOVASCULAR\nKEY FACT",
    "KEY FACT",
    "TIME COMPLICATIONS",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CAROTID ARTERY STENOSIS",
    "DYSLIPIDEMIA",
    "KEY FACT",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "PATIENT AGE CRITERIA TREATMENTS IN ADDITION TO LIFESTYLE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CLASS EXAMPLES EFFECT ON LIPID PROFILE ADVERSE EFFECTS\nHMG",
    "HDL GI",
    "HYPERTENSION\nHTN",
    "KEY FACT\nPRIMARY",
    "ESSENTIAL",
    "HYPERTENSION",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "STAGE BP",
    "GENERAL PRACTICE GUIDELINES",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "FIGURE",
    "MNEMONIC",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "IF HISTORY OF",
    "THEN BEST INITIAL TREATMENT",
    "CLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS\nK",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "CLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS",
    "CATEGORY DEFINITION",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "SECONDARY HYPERTENSION MNEMONIC",
    "HYPERTENSIVE EMERGENCY",
    "URGENCY",
    "KEY FACT",
    "KEY FACT",
    "CONDITION DEFINITION",
    "YIELD FACTS IN CARDIOVASCULAR\nA KEY FACT\nPERICARDIAL DISEASE",
    "ACUTE PERICARDITIS",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT\nPERICARDIAL DISEASE I",
    "ACUTE PERICARDITIS III",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "CONSTRICTIVE PERICARDITIS",
    "YIELD FACTS IN CARDIOVASCULAR",
    "PERICARDIAL EFFUSION",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "CARDIAC TAMPONADE",
    "KEY FACT",
    "JVD\nRV",
    "ENDOCARDITIS",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "PROSTHETIC VALVE NON",
    "BACTERIAL THROMBOTIC ENDOCARDITIS\nNATIVE VALVE",
    "HIGHEST RISK",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "MNEMONIC",
    "FROM JANE",
    "A B C D\nFIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "MNEMONIC",
    "CRITERIA COMPONENTS MNEMONIC",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "BLOOD CULTURE",
    "POSSIBLE TREATMENT REGIMENS",
    "BLOOD CULTURE",
    "MUST HAVE ONE AND MUST HAVE ONE\nQUALIFYING CARDIAC INDICATION QUALIFYING PROCEDURE INDICATION",
    "YIELD FACTS IN CARDIOVASCULAR\nVALVULAR HEART DISEASE\nKEY FACT",
    "KEY FACT",
    "TYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS",
    "TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "TYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS",
    "TREATMENT",
    "YIELD FACTS IN CARDIOVASCULAR\nTABLE",
    "TYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS",
    "TREATMENT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "VASCULAR DISEASES\nAORTIC ANEURYSM",
    "KEY FACT",
    "A FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "AORTIC DISSECTION",
    "KEY FACT",
    "USPSTF",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "CTA\nTEE",
    "CT\nFIGURE",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "DEEP VENOUS THROMBOSIS",
    "KEY FACT",
    "CRITERIA SCORE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "FIGURE",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR\nKEY FACT",
    "POSTTHROMBOTIC",
    "POSTPHLEBITIC",
    "SYNDROME\nKEY FACT",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "PERIPHERAL ARTERIAL DISEASE",
    "KEY FACT",
    "MNEMONIC",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "LYMPHEDEMA\nA",
    "SYNCOPE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "HOCM GI",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN CARDIOVASCULAR",
    "KEY FACT",
    "KEY FACT",
    "MOST LIKELY\nPATIENT PRESENTATION DIAGNOSIS WORKUP MANAGEMENT\nNEURALLY MEDIATED",
    "REFLEX",
    "SYNCOPE",
    "PPMM\n\nCARDIOVASCULAR HIGH",
    "YIELD FACTS IN",
    "MOST LIKELY\nPATIENT PRESENTATION DIAGNOSIS WORKUP MANAGEMENT\nORTHOSTATIC SYNCOPE",
    "ABPM\nA",
    "YIELD FACTS IN CARDIOVASCULAR\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nDERMATOLOGY",
    "YIELD FACTS IN DERMATOLOGY\nLAYERS OF THE SKIN",
    "LESION CHARACTERISTICS EXAMPLES",
    "A B C D E\nF G H I J",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "ALLERGIC AND IMMUNE",
    "MEDIATED SKIN DISORDERS\nHYPERSENSITIVITY REACTIONS",
    "DESCRIPTION MECHANISM COMMENTS EXAMPLES\nTYPE I",
    "TYPE II",
    "TYPE III",
    "TYPE IV",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "KEY FACT",
    "ATOPIC DERMATITIS",
    "ECZEMA",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "CONTACT DERMATITIS\nA",
    "FIGURE",
    "KEY FACT\nSEBORRHEIC DERMATITIS",
    "YIELD FACTS IN DERMATOLOGY\nA B\nFIGURE",
    "PSORIASIS\nA T",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "KEY FACT",
    "KEY FACT",
    "URTICARIA",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "KEY FACT\nDRUG ERUPTION",
    "IV\nFIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "ERYTHEMA MULTIFORME",
    "FIGURE",
    "KEY FACT",
    "KEY FACT\nSTEVENS",
    "JOHNSON SYNDROME",
    "TOXIC EPIDERMAL NECROLYSIS A",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "KEY FACT",
    "MNEMONIC",
    "NODOSUM\nNO",
    "ERYTHEMA NODOSUM",
    "FIGURE",
    "BULLOUS PEMPHIGOID",
    "PEMPHIGUS VULGARIS",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "VARIABLE BULLOUS PEMPHIGOID PEMPHIGUS VULGARIS",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY\nNUMMULAR ECZEMA",
    "PYODERMA GANGRENOSUM\nFIGURE",
    "INFECTIOUS DISEASE MANIFESTATIONS OF THE SKIN\nVIRAL DISEASES",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "VIRUS HISTORY AND MANIFESTATIONS DIAGNOSIS MANAGEMENT\nHHV",
    "YIELD FACTS IN DERMATOLOGY\nTABLE",
    "VIRUS HISTORY AND MANIFESTATIONS DIAGNOSIS MANAGEMENT\nHHV",
    "AIDS HHV",
    "KEY FACT",
    "A B\nFIGURE",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "CN VII",
    "CN VIII",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "PE\nFIGURE",
    "KEY FACT",
    "A B\nFIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "BACTERIAL INFECTIONS",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN DERMATOLOGY\nFUNGAL INFECTIONS",
    "A B\nFIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY\nA B C\nFIGURE",
    "PARASITIC INFECTIONS",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "A B\nFIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "ISCHEMIC SKIN DISORDERS\nDECUBITUS ULCERS",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "GANGRENE",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY\nMISCELLANEOUS SKIN DISORDERS\nSTASIS DERMATITIS",
    "FIGURE",
    "ACANTHOSIS NIGRICANS",
    "LICHEN PLANUS\nA",
    "FIGURE",
    "ROSACEA\nA",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "PITYRIASIS ROSEA",
    "FIGURE",
    "VITILIGO",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "EYELID LESIONS",
    "EPIDERMAL INCLUSION CYSTS",
    "FIGURE",
    "DERMATOFIBROMA",
    "HIDRADENITIS SUPPURATIVA",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "ICHTHYOSIS VULGARIS",
    "FIGURE",
    "RELATED SKIN CHANGES",
    "SUN PROTECTION\nUV",
    "FIGURE",
    "SUNBURN",
    "NEOPLASMS OF THE SKIN\nSEBORRHEIC KERATOSIS\nA",
    "YIELD FACTS IN DERMATOLOGY",
    "FIGURE",
    "ACTINIC KERATOSIS",
    "KEY FACT",
    "CUTANEOUS SQUAMOUS CELL CARCINOMA",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "BASAL CELL CARCINOMA",
    "FIGURE",
    "MNEMONIC",
    "MELANOMA",
    "YIELD FACTS IN DERMATOLOGY\nTABLE",
    "TYPE PRESENTATION",
    "A B C D",
    "FIGURE",
    "PPMM\n\nDERMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KAPOSI SARCOMA\nA",
    "FIGURE",
    "KEY FACT\nMYCOSIS FUNGOIDES",
    "CUTANEOUS T",
    "CELL LYMPHOMA",
    "FIGURE",
    "YIELD FACTS IN DERMATOLOGY",
    "CHERRY ANGIOMAS",
    "HEMANGIOMAS",
    "INFANTILE HEMANGIOMAS\nFIGURE",
    "PYOGENIC GRANULOMA",
    "FIGURE",
    "NECROBIOSIS LIPOIDICA",
    "FIGURE",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nENDOCRINOLOGY",
    "YIELD FACTS IN ENDOCRINOLOGY\nDISORDERS OF GLUCOSE METABOLISM\nMETABOLIC SYNDROME\nMNEMONIC",
    "WEIGHHT",
    "DIABETES MELLITUS\nDM",
    "KEY FACT",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "COMPLICATION DESCRIPTION",
    "MANAGEMENT",
    "AND PREVENTIVE CARE",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY",
    "LIFESTYLE MODIFICATIONS RECOMMENDATION",
    "DIABETIC KETOACIDOSIS AND HYPERGLYCEMIC HYPEROSMOLAR SYNDROME",
    "ENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nTABLE",
    "PHARMACOTHERAPY",
    "MONOTHERAPY OR COMBINATION THERAPY IF POOR GLYCEMIC CONTROL",
    "DRUG MECHANISM ADVERSE EFFECTS NOTEWORTHY BENEFITS",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "DIABETIC KETOACIDOSIS HYPERGLYCEMIC HYPEROSMOLAR SYNDROME",
    "HYPOGLYCEMIA",
    "YIELD FACTS IN ENDOCRINOLOGY",
    "THYROID DISORDERS\nTHYROID PHYSIOLOGY",
    "HYPERTHYROIDISM AND THYROTOXICOSIS",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "TRH\nTG TG",
    "MIT\nMIT\nPTU",
    "TG\nDIT",
    "DIT DIT",
    "TSI\nT MIT MIT\nT",
    "T TG DDIITT TG DIT",
    "PTU\nFIGURE",
    "TRH SS",
    "TSH\nTSI",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nTABLE",
    "DIAGNOSIS TSH T T CAUSES",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "RADIOACTIVE IODINE THYROGLOBULIN",
    "LEVEL\nDIAGNOSIS",
    "UPTAKE RAI SCAN FINDINGS IN BLOOD",
    "YIELD FACTS IN ENDOCRINOLOGY\nTABLE",
    "TREATMENT ADVERSE REACTIONS AND OTHER CONSIDERATIONS",
    "HYPOTHYROIDISM",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "THYROIDITIS",
    "YIELD FACTS IN ENDOCRINOLOGY\nTHYROID NEOPLASMS",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "TYPE CHARACTERISTICS PROGNOSIS",
    "BONE AND MINERAL DISORDERS",
    "KEY FACT\nOSTEOPOROSIS",
    "YIELD FACTS IN ENDOCRINOLOGY\nPTH",
    "FIGURE",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "PAGET DISEASE OF BONE",
    "KEY FACT",
    "FIGURE",
    "MNEMONIC",
    "PANICS",
    "HYPERPARATHYROIDISM",
    "KEY FACT",
    "YIELD FACTS IN ENDOCRINOLOGY",
    "FIGURE",
    "KEY FACT",
    "KEY FACT\nTABLE",
    "PTH CALCIUM PO",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "PITUITARY AND HYPOTHALAMIC DISORDERS",
    "DEFICIENCY OF PITUITARY HORMONES",
    "TRH GHRH DA",
    "ACTH LH FSH TSH GH",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY",
    "DIABETES INSIPIDUS",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "DEFICIENT\nHORMONE CLINICAL MANIFESTATION DIAGNOSIS NOTES\nACTH",
    "FIGURE",
    "CENTRAL DI NEPHROGENIC DI PRIMARY POLYDIPSIA",
    "EXCESS OF PITUITARY HORMONES",
    "YIELD FACTS IN ENDOCRINOLOGY",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nFIGURE",
    "KEY FACT",
    "HYPERPROLACTINEMIA",
    "KEY FACT",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION",
    "KEY FACT",
    "YIELD FACTS IN ENDOCRINOLOGY\nKEY FACT ADRENAL GLAND DISORDERS",
    "ADRENAL INSUFFICIENCY",
    "KEY FACT",
    "MNEMONIC",
    "HORMONE",
    "HORMONE\nANATOMY HISTOLOGY",
    "REGULATION BY CLASS PRODUCED",
    "CORTEX",
    "MEDULLA",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "CORTISOL ALDOSTERONE ACTH SODIUM POTASSIUM",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nMNEMONIC PHEOCHROMOCYTOMA",
    "MNEMONIC",
    "KEY FACT",
    "A B\nFIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "CUSHING SYNDROME",
    "PE MSH",
    "FIGURE",
    "KEY FACT",
    "MNEMONIC",
    "CUSHINGOID",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nKEY FACT",
    "CT MRI",
    "FIGURE",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "CUSHING DISEASE ECTOPIC ACTH ADRENAL CORTISOL",
    "PITUITARY HYPERSECRETION",
    "EXOGENOUS STEROID USE SECRETION HYPERSECRETION",
    "HYPERALDOSTERONISM",
    "YIELD FACTS IN ENDOCRINOLOGY\nTABLE",
    "ENZYME DEFICIENCY MINERALOCORTICOIDS CORTISOL SEX HORMONES BP",
    "LABORATORY TESTS PRESENTATION",
    "MNEMONIC CONGENITAL ADRENAL HYPERPLASIA",
    "KEY FACT",
    "PPMM\n\nENDOCRINOLOGY HIGH",
    "YIELD FACTS IN",
    "MULTIPLE ENDOCRINE NEOPLASIAS\nA",
    "FIGURE",
    "YIELD FACTS IN ENDOCRINOLOGY\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nEPIDEMIOLOGY",
    "PPMM\n\nASSESSMENT OF DISEASE FREQUENCY\nKEY FACT",
    "KEY FACT",
    "PERSON",
    "TIME ESTIMATE",
    "ASSESSMENT OF DIAGNOSTIC STUDIES\nSENSITIVITY AND SPECIFICITY",
    "TP FP\nFN",
    "NPV\nTN",
    "YIELD FACTS IN EPIDEMIOLOGY",
    "FIGURE",
    "NPV B A",
    "PPV\nFN FP",
    "MNEMONIC",
    "POSITIVE AND NEGATIVE PREDICTIVE VALUES",
    "PPV\nB C",
    "FIGURE",
    "PT\nEPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN EPIDEMIOLOGY",
    "LIKELIHOOD RATIO",
    "MEASURES OF EFFECT\nA",
    "ARR\nFIGURE",
    "TYPES OF CLINICAL STUDIES",
    "EXPOSED",
    "YES NO",
    "EPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN EPIDEMIOLOGY",
    "FIGURE",
    "SECTIONAL STUDY\nA",
    "KEY FACT",
    "COHORT STUDY\nOR",
    "KEY FACT",
    "KEY FACT",
    "CONTROL STUDY",
    "KEY FACT",
    "EPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN EPIDEMIOLOGY",
    "KEY FACT",
    "RANDOMIZED CONTROLLED TRIAL\nKEY FACT",
    "KEY FACT\nPHASES OF CLINICAL TRIALS\nA",
    "PPMM\n\nEPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "VARIABLE RCT COHORT CROSS",
    "SECTIONAL CASE CONTROL",
    "EVALUATING CLINICAL STUDIES\nBIAS\nA",
    "YIELD FACTS IN EPIDEMIOLOGY\nTABLE",
    "PHASE GOALS NUMBER OF PARTICIPANTS TYPE OF PARTICIPANTS",
    "KEY FACT",
    "PPMM\n\nEPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "TRIAL PROGRESSION",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN EPIDEMIOLOGY\nSTATISTICAL TESTING",
    "SCENARIOS",
    "PPMM\n\nEPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "COMMONLY USED STATISTICAL TESTS",
    "FIGURE",
    "YIELD FACTS IN EPIDEMIOLOGY\nPREVENTION",
    "KEY FACT",
    "VACCINATION",
    "VACCINE TYPE TARGETED DISEASES",
    "FIGURE",
    "PPMM\nEPIDEMIOLOGY\nHIGH",
    "YIELD\nFACTS\nIN",
    "FIGURE",
    "YIELD FACTS IN EPIDEMIOLOGY",
    "FIGURE",
    "VACCINES",
    "EPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN EPIDEMIOLOGY\nSCREENING RECOMMENDATIONS",
    "RECOMMENDATION\nAGE IN\nYEARS CARDIOVASCULAR BREAST",
    "REPRODUCTIVE OTHER",
    "PPMM\n\nEPIDEMIOLOGY HIGH",
    "YIELD FACTS IN",
    "RECOMMENDATION\nAGE IN\nYEARS CARDIOVASCULAR REPRODUCTIVE OTHER",
    "YIELD FACTS IN EPIDEMIOLOGY\nREPORTABLE DISEASES",
    "DISEASE CATEGORY EXAMPLES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nHEALTH SYSTEMS SCIENCE",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nHEALTH SYSTEM DELIVERY\nHEALTH INSURANCE PLANS",
    "MEDICARE AND MEDICAID",
    "MEDICARE MEDICAID",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "PALLIATIVE CARE",
    "COMMUNICATION\nPATIENT",
    "CENTERED",
    "EVIDENCE",
    "BASED INTERVIEWING",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE",
    "EFFORTS TO ESTABLISH RAPPORT",
    "PEARLS",
    "PEARLS",
    "KEY STEP DEFINITION EXAMPLE",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "CHALLENGING CONVERSATIONS",
    "SPIKES",
    "GENDER",
    "AND SEXUALITY",
    "INCLUSIVE HISTORY TAKING",
    "CULTURALLY INCLUSIVE HISTORY TAKING",
    "KEY FACT",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nMOTIVATIONAL INTERVIEWING",
    "COMMUNICATING WITH PATIENTS WITH DISABILITIES",
    "INTERPRETERS",
    "BEHAVIORAL COUNSELING",
    "PATIENT SAFETY AND QUALITY\nSAFETY CULTURE",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "STAGE OF CHANGE CHARACTERIZATION EXAMPLE",
    "FIGURE",
    "PDSA CYCLE",
    "FIGURE",
    "SWISS CHEESE MODEL",
    "FIGURE",
    "MEASURING QUALITY OUTCOMES",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE",
    "ERRORS IN HEALTHCARE",
    "HEALTHCARE WORKER BURNOUT AND FATIGUE",
    "TYPE OF ERROR DESCRIPTION IMPACT",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "ANALYZING MEDICAL ERRORS",
    "ETHICS AND LEGAL ISSUES\nGENERAL",
    "CORE PRINCIPLES\nKEY FACT",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE",
    "DOCTOR",
    "PATIENT PROFESSIONAL RELATIONSHIP",
    "KEY FACT",
    "DOCTOR",
    "PATIENT SEXUAL RELATIONSHIP",
    "COMPETENCE AND DECISION",
    "MAKING CAPACITY\nCOMPETENCE",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "DECISION",
    "MAKING CAPACITY",
    "INFORMED CONSENT A",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nKEY FACT",
    "MNEMONIC",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "LIFE ISSUES\nADVANCE DIRECTIVES",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nMNEMONIC SURROGATE DECISION MAKING",
    "KEY FACT",
    "WITHDRAWAL OF LIFE",
    "SUSTAINING TREATMENT",
    "EUTHANASIA AND CLINICIAN",
    "ASSISTED SUICIDE",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "HOSPICE CARE",
    "FUTILE TREATMENT",
    "COMPLEMENTARY AND ALTERNATIVE MEDICINE THERAPY",
    "DISCLOSURE\nFULL DISCLOSURE",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE",
    "SETTING FOR DELIVERING NEWS",
    "SPIKES",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "CONFIDENTIALITY\nMNEMONIC",
    "WOUNDS",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nKEY FACT",
    "CLINICAL RESEARCH",
    "CORE PRINCIPLES OF CLINICAL RESEARCH",
    "KEY FACT ETHICAL CONCERNS",
    "PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH",
    "YIELD FACTS IN",
    "CONFLICT OF INTEREST",
    "GIFTS FROM PATIENTS",
    "GIFTS FROM DRUG COMPANIES",
    "YIELD FACTS IN HEALTH SYSTEMS SCIENCE",
    "MALPRACTICE\nDEFINING MALPRACTICE",
    "MNEMONIC",
    "IMPAIRED PRACTICING CLINICIAN",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nGASTROINTESTINAL",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nGASTROINTESTINAL",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "ORAL AND SALIVARY GLAND DISEASE\nORAL LESIONS",
    "CONDITION AND ETIOLOGY PRESENTATION DIAGNOSIS AND TREATMENT",
    "A B C\nFIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "OROPHARYNGEAL CANCERS",
    "MNEMONIC",
    "SALIVARY GLAND DISEASE",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "CONDITION ETIOLOGY PRESENTATION DIAGNOSIS TREATMENT",
    "NSAIDS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "CONDITION ETIOLOGY PRESENTATION DIAGNOSIS TREATMENT",
    "FIGURE",
    "ESOPHAGEAL DISEASE\nDYSPHAGIA",
    "ODYNOPHAGIA KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "INFECTIOUS ESOPHAGITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "ETIOLOGIC AGENT EXAM FINDINGS UPPER ENDOSCOPY TREATMENT",
    "KEY FACT",
    "MEDICATION",
    "INDUCED",
    "ESOPHAGITIS\nKEY FACT",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "EOSINOPHILIC ESOPHAGITIS",
    "KEY FACT",
    "A B\nFIGURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "ESOPHAGEAL RINGS",
    "FIGURE",
    "KEY FACT",
    "PLUMMER",
    "VINSON SYNDROME",
    "KEY FACT",
    "MNEMONIC\nDISTAL ESOPHAGEAL SPASM",
    "YIELD FACTS IN GASTROINTESTINAL\nA B\nFIGURE",
    "KEY FACT",
    "ACHALASIA",
    "FIGURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "ESOPHAGEAL DIVERTICULA\nB",
    "GASTROESOPHAGEAL REFLUX DISEASE",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "HIATAL HERNIA A",
    "FIGURE",
    "ESOPHAGEAL CANCER\nSCC",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "GASTROINTESTINAL BLEEDING\nKEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "VARIABLE UPPER GI BLEEDING LOWER GI BLEEDING",
    "UPPER GI BLEEDING",
    "FIGURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "IV PPI",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL\nDISORDERS OF THE STOMACH AND DUODENUM\nDYSPEPSIA",
    "KEY FACT",
    "GASTRITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT\nFIGURE",
    "KEY FACT\nPUD",
    "KEY FACT",
    "TEST DESCRIPTION TEST CHARACTERISTICS",
    "YIELD FACTS IN GASTROINTESTINAL\nKEY FACT",
    "KEY FACT\nGASTRIC CANCER",
    "KEY FACT",
    "PEPTIC ULCER DISEASE",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "ZOLLINGER",
    "ELLISON SYNDROME",
    "KEY FACT",
    "GASTROPARESIS",
    "YIELD FACTS IN GASTROINTESTINAL",
    "DISEASE",
    "GASTRIC BEZOAR",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "BARIATRIC SURGERY",
    "YIELD FACTS IN GASTROINTESTINAL",
    "DISORDERS OF THE SMALL BOWEL\nKEY FACT DIARRHEA",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "STOOL OSMOTIC GAP DESCRIPTION EXAMPLES",
    "INFECTIOUS EXAM AND TEST RESULTS",
    "ALL\nAGENT HISTORY HAVE FECAL",
    "COMMENTS TREATMENT",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "INFECTIOUS EXAM AND TEST RESULTS",
    "ALL\nAGENT HISTORY HAVE FECAL",
    "COMMENTS TREATMENT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "MALABSORPTION",
    "MALDIGESTION",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL",
    "CARBOHYDRATE MALDIGESTION",
    "KEY FACT\nCARCINOID SYNDROME",
    "MNEMONIC",
    "SMALL BOWEL OBSTRUCTION\nKEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "ILEUS KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "ACUTE ABDOMEN",
    "ETIOLOGY CAUSE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL",
    "FIGURE",
    "DUODENAL HEMATOMA",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "MESENTERIC ISCHEMIA",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "ACUTE MESENTERIC ISCHEMIA ISCHEMIC COLITIS CHRONIC MESENTERIC ISCHEMIA",
    "KEY FACT",
    "ACUTE APPENDICITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "RLQ\nFIGURE",
    "KEY FACT",
    "KEY FACT\nDISORDERS OF THE LARGE BOWEL",
    "CLOSTRIDIUM DIFFICILE COLITIS",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "DIVERTICULAR DISEASE",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "KEY FACT\nVARIABLE SMALL BOWEL OBSTRUCTION LARGE BOWEL OBSTRUCTION",
    "MNEMONIC\nLARGE BOWEL OBSTRUCTION",
    "IRRITABLE BOWEL SYNDROME",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "A B KEY FACT",
    "FIGURE",
    "MNEMONIC",
    "LARGE BOWEL OBSTRUCTION",
    "IRRITABLE BOWEL SYNDROME",
    "YIELD FACTS IN GASTROINTESTINAL\nA",
    "COLORECTAL CANCER",
    "FIGURE",
    "RISK FACTOR COMMENTS",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "RISK CATEGORY RECOMMENDATIONS",
    "COLORECTAL CANCER",
    "ASSOCIATED CONDITIONS",
    "YIELD FACTS IN GASTROINTESTINAL",
    "FIGURE",
    "ISCHEMIC COLITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "DISEASE CLASSIC PRESENTATION RISK FACTORS TREATMENT",
    "MICROSCOPIC COLITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "ANORECTAL DISEASE",
    "HEMORRHOID GRADING\nI",
    "INFLAMMATORY BOWEL DISEASE",
    "A B C\nFIGURE",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "FIGURE",
    "VARIABLE ULCERATIVE COLITIS CROHN DISEASE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "HERNIA\nTYPE LOCATION ETIOLOGY PREVALENCE",
    "KEY FACT\nHERNIAS",
    "KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL\nBILIARY DISEASE\nL\nCHOLELITHIASIS AND BILIARY COLIC",
    "FIGURE",
    "MNEMONIC",
    "KEY FACT",
    "CHOLECYSTITIS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "LABORATORY\nDISORDER DEFINITION PRESENTATION RESULTS DIAGNOSIS MANAGEMENT",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "CHOLEDOCHOLITHIASIS",
    "CHOLANGITIS",
    "GALLSTONE ILEUS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "POSTCHOLECYSTECTOMY SYNDROME",
    "KEY FACT",
    "BILIARY CYST",
    "CHOLANGIOCARCINOMA",
    "YIELD FACTS IN GASTROINTESTINAL",
    "LIVER DISEASE\nABNORMAL LIVER ASSOCIATED ENZYMES",
    "FIGURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "HEPATITIS",
    "KEY FACT",
    "HCV MNEMONIC",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "VIRUS MODE OF\nTYPE TRANSMISSION PRESENTATION NOTES\nHAV",
    "MNEMONIC",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "SEROLOGIC\nMARKER DESCRIPTION",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "FIGURE",
    "KEY FACT",
    "CIRRHOSIS",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "GRADE MENTAL STATUS ASTERIXIS ELECTROENCEPHALOGRAPHY",
    "YIELD FACTS IN GASTROINTESTINAL\nTABLE",
    "SAAG\nSAAG",
    "KEY FACT",
    "SPONTANEOUS BACTERIAL PERITONITIS",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "COMPLICATION MECHANISM",
    "HISTORY MANAGEMENT",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "ISCHEMIC HEPATITIS",
    "KEY FACT",
    "ACUTE LIVER FAILURE",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "HEPATORENAL SYNDROME",
    "HEPATOPULMONARY SYNDROME",
    "YIELD FACTS IN GASTROINTESTINAL",
    "HEPATIC HYDROTHORAX",
    "TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT PROCEDURE",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "PRIMARY SCLEROSING CHOLANGITIS",
    "IBD\nKEY FACT",
    "PRIMARY BILIARY CHOLANGITIS",
    "KEY FACT",
    "NONALCOHOLIC FATTY LIVER DISEASE",
    "HEPATOCELLULAR CARCINOMA",
    "YIELD FACTS IN GASTROINTESTINAL",
    "KEY FACT",
    "HEMOCHROMATOSIS\nA",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "WILSON DISEASE",
    "HEPATOLENTICULAR DEGENERATION",
    "PE\nFIGURE",
    "LIVER TRANSPLANTATION\nA",
    "YIELD FACTS IN GASTROINTESTINAL\nA B C\nFIGURE",
    "BENIGN LIVER LESIONS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN GASTROINTESTINAL",
    "PANCREATIC DISEASE\nPANCREATITIS",
    "PANCREATIC CYSTS",
    "KEY FACT",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "VARIABLE ACUTE PANCREATITIS CHRONIC PANCREATITIS",
    "A B\nP\nP",
    "YIELD FACTS IN GASTROINTESTINAL\nPANCREATIC NEUROENDOCRINE TUMORS",
    "PPMM\n\nGASTROINTESTINAL HIGH",
    "YIELD FACTS IN",
    "PANCREATIC CANCER",
    "KEY FACT",
    "YIELD FACTS IN GASTROINTESTINAL\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nHEMATOLOGY",
    "YIELD FACTS IN HEMATOLOGY\nCOAGULATION DISORDERS\nNORMAL HEMOSTASIS",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "ANTICOAGULANTS",
    "ANTICOAGULANTS",
    "THROMBOLYTICS",
    "FIGURE",
    "HEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "PLATELET DISORDERS COAGULATION DISORDERS",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "MEDICATION MECHANISM LAB VALUES",
    "MISCELLANEOUS",
    "PTT LMWH",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "WARFARIN DOAC",
    "MANAGEMENT",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "FFP PCC CRYOPRECIPITATE PRBC PLATELETS",
    "TACO TACO",
    "FFP\nABO",
    "TRANSFUSION PRODUCTS",
    "HEMOPHILIA",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN HEMATOLOGY",
    "TXA\nADP",
    "FIGURE",
    "VON WILLEBRAND DISEASE",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "HYPERCOAGULABLE STATES",
    "GENETIC ACQUIRED PHYSIOLOGIC",
    "YIELD FACTS IN HEMATOLOGY",
    "ACTIVATED PROTEIN C",
    "RESISTANCE",
    "FACTOR V LEIDEN\nKEY FACT",
    "PE\nKEY FACT",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "HEPARIN",
    "INDUCED THROMBOCYTOPENIA",
    "KEY FACT",
    "MNEMONIC",
    "ANTIPHOSPHOLIPID SYNDROME",
    "YIELD FACTS IN HEMATOLOGY",
    "KEY FACT PT",
    "KEY FACT",
    "DISSEMINATED INTRAVASCULAR COAGULATION",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "PLATELET DISORDERS\nTHROMBOTIC THROMBOCYTOPENIC PURPURA",
    "ADAMTS",
    "PE\nTTP",
    "ADAMTS",
    "YIELD FACTS IN HEMATOLOGY",
    "CBC\nRBC",
    "FIGURE",
    "HEMOLYTIC UREMIC SYNDROME",
    "ADAMTS",
    "FIGURE",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "DIC\nTTP HUS DIC",
    "ADAMTS",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "THROMBOCYTOPENIA VWD HEMOPHILIA VITAMIN K DEFICIENCY LIVER DISEASE DIC",
    "IDIOPATHIC THROMBOCYTOPENIC PURPURA",
    "IMMUNE THROMBOCYTOPENIA",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "RED BLOOD CELL DISORDERS\nANEMIAS",
    "FIGURE",
    "YIELD FACTS IN HEMATOLOGY\nMICROCYTIC ANEMIAS",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "MNEMONIC",
    "IRON LAST",
    "IRON DEFICIENCY CHRONIC DISEASE THALASSEMIA TRAIT",
    "FIGURE",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN HEMATOLOGY",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "NUMBER\nOF GENES\nSUBTYPE PRESENT CLINICAL FEATURES",
    "KEY FACT",
    "NONHEMOLYTIC",
    "NORMOCYTIC ANEMIAS",
    "YIELD FACTS IN HEMATOLOGY",
    "FIGURE",
    "HEMOLYTIC",
    "NORMOCYTIC ANEMIAS",
    "KEY FACT",
    "MNEMONIC",
    "MOM PASS",
    "GLUCOSE",
    "GLUCOSE",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "DEFICIENCY",
    "KEY FACT",
    "MNEMONIC",
    "FAVA BEANS",
    "FAVA BEANS\nPAROXYSMAL NOCTURNAL HEMOGLOBINURIA",
    "HEREDITARY SPHEROCYTOSIS",
    "FIGURE",
    "KEY FACT",
    "AUTOIMMUNE HEMOLYTIC ANEMIA",
    "KEY FACT",
    "YIELD FACTS IN HEMATOLOGY",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "MEGALOBLASTIC",
    "MACROCYTIC ANEMIA",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "DISEASE AFFECTED ENZYME ACCUMULATED SUBSTRATE SYMPTOMS AND TREATMENT",
    "PORPHYRIAS",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "POLYCYTHEMIAS",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT\nPCV",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "FEBRILE NONHEMOLYTIC\nVARIABLE ALLERGIC REACTION ANAPHYLACTIC REACTION REACTION HEMOLYTIC TRANSFUSION REACTION",
    "KEY FACT\nBLOOD TRANSFUSION REACTIONS",
    "WHITE BLOOD CELL DISORDERS",
    "NEUTROPENIA",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "LYMPHOPENIA EOSINOPENIA",
    "HIV ART",
    "LYMPHOPENIA AND EOSENOPENIA",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "INFECTIOUS AUTOIMMUNE NEOPLASM ALLERGIC MISCELLANEOUS",
    "EOSINOPHILIA\nMNEMONIC",
    "NAAACPDD",
    "YIELD FACTS IN HEMATOLOGY",
    "KEY FACT",
    "LEUKEMIAS",
    "FIGURE",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "VARIABLE MYELOBLAST LYMPHOBLAST",
    "FIGURE",
    "KEY FACT",
    "CHRONIC MYELOGENOUS LEUKEMIA",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "LEUKEMOID REACTION CML KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "HODGKIN LYMPHOMA HODGKIN LYMPHOMA",
    "FIGURE",
    "KEY FACT",
    "LYMPHOMAS",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "TYPE OCCURS IN GENETICS",
    "ETIOLOGY COMMENTS\nB",
    "CELL NEOPLASMS",
    "CELL NEOPLASMS",
    "YIELD FACTS IN HEMATOLOGY\nA B\nFIGURE",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "PLASMA CELL DISORDERS",
    "FIGURE",
    "MULTIPLE MYELOMA",
    "KEY FACT",
    "MNEMONIC",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN HEMATOLOGY\nKEY FACT",
    "KEY FACT",
    "MACROGLOBULINEMIA\nKEY FACT",
    "AMYLOIDOSIS",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "AMYLOID CAUSE\nAL A",
    "TRANSPLANT MEDICINE",
    "YIELD FACTS IN HEMATOLOGY\nTABLE",
    "VARIABLE HYPERACUTE ACUTE CHRONIC",
    "MULTISYSTEM HEMATOLOGY",
    "HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS",
    "PPMM\n\nHEMATOLOGY HIGH",
    "YIELD FACTS IN",
    "MASTOCYTOSIS",
    "LANGERHANS CELL HISTIOCYTOSIS",
    "YIELD FACTS IN HEMATOLOGY",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nMUSCULOSKELETAL",
    "YIELD FACTS IN MUSCULOSKELETAL\nWHOLE BODY\nKEY FACT COMMON ADULT ORTHOPEDIC INJURIES",
    "UPPER EXTREMITY\nINJURY PRESENTATION TREATMENT",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "UPPER EXTREMITY\nINJURY PRESENTATION TREATMENT",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "UPPER EXTREMITY\nINJURY PRESENTATION TREATMENT",
    "G FOOSH",
    "LOWER EXTREMITY\nINJURY PRESENTATION TREATMENT",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "LUOPWPEERR EEXXTTRREEMMIITTYY\nINJURY PRESENTATION TREATMENT",
    "L M N O",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "LUOPWPEERR EEXXTTRREEMMIITTYY\nINJURY PRESENTATION TREATMENT",
    "NSAIDS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "PCL ACL\nLCL\nMM\nKEY FACT\nMCL LM",
    "FIGURE",
    "OTTAWA ANKLE RULES\nA",
    "SALTER",
    "HARRIS PEDIATRIC FRACTURE CLASSIFICATION\nA",
    "FIGURE",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "V\nS A L T R",
    "FIGURE",
    "MNEMONIC",
    "SALTERR",
    "COMMON PERIPHERAL NERVE INJURIES",
    "NERVE MOTOR DEFICIT SENSORY DEFICIT COMMON CAUSES CLINICAL FINDINGS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "NERVE MOTOR DEFICIT SENSORY DEFICIT COMMON CAUSES CLINICAL FINDINGS",
    "C\nA\nB D E F",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "FIGURE",
    "KEY FACT\nCOMPLEX REGIONAL PAIN SYNDROME",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "OSTEOSARCOMA",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "BENIGN TUMORS\nDISEASE CLASSIC FINDINGS KEY HISTORY FINDINGS TREATMENT",
    "MALIGNANT TUMORS",
    "KEY FACT",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "SEPTIC ARTHRITIS A B",
    "FIGURE",
    "NORMAL NONINFLAMMATORY",
    "SEPTIC",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "FIGURE",
    "BACTERIA RISK FACTORS",
    "HISTORY TREATMENT",
    "KEY FACT",
    "KEY FACT\nOSTEOMYELITIS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "OSTEOARTHRITIS",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "KEY FACT\nVARIABLE OSTEOARTHRITIS RHEUMATOID ARTHRITIS",
    "KEY FACT",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "FIGURE",
    "OSTEOPOROSIS",
    "RHEUMATOID ARTHRITIS\nKEY FACT\nA",
    "KEY FACT",
    "YIELD FACTS IN MUSCULOSKELETAL\nKEY FACT",
    "KEY FACT",
    "KEY FACT",
    "SERONEGATIVE SPONDYLOARTHROPATHY",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "MNEMONIC",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "POLYMYOSITIS DERMATOMYOSITIS",
    "POLYMYOSITIS AND DERMATOMYOSITIS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "ANTIBODY DISEASE ASSOCIATION\nANA",
    "CCP RA",
    "KEY FACT",
    "TEMPOROMANDIBULAR JOINT DISORDERS",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "MYOFASCIAL PAIN SYNDROME",
    "MNEMONIC SYSTEMIC SCLEROSIS\nCREST",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "MNEMONIC",
    "DOPAMINE RASH",
    "SYSTEMIC LUPUS ERYTHEMATOSUS\nA",
    "DOPAMINE RASH",
    "FIGURE",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "SERUM SICKNESS",
    "LIKE REACTION",
    "KEY FACT",
    "GIANT CELL ARTERITIS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "TAKAYASU ARTERITIS",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "CHARACTERISTIC FIBROMYALGIA POLYMYALGIA RHEUMATICA",
    "SYNDROME",
    "FIBROMYALGIA\nA",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "POLYMYALGIA RHEUMATICA",
    "UPPER EXTREMITY\nADHESIVE CAPSULITIS",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "DISEASE TEST DESCRIPTION",
    "KEY FACT ROTATOR CUFF INJURIES",
    "KEY FACT",
    "COMPARTMENT SYNDROME",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "RHABDOMYOLYSIS",
    "KEY FACT",
    "YIELD FACTS IN MUSCULOSKELETAL\nKEY FACT CARPAL TUNNEL SYNDROME",
    "KEY FACT",
    "GANGLION CYST\nB\nFIGURE",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "DUPUYTREN CONTRACTURE",
    "FIGURE",
    "AVASCULAR NECROSIS\nAVN",
    "FIGURE",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "RAYNAUD PHENOMENON",
    "KEY FACT",
    "HAND INFECTIONS AND BITE WOUNDS",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "LOWER EXTREMITY\nOSTEOCHONDRITIS DISSECANS",
    "FIGURE",
    "BURSITIS",
    "PES ANSERINUS PAIN SYNDROME",
    "YIELD FACTS IN MUSCULOSKELETAL",
    "PATELLOFEMORAL PAIN SYNDROME",
    "KEY FACT",
    "KEY FACT",
    "MORTON NEUROMA",
    "KEY FACT GOUT",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "CRYSTAL\nDISORDER HISTORY JOINTS AFFECTED CRYSTAL SHAPE BIREFRINGENCE",
    "FIGURE",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN MUSCULOSKELETAL\nFIGURE",
    "FIGURE",
    "KEY FACT",
    "KEY FACT\nPSEUDOGOUT",
    "LOW BACK PAIN",
    "PPMM\n\nMUSCULOSKELETAL HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "HERNIATED DISK",
    "PE KEY FACT",
    "FIGURE",
    "SPINAL STENOSIS",
    "YIELD FACTS IN MUSCULOSKELETAL\nTABLE",
    "ASSOCIATED DEFICIT\nNERVE ROOT MOTOR REFLEX SENSORY",
    "KEY FACT",
    "SPONDYLOLISTHESIS AND SPONDYLOSIS",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nNEUROLOGY",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nNEUROLOGY",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "CLINICAL NEUROANATOMY\nBRAIN",
    "KEY FACT",
    "FIGURE",
    "CIRCLE OF WILLIS AND ARTERIAL SUPPLY",
    "VENOUS DRAINAGE OF BRAIN",
    "YIELD FACTS IN NEUROLOGY\nN T",
    "FIGURE",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "ICA\nACA",
    "PCA\nICA",
    "OF\nMCA",
    "ICA\nECA\nCCA VA",
    "VA\nPICA",
    "OBLIQUE",
    "LATERAL VIEW\nINFERIOR VIEW",
    "ASA\nFIGURE",
    "MENINGES",
    "FIGURE",
    "YIELD FACTS IN NEUROLOGY\nLUMBAR PUNCTURE",
    "V\nW\nX\nPERIPHERAL AND CRANIAL NERVES\nY",
    "CRANIAL\nNERVE FEATURES\nCN III CN III",
    "FIGURE",
    "CN XII",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TYPE DESCRIPTION UMN LMN\nSIGNS LESION LESION",
    "CN VII",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "REFLEXES",
    "SPINAL CORD",
    "TRACT FUNCTION CLINICAL EFFECTS OF LESION",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "AREA AFFECTED DISEASE CHARACTERISTICS",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "AREA AFFECTED DISEASE CHARACTERISTICS",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "ASCENDING",
    "DESCENDING S",
    "ASCENDING",
    "FIGURE",
    "HEADACHES",
    "MIGRAINE HEADACHE",
    "MIGRAINE HEADACHE CLUSTER HEADACHE TENSION",
    "TYPE HEADACHE",
    "YIELD FACTS IN NEUROLOGY",
    "CLUSTER HEADACHE",
    "KEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TENSION",
    "TYPE HEADACHE KEY FACT",
    "SECONDARY HEADACHES",
    "KEY FACT",
    "CN III",
    "YIELD FACTS IN NEUROLOGY",
    "TRIGEMINAL NEURALGIA",
    "VASCULAR DISORDERS\nTRANSIENT ISCHEMIC ATTACK\nA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "STROKE TABLE",
    "MODIFIABLE RISK NONMODIFIABLE",
    "FACTORS RISK FACTORS",
    "VESSEL TERRITORY DISTINGUISHING SYMPTOMS",
    "CN III",
    "YIELD FACTS IN NEUROLOGY\nA B C",
    "FIGURE",
    "MNEMONIC",
    "SAMPLE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "MNEMONIC",
    "SAMPLE",
    "F B IGURE",
    "YIELD FACTS IN NEUROLOGY\nSUBARACHNOID HEMORRHAGE",
    "KEY FACT",
    "KEY FACT",
    "MNEMONIC",
    "A\nC D\nB\nA B C D\nFIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "P H\nT\nINTRACEREBRAL HEMORRHAGE",
    "FIGURE",
    "KEY FACT",
    "SUBDURAL AND EPIDURAL HEMORRHAGE",
    "CAVERNOUS SINUS THROMBOSIS",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "ACUTE SUBDURAL CHRONIC SUBDURAL EPIDURAL",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT\nCOMA AND ENCEPHALOPATHY",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "KEY FACT\nVARIABLE",
    "LOCKED",
    "SYNDROME PERSISTENT VEGETATIVE STATE COMA BRAIN DEATH",
    "KEY FACT",
    "APHASIA",
    "EXPRESSIVE APHASIA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "KEY FACT",
    "WERNICKE",
    "RECEPTIVE APHASIA",
    "APHASIA",
    "FIGURE",
    "SEIZURE DISORDERS\nMNEMONIC\nBROCA",
    "EXPRESSIVE APHASIA",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "INFANTS CHILDREN ADOLESCENTS ADULTS ADULTS",
    "KEY FACT",
    "KEY FACT",
    "CLASSIFICATION OF SEIZURE",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN NEUROLOGY",
    "STATUS EPILEPTICUS\nA",
    "KEY FACT",
    "MNEMONIC",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "VERTIGO",
    "BENIGN PAROXYSMAL POSITIONAL VERTIGO\nA",
    "KEY FACT",
    "YIELD FACTS IN NEUROLOGY\nACUTE PERIPHERAL VESTIBULOPATHY",
    "LABYRINTHITIS OR VESTIBULAR\nNEURITIS",
    "KEY FACT",
    "DISEASE\nA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "CNS INFECTIONS\nMENINGITIS",
    "VIRAL\nBACTERIAL",
    "ASEPTIC",
    "FIGURE",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "OPENING GAMMA\nGLUCOSE PROTEIN PRESSURE GLOBULIN\nRBCS",
    "APPEARANCE",
    "PROTEIN",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "AGE CAUSATIVE ORGANISM TREATMENT",
    "CRYPTOCOCCAL MENINGITIS\nKEY FACT",
    "TOXOPLASMOSIS",
    "YIELD FACTS IN NEUROLOGY",
    "KEY FACT",
    "KEY FACT",
    "ENCEPHALITIS",
    "KEY FACT",
    "PE\nCNS",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "BRAIN ABSCESS\nKEY FACT\nA",
    "YIELD FACTS IN NEUROLOGY\nKEY FACT",
    "DISORDERS OF THE NEUROMUSCULAR JUNCTION\nMYASTHENIA GRAVIS",
    "FIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "LAMBERT",
    "EATON\nKEY FEATURES MYASTHENIA GRAVIS MYASTHENIC SYNDROME",
    "MNEMONIC",
    "DUMBELLS",
    "KEY FACT",
    "LAMBERT",
    "EATON MYASTHENIC SYNDROME",
    "YIELD FACTS IN NEUROLOGY",
    "KEY FACT",
    "KEY FACT",
    "BOTULISM",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "FOODBORNE INFANT WOUND",
    "DEMYELINATING DISORDERS\nMULTIPLE SCLEROSIS",
    "KEY FACT",
    "YIELD FACTS IN NEUROLOGY",
    "GUILLAIN",
    "SYNDROME\nMNEMONIC",
    "KEY FACT",
    "NEURODEGENERATIVE DISORDERS",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "CONDITION CRITERIA",
    "REVERSIBLE CAUSES OF DEMENTIA IRREVERSIBLE CAUSES OF DEMENTIA",
    "YIELD FACTS IN NEUROLOGY\nKEY FACT DEMENTIA",
    "ALZHEIMER DISEASE",
    "TIME COURSE",
    "TYPE KEY EARLY PRESENTATION PATHOLOGIC FINDINGS IMAGING",
    "STUDIES",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TIME COURSE",
    "TYPE KEY EARLY PRESENTATION PATHOLOGIC FINDINGS IMAGING",
    "STUDIES",
    "MNEMONIC",
    "YIELD FACTS IN NEUROLOGY",
    "VASCULAR DEMENTIA",
    "KEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "FRONTOTEMPORAL DEMENTIA",
    "PICK DISEASE",
    "NORMAL",
    "PRESSURE HYDROCEPHALUS\nA",
    "YIELD FACTS IN NEUROLOGY",
    "FIGURE",
    "KEY FACT",
    "CREUTZFELDT",
    "JAKOB DISEASE\nKEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "LEWY BODY DEMENTIA",
    "YIELD FACTS IN NEUROLOGY\nMOVEMENT DISORDERS\nHUNTINGTON DISEASE",
    "FIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "PARKINSON DISEASE AND PARKINSONISM\nA",
    "KEY FACT",
    "TRAPSS",
    "MNEMONIC",
    "TRAPSS",
    "YIELD FACTS IN NEUROLOGY",
    "TRAPSS",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "DOPA KEY FACT\nDECARBOXYLASE",
    "CIRCULATION",
    "OMD\nINHIBITOR",
    "DOPA COMT INHIBITORS",
    "DDC COMT",
    "BRAIN\nBARRIER",
    "DDC COMT INHIBITOR",
    "PRESYNAPTIC",
    "TERMINAL FROM THE",
    "SUBSTANTIA NIGRA",
    "MT\nDOPAC",
    "MAO TYPE B",
    "INHIBITORS KEY FACT",
    "DOPAMINE",
    "AVAILABILITY",
    "DOPAMINE AGONISTS\nPOSTSYNAPTIC",
    "TERMINAL IN\nTHE STRIATUM",
    "FIGURE",
    "KEY FACT\nAMYOTROPHIC LATERAL SCLEROSIS",
    "YIELD FACTS IN NEUROLOGY\nKEY FACT",
    "LMN UMN",
    "KEY FACT",
    "CN XII",
    "RESTLESS LEGS SYNDROME",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TREMORS KEY FACT\nA",
    "FIGURE",
    "WILSON DISEASE OR HEPATOLENTICULAR DEGENERATION",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "TREMOR TYPE TREMOR SUBTYPE FEATURES ETIOLOGIES IMPROVE TREATMENT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "NEOPLASMS",
    "KEY FACT",
    "MNEMONIC",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "TUMOR AND APPEARANCE BENIGN VS MALIGNANT PRESENTATION TREATMENT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TUMOR AND APPEARANCE BENIGN VS MALIGNANT PRESENTATION TREATMENT",
    "CN VIII",
    "A B C D\nE G H\nF",
    "YIELD FACTS IN NEUROLOGY\nNEUROCUTANEOUS DISORDERS\nNEUROFIBROMATOSIS",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "TUBEROUS SCLEROSIS",
    "A B\nFIGURE",
    "YIELD FACTS IN NEUROLOGY\nKEY FACT",
    "STURGE",
    "WEBER SYNDROME",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "VON HIPPLE",
    "LINDAU SYNDROME",
    "II VHL",
    "YIELD FACTS IN NEUROLOGY\nATAXIA",
    "TELANGIECTASIA",
    "OTHER NEUROLOGIC DISEASES\nNUTRITIONAL DEFICIENCIES",
    "IDIOPATHIC INTRACRANIAL HYPERTENSION\nA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "VITAMIN SYNDROME SIGNS",
    "SYMPTOMS CLASSIC PATIENTS TREATMENT",
    "YIELD FACTS IN NEUROLOGY",
    "OPHTHALMOLOGY\nVISUAL FIELD DEFECTS",
    "HORDEOLUM",
    "CHALAZION",
    "FIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "A\nFIGURE",
    "BLEPHARITIS\nA",
    "FIGURE",
    "CORNEAL ABRASION",
    "PRESEPTAL",
    "PERIORBITAL",
    "CELLULITIS",
    "ORBITAL",
    "POSTSEPTAL",
    "CELLULITIS",
    "YIELD FACTS IN NEUROLOGY",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "CONJUNCTIVITIS",
    "FIGURE",
    "ACUTE DACRYOCYSTITIS",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "PATHOGEN CHARACTERISTICS DIAGNOSIS TREATMENT",
    "HERPES SIMPLEX KERATITIS",
    "CONTACT LENS KERATITIS\nFIGURE",
    "YIELD FACTS IN NEUROLOGY",
    "UVEITIS",
    "FIGURE",
    "REFRACTIVE ERRORS",
    "PRESBYOPIA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "GLAUCOMA KEY FACT",
    "KEY FACT",
    "CATARACT",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN NEUROLOGY\nTABLE",
    "CLOSED",
    "ANGLE GLAUCOMA OPEN",
    "ANGLE GLAUCOMA",
    "RELATED MACULAR DEGENERATION",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "RETINAL VASCULAR OCCLUSION",
    "FIGURE",
    "OPTIC NEURITIS",
    "KEY FACT",
    "YIELD FACTS IN NEUROLOGY",
    "CENTRAL RETINAL ARTERY OCCLUSION CENTRAL RETINAL VEIN OCCLUSION",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "RETINAL DETACHMENT",
    "FIGURE",
    "KEY FACT",
    "DIABETIC RETINOPATHY",
    "HYPERTENSIVE RETINOPATHY",
    "RETINITIS PIGMENTOSA",
    "YIELD FACTS IN NEUROLOGY",
    "PAPILLEDEMA",
    "LEUKOCORIA\nFIGURE",
    "RELATIVE AFFERENT PUPILLARY DEFECT",
    "HORNER SYNDROME",
    "FIGURE",
    "FIGURE",
    "ORBITAL BLOWOUT FRACTURE",
    "CAVERNOUS SINUS SYNDROME",
    "FIGURE",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "INTRANUCLEAR OPHTHALMOPLEGIA",
    "CN III",
    "CN VI CN III",
    "CN III",
    "CN III",
    "CN III",
    "CN III",
    "FIGURE",
    "OTOLOGY",
    "OTITIS MEDIA\nMNEMONIC",
    "YIELD FACTS IN NEUROLOGY",
    "OTITIS EXTERNA",
    "MALIGNANT OTITIS EXTERNA",
    "PPMM\n\nNEUROLOGY HIGH",
    "YIELD FACTS IN",
    "SENSORINEURAL HEARING LOSS",
    "CN VIII",
    "CN VII",
    "CN VIII",
    "FIGURE",
    "YIELD FACTS IN NEUROLOGY\nCONDUCTIVE HEARING LOSS",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nOBSTETRICS",
    "YIELD FACTS IN OBSTETRICS\nTHE BASICS OF PREGNANCY",
    "KEY FACT",
    "DIAGNOSIS OF PREGNANCY\nKEY FACT",
    "HUMAN CHORIONIC GONADOTROPIN",
    "ULTRASONOGRAPHY",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "PHYSIOLOGIC CHANGES IN PREGNANCY",
    "SYSTEM CHANGES MECHANISMS",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "SYSTEM CHANGES MECHANISMS",
    "PRENATAL CARE AND DIAGNOSTIC TESTING",
    "TSH\nTABLE",
    "CATEGORY RECOMMENDATIONS",
    "FIGURE",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "GROUP B STREPTOCOCCUS TESTING AND TREATMENT",
    "PRENATAL DIAGNOSTIC TESTING",
    "PRENATAL DIAGNOSTIC TESTING",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "MSAFP ESTRIOL INHIBIN A",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "VARIABLE CELL",
    "FREE FETAL DNA CHORIONIC VILLUS SAMPLING AMNIOCENTESIS\nGA",
    "FIGURE",
    "YIELD FACTS IN OBSTETRICS\nTERATOLOGY",
    "DRUGS AND CHEMICALS DEFECTS",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "MNEMONIC\nCONGENITAL INFECTIONS",
    "KEY FACT",
    "DISEASE TRANSMISSION SYMPTOMS DIAGNOSIS TREATMENT PREVENTION",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "DISEASE TRANSMISSION SYMPTOMS DIAGNOSIS TREATMENT PREVENTION",
    "ABORTION\nSPONTANEOUS ABORTION",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "PE\nSAB",
    "TYPE SYMPTOMS",
    "SIGNS DIAGNOSIS TREATMENT",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "TRIMESTER PROCEDURE GESTATIONAL AGE",
    "KEY FACT",
    "ELECTIVE TERMINATION OF PREGNANCY",
    "COMPLICATIONS OF ABORTION\nMNEMONIC",
    "MATERNAL COMPLICATIONS OF PREGNANCY\nHYPEREMESIS GRAVIDARUM",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "PE KEY FACT",
    "IV\nDIABETES",
    "KEY FACT",
    "YIELD FACTS IN OBSTETRICS",
    "KEY FACT",
    "MATERNAL COMPLICATIONS FETAL COMPLICATIONS",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "HYPERTENSIVE DISEASE IN PREGNANCY",
    "YIELD FACTS IN OBSTETRICS",
    "MNEMONIC",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "DISEASE SEVERITY SIGNS AND SYMPTOMS DELIVERY",
    "KEY FACT",
    "YIELD FACTS IN OBSTETRICS",
    "URINARY TRACT INFECTION AND ASYMPTOMATIC BACTERIURIA",
    "GBS UTI",
    "INTRAHEPATIC CHOLESTASIS",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "ACUTE FATTY LIVER IN PREGNANCY",
    "OBSTETRIC COMPLICATIONS OF PREGNANCY\nCM\nECTOPIC PREGNANCY\nFIGURE",
    "MNEMONIC",
    "KEY FACT",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "VARIABLE COMPLETE PARTIAL",
    "GESTATIONAL TROPHOBLASTIC DISEASE\nA",
    "FIGURE",
    "ANTEPARTUM HEMORRHAGE AND ABNORMAL PLACENTATION",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "VARIABLE PLACENTAL ABRUPTION PLACENTA PREVIA VASA PREVIA",
    "YIELD FACTS IN OBSTETRICS",
    "FIGURE",
    "FIGURE",
    "KEY FACT",
    "MULTIPLE GESTATION",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "FETAL GROWTH RESTRICTION",
    "FETAL MACROSOMIA\nA",
    "YIELD FACTS IN OBSTETRICS\nPOLYHYDRAMNIOS",
    "OLIGOHYDRAMNIOS",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "A B C D\nFIGURE",
    "RH ISOIMMUNIZATION",
    "ANTEPARTUM FETAL SURVEILLANCE",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "FIGURE",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "COMPONENT NORMAL FINDING SCORE",
    "YIELD FACTS IN OBSTETRICS\nKEY FACT",
    "MNEMONIC\nNORMAL LABOR AND DELIVERY",
    "DEFINITION AND STAGES OF LABOR",
    "OBSTETRIC EXAMINATION\nKEY FACT",
    "DURATION\nSTAGE STARTS",
    "ENDS NULLIPAROUS MULTIPAROUS COMMENTS",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "FETAL HEART RATE MONITORING",
    "MNEMONIC",
    "VEAL CHOP",
    "OBSTETRIC ANALGESIA AND ANESTHESIA",
    "YIELD FACTS IN OBSTETRICS\nTABLE",
    "TYPE DESCRIPTION ETIOLOGY SCHEMATIC",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "ABNORMAL LABOR AND DELIVERY\nINDICATIONS FOR C",
    "SECTION",
    "PRETERM LABOR",
    "KEY FACT",
    "MATERNAL FACTORS FETAL AND MATERNAL FACTORS FETAL FACTORS",
    "YIELD FACTS IN OBSTETRICS",
    "RUPTURE OF MEMBRANES",
    "KEY FACT",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "FAILURE TO PROGRESS",
    "STAGE DEFINITION",
    "YIELD FACTS IN OBSTETRICS\nINTRA",
    "AMNIOTIC INFECTION",
    "FETAL MALPRESENTATION",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "UMBILICAL CORD PROLAPSE",
    "SHOULDER DYSTOCIA",
    "FIGURE",
    "EPISIOTOMY",
    "YIELD FACTS IN OBSTETRICS\nUTERINE INVERSION",
    "UTERINE RUPTURE",
    "PUERPERIUM",
    "POSTPARTUM HEMORRHAGE\nA",
    "POSTPARTUM INFECTION\nA",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "VARIABLE UTERINE ATONY",
    "GENITAL TRACT TRAUMA",
    "RETAINED PLACENTAL TISSUE",
    "KEY FACT",
    "YIELD FACTS IN OBSTETRICS\nMNEMONIC",
    "PERIPARTUM CARDIOMYOPATHY",
    "SHEEHAN SYNDROME",
    "POSTPARTUM PITUITARY NECROSIS",
    "LACTATION AND BREASTFEEDING",
    "PHYSIOLOGY",
    "FIGURE",
    "PPMM\n\nOBSTETRICS HIGH",
    "YIELD FACTS IN",
    "INFECTIOUS NONINFECTIOUS",
    "CONTRAINDICATIONS TO BREASTFEEDING",
    "MASTITIS",
    "BREAST ABSCESS",
    "YIELD FACTS IN OBSTETRICS",
    "BREAST ENGORGEMENT",
    "NIPPLE INJURY",
    "LOCALIZED PLUGGED DUCT",
    "GALACTOCELE",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nGYNECOLOGY",
    "PPMM\n\nKEY FACT\nMENARCHE AND NORMAL FEMALE DEVELOPMENT",
    "NORMAL MENSTRUAL CYCLE",
    "FIGURE",
    "YIELD FACTS IN GYNECOLOGY\nPHASES OF OVARIAN CYCLE",
    "FOLLICULAR PHASE LUTEAL PHASE\nLH\nFSH",
    "LH FSH",
    "PHASES OF UTERINE CYCLE",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "LH KEY FACT",
    "ABNORMALITIES OF THE MENSTRUAL CYCLE KEY FACT",
    "PRECOCIOUS PUBERTY",
    "CENTRAL",
    "DEPENDENT",
    "PERIPHERAL",
    "INDEPENDENT",
    "YIELD FACTS IN GYNECOLOGY\nKEY FACT",
    "KEY FACT",
    "PRIMARY AMENORRHEA",
    "DELAYED PUBERTY",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "GNRH LH",
    "FSH ESTROGEN",
    "PROGESTERONE ETIOLOGY",
    "FIGURE",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "C L O H",
    "FIGURE",
    "SECONDARY AMENORRHEA",
    "YIELD FACTS IN GYNECOLOGY",
    "KEY FACT",
    "PRIMARY DYSMENORRHEA",
    "SECONDARY DYSMENORRHEA",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "PID KEY FACT",
    "VARIABLE ENDOMETRIOSIS ADENOMYOSIS",
    "YIELD FACTS IN GYNECOLOGY\nABNORMAL UTERINE BLEEDING",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN GYNECOLOGY",
    "FIGURE",
    "KEY FACT",
    "KEY FACT\nCONTRACEPTION",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "METHOD MECHANISM ADVANTAGES DISADVANTAGES\nMOST EFFECTIVE",
    "VERY EFFECTIVE",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "METHOD MECHANISM ADVANTAGES DISADVANTAGES\nMODERATELY EFFECTIVE",
    "LESS EFFECTIVE",
    "ESTROGEN",
    "CONTAINING HORMONAL",
    "PROGESTERONE AND COPPER",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "METHOD AND MECHANISM ADVANTAGES",
    "KEY FACT\nREPRODUCTIVE ENDOCRINOLOGY",
    "CONGENITAL ADRENAL HYPERPLASIA",
    "YIELD FACTS IN GYNECOLOGY",
    "II\nZONA GLOMERULOSA ZONA FASCICULATA ZONA RETICULARIS PERIPHERAL TISSUE",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "SEX\nENZYME DEFICIENCY MINERALOCORTICOIDS CORTISOL HORMONES BP",
    "LABS PRESENTATION",
    "POLYCYSTIC OVARIAN SYNDROME\nA",
    "MNEMONIC",
    "YIELD FACTS IN GYNECOLOGY",
    "FIGURE",
    "KEY FACT",
    "INFERTILITY\nKEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "ETIOLOGY HISTORY",
    "PE DIAGNOSIS TREATMENT",
    "IVF\nTSH",
    "YIELD FACTS IN GYNECOLOGY\nMENOPAUSE",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "GYNECOLOGIC DISORDERS\nCYST AND ABSCESS OF THE BARTHOLIN DUCT",
    "VAGINITIS\nA",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "VARIABLE BACTERIAL VAGINOSIS TRICHOMONIASIS CANDIDIASIS",
    "PID\nA B C\nA B C",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "FIGURE",
    "CERVICITIS",
    "KEY FACT",
    "PELVIC INFLAMMATORY DISEASE",
    "YIELD FACTS IN GYNECOLOGY",
    "MNEMONIC",
    "A ROPE",
    "KEY FACT",
    "OVARIAN TORSION",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "PEDIATRIC VAGINAL DISCHARGE",
    "KEY FACT",
    "TOXIC SHOCK SYNDROME",
    "KEY FACT",
    "YIELD FACTS IN GYNECOLOGY",
    "BENIGN BREAST DISORDERS\nNONPROLIFERATIVE BREAST LESIONS",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "PROLIFERATIVE BREAST LESIONS WITHOUT ATYPIA",
    "INTRADUCTAL PAPILLOMA",
    "YIELD FACTS IN GYNECOLOGY\nPHYLLODES TUMOR",
    "ATYPICAL HYPERPLASIA\nFIGURE",
    "MNEMONIC\nBREAST CANCER",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "A B C\nA B\nFIGURE",
    "KEY FACT",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "PRIMARY TUMOR",
    "REGIONAL LYMPH NODES",
    "METASTASIS",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "BENIGN GYNECOLOGIC DISORDERS",
    "UTERINE LEIOMYOMAS",
    "FIBROIDS",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "TYPE INFORMATION",
    "NONNEOPLASTIC OVARIAN CYSTS",
    "KEY FACT\nGYNECOLOGIC NEOPLASMS",
    "ENDOMETRIAL CANCER",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "VARIABLE TYPE I",
    "ENDOMETRIOID TYPE II",
    "SEROUS",
    "KEY FACT",
    "KEY FACT",
    "F\nCERVICAL CANCER",
    "FIGURE",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "CIN BETHESDA SYSTEM",
    "US\nASC",
    "H\nCIN I LSIL\nCIN II HSIL\nCIN III HSIL",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "USPSTF",
    "OR HPV",
    "FIGURE",
    "USPSTF",
    "CIN II",
    "CIN III",
    "CIN II",
    "CIN II",
    "YIELD FACTS IN GYNECOLOGY\nSTAGE",
    "IIA IIB IIIA",
    "IB\nIIIB\nIA",
    "IVB\nFIGURE",
    "VULVAR CANCER",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "VAGINAL CANCER",
    "OVARIAN CANCER",
    "KEY FACT",
    "YIELD FACTS IN GYNECOLOGY\nTABLE",
    "FINDING BENIGN MALIGNANT\nEXAMINATION",
    "PELVIC MASS",
    "TRANSVAGINAL ULTRASONOGRAPHY",
    "ADNEXAL MASS",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "TUMOR MARKER CHARACTERISTICS",
    "YIELD FACTS IN GYNECOLOGY\nUROLOGIC GYNECOLOGY\nPELVIC ORGAN PROLAPSE",
    "FIGURE",
    "PPMM\n\nGYNECOLOGY HIGH",
    "YIELD FACTS IN",
    "SEXUAL DISORDERS\nGENITOPELVIC PAIN DISORDER",
    "VAGINISMUS",
    "VULVODYNIA",
    "FEMALE SEXUAL INTEREST",
    "AROUSAL DISORDER",
    "YIELD FACTS IN GYNECOLOGY\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nPEDIATRICS",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nPEDIATRICS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "CHILD DEVELOPMENT",
    "KEY FACT",
    "DEVELOPMENTAL MILESTONES",
    "PRIMITIVE REFLEXES",
    "GROWTH",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "GROSS MOTOR FINE MOTOR LANGUAGE SOCIAL",
    "COGNITIVE",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISORDER NOTES",
    "REFLEX DESCRIPTION",
    "YIELD FACTS IN PEDIATRICS\nKEY FACT",
    "KEY FACT",
    "SEXUAL DEVELOPMENT",
    "KEY FACT",
    "MNEMONIC\nGENETIC DISEASE",
    "CYSTIC FIBROSIS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "DISEASE GENETIC ABNORMALITY PRESENTATION",
    "FEATURES ASSOCIATED DISEASES OTHER FACTS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISEASE GENETIC ABNORMALITY PRESENTATION",
    "FEATURES ASSOCIATED DISEASES OTHER FACTS",
    "DISEASE ETIOLOGY MODE OF INHERITANCE",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "DISEASE ETIOLOGY MODE OF INHERITANCE",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISEASE FEATURES",
    "PRESENTATION MODE OF INHERITANCE",
    "YIELD FACTS IN PEDIATRICS\nPLUS",
    "NEONATOLOGY\nKEY FACT APGAR SCORING",
    "KEY FACT",
    "CONGENITAL MALFORMATIONS",
    "NEONATAL JAUNDICE",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "POINTS",
    "POINTS",
    "MALFORMATION PRESENTATION DIAGNOSIS TREATMENT",
    "CHARGE",
    "VACTERL",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "MALFORMATION PRESENTATION DIAGNOSIS TREATMENT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "MNEMONIC\nPHYSIOLOGIC JAUNDICE PATHOLOGIC JAUNDICE",
    "KEY FACT\nUNCONJUGATED",
    "CONJUGATED",
    "FIGURE",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "MECHANISM EXAMPLE",
    "PREDOMINANT BILIRUBIN SPECIES",
    "RESPIRATORY DISTRESS SYNDROME",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISEASE PROCESS KEY FINDINGS\nNRDS",
    "YIELD FACTS IN PEDIATRICS",
    "GERMINAL MATRIX HEMORRHAGE",
    "APNEA OF PREMATURITY",
    "NEONATAL EXTRACRANIAL INJURIES",
    "CONGENITAL HYPOTHYROIDISM",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "TYPE OF INJURY DESCRIPTION",
    "MNEMONIC",
    "BENIGN NEONATAL RASHES",
    "NEONATAL ABSTINENCE SYNDROME",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "MNEMONIC\nRASH DESCRIPTION MANAGEMENT",
    "KEY FACT",
    "MNEMONIC",
    "VACTERL",
    "ACYANOTIC CONGENITAL HEART LEFT",
    "RIGHT SHUNTS",
    "KEY FACT",
    "SEPTAL DEFECTS",
    "KEY FACT\nA",
    "CONGENITAL HEART DISEASE",
    "KEY FACT",
    "MNEMONIC CHD",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "MNEMONIC\nDEFECT ASSOCIATION",
    "KEY FACT\nVSD",
    "MNEMONIC\nVACTERL",
    "ACYANOTIC CONGENITAL HEART LEFT",
    "RIGHT SHUNTS",
    "KEY FACT",
    "SEPTAL DEFECTS\nKEY FACT\nA",
    "KEY FACT",
    "MNEMONIC",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "VSD\nASD",
    "SEE IMAGE A",
    "SEE IMAGE B",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "PATENT DUCTUS ARTERIOSUS\nPDA",
    "FIGURE",
    "MNEMONIC",
    "KEY FACT",
    "COARCTATION OF THE AORTA",
    "KEY FACT",
    "YIELD FACTS IN PEDIATRICS\nA B",
    "FIGURE",
    "FIGURE",
    "MNEMONIC",
    "MNEMONIC\nTETRALOGY OF FALLOT\nCATCH",
    "KEY FACT",
    "KEY FACT",
    "CYANOTIC CONGENITAL HEART RIGHT",
    "LEFT SHUNTS",
    "TRANSPOSITION OF THE GREAT ARTERIES",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "MNEMONIC",
    "TETRALOGY OF FALLOT\nCATCH",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN PEDIATRICS",
    "PEDIATRIC GASTROINTESTINAL DISEASE\nPYLORIC STENOSIS",
    "B\nL\nGB",
    "FIGURE",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "INTUSSUSCEPTION\nA",
    "YIELD FACTS IN PEDIATRICS",
    "MALROTATION WITH VOLVULUS",
    "FIGURE",
    "FIGURE",
    "MECKEL DIVERTICULUM",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "MNEMONIC",
    "KEY FACT",
    "HIRSCHSPRUNG DISEASE",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN PEDIATRICS\nNECROTIZING ENTEROCOLITIS\nA",
    "FIGURE",
    "KEY FACT",
    "FOOD PROTEIN",
    "INDUCED ALLERGIC PROCTOCOLITIS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "PEDIATRIC CONSTIPATION",
    "YIELD FACTS IN PEDIATRICS\nKEY FACT",
    "PEDIATRIC UROLOGY",
    "VESICOURETERAL REFLUX",
    "KEY FACT",
    "A VCUG",
    "FIGURE",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "CRYPTORCHIDISM",
    "KEY FACT\nINGUINAL HERNIA",
    "YIELD FACTS IN PEDIATRICS\nA TABLE",
    "PARAMETERS HYPOSPADIAS",
    "SEE FIG",
    "EPISPADIAS",
    "SEE FIG",
    "FIGURE",
    "KEY FACT",
    "HYPOSPADIAS AND EPISPADIAS",
    "PEDIATRIC IMMUNOLOGY",
    "IMMUNODEFICIENCY DISORDERS",
    "KEY FACT",
    "FIGURE",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISORDER DESCRIPTION INFECTION RISK",
    "TYPE DIAGNOSIS",
    "TREATMENT\nB",
    "CELL DISORDERS",
    "CELL DISORDERS",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "DISORDER DESCRIPTION INFECTION RISK",
    "TYPE DIAGNOSIS",
    "TREATMENT\nCOMBINED DISORDERS",
    "PEDIATRIC PHAGOCYTIC DEFICIENCIES",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISORDER DESCRIPTION INFECTION RISK",
    "TYPE DIAGNOSIS",
    "TREATMENT",
    "COMPLEMENT DISORDERS",
    "YIELD FACTS IN PEDIATRICS\nKEY FACT",
    "KAWASAKI DISEASE",
    "MNEMONIC",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "SUBTYPE PRESENTATION RF AND ANA STATUS NOTES",
    "JUVENILE IDIOPATHIC ARTHRITIS",
    "YIELD FACTS IN PEDIATRICS",
    "PEDIATRIC INFECTIOUS DISEASE\nACUTE OTITIS MEDIA\nA",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "BRONCHIOLITIS KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN PEDIATRICS\nCROUP",
    "LARYNGOTRACHEOBRONCHITIS",
    "FIGURE",
    "VARIABLE CROUP",
    "MOST COMMON",
    "EPIGLOTTITIS TRACHEITIS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "EPIGLOTTITIS\nH",
    "BRONCHIOLITIS\nRSV",
    "FIGURE",
    "EPIGLOTTITIS\nA",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "VARIABLE RETROPHARYNGEAL ABSCESS PERITONSILLAR ABSCESS",
    "FIGURE",
    "MENINGITIS",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "OCULAR INFECTIONS OF THE NEONATE",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "CAUSATIVE AGENT CHARACTERISTICS TREATMENT",
    "PERTUSSIS",
    "WHOOPING COUGH",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "VIRAL EXANTHEMS",
    "TORCH INFECTIONS",
    "PINWORM INFECTION",
    "NEONATAL FEVER",
    "DAYS OLD",
    "FEVER OF UNKNOWN ORIGIN",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "DISEASE CAUSE SYMPTOMS COMPLICATIONS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "DISEASE CAUSE SYMPTOMS COMPLICATIONS",
    "PEDIATRIC NEUROLOGIC DISEASE\nCEREBRAL PALSY\nA",
    "YIELD FACTS IN PEDIATRICS\nKEY FACT",
    "FEBRILE SEIZURES",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "INFANTILE HYPOTONIA",
    "DISORDER ETIOLOGY PRESENTATION TREATMENT",
    "YIELD FACTS IN PEDIATRICS\nCOMMON BRAIN NEOPLASMS IN CHILDREN",
    "TUMOR PATHOLOGY PRESENTATION TREATMENT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "TUMOR PATHOLOGY PRESENTATION TREATMENT",
    "A B C D E",
    "SPINAL DYSRAPHISM\nA",
    "YIELD FACTS IN PEDIATRICS",
    "BREATH",
    "HOLDING SPELLS\nKEY FACT",
    "RETT SYNDROME",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "CHIARI MALFORMATIONS",
    "FIGURE",
    "BENIGN FAMILIAL MICROCEPHALY AND MACROCEPHALY",
    "YIELD FACTS IN PEDIATRICS\nPEDIATRIC HEMATOLOGY\nDIAMOND",
    "BLACKFAN ANEMIA\nA",
    "DIAMOND",
    "BLACKFAN ANEMIA FANCONI ANEMIA",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FANCONI ANEMIA",
    "VACTERL",
    "VACTERL",
    "INHERITED BONE MARROW FAILURE SYNDROMES ACQUIRED BONE MARROW FAILURE",
    "YIELD FACTS IN PEDIATRICS",
    "CYCLIC NEUTROPENIA",
    "THROMBOCYTOPENIA ABSENT RADIUS SYNDROME",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "KASABACH",
    "MERRITT SYNDROME\nA",
    "FIGURE",
    "SICKLE CELL DISEASE",
    "KEY FACT",
    "YIELD FACTS IN PEDIATRICS",
    "FIGURE",
    "KEY FACT",
    "MNEMONIC",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "PEDIATRIC ONCOLOGY\nLEUKEMIA\nA",
    "KEY FACT",
    "YIELD FACTS IN PEDIATRICS",
    "KEY FACT",
    "MNEMONIC",
    "NEUROBLASTOMA",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "WILMS TUMOR",
    "MNEMONIC",
    "CHILDHOOD BONE TUMORS",
    "LANGERHANS HISTIOCYTOSIS\nA",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "VARIABLE OSTEOSARCOMA EWING SARCOMA",
    "ESR\nA B",
    "PEDIATRIC MUSCULOSKELETAL DISORDERS\nCOMMON PEDIATRIC ORTHOPEDIC INJURIES",
    "DUCHENNE MUSCULAR DYSTROPHY",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "INJURY MECHANICS TREATMENT",
    "SALTER",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "CHARACTERISTIC DUCHENNE MUSCULAR DYSTROPHY BECKER MUSCULAR DYSTROPHY",
    "KEY FACT",
    "MYOTONIC DYSTROPHY",
    "SPONDYLOLISTHESIS",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "METATARSUS ADDUCTUS",
    "CLUBFOOT",
    "TALIPES EQUINOVARUS",
    "DEVELOPMENTAL DYSPLASIA OF THE HIP",
    "FIGURE",
    "YIELD FACTS IN PEDIATRICS",
    "AA LEGG",
    "PERTHES DISEASE",
    "FIGURE",
    "SLIPPED CAPITAL FEMORAL EPIPHYSIS",
    "KEY FACT",
    "MNEMONIC",
    "STARTSS HOT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "SCOLIOSIS",
    "CHILD ABUSE",
    "PE KEY FACT",
    "YIELD FACTS IN PEDIATRICS\nTABLE",
    "TYPE OF ABUSE PRESENTATION",
    "IMAGING FINDINGS MIMICS",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "CHILD CARE\nANTICIPATORY GUIDANCE",
    "KEY FACT",
    "HEARING AND VISION SCREENING",
    "YIELD FACTS IN PEDIATRICS",
    "KEY FACT",
    "CHILDHOOD VACCINATIONS",
    "LEAD POISONING",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN PEDIATRICS",
    "PERIANAL DERMATITIS",
    "DIAGNOSIS DESCRIPTION TREATMENT",
    "PPMM\n\nPEDIATRICS HIGH",
    "YIELD FACTS IN",
    "PIGMENTED LESIONS IN CHILDHOOD",
    "LESION DESCRIPTION",
    "YIELD FACTS IN PEDIATRICS\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nPSYCHIATRY",
    "YIELD FACTS IN PSYCHIATRY\nCHILDHOOD AND ADOLESCENT DISORDERS\nATTENTION",
    "DEFICIT",
    "HYPERACTIVITY DISORDER\nA",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "AUTISM SPECTRUM DISORDER",
    "KEY FACT",
    "DISRUPTIVE BEHAVIORAL DISORDERS",
    "YIELD FACTS IN PSYCHIATRY",
    "KEY FACT",
    "INTELLECTUAL DEVELOPMENTAL DISORDER",
    "INTELLECTUAL DISABILITY",
    "KEY FACT",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "TOURETTE SYNDROME",
    "KEY FACT",
    "SEPARATION ANXIETY DISORDER",
    "YIELD FACTS IN PSYCHIATRY",
    "PSYCHOTIC DISORDERS\nSCHIZOPHRENIA",
    "KEY FACT",
    "MNEMONIC",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "SCHIZOPHRENIFORM",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT\nTABLE",
    "DISORDER DURATION",
    "CHARACTERISTICS",
    "KEY FACT",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DRUG CLASS MECHANISM EXAMPLES INDICATIONS ADVERSE EFFECTS",
    "WITHOUT",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "MNEMONIC\nTIME OF",
    "SUBTYPE DESCRIPTION ONSET TREATMENT",
    "DISSOCIATIVE DISORDERS",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DISORDER CHARACTERISTICS",
    "ANXIETY DISORDERS\nGENERALIZED ANXIETY DISORDER",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "MNEMONIC",
    "KEY FACT",
    "PANIC DISORDER",
    "DRUG CLASS INDICATIONS ADVERSE EFFECTS",
    "YIELD FACTS IN PSYCHIATRY",
    "KEY FACT",
    "PHOBIAS",
    "SOCIAL AND SPECIFIC",
    "KEY FACT",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "OBSESSIVE",
    "COMPULSIVE DISORDER AND RELATED DISORDERS\nKEY FACT",
    "OBSESSIVE",
    "COMPULSIVE DISORDER",
    "PE KEY FACT",
    "OBSESSIVE",
    "COMPULSIVE",
    "RELATED DISORDERS",
    "OBSESSIVE",
    "COMPULSIVE DISORDER OBSESSIVE",
    "COMPULSIVE PERSONALITY DISORDER",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DISORDER CHARACTERISTICS",
    "TRAUMA AND STRESSOR",
    "RELATED DISORDERS",
    "TRAUMATIC STRESS DISORDER",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "PE KEY FACT",
    "MNEMONIC",
    "DEMENTIASS",
    "NEUROCOGNITIVE DISORDERS",
    "DEMENTIA",
    "MAJOR NEUROCOGNITIVE DISORDER",
    "DEMENTIASS",
    "YIELD FACTS IN PSYCHIATRY",
    "CHARACTERISTIC DELIRIUM DEMENTIA",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "DELIRIUM",
    "MNEMONIC",
    "I WATCH DEATH",
    "YIELD FACTS IN PSYCHIATRY\nKEY FACT",
    "MNEMONIC",
    "SIG E CAPS",
    "MOOD DISORDERS",
    "MAJOR DEPRESSIVE DISORDER",
    "KEY FACT",
    "KEY FACT",
    "DISORDER DESCRIPTION AND EXAMPLES",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "SUBTYPE TIME OF ONSET SYMPTOMS",
    "MNEMONIC",
    "KEY FACT",
    "SIG E CAPS",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DRUG CLASS EXAMPLES INDICATIONS ADVERSE EFFECTS",
    "OCD TCA",
    "PERSISTENT DEPRESSIVE DISORDER",
    "DYSTHYMIA",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "ADJUSTMENT DISORDER",
    "KEY FACT",
    "BIPOLAR AND RELATED DISORDERS",
    "MNEMONIC",
    "DIG FAST",
    "DIG FAST",
    "SIG E CAPS",
    "MANIA HYPOMANIA",
    "YIELD FACTS IN PSYCHIATRY",
    "DRUG CLASS INDICATIONS ADVERSE EFFECTS",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "SLEEP DISORDERS",
    "CHILDHOOD DISORDERS",
    "ANXIETY DISORDERS",
    "PSYCHOTIC DISORDERS",
    "MOOD DISORDERS",
    "FIGURE",
    "PERSONALITY DISORDERS",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DISORDER CHARACTERISTICS CLINICAL PRESENTATION\nCLUSTER A",
    "CLUSTER B",
    "CLUSTER C",
    "WORRIED AND WIMPY",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "DISORDER CHARACTERISTICS CLINICAL PRESENTATION",
    "IMMATURE",
    "MATURE",
    "YIELD FACTS IN PSYCHIATRY\nMNEMONIC",
    "SUBSTANCE USE DISORDERS",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "DRUG INTOXICATION WITHDRAWAL\nDEPRESSANTS",
    "STIMULANTS",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DRUG INTOXICATION WITHDRAWAL",
    "HALLUCINOGENS",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "ALCOHOL USE DISORDER",
    "PE\nMNEMONIC",
    "KEY FACT",
    "ALCOHOLIC HALLUCINOSIS DELIRIUM TREMENS",
    "FIGURE",
    "YIELD FACTS IN PSYCHIATRY\nTABLE",
    "DRUG WITHDRAWAL SYMPTOMS TREATMENT",
    "KEY FACT MANAGEMENT OF DRUG WITHDRAWAL",
    "EATING DISORDERS\nANOREXIA NERVOSA",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "CHARACTERISTIC ANOREXIA NERVOSA BULIMIA NERVOSA",
    "CONSTITUTIONAL CARDIAC GASTROINTESTINAL GENITOURINARY OTHER",
    "YIELD FACTS IN PSYCHIATRY\nBULIMIA NERVOSA",
    "SEXUAL DISORDERS\nSEXUAL CHANGES WITH AGING",
    "PARAPHILIC DISORDERS",
    "GENDER DYSPHORIA",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "SEXUAL DYSFUNCTION",
    "DISORDER CLINICAL MANIFESTATIONS",
    "YIELD FACTS IN PSYCHIATRY\nSLEEP DISORDERS",
    "PRIMARY INSOMNIA\nKEY FACT",
    "PRIMARY HYPERSOMNIA",
    "NARCOLEPSY",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "MNEMONIC",
    "SLEEP APNEA",
    "CIRCADIAN RHYTHM SLEEP DISORDER\nA",
    "YIELD FACTS IN PSYCHIATRY\nSOMATIC SYMPTOM AND RELATED DISORDERS\nSOMATIC SYMPTOM DISORDER",
    "ILLNESS ANXIETY DISORDER",
    "KEY FACT",
    "CONVERSION DISORDER",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "FACTITIOUS DISORDERS AND MALINGERING",
    "KEY FACT",
    "SEXUAL AND PHYSICAL ABUSE",
    "KEY FACT",
    "YIELD FACTS IN PSYCHIATRY\nSEXUAL ASSAULT",
    "MNEMONIC\nSUICIDALITY",
    "SAD PERSONS",
    "SAD PERSONS",
    "PPMM\n\nPSYCHIATRY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN PSYCHIATRY\nNOTES",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nPULMONARY",
    "YIELD FACTS IN PULMONARY\nKEY FACT\nOBSTRUCTIVE LUNG DISEASE\nFEV",
    "ASTHMA",
    "MNEMONIC",
    "PE\nABCO",
    "KEY FACT\nTABLE",
    "TEST NORMAL OBSTRUCTIVE RESTRICTIVE",
    "KEY FACT\nTLC",
    "IC VC TLC",
    "FRC\nKEY FACT\nRV",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "MNEMONIC",
    "ASTHMA",
    "OBSTRUCTIVE NORMAL RESTRICTIVE",
    "FIGURE",
    "PULMONARY HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN PULMONARY\nTABLE",
    "DRUG MECHANISM OF ACTION",
    "KEY FACT",
    "KEY FACT",
    "BRONCHIECTASIS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "PREFERRED",
    "LAMA\nICS",
    "FIGURE",
    "YIELD FACTS IN PULMONARY",
    "CHRONIC OBSTRUCTIVE PULMONARY DISEASE\nKEY FACT A",
    "KEY FACT",
    "KEY FACT",
    "COPD TYPE DEFINITION APPEARANCE ACID",
    "BASE STATUS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "A\nTREATMENT",
    "FIGURE",
    "KEY FACT",
    "MNEMONIC",
    "COPD\nRESTRICTIVE LUNG DISEASE",
    "YIELD FACTS IN PULMONARY",
    "SABA PRN SABA PRN SABA PRN",
    "ICS\nFIGURE",
    "MNEMONIC INTERSTITIAL LUNG DISEASE",
    "KEY FACT",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "IPF\nCRYPTOGENIC ORGANIZING PNEUMONIA",
    "FIGURE",
    "SYSTEMIC SARCOIDOSIS\nA",
    "YIELD FACTS IN PULMONARY",
    "FIGURE",
    "MNEMONIC",
    "GRUELING",
    "HYPERSENSITIVITY PNEUMONITIS",
    "KEY FACT",
    "PNEUMOCONIOSIS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "DISORDER HISTORY IMAGING",
    "COMPLICATIONS",
    "EOSINOPHILIC PULMONARY SYNDROMES\nA",
    "YIELD FACTS IN PULMONARY\nKEY FACT",
    "ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS\nABPA",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "ACUTE RESPIRATORY FAILURE\nHYPOXEMIA",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN PULMONARY\nTABLE",
    "OXYGENATION",
    "VENTILATION",
    "VT ACUTE RESPIRATORY DISTRESS SYNDROME",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "MECHANICAL VENTILATION",
    "KEY FACT",
    "PPMM\n\nTABLE",
    "AIRWAY PRESSURE",
    "TIME CURVE",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN PULMONARY",
    "DEFINITIONS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "CAUSES AND\nWAVE FORM P P PATHOPHYSIOLOGY MANAGEMENT\nPEAK PLAT",
    "CORONAVIRUSES AND COVID",
    "A\nCOVID",
    "YIELD FACTS IN PULMONARY",
    "PE\nTABLE",
    "ABG VENTILATOR",
    "ABNORMALITY ADJUSTMENT",
    "FIGURE",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "PULMONARY VASCULAR DISEASE\nPULMONARY HYPERTENSION",
    "COR PULMONALE",
    "PE KEY FACT",
    "YIELD FACTS IN PULMONARY\nTABLE",
    "VENOUS STASIS ENDOTHELIAL INJURY HYPERCOAGULABILITY",
    "MNEMONIC",
    "SHIT PMH\nPULMONARY THROMBOEMBOLISM",
    "MNEMONIC",
    "FIGURE",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "CRITERIA POINTS",
    "TRADITIONAL CLINICAL PROBABILITY ASSESSMENT",
    "SIMPLIFIED CLINICAL PROBABILITY ASSESSMENT",
    "KEY FACT",
    "YIELD FACTS IN PULMONARY",
    "KEY FACT\nFIGURE",
    "NEOPLASMS OF THE LUNGS\nSOLITARY PULMONARY NODULES",
    "PPMM\n\nTABLE",
    "VARIABLE LOW INTERMEDIATE HIGH",
    "MNEMONIC",
    "FIGURE",
    "MNEMONIC",
    "LUNG CANCER",
    "PULMONARY HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN PULMONARY\nTABLE",
    "TYPE LOCATION CHARACTERISTICS HISTOLOGY\nSMALL CELL",
    "SMALL CELL",
    "LESS LIKELY THAN SCLC TO METASTASIZE AT AN EARLY STAGE",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "A B C\nFIGURE",
    "FIGURE",
    "YIELD FACTS IN PULMONARY\nTABLE",
    "CLASSIFICATION SYNDROME HISTOLOGIC TYPE",
    "RESPIRATORY TRACT INFECTIONS",
    "PNEUMONIA",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "A B\nFIGURE",
    "CATEGORY ETIOLOGY",
    "MNEMONIC",
    "YIELD FACTS IN PULMONARY\nA TABLE",
    "CONDITIONS ETIOLOGY",
    "COPD H",
    "FIGURE",
    "KEY FACT",
    "INFLUENZA\nA",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "PATIENT TYPE SUSPECTED PATHOGENS EMPIRIC COVERAGE",
    "YIELD FACTS IN PULMONARY",
    "ASPERGILLOSIS\nA",
    "FIGURE",
    "HISTOPLASMOSIS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "HISTOPLASMOSIS COCCIDIOIDOMYCOSIS BLASTOMYCOSIS",
    "FIGURE",
    "YIELD FACTS IN PULMONARY\nKEY FACT",
    "COCCIDIOIDOMYCOSIS\nA",
    "PE\nFIGURE",
    "KEY FACT",
    "BLASTOMYCOSIS\nA",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "MYCOBACTERIAL INFECTIONS\nTUBERCULOSIS",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN PULMONARY\nA",
    "FIGURE",
    "MNEMONIC",
    "NONTUBERCULOUS MYCOBACTERIA",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "PNEUMOCYSTIS JIROVECII PNEUMONIA",
    "PE\nFIGURE",
    "B\nA\nFIGURE",
    "YIELD FACTS IN PULMONARY",
    "KEY FACT",
    "ANTHRAX",
    "FIGURE",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "ACUTE PHARYNGITIS",
    "KEY FACT",
    "FIGURE",
    "CRITERIA POINTS",
    "YIELD FACTS IN PULMONARY\nKEY FACT",
    "KEY FACT ORAL INFECTIONS",
    "LUDWIG ANGINA",
    "ACUTE LYMPHADENITIS",
    "SINUSITIS\nKEY FACT",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "HEMOPTYSIS",
    "YIELD FACTS IN PULMONARY",
    "FIGURE",
    "PLEURAL DISEASE\nPLEURAL EFFUSION",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "TRANSUDATES EXUDATES",
    "LUNG CONSOLIDATION",
    "LOBAR PNEUMONIA",
    "PLEURAL EFFUSION PNEUMOTHORAX",
    "YIELD FACTS IN PULMONARY\nE TA",
    "MEASURE VALUE",
    "KEY FACT",
    "PNEUMOTHORAX",
    "MNEMONIC",
    "THORAX",
    "KEY FACT",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "UNCOMPLICATED PARAPNEUMONIC EFFUSION COMPLICATED PARAPNEUMONIC EFFUSION EMPYEMA",
    "B\nPULMONARY SLEEP DISORDERS\nOBSTRUCTIVE SLEEP APNEA",
    "FIGURE",
    "YIELD FACTS IN PULMONARY\nKEY FACT",
    "OBESITY HYPOVENTILATION SYNDROME",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "NOSE AND THROAT\nRHINITIS",
    "YIELD FACTS IN PULMONARY",
    "NASAL POLYPS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "EPISTAXIS",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN PULMONARY\nADENOTONSILLAR HYPERTROPHY",
    "ACUTE AND CHRONIC LARYNGITIS",
    "PPMM\n\nPULMONARY HIGH",
    "YIELD FACTS IN",
    "LARYNGOPHARYNGEAL REFLUX",
    "BENIGN AND MALIGNANT LARYNGEAL LESIONS",
    "YIELD FACTS IN PULMONARY",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nRENAL",
    "GENITOURINARY",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nKEY FACT\nELECTROLYTE DISORDERS",
    "HYPERNATREMIA",
    "MNEMONIC",
    "HYPONATREMIA",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "HYPERKALEMIA",
    "FIGURE",
    "PE\nKEY FACT",
    "KEY FACT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "IV QRS",
    "P\nHYPOKALEMIA",
    "FIGURE",
    "II RTA",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "ICF ECF",
    "MNEMONIC\nK",
    "C BIG K",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nFIGURE",
    "HYPERCALCEMIA\nMNEMONIC",
    "CHIMPANZEES",
    "CHIMPANZEES",
    "KEY FACT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "HYPOCALCEMIA",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nKEY FACT",
    "KEY FACT",
    "KEY FACT",
    "HYPOMAGNESEMIA",
    "KEY FACT",
    "MNEMONIC",
    "MUDPILES",
    "BASE DISORDERS",
    "GOLDMARK",
    "FIGURE",
    "URINE ANION GAP",
    "GI HCO",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "HARDASS",
    "PRIMARY DISORDER EXPECTED COMPENSATION",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "UAG\nRENAL TUBULAR ACIDOSIS\nA",
    "KEY FACT",
    "ACUTE KIDNEY INJURY",
    "MNEMONIC",
    "CHRONIC KIDNEY DISEASE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "VARIABLE TYPE I",
    "DISTAL",
    "TYPE II",
    "PROXIMAL",
    "TYPE IV",
    "IMPAIRED MINERALOCORTICOID EFFECT",
    "PRERENAL INTRINSIC POSTRENAL",
    "LAB VALUES\nBUN",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "LAB VALUES",
    "A B C\nDIURETICS",
    "KEY FACT A",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "DIURETICS",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "TYPE DRUGS SITE OF ACTION MECHANISM OF ACTION ADVERSE EFFECTS",
    "KEY FACT",
    "GLOMERULAR DISEASE",
    "NEPHRITIC SYNDROME\nKEY FACT\nA",
    "FIGURE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "DISORDER DESCRIPTION HISTORY",
    "PE LABS",
    "HISTOLOGY TREATMENT",
    "PROGNOSIS\nIMMUNE COMPLEX",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "DISORDER DESCRIPTION HISTORY",
    "PE LABS",
    "HISTOLOGY TREATMENT",
    "PROGNOSIS",
    "IMMUNE",
    "NO IG DEPOSITS ON IMMUNOFLUORESCENCE",
    "GLOMERULAR BASEMENT MEMBRANE",
    "DISEASE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "DISORDER DESCRIPTION HISTORY",
    "PE LABS",
    "HISTOLOGY TREATMENT",
    "PROGNOSIS",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nA NEPHROTIC SYNDROME",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "DISORDER DESCRIPTION HISTORY",
    "PE LABS",
    "HISTOLOGY TREATMENT",
    "PROGNOSIS",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "DISORDER DESCRIPTION HISTORY",
    "PE LABS",
    "HISTOLOGY TREATMENT",
    "PROGNOSIS",
    "NEPHROLITHIASIS",
    "KEY FACT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "TYPE ETIOLOGY AND CHARACTERISTICS URINARY PH TREATMENT",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "TYPE ETIOLOGY AND CHARACTERISTICS URINARY PH TREATMENT",
    "FIGURE",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "POLYCYSTIC KIDNEY DISEASE B",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nA",
    "HYDRONEPHROSIS",
    "FIGURE",
    "KEY FACT",
    "SCROTAL PAIN AND SWELLING",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "KEY FACT",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "MNEMONIC URINARY INCONTINENCE",
    "DIAPPERS",
    "DIAPPERS",
    "TYPE HISTORY OF URINE LOSS MECHANISM TREATMENT",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "INTERSTITIAL CYSTITIS",
    "PAINFUL BLADDER SYNDROME",
    "ERECTILE DYSFUNCTION",
    "KEY FACT",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "KEY FACT",
    "BENIGN PROSTATIC HYPERPLASIA",
    "KEY FACT",
    "BPH PROSTATE CANCER",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "UROLOGIC CANCER\nKEY FACT",
    "PROSTATE CANCER",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "KEY FACT",
    "MNEMONIC",
    "I PEE RBCS",
    "BLADDER CANCER",
    "FIGURE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "RENAL CELL CARCINOMA",
    "KEY FACT",
    "KEY FACT",
    "FIGURE",
    "TESTICULAR CANCER A",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "TYPE TUMOR MARKER\nGERM CELL TUMORS",
    "OF ALL TESTICULAR TUMORS",
    "KEY FACT",
    "GERM CELL TUMORS",
    "OF ALL TESTICULAR TUMORS",
    "GENITOURINARY INFECTIONS\nURINARY TRACT INFECTIONS",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "TYPE CRITERIA TREATMENT",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "SPECIES FEATURES COMMENTS",
    "MNEMONIC",
    "SEEKS PP",
    "UNCOMPLICATED UTI",
    "LOWER UTI",
    "ACUTE SIMPLE CYSTITIS",
    "PYELONEPHRITIS",
    "UPPER UTI",
    "ONE FORM OF COMPLICATED UTI",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "KEY FACT",
    "PROSTATITIS",
    "ONE FORM OF COMPLICATED UTI",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "SEXUALLY TRANSMITTED DISEASES\nKEY FACT\nCHLAMYDIA",
    "KEY FACT",
    "FIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY",
    "GONORRHEA",
    "FIGURE",
    "KEY FACT",
    "FIGURE",
    "FIGURE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "SYPHILIS",
    "A B C D\nE F G H\nFIGURE",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nKEY FACT\nKEY FACT",
    "TEST COMMENTS",
    "FIGURE",
    "PPMM\n\nRENAL",
    "GENITOURINARY HIGH",
    "YIELD FACTS IN",
    "KEY FACT\nKEY FACT",
    "KEY FACT",
    "GENITAL LESIONS",
    "KEY FACT",
    "KLEBSIELLA",
    "HAEMOPHILUS HUMAN TREPONEMA PALLIDUM\nVARIABLE",
    "GRANULOMA INGUINALE",
    "DUCREYI",
    "CHANCROID",
    "OR HSV",
    "PAPILLOMAVIRUS",
    "SYPHILIS",
    "YIELD FACTS IN RENAL",
    "GENITOURINARY\nTABLE",
    "KLEBSIELLA",
    "HAEMOPHILUS HUMAN TREPONEMA PALLIDUM\nVARIABLE",
    "GRANULOMA INGUINALE",
    "DUCREYI",
    "CHANCROID",
    "OR HSV",
    "PAPILLOMAVIRUS",
    "SYPHILIS",
    "A B C D E",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nMULTISYSTEM",
    "YIELD FACTS IN MULTISYSTEM\nKEY FACT\nSHOCK",
    "CARDIAC\nTYPE MAJOR CAUSES OUTPUT PCWP PVR TREATMENT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "KEY FACT\nFEVER",
    "POSTOPERATIVE FEVER",
    "KEY FACT",
    "FEVER OF UNKNOWN ORIGIN",
    "KEY FACT",
    "FIGURE",
    "TIMING ETIOLOGY PREVENTION MNEMONIC",
    "YIELD FACTS IN MULTISYSTEM",
    "SEPSIS",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "HEMATOLOGIC INFECTIONS\nMALARIA\nA",
    "FIGURE",
    "YIELD FACTS IN MULTISYSTEM\nKEY FACT",
    "KEY FACT",
    "OTHER MOSQUITO",
    "BORNE VIRUSES",
    "BORNE INFECTIONS\nLYME DISEASE\nA",
    "KEY FACT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "BABESIOSIS",
    "ROCKY MOUNTAIN SPOTTED FEVER\nA",
    "YIELD FACTS IN MULTISYSTEM",
    "INFECTIOUS MONONUCLEOSIS",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "HUMAN IMMUNODEFICIENCY VIRUS\nA",
    "FIGURE",
    "YIELD FACTS IN MULTISYSTEM\nVIRAL ANATOMY AND PATHOPHYSIOLOGY",
    "TRANSMISSION\nHIV",
    "RISK WITH EACH EVENT\nMODE OF TRANSMISSION",
    "RISK WITH",
    "VIRAL LOAD",
    "DO NOT",
    "FIGURE",
    "HIV\nRNA",
    "MULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "HIV RNA\nHIV SEROLOGY MONITORS DISEASE PROGRESSION",
    "FIGURE",
    "YIELD FACTS IN MULTISYSTEM",
    "NAAT HIV",
    "NAAT\nNAAT",
    "FIGURE",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "OPPORTUNISTIC INFECTIONS IN HIV PATIENTS",
    "PATHOGEN PRESENTATION FINDINGS",
    "CELL COUNT",
    "CELL COUNT",
    "PPMM\n\nTABLE",
    "PATHOGEN PRESENTATION FINDINGS",
    "CELL COUNT",
    "FIGURE",
    "YIELD FACTS IN MULTISYSTEM",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "MANAGEMENT AND PREVENTION OF HIV\nART",
    "IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME",
    "PROPHYLAXIS FOR OPPORTUNISTIC INFECTIONS AND VACCINATIONS",
    "PPMM\n\nENTRY\nATTACHMENT",
    "REVERSE\nTRANSCRIPTASE\nPENETRATION",
    "INTEGRASE",
    "PROTEASE",
    "CLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS",
    "DNA ZDV",
    "YIELD FACTS IN MULTISYSTEM\nHIV ANTIVIRAL\nTHERAPY",
    "T CELL",
    "FIGURE",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "CLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS",
    "YIELD FACTS IN MULTISYSTEM",
    "FIGURE",
    "KEY FACT\nHIV",
    "KEY FACT",
    "KEY FACT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "CYTOMEGALOVIRUS",
    "CENTRAL LINE",
    "ASSOCIATED BLOODSTREAM INFECTIONS",
    "YIELD FACTS IN MULTISYSTEM",
    "THERMAL DYSREGULATION\nHYPOTHERMIA",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "KEY FACT",
    "HYPERTHERMIA",
    "KEY FACT",
    "ENVIRONMENT\nBURNS\nA",
    "YIELD FACTS IN MULTISYSTEM\nTABLE",
    "TYPE OF BURN COMPLICATIONS MANAGEMENT",
    "ECG\nSUPERFICIAL",
    "THICKNESS",
    "SUPERFICIAL\nPARTIAL",
    "THICKNESS",
    "DEEP PARTIAL\nTHICKNESS",
    "FULL THICKNESS",
    "FIGURE",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN MULTISYSTEM",
    "DROWNING",
    "ALTITUDE SICKNESS",
    "KEY FACT",
    "KEY FACT",
    "BITES AND STINGS",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "SOURCE POTENTIAL COMPLICATION MANAGEMENT",
    "YIELD FACTS IN MULTISYSTEM\nTABLE",
    "SOURCE POTENTIAL COMPLICATION MANAGEMENT",
    "TOXICOLOGY\nRESUSCITATION OF THE POISONED PATIENT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "YIELD TOXICITIES",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN MULTISYSTEM\nKEY FACT",
    "TOXIN ANTIDOTE",
    "TREATMENT NOTES",
    "CONTRAINDI",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "TOXIN ANTIDOTE",
    "TREATMENT NOTES",
    "YIELD FACTS IN MULTISYSTEM\nCOMMON DRUG INTERACTIONS AND REACTIONS",
    "INTERACTION",
    "REACTION DRUGS",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "MAJOR DRUG ADVERSE EFFECTS",
    "DRUG ADVERSE EFFECTS",
    "YIELD FACTS IN MULTISYSTEM\nTABLE",
    "DRUG ADVERSE EFFECTS",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "DRUG ADVERSE EFFECTS",
    "YIELD FACTS IN MULTISYSTEM\nVITAMIN DEFICIENCIES",
    "VITAMIN SIGNS",
    "SYMPTOMS OF DEFICIENCY",
    "COAT RACK",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "DISEASES ASSOCIATED WITH NEOPLASMS",
    "CONDITION NEOPLASM",
    "TRAUMA MANAGEMENT",
    "KEY FACT",
    "YIELD FACTS IN MULTISYSTEM\nTABLE",
    "EYE OPENING RESPONSE VERBAL RESPONSE MOTOR RESPONSE\nSCORE",
    "POINTS",
    "FOUR EYES",
    "POINTS",
    "JACKSON",
    "POINTS",
    "ENGINE",
    "PRIMARY SURVEY",
    "FIGURE",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "KEY FACT",
    "KEY FACT\nA",
    "PE\nPE\nSECONDARY SURVEY",
    "FIGURE",
    "YIELD FACTS IN MULTISYSTEM",
    "KEY FACT",
    "PENETRATING TRAUMA",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN MULTISYSTEM\nKEY FACT",
    "KEY FACT",
    "ABDOMEN",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "EXTREMITIES",
    "BLUNT AND DECELERATION TRAUMA\nHEAD AND FACE",
    "YIELD FACTS IN MULTISYSTEM\nA",
    "FIGURE",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN MULTISYSTEM\nCHEST",
    "FIGURE",
    "KEY FACT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "FIGURE",
    "FIGURE",
    "BLUNT CARDIAC INJURY A",
    "YIELD FACTS IN MULTISYSTEM",
    "FIGURE",
    "ABDOMEN",
    "KEY FACT",
    "KEY FACT\nTABLE",
    "ORGAN NOTES",
    "KEY FACT",
    "PPMM\n\nMULTISYSTEM HIGH",
    "YIELD FACTS IN",
    "ABDOMEN FIGURE",
    "PELVIS\nKEY FACT",
    "FIGURE",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "KEY FACT",
    "YIELD FACTS IN MULTISYSTEM",
    "PPMM\n\nH I G H",
    "Y I E L D F A C T S I N\nRAPID REVIEW",
    "YIELD FACTS IN RAPID REVIEW\nCARDIOVASCULAR",
    "EF ACE",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "BP\nECG",
    "MI CHF",
    "YIELD FACTS IN RAPID REVIEW",
    "DERMATOLOGY",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "ENDOCRINOLOGY",
    "YIELD FACTS IN RAPID REVIEW",
    "DI DDAVP",
    "EPIDEMIOLOGY",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN RAPID REVIEW\nHEALTH SYSTEMS SCIENCE",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "SPIKES",
    "GASTROINTESTINAL",
    "YIELD FACTS IN RAPID REVIEW",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN RAPID REVIEW\nHEMATOLOGY",
    "IRON LAST",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "AML\nAML",
    "MUSCULOSKELETAL",
    "YIELD FACTS IN RAPID REVIEW\nX",
    "NEUROLOGY",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "YIELD FACTS IN RAPID REVIEW",
    "MS\nOBSTETRICS",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "GYNECOLOGY",
    "PEDIATRICS",
    "YIELD FACTS IN RAPID REVIEW",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "PSYCHIATRY",
    "YIELD FACTS IN RAPID REVIEW",
    "PULMONARY",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "SIADH SCLC",
    "YIELD FACTS IN RAPID REVIEW",
    "NSAIDS",
    "NSAIDS",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "GENITOURINARY",
    "C BIG K",
    "RTA\nRTA",
    "RTA\nAKI",
    "YIELD FACTS IN RAPID REVIEW",
    "MULTISYSTEM",
    "PPMM\n\nRAPID REVIEW HIGH",
    "YIELD FACTS IN",
    "SLE INH",
    "YIELD FACTS IN RAPID REVIEW",
    "PPMM\n\nS E C T I O N",
    "RATED REVIEW\nRESOURCES",
    "SECTION",
    "RATED REVIEW RESOURCES\nS E C T I O N",
    "HOW TO USE THE DATABASE\nTOP",
    "RATED REVIEW RESOURCES",
    "PPMM\n\nTOP",
    "RATED REVIEW RESOURCES SECTION",
    "DISCLAIMER",
    "CONFLICT",
    "INTEREST STATEMENT",
    "SECTION",
    "RATED REVIEW RESOURCES\nTOP",
    "RATED REVIEW RESOURCES",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "AMBOSS",
    "AMBOSS",
    "B USMLE",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "A A MBOSS",
    "AMBOSS",
    "A USMLE",
    "PPMM\n\nTOP",
    "RATED REVIEW RESOURCES SECTION",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "GYN\nAUTHOR PUBLISHER TYPE PRICE\nA",
    "SECTION",
    "RATED REVIEW RESOURCES",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "AUTHOR PUBLISHER TYPE PRICE\nA",
    "PPMM\n\nTOP",
    "RATED REVIEW RESOURCES SECTION",
    "COMMERCIAL REVIEW COURSES",
    "SECTION",
    "RATED REVIEW RESOURCES\nNOTES",
    "PPMM\n\nA P P E N D I X I\nABBREVIATIONS AND SYMBOLS\nABBREVIATION MEANING ABBREVIATION MEANING\nAA",
    "APPENDIX I ABBREVIATIONS AND SYMBOLS\nS E C T I O N",
    "ABBREVIATION MEANING ABBREVIATION MEANING\nAVNRT",
    "ABBREVIATIONS AND SYMBOLS",
    "PPMM\n\nABBREVIATIONS AND SYMBOLS APPENDIX I",
    "ABBREVIATION MEANING ABBREVIATION MEANING\nDHEAS",
    "APPENDIX I ABBREVIATIONS AND SYMBOLS\nABBREVIATION MEANING ABBREVIATION MEANING",
    "PPMM\n\nABBREVIATIONS AND SYMBOLS APPENDIX I",
    "ABBREVIATION MEANING ABBREVIATION MEANING\nJVD",
    "NAPLLR",
    "APPENDIX I ABBREVIATIONS AND SYMBOLS\nABBREVIATION MEANING ABBREVIATION MEANING\nNIF",
    "NMDA N",
    "A PPROM",
    "PPMM\n\nABBREVIATIONS AND SYMBOLS APPENDIX I",
    "ABBREVIATION MEANING ABBREVIATION MEANING\nPS",
    "ADH\nRAI",
    "STE ST",
    "RNA SVC",
    "APPENDIX I ABBREVIATIONS AND SYMBOLS\nABBREVIATION MEANING ABBREVIATION MEANING\nTDF",
    "USPSTF",
    "VACTERL",
    "PPMM\n\nA P P E N D I X I I\nCOMMON LABORATORY VALUES",
    "APPENDIX II COMMON LABORATORY VALUES",
    "ADAMTS",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "INDEX\nCVS",
    "PPMM\n\nINDEX",
    "DOPAMINE RASH",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "NSTEMI",
    "PPMM\n\nINDEX",
    "PEARLS",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "SAD PERSONS",
    "SPIKES",
    "PPMM\n\nINDEX",
    "PPMM\n\nINDEX",
    "NSTEMI",
    "TRAPSS",
    "VACTERL",
    "PPMM\n\nINDEX",
    "ABOUT THE AUTHORS"
  ],
  "mnemonics": [
    {
      "acronym": "CONDITIONS",
      "explanation": "WHAT WILL THE CBT BE LIKE?",
      "length": 10
    },
    {
      "acronym": "ERP",
      "explanation": "Effective refractory period. (Repro-",
      "length": 3
    },
    {
      "acronym": "ECG",
      "explanation": "Diagnosis confirmed on ECG (Fig. 2.1-10).",
      "length": 3
    },
    {
      "acronym": "ECG",
      "explanation": "May show MI, heart block, arrhythmia, or other diagnostic",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "May show cardiomegaly, cephalization of pulmonary vessels,",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "This is to primarily help rule out other causes of chest pain, like aor-",
      "length": 3
    },
    {
      "acronym": "STEMI",
      "explanation": "ECGâ€”ST elevation; cardiac",
      "length": 5
    },
    {
      "acronym": "ECG",
      "explanation": "Best initial diagnostic test. Best initial diagnostic test. Serial ECGs",
      "length": 3
    },
    {
      "acronym": "ECG",
      "explanation": "ST-segment elevations, hyperacute (tall) T waves, or new LBBB",
      "length": 3
    },
    {
      "acronym": "NSTEMI",
      "explanation": "No ST elevation; cardiac",
      "length": 6
    },
    {
      "acronym": "STEMI",
      "explanation": "ST elevation; cardiac",
      "length": 5
    },
    {
      "acronym": "HTN",
      "explanation": "Once primary HTN is diagnosed, the next best step is to",
      "length": 3
    },
    {
      "acronym": "HTN",
      "explanation": "If suspected, order appropriate tests (see sec-",
      "length": 3
    },
    {
      "acronym": "CNS",
      "explanation": "Encephalopathy (confusion), stroke, retinal hemorrhage (blurry vision), â†‘ intracerebral",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Cardiomegaly may indicate a pericardial effusion.",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Cardiomegaly may indicate a pericardial effusion. exertion).",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "May show calcifications around the cardiac silhouette.",
      "length": 3
    },
    {
      "acronym": "NBTE",
      "explanation": "Clostridium septicum â†’ colonoscopy (Streptococci) Pseudomonas Cancer/illnesses â†’ Marantic NBTE",
      "length": 4
    },
    {
      "acronym": "HACEK",
      "explanation": "Haemophilus species (subsequently called Aggregatibacter",
      "length": 5
    },
    {
      "acronym": "DVT",
      "explanation": "DVT thought to be develops into sometimes severe symptoms that impair quality of life. Thought",
      "length": 3
    },
    {
      "acronym": "DVT",
      "explanation": "No known DVT, and residual thrombus within the first 6 months after thrombotic",
      "length": 3
    },
    {
      "acronym": "TEN",
      "explanation": "Biopsy shows full-thickness eosinophilic epidermal necrosis.",
      "length": 3
    },
    {
      "acronym": "SSSS",
      "explanation": "Systemic dissemination of exfoliative toxin destroys",
      "length": 4
    },
    {
      "acronym": "SSSS",
      "explanation": "Nafcillin, vancomycin, and wound care.",
      "length": 4
    },
    {
      "acronym": "SIADH",
      "explanation": "ADH antagonists (eg, tolvaptan, conivaptan)",
      "length": 5
    },
    {
      "acronym": "PPV",
      "explanation": "The probability that a patient with a âŠ• test result truly has the dis-",
      "length": 3
    },
    {
      "acronym": "NPV",
      "explanation": "The probability that a patient with a âŠ– test result truly does not",
      "length": 3
    },
    {
      "acronym": "SCC",
      "explanation": "Nonhomogeneous lesions, large",
      "length": 3
    },
    {
      "acronym": "SCC",
      "explanation": "Alcohol use, tobacco use, and nitrosamines in the upper and middle thirds of the",
      "length": 3
    },
    {
      "acronym": "SBO",
      "explanation": "Continued passage of flatus, but no stool",
      "length": 3
    },
    {
      "acronym": "SBO",
      "explanation": "No passage of flatus or stool (obstipation)",
      "length": 3
    },
    {
      "acronym": "SBO",
      "explanation": "Most commonly from adhesions years after abdominal surgery,",
      "length": 3
    },
    {
      "acronym": "PCS",
      "explanation": "IBS, pancreatitis, pancreatic tumors, pan-",
      "length": 3
    },
    {
      "acronym": "PCS",
      "explanation": "Intercostal neuritis, wound neuroma, cor-",
      "length": 3
    },
    {
      "acronym": "AST",
      "explanation": "ALT ratio, APRI, FIB-4,",
      "length": 3
    },
    {
      "acronym": "APS",
      "explanation": "Most commonly in young and middle-aged females with recurrent mis- to the hospital for anticoagulation",
      "length": 3
    },
    {
      "acronym": "APS",
      "explanation": "Lupus anticoagulant and anticardiolipin",
      "length": 3
    },
    {
      "acronym": "TTP",
      "explanation": "Associated with SLE, malignancy, pregnancy, cyclosporine, quinidine,",
      "length": 3
    },
    {
      "acronym": "TTP",
      "explanation": "Plasma exchange is the best initial treatment. Steroids and rituximab",
      "length": 3
    },
    {
      "acronym": "HUS",
      "explanation": "Can present similarly to TTP with the absence of neurologic features.",
      "length": 3
    },
    {
      "acronym": "HUS",
      "explanation": "Dialysis for AKI may be needed. Plasma exchange is used for",
      "length": 3
    },
    {
      "acronym": "PCV",
      "explanation": "Best initial test is a CBC showing elevated RBCs/WBCs/platelets (â†‘",
      "length": 3
    },
    {
      "acronym": "PCV",
      "explanation": "Target is hematocrit <45%. Phlebotomy and aspirin provide symp- increased EPO with low O 2 levels.",
      "length": 3
    },
    {
      "acronym": "ABPA",
      "explanation": "Serum IgE against A fumigatus or elevated total serum IgE pressure (BP) and Hb. The following",
      "length": 4
    },
    {
      "acronym": "EGPA",
      "explanation": "Eosinophilia (â‰¥1500 cells/microL), asthma, rhinosinusitis, and room, where he begins to complain of",
      "length": 4
    },
    {
      "acronym": "CEP",
      "explanation": "Bronchoalveolar lavage showing eosinophilia with CT chest imag- the most likely diagnosis?",
      "length": 3
    },
    {
      "acronym": "ABPA",
      "explanation": "Steroids are the mainstay of treatment. Antifungal therapy with",
      "length": 4
    },
    {
      "acronym": "EGPA",
      "explanation": "Steroids are the mainstay of treatment. During remission, steroid-",
      "length": 4
    },
    {
      "acronym": "CEP",
      "explanation": "Steroids are the mainstay of treatment.",
      "length": 3
    },
    {
      "acronym": "ALL",
      "explanation": "Age <1 year or >10 years; an â†‘ in WBC count to >50,000/mm3;",
      "length": 3
    },
    {
      "acronym": "AML",
      "explanation": "Age >60 years; elevated LDH; poor-risk or complex karyotype",
      "length": 3
    },
    {
      "acronym": "CNS",
      "explanation": "Can manifest as cognitive dysfunction and ataxia.",
      "length": 3
    },
    {
      "acronym": "III",
      "explanation": "Fracture extends through both the physis and epiphysis.",
      "length": 3
    },
    {
      "acronym": "SLE",
      "explanation": "It is associated with âŠ• anti-Ro antibodies transmitted",
      "length": 3
    },
    {
      "acronym": "AVN",
      "explanation": "Wrist splints after fall; surgical referral for displaced frac-",
      "length": 3
    },
    {
      "acronym": "AVN",
      "explanation": "Total hip replacement",
      "length": 3
    },
    {
      "acronym": "EEG",
      "explanation": "Evaluate for seizure activity.",
      "length": 3
    },
    {
      "acronym": "AMD",
      "explanation": "No treatment is currently available, although a combina-",
      "length": 3
    },
    {
      "acronym": "AMD",
      "explanation": "Intravitreal injections of VEGF inhibitors have been",
      "length": 3
    },
    {
      "acronym": "MLF",
      "explanation": "Pair of tracts that interconnect CN VI and CN III nuclei to left",
      "length": 3
    },
    {
      "acronym": "MLF",
      "explanation": "Internuclear ophthalmoplegia (INO), a conjugate hori-",
      "length": 3
    },
    {
      "acronym": "MSAFP",
      "explanation": "Produced by the fetus and enters the maternal circulation.",
      "length": 5
    },
    {
      "acronym": "SAB",
      "explanation": "Two or more consecutive SABs or three SABs in 1 year;",
      "length": 3
    },
    {
      "acronym": "GTD",
      "explanation": "Molar pregnancy may progress to malignant GTD,",
      "length": 3
    },
    {
      "acronym": "AFI",
      "explanation": "Sum of the measurements of the deepest cord-free amniotic fluid",
      "length": 3
    },
    {
      "acronym": "ROM",
      "explanation": "Occurs after or at the onset of labor.",
      "length": 3
    },
    {
      "acronym": "ROM",
      "explanation": "ROM occurring >18 hours before delivery. Risk fac-",
      "length": 3
    },
    {
      "acronym": "CYCLE",
      "explanation": "FOLLICULAR PHASE LUTEAL PHASE",
      "length": 5
    },
    {
      "acronym": "CYCLE",
      "explanation": "Menses Proliferative Secretory Menses",
      "length": 5
    },
    {
      "acronym": "CAH",
      "explanation": "Can present as virilization with amenorrhea or oligomenorrhea; The first step in the workup of",
      "length": 3
    },
    {
      "acronym": "FSH",
      "explanation": "Primary ovarian insufficiency. Obtain karyotype for Turner",
      "length": 3
    },
    {
      "acronym": "FSH",
      "explanation": "Central hypogonadism, constitutional growth delay.",
      "length": 3
    },
    {
      "acronym": "IUD",
      "explanation": "Copper particles disrupt sperm The most effective emergency contraceptive High initial cost of insertion",
      "length": 3
    },
    {
      "acronym": "PID",
      "explanation": "Nucleic acid amplification testing (NAAT) or",
      "length": 3
    },
    {
      "acronym": "FNA",
      "explanation": "A good initial biopsy, especially for lesions close to the skin; how-",
      "length": 3
    },
    {
      "acronym": "MRI",
      "explanation": "Can delineate intramural, subserosal, and submucous myomas. The",
      "length": 3
    },
    {
      "acronym": "CBC",
      "explanation": "To assess for anemia.",
      "length": 3
    },
    {
      "acronym": "IIA",
      "explanation": "May be treated either with radical hysterec-",
      "length": 3
    },
    {
      "acronym": "VIN",
      "explanation": "Topical chemotherapy, laser ablation, wide local exci-",
      "length": 3
    },
    {
      "acronym": "CHD",
      "explanation": "VSD, PDA, ASD Death usually occurs",
      "length": 3
    },
    {
      "acronym": "CNS",
      "explanation": "Holoprosencephaly with incomplete within 1 year of birth",
      "length": 3
    },
    {
      "acronym": "WIPE",
      "explanation": "Wiskott-Aldrich, Infections, Purpura",
      "length": 4
    },
    {
      "acronym": "CBC",
      "explanation": "Thrombocytopenia is present. â†‘ eosinophil count may be found",
      "length": 3
    },
    {
      "acronym": "VOC",
      "explanation": "Dactylitis (occurs <3 years of age), mesenteric ischemia",
      "length": 3
    },
    {
      "acronym": "III",
      "explanation": "Epiphysis and physis (Lower)",
      "length": 3
    },
    {
      "acronym": "SIDS",
      "explanation": "Sudden infant death syndrome.",
      "length": 4
    },
    {
      "acronym": "BRUE",
      "explanation": "Brief resolved unexplained",
      "length": 4
    },
    {
      "acronym": "ODD",
      "explanation": "A pattern of negative, defiant, disobedient, and hostile behavior",
      "length": 3
    },
    {
      "acronym": "DMDD",
      "explanation": "A pattern of severe, recurrent verbal (eg, screaming) or behav-",
      "length": 4
    },
    {
      "acronym": "PTSD",
      "explanation": "CBT + SSRIs or SNRIs MNEMONIC",
      "length": 4
    },
    {
      "acronym": "ECT",
      "explanation": "A small electrical current is used to induce a generalized seizure",
      "length": 3
    },
    {
      "acronym": "OSA",
      "explanation": "Nasal continuous positive airway pressure (CPAP). Weight loss if",
      "length": 3
    },
    {
      "acronym": "CSA",
      "explanation": "Mechanical ventilation (eg, bilevel positive airway pressure [BiPAP])",
      "length": 3
    },
    {
      "acronym": "HIV",
      "explanation": "Antiretroviral drug offered within 72 hours of assault; options are",
      "length": 3
    },
    {
      "acronym": "ICS",
      "explanation": "Maintenance and reliever therapy (MART) with both short-acting and long-acting effects",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Shows â†‘ bronchovascular markings and tram lines (parallel lines and thick-walled airways (arrows) con-",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Hyperinflated lungs, â†“ lung markings with flat diaphragms, and a COPD exacerbation, antibiotics may",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Shows pulmonary infiltrates",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "To evaluate for an infiltrative process (eg, pneumonia), atelectasis, a inspired oxygen, the A-a gradient will",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Bilateral alveolar opacities consistent with pulmonary edema. Pul-",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "Shows enlargement of central pulmonary arteries with rapid taper-",
      "length": 3
    },
    {
      "acronym": "ECG",
      "explanation": "Demonstrates right ventricular hypertrophy (RVH)",
      "length": 3
    },
    {
      "acronym": "CXR",
      "explanation": "May appear normal or show atelectasis, pleural effusion, Hampton",
      "length": 3
    },
    {
      "acronym": "ECG",
      "explanation": "Most commonly reveals sinus tachycardia. The classic triad of",
      "length": 3
    },
    {
      "acronym": "SDB",
      "explanation": "History of excessive daytime somnolence, failure to thrive, enuresis,",
      "length": 3
    },
    {
      "acronym": "SDB",
      "explanation": "Best diagnostic test: Polysomnography.",
      "length": 3
    },
    {
      "acronym": "INH",
      "explanation": "GI lavage, charcoal (isoniazid",
      "length": 3
    },
    {
      "acronym": "COLA",
      "explanation": "Cystine, Orni- Alkanize urine",
      "length": 4
    },
    {
      "acronym": "ARPKD",
      "explanation": "Hypertension, abdominal distention, and flank masses are the hemorrhage from a ruptured berry",
      "length": 5
    },
    {
      "acronym": "NSGCT",
      "explanation": "Retroperitoneal lymph node dissection for low-stage disease",
      "length": 5
    },
    {
      "acronym": "PROSTATITIS",
      "explanation": "ONE FORM OF COMPLICATED UTI",
      "length": 11
    },
    {
      "acronym": "HIV",
      "explanation": "Initial infection is asymptomatic in 10% to 60% of cases. If",
      "length": 3
    },
    {
      "acronym": "HIV",
      "explanation": "Can be asymptomatic for a period of 8 to",
      "length": 3
    },
    {
      "acronym": "AIDS",
      "explanation": "The average time, in the absence of treatment, from exposure â†’",
      "length": 4
    },
    {
      "acronym": "HIV",
      "explanation": "A combination test (may not be âŠ• until âˆ¼2 weeks",
      "length": 3
    },
    {
      "acronym": "HIV",
      "explanation": "Maternal HIV antibodies (Abs) â†’ newborn (cannot",
      "length": 3
    },
    {
      "acronym": "AIDS",
      "explanation": "HIV and one or more of the following:",
      "length": 4
    },
    {
      "acronym": "HIV",
      "explanation": "Prenatal testing for HIV is standard and uses",
      "length": 3
    },
    {
      "acronym": "DVT",
      "explanation": "In up to 50% of patients with lower extremity amputation",
      "length": 3
    },
    {
      "acronym": "WIPE",
      "explanation": "Wiskott-Aldrich, Infections,",
      "length": 4
    }
  ],
  "clinical_pearls": [
    "always due to intrinsic Atropine as clinically\ndisease indicated\n(continues)\n22002222__0022.",
    "always be considered).",
    "always caused\nby exfoliative toxin-producing strains of S aureus and can evolve into SSSS.",
    "always prompt a check of TSH.",
    "always imply clinical signifi-\ncance (usually noted with meta-analysis where the sample size is large\nenough to identify a small but clinically insignificant difference in out-\ncome).",
    "always assumes that\nthere is no association between the\nexposure and outcome variables.",
    "Always start with open-ended ques-\ntions or requests and use nonverbal cues (eg, patient gestures) to obtain\nmore information.",
    "always ask first\nwhat the patient thinks about their illness and what their understanding of\ntheir current state of health is.",
    "always be empathetic to their responses and listen to them without\ninterrupting.",
    "always take into consideration the following\npoints:\nâ–  Avoid making assumptions about a patientâ€™s sexual orientation, gender\nidentity, gender expression, or sexual behavior without first asking the\npatient about these.",
    "Always reassure the patient that whatever they share is confidential and\neven if they are not open about their sexual orientation or gender identity,\nthis information will not be revealed to anyone else without the patientâ€™s\nprior permission or request.",
    "Always KEY FACT\nnote the following points when interviewing patients:\nWhen treatment can save a childâ€™s\nâ–  Try to think about the illness from the patientâ€™s perspective.",
    "always use a professionally trained medical interpreter for com-\nmunication unless the clinician is conversationally fluent in the patientâ€™s pre-\nferred language.",
    "always inappropri-\nate, independent of who initiates contact.",
    "always require a psychiatric\nconsultation.",
    "Always give information bit by bit, and make sure that you consider the\npatientâ€™s current emotional state prior to giving information.",
    "Always be gentle and caring.",
    "always consider a gynecologic etiology in females\nand nonsurgical causes of acute abdomen (see Table 2.",
    "always an Indication\npected infectious processes (cholecystitis, diverticulitis, pyelonephritis).",
    "always be assumed to have a subdural or epidural subdural hematoma, such changes can\nhematoma and are in need of urgent neuroimaging.",
    "always clues\nto the diagnosis and differentiation among similarly appearing clinical\nsymptoms.",
    "always beats in one direc-\ntion, towards the opposite side of the lesion\nâ–  No vertical eye misalignment by alternate cover testing\nâ–  If patients are â€œhigh riskâ€ (ie, atypical eye findings or neurologic symptoms\nor signs; cannot stand independently; have a new-onset headache, head, or\nneck pain; are >50 years of age; or have one or more stroke risk factors),\nMRI with diffusion-weighted imaging and MRA are indicated.",
    "always prompt\n+ sulfadiazine and leucovorin (a folic acid analog to prevent hematologic\nconsideration of toxoplasmosis and\ntoxicity) for 4 to 8 weeks; maintenance with a low-dose regimen until the\nCNS lymphoma.",
    "always progresses to respira-\nneuron signs) but without bladder\ntory failure and death, usually within 5 years of diagnosis.",
    "Always give thiamine\nfibers), hyperemesis, before glucose\nstarvation, renal dialysis,\nAIDS.",
    "always warranted\nMNEMONIC\nNORMAL LABOR AND DELIVERY\nWhen performing a BPPâ€”\nTest the Baby, MAN!\nDEFINITION AND STAGES OF LABOR\nFetal Tone\nFetal Breathing\nLabor is the process whereby contractions of the uterus are accompanied by\nFetal Movement\nprogressive effacement (thinning) and dilation of the cervix, resulting in deliv-\nAmniotic fluid volume\nery of the fetus and placenta through the birth canal (Table 2.",
    "always distinguish\n(â€œraspberryâ€) or dark brown (â€œpowder- between leiomyoma and\nburnedâ€) appearance adenomyosis\nThe ovaries may have endometriomas Ultimately, adenomyosis is a\n(â€œchocolate cystsâ€) pathologic diagnosis\nTreatment Pharmacologic: Inhibition of ovulation; Pharmacologic: Largely\ncombination hormonal contraception symptomatic relief; NSAIDs\n(first-line), GnRH analogues (leuprolide), (first-line) plus combined\ndanazol, NSAIDs, or progestins hormonal contraception or\nConservative surgical treatment: Excision, progestins\ncauterization, or ablation of the lesions Conservative surgical treat-\nand lysis of adhesions ment: Endometrial ablation;\nDefinitive surgical treatment: Hysterec- however, complete eradica-\ntomy/bilateral salpingo-oophorectomy tion of deep adenomyosis is\n(TAH/BSO) Â± lysis of adhesions difficult and usually results\nin treatment failure\nDefinitive surgical treatment: A 28-year-old woman presents for\nHysterectomy is the only a wellness exam.",
    "always remembered.",
    "Always pathologic.",
    "always pathologic.",
    "always necessary,\nAspergillus Staphylococci\nbut enuresis alarms are generally\nconsidered the first-line option in\nViruses\nprimary enuresis.",
    "always seen\non blood smear, regardless of whether the patient is having a sickle cell crisis.",
    "always care for her, and now these\ndecisions are overwhelming.",
    "always a reliable\ndesired effects\nsign of opioid ingestion, because\n11.",
    "always inquire about smoking and exposure history, which\nare associated with â†‘ cancer risk.",
    "always seen on x-ray)\nHexagonal crystals\nFrequency: 1%\nImage A reproduced with permission from Nair S, George J, Kumar S, Gracious N.",
    "always occurs with central IV cathetersâ€”peripheral venous/arterial catheters\nare rarely implicated.",
    "always take precedence in the resuscita-\ntion of the potentially poisoned patient.",
    "Always administer NAC in acute overdose >7.",
    "Always supplement B when administering INH\n6\nVitamin B (biotin) Dermatitis, enteritis\n7\nCan be caused by ingestion of raw eggs or antibiotic use\nVitamin B (folic acid) Glossitis, megaloblastic anemia without neurologic symptoms\n9\nMore common than B deficiency because B stores in liver can last 3â€“5 years\n12 12\nVitamin B (cobalamin) Megaloblastic anemia; glossitis; neurologic symptoms (eg, optic neuropathy, subacute combined degeneration,\n12\nparesthesias)\nVitamin C Scurvy: Swollen gums, bruising, anemia, poor wound healing; immunosuppression\nVitamin D Rickets in children (bending bones), osteomalacia in adults (soft bones), hypocalcemic tetany\nAll breastfed babies should receive supplemental vitamin D\nVitamin E â†‘ fragility of RBCs â†’ hemolytic anemia, degeneration of posterior column\nMay look like B deficiency with anemia and neurologic symptoms, but anemia is hemolytic rather than\n12\nmegaloblastic\nVitamin K â†‘ prothrombin time and activated partial thromboplastin time, normal bleeding time; neonatal hemorrhage\nGive all babies IM vitamin K (suspect neonatal hemorrhage in babies born at home)\nSelenium Cardiomyopathy (Keshan disease), impaired phagocytic function in macrophages\nZinc Dysgeusia (impaired taste), impaired wound healing, alopecia, hypogonadism, acrodermatitis enteropathica,\nanosmia (impaired smell)\n22002222__0022.",
    "always rule\nPENETRATING TRAUMA\nout urethral injury before placing a\nurinary catheter.",
    "Always rule out injuries to other pelvic structures.",
    "Always deliver bad news face-to-face\nFollow the SPIKES framework (ensure appropriate Setting, assess\npatientâ€™s Perception, Invite questions and assess how much infor-\nmation they know and would like, impart Knowledge, acknowledge\nEmotions, Strategize next step when ready)\nPatientâ€™s family asks you not to provide information about a serious Do not deliver the diagnosis initially\ndiagnosis to patient.",
    "always be done before LP? Check for â†‘ ICP; look for papilledema\nCSF findings:\nâ–  Low glucose, PMN predominance Bacterial meningitis\nâ–  Normal glucose, lymphocytic predominance Aseptic (viral) meningitis\nâ–  Numerous RBCs in serial CSF samples SAH\nâ–  Gamma globulins MS\nOBSTETRICS\nScreening time for GBS.",
    "Always read something that will make you look good if you die in the\nmiddle of it.",
    "Always finding the long shortcut, Vikas is\nMedsn, and served as its chief medical officer.",
    "never pos-\nsible.",
    "Never diagnose HTN on one reading unless severe HTN\nor end-organ damage is present.",
    "never be given first, as unopposed Î±-adrenergicâ€“mediated vasocon-\nIn pheochromocytoma, administration\nstriction can lead to severe hypertension.",
    "Never event Errors that should never happen Major error that should never occur (eg, wrong foot amputated).",
    "never use the term\nwithdrawal of care because healthcare staff do not stop caring for a patient.",
    "never delivering news so that all these concerns, and more, can\nbe addressed directly.",
    "never accept cash.",
    "never possible, avoiding\nhepatitis, even if recognized in less than\nhepatotoxic medications, and addressing complications that can occur\n26 weeks, are considered to have acute-\nâ–  Complications: Hemodynamic derangement, bleeding, malnutrition,\non-chronic severe alcoholic hepatitis\nelectrolyte derangements (hypokalemia, hyponatremia, hypophosphate-\nas opposed to acute liver failure, since\nmia, and hypoglycemia), hepatic encephalopathy, cerebral edema with\nthere is usually a long history of alcohol\nassociated increased intracranial pressure elevation, seizures, acute renal\nuse disorder.",
    "never childbearing is\ncompleted.",
    "Never Yes Yes\nYears since smoking cessation >15 5â€“15 <5\nNodule characteristics Smooth Scalloped Corona radiata or\nspiculated\nCalcification Central, uniform, â€“ Absent or irregular\nor popcorn calcification\ncalcification\nDetermine risk for malignancy\nBenign Low to\nHigh\nfeatures intermediate\nSurgical\nSerial CT scans\nresection\nDetermine\nnodule size\n5-7 mm\nMalignancy risk PET or biopsy\nMNEMONIC\nSquamous and Small cell cancers are\nSentral lesions\nNo further SSuurrggiiccaall\nSerial CT scans\nevaluation rreesseeccttiioonn\nFIGURE 2.",
    "Never immunized - vaccine + rabies Ig\nFIGURE 2.",
    "never used because of the risk for â†‘ damage\ncaused by emesis and the lack of demonstrated benefit.",
    "Never use flumazenil in the setting of chronic benzodiazepine use, even\nsary), flumazenil if patient is acutely intoxicated; it can produce deadly withdrawal\nseizures\nCopper, arsenic, lead, Penicillamine Penicillamine is a chelating agent that sequesters heavy metals\ngold\nCyanide Hydroxocobalamin, amyl nitrate, Nitrites induce methemoglobinemia, which binds cyanate\nsodium nitrite, sodium thiosulfate\nDigitalis Digoxin immune Fab (fragment antigen Do not treat hyperkalemia or hypocalcemia before giving antidote\nbinding antibodies in symptom- because these conditions often correct themselves once the\natic patients; arrhythmia, altered Na+/K+ pump is working\nmental status, acute kidney injury,\nhyperkalemia)\nHeparin Protamine sulfate Protamine-heparin antibodies may induce a clinical syndrome similar to\nHITT\nIron Deferoxamine Look for radiopaque tablets on x-ray in a child with hematemesis and\nmetabolic acidosis\nLead Succimer, ethylenediaminetetraacetic Sources of lead include old paint, soil, toys, jewelry, and drinking water\nacid, dimercaprol\nMethanol Fomepizole is the treatment of choice; Poisoning from methanol and ethylene glycol results from the active\nEthylene glycol ethanol can be used if fomepizole is metabolites, which are produced by a reaction mediated by alcohol\n(antifreeze) contraindicated or unavailable dehydrogenase; fomepizole and ethanol inhibit the reaction that forms\nthe toxic metabolite\nOpioids Naloxone It is common to empirically treat patients found unconscious with naloxone\nSalicylates Urine alkalinization, dialysis, activated Symptoms of poisoning include nausea, vomiting, and tinnitus\ncharcoal\nTricyclic Sodium bicarbonate, diazepam, or Monitor closely and only give sodium bicarbonate if QRS >100 msec or\nantidepressants lorazepam for seizures/agitation ventricular arrhythmia is present\nTissue plasmin- Aminocaproic acid Overdose may result in hemorrhage and/or angioedema\nogen activator,\nstreptokinase\nWarfarin Fresh frozen plasma (immediate Warfarin overdose may occur if a patient is concomitantly taking CYP450\nreversal in hemorrhaging patient), inhibitors\nvitamin K (long-term reversal)\n22002222__0022.",
    "never to be done.",
    "never cause hypovolemic shock because herniation and and shift of the mediastinal structures\ndeath will occur before enough volume is lost to cause shock.",
    "Never event, 184t\ntrigeminal neuralgia, 364 preseptal (periorbital) cellulitis, 413 Never-competent person, informed consent,\nidiopathic intracranial hypertension, 380t, refractive errors, 416 188\n410â€“412, 411f relative afferent pupillary defect, 422 Nevus(i)\nintracranial neoplasms, 403, 404tâ€“406t retinal detachment, 420, 421, 421f congenital melanocytic, 583t\nmovement disorders, 396â€“402 retinal vascular occlusion, 419, 420t multiple dysplastic, neoplasms, 751t\namyotrophic lateral sclerosis, 359t, 398, retinitis pigmentosa, 421â€“422, 422f New York Heart Association (NYHA) classifica-\n399â€“400 uveitis, 416, 416f tion, congestive heart failure, 35, 35t\nHuntington disease, 396â€“397, 396f visual field defects, 412, 412f News, setting for delivering, 192â€“193\nParkinson disease and parkinsonism, otology, 423â€“426 NF (neurofibromatosis), 406â€“407, 406f\n397â€“399, 399f conductive hearing loss, 425f, 426 neoplasms, 751t\nrestless legs syndrome, 400â€“401 malignant otitis externa, 424 NHL (non-Hodgkin lymphoma), 304â€“306, 304t,\ntremors, 401, 401f, 402t otitis externa, 424 305t\nWilson disease (hepatolenticular degen- otitis media, 423â€“424 Niacin, 57t\neration), 401â€“402 sensorineural hearing loss, 425, 425f adverse effects, 748t\nneurocognitive disorders (dementia), pediatric, 557â€“563 Niacin deficiency, 750t\n388â€“395, 389t benign familial microcephaly and macro- Nicotine abuse, 612t\nAlzheimer disease, 390â€“392, 390t cephaly, 563 Niemann-Pick disease, 518t\nCreutzfeldt-Jakob disease, 390t, 394â€“395 breath-holding spells, 562 â€œNightstick fracture,â€ 315t\nfrontotemporal (Pick disease), 390t, cerebral palsy, 557â€“558 Nikolsky sign, 97t, 104\n393 Chiari malformations, 563, 563f Nipple injury, 466\nLewy body, 391t, 395 cranial neoplasms, 560, 560tâ€“561t Nit(s), 111\nmajor, 389t febrile seizures, 558â€“559 Nitrates\nmild, 389t infantile hypotonia, 559, 559t chronic stable angina, 49\nvs.",
    "never miss a sunset with his two sons and prioritizes time with his family.",
    "most common format is\nthe single one-best-answer question.",
    "most common congenital cause of\nLQTS with autosomal dominant inheritance.",
    "Most common cause of tachyarrhythmias.",
    "most common sustained cardiac arrhythmia.",
    "Most common indica-\nmias and bradyarrhythmias or bradycardia; AF and tion for pacemaker\nthromboembolism may placement\noccur â†’ syncope, palpi- Anticoagulate in AF/\ntations, dyspnea, chest flutter to prevent sys-\npain, transient ischemic temic emboli\nattack (TIA), and/or stroke\n(Images adapted with permission from USMLE-Rx.",
    "most common arrhythmia associated with WPW syndrome (see lightheadedness\nlater)\nWolff-Parkinson-White syndrome ECG findings: Early upslope\nof QRS complex (delta wave,\nB\nred arrow in Image A) seen\ndue to early activation of\nventricles through acces-\nsory pathway.",
    "most common cause of right-sided\nheart failure is left-sided heart failure.",
    "most common cause of dilated car- gallop sounds similar to the word\ndiomyopathy (DCM) phenotype is myocardial ischemia; however, this is clas- â€œKEN-tuc-ky.",
    "most common cause\nNote: Other causes of LVH include HTN (most common cause), aortic\nof sudden death in young, healthy\nstenosis, and systemic diseases (glycogen/lysosomal storage diseases, Fabry,\nathletes in the United States.",
    "Most common presentation: Syncope or SCD in a young, healthy\nathlete.",
    "most common cause of SCD in young people (after HOCM).",
    "Most common presentation: Palpitations due to ventricular arrhythmias.",
    "most common is AV block) or SCD associated with Management of cardiovascular\nthat is initially restrictive and known extracardiac sarcoidosis (eg, cough, dyspnea, bilateral hilar risks.",
    "most common associated symptom),\nIt is important to check for aortic\nshortness of breath, lightheadedness, anxiety, nausea/vomiting, epigastric\ndissection clinically prior to\npain (more common in women), and syncope.",
    "most common complications and the\nmost common causes of sudden death after acute MI.",
    "most common disease in the United States and the key risk factor\nin MI and stroke.",
    "most common cause in young women; exogenous glucocorticoids, stimulants (cocaine),\ndecongestants (contain sympathomimetic agents), TCAs/SNRIs (block norepinephrine reuptake), nicotine,\ncaffeine, NSAIDs (â†“ renal prostaglandin synthesis â†’ â†“ GFR â†’ â†‘ Na+/HO retention)\n2\nEndocrine causes Hyperaldosteronism (eg, Connâ€™s syndrome), hypercortisolism (eg, Cushing disease), pheochromocytoma (eg,\nMEN 2A/B), congenital adrenal hyperplasia, thyroid (hyperthyroidism and hypothyroidism), hyperparathy-\nroidism, acromegaly (â†‘ growth hormone/IGF-1)\nRenal causes Renal artery stenosis = most common (atherosclerosis > fibromuscular dysplasia) overall cause; chronic\nkidney disease also very common cause; glomerular diseases (eg, glomerulonephritis, diabetic nephrop-\nathy); polycystic kidney disease\n22002222__0022.",
    "most common infection, likely etiology Coxsackie B virus,\nRV Staphylococcus, Streptococcus, tuberculosis [TB])\nâ–  Connective tissue disorder (ie, systemic lupus erythematosus [SLE], rheu-\nmatoid arthritis, Goodpasture syndrome)\nLV\nâ–  Post-MI (either within days after MI or as a delayed phenomenon, ie,\nDressler syndrome)\nâ–  Uremia\nâ–  Neoplasms\nâ–  Drugs\nFIGURE 2.",
    "most common infection, likely etiology Coxsackie B virus,\nStaphylococcus, Streptococcus, tuberculosis [TB])\nâ–  Connective tissue disorder (ie, systemic lupus erythematosus [SLE], rheu-\nmatoid arthritis, Goodpasture syndrome) â–  Blood tests: Full blood count (FBC), ESR, urea and electrolytes (U&Es), KEY FACT\nâ–  Post-MI (either within days after MI or as a delayed phenomenon, ie, cardiac enzymes (troponin may be raised), viral serology, and if indicated, ST-segment elevations in pericarditis\nDressler syndrome) autoantibodies, fungal precipitins, and thyroid function tests (TFTs).",
    "Most common cause of acute IE in all patients (fatal\nwithout treatment in 6 weeks).",
    "Most common cause of subacute endocarditis.",
    "Most common causes of fungal endo-\ncarditis typically in immunocompromised patients (HIV/AIDS, trans-\nplant), IV drug use (IVDUs), long-term IV catheter use.",
    "Most common manifestation of chronic Q fever\n(Coxiella burnetii).",
    "Most common Asymptomatic: Years despite severe stenosis Severity categorized based on\nDystrophic calcification of a Symptomatic: Angina, Syncope, CHF (ASC), pressure gradient across aortic\ntricuspid valve in order of worsening prognosis without valve or valve area into mild\nElderly >60 years of age treatment (15â€“25 mm Hg, >1.",
    "most common sites of origin are above the aortic valve and distal\nAortic aneurysm is most often to the left subclavian artery.",
    "most common and involves the ascending aorta, dissections are still emergencies but\nirrespective of the site of the tear.",
    "most common etiology\nor bradycardia or both.",
    "most common etiology\nâ–  Ischemia: Cardiac stress tests to look for ischemia\nof syncope.",
    "most common in young children and in\nAIDS patients.",
    "Most common in young men with excessive body hair.",
    "most common skin cancer, with locally destructive effects as well\nas the potential for metastasis and death.",
    "most common malignant skin cancer, BCC is slow growing and locally\ndestructive but has virtually no metastatic potential.",
    "most common life-threatening dermatologic disease.",
    "most common HIV-associated\nmalignancy.",
    "most common benign vascular tumor, and it often appears with\nage.",
    "most common cause of\ncomplications death in diabetic patients.",
    "Most common cause of hyperthyroidism.",
    "Most common side effect is subsequent hypothyroidism (most\nthyroid ablation common when treating patients with Graves disease).",
    "Most common etiology is thyroid dysgenesis.",
    "most common cause\nof pathologic fractures in women with Diagnosis\nlow body weight and men >60 years\nâ–  Diagnostic test: Dual-energy x-ray absorptiometry (DEXA) scan is the rec-\nof age.",
    "most common endogenous cause is hypersecretion of ACTH\nfrom a pituitary adenoma (known as Cushing disease; see Fig.",
    "most common oral cancer (up to 90% of all oral\nneoplasms).",
    "most common locations are the lateral and ventrolateral parts of the tongue,\nalthough other areas may also be affected.",
    "Most common cause: viral par- Viral prodrome of fever, Real-time reverse Observation and supportive care\notitis due to mumps virus; malaise, headache transcriptaseâ€“ (hydration, pain control)\nsuppurative\nother viral causes include cox- Acute, multifocal parotid polymerase chain Prevention: vaccination (measles,\nsialadenitis\nsackie and cytomegalovirus gland swelling and pain reaction (RT-PCR) mumps, and rubella [MMR])\n(CMV) (ie, initially unilateral, pro- of samples (serum,\nMost common in children <15 gressing to bilateral) buccal, or oral\nyears of age May be associ- swabs)\nHighly contagious by airborne ated with aseptic Viral culture\ndroplets meningitis, encephalitis, Serology (positive IgM)\nor pancreatitis\nSialolithiasis Caused by stone in salivary duct Acute, unifocal salivary Ultrasound Initial: sialagogues (eg, sour candy),\nMost often affects sub- gland swelling and pain Noncontrast CT warm compress, hydration,\nmandibular gland (up to 90%), that are intermittent and massage of gland, and NSAIDS\nfollowed by parotid occur after meals (post- Antibiotics for infection\nMost common cause of acute, prandial pain) If conservative treatment is inef-\nunifocal salivary gland swelling fective, minimally invasive (eg,\nRisk factors: smoking, hypovo- sialoendoscopy) or surgical (eg,\nlemia, anticholinergics sialoadenectomy) treatment\nmay be indicated\nPrevention: risk factor modification\n(ie, stop smoking and using an-\nticholinergics; avoid dehydration)\nRanula Pseudocysts of the major salivary Translucent blue swelling in Diagnosis based on Generally, resolve spontaneously\nglands (sublingual or subman- floor of mouth lateral to clinical appearance Persistent, recurrent, or symptom-\ndibular ducts) midline Imaging (ultrasound atic lesions may be treated by\nMay be congenital or acquired sonography [USG], surgical excision, marsupializa-\n(due to oral trauma) CT, MRI) can help tion, or other techniques (eg,\nto assess cause laser ablation, cryotherapy,\nMucocele Pseudocysts of minor salivary Smooth swellings in the and extent and electrocautery)\nglands buccal mucosa on oc- determine surgical Aspiration is not effective due to\nclusive plane; not blue in approach high recurrence rates\nappearance\n22002222__0022.",
    "Most common salivary gland Chronic, unifocal, painless, Ultrasonography, Surgical excisionâ€”mainstay of\nnomas (benign) tumor in adults slow-growing mass or CT, MRI, and treatment no matter if benign\nMajority in parotid gland, fol- swelling in malignant and sometimes or malignant\nlowed by submandibular benign disease PET-CT Postoperative radiation therapy in\nMay undergo malignant trans- Signs of malignancy: pain, Fine-needle aspi- select cases\nformation and recurrence facial paresis, fixed mass, and ration biopsy Cervical lymph node dissection\nAssociated with ionizing cervical lymphadenopathy or ultrasound- may be required in malignant\nradiation exposure, viral guided core disease or with presence of other\ninfection, smoking, and needle biopsy high-risk features (eg, high-grade\nexposure to chemicals (eg, can confirm tumors, facial nerve weakness)\nrubber manufacturers, diagnosis Important risks of surgery: facial\ncosmetics) nerve dysfunction and Frey syn-\ndrome (sweating when chewing)\nMucoepidermoid Most common malignant Painless, slow-growing mass Based on Surgical excision recommended\ncarcinoma salivary gland neoplasm that is firm or hard histologic for localized resectable disease\n(malignant) Commonly in parotid examination Postoperative or palliative radio-\nLow-grade with good prog- therapy may be used\nnosis if treated early\nAdenoid cystic Second most common Most commonly arises in the Based on Standard therapy includes surgical\ncarcinoma (ACC; malignant salivary gland salivary glands or other areas histologic removal of the malignancy and\nmalignant) neoplasm within the head and neck examination affected tissue followed by radia-\nMost common in sub- region; symptoms of ACC tion; if initial surgery is not an\nmandibular gland of the salivary glands may option due to the specific loca-\nInvades facial nerve early, thus include numbness of the tion and/or progression of the\nfacial weakness or paralysis lower lip and/or other facial malignancy, therapy may include\nLocal recurrence after excision areas, nerve impairment radiation alone\ncausing weakness of certain\nfacial muscles, ongoing pain,\nand/or other associated\nabnormalities\nSalivary gland swelling\nAcute Chronic/progressive\nUnifocal Multifocal Unifocal Multifocal\nBacterial sialadenitis Mumps Benign tumors Autoimmune\nSialolithiasis Drug side effects Malignant tumors Granulomatous\nInflammatory HIV-associated\nJuvenile recurrent parotitis Metabolic sialosis\nFIGURE 2.",
    "most common type of esophageal cancer worldwide.",
    "most common type of esophageal cancer in the United States,\nEurope, and Australia.",
    "most common reason for increased portal pressure is hepatic cirrhosis\nFIGURE 2.",
    "most common mechanisms are malabsorption/osmotic, secretory,\nassociated with chronic diarrhea in\ninflammatory/infectious, and â†‘ motility (see Tables 2.",
    "most common Frequently presents with Rule out appendicitis and Supportive treatment first,\njejuni etiology of bacterial bloody diarrhea IBD then fluoroquinolones\ndiarrhea (eg, ciprofloxacin) or\nCaused by ingestion of azithromycin\ncontaminated food or\nwater\nAffects young children\nand young adults; gen-\nerally lasts 7â€“10 days\nClostridioides Associated with recent Presents with fever, abdominal Most commonly causes Cessation of the inciting\ndifficile treatment with pain, and possible systemic colitis, but can involve antibiotic\nantibiotics (penicil- toxicity the small bowel Nonsevere: PO fidaxomicin\nlins, quinolones, Identify C difficile toxin in or vancomycin\nclindamycin) the stool Severe (first episode):\nAffects hospitalized adult Sigmoidoscopy shows PO fidaxomicin > PO\npatients vancomycin\npseudomembranes\nImportant to watch for Recurrent (first episode): PO\ntoxic megacolon (on fidaxomicin is preferred\nx-ray of the abdomen) over PO vancomycin\nRecurrent (second or sub-\nsequent recurrence):\nPO fidaxomicin > PO\nvancomycin\nFulminant without ileus: PO\nvancomycin + parenteral\nmetronidazole\nFulminant with ileus: PO or\nrectal vancomycin + par-\nenteral metronidazole\nEchinococcus Contracted from close â€œEggshell calcificationâ€ on CT scan Cyst aspiration may cause Surgical resection and\ngranulosus contact with dogs, Usually found incidentally, but cyst rupture and anaphy- albendazole\ndefinitive host for may cause mild right upper lactic shock\ntapeworm quadrant (RUQ) pain caused\nCauses simple liver cysts by compression of other\nstructures\n(continues)\n22002222__0022.",
    "most common manifestations.",
    "Most common in male\nsmokers >65 years of age.",
    "most common cause\niary colic is most common in multiparous, overweight women (female, of small bowel obstruction in patients\nforty, fertile, and fat).",
    "most common causes are as follows:\nâ–  Embolism: Most commonly originates in the heart.",
    "most common cause of\nacute lower GI bleeding in patients >40 years of age.",
    "most common GI conditions seen in primary care and GI clinics,\nwith a prevalence of 4% to 10%.",
    "most common GI conditions seen in primary care and GI clinics,\nâ–  Psychosocial: Patients benefit from a strong patient-physician relationship.",
    "Most common in Caucasians and those of\nAshkenazi Jewish decent, with onset most frequently occurring in the teens to\nC\n50s.",
    "Most common causes are viruses (hepatitis A virus [HAV], hepatitis Hepatitis C virus (HCV) is Chronic; 70%\nB virus [HBV], hepatitis C virus [HCV], hepatitis D virus [HDV], hepati-\nto 80% of patients with HCV infection\ntis E virus [HEV]) and drugs (alcohol, acetaminophen, isoniazid [INH],\nwill develop chronic hepatitis.",
    "most common causes are chronic viral infection (HCV MNEMONIC\nmost common in United States, HBV worldwide), alcohol, autoimmune\nHepatitis virusâ€”\nhepatitis, and metabolic syndromes (Wilson disease, hemochromatosis,\nÎ± -antitrypsin deficiency).",
    "Most common cause of acute viral hepatitis worldwide\nMay lead to fulminant hepatic failure\nHBV Bodily fluids/ May be asymptomatic, but may present as viral pro- <10% of infections in adults become chronic, while\nblood- drome (this is listed above) and/or jaundice most vertically transmitted become chronic\nborne May lead to fulminant hepatic failure and require Extremely high transmission rate\ntreatment with antivirals or liver transplant in severe\ncases\nHCV Bodily fluids Asymptomatic or viral prodrome and/or jaundice 80% become chronic\nLess likely to be sexually transmitted than HBV\nMay present with very mild acute phase\nVery rarely leads to acute liver failure\nIf palpable purpura, arthralgia, and low complement\nlevels, cryoglobulinemia a possibility\nHDV Bodily fluids Co-infection with HBV or superinfection in patient with Requires HBV surface antigen.",
    "Most common etiologies in the United States are alcohol, chronic HCV,\ncirrhosis and ascites, and if they present\nand nonalcoholic steatohepatitis.",
    "Most common cause is Escherichia coli.",
    "most common of which are due to\ndrug-induced and viral hepatitis\nâ–  Hx/PE: Fatigue/malaise, lethargy, anorexia, nausea/vomiting, RUQ pain,\npruritis, jaundice, abdominal distention (secondary to ascites), and hepatic\nencephalopathy\nâ–  Dx: Must have elevated transaminases, hepatic encephalopathy (any\ngrade), and prolonged PT (INR â‰¥1.",
    "most common cancers worldwide\ndespite its relatively low incidence in the United States.",
    "most common benign liver lesion.",
    "Most common benign liver lesion\nâ–  Hx/PE: Typically asymptomatic and discovered incidentally on contrast-\nenhanced imaging.",
    "most common visceral abscess.",
    "most common cause of acute pancreatitis in children), drug side CF, smoking, pancreatic divisum, family\neffects (thiazide diuretics), viral infections, post-ERCP, scorpion sting history autoimmune (IgG4) pancreatitis\nHistory/PE Severe epigastric pain (radiating to the back); nausea, vomiting, weakness, Recurrent episodes of persistent epigastric\nfever, shock, pleural effusions, acute respiratory distress syndrome (ARDS) pain; anorexia, nausea, constipation, flatu-\nFlank bruising (Grey Turner sign) and periumbilical discoloration (Cullen lence, steatorrhea, weight loss, DM\nsign) may be evident on exam\nDiagnosis â†‘ lipase (more sensitive and specific than amylase), â†‘ amylase, â†“ calcium if â†‘ to normal amylase and lipase, â†“ stool elastase,\nsevere; â€œsentinel loopâ€ or â€œcolon cutoff signâ€ on x-ray of the abdomen pancreatic calcifications (arrows in Image B),\nUltrasound of the abdomen or CT may show an enlarged pancreas with and alternating stenosis and dilation (arrow-\nperipancreatic fluid and fat stranding (arrows in Image A), abscess, head in Image B) of the main pancreatic duct\nhemorrhage, necrosis, or pseudocyst on CT or ultrasound (â€œchain of lakesâ€)\nTreatment Removal of the offending agent if possible Analgesia, pancreatic enzyme replacement,\nSupportive care, including IV fluids/electrolyte replacement, analgesia, avoidance of causative agents (EtOH), celiac\nbowel rest, NG suction, nutritional support, and O nerve block; endoscopic dilation of pan-\n2\nInfected pancreatic necrosis should be treated with antibiotics, though creatic duct; surgery for intractable pain or\nprophylactic antibiotics are not recommended structural causes\nEndoscopic, percutaneous, or surgical debridement may be considered\nPrognosis Roughly 85%â€“90% are mild and self-limited; 10%â€“15% are severe, Patients can have chronic pain and pancreatic\nrequiring ICU admission dysfunction\nMortality may approach 50% in severe cases\nComplications Pancreatic pseudocyst, fistula formation, hypocalcemia, renal failure, Chronic pain, opiate addiction, diabetes mel-\npleural effusion, chronic pancreatitis, sepsis, and ARDS litus, malnutrition/weight loss, splenic vein\nMortality secondary to acute pancreatitis can be predicted with Ranson thrombosis, pancreatic cancer\ncriteria\nA B\nP\nP, Pancreas.",
    "most common in\nâ–  Hemophilia presents in a young male (think child that is beginning to people with Ashkenazi Jewish heritage,\nwalk; 1â€“2 years of age) with spontaneous bleeding into the tissues, mus- and it is often autosomal recessive.",
    "most common inherited bleeding disor-\nder (1% of the population).",
    "most common form of vWD is type 1 vWD (Mild to moderate quan-\nmanifestations of platelet dysfunction\ntitative deficiency in vWF).",
    "most common cause of inherited thrombophilia.",
    "most common immunologic disorder in females of childbearing age.",
    "most common cause\nâ–  It is important to rule out pseudothrombocytopenia due to platelet\nof acute renal failure in children.",
    "most common among people of African, Middle Eastern, and\nAsian descent.",
    "most common cause)\nNitrofurantoin\nDapsone\nCD55 (complement decay-accelerating factor) and CD59 (membrane inhibi-\nIsoniazid\ntor of reactive lysis) proteins normally found on the RBC surfaces protect\nAntimalarials (quinines)\nthem from complement-mediated hemolysis.",
    "Most common porphyria\nExacerbated by alcohol consumption\nCauses are familial and seen in hepatitis C\nTreated with phlebotomy, sun avoidance, and antimalarials\n(hydroxychloroquine)\nTreatment\nAddressing underlying cause.",
    "most common cause in the developed world is allergy, whereas in eosinophiliaâ€”\nthe developing world, it is parasitic infection.",
    "most common hemato-\npoietic neoplasm and is five times more common than HL.",
    "Most common NHL in adults\nand elderly Often presents with single rapidly growing mass\nHigh cure rate with R-CHOP therapy (rituximab, cyclophosphamide,\ndoxorubicin, vincristine, and prednisone)\nBurkitt lymphoma Children and t(8;14)â€”translocation of High grade, â€œstarry skyâ€ appearance on lesion biopsy\nadolescents c-myc (8) and heavy- Jaw lesion in Africa, abdominal lesion in Americas\nchain Ig (14) Associated with EBV and t(8;14) translocation\nAggressive treatment with chemotherapy\nMantle cell Older adult t(11;14)â€”translocation CD5+\nlymphoma Males of cyclin D1 (11) and Rarest form of NHL\nheavy-chain Ig (14),\nCD5+\nPrimary CNS Adults EBV related; associated An AIDS-defining illness\nlymphoma with HIV/AIDS Variable presentation: confusion, memory loss, seizures\nCNS mass (often single, ring-enhancing lesion on MRI) in immunocom-\npromised patients\nDistinguished from toxoplasmosis via CSF analysis or other lab tests\nT-CELL NEOPLASMS\nAdult T-cell Adults Caused by HTLV (associ- High grade, can progress to ALL\nlymphoma ated with IV drug use) Presents with cutaneous lesions\nCaused by HTLV, associated with IVDA\nMycosis fun- Adults Mycosis fungoides is a T-cell lymphoma of the skin\ngoides/SÃ©zary Cutaneous eczema-like lesions and pruritus are common presentations\nsyndrome On skin biopsy see lymphoid cells with â€œcerebriformâ€ nuclei\nCan progress to SÃ©zary syndrome (T-cell leukemia) with characteristic\nSÃ©zary cells seen on blood smear\nAdapted with permission from Le T et al.",
    "most common forms of systemic amyloidosis, primary\n(AL) and secondary (AA), the major sites of clinically important amyloid\ndeposition are in the kidneys, heart, and liver.",
    "Most common (95%); risk for axillary Reduction followed by a sling and swath.",
    "most common primary malig-\nnancy of bone in children and adolescents (Table 2.",
    "most common benign bone tumor\nperiosteal new bone at the diaphyseal end of the lesion) or a â€œsunburstâ€\nis an osteochondroma.",
    "Most common organisms: Staphylococcus, Streptococcus, and gram âŠ–\nrods (see Table 2.",
    "most common in adults, whereas infection caused by hematoge-\nanaerobes.",
    "Most common of the systemic vasculitides.",
    "Most common in females 30 to 50 years of age; associated with\ndepression, anxiety, sleep disorders, irritable bowel syndrome (IBS), and\ncognitive disorders (â€œfibro fogâ€).",
    "most common joints\ninvolved include the knee, elbow, and ankle (often with a history of ankle\ninversion).",
    "most common site) and L4â€“L5 (second most common site).",
    "most common types of\nbrain herniation include:\nâ–  Cingulate (subfalcine) herniation under the falx cerebri, which can com-\npress the anterior cerebral artery.",
    "most common sites of aneurysm are in the anterior circulation.",
    "most common sites (âˆ¼85% of all intracranial aneurysms) are the junc-\ntion of the anterior communicating artery with the anterior cerebral artery\n(35%), junction of the posterior communicating artery with the internal\ncarotid artery (30%), and bifurcation of the middle cerebral artery (22%).",
    "most common cause of intracerebral hemorrhage, followed by\namyloid angiopathy (in older adults).",
    "most common presenting symptom.",
    "Most common Central pontinemyelinolysis Diffuse cortical injury or Diffuse hypoxic encephalopathy, Same as coma\ncauses (after rapid sodium cor- hypoxic ischemic injury widespread infection, electro-\nrection), brainstem stroke, lyte disturbances, toxins\nadvanced ALS\nVoluntary motor Eyes and eyelids None None None\nability\nRespiratory drive Yes Yes Yes None\nKEY FACT â–  Rule out catatonia, conversion unresponsiveness, â€œlocked-inâ€ syndrome,\nor persistent vegetative state (PVS), all of which can be confused with true\nArtificial life support can be\ncoma (see Table 2.",
    "most common causes of encephalitis.",
    "most common pathogens are Streptococci, Staphylococci, and anaerobes; 80% fever, and a focal neurologic deficit\nto 90% are polymicrobial.",
    "most common initially: ptosis, diplopia), facial weak-\nness, bulbar symptoms (chewing fatigue, dysphagia, dysarthria), and\nupper/lower extremity muscle weakness notably worse at the end of the\nday and with sustained activity.",
    "most common type is called acute inflammatory demyelinating\nAlbuminocytologic dissociation (increased\npolyneuropathy.",
    "most common cause of dementia (66%).",
    "most common type of dementia.",
    "most common prion disease, Creutzfeldt-Jakob disease\nCJDâ€™s rapid progression and presence (CJD) remains an extremely rare form of dementia.",
    "most common cause of dementia (10%â€“20%\nof cases) and classically presents in patients age >65 and classically presents\nin patients age >65 with associated depression and suicidality.",
    "most common hypo-\nkinetic movement disorder and is characterized by a unilateral hand tremor\n(â€œpill rollingâ€), oscillating rigidity (cogwheel), akinesia/bradykinesia (shuffling\ngait), and postural instability (frequent falls).",
    "most common primary CNS\nâ–  Metastatic tumors are most often from primary lung, breast, kidney, and\ntumors in adults are glioblastoma\nGI tract neoplasms and melanoma.",
    "most common primary CNS tumors in\ninvasiveness, necrosis, and neovascularization.",
    "most common MNEMONIC\npresenting features.",
    "Most common cancers that\nâ–  Although headaches are often thought of as the main presenting symptom,\nmetastasize to the brainâ€”\nonly 31% of patients present with headache at diagnosis, and only 8% have\nLung and Skin Go to the BRain\nheadache as the sole presenting feature.",
    "most common malignant results\n(GFAP) âŠ• staining (Image A).",
    "most common neurocutaneous disorder.",
    "most common etiologic agents.",
    "most common pathogens involved in congenital infections can be\nremembered through use of the ToRCHHeS mnemonic (see Table 2.",
    "Most common signs preceding an eclamptic Immediate delivery\nattack: Headache, visual changes, and RUQ/\nepigastric pain\nSeizures severe if not controlled with anticonvul-\nsant therapy\nâ–  Far from term (<34 weeks): Provide expectant management with close\nsurveillance; hospital admission for uncontrolled severe-range blood\npressures.",
    "Most common causes: Placental abruption and placenta previa (see\nTable 2.",
    "most common in monochori-\nonic twins), cord entanglement (commonly in monoamniotic twins),\nFGR, preterm labor, and â†‘ incidence of congenital malformations.",
    "most common form and involve presentation of\nthe fetal lower extremities or buttocks into the maternal pelvis (see\nFig.",
    "Most common cause of postpartum the lower genital tract for any centa and uterine cavity for missing\nhemorrhage laceration >2 cm long cotyledons\nUS to look for retained intrauterine tissue\nTreatmenta Bimanual uterine massage (usually Surgical correction of the phys- Manual removal of remaining placental\nsuccessful) ical defect tissue\nOxytocin infusion Curettage with suctioning (carries risk for\nMethylergonovine if not hypertensive uterine perforation or scarring [Ash-\nPGFÎ± erman syndrome])\n2\naFor all uterine causes, when bleeding persists after conventional therapy, uterine/internal iliac artery ligation, uterine artery embolization, or\nhysterectomy can be lifesaving.",
    "Most common presenting symptom: Failure to lactate (caused by â†“ prolac-\ntin levels)\nâ–  Other symptoms: Hypotension, weakness, lethargy, cold intolerance, geni-\ntal atrophy, and menstrual disorders\nDiagnosis\nâ–  Best initial test: Adrenocorticotropic hormone (ACTH) stimulation test\nâ–  Most accurate test: MRI of the pituitary gland and hypothalamus to rule\nout tumor or other pathology\nTreatment\nReplacement of all deficient hormones.",
    "Most common cause (âˆ¼50%).",
    "most common cause Abnormal uterine bleeding,\nthat lasts a couple of hours.",
    "most common cause of adrenal\nhyperplasia.",
    "most common causes are\nbacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis (see\nTable 2.",
    "Most common times for torsion in pregnancy: 18 weeksâ€™ gestation, when\nthe uterus is rising over the pelvic brim or immediately postpartum with\nuterine involution.",
    "Most common cause of vaginal discharge in pediatric\npatients\nâ–  Infectious vulvovaginitis: May present with a malodorous, yellow-green,\npurulent discharge.",
    "most common infectious cause\nâ–  Candida: Recent antibiotic therapy, immunosuppression (eg, diabe-\ntes); rare in children KEY FACT\nâ–  STIs: Typically from sexual abuse Pediatric vaginal discharge may be\nâ–  Noninfectious vulvovaginitis: Potential causes include poor hygiene, con- normal, but STDs resulting from sexual\ntact dermatitis, and eczema\nabuse must be ruled out and, if found,\nâ–  Sarcoma botryoides (rhabdomyosarcoma): A malignancy with lesions reported to Child Protective Services.",
    "most common cancer (affects one in eight women) and the second most\nBreast\ncommon cause of cancer death in females (after lung cancer) in the United\nLung\nStates.",
    "most common benign neoplams of the female genital tract.",
    "most common cause of ovarian enlargement (see\nTable 2.",
    "most common female reproductive cancer in the\nUnited States.",
    "Most common malignant stromal tumor.",
    "most common severe genetic disease in the United States and is most\nfrequently found in Northern European ancestry.",
    "Most common cardiac malformation: of intellectual\nRobertsonian palmar crease, general Complete AV canal defect (both sys- disabilities\ntranslocation hypotonia, and extra neck tolic ejection murmur and holosystolic Associated with\n(4%), or mosa- folds (nuchal folds are murmur present) (60%); ASDs, VSDs, advanced maternal\nicism (1%) sometimes seen on prenatal PDA, and complex CHD make up the age\nultrasound) remainder\nGI anomalies (duodenal atresia or stenosis,\nimperforate anus, and esophageal atresia)\nOphthalmologic disorders (refractive errors,\nstrabismus, nystagmus, cataracts, and\nkeratoconus)\nEndocrine disorders (type 1 DM,\nhypothyroidism)\nRisk for ALL, hypothyroidism, and early-\nonset Alzheimer disease\nEdwards Trisomy 18, Presents with severe intel- CHD (most often VSD, PDA) Second most common\nsyndrome which occurs lectual disabilities, rocker GI involvement common (Meckel diver- autosomal trisomy\ndue to meiotic bottom feet, low-set ears, ticulum, malrotation) Death usually occurs\nnondisjunction micrognathia, clenched Renal involvement (eg, horseshoe within 1 year of birth\nhands (overlapping of the kidneys, vesicoureteral reflux, and other Associated with\nindex finger over the third anomalies) advanced maternal\nfinger and the pinky over age\nthe fourth finger), and a 3:1 female-to-male ratio\nprominent occiput\nPatau Trisomy 13, Presents with classic triad CHD: VSD, PDA, ASD Death usually occurs\nsyndrome which occurs of microphthalmia/ CNS: Holoprosencephaly with incomplete within 1 year of birth\ndue to meiotic anophthalmia/microcephaly; development of forebrain and olfactory Associated with\nnondisjunction cleft lip/palate; postaxial and optic nerves, intellectual disabilities advanced maternal\npolydactyly; other features age\nare holoprosencephaly,\nâ€œpunched-outâ€ scalp lesions,\nand omphalocele\nALL, Acute lymphocytic leukemia; ASD, atrial septal defect; AV, atrioventricular; CHD, congenital heart disease; CNS, central nervous system;\nDM, diabetes mellitus; PDA, patent ductus arteriosus; VSD, ventricular septal defects.",
    "Most common cause of Characterized by the presence of\nsyndrome occurs due to atrophy, a eunuchoid body primary hypogonadism an inactivated X chromosome\n(male) nondisjunction of shape, tall stature, long in males (Barr body)\nsex chromosomes extremities, gynecomastia, â†‘ risk for breast cancer, psychi-\n(maternal or and female hair distribution atric disorders, autosomal\npaternal origin) Male newborns: Normal in spectrum disorders, and social\nphenotype with no dysmor- problems\nphic features Associated with advanced\nmaternal age\nSex chromosome karyotyping\nused to diagnose\nTreated with testosterone\n(prevents gynecomastia;\nimproves secondary sexual\ncharacteristics)\nTurner syndrome 45,XO Presents with short stature, The most common cause Missing one X chromosome; no\n(female) shield chest, widely spaced of primary amenor- Barr body\nnipples, a webbed neck, rhea; caused by ovarian Sex chromosome karyotyping\npubertal delay (due to dysgenesis (treat with used to diagnose\novarian failure), coarcta- estrogen) Not associated with advanced\ntion of the aorta (â†“ femoral May have horseshoe maternal age\npulses), and/or bicuspid kidney\naortic valve\nMay present with lymphedema\nof the hands and feet in the\nneonatal period\nDouble Y males 47,XYY Often look normal; some Observed with â†‘ frequency\npatients very tall with severe among inmates of penal\nacne (seen in 1%â€“2% of XYY institutions\nmale patients) Sex chromosome karyotyping\nused to diagnose\nTABLE 2.",
    "most common genetic cause\nA triplet repeat disorder that may show genetic of intellectual disabilities\nanticipation\nPresents in childhood; features include long and narrow\nface, prominent forehead and chin, large ears, testicular\nenlargement, and autistic behaviors\nFriedrich ataxia Caused by a loss-of-function mutation in frataxin (FXN) Autosomal recessive degenerative disorder\ngene â†’ trinucleotide repeat expansion of GAA â†’â†“ The most common hereditary ataxia\nexpression of frataxin protein\nPresents in adolescence primarily with neurologic dys-\nfunction (limb, gait ataxia) and cardiomyopathy; other\nfeatures: optic atrophy, dysphagia, dysarthria, motor\nweakness, loss of distal proprioception, deafness, â†“\nvisual acuity, kyphoscoliosis, diabetes mellitus\nPrader-Willi syndrome Presents with hypotonia, hyperphagia, obesity, hypogo- Deletion of paternal 15q11-q13 (imprinting\nnadism, almond-shaped eyes, â†“ cognition disorder)\nCauses sleep apnea, DM type 2, gastric distention and Paternal deletion â†’ Prader-Willi\nrupture, and obesity-related complications Most common syndromic form of obesity\nClassic galactosemia Caused by a deficiency of galactose-1-phosphate uridyl Autosomal recessive inheritance\ntransferase (GALT) Most common and severe type of\nIf not treated shortly after birth, will present in infancy galactosemia\nwith jaundice, vomiting, and hepatomegaly after Tested in newborn screening\nfeeding.",
    "most common cause of respiratory failure in\nrectosigmoid obstruction, and a rectal\nDexiraemct m(caoyn rjuesgualtte idn) e hxyppuelsrbioilnir uobf sintoeoml.",
    "most common cause in underdeveloped countries), dyshor-\nmonogenesis (autosomal recessive), and transfer of maternal antibodies.",
    "most common type of CHD.",
    "most common type of CHD.",
    "most common type of CHD.",
    "most common type of CHD.",
    "most common location in\nchildren.",
    "most common cause of bowel obstruction in children between 6 months\nand 3 years of age (boys > girls).",
    "most common congenital abnormality of the\nof the gastric outlet secondary to small intestine, affecting up to 2% of children (boys > girls).",
    "most common GI\nemergency in neonates; it is most frequently seen in premature infants, but\ncan rarely occur in full-term infants as well.",
    "most common congenital urethral changes, laxatives, and bowel retraining until laxative doses can be tapered.",
    "most common Usually asymptomatic; possibility Quantitative IgA levels; treatment of\nimmunodeficiency for patients to develop recur- infections\nâ†“ IgA levels only rent respiratory or GI infections Be careful giving IVIG, as it can lead\n(Giardia) to the production of anti-IgA anti-\nAnaphylactic transfusion reaction bodies and cause severe allergic\ncaused by anti-IgA antibodies is reactions; if IVIG is necessary, give\na commonly tested presentation IgA-depleted IVIG\nHyper-IgM syndrome An X-linked recessive disease; absence Severe, recurrent sinopulmonary Treatment with antibiotic prophy-\nof CD40 ligand that allows class- infections caused by impaired Ig laxis and IVIG\nswitching from IgM to other Ig classes\nâ†‘ IgM levels, low levels of all other Ig,\nand normal numbers of lymphocytes\nT-CELL DISORDERS\nThymic aplasia See the mnemonic CATCH 22 Variable risk for infection Absolute T-lymphocyte count;\n(DiGeorge Presents with tetany (secondary to â†‘â†‘â†‘ infections with viruses, fungi, mitogen stimulation response;\nsyndrome) hypocalcemia) in the first days of life and pneumocystis pneumonia delayed hypersensitivity skin\nAutosomal dominant (PCP) testing\nX-ray possibly showing absent Treatment with bone marrow\nthymic shadow transplantation (BMT) and IVIG\nfor antibody deficiency; PCP\nprophylaxis\nThymus transplantation an\nalternative\n(continues)\n22002222__0022.",
    "most common clinical and laboratory\nhistory of recurrent infections.",
    "most common cause; others include parainfluenza,\nare often characteristic.",
    "most common cause of\nâ–  PE: Tachypnea, hypoxia, intercostal retractions, crackles or coarse breath bronchiolitis.",
    "most common agents of viral meningitis, and they infect\nwith permission from Stone CK, Humphries RL.",
    "Most common causes of bacterial meningitis by age are as follows:\nKEY FACT â–  Neonates: Group B Streptococcus (GBS), E coli, Listeria\nâ–  Infants/children: S pneumoniae, N meningitidis, H influenzae\nEpiglottitis is a true emergency and â–  Adolescents: N meningitidis, S pneumoniae\ncan lead to life-threatening airway\nobstruction.",
    "most common causative agents include Chlamydia trachomatis and\nHSV (usually HSV-2).",
    "most common indications for hospitalization\nâ–  Neonates have a high risk of invasive bacterial infection (IBI) or a viral\ninfection; most severe is HSV\nâ–  Presentation of illness can be subtle with history of poor feeding, lethargy,\nand decreased activity\nDiagnosis\nCBC with differential; complete metabolic panel; cultures of blood, urine,\nand cerebrospinal fluid (CSF)\nMost common bacterial pathogens:\nâ–  Early onset (< 30 days): Predominantly GBS infection, followed by\ngram âŠ– organisms (predominantly E coli), and Listeria\nâ–  Late onset (>30 days): Predominantly GBS infection, followed by gram\nâŠ– organisms (predominantly E coli)\nTreatment\nBroad-spectrum antibiotic coverage with ampicillin and cefotaxime\nFEVER OF UNKNOWN ORIGIN\nâ–  Refers to children with a fever â‰¥38.",
    "most common presenting\nsymptom of cerebral palsy is delayed\nDiagnosis\nmotor development.",
    "Most common onset in 20sâ€“40s\nmother Associated with mental retardation, cata-\nracts, and arrhythmias\n22002222__0022.",
    "Most common CNS tumor in children Resection if possible;\n(Images A and B) tumor of astrocyte origin; stains Presents with drowsiness, headache, ataxia, radiation\nâŠ• for glial fibrillary acidic protein nausea, vomiting, cranial neuropathy\n(GFAP) Slow growing with protracted course and favor-\nPosterior fossa/infratentorial tumor able prognosis\nBipolar neoplastic cells with hairlike projections;\nassociated with microcysts and Rosenthal\nfibers (eosinophilic, corkscrew fibers); cystic +\nsolid mass (gross)\nMedulloblastoma\nA primitive neuroectodermal tumor Highly malignant but radiosensitive; may seed Surgical resection\n(Image C)\n(PNET) of the posterior fossa/ the subarachnoid space or spread â€œdrop coupled with\ninfratentorial region metastasesâ€ to the spinal cord radiation and\nArises from the fourth ventricle or cer- May cause obstructive hydrocephalus by com- chemotherapy\nebellar vermis pressing the fourth ventricle â†’ headaches,\nHomer-Wright rosettes, small blue cells papilledema, vomiting\nSynaptophysin âŠ• Truncal ataxia caused by involvement of cer-\nebellar vermis\nEpendymoma Ependymal cell tumor most commonly Causes obstructive hydrocephalus by com- Surgical resection fol-\nfound in the fourth ventricle, but pressing the fourth ventricle â†’ headaches, lowed by radiation\nmay present as primary spinal cord papilledema, vomiting or chemotherapy\ntumors Myelopathy and radiculopathy possible pre-\nCharacteristic perivascular pseudoro- senting symptoms with involvement of spinal\nsettes; rod-shaped blepharoplasts cord\n(basal ciliary bodies) found near the\nnucleus\nCraniopharyngioma The most common suprasellar tumor Benign Surgical resection\n(Images D and E) in children Most commonly causes bitemporal hemianopsia\nCalcification common (distinguishes it due to compression of the optic chiasm\nfrom pituitary adenoma) Associated with a high recurrence rate\nDerived from remnants of Rathke\npouch (ectoderm); cholesterol crys-\ntals found in â€œmotor oilâ€â€“like fluid\nwithin tumor\n(continues)\n22002222__0022.",
    "most common cause of\nin splenic sequestration.",
    "most common in non-\nHispanic White males between 2 and 5 years of age, whereas AML is seen KEY FACT\nmost frequently in Black boys throughout childhood.",
    "most common childhood\n21, Fanconi anemia, prior radiation, severe combined immunodeficiency\nmalignancy, followed by CNS tumors\n(SCID), and congenital bone marrow failure states, ALL in children has a\nand lymphomas.",
    "most common pediatric elbow fracture Cast immobilization; closed reduction\nTends to occur at 5â€“8 years of age after a fall on an with percutaneous pinning if signifi-\noutstretched hand cantly displaced\nInjury to median nerve or brachial artery\nCompartment syndrome possible as pain increases\ndespite analgesics\nProximity to the brachial artery increases the risk\nof Volkmann contracture; the physician should\nbeware of brachial artery entrapment (check radial\npulse)\nOsgood-Schlatter disease Overuse apophysitis of the tibial tubercle; causes Decreased activity for 2â€“3 months or\nlocalized pain, especially with quadriceps contrac- until asymptomatic\ntion, in adolescent athletes Brace for symptomatic relief\nSalter-Harris fracture Fractures of the growth plate in children.",
    "Most common in boys 4 to 10 years of age.",
    "most common hip disorder in adoles-\npainFULL.",
    "Most common physical finding Congenital dermal melanocytosis, formerly called\nOften located on head and torso â€œMongolian spotsâ€\nMay be in pattern reflecting implement (hand, belt) Coining/cupping (a therapy used in certain cultures\nwhere suction cups are attached to the skin)\nBleeding diathesis\nBurns Contact burns: Cigarette/curling iron Scalded skin syndrome, severe contact dermatitis,\nImmersion burns: Hot water; on buttocks, with sparing accidental burn injury\nof flexor surfaces, or stocking-glove distribution with\nsharp lines of demarcation and uniform burn depth\nFractures Spiral fractures: Humerus/femur (in children not yet Osteogenesis imperfecta (blue sclerae, hearing loss,\nwalking); epiphyseal-metaphyseal â€œbucketâ€ fractures opalescent teeth)\nPosterior rib fractures: Indication of squeezing\nAbusive head trauma Lethargy, feeding difficulty, apnea, seizures, retinal Accidental head trauma\nhemorrhage, subdural/epidural hematoma\nImage reproduced with permission from Wolff K et al.",
    "Most common cause of unexplained\nthe car (seats can face forward if the child is >2 years of age and weighs\ndeath in children <1 year of age.",
    "most common cause of childhood conductive hearing loss is\nof this childâ€™s apnea?\nrepeated ear infections.",
    "most common in 3- to LEAD POISONING\n4-month-old infants and presents\nearly with nonspecific symptoms\nMost exposure in children is caused by lead-contaminated household dust\n(lethargy, irritability, poor feeding,\nfrom lead paint.",
    "Most common in infants.",
    "most common in infants.",
    "most common cause of inherited intellectual\ndisability and autism; presents with the following characteristics:\nmacro-orchidism, long face, prominent jaw and forehead, high arched\npalate, large and everted ears, autism, connective tissue laxity, and /or\nmitral valve prolapse\nTreatment\nâ–  Intensive special education, behavioral management (specifically applied KEY FACT\nbehavior analysis therapy), and symptom-targeted medications (eg, stimu-\nIn patients with ASD, think about\nlants or Î± -agonists for ADHD; neuroleptics for aggression and mood insta-\n2 associated congenital conditions, such\nbility; selective serotonin reuptake inhibitors [SSRIs] for stereotypical\nas Rett syndrome, tuberous sclerosis,\nbehavior, anxiety, and mood)\nand fragile X syndrome.",
    "most common chromosomal cause Treatment\nof intellectual disability\nâ–  Fetal alcohol syndrome (FAS): The â–  Primary prevention: Educating the public about possible causes of intel-\nlectual disability and providing optimal prenatal screening and care to\nmost common preventable cause\npregnant patients\nof intellectual disability\nâ–  Fragile X syndrome: The most â–  Treatment measures: Family counseling and support, speech and lan-\nguage therapy, occupational/physical therapy, behavioral intervention,\ncommon inherited form of\neducational assistance, and social skills training\nintellectual disability\nâ–  Learning disorder: Remedial therapy directed toward patientâ€™s deficiency\n22002222__0022.",
    "most common causes are\nischemia, vasculitis, normal-pressure\nAlzheimer disease (65%) and vascular dementia (20%).",
    "most common malignancy associ-\nexposure bodies in alveolar septum ated with asbestos exposure is\nbronchogenic carcinoma\nCoal workersâ€™ Work in underground coal mines Small nodular opacities (<1 cm) in upper Progressive massive fibrosis\ndisease lung zones\nSilicosis Work in mines or quarries or with glass, Small (<1 cm) nodular opacities in upper â†‘ risk for TB; need annual TB test\npottery, or silica lung zones; eggshell calcifications Progressive massive fibrosis\nBerylliosis Work in high-technology fields such as Diffuse infiltrates; hilar adenopathy Requires chronic corticosteroid\naerospace, nuclear, and electronics treatment\nplants; ceramics industries; foundries;\nplating facilities; dental material sites;\nor dye manufacturing\nA B\naSpirometry, consistent with restrictive disease.",
    "Most common lung cancer in female patients, nonsmokers, and overall Glandular pattern on his-\n(except for metastases); activating mutations include KRAS, EGFR, and tology, often stains mucin\nALK translocation âŠ• (Fig.",
    "most common initial symptom) and\nweight heparin (LMWH).",
    "most common finding among typical hosts is a cavitary infiltrate in\nthe upper lobe on CXR (see Fig.",
    "most common bacterial\ncause of pharyngitis.",
    "Most common causes of massive\nidentified hemoptysis: bronchiectasis, active\npulmonary TB, malignancy\nEvaluate and\ntreat findings\nFIGURE 2.",
    "most common tumors of the nasal cavity.",
    "most common (90%) and tends to be self- Anterior packing (tampon, Consider admission and\nlimited.",
    "most common bacterial pathogen): Absence of cough, swol-\nlen/tender anterior cervical lymph nodes, temperature >38Â°C (100.",
    "Most common benign laryngeal lesion.",
    "most common type of hyponatremia and is further catego-\nrized by volume status.",
    "most common causes are the following:\nCauses of hypercalcemiaâ€” â–  Hyperparathyroidism\nâ–  Malignancy (eg, breast cancer, squamous cell carcinoma, multiple\nCHIMPANZEES\nmyeloma)\nCalcium supplementation\nâ–  Other causes in the mnemonic CHIMPANZEES.",
    "most common form (see\nKEY FACT Table 2.",
    "most common cause\na concurrent respiratory alkalosis.",
    "most common cause (and most Management\ncommon cause of death in pediatric\nâ–  Ensure tight BP controlâ€”target <130/80 mm Hg in adults.",
    "most common cause (and most\ncommon cause of death in pediatric Loop of Henle\ndialysis and transplant patients).",
    "Most common cause in\nchildren\nIgA nephropathy Most common cause of Episodic gross hematuria with Normal C3; IgA deposits on ACE inhibitors in\n(Berger disease) glomerulonephritis respiratory and/or GI infec- immunofluorescence patients with persis-\nin adults; typically tions; often with persistent tent hypertension\noccurs concurrent microscopic hematuria and/or proteinuria;\nwith an upper respi- between infections; patient glucocorticoids\nratory or GI infection may also have chronic HTN in select severe\n(IgA-producing and low to moderate levels inflammatory\nmucosa); this is the of proteinuria presentations\nrenal manifestation HSP is diagnosed when there Nonresponsive\nof HSP (IgA vasculitis) is palpable purpura without patients have slow\nthrombocytopenia and one progression to ESRD\nof the following three: renal Treatment for HSP in\ndisease, arthralgia, abdom- the absence of renal\ninal pain involvement is gen-\nerally supportive\nMembranoproliferative Immune complexâ€“ May present with nephrotic â€œTram-track,â€ double-layered Prednisone Â± immu-\nnephropathy type I/ mediated MPGN syndrome; clinical features basement membrane; nosuppressive\nIII (nomenclature is either primary may include gross hema- subendothelial and therapy the main-\nchanging, but these (especially in chil- turia, HTN, and/or edema mesangial deposits are stays of treatment;\nare the classic terms, dren) or secondary present RAAS inhibition is\nbased on electron to HBV, HCV, SLE, or often given\nmicroscopy) cryoglobulinemia\nMembranoprolif- Complement-mediated This nephritis may also present Intramembranous dense Antihypertensive\nerative nephropathy MPGN (dense deposit with a nephrotic syndrome; deposits.",
    "most common cause is minimal change disease, a primary disease of the\nkidney and not a systemic disease.",
    "most common Sudden onset of Biopsy is recommended Steroids; favorable\nA cause of nephrotic edema in treatment-resistant prognosis\nsyndrome in children disease or with age >12\nIdiopathic etiology; years; otherwise diag-\nsecondary causes nosis is clinical; light\ninclude NSAIDs and microscopy appears\nhematologic malig- normal; electron\nnancies (eg, Hodgkin microscopy shows\nB\ndisease) diffuse effacement of\nepithelial foot processes\n(see Image A)\nImage B shows a normal\nglomerulus\nFocal segmental glomeruloscle- Idiopathic, but also can Presents with hyper- Biopsy shows focal For idiopathic FSGS,\nrosis (FSGS) be secondary to IV tension and often glomerular sclerosis treatment is predni-\nC drug use (heroin), with edema in capillary tufts (see sone and/or other\nHIV, sickle cell Image C) immunosuppressant\ndisease, and obesity; therapy; in addition,\nfocal segmental and for all other\nglomerulosclerosis cases, supportive\nis the most common treatments with ACE\ncause of nephrotic inhibitors/ARBs to â†“\nsyndromes in adults, proteinuria and treat\nespecially in people hypertension\nof African descent\nMembranous nephropathy Accounts for Â±30% of May be primary â€œSpike-and-domeâ€ RAAS inhibition is first\nD nephrotic syndromes (antibodies to appearance caused by line; prednisone\nin adults; membra- phospholipase granular deposits of and immunosup-\nnous nephropathy [PLA]2 receptors) or IgG and C3 at the sub- pressive therapy are\nis the most common secondary to solid epithelial side of the for severe disease\ncause of nephrotic tumor malignan- basement membrane; refractory to RAAS\nsyndrome in people cies, infections (HBV, on light microscopy, inhibition alone\nof European descent malaria), autoim- GBM thickening is seen\nmune diseases (SLE), (arrows in Image D)\ndrugs (NSAIDs, gold) Antiphospholipase A\n2\nPatients present with receptor (PLA2R) anti-\nanasarca bodies are associated\nMembranous nephrop- with primary membra-\nathy has the highest nous nephropathy\nrate of thrombosis,\nlikely related to\nseverity of protein\nlosses\n(continues)\n22002222__0022.",
    "most common rheumatoid green birefringence multiple myeloma;\narthritis, TB) with Congo red stain AA amyloidosis\nis managed by\ntreating the under-\nlying inflammatory\ncondition\nImage A reproduced with permission from Teoh DC, El-Modir A.",
    "Most common causes are idio- Calcium oxalate precipitates Hydration, dietary sodium\nA pathic hypercalciuria, but also with hypocitraturia, which is restriction, thiazide diuretic\nmay see in fat malabsorption often associated with â†“ pH Do not decrease calcium\n(eg, with Crohn disease or intake (can lead to hyp-\nbowel resection) eroxaluria and risk for\nStones are radiopaque osteoporosis)\nEnvelope- or dumbbell-shaped May also begin citrate supple-\nstones (Image A) ments, but pH must not be\nraised too high\nCalcium phosphate Most common causes are idio- Calcium phosphate precipitates Hydration, dietary sodium\npathic hypercalciuria but also at â†‘ pH restriction\nmay see in primary hyper- Thiazide diuretic only for\nparathyroidism or immobility idiopathic etiology and not\nsyndromes that result in high when hyperparathyroidism\nbone loss is etiology\nStones are radiopaque Do not decrease calcium\nWedge-shaped prism stones intake (can lead to hyp-\neroxaluria and risk for\nosteoporosis)\nStruvite (MgNHPO) or â€œtriple Associated with urease-pro- â†‘ pH Hydration\n4 4\nphosphateâ€ ducing organisms (eg, Proteus) Treat UTI if present\nB Patients may have history of Surgically remove staghorn\nrecurrent UTIs stones (antibiotics alone are\nStones are radiopaque not enough)\nStaghorn-shaped stones (Image\nB)\nFrequency: 9%\nUric acid Associated with gout, xanthine â†“ pH Hydration\nC oxidase deficiency, and high Alkalize urine\npurine turnover states (eg, First-line management:\nchemotherapy) Restrict dietary purines\nStones are radiolucent on plain If stones recur despite dietary\nfilm, but can be detectable management, consider\nwith CT (not as bright as allopurinol\ncalcium stones on CT)\nRhomboid-shaped stones\n(Image C)\nFrequency: 7%\n(continues)\n22002222__0022.",
    "most common presenting findings.",
    "most common nonskin cancer in men and the second leading cause of\n3.",
    "most common urologic cancer and the most frequent malignant\ntumor of the urinary tract; usually a transitional cell carcinomaâ€”now called\nurothelial carcinoma (see Fig.",
    "most common presenting symptom.",
    "most common malignancy in males 15 to 34 years of age.",
    "most common Usually âŠ–, Î²-human chorionic gonadotropin (Î²-hCG) in\ntesticular tumor) some cases\nYolk sac (endodermal sinus â†‘ Î±-fetoprotein (AFP)\ntumor)\nKEY FACT\nChoriocarcinoma â†‘ Î²-hCG\nÎ²-hCG in males = choriocarcinoma\nTeratoma AFP and/or Î²-hCG\nNONâ€“GERM CELL TUMORS (5% OF ALL TESTICULAR TUMORS)\nLeydig cell â†‘ testosterone and estrogen (causing â†“ luteinizing\nhormone and follicle-stimulating hormone)\nSertoli cell None\nTesticular lymphoma None; arises from metastasis to testes\nâ–  Tumor markers are useful for diagnosis and in monitoring treatment\nresponse (see Table 2.",
    "most common bacterial sexually transmitted disease (STD) in the United with acute bacterial prostatitis, as it can\nStates.",
    "most common etiologies, based on post- KEY FACT\noperative day (POD) of onset.",
    "most common during June and July and\nin Midwestern and Eastern states (Arkansas, Missouri, Virginia, and North\nCarolina).",
    "most common KEY FACT\ncause of death in affected males.",
    "Most common if CD4+ cell count <50/mm3\nintracellulare, Mycobacte- sweats, weight loss) or focal lymphadenitis\nrium avium complex\nToxoplasma gondii Brain abscesses Multiple ring-enhancing lesions on MRI\nImage reproduced with permission from the National Cancer Institute.",
    "most common overall cause] > Enterococci\n> Staphylococcus aureus); gram âŠ bacteria (20%â€“30% of cases: Klebsiella\n> Enterobacter > Pseudomonas > Escherichia coli > Acinetobacter); and\nfungi (11.",
    "Most common source is antihistamine medications with anticholinergic\nanticholinergic adverse effects\nagents\nArsenic, mercury Succimer, dimercaprol Arsenic poisoning from contaminated industrial areas or landfills; acute\ntoxicity is associated with garlic breath and GI symptoms; chronic tox-\nicity is associated with skin discoloration and peripheral neuropathy\nMercury poisoning from thermometers and old paints\n(continues)\nCocaine use may lead to\nnonobstructive mesenteric ischemia\nbecause of perfusion deficits\nsecondary to cardiac arrhythmias.",
    "most common in the proximal thoracic aorta near the ligamen-\ntum arteriosum, which anchors the aorta in place.",
    "most common in the proximal thoracic aorta near the ligamen- Blunt abdominal trauma FAST or DLP\ntum arteriosum, which anchors the aorta in place.",
    "most common in association with pelvic\nfractures.",
    "Most common cause of cardioembolic stroke Atrial fibrillation\nManagement of symptomatic bradycardia Initially atropine, temporary pacing if refractory to medication\nOnly medications that reduce mortality in HF with preserved EF Empagliflozin and dapagliflozin\nMedications that provide mortality benefit in HF with reduced EF ACE inhibitors/ARBs, ARNIs, Î²-blockers, spironolactone, hydralazine +\nisosorbide dinitrate (in Black patients)\nDiagnostic test for hypertrophic cardiomyopathy Echocardiogram (showing a thickened left ventricular wall and\noutflow obstruction)\nYoung patient with family history of sudden death collapses and dies Hypertrophic cardiomyopathy\nwhile exercising\nYoung patient with angina at rest and ST-segment elevation with Prinzmetal angina\nnormal cardiac enzymes\nDefinition of unstable angina Angina that is new or worsening with no â†‘ in troponin level\n22002222__0022.",
    "Most common malignant skin cancer.",
    "most common skin cancer.",
    "Most common cause of hypothyroidism Hashimoto thyroiditis\nLab findings in Hashimoto thyroiditis High TSH, low T, antibodies to thyroid peroxidase or to thyroglobulin\n4\nExophthalmos, pretibial myxedema, and â†“ TSH Graves disease\nMost common cause of Cushing syndrome Iatrogenic corticosteroid administration; the second most common\ncause is Cushing disease\nPost-thyroidectomy patient presents with signs of hypocalcemia and Hypoparathyroidism (iatrogenic)\nhyperphosphatemia\nâ€œStones, bones, groans, psychiatric overtonesâ€ Signs and symptoms of hypercalcemia (kidney stones, bone disease,\ngastrointestinal symptoms, alterations in mentation)\nHypertension, hypokalemia, and metabolic alkalosis Primary hyperaldosteronism (caused by Connâ€™s syndrome or bilateral\nadrenal hyperplasia)\nPatient presents with tachycardia, wild swings in BP, headache, dia- Pheochromocytoma\nphoresis, altered mental status, and a sense of panic\nWhich should be used first in treating pheochromocytoma, Î±- or Î±-antagonists (phenoxybenzamine)\nÎ²-antagonists?\n22002222__0022.",
    "Most common cancer in men and most common cause of death from Prostate cancer is the most common cancer in men, but lung cancer\ncancer in men causes more deaths\nBirth rate? Number of live births per 1000 population in 1 year\nMortality rate? Number of deaths per 1000 population in 1 year\nNeonatal mortality rate? Number of deaths from birth to 28 days per 1000 live births in 1 year\nInfant mortality rate? Number of deaths from birth to 1 year of age per 1000 live births\n(neonatal + postnatal mortality) in 1 year\nMaternal mortality rate? Number of deaths during pregnancy to 90 days postpartum per\n100,000 live births in 1 year\n22002222__0022.",
    "Most common cause of SBO in patients with no history of abdominal Hernia (also concerning for cancer)\nsurgery\nMost common cause of SBO in patients with a history of abdominal Adhesions\nsurgery\nIdentify key organisms causing diarrhea:\nâ–  Most common bacterial organism Campylobacter\nâ–  Recent antibiotic use Clostridium difficile\nâ–  Camping Giardia\nâ–  Travelerâ€™s diarrhea Enterotoxigenic Escherichia\nâ–  Church picnics/mayonnaise S aureus\nâ–  Uncooked hamburgers E coli O157:H7\nâ–  Fried rice Bacillus cereus\nâ–  Poultry/eggs Salmonella\nâ–  Raw seafood Vibrio, HAV\nâ–  AIDS Isospora, Cryptosporidium, Mycobacterium avium complex\nâ–  Pseudoappendicitis Yersinia, Campylobacter\n25-year-old man presents with pain and watery diarrhea after meals.",
    "Most common inherited cause of hypercoagulability Factor V Leiden mutation\nMost common inherited bleeding disorder von Willebrand disease\nMost common inherited hemolytic anemia Hereditary spherocytosis\nDiagnostic test for hereditary spherocytosis Osmotic fragility test\nHow do you differentiate between AIHA and hereditary Spherocytes, âŠ• ve osmotic fragility tests, but only AIHA has âŠ• direct\nspherocytosis? Coombs test\nPure RBC aplasia Diamond-Blackfan anemia\nAnemia associated with absent radii and thumbs, diffuse hyperpig- Fanconi anemia\nmentation, cafÃ© au lait spots, microcephaly, and pancytopenia\nMedications and viruses causing Aplastic anemia Chloramphenicol, sulfonamides, radiation, HIV, chemotherapeutic\nagents, hepatitis, parvovirus B19, EBV\nHow to distinguish polycythemia vera from secondary polycythemia? Both have â†‘ hematocrit and RBC mass, but polycythemia vera should\nhave normal O saturation and low erythropoietin levels\n2\nTTP pentad LMNOPâ€”Low platelet count (thrombocytopenia), Microangiopathic\nhemolytic anemia, Neurologic changes, â€œObsoleteâ€ renal function,\nPyrexia\nTreatment for TTP Emergent large-volume plasmapheresis, corticosteroids, antiplatelet\ndrugs\nHUS triad Anemia (microangiopathic hemolytic anemia), thrombocytopenia,\nand acute renal failure\nITP treatment? Children: Usually resolves spontaneously\nAdults: May require IVIG and/or corticosteroids\nDiagnostic tests in DIC? Fibrin split products and d-dimer are â†‘; platelets, fibrinogen, and\nhematocrit are â†“\n8-year-old boy presents with hemarthrosis and â†‘ PTT with normal PT Hemophilia A or B; consider desmopressin (for hemophilia A) or factor\nand bleeding time.",
    "Most common hip dislocation.",
    "Most common pituitary tumor.",
    "Most common cause of SAH Trauma (second most common is berry aneurysm)\nCSF findings with SAH â†‘ ICP, RBCs, xanthochromia\nLens-shaped hypedensity on CT head; patient has a lucid interval Epidural hematoma; middle meningeal artery\n22002222__0022.",
    "Most common cause of brain neoplasm Metastases, primary neoplasms are much less common\nMost common primary sources of metastases to the brain Lung, breast, skin (melanoma), kidney, GI tract\nMost common cause of seizures in children (2â€“10 years of age) Infection, febrile seizures, trauma, idiopathic\nMost common cause of seizures in young adults (18â€“35 years of age) Trauma, alcohol withdrawal, brain tumor\nClassic EEG finding of absence seizures? 3-per-second spike and wave discharges\nFirst-line medication for status epilepticus IV benzodiazepine\nHearing loss in presbycusis High frequency\nRing enhancing lesions in patients with AIDS Toxoplasmosis, CNS lymphoma\nDifferences between myasthenia gravis and Lambert-Eaton myas- Decremental response in MG, Incremental response in LEMS\nthenic syndrome on nerve stimulation\nSymptoms seen in normal pressure hydrocephalus? Gait ataxia (wobbly), urinary incontinence (wet), dementia (wacky)\nRisk factors for intracranial hypertension? Obesity, Tetracycline, growth hormone, excess vitamin A\nWernicke encephalopathy Confusion, ophthalmoplegia, ataxia caused by a deficiency of thia-\nmine (B)\n1\nMost common causes of dementia Alzheimer disease and vascular\nCombined UMN and LMN disorder ALS\nRigidity and stiffness with unilateral resting tremor and masked facies Parkinson disease\nTreatment for Parkinson disease Levodopa/carbidopa\nTreatment for Guillain-BarrÃ© syndrome IVIG or plasmapheresis; avoid steroids\nRigidity and stiffness that progress to choreiform movements, accom- Huntington disease; autosomal dominant\npanied by moodiness and altered behavior\nPort-wine stain in the V distribution as well as with intellectual dis- Sturge-Weber syndrome; treat symptomatically; possible focal cere-\n1\nability, seizures, and ipsilateral leptomeningeal angioma bral resection of affected lobe\nMultiple cafÃ©-au-lait spots on skin Neurofibromatosis type 1\nHyperphagia, hypersexuality, hyperorality, and hyperdocility KlÃ¼ver-Bucy syndrome (amygdala)\nName the organism:\nâ–  Meningitis in adults Neisseria meningitidis\nâ–  Meningitis in elderly Streptococcus pneumoniae\nâ–  Meningoencephalitis in AIDS patients Cryptococcus neoformans\nCauses of ring-enhancing brain lesions Abscess, toxoplasmosis, metastasis, lymphoma, AIDS, neurocysticercosis\n22002222__0022.",
    "Most common cause of amenorrhea Pregnancy\nUse of OCPs decreases risk of which cancers? Endometrial, ovarian\nCause of amenorrhea with normal prolactin, no response to estrogen- Asherman syndrome\nprogesterone challenge, and a history of D&C\nTherapy for polycystic ovarian syndrome Weight loss and OCPs\nMedication used to induce ovulation Clomiphene\nDiagnostic step required in a postmenopausal woman who presents Endometrial biopsy for suspected endometrial carcinoma\nwith vaginal bleeding\nIndications for medical treatment of ectopic pregnancy in a stable Unruptured ectopic pregnancy of <35 cm at <6 weeks gestation\npatient\nMedical treatment for endometriosis OCPs, danazol, GnRH agonists\nLaparoscopic findings in endometriosis Powder burns, â€œchocolate cystsâ€\nMost common location for an ectopic pregnancy Ampulla of the fallopian tube\nNatural history of a leiomyoma Regresses after menopause\nTreatment for bacterial vaginosis Oral metronidazole\nDiagnostic step for breast mass in premenopausal and postmeno- Premenopausal and <30 years of age: Ultrasound\npausal, >30 years of age women? Postmenopausal and >30 years of age: Mammogram\nMost common cause of bloody nipple discharge Intraductal papilloma, mammary duct ectasia\nUnopposed estrogen is contraindicated in which cancers? Endometrial or estrogen receptor âŠ• breast cancer\nSide effects of tamoxifen? Hot flashes, endometrial cancer, venous thromboembolism\nPatient presents with recent PID with RUQ pain Consider Fitz-Hughâ€“Curtis syndrome\nScreening for women with a strong family history of ovarian cancer CA-125 and transvaginal ultrasonography\nLab values suggestive of menopause â†‘ serum FSH\nTwo consecutive findings of ASCUS on Pap smear.",
    "Most common type of TEF? How does it present? Esophageal atresia with distal TEF (85%); inability to pass NG tube\n22002222__0022.",
    "Most common primary immunodeficiency Selective IgA deficiency\nInfant has high fever and onset of rash as fever breaks.",
    "Most common pathogen causing croup Parainfluenza virus type 1\nHomeless child is small for his age and has peeling skin and a swollen Kwashiorkor (protein malnutrition)\nbelly\nDefect in an X-linked syndrome with intellectual disability, gout, self- Lesch-Nyhan syndrome (purine salvage problem with HGPRTase\nmutilation, and choreoathetosis deficiency)\nNewborn girl has continuous â€œmachinery murmur.",
    "Most common cause of chronic cough are (name 3)? Asthma, upper airway cough syndrome (postnasal drip), and gastro-\nesophageal reflux disease\nMost effective agent for the treatment of allergic rhinitis? Glucocorticoid nasal spray\nA patient has asthma, wheezing with aspirin/NSAIDS, and recurrent Nasal polyps\nnasal discharge.",
    "Most common ECG changes in hyperkalemia Peaked T waves and widened QRS\nTreatment of hyperkalemia C BIG Kâ€”Calcium gluconate, Bicarbonate, Insulin + Glucose,\nKayexalate\nMost common ECG changes in hypokalemia T-wave flattening and U waves\nMost common causes of hypercalcemia Malignancy and hyperparathyroidism\nFacial spasm elicited from tapping the facial nerve (Chvostek sign), Hypocalcemia\ncarpal spasm after arterial occlusion by a BP cuff (Trousseau sign)\nSalicylate ingestion can lead to which type(s) of acid-base disorder? Anion gap metabolic acidosis and primary respiratory alkalosis\ncaused by central respiratory stimulation\nAcid-base disturbance commonly seen in pregnant women Respiratory alkalosis\nRTA associated with abnormal H+ secretion and nephrolithiasis Type I (distal) RTA\nRTA associated with abnormal HCOâ€“ reabsorption and rickets Type II (proximal) RTA\n3\nRTA associated with low aldosterone state Type IV (distal) RTA\nAKI in a patient with BUN/creatinine >20:1 and/or FEN <1% Prerenal (caused by â†“ renal perfusion)\na\nMuddy brown casts Acute tubular necrosis\nDrowsiness, asterixis, nausea, and pericardial friction rub Uremic syndrome seen in patients with renal failure\nHematuria, hypertension, oliguria, and RBC casts in the urine Nephritic syndrome\nPalpable purpura, arthralgias, abdominal pain, renal failure Henoch-SchÃ¶nlein purpura (IgA vasculitis)\nGlomerulonephritis with deafness Alport syndrome\nGlomerulonephritis with hemoptysis Granulomatosis with polyangiitis (Wegener) or Goodpasture syndrome\nProteinuria (â‰¥3.",
    "Most common form of nephrotic syndrome in adults Focal segmental glomerulosclerosis\nMost common composition of kidney stone Calcium oxalate\nTest of choice for nephrolithiasis Noncontrast CT of abdomen\nUltrasonography shows bilateral enlarged kidneys with cysts.",
    "Most common histology of bladder cancer Transitional cell carcinoma\nMost common type of testicular cancer Seminoma, a type of germ cell tumor\nTesticular cancer associated with â†‘ Î²-hCG Choriocarcinoma\nRisk factors for pyelonephritis Pregnancy, vesicoureteral reflux, anatomic anomalies, indwelling\ncatheters, kidney stones\nFindings in primary syphilis Painless chancre and lymphadenopathy\nFindings in 3Â° syphilis Tabes dorsalis, gummas, Argyll Robertson pupils, aortitis, aortic root\naneurysms\nName the organism: Painful chancroid Haemophilus ducreyi\nMULTISYSTEM\nSigns of neurogenic shock Hypotension and bradycardia\nâ†“ CO, â†“ PCWP, â†‘ PVR Hypovolemic shock\nâ†“ CO, â†‘ PCWP, â†‘ PVR Cardiogenic (or obstructive) shock\nâ†‘ CO, â†“ PCWP, â†“ PVR Distributive (eg, septic or anaphylactic) shock\nTreatment of septic shock Fluids and antibiotics\nTreatment of cardiogenic shock Identify cause; inotropes (eg, dobutamine)\nTreatment of hypovolemic shock Identify cause; fluid and blood repletion\nTreatment of anaphylactic shock Epinephrine 1:1000 and diphenhydramine\nThe three most common causes of FUO Infection, cancer, and autoimmune disease\nSIRS criteria Temp <36Â°C (96.",
    "Most common organism in burn-related infections Pseudomonas\nMethod of calculating fluid repletion in burn patients Parkland formula: 24-hour fluid (mL) = 4 Ã— kg Ã— % BSA\nName the organism:\nâ–  Dog or cat bite Pasteurella multocida\nâ–  Infection in burn victims Pseudomonas\nClass of drugs that may cause syndrome of muscle rigidity, hyper- Antipsychotics (neuroleptic malignant syndrome)\nthermia, autonomic instability, and extrapyramidal symptoms\nSide effects of corticosteroids Acute mania, immunosuppression, thin skin, osteoporosis, easy\nbruising, myopathies\nTreatment for delirium tremens Benzodiazepines\nTreatment for acetaminophen overdose N-acetylcysteine\nTreatment for opioid overdose Naloxone\nTreatment for benzodiazepine overdose Flumazenil (monitor for withdrawal and seizures)\nTreatment for neuroleptic malignant syndrome and malignant Dantrolene\nhyperthermia\nCauses of drug-induced SLE INH, penicillamine, hydralazine, procainamide, chlorpromazine, meth-\nyldopa, quinidine\nBurn patient presents with cherry-red, flushed skin and coma.",
    "first-line therapy for chronic stable angina.",
    "first-line for dental procedure; allergy â†’ macrolide, cephalexin, or doxycycline).",
    "first-line for valvular\nYoung adult immigrant is Murmur: Opening snap (think: steno-snap) A-fib\nclassic with mid-diastolic rumbling at apex Loud Surgical valve repair/replace-\nS1 with valve closer; the closer in time the ment or catheter-based\nopening snap is to S2, the worse stenosis is; balloon valvuloplasty only\nloud S2 with pulmonary HTN for severe + symptomatic MS\nIncrease murmur = increase venous return and due to RHD, as it can break up\ndecrease afterload fibrous tissue\n(continues)\n22002222__0022.",
    "first-line therapy for flares, but atrophy, telangi-\nectasias, and rebound flares can occur with prolonged use.",
    "first-line agents\nmanagement when proteinuria is present.",
    "first-line agent, except dur-\ning the first trimester of pregnancy, during which propylthiouracil (PTU)\nis preferred (methimazole is teratogenic).",
    "first-line treatment) and\nting of hyperplasia, 3.",
    "First-line treatment options are laparoscopic Heller myotomy,\nPOEM, and less often, pneumatic dilation.",
    "first-line options are unsuitable, the physician may administer injection\nKillian triangle\nof botulinum toxin.",
    "First-line treatments are hydration and diet modifications.",
    "First-line treatment is general avoid-\nstress.",
    "first-line to evaluate bones for possi-\nble fracture or osteomyelitis, foreign bodies, affected joints, or subcutane-\nous gas.",
    "first-line until cultures can guide\ntherapy.",
    "first-line prevention in pregnant\npatients).",
    "first-line treatment, typically pre-\nscribed with prednisone (10-day course); alternatives include lithium, val-\nproic acid, and topiramate\n22002222__0022.",
    "first-line abortive therapy.",
    "first-line anticonvulsant.",
    "First-line is ethosuximide; second-line is valproic acid.",
    "first-line treatment of mild to moderate AD: Acetylcholinesterase\ninhibitors.",
    "first-line treatment in patients age >65 years.",
    "First-line treatment for respi-\nratory insufficiency is noninvasive positive-pressure ventilation (PPV).",
    "First-line fish is generally advised.",
    "first-line treatment is with vigabatrin,\nwhich enhances GABA transmission.",
    "first-line therapy; physical\nchanges regress or cease to progress.",
    "first-line treatment for\npatients >45 years of age for whom\nâ–  NSAIDs â†“ blood loss.",
    "first-line treatment for ovulatory stimulation.",
    "first-line option in\nViruses\nprimary enuresis.",
    "first-line prophylaxis.",
    "First-line treatment involves physical long ambulation.",
    "first-line treatment for all disruptive behavioral disorders.",
    "First-line treatment for schizophrenia,\n2\npsychotics nist, 5-HT quetiapine, given fewer EPSs and anticholinergic\n2A\nantagonist olanzapinea, effects\npaliperidonea, Clozapine is reserved for severe treat- â†“ EPSs (due to 5- HT antagonism)\n2A\nziprasidone, ment resistance and severe tardive Weight gain, dyslipidemia, type 2 DM,\nclozapine dyskinesia somnolence, sedation, and QTc\nprolongation (ziprasidone); hyperp-\nD partial agonist, Aripiprazolea Same as other atypicals, except it does\n2 rolactinemia (risperidone)\n5-HT partial not cause hyperprolactinemia due\n1A Clozapine can cause agranulocytosis;\nagonist, 5-HT to its ability to act as a D receptor\n2A 2 its use requires weekly CBC moni-\nantagonist agonist under hypodopaminergic\ntoring during first 6 months\nconditions and as a D receptor\n2\nantagonist during hyperdopami-\nnergic conditions\naAlso available as a long-acting depot injection.",
    "First-line treatment for GAD, OCD, panic Nausea, GI upset, somnolence, sexual dys-\noxetine, citalopram, escitalopram) disorder function, agitation\nSNRIs (eg, venlafaxine, duloxetine) First-line treatment for GAD Hypertension, stimulant effects\n5-HT partial agonist (eg, buspirone) Second-line treatment for GAD, social Headaches, dizziness, nausea\nphobia No tolerance, dependence, or withdrawal\nUsed if sexual dysfunction experienced with\nSSRIs\nÎ²-Blocker (propranolol) Performance-only social anxiety disorder Bradycardia, hypotension\nBenzodiazepines (eg, clonazepam, Anxiety (short-term), insomnia, alcohol â†‘ sleep duration; risk for abuse, tolerance,\nalprazolam) withdrawal, muscle spasm, night terrors, and dependence; disinhibition in young or\nsleepwalking older patients; confusion\nAbruptly stopping a short-acting benzo-\ndiazepine (eg, alprazolam) can result in\nseizures\nGAD, Generalized anxiety disorder; GI, gastrointestinal; OCD, obsessive-compulsive disorder.",
    "First-line treatment with Î²-blockers (eg, KEY FACT\npropranolol) before the event or as needed.",
    "First-line treatment is CBT.",
    "first-line agent (SSRI).",
    "First-line mood stabilizer Narrow therapeutic window (0.",
    "First-line treatment for long-term control of asthma\nBeclomethasone, prednisone: Inhibit the synthesis of cytokines\nMuscarinic antagonists Ipratropium: Short-acting muscarinic antagonist (SAMA); competitively blocks muscarinic receptors, preventing\nbronchoconstriction\nTiotropium: Long-acting muscarinic antagonist (LAMA)\nMethylxanthines Theophylline: Causes bronchodilation by inhibiting phosphodiesterase, thereby â†“ cAMP hydrolysis and cAMP\nlevels; limited usage because of narrow therapeutic-toxic index (cardiotoxicity, neurotoxicity)\nCromolyn Prevents the release of vasoactive mediators from mast cells\nUseful for exercise-induced bronchospasm\nEffective only for the maintenance of asthma; not effective during an acute attack; toxicity is rare\nAntileukotrienes Zileuton: A 5-lipoxygenase pathway inhibitor; blocks conversion of arachidonic acid to leukotrienes\nMontelukast, zafirlukast: Block leukotriene receptors\nAnti-IgE Omalizumab: Monoclonal antibody against IgE; inhibits IgE binding to IgE receptor (FcÎµRI) on mast cells; used in\npatients with allergic asthma and high baseline IgE level\nAnti-IL-5/anti-IL-5R Mepolizumab, reslizumab: Monoclonal antibody against interleukin (IL)-5 (potent chemoattractant for eosinophils)\nBenralizumab: Monoclonal antibody against IL-5 receptor, which blocks binding of IL-5, resulting in inhibition of\neosinophil differentiation and maturation in bone marrow; refer to Table 2.",
    "first-line imaging modality.",
    "First-line management:\nchemotherapy) Restrict dietary purines\nStones are radiolucent on plain If stones recur despite dietary\nfilm, but can be detectable management, consider\nwith CT (not as bright as allopurinol\ncalcium stones on CT)\nRhomboid-shaped stones\n(Image C)\nFrequency: 7%\n(continues)\n22002222__0022.",
    "First-line treatment: Avoid dietary triggers\nsyndrome + UTI suprapubic pain/discomfort, dysuria, frequency, dys- Amitriptyline, pain management (phenazopyridine or\nmimics pareunia, pelvic pain, relief after voiding that lasts methenamine), bladder hydrodistention\n>6 weeks without an underlying medical cause; classi-\ncally in women with psychiatric disease (analogous to\nfibromyalgia, IBS); notably, painful bladder syndrome\nis a UTI mimic; other UTI mimics include hemorrhagic\ncystitis (after cyclophosphamide) and bladder irritation\nfrom radiation therapy to pelvis\n22002222__0022.",
    "First-line antibiotics: TMP-SMX (3 days), nitrofurantoin (5â€“7 days)\nâ–  Pain: Pentosan (relieves cystitis pain) or phenazopyridine (relieves urinary\ntract pain)\nPYELONEPHRITIS/UPPER UTI/ONE FORM OF COMPLICATED UTI\nHistory/PE\nInfection ascends from urethra â†’ bladder (cystitis symptoms of frequency +\nsuprapubic pain + urgency + dysuria) â†’ kidney (pyelonephritis symptoms of\n22002222__0022.",
    "first-line management, especially\nwith exposure of cartilaginous tissue.",
    "First-line medication for status epilepticus IV benzodiazepine\nHearing loss in presbycusis High frequency\nRing enhancing lesions in patients with AIDS Toxoplasmosis, CNS lymphoma\nDifferences between myasthenia gravis and Lambert-Eaton myas- Decremental response in MG, Incremental response in LEMS\nthenic syndrome on nerve stimulation\nSymptoms seen in normal pressure hydrocephalus? Gait ataxia (wobbly), urinary incontinence (wet), dementia (wacky)\nRisk factors for intracranial hypertension? Obesity, Tetracycline, growth hormone, excess vitamin A\nWernicke encephalopathy Confusion, ophthalmoplegia, ataxia caused by a deficiency of thia-\nmine (B)\n1\nMost common causes of dementia Alzheimer disease and vascular\nCombined UMN and LMN disorder ALS\nRigidity and stiffness with unilateral resting tremor and masked facies Parkinson disease\nTreatment for Parkinson disease Levodopa/carbidopa\nTreatment for Guillain-BarrÃ© syndrome IVIG or plasmapheresis; avoid steroids\nRigidity and stiffness that progress to choreiform movements, accom- Huntington disease; autosomal dominant\npanied by moodiness and altered behavior\nPort-wine stain in the V distribution as well as with intellectual dis- Sturge-Weber syndrome; treat symptomatically; possible focal cere-\n1\nability, seizures, and ipsilateral leptomeningeal angioma bral resection of affected lobe\nMultiple cafÃ©-au-lait spots on skin Neurofibromatosis type 1\nHyperphagia, hypersexuality, hyperorality, and hyperdocility KlÃ¼ver-Bucy syndrome (amygdala)\nName the organism:\nâ–  Meningitis in adults Neisseria meningitidis\nâ–  Meningitis in elderly Streptococcus pneumoniae\nâ–  Meningoencephalitis in AIDS patients Cryptococcus neoformans\nCauses of ring-enhancing brain lesions Abscess, toxoplasmosis, metastasis, lymphoma, AIDS, neurocysticercosis\n22002222__0022.",
    "First-line treatment for otitis media Amoxicillin\nMost common pathogen causing croup Parainfluenza virus type 1\nHomeless child is small for his age and has peeling skin and a swollen Kwashiorkor (protein malnutrition)\nbelly\nDefect in an X-linked syndrome with intellectual disability, gout, self- Lesch-Nyhan syndrome (purine salvage problem with HGPRTase\nmutilation, and choreoathetosis deficiency)\nNewborn girl has continuous â€œmachinery murmur.",
    "First-line pharmacotherapy for depression SSRIs\nGalactorrhea, impotence, menstrual dysfunction, and â†“ libido Adverse effects of dopamine antagonists\n17-year-old girl has left arm paralysis after her boyfriend dies in a car Conversion disorder\ncrash.",
    "gold standard for diagnosis of\nAssociated with Kaposi sarcoma in HIV/AIDS HHV-8.",
    "gold standard for such evaluation is a randomized, Assume that the data below are from\ndouble-blind controlled trial, other types of studies may be used as well (eg, a hypothetical case-control study.",
    "gold standard for studying treatment effects.",
    "gold standard treatment and adverse effects\nSample size: 20-100 healthy 100-300 patients with 300-3000 patients with All patients with disease\nvolunteers disease of interest disease of interest of interest taking drug\n(Reproduced with permission from USMLE-Rx.",
    "Gold standard for diagnosis of gastritis and H pylori\ncan also detect intestinal metaplasia, mucosa-associated Most invasive test\nlymphoid tissue (MALT), or widespread gastritis Must be off PPI Ã—2 weeks prior to endoscopy\n22002222__0022.",
    "gold standard for diagnosis and\nsion from Caproni M et al.",
    "gold standard is intestinal biopsy,\nabdominal surgery, GI cancer), metabolic and systemic disorders (eg, dia-\nwhich will show increased intraepi-\nbetes), and immune disorders (eg, IgA deficiency)\nthelial lymphocytes (>25 per 100\nâ–  Hx/PE: Presents with pale, foul-smelling, bulky stools (steatorrhea or\nenterocytes), crypt hyperplasia, and\nfat maldigestion) associated with abdominal pain, flatus, bloating,\nvillous atrophy.",
    "gold standard for\ndiagnosis of arterial occlusive disease, but conventional angiography A 65-year-old male smoker is brought\nto the emergency department for\nallows for intervention of thrombosis/embolism.",
    "gold standard for those with nega- alternative option.",
    "gold standard if dietary control is insufficient.",
    "gold standard but not necessary if â†‘â†‘ 17-OH.",
    "gold standard and still occasion-\ngammaglobulinemia may be present Candida, Klebsiella, Pseudo- ally used\nmonas, Aspergillus) Treat with daily trimethoprim-\nPatients may have granulomas of sulfamethoxazole (TMP-SMX);\nthe skin and GI/genitourinary make judicious use of antibiotics\n(GU) tracts during infections.",
    "gold standard for sus-\npected gonococcal or chlamydial conjunctivitis.",
    "gold standard for the diagnosis of\nkidney stones (see Fig.",
    "gold standard for tissue-invasive dis-\nease), serum polymerase chain reaction (PCR).",
    "classic presentation of pellagra metabolite 5-hydroxyindoleacetic acid (5-HIAA) (best initial test) are diag-\n(deficiency in niacin/vitamin B) is the 4\n3 nostic.",
    "CLASSIC PRESENTATION RISK FACTORS TREATMENT\nExternal hemorrhoids Pruritic and painful Obesity, constipation, older High-fiber diet, sitz baths, stool soft-\n(below dentate May appear blue if thrombosed age, and pregnancy eners, topical analgesia\nline) Hemorrhoidectomy if refractory\nInternal hemorrhoids Painless, bright-red bleeding after defecation Obesity, sitting on toilet for High-fiber diet, sitz baths, stool soft-\n(above dentate or wiping extended times, older eners, topical analgesia\nline) age, and pregnancy Rubber band ligation if refractory\nRectal prolapse Protruding, erythematous mass with concentric Multiparity, prior pelvic Diet and lifestyle modifications\nrings seen when patient bears down surgery, older age, (increased fiber and water intake)\nMay have preceding discomfort, constipation, chronic constipation or If refractory and symptomatic, pos-\nincontinence diarrhea, or post-stroke sibly surgery (rectopexy)\nAnal fissure Intense pain lasting for hours typically following Constipation or diar- Diet and lifestyle modifications;\ndefecation Â± blood on toilet paper rhea, Crohn disease, or topical anesthetics and vasodilators\nClassically seen on examination at posterior malignancy If refractory, lateral sphincterotomy\nmidline of anal canal\nAbscess Tender, fluctuant mass at anal verge Constipation, DM, and Prompt incision and drainage fol-\nMay have fever or other systemic symptoms immunosuppression lowed by empiric antibiotics\nAnorectal fistula Intermittent, malodorous perianal drainage Perianal abscesses, Crohn Surgical closure (fistulotomy)\nand pain with defecation disease, and malignancy\nProctalgia fugax Recurrent rectal pain unrelated to defecation, Higher incidence among Reassurance, biofeedback therapy,\nlasting seconds to minutes females and age <45 or possibly inhaled albuterol when\nNo organic cause identifiable years symptomatic\nRadiation proctitis Acute: Within 3 months following pelvic Pelvic radiation in the Acute: May be self-limited\nradiation setting of rectal, prostate, Antidiarrheals and butyrate enema\nDiarrhea, mucus, and minimal bleeding or other malignancy Chronic: Sucralfate or steroid enemas\nChronic: Within 3 months to 2 years of pelvic Endoscopic thermal coagulation for\nradiation bleeding\nConstipation, rectal pain, and severe bleeding\nMICROSCOPIC COLITIS\nChronic, inflammatory cause of diarrhea subdivided into lymphocytic and\ncollagenous colitis.",
    "Classic presentation is a subacute SBO in an older adult female.",
    "classic presentation of G6PD\nwho present with sudden anemia, episodic dark urine, and jaundice and\ndeficiency is a Black male patient\nwho have a normal-sized spleen with an infection or use drugs that induce\npresenting with fatigue, dark urine, and\noxidative damage to RBCs.",
    "classic presentation involves isms; think back to how IgM Patients rarely survive to adulthood\nbleeding, eczema, and recurrent otitis functions) Patients with severe infections may\nmedia be treated with BMT\nRemember the mnemonic WIPE:\nWiskott-Aldrich, Infections, Purpura\n(thrombocytopenic), Eczema\nPEDIATRIC PHAGOCYTIC DEFICIENCIES\nChronic granuloma- An X-linked (two-thirds) or autosomal Chronic skin, lymph node, pul- Absolute neutrophil count with\ntous disease (CGD) recessive (one-third) disease with monary, GI, and urinary tract neutrophil assays\ndeficient superoxide production by infections; osteomyelitis and The dihydrorhodamine (DHR) test\npolymorphonuclear leukocytes and hepatitis is diagnostic for CGD; nitroblue\nmacrophages Infecting organisms are catalase tetrazolium test is the previous\nAnemia, lymphadenopathy, and hyper- âŠ• (S aureus, Escherichia coli, gold standard and still occasion-\ngammaglobulinemia may be present Candida, Klebsiella, Pseudo- ally used\nmonas, Aspergillus) Treat with daily trimethoprim-\nPatients may have granulomas of sulfamethoxazole (TMP-SMX);\nthe skin and GI/genitourinary make judicious use of antibiotics\n(GU) tracts during infections.",
    "classic presentation of pertussis â–  Has the following three stages:\nis an infant <6 months of age with â–  Catarrhal (mild URI symptoms; lasts 1â€“2 weeks)\nparoxysmal coughing, post-tussive â–  Paroxysmal (paroxysms of cough with inspiratory whoop and post-\ntussive emesis; lasts 2â€“3 months)\nemesis, and apnea.",
    "Classic presentation of pain crisis: Patient of sub-Saharan African descent\nwith sudden onset of severe chest pain, back pain, or thigh pain."
  ],
  "metadata": {
    "source": "First Aid for USMLE Step 2 CK, 11th Edition",
    "total_pages": 865,
    "extraction_date": "2025-11-19"
  },
  "specialty_knowledge": {
    "Critical Care": {
      "specialty": "Critical Care",
      "facts": [],
      "diseases": [
        "Graw Hill",
        "The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that",
        "Cs",
        "She",
        "University and",
        "He",
        "Washington\nCaroline",
        "Abhishek",
        "This recommendation",
        "Vikas",
        "She is an avid tennis Resuscitation Fellowship at the University of Pennsylvania and",
        "North Carolina and her Dan",
        "This",
        "Use of this work",
        "Stephanie",
        "Tao developed a passion for medical education as a medical Vikas",
        "Medicine"
      ],
      "treatments": [],
      "diagnostics": [
        "ultrasound\n"
      ]
    },
    "Emergency Medicine": {
      "specialty": "Emergency Medicine",
      "facts": [],
      "diseases": [
        "Fracture line",
        "What",
        "Time",
        "It is",
        "These are sets of",
        "The session",
        "The following",
        "Herpes\nsimplex",
        "The overlying renal cortex",
        "Epiglottitis",
        "Symptomatic treatment is all that",
        "Canadian students but",
        "This adolescent patient",
        "Croup",
        "Presentation",
        "Loss of function of the affected limb",
        "High fluid intake",
        "Aortic disruption",
        "Injury",
        "What pathogen",
        "The pain",
        "Nikolsky sign",
        "The cost",
        "This\nfeedback is intended for use as a study tool only and",
        "Cystinuria",
        "Fevers and chills can be seen if the patient",
        "If a patient\ntion",
        "Pain",
        "This",
        "The most likely diagnosis",
        "Prevention",
        "Referral to a chronic pain specialist",
        "Bacterial meningitis in older children classically",
        "While management of specific organ damage",
        "It",
        "The diaper area",
        "Septic arthritis",
        "Emergency surgery",
        "The most common format",
        "The classic presentation\nof fat embolism",
        "Amputation possibly necessary\ndisability",
        "Ultrasound is preferred for pregnant patients and children when there",
        "Initial lesion is classically a herald patch that",
        "Prometric if space",
        "There",
        "Mucosal\ninvolvement",
        "Because complete aortic rupture",
        "The diagnosis",
        "Treatment",
        "Also let us\nknow about material in this edition that you feel"
      ],
      "treatments": [
        "all that",
        "permission from",
        "to administer",
        "cool",
        "Limited plantar"
      ],
      "diagnostics": [
        "clinical impression",
        "KOH exam to rule out fungus ",
        "characteristic findings on x",
        "CTA in stable patients"
      ]
    },
    "Surgery": {
      "specialty": "Surgery",
      "facts": [],
      "diseases": [
        "Normal hemostasis",
        "Needle aspiration indicated if septic bursitis",
        "Rectal and Vaginal Injuries\nUsually managed nonoperatively unless reconstruction",
        "Spinal stenosis",
        "Chronic functional constipation",
        "Treatment\nThe most likely diagnosis",
        "Emotional support",
        "Asymptomatic bacteriuria",
        "Proton pump inhibitors are needed if reflux",
        "Concurrent initiation with heparin is needed until\nwarfarin dosing",
        "Stiffness",
        "Most common etiology",
        "Testicular cancer",
        "Facial Nerve Palsy\nFacial weakness",
        "Cumulative sun exposure",
        "If gender or sexuality",
        "Signs of active",
        "It is your job to\ndetermine which information is superfluous and which",
        "Healthcare",
        "Diligent fluid resuscitation and avoidance of antihypertensives\nare pursued to avoid hypoperfusion and secondary",
        "Immediate surgery",
        "Surgical resection",
        "Prostatic massage",
        "This signifies an ability to integrate your clinical and\nfactual knowledge to an extent that",
        "Less acute presentation than",
        "If the condition",
        "Adjuvant therapy",
        "If negative but degree of suspicion",
        "Heart rate goal",
        "Delivery",
        "Jaundice",
        "Xanthogranulomatous pyelonephritis",
        "Diagnosis\nClinical diagnosis",
        "This section",
        "The\nphysician may require a liver biopsy if diagnosis",
        "Patients",
        "It may be\neither the first manifestation of an underlying systemic disease or represent an",
        "The proximal portion of the stomach",
        "Spigelian Just lateral to the lateral border of the rectus Caused by a defect in the spigelian aponeurosis Usually occur in\nmuscle that",
        "An inflammatory rheumatic condition",
        "White or Asian\ndeficiency that",
        "Granulomatous lesion of the eyelid that",
        "The posterior urethra",
        "Histologic analysis of duodenal biopsies",
        "Obstruction",
        "The gold standard",
        "Mortality",
        "Diagnosis\nThe diagnosis",
        "Levothyroxine",
        "If tissue damage is significant or urethral repair"
      ],
      "treatments": [
        "antacids",
        "monitoring of",
        "beyond the",
        "useful to",
        "supportive\nNSAIDs",
        "inef",
        "immediate Transillumination",
        "with vigabatrin",
        "general avoid",
        "chemical or",
        "soluble fiber",
        "not recom",
        "surgical correction",
        "antivirals",
        "pain",
        "alben",
        "typically supportive",
        "assigned randomly",
        "curative intent",
        "surgical\ncarcinoma",
        "IV fluids",
        "Diagnosis with",
        "NSAIDs",
        "somatostatin analogs",
        "erythromycin\nFIGURE",
        "pelvic ultrasonography",
        "iso",
        "endoscopic eradication",
        "than the",
        "limited to",
        "topical anes",
        "surgical\nirrigation",
        "dantrolene\nand",
        "daily itraconazole",
        "in widespread",
        "ciprofloxacin or",
        "penicillinase",
        "intranasal corticosteroids",
        "often needed",
        "these antibiotics",
        "corticosteroids results",
        "the best",
        "not necessary",
        "symptomatic",
        "to respectfully",
        "surgical resection",
        "the back",
        "gabapentin",
        "levothyroxine if",
        "warm compress"
      ],
      "diagnostics": [
        "clinical presentation and physical examination\n",
        "suspected stable angina",
        "matrix",
        "a\nClotting factor deficiencies of factors VIII ",
        "shave\nbiopsy",
        "MRI",
        "a ",
        "pancreatic cancer",
        "shave biopsy",
        "permission from Lee JH",
        "UA ",
        "COPD",
        "hemodialysis",
        "CTA in stable patients",
        "hypertension without risk factors or a family history of hypertension",
        "two abnormal values obtained\nwhile the patient is asymptomatic and untreated",
        "two of three clinical history criteria",
        "barium swallow or EGD",
        "the presence of acute lower abdominal or pelvic pain plus\none of the following",
        "histology on nephrectomy specimen",
        "biopsy stoning",
        "immunodiffusion testing",
        "biopsy\nTreatment ",
        "CT imaging of the abdomen and pelvis"
      ]
    },
    "Pediatrics": {
      "specialty": "Pediatrics",
      "facts": [],
      "diseases": [
        "Treatment murmur",
        "What",
        "If the foot",
        "Intrathecal chemotherapy for neurologic prophylaxis",
        "Ultrasonography",
        "Onset",
        "The pattern of\ngrowth",
        "Yield Facts",
        "The risk for recurrence",
        "Tumor lysis syndrome",
        "Transmission",
        "This disorder",
        "Categorization",
        "Emergent surgical correction is needed when there is",
        "The content contained herein",
        "Fever",
        "The disease",
        "This infant",
        "There",
        "Treatment for bronchiolitis",
        "Surgical resection",
        "Pinworm",
        "Developmental disorder",
        "If indomethacin fails or if the infant",
        "Management",
        "Idiopathic disease",
        "Documentation",
        "If isolated language delay",
        "Etiology",
        "Microcephaly",
        "Thrombocytopenia",
        "Physical examination",
        "If it",
        "Kernicterus",
        "Deoxygenated\nblood from the right ventricle",
        "If the degree of pulmonary stenosis",
        "Antibiotic prophylaxis",
        "Observation",
        "Abuse should be suspected if the history is not consistent with the injury\nSuspect sexual abuse if there",
        "Higashi\nsyndrome",
        "Diagnosis\nDiagnosis",
        "Cyclic neutropenia is a rare genetic disorder",
        "No treatment",
        "If sexual abuse",
        "Bronchiolitis",
        "Salmonella",
        "More severe\ncases can be",
        "Objective hearing screening",
        "Chronic hemolysis",
        "It"
      ],
      "treatments": [
        "anticoagulation",
        "not\nileus",
        "indicated",
        "bronchodilators may",
        "bone marrow",
        "largely supportive",
        "used to",
        "not always",
        "IVIG",
        "serial\ncasting",
        "antibiotic prophy",
        "vitamin A",
        "ASA to",
        "hydroxyurea",
        "fluids",
        "prophylactic antibiotics",
        "required",
        "surgical",
        "often supportive",
        "needed",
        "required for",
        "by volume",
        "daily trimethoprim"
      ],
      "diagnostics": [
        "perianal bacterial culture",
        "a DNA analysis\nshowing mutations in the MECP",
        "clinical impression",
        "an insufflator bulb"
      ]
    },
    "Cardiovascular": {
      "specialty": "Cardiovascular",
      "facts": [],
      "diseases": [
        "What",
        "Tumor",
        "Critical limb",
        "Sjogren syndrome",
        "Education and reassurance\nwith history of drug use that",
        "Digoxin toxicity",
        "Pericardial effusion is",
        "Aspirin",
        "Diagnosis",
        "His\nurine dipstick",
        "Nitrates\ncardiac",
        "Low Normal\ninduced nephropathy and would have\nbenefited from",
        "Chest pain that",
        "Ensure patient",
        "Thrombosis",
        "Empagliflozin",
        "Avoidance of\nMonocular amaurosis fugax",
        "Addressing underlying causes of",
        "Inflammation",
        "Ischemic pain",
        "Disturbance in gut flora",
        "Chronic",
        "If cancer or bacterial infection",
        "Acute therapy",
        "Surgical septal myomectomy",
        "Management of cardiovascular\nthat",
        "Nielsen syndrome",
        "Storage cardiomyopathy that",
        "Complications\nThe most feared manifestation is blindness from anterior",
        "Romano Ward syndrome",
        "Treat acute symptomatic",
        "Pain",
        "This",
        "Risk Factors pathway is still refractory but the slow\npathway",
        "Echocardiography should be done routinely to assess for signs of",
        "Etiologies\nMost common cause",
        "The duration of stable angina",
        "Generally",
        "Typical onset",
        "It",
        "Altered mental status",
        "Dermatomyositis",
        "Hypertensive emergency",
        "Symptomatic disease is",
        "Key finding",
        "Cholesterol emboli Hypersensitivity vasculitis",
        "Mary Jane",
        "Ranolazine",
        "Also known as",
        "Echocardiography"
      ],
      "treatments": [
        "indicated",
        "not protective",
        "cautious use",
        "aspirin and",
        "history of",
        "absolutely necessary",
        "penicillin IV",
        "IV fluids",
        "procainamide\nthe",
        "altered",
        "benzathine penicillin",
        "NSAIDs and"
      ],
      "diagnostics": [
        "new",
        "physician or nurse Bone",
        "repeating laboratory assessment ",
        "physician hypertension\nmen ",
        "physician or nurse if blood pressure higher than "
      ]
    },
    "Pulmonary": {
      "specialty": "Pulmonary",
      "facts": [],
      "diseases": [
        "Sensorineural deafness and treatment if there\neye disorders are also noted",
        "What",
        "This\nresults in blood being delivered to the left side of the heart that",
        "Doxycycline",
        "Minimal change disease The most common Sudden onset of Biopsy",
        "This patient",
        "Diagnosis\nVirus",
        "Critical limb",
        "Liver transplantation",
        "Treatment\nPrimary sclerosing cholangitis",
        "Respiratory alkalosis",
        "Treatment\nThe preferred regimen",
        "Dental splints if bruxism",
        "Loffler syndrome is a form of\neosinophilic pulmonary disease\nDiagnosis",
        "Primary biliary cholangitis",
        "Presentation of key syncope syndromes",
        "An idiopathic disorder",
        "The maxillary sinuses are\nLudwig angina",
        "This is contraindicated if there",
        "Sepsis",
        "If a specific pathogen",
        "Limb",
        "If ceruloplasmin level",
        "Methylene blue\nSerum cyanide concentration",
        "If the tick",
        "Acute hypotension with tachycardia and sudden\nincrease in peak inspiratory pressure",
        "Leukoplakia",
        "If the patient",
        "Orthostatic syncope",
        "Maximal intervention",
        "Asystole and pulseless electrical\nrepolarization",
        "Euthanasia",
        "Superinfection in burns",
        "If the living will",
        "Pancreatic",
        "Typically",
        "Heart rate",
        "Biopsy is required if diagnosis",
        "Ts are normal but asthma",
        "Overall mortality",
        "Timely diagnosis of the correct species",
        "The classic sign",
        "Alport Progressive proteinuria and ance and have areas of hypertension\nsyndrome",
        "Hypoxemia",
        "Septic shock",
        "Unilateral diaphragm paralysis",
        "Bilateral\nparalysis is diagnosed with clinical history and",
        "There",
        "The first step in management",
        "The area"
      ],
      "treatments": [
        "indicated",
        "to proceed",
        "largely supportive",
        "supportive care",
        "possible addition",
        "doxycycline",
        "HAART regimens",
        "oseltamivir",
        "clinical identification",
        "rifampin for",
        "antibiotics",
        "penicillin for",
        "salt restriction",
        "determined by",
        "ganciclovir",
        "determined ure",
        "oral azithromycin",
        "antibiotics and",
        "CPAP fails",
        "amoxicillin",
        "supportive",
        "bronchoscopy",
        "Ca",
        "vancomycin",
        "required",
        "macrolide",
        "amphotericin B",
        "benztropine or",
        "dantrolene",
        "symptom driven",
        "radiotherapy",
        "predni",
        "tetanus vaccination",
        "steroids"
      ],
      "diagnostics": [
        "sputum Gram stain and culture",
        "interferon",
        "biopsy and indirect\nimmunofluorescence of the skin lesion",
        "clinical history and is aided by reduced forced\nvital capacity ",
        "polysomnography",
        "a\nfluoroscopic sniff test",
        "cytology of induced sputum or bronchoscopy specimen with NY",
        "clinical evaluation",
        "the following",
        "serology",
        "streptococcal pharyngitis "
      ]
    },
    "Infectious Disease": {
      "specialty": "Infectious Disease",
      "facts": [],
      "diseases": [
        "There",
        "Protected health information is any information that",
        "Unilateral and",
        "It",
        "The patient",
        "The harm",
        "The formal definition of clinical research",
        "Accepting gifts or cash to influence care or preferential treatment",
        "Dereliction",
        "While\nthe pathogenesis",
        "The initial infection",
        "This law addresses three main",
        "Diagnosis",
        "This",
        "The role of ethics in research",
        "Onset"
      ],
      "treatments": [
        "unac",
        "use of"
      ],
      "diagnostics": []
    },
    "Dermatology": {
      "specialty": "Dermatology",
      "facts": [],
      "diseases": [
        "Postexposure prophylaxis",
        "The cyst",
        "What",
        "Venous hypertension",
        "Patient surveillance",
        "If the diagnosis",
        "Varicella",
        "Impetigo\nFebrile patient with history of diabetes",
        "Erysipelas",
        "Diagnosis",
        "Later\nlesions are",
        "The term ringworm",
        "Obese patient",
        "Spread",
        "Scleroderma renal crisis is",
        "Widespread or internal disease",
        "Nikolsky sign",
        "No treatment",
        "Bullous impetigo",
        "Pseudomonas",
        "Oral ivermectin",
        "Ulceration",
        "Impetigo\nLocal infection of the epidermis that primarily occurs in children and",
        "Oral thrush",
        "Transmitted via respiratory secretions and Infectious mononucleosis can be Treatment",
        "This",
        "Nikolsky",
        "Candida species\nbut",
        "Acute urticaria",
        "Result from",
        "Kaposi sarcoma",
        "It",
        "Early localized disease",
        "Excluding other causes",
        "Antibiotics are not needed for pilonidal\ncysts unless cellulitis",
        "When acne",
        "Isotretinoin",
        "More severe\ndisease",
        "Crusted scabies",
        "The surface",
        "Mortality",
        "The lesion",
        "The disease",
        "Given\nthe teratogenicity of",
        "What organism",
        "Treatment",
        "The primary goal of therapy",
        "Malignancy",
        "The skin",
        "Chronic urticaria"
      ],
      "treatments": [
        "penicillin",
        "fluoroquinolones and",
        "podophyllin",
        "necessary",
        "topical steroids",
        "not\nnecessary",
        "emollients and",
        "itraconazole",
        "to break",
        "mostly supportive",
        "topical permethrin",
        "ivermectin",
        "an effective",
        "acyclovir",
        "the same",
        "excision for",
        "with incision",
        "steroids",
        "imiquimod"
      ],
      "diagnostics": [
        "clinical features and histology",
        "history",
        "identifying het",
        "biopsy"
      ]
    },
    "Endocrinology": {
      "specialty": "Endocrinology",
      "facts": [],
      "diseases": [
        "Your hospital",
        "The next best step",
        "What",
        "Osteoporosis",
        "Hypomagnesemia",
        "Interview strategy in patient with alcoholism when patient",
        "Infusion of regular insulin intravenously if serum potassium",
        "Patient",
        "Best initial treatment",
        "When can a physician refuse to continue treating a patient on the When there",
        "If potassium",
        "The best initial test to screen for thyroid disease",
        "The prevalence of a disease",
        "The likelihood or risk of observing an\noutcome following an exposure",
        "If you want to know if geographic location affects infant mortality Confounding variable\nrate but most variation in infant mortality",
        "Blood glucose\nlevel",
        "Accuracy and validity measure\nexposure",
        "Parathyroidectomy if the patient",
        "Cardiovascular risk The presence of diabetes",
        "If there",
        "Survival analysis",
        "Most common cancer in men and most common cause of death from Prostate cancer",
        "Oral",
        "The difference in risk that",
        "When prognosis",
        "Patient with history of lithium use",
        "As insulin",
        "Root cause analysis\nInvoluntary psychiatric hospitalization can be undertaken for which The patient",
        "Management\nAfter the cause of hypoglycemia",
        "Hypercalcemia",
        "The ideal test",
        "Postoperative patient with significant pain",
        "This",
        "Rapid administration of\noral or intravenous carbohydrates",
        "Management\nTreatment of both entities",
        "The most likely diagnosis",
        "If access to water",
        "High sensitivity",
        "Secondary adrenal insufficiency",
        "Obtaining a detailed history",
        "Pancreatic",
        "Symptomatic hypoglycemia",
        "It",
        "High specificity",
        "The presentation of diabetes",
        "Bias introduced into a study when a clinician",
        "Antihyperglycemic agent associated with lactic acidosis Metformin\nPatient",
        "The drug is still available but",
        "Reproduced with",
        "Obtain a court order before treatment\nWhat"
      ],
      "treatments": [
        "glucocorti",
        "no\nlonger",
        "exogenous cortico",
        "lifestyle modification"
      ],
      "diagnostics": [
        "ACTH is dependent on the renin",
        "high sensitivity",
        "their medication regimen reviewed and medication doses reduced in cases\nDKA",
        "adrenal CT MRI of the pituitary\n",
        "high sensitivity or specificity will have Posttest odds "
      ]
    },
    "Oncology": {
      "specialty": "Oncology",
      "facts": [],
      "diseases": [
        "Commonly",
        "Motility disorder in which normal peristalsis",
        "Diagnosis",
        "Biopsy",
        "Vinson syndrome",
        "Increased severity of symptoms",
        "History\nCandida esophagitis",
        "Yoshida\nGoal of therapy"
      ],
      "treatments": [
        "to relieve",
        "biopsy shows"
      ],
      "diagnostics": []
    },
    "Hematology": {
      "specialty": "Hematology",
      "facts": [],
      "diseases": [
        "Acute cholecystitis from pigmented gallstones",
        "What",
        "This patient",
        "It is associated with many\nsevere illnesses and",
        "Heparin discontinuation",
        "Lymphocytosis",
        "This disease",
        "Occurs when bone marrow production",
        "Plasma exchange",
        "Hematuria with eosinophilia",
        "Typically",
        "Thromboprophylaxis",
        "Avoiding triggers",
        "Platelet transfusion",
        "His past medical history",
        "There",
        "No heparin interruption",
        "Heyde syndrome is a multisystem disorder",
        "Reduced agglutination",
        "This gastric cancer and is the most common\ntest",
        "Eastern\nEurope",
        "This difference",
        "Prophylactic administration of clotting factor concentrates",
        "Bone marrow\nproduction of platelets",
        "Cryoglobulinemia",
        "Most accurate test",
        "No treatment",
        "Urine",
        "Allogeneic bone marrow\ntransplant",
        "It",
        "Warfarin should be commenced after a direct thrombin inhibitor",
        "Sideroblastic anemia",
        "Eosinophilia as a primary disorder Causes of secondary",
        "Treatment",
        "Proliferative disorders of Langerhans cells",
        "Best initial test",
        "Adults Mycosis fungoides",
        "Leukoreduction of donor urine output\nGive epinephrine",
        "No change in platelet count",
        "Bone\nmarrow transplantation",
        "Starting nonheparin anticoagulation",
        "If bleeding is not severe and factor level",
        "Iron",
        "Tacrolimus",
        "Thalassemia",
        "Bone marrow biopsy",
        "Median survival without treatment",
        "Rasburicase",
        "The most likely diagnosis",
        "Polycythemias are"
      ],
      "treatments": [
        "LMWH or",
        "intravenous",
        "recombinant EPO",
        "broad",
        "required",
        "itraconazole or",
        "stage dependent",
        "aggressive chemotherapy",
        "generally palliative",
        "out treatable",
        "chemotherapy\nMantle",
        "necessary"
      ],
      "diagnostics": [
        "the addition of intrinsic factor",
        "clinical presentation and CBC\n"
      ]
    },
    "Neurology": {
      "specialty": "Neurology",
      "facts": [],
      "diseases": [
        "What",
        "The origin of the meningioma",
        "This patient",
        "If repetition",
        "Hypertension",
        "If a certain antiepileptic",
        "Central vertigo",
        "Poliomyelitis",
        "Dementia is",
        "Patient can\nthe lesion",
        "Another subtype",
        "The most common type",
        "Typically",
        "To smooth muscle of eyelid\nTo pupillary dilator\nInternal\ncarotid To sweat glands of face\nartery External carotid artery Cavernous sinus syndrome",
        "If temporal arteritis",
        "Oken and Wernicke",
        "Aggressive physical rehabilitation",
        "Innermost layer of the meninges that",
        "The magnetic gait",
        "Convergence",
        "Peripheral vertigo",
        "Supportive therapy",
        "This disorder of the inner ear is",
        "There",
        "Acute bacterial meningitis",
        "If an adult patient",
        "Drug use\nate",
        "His right eye",
        "Encephalitis",
        "Age",
        "The brain",
        "Although it",
        "Aura",
        "Where",
        "Neisseria meningitidis",
        "Nerve supply",
        "Diagnosis\nDiagnosis",
        "Optic neuritis produces painful vision loss that",
        "Therapy",
        "No treatment",
        "Ureaplasma\nYoung woman",
        "Although evidence",
        "It",
        "Headache that",
        "If fever",
        "If a patient",
        "If observation period",
        "The treatment of choice",
        "Oligodendroglioma most commonly presents Surgical resection",
        "Affected eye unable to abduct and"
      ],
      "treatments": [
        "an emphasis",
        "with\nwarm",
        "required for",
        "broad",
        "acetylcholinesterase inhibitors",
        "currently available",
        "highly dependent",
        "allopurinol or",
        "the mainstay",
        "baclofen for",
        "symptomatic and",
        "sometimes\ntoma"
      ],
      "diagnostics": [
        "MRI of the orbits",
        "ullary",
        "psychiatric conditions"
      ]
    },
    "Ophthalmology": {
      "specialty": "Ophthalmology",
      "facts": [],
      "diseases": [
        "What",
        "Ophthalmologic evaluation",
        "The patient",
        "Best first treatment when patients have minimal symptoms"
      ],
      "treatments": [],
      "diagnostics": []
    },
    "Obstetrics": {
      "specialty": "Obstetrics",
      "facts": [],
      "diseases": [
        "Hydrops fetalis when fetal hemoglobin",
        "Loss of fetal station",
        "Attempt trial only if delivery",
        "Augmentation with oxytocin should be considered when contraction frequency",
        "The fundus",
        "The goal of prenatal care",
        "Oligohydramnios",
        "Bilateral transvaginal injection of local anesthetic in and around\npudendal nerve as it passes around",
        "This topic",
        "The clot",
        "Septic pelvic thrombophlebitis",
        "Delivery of the fetus",
        "Fern test",
        "Consider ondansetron if vomiting",
        "If the patient",
        "This",
        "Maternal failure to gain appropriate weight",
        "Pituitary",
        "Initiate emergent delivery once the patient",
        "Diabetes in pregnancy",
        "She",
        "It",
        "Insulin is the gold standard if dietary control",
        "Escherichia coli",
        "Determine station or engagement of the fetal head relative to a line\nthrough the",
        "Breech presentation",
        "The success rate",
        "The risk for postpartum hemorrhage",
        "Immunologic",
        "Infection",
        "Anatomic",
        "The\ndose",
        "Fetal Tone\nFetal Breathing\nLabor",
        "Rh",
        "Postpartum management",
        "Urethral\ncatheterization",
        "Postpartum urinary retention",
        "If patient",
        "If the baby",
        "Nitrazine paper test",
        "Testing",
        "Strict glucose control",
        "If diagnosis",
        "Transient hypotension from sympathetic blockade",
        "Endocrinologic",
        "Spinal headache is another common complication if there",
        "Placenta",
        "Diuretics can aggravate low plasma volume to the point of uterine"
      ],
      "treatments": [
        "ampicillin",
        "vanco",
        "nursing tech",
        "required",
        "appropriate antihypertensives",
        "with supportive",
        "the same",
        "close\nsurveillance"
      ],
      "diagnostics": [
        "contraction stress test ",
        "a prolonged second stage of labor"
      ]
    },
    "Gynecology": {
      "specialty": "Gynecology",
      "facts": [],
      "diseases": [
        "If the\nsecond number",
        "Mammography",
        "What",
        "Anovulation that",
        "The first step in the workup of\noften presents in infancy with ambiguous genitalia primary or secondary amenorrhea",
        "Usually resolves when underlying condition or medication",
        "The vaccine",
        "Delayed puberty",
        "Primary infertility",
        "The\nBethesda system",
        "The physician should look",
        "Ultrasonography",
        "Observation",
        "Postmenopausal vaginal bleeding",
        "Excisional biopsy is indicated if no fluid is obtained or\nif the fluid",
        "Normal male development",
        "Treatment based on biopsy results for invasive disease",
        "Etiologies are shown in\nanalysis",
        "No treatment",
        "If the patient",
        "Lifetime risk for breast cancer that",
        "No intervention",
        "Treatment\nTreatment",
        "This",
        "Dominant follicle",
        "If estrogen",
        "The most likely diagnosis",
        "Uterus",
        "The average age of onset",
        "The progression of a normal menstrual cycle",
        "Treatment\nLaparoscopy or laparotomy with detorsion if the ovary",
        "It",
        "Requires close monitoring of ovulation\nwhich conception",
        "An intraductal\npapilloma",
        "The patient",
        "All congenital adrenal enzyme deficiencies are",
        "If the uterus",
        "Albright\nsyndrome",
        "Leuprolide",
        "Primary amenorrhea",
        "Ds Can be difficult to use\ninserted into the vagina\nFertility awareness Sexual intercourse",
        "Menopause",
        "If patient",
        "There",
        "Excision",
        "If the endometrium",
        "Elevation",
        "If bleeding",
        "Diagnosis\nThe most likely diagnosis",
        "Hysterectomy"
      ],
      "treatments": [
        "combined oral",
        "systematic\ndesensitization",
        "cone biopsy",
        "daily calcium",
        "pelvic floor",
        "based on",
        "glucocorticoids",
        "radiation therapy",
        "etiology specific",
        "necessary"
      ],
      "diagnostics": [
        "core needle biopsy"
      ]
    },
    "Psychiatry": {
      "specialty": "Psychiatry",
      "facts": [],
      "diseases": [
        "Use of stimulants",
        "The most common causes are",
        "Girl who",
        "Clinical presentation",
        "What",
        "Tc prolongation and torsades\nIf compliance is a major",
        "Anorexia nervosa",
        "Suicide",
        "Antisocial personality disorder",
        "Resistance",
        "Suicide risk may increase after antidepressant therapy is initiated and",
        "No organic medical cause",
        "Opioid withdrawal",
        "Conduct disorder",
        "Best initial treatment",
        "Agoraphobia",
        "Diagnosis",
        "Prognosis is best determined by language development because its\ndevelopment",
        "Naltrexone",
        "Homeless child",
        "Time from last\ndrink",
        "American boy",
        "Unlike patients with Disorder",
        "Onset",
        "Schizophrenia",
        "Psychiatric illnesses",
        "Diagnosis\nDiagnosis",
        "The course",
        "Psychotherapy",
        "Clinical onset",
        "Sleep apnea",
        "Severe restriction of food intake",
        "Dementia is",
        "Acute pain management is the same for individual",
        "Insomnia",
        "This",
        "Patient education",
        "Disorder of thought process",
        "The average age of onset",
        "It",
        "Reading disorder",
        "Modafinil",
        "Treatment\nPsychotherapy",
        "Substance use disorder",
        "Dissociative identify disorder",
        "Food intake",
        "Severity",
        "Occur as the patient",
        "Disturbance",
        "Disorders characterized by excessive fear that"
      ],
      "treatments": [
        "most effec",
        "or\nKEY",
        "CBT",
        "reserved for",
        "the first",
        "benzodiazepines",
        "effective",
        "with an",
        "the most",
        "the same",
        "dependent on",
        "initiated and",
        "usually lifelong"
      ],
      "diagnostics": [
        "cerebrospinal fluid "
      ]
    },
    "Rheumatology": {
      "specialty": "Rheumatology",
      "facts": [],
      "diseases": [],
      "treatments": [],
      "diagnostics": []
    }
  },
  "searchable_chunks": [
    {
      "chunk_id": 0,
      "text": "USMLE Step 2 CK\nEleventh Edition\nTAO LE, MD, MHS VIKAS BHUSHAN, MD\nFounder, ScholarRx Founder, First Aid for the USMLE Step 1\nAssociate Clinical Professor, Department of Medicine Boracay, Philippines\nUniversity of Louisville School of Medicine\nMONA ASCHA, MD ABHISHEK BHARDWAJ, MD\nFellow, Department of Plastic Surgery Pulmonologist and Intensivist\nJohns Hopkins University Coast Pulmonary Associates, Orange County, California\nAssistant Clinical Professor, Health Sciences\nUniversity of California, Riverside\nMARINA BOUSHRA, MD DANIEL GRIFFIN, DO\nEmergency Medicine and Critical Care Medicine Intensivist, Saint Francis Medical Center\nCleveland Clinic Foundation, Cleveland, Ohio\nCAROLINE COLEMAN, MD STEPHANIE JONES, PhD\nResident, Department of Medicine Emory University Laney Graduate School\nEmory University School of Medicine\nKIMBERLY KALLIANOS, MD\nAssistant Professor, Department of Radiology and Biomedical Imaging\nUniversity of California, San Francisco School of Medicine\nNew York Chicago San Francisco Athens London Madrid Mexico City\nMilan New Delhi Singapore Sydney Toronto\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 11 1100//1188//2222 11::3388 PPMM\n\nCopyright Â© 2023, 2019, 2016, 2012, 2010, 2007, by Tao Le. All rights reserved. Except as permitted under the United States Copyright Act of 1976,\nno part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior\nwritten permission of the publisher.\nISBN: 978-1-26-485651-0\nMHID: 1-26-485651-2\nThe material in this eBook also appears in the print version of this title: ISBN: 978-1-26-485510-0,\nMHID: 1-26-485510-9.\neBook conversion by codeMantra\nVersion 1.0\nAll trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, we use\nnames in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement",
      "char_start": 0,
      "char_end": 2000
    },
    {
      "chunk_id": 1,
      "text": " of the trademark. Where such designa-\ntions appear in this book, they have been printed with initial caps.\nMcGraw Hill eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate training programs. To\ncontact a representative, please visit the Contact Us page at www.mhprofessional.com.\nMcGraw Hill, the McGraw Hill logo, Practice Makes Perfect, and related trade dress are trademarks or registered trademarks of McGraw Hill and/\nor its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their\nrespective owners. McGraw Hill is not associated with any product or vendor mentioned in this book.\nNOTICE\nMedicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are\nrequired. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is com-\nplete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in\nmedical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants\nthat the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the\nresults obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other\nsources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to\nadminister to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the\ncontraindications for administration. This rec",
      "char_start": 2000,
      "char_end": 4000
    },
    {
      "chunk_id": 2,
      "text": "ommendation is of particular importance in connection with new or infrequently used drugs.\nTERMS OF USE\nThis is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject to these terms.\nExcept as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not decompile, disassemble,\nreverse engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense the work or any\npart of it without McGraw-Hill Educationâ€™s prior consent. You may use the work for your own noncommercial and personal use; any other use of the\nwork is strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.\nTHE WORK IS PROVIDED â€œAS IS.â€ McGRAW-HILL EDUCATION AND ITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES\nAS TO THE ACCURACY, ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUD-\nING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR OTHERWISE, AND EXPRESSLY\nDISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANT-\nABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant or guarantee that the functions\ncontained in the work will meet your requirements or that its operation will be uninterrupted or error free. Neither McGraw-Hill Education nor its\nlicensors shall be liable to you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any damages resulting\ntherefrom. McGraw-Hill Education has no responsibility for the content of any information accessed through the work. Under no circumstances shall\nMcGraw-Hill Education and/or its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages that result from\nthe use of or inability to use the work, even if ",
      "char_start": 4000,
      "char_end": 6000
    },
    {
      "chunk_id": 3,
      "text": "any of them has been advised of the possibility of such damages. This limitation of liability shall apply\nto any claim or cause whatsoever whether such claim or cause arises in contract, tort or otherwise.\n\niii\nDEDICATION\nTo the contributors to this and past editions,\nwho took time to share their knowledge, insight, and\nhumor for the benefit of students and physicians everywhere.\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 33 1100//1188//2222 11::3388 PPMM\n\nThis page intentionally left blank\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 44 1100//1188//2222 11::3388 PPMM\n\nv\nContents\nContributing Authors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi Pediatrics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509\nFaculty Reviewers  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii\nPsychiatry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 585\nPreface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix\nPulmonary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625\nAcknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .x\nHow to Contribute  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .xi Renal/Genitourinary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 675\nHow to Use This Book  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii Multisystem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 717\nRapid Review  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 765\nSECTION 1: GUIDE TO EFFICIENT EXAM\nPREPARATION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2\nSECTION 3: TOP-RATED REVIEW RESOURCES  . . . 791\nIntroduction  . . . . . . . . . . . . . . . . . ",
      "char_start": 6000,
      "char_end": 8000
    },
    {
      "chunk_id": 4,
      "text": ". . . . . . . . . . . . . . . . . . . . . . . 2\nUSMLE Step 2 CKâ€”Computer-Based Testing Basics . . 2 How to Use the Database  . . . . . . . . . . . . . . . . . . . . . . . . . 792\nDefining Your Goal  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 10\nComprehensive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 794\nStudy Resources  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12\nQuestion Banks  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 794\nTest-Day Checklist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13\nTesting Agencies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 Internal Medicine, Emergency Medicine,\nFamily Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795\nSECTION 2: DATABASE OF HIGH-YIELD FACTS  . . . 15\nNeurology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795\nHow to Use the Database  . . . . . . . . . . . . . . . . . . . . . . . . . . 16\nOB/GYN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 795\nCardiovascular  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17\nDermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .87 Pediatrics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796\nEndocrinology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123\nPsychiatry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796\nEpidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157\nSurgery  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 796\nHealth Systems Science  . . . . . . . . . . . . . . . . . . . . . . . . . . . 177\nGastrointestinal  . . . . . . . . . . . . . . . . . . . . . . . . ",
      "char_start": 8000,
      "char_end": 10000
    },
    {
      "chunk_id": 5,
      "text": ". . . . . . . . . . . 197 Commercial Review Courses  . . . . . . . . . . . . . . . . . . . . . . 797\nHematology/Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269 Appendix I: Acronyms and Abbreviations . . . . . . . . . . 799\nMusculoskeletal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 313\nAppendix II: Common Laboratory Values  . . . . . . . . . . 807\nNeurology  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351\nIndex  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809\nObstetrics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 427\nGynecology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 467 About the Authors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 842\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 55 1100//1188//2222 11::3388 PPMM\n\nvi\nCONTRIBUTING AUTHORS\nManik Aggarwal, MD, MBBS Waneeza Mughees, MD\nFellow, Gastroenterology and Hepatology Resident, Obstetrics and Gynecology\nMayo Clinic, Rochester, Minnesota Drexel University College of Medicine, Philadelphia\nJohn Carl Barba II, MPH Christian Cuvillier Padilla, MD\nMD Candidate Chief Resident, Internal Medicine\nOhio State University College of Medicine Cleveland Clinic and Cleveland Veterans Affairs Medical Center,\nCleveland, Ohio\nAnup Chalise, MBBS, MS\nNepal Vivek Podder, MBBS\nIntern\nPaola Ghanem, MD BIRDEM General Hospital, Bangladesh\nPhysician, Department of Internal Medicine\nJohns Hopkins University Vikram Shee, MBBS, MSc\nPhysician Case Manager\nMyles Mowery, DO, MBA Teladoc Health, Inc.\nResident, Diagnostic and Interventional Radiology\nSpectrum Health/Michigan State University Collin Andrew Weintraub, MD\nGrand Rapids, Michigan Resident, General Surgery\nState University of New York Upstate Medical University\nIMAGE AND ILLUSTRATION TEAM\nYoree Grace Chung Victor Jose Martinez Leon, M",
      "char_start": 10000,
      "char_end": 12000
    },
    {
      "chunk_id": 6,
      "text": "D\nMD/PhD Candidate Resident, Internal Medicine\nEmory University School of Medicine Einstein Medical Center, Philadelphia\nNikitha Crasta, MBBS Angel Xiao, MD, MSE\nMangalore, India Resident, Orthopedic Surgery\nUniversity of Californiaâ€“San Francisco\nSean Evans, MD\nResident, Internal Medicine\nEmory University School of Medicine\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 66 1100//1188//2222 11::3388 PPMM\n\nvii\nASSOCIATE AUTHORS\nAparna Savitri Bhat, MD Abdul Rehman Mustafa, MBBS\nFellow, Pulmonary and Critical Care Medicine Alfaisal University College of Medicine, Saudi Arabia\nCleveland Clinic, Cleveland, Ohio\nAaron Panicker, MD\nNaveena Daram, MD Resident, Emergency Medicine\nResident, Obstetrics and Gynecology University of Florida College of Medicine\nWright State University\nAustin Patrick, DO\nIfrah Fatima, MBBS Resident\nResident, Internal Medicine Franciscan Health Olympia Fields\nUniversity of Missouriâ€“Kansas City School of Medicine\nFaateh Ahmad Rauf, MBBS\nLindsay Friedman, MD, MS CMH Lahore Medical College and Institute of Dentistry, Pakistan\nResident, General Surgery\nRush University Medical Center Jaimie Rogner, MD, MPH\nResident, Internal Medicine/Pediatrics\nLuise Josefine Froessl, MD University of Rochester Medical Center/Strong Memorial Hospital\nResident\nUniversitÃ© dâ€™Aix-Marseille, FacultÃ© de Medecine Kyle Robert Wagner\nMD Candidate\nIzhan Hamza, MBBS University of Illinois College of Medicine, Peoria\nResident\nUniversity of Texas Medical Branch, Internal Medicine\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 77 1100//1188//2222 11::3388 PPMM\n\nviii\nFACULTY REVIEWERS\nBrooks D . Cash, MD Soroush Rais-Bahrami, MD\nProfessor, Department of Medicine Professor of Urology and Radiology and Interim Chair, Department\nChief, Gastroenterology, Hepatology, and Nutrition of Urology\nUniversity of Texas Health Science Center at Houston University of Alabama at Birmingham School of Medicine\nDimitri Cassimatis, MD Keisha Ray, Ph",
      "char_start": 12000,
      "char_end": 14000
    },
    {
      "chunk_id": 7,
      "text": "D\nAssociate Professor, Department of Medicine Assistant Professor, McGovern Center for Humanities and Ethics\nEmory University School of Medicine University of Texas Health Science Center at Houston\nBradley Cole, MD Rachel Marie E . Salas, MD, MEd\nAssistant Professor of Neurology Professor, Neurology and Nursing\nLoma Linda University School of Medicine Johns Hopkins Medicine\nMeredith K . Greer, MD Sarah Schimansky, MB BCh BAO\nAssistant Professor, Department of Medicine Resident, Department of Ophthalmology\nEmory University School of Medicine Bristol Eye Hospital\nJennifer O . Howell, MD Shireen Madani Sims, MD\nAssociate Professor, Department of Obstetrics and Gynecology Associate Professor and Vice Chair for Education, Obstetrics and\nDuke University Medical Center Gynecology\nUniversity of Florida College of Medicine\nMatthew Kraybill, PhD\nClinical Neuropsychologist Nathan Wm . Skelley, MD\nCottage Health, Santa Barbara, California Associate Professor, Medical Director of Orthopaedic Surgery\nSanford Healthâ€“University of South Dakota School of Medicine\nPatrick M . Lank, MD, MS\nAssistant Professor, Department of Emergency Medicine Matthew Sochat, MD\nNorthwestern University, Feinberg School of Medicine Physician, Hematology/Oncology\nSoutheastern Medical Oncology Center\nKachiu C . Lee, MD, MPH\nAssistant Professor (Adjunct), Department of Dermatology Lorrel Toft, MD\nLewis Katz School of Medicine at Temple University Associate Professor of Cardiology, Department of Medicine\nUniversity of Nevada, Reno School of Medicine\nCarl Marfurt, PhD\nProfessor Emeritus, Department of Anatomy, Cell Biology and Tisha Wang, MD\nPhysiology Professor of Clinical Medicine, Department of Medicine\nIndiana University School of Medicineâ€“Northwest, Gary David Geffen School of Medicine at UCLA\nPeter Marks, MD, PhD Sylvia Wassertheil-Smoller, PhD\nCenter for Biologics Evaluation and Research Professor Emerita, Department of Epidemiology and Population\nUS Food and Drug Administration Health\nAlbert Einstein",
      "char_start": 14000,
      "char_end": 16000
    },
    {
      "chunk_id": 8,
      "text": " College of Medicine\nKristen L . Pagel, MD, MPH\nAssistant Professor, Department of Psychiatry Adam Weinstein, MD\nUniversity of Utah School of Medicine Associate Professor of Medical Sciences and Pediatrics\nFrank H. Netter MD School of Medicine at Quinnipiac University\nMahesh Patel, MD\nProfessor, Department of Medicine James S . Yeh, MD, MPH\nUniversity of Illinois at Chicago College of Medicine Department of Medicine\nMassachusetts General Hospital, Harvard Medical School\nDiane Payne, MD, MPT\nOrthopedic, Hand and Microvascular Surgery Kristal Young, MD\nOrthoAtlanta Newnan, Georgia Clinical Instructor, Department of Cardiology\nHuntington Hospital, Pasadena, California\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 88 1100//1188//2222 11::3388 PPMM\n\nix\nPreface\nWith the 11th edition of First Aid for the USMLE Step 2 CK, we continue our commitment to pro-\nviding students with the most high-yield and up-to-date preparation guide for the USMLE Step 2 CK\nexam. Preparation for and performance on the Step 2 CK exam are more important than ever with the\ntransition of the Step 1 exam to a pass/fail scoring system in 2022. With this in mind, we have greatly\nexpanded the content and depth for the 11th edition. This revision includes:\nâ–  Over 200 additional pages of content incorporating the most current evidence-based reviews and rec-\nommendations to help students on the Step 2 CK exam and in clinical practice.\nâ–  163 new and revised diagrams and illustrations, including more than 40 new diagnostic and manage-\nment algorithms, to further drive home the next best diagnostic and management options.\nâ–  140 new and revised photos/images to help visualize various disorders, descriptive findings, and clini-\ncal content tie-ins.\nâ–  Extensive text revisions, new mnemonics, and clarifications curated by a team of 26 medical student\nand resident physician authors who excelled on their USMLE exams and verified by a team of expert\nfaculty advisors and nationally recogn",
      "char_start": 16000,
      "char_end": 18000
    },
    {
      "chunk_id": 9,
      "text": "ized USMLE instructors.\nâ–  Continued focus on clinical presentation and the best initial step in diagnosis and management, mir-\nroring the content outline and blueprint of Step 2 CK.\nâ–  Vignette-style flash cards embedded in the margins to reinforce key concepts.\nâ–  Heavily updated and revised Rapid Review section for last-minute preparation.\nâ–  Revised rating of current high-yield review resources, with clear explanations of their relevance to\nStep 2 CK exam review.\nâ–  Improved organization and integrations of text, illustrations, clinical images, tables, and algorithms\nthroughout for focused review of high-yield topics.\nThe 11th edition of First Aid for the USMLE Step 2 CK truly is a completely revised, in-depth, student-\nto-student guide for preparation for the Step 2 CK exam. The 11th edition would not have been pos-\nsible without the help from hundreds of students and faculty members who contributed their feedback\nand suggestions. We invite students and faculty to continue sharing their thoughts and ideas to help us\nimprove First Aid for the USMLE Step 2 CK (see How to Contribute, p. xi).\nTao Le\nLouisville\nVikas Bhushan\nBoracay\nMona Ascha\nBaltimore\nAbhishek Bhardwaj\nOrange County\nMarina Boushra\nCleveland\nDaniel Griffin\nCape Girardeau, Missouri\nCaroline Coleman\nAtlanta\nStephanie Jones\nTumwater, Washington\nKimberly Kallianos\nSan Francisco\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 99 1100//1188//2222 11::3388 PPMM\n\nx\nAcknowledgments\nThis has been a collaborative project from the start. We gratefully acknowledge the thoughtful comments, correc-\ntions, and advice of the many medical students, international medical graduates, and faculty who have supported\nthe authors in the continuing development of First Aid for the USMLE Step 2 CK.\nThanks to our publisher, McGraw Hill, for the valuable assistance of its staff, including Bob Boehringer, Christina\nThomas, and Jeffrey Herzich. For outstanding editorial work, we thank Megan Chandler and Lis",
      "char_start": 18000,
      "char_end": 20000
    },
    {
      "chunk_id": 10,
      "text": "a Nahach. We are\nalso grateful to our medical illustrator, Rachael Williams, and illustration manager, Susan Mazik. For administra-\ntive support we thank Miranda Carter, Katherine Knight, and Louise Petersen. A special thanks to GW, Inc. for\nremarkable production work.\nFor contributions and corrections, we thank Ataa Ahmed, Arjun Basnet, Jeffrey Beach, Monica I. Burgos Claudio,\nFiorella B. Castillo, Mallory Castillo, Christian Casteel, Anthony Chung, Jonathan Daou, Karanpal Dhaliwal, Fadi\nDib, Celia Escamilla, Arber Frakulli, Mohan Bharadwaj Gudivada, Jacqueline Hairston, Nathaniel Hayward, Lydia\nKaotzani, Panagiotis Kaparaliotis, Alex Lu, Juliana Maya, Austin McCullough, Nupur Mishra, Mounika Mukherjee\nPeethala, Majd Oteibi, Shannon D. Powell, Aubtin Saedi, Tanjot Saini, Angelica Maria Sanchez Ruiz, Charles\nSanky, Maida Sarfraz Chaudhry, Neetu Scariya, Ryan Schusler, Tarif Shaaban, Tomonari Shimoda, Biraj Singh\nKarki, Colton Southall, Charles Starling, Ari Stone, Erica Stratton, Jennifer Tram, Nicholas Ting, Vivekanand\nTiwari, Sheela Vaswani, and Earl Vialpando.\nTao Le\nLouisville\nVikas Bhushan\nBoracay\nMona Ascha\nBaltimore\nAbhishek Bhardwaj\nOrange County\nMarina Boushra\nCleveland\nDaniel Griffin\nCape Girardeau, Missouri\nCaroline Coleman\nAtlanta\nStephanie Jones\nTumwater, Washington\nKimberly Kallianos\nSan Francisco\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 1100 1100//1188//2222 11::3388 PPMM\n\nxi\nHow to Contribute\nIn our effort to continue to produce a high-yield review source for the Step 2 CK exam, we invite you to submit any\nsuggestions or corrections. We also offer paid internships in medical education and publishing ranging from three\nmonths to one year (see below for details). Please send us your suggestions for the following:\nâ–  Study and test-taking strategies for the Step 2 CK exam\nâ–  New high-yield facts, mnemonics, diagrams, and illustrations\nâ–  Low-yield topics to remove\nFor each entry incorporated into the next edition, you will",
      "char_start": 20000,
      "char_end": 22000
    },
    {
      "chunk_id": 11,
      "text": " receive up to a $20 gift certificate to Amazon as well as\npersonal acknowledgment in the next edition. Diagrams, tables, partial entries, updates, corrections, and study hints\nare also appreciated, and significant contributions will be compensated at the discretion of the authors. Also let us\nknow about material in this edition that you feel is low yield and should be deleted.\nThe preferred way to submit entries, suggestions, or corrections is via our blog:\nwww.firstaidteam.com\nWe are also reachable by e-mail at firstaid@scholarrx.com.\nNOTE TO CONTRIBUTORS\nAll entries become property of the authors and are subject to editing and reviewing. Please verify all data and spell-\nings carefully. If similar or duplicate entries are received, only the first entry received will be used. Include a refer-\nence to a standard textbook to facilitate verification of the fact. Please follow the style, punctuation, and format of\nthis edition if possible.\nINTERNSHIP OPPORTUNITIES\nThe author team is pleased to offer part-time and full-time paid internships in medical education and publishing to\nmotivated physicians. Internships may range from three months (eg, a summer) up to a full year. Participants will\nhave an opportunity to author, edit, and earn academic credit on a wide variety of projects, including the popular\nFirst Aid series. Writing/editing experience, familiarity with Microsoft Word and Google Docs, and illustration skills\nare highly desired. For more information, e-mail a rÃ©sumÃ© or a short description of your experience along with a\ncover letter to firstaidteam@usmle-rx.com.\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 1111 1100//1188//2222 11::3388 PPMM\n\nxii\nHow to Use This Book\nWe have made many improvements and added several new features to this edition of First Aid for the USMLE Step\n2 CK. In particular, we have added more than two hundred pages of content and hundreds of new illustrations and\nimages throughout the text to facilitate stu",
      "char_start": 22000,
      "char_end": 24000
    },
    {
      "chunk_id": 12,
      "text": "dying. We encourage you to read all aspects of the text to learn the ma-\nterial in context. We have also included comments in the margins and vignette questions to periodically test your\nknowledge of key concepts. These questions are located in the lower corner of certain pages. To prevent peeking at\nthe answers, youâ€™ll find the answer on the back of the same page in the lower corner. These questions are not always\nrepresentative of test questions.\nTo practice for the exam and simulate the actual test day, you can use the USMLE-Rx Step 2 CK Qmax question\ntest bank (www.usmle-rx.com). If you are constantly on the move, use the USMLE-Rx Step 2 CK app. The question\nbank and this text are more than enough to allow many students to ace the exam.\nGood luck!\n22002222__0000..0011__SStteepp22CCKK__FFMM__1111ee__ii--xxiiii__..iinndddd 1122 1100//1188//2222 11::3388 PPMM\n\nS E C T I O N 1\nGUIDE TO EFFICIENT EXAM PREPARATION\nIntroduction 2 When to take the exam 11\nhoW Will the step 2 Ck sCoRe aFFeCt my matCh? 12\nUSMLE Step 2 CKâ€”Computer-Based Testing Basics 2\nWho Can RegisteR FoR the exam? 2 Study Resources 12\nhoW Will the CBt Be stRuCtuRed? 2 Quality ConsideRations 12\ntesting Conditions: What Will the CBt Be like? 3 CliniCal RevieW Books 12\nWhat does the CBt FoRmat mean FoR me? 3 test Banks 12\nhoW do i RegisteR to take the examination? 4 texts and notes 13\nWhat iF i need to ResChedule the examination? 5 CommeRCial CouRses 13\nWhat aBout time? 6 nBme/usmle puBliCations 13\nseCuRity measuRes 6\nTest-Day Checklist 13\niF i leave duRing the examination, What happens to my sCoRe? 6\nthings to BRing With you to the exam 13\nWhat types oF Questions aRe asked? 6\nTesting Agencies 14\nhoW long Will i have to Wait BeFoRe i get my sCoRes? 8\nhoW aRe the sCoRes RepoRted? 9\nDefining Your Goal 10\n1\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 11 1100//2211//2222 1111::2211 AAMM\n\n2 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\nINTRODUCTION\nThe United States Medica",
      "char_start": 24000,
      "char_end": 26000
    },
    {
      "chunk_id": 13,
      "text": "l Licensing Examination (USMLE) Step 2 allows\nyou to pull together your clinical experience on the wards with the numerous\nâ€œfactoidsâ€ and classical disease presentations that you have memorized over\nthe years. Where Step 1 stresses basic disease mechanisms and principles,\nStep 2 places more emphasis on clinical diagnosis and management, disease\npathogenesis, and preventive medicine. Previously, the Step 2 examination\nconsisted of the Step 2 Clinical Knowledge examination (Step 2 CK), and the\nKEY FACT Step 2 Clinical Skills examination (Step 2 CS). However, recent changes\nhave removed the Step 2 CS exam as a requirement for ECFMG certification\nThe goal of the Step 2 CK is to apply\nafter the onset of the pandemic, and this change has been recorded as perma-\nyour knowledge of medical facts\nnent by the ECFMG.\nto clinical scenarios that you may\nThe USMLE Step 2 CK is the second of three examinations that you must\nencounter as a resident.\npass to become a licensed physician in the United States. The computerized\nStep 2 CK is a 1-day (9-hour) multiple-choice examination.\nUSMLE STEP 2 CKâ€”COMPUTER-BASED TESTING BASICS\nWHO CAN REGISTER FOR THE EXAM?\nThe eligibility requirement for USMLE Step 2 CK exam is same as that of\nUSMLE Step 1 and can be taken either before or after the Step 1 exam. This\nmeans that you should be:\nâ–  Officially enrolled in, or be a graduate of, a US or Canadian medical\nschool leading to the MD degree (LCME accredited), or\nâ–  Officially enrolled in, or be a graduate of, a US medical school leading to\nthe DO degree (COCA accredited), or\nâ–  Officially enrolled in, or be a graduate of, a medical school outside the US\nand Canada and listed in the World Directory of Medical Schools as meet-\ning ECFMG eligibility requirements and meet other ECFMG criteria.\nThese criteria should be met at the time of application and on the test day.\nHOW WILL THE CBT BE STRUCTURED?\nThe Step 2 CK exam is a computer-based test (CBT) administered by Prometric,\nInc. It is a 1-day examin",
      "char_start": 26000,
      "char_end": 28000
    },
    {
      "chunk_id": 14,
      "text": "ation with a maximum of 318 items divided into eight\n1-hour blocks that are administered during a single 9-hour testing session. The\nnumber of items in a block are displayed at the beginning of each block. This\nnumber may vary from block to block but will not exceed 40 items per block.\nKEY FACT Two question styles predominate throughout. The most common format is\nthe single one-best-answer question. This is the traditional multiple-choice\nSometimes the answer to the previous\nformat in which you are tasked with selecting the â€œmost correctâ€ answer.\nquestion in a sequential question set\nSequential item sets comprises the second question style. These are sets of\nis provided to you once you lock your\nmultiple-choice questions that are related and must all be answered in\nanswer. Do not be disheartened if\nsequence without skipping a question in the set. As you answer questions in a\nyou got it wrong. Simply understand\nset, the previous answers become locked and cannot be changed. These are\nthat you now have an opportunity to\nthe only questions on the USMLE examination that are locked in such a way.\nget at least one answer correct in the\nThere are no more than five sequential item sets within each USMLE Step 2\nsequence.\nCK exam.\nDuring the time allotted for each block in the USMLE Step 2 CK exam,\nyou can answer test questions in any order and can also review responses and\nchange your answers (except for responses within the sequential item sets\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 22 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 3\ndescribed earlier). However, under no circumstances can you return to previ-\nous blocks and change your answers. Once you have finished a block, you\nmust click on a screen icon to continue to the next block. Time not used dur-\ning a testing block will be added to your overall break time (45 minutes total\nat start of exam), but it cannot be used to complete other testing",
      "char_start": 28000,
      "char_end": 30000
    },
    {
      "chunk_id": 15,
      "text": " blocks. Also KEY FACT\nnote that a short tutorial (shorter than the one available at the USMLE web-\nExpect to spend up to 9 hours at the\nsite) is present at the start of the exam, which if you choose to skip, can add\ntest center.\n15 minutes to your total break time.\nTESTING CONDITIONS: WHAT WILL THE CBT BE LIKE?\nEven if you are familiar with CBT and the Prometric test centers, you should\nstill access the latest practice software from the USMLE Web site (http://www.\nusmle.org) and try out prior to the examination.\nFor security reasons, you are not allowed to bring personal equipment\n(except those needed for medical reasons and soft-foam earplugs as detailed\nlater) into the testing areaâ€”which means that writing implements, outerwear,\nwatches (even analog), cellular telephones, and electronic paging devices are\nall prohibited. Food and beverages are prohibited as well. The proctor will\nassign you a small locker to store your belongings and any food you bring for\nthe day. You will also be given two 8 cm Ã— 11 cm laminated writing surfaces,\npens, and erasers for note taking and for recording your test Candidate Identifi-\ncation Number (CIN). You must return these materials after the examination.\nNote that you are not allowed to write on these until you enter the CIN number\nin the computer. Testing centers are monitored by audio and video surveillance\nequipment, and minimum of 2 surveillance rounds by the exam monitor per\nhour. Each time you enter the testing room, you will have to undergo a screen-\ning process to ensure that you are not bringing in personal items.\nYou should become familiar with a typical question screen. A window to\nthe left displays all the questions in the block and shows you the unanswered\nquestions (marked with an â€œiâ€). Some questions will contain figures, color\nillustrations, audio, or video adjacent to the question. Although the contrast\nand brightness of the screen can be adjusted, there are no other ways to\nmanipulate the picture (eg, zooming or ",
      "char_start": 30000,
      "char_end": 32000
    },
    {
      "chunk_id": 16,
      "text": "panning). Larger images are accessed\nwith an â€œexhibitâ€ button. You can also call up a window displaying normal\nlab values. You may mark questions to review at a later time by clicking the\ncheck mark at the top of the screen. The annotation feature functions like the KEY FACT\nprovided dry-erase sheets and allows you to jot down notes during the exami-\nKeyboard shortcuts:\nnation. Play with the highlighting/strike-out and annotation features with the\nâ–  Aâ€“Eâ€”Letter choices.\nvignettes and multiple answers.\nâ–  Enter or space barâ€”Move to the\nYou should also do a few practice blocks to determine which tools will\nnext question.\nhelp you process questions more efficiently and accurately. If you find that\nâ–  Escâ€”Exit pop-up Lab and Exhibit\nyou are not using the marking, annotation, or highlighting tools, then key-\nwindows.\nboard shortcuts can be quicker than using a mouse. Headphones are pro-\nâ–  Alt-Tâ€”Countdown and time-\nvided for listening to audio and blocking outside noise. Alternatively, you can\nelapsed clocks for current session\nbring soft earplugs to block excess noise. These earplugs must be examined by\nand overall test.\nPrometric staff before you can take them into the testing area.\nWHAT DOES THE CBT FORMAT MEAN FOR ME?\nThe CBT format is the same format as that used on the USMLE Step 1. If\nyou are uncomfortable with this testing format, spend some time playing with\na Windows-based system and pointing and clicking icons or buttons with a\nmouse.\nThe USMLE also offers students an opportunity to take a simulated test,\nor practice session, at a Prometric center. The session is divided into three\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 33 1100//2211//2222 1111::2211 AAMM\n\n4 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\n1-hour blocks of up to 50 questions each. The approximately 127 Step 2 CK\nsample test items that are available on the USMLE Web site (http://www.\nusmle.org) are the same as those used at CBT practice sessions. No new\nitem",
      "char_start": 32000,
      "char_end": 34000
    },
    {
      "chunk_id": 17,
      "text": "s are presented. The cost is about $75 for US and Canadian students but\nis higher for international students. Students receive a printed percent-correct\nscore after completing the session. No explanations of questions are provided.\nYou may register for a practice session online at http://www.usmle.org.\nThe National Board of Medical Examiners (NBME) provides another\noption for students to assess their Step 2 CK knowledge with the Comprehen-\nsive Clinical Science Self-Assessment (CCSSA) test. This test is available on\nthe NBME Web site for $60, which will display at the end of the exam all of\nthe questions that you answered incorrectly. The current versions of the test\nalso have answer explanations. The content of the CCSSA items resembles\nthat of the USMLE Step 2 CK. After you complete the CCSSA, you will be\ngiven a performance profile indicating your strengths and weaknesses. This\nfeedback is intended for use as a study tool only and is not necessarily an indi-\ncator of Step 2 CK performance. For more information on the CCSSA exami-\nnation, visit the NBMEâ€™s Web site at http://www.nbme.org, and click on the\nlink for â€œStudents and Residents.â€\nHOW DO I REGISTER TO TAKE THE EXAMINATION?\nInformation on the Step 2 CK examâ€™s format, content, and registration require-\nments are found on the USMLE Web site. To register for the examination,\nstudents/graduates of accredited schools in the United States and Canada can\napply online at the NBME Web site (http://www.nbme.org), whereas students/\ngraduates of non-US/Canadian schools should apply through the Educational\nCommission for Foreign Medical Graduates (ECFMG) (https://iwa2.ecfmg.\norg). A printable version of the application is also available on these sites.\nThe preliminary registration process for the USMLE Step 2 CK exam is as\nfollows:\nâ–  Complete a registration form and send your examination fees to the\nNBME (online) for students in US/Canada medical schools, and to the\nECFMG (online) for international medical students. The",
      "char_start": 34000,
      "char_end": 36000
    },
    {
      "chunk_id": 18,
      "text": " fees payable are\noutlined in Table 1.1.\nâ–  Select a 3-month block in which you wish to be tested (eg, June/July/August).\nâ–  Attach a passport-type photo to your completed application form.\nâ–  Complete a Certification of Identification and Authorization form. This\nform must be signed by an official at your medical school such as from the\nregistrarâ€™s office (if you are a student) or a notary public (if you have gradu-\nated) to verify your identity. It is valid for 5 years, allowing you to use only\nyour USMLE identification number for future transactions.\nâ–  Send your certified application form to the NBME for processing. Appli-\ncations may be submitted more than 6 months before the test date, but\nexaminees will not receive their scheduling permits until 6 months prior\nto the eligibility period.\nâ–  The NBME will process your application within 4â€“6 weeks and will send\nyou a slip of paper that will serve as your scheduling permit.\nâ–  Once you have received your scheduling permit, decide when and where\nyou would like to take the examination. For a list of Prometric locations\nnearest you, visit https://www.prometric.com.\nâ–  Call Prometricâ€™s toll-free number or visit https://www.prometric.com to\narrange a time to take the examination.\nThe Step 2 CK is offered on a year-round basis except for the first 2 weeks\nin January. For the most up-to-date information on available testing days at\nyour preferred testing location, refer to http://www.usmle.org.\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 44 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 5\nTABLE 1.1 Exam Fees for the USMLE Step 2 CK\nFEE PAYABLE TO NBME FEE PAYABLE TO ECFMG\n(US AND CANADA SCHOOLS ONLY) (ALL OTHER SCHOOLS)\nExam fee $645 $985\nScheduling charge None $210\nEligibility period extension $70 $100\nChanging testing region $90 $90\nRequesting exam recheck $80 $80\nThe scheduling permit you receive from the NBME will contain the fol-\nlowing important info",
      "char_start": 36000,
      "char_end": 38000
    },
    {
      "chunk_id": 19,
      "text": "rmation:\nâ–  Your USMLE identification number.\nâ–  The eligibility period during which you may take the examination.\nâ–  Your â€œscheduling number,â€ which you will need to make your examina-\ntion appointment with Prometric.\nâ–  Your CIN, which you must enter at your Prometric workstation in order to\naccess the examination.\nKEY FACT\nPrometric has no access to the codes and will not be able to supply these\nBecause the Step 2 CK examination\nnumbers, so do not lose your permit! You will not be allowed to take the Step\nis scheduled on a â€œfirst-come, first-\n2 CK unless you present your permit along with an unexpired, government-\nservedâ€ basis, you should be sure to call\nissued photo identification that contains your signature (eg, driverâ€™s license,\nPrometric as soon as you receive your\npassport). Make sure the name on your photo ID exactly matches the name\nscheduling permit.\nthat appears on your scheduling permit.\nWHAT IF I NEED TO RESCHEDULE THE EXAMINATION?\nYou can change your date and/or center within your 3-month period by con-\ntacting Prometric if space is available. When you reschedule, a fee may apply\n(Table 1.2).\nIf you need to reschedule outside your initial 3-month period, you can\napply for a single 3-month extension (eg, April/May/June can be extended\nthrough July/August/September) after your eligibility period has begun. For\nother rescheduling needs, you must submit a new application along with\nanother application fee.\nTABLE 1.2 Rescheduling Fees Payable to Prometric for USMLE Step 2 CK (1 Jan, 2022)\nRESCHEDULING TIME FEES FOR THE US FEES FOR TESTING REGIONS\nBEFORE EXAM DATE AND CANADA TESTING REGION OTHER THAN THE US AND CANADA\n46 days or more No fee No fee\nBetween 31 and 45 days $35 $35\nBetween 6 days and 30 days $100 $100\nLess than 5 days $144 $369\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 55 1100//2211//2222 1111::2211 AAMM\n\n6 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\nWHAT ABOUT TIME?\nTime is of special interest on the CB",
      "char_start": 38000,
      "char_end": 40000
    },
    {
      "chunk_id": 20,
      "text": "T examination. The following is a break-\ndown of the examination schedule:\nTutorial 15 minutes\n1-hour question blocks (40 questions per block) 8 hours\nBreak time (includes time for lunch) 45 minutes\nTotal test time 9 hours\nThe computer will keep track of how much time has elapsed during the\nexamination. However, the computer will show you only how much time you\nhave remaining in a block. Therefore, it is up to you to determine if you are\npacing yourself properly.\nThe computer will not warn you if you are spending more than the 45\nminutes allotted for break time. The break time includes not only the usual\nconcept of a breakâ€”when you leave the testing areaâ€”but also the time it\ntakes for you to make the transition to the next block, such as entering your\nCIN or even taking a quick stretch. If you do exceed the 45-minute break\ntime, the time to complete the last block of the test will be reduced. How-\never, you can elect not to use all of your break time, or you can gain extra\nbreak time either by skipping the tutorial or by finishing a block ahead of the\nallotted time.\nSECURITY MEASURES\nSmile! The USMLE uses a check-in/check-out process that includes elec-\ntronic capture of your fingerprints and photograph. Fingerprints from a finger\non each hand will be used for this process. These measures are intended to\nincrease security by preventing fraud, thereby safeguarding the integrity of the\nexamination. These procedures also decrease the amount of time needed to\ncheck in and out of the examination throughout the day, thereby maximizing\nyour break time. However, you still need to sign out and sign in with the Test\nCenter Log when exiting and entering the testing area.\nIF I LEAVE DURING THE EXAMINATION, WHAT HAPPENS TO MY SCORE?\nYou are considered to have started the examination once you have entered\nyour CIN onto the computer screen, but to receive an official score, you must\nfinish the entire examination. This means that you must start and either finish\nor run out of time ",
      "char_start": 40000,
      "char_end": 42000
    },
    {
      "chunk_id": 21,
      "text": "for each block of the examination. If you do not complete\nall of the question blocks, your examination will be documented on your\nUSMLE score transcript as an incomplete attempt, but no actual score will\nbe reported.\nThe examination ends when all blocks have been completed or time has\nexpired. As you leave the testing center, you will receive a written test comple-\ntion notice to document your completion of the examination.\nWHAT TYPES OF QUESTIONS ARE ASKED?\nThe Step 2 CK is an integrated examination that tests understanding of nor-\nmal conditions, disease categories, and physician tasks. Almost all questions\non the examination are case based. Some questions will involve interpreting a\nstudy or drug advertisement. A substantial amount of extraneous information\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 66 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 7\nmay be given, or a clinical scenario may be followed by a question that could TABLE 1.3 Exam Content Specification\nper Discipline\nbe answered without actually requiring that you read the case. It is your job to\ndetermine which information is superfluous and which is pertinent to the COMPETENCY RANGE, %\ncase at hand. Content areas include internal medicine, OB/GYN, pediatrics,\nMedicine 50â€“60\npreventive services, psychiatry, surgery, and other areas relevant to the provi-\nsion of care under supervision (see Tables 1.3, 1.4, and 1.5).\nSurgery 25â€“30\nMost questions on the examination have a single best-answer format. The\npart of the vignette that actually asks the questionâ€”the stemâ€”is usually Pediatrics 20â€“25\nfound at the end of the scenario and generally relates to the physician task.\nFrom student experience, there are a few stems that are consistently addressed Obstetrics & Gynecology 10â€“20\nthroughout the examination:\nPsychiatry 10â€“15\nâ–  What is the most likely diagnosis? (40%)\nâ–  Which of the following is the most appropriate initial step in manage-",
      "char_start": 42000,
      "char_end": 44000
    },
    {
      "chunk_id": 22,
      "text": "\nment? (20%)\nâ–  Which of the following is the most appropriate next step in management?\n(20%)\nTABLE 1.4 Exam Content Specification per System\nSYSTEM RANGE, %\nGeneral Principles Of Foundational Sciencea 2â€“4\nImmune System 3â€“5\nBlood & Lymphoreticular System 4â€“6\nBehavioral Health 6â€“8\nNervous System & Special Senses 6â€“8\nMusculoskeletal System/Skin & Subcutaneous Tissue 6â€“10\nCardiovascular System 8â€“10\nRespiratory System 7â€“9\nGastrointestinal System 7â€“9\nRenal & Urinary System & Male Reproductive 4â€“6\nPregnancy, Childbirth & The Puerperium 4â€“6\nFemale Reproductive System & Breast 4â€“6\nEndocrine System 4â€“6\nMultisystem Processes & Disorders 4â€“6\nBiostatistics & Epidemiology/Population Health/Interpretation 3â€“5\nOf Medical Literature\nSocial Sciences: Legal/Ethical Issues & Professionalism/ 10â€“15\nSystems-Based Practice & Patient Safety\nPercentages are subject to change at any time.\naThe Step 2 CK General Principles category includes normal and abnormal processes that are not\nlimited to specific organ systems.\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 77 1100//2211//2222 1111::2211 AAMM\n\n8 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\nTABLE 1.5 Exam Content Specification per Physician Tasks/Competencies\nCOMPETENCY RANGE, %\nMedical Knowledge: Applying Foundational Science Concepts 0a\nPatient Care: History And Physical Exam 0b\nPatient Care: Laboratory/Diagnostic Studies 13â€“17\nPatient Care: Diagnosis 16â€“20\nPatient Care: Prognosis/Outcome 5â€“9\nPatient Care: Health Maintenance/Disease Prevention 8â€“12\nPatient Care: Pharmacotherapy 8â€“12\nPatient Care: Clinical Interventions 6â€“10\nPatient Care: Mixed Management 12â€“16\nPractice-Based Learning & Improvement 3â€“5\nProfessionalism 5â€“7\nSystems-Based Practice & Patient Safety 5â€“7\nPercentages are subject to change at any time.\naTest items that assess patient care competencies may also assess knowledge of underlying\nfoundational science concepts.\nbTest items that assess history and physical exam competencies are cove",
      "char_start": 44000,
      "char_end": 46000
    },
    {
      "chunk_id": 23,
      "text": "red in Step 1 and Step 3\nexaminations.\nâ–  Which of the following is the most likely cause ofâ€¦? (5%)\nâ–  Which of the following is the most likely pathogenâ€¦? (3%)\nâ–  Which of the following would most likely preventâ€¦? (2%)\nâ–  Other (10%)\nAdditional examination tips are as follows:\nâ–  Note the age and race of the patient in each clinical scenario. When eth-\nnicity is given, it is often relevant. Know these well (see high-yield facts),\nespecially for more common diagnoses.\nâ–  Be able to recognize key facts that distinguish major diagnoses.\nâ–  Questions often describe clinical findings rather than naming eponyms\n(eg, they cite â€œaudible hip clickâ€ instead of â€œpositive Ortolani signâ€).\nâ–  Questions about acute patient management (eg, trauma) in an emergency\nsetting are common.\nThe cruel reality of the Step 2 CK examination is that no matter how\nmuch you study, there will still be questions you will not be able to answer\nwith confidence. If you recognize that a question cannot be solved in a rea-\nsonable amount of time, make an educated guess and move on; you will not\nbe penalized for guessing. Also bear in mind that some of the USMLE ques-\ntions are â€œexperimentalâ€ and will not count toward your score.\nHOW LONG WILL I HAVE TO WAIT BEFORE I GET MY SCORES?\nThe USMLE reports scores 3â€“4 weeks after the examineeâ€™s test date. During\npeak periods, however, as many as 6 weeks may pass before reports are scored.\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 88 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 9\nThis usually includes scheduled delays after the first two weeks of the year in\nJanuary when the scores may get delayed up to March. Official information\nconcerning the time required for score reporting is posted on the USMLE\nWeb site, http://www.usmle.org and recent changes may need to be checked\nevery testing session.\nHOW ARE THE SCORES REPORTED?\nLike the Step 1 score report, your Step 2 CK report includes your pass/",
      "char_start": 46000,
      "char_end": 48000
    },
    {
      "chunk_id": 24,
      "text": "fail\nstatus, a numeric score, and a performance profile organized by discipline\nand disease process (see Fig. 1.1). The score is a 3-digit scaled score based\non a predefined proficiency standard. The current required passing score is\n214. This score requires answering 60â€“70% of questions correctly. Any\nadjustments in the required passing score will be available on the USMLE\nWeb site.\nUnited States Medical Licensing Examinaï¿½onÂ®\nStep 2 CK Score Report\nFOR EXAMINEE USE ONLY. THIRD-PARTY USERS OF USMLE SCORES\nSHOULD RELY SOLELY ON OFFICIAL TRANSCRIPTS RECEIVED DIRECTLY\nFROM THE EXAMINEEâ€™S USMLE REGISTRATION ENTITY.\nNAME: Smith, John\nUSMLE ID: 1-234-567-8 TEST DATE: March 31, 2022\nYour Performance\nTest Result Test Score\nPASS 262\nYour Performance Compared to Other Examinees\nThe chart below represents the distribuï¿½on of scores for examinees from US and Canadian medical schools taking Step 2 CK\nfor the first ï¿½me between July 1, 2017 and June 30, 2018. Reported scores range from 1-300 with a mean of 244and a\nstandard deviaï¿½on of 17.\n262\nYour Score\n209\nMinimum\nPassing Score\nIf you tested repeatedly under the same condiï¿½ons on a different set of items covering the same content, without\nlearning or forgeï¿½ng, your score would fall within one standard error of the esï¿½mate (SEE) of your current score\ntwo-thirds of the ï¿½me. The SEE on this exam is 8 points.\nYour score +/- SEE:254 â€“ 270\nFIGURE 1-1. Sample score reportâ€”front page.\nPage 1 of 4\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 99 1100//2211//2222 1111::2211 AAMM\n\n10 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\nUnited States Medical Licensing Examinaï¿½on\nStep 2 CK Score Report\nSupplemental Informaï¿½on: Understanding the Content Areas\nThe informaï¿½on below is a visual representaï¿½on of the content weighï¿½ng on this examinaï¿½on that may be informaï¿½ve in\nguiding remediaï¿½on. Descripï¿½ons of the topics covered in these content areas, as well as other topics covered on USMLE\nStep 2 CK, can be found ",
      "char_start": 48000,
      "char_end": 50000
    },
    {
      "chunk_id": 25,
      "text": "in the informaï¿½on materials on the USMLE website (hï¿½ps://www.usmle.org). Please use the\ncontact form on the USMLE website (hï¿½ps://www.usmle.org/contact/) if you have addiï¿½onal quesï¿½ons.\nPhysician Task (% Items Per Test)\nPC: Diagnosis (40 - 50%)\nPC: Pharmacotherapy, Intervenï¿½ons & Management (22 - 27%)\nMK: Applying Foundaï¿½onal Science Concepts (12 - 16%)\nPC: Health Maint, Prevenï¿½on & Surveillance (7 - 11%)\nAbbreviaï¿½ons: MK, Medical Knowledge; PC, Paï¿½ent Care.\nSystem (% Items Per Test)\nCardiovascular System (8 - 12%)\nGastrointesï¿½nal System (7 - 11%)\nRespiratory System (7 - 11%)\nBehavioral Health (6 - 10%)\nMusculoskeletal Sys/Skin & Subcutaneous Tissue (6 - 10%)\nNervous System & Special Senses (6 - 10%)\nMulï¿½system Processes & Disorders (5 - 9%)\nEndocrine System (4 - 8%)\nFemale Reproducï¿½ve & Breast (4 - 8%)\nPregnancy, Childbirth & the Puerperium (4 - 8%)\nRenal & Urinary System & Male Reproducï¿½ve (4 - 8%)\nBlood & Lymphoreï¿½cular System (4 - 7%)\nImmune System (4 - 6%)\nDiscipline (% Items Per Test)\nMedicine (50 - 60%)\nSurgery (25 - 30%)\nPediatrics (20 - 25%)\nObstetrics & Gynecology (10 - 20%)\nPsychiatry (10 - 15%)\nFIGURE 1-1. Sample score reportâ€”back paPgagee. 4 of 4\nDEFINING YOUR GOAL\nStep 2 CK scores are becoming increasingly used for residency selection. The\namount of time spent in preparation for this examination varies widely among\nmedical students. Possible goals include the following:\nâ–  Beating the mean. This signifies an ability to integrate your clinical and\nfactual knowledge to an extent that is superior to that of your peers\n(around 247 for recent examination administrations). Others redefine this\ngoal as achieving a score 1 standard deviation above the mean (usually in\nthe range of 250â€“260). Highly competitive residency programs may use\nyour Step 1 and Step 2 scores (if available) as a screening tool or as a selec-\ntion requirement. International medical graduates should aim to beat the\nmean, as USMLE scores are likely to be a selection factor even for less\ncomp",
      "char_start": 50000,
      "char_end": 52000
    },
    {
      "chunk_id": 26,
      "text": "etitive US residency programs.\nâ–  Acing the exam. Perhaps you are one of those individuals for whom noth-\ning less than the best will doâ€”and for whom excelling on standardized\nexaminations is a source of pride and satisfaction.\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 1100 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 11\nâ–  Evaluating your clinical knowledge. In many ways, this goal should serve\nas the ultimate rationale for taking the Step 2 CK, as it is technically the\nreason the examination was initially designed. The case-based nature of\nthe Step 2 CK differs significantly from the more fact-based Step 1 exami-\nnation in that it more thoroughly assesses your ability to recognize classic\nclinical presentations, deal with emergent situations, and follow the step-\nby-step thought processes involved in the treatment of particular diseases.\nâ–  Preparing for internship. Studying for the USMLE Step 2 CK is an excel-\nlent way to review and consolidate all of the information you have learned\nin preparation for internship.\nMatching statistics, including examination scores related to various special-\nties, are available at the National Resident Matching Program Web site at\nhttps://www.nrmp.org under â€œData and Reports.â€\nWHEN TO TAKE THE EXAM\nThe second most important thing to do in your exam preparation is to decide\nwhen to take the examination. With the CBT, you now have a wide variety of\noptions regarding when to take the Step 2 CK. Here are a few factors to consider:\nâ–  The nature of your objectives, as defined earlier.\nâ–  The specialty to which you are applying. An increasing number of resi-\ndency programs are viewing the Step 2 CK as an integral part of the resi-\ndency application process. Several research publications demonstrate the\nincreasing importance placed on this examination by residency directors.\nSome programs are now requiring the Step 2 CK score in order to rank\ncandidates for a residenc",
      "char_start": 52000,
      "char_end": 54000
    },
    {
      "chunk_id": 27,
      "text": "y position. It is therefore in the best interest of\ncandidates to have this examination done in time for scores to be available\nfor the residency application. Taking the examination in June or July\nensures that scores will be available for the Match period that begins in\nSeptember. Some programs, however, will accept scores after the applica-\ntion process starts. Check with programs in your desired specialty to deter-\nmine when to take the exam.\nâ–  Prerequisite to graduation. If passing the USMLE Step 2 CK is a prereq-\nuisite to graduation at your medical school, you will need to take the\nexamination in the fall or winter at the latest.\nâ–  Proximity to clerkships. Many students feel that the core clerkship mate-\nrial is fresher in their minds early in the fourth year, making a good argu-\nment for taking the Step 2 CK earlier in the fall.\nâ–  The nature of your schedule.\nâ–  Considerations for MD/PhD students. The dates of passing the Step 1,\nStep 2, and Step 3 examinations should occur within a 7-year period.\nHowever, the typical pathway for MD/PhD students consists of 2â€“3 years\nof preclinical (and sometimes clinical) work in medical school, 3â€“4 years\nof graduate work with research, and finally returning to medical school for\nclinical work. MD/PhD students typically exceed the 7-year limit.\nDepending on the state in which licensure is sought, such students may\nneed to petition their licensure body for an exception to this rule.\nâ–  Considerations for International Medical Graduates. A passing score on KEY FACT\nthe Step 2 CK is required to qualify for ECFMG certification which is\nThe Step 2 CK is an opportunity to\nnecessary to match. It is generally recommended to take the Step 2 CK\nconsolidate your clinical knowledge\nearly enough to obtain ECFMG certification before interview season is\nand prepare for internship.\ncompleted, ideally even before applications are reviewed by programs.\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 1111 1100/",
      "char_start": 54000,
      "char_end": 56000
    },
    {
      "chunk_id": 28,
      "text": "/2211//2222 1111::2211 AAMM\n\n12 SECTION 1 GUIDE TO EFFICIENT EXAM PREPARATION\nHOW WILL THE STEP 2 CK SCORE AFFECT MY MATCH?\nSince Step 1 is now being reported as pass or fail, it is expected that the Step 2\nCK score may take on more importance. Programs receive hundreds if not\nthousands of applications yearly, and they rely on certain objective metrics to\nselect applicants to interview. Having a competitive Step 2 CK score will not\nguarantee a match at a top choice program but it will strengthen your applica-\ntion. It is one of many elements that programs will consider.\nSTUDY RESOURCES\nQUALITY CONSIDERATIONS\nAlthough an ever-increasing number of USMLE Step 2 CK review books and\nsoftware packages are available on the market, the quality of these materials is\nhighly variable (see Section 3). Some common problems include the following:\nâ–  Some review books are too detailed to be reviewed in a reasonable amount\nof time or cover subtopics that are not emphasized on the examination\n(eg, a 400-page anesthesiology book).\nâ–  Many sample question books have not been updated to reflect current\ntrends on the Step 2 CK.\nâ–  Many sample question books use poorly written questions, contain factual\nerrors in their explanations, give overly detailed explanations, or offer no\nexplanations at all.\nâ–  Software for boards review is of highly variable quality, may be difficult to\ninstall, and may be fraught with bugs.\nCLINICAL REVIEW BOOKS\nKEY FACT\nMany review books are available, so you must decide which ones to buy by\nThe best review book for you reflects\ncarefully evaluating their relative merits. Toward this goal, you should com-\nthe way you like to learn. If a given\npare different opinions from other medical students; read the reviews and rat-\nreview book is not working for you, stop\nings in Section 3 of this guide, and examine the various books closely in the\nusing it no matter how highly rated it\nbookstore. Do not worry about finding the â€œperfectâ€ book, as many subjects\nmay be.\nsimply ",
      "char_start": 56000,
      "char_end": 58000
    },
    {
      "chunk_id": 29,
      "text": "do not have one.\nThere are two types of review books: those that are stand-alone titles and\nthose that are part of a series. Books in a series generally have the same style, and\nyou must decide if that style is helpful for you and optimal for a given subject.\nTEST BANKS\nA test bank can serve multiple functions, including the following:\nâ–  Provide information about strengths and weaknesses in your fund of\nknowledge.\nâ–  Add variety to your study schedule.\nâ–  Serve as the main form of study.\nâ–  Improve test-taking skills.\nâ–  Familiarize examinees with the style of the USMLE Step 2 CK\nexamination.\nStudents report that some test banks have questions that are, on average,\nshorter and less clinically oriented than those on the current Step 2 CK exam.\nStep 2 CK questions demand fast reading skills and the application of clinical\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 1122 1100//2211//2222 1111::2211 AAMM\n\nGUIDE TO EFFICIENT EXAM PREPARATION SECTION 1 13\nfacts in a problem-solving format. Approach sample examinations critically, KEY FACT\nand do not waste time with low-quality test bank questions until you have\nUse test banks to identify concepts and\nexhausted better sources.\nareas of weakness, not just facts that\nAfter you have taken a practice test, try to identify concepts and areas of\nyou missed.\nweakness, not just the facts that you missed. Use this experience to motivate\nyour study and to prioritize the areas in which you need the most work. Ana-\nlyze the pattern of your responses to questions to determine if you have made\nsystematic errors in answering questions. Common mistakes include reading\ntoo much into the question, second-guessing your initial impression, and mis-\ninterpreting the question.\nTEXTS AND NOTES\nMost textbooks are too detailed for high-yield boards review and should be\navoided. When using texts or notes, engage in active learning by making\ntables, diagrams, new mnemonics, and conceptual associations whenever pos-",
      "char_start": 58000,
      "char_end": 60000
    },
    {
      "chunk_id": 30,
      "text": "\nsible. If you already have your own mnemonics, do not bother trying to mem-\norize someone elseâ€™s. Textbooks are useful; however, they are best used to\nsupplement incomplete or unclear material.\nCOMMERCIAL COURSES\nCommercial preparation courses can be helpful for some students, as they\noffer an effective way to organize study material. However, multiweek courses\nare costly and require significant time commitment, leaving limited time for\nindependent study. Also note that some commercial courses are designed for\nfirst-time test takers, students who are repeating the examination, or interna-\ntional medical graduates.\nNBME/USMLE PUBLICATIONS\nWe strongly encourage students to use the free materials provided by the test-\ning agencies and to study the following NBME publications:\nâ–  USMLE Step 2 Clinical Knowledge (CK): Content Description and\nGeneral Information. This publication provides you with nuts-and-bolts\ndetails about the examination (included on the Web site http://www.\nusmle.org; free to all examinees).\nâ–  USMLE Step 2 Clinical Knowledge (CK): Sample Test Questions. This\nis a PDF version of the test questions and test content also found at http://\nwww.usmle.org under â€œPrepare for your examâ€.\nâ–  USMLE Web site (http://www.usmle.org). In addition to allowing you to\nbecome familiar with the CBT format, the sample items on the USMLE\nWeb site provide the only questions that are available directly from the test\nmakers. Student feedback varies as to the similarity of these questions to\nthose on the actual exam, but they are nonetheless worthwhile to know.\nTEST-DAY CHECKLIST\nTHINGS TO BRING WITH YOU TO THE EXAM\nâ–  Be sure to bring your scheduling permit as a hard copy and a photo ID\nwith signature. (You will not be admitted to the examination if you fail to\nbring your permit, and Prometric will charge a rescheduling fee.)\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 1133 1100//2211//2222 1111::2211 AAMM\n\n14 SECTION 1 GUIDE TO EFFICIENT",
      "char_start": 60000,
      "char_end": 62000
    },
    {
      "chunk_id": 31,
      "text": " EXAM PREPARATION\nâ–  Remember to bring lunch, snacks (for a little â€œsugar rushâ€ on breaks), and\nfluids (including a caffeine-containing drink if needed).\nâ–  Bring clothes to layer to accommodate temperature variations at the test-\ning center.\nâ–  Earplugs will be provided at the Prometric center.\nâ–  Remove all jewelry (eg, earrings, necklaces) before entering the testing center.\nâ–  Bring acetaminophen/ibuprofen, in case you develop a headache during\nthe exam.\nâ–  Check the USMLE Web site (http://www.usmle.org/test-accommodations/\nPIEs.html) for the personal item exception list to see if a medical device or\npersonal item that you need is allowed into the testing facility without sub-\nmitting a special request.\nâ–  If you have a medical condition that requires use of an item NOT on\nthe above list, contact the NBME personal item exception (PIE) coor-\ndinator at disabilityservices@NBME.org or (215) 590-9700 for addi-\ntional information on how to request a personal item exception.\nâ–  If you need test accommodation for one of the following reasons: assis-\ntance with keyboard tasks, audio rendition, extended testing time, addi-\ntional break time, you need to fill in a request by going to the website\nhttps://www.usmle.org/step-exams/test-accommodations\nTESTING AGENCIES\nNational Board of Medical Examiners (NBME)\nDepartment of Licensing Examination Services\n3750 Market Street\nPhiladelphia, PA 19104-3102\nCustomer Service: (215) 590-9700, Front Desk: (215) 590-9500\nFax: (215) 590-9460\nhttp://www.nbme.org/contact/\ne-mail: webmail@nbme.org\nUSMLE Secretariat\n3750 Market Street\nPhiladelphia, PA 19104-3190\n(215) 590-9700\nFax: (215) 590-9460\nhttp://www.usmle.org\ne-mail: webmail@nbme.org\nEducational Commission for Foreign Medical Graduates (ECFMG)\n3624 Market Street\nPhiladelphia, PA 19104-2685\n(215) 386-5900\nFax: (215) 386-9196\nhttp://www.ecfmg.org/contact.html\ne-mail: info@ecfmg.org\nFederation of State Medical Boards (FSMB)\n400 Fuller Wiser Road, Suite 300\nEuless, TX 76039\n(817) 868-4041\nFax: (",
      "char_start": 62000,
      "char_end": 64000
    },
    {
      "chunk_id": 32,
      "text": "817) 868-4098\nhttp://www.fsmb.org/contact-us\ne-mail: usmle@fsmb.org\n22002222__0022..0000__SStteepp22CCKK__IInnttrroo__1111ee__000011--001144..iinndddd 1144 1100//2211//2222 1111::2211 AAMM\n\nS E C T I O N 2\nDATABASE OF HIGH-YIELD FACTS\nCardiovascular Obstetrics\nDermatology Gynecology\nEndocrinology Pediatrics\nEpidemiology Psychiatry\nHealth Systems Science Pulmonary\nGastrointestinal Renal/Genitourinary\nHematology Multisystem\nMusculoskeletal Rapid Review\nNeurology\n15\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 1155 1100//2211//2222 44::0055 PPMM\n\n16\nHOW TO USE THE DATABASE\nThe 11th edition of First Aid for the USMLE Step 2 CK contains a revised\nand expanded database of clinical material that student authors and faculty\nhave identified as high yield for boards review. We have organized informa-\ntion according to subject matter, whether medical specialty (eg, Cardiovascu-\nlar, Renal) or high-yield topic (eg, Health Systems Science). Each subject\nthen branches out into smaller subsections of related facts.\nIndividual facts appear in a logical fashion, from basic definitions and epi-\ndemiology to history/physical exam, diagnosis, and treatment. Lists, mnemon-\nics, pull quotes, vignette flash cards, and tables help the reader form key\nassociations. In addition, we have interspersed color and black-and-white pho-\ntos throughout the text. At the end of Section 2, we also feature a Rapid\nReview chapter consisting of key facts and classic associations that can be\nstudied a day or two before the exam.\nThe content contained herein is useful primarily for the purpose of\nreviewing material already learned. The information presented is not ideal for\nlearning complex or highly conceptual material for the first time.\nThe Database of High-Yield Facts is not meant to be comprehensive. Use\nit to complement your core study material, not as your primary study source.\nWe have condensed and edited the facts and notes to emphasize essential\nmaterial. Wo",
      "char_start": 64000,
      "char_end": 66000
    },
    {
      "chunk_id": 33,
      "text": "rk with the material, add your own notes and mnemonics, and\nrecognize that not all memory techniques work for all students.\nWe update material to keep current with new trends in boards content, as\nwell as to expand our database of high-yield information. However, we must\nnote that our database inevitably does not include many other high-yield\nentries and topics.\nWe actively encourage medical students and faculty to submit entries and\nmnemonics so that we may enhance the database for future students. We also\nsolicit recommendations for additional study tools that may be useful in pre-\nparing for the exam, such as diagrams, charts, and computer-based tutorials\n(see How to Contribute, p. xi).\nDISCLAIMER\nThe entries in this section reflect student opinions of what is high yield.\nOwing to the diverse sources of material, we have made no attempt to trace\nor reference origins of individual entries. We have regarded mnemonics as\nessentially in the public domain. We will gladly correct errors and omissions\nif brought to the attention of the authors, either through the publisher or\ndirectly by email.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 1166 1100//2211//2222 44::0055 PPMM\n\nH I G H - Y I E L D F A C T S I N\nCARDIOVASCULAR\nElectrocardiogram 18 Dyslipidemia 55\nCardiac Physical Exam 22 Hypertension 57\nPrimary (essential) hyPertension 57\nArrhythmias 25\nseCondary hyPertension 63\nBradyarrhythmias and ConduCtion aBnormalities 25\nhyPertensive emergenCy/urgenCy 63\ntaChyarrhythmias 25\nPericardial Disease 64\nCardiac Life Support Basics 34\naCute PeriCarditis 64\nCongestive Heart Failure 34 ConstriCtive PeriCarditis 65\nClassifiCation 34 PeriCardial effusion 66\nsystoliC dysfunCtion/heart failure with reduCed ejeCtion fraCtion 35 CardiaC tamPonade 67\nheart failure with Preserved ejeCtion fraCtion 39\nEndocarditis 67\nCardiomyopathy 40\nValvular Heart Disease 72\ndilated CardiomyoPathy 41\nhyPertroPhiC CardiomyoPathy 41 Vascular Diseases 75\narrhythmog",
      "char_start": 66000,
      "char_end": 68000
    },
    {
      "chunk_id": 34,
      "text": "eniC right ventriCular dysPlasia 42 aortiC aneurysm 75\nrestriCtive CardiomyoPathy 43 aortiC disseCtion 76\nseCondary CardiomyoPathy 44 deeP venous thromBosis 78\nother CardiomyoPathies 46 PostthromBotiC (PostPhleBitiC) syndrome 80\nPeriPheral arterial disease 81\nCoronary Artery Disease 47\nlymPhedema 82\nangina PeCtoris 47\nPrinzmetal (variant) angina 49 Syncope 82\nAcute Coronary Syndromes 49\nunstaBle angina/non-st-segment elevation myoCardial infarCtion 49\nst-segment elevation myoCardial infarCtion 51\nCarotid artery stenosis 55\n17\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 1177 1100//2211//2222 44::0055 PPMM\n\n18 HIGH-YIELD FACTS IN CARDIOVASCULAR\nELECTROCARDIOGRAM\nKEY FACT An ECG provides an assessment of the electrical activity of the heart. The\nheart rate, rhythm, axis, intervals, ischemia, and chamber enlargement can be\n*Heart rate = 300/number of large evaluated (Fig. 2.1-1).\nboxes between two consecutive\nQRS complexes. Rate\n*Presuming ECG recorded at usual\nNormal adult heart rate (HR) is 60â€“100 beats/min (bpm). HR <60 bpm is\nspeed (25 mm/sec), where each large\nbradycardia. Heart rate >100 bpm is tachycardia. Common causes of sinus\nbox = 200 msec and each small box =\nbradycardia are physical fitness, sick sinus syndrome, drugs, vasovagal\n40 msec.\nattacks, acute myocardial infarction (MI), and â†‘ intracranial pressure. Com-\nmon causes of sinus tachycardia are anxiety, anemia, pain, fever, sepsis,\ncongestive heart failure (CHF), pulmonary embolism, hypovolemia, thyro-\ntoxicosis, carbon dioxide (CO ) retention, and sympathomimetics.\n2\nRhythm\nSinus rhythm: Normal rhythm that originates from the sinus node. It is char-\nacterized by a P wave (upright in leads II, III, and aVF; inverted in lead aVR)\npreceding every QRS complex and a QRS complex following every P wave.\nSinus arrhythmia is a sinus rhythm originating from the sinoatrial (SA) node\nwith cyclical beat-to-beat variation (>120 milliseconds [msec]) in the P-P\ninterval and a c",
      "char_start": 68000,
      "char_end": 70000
    },
    {
      "chunk_id": 35,
      "text": "onstant P-R interval, which results in an irregular ventricular\nrate. It is common in young adults and is considered a normal variant.\nAxis\nThe QRS axis represents the direction in which the mean QRS current flows.\nIt can be determined by examining the QRS in leads I, II, and aVF (see\nTable 2.1-1 and Fig. 2.1-2).\nFIGURE 2.1-1. Normal electrocardiogram from a healthy subject. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 1188 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 19\nTABLE 2.1-1. Axis Deviation by ECG Findings\nDEGREES\nNormal axis Mean left ventricular (LV) depolarization vector (red arrow) toward\nleads I, II, and aVF, resulting in upward deflection (eg, positive\nQRS) in these leads\nLeft axis deviation LV vector toward lead I (+ve QRS), away from lead aVF (â€“ve QRS)\nSeen in ventricular tachycardia, inferior MI, LV hypertrophy, left\nanterior hemiblock\nRight axis deviation LV vector toward lead aVF (+ve QRS), away from lead II (â€“ve QRS)\nSeen in right ventricular hypertrophy, anterolateral MI, left posterior\nhemiblock (also consider pulmonary embolism)\nExtreme axis LV vector opposing lead aVF and lead II (both â€“ve QRS deflections)\nSome common causes include misplaced limb leads (reversal of\nright and left), ventricular rhythms, and ventricular pacing\nâ€’90o\nâ€’150o\nR\nExtreme\na\nâ€’30o\na V axis LAD V L\ndeviation\n180o\nI\n0o\nNormal\nRAD\nQRSaxis\nIII II\naVF\n+120o +60o\n+90o\nFIGURE 2.1-2. ECG axis interpretation. QRS axis and frontal leads. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 1199 1100//2211//2222 44::0055 PPMM\n\n20 HIGH-YIELD FACTS IN CARDIOVASCULAR\nIntervals\nKEY FACT\nâ–  PR interval: Normally 120 to 200 msec (3â€“5 small boxes).\nSmith-Modified Sgarbossa Criteria are\nâ–  Prolonged = delayed atrioventricular (AV) conduction (eg, first-degree\nused to diagnose MI in the presence of\nheart ",
      "char_start": 70000,
      "char_end": 72000
    },
    {
      "chunk_id": 36,
      "text": "block).\nLBBB should be suspected in a patient\nâ–  Short = fast AV conduction down accessory pathway (eg, Wolff-\nwith LBBB and the following ECG\nParkinson-White [WPW] syndrome).\nfindings:\nâ–  Concordant ST elevation (STE) â‰¥1 â–  QRS interval: Normally <120 msec. A normal Q wave is <40 msec wide\nmm in â‰¥1 lead and <2 mm deep. Ventricular conduction defects can cause a widened\nâ–  Concordant ST depression â‰¥1 mm QRS complex (>120 msec):\nin â‰¥1 lead of V 1 â€“V 3 â–  Left bundle-branch block (LBBB): Deep S wave and no R wave in V 1\nâ–  Excessive discordant STE in â‰¥1 lead (â€œWâ€ shaped); wide, tall and broad, or notched (â€œMâ€-shaped) R waves\nwith â‰¥1 mm STE, where excessive in I, V 5 , and V 6 (Fig. 2.1-3). A new LBBB is pathologic, and it may be\ndiscordance is defined as STE to suggestive of acute MI. However, this is not diagnostic in isolation.\nthe maximum QRS amplitude ratio Rather, the Modified Sgarbossa Criteria (see key fact) should be used\nâ‰¥25% for the ECG diagnosis of acute MI in this situation (higher sensitivity\nand specificity).\nâ–  Right bundle-branch block (RBBB): RSRâ€² complex (â€œrabbit ears;â€\nâ€œMâ€-shaped); qR or R morphology with a wide R wave in V ; QRS pat-\n1\ntern with a wide S wave in I, V , and V (see Fig. 2.1-3).\n5 6\nâ–  QT interval: Normally QTc (the QT interval corrected for extremes in\nheart rate) is 380 to 440 msec (QTc = QT/âˆšRR). QTc may be prolonged\n(QTc >440 msec) due to acquired causes, including electrolyte derange-\nments (â†“ K+, â†“ Ca2+, â†“ Mg2+) and medications (macrolides, fluroquino-\nlones, opioids, ondansetron, Classes Ia [quinidine, procainamide] and III\n[sotalol, amiodarone] antiarrhythmic drugs). Congenital causes include\nlong QT syndrome (LQTS), an underdiagnosed disorder that predisposes\nto ventricular tachyarrhythmias (eg, torsade de pointes) and sudden car-\ndiac death (SCD, see later).\nâ–  Romano Ward syndrome is the most common congenital cause of\nLQTS with autosomal dominant inheritance. Presents as a purely car-\ndiac phenotype (no deafness).\nâ–  Jervell and Lan",
      "char_start": 72000,
      "char_end": 74000
    },
    {
      "chunk_id": 37,
      "text": "ge-Nielsen syndrome is an autosomal recessive cause\nof LQTS caused by a defect in K+ channel conduction. Most likely\ndiagnosis in a child with sensorineural deafness, syncope on exercise,\nventricular arrhythmias, and prolonged QT. Treat with Î²-blockers and\nimplantable cardiac defibrillator (ICD) or pacemaker.\nA\nV V\n1 6\nB\nV\n6\nV\n1\nFIGURE 2.1-3. Bundle branch block. Characteristic ECG findings in left bundle branch block\n(A) and right bundle branch block (B) are seen in leads V 1 and V 6 . (Modified with permission from\nUSMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2200 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 21\nNormal Hyperacute Acute and subacute Postacute Stable Chronic\nNormal ST segment\nST elevation T-wave inversion Normal ST segment\nNormal Hyperacute T waves Normal T wave\nQ wave begins Deeper Q wave T-wave inversion\nPersistent Q wave\n0 minutes Seconds after Minutes to hours <24 hours Days to weeks Months to years\nFIGURE 2.1-4. ECG changes in acute ST-elevation myocardial infarction (STEMI) over time.\n(Reproduced with permission from USMLE-Rx.com.)\nIschemia/Infarction\nAcute ischemia: See Figure 2.1-4 describing progression of ECG changes\nMNEMONIC\nover time in ST-segment elevation MI (STEMI).\nPulmonale causes Peaked P waves.\nâ–  Within hours, peaked T-waves and ST-segment changes (either depression\nMitrale causes M-shaped P waves.\nor elevation).\nâ–  Within 24 hours, T-wave inversion and ST-segment resolution.\nâ–  Within a few days, pathologic Q waves (>40 msec or more than one-third of\nthe QRS amplitude). Q waves usually persist, but may resolve in 10% of\npatients. Because of this, Q waves signify either acute or prior ischemic events.\nâ–  Nonâ€“Q-wave infarcts (also known as subendocardial infarcts) have ST and\nT changes without Q waves.\nâ–  In a normal ECG, R waves increase in size compared to the S wave\nbetween leads V and V . Poor R-wave progression refers to abnormalities\n1 5\nin this pattern (",
      "char_start": 74000,
      "char_end": 76000
    },
    {
      "chunk_id": 38,
      "text": "eg, reversed progression [R in V > V ], transition point\n2 3\nbeyond V , R in V <3 mm) and can be a sign of new or prior anterior\n4 3\ninfarction, although it is not specific.\nV V V V\nChamber Enlargement 1 2 5 6\nA B\nAtrial enlargement:\nâ–  Right atrial abnormality (P pulmonale): Generally, the right atrium (RA)\ndepolarizes before the left. Right atrial enlargement (due to pulmonary\nhypertension [eg, chronic obstructive, pulmonary disease, tetralogy of Fal-\nlot, tricuspid atresia]) causes slowed conduction; therefore peak right atrial\ndepolarization coincides with left. This results in inVc1reased P-wave aVm2pli- V 5 V 6\ntude (>2.5 mm in lead II). A B\nFIGURE 2.1-5. Left ventricular hypertro-\nâ–  Left atrial abnormality (P mitrale): Left atrial enlargement causes prolonged\nphy. Shown are leads V, V, V, and V.\nleft atrial (LA) depolarization, increased P-wave duration (>120 msec in lead\nS wave in V + R wave in\n1\nV\n2\n= 4\n5\n5 mm.\n6\n1 5\nII), and sometimes a notched P wave (also in lead II). Also, the P wave in Note ST changes and T-wave inversion\nlead V 1 may have a large negative deflection (>1 small square wide and 1 in V 5 and V 6 , suggesting strain. (Reproduced\nsmall square deep in a standard tracing). Commonly seen in isolation in with permission from USMLE-Rx.com.)\nmitral stenosis or associated with LV hypertrophy.\nâ–  Left ventricular hypertrophy (LVH, Fig. 2.1-5):\nâ–  Amplitude of S in V + R in V or V is >35 mm.\n1 5 6\nâ–  Alternative criteria: The amplitude of R in aVL + S in V is >28 mm\n3\nin men or >20 mm in women.\nKEY FACT\nâ–  Usually associated with ST depression and T-wave changes.\nâ–  Causes include hypertension (most common), aortic stenosis/regurgita-\nAxis deviation can be a sign of\ntion, mitral regurgitation, coarctation of the aorta, and hypertrophic\nventricular enlargement.\ncardiomyopathy.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2211 1100//2211//2222 44::0055 PPMM\n\n22 HIGH-YIELD FACTS IN CARDIOVASCULAR\nMNEMONIC â–  Right ventr",
      "char_start": 76000,
      "char_end": 78000
    },
    {
      "chunk_id": 39,
      "text": "icular hypertrophy (RVH):\nâ–  Right-axis deviation and an R wave in V >7 mm.\nâ€œD ARMS PITSâ€ 1\nâ–  Causes include pulmonary hypertension, pulmonary embolism,\nDiastolic Murmurs chronic lung disease (cor pulmonale), mitral stenosis, and congenital\nAortic Regurgitation heart disease (eg, tetralogy of Fallot, pulmonary stenosis).\nMitral Stenosis\nPulmonary Insufficiency\nTricuspid Stenosis CARDIAC PHYSICAL EXAM\nKey exam findings that can narrow the differential include the following:\nMNEMONIC\nâ–  Jugular venous distention (JVD): >3 cm above the sternal angle when\nSystolic Murmurs head of the bed is at 30 to 45 degrees of inclination. Most typically from\nvolume overload, stemming from conditions such as right heart failure or\nChange regurgitation (or insufficiency)\npulmonary hypertension.\nto stenosis, and the stenosis to\nregurgitation in â€œARMS PITSâ€ to â–  Hepatojugular reflux: Distention of neck veins upon applying pressure to\nderive systolic murmurs. the liver. Seen in same conditions as JVD.\nAortic stenosis â–  Kussmaul sign: â†‘ in jugular venous pressure (JVP) with inspiration. Often\nMitral regurgitation (Mitral valve prolapse) seen in constrictive pericarditis.\nPulmonary stenosis â–  Systolic and diastolic murmurs are detailed in Table 2.1-2 and Figures\nTricuspid regurgitation 2.1-6, 2.1-7, and 2.1-8.\nâ–  Flow murmur: Usually a soft murmur that is position dependent (very\ncommon and does not imply cardiac disease).\nâ–  Gallops:\nâ–  S gallop: A sign of fluid overload (eg, heart failure, mitral valve dis-\n3\nease); often normal in younger patients and in high-output states (eg,\npregnancy).\nâ–  S gallop: A sign of decreased compliance (eg, hypertension, aortic ste-\n4\nnosis, diastolic dysfunction); usually pathologic but can be normal in\nyounger patients and in athletes.\n111\n2\nA P\n3\n4\nT\n5\nM\nAortic 6\nPulmonic\nTricuspid 7777777\nMitral\nFIGURE 2.1-6. Auscultation locations. Auscultation sites are shown with associated valves. A, aortic valve; M, mitral\nvalve; P, pulmonic valve; T, tricuspid valve. (",
      "char_start": 78000,
      "char_end": 80000
    },
    {
      "chunk_id": 40,
      "text": "Modified with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2222 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 23\nSâ‚ Sâ‚‚\nAortic stenosis A harsh crescendo-decrescendo systolic ejection\nSâ‚ murmur heard best at the aortic valve area (para-\nSâ‚‚ sternal 2nd right intercostal space [ICS]) or Erbâ€™s point\nSâ‚ Sâ‚‚\n(parasternal 3rd left ICS) that radiates to the carotids.\nSâ‚ Sâ‚‚\nMitral/tricuspid regurgitation Mitral regurgitation: A holosystolic murmur heard best\nSâ‚ at the apex (midclavicular fifth left intercostal space\nSâ‚ Sâ‚‚\nSâ‚‚\nSâ‚ MC Sâ‚‚ [ICS]) that radiates to the axilla.\nTricuspid regurgitation: A holosystolic murmur heard\nSâ‚ Sâ‚‚\nSâ‚ best at the tricuspid valve (parasternal fourth left ICS).\nSâ‚‚\nMit\nSSâ‚â‚ral\nvalve prolapse\nSSâ‚‚â‚‚\nA midsystolic or late systolic crescendo murmur heard\nS S â‚ â‚ MC S S â‚‚ â‚‚ best at the apex (midclavicular fifth left ICS) with a\nSâ‚ Sâ‚‚\nSâ‚ Sâ‚‚\npreceding click (due to tensioning of cordae as mitral\nSSâ‚â‚ Sâ‚‚ OS\nSâ‚‚ leaflets prolapse). Fig. 2.1-8 compares mitral valve\nSâ‚\nSSSSâ‚â‚â‚â‚ MC SSSSâ‚‚â‚‚â‚‚â‚‚ prolapse and stenosis.\nVenSSâ‚â‚tricular septal defSSSeâ‚‚â‚‚â‚‚ct Holosystolic, harsh-sounding murmur heard best at\nSâ‚ Sâ‚‚ tricuspid area (parasternal fourth left ICS). Larger\nSS S Sâ‚â‚ â‚ â‚ SS S â‚‚â‚‚ â‚‚ OS\nventricular septal defects (VSDs) have a lower inten-\nSâ‚‚\nSâ‚ MC Sâ‚‚\nsity murmur than smaller VSDs.\nSâ‚ MC Sâ‚‚\nAoSS S r Sâ‚â‚ â‚â‚ tic regurg M it C ationSS S Sâ‚‚â‚‚ â‚‚ â‚‚ OS A high-pitched â€œblowingâ€ early diastolic decrescendo\nmurmur heard best at the aortic valve (parasternal\nSâ‚ Sâ‚‚\nsecond right ICS).\nSâ‚ Sâ‚‚\nSSSâ‚â‚â‚ MC SSSâ‚‚â‚‚â‚‚\nSâ‚ Sâ‚‚ OS\nKEY FACT\nMitral stenosis A mid to late low-pitched diastolic murmur preceded by\nSâ‚ Sâ‚‚ OS\nSSâ‚â‚ Sâ‚‚Sâ‚‚ OS an opening snap (mitral opening murmur) heard best More blood (â†‘ preload) = Increased\nSâ‚ Sâ‚‚ at the apex (midclavicular fifth left ICS). The duration murmur in everything except mitral\nSâ‚ Sâ‚‚ of the murmur correlates with the severity of mitral valve prolapse (MVP) and hypertrophic\nS",
      "char_start": 80000,
      "char_end": 82000
    },
    {
      "chunk_id": 41,
      "text": "Sâ‚â‚ SSâ‚‚â‚‚ OS stenosis. Most often caused by rheumatic fever. obstructive cardiomyopathy (HOCM).\nPatent ductus arteriosus Continuous machine-like murmur that is loudest at S\n2\nand is best heard at the left infraclavicular area.\nSâ‚ Sâ‚‚\nKEY FACT\nRight-sided murmurs increase with\nFIGURE 2.1-7. Heart murmurs. Visual representations of common heart murmurs are shown in inspiration. Left-sided murmurs increase\nrelation to S 1 and S 2 . MC, Midsystolic click; OS, opening snap. (Adapted with permission from USMLE- with expiration.\nRx.com.)\nâ–  Edema:\nâ–  Pulmonary edema: Left heart failure (fluid â€œbacks upâ€ into the lungs).\nâ–  Peripheral edema: Right heart failure and biventricular failure (fluid\nâ€œbacks upâ€ into the periphery), nephrotic syndrome, hepatic disease,\nlymphedema, hypoalbuminemia, and drugs.\nâ–  Hands:\nâ–  Finger clubbing: Congenital cyanotic heart disease; endocarditis.\nâ–  Infective endocarditis: Splinter hemorrhages, Osler nodes, Janeway\nlesions.\nâ–  Peripheral pulses:\nâ–  Increased: Compensated aortic regurgitation (bounding pulses); coarc-\ntation (greater in arms than in legs); patent ductus arteriosus.\nâ–  Decreased: Peripheral arterial disease; late-stage heart failure.\nâ–  Collapsing (\"waterhammer\"): Aortic incompetence; AV malforma-\ntions; patent ductus arteriosus; thyrotoxicosis, severe anemia.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2233 1100//2211//2222 44::0055 PPMM\n\n24 HIGH-YIELD FACTS IN CARDIOVASCULAR\nMitral valve prolapse\nï¨murmur intensity ï©murmur intensity\nï© afterload ï¨ afterload\nS1 ï© preload MC S2 ï¨ preload S1\nSystole Diastole\nMitral stenosis\nï¨murmur intensity ï©murmur intensity\nï¨ preload ï© preload\nS1 S2 OS S1\nSystole Diastole\nFIGURE 2.1-8. Murmurs of mitral valve prolapse and mitral stenosis. Visual representations of\ncommon heart murmurs are shown in relation to S and S. MC, midsystolic click; OS, opening\n1 2\nsnap. (Adapted with permission from USMLE-Rx.com.)\nTABLE 2.1-2. Differentiating Murmurs Based on Maneuvers\nHYPER",
      "char_start": 82000,
      "char_end": 84000
    },
    {
      "chunk_id": 42,
      "text": "TROPHIC\nMANEUVER HEMODYNAMICSa MITRAL VALVE PROLAPSE CARDIOMYOPATHY AORTIC STENOSIS AR, MR, VSD\nSquatting â†‘ venous return â†“ prolapse, delayed â†“ obstruction â†‘ ejection â†‘ murmur\nValsalva: Release â†‘ SVR click, shorter murmur â†“ murmur â†‘ murmur\nLeg raise â†‘ venous return\nStanding â†“ venous return â†‘ prolapse, early click, â†‘ obstruction â†“ ejection â†“ murmur\nValsalva: Strain â†“ SVR longer murmur â†‘ murmur â†“ murmur\nHand grip â†‘ SVR â†“ prolapse, delayed â†“ murmur â†“ murmur â†‘ murmur\nclick, shorter murmur\nInspiration â†‘ venous return (right heart) â†‘ flow to right heart = â†‘ right-sided murmurs\nâ†“ venous return (left heart) â†“ flow to left heart = â†“ left-sided murmurs\naVenous return: preload; systemic vascular resistance (SVR): afterload.\nAR, Aortic regurgitation; MR, mitral regurgitation; VSD, ventricular septal defect.\nKEY FACT\nAtrial myxoma (benign tumor of the\nheart): Commonly in the left atrium on â–  Pulsus paradoxus (â†“ systolic blood pressure [BP] >10 mm Hg with\ninspiration): Cardiac tamponade; pericardial constriction; also seen in\nthe interatrial septum. Patients may\nobstructive lung diseases (eg, severe asthma), tension pneumothorax,\ndevelop intermittent mitral obstruc-\nand foreign body in airway.\ntion, systemic embolization from tumor\nbreakage, arrhythmias, or nonspecific â–  Pulsus alternans (alternating weak and strong pulses): Cardiomyopa-\nthy; impaired left ventricular systolic function (LVF). Poor prognosis.\nsymptoms (fever, weight loss). May\npresent with atrial fibrillation or mimic â–  Pulsus parvus et tardus (weak and delayed pulse): Aortic stenosis.\ninfective endocarditis. On auscultation, â–  Jerky: Hypertrophic obstructive cardiomyopathy (HOCM).\ntumor â€œplopâ€ is audible. Tumor is visual- â–  Pulsus bisferiens (bifid pulse/â€œtwice beatingâ€): Aortic regurgitation;\ncombined aortic stenosis and aortic regurgitation, HOCM.\nized on echocardiography. Treatment:\ntumor resection.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2244 1100//2211//2222 44::0",
      "char_start": 84000,
      "char_end": 86000
    },
    {
      "chunk_id": 43,
      "text": "055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 25\nA Atrium B\nARRHYTHMIAS\nSlow AV Fast AV\nERP\npathway node pathway node\nBRADYARRHYTHMIAS AND CONDUCTION ABNORMALITIES\nHis Bundle\nTable 2.1-3 outlines the etiologies, clinical presentation, and treatment of\ncommon bradyarrhythmias and conduction abnormalities.\nVentricles Ventricles\nTACHYARRHYTHMIAS\nTables 2.1-4 and 2.1-5 outline the etiologies, clinical presentation, and treat-\nment of common supraventricular and ventricular tachyarrhythmias. Normal Premature beat initiates\nconduction re-entrant circuit\nMechanism of Tachyarrhythmias\nC D\nThe primary mechanisms of tachyarrhythmias include abnormal automatic-\nAV AV Reentry\nity, triggered activity, and re-entry. node node circuit\nâ–  Abnormal automaticity: Myocardial tissue that does not normally pace\nthe heart (ie, no automaticity) may develop automaticity due to pathologic\nmechanisms (eg, ischemia, metabolic disturbances). Examples include\naccelerated idioventricular rhythm or multifocal atrial tachycardia.\nVentricles Ventricles\nâ–  Triggered activity: Due to oscillations (called afterdepolarizations) in\nthe membrane potential of cardiomyocytes that occur during or immedi-\nately after an action potential. If afterdepolarizations cross a critical\nthreshold, a new action potential is generated. Examples include torsade\nde pointes. Conduction retrograde Re-entry circuit\nup the \"fast\" pathway established\nâ–  Reentry: Most common cause of tachyarrhythmias. Two distinct pathways\nconnect to form a circuit. Conduction down this circuit could sustain a FIGURE 2.1-9. Mechanism of re-entry\nfixed and stable wavefront, which depolarizes the myocardium (Fig. 2.1- at the AV node. The AV node has a\n9). Examples include AVRT and AVNRT. slow-conducting pathway with a short\nrefractory period and a fast-conducting\npathway with a long refractory period.\nAtrial Fibrillation\nDuring normal sinus rhythm, impulses\nAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It are conducted do",
      "char_start": 86000,
      "char_end": 88000
    },
    {
      "chunk_id": 44,
      "text": "wn both pathways\nsimultaneously but only transmitted to\nresults in disorganized atrial electrical activity and an irregularly irregular ven-\nthe His bundle down the fast pathway\ntricular rhythm. This causes increased rates of stroke, heart failure, and mor-\n(myocardium is refractory once the slow\ntality. See Table 2.1-4 for a summary. impulse arrives) (A). A premature atrial\ncontraction could arrive when the fast\nRisk Factors pathway is still refractory but the slow\npathway is able to conduct (B). When\nâ–  AF is associated with increased age, hypertension, valvular disease, heart the impulse from the slow pathway\nfailure (HF), CAD, lung disease (PE, chronic lung disease, obstructive reaches the His bundle, the fast pathway\nsleep apnea). is no longer refractory, thus allowing ret-\nâ–  Other reversible causes such as hyperthyroidism, electrolyte derangements, rograde conduction up the fast pathway\n(C). This impulse may continuously\nand substance use (caffeine or drugs) should be excluded on initial evaluation.\ncycle through the fast and slow pathways,\nresulting in a reentry tachycardia, ie,\nPathophysiology\nAVNRT (D). Other reentrant tachycar-\nâ–  Often triggered by irregularly depolarizing cells near the ostia of the pul- dias may share a similar mechanism.\nmonary veins that result in disorganized atrial electrical activity. ERP: Effective refractory period. (Repro-\nduced with permission from USMLE-RX.com.)\nâ–  This results in an irregularly irregular pattern of ventricular contractions.\nChronic AF may results in structural changes to the atrium.\nClassification\nâ–  AF may be valvular (associated with mitral stenosis or prosthetic valve) or\nnonvalvular.\nâ–  It may be new-onset/recurrent, paroxysmal (self-limited), persistent (>7\ndays), long-standing (>12 months), or permanent (not looking to restore\nsinus rhythm).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2255 1100//2211//2222 44::0055 PPMM\n\n26 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1",
      "char_start": 88000,
      "char_end": 90000
    },
    {
      "chunk_id": 45,
      "text": "-3. Bradyarrhythmias and Conduction Abnormalities\nTYPE/ETIOLOGY SIGNS/SYMPTOMS TREATMENT\nSinus bradycardia ECG findings: Sinus rhythm. Ventricular rate <60 bpm\nNormal response to cardiovascular conditioning May be asymptomatic, None if asymptomatic; if\nCan also result from sinus node dysfunction, AV nodal blocking drugs; therefore it but may also present symptomatic:\nis important to review medications with lightheadedness, Initial Rx:\nsyncope, chest pain, or â–  First line: atropine\nhypotension â–  Second line:\ntranscutaneous\npacing or dopamine/\nepinephrine infusion\nâ–  Third line: temporary\ntransvenous pacing\nDefinitive Rx: perma-\nnent pacemaker\nimplantation\nFirst-degree AV block ECG findings: PR interval >200 msec\nPR = PR = PR = PR\n1 2 3 4\nCan occur in normal individuals; associated with â†‘ vagal tone, Î²-blocker, or CCB Asymptomatic None necessary\nuse\nSecond-degree AV block (Mobitz type I/Wenckebach) ECG findings: Progressive PR lengthening until a\ndropped beat occurs (arrow); the PR interval then\nresets\nPR < PR < PR < PR P wave, absent QRS\n1 1 2 3\nDrug effects (digoxin, Î²-blockers, CCBs) or â†‘ vagal tone; right coronary ischemia or Usually asymptomatic None if asymptomatic\ninfarction Stop the offending drug\nSuggests progressively delayed AV node conduction; not always due to intrinsic Atropine as clinically\ndisease indicated\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2266 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 27\nTABLE 2.1-3. Bradyarrhythmias and Conduction Abnormalities (continued)\nTYPE/ETIOLOGY SIGNS/SYMPTOMS TREATMENT\nSecond-degree AV block (Mobitz type II) ECG findings: Unexpected dropped beats without a\nchange in PR interval\nPR = PR = PR P wave, absent QRS\n1 1 2\nResults from fibrotic disease of the conduction system or from acute, subacute, or Occasionally syncope; Pacemaker placement\nprior MI frequent progression to (even if asymptomatic)\nSuggests intrinsic disease of His Purkinje sys",
      "char_start": 90000,
      "char_end": 92000
    },
    {
      "chunk_id": 46,
      "text": "tem third-degree AV block\nThird-degree AV block (complete) ECG findings: P and QRS waves occur regularly but at\nRR = RR different rates (different PP and RR intervals shown\n1 2\nin the figure; ie, atrial contraction is dissociated from\nP wave on QRS complex P wave\non T wave ventricular contraction). Note: Some P waves are not\nvisible or are partially visible due to fusion with QRS\nPP = PP = PP = PP\n1 2 3 4 complex\nNo electrical communication between the atria and ventricles Syncope, dizziness, acute Pacemaker placement\nSuggests disease of His Purkinje system heart failure, hypoten-\nsion, cannon A waves\nSick sinus syndrome/tachycardia- ECG findings: ECG shows an SA pause (no P waves\nbradycardia syndrome generated, suggesting no activation at the SA node),\nfollowed by a junctional escape beat (QRS with no\npreceding P wave), and then reappearance of P waves\n(resumption of SA node activity). Other supraven-\ntricular tachyarrhythmias and bradyarrhythmias may\noccur intermittently in sick sinus syndrome (see ECGs\nearlier)\nHeterogeneous disorder that leads to intermittent supraventricular tachyarrhyth- Secondary to tachycardia Most common indica-\nmias and bradyarrhythmias or bradycardia; AF and tion for pacemaker\nthromboembolism may placement\noccur â†’ syncope, palpi- Anticoagulate in AF/\ntations, dyspnea, chest flutter to prevent sys-\npain, transient ischemic temic emboli\nattack (TIA), and/or stroke\n(Images adapted with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2277 1100//2211//2222 44::0055 PPMM\n\n28 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-4. Supraventricular Tachyarrhythmias\nTYPE/ETIOLOGY SIGNS/SYMPTOMS TREATMENT\nSinus tachycardia ECG findings: Sinus rhythm, ventricular rate >100 bpm\nNormal physiologic response to fear, pain, and exercise Palpitations, shortness of Treat the underlying cause\nCan also be secondary to hyperthyroidism, volume contraction, infection, breath\nor pulmonary embolism (PE)\n",
      "char_start": 92000,
      "char_end": 94000
    },
    {
      "chunk_id": 47,
      "text": "Atrial flutter ECG findings: Regular rhythm; â€œsawtoothâ€ appearance of P\nRR = RR = RR waves; atrial rate is usually 240â€“320 bpm, ventricular rate\n1 2 3\ndepends on conduction block through AV node (in example,\natrial rate 300 bpm, ventricular rate 60 bpm)\n4:1 sawtooth pattern\nCircular movement of electrical activity around the atrium at a rate of Usually asymptomatic but Anticoagulation, rate control,\napproximately 300 times per minute. Reentrant circuit most commonly can present with palpi- and cardioversion guidelines\npasses between inferior vena cava and tricuspid annulus (cavotricuspid tations, syncope, and as in atrial fibrillation (see\nisthmus). Interventions to ablate the cavotricuspid isthmus may break lightheadedness earlier)\nthe reentrant circuit\nAtrioventricular nodal reentry tachycardia (AVNRT) ECG findings: HR about 150 bpm, with retrograde P waves. Note\nno P waves before the QRS complex\nA reentry circuit in the AV node depolarizes the atrium and ventricle nearly Palpitations, shortness of Cardiovert if hemodynamically\nsimultaneously breath, angina, syncope, unstable\nlightheadedness. AVRT and If stable, initial trial of vagal\nAVNRT are often indistin- maneuvers (eg, Valsalva,\nguishable on ECG. P waves carotid sinus massage, [CSM],\nmay occur during or after ice immersion), followed by\nQRS. These P waves may adenosine if ineffective\nappear as a pseudo Râ€² in V, CSM contraindicated in MI/TIA/\n1\nor pseudo S in inferior leads stroke in previous 3 months,\n(II, III, aVF), a finding that carotid stenosis/atheroma,\nsupports AVNRT over AVRT ventricular fibrillation (VF)/\nventricular tachycardia (VT),\nor previous adverse reaction\nto CSM\nAtrioventricular ECG findings: Patientâ€™s baseline ECG may show preexcitation\nreentrant tachycardia (AVRT) (see WPW syndrome later). During tachycardia, ECG is similar to\nAVNRT noted earlier. A retrograde P wave is often seen on the\nST segment or T wave.\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--00",
      "char_start": 94000,
      "char_end": 96000
    },
    {
      "chunk_id": 48,
      "text": "8866..iinndddd 2288 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 29\nTABLE 2.1-4. Supraventricular Tachyarrhythmias (continued)\nTYPE/ETIOLOGY SIGNS/SYMPTOMS TREATMENT\nAn ectopic connection between the atrium and ventricle that causes a Palpitations, shortness of Except for WPW, same as that\nreentry circuit breath, angina, syncope, for AVNRT\nAVRT is the most common arrhythmia associated with WPW syndrome (see lightheadedness\nlater)\nWolff-Parkinson-White syndrome ECG findings: Early upslope\nof QRS complex (delta wave,\nB\nred arrow in Image A) seen\ndue to early activation of\nventricles through acces-\nsory pathway. Thus, QRS is\nA widened and PR interval is\nDelta wave\nshortened (blue). Compare\nwith diagrammatic represen-\ntation of ECG morphology in\nPR interval\nShortened PR interval WPW (Image B).\nNormal PR interval\nWPW syndrome constitutes a group of ECG findings when there is an Palpitations, dyspnea, diz- Observation for patients\nabnormal fast accessory conduction pathway from atria to ventricle ziness, and rarely cardiac without symptoms\n(bundle of Kent) that bypasses the AV node and causes preexcitation of death Acute therapy is procainamide\nthe ventricles. It is commonly associated with AVRT (see earlier). or amiodarone\nSupraventricular tachycardia\n(SVT) gets worse after AV\nnodal blockers (dangerous\nin WPW)\nRadiofrequency catheter abla-\ntion is curative\nAtrial tachycardia ECG findings: Rate >100 bpm; P wave with an unusual axis\n(inverted P in aVF suggests abnormal P axis) before each\nnormal QRS\nRapid ectopic pacemaker in the atrium (not sinus node) Palpitations, shortness of Adenosine can be used to\nbreath, angina, syncope, unmask underlying atrial\nlightheadedness activity by slowing down\nthe rate\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 2299 1100//2211//2222 44::0055 PPMM\n\n30 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-4. Supraventricular Tachyarrhythmias (continued)\nTYPE/ETIOLOGY SIGNS/SY",
      "char_start": 96000,
      "char_end": 98000
    },
    {
      "chunk_id": 49,
      "text": "MPTOMS TREATMENT\nMultifocal atrial tachycardia ECG findings: Three or more unique P-wave morphologies are\nvisible (red arrows); rate >100 bpm\nMultiple atrial pacemakers or reentrant pathways; associated with many May be asymptomatic. At Treatment of underlying condi-\ncardiopulmonary conditions, eg, chronic obstructive pulmonary disease least three different P-wave tion is first step\n(COPD), hypoxemia, CHF morphologies Consider intravenous (IV)\nnon-dihydropyridine CCBs\nand Î²-blockers for acute\nmanagement\nIf recurrent and symptomatic,\noral non-dihydropyridine\nCCBs and Î²-blockers chroni-\ncally (unless contraindicated)\n(Images adapted and reproduced with permission from USMLE-Rx.com.)\nHistory/PE\nâ–  Presentation ranges from asymptomatic to hemodynamically unstable.\nMay have palpitations, fatigue, and dyspnea. Sometimes chest discomfort\nor even syncope.\nâ–  Importantly, can present with thromboembolic complications initially (eg,\nstroke, mesenteric).\nâ–  PE: Irregular pulse, irregular jugular venous pulsations.\nInvestigations\nâ–  12-lead ECG: Diagnosis confirmed on ECG (Fig. 2.1-10).\nRR â‰  RR â‰  RR â‰  RR â–  Labs: Electrolytes, complete blood count (CBC), and thyroid-stimulating\n1 2 3 4\nhormone (TSH; hyperthyroidism should always be considered).\nâ–  Transthoracic echocardiography (TTE): To identify structural issues (eg,\natrial size, valve disease).\nIrregular baseline (absent P waves)\nTreatment\nFIGURE 2.1-10. ECG findings in atrial\nfibrillation. No discernible P waves, with Patients with AF may require anticoagulation to prevent thromboembolism.\nvariable and irregular QRS response (RR\nAlso, either a rate control or rhythm control strategy may be implemented to\ninterval varies irregularly). (Reproduced with\nmanage the arrythmia (see p. 32).\npermission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3300 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 31\nTABLE 2.1-5. Ventricular Tachyarrhythmias\nTYPE/ETIOLOGY SIG",
      "char_start": 98000,
      "char_end": 100000
    },
    {
      "chunk_id": 50,
      "text": "NS/SYMPTOMS TREATMENT\nPremature ventricular contraction (PVC) ECG findings: Early, wide QRS (red arrow) not preceded by a P wave; PVCs are\nusually followed by a compensatory pause\nEctopic beats arise from ventricular foci. Associated with Usually asymptomatic, but may lead Treat the underlying cause. Decrease\nhypoxia, fibrosis, â†“ LV function, electrolyte abnormalities, to palpitations caffeine and alcohol consumption.\nand hyperthyroidism, but may be a normal finding If symptomatic, give Î²-blockers or,\noccasionally, other antiarrhythmics\nVentricular tachycardia (VT) ECG findings: Wide QRS complexes in a regular rapid rhythm; may see AV\ndissociation (P wave not seen in this example)\nCan be associated with coronary artery disease (CAD), MI, Three or more consecutive PVCs Synchronized cardioversion if hemody-\nand structural heart disease Nonsustained VT (lasts <30 seconds) namically unstable\nis often asymptomatic; sustained Defibrillation if pulseless VT\nVT (lasts >30 seconds) can lead to Antiarrhythmics (eg, amiodarone, lido-\npalpitations, hypotension, angina, caine, procainamide) if stable\nand syncope\nCan progress to VF and death\nVentricular fibrillation (VF) ECG findings: Totally erratic wide-complex tracing\nNo discernible rhythm\nAssociated with CAD and structural heart disease Syncope, absence of BP, no pulse Immediate electrical defibrillation and\nAlso associated with cardiac arrest (together with asystole) advanced cardiac life support (ACLS)\nprotocol\n(continues)\nA college-aged man passes out\nwithout any inciting factors and has\nno prodromal symptoms or signs of\nseizure. After recovery, his cardiac\nexam is unremarkable, and an ECG\nshows a slurred upstroke of the QRS.\nWhat are the next best steps?\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3311 1100//2211//2222 44::0055 PPMM\n\n32 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-5. Ventricular Tachyarrhythmias (continued)\nTYPE/ETIOLOGY SIGNS/SYMPTOMS TREATMENT\nNo discernible rhyt",
      "char_start": 100000,
      "char_end": 102000
    },
    {
      "chunk_id": 51,
      "text": "hmTorsades de pointes ECG findings: Polymorphous QRS with variations in amplitude and cycle\nlength such that QRS appears to be twisting around an isoelectric base (blue\nand red lines); VT with rates between 150 and 250 bpm\nAssociated with long QT syndrome, proarrhythmic response Can present with SCD; typically Synchronized cardioversion if hemody-\nto medications, hypokalemia, hypocalcemia, hypomagne- associated with palpitations, dizzi- namically unstable\nsemia, congenital deafness, and alcoholism ness, and syncope Defibrillation if pulseless\nInitial pharmacotherapy: magnesium\nCorrect hypokalemia; withdraw\noffending drugs\n(Images adapted with permission from USMLE-Rx.com.)\nKEY FACT\nThe CHADS-VASc scoring system â–  Stroke prevention with long-term anticoagulation.\n2 2\ncan estimate stroke risk in AF. Score â–  Consider the risk of thromboembolism (estimated by CHADS-VASc\nscore; refer to Key Fact) and risk of bleeding (HASBLED score) when\nof â‰¥2 in men or â‰¥3 in women:\ndeciding on anticoagulation. Generally, CHA2DS2-VASc score â‰¥2 in\nRecommend anticoagulation with a\nmen and â‰¥3 in women merits anticoagulation with warfarin, dabiga-\ndirect oral anticoagulant or warfarin.\ntran (thrombin inhibitor), or rivaroxaban (factor Xa inhibitor).\nAnticoagulation may be considered at a\nlower score (1 in men, 2 in women): â–  In patients with a low risk of bleeding, anticoagulation may be consid-\nered in men with a score â‰¥1 and women with a score â‰¥2.\nâ–  CHF (1 point)\nâ–  HTN (1 point) â–  Stroke prevention with devices:\nâ–  Age â‰¥75 (2 points) â–  Often, thrombi that cause stroke in AF form within the left atrial\nappendage (LAA), a small outpouching of the LA.\nâ–  Diabetes (1 point)\nâ–  Stroke or TIA history (2 points) â–  As an alternative to anticoagulation, minimally invasive occlusion of\nthe LAA can prevent stroke. Considered for patients at risk for stroke\nâ–  Vascular disease (1 point)\nbut who cannot tolerate anticoagulation (eg, high bleeding risk).\nâ–  Age 65â€“74 (1 point)\nâ–  Sex category (female) (1 point",
      "char_start": 102000,
      "char_end": 104000
    },
    {
      "chunk_id": 52,
      "text": ") â–  Surgical closure of LAA is also possible in those who require cardiac\nsurgery.\nâ–  Rate control:\nâ–  Control of ventricular rate is equal to (and often preferred over)\nrhythm control with regard to mortality benefit. Target ventricular rate\nof <110 bpm is often used.\nâ–  Medications: Î²-blockers (best initial Rx) and nondihydropyridine\nCCBs. Digitalis is sometimes used as an adjunct to improve rate\ncontrol.\nâ–  Procedures: Last resort for rate control is AV nodal ablation with\nimplantation of a pacemaker.\nThis is WPW syndrome. The next best\nsteps include prescribing procainamide, â–  Rhythm control: Rhythm control does not improve mortality but may\nwhich treats arrhythmias, as well as relieve symptoms and improve quality of life in select patients. Options\nreferring for electrophysiologic evalu-\ninclude electrical cardioversion, pharmacologic cardioversion, and cathe-\nation and advising against physical\nter ablation.\nactivity. Syncope suggests unstable\nâ–  Hemodynamically unstable patient: Immediate electrical cardiover-\nhemodynamics and raises suspicion\nsion is indicated.\nfor concurrent atrial fibrillation (AF).\nAV node blockers are contraindicated â–  Elective cardioversion and anticoagulation: For stable patients\n(adenosine, Î²-blockers, nondihydropyri- requiring cardioversion.\ndine calcium channel blockers [CCBs]), â–  AF duration >48 hours: High risk of thromboembolism. Three\neven if AF develops. weeks anticoagulation given before cardioversion. Alternatively,\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3322 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 33\ntransesophageal echocardiography can rule out LA thrombus, fol- KEY FACT\nlowed by cardioversion.\nEvidence of Wolff-Parkinson-White\nâ–  AF duration <48 hours: Lower thromboembolic risk. May cardio-\nsyndrome (Î´ waves) on ECG calls for use\nvert without prior anticoagulation. Some patients should still\nof procainamide, not nodal blockers, for\nreceive anticoagulation a",
      "char_start": 104000,
      "char_end": 106000
    },
    {
      "chunk_id": 53,
      "text": "s soon as possible or after cardioversion\nsupraventricular tachycardias.\nbased on thromboembolic risk.\nâ–  Anticoagulation should be continued for 4 weeks post-cardioversion.\nâ–  Anticoagulant choice: Nonvalvular AF: IV heparin, low-molecular-\nweight heparin (LMWH), warfarin, and new oral anticoagulants.\nValvular AF: Only warfarin for mitral stenosis.\nâ–  Pharmacologic cardioversion: Drugs can be used to cardiovert and\nmaintain sinus rhythm (eg, flecainide, propafenone, dofetilide, amiod-\nKEY FACT\narone, or IV ibutilide).\nâ–  Ablation: Avoid vasopressors in hypovolemic\nâ–  A minimally invasive procedure that can electrically isolate pulmo- shock until adequate fluid resuscitation\nnary veins (from which abnormal cells that cause AF discharge) from has been provided. Vasopressors â†‘\nthe rest of the LA. This can result in restoration of sinus rhythm. total peripheral resistance and BP but\nâ–  A similar procedure can be done surgically (Cox-maze procedure) â†“ blood flow in tissues that undergo\nfor individuals requiring cardiac surgery. vasoconstriction. Autoregulation\nreduces the effect of vasopressors on\nvital organs so they maintain perfusion.\nCARDIAC LIFE SUPPORT BASICS\nTable 2.1-6 summarizes the basic management of cardiac arrhythmias in an\nacute setting. Table 2.1-7 compares cardioversion and defibrillation.\nTABLE 2.1-6. Management of Cardiac Arrhythmiasa,b\nARRHYTHMIA TREATMENT\nAsystole or pulseless electrical Initiate cardiopulmonary resuscitation (CPR)\nactivity Give epinephrine or vasopressin; simultaneously search for the underlying cause (see the 5 Hs and 5 Ts mne-\nmonics) and provide empiric treatment\nVentricular fibrillation or Initiate CPR. Defibrillate with 120â€“200 J (biphasic) immediately â†’ defibrillate again â†’ epinephrine â†’\npulseless ventricular defibrillate â†’ amiodarone â†’ defibrillate â†’ epinephrine\ntachycardia (â€œâ†’â€ represents five cycles of CPR followed by a pulse or rhythm check)\nSupraventricular tachycardia If unstable, perform synchronized electrical cardioversion\n",
      "char_start": 106000,
      "char_end": 108000
    },
    {
      "chunk_id": 54,
      "text": "If stable, attempt vagal maneuvers (Valsalva, carotid massage, or advance life support [ALS])\nIf resistant, give adenosine (if arrhythmia gets worse, think WPW)\nIf resistant, give other AV-nodal blocking agents (CCBs or Î²-blockers) if rhythm fails to convert\nAtrial fibrillation/flutter If unstable, perform synchronized electrical cardioversion at 120â€“200 J (biphasic)\nIf stable, control rate with diltiazem or Î²-blockers and anticoagulate if duration is >48 hours\nElective cardioversion may be performed if duration is <48 hours; otherwise, the clinician must rule out atrial\nthrombus with transesophageal echocardiography (TEE) before cardioversion (atrial synchronization can\ndislodge atrial thrombus after cardioversion)\nBradycardia If symptomatic, give atropine\nIf ineffective, use temporary pacing (eg, transcutaneous), dopamine, or epinephrine\nPatient may require permanent pacemaker\naIn all cases, disruptions of CPR should be minimized. After a shock or administration of a drug, CPR should be resumed immediately, and five\ncycles of CPR should be given before checking for a pulse or rhythm.\nbDoses of electricity listed assume a biphasic defibrillator.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3333 1100//2211//2222 44::0055 PPMM\n\n34 HIGH-YIELD FACTS IN CARDIOVASCULAR\nKEY FACT TABLE 2.1-7. Synchronized Cardioversion vs Defibrilation\nUNSYNCHRONIZED CARDIOVERSION\nTreatments for unstable\nSYNCHRONIZED CARDIOVERSION (DEFIBRILLATION)\ntachyarrhythmias:\nAlive (has pulse) = Synchronized Purpose Low-energy shock is timed with the High-energy shock. An urgent pro-\ncardioversion (regardless of wide or\nR wave of QRS complex. Used to cedure indicated for nonperfusing\nnarrow complex)\nconvert abnormal yet perfusing rhythms or when synchronization\nDead (pulseless) = Defibrillate* (for VF,\nrhythm to a sinus rhythm. fails.\npulseless VT, or pulseless torsades)\n*Pulseless electrical activity and asystole are\nIndications VT, SVT, AF, atrial flutter VF,",
      "char_start": 108000,
      "char_end": 110000
    },
    {
      "chunk_id": 55,
      "text": " pulseless VT\nnot shockable rhythms. Rx = Epinephrine.\nNotes Shocking during T wave (ie, while Asystole and pulseless electrical\nrepolarization is in progress) activity are NOT indications for\nmay precipitate arrhythmias defibrillation\nMNEMONIC\n(VF/VT) as myocardium is het-\nPossible causes of pulseless erogeneously depolarized\nelectrical activityâ€”\n5 Hs 5 Ts\nHypovolemia Tablets: drug\nHypoxia overdose, ingestion CONGESTIVE HEART FAILURE\nHydrogen ion: Tamponade: cardiac\nacidosis Tension\nHF is a syndrome typified by a constellation of clinical symptoms (eg,\nHyper/Hypo: pneumothorax\nbreathlessness, ankle swelling) and signs (eg, JVP, pulmonary crackles). Struc-\nK+, other Thrombosis: coronary\ntural or functional cardiac abnormalities result in elevated cardiac pressures\nmetabolite Thrombosis:\nand/or inadequate cardiac output at rest and/or on exertion. Etiologically, it\nHypothermia pulmonary\nembolism can be related to valvular, pericardial, endocardial, vascular, or conduction\nabnormalities, among other causes. Risk factors include coronary heart dis-\nease, hypertension, cardiomyopathy, valvular heart disease, diabetes, and\nCOPD (cor pulmonale).\nCLASSIFICATION\nBased on Ejection Fraction\nHF is divided into distinct phenotypes based on left ventricular ejection frac-\ntion (LVEF).\nâ–  LVEF >40% is heart failure with reduced ejection fraction (HFrEF). Also\nknown as systolic HF (Table 2.1-8).\nâ–  LVEF 41% to 49% is heart failure with moderately reduced ejection frac-\ntion (HFmrEF).\nâ–  LVEF â‰¥50% is heart failure with preserved ejection fraction (HFpEF).\nFor diagnosis of HFpEF there must be evidence of symptoms/signs of HF,\nstructural/functional abnormalities supporting LV diastolic dysfunction,\nand/or increased natriuretic peptides. Also known as diastolic HF (see\nTable 2.1-8).\nâ–  There may also be primarily right ventricular (RV) heart failure (Table\n2.1-9).\nBased on Timing of Onset\nHeart failure may be chronic (gradual progression with established diagnosis).\nChronic HF may acutely",
      "char_start": 110000,
      "char_end": 112000
    },
    {
      "chunk_id": 56,
      "text": " worsen (acute decompensated HF). Also, acute\nexacerbations of HF can occur without chronic HF.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3344 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 35\nTABLE 2.1-8. Comparison of Systolic and Diastolic Dysfunction\nSYSTOLIC DYSFUNCTION/HEART FAILURE WITH REDUCED EJECTION DIASTOLIC DYSFUNCTION/HEART FAILURE WITH PRESERVED\nVARIABLE FRACTION (HFREF) EJECTION FRACTION (HFPEF)\nPatient age Often <65 years of age Often >65 years of age\nComorbidities Dilated cardiomyopathy, valvular heart disease, MI Restrictive or hypertrophic cardiomyopathy; renal\ndisease or hypertension (HTN)\nPhysical exam Displaced point of maximum impulse (PMI), S3 gallop Sustained PMI, S4 gallop (â€œTennâ€-es-SEE)\n(â€œKENâ€-tuc-ky)\nX-ray of the chest (CXR) Pulmonary congestion, cardiomegaly Pulmonary congestion\nECG/echocardiography Q waves, â†“ EF (<40%), dilation of the heart Left ventricular hypertrophy (LVH), normal/pre-\nserved EF (>50%), abnormal LV diastolic indices\nTABLE 2.1-9. Left-Sided vs Right-Sided Heart Failure\nLEFT-SIDED CHF SYMPTOMS RIGHT-SIDED CHF SYMPTOMS\nDyspnea predominates Fluid retention predominates\nLeft-sided S3/S4 gallop Right-sided S3/S4 gallop\nBilateral basilar rales JVD\nPleural effusions Hepatojugular reflux\nPulmonary edema Peripheral edema\nOrthopnea, paroxysmal nocturnal dyspnea Hepatomegaly, ascites\nTABLE 2.1-10. NYHA Functional Classification of Congestive Heart Failure\nCLASS DESCRIPTION\nI No limitation of activity; no symptoms (palpitations, dyspnea, and fatigue) with\nnormal activity\nII Slight limitation of activity; comfortable at rest or with mild exertion\nIII Marked limitation of activity; comfortable only at rest\nIV Any physical activity brings on discomfort; symptoms (palpitations, dyspnea, and\nfatigue) present at rest\nOther Classifications\nâ–  New York Heart Association (NYHA) classification is based on func-\ntional status (Table 2.1-10).\nâ–  Killip classification grades HF se",
      "char_start": 112000,
      "char_end": 114000
    },
    {
      "chunk_id": 57,
      "text": "verity after acute coronary syndrome\n(ACS). Predicts mortality at 30 days.\nSYSTOLIC DYSFUNCTION/HEART FAILURE WITH REDUCED EJECTION FRACTION\nâ†“ LVEF (<40%) and â†‘ LV end-diastolic volumes result in typical HF symp-\ntoms and signs.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3355 1100//2211//2222 44::0055 PPMM\n\n36 HIGH-YIELD FACTS IN CARDIOVASCULAR\nEtiology\nâ–  HFrEF (aka systolic HF) is caused by compensatory mechanisms (sympa-\nthetic nervous system [SNS] and renin-angiotensin-aldosterone system\n[RAAS] activation) to inciting conditions (eg, valvular disease, HTN) that\nmay be acutely beneficial but may become maladaptive chronically (Fig.\n2.1-11).\nâ–  Chronic activation of the SNS and RAAS results in cardiac and vascular\nremodeling (eg, hypertrophy, fibrosis, vasoconstriction), as well as sodium\nand water retention. Activation of the SNS leads to increased afterload\nKEY FACT (vasoconstriction/hypertension), whereas activation of the RAAS results in\nincreased preload (salt and water retention).\nThe most common cause of right-sided\nheart failure is left-sided heart failure.\nHistory/PE\nâ–  Exertional dyspnea that progresses to orthopnea, paroxysmal nocturnal\ndyspnea (PND), and finally dyspnea at rest.\nâ–  Chronic cough, fatigue, and peripheral edema may be reported.\nKEY FACT â–  Exam: Weight gain, bilateral pulmonary rales, increased JVP, positive\nhepatojugular reflex, peripheral edema, elevated and sustained LV\nHyponatremia parallels the severity of impulse, and an S gallop.\n3\nHF and is an independent predictor of\nmortality in these patients. Diagnosis\nâ–  HFrEF presents with the clinical syndrome of HF, with typical signs and\nsymptoms, in addition to reduced EF(<40%).\nâ–  Studies that may support the diagnosis include the following:\nâ–  Best initial test: Echocardiogram (transthoracic echocardiogram).\nâ†“ EF helps establish HFrEF; structural abnormalities may help iden-\ntify cause (eg, AF, old MI, or LVH).\nâ–  ECG: May show MI, heart block, arrhyth",
      "char_start": 114000,
      "char_end": 116000
    },
    {
      "chunk_id": 58,
      "text": "mia, or other diagnostic\nclues.\nMRA\nï© CO\nÎ²-blocker ACEi, ARB, or ARNi\nDeleterious cardiac Deleterious cardiac\nï¨ sympathetic tone ï¨ renin-angiotensin-aldosterone system\nremodeling (Î²1) remodeling (aldosterone)\nAngiotensin II (AT1) Angiotensin II, aldosterone (multiple receptors)\nCatecholamines (Î²) Catecholamines (Î±)\n1 1 ADH (V) ADH (V)\n1 2\nDiuretics\nHydralazine + Pulmonary and\nInotropes ï¨ contractility ï¨ heart rate Vasoconstriction ï¨ circulating volume\nisosorbide dinitrate peripheral edema\nï¨ arterial tone ï¨ venous tone\nï¨ afterload\nMaintained BP\nï© CO Compensated physiology\nï¨ venus return to Decompensated physiology\nheart (ï¨ preload) Medical therapy\nMaintained CO MRA = mineralocorticoid receptor antagonist\nACEi = ACE inhibitor\nARB = angiotensin receptor blocker\nï¨ stroke volume ARNi = angiotensin receptor-neprilysin inhibitor\nFIGURE 2.1-11. Pathophysiology of heart failure. Activation of the RAAS and SNS may initially help the failing heart adapt by increas-\ning contractility, heart rate, and circulating volume. However, deleterious cardiac remodeling may lead to worsening HF and pulmonary\nedema over time (red boxes). Drugs that target the various maladaptive processes are shown (blue boxes). (Reproduced with permission from USMLE-\nRx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3366 1100//2211//2222 44::0055 PPMM\n\nâ–  CXR: May show cardiomegaly, cephalization of pulmonary vessels,\npleural effusions, vascular congestion, pulmonary edema, and promi-\nnent hila (Fig. 2.1-12).\nâ–  Lab abnormalities: Brain natriuretic peptide >500 pg/mL, â†“ CBC\n(anemia), â†‘ creatinine (sometimes), â†“ sodium in later stages, â†‘ or â†“\nTSH/T levels.\n4\nTreatment\nAcute congestive heart failure:\nâ–  The first step in management is clinical identification of the hemody- FIGURE 2.1-12. X-ray of the chest (CXR)\nnamic profile. Specifically, the level of congestion (â€œwetâ€ vs â€œdryâ€) and with evidence of congestive heart fail-\nperfusion (â€œwarmâ€ vs â€œcoldâ€) must be evalua",
      "char_start": 116000,
      "char_end": 118000
    },
    {
      "chunk_id": 59,
      "text": "ted. Treatment is determined ure. Frontal CXR demonstrates marked\ncardiomegaly, cephalization of vessels\nbased on this evaluation, as illustrated in Table 2.1-11.\n(arrow), interstitial edema (circle), and\nsmall left-sided pleural effusion, which\nraise concern for CHF. (Reproduced with\npermission from Tintinalli JE et al. Tintinalliâ€™s Emergency\nMedicine: A Comprehensive Study Guide. 7th ed. New\nYork, NY: McGraw-Hill; 2011.)\nWET DRY\n(CONGESTED) (NOT CONGESTED)\nMNEMONIC\nCXR findings in CHF diagnosisâ€”\nABCDE\nAlveolar edema (â€œbatâ€™s wingsâ€)\nKerley B lines (interstitial edema)\nCardiomegaly\nDilated prominent upper lobe vessels\nEffusion (pleural)\nKEY FACT\nAcute CHF management\nâ–  Upright positioning\nâ–  Vasodilators\nâ–  Diuretics\nâ–  Inotropes\nâ–  Oxygen if hypoxic\nâ–  Noninvasive positive-pressure\nventilation\nâ–  Mechanical support\nMRAW\n)noisufreP\netauqedA(\nWet and Warm Dry and Warm\nCongested, adequate perfusion Not congested, adequate perfusion\nâ–  Rx: â–  Rx:\nâ–  Initial diuretics and vasodilators â–  Optimize oral therapy\nâ–  Ultrafiltration if refractory\nDLOC\n)noisufrepopyH(\nCARDIOVASCULAR HIGH-YIELD FACTS IN 37\nTABLE 2.1-11. Hemodynamic Profiles in Heart Failure\nWet and Cold Dry and Cold\nCongested, hypoperfusion Not congested (hypovolemic),\nâ–  Rx if hypotensive (systolic blood hypoperfusion\npressure [SBP] <90 mm Hg): â–  Rx:\nâ–  Ionotropic agent initially; â–  Consider initial fluid challenge\nvasopressor if refractory â–  Inotropic agents if still\nâ–  Diuretic after perfusion is corrected hypoperfused\nâ–  Circulatory support/renal\nreplacement therapy (RRT) if\nunresponsive to medication\nâ–  Rx if NOT hypotensive (SBP >90\nmm Hg):\nâ–  Initial diuretics and vasodilators\nâ–  Inotropic agents if refractory\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3377 1100//2211//2222 44::0055 PPMM\n\n38 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-12. Types of Diuretics\nCLASS EXAMPLES ADVERSE EFFECTS\nLoop diuretics Furosemide, ethacrynic acid, Ototoxicity, hypokalemia, hypocalcemia, hyperuric",
      "char_start": 118000,
      "char_end": 120000
    },
    {
      "chunk_id": 60,
      "text": "emia, dehydration,\nbumetanide, torsemide gout\nThiazide diuretics Hydrochlorothiazide, chlorothiazide, Hypokalemic metabolic alkalosis, hyponatremia, and hyperGLUC (hyper-\nchlorthalidone Glycemia, hyperLipidemia, hyperUricemia, hyperCalcemia)\nPotassium -sparing Spironolactone, eplerenone, triam- Hyperkalemia, gynecomastia, sexual dysfunction; eplerenone does not\nagents terene, amiloride have antiandrogenic effects that lead to gynecomastia\nCarbonic anhydrase Acetazolamide Hyperchloremic metabolic acidosis, neuropathy, NH3 toxicity, sulfa allergy\ninhibitors\nOsmotic agents Mannitol Pulmonary edema, dehydration; contraindicated in anuria and CHF\nâ–  In â€œwarm and wetâ€ patients (adequately perfused), loop diuretics and vaso-\ndilators are the best initial treatment.\nâ–  In â€œcold and wetâ€ patients with hypotension (hypoperfused), loop diuretics\nmay actually worsen perfusion by reducing intravascular volume. There-\nfore inotropic agents are used initially to augment perfusion, and direct\nvasodilators are added if BP can tolerate it.\nPharmacotherapy (Table 2.1-12):\nâ–  Oxygen administered only if hypoxemic (SpO <90%).\n2\nâ–  Loop diuretics (most commonly) for preload reduction.\nâ–  Vasodilators to counter elevated filling pressures or LV afterload. Nitro-\nglycerin is better for preload reduction (primarily venous vasodilation; use-\nful in HF with predominant congestion) and nitroprusside for afterload\nreduction (arterial and venous vasodilation; useful in HF with severe\nHTN).\nâ–  Inotropic agents (milrinone, dobutamine, dopamine) and vasopressors\n(norepinephrine, high-dose dopamine, and vasopressin) may increase\nmyocardial oxygen demand and worsen HF. Their use is indicated in\nhypotensive patients with impaired perfusion (â€œwet and coldâ€), who would\nnot be able to tolerate diuretics. Once perfusion is restored, diuretics can\nbe used.\nâ–  Other treatments include sodium and fluid restriction and venous\nthromboembolism (VTE) prophylaxis (LMWH, fondaparinux or unfrac-\ntionated heparin).\nâ–  Initi",
      "char_start": 120000,
      "char_end": 122000
    },
    {
      "chunk_id": 61,
      "text": "ation of Î²-blockers is contraindicated during decompensated HF,\nbut should be restarted once the patient is euvolemic. If the patient was\npreviously on Î²-blockers, continuation may be considered, with or without\ndose reduction, based on the severity of decompensation.\nâ–  Opiates (such as morphine) should be avoided if possible.\nâ–  Mechanical circulatory support (MCS: intra-aortic balloon counterpulsa-\ntion device, extracorporeal membrane oxygenation, short-term LV assist\ndevices) considered in patients with HFrEF and severe hemodynamic\ncompromise.\nâ–  Correct underlying causes such as arrhythmias, myocardial ischemia, and\ndrugs (eg, CCBs, antiarrhythmics, nonsteroidal anti-inflammatory drugs\n[NSAIDs], alcohol, anemia, thyroid and valvular disease, high-output\nstates).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3388 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 39\nChronic heart failure:\nKEY FACT\nâ–  Lifestyle: Control comorbid conditions (eg, use of CPAP in sleep apnea\nmay increase LVEF) and limit dietary sodium and fluid intake. Exercise\nACEIs/ARBs, ARNI, Î²-blockers,\nas tolerated. Cardiac rehabilitation programs.\nspironolactone or eplerenone,\nâ–  Pharmacologic therapy: hydralazine-isosorbide dinitrate, and\nâ–  Î²-blockers and angiotensin-converting enzyme inhibitors/angioten- implantable defibrillators have mortality\nsin receptor blockers/angiotensin receptor-neprilysin inhibitors\nbenefit in HFrEF (systolic dysfunction)\n(ACEIs/ARBs/ARNIs): Help prevent remodeling of the heart and â†“\nbut not HFpEF (diastolic dysfunction).\nmortality and â†“ morbidity for NYHA class IIâ€“V patients. Avoid CCBs\nDapagliflozin and empagliflozin have\n(can worsen edema).\nmortality benefit in HFpEF and HFrEF.\nâ–  Ivabradine: Reduces heart rate through SA nodal inhibition of the Loop diuretics and digoxin (as well as\nâ€œfunny channels.â€ Indicated in stable chronic HFrEF patients when\nother positive inotropic agents) are for\npulse is >70 bpm despite r",
      "char_start": 122000,
      "char_end": 124000
    },
    {
      "chunk_id": 62,
      "text": "eceiving optimal HF therapy and maximum\nsymptomatic relief only and confer no\ntolerable dose of Î²-blockers.\nmortality benefit. CCBs may â†‘ mortality.\nâ–  Low-dose spironolactone: Shown to â†“ mortality risk in patients with\nNYHA class II to V heart failure under specific conditions (LVEF\n<35% [<40% post-MI], estimated glomerular filtration rate [GFR] >30\nKEY FACT\nmL/min, potassium <5.0 mEq/dL).\nâ–  Dapagliflozin or empagliflozin are sodium-glucose transporter 2\nLoop diuretics lose calcium; thiazides\n(SGLT-2) inhibitors. Indicated for patients with HFrEF to â†“ hospital-\ntake it in. Both cause hypokalemia and\nization and mortality regardless of whether the patient has diabetes.\nhyperuricemia.\nâ–  Hydralazine and isosorbide dinitrate: May â†“ mortality and â†“ morbid-\nity in persistently symptomatic (NYHA IIIâ€“V) Black Americans.\nâ–  Loop diuretics: Shown to â†“ symptoms (no mortality benefit). Used in\npatients with NYHA IIâ€“V. KEY FACT\nâ–  Digoxin: Increases cardiac contractility. Symptomatic control of dys-\npnea and â†“ frequency of hospitalizations.\nâ–  Acetylsalicylic acid (ASA) and a statin are recommended if the under-\nlying cause is a prior MI.\nâ–  Device therapy:\nâ–  ICD indicated in symptomatic patients (NYHA II/III) with an EF\nDigoxin toxicity presents with\n<35% at 40 days post-MI and 3 months post-revascularization. Shown\ncardiovascular, GI, and neurologic\nto â†“ mortality.\nsymptoms. Drugs such as amiodarone,\nâ–  ICD indicated in asymptomatic patients (NYHA I) with an EF <30%\nÎ²-blockers, verapamil, macrolides, or\nat 40 days post-MI and 3 months post-revascularization. Shown to â†“\namphotericin B may precipitate digoxin\nmortality risk.\ntoxicity. Cardiotoxicity may result in\nâ–  Cardiac resynchronization therapy (CRT, aka biventricular pace-\natrial tachycardia with AV block, as\nmaker) is most beneficial for symptomatic patients (NYHA class II/III/\nseen in the figure (P waves [red arrows]\nambulatory IV symptoms) with LVEF â‰¤35%, sinus rhythm, LBBB\nand only one QRS is conducted [green\nwith a QRS â‰¥150",
      "char_start": 124000,
      "char_end": 126000
    },
    {
      "chunk_id": 63,
      "text": " msec, who are on optimal HF therapy.\narrow], ie, 5:1 block).\nâ–  Left ventricular assist device (LVAD), cardiac transplantation, other\ninvestigational therapies, or palliative care may be necessary in patients\nwho are unresponsive to optimal medical and device therapies (such as\nICD and CRT).\nHEART FAILURE WITH PRESERVED EJECTION FRACTION\nDigoxin effect refers to â€œnormalâ€ ECG\nchanges in patients taking digoxin.\nHFpEF is defined by â†“ ventricular compliance with normal systolic function\nDownsloping ST depression that looks\n(LVEF â‰¥50%). The ventricle has either impaired active relaxation (secondary to\nlike a â€œreverse tickâ€ (red arrow).\nhypertension, ischemia, aging, and/or hypertrophy) or impaired passive filling\n(scarring from prior MI, restrictive cardiomyopathy). Left ventricular end-diastolic (Images reproduced with permission from USMLE-Rx.\ncom.)\npressure â†‘, cardiac output remains essentially normal, and EF is normal or â†‘.\nHistory/PE\nAssociated with stable and unstable angina, shortness of breath, dyspnea on\nexertion, arrhythmias, MI, heart failure, and sudden death.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 3399 1100//2211//2222 44::0055 PPMM\n\n40 HIGH-YIELD FACTS IN CARDIOVASCULAR\nDiagnosis\nâ–  HFpEF presents with a clinical syndrome of HF with typical signs and\nsymptoms in addition to preserved EF (â‰¥50%). There must be evidence\nof structural and/or functional cardiac abnormalities supporting the pres-\nence of LV diastolic dysfunction.\nâ–  Investigations that may support the diagnosis include the following:\nâ–  Best initial test: Echocardiogram (transthoracic echocardiogram).\nEstablishes preserved EF (â‰¥50%) and signs of diastolic dysfunction/\nraised LV filling pressures (LV mass index, LA volume index, E/eâ€™ ratio\nat rest).\nâ–  Lab tests: Natriuretic peptides generally elevated, although 20% of\npatients have normal values.\nâ–  Invasive exercise testing.\nTreatment\nâ–  Best initial treatments: Diuretics for symptom relief only (see Tabl",
      "char_start": 126000,
      "char_end": 128000
    },
    {
      "chunk_id": 64,
      "text": "e\n2.1-12).\nâ–  Investigational therapy: Empagliflozin is the only drug to reduce mortal-\nity in HFpEF.\nKEY FACT\nâ–  Screening for specific etiologies and instituting relevant treatments.\nDapagliflozin and Empagliflozin reduce â–  Treatment of comorbidities (eg, maintain rate and BP control via\nÎ²-blockers [first-line], ACEIs, ARBs, or CCBs).\nmortality in HFpEF.\nâ–  Digoxin and spironolactone are not beneficial in these patients.\nCARDIOMYOPATHY\nMyocardial disease; categorized as dilated, hypertrophic, or restrictive (Table\n2.1-13 and Fig. 2.1-13). Pathology may be confined to the heart (primary) or\ndue to systemic conditions affecting the heart (secondary).\nTABLE 2.1-13. Differential Diagnosis of Cardiomyopathies\nTYPE\nVARIABLE DILATED HYPERTROPHIC RESTRICTIVE\nMajor abnormality Impaired Impaired Impaired elasticity\ncontractility relaxation\nLeft ventricular cavity size â†‘ â†‘ â†“ â†“\n(end diastole)\nLeft ventricular cavity size â†‘ â†‘ â†“ â†“ â†“\n(end systole)\nEF â†“ â†“ â†‘ (or normal) Normal\nWall thickness Normal or â†“ â†‘ â†‘ Usually â†‘\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4400 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 41\nA B C\nFIGURE 2.1-13. Cardiomyopathies. Echocardiogram four-chamber views of (A) a normal heart,\n(B) dilated cardiomyopathy, and (C) hypertrophic cardiomyopathy. (Reproduced with permission from\nFuster V et al. Hurstâ€™s The Heart. 12th ed. New York, NY: McGraw-Hill; 2008.)\nDILATED CARDIOMYOPATHY\nLV dilation and â†“ EF must be present for diagnosis. Most cases are idiopathic KEY FACT\nor genetic, but secondary (and acquired) causes include alcohol, postviral\nmyocarditis, postpartum status, drugs (doxorubicin, zidovudine, cocaine), An S gallop signifies rapid ventricular\n3\nradiation, endocrinopathies (thyrotoxicosis, acromegaly, pheochromocytoma), filling in the setting of fluid overload\ninfection (coxsackievirus, HIV, Chagas disease, parasites), genetic factors, and and is associated with DCM. An S\n3\nnutritional disorde",
      "char_start": 128000,
      "char_end": 130000
    },
    {
      "chunk_id": 65,
      "text": "rs (wet beriberi). The most common cause of dilated car- gallop sounds similar to the word\ndiomyopathy (DCM) phenotype is myocardial ischemia; however, this is clas- â€œKEN-tuc-ky.â€\nsified as a separate condition.\nKEY FACT\nHistory/PE\nâ–  Often presents with gradual development of CHF symptoms such as dys- An S gallop signifies a stiff,\n4\npnea on exertion and diffuse edema of the ankles, feet, legs, and abdomen. noncompliant ventricle and â†‘ â€œatrial\nâ–  Exam often reveals displacement of the LV impulse, JVD, rales, an S /S kickâ€ and may be associated with\n3 4\ngallop, or mitral/tricuspid regurgitation. hypertrophic cardiomyopathy. An\nS gallop sounds similar to the word\n4\nDiagnosis â€œTenn-es-SEE.â€\nâ–  Best diagnostic test: Echocardiography.\nâ–  CXR shows an enlarged, â€œballoon-likeâ€ heart and pulmonary congestion.\nTreatment\nâ–  Address the underlying etiology (eg, alcohol use, endocrine disorders,\ninfection).\nâ–  Treat CHF as noted in earlier section with lifestyle changes, and pharma-\ncologic treatments.\nHYPERTROPHIC CARDIOMYOPATHY\nHypertrophic cardiomyopathy (HCM) is a genetic condition with autosomal\ndominant inheritance characterized by impaired LV relaxation and filling\n(diastolic dysfunction) due to thickened ventricular walls. In HCM, asymmet- A man was admitted to the hospital\nric hypertrophy of the interventricular septum may occur, which may result for a CHF exacerbation with low\nin LV outflow tract obstruction and impaired ejection of blood, ie, HCM with EF. The patient is now ready for\nobstruction (aka hypertrophic obstructive cardiomyopathy [HOCM]). HCM discharge, and his medications\ninclude furosemide and metoprolol.\nAssuming no contraindications, what\nmedications would be appropriate to\nadd to his treatment regimen?\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4411 1100//2211//2222 44::0055 PPMM\n\n42 HIGH-YIELD FACTS IN CARDIOVASCULAR\nKEY FACT\nwith obstruction is the most likely cause of SCD in young adults in the\nUnited States, med",
      "char_start": 130000,
      "char_end": 132000
    },
    {
      "chunk_id": 66,
      "text": "iated primarily by VF.\nHOCM is the most common cause\nNote: Other causes of LVH include HTN (most common cause), aortic\nof sudden death in young, healthy\nstenosis, and systemic diseases (glycogen/lysosomal storage diseases, Fabry,\nathletes in the United States.\namyloid, sarcoid, and hemochromatosis), but these are considered separate\nentities from HCM.\nHistory/PE\nâ–  Most common presentation: Syncope or SCD in a young, healthy\nathlete.\nâ–  Patients are often asymptomatic but may also present with syncope, light-\nheadedness, dyspnea, palpitations, angina, or SCD.\nâ–  Key finding is a harsh systolic ejection crescendo-decrescendo murmur in\nthe lower left sternal edge that â†‘ with â†“ preload (eg, Valsalva maneuver,\nstanding) and â†“ with â†‘ preload (eg, passive leg raise).\nâ–  Symptoms worsen with exercise, diuretics, dehydration, ACEIs/ARBs,\ndigoxin, and hydralazine.\nKEY FACT\nâ–  Exam also often reveals a sustained apical impulse, an S gallop, paradoxi-\n4\nAthleteâ€™s heart may also present with cal S , and an abnormal bifid or bisferiens pulse (sudden quick rise fol-\n2\nLVH and must be differentiated from lowed by a slower longer rise due to LV outflow tract obstruction).\nHCM. Characteristics of HCM that\ndistinguish it from athleteâ€™s heart Diagnosis\ninclude positive family history, ECG â–  Best initial test: Echocardiography is diagnostic and shows an asymmetri-\nfeatures (presence of depolarization/ cally hypertrophied interventricular septum. Dynamic obstruction of\nrepolarization abnormalities in blood flow (due to systolic anterior motion of the mitral valve against\nHCM), and echocardiographic hypertrophied septum) may also be seen (HOCM).\nfeatures (enlarged LA, â†“ LV cavity â–  ECG may be normal or show signs of LVH and nonspecific ST- and\nsize, LV thickness >15 mm, focal T-wave changes. Septal Q waves are common in HCM (inferior and lat-\nseptal hypertrophy, and LV diastolic eral leads).\ndysfunction in HCM). â–  CXR may reveal left atrial enlargement (LAE) secondary to mitral\nregurgitation.",
      "char_start": 132000,
      "char_end": 134000
    },
    {
      "chunk_id": 67,
      "text": "\nTreatment\nKEY FACT â–  Best initial treatment: Î²-blockers are the best initial therapy for symptom-\natic relief in both HCM and HOCM; nondihydropyridine CCBs (nega-\nInfants born to mothers with diabetes tive inotropic effect) and ventricular pacemakers are second-line agents.\nare at risk of developing HCM caused â–  Digoxin and spironolactone are contraindicated, as they worsen obstruc-\nby fetal hyperinsulinemia in response to tion in HOCM. Diuretics may help in HCM but are contraindicated in\nmaternal hyperglycemia. Most infants HOCM.\nare asymptomatic, but some develop â–  Implantable defibrillators should be used in symptomatic HOCM\nLV outflow tract obstruction and HF. patients.\nTreatment is IV fluids and Î²-blockers. â–  Patients should avoid intense athletic competition and training.\nThe condition spontaneously regresses â–  Surgical options for HOCM with persistent symptoms include partial exci-\nby age 1. sion or alcohol ablation of the myocardial septum.\nâ–  Surgical septal myomectomy is reserved for patients when medical and\ncatheter procedures fail.\nARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA\nAppropriate medications to add\nArrhythmogenic right ventricular dysplasia (ARVD) is a genetic disease with\nwould be an ACEI (or ARB/ARNI),\nautosomal dominant inheritance. Myocytes are replaced with fibrofatty tissue,\nspironolactone, and empagliflozin (or\ndapagliflozin) to this patientâ€™s current\nregimen. These have been shown to\nhave a âŠ• mortality benefit in patients\nwith HF with reduced EF.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4422 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 43\ncausing RV dilation, resulting in ventricular arrhythmias, HF, and SCD. It is\nthe second most common cause of SCD in young people (after HOCM).\nHistory/PE\nâ–  Most common presentation: Palpitations due to ventricular arrhythmias.\nAlso may present with syncope, dyspnea, chest pain, SCD, or without\nsymptoms.\nDiagnosis\nâ–  Diagnosis is based on st",
      "char_start": 134000,
      "char_end": 136000
    },
    {
      "chunk_id": 68,
      "text": "ructural (echocardiography or MRI), histologic FIGURE 2.1-14. ECG in ARVD shows typi-\n(endocardial biopsy), and ECG abnormalities, combined with family cal epsilon waves (arrow) in V 1 . (Repro-\nduced with permission from USMLE-Rx.com.)\nhistory.\nâ–  Echocardiography shows RV dilatation and wall motion abnormalities.\nECG shows inverted T waves in V â€“V , with epsilon waves at the end of\n1 3\nthe QRS complex (Fig. 2.1-14).\nTreatment\nâ–  Avoid physical activity.\nâ–  Goals: Prevention of SCD (ICD), suppression of arrhythmia (Î²-blockers\n[first line], antiarrhythmic drugs [amiodarone, sotalol]), treatment of CHF\n(as described earlier), and anticoagulation (ie, for RV thrombus only).\nâ–  Invasive: ICD, heart transplantation (severe cases), genetic counseling for\nrelatives.\nRESTRICTIVE CARDIOMYOPATHY\nDecreased elasticity of myocardium leading to impaired diastolic filling with-\nout significant systolic dysfunction (a normal or near-normal EF). It is caused\nby infiltrative disease (eg, amyloidosis, sarcoidosis, hemochromatosis [Table\n2.1-14]), scleroderma, Loeffler eosinophilic endocarditis, endomyocardial\nfibrosis, or scarring and fibrosis (secondary to radiation).\nHistory/PE\nSigns and symptoms of right-sided heart failure (JVD, peripheral edema,\nascites, hepatomegaly) often predominate over left-sided failure, but dyspnea\nis the most common complaint.\nDiagnosis\nâ–  Echocardiography is key for diagnosis, with rapid early filling and a near-\nnormal or elevated EF. CXR, MRI, and cardiac catheterization are help-\nful for characterization (eg, sarcoid, amyloidosis).\nâ–  Cardiac biopsy may reveal fibrosis or evidence of infiltration.\nâ–  ECG frequently shows LBBB; low voltages are seen in amyloidosis.\nTreatment\nTreat the underlying cause. Therapeutic options are limited and are generally\npalliative only. Medical treatment includes cautious use of diuretics for fluid\noverload and vasodilators to â†“ filling pressure. A woman with HTN and prior MI has\nan exam notable for a displaced PMI,\nan S, a no",
      "char_start": 136000,
      "char_end": 138000
    },
    {
      "chunk_id": 69,
      "text": "nelevated JVP, and bibasilar\n3\nrales. What is the next best step in\ndiagnosis?\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4433 1100//2211//2222 44::0055 PPMM\n\n44 HIGH-YIELD FACTS IN CARDIOVASCULAR\nSECONDARY CARDIOMYOPATHY\nKEY FACT\nâ–  Secondary cardiomyopathies are caused by systemic diseases that affect the\nFifty to seventy percent of patients heart.\nwith AL amyloidosis have cardiac â–  Classified into infiltrative (hemochromatosis), inflammatory (sarcoidosis),\ninvolvement, and this is the main endocrine (acromegaly, hyperthyroidism/hypothyroidism, diabetes melli-\nprognostic determinant. tus [DM]), and drug induced (anthracyclines, cyclophosphamide, radia-\ntion). Some examples are provided in Table 2.1-14.\nTABLE 2.1-14. Selected Secondary Cardiomyopathies\nCONDITION AND ETIOLOGY SIGNS, SYMPTOMS, DIAGNOSIS TREATMENT\nCardiac amyloidosis Presentation: â–  Treatment of HF: Diuretics are\nâ–  â€œInfiltrativeâ€ cardiomyopathy â–  Presents with right heart failure (eg, lower limb edema, elevated mainstay.\ncausing a restrictive cardiomy- JVP), syncope (bradyarrhythmias and AV block), cardiac throm- â–  ACEI and Î²-blockers not ben-\nopathy phenotype. boembolism (abnormal atrial hemodynamics), and decreased eficial. CCBs contraindicated\nâ–  Amyloid fibril deposition in cardiac output (only when severe). (negative inotropic effect).\nextracellular space of heart. â–  Associated with extracardiac manifestations of amyloidosis (eg, â–  Treatment of bradyarrhyth-\nâ–  Most due to transthyretin amy- easy bruising, proteinuria, hepatomegaly, macroglossia). mias with pacemaker.\nloidosis (ATTR, transthyretin Diagnosis: â–  Treatment of underlying\ndeposits) or light chain amyloi- â–  Lab tests: Abnormal kidney function test (KFT), liver function test cause: In AL amyloidosis,\ndosis (AL, Ig light chain deposits (LFT). Raised cardiac markers (eg, TnI/T, BNP). treatment of plasma cell dys-\ndue to plasma cell dyscrasias). â–  ECG: â†‘ LV wall thickness on echocardiography, but â†“ QR",
      "char_start": 138000,
      "char_end": 140000
    },
    {
      "chunk_id": 70,
      "text": "S voltage crasias may improve cardiac\non ECG (mostly in AL). Abnormal cardiac conduction (mostly in condition.\nATTR). â–  Heart transplantation.\nâ–  Best initial imaging: Echocardiography shows relative apical\nsparing of longitudinal strain (a measure of systolic function),\nbiventricular hypertrophy without dilation, thickened valves, and\nspeckled appearance of myocardium.\nâ–  Other imaging tests: Cardiac MRI and bone scintigraphy (for ATTR).\nâ–  Most accurate test: Tissue biopsy.\n(continues)\nThis patient has evidence of DCM. An\nechocardiogram would be the next\nbest diagnostic step.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4444 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 45\nTABLE 2.1-14. Selected Secondary Cardiomyopathies (continued)\nCONDITION AND ETIOLOGY SIGNS, SYMPTOMS, DIAGNOSIS TREATMENT\nCardiac hemochromatosis Presentation: Standard treatment for HF (dis-\nâ–  Storage cardiomyopathy that is â–  Diastolic dysfunction and arrhythmias (followed by DCM at a later cussed earlier).\ninitially restrictive, later dilated. stage) in patients presenting with bronze skin, arthritis, diabetes, or Iron chelation therapy and\nâ–  Intracellular iron accumula- cirrhosis. therapeutic phlebotomy.\ntion systemically, including Diagnosis: Treatment of associated dis-\ncardiomyocytes. â–  Iron overload (â†‘ transferrin, â†‘ ferritin, â†‘ serum iron), liver dysfunc- eases (eg, diabetes).\nâ–  Human homeostatic iron regu- tion (â†‘ ALT, â†‘ AST).\nlator protein mutations cause â–  Genetic testing, imaging (MRI, CXR), liver biopsy.\nhereditary type (autosomal â–  Testing to establish cardiac involvement: Echocardiography (early\nrecessive [AR] with incomplete diastolic dysfunction, late dilation, and systolic dysfunction).\npenetrance). Cardiac MRI (best diagnostic test, can detect and quantify myocar-\ndial iron overload).\nCardiac sarcoidosis Presentation: Standard HF treatment.\nâ–  Inflammatory cardiomyopathy â–  HF, arrhythmias (most common is AV block) or SCD",
      "char_start": 140000,
      "char_end": 142000
    },
    {
      "chunk_id": 71,
      "text": " associated with Management of cardiovascular\nthat is initially restrictive and known extracardiac sarcoidosis (eg, cough, dyspnea, bilateral hilar risks.\nlater dilated. lymphadenopathy, uveitis). Treatment of conduction\nâ–  Infiltration of myocardium by Diagnosis: abnormalities.\nnoncaseating granulomas. â–  Initially, history, ECG, and echocardiography must have features Prevention of SCD if at risk (ICD\nâ–  Unknown etiology. suggestive of cardiomyopathy. implantation).\nâ–  Subsequent advanced imaging (fluorodeoxyglucose-positron Immunosuppressants.\nemission tomography CT, cardiac MRI) supports diagnosis. Periodic monitoring of cardiac\nâ–  Biopsy (either cardiac or extracardiac). function.\nâ–  Other possible causes must be excluded for diagnosis.\nEndocrine Acromegalic cardiomyopathy: Patient with enlarged hands, Cardiac benefit in treating GH\nAcromegaly, hyperthyroidism, feet, and facial features and biventricular hypertrophy. Cardiac and IGH-1 levels early. Fifty\nhypothyroidism, DM, etc. involvement shows diastolic and systolic dysfunction and valvular percent of patients may\nregurgitation. Leading cause of morbidity and mortality in patients recover LVEF.\nwith acromegaly. Optimize HF therapy.\nDiabetic cardiomyopathy: Diabetic patient with myocardial struc- Optimize HF therapy.\ntural and functional abnormalities in absence of risk factors such Optimize diabetes\nas CAD, HTN, and valvular disease. Initially diastolic HF (LV hyper- management.\ntrophy, fibrosis), subsequently systolic HF (with LV dilation).\nDrugs Chemotherapy-related cardiomyopathy: Consider in a patient on Optimization of cardiac risk\nAnthracyclines, cyclophospha- cardiotoxic cancer treatments (eg, anthracyclines [most common], factors.\nmide, radiation. cyclophosphamide, trastuzumab) presenting with signs and symp- Baseline and serial cardiac\ntoms of heart failure. monitoring (eg, echocardio-\nDiagnosis: graph, ECG).\nâ–  Any of the following: Reduced LVEF, symptoms/signs of HF, 5% â†“ in If HFrEF or significant â†“ in ",
      "char_start": 142000,
      "char_end": 144000
    },
    {
      "chunk_id": 72,
      "text": "LVEF\nLVEF on serial monitoring with symptoms, or 10% â†“ without symp- develops, hold medication\ntoms to <55% LVEF. and give optimal HF therapy.\nConsider secondary prevention\nfor those at risk with ACEI/\nARB, and Î²-blockers.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4455 1100//2211//2222 44::0055 PPMM\n\n46 HIGH-YIELD FACTS IN CARDIOVASCULAR\nOTHER CARDIOMYOPATHIES\nTable 2.1-15 describes myocarditis, peripartum cardiomyopathy, and Takot-\nsubo cardiomyopathy.\nTABLE 2.1-15. Other Cardiomyopathies: Myocarditis, Peripartum Cardiomyopathy, and Takotsubo Cardiomyopathy\nCONDITION ETIOLOGY SIGNS, SYMPTOMS, DIAGNOSIS TREATMENT\nMyocarditis Acute or chronic myocardial Presentation: Treat CHF and arrhythmia (as\ninflammation resulting in â–  Healthy individual with acute earlier).\nmyocyte necrosis and fibrosis. decompensated HF and Temporary transvenous pacing\nVariable etiology, eg, infections arrhythmia. for complete heart block.\n(viral, bacterial, rickettsial, â–  May have fever, chills, chest Cardiac transplantation, LVAD,\nfungal), autoimmune. pain, palpitations, syncope, ECMO in severe cases, if\nor SCD. May have history of indicated.\nrecent flulike illness.\nDiagnosis:\nâ–  Most often clinical. Supported\nby inflammatory markers, ECG,\nand echocardiography.\nâ–  Most accurate test: Myocar-\ndial biopsy (rarely done).\nPeripartum Unknown and likely multifacto- Presentation: Peripartum Treated as CHF (see earlier).\nrial; some research suggests woman with dyspnea, Avoid teratogens (ACEIs, ARBs,\na predisposition in those with orthopnea, paroxysmal noc- ARB/neprilysin-inhibitors,\nDCM-associated mutations. turnal dyspnea, pedal edema, and aldosterone receptor\nand hemoptysis. antagonists).\nDiagnosis: Use diuretics, Î²-blockers,\nâ–  HF at end of pregnancy or hydralazine + nitrate if\n(usually â‰¥ 36 weeks) or in the intrapartum.\n5 months after delivery. Echocardiogram monitoring\nâ–  Echocardiography: LV dysfunc- biannually.\ntion (LVEF <45%); the LV may Avoid future pr",
      "char_start": 144000,
      "char_end": 146000
    },
    {
      "chunk_id": 73,
      "text": "egnancy if per-\nor may not be dilated. sistent EF <50%, especially if\nâ–  No identifiable cause. persistent EF <25%.\nTakotsubo cardiomyopathy â€œBroken heart syndrome.â€ Presentation: Older woman Initially managed as ACS.\nCaused by severe psychological with symptoms of ACS, recent Subsequent treatment as HFrEF.\nstress, without CAD. psychological stress, and no Serial echocardiography.\nCAD.\nDiagnosis:\nâ–  LV apical ballooning on angi-\nography with nonobstructive\ncoronary angiography.\nâ— Cardiac enzymes may be\nelevated, ECG may show ST\nelevation.\n(Image adapted with permission from Gangadhar TC et al. Takotsubo cardiomyopathy in a patient with esophageal cancer: A case report. J Med\nCase Rep. 2008;2:379. Published 2008 Dec 8. doi:10.1186/1752-1947-2-379.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4466 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 47\nCORONARY ARTERY DISEASE\nAlso known as ischemic heart disease (IHD) or atherosclerotic heart disease.\nClinical manifestations include stable and unstable angina, shortness of\nbreath, dyspnea on exertion, arrhythmias, MI, HF, and sudden death.\nRisk factors include the following:\nâ–  DM\nâ–  Family history of premature CAD (men <55 years of age, women <65\nyears of age).\nâ–  Smoking KEY FACT\nâ–  Hyperlipidemia\nâ–  Abdominal obesity Major risk factors for CAD include\nâ–  HTN advanced age, male sex, â†‘ LDL\nâ–  Age (men >45 years of age, women age >55 years of age) cholesterol, â†“ HDL cholesterol, HTN,\nâ–  Male sex a family history, and smoking. MI in\nâ–  CAD risk equivalents include DM, symptomatic carotid artery disease, menstruating women is rare.\nperipheral arterial disease, chronic kidney disease, and abdominal aortic\naneurysm (AAA).\nANGINA PECTORIS\nSubsternal chest pain secondary to myocardial ischemia (O supply and\n2\ndemand mismatch). This is most often caused by atheroma (likely >70% ste-\nnosis of a coronary vessel). Less frequently caused by anemia, aortic stenosis,\ntachyarrhythmias, HC",
      "char_start": 146000,
      "char_end": 148000
    },
    {
      "chunk_id": 74,
      "text": "M, and small vessel disease.\nHistory/PE\nâ–  The classic triad consists of (1) substernal chest pain that is (2) provoked\nby stress or exertion and is (3) relieved by rest or nitrates (stable angina).\nâ–  If the chest pain meets 3/3 of these characteristics, it is considered typical\nchest pain. If the chest pain meets 2/3 of these characteristics, it is consid- KEY FACT\nered atypical chest pain.\nâ–  The duration of stable angina is usually from 2 to 10 minutes (ACS is nor- Chest pain that is sharp/stabbing\nmally 10â€“30 minutes in duration). (pleuritic chest pain) or chest pain that\nâ–  Pain can radiate to the neck or arm and may be associated with shortness changes with position, breathing, or\nof breath, nausea/vomiting, diaphoresis, dizziness, or lightheadedness. touch is less likely to be ischemic.\nâ–  Pain is usually described as dull, squeezing, tightness, or pressure-like\n(Patients often describe it as â€œsomeone sitting on my chestâ€).\nâ–  Ischemic pain is not tender, positional, or pleuritic.\nDiagnosis\nâ–  Best initial test: ECG for any type of chest pain. It is usually normal in\nangina pectoris, but it may show ST depression, flat or inverted T waves,\nor signs of past MI.\nâ–  Cardiac enzymes (CK-MB/troponin): Stable angina will have normal tro-\nponins. These are usually drawn in the emergent setting subsequently\nafter the ECG.\nâ–  CXR: This is to primarily help rule out other causes of chest pain, like aor-\ntic dissection (widened mediastinum), esophageal perforation (widened\nmediastinum/pleural effusion), PE, or pneumonia (pleural effusion/lung\nconsolidation).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4477 1100//2211//2222 44::0055 PPMM\n\n48 HIGH-YIELD FACTS IN CARDIOVASCULAR\nKEY FACT â–  Stress testing: Exercise or pharmacologic stress tests detect inducible myo-\ncardial ischemia. Figure 2.1-15 details diagnostic test selection in patients\nDipyridamole and adenosine stress test\nwith suspected stable angina.\nare contraindicated in:\nâ–  Stress",
      "char_start": 148000,
      "char_end": 150000
    },
    {
      "chunk_id": 75,
      "text": " tests are appropriate for diagnosis of CAD among patients with\n1. Active bronchospasm/reactive\nintermediate pretest probability (predictive value is low with low pre-\nairway disease (ie, asthma)\ntest probability).\n2. Second-degree or third-degree\nâ–  Î²-blockers, CCBs, and nitrates are held 48 hours prior to stress test\nheart block, sick sinus syndrome,\n(cause false-negative results).\nor severe bradycardia\nâ–  ST-segment or wall-motion changes (using echo) with exercise or phar-\n3. SBP <90 mm Hg\nmacologic stress (dobutamine echo or dipyridamole thallium) are diag-\n4. With methylxanthines\nnostic of CAD.\nâ–  Coronary angiography or CT coronary angiogram: Coronary angiogra-\nphy, or a less invasive diagnostic test, CT coronary angiogram (availability\nvaries among centers), may be used as a last resort if ECG or stress testing\nis equivocal.\nâ–  Rule out pulmonary, GI, or other cardiac causes of chest pain.\nDifferential Diagnosis\nâ–  Gastroesophageal reflux disease (GERD): History of hoarseness, bad\ntaste, and cough; relief of symptoms with proton pump inhibitors confirms\nKEY FACT\ndiagnosis.\nCoronary Steal Syndrome â–  Musculoskeletal/costochondritis: Tenderness to palpation and\nAdenosine and dipyridamole are movement.\ncoronary vasodilators that dilate normal â–  Pneumonia/pleuritis: Pain worsening with breathing (pleuritic) and often\ncoronary arteries more than rigid accompanied by fever and productive cough.\nstenosed arteries. These drugs may â–  Pulmonary embolism: Shortness of breath/hypoxia, tachycardia, hemop-\ncause perfusion to improve in normal tysis, signs of deep vein thrombosis on physical exam, history of cancer, or\nvessels and decrease in diseased vessels recent surgery. Chest pain may also be pleuritic.\n(\"steal of flow\") which can result in â–  Aortic dissection: Tearing chest pain that radiates to the back along with\ndetectable ischemia. Vasodilator stress unequal radial pulses.\ntests do not rely on inducing coronary â–  Esophageal perforation: History of vomiting/recent endos",
      "char_start": 150000,
      "char_end": 152000
    },
    {
      "chunk_id": 76,
      "text": "copy with pre-\nsteal, although sometimes they cause it. sentation of fever, chest pain, crepitus/subcutaneous emphysema on physi-\ncal exam.\nPretest probability of coronary artery disease\nLow Intermediate High\nNo testing Able to exercise? Treat CAD\nÂ± cardiac catheterization\nYes NNoo\nIschemic changes Pharmacologic stress test\ninterpretable on ECG (ie, no (dobutamine echo or\nactive pacing or LBBB) dipyramidole thallium)\nPositive\nYes Positive\nExercise ECG\nCoronary angiography\nNo Exercise imaginga Positive\naIf LBBB, then pharmacological stress imaging or coronary CTA.\nFIGURE 2.1-15. Selections of appropriate investigation for patients with suspected stable\nangina. Examples where ECG cannot be interpreted regarding ischemic changes include\nLBBB or paced ventricular rhythm. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4488 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 49\nâ–  Anxiety: Patients may have history of panic disorder or anxiety attacks.\nâ–  Shingles: Pain and vesicular rash in a unilateral bandlike (dermatomal)\ndistribution that does not cross the midline.\nTreatment\nâ–  Chronic stable angina: ASA and antianginal drugs (see later).\nâ–  Î²-blockers are the first-line therapy for chronic stable angina. They\nwork by reducing myocardial contractility and heart rate (reduced oxy-\ngen demand relieves ischemia). Nondihydropyridine CCBs (vera-\npamil, diltiazem) are an alternative that work through a similar\nmechanism.\nâ–  Nitrates (eg, nitroglycerin) relieve pain by dilating capacitance veins\n(â†“ preload) resulting in â†“ in LV end-diastolic pressure and wall stress.\nâ–  Ranolazine is used in refractory angina and reduces intracellular cal-\ncium in myocytes, thus allowing complete relaxation during diastole,\nâ†“ myocardial wall stress and end-diastolic pressure.\nâ–  Antiplatelet drugs as indicated (eg, aspirin, clopidogrel). Initiate risk factor\nreduction (eg, smoking, cholesterol, HT",
      "char_start": 152000,
      "char_end": 154000
    },
    {
      "chunk_id": 77,
      "text": "N) and start ACEIs/ARBs, lipid-\nlowering therapies (ie, statins), and smoking cessation. Hormone replace-\nment therapy is not protective in postmenopausal women.\nPRINZMETAL (VARIANT) ANGINA KEY FACT\nâ–  Mimics angina pectoris but is caused by vasospasm of smooth muscles of ASA and Î²-blockers may have mortality\nthe coronary arteries. benefit in many patients with angina\nâ–  Typically occurs in young smokers (age <50 years) with minimal risk fac- caused by coronary artery disease.\ntors for atherosclerosis. However, it is important to avoid these\nâ–  Treatment: Non-dihydropyridine CCBs with or without long-acting medications if the angina is purely\nnitrates. Aspirin is avoided, as it can aggravate the ischemic attacks. vasospastic (Prinzmetal angina).\nÎ²-blockers are contraindicated, as they can â†‘ vasospasm.\nACUTE CORONARY SYNDROMES\nA spectrum of clinical syndromes caused by plaque disruption or vasospasm\nthat leads to acute myocardial ischemia.\nUNSTABLE ANGINA/NONâ€“ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION\nPatient history and cardiac biomarkers distinguish unstable angina, stable\nangina, and nonâ€“ST-elevation myocardial infarction (NSTEMI). Figure 2.1-\n16 compares key features of stable angina, unstable angina, NSTEMI, and\nKEY FACT\nSTEMI.\nâ–  Unstable angina (UA): Chest pain that is (1) new onset, (2) accelerating Acute coronary syndrome:\n(ie, occurs with less exertion, lasts longer, or is less responsive to medica- â–  UA: ECGâ€”no ST elevation; cardiac\ntions), or (3) occurs at rest suggests UA (in contrast to stable angina). Like biomarkers âŠ–.\nstable angina, UA has no elevated cardiac biomarkers, suggesting myocar- â–  NSTEMI: ECGâ€”no ST elevation;\ndial ischemia without necrosis. However, unlike stable angina, UA sug- cardiac biomarkers âŠ•.\ngests possible impending infarction due to plaque instability. â–  STEMI: ECGâ€”ST elevation; cardiac\nâ–  In contrast to UA, NSTEMI presents with myocardial necrosis, as evi- biomarkers âŠ•.\ndenced by elevations in troponins and creatine kinaseâ€“MB isoenzy",
      "char_start": 154000,
      "char_end": 156000
    },
    {
      "chunk_id": 78,
      "text": "me\n(CK-MB). ST-segment elevations are not seen on ECG, differentiating it\nfrom STEMI).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 4499 1100//2211//2222 44::0055 PPMM\n\n50 HIGH-YIELD FACTS IN CARDIOVASCULAR\nDiagnosis\nâ–  ECG: Best initial diagnostic test. Best initial diagnostic test. Serial ECGs\nshould be performed (at baseline, then every 15â€“30 minutes initially) to\nidentify progression to MI. UA and NSTEMI are not associated with ST\nelevation, but other ECG changes may be seen (eg, ST depression,\nT-wave inversion, nonspecific changes).\nâ–  Cardiac markers (CK-MB/troponin):\nâ–  UA is not associated with elevated cardiac markers.\nâ–  NSTEMI is associated with elevations in cardiac markers.\nâ–  Risk stratification: Assess mortality risk (eg, TIMI, GRACE, and HEART\nscores). Timing of coronary angiography Â± percutaneous coronary inter-\nvention (PCI) depends on risk assessment.\nâ–  Echocardiography should be done routinely to assess for signs of isch-\nemia, rule out other causes of chest pain, and assess baseline cardiac func-\ntion (predictor of prognosis).\nTreatment\nBest initial treatment:\nâ–  Admit to cardiac care unit (CCU) and monitor closely.\nâ–  Oxygen administration if SaO <90% or breathless.\n2\nâ–  Antiplatelet therapy: ASA (â†“ mortality in ACS) in combination with a sec-\nond agent (ie, clopidogrel, prasugrel, or ticagrelor), unless contraindicated.\nâ–  Nitrates (IV, topical, or sublingual) for symptomatic relief of angina\nunless contraindicated (eg, hypotension, sildenafil use within 24 hours).\nIV nitrates may be used with concomitant uncontrolled HTN or HF.\nâ–  Î²-blockers should be given to all patients unless contraindicated (eg, HF,\ncardiogenic shock, bronchoconstriction) to reduce ischemia and mortality.\nâ–  LMWH (eg, enoxaparin) or heparin drip to prevent clot formation in the\ncoronary arteries.\nStable Angina Unstable Angina NSTEMI STEMI\nPain On exertion At rest At rest At rest\nTroponin level No elevation No elevation Elevated Elevated\nRV LV",
      "char_start": 156000,
      "char_end": 158000
    },
    {
      "chunk_id": 79,
      "text": " RV LV\nInfarction None None\nSubendocardial Transmural\nST elevation\nPossible ST\nECG changes None depressions or\nT-wave inversions\nST depression\nFIGURE 2.1-16. Comparison between key features of stable angina and acute coronary syn-\ndromes (unstable angina, NSTEMI, STEMI). (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5500 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 51\nInterventions:\nâ–  Immediate invasive strategy: Immediate coronary angiography for\npatients who have signs of refractory angina, hemodynamic instability (HF\nor worsening mitral regurgitation), or electrical instability (VT/VF).\nâ–  Early invasive strategy: Coronary angiography within 24 hours for other\nhigh-risk patients.\nâ–  Ischemia-guided strategy: For low-risk patients, optimal medical therapy,\nwith coronary angiography only in patients who develop refractory or\nrecurrent angina, or with hemodynamic instability.\nLong-term treatment:\nâ–  Dual antiplatelet therapy with aspirin and prasugrel or ticagrelor (also\nP2Y inhibitors, but superior to clopidogrel) should be considered for up\n12\nto 12 months after angioplasty and stenting to prevent in-stent thrombosis.\nâ–  Ensure patient is on long-term Î²-blockers (if depressed LV function),\nACEIs/ARBs, and high-intensity statins.\nâ–  Address modifiable risk factors (ie, smoking, HTN, hyperlipidemia, KEY FACT\ndiabetes).\nInitial Treatment for MIâ€”\nOxygen â€“ if hypoxic\nST-SEGMENT ELEVATION MYOCARDIAL INFARCTION ASA + additional second antiplatelet\nagent (NSTEMI)\nST-segment elevations and cardiac enzyme release secondary to prolonged Nitrates\ncardiac ischemia and necrosis. STEMI is a common medical emergency, and Î²-blockers â€“ unless in cardiogenic shock\nprompt treatment is absolutely necessary. Revascularization â€“ as soon as indicated\n(STEMI vs NSTEMI)\nHistory/PE\nâ–  Presentation: Acute-onset substernal chest pain (>10â€“30 min), com-\nmonly described as a pressure, tightnes",
      "char_start": 158000,
      "char_end": 160000
    },
    {
      "chunk_id": 80,
      "text": "s, or heaviness that can radiate to\nthe left arm, shoulders, neck, or jaw. May present without chest pain\n(â€œsilentâ€ infarct). KEY FACT\nâ–  Associated symptoms: Diaphoresis (most common associated symptom),\nIt is important to check for aortic\nshortness of breath, lightheadedness, anxiety, nausea/vomiting, epigastric\ndissection clinically prior to\npain (more common in women), and syncope.\nadministering anticoagulants or\nâ–  PE: May reveal arrhythmias, hypotension (cardiogenic shock), new S ,\n4\nthrombolytics. Aortic dissection chest\npansystolic murmur, and evidence of new CHF. Clear lung fields are seen\npain will be a tearing pain that radiates\nin RV MI (inferior MI). In a young, otherwise healthy person, consider\nto the back along with unequal\ncocaine use as the etiology.\nradial pulses. Initial test to assess for\nâ–  Best predictor of survival: LVEF.\ndissection includes a CXR, which may\nDiagnosis reveal widened mediastinum.\nâ–  ECG: ST-segment elevations, hyperacute (tall) T waves, or new LBBB\nwithin hours (see Sgarbossa criteria in Electrocardiogram section). ST-\nsegment depressions and dominant R waves in leads V â€“V can also be a\n1 2\nreciprocal change indicating posterior wall infarct. T-wave inversion and\npathologic Q waves develop within hours to days.\nâ–  Sequence of ECG changes: Peaked T waves â†’ ST-segment elevation\nâ†’ Q waves â†’ T-wave inversion â†’ ST-segment normalization â†’\nT-wave normalization over several hours to days. Figure 2.1-4 illus-\ntrates these ECG changes over time.\nâ–  Cardiac Enzymes:\nâ–  Troponin (T and I) is the most sensitive and specific cardiac marker.\nâ–  CK-MB and the CK-MB/total CK ratio (CK index) are also regularly\nchecked.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5511 1100//2211//2222 44::0055 PPMM\n\nKEY FACT\nFemales, people with diabetes, older\nadults, and patients who have had\nheart transplants may have atypical or\nclinically silent MIs.\nâ–  Both troponin and CK-MB can take up to 3 to 12 hours to rise after the\no",
      "char_start": 160000,
      "char_end": 162000
    },
    {
      "chunk_id": 81,
      "text": "nset of chest pain. Troponin peaks at 24 to 48 hours, and CK-MB\n50 peaks within 24 hours (Fig. 2.1-18).\ncTnl\nâ–  Localization of MI based on ST-segment abnormalities: Fig. 2.1-19\n10 illustrates how identifying the pattern of ECG changes can be used to\nlocalize the anatomic location of STEMI. Examples are provided later.\n5 Myoglobin â–  Inferior MI (involving the right coronary artery/patent ductus arteriosus\nCK-MB\nMLC [RCA/PDA]): ST-segment elevation in leads II, III, and aVF (Fig. 2.1-20).\n2 LD1 Normal\n1 Obtain a right-sided ECG to look for ST elevations in the RV.\n1 2 3 4 5 6 7 8 â–  Anterior MI (involving left anterior descending artery [LAD] and diago-\nnal branches): ST-segment elevation in leads V â€“V (Fig. 2.1-21).\n1 4\nâ–  Lateral MI (involving left coronary artery [LCA]): ST-segment elevation\nin leads I, aVL, and V â€“V .\n5 6\nINFARCT LOCATION LEADS WITH ST-SEGMENT ELEVATIONS OR Q WAVES\nAnteroseptal (LAD) Vâ€“V\n1 2\nAnteroapical (distal LAD) Vâ€“V\n3 4\nAnterolateral (LAD or LCX) Vâ€“V\n5 6\nLateral (LCX) I, aVL\nInFerior (RCA) II, III, aVF\nPosterior (PDA) Vâ€“V, ST depression in Vâ€“V with tall R waves\n7 9 1 3\nScapula\nI aVR V1 V4\nSternum II aVL V2 V5\naVR\nIII aVF V3 V6\nII\nFIGURE 2.1-19. Localization of ST elevation myocardial infarction (STEMI). (Reproduced with per-\nmission from USMLE-Rx.com.)\nlamron\nfo\ntimil\nreppu\nfo\nselpitluM\n52 HIGH-YIELD FACTS IN CARDIOVASCULAR\nSTEMI\nAll patients\nEmergent coronary angiography *Medical therapies below may all\nbe considered but should not and intervention* delay emergent procedure\nSupplemental Oâ‚‚ to maintain SpOâ‚‚ 90%\nAspirin 325 mg\nAntiplatelet therapy (eg, clopidogrel)\nAnticoagulation (eg, heparin drip)\nHigh-dose statin (eg, atorvastatin)\nÎ²-blocker (if no heart failure symptoms,\nhypotension, bradycardia, or severe asthma)\nPer f s a i i s i l n t u e s r n t e a t s b c y i h l m it e y p s t a t o p n m a d i s n n , w o h i u y th s p e e n r o o t f e h P n e D s m i E o o n in d o h y r i n b h a i e t m o a r i r c s t Un b st r a a b d l y e c ",
      "char_start": 162000,
      "char_end": 164000
    },
    {
      "chunk_id": 82,
      "text": "s a i r n d u ia s Left he s a y r m t p fa t i o lu m re s\nSublingual nitroglycerin Consider IV atropine,\nIV furosemide\nAdd IV for persistent symptoms pacing\nFIGURE 2.1-17. Initial management of STEMI. PDE, Phosphodiesterase. (Reproduced with permission\nfrom USMLE-Rx.com.)\n100\ncTnT\nDays after MI onset\nFIGURE 2.1-18. Typical pattern of serum\nmarker elevation after an acute myocar-\ndial infarction. CK-MB, Creatine kinase\nMB isoenzyme; cTnI, cardiac troponin I;\ncTnT, cardiac troponin T; LD1, lactate\ndehydrogenase isoenzyme 1; MLC, myo-\nsin light chain. (Reproduced with permission\nfrom USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5522 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 53\nI aVR V1\nV4\nI aVR V1 V4\nII aVL V2 V5\nII\naVL V2\nV5\nIII aVF V3 V6 III aVF V3 V6\nFIGURE 2.1-20. Inferior wall myocardial infarction. In this patient FIGURE 2.1-21. Anterior wall myocardial infarction. This patient\nwith acute chest pain, the ECG demonstrates acute ST-segment presented with acute chest pain. The ECG showed acute ST-segment\nelevation in leads II, III, and aVF with reciprocal ST-segment depres- elevation in leads V 1 â€“V 6 and hyperacute T waves. (Reproduced with per-\nsion and T-wave flattening in leads I, aVL, and V 4 â€“V 6 . (Reproduced with mission from USMLE-Rx.com.)\npermission from USMLE-Rx.com.)\nâ–  Posterior MI: ST-segment depression in leads V â€“V (anterior leads) can\n1 2\nbe indicative. Obtain posterior ECG leads V â€“V (15-lead) to assess for\n7 9\nST-segment elevations.\nâ–  Differential diagnosis: Angina, myocarditis, pericarditis, aortic dissection,\nPE, esophageal reflux/spasm. These presentations are discussed in the sta-\nble angina differential diagnosis section.\nKEY FACT\nTreatment\nSummary of ACS medical management:\nBest initial treatment: An overview of the initial management of STEMI is\nâ–  UA: No ST elevation; cardia\nprovided in Figure 2.1-17.\nbiomarkers âŠ–. Tx: Aspirin.\nâ–  First line: Antiplatelet therap",
      "char_start": 164000,
      "char_end": 166000
    },
    {
      "chunk_id": 83,
      "text": "y; ASA (â†“ mortality in ACS) + P2Y12 inhibi- â–  NSTEMI: No ST elevation; cardiac\ntor (prasugrel or ticagrelor if PCI planned [superior to clopidogrel]; if biomarkers âŠ•. Tx: Aspirin,\nundergoing fibrinolysis, clopidogrel is used [prasugrel/ticagrelor relatively clopidogrel/ticagrelor, and LMWH\ncontraindicated]). or heparin drip.\nâ–  Nitrates (IV, topical, or sublingual): For symptomatic relief of angina â–  For both UA and NSTEMI: Tx:\nunless contraindicated (eg, hypotension, sildenafil used within 24 hours). Nitrates and Î²-blockers if not\nIV nitrates may be used with concomitant uncontrolled HTN or HF. hypotensive.\nâ–  If SaO <90% to 92%, breathless, or in acute LVF, administer O . â–  STEMI: ST elevation; cardiac\n2 2\nâ–  Î²-blockers should be given to all patients unless contraindicated (eg, HF, biomarkers âŠ•. Tx: Angioplasty with\ncardiogenic shock, bronchoconstriction) to reduce ischemia and mortality. stent placement.\nâ–  If the patient is in HF or in cardiogenic shock, do not give Î²-blockers.\nConsider ACEIs in HF provided that the patient is not hypotensive.\nâ–  In inferior wall MI (ie, RV infarction), avoid nitrates and diuretics due to\nrisk for severe hypotension (preload dependent). IV fluids can improve\nhemodynamics by increasing preload. KEY FACT\nInterventions: Contraindications to thrombolysis:\nâ–  Previous intracranial hemorrhage or\nâ–  Emergent angiography and PCI should be performed if possible (superior\nmajor GI bleed.\nto thrombolysis).\nâ–  Recent major trauma/surgery/head\nâ–  If PCI cannot be performed <120 minutes (door-to-balloon time should\ninjury.\nideally be <90 minutes), and there are no contraindications to thromboly-\nâ–  Ischemic stroke within the last 6\nsis, thrombolysis with alteplase (tPA), reteplase, or streptokinase should be\nmonths.\nperformed instead of PCI.\nâ–  Severe hypertension (>180/110\nâ–  Although thrombolysis should be performed within 3 hours of chest pain\nmm Hg).\nonset, it can be used up to 12 hours from the onset of symptoms (mortality\nâ–  Known bleeding disorder",
      "char_start": 166000,
      "char_end": 168000
    },
    {
      "chunk_id": 84,
      "text": ".\nbenefit extends to 12 hours). Thrombolysis is contraindicated if >24 hours.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5533 1100//2211//2222 44::0055 PPMM\n\n54 HIGH-YIELD FACTS IN CARDIOVASCULAR\nKEY FACT Long-term treatment:\nâ–  Long-term management for all patients includes ASA, ACEIs, Î²-blockers,\nIndications for coronary artery bypass\nnitrates, and high-dose statins.\ngraft surgery (CABG):\nâ–  After PCI is performed, dual antiplatelet therapy (aspirin and a P2Y12\nâ–  Left main CAD.\nreceptor blocker, eg, clopidogrel, prasugrel, ticagrelor) is necessary:\nâ–  Triple-vessel disease with â‰¥70% in\nâ–  If bare metal stent is placed, >30 days of dual antiplatelet therapy is\neach vessel.\nnecessary.\nâ–  Two-vessel disease in diabetic\nâ–  If drug-eluting stent is placed, >12 months of dual antiplatelet therapy\npatient.\nis necessary.\nâ–  Symptomatic patient despite\nmaximal medical therapy. â–  Address modifiable risk factors (eg, smoking, HTN, hyperlipidemia, diabetes).\nâ–  Coronary obstruction not amenable\nto PCI. Complications\nâ–  Arrhythmia: VF and VT are the most common complications and the\nmost common causes of sudden death after acute MI. Sinus bradycardia\nKEY FACT and third-degree (complete) heart block are also very common.\nâ–  Less common complications include reinfarction, LV wall rupture, VSD,\nRV MI is caused by occlusion of the\npericarditis, papillary muscle rupture (with mitral regurgitation), LV aneu-\nRCA. As dysfunctional RV is dependent\nrysm or pseudoaneurysm, and mural thrombi (with subsequent acute limb\non preload to maintain stroke volume,\nischemia, TIA, or stroke).\npreload-reducing drugs (nitrates and\nâ–  Complications noted earlier tend to occur at different times in the course\ndiuretics) can cause severe hypotension\nof this disease. This is detailed in Table 2.1-16.\nand must be avoided. In RV MI with\nâ–  RV infarction: Caused by occlusion of the RCA. Presents with hypoten-\nshock, treat with IV fluids to optimize\nsion, JVD, and clear lungs. ",
      "char_start": 168000,
      "char_end": 170000
    },
    {
      "chunk_id": 85,
      "text": "Treat with revascularization and volume\npreload, and add inotropes if necessary.\nreplacement (preload dependent). Avoid nitrates and diuretics.\nTABLE 2.1-16. A Timeline of Common Post-MI Complications\nTIME COMPLICATIONS\nFirst day Life-threatening arrhythmia (eg, VT, VF)\n2â€“4 days Arrhythmia\nPeri-infarction pericarditis\nTreatment is supportive\nNSAIDs avoided (impair collagen deposition and increase risk of\nventricular wall rupture)\nCompare to Dressler syndrome (see later)\n5 daysâ€“2 weeks LV wall rupture (acute pericardial tamponade causing electrical alternans,\npulseless electrical activity, and JVD)\nPapillary muscle rupture (severe mitral regurgitation, pulmonary edema)\nSeptal rupture (lower-left sternal border murmur, increase in O saturation\n2\nin the RV)\nWeeks to months Dressler syndrome\nAutoimmune process occurring 2â€“10 weeks post-MI; presents with\nfever, pericarditis, pleural effusion, leukocytosis, and â†‘ erythrocyte\nsedimentation rate (ESR)\nTreat with NSAIDs (unlike peri-infarction pericarditis)\nVentricular aneurysm\nCHF, arrhythmia, persistent ST-segment elevation, mitral regurgitation,\nthrombus formation\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5544 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 55\nCAROTID ARTERY STENOSIS\nAtherosclerotic lesion of either or both carotid arteries. Accounts for 20% of\nTIAs and embolic strokes.\nHistory/PE\nâ–  Often asymptomatic.\nâ–  Symptomatic disease is characterized by sudden-onset focal neurologic\ndefect in the past 6 months (ie, TIA or stroke).\nâ–  PE may reveal carotid artery bruit.\nâ–  Risk factors: Advanced age, smoking, HTN, hyperlipidemia, diabetes,\nobesity, and family history of CAD and/or carotid artery disease.\nDiagnosis\nDuplex ultrasonography can determine percent occlusion.\nTreatment\nâ–  Definitive treatment: Carotid endarterectomy (CEA). Carotid stenting in\nsome select cases.\nâ–  CEA recommended in symptomatic (TIA/stroke in last 6 months) patients\nwith 70% to 99% ",
      "char_start": 170000,
      "char_end": 172000
    },
    {
      "chunk_id": 86,
      "text": "stenosis.\nâ–  Based on procedural risk and patient factors (eg, age, sex, comorbidities,\nlife expectancy), consider in symptomatic patients with 50% to 69% or\nasymptomatic with 60% to 99% stenosis.\nâ–  With 100% blockage, CEA or stenting is contraindicated (there can be no\nthromboembolism from a completely occluded vessel).\nDYSLIPIDEMIA\nâ–  Increased total cholesterol, LDL-C, or triglyceride levels or decreased\nHDL levels. Although these are all risk factors for atherosclerotic cardio-\nvascular disease (ASCVD; ie, CAD, stroke), LDL-C is the dominant ath-\nerogenic cholesterol.\nâ–  Dyslipidemia may be due to primary (genetic conditions such as familial\ncombined hypercholesterolemia or familial hypertriglyceridemia) or sec-\nondary causes.\nâ–  Secondary causes include DM, cholestatic liver disease, nephrotic syn-\ndrome, chronic renal disease, hypothyroidism, obesity, cigarette smoking,\nexcessive alcohol consumption, and certain medications (eg, thiazide\ndiuretics, Î²-blockers, oral contraceptive pills [OCPs], clozapine). Optimiz-\ning treatment of secondary causes is indicated in all patients.\nHistory/PE\nâ–  Most patients have no specific signs or symptoms.\nâ–  Patients with extremely high triglyceride or LDL levels may have xanthomata\nKEY FACT\n(eruptive itchy nodules, orange streaks in palmar creases, or tuberous plaques\non the elbows and knees); xanthelasma (yellow fatty deposits in the skin\nCauses of secondary hyperlipidemia\naround the lids just below the eyes); lipemia retinalis (creamy appearance of\ninclude Cushing syndrome,\nretinal vessels); or corneal arcus (deposition of lipid in the corneal stroma).\nhypothyroidism, nephrotic syndrome,\nâ–  Patients with very high triglyceride levels (>500 mg/dL) may initially pres-\nand cholestasis.\nent with pancreatitis.\nâ–  Patients may have a history of primary familial hyperlipidemias.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5555 1100//2211//2222 44::0055 PPMM\n\n56 HIGH-YIELD FACTS IN CARDIOVASCULAR\nDi",
      "char_start": 172000,
      "char_end": 174000
    },
    {
      "chunk_id": 87,
      "text": "agnosis\nâ–  Best initial test: Lipid profile may show â†‘ total cholesterol, â†‘ LDL-C, â†‘\ntriglycerides, or â†“ HDL.\nâ–  Indications for testing: Screen all patients >35 years of age or those â‰¥20\nyears of age with risk factors for ASCVD and repeat every 5 years or sooner\nKEY FACT if lipid levels are elevated. Additionally, smokers of all ages should be\nscreened for dyslipidemias due to their â†‘ risk.\nAs you cannot calculate the patientâ€™s â–  Interpretation of results:\nASCVD risk on the USMLE, focus on â–  Risk of ASCVD: 10-year risk of ASCVD, estimated using the Pooled\nobvious signs of â†‘ risk (smoking, Cohort Equations tool, directs further treatment.\ndiabetes) or â†“ risk (young, healthy) â–  Individuals with LDL >190 mg/dL, triglycerides â‰¥500 mg/dL, family\nwhen deciding if statin therapy is history of premature atherosclerotic disease, or physical signs of dyslip-\nappropriate. idemia (eg, tendon xanthoma) should also be evaluated for primary\ncauses of hyperlipidemia.\nTreatment\nElevated LDL-C: Lowering LDL-C may reduce the risk of ASCVD.\nâ–  Lifestyle therapies: Dietary modification (eg, low fat, reduced red meat,\nincreased fiber), aerobic exercise, and weight loss are recommended in all\npatients.\nâ–  Indications for pharmacotherapy: The American College of Cardiology/\nAmerican Heart Association recommendations are presented in Table\n2.1-17.\nâ–  Statins are the initial drug of choice for the treatment of hypercholes-\nterolemia. Commonly used lipid-lowering agents are listed in Table\n2.1-18.\nâ–  Intensity of therapy: Medication regimen varies based on the goal\nLDL reduction. High-intensity statin therapy (eg, atorvastatin 40 and\n80 mg or rosuvastatin 20 and 40 mg) reduces LDL-C >50%, while moderate-\nintensity therapy lowers LDL-C by 30%â€“50%.\nElevated triglycerides:\nâ–  Initial treatment: Lifestyle therapies (diet, exercise, weight loss), treat-\nment of secondary causes (eg, optimization of chronic kidney disease\n[CKD] or diabetes therapy), and avoidance of medications that may cause\nhypertrigly",
      "char_start": 174000,
      "char_end": 176000
    },
    {
      "chunk_id": 88,
      "text": "ceridemia.\nTABLE 2.1-17. American College of Cardiology/American Heart Association Treatment Guidelines for Management of Hyperlipidemia\nPATIENT AGE CRITERIA TREATMENTS IN ADDITION TO LIFESTYLE\nAll ages Atherosclerotic cardiovascular disease (ASCVD, eg, CAD, cerebro- High-intensity statin Â± ezetimibe\nvascular accident, or peripheral artery disease) Very high risk: Add PCSK9 inhibitors if required\n20â€“75 years LDL-C â‰¥190 mg/dL, without ASCVD High-intensity statin\n20â€“39 years Family history of premature ASCVD and LDL-C â‰¥160 mg/dL, Consider statin\nwithout ASCVD\n40â€“75 years Type DM, without ASCVD Moderate-intensity or high-intensity statin based on risk\n40â€“75 years LDL-C 70â€“189 mg/dL with diabetes; LDL-C 70â€“189 mg/dL, 5%â€“7.5% 10-year risk: moderate-intensity statin\nwithout type 2 DM or ASCVD 7.5%â€“19% 10-year risk: moderate-intensity statin\nâ‰¥20% 10-year risk: high-intensity statin\n>75 years No ASCVD, regardless of LDL-C Clinical assessment and risk discussion\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5566 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 57\nTABLE 2.1-18. Lipid-Lowering Agents\nCLASS EXAMPLES EFFECT ON LIPID PROFILE ADVERSE EFFECTS\nHMG-CoA reductase inhibitors Atorvastatin, simvastatin, lovastatin, â†“ LDL, â†“ triglycerides â†‘ LFTs, myositis, warfarin\n(statins) pravastatin, rosuvastatin potentiation\nLipoprotein lipase stimulators Gemfibrozil â†“ triglycerides, â†‘ HDL GI upset, cholelithiasis, myositis\n(fibrates) (especially in combination with\nstatins), â†‘ LFTs, pancreatitis\nCholesterol absorption Ezetimibe â†“ LDL Diarrhea, abdominal pain; can cause\ninhibitors angioedema\nNiacin Niaspan â†‘ HDL, â†“ LDL Skin flushing (can be prevented with\nASA, due to â†‘ prostaglandins), par-\nesthesias, pruritus, GI upset, â†‘ LFTs\nBile acid resins Cholestyramine, colestipol, â†“ LDL Constipation, GI upset, LFT abnormal-\ncolesevelam ities, myalgias; can â†“ absorption\nof other drugs from the small\nintestine\nProprotein convertase sub- E",
      "char_start": 176000,
      "char_end": 178000
    },
    {
      "chunk_id": 89,
      "text": "volocumab, alirocumab (inject- â†“â†“ LDL Injection-site swelling, rash, muscle/\ntilisin/kexin type 9 (PCSK9) able medications taken every 2â€“4 limb pain, backache\ninhibitors weeks)\nâ–  If ASCVD risk â‰¥7.5% after initial treatment, statins may be considered.\nâ–  Prevention of pancreatitis: Patients with severe hypertriglyceridemia\n(especially triglycerides â‰¥1000 mg/dL) benefit from fibrate therapy to pre-\nvent pancreatitis.\nHYPERTENSION\nHTN is the most common disease in the United States and the key risk factor\nin MI and stroke. Stage 1 HTN is defined as an SBP â‰¥130 to 139 mm Hg or\na diastolic blood pressure (DBP) â‰¥80 to 89 mm Hg. Measurements are based\non an average of â‰¥2 readings obtained on â‰¥2 occasions separated in time in\nadults (see Table 2.1-19 for classifications). HTN is classified as primary or\nessential without an identifiable cause and secondary when an identifiable\ncause exists.\nKEY FACT\nPRIMARY (ESSENTIAL) HYPERTENSION\nPCSK9 inhibitors are a new class\nof LDL-lowering drugs. They\nHypertension that has no identifiable cause and represents ~95% of cases.\nsignificantly increase hepatic\nRisk factors: clearance of LDL. Indicated in familial\nhypercholesterolemia and statin-\nâ–  Nonmodifiable: Increasing age, male sex, Black race, family history. resistant or statin-intolerant patients\nâ–  Modifiable: High-salt diet, alcohol (amount varies), obesity, sedentary with severe hyperlipidemia.\nlifestyle.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5577 1100//2211//2222 44::0055 PPMM\n\n58 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-19. Definitions of Blood Pressure Values for Adults (>18 years) and General\nPractice Guidelines\nSTAGE BP (MM HG) GENERAL PRACTICE GUIDELINES\nNormotensive SBP <120 Routine follow-up and continued promotion of a healthy\nand lifestyle\nDBP <80\nPrehyperten- SBP 120â€“129 Lifestyle modifications recommended with routine\nsive and follow-upa\nDBP <80\nStage I hyper- SBP â‰¥130â€“139 Lifestyle modifications recommended to all pat",
      "char_start": 178000,
      "char_end": 180000
    },
    {
      "chunk_id": 90,
      "text": "ientsb\ntension or Lifestyle modifications + medication(s) for high-risk\nDBP â‰¥80â€“89 patientsc\nStage II hyper- SBP â‰¥140 Lifestyle modifications + medication(s) for all patients\ntension or\nDBP â‰¥90\nSevere hyper- SBP >180 Severe hypertension + no end-organ damage = hyperten-\ntension or sive urgency\nDBP >120 Severe hypertension + end-organ damage = hypertensive\n(no gener- emergency\nally agreed Treatment goal for both: 25% reduction in BP from base-\nupon BP line or <160/100 mm Hg (see associated Key Fact for\nvalues) more details)\naLifestyle modifications (listed in order of effectiveness): Weight loss > DASH diet > Exercise >\nRestricting salt intake > alcohol limitation.\nbLifestyle modifications alone are usually given a trial period of 3â€“6 months for lower-risk patients\nbefore medications are considered.\ncHigh-risk patients: Heart failure, coronary artery disease, chronic kidney disease, diabetes, age\n>65 (debated), ASCVD 10-year risk >10%.\nNote: Medication follow-up: Start new medication (1 month) â†’ medication working (3â€“6 months).\nIf medication not working â†’ Follow-up 1 month OR change dose Â± medication.\nHistory/PE/Complications\nâ–  Majority of patients are asymptomatic (â€œsilent killerâ€) and found on rou-\ntine screening.\nâ–  Symptomatic patients exhibit end-organ damage as HTN â†‘ atherosclerosis\n+ â†‘ arteriosclerosis:\nâ–  Eyes: Early (AV nicking, cotton wool spots) â†’ later (hemorrhage, exu-\ndates, papilledema). See Figure 2.1-22.\nâ–  Central nervous system (CNS): Encephalopathy, stroke (intracerebral\nhemorrhage, lacunar, ischemic, TIAs).\nâ–  Cardiovascular: CAD â†’ MI, LV hypertrophy â†’ CHF, peripheral\narterial disease (PAD), aortic aneurysms/dissections.\nâ–  Kidney: Arteriosclerosis of glomerulus â†’ nephrosclerosis, â†“ GFR/dys-\nfunctional tubules â†’ failure. See Figure 2.1-23.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5588 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 59\nA B\nFIGURE 2.1-23. Hyaline arteriolosclerosis\nFIGURE 2.",
      "char_start": 180000,
      "char_end": 182000
    },
    {
      "chunk_id": 91,
      "text": "1-22. Hypertensive retinopathy. (A) Cotton wool spots (blue arow) and hard exu- occurs secondary to plasma protein leak-\ndates (red arrow). (B) Papilledema (black arrows). (Adapted with permission from Diallo JW, MÃ©da N, Tou- age into the endothelium due to essential\ngouma SJ, et al. IntÃ©rÃªts de lâ€™examen du fond dâ€™Å“il en pratique de ville: bilan de 438 cas [Interests of the examination of the hypertension or diabetes mellitus. (Repro-\nfundus in general practice: review of 438 cases]. Pan Afr Med. 2015;20. doi:10.11604/pamj.2015.20.363.6629. B: Adapted with duced with permission from Sostaric-Zuckermann\npermission Kanonidou E, Chatziralli I, Kanonidou C, Parava M, Ziakas N. Unilateral optic disc edema in a paediatric patient: IC, Borel N, Kaiser C, et al. Chlamydia in canine or\nDiagnostic dilemmas and management. Case Rep Med. 2010;2010:529081. doi:10.1155/2010/529081.). feline coronary arteriosclerotic lesions. BMC Res Notes.\n2011;4:350. doi: 10.1186/1756-0500-4-350.)\nDiagnosis\nâ–  Measurement: Never diagnose HTN on one reading unless severe HTN\nor end-organ damage is present. Measurements are based on an average of\nâ‰¥2 readings obtained on â‰¥2 occasions separated in time (days, weeks) in\nadults. Ambulatory BP monitoring is the gold standard. Ambulatory BP\nand outpatient BP (with home BP monitors) monitoring help exclude\nwhite coat hypertension (elevated BP only in clinic) as a cause of HTN.\nSerial clinic BP checks can also be used.\nâ–  New-onset HTN: Once primary HTN is diagnosed, the next best step is to\nscreen for complications and comorbid conditions, which include\nHbA1c or fasting glucose, lipid panel, chemistry panel (serum Cr, blood\nurea nitrogen [BUN], K), ECG (screen for LV hypertrophy, Q waves for\nprevious MI), and a urinalysis (protein).\nâ–  Secondary cause of HTN: If suspected, order appropriate tests (see sec-\nondary HTN key fact).\nTreatment\nMNEMONIC\nâ–  Best initial treatment: Lifestyle modifications listed in order of effective-\nInitial Drug Treatment of HTNâ€”\nn",
      "char_start": 182000,
      "char_end": 184000
    },
    {
      "chunk_id": 92,
      "text": "ess: Weight loss (in overweight people) > DASH diet > exercise >\nrestricting salt intake > alcohol limitation (if patient has refractory HTN, TAC\nlimiting alcohol may be the answer). Depending on patient, usually tried T (Thiazide diuretics usually initial choice)\nfor 3 to 6 months before drugs are considered. ACEIs/ARBs\nâ–  Best initial medications: Choice of thiazide diuretics (usually), ACEs/ CCBs\nARBs, or dihydropyridine CCBs unless a compelling indication exists\n(Tables 2.1-20 and 2.1-21).\nâ–  General management goals: BP should be lowered to <130/80 mm Hg in\nmost patients with hypertension as tolerated. Although 70% of patients are\ncontrolled with one drug, 90% are controlled with two to three drugs. For\nA patient is diagnosed with new-\nexample, if a thiazide diuretic alone doesnâ€™t control HTN, consider add-\nonset primary HTN. The physician\ning an ACEI/ARB, a CCB, or a Î²-blocker (depending on the patient/com-\nrecommends lifestyle modifications\npelling indications).\nwith a focus on weight loss, with\nfollow-up scheduled 3 months later\nto evaluate the need for medications.\nWhat is the next best step in\nevaluating this patient?\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 5599 1100//2211//2222 44::0055 PPMM\n\n60 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-20. Compelling Indications for Treatment of Primary Hypertension\nIF HISTORY OFâ€¦ â€¦THEN BEST INITIAL TREATMENT(S)\nPrior myocardial infarction, Î²-blockers are a high-yield answer for exams + practice\ncoronary artery disease, com- (others may include CCBs, ACE/ARBs, diuretics, and\npensated heart failure, atrial aldosterone antagonists, depending on condition)\nfibrillation, hyperthyroidism\nCKD, proteinuria, diabetes ACEIs or ARBs (renal protective in diabetics)\nBenign prostatic hyperplasia Î±-Blockers â†’ smooth muscle relaxation\nof blood vessels (vasodilation) + bladder/prostrate\nOsteoporosis Thiazides â†’ blocks Na-Cl reabsorption in DCT â†’â†‘\nBlack racea calcium reabsorption\nCurrent preg",
      "char_start": 184000,
      "char_end": 186000
    },
    {
      "chunk_id": 93,
      "text": "nancy â€œHe Likes My Neonateâ€\nHydralazine, Labetalol (use first), Methyldopa, Nifedipine\nAsthma ARBs (NOT ACEIs because bradykinin â†’ cough), CCBs,\nthiazide diuretics, cardioselective (Î²) Î²-blockers\n1\naControversial â€œsalt-sensitive HTNâ€ in Black individuals. CCBs are equally first line.\nTABLE 2.1-21. Major Classes of Antihypertensive Agents, Mechanism of Actions, and Adverse Effects\nCLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS\nThiazide Hydrochlorothiazide, chlorthali- Thiazides â†’ block Na+/Clâ€“ reabsorption Elevate blood levels (hyperGLUC) of\ndiuretics done, metolazone. in DCT â†’ Na+/HO excretion â†’ â†“ BP. Glucose, Lipids, Uric acid, Calcium. So,\n2\nâ€œThiazides get it done = caution use in diabetes, â†‘ TGs, â†‘ uric\nchlorthalidone.â€ acid â†’ gout, hypercalcemia.\nâ€œGet in the zone with a thiazide = Causes metabolic alkalosis, â†“ K+, can lead\nmetolazone.â€ to hyponatremia (promotes Na+ loss with\nno change to medullary gradientsâ€™ osmo-\nlarity that drive HO reabsorption â†’ if\n2\npatient â†‘ HO intake â†’ hyponatremia).\n2\nLoop diuretics Sulfonamides: furosemide, torse- Loops â†’ block Na+/K+/2Clâ€“ pump in Metabolic alkalosis, â†“ K+, â†“ Ca2+, â†“ Mg2+,\nmide, bumetanide. thick ascending loop of Henle â†’ â†“ â†‘ uric acid â†’ gout, ototoxicity (all +\nNon-sulfonamide: ethacrynic acid. medullary osmotic gradients â†’ â†‘ â†‘ risk ethacrynic acid). â€œLoop ear-\nâ†‘â†‘â†‘ Na+/ HO excretion â†’ â†“ BP. rings hurt your ears.â€ Sulfonamides â†’\n2\nrash + acute interstitial nephritis.\n(continues)\nOnce primary HTN is diagnosed,\nthe next best step is to screen\nfor complications and comorbid\nconditions, which include HbA1c or\nfasting glucose, lipid panel, chemistry\npanel (serum Cr, BUN, K), ECG (screen\nfor LV hypertrophy, Q waves for\nprevious MI), and a urinalysis (protein).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6600 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 61\nTABLE 2.1-21. Major Classes of Antihypertensive Agents, Mechanism of Actions, and Adverse Effects (continued",
      "char_start": 186000,
      "char_end": 188000
    },
    {
      "chunk_id": 94,
      "text": ")\nCLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS\nK+-sparing Spironolactone, Triamterene, Eplere- Spironolactone + eplerenone â†’ aldo- Hyperkalemia + metabolic acidosis.\ndiuretics none, Amiloride, K+-sparing = sterone-R inhibitors. Spironolactone mimics/blocks testosterone\nSTEAK. Triamterene + amiloride â†’ inhibit epi- + progesterone effects â†’ gynecomastia\nthelial Na+ channels. (men) + amenorrhea (women).\nÎ²-blockers Cardioselective (Î²- > Î²-blockers) Block Î² on heart + kidney â†’ â†“ HR, Caution in obstructive lung diseases\n1 2 1\nare mostly in first part of alphabet cardiac contractility, renin release â†’ (nonselective agents â†’ broncho-\n(Aâ€“M): Atenolol, Acebutolol (partial â†“ effective circulating volume, CO spasm), decompensated HF (â†“\nagonist), Betaxolol, Bisoprolol, â†’ â†“ BP. mortality in compensated HF), heart\nEsmolol, Metoprolol (â€œABEAMâ€). Block Î² on lungs + liver â†’ broncho- block (block Î² â†’ bradycardia), dia-\n2 1\nNon-Zelective (Î² = Î² blockers) are constriction + â†“ portal blood flow betes (commonly used but can mask\n1 2\nmostly in second part of alphabet (useful to treat portal hypertension hypoglycemia), depression.\n(Nâ€“Z): Nadolol, Pindolol (partial in cirrhosis patients). Sleep disturbances (insomnia), fatigue,\nagonist), Propranolol, Timolol. erectile dysfunction, â†“ HDL, â†‘ TGs.\nNonselective Î²- and Î±-blockers Overdose treatment: glucagon.\n(Î² = Î² â‰¥ Î± > Î±) have a modi-\n1 2 1 2\nfied suffix (instead of â€œ-ololâ€):\ncarvedilol, labetalol.\nACEIs + ARBs ACEIs: end in pril (lisinopril, captopril). ACEI: inhibit angiotensin I â†’ angio- ACEI â†’ â†‘ bradykinin â†’ cough + angio-\n+ related Please celebrate April as national tensin II conversion = vasodilation + edema. ARBs have less risk.\nagents ACEI month. â†“ aldosterone â†’ â†‘ Na+/HO excre- ACEI, ARBs, Aliskiren â†’ â†“ GFR (acute\n2\nARBs: end in sartan (losartan, tion â†’ â†“ BP. renal failure) as efferent arteriole vaso-\nvalsartan). ARBs: inhibit angiotensin II receptor â†’ constriction controlled by angiotensin\nEntresto = valsartan/sacubitril same as e",
      "char_start": 188000,
      "char_end": 190000
    },
    {
      "chunk_id": 95,
      "text": "arlier. II. â†“ aldosterone â†’ â†‘ K+.\n(inhibits neprilysin). Neprilysin inhibition â†’ â†‘ angiotensin II Renal teratogens, cause rash.\nAliskiren = direct renin inhibitor. (pair w/ ARB) + â†‘ natriuretic peptides *Entrestoâ€™s main side effects = ARBs.\n(A/BNP).\nAliskiren inhibits renin â†’ â†“ angioten-\nsinogen conversion â†’ angiotensin\nI â†’ â†“ angiotensin II + aldosterone â†’\ndiuresis + â†“ BP.\nCCBs Dihydropyridine CCBs (amlodipine, Block voltage-dependent L-type Ca2+ Gingival hyperplasia.\nnifedipine) = more selective for channels in cardiac (â†“ HR, contrac- Dihydropyridines â†’ vasodilation â†’\nvascular smooth muscle. tility) + vascular smooth muscle (â†“ headache, flushing, peripheral edema,\nNondihydropyridine CCBs (diltiazem, BP) to varying degrees. reflex tachycardia (may coadminister\nverapamil) = more selective for Î²-blocker).\ncardiac muscle. Nondihydropyridines: âŠ– inotropes â†’\nprecipitate HF, AV block, â†“ HR/con-\ntractility, verapamil (constipation, â†‘\nprolactin).\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6611 1100//2211//2222 44::0055 PPMM\n\n62 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-21. Major Classes of Antihypertensive Agents, Mechanism of Actions, and Adverse Effects (continued)\nCLASS AGENTS MECHANISM OF ACTION ADVERSE EFFECTS\nÎ±-Antagonists Common -osin suffix: prazosin, Block Î± â†’ inhibits smooth muscle Although any anti-HTN agent can cause\n1 1\ndoxazosin, terazosin, alfuzosin, contraction in vasculature (â†“ BP) + postural hypotension, these agents\ntamsulosin. bladder/prostate (â†‘ urine flow). are notorious. Headache, dizziness,\nreflex tachycardia (may coadminister\nÎ²-blocker).\nTamsulosin = uroselective = less â†“ BP.\nÎ±-Agonists Methyldopa (a drug of choice in Stimulate presynaptic CNS Î± receptors Clonidine â†’ â†“ sympathetic response\n2 2\npregnancy), clonidine. â†’ âŠ– feedback â†’ â†“ norepinephrine â†’ somnolence, â†“ HR, â†“ respirations,\nâ†’ â†“ BP. miosis. Dry mouth and severe rebound\nHTN with sudden dose stoppage â†’\nâ†‘â†‘â†‘ sympathetic response.\nMethyldop",
      "char_start": 190000,
      "char_end": 192000
    },
    {
      "chunk_id": 96,
      "text": "a: direct Coombs âŠ• warm\nautoimmune hemolytic anemia,\nsedation, drug-induced lupus âŠ•), anti-\nhistone Abs, hyperprolactinemia.\nVasodilators Hydralazine (a drug of choice in Hydralazine â†’ â†‘ NO â†’ â†‘ cGMP â†’ Hydralazine: drug-induced lupus âŠ•\npregnancy), minoxidil. arteriolar vasodilation (â†“ BP). anti-histone Abs, fluid retention,\nMinoxidil â†’ opens K+ channels â†’ reflex tachycardia (may coadminister\nvasodilation (â†“ BP). Î²-blocker). Minoxidil = rogaine =\nhypertrichosis.\nHypertensive Î²-blockers (labetalol or esmolol), Nitroprusside â†’ â†‘ NO â†’ â†‘ cGMP â†’ Nitroprusside prolonged use â†’ cyanide\nemergency CCBs (clevidipine or nicardipine), vein/arteries dilate â†’ â†“ BP. poisoning â†’ inhibition ETC â†’ severe\nagents hydralazine, enalapril, nitroprus- Fenoldopam D1 agonist, arteries dilate, lactic acidosis.\nside and fenoldopam (explained especially in kidneys â†’ maintenance Fenoldopam â†’ vasodilation â†’ head-\nhere). renal perfusion + â†‘ Na+/HO ache, flushing, nausea.\n2\nexcretion â†’ â†“ BP.\nTABLE 2.1-22. Subset of Identifiable Causes of Secondary Hypertension\nCATEGORY DEFINITION\nCardiovascular causes Coarctation of the aorta, aortic regurgitation, pre-eclampsia/eclampsia (vascular issue of placental spiral arteries)\nObstructive sleep apnea Hypoxia â†’ â†‘ sympathetic tone â†’ systemic + later pulmonary hypertension\nDrug-induced Birth control pills = most common cause in young women; exogenous glucocorticoids, stimulants (cocaine),\ndecongestants (contain sympathomimetic agents), TCAs/SNRIs (block norepinephrine reuptake), nicotine,\ncaffeine, NSAIDs (â†“ renal prostaglandin synthesis â†’ â†“ GFR â†’ â†‘ Na+/HO retention)\n2\nEndocrine causes Hyperaldosteronism (eg, Connâ€™s syndrome), hypercortisolism (eg, Cushing disease), pheochromocytoma (eg,\nMEN 2A/B), congenital adrenal hyperplasia, thyroid (hyperthyroidism and hypothyroidism), hyperparathy-\nroidism, acromegaly (â†‘ growth hormone/IGF-1)\nRenal causes Renal artery stenosis = most common (atherosclerosis > fibromuscular dysplasia) overall cause; chronic\nkidney disease al",
      "char_start": 192000,
      "char_end": 194000
    },
    {
      "chunk_id": 97,
      "text": "so very common cause; glomerular diseases (eg, glomerulonephritis, diabetic nephrop-\nathy); polycystic kidney disease\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6622 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 63\nSECONDARY HYPERTENSION MNEMONIC\nCauses of secondary hypertension\nHTN that occurs secondary to an identifiable cause (see Table 2.1-22). Identi-\nCODER\nfiable causes of HTN account for a minority (~5%) of cases. Patients should\nbe worked up for secondary causes of HTN if they are younger (age <35), Cardiovascular cause\nhave a severely elevated or refractory-to-treatment BP, or a specific sign indi- Obstructive sleep apnea\ncating a secondary cause. Drug induced\nEndocrine causes\nRenal causes\nHYPERTENSIVE EMERGENCY/URGENCY\nPresentation KEY FACT\nThe features of severe HTN, hypertensive urgency, and emergency are com-\nHypertensive emergency is diagnosed\npared in Table 2.1-23.\nbased on the presence of hypertension-\ninduced end-organ damage, NOT a\nTreatment\nspecific BP measurement. Generally,\nGoal: A 25% reduction in BP from baseline or <160/100 mm Hg for both however, severe hypertension has an\nhypertensive urgency and emergency. Medications: eg, labetalol, captopril. SBP >180 mm Hg or DBP >120 mm Hg\npresent.\nâ–  Hypertensive urgency: Lower to goal within 24 hours with oral\nmedications.\nâ–  Hypertensive emergency: â†“ mean arterial pressure (MAP) by ~20%\nKEY FACT\nwithin first hour, not exceeding 25% in 24 hours. Do NOT lower too\nquickly or to normal BP, as autoregulation of BP cannot adjust quickly\nCyanide poisoning classically presents\nenough â†’ ischemia (eg, stroke, MI). Classically occurs in a patient with long-\nwith hypertensive emergency after\nstanding HTN who stops medications.\nnitroprusside therapy with altered\nâ–  Medications: Any IV antihypertensive medication can be acceptable, as\nmental status + widespread features\nthe specific drug available is not as important as proper dosing of it to\nof tissue h",
      "char_start": 194000,
      "char_end": 196000
    },
    {
      "chunk_id": 98,
      "text": "ypoxia. Immediately initiate\nmanage BP to goal. Drugs commonly used: Î²-blockers (labetalol or esmo-\nantidote(s):\nlol), CCBs (clevidipine or nicardipine), D1 agonist (fenoldopam), hydral-\nâ–  Hydroxocobalamin (first-line)\nazine, enalapril, nitroprusside (prolonged use â†’ cyanide poisoning â†’\nâ–  Sodium thiosulfate (coadminister\ninhibition of electron transport chain [ETC] â†’ severe lactic acidosis).\nwith hydroxocobalamin)\nâ–  Sodium or amyl nitrate\nTABLE 2.1-23. Presentation of Hypertensive Urgency and Emergency\nCONDITION DEFINITION\nSevere hypertension SBP >180 or DBP >120 mm Hg\nHypertensive urgency Severe hypertension + no end-organ damage* (perhaps\nmild headache)\nHypertensive emergency Severe hypertension + end-organ damagea\na End-organ damage is defined as any of the following manifestations:\nâ–  CNS: Encephalopathy (confusion), stroke, retinal hemorrhage (blurry vision), â†‘ intracerebral\npressure (papilledema).\nâ–  Cardiovascular: Acute coronary syndromes, angina, dyspnea, heart failure, aortic dissection,\nmicroangiopathic hemolytic anemia (MAHA) (endothelial injury â†’ thrombus â†’ MAHA; mostly\nhistorical).\nâ–  Key pathologic finding: Hyperplastic arteriosclerosis â†’ widespread ischemia.\nA 20-year-old man presents with\nâ–  Renal: Acute kidney injury, hematuria, proteinuria.\nan initial BP of 150/85 mm Hg, and\nrepeat measurement yields 147/85\nmm Hg. The patientâ€™s potassium level\nis 3.2 mg/dL. What is the next best\ndiagnostic step?\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6633 1100//2211//2222 44::0055 PPMM\n\n64 HIGH-YIELD FACTS IN CARDIOVASCULAR\nA KEY FACT\nPERICARDIAL DISEASE\nPericardial calcification seen on\nThe pericardium is a fibroelastic sac made up of visceral and parietal layers CXR strongly suggests constrictive\nseparated by a potential space, the pericardial cavity. In healthy individuals, pericarditis due to chronic fibrosis and\nthe pericardial cavity contains 30 to 50 mL of an ultrafiltrate of plasma. calcification of the pericardium",
      "char_start": 196000,
      "char_end": 198000
    },
    {
      "chunk_id": 99,
      "text": ".\nDiseases of the pericardium present as acute pericarditis, constrictive peri-\ncarditis, pericardial effusion, and cardiac tamponade.\nACUTE PERICARDITIS\nAcute pericarditis refers to inflammation of the pericardial sac. It may be\neither the first manifestation of an underlying systemic disease or represent an\nB\nisolated process. Etiologies include:\nâ–  Idiopathic\nâ–  Infectious (most common infection, likely etiology Coxsackie B virus,\nRV Staphylococcus, Streptococcus, tuberculosis [TB])\nâ–  Connective tissue disorder (ie, systemic lupus erythematosus [SLE], rheu-\nmatoid arthritis, Goodpasture syndrome)\nLV\nâ–  Post-MI (either within days after MI or as a delayed phenomenon, ie,\nDressler syndrome)\nâ–  Uremia\nâ–  Neoplasms\nâ–  Drugs\nFIGURE 2.1-24. Radiographic findings â–  Radiation\nin pericarditis. (A) MRI demonstrates an\nâ–  Trauma or open heart surgery (Fig. 2.1-24).\neffusion (yellow arrows) within the peri-\ncardial sac (red arrows). Pericardial effu- Acute pericarditis can compromise cardiac output via tamponade (extrava-\nsion is diagnosed when the pericardial\nsation of large amounts of fluid secondary to pericarditis) or constrictive peri-\nspace is >3 to 4 mm in diameter (a nor-\ncarditis (chronic pericarditis).\nmal pericardial space has 30â€“50 mL of\nfluid, and this space is â‰¤2 mm in diam-\neter). (B) Echocardiography showing History/PE\npericardial effusion (red arrows). (Image A\nâ–  Presentation: Sharp pleuritic chest pain, dyspnea, cough, and fever.\nadapted with permission from Bogaert J, Francone\nM. Cardiovascular magnetic resonance in pericardial â–  Key feature: Chest pain tends to worsen in the supine position and with\ndiseases. J Cardiovasc Magn Reson. 2009;11[1]:14. inspiration. Classically, patient is seen sitting up (pain improves in prone\ndoi:10.1186/1532-429X-11-14. Image B adapted with position) and bending forward.\npermission from Yousuf T, Kramer J, Kopiec A, et al. A â–  Exam: May reveal a pericardial friction rub. Elevated JVP, tachycardia,\nrare case of cardiac tamponade i",
      "char_start": 198000,
      "char_end": 200000
    },
    {
      "chunk_id": 100,
      "text": "nduced by chronic\nmuffled S and S , and pulsus paradoxus (â†“ in SBP >10 mm Hg on inspi-\nrheumatoid arthritis. J Clin Med Res. 2015;7[9]:720â€“723. 1 2\nration) can be present with pericardial tamponade. Kussmaul sign can be\ndoi:10.14740/jocmr2226w.)\npresent with constrictive pericarditis.\nDiagnosis\nâ–  ECG:\nâ–  Stage 1: Diffuse ST-segment elevation (concave or saddle shaped) and\nPR-segment depressions.\nâ–  Stage 2: Normalization of ST segment and PR-segment changes.\nâ–  Stage 3: Development of diffuse T-wave inversions (Fig. 2.1-25). Typi-\ncally seen after ST segment becomes iso-electric.\nA hyperaldosteronism workup with â–  Stage 4: Normalization of ECG.\nserum aldosterone and renin levels is â–  CXR: Cardiomegaly may indicate a pericardial effusion.\nan appropriate next best diagnostic\nstep.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6644 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 65\nKEY FACT\nPERICARDIAL DISEASE I aVR V V\n1 4 ST\nPR\nPericardial calcification seen on\nThe pericardium is a fibroelastic sac made up of visceral and parietal layers CXR strongly suggests constrictive\nST\nseparated by a potential space, the pericardial cavity. In healthy individuals, pericarditis due to chronic fibrosis and\nthe pericardial cavity contains 30 to 50 mL of an ultrafiltrate of plasma. II aVL V 2 V 5 PR calcification of the pericardium.\nDiseases of the pericardium present as acute pericarditis, constrictive peri-\ncarditis, pericardial effusion, and cardiac tamponade.\nACUTE PERICARDITIS III aVF V 3 V 6\nAcute pericarditis refers to inflammation of the pericardial sac. It may be\neither the first manifestation of an underlying systemic disease or represent an\nisolated process. Etiologies include:\nFIGURE 2.1-25. Acute pericarditis. Diffuse ST-segment elevations in multiple leads not con-\nsistent with any discrete coronary vascular territory and PR-segment depressions. (Reproduced with\nâ–  Idiopathic\npermission from USMLE-Rx.com.)\nâ–  Infect",
      "char_start": 200000,
      "char_end": 202000
    },
    {
      "chunk_id": 101,
      "text": "ious (most common infection, likely etiology Coxsackie B virus,\nStaphylococcus, Streptococcus, tuberculosis [TB])\nâ–  Connective tissue disorder (ie, systemic lupus erythematosus [SLE], rheu-\nmatoid arthritis, Goodpasture syndrome) â–  Blood tests: Full blood count (FBC), ESR, urea and electrolytes (U&Es), KEY FACT\nâ–  Post-MI (either within days after MI or as a delayed phenomenon, ie, cardiac enzymes (troponin may be raised), viral serology, and if indicated, ST-segment elevations in pericarditis\nDressler syndrome) autoantibodies, fungal precipitins, and thyroid function tests (TFTs).\nare differentiated from MI in that\nâ–  Uremia â–  Echo: Pericardial thickening or effusion may be evident. they are not localized to one region\nâ–  Neoplasms of the heart; widespread ST-segment\nâ–  Drugs Treatment elevations are seen.\nâ–  Radiation\nGoal of treatment is pain relief, resolution of inflammation, and prevention of\nâ–  Trauma or open heart surgery (Fig. 2.1-24).\nrecurrence.\nAcute pericarditis can compromise cardiac output via tamponade (extrava-\nsation of large amounts of fluid secondary to pericarditis) or constrictive peri- â–  Activity restriction: Patients should be instructed to restrict strenuous phys-\nical activity until symptoms have resolved and biomarkers have\ncarditis (chronic pericarditis).\nnormalized.\nHistory/PE â–  NSAIDs + colchicine: For patients with idiopathic or viral pericarditis.\nâ–  Glucocorticoids should be used for initial treatment of acute pericarditis\nâ–  Presentation: Sharp pleuritic chest pain, dyspnea, cough, and fever. only in patients with contraindications to NSAIDs or for specific indica- KEY FACT\nâ–  Key feature: Chest pain tends to worsen in the supine position and with tions (SLE, renal failure). Avoid corticosteroids within a few days after MI,\ninspiration. Classically, patient is seen sitting up (pain improves in prone as they can predispose to ventricular wall rupture. Consider uremic pericarditis in a\nposition) and bending forward. â–  For patients in whom etio",
      "char_start": 202000,
      "char_end": 204000
    },
    {
      "chunk_id": 102,
      "text": "logy for pericarditis is known, specific treatment for patient with end-stage renal disease\nâ–  Exam: May reveal a pericardial friction rub. Elevated JVP, tachycardia, the underlying cause is indicated (dialysis in uremia, ASA for post-MI pericar- and azotemia. It is characterized by\nmuffled S 1 and S 2 , and pulsus paradoxus (â†“ in SBP >10 mm Hg on inspi- ditis, corticosteroids/immunosuppression for SLE-related pericarditis). prominent fibrin deposition but no\nration) can be present with pericardial tamponade. Kussmaul sign can be â–  When acute symptoms are resolved, NSAIDs are tapered weekly to reduce epicardial inflammation; thus classical\npresent with constrictive pericarditis. recurrence rate, and colchicine is used for a total duration of 3 months. ECG changes (diffuse ST elevation, PR\ndepression) are not seen. Treatment is\nDiagnosis with hemodialysis.\nCONSTRICTIVE PERICARDITIS\nâ–  ECG:\nâ–  Stage 1: Diffuse ST-segment elevation (concave or saddle shaped) and\nConstrictive pericarditis is the result of scarring and consequent loss of the\nPR-segment depressions.\nnormal elasticity of the pericardial sac. Typically, it is chronic in nature.\nâ–  Stage 2: Normalization of ST segment and PR-segment changes.\nâ–  Stage 3: Development of diffuse T-wave inversions (Fig. 2.1-25). Typi- History/PE\ncally seen after ST segment becomes iso-electric.\nâ–  Stage 4: Normalization of ECG. â–  Presents with symptoms suggesting fluid overload (edema of lower limbs\nand ascites) and low cardiac output (fatiguability and dyspnea on\nâ–  CXR: Cardiomegaly may indicate a pericardial effusion. exertion).\nâ–  Clinical exam: JVD, hepatosplenomegaly, Kussmaul sign, and pericardial\nknock (produced from heart hitting the calcified pericardium in diastole).\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6655 1100//2211//2222 44::0055 PPMM\n\n66 HIGH-YIELD FACTS IN CARDIOVASCULAR\nDiagnosis\nâ–  Echocardiography: Should see septal bounce, respiratory septal shift, peri-\ncardial thicken",
      "char_start": 204000,
      "char_end": 206000
    },
    {
      "chunk_id": 103,
      "text": "ing, and a decrease in ventricular filling flow during\ninspiration.\nâ–  CXR: May show calcifications around the cardiac silhouette.\nâ–  CT scan shows thickened pericardium.\nâ–  ECG may show low-voltage complexes.\nTreatment\nâ–  Diuretics to control edema and ascites.\nâ–  Medical management with NSAIDs and colchicine if features are mild.\nâ–  Pericardial stripping (ie, surgical removal of the pericardium) is the\ndefinitive management. Performed if patient fails medical management or\nif he or she has severe symptoms.\nPERICARDIAL EFFUSION\nPericardial effusion is characterized by an increased amount of fluid in the\npericardial cavity. Many patients with pericardial effusion are asymptomatic,\nand the effusion is detected incidentally. Common causes include idiopathic\n(most common), malignancy, infections, autoimmune disease, hypothyroid-\nism, ascending aortic dissection, anticoagulants, and medication. In countries\nwhere TB is endemic, more than 60% of effusions are due to TB.\nHistory/PE\nâ–  Patient may present with signs suggestive of acute pericarditis.\nâ–  Important to obtain history for recent illnesses, malignancy, history of TB\nand vaccination status, autoimmune disorders, history of CKD or renal\nfailure, or history of CHF, hypothyroidism, or liver disease.\nâ–  Physical exam may show muffled/distant heart sounds.\nâ–  Ewart sign/dullness to percussion at the base of the left inferior scapular\nFIGURE 2.1-26. Pericardial effusion. border in conjunction with tubular breath sounds and egophony.\nWater bottleâ€“shaped heart seen on CXR\nwith pericardial effusion. (Reproduced with\npermission from Chen MY et al. Basic Radiology, 2nd Diagnosis\ned. New York, NY: McGraw-Hill; 2011.)\nâ–  CXR may show an enlarged, globular, water bottleâ€“shaped heart with a\nlarge effusion (Fig. 2.1-26).\nâ–  Cardiac echo may show increased fluid in pericardial space. On CT imag-\ning, pericardial effusion is diagnosed when the pericardial space is >3 to 4\nmm in diameter (a normal pericardial space has 30â€“50 mL of fluid and is",
      "char_start": 206000,
      "char_end": 208000
    },
    {
      "chunk_id": 104,
      "text": "\nequal to or less than 2 mm in diameter).\nâ–  If present on ECG, electrical alternans (due to swinging motion of heart\nin fluid filled cavity) is diagnostic of a large pericardial effusion (Fig.\n2.1-27).\nTreatment\nFIGURE 2.1-27. Electrical alternans,\nwhere voltage of QRS changes with\nâ–  Treatment focused on the cause of the disease.\neach beat. If seen, diagnostic of peri-\ncardial effusion. (Modified with permission â–  In patients with pericardial effusion of unknown cause and elevated\ninflammatory markers, empiric treatment for pericarditis is reasonable.\nfrom Maharaj SS, Chang SM. Cardiac tamponade\nas the initial presentation of systemic lupus erythe- â–  If cancer or bacterial infection is suspected, pericardiocentesis with or\nmatosus: A case report and review of the literature. without a pericardial biopsy is recommended.\nPediatr Rheumatol Online J. 2015;13:9. doi: 10.1186/\ns12969-015-0005-0.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6666 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 67\nâ–  If idiopathic effusions are present for more than 3 months, pericardial\ndrainage should be considered, as the likelihood to convert into cardiac\ntamponade is high in these individuals.\nâ–  In patients with symptoms suggestive of cardiac tamponade, immediate\npericardial drainage is advised (Cardiac Tamponade section to follow).\nCARDIAC TAMPONADE\nExcess fluid in the pericardial sac â†‘ the intrapericardial pressure, leading to\ncompromised ventricular filling and â†“ cardiac output. The rate of fluid for-\nmation is more important than the size of the effusion. Risk factors include\npericarditis, malignancy, SLE, TB, and trauma (commonly stab wounds\nmedial to the left nipple).\nHistory/PE\nâ–  Presents with fatigue, dyspnea, anxiety, tachycardia, and tachypnea that\ncan rapidly progress to shock and death.\nâ–  Exam of a patient with acute tamponade may reveal Beck triad (hypoten-\nsion, distant or muffled S and S heart sounds, and JVD), a ",
      "char_start": 208000,
      "char_end": 210000
    },
    {
      "chunk_id": 105,
      "text": "narrow pulse\n1 2\npressure, and pulsus paradoxus.\nâ–  Lung fields are clear on exam (high yield and frequently tested in CK).\nKEY FACT\nDiagnosis\nâ–  Echo is diagnostic and shows right atrial and right ventricular diastolic col- Beck triad can diagnose acute cardiac\nlapse and echo-free zone around the heart. tamponade:\nâ–  Right heart catheterization will show equalization of all the pressures (RA, â–  JVD\nRV, pulmonary capillary wedge pressure [PCWP]) in the heart during â–  Hypotension\ndiastole. â–  Distant heart sounds\nTreatment\nâ–  Aggressive volume expansion with IV fluids.\nâ–  Urgent pericardiocentesis (aspirate will be nonclotting blood) with a peri-\ncardial drain. Send fluid to lab analysis to determine etiology.\nâ–  If significant drainage continues for more than 3 to 4 days or if effusions\nare recurrent, a pericardial window should be considered.\nENDOCARDITIS\nEndocarditis is inflammation of the endocardium, the inner layer of the heart\noverlying the valves. It has noninfective (NBTE) and infective (bacteria/fungi)\ncauses. Infective endocarditis (IE) is the consequence of bacteremia (dental\nprocedures, injections, surgery) and usually causes tricuspid, mitral, and aor-\ntic valve lesions, resulting in regurgitation. Acute IE occurs over hours to\ndays, whereas subacute IE progresses over weeks to months. Causes are dis-\ncussed in Table 2.1-24.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6677 1100//2211//2222 44::0055 PPMM\n\n68 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-24. Etiologies of Endocarditis\nPROSTHETIC VALVE NON-BACTERIAL THROMBOTIC ENDOCARDITIS\nNATIVE VALVE (HIGHEST RISK) IVDUS (NBTE)\nViridans streptococci (most common, <60 days surgery: S aureus (most common) Causes of NBTE:\ndamaged valves) Early-onset causes (Staph- Enterococci Immune complexes\nStaphylococcus aureus (highly viru- ylococcus epidermidis Streptococci Hypoxia\nlent, undamaged valves) >> S aureus) Fungus (Candida, Asper- Hypercoagulability\nStreptococcus gallolyticus",
      "char_start": 210000,
      "char_end": 212000
    },
    {
      "chunk_id": 106,
      "text": " (S bovis >60 days surgery: gillus [may see in HIV/ Carcinomatosis\ntype 1 â†’ colonoscopy) Late-onset causes AIDS patient]) Key terms of NBTE:\nClostridium septicum â†’ colonoscopy (Streptococci) Pseudomonas Cancer/illnesses â†’ Marantic NBTE\nEnterococci spp. (older men after GI/ Lupus â†’ verrucous or Libman-Sacks\nGU procedure) NBTE (both sides of valvea)\nCulture âŠ– organisms, Coxiella bur- Key presentation/finding:\nnetii (farm exposure), Bartonella Asymptomatic, found on autopsy. Symp-\nquintana/henselae (lice/cat), Cuti- tomatic â†’ sterile lesions of thrombus\nbacterium acnes Brucella (farm), + immune complexes on left-sided\nMycobacteria (aerosolized particles), valves (most common) embolize â†’\nTropheryma whipplei (farm exposure) systemic circulation.\nHACEK (no longer culture [â€“] causes of Treatment: Anticoagulation\nIE with modern culture techniques)\naNBTE and infective causes of endocarditis usually infect and cause lesions on one side of the valve.\nSelect organisms from Table 2.1-24:\nâ–  Staphylococcus aureus: Gram/catalase/coagulase âŠ• cocci â†’ Use of IV\ndrugs may result in cocci from skin being introduced into veins â†’ high\nvirulence â†’ attacks normal right-sided heart valves (tricuspid valve â†’ tri-\ncuspid regurgitation). Most common cause of acute IE in all patients (fatal\nwithout treatment in 6 weeks). Infects any heart valve (Fig. 2.1-28A).\nâ–  Staphylococcus epidermidis: Gram/catalase âŠ• and coagulase âŠ– cocci of\nskin flora. Low virulence â†’ usually need prosthetic heart valves to cause\nIE.\nâ–  Viridans streptococci (S mitis, S mutans, S sanguinis): Gram âŠ• and cata-\nlase âŠ– cocci of oral flora. Most common cause of subacute endocarditis.\nDental procedure â†’ bacteremia â†’ low virulence â†’ Viridans produce\ndextrans â†’ dextrans adhere to fibrin on damaged valve â†’ IE.\nâ–  Streptococcus gallolyticus (S bovis type 1) and Clostridium septicum are\ngram âŠ• cocci and rods, respectively, normally found in the GI tract. If\neither one causes IE, a colonoscopy is indicated because both are associ-\nated ",
      "char_start": 212000,
      "char_end": 214000
    },
    {
      "chunk_id": 107,
      "text": "with colonic pathology, especially colon cancer.\nâ–  Enterococci: Gram âŠ• cocci normally found in the GI tract. After GI or\ngenitourinary (GU) procedures (abdominal surgery, urinary catheter,\ntransurethral resection of prostate for benign prostatic hypertrophy [BPH])\nâ†’ subacute endocarditis in older men.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6688 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 69\nâ–  HACEK: Haemophilus species (subsequently called Aggregatibacter\naphrophilus + Aggregatibacter paraphrophilus); Actinobacillus actinomy-\ncetemcomitans (subsequently called Aggregatibacter actinomycetemcomi-\ntans); Cardiobacterium hominis; Eikenella corrodens; and Kingella kingae.\nNormal flora of oropharyngeal region that typically cause subacute IE\nassociated with poor dental hygiene/procedures. No longer considered\nimportant causes of culture âŠ– IE with modern culture techniques.\nâ–  Candida + Aspergillus fumigatus: Most common causes of fungal endo-\ncarditis typically in immunocompromised patients (HIV/AIDS, trans-\nplant), IV drug use (IVDUs), long-term IV catheter use.\nâ–  Culture negative IE: Most common manifestation of chronic Q fever\n(Coxiella burnetii). Bartonella quintana Gram âŠ– rod â†’ lice spread â†’\nindividuals with poor hygeine.\nHistory/PE\nâ–  IE should be suspected in any patient with unexplained fever(s) Â± bacte-\nMNEMONIC\nremia and a new regurgitant heart murmur of the tricuspid, mitral, or aor-\ntic valve. Fulminant HF due to severe regurgitant lesions may also occur.\nPresentation of Infective\nâ–  Septic emboli: Coronary artery (MI), brain (stroke), spinal cord (paraly- Endocarditisâ€”\nsis), eye (blindness), extremities (septic arthritis), splenic/renal infarctions,\nFROM JANE with â™¥\nPE (from tricuspid lesions), mycotic aneurysm, abscesses, Janeway lesions\n(painless erythematous microabscesses on palms/soles). Fever\nâ–  Immune phenomena: Eyes (Roth spots = oval red retinal lesions with Roth spots\nOsler nodes (pain",
      "char_start": 214000,
      "char_end": 216000
    },
    {
      "chunk_id": 108,
      "text": "ful, â€œOuchler nodesâ€)\nclear/pale center; see Fig. 2.1-28B), glomerulus (signs/symptoms of glo-\nMurmur\nmerulonephritis), Osler nodes (painful/raised lesions on digits/feet;\nJaneway lesions (â€œMary Jane is painlessâ€)\nâ€œOuchler nodes,â€ see Fig. 2.1-28C), splinter hemorrhages (vasculitis\nAnemia of chronic disease\nunderneath fingernails that follows direction of growth, see Fig. 2.1-28D),\nNail hemorrhage\nrheumatoid factor.\nEmboli\nâ–  Paravalvular abscess: Persistent fever + bacteremia despite treatment â†’\nparavalvular abscess formation. Notably, paravalvular abscess of aortic\nvalve â†’ new-onset AV block on ECG.\nA B C D\nFIGURE 2.1-28. Features of infective endocarditis. (A) Large vegetations due to Haemophilus parainfluenzae; (B) Roth spots on the retina; (C)\nOsler nodes; (D) splinter hemorrhages. (Image A adapted with permission from The US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr. Image C Yang\nML, Chen YH, Lin WR, et al. Case report: infective endocarditis caused by Brevundimonas vesicularis. BMC Infect Dis. 2006;6:179. DOI: 10.1186/1471-2334-6-179. Images B and D reproduced\nwith permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 6699 1100//2211//2222 44::0055 PPMM\n\n70 HIGH-YIELD FACTS IN CARDIOVASCULAR\nDiagnosis\nâ–  CBC with leukocytosis and left shift,â†‘ ESR and C-reactive protein (CRP)\nmay be seen.\nâ–  Duke clinical criteria (see mnemonic and Table 2.1-25). Two major, one\nmajor + three minor, or five minor criteria must be present to diagnose IE.\nâ–  Best initial test: Blood culture (95%â€“99% sensitive).\nâ–  Best imaging test: TEE (95% sensitive/specific) > TTE (60% sensitive,\n95%â€“100% specific) in diagnosing endocarditis. Most patients should first\nget a TTE as initial screening test.\nMNEMONIC â–  ECG not routinely used. If treatment failures, aortic paravalvular abscess\nâ†’ new AV block.\nDuke Criteria Mnemonic:\n\"BE Duke fivor\"\nTreatment\nStep 1:\nâ–  Capital letters = Major Criteria. â–  General guide",
      "char_start": 216000,
      "char_end": 218000
    },
    {
      "chunk_id": 109,
      "text": "lines: At least two, preferably three, sets of blood cultures\nâ–  Lowercase letters = minor criteria. should be drawn prior to initiating antibiotics, generally even in acutely ill\nâ–  The number/type of letters in each word patients. If empiric antibiotics are given for native or prosthetic valve endo-\nthen represents a diagnostic category:\ncarditis, the best initial treatment is vancomycin Â± gentamicin or another\nâ–  Two Major Criteria (BE).\nantibiotic. Blood culture results are used to tailor therapy. Antibiotics are\nâ–  One Major + three minor (Duke) or five\ndelivered parenterally for 4 to 6 weeks for left-sided lesions and 2 weeks for\nminor criteria (fivor)\nStep 2 right-sided lesions, and are targeted toward the specific microorganism\n(Table 2.1-26).\nâ–  BE: (Bacteremia [blood cultures] +\nEndocardial involvement [echo or â–  Surgical considerations: Early surgical consultation + intervention is con-\nmurmur]) = Major Criteria sidered with\nâ–  Duke (diagnostic category, name of â–  Valvular damage â†’ acute HF\ncriteria) â–  Fungal IE\nâ–  fivor: (fever, immune phenomena, â–  Left-sided IE with highly resistant microbes (eg, methicillin-resistant S\nvascular phenomena, organism cultures aureus [MRSA])\nnot meeting major criteria, risk factors) â–  Persistent fever or bacteremia 5 to 7 days post-antibiotic treatment\n= minor criteria\nâ–  Prosthetic valves\nâ–  Antibiotics cannot penetrate large vegetations: Vegetation >15 mm or\nvegetation >10 mm + systemic emboli\nâ–  Perivalvular extension (eg, paravalvular abscess: aortic paravalvular\nabscess â†’ new-onset AV block), pseudoaneurysm, or fistula formation\nTABLE 2.1-25. Duke Clinical Criteria for the Diagnosis of Infective Endocarditis\nCRITERIA COMPONENTS MNEMONIC\nMajor 1. Bacteremia (one of the following): two separate âŠ• blood cultures of typical IE organisms (Staphylococcus, Strep- BE\ntococcus, enterococci, HACEK) or persistently âŠ• blood cultures (at least two samples drawn >12 hours apart for\ntypical IE organisms or three or majority of >4 separate blo",
      "char_start": 218000,
      "char_end": 220000
    },
    {
      "chunk_id": 110,
      "text": "od cultures for typical skin contaminant organisms\nwith the first and last drawn at least 1 hour apart) or single âŠ• blood culture or phase IgG antibody titer for Coxi-\nella burnetii.\n2. Endocardial involvement (one of the following): echocardiogram evidence of vegetation, abscess, valve perfo-\nration, or prosthetic dehiscence or new valvular regurgitation murmur\nMinor 1. Fever â‰¥38Â°C (100.4Â°F) fivor\n2. Immune phenomena: glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor\n3. Vascular phenomena: septic arterial/pulmonary emboli, mycotic aneurysm, intracranial/conjunctival hemor-\nrhages, Janeway lesions\n4. Organism culture not meeting major criteria or serologic evidence of active infection with IE organism\n5. Risk factors: abnormal risk of bacteremia (IVDUs) or abnormal heart (prosthetic valve or lesion with significant\nregurgitation)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7700 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 71\nTABLE 2.1-26. Targeted Treatment Regimens for Infective Endocarditis\nBLOOD CULTURE âŠ• FORâ€¦ POSSIBLE TREATMENT REGIMENS\nMethicillin-susceptible staphylo- Oxacillin, nafcillin, or cefazolin â†’ native valve\ncocci (coagulase âŠ– or âŠ•) Oxacillin or nafcillin Â± gentamicin, rifampin â†’ prosthetic\nvalve\nMethicillin-resistant staphylococci Vancomycin â†’ native valve\n(coagulase âŠ– or âŠ•) Vancomycin Â± gentamicin, rifampin â†’ prosthetic valve\nFungus Amphotericin + valve replacement\nEnterococcus spp. E faecalis (usually penicillin sensitive) â†’ ampicillin +\ngentamicin\nE faecium (usually penicillin resistant) â†’ vancomycin +\ngentamicin\nViridans streptococci, S. Ceftriaxone Â± gentamicin\ngallolyticus\nHACEK First line is ceftriaxone\nBLOOD CULTURE âŠ– FORâ€¦\nCoxiella, Bartonella Ceftriaxone\nProphylaxis\nProphylactic antibiotics may be indicated to prevent IE in certain patients at\nhigh risk of poor outcomes. These are discussed in Table 2.1-27.\nTABLE 2.1-27. Indications for Endocarditis Antibiotic Prophy",
      "char_start": 220000,
      "char_end": 222000
    },
    {
      "chunk_id": 111,
      "text": "laxis\nMUST HAVE ONE AND MUST HAVE ONE\nQUALIFYING CARDIAC INDICATION QUALIFYING PROCEDURE INDICATION\nProsthetic heart valve(s) Dental â†’ bleeding (even cleanings)\nHistory of infective endocarditis (scarring â†‘ Respiratory â†’ bleeding (biopsy/incision)\nvulnerability) Skin/musculoskeletal tissue â†’ bleeding\nCongenital heart disease (unrepaired cya- (biopsy/incision)\nnotic CHD or repaired with prosthetic Cardiac surgery with prosthetic material\nmaterial in last 6 months)\nCardiac transplant with valvulopathy\nIf patient has one qualifying cardiac + one qualifying procedure indication â†’ antibiotic\nprophylaxis is recommended 30 to 60 minutes prior to indicated procedure (eg, amoxicillin is\nfirst-line for dental procedure; allergy â†’ macrolide, cephalexin, or doxycycline). Prophylaxis is\nNOT recommended for native mitral stenosis/mitral valve prolapse or routine GI endoscopy or GU\ncystoscopy.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7711 1100//2211//2222 44::0055 PPMM\n\n72 HIGH-YIELD FACTS IN CARDIOVASCULAR\nVALVULAR HEART DISEASE\nKEY FACT\nSubtypes of valvular heart disease appear in Table 2.1-28 along with their spe-\nMitral regurgitation classically occurs cific etiologies, presentations, diagnoses, and treatments. Overarching high-\nsecondary to posteromedial papillary yield concepts for all valvular diseases are briefly presented.\nmuscle rupture 2 to 7 days after a\nâ–  Identification: Murmur descriptions are usually the most specific identifi-\nposterior descending coronary artery\ners in questions. Right-sided murmurs increase in intensity with inhalation\nMI due to its singular blood supply.\n(like sipping a straw, this increases venous return), whereas left-sided mur-\nConversely, anterolateral papillary\nmurs decrease with inhalation. Exhalation is the exact opposite.\nmuscle rupture is 6 to12 times less\nâ–  Rheumatic heart disease can cause any valvular disease. Mitral stenosis is\nlikely due to its dual blood supply from\nmost common.\nthe left",
      "char_start": 222000,
      "char_end": 224000
    },
    {
      "chunk_id": 112,
      "text": " anterior descending + left\nâ–  Best initial test: Echocardiogram. TTE is less invasive; TEE is more sensitive/specific.\ncircumflex arteries.\nâ–  Most accurate test: Cardiac catheterization, which measures valvular\ndiameters and pressure gradients.\nâ–  Not ECG/x-ray: Often listed as answer distractions. Both can indicate\nchamber enlargement.\nKEY FACT\nBroad treatment guidelines:\nMany cardiovascular conditions have â–  Endocarditis prophylaxis is only for replaced valves or valves with previ-\nan increased risk during pregnancy. ous endocarditis.\nFor example, pregnancy is not advised â–  Diuretics are helpful for fluid overload that can occur in all forms of val-\nwith severe obstructive valvular vular heart diseases.\nlesions (mitral stenosis, aortic stenosis), â–  Surgery is indicated only for symptomatic + severe valvular disease.\nsymptomatic HF with EF <30%, â–  Severe stenotic lesions are treated with surgery to restore functional anatomy.\nunstable/dilated aorta (eg, Marfan â–  Severe regurgitant lesions can initially be treated with vasodilators to\nsyndrome), and pulmonary HTN. decrease afterload and encourage forward blood flow. Surgery is done\nprior to significant dilatation of the heart.\nTABLE 2.1-28. Types, Etiologies, Clinical Features, and Diagnosis/Treatment of Valvular Lesions\nTYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS/TREATMENT\nAortic Stenosis (AS) Senile AS Signs/Symptoms Diagnosis\nMost common Asymptomatic: Years despite severe stenosis Severity categorized based on\nDystrophic calcification of a Symptomatic: Angina, Syncope, CHF (ASC), pressure gradient across aortic\ntricuspid valve in order of worsening prognosis without valve or valve area into mild\nElderly >60 years of age treatment (15â€“25 mm Hg, >1.5 cm2), mod-\nBicuspid AS Murmur: Harsh systolic crescendo-decrescendo erate (25â€“40 mm Hg, 1.0â€“1.5\nCongenital, Turner disease murmur, heard best at the second right inter- cm2), severe (>40 mm Hg,\nDystrophic calcification of a costal space, radiates to carotids, paradoxica",
      "char_start": 224000,
      "char_end": 226000
    },
    {
      "chunk_id": 113,
      "text": "l 0.7â€“1.0 cm2) or critical (<0.7 cm2)\nbicuspid valve splitting due to delayed LV outflow TTE is best initial test\n<60 years of age Increase murmur = Increase venous return and Severity of stenosis can also be\nRheumatic heart disease decrease afterload assessed from TTE\n(RHD) AS Severe AS: Soft, single S2 as cusp movement Treatment\nDistinguished by commis- becomes more restricted; pulsus parvus et Based on severity\nsure fusion tardus (weak/delayed carotid upstroke); late- Asymptomatic: No treatment\npeaking murmur; LVH develops â†’ LV dilates Severe stenosis with symptoms\nonce cannot compensate â†’ heart failure or LVEF <50% or other planned\nwithout treatment cardiac surgery: surgical valve\nreplacement or transcatheter\naortic valve replacement\n(TAVR), which is the superior\noption in appropriate patients\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7722 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 73\nTABLE 2.1-28. Types, Etiologies, Clinical Features, and Diagnosis/Treatment of Valvular Lesions (continued)\nTYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS/TREATMENT\nAortic Causes of AR: Signs/Symptoms Diagnosis\nRegurgitation Root Dilation Acute (aortic dissection, endocarditis) â†’ shock TTE is best initial test\n(AR) or Aortic Inflammation (syphilis, Chronic: Angina, palpitations, heart failure Treatment\nInsufficiency ankylosing spondylitis), Murmur: Early blowing decrescendo diastolic Acute AR: Emergent\ntrauma, aortic dissection, murmur, heard best at third left intercostal valve surgery\nMI, HTN-induced/Marfan- space Chronic AR: Use of vasodilators\nrelated aortic aneurysm May also hear Austin Flint murmur at apex to decrease afterload, but they\nValve Disease Increase murmur = Increase venous return and donâ€™t delay progression\nRHD, bicuspid valve (AS > increase afterload Serial TTEs are done to monitor\nAR), connective tissue Wide pulse pressure is central to AR: Blood LV dilation and need for valve\ndisorders,",
      "char_start": 226000,
      "char_end": 228000
    },
    {
      "chunk_id": 114,
      "text": " endocarditis leaks into LV in diastole, which â†“ DBP and replacement, the definitive\nâ†‘ preload/SV which â†‘ SBP; hyperdynamic treatment\ncirculation can lead to bounding pulses, nail\nbed pulsations, head/uvula bobbing with\nheartbeat, and femoral bruit; volume over-\nload leads to eccentric hypertrophy of LV and\ndisplacement of PMI down and to the left\nMitral Stenosis Chronic Rheumatic Heart Signs/Symptoms Diagnosis\n(MS) Disease Patient may not recall history of rheumatic TTE is best initial test\nUntreated streptococcal fever Treatment\ninfections lead to bouts of â†‘ left atrial pressure â†’ pulmonary conges- Diuretics cautiously treat\nacute rheumatic fever â†’ tion (dyspnea, orthopnea, PND, hemoptysis, congestion\nscarring/fibrous and com- pulmonary HTN/RV failure); â†‘ left atrial size Î²-blockers, CCBs, digoxin for rate\nmissure fusion of mitral (A-fib/thrombus/stroke; laryngeal nerve/ control to â†‘ filling time; tachy-\nvalve esophagus compression = dysphagia/ cardia is poorly tolerated\nRare in United States hoarseness) Warfarin first-line for valvular\nYoung adult immigrant is Murmur: Opening snap (think: steno-snap) A-fib\nclassic with mid-diastolic rumbling at apex Loud Surgical valve repair/replace-\nS1 with valve closer; the closer in time the ment or catheter-based\nopening snap is to S2, the worse stenosis is; balloon valvuloplasty only\nloud S2 with pulmonary HTN for severe + symptomatic MS\nIncrease murmur = increase venous return and due to RHD, as it can break up\ndecrease afterload fibrous tissue\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7733 1100//2211//2222 44::0055 PPMM\n\n74 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTABLE 2.1-28. Types, Etiologies, Clinical Features, and Diagnosis/Treatment of Valvular Lesions (continued)\nTYPE ETIOLOGIES CLINICAL FEATURES DIAGNOSIS/TREATMENT\nMitral Primary MR Signs/Symptoms Diagnosis\nRegurgitation (MR) MVP (myxomatous): Spo- Primary MR: Most patients are asymptomatic, TTE for first-/second-de",
      "char_start": 228000,
      "char_end": 230000
    },
    {
      "chunk_id": 115,
      "text": "gree MR\nMitral valve prolapse radic, familial, connective may be related to anxiety, murmur detected Treatment\n(MVP) tissue disease (EDS/ Murmur: Leaflets billow above annulus â†’ mid- First-degree MR: Reassurance\nMarfan) systolic nonejection click + MR murmur Acute second-degree MR: Emer-\nAcute secondary MR Increase murmur = reduce LV size by gent valve surgery\nPosteromedial papillary decreasing venous return (stand/Valsalva); Chronic second-degree MR: Use\nmuscle rupture due to think: Billowing leaflets are like a para- of vasodilators to decrease\nposterior descending chuteâ€”small parachute is bad, small LV size afterload, donâ€™t delay pro-\nartery occlusion or isch- is bad gression; manage heart\nemic dysfunction with MI, Acute secondary MR: Abrupt â†‘ left atrial failure/A-fib\nendocarditis pressure â†’ flash pulmonary congestion, Functional MR treat\nChronic secondary MR hypotension, shock with diuretic to â†“ LV size;\nRheumatic fever, â€œfunc- Chronic secondary MR: Asymptomatic to surgery if severe: Prefer clip-\ntional MRâ€ LV dilates, â†‘ heart failure ping valve > replacing\nannulus, normal cusps â‰  Murmur: Holosystolic at apex, radiates to axilla\nclose Increase murmur = Increase venous return and\nincrease afterload\nTricuspid Tricuspid endocarditis (IV Signs/Symptoms Diagnosis\nRegurgitation drug use) Majority asymptomatic â†’ symptoms manifest TTE is best initial test; can assess\n(TR) Ebstein anomaly (con- with pulmonary HTNâ†’ right HF and may pulmonary pressures via TR\ngenital downward include ascites, pulsatile/enlarged liver, velocity\ndisplacement of tricuspid edema, prominent V waves + rapid y descent Treatment\nvalve â†’ RV); carcinoid in jugular venous pulse, JVD; right atrial dila- Treat underlying cause\nsyndrome (see later), tation â†’ AF Diuretics for congestion\nlupus, myxomatous Murmur: Sound of TR murmur = second- Surgery for severe + symptom-\ndegeneration degree MR murmur (holosystolic) but is at atic TR without pulmonary\nNormal: Up to 70% of lower-left sternal border HTN\nadu",
      "char_start": 230000,
      "char_end": 232000
    },
    {
      "chunk_id": 116,
      "text": "lts have physi- Increase murmur = â†‘ venous return via inhala-\nologic TR; majority are tion (like sipping a straw) + leg raise\nasymptomatic\nRV dilation: LV failure (most\ncommon), RV MI, inferior\nwall MI, pulmonary HTN\nâ†’ cor pulmonale.\nRight-sided valve disease: Murmur-like left-sided counterpart with different listening area. Tricuspid/pulmonic stenosis/regurgitation is caused\nby carcinoid heart disease (tumor releases serotonin â†’ neutralized in lungs = only right-sided valves coated/fibrosed). TR: classically endocarditis\nin IVDU, RV enlargement. PR classically in TOF patient years after repair.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7744 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 75\nVASCULAR DISEASES\nAORTIC ANEURYSM\nGreater than 50% dilation of all three layers of the aortic wall. Aortic aneu-\nrysms are most commonly associated with atherosclerosis. Most are abdomi-\nnal, and >90% originate below the renal arteries.\nâ–  Etiologies: Degeneration (atherosclerosis, fibromuscular dysplasia), infec-\ntion (syphilis), trauma, inflammation (Takayasu), connective tissue dis-\neases (Marfans, Ehlers-Danlos syndrome), and congenital (Turner\nsyndrome, tuberous sclerosis)\nâ–  Ascending aortic aneurysmâ€”think cystic medial necrosis or connec-\ntive tissue disease\nâ–  Descending aortic aneurysmâ€”think atherosclerosis\nâ–  Complications: Rupture, thrombosis, embolism, fistulae, pressure on sur-\nrounding structures\nHistory/PE\nâ–  Usually asymptomatic and discovered incidentally on exam or radiologic\nstudy. It may cause mild abdominal or back pain. Less frequently, those\nwith symptomatic but unruptured aneurysms may present with signs of\nlimb ischemia (acute or chronic) or systemic symptoms (fever, malaise).\nâ–  Exam can demonstrate a pulsatile abdominal mass or abdominal bruits.\nâ–  Risk factors include HTN, high cholesterol, other vascular disease, a âŠ• KEY FACT\nfamily history, smoking (strongest predictor of rupture), gender (males",
      "char_start": 232000,
      "char_end": 234000
    },
    {
      "chunk_id": 117,
      "text": " >\nfemales), and age. AAA is generally defined as abdominal\nâ–  Ruptured aneurysm leads to hypotension and severe, tearing abdominal aortic dilation in adults >3.0 cm.\npain that radiates to the back, iliac fossae, or groin and syncope.\nDiagnosis\nâ–  Screening: All men 65 to 75 years of age with a history of smoking are rec-\nommended for a one-time screening by ultrasound for AAA (Fig. 2.1-29).\nFigure 2.1-30 suggests an algorithm for the diagnosis and initial manage-\nment of AAA.\nâ–  Abdominal ultrasound is used for diagnosis or to follow the course of an\naneurysm over time.\nA B\nAo\nA 70-year-old man with HTN presents\nfor a routine appointment. He quit\nsmoking 20 years ago but has a\nA FIGURE 2.1-29. Abdominal aortic aneurysm B . (A) Ultrasound image of an AAA (Ao, Aorta). (B) 20-pack-year history. What screening,\nif any, is indicated?\nTransaxial image from a contrast-enhanced CT showing an aneurysm with extensive mural\nthrombus (arrowhead). (A reproduced with permission from Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine: A Com-\nprehensive Study Guide 6th ed. New York, NY: McGraw-Hill; 2004. B reproduced with permission from Doherty GM. Current\nDiagnosis & Treatment: Surgery 13th ed. New York, NY: McGraw-Hill; 2010.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7755 1100//2211//2222 44::0055 PPMM\n\n76 HIGH-YIELD FACTS IN CARDIOVASCULAR\nSuspected symptomatic abdominal aortic aneurysm (AAA)\nAbdominal, flank, or back pain,\npulsatile abdominal mass,\n+/- flank ecchymosis\nAssess hemodynamic stability\nStable Unstable\nHistory of AAA\nYes No\nCT abdomen Ultrasound abdomen\nUnruptured Ruptured AAA present AAA absent\nCardiovascular evaluation\nEmergent endovascular or Evaluate cause\nUrgent endovascular or surgical surgical AAA repair of symptoms\nrepair if the lesion is >5.5 cm\nFIGURE 2.1-30. Diagnosis of suspected abdominal aortic aneurysm (AAA). (Reproduced with per-\nmission from USMLE-Rx.com.)\nKEY FACT\nSize of AAA determines treatment: â–  CT w",
      "char_start": 234000,
      "char_end": 236000
    },
    {
      "chunk_id": 118,
      "text": "ith contrast or magnetic resonance angiography (MRA) may be use-\nful to determine the precise anatomy.\nâ–  <5 cm â†’ monitoring\nâ–  >5 cm â†’ surgical correction\nTreatment\nâ–  In asymptomatic patients, monitoring is appropriate for lesions\nâ–  Surgical or endovascular correction is indicated if the lesion is â‰¥5.5 cm\n(abdominal), >6 cm (thoracic), or smaller but rapidly enlarging (watch\nKEY FACT\nfor bowel ischemia and infarction).\nRapidly expanding aortic aneurysms are â–  Emergent surgery for symptomatic or ruptured aneurysms.\ndefined as >5 mm increase in size in 6\nmonths or >10 mm increase in size in AORTIC DISSECTION\n12 months.\nA transverse tear in the intima of a vessel that results in blood entering the\nmedia, creating a false lumen and leading to a hematoma that propagates lon-\nKEY FACT gitudinally. Most commonly secondary to HTN, but also due to blunt chest\ntrauma. The most common sites of origin are above the aortic valve and distal\nAortic aneurysm is most often to the left subclavian artery. Most often occurs at 40 to 60 years of age, with a\nassociated with atherosclerosis, greater frequency in males than in females.\nwhereas aortic dissection is commonly\nlinked to HTN. History/PE\nâ–  History: HTN, Marfan syndrome, mitral valve prolapse, trauma\nâ–  Presentation: Sudden tearing/ripping pain in the anterior chest (ascend-\ning) with or without radiation to the back (descending), typically between\nthe scapulae\nâ–  PE:\nâ–  Patients are typically hypertensive. If hypotensive, consider pericardial\ntamponade, hypovolemia from blood loss, or other cardiopulmonary\nThe United States Preventive Services\netiologies.\nTask Force (USPSTF) guidelines\nrecommend one-time screening for\nAAA by ultrasound in men 65 to 75\nyears of age who have ever smoked.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7766 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 77\nâ–  Asymmetric pulses and BP measurements or acute limb ischemia.\nâ–  A murmur of aortic regurg",
      "char_start": 236000,
      "char_end": 238000
    },
    {
      "chunk_id": 119,
      "text": "itation may be heard if the aortic valve is\ninvolved with a proximal dissection.\nâ–  Neurologic deficits, such as paraplegia, may be seen if the aortic arch\nor spinal arteries are involved.\nâ–  Anuria may be seen if renal arteries are involved.\nâ–  Signs of pericarditis or pericardial tamponade may be seen.\nDiagnosis\nâ–  Aortic dissection suspected based on history and physical exam findings.\nâ–  Best initial test for hemodynamically stable patients: CT angiography.\nMRA can be used if contrast CT is contraindicated.\nâ–  TEE. Visualization of an intimal flap as well as a false lumen is diagnostic.\nIt may also be used to visualize details of the proximal aorta and coronary\nvessels and can also evaluate for pericardial effusion.\nKEY FACT\nâ–  The Stanford system classifies any dissection proximal to the left subcla-\nvian artery as type A and all others as type B (Fig. 2.1-31).\nAscending aortic dissections are\nâ–  See diagnostic algorithm in Fig. 2.1-32. surgical emergencies; descending\nâ–  Type A (~70%) is the most common and involves the ascending aorta, dissections are still emergencies but\nirrespective of the site of the tear. Type B does not involve the ascending\ncan often be treated medically.\naorta.\nStanford Classification\nSuspected aortic dissection\nType A Type B\nDescending Descending\nInitial evaluation:\nhistory, physical exam, labs,\nECG, CXR suggestive of aortic dissection\nAscending\nNo Yes\nEvaluate for other\nDetermine appropriate\ndiagnoses and\ndiagnostic imaging\ntreat appropriately\nHemodynamically Hemodynamically\nunstable stable\nCTA\nTEE\nIf contrast CT\nFIGURE 2.1-31. Stanford classification of aortic dissec- If not available, CTA contraindicated, MRA\ntion. Type A involves the ascending aorta and may progress\nto involve the arch and thoracoabdominal aorta. Type B\nDiagnosis\ninvolves the descending thoracic or thoracoabdominal aorta confirmed\ndistal to the left subclavian artery without involvement of the\nControl heart rate and blood\nascending aorta. (Reproduced with permission from ",
      "char_start": 238000,
      "char_end": 240000
    },
    {
      "chunk_id": 120,
      "text": "USMLE-Rx.com.) pressure with Î²-blocker\nSurgical consult\nType A Type B\nEmergency surgery Evidence of ischemia\nNo Yes\nContinue medical\nUrgent surgery\nmanagement\nFIGURE 2.1-32. Diagnosis of suspected aortic dissection.\n(Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7777 1100//2211//2222 44::0055 PPMM\n\n78 HIGH-YIELD FACTS IN CARDIOVASCULAR\nTreatment\nâ–  BP control: Important to monitor and medically manage BP and heart\nrate as necessary. Avoid thrombolytics. Begin IV Î²-blockers (eg, IV labet-\nalol) before starting vasodilators (nitroprusside) to prevent reflex tachycar-\ndia. BP goals in the management of aortic dissection aim to decrease shear\nstress on the dissection, but maintain adequate organ perfusion with sys-\ntolic blood pressure of 100 to 120 mm Hg. Heart rate goal is <60 bpm.\nâ–  All patients with type A thoracic dissection (ascending dissections) should\nhave surgery.\nâ–  Patients with type B thoracic dissection (descending dissections) may be\nmanaged medically with BP and heart rate control; surgery is reserved if\nthere is a leakage, rupture, or compromised organs.\nDEEP VENOUS THROMBOSIS\nClot formation in the large veins of the extremities or pelvis. The classic Vir-\nchow triad of risk factors includes venous stasis (eg, from long-haul flights,\nKEY FACT prolonged bed rest, obesity, immobility, or incompetent venous valves in the\nlower extremities), endothelial trauma (eg, surgery, injury to the lower\nVirchow triad: (1) venous stasis, (2) extremities, IV catheters, trauma), and hypercoagulable states (eg, thrombo-\ntrauma (endothelial damage), (3) philia, malignancy, pregnancy, OCP use, hyperhomocysteinemia). A com-\nhypercoagulability mon scoring system for determining the likelihood of a deep venous\nthrombosis (DVT)â€”the Wellsâ€™ DVT Criteriaâ€”guides management of a\npatient with suspected DVT (Table 2.1-28).\nHistory/PE\nâ–  Presents with unilateral lower extremity pain and swelling. Calf w",
      "char_start": 240000,
      "char_end": 242000
    },
    {
      "chunk_id": 121,
      "text": "armth,\ntenderness, and erythema may be present.\nTABLE 2.1-28. Wellsâ€™ DVT Criteriaa\nCRITERIA SCORE\nActive cancer (treatment ongoing or within previous 6 months or palliative) 1\nParalysis, paresis, or recent plaster immobilization of the lower extremities 1\nRecently bedridden for 3 days or more, or major surgery within the previous 12 1\nweeks requiring general or regional anesthesia\nLocalized tenderness along the distribution of the deep venous system 1\nEntire leg swelling 1\nCalf swelling at least 3 cm larger than that on the asymptomatic leg (measured 10 1\ncm below the tibial tuberosity)\nPitting edema confined to the symptomatic leg 1\nCollateral superficial veins (nonvaricose) 1\nPreviously documented DVT 1\nAlternative diagnosis at least as likely as DVT -2\naHigh probability of DVT if score is 3 or more, moderate if score is 1 or 2, and low if score is 0 or less.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7788 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 79\nKEY FACT\nPhlegmasia alba dolens (literally,\nâ€œedema, pain, and white, blanching\nskinâ€) is a PE finding sometimes seen in\nacute DVT.\nFIGURE 2.1-33. Phlegmasia cerulea dolens. (Adapted with permission from Hu H, Cai Y, Wang C, et al. Success- Phlegmasia cerulea dolens (â€œedema,\nful treatment of posttraumatic phlegmasia cerulea dolens by reconstructing the external iliac vein: a case report. J Med Case pain, and blue skinâ€) is a more severe\nRep. 2014;8:149 doi:10.1186/1752-1947-8-149) form of phlegmasia alba dolens,\nwhere the skin turns blue as the DVT\nâ–  Homans sign is calf tenderness with passive foot dorsiflexion (poor sensitiv- progressively worsens (Fig. 2.1-33).\nity and specificity for DVT).\nâ–  Use pretest clinical probability scoring for DVT, the Wellsâ€™ score.\nâ–  May see phlegmasia alba dolens or phlegmasia cerulea dolens (see Fig.\n2.1.33) in more severe cases.\nâ–  Important differential diagnosis includes Baker cyst, muscle strain/tear/\ntwisting injury t",
      "char_start": 242000,
      "char_end": 244000
    },
    {
      "chunk_id": 122,
      "text": "o leg, cellulitis, edema secondary to infection, and varicose KEY FACT\nveins.\nâ–  D-dimer is sensitive but not specific\nfor DVT (elevated in many other\nDiagnosis\nclinical situations such as infection,\nModerate- or high-sensitivity D-dimer and lower extremity ultrasound may be malignancy, pregnancy, and\nordered based on pretest probability of DVT (see Fig. 2.1-34 for management postoperative states, to name a\nrecommendations). few).\nâ–  Therefore a âŠ– D-dimer test can be\nTreatment used to rule out the possibility of\nVTE in low-risk patients.\nâ–  Anticoagulate with subcutaneous LMWH, a direct oral anticoagulant\n(DOAC), or IV unfractionated heparin followed by oral warfarin or\nDOACs for a total of 3 months (total duration dependent on cause, num-\nber of occurrences, and bleeding risk).\nNormal No DVT\nLow D-dimer\nHigh\nDVT Imaging\ntest\nneeded\nNot low\nClinical suspicion for\nAssess clinical liklihood\nDVT or PE\nNormal No PE\nNot high D-dimer\nHigh\nPE Imaging\ntest\nneeded\nHigh\nFIGURE 2.1-34. Management of suspected DVT based on Wellsâ€™ score. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 7799 1100//2211//2222 44::0055 PPMM\n\n80 HIGH-YIELD FACTS IN CARDIOVASCULAR\nKEY FACT â–  First-occurrence unprovoked DVT or provoked DVT by a reversible risk\nfactor is unlikely to recur and only requires 3 months of anticoagulation\nExtended anticoagulation therapy (no treatment.\nscheduled stop date) for the treatment â–  DVT secondary to cancer or a second unprovoked DVT is likely to recur\nof DVT is based on bleeding risk and and requires indefinite anticoagulation treatment (extended therapy).\nunderlying cause of DVT; those who â–  In patients with contraindications for anticoagulation, inferior vena cava\nare at low risk of bleeding may be filters should be placed.\ncandidates for extended therapy and â–  Hospitalized patients should receive DVT prophylaxis consisting of exer-\nshould receive scheduled (eg, annual) cise as tole",
      "char_start": 244000,
      "char_end": 246000
    },
    {
      "chunk_id": 123,
      "text": "rated, antithromboembolic stockings, and subcutaneous\nreassessments of risk of bleeding to LMWH or unfractionated heparin.\nreassess risks/benefits of continuing â–  Catheter-directed thrombolysis is sometimes used as an adjunct to antico-\ntherapy. agulation in order to help prevent postthrombotic (postphlebitis) syn-\ndrome in patients with low bleeding risk who have a decent life\nexpectancy.\nPOSTTHROMBOTIC (POSTPHLEBITIC) SYNDROME\nKEY FACT\nChronic venous insufficiency that develops after a patient has a DVT, which\nProvoked DVT: DVT thought to be develops into sometimes severe symptoms that impair quality of life. Thought\ncaused by an identifiable risk factor to be due to long-standing venous hypertension from a combination of venous\nsuch as a recent hospital admission/ valvular incompetence leading to reflux and thrombotic obstruction.\nsurgery, beginning estrogen therapy, Risk factors: Preexisting venous insufficiency, old age, obesity, varicose\npregnancy, a long flight, etc. veins, recurrent ipsilateral DVT, symptomatic DVT, iliofemoral (proximal)\nUnprovoked DVT: No known DVT, and residual thrombus within the first 6 months after thrombotic\nidentifiable cause; possibly due to episode.\nhereditary factors.\nHistory/PE\nâ–  Extremity pain and sensation of â€œheavinessâ€\nâ–  Venous dilation\nâ–  Skin pigmentation/phlegmasia, trophic skin changes/stasis dermatitis,\nvenous ulcers (when severe)\nâ–  Edema\nDiagnosis\nDiagnosis is made clinically in patients with a history of DVT and obvious\nsymptoms of chronic venous insufficiency. Imaging modalities such as ultra-\nsound can help identify underlying venous valvular insufficiency and residual\nclot burden, and blood tests can help elucidate potential underlying clotting\ndisorders.\nTreatment\nâ–  Conservative management (first line): exercise, compression therapy\n(compressive stockings), skin care (eg, moisturizers for dry/pruritic skin)\nâ–  Venous intervention (eg, endovascular catheter-directed thrombolysis,\nstenting, surgical correction of venou",
      "char_start": 246000,
      "char_end": 248000
    },
    {
      "chunk_id": 124,
      "text": "s reflux) for acute clot\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8800 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 81\nPERIPHERAL ARTERIAL DISEASE\nDefined as a restriction of the blood supply to the extremities by atheroscle-\nrotic plaque. The lower extremities are most commonly affected. Clinical\nmanifestations depend on the vessels involved, the extent and rate of obstruc-\ntion, and the presence of collateral blood flow.\nHistory/PE\nâ–  Presents with intermittent claudication; reproducible cramping pain in\nthe calf, thigh, or buttock after walking for a certain distance (claudication\ndistance) and is relieved with rest.\nâ–  As the disease progresses, it causes critical limb ischemia. Pain occurs at\nrest and affects the distal extremities. Dorsal foot ulcerations may develop KEY FACT\nsecondary to poor perfusion. A painful, cold, numb foot is characteristic of\ncritical limb ischemia (chronic limb-threatening ischemia). Critical limb ischemia (chronic limb-\nâ–  For more proximal lesions, there will be claudication and weak pulses threatening ischemia): Presence of\nbelow the area of occlusion (ie, aortoiliac disease [Leriche syndrome] is PAD in combination with pain at rest,\ncharacterized by the triad of hip, thigh, and buttock claudication; impo- gangrene, or a lower limb ulceration\ntence; and symmetric atrophy of bilateral lower extremities). >2 weeks duration\nâ–  Capillary filling of >15 seconds is seen in severe ischemia.\nâ–  Acute ischemia:\nâ–  May be due to thrombosis in situ (most common), emboli (usually of\ncardiac origin), graft/angioplasty occlusion, or trauma. Acute occlu-\nsions commonly occur at bifurcations distal to the last palpable pulse\n(see mnemonic for signs and symptoms). MNEMONIC\nâ–  May also be secondary to cholesterol atheroembolism (â€œblue toe syn-\ndromeâ€), which is characterized by blue toes, livedo reticularis, and The 6 Ps of acute ischemiaâ€”\nrenal failure (often secondary to catheterization).",
      "char_start": 248000,
      "char_end": 250000
    },
    {
      "chunk_id": 125,
      "text": " Pain\nPallor\nâ–  Chronic ischemia: Lack of blood perfusion leads to muscle atrophy, pal- Paralysis\nlor, loss of sweat and sebaceous glands, cyanosis, hair loss, and gangrene/\nPulse deficit\nnecrosis. Paresthesias\nPoikilothermia\nDiagnosis\nâ–  Identify cardiovascular risk factors, especially smoking, diabetes, HTN,\nand hyperlipidemia.\nâ–  Best initial test: Ankle-brachial index (ABI) test (1â€“1.4 is normal); can\nprovide objective evidence of atherosclerosis (â‰¤0.9 is highly sensitive and\nKEY FACT\nspecific for PAD, rest pain usually occurs with an ABI <0.4).\nâ–  Doppler ultrasound: Identifies stenosis and occlusion. Normal ankle Rest pain seen with an ABI <0.4. (normal\nDoppler readings are >90% of brachial readings.\nABI: 1.0â€“1.4)\nâ–  Most accurate test: Angiography (invasive); computed tomography angi-\nography (CTA) with runoff (noninvasive); often not necessary unless revas-\ncularization is indicated.\nKEY FACT\nTreatment Calf claudication = femoral disease\nButtock claudication = iliac disease\nâ–  Treat acute symptomatic ischemia with heparin and prompt\nButtock claudication + impotence\nrevascularization.\n= Leriche syndrome (aortoiliac\nâ–  Smoking cessation (vital); optimally treat HTN, hyperlipidemia, and\nocclusive disease)\ndiabetes.\nâ–  Educate regarding careful hygiene and foot care. Exercise helps develop\ncollateral circulation.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8811 1100//2211//2222 44::0055 PPMM\n\n82 HIGH-YIELD FACTS IN CARDIOVASCULAR\nâ–  Antiplatelet agents (ASA or vorapaxar) do not consistently reduce symp-\nKEY FACT toms but â†“ the risk for associated cardiovascular mortality.\nâ–  Cilostazol is effective medication in intermittent claudication, although it\nThe major cause of mortality in patients\nis contraindicated in those with CHF.\nwith PAD is cardiovascular disease (MI,\nâ–  Surgery (arterial bypass), percutaneous transluminal angioplasty, and\nstroke); there is a 20% to 30% risk for\nstenting or amputation can be employed when conservativ",
      "char_start": 250000,
      "char_end": 252000
    },
    {
      "chunk_id": 126,
      "text": "e treatment fails\nthese complications. There is only a 1%\nor in acute limb ischemia.\nto 2% risk for developing limb ischemia.\nLYMPHEDEMA\nA disruption of the lymphatic circulation that results in peripheral edema and\nchronic infection of the extremities. Primary (or congenital) lymphedema is\nrare. Most often caused secondarily by surgeries involving lymph node dissec-\ntion or, in developing countries, parasitic infections.\nHistory/PE\nHistory will differ by cause. Examples include the following:\nâ–  Postmastectomy patients present with unexplained swelling of the upper\nextremity (secondary to surgery).\nâ–  Patients originating from developing countries present with progressive\nswelling of the lower extremities bilaterally with no cardiac abnormalities\n(ie, filariasis infection).\nâ–  Children present with progressive, bilateral swelling of the extremities\n(primary).\nâ–  Patients with Turner syndrome will have lymphatic edema.\nDiagnosis\nDiagnosis is clinical. Rule out other causes of edema, such as cardiac/meta-\nbolic disorders and DVT.\nTreatment\nâ–  Directed at symptom management, including exercise, massage therapy,\nand pressure garments to mobilize and limit fluid accumulation.\nâ–  Diuretics are ineffective and relatively contraindicated.\nâ–  Maintain vigilance for cellulitis with prompt gram âŠ• antibiotic coverage\nfor infection.\nSYNCOPE\nSyncope is defined as a transient loss of consciousness (TLOC) secondary to\ncerebral hypoperfusion. It is characterized by a rapid onset, short duration,\nand spontaneous complete recovery. It may be cardiac, neurocardiogenic\n(reflex), orthostatic, or due to other rare causes (Figs. 2.1-35 and 2.1-36, Table\n2.1-29). Syncope should be differentiated from other causes of loss of con-\nsciousness such as epileptic seizure, hypoglycemia, SCD, and psychogenic\ncauses that are not mediated by cerebral hypoperfusion.\nClassification\nâ–  Cardiac syncope: Unstable tachyarrhythmias, bradyarrhythmias, or struc-\ntural disease (eg, HOCM, aortic stenosis, aortic disse",
      "char_start": 252000,
      "char_end": 254000
    },
    {
      "chunk_id": 127,
      "text": "ction, cardiac tam-\nponade) may cause cerebral hypoperfusion and syncope. They are\ndiscussed in detail in their relevant sections.\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8822 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 83\nSyncope\nï© cardiac output ï© peripheral resistance\nCardiac etiology Hypovolemia ï© sympathetic tone ï¨ parasympathetic tone\nAortic stenosis Hemorrhage Drugs Vasovagal\nHOCM GI losses Autonomic failure Situational\nPulmonary hypertension ï© oral intake (eg, Parkinson disease, Carotid sinus syndrome\nPericardial effusion diabetes mellitus)\nArrhythmia\nFIGURE 2.1-35. Pathophysiologic basis of syncope classification. (Reproduced with permission from\nUSMLE-Rx.com.)\nKEY FACT\nâ–  Neurally mediated (reflex): There is generally a trigger (eg, carotid stimu-\nlation) that induces cardiovascular reflexes, instigating either hypotension Vasovagal is the most common etiology\nor bradycardia or both. Examples include carotid sinus syndrome, situa- of syncope.\ntional, and vasovagal syncope (see Table 2.1-29).\nâ–  Orthostatic: Orthostatic syncope is due to venous pooling that occurs on\nchanging from a supine to an upright posture. Volume depletion or failure\nof arterial baroreceptors to provoke vasoconstriction of the systemic resis-\ntance vessels results in a dip in BP and syncope. Causes include drugs,\npostural tachycardia syndrome, volume depletion, and primary/secondary\nautonomic failure (see Table 2.1-29). KEY FACT\nHistory/PE Red flags with syncope include onset\nwith exertion, chest pain, dyspnea,\nâ–  Age, triggers, prodromal symptoms, and associated symptoms should be\npalpitations, severe headache, focal\ninvestigated. Family history should be elucidated (HOCM, LQTS).\nneurologic deficits, diplopia, ataxia,\nâ–  Syncope can be confused with seizures. Unlike syncope, seizures may be\ndysarthria, low back pain, or family\ncharacterized by a preceding aura, tonic-clonic activity, tongue-biting, blad-\nhistory of SCD.\n",
      "char_start": 254000,
      "char_end": 256000
    },
    {
      "chunk_id": 128,
      "text": "der and bowel incontinence, and a postictal phase (ie, recovery is gradual).\nâ–  Presentation of key syncope syndromes is shown in Table 2.1-29.\nKEY FACT\nDiagnosis\nInitial syncope evaluation includes history, physical examination (including supine Cardiac syncope is associated with\nand standing BP), and ECG. Further testing depends on the suspected etiology. 1-year SCD rates of up to 40%.\nIs there actual complete loss of consciousness?\nNo Yes\nEvaluate for etiologies not Assess timing of onset\ndue to cerebral hypoperfusion\nRapid Gradual\n(eg, altered mental status, falls, ect.)\nHypoglycemia, drugs\nAssess timing of recovery\n(i.e. benzodiazepines)\nGradual Spontaneous\nNeurogenic (reflex)\nSeizure Cardiac syncope Orthostatic syncope\nsyncope\nFIGURE 2.1-36. Approach to diagnosis of syncope. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8833 1100//2211//2222 44::0055 PPMM\n\n84 HIGH-YIELD FACTS IN CARDIOVASCULAR\nâ–  Investigations for suspected cardiac causes:\nKEY FACT â–  Arrhythmias: Holter monitor or 2-week event recorder\nâ–  Structural heart disease: Echocardiogram\nVasovagal is the most common etiology\nâ–  Ischemia: Cardiac stress tests to look for ischemia\nof syncope.\nâ–  Exercise testing for exertion-induced syncope\nâ–  Investigations for neurally mediated (reflex) and orthostatic syncope:\nâ–  CSM to assess for carotid sinus hypersensitivity\nâ–  Head-up tilt testing to rule out vasovagal, situational, or orthostatic\ncauses\nKEY FACT â–  Autonomic function tests (eg, analyzing BP, HR during Valsalva, deep\nbreathing) to identify autonomic failure\nSyncope with: â–  Other: Blood tests as indicated (oxygen saturation for hypoxemia, hemato-\n1. Exertion: Aortic stenosis, mitral crit for hemorrhage, troponins for ACS, D-dimers for PE)\nstenosis, pulmonary hypertension,\nHOCM, and coronary artery disease. Treatment\n2. Dysarthria, diplopia, vertigo,\nTailored to the etiology.\nneurologic symptoms: TIA or stroke\nâ–  Treatment",
      "char_start": 256000,
      "char_end": 258000
    },
    {
      "chunk_id": 129,
      "text": " of cardiac arrhythmias and structural cardiac diseases that\n3. Arm exercise: Subclavian steal\ncause syncope is specific to the underlying condition and is described ear-\nsyndrome\nlier in the text.\n4. Changing position: Atrial myxoma/\nâ–  In patients with unexplained syncope or high risk of SCD (CAD, DCM,\nthrombus\nHCM, arrhythmogenic right ventricular cardiomyopathy, LQTS, Bru-\n5. Severe chest/back pain, differential\ngada), consider ICD.\nBP in arms: Aortic dissection\nâ–  Treatment of important neurally mediated and orthostatic syncope syn-\ndromes is covered in Table 2.1-29.\nTABLE 2.1-29. Selected Syncope Syndromes\nMOST LIKELY\nPATIENT PRESENTATION DIAGNOSIS WORKUP MANAGEMENT\nNEURALLY MEDIATED (REFLEX) SYNCOPE\nSyncope after wearing tight collar/tie, Carotid sinus If diagnosis is highly likely: Predictable onset or low-recurrence\nshaving, or neck movements (carotid syndrome â–  No further evaluation is syncope:\nstimulation) needed (ie, treat directly) â–  Patient education, reassurance, and\nIf diagnosis unclear: avoidance of triggers\nSyncope on coughing/defecation/ Situational\nâ–  Investigations to consider: â–  Increased fluid intake and salt intake\nurination\nâ–  Carotid sinus massage (for Unpredictable onset or high-recurrence\ncarotid sinus syndrome) syncope:\nSyncope associated with fear, noxious Vasovagal\nâ–  Tilt-table testing (for â–  Consider specific associations and treat;\nstimuli, heat exposure, prolonged\nsituation and vasovagal some examples follow:\nstanding\nsyncope) â–  Low BP: Consider fludrocortisone,\nâ–  Rule out other serious midodrine; stop or reduce\ncauses of syncope (eg, hypotensive drugs\ncardiac) â–  Prodromes: Counterpressure\nmaneuvers (ie, handgrip, arm tensing\nor leg crossing maneuvers) or tilt\ntraining (physical therapy to improve\northostatic tolerance)\nâ–  Treatment of arrhythmias based on\nloop recorder findings (eg, permanent\npacing for significant cardiac\ninhibition; asystolic pause >3 seconds)\n(continues)\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001",
      "char_start": 258000,
      "char_end": 260000
    },
    {
      "chunk_id": 130,
      "text": "155--008866..iinndddd 8844 1100//2211//2222 44::0055 PPMM\n\nCARDIOVASCULAR HIGH-YIELD FACTS IN 85\nTABLE 2.1-29. Selected Syncope Syndromes (continued)\nMOST LIKELY\nPATIENT PRESENTATION DIAGNOSIS WORKUP MANAGEMENT\nORTHOSTATIC SYNCOPE\nSyncope on change in body posture Volume depletion Orthostatic challenge: â–  Education and reassurance\nwith history of drug use that is associ- Change in BP from supine â–  Expansion of extracellular volume:\nated with orthostasis (eg, alcohol, to erect posture can be Maintain hydration, avoid extreme heat,\nvasodilators, diuretics, phenothiazine, evaluated in several ways: increased sodium intake\nantidepressants) â–  Active standing test â–  Stop or reduce antihypertensive\nâ–  Head-up tilt-table test treatments\nSyncope with volume loss such as hem- Primary autonomic\nâ–  24-hour ambulatory â–  Counterpressure maneuvers when\norrhage, diarrhea, vomiting failure\nBP monitoring (ABPM) warning symptoms are present\nSyncope with neurologic diseases such\nmay allow assessment â–  Compression stockings or abdominal\nas pure autonomic failure, multiple\nof BP with changes in binders (to increase venous return)\nsystem atrophy, Parkinson disease, or\npostures or on performing â–  Head-up tilt sleeping >10 degrees\ndementia with Lewy bodies\nmaneuvers (prevents nocturnal polyuria, maintains\nAutonomic function: To better distribution of body fluids, and\ndetect autonomic failure ameliorates nocturnal hypertension)\nSyncope with history of diabetes, Secondary auto-\nas cause: â–  Medications: Midodrine (first line in\namyloidosis, spinal cord injuries, nomic failure\nâ–  Valsalva maneuver chronic autonomic failure, increases\nautoimmune autonomic neuropathy,\nâ–  Deep breathing test: BP), fludrocortisone (expands volume),\nparaneoplastic autonomic neurop-\nReduced variability in HR Î²-blockers, pyridostigmine, clonidine\nathy, kidney failure\nmay suggest autonomic\ndysfunction\nâ–  24-hour ABPM\nA young woman with history of tachy- Postural tachy- â–  Exclude cardiomyopathy In addition to treatments ment",
      "char_start": 260000,
      "char_end": 262000
    },
    {
      "chunk_id": 131,
      "text": "ioned\ncardia on assuming upright posture, cardia syndrome or pheochromocytoma earlier, consider exercise reconditioning\nmental clouding, chronic fatigue, (POTS) â–  ECG, 24-hour Holter\nand other systemic symptoms pres- Note: Most patients monitoring\nents with syncope on change in with POTS\nbody posture; there is no orthostatic present without\nhypotension syncope\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8855 1100//2211//2222 44::0055 PPMM\n\n86 HIGH-YIELD FACTS IN CARDIOVASCULAR\nNOTES\n22002222__0022..0011__SStteepp22CCKK__CCaarrddiioo__1111ee__001155--008866..iinndddd 8866 1100//2211//2222 44::0055 PPMM\n\nH I G H - Y I E L D F A C T S I N\nDERMATOLOGY\nLayers of the Skin 88 licHen planUs 114\nrosacea 114\nAllergic and Immune-Mediated Skin Disorders 89\npityriasis rosea 115\nHypersensitivity reactions 89\nvitiligo 115\natopic Dermatitis (eczema) 90\neyeliD lesions 116\ncontact Dermatitis 91\nepiDermal inclUsion cysts 116\nseborrHeic Dermatitis 91\nDermatofibroma 116\npsoriasis 92\nHiDraDenitis sUppUrativa 116\nUrticaria (Hives) 93\nicHtHyosis vUlgaris 117\nDrUg erUption 94\nage-relateD skin cHanges 117\nerytHema mUltiforme 95\nsUn protection 117\nstevens-JoHnson synDrome/toxic epiDermal necrolysis 95\nsUnbUrn 117\nerytHema noDosUm 96\nbUlloUs pempHigoiD/pempHigUs vUlgaris 96 Neoplasms of the Skin 117\nnUmmUlar eczema 98 seborrHeic keratosis 117\npyoDerma gangrenosUm 98 actinic keratosis 118\ncUtaneoUs sqUamoUs cell carcinoma 118\nInfectious Disease Manifestations of the Skin 98\nbasal cell carcinoma 119\nviral Diseases 98\nmelanoma 119\nbacterial infections 103\nkaposi sarcoma 121\nfUngal infections 108\nmycosis fUngoiDes (cUtaneoUs t-cell lympHoma) 121\nparasitic infections 110\ncHerry angiomas (Hemangiomas) 122\nIschemic Skin Disorders 112 infantile Hemangiomas 122\nDecUbitUs Ulcers 112 pyogenic granUloma 122\ngangrene 113 necrobiosis lipoiDica 122\nMiscellaneous Skin Disorders 114\nstasis Dermatitis 114\nacantHosis nigricans 114\n87\n22002222__0022..0022__SStteepp22CCKK__",
      "char_start": 262000,
      "char_end": 264000
    },
    {
      "chunk_id": 132,
      "text": "DDeerrmm__1111ee__008877--112222..iinndddd 8877 1100//2211//2222 1122::1111 PPMM\n\n88 HIGH-YIELD FACTS IN DERMATOLOGY\nLAYERS OF THE SKIN\nThe skin is the largest organ in the human body. It provides a barrier and\nimmunologic protection against the environment; regulates body tempera-\nture, fluids, and electrolytes; and allows for touch and sensation. Table 2.2-1\noutlines common terminology related to the skin.\nTABLE 2.2-1. Dermatologic Macroscopic Terms\nLESION CHARACTERISTICS EXAMPLES\nMacule Flat lesion <1 cm Freckle, labial macule (see Image A)\nPatch Flat lesion â‰¥1 cm Salmon patch (see Image B)\nPapule Elevated palpable lesion <1 cm Mole (nevus; see Image C), acne\nPlaque Elevated lesion â‰¥1 cm Psoriasis (see Image D)\nVesicle Fluid-containing blister <1 cm Chickenpox (varicella), shingles (zoster; see Image E)\nBulla Fluid-containing blister â‰¥1 cm Bullous pemphigoid (see Image F)\nCyst Epithelium-lined sac containing material or fluid Pilar cyst (follicular cyst on scalp)\nPustule Vesicle containing pus Pustular psoriasis (see Image G)\nWheal Transient edematous papule or plaque Hives (urticaria; see Image H)\nScale Flaking off of stratum corneum Psoriasis (see Image I)\nCrust Exudate of dried serum, blood, and/or pus Impetigo (see Image J)\nUlcer Defect extending through the epidermis and upper dermis Diabetic foot ulcer\nLichenification Hypertrophy and thickening of the epidermis with accentuation Chronic scratching (pruritic scabies, eczema)\nof normal skin markings\nA B C D E\nF G H I J\nImages reproduced with permission from Dr. Richard Usatine.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 8888 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 89\nALLERGIC AND IMMUNE-MEDIATED SKIN DISORDERS\nHYPERSENSITIVITY REACTIONS\nFigure 2.2-1 illustrates the algorithm for a skin rash workup. Table 2.2-2 out-\nlines information regarding the four types of hypersensitivity reactions.\nTABLE 2.2-2. Types and Mechanisms of Hypersensitivity React",
      "char_start": 264000,
      "char_end": 266000
    },
    {
      "chunk_id": 133,
      "text": "ions\nDESCRIPTION MECHANISM COMMENTS EXAMPLES\nTYPE I\nAnaphylactic and atopic Antigen cross-links preformed First and Fast (like Anaphylaxis (bee sting, food\nsurface-bound IgE on mast anaphylaxis) allergy), asthma, urticaria,\nMast cell or Fc receptor\nbasophil\ncells and basophils, triggering Types I, II, and III are all anti- urticarial drug reactions,\nthe release of vasoactive body mediated local wheal and flare\namines like histamine\nReaction develops rapidly as a\nIgE Ag result of preformed antibody\nTYPE II\nCytotoxic IgM and IgG bind to antigen Cy-2-toxic Autoimmune hemolytic\non an â€œenemyâ€ cell, leading Antibody and comple- anemia, erythroblastosis\nIgG to lysis by complement or ment lead to formation fetalis, Goodpasture syn-\nC phagocytosis of the membrane attack drome, rheumatic fever\nCell complex (MAC)\nIgG\nC = complement\nTYPE III\nImmune complex Antigen-antibody complexes fix Imagine an immune Polyarteritis nodosa, immune\ncomplement, which attracts complex as three things complex glomerulonephritis,\nAg\npolymorphonuclear neutro- stuck together: antigen- systemic lupus erythema-\nphils (PMNs; PMNs release antibody-complement tosus (SLE), rheumatoid\nC\nlysosomal enzymes) Includes many glomerulone- arthritis\nAg phritides and vasculitides\nTYPE IV\nDelayed (cell-mediated) type Sensitized T lymphocytes Fourth and final Tuberculosis (TB) skin tests,\nencounter antigen and then (last)â€”delayed transplant rejection, contact\nAPC\nrelease lymphokines (leading Cell mediated, not antibody dermatitis\nto macrophage activation) mediated; therefore it is\nnot transferable by serum\nTh cells\nAPC, Antigen-presenting cell; Th cells, T-helper cells. Modified with permission from Le T et al. First Aid for the USMLE Step 1 2015. New York, NY:\nMcGraw-Hill Education; 2015.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 8899 1100//2211//2222 1122::1111 PPMM\n\n90 HIGH-YIELD FACTS IN DERMATOLOGY\nSkin rash\nScaly erythematous Sharply demarcated scaly\npapules and plaques pa",
      "char_start": 266000,
      "char_end": 268000
    },
    {
      "chunk_id": 134,
      "text": "pules and plaques\nNonpurulent\nPurulent blisters blisters\nPustular Vesiculobullous Eczematous Papulosquamous\nWell-defined Hyperpigmented edema\nErythematous erythematous Â± venous ulcer\npapules and vesicles papules and vesicles usually on medial ankle\nAtopic dermatitis (eczema) Contact dermatitis Stasis dermatitis Seborrheic dermatitis\nInfants Children and adults\nDiaper rash (red and\nyellow scales, blisters Red, scaly, thin\nand erosions) plaques on face,\nÂ± cradle cap (scaling mid-chest Â± scalp\nand crusting on scalp)\nFIGURE 2.2-1. Algorithm for eczematous skin rash workup. Management depends on the appearance of the rash and the age\ngroup affected. Eczematous lesions require further workup to determine the type of dermatitis. (Reproduced with permission from USMLE-\nRx.com.)\nKEY FACT\nLong-term use of immunomodulating\nmedications (particularly TNF-Î±\ninhibitors) may â†‘ the risk for developing\nlymphoma. ATOPIC DERMATITIS (ECZEMA)\nA chronic inflammatory dermatitis that classically manifests in infancy and\npersists into adulthood. It is characterized by epidermal barrier dysfunction\nKEY FACT\n(multifactorial; however, likely due to filaggrin deficiency), causing sensitiza-\ntion, which in turn leads to inflammation, pruritus, and ultimately lichenifi-\nErythema toxicum neonatorum typically\ncation (Fig. 2.2-2).\nbegins 1 to 3 days after delivery and\npresents with red papules, pustules,\nHistory/PE\nand/or vesicles with surrounding\nerythematous halos. â†‘ eosinophils are â–  Look for a family history of asthma, eczema, and allergic rhinitis (â€œatopic\npresent in the pustules or vesicles. This triadâ€), as well as food allergies.\nbenign eruption usually resolves in 1 to 2 â–  Patients are at â†‘ risk for secondary bacterial (Staphylococcus aureus or\nweeks with no treatment. Streptococcus pyogenes) and viral (herpes simplex virus or molluscum)\ninfection due to constant waxing and waning cycles of pruritus and\nexcoriation.\nâ–  Triggers include climate, food, skin irritants, and allergens.\nâ–  Manifesta",
      "char_start": 268000,
      "char_end": 270000
    },
    {
      "chunk_id": 135,
      "text": "tions by age group:\nâ–  Infants (Fig. 2.2-3): Erythematous, edematous, weeping, pruritic vesi-\ncles, papules, and plaques on the face, scalp, and extensor surfaces of\nthe extremities. The diaper area is often spared.\nâ–  Children: Dry, scaly, pruritic, excoriated vesicles, papules, and plaques\nin the flexural areas and neck.\nâ–  Adults: Lichenification and dry, fissured skin in a flexural distribution.\nOften, there is hand, wrist, neck involvement.\nDiagnosis\nFIGURE 2.2-2. Atopic dermatitis. Lichen-\nification, excoriations, and ill-defined, Characteristic exam findings and history are sufficient. Excluding contact der-\nscaly erythematous plaques are character-\nmatitis by history and anatomic distribution is important. Potassium hydrox-\nistic. (Reproduced with permission from Tintinalli JE\nide (KOH) prep can help distinguish chronic eczema from tinea. Mild\net al. Tintinalliâ€™s Emergency Medicine: A Comprehensive\nStudy Guide, 7th ed. New York, NY: McGraw-Hill; 2011.) peripheral eosinophilia and â†‘ IgE may be seen but have no diagnostic value.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9900 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 91\nTreatment\nâ–  The primary goal of therapy is to break the itch-scratch cycle with agents\ntargeted at inflammation, pruritus, and xerosis (dry skin).\nâ–  Topical corticosteroids are first-line therapy for flares, but atrophy, telangi-\nectasias, and rebound flares can occur with prolonged use. Topical calci-\nneurin inhibitors (eg, tacrolimus) are useful as steroid-sparing agents for\nmoderate to severe eczema for patients >2 years of age.\nâ–  H -blockers may be used for relief of pruritus. A first-generation H -blocker\n1 1\n(eg, hydroxyzine) would be appropriate for nighttime use.\nâ–  Aggressive use of emollients, avoidance of harsh soaps, and limiting hot\nshowers after resolution of acute flares will prevent future episodes. Con- FIGURE 2.2-3. Atopic dermatitis in an\ninfant. Characteristic involve",
      "char_start": 270000,
      "char_end": 272000
    },
    {
      "chunk_id": 136,
      "text": "ment of the\nsider phototherapy and dupilumab treatment.\nface and cheeks, which is not commonly\nseen in adults. (Reproduced with permission\nfrom Dr. Richard Usatine.)\nCONTACT DERMATITIS\nA type IV hypersensitivity reaction that results from contact with an allergen to\nwhich the patient has previously been exposed and sensitized such as nickel,\npoison ivy, perfumes/deodorants, and neomycin. More common in adults.\nHistory/PE\nâ–  Presents with pruritus and an eczematous rash, with the distribution of the\nrash often mimicking the contact event (Fig. 2.2-4). Characteristic distri-\nbutions are seen where makeup, clothing, perfume, nickel jewelry, and\nplants come into contact with the skin.\nâ–  Often described as a â€œlinearâ€ or â€œangularâ€ rash. It can spread over the body\nvia transfer of allergen by the hands or via circulating T lymphocytes.\nâ–  Frequently implicated allergens: Poison ivy, poison oak, nickel, topical\nover-the-counter antibiotics, cosmetics, and latex.\nDiagnosis FIGURE 2.2-4. Contact dermatitis.\nShown are erythematous papules and\nCharacteristic exam findings and history are sufficient. Excluding atopic der- vesicles with serous weeping localized\nmatitis (eczema) is important. Patch testing can be used to establish the caus- to areas of contact with the offending\nagent. (Reproduced with permission from Hurwitz\native allergen after the acute-phase eruption has been treated.\nRM. Pathology of the Skin: Atlas of Clinical-Pathological\nCorrelation, 2nd ed. Stamford, CT: Appleton & Lange;\nTreatment\n1998.)\nThe best initial treatment involves topical corticosteroids and allergen avoid-\nance. In severe cases, a systemic corticosteroid may be needed.\nKEY FACT\nSEBORRHEIC DERMATITIS Patch testing results are affected\nby topical steroids and calcineurin\ninhibitors but not by antihistamines,\nA common chronic inflammatory skin disease that may be caused by a reac-\nbecause type IV hypersensitivity\ntion to Malassezia furfur, a generally harmless yeast found in sebum and hair\nreactions",
      "char_start": 272000,
      "char_end": 274000
    },
    {
      "chunk_id": 137,
      "text": " are not histamine mediated.\nfollicles. It has a predilection for areas with sebaceous glands such as the eye-\nbrows, nasolabial folds, and posterior ears.\nHistory/PE\nRash presentation varies with age:\nâ–  Infants: Severe, red diaper rash with yellow scale, erosions, and blisters. Scal- A 23-year-old woman is seen for an\ning and crusting (â€œcradle capâ€) may be seen on the scalp (see Fig. 2.2-5A). itchy, linear rash on her right leg.\nâ–  Children/adults: Ill-defined red, scaly, thin plaques are seen around the She returned from a camping trip 4\nears, eyebrows, nasolabial fold, midchest, and scalp (see Fig. 2.2-5B). days ago and denies using any new\nâ–  Patients with HIV/AIDS, psychotic disorders, and Parkinson disease makeup, clothing, or jewelry. What\ncan develop severe, widespread seborrheic dermatitis. features of this presentation favor a\ncontact dermatitis?\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9911 1100//2211//2222 1122::1111 PPMM\n\n92 HIGH-YIELD FACTS IN DERMATOLOGY\nA B\nFIGURE 2.2-5. Seborrheic dermatitis. (A) Seborrheic dermatitis (cradle cap) in an infant. Note the\nyellow, scaly crust present on the infantâ€™s scalp with an area of erosion. (B) Photo-exacerbated\nseborrheic dermatitis, affecting the face only at sites of predilection for the seborrheic eruption.\n(A reproduced with permission from Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine: A Comprehensive Study Guide, 7th ed. New\nYork, NY: McGraw-Hill; 2011. B reproduced with permission from Gold-smith LA et al. Fitzpatrickâ€™s Dermatology in General Medi-\ncine, 8th ed. New York, NY: McGraw-Hill; 2012.)\nDiagnosis\nCharacteristic exam findings and history are sufficient. Can be confused with\natopic dermatitis, contact dermatitis, tinea, or psoriasis.\nTreatment\nTreat adults with ketoconazole, selenium sulfide, or zinc pyrithione sham-\npoos for the scalp and topical antifungals (ketoconazole cream) and/or topical\ncorticosteroids for other areas. Cradle cap often resolves w",
      "char_start": 274000,
      "char_end": 276000
    },
    {
      "chunk_id": 138,
      "text": "ith routine bathing\nand application of emollients in infants.\nPSORIASIS\nA T-cellâ€“mediated inflammatory dermatosis characterized by well-demarcated,\nerythematous plaques with silvery scales (Fig. 2.2-6A) due to dermal inflamma-\ntion and epidermal hyperplasia. Psoriasis can begin at any age.\nHistory/PE\nâ–  Lesions are classically found on the extensor surfaces, including the\nelbows and knees. Scalp and lumbosacral regions are often involved. Nails\nare frequently affected with pitting, â€œoil spots,â€ and onycholysis (lifting of\nthe nail plate, see Fig. 2.2-6B).\nâ–  Lesions initially appear small but may become confluent and can be pro-\nvoked by local irritation or trauma (Koebner phenomenon). Some medi-\ncations such as Î²-blockers, lithium, and angiotensin-converting enzyme\n(ACE) inhibitors can worsen psoriatic lesions.\nThe asymmetric involvement of the\nrash, its linear arrangement (possibly â–  Up to 30% develop psoriatic arthritis (affecting small joints of the hands\nfrom contact with a plant during the and feet).\ncamping trip), and the time from\nexposure to rash presentation all\npoint to contact dermatitis.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9922 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 93\nA B\nFIGURE 2.2-6. Psoriasis. (A) Skin changes. The classic sharply demarcated plaques with silvery\nscales are commonly located on the extensor surfaces (eg, elbows, knees). (B) Nail changes.\nNote the pitting, onycholysis, and â€œoil spots.â€ (A reproduced with permission from Wolff K et al. Fitzpatrickâ€™s Color\nAtlas and Synopsis of Clinical Dermatology, 7th ed. New York, NY: McGraw-Hill; 2013. B reproduced with permission from Hurwitz\nRM. Pathology of the Skin: Atlas of Clinical-Pathological Correlation, 2nd ed. Stamford, CT: Appleton & Lange; 1998.)\nDiagnosis\nâ–  Characteristic exam findings and history are sufficient. Classical pre-\nsentation: Auspitz sign (pinpoint bleeding when scale is scraped) over-\nlying well-demarcat",
      "char_start": 276000,
      "char_end": 278000
    },
    {
      "chunk_id": 139,
      "text": "ed, erythematous plaques with silvery â€œmicaceousâ€\nscale.\nâ–  Perform a biopsy if diagnosis is uncertain. Histology shows a thickened KEY FACT\nepidermis, elongated rete ridges, an absent granular cell layer, preservation\nof nuclei in the stratum corneum (parakeratosis), and a sterile neutro- If a rash involves the extensor surfaces,\nphilic infiltrate in the stratum corneum (Munro microabscesses). think psoriasis. If a rash involves the\nflexor surfaces, think atopic dermatitis.\nTreatment\nâ–  Local disease: Manage with topical steroids, calcipotriene (vitamin D\nderivative), and retinoids such as tazarotene or acitretin (vitamin A\nderivative).\nâ–  Severe disease or presence of psoriatic arthritis: Methotrexate or antiâ€“\ntumor necrosis factor (TNF) biologics (etanercept, infliximab, adalim-\numab). Other agents such as ustekinumab (anti-interleukin [IL]-12/23),\nsecukinumab (anti-IL17), and ultraviolet (UV) light therapy can be used\nfor extensive skin involvement, except in immunosuppressed patients who\ncan develop skin cancer from UV light.\nâ–  Before starting methotrexate or anti-TNF biologics, patients should, at a\nminimum, get a complete blood count (CBC), comprehensive metabolic\nKEY FACT\npanel (CMP), hepatitis panel, and testing for TB (purified protein deriva-\ntive [PPD] or interferon gamma release assay [IGRA]). â€œSausage digitsâ€ and pencil-in-cup x-ray\nfindings are suggestive of psoriatic\narthritis.\nURTICARIA (HIVES)\nResults from the release of histamine and prostaglandins from mast cells in a\ntype I hypersensitivity response. Sharply demarcated edematous plaques with\nsurrounding erythema (â€œwheal and flareâ€) are seen, with each lesion lasting\n<24 hours. Can be acute or chronic (lasting >6 weeks).\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9933 1100//2211//2222 1122::1111 PPMM\n\n94 HIGH-YIELD FACTS IN DERMATOLOGY\nHistory/PE\nâ–  Urticaria lesions (wheals) are erythematous or white transient papules or\nplaques representing dermal edema. Lesion",
      "char_start": 278000,
      "char_end": 280000
    },
    {
      "chunk_id": 140,
      "text": "s may be widespread.\nâ–  In severe allergic reactions, extracutaneous manifestations can include\ntongue swelling, angioedema (deep, diffuse swelling often around the eyes\nand mouth; Fig. 2.2-7), asthma, gastrointestinal (GI) symptoms, joint\nswelling, and fever.\nâ–  Acute urticaria is a response to some often-unidentified trigger: food, drug,\nvirus, insect bite, or physical stimulus (cold, heat, sun). Chronic urticaria\nis usually idiopathic.\nFIGURE 2.2-7. Urticaria (hives) and Diagnosis\nangioedema. This patient has urticaria\nCharacteristic exam findings and history are sufficient. Positive dermatogra-\noccurring on the face, neck, and shoul-\nphism (formation of wheals where the skin is stroked) may help. If in doubt,\nders with orbital angioedema. (Reproduced\ndrawing a serum tryptase (co-released with histamine from mast cells) can\nwith permission from Goldsmith LA et al. Fitzpatrickâ€™s\nDermatology in General Medicine, 8th ed. New York, NY: help clinch the diagnosis. It can often be difficult to determine the cause of\nMcGraw-Hill; 2012.) urticaria.\nTreatment\nTreat urticaria with systemic antihistamines. Anaphylaxis (rare) requires intra-\nmuscular epinephrine, antihistamines, IV fluids, and airway support.\nKEY FACT\nDRUG ERUPTION\nPatients with drug eruptions often have\nperipheral eosinophilia and eosinophils Drug eruptions can range from a mild morbilliform rash (most common; Fig.\non histopathology. 2.2-8) to the rare but life-threatening toxic epidermal necrolysis (TEN). Main-\ntain a high suspicion for a cutaneous drug reaction in patients who are hospi-\ntalized and develop rashes. Drugs can cause all four types of hypersensitivity\nreactions (Table 2.2-2), and the same drug may cause different types of reac-\ntions in different persons.\nHistory/PE\nâ–  Non-anaphylactoid eruptions usually occur 7 to 14 days after exposure: If a\npatient reacts within 1 to 2 days of starting a new drug, it is probably not\nthe causative agent.\nâ–  Eruptions are generally widespread, relatively symmetr",
      "char_start": 280000,
      "char_end": 282000
    },
    {
      "chunk_id": 141,
      "text": "ic, and pruritic.\nâ–  Most disappear within 1 to 2 weeks following removal of the offending\nagent.\nâ–  Extreme complications of drug eruptions include erythroderma, drug\nreaction with eosinophilia and systemic symptoms (DRESS), Stevens-\nJohnson syndrome (SJS), and TEN.\nDiagnosis\nCharacteristic exam findings and history are sufficient. Excluding other causes\nis important, including viral exanthema, graft-versus-host disease, and autoim-\nmune dermatoses. A skin biopsy may be helpful if the diagnosis is not clear.\nTreatment\nDiscontinue the offending agent; treat symptoms with antihistamines and top-\nical steroids to relieve pruritus. In severe cases, systemic steroids and/or IV\nFIGURE 2.2-8. Morbilliform rash. Morbil-\nimmunoglobulin (IVIG) may be used.\nliform rash following drug administra-\ntion. (Reproduced with permission from Longo DL\net al. Harrisonâ€™s Principles of Internal Medicine, 18th ed.\nNew York, NY: McGraw-Hill; 2011.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9944 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 95\nERYTHEMA MULTIFORME\nErythema multiforme (EM) is a cutaneous reaction pattern with classic targe-\ntoid lesions (Fig. 2.2-9) that has many triggers and is often recurrent. Herpes\nsimplex is the most common agent.\nHistory/PE\nâ–  Initially, lesions start as erythematous, dusky macules that develop into the\ncharacteristic target lesion that commonly affects the palms and soles. The\ntarget lesions are described as a central, dusky blister surrounded by a pale\nedematous ring with a peripheral halo of erythema. The palms, soles, and FIGURE 2.2-9. Erythema multiforme.\n(Reproduced with permission from Dr. Richard\nlips are often affected.\nUsatine.)\nâ–  EM minor is uncomplicated and localized to the skin.\nâ–  EM major involves mucous membranes. It is a distinct entity from SJS,\nand there is no risk for progression to TEN.\nâ–  May have systemic symptoms, including fever, myalgias, arthralgias, and\nheadache.\nDiagnosi",
      "char_start": 282000,
      "char_end": 284000
    },
    {
      "chunk_id": 142,
      "text": "s\nKEY FACT\nCharacteristic exam findings and history are sufficient. As opposed to SJS or\nTEN, in EM the Nikolsky sign is âŠ–. EM is often triggered by infections such\nas HSV or mycoplasma. SJS and TEN are\nTreatment\ntypically caused by drugs. Both are type\nâ–  Symptomatic treatment is all that is necessary; systemic corticoste- IV hypersensitivity reactions.\nroids are of no benefit.\nâ–  EM minor can be managed supportively; EM major should be treated as\nburns.\nKEY FACT\nSTEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS A differential diagnosis should always\ninclude SJS and TEN if a âŠ• Nikolsky sign\nSJS and TEN constitute two different points on the spectrum of life-threatening is present.\nexfoliative mucocutaneous diseases that are often caused by a drug-induced\nimmunologic reaction. The epidermal separation of SJS involves <10% of\nbody surface area (BSA), whereas TEN involves >30% of BSA. Mucosal\ninvolvement is present in >90% of cases of SJS/TEN.\nHistory/PE\nâ–  Exam reveals severe mucosal erosions with widespread erythematous, dusky\nred or purpuric macules, or atypical targetoid lesions (Fig. 2.2-10). The epi-\ndermal lesions often become confluent and show a âŠ• Nikolsky sign (separa-\ntion of the superficial skin layers with slight rubbing) and epidermal\ndetachment.\nâ–  Mucous membranes (eyes, mouth, and genitals) often become eroded and\nhemorrhagic.\nâ–  Associated with first-time exposure to drugs: sulfonamides, penicillin, sei-\nzure medications (phenytoin, carbamazepine), quinolones, cephalospo-\nrins, steroids, nonsteroidal anti-inflammatory drugs (NSAIDs).\nFIGURE 2.2-10. Toxic epidermal necroly-\nsis. Note the diffuse erythematous bullae\nand areas of sloughing secondary to the\nfull-thickness necrosis of the epidermis.\n(Reproduced with permission from Tintinalli JE et al.\nTintinalliâ€™s Emergency Medicine: A Comprehensive Study\nGuide, 7th ed. New York, NY: McGraw-Hill; 2011.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9955 1100//2211//2222 11",
      "char_start": 284000,
      "char_end": 286000
    },
    {
      "chunk_id": 143,
      "text": "22::1111 PPMM\n\n96 HIGH-YIELD FACTS IN DERMATOLOGY\nDiagnosis\nKEY FACT\nâ–  SJS/TEN: Biopsy shows full-thickness eosinophilic epidermal necrosis.\nDo not confuse SJS and TEN with SSSS. â–  Differential diagnosis should include staphylococcal scalded-skin syn-\nSSSS is usually seen in children <6 drome (SSSS), graft-versus-host reaction (usually after bone marrow trans-\nyears of age and does not present with plant), radiation therapy, and burns.\ntargetoid lesions. SJS/TEN is generally\nseen in adults and is usually caused by a Treatment\ndrug rewaction.\nâ–  High risk for mortality. Early diagnosis and discontinuation of offending\nagent are critical in improving survival.\nâ–  Patients have the same complications as burn victimsâ€”thermoregulatory\nand electrolyte disturbances and secondary infections, so use wound dress-\nMNEMONIC ings for the skin and manage fluids and electrolytes.\nâ–  Data on pharmacologic therapy with steroids, cyclosporine, and IVIG are\nCauses of erythema nodosumâ€” mixed.\nNODOSUM\nNO cause (60% idiopathic)\nERYTHEMA NODOSUM\nDrugs: sulfa, iodides, penicillins\nOral contraceptives\nSarcoidosis A panniculitis (inflammatory process of the subcutaneous adipose tissue) trig-\nUlcerative colitis/Crohn disease gered by infection (Streptococcus, Coccidioides, Yersinia, TB), drugs (sulfon-\nMicrobiology (TB, leprosy, histoplasmosis, amides, antibiotics, oral contraceptive pills [OCPs]), and chronic inflammatory\nchronic infection) diseases (sarcoidosis, Crohn disease, ulcerative colitis, BehÃ§et disease).\nHistory/PE\nâ–  Painful, erythematous nodules appear on the patientâ€™s anterior shins\n(Fig. 2.2-11) and slowly spread, turning brown or purple. Patients\nmay present with fever and joint pain.\nâ–  Patients with erythema nodosum may have a false-âŠ• Venereal Disease\nResearch Laboratory result (as in SLE).\nDiagnosis\nCharacteristic exam findings and history are sufficient. A biopsy may help\nestablish the diagnosis. Workup with an ASO titer, PPD in high-risk patients,\nand CXR to rule out sarcoidos",
      "char_start": 286000,
      "char_end": 288000
    },
    {
      "chunk_id": 144,
      "text": "is, or inflammatory bowel disease workup based\non the patientâ€™s complaints.\nTreatment\nInvestigate and treat the underlying disease. Cool compresses, bed rest, and\nNSAIDs are helpful. Potassium iodide may be considered for persistent cases.\nFIGURE 2.2-11. Erythema nodosum. Ery-\nthematous plaques and nodules are com- BULLOUS PEMPHIGOID/PEMPHIGUS VULGARIS\nmonly located on pretibial areas. Lesions\nare painful and indurated but heal spon-\ntaneously without ulceration. (Reproduced Table 2.2-3 contrasts the clinical features of bullous pemphigoid with those of\nwith permission from Hurwitz RM. Pathology of the pemphigus vulgaris. Fig. 2.2-12 shows the location of antibodies.\nSkin: Atlas of Clinical-Pathological Correlation, 2nd ed.\nStamford, CT: Appleton & Lange; 1998.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9966 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 97\nTABLE 2.2-3. Acquired, Autoimmune Blistering Dermatoses\nVARIABLE BULLOUS PEMPHIGOID PEMPHIGUS VULGARIS\nLocation of blisters Basement membrane zone Intraepidermal\nAutoantibodies Against hemidesmosomes (bullous pemphigoid antigens Against desmosomes (desmogleins 1 and 3)\n1 and 2)\nBlister appearance Firm, stable blisters (see Image A); prodromal phase of pru- Erosions are more common than intact blisters\nritic eczematous or urticaria-like lesions that precede the (see Image B) because of the lack of keratinocyte\ndevelopment of tense bullae adherence\nNikolsky sign âŠ âŠ•\nMucosal involvement Rare Common\nPatient age Usually >60 years of age Usually 40â€“60 years of age\nAssociated medication Generally idiopathic ACE inhibitors, penicillamine, phenobarbital,\ntriggers penicillin\nMortality Rare Possible\nDiagnosis Tense bullae on the trunk are indicative of bullous Flaccid/unroofed bullae and erosions on the extrem-\npemphigoid ities and mucous membranes are indicative of\nMost accurate test: skin biopsy with direct immunofluo- pemphigus vulgaris\nrescence enzyme-linked immu",
      "char_start": 288000,
      "char_end": 290000
    },
    {
      "chunk_id": 145,
      "text": "nosorbent assay (ELISA)\nTreatment Topical: High-potency corticosteroids High-does steroids + immunomodulatory therapy\nSystemic: Corticosteroid, doxycycline\nA B\nImages reproduced with permission from Wolff K, Johnson RA. Fitzpatrickâ€™s Color Atlas & Synopsis of Clinical Dermatology, 6th ed. New York, NY:\nMcGraw-Hill; 2009.\nBullous pemphigoid\nNNoorrmmaall Pemphigus vulgaris\nDisrupted\ndesmosomes\nIntact\nEpidermis desmosomes\nBasal IgG antibodies\nlayer\nA 28-year-old Black woman presents\nDermis\nto the physician for a new-onset,\nBasement membrane Intact Disrupted painful rash. She noticed the\n(ECM/collagen) hemidesmosomes hemidesmosomes\nerythematous nodules on both lower\nlegs 3 days ago. She has a history of\nFIGURE 2.2-12. Blistering dermatosis. Compare and contrast the layers of the epidermis in\nnormal skin with the blistering dermatosis. Pemphigus vulgaris involves disruption of desmo- uveitis. What is the next best step to\nsomes and shows separation of the stratum spinosum from the stratum basale, causing a â€œrow identify the underlying cause of this\nof tombstones appearance.â€ Bullous pemphigoid involves separation of the epidermis from the rash?\ndermis due to disruption of hemidesmosomes. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9977 1100//2211//2222 1122::1111 PPMM\n\n98 HIGH-YIELD FACTS IN DERMATOLOGY\nNUMMULAR ECZEMA\nChronic relapsing-remitting, pruritic, coin-shaped, scaly plaques (Fig. 2.2-13)\nmost commonly found on the extremities (nummun is Latin for coin). While\nthe pathogenesis is unclear, it is thought to be associated with xerosis and\ndecreased skin lipids. Diagnosis is clinical, and treatment includes use of\nemollients and avoidance of harsh soaps to prevent dry skin and use of topical\nglucocorticoids.\nPYODERMA GANGRENOSUM\nFIGURE 2.2-13. Nummular eczema.\n(Reproduced with permission from Bissek AC, Tabah Neutrophilic dermatosis associated with inflammatory bowel disease, rheuma",
      "char_start": 290000,
      "char_end": 292000
    },
    {
      "chunk_id": 146,
      "text": "-\nEN, Kouotou E, et al. The spectrum of skin diseases in toid arthritis, and underlying malignancy. Presents as papules or pustules that\na rural setting in Cameroon (sub-Saharan Africa). BMC rapidly progress to a painful ulcer with a violaceous border and purulent base\nDermatol. 2012;12:7. doi:10.1186/1471-5945-12-7.)\n(Fig. 2.2-14). Demonstrates pathergy (formation of ulcers at sites of injury).\nDiagnosis depends on recognizing the clinical presentation and excluding\nother causes. Treatment involves local or systemic glucocorticoids.\nINFECTIOUS DISEASE MANIFESTATIONS OF THE SKIN\nVIRAL DISEASES\nHuman Herpesviruses\nThe human herpesviruses (HHVs) are a group of DNA viruses that result in\nFIGURE 2.2-14. Pyoderma gangreno- lifelong latent infection and are usually transmitted via physical contact\nsum. (Reproduced with permission from Fonder MA,\n(Table 2.2-4).\nCummins DL, Ehst BD, et al. Adalimumab therapy for\nrecalcitrant pyoderma gangrenosum. J Burns Wounds.\n2006;5:e8.) Herpes Simplex\nPainful, recurrent vesicular eruption of the mucocutaneous surfaces due to\nKEY FACT infection with HSV. Both serotypes can affect both genital and extragenital\nregions. The virus spreads through epidermal cells, fusing them into giant\nDermatitis herpetiformis (DH) has cells. The local host inflammatory response causes erythema and swelling.\nvesicles and erosions like herpes but\nis NOT caused by HSV. DH consists of History/PE\nsymmetric, bilateral pruritic papules,\nâ–  The initial infection is by direct contact with oral or genital fluids; after\nvesicles, bullae, and erosions on the\nthe primary episode, the virus remains dormant in local nerve ganglia:\nelbows (Fig. 2.2-15), knees, buttocks,\nHSV-1 in the trigeminal ganglia and HSV-2 in sacral ganglia. First epi-\nneck, and scalp, and it is associated with\nsodes are generally longer and more severe than recurrences.\nceliac disease (15%â€“25%). Treat with\nâ–  Onset is preceded by prodromal tingling, burning, or pain but can also\ndapsone and a gluten-f",
      "char_start": 292000,
      "char_end": 294000
    },
    {
      "chunk_id": 147,
      "text": "ree diet.\npresent with lymphadenopathy, fever, discomfort, malaise, and edema of\ninvolved tissue.\nâ–  Recurrences are limited to mucocutaneous areas innervated by the involved\nnerve:\nâ–  Recurrent oral herpes (HSV-1): The common â€œcold sore,â€ or herpes\nlabialis, which presents as a cluster of crusted vesicles on an erythema-\ntous base (Fig. 2.2-16A). Often triggered by stress, sunlight, or\nX-ray of the chest (CXR) to look for\ninfections.\nbilateral hilar adenopathy, which is\nâ–  Recurrent genital herpes (HSV-2): Unilateral and characterized by a\nsuggestive of sarcoidosis. Erythema\ncluster of ulcers on an erythematous base, but with less pain and sys-\nnodosum is the most common\ntemic involvement than the primary infection.\nnonspecific cutaneous manifestation\nof sarcoidosis, after cutaneous\nsarcoidosis.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9988 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 99\nTABLE 2.2-4. Human Herpesviruses\nVIRUS HISTORY AND MANIFESTATIONS DIAGNOSIS MANAGEMENT\nHHV-1 and HHV-1: Transmitted via respiratory/oral Clinical diagnosis should be con- Lesions and other manifestations\nHHV-2 (herpes secretions. Usually causes oral vesicles and firmed by laboratory testing can be treated or suppressed\nsimplex ulcers. Causes temporal lobe encephalitis. if possible. Vesicles can be with acyclovir, valacyclovir,\nviruses) HHV-2: Transmitted via sexual contact. unroofed and swabbedâ€” or famciclovir. Choose IV acy-\nUsually manifests as genital lesions. samples can be sent for viral clovir for severe infections in\nCauses viral meningitis. culture or polymerase chain immunocom promised, or in\nreaction (PCR). cases of central nervous system\n(CNS) infection.\nHHV-3 The only herpesvirus with airborne VZV lesions can be swabbed Contact and airborne precautions\n(varicella- transmission. and sent for PCR for definitive for hospitalized patients with\nzoster virus Chickenpox (primary infection) character- diagnosis. Samples ",
      "char_start": 294000,
      "char_end": 296000
    },
    {
      "chunk_id": 148,
      "text": "from other VZV infection or disseminated\n[VZV]) ized by pruritic vesicles with centrifugal suspected sites of infection zoster.\ndistribution. Severe cases can develop (e.g., cerebrospinal fluid [CSF]] Treatment with acyclovir/valacy-\npneumonia, hepatitis, and encephalitis. in suspected CNS infection, or clovir within 72 hours of rash\nShingles (reactivation) presents with vesicu- bronchoalveolar lavage [BAL] onset significantly decreases the\nlar rash that is painful and appears in fluid in suspected pneumonia) intensity and duration of pain\ndermatomal distribution. Can manifest can also be sent for PCR. associated with lesions. IV acy-\nas Ramsay Hunt syndrome (external ear clovir should be used for severe\nlesions, facial palsy, hearing loss). infections. Vaccines are available\nto prevent primary infection and\nreactivation.\nHHV-4 (Epstein- Transmitted via respiratory secretions and Infectious mononucleosis can be Treatment is mostly supportive.\nBarr virus saliva. diagnosed by identifying het- Patients should avoid contact\n[EBV]) Main cause of infectious mononucleosis erophile antibodies (Monospot sports for 4 weeks out of risk of\n(exudative pharyngitis, fever, fatigue, test) or IgM against the EBV viral splenic rupture.\nhepatitis, splenomegaly). capsid antigen. Note: Maculopapular rash can be\nAssociated with development of Burkitt and Blood smear can show atypical seen in cases of infectious mono-\nHodgkin lymphomas, B- and T-cell lym- lymphocytes. nucleosis that are treated with\nphomas, nasopharyngeal carcinoma, and amoxicillin (ie, when confused\nposttransplant lymphoproliferative disease. with streptococcus-associated\npharyngitis).\nHHV-5 (cyto- Transmitted via saliva, sexual contact, blood Diagnosis can be made by PCR of IV ganciclovir or oral valganciclovir\nmegalovirus transfusions, and organ transplants. samples from affected sites. for treatment.\n[CMV]) Can cause CMV mononucleosis (similar\nto EBV mononucleosis, but with negative\nMonospot).\nIn the immunocompromised",
      "char_start": 296000,
      "char_end": 298000
    },
    {
      "chunk_id": 149,
      "text": ", CMV can cause\nencephalitis, retinitis, pneumonitis, colitis,\nhepatitis, and esophagitis (â€œshallowâ€ ulcers\non endoscopy), and cytopenias.\n(continues)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 9999 1100//2211//2222 1122::1111 PPMM\n\n100 HIGH-YIELD FACTS IN DERMATOLOGY\nTABLE 2.2-4. Human Herpesviruses (continued)\nVIRUS HISTORY AND MANIFESTATIONS DIAGNOSIS MANAGEMENT\nHHV-6 and Transmitted via saliva. Typically a clinical diagnosis. Self-limited illness.\nHHV-7 (roseo- Can cause roseola infantum in childrenâ€”\nloviruses) high fevers for several days followed by\nonset of macular rash with centrifugal\nspread.\nHHV-8 Transmitted via sexual contact. No gold standard for diagnosis of\nAssociated with Kaposi sarcoma in HIV/AIDS HHV-8.\nand transplant patients. Kaposi sarcoma diagnosed by\nbiopsy.\nDiagnosis\nâ–  Clinical diagnosis: Grouped vesicles on an erythematous base.\nâ–  Most accurate test: Viral culture or PCR test of lesion. Direct fluorescent\nantigen is the most rapid test.\nâ–  Classic multinucleated giant cells on Tzanck smear (see Fig. 2.2-16B)\nsupport the diagnosis.\nTreatment\nKEY FACT â–  First episode: Immunocompetent patients with small lesions only need\nsupportive therapy, but acyclovir, famciclovir, or valacyclovir may be given\nHerpetic whitlow presents as painful to speed healing and reduce viral shedding.\nblisters/sores on the hand resembling â–  Immunocompromised patients or those with a severe painful outbreak\nâ€œdew drops on a rose.â€ It is common should receive an antiviral drug within 72 hours of the start of the\nin healthcare workers, respiratory outbreak.\ntherapists, dentists, and dishwashers. â–  Recurrent episodes: Minor lesions can be managed supportively. Acyclo-\nvir, famciclovir, or valacyclovir can be given during the episode to reduce\nhealing time by ~2 days.\nâ–  Severe frequent recurrences (>6 outbreaks per year): Daily prophylaxis\nwith acyclovir, famciclovir, or valacyclovir.\nâ–  In patients with AIDS, HSV can persist, with ulcers ",
      "char_start": 298000,
      "char_end": 300000
    },
    {
      "chunk_id": 150,
      "text": "remaining resistant to\nantiviral therapy. Symptomatic HSV infection lasting >1 month can be\nconsidered an AIDS-defining illness.\nA B\nFIGURE 2.2-15. Dermatitis herpetifor-\nmis. This disorder typically displays pru-\nritic, grouped papulovesicles on elbows,\nknees, buttocks, and posterior scalp. Ves-\nicles are often excoriated due to associ-\nated pruritus. (Reproduced with permission from FIGURE 2.2-16. Herpes simplex. (A) Herpes labialis. (B) HSV-1 lesions of the oral mucosa and\nLongo DL et al. Harrisonâ€™s Principles of Internal Medicine, tongue. (Image A reproduced with permission from the US Department of Health and Human Services and Dr. Herrmann.\n18th ed. New York, NY: McGraw-Hill; 2011.) Image B reproduced with permission from the US Department of Health and Human Services and Robert E. Sumpter.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110000 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 101\nVaricella-Zoster Virus\nVZV causes two different diseasesâ€”varicella and herpes zosterâ€”with trans-\nmission occurring via respiratory droplet or by direct contact. VZV has an\nincubation period of 10 to 20 days, with contagion beginning 24 hours before\nthe eruption appears and lasting until lesions have crusted.\nHistory/PE\nVaricella:\nâ–  A prodrome of malaise, fever, headache, and myalgia occurs 24 hours\nbefore the rash.\nâ–  Pruritic lesions appear in crops over 2 to 3 days, evolving from red mac-\nules to vesicles that then crust over.\nâ–  At any given time, patients may have all stages of lesions present. The\ntrunk, face, scalp, and mucous membranes are involved.\nâ–  In adults, chickenpox is often more severe, with systemic complications\nsuch as pneumonia and encephalitis.\nZoster:\nâ–  Herpes zoster (shingles) represents the recurrence of VZV in a specific\nnerve, with lesions appearing along the nerveâ€™s dermatomal distribution.\nOutbreaks are usually preceded by intense local pain (acute herpetic neu-\nralgia) followed by grouped bli",
      "char_start": 300000,
      "char_end": 302000
    },
    {
      "chunk_id": 151,
      "text": "sters on an erythematous base (Fig. 2.2-17).\nZoster can become disseminated in immunocompromised persons.\nâ–  Acute herpetic neuralgia: Pain persisting less than 30 days from rash onset.\nâ–  Subacute herpetic neuralgia: Pain persisting longer than 30 days but less\nthan 4 months from rash onset.\nâ–  Postherpetic neuralgia: Pain persisting greater than 4 months from rash onset.\nâ–  Herpes zoster oticus (Ramsay Hunt syndrome): Reactivation of VZV in\nthe geniculate ganglion affecting cranial nerves (CNs) VII and VIII. Pres-\nents with shingles in the ear canal and pinna; CN VII involvement causes\nfacial paralysis, and CN VIII involvement causes vertigo and sensorineural\nhearing loss.\nâ–  Herpes zoster ophthalmicus: Reactivation of VZV along trigeminal nerve dis-\ntribution. Presents with shingles in the trigeminal nerve distribution of V1,\nherpes zoster keratitis. This is a medical emergency, as it can cause blindness.\nâ–  Older patients with zoster can develop postherpetic neuralgia (severe\nnerve pain that persists for >4 months at the infection site after rash onset).\nDiagnosis\nPCR or viral culture test of lesion. Characteristic exam findings and history.\nTreatment\nâ–  Varicella is self-limited in healthy children. A live attenuated vaccine is\navailable that should be given to children in two doses at ages 1 and 4.\nAlso recommended for adults over 60 years of age. May be given to HIV\npatients with CD4+ cell count >200.\nâ–  Adults should be treated with systemic acyclovir to treat symptoms and\nprevent complications. Pain control with NSAIDs for acute and subacute\nherpetic neuralgia and neuropathic agents (gabapentin, pregabalin, tricy-\nclic antidepressants) for postherpetic neuralgia. FIGURE 2.2-17. Varicella zoster. The\nâ–  Postexposure prophylaxis is rarely needed, as most patients in the United unilateral dermatomal distribution of\nStates have been vaccinated or had childhood varicella. If needed, immuno- the grouped vesicles on an erythematous\nbase is characteristic. (Reproduced with ",
      "char_start": 302000,
      "char_end": 304000
    },
    {
      "chunk_id": 152,
      "text": "per-\ncompromised individuals, pregnant women, and newborns should receive\nmission from Wolff K et al. Fitzpatrickâ€™s Color Atlas &\nvaricella-zoster immune globulin within 10 days of exposure. Immunocom-\nSynopsis of Clinical Dermatology, 5th ed. New York, NY:\npetent adults should receive a varicella vaccine within 5 days of exposure. McGraw-Hill; 2005.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110011 1100//2211//2222 1122::1111 PPMM\n\n102 HIGH-YIELD FACTS IN DERMATOLOGY\nComplications\nHerpes zoster ophthalmicus, herpes zoster oticus (Ramsay Hunt syndrome),\nand congenital varicella syndrome.\nMolluscum Contagiosum\nA poxvirus infection that is most common in young children and in\nAIDS patients. It is spread by direct skin-to-skin contact (sports, sex) or\nsharing infected clothing or towels.\nHistory/PE\nFIGURE 2.2-18. Molluscum contagiosum.\nFlesh-colored, dome-shaped papules pres- â–  Presents as tiny, flesh-colored, dome-shaped, waxy papules, frequently\nent on the face of an adolescent. (Repro- with central umbilication. In children, lesions are found on the trunk,\nduced with permission from Dr. Richard Usatine.) extremities, or face (Fig. 2.2-18). In adults, they are considered sexually\ntransmitted infections (STIs) and are commonly found on the genitalia\nand in the perineal region. Typically spares palms and soles.\nâ–  Lesions are asymptomatic unless they become inflamed or irritated.\nDiagnosis\nâ–  Characteristic exam findings and history are sufficient.\nâ–  Most accurate test: If the diagnosis is uncertain, Wright and Giemsa\nKEY FACT\nstains show presence of large inclusion or molluscum bodies on histology.\nIf you see giant molluscum\nTreatment\ncontagiosum, think HIV or â†“ cellular\nimmunity. â–  Local destruction: Curetting, cryotherapy, laser ablation, or applying can-\ntharidin (a blistering agent) to the lesions.\nâ–  In children, lesions resolve spontaneously over months to years and are\noccasionally left untreated.\nVerrucae (Warts)\nWarts are c",
      "char_start": 304000,
      "char_end": 306000
    },
    {
      "chunk_id": 153,
      "text": "aused by human papillomavirus (HPV) and can occur on skin,\nmucous membranes, and other epithelia. Although usually benign, some sub-\ntypes of HPV (especially 16 and 18) lead to squamous malignancies. Spread is\nby direct contact.\nHistory/PE\nâ–  Common warts are most often seen on the hands, though they can occur\nanywhere.\nâ–  Classic genital warts (condyloma acuminatum, caused by HPV subtypes 6\nand 11) are cauliflower-like papules or plaques appearing on the penis,\nvulva, or perianal region (Fig. 2.2-19).\nA B\nFIGURE 2.2-19. Verrucae (warts) caused by HPV. (A) Soft, tan-colored, cauliflower-like papules on\nhands. (B) Condyloma acuminatum on genitals. (Reproduced with permission from Dr. Richard Usatine.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110022 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 103\nâ–  Mothers with genital warts can transmit HPV to the infant by aspiration\nduring delivery, causing respiratory papillomatosis. Presents as a weak cry,\nhoarseness, and stridor.\nDiagnosis\nâ–  Characteristic exam findings and history are sufficient. Acetic acid turns\nlesions white and can be used to visualize mucosal lesions.\nâ–  Most accurate test: PCR of the lesion for HPV.\nTreatment\nGenital warts are treated surgically with cryotherapy, laser therapy, and exci-\nsion. Chemical treatment includes podophyllin (contraindicated in preg-\nnancy) and trichloroacetic acid, and immunologic treatment includes\nimiquimod (contraindicated in pregnancy). Cervical lesions are monitored\nfor evidence of malignancy. Prevent via vaccination and barrier methods of\ncontraception.\nBACTERIAL INFECTIONS\nSkin and soft tissue bacterial infections are a diverse group of diseases that\nmanifest in different ways: red, inflamed papules and pustules centered\naround hair follicles are characteristic of folliculitis, while rapidly expanding,\ncrepitant, dusky plaques suggest necrotizing fasciitis. Often, the clinical mani-\nfestation and treatment approach",
      "char_start": 306000,
      "char_end": 308000
    },
    {
      "chunk_id": 154,
      "text": " are dictated by the causative organism and\nthe location of the infectious process within the layers of the skin and soft tis-\nsues. See Figure 2.2-20 for an illustration of the layers of the skin and associ-\nated depths of infection.\nImpetigo\nLocal infection of the epidermis that primarily occurs in children and is\ncaused by both group A streptococcal and staphylococcal organisms. It is\nhighly contagious and transmitted by direct contact.\nFolliculitis\nImpetigo\nEpidermis\nErysipelas\nDermis\nHair follicle\nCellulitis\nSubcutaneous fat\nNecrotizing\nfasciitis\nFascia\nMuscle\nFIGURE 2.2-20. Skin layers (blue) and depths of infection (red). (Reproduced with permission from USMLE-\nRx.com.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110033 1100//2211//2222 1122::1111 PPMM\n\n104 HIGH-YIELD FACTS IN DERMATOLOGY\nHistory/PE\nâ–  Nonbullous type: Pustules and honey-colored crusts on an erythematous\nbase, often on the face around the mouth, nose, or ears (Fig. 2.2-21).\nCommonly caused by S aureus or group A streptococci (GAS).\nâ–  Bullous type: Characterized by flaccid bullae confined to the area of pri-\nmary infection that form crusts when they rupture. Can involve the acral\nsurfaces. Nikolsky sign is positive. Bullous impetigo is almost always caused\nby exfoliative toxin-producing strains of S aureus and can evolve into SSSS.\nâ–  SSSS: Systemic dissemination of exfoliative toxin destroys\ndesmoglein-1 in the stratum granulosum of the skin. Presents as\nfever, generalized erythema, and widespread superficial blisters that\ndo not form crusts when they rupture. Nikolsky is positive. Common\nin neonates, children, and adults with renal insufficiency.\nâ–  Ecthyma: Characterized by ulcerative lesions that extend into der-\nmis. Appear as punched-out ulcers with yellow crusts.\nFIGURE 2.2-21. Impetigo. Dried pustules\nwith a superficial golden-brown crust are\nmost commonly found around the nose Diagnosis\nand mouth. (Reproduced with permission from\nClinical. Gram stain ",
      "char_start": 308000,
      "char_end": 310000
    },
    {
      "chunk_id": 155,
      "text": "or culture to identify causative organism (not necessary\nBondi EE. Dermatology: Diagnosis and Therapy. Stam-\nto start treatment).\nford, CT: Appleton & Lange; 1991.)\nKEY FACT Treatment\nUse antibiotics with antistaphylococcal activity based on severity and suspi-\nScarlet fever: â€œSandpaperâ€ rash\ncion of methicillin-resistant S aureus (MRSA):\nor â€œsunburn with goose bumpsâ€\nappearance; strawberry tongue. Caused â–  Mild localized disease: Topical antibiotics (mupirocin) are sufficient.\nby S pyogenes. Treat with penicillin. â–  Severe disease (non-MRSA) or ecthyma: Oral cephalexin or dicloxacillin.\nâ–  Severe disease (MRSA likely): Oral trimethoprim-sulfamethoxazole,\nclindamycin, or doxycycline.\nKEY FACT\nâ–  SSSS: Nafcillin, vancomycin, and wound care.\nSalmonella typhi: Small pink papules â–  Return to school: The child may return to school 24 hours after the initia-\ntion of therapy.\non the trunk (â€œrose spotsâ€) in groups of\n10 to 20 plus fever and GI involvement.\nComplications\nTreat with fluoroquinolones and third-\ngeneration cephalosporins. Consider â–  Acute poststreptococcal glomerulonephritis (PSGN)\ncholecystectomy for chronic carrier state. â–  SSS\nCellulitis\nA deeper skin infection involving dermis and subcutaneous tissue. Commonly\ncaused by staphylococci or group A streptococci originating from damaged skin\nor a systemic source. Community-acquired MRSA is an increasingly common\ncause of purulent cellulitis. Risk factors include diabetes mellitus (DM), IV\ndrug use, venous stasis, and immune compromise.\nHistory/PE\nâ–  Presents with red, hot, swollen, tender skin. Fever and chills are common.\nâ–  Erysipelas is a type of cellulitis usually caused by GAS that is confined to\nthe dermis and lymphatic tissue, creating a characteristically raised, indu-\nrated, well-demarcated, erythematous area of skin (Fig. 2.2-22).\nDiagnosis\nâ–  Characteristic exam findings and history are sufficient. Wound and/or\nblood cultures may aid in diagnosis and help determine antibiotic\nsensitivities.\nâ–  Rule out absc",
      "char_start": 310000,
      "char_end": 312000
    },
    {
      "chunk_id": 156,
      "text": "ess, osteomyelitis, and necrotizing fasciitis.\nFIGURE 2.2-22. Erysipelas of the face.\n(Reproduced from Goldsmith LA et al. Fitzpatrickâ€™s\nDermatology in General Medicine, 8th ed. New York, NY:\nMcGraw-Hill; 2012.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110044 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 105\nTreatment\nâ–  Topical antibiotics are ineffective due to depth of infection.\nâ–  Use 5 to 10 days of oral antibiotics. IV antibiotics are indicated if there is\nevidence of systemic toxicity, comorbid conditions, DM, extremes of age,\nor hand or orbital involvement.\nâ–  Choice of antibiotic is similar to that used to treat impetigo (empiric treat-\nment of S aureus and GAS).\nNecrotizing Fasciitis\nFIGURE 2.2-23. Necrotizing fasciitis of\nDeep infection along a fascial plane causing severe pain followed by anesthe- the lower extremity. Patient presented\nsia and necrosis. Can be monomicrobial (GAS) or polymicrobial, usually with hypotension due to late necrotizing\nfasciitis and myositis due to Î²-hemolytic\ncaused by a mixed infection of anaerobic and aerobic bacteria that includes S\nstreptococcal infection. (Reproduced with per-\naureus, Escherichia coli, and Clostridium perfringens. Ten percent of cases are\nmission from Brunicardi FC et al. Schwartzâ€™s Principles\ncaused by S pyogenes. A history of trauma or recent surgery to the affected of Surgery, 9th ed. New York, NY: McGraw-Hill; 2010.)\narea is sometimes present.\nKEY FACT\nHistory/PE\nFournier gangrene is a form of\nâ–  Systemic: Fever, chills, altered mental status (AMS).\nnecrotizing fasciitis that is localized to\nâ–  Acute onset of pain out of proportion to findings and swelling progressing\nthe genital and perineal area.\nto anesthesia at the site of trauma or surgery.\nâ–  An area of erythema quickly spreads over the course of hours to days. Mar-\ngins move out into normal skin, and skin becomes dusky or purplish near\nKEY FACT\nthe site of insult, ultimately leading to necr",
      "char_start": 312000,
      "char_end": 314000
    },
    {
      "chunk_id": 157,
      "text": "osis (Fig. 2.2-23).\nâ–  If a necrotic area is open, gloved fingers can easily pass between two layers to Pseudomonas aeruginosa infection\nreveal yellow-green necrotic fascia (infection spreads quickly in deep fascia). leads to â€œhot tub folliculitis,â€ a pruritic,\nâ–  Important signs of tissue necrosis are gas production (crepitus on physical pustular folliculitis. Look for a history of\nexam); a putrid, gray-colored discharge (colloquially named dishwater fluid); exposure to wet, aquatic environments.\nbullae; severe pain; lack of inflammatory signs; and intravascular volume loss.\n1\nDiagnosis\nStrong suspicion of necrotizing fasciitis based on clinical exam and imaging\nA 7-year-old girl presents to the\n(showing gas in soft tissue) requires immediate surgical exploration and\nphysician with fever, sore throat, and\ndebridement; tissue culture helps determine causative organisms.\na facial rash. Physical examination\nreveals an erythematous pharynx\nTreatment\nwithout exudates and a red, painful\nâ–  Surgical emergency: Early and aggressive surgical debridement is critical. patch on the childâ€™s cheek that the\nâ–  In most cases, systemic broad-spectrum coverage is necessary. If Strepto- mother notes has been expanding.\ncoccus is the principal organism involved, penicillin G is the drug of What is the appropriate therapy?\nchoice. Clindamycin is added to â†“ exotoxin production. For anaerobic\ncoverage, give metronidazole or a third-generation cephalosporin.\nFolliculitis 2\nInflammation and/or infection of a hair follicle. Typically caused by infection\nwith Staphylococcus, Streptococcus, and gram âŠ– bacteria. Occasionally can A 42-year-old man is admitted to the\nhospital for cellulitis after injuring\nbe caused by yeast such as Candida albicans or M furfur. Can occur on any\nhis leg while swimming. He is febrile\narea with follicles.\nand has a well-demarcated area of\nerythema on the anterior aspect of\nHistory/PE\nhis right knee. Antibiotics are started.\nâ–  Presents as a tiny pustule at the opening o",
      "char_start": 314000,
      "char_end": 316000
    },
    {
      "chunk_id": 158,
      "text": "f a hair follicle with a hair pene- Six hours later, the patient is in\ntrating it. When the infection is deeper, a furuncle, or hair follicle abscess, excruciating pain. The erythema has\ndevelops. Furuncles may disseminate to adjacent follicles to form a car- spread circumferentially around the\nbuncle (Fig. 2.2-24). knee, and the anterior aspect of the\nknee now has a purplish hue. What is\nthe next best step?\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110055 1100//2211//2222 1122::1111 PPMM\n\n106 HIGH-YIELD FACTS IN DERMATOLOGY\nâ–  Patients with exposure to hot tubs, DM, or immunosuppression are at â†‘\nrisk. Eosinophilic folliculitis can occur in AIDS patients, in whom the dis-\nease is intensely pruritic and resistant to therapy.\nDiagnosis\nCharacteristic exam findings and history are sufficient. KOH prep or biopsy\nmay be needed if fungus or eosinophilic folliculitis is suspected.\nTreatment\nTopical antibiotics (mupirocin) treat mild superficial disease. More severe\ndisease is treated similarly to impetigo, with cephalexin or dicloxacillin orally,\nescalating to clindamycin or doxycycline if MRSA is suspected. Hot tub follic-\nulitis due to Pseudomonas is self-limiting and does not usually require treat-\nmentâ€”severe disease can be treated with ciprofloxacin.\nAcne Vulgaris\nA skin disease common among adolescents. The pathogenesis involves hor-\nmonal activation of sebaceous glands, the development of comedones\nFIGURE 2.2-24. Carbuncle due to\nmethicillin-sensitive S aureus. A very (plugged pilosebaceous units), and involvement of Cutibacterium acnes (for-\nlarge, inflammatory plaque studded with merly Propionibacterium) in the follicle, causing inflammation. Acne lesions\npustules, draining pus, on the nape of the can be caused by medications (lithium, corticosteroids) or by topical occlu-\nneck. Infection extends down to the fascia\nsion (cosmetics). Commonly seen with congenital adrenal hyperplasia, poly-\nand has formed from a confluence of ma",
      "char_start": 316000,
      "char_end": 318000
    },
    {
      "chunk_id": 159,
      "text": "ny\ncystic ovarian syndrome (PCOS), and Cushing syndrome.\nfuruncles. (Reproduced with permission from Wolff\nK et al. Fitzpatrickâ€™s Color Atlas & Synopsis of Clinical Derma-\nHistory/PE\ntology, 7th ed. New York, NY, McGraw-Hill; 2013.)\nâ–  There are three stages of acne lesions:\nâ–  Comedonal: Open (â€œblackheadsâ€) or closed (â€œwhiteheadsâ€)\nKEY FACT\ncomedones.\nIronically, erythromycin does not cause â–  Inflammatory: The comedones rupture, creating inflammatory pap-\nules, pustules, nodules, and cysts.\nerythema with sun exposure. It is\ntetracyclines (ie, doxycycline) that can â–  Scar: May develop as inflammation heals. Picking at lesions exacer-\nbates scarring.\ncause photosensitivity!\nâ–  Acne develops at puberty and typically persists for several years. Male ado-\nlescents are more likely to have severe cystic acne than females due to\n1 greater androgen production.\nâ–  Women in their 20s can have a variant that flares cyclically with menstrua-\ntion, with fewer comedones but more painful lesions on the chin.\nThis child has erysipelas, a rash\ncommonly caused by a GAS â–  Drug-induced acne is a common adverse effect of glucocorticoid use.\ninfection. It can present as a small red These lesions are monomorphic papules without comedones, nodules, or\npatch on the cheek or extremities cysts and do not respond to standard acne therapy. However, they usually\nthat turns into a painful, shiny resolve with discontinuation of the steroids.\nred plaque. Patients often have a â–  Acne mechanica occurs due to pressure or friction. Constant mechanical\nhistory of chronic cutaneous ulcers, pressure damages pilosebaceous units causing obstruction and acne forma-\nlymphedema, or pharyngitis. Treat\ntion. Treat by eliminating the source of pressure. Can be caused by\nwith penicillin.\ncrutches, bra straps, and heavy backpacks.\nDiagnosis\nCharacteristic exam findings and history are sufficient.\n2\nTreatment\nEmergent surgical consult for â–  Mild to moderate acne: Topical retinoids are the most effective topical\ndebridem",
      "char_start": 318000,
      "char_end": 320000
    },
    {
      "chunk_id": 160,
      "text": "ent given the clinical agent for comedonal acne. Topical benzoyl peroxide kills C acnes. Con-\nsuspicion for necrotizing fasciitis, a sider adding a topical antibiotic (clindamycin, erythromycin) if response\nsurgical emergency. to other topicals is inadequate.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110066 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 107\nâ–  Moderate to severe acne: In addition to topical treatment as noted earlier,\nadd oral antibiotics such as doxycycline or minocycline. When acne is\nsevere and all treatments are failing, oral retinoids (isotretinoin) are the\nmost effective treatment. All other acne medications are stopped.\nâ–  Isotretinoin is a teratogen and elevates LFTs. Patients require periodic\nblood tests to check liver function, cholesterol, and triglycerides. Given\nthe teratogenicity of isotretinoin, female patients must be on two forms\nof contraception (ie, barrier and hormonal) and are monitored with\nbaseline and serial pregnancy tests.\nPilonidal Cysts\nFIGURE 2.2-25. Pilonidal cyst. Note the\nAbscesses in the sacrococcygeal region. Thought to be a foreign body reaction characteristic location in the superior\ngluteal cleft. May have purulent dis-\nto entrapped hair. Most common in young men with excessive body hair.\ncharge, surrounding erythema, or a tuft\nof hair. (Reproduced with permission from Awad\nHistory/PE\nMM, Elbaset AA, Ebraheem S, Tantawy E, Elhafez MA,\nPresents as an abscess at the superior gluteal cleft (Fig. 2.2-25) that can be tender, Elsayed AM. A scoring system as a method to evaluate\npilonidal sinus disease to make an easy decision for\nfluctuant, and warmâ€”sometimes associated with purulent drainage or cellulitis.\nits management. Indian J Plast Surg. 2009;42(1):43-48.\nSystemic symptoms are uncommon, but cysts can develop into perianal fistulas.\ndoi:10.4103/0970-0358.53011.)\nDiagnosis\nCharacteristic exam findings and history are sufficient.\nTreatment\nKEY FACT\nâ–  Treatment ",
      "char_start": 320000,
      "char_end": 322000
    },
    {
      "chunk_id": 161,
      "text": "is with incision and drainage of the abscess followed by sterile\nGeneral progression of acne treatment\npacking of the wound.\nbased on severity: topical benzoyl\nâ–  Excision of sinus tract if present.\nâ–  Good local hygiene and shaving of the sacrococcygeal skin can help pre- peroxide, retinoid, or antibiotic â†’ oral\nvent recurrence. antibiotic â†’ oral isotretinoin\nLeprosy\nDisease of skin and peripheral nerves, found in the Southwest United States KEY FACT\nand developing countries. Caused by acid-fast bacterium Mycobacterium lep-\nrae and causes chronic granuloma formation. Antibiotics are not needed for pilonidal\ncysts unless cellulitis is present; if\nHistory/PE antibiotics are prescribed, both aerobic\nand anaerobic coverage is required.\nPatients present with hypopigmented, hypoesthetic skin lesions, nerve thickening,\nand palsies of peripheral nerves. Clinical manifestations depend on type of leprosy.\nâ–  Tuberculoid: One to two localized hypopigmented anesthetic plaques\nâ–  Lepromatous: Many plaques or nodules, leonine facies, hair loss (particu-\nlarly eyebrows and lashes), septal perforation\nDiagnosis\nâ–  Skin scraping\nâ–  Punch biopsy\nâ–  Lepromin test\nTreatment\nA 17-year-old female presents to the\nâ–  Treat tuberculoid leprosy with dapsone and rifampin. dermatologist for severe cystic acne\nâ–  Add clofazimine for lepromatous or multibacillary leprosy. that has been refractory to both\ntopical and systemic antibiotics. She\ninquires about isotretinoin. Given this\ndrugâ€™s potentially hazardous adverse\neffects, what laboratory tests would\nbe performed monthly if this patient\nwere to be placed on isotretinoin?\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110077 1100//2211//2222 1122::1111 PPMM\n\n108 HIGH-YIELD FACTS IN DERMATOLOGY\nFUNGAL INFECTIONS\nTinea Versicolor\nCaused by Malassezia species, a yeast that is part of normal skin flora. Humid\nand sweaty conditions, as well as oily skin, can make the organism patho-\ngenic. Cushing syndrome and immunosuppre",
      "char_start": 322000,
      "char_end": 324000
    },
    {
      "chunk_id": 162,
      "text": "ssion are also risk factors.\nHistory/PE\nâ–  Presents with small scaly patches of varying color on the chest or back\n(Fig. 2.2-26A).\nâ–  Patches can be hypopigmented (alba) as a result of interference with mela-\nnin production or hyperpigmented/pink (rubra) due to inflammation.\nâ–  Often discovered after sun exposure when lesions fail to tan and stand out.\nDiagnosis\nâ–  Characteristic exam findings and history are usually sufficient, but confir-\nmatory testing is useful to differentiate from other dermatologic disorders\nwith similar findings.\nâ–  Best initial test: KOH preparation of the scale revealing â€œspaghetti and\nmeatballsâ€ pattern of hyphae and spores (see Fig. 2.2-26B).\nTreatment\nTreat lesions with topical ketoconazole or selenium sulfide.\nCandidiasis\nYeast infection or thrush, candidiasis can be caused by any Candida species\nbut is most commonly caused by C albicans. In immunocompetent patients,\nit typically presents as eroded erythematous papules and plaques in intertrigi-\nnous, moist areas such as the groin, skinfolds, axillae, vagina, and below the\nbreasts. Oral thrush is common in infancy, but in adults it is often a sign of a\nweakened immune system.\nHistory/PE\nâ–  Patients often have a history of antibiotic or steroid use, DM, or\nimmunocompromise.\nA B\nFIGURE 2.2-26. Tinea versicolor. (A) Note the discrete, hypopigmented patches extensively\nThe laboratory tests to be performed involving the patientâ€™s back. Tinea versicolor may also present as hyperpigmented macules\nmonthly for a female patient taking or patches in some individuals. (B) KOH preparation shows the characteristic â€œspaghetti and\nisotretinoin for severe cystic acne meatballsâ€ pattern of hyphae and spores. (A reproduced with permission from Tintinalli JE et al. Tintinalliâ€™s Emer-\nwould be serum or urine Î²-human gency Medicine: A Comprehensive Study Guide, 7th ed. New York, NY: McGraw-Hill; 2011. B reproduced with permission from\nWolff K et al. Fitzpatrickâ€™s Dermatology in General Medicine, 7th ed. New York,",
      "char_start": 324000,
      "char_end": 326000
    },
    {
      "chunk_id": 163,
      "text": " NY: McGraw-Hill; 2008.)\nchorionic gonadotrophin to rule out\npregnancy, liver function tests (LFTs),\ncholesterol, and triglycerides.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110088 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 109\nâ–  Oropharyngeal candidiasis (thrush): Presents with painless white plaques\non intraoral mucosal surfaces that can be easily scraped off to reveal\nerosions.\nâ–  Candidiasis of the skin: Presents as markedly erythematous papules and\nplaques with occasional erosions and smaller satellite lesions (Fig. 2.2-27)\nseen nearby, often in skinfolds. In infants, infection is often seen in the\ndiaper area and along the inguinal folds.\nâ–  Vulvovaginal candidiasis: Vaginal burning, dysuria, pruritis, white â€œcot-\ntage-cheeseâ€ discharge.\nâ–  Candida esophagitis: Odynophagia in a patient with hematologic malig-\nnancy or AIDS.\nDiagnosis FIGURE 2.2-27. Cutaneous candidiasis\nâ–  Characteristic exam findings and history are sufficient. with satellite lesions. (Reproduced with\npermission from Goldsmith LA et al. Fitzpatrickâ€™s Der-\nâ–  Best initial test: KOH preparation of a scraping of the affected area. KOH\nmatology in General Medicine, 8th ed. New York, NY:\ndissolves the skin cells but leaves the Candida untouched such that Can-\nMcGraw-Hill; 2012.)\ndida spores and pseudohyphae become visible.\nâ–  Most accurate test: Blood culture.\nâ–  Endoscopy if esophageal involvement, antigen testing, tissue biopsy.\nTreatment\nâ–  Oral candidiasis: Oral fluconazole tablets; nystatin swish and swallow,\nclotrimazole troches.\nâ–  Esophageal candidiasis: Systemic fluconazole, echinocandins, amphotericin\nB.\nâ–  Superficial (skin) candidiasis: Topical antifungals; keep skin clean and\ndry.\nâ–  Vulvovaginal candidiasis: Topical antifungal, single dose of oral\nfluconazole.\nâ–  Diaper rash: Topical nystatin.\nDermatophyte Infections\nDermatophytes are found in tissues with keratin (skin, nails, and hair). Caus-\native organisms include Trichophyton (m",
      "char_start": 326000,
      "char_end": 328000
    },
    {
      "chunk_id": 164,
      "text": "ost common), Microsporum, and\nEpidermophyton species. Risk factors include DM, â†“ peripheral circulation,\nimmune compromise, and chronic maceration of skin (from athletic activi-\nties). A common cause of recurrent infections is autoinoculation from a tinea\ninfection on another site of the body.\nHistory/PE\nVaries according to subtype:\nâ–  Tinea corporis (ringworm): Scaly, pruritic eruption with a well-demarcated,\nirregular border, often with central clearing (Fig. 2.2-28). Can be seen in\nimmunocompromised patients or in children following contact with infected\npets. The term ringworm is a misnomer due to the characteristic appearance\nof the lesionâ€”it is caused by a fungus, not a worm or parasitic infection.\nâ–  Tinea pedis/manuum (Fig. 2.2-29A): Presents as chronic interdigital scal-\ning with erosions between the toes (athleteâ€™s foot) or as a thickened, scaly\nskin on the soles (moccasin distribution). In addition, involvement of one FIGURE 2.2-28. Tinea corporis. Note the\nringworm rash with a scaly, erythema-\nhand is typical in the â€œone hand two feet syndrome.â€\ntous, distinct border and central clearing.\nâ–  Tinea cruris (jock itch) (Fig. 2.2-29B): A fungal infection of the groin that\n(Reproduced with permission from Wolff K et al. Fitz-\nis usually associated with tinea pedis. Pruritic plaque without central clear-\npatrickâ€™s Dermatology in General Medicine, 7th ed. New\ning, typically sparing the scrotum. York, NY: McGraw-Hill; 2008.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 110099 1100//2211//2222 1122::1111 PPMM\n\n110 HIGH-YIELD FACTS IN DERMATOLOGY\nA B C\nFIGURE 2.2-29. Cutaneous mycoses. (A) Tinea pedis; (B) Tinea cruris; (C) Tinea capitis.\n(Reproduced with permission from Dr. Richard Usatine.)\nâ–  Tinea capitis (Fig. 2.2-29C): A fungal scalp infection causing scaling and\nhair loss with scarring. A large inflammatory boggy mass caused by tinea\ncapitis is called a kerion.\nâ–  Tinea unguium (onychomycosis): A fungal nail infection causing ",
      "char_start": 328000,
      "char_end": 330000
    },
    {
      "chunk_id": 165,
      "text": "brittle,\ndiscolored nails.\nDiagnosis\nâ–  Clinical\nâ–  Best initial test: KOH skin scraping showing hyphae\nâ–  Most accurate test: Fungal culture\nâ–  Woodâ€™s lamp exam for Microsporum species\nTreatment\nStart with topical antifungals; escalate to oral griseofulvin or terbinafine if\ninfection is widespread or unresponsive to topicals. Oral antifungals are indi-\ncated for nail involvement and tinea capitis (to penetrate into hair follicles);\nconsider oral treatment for immunocompromised patients.\nSporotrichosis\nInfection caused by Sporothrix schenckii, a fungus found in plant matter.\nOften called â€œrose-gardener disease.â€ Acquired by direct contact, which\ncauses a papule that drains odorless fluid. Additional lesions form over time\nalong lines of lymphatic drainage, although lymphadenopathy is absent. Treat\nwith itraconazole.\nPARASITIC INFECTIONS\nLice\nLice live off blood and on specific parts of the body, depending on their spe-\ncies (head lice, body lice, pubic lice). They are spread through body contact\nor by the sharing of bedclothes and other garments or hair accessories. Lice\nsecrete local toxins that lead to pruritus.\nHistory/PE\nâ–  Patients with lice often experience severe pruritus, and secondary bacterial\ninfection of the excoriations is a risk. Classroom breakouts of head lice are\ncommon.\nâ–  Body lice are seen in persons with inadequate hygiene or in those with\ncrowded living conditions. Pubic lice (called â€œcrabsâ€ because of their\nsquat, crablike body shape) contain anticoagulant in their saliva, so their\nbites often become ecchymotic.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111100 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 111\nDiagnosis\nLice and their eggs (nits) can be seen on hairs or in clothes with the naked\neye. Microscopy can reveal the arthropods, their eggs, and their droppings.\nTreatment\nâ–  Head lice: Treat with topical permethrin, pyrethrin, benzyl alcohol, and\nmechanical removal.\nâ–  Body lice: Wash b",
      "char_start": 330000,
      "char_end": 332000
    },
    {
      "chunk_id": 166,
      "text": "ody, clothes, and bedding thoroughly. Rarely, topical\npermethrin is needed.\nâ–  Pubic lice: Treat with the same medications as for head lice.\nScabies\nCaused by Sarcoptes scabiei. The burrowing of this arthropod into the epider-\nmis leads to pruritus that â†‘ in intensity once an allergy to the mite or its prod-\nucts develops. Secondary bacterial infections due to scratching are common.\nScabies mites are spread through close contact.\nHistory/PE\nâ–  Patients present with intense pruritus, especially at night and after hot\nshowers, and erythematous papules with linear tracts, representing the\nburrows of the mite (Fig. 2.2-30A).\nâ–  The most commonly affected sites are the skinfolds of the hands (often\nincludes the interdigital finger webs), axillae, genitals, and flexor surfaces\nof the wrists (see Fig. 2.2-30B).\nâ–  Crusted scabies is severe, diffuse skin involvement with crusts and scales\nseen in the immunocompromised (eg, HIV). KEY FACT\nLice can be seen with the naked eye.\nDiagnosis Scabies mites are too small and can\nA history of pruritus in several family members is suggestive. The mite may be only be identified with a microscope/\nidentifiable by scraping an intact tunnel and looking under the microscope dermatoscope.\nfor the arthropods, their eggs, and their droppings.\nA B\nFIGURE 2.2-30. Scabies. (A) Linear tracts made as the mite burrows into the skin (yellow\narrow). (B) Erythema-tous papules in interdigital web spaces (black arrow). (A reproduced with\npermission from Micali G et al. Scabies: Advances in noninvasive diagnosis. PloS Negl Trop Dis. Published 16 Jun. 2016;10.\n(6):e0004691. doi:10.1371/journal.pntd.0004691. B reproduced with permission from Siegfried EC, Hebert AA. Diagnosis of\natopic dermatitis: Mimics, overlaps, and complications. J Clin Med. 2015;4[5]:884-917. doi:10.3390/jcm4050884)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111111 1100//2211//2222 1122::1111 PPMM\n\n112 HIGH-YIELD FACTS IN DERMATOLOGY\nTreatment\nâ–  Patien",
      "char_start": 332000,
      "char_end": 334000
    },
    {
      "chunk_id": 167,
      "text": "ts should be treated with 5% permethrin from the neck down (head\nto toe for infants) for at least two treatments separated by 1 week, and their\nclose contacts should be treated as well. Oral ivermectin is also effective.\nâ–  Treatment for crusted scabies: Oral ivermectin in combination with topi-\ncal permethrin.\nâ–  Pruritus can persist up to 2 weeks after treatment.\nâ–  Clothes and bedding should be thoroughly washed.\nBed Bugs\nPainless erythematous papules on exposed skin due to bites from Cimex lectu-\nlarius at night. Mild pruritus, which is worse at night and in the morning.\nLesions seen in a linear â€œbreakfast, lunch, and dinnerâ€ pattern. Transmitted\nby contact with infested beddings and furniture. Treat pruritis with topical\nsteroids and antihistamines; use insecticides or heat to remove infestation.\nCutaneous Larva Migrans\nErythematous, serpentine, migratory rash marked by pruritic maculopapular\nlesion at the site of larval entry due to infection with hookworm larvae, com-\nmonly acquired by walking barefoot on grass or sand. Treat with ivermectin.\nISCHEMIC SKIN DISORDERS\nDECUBITUS ULCERS\nResult from ischemic necrosis following continuous pressure on an area of\nskin that restricts microcirculation (Fig. 2.2-31).\nStage 1 Stage 2 Stage 3 Stage 4 Unstageable\nEpidermis\nDermis\nAdipose\ntissue\nMuscle\nBone\nIntact skin with Partial-thickness Full-thickness Full-thickness loss Loss of tissue\nnonblancheable loss of dermis loss of dermis, of adipose tissue, covered by a\nerythema adipose tissue muscle, or bone black eschar*\nmay be visible may be visible\n*Eschar covering ulcer, ulcer depth not visualized\nFIGURE 2.2-31. Depth of skin ulcers. Stage 1 involves intact skin with nonblanchable ery-\nthema. Stage 2 involves partial-thickness loss of dermis; however, deeper structures are intact.\nStage 3 involves full-thickness loss of epidermis and subcutaneous fascia; however, muscle\nand bone are not exposed. Stage 4 involves full-thickness tissue loss with exposed underlying\nstructures s",
      "char_start": 334000,
      "char_end": 336000
    },
    {
      "chunk_id": 168,
      "text": "uch as muscle or bone. Unstageable ulcers are covered with black eschar, making it\ndifficult to determine depth of injury. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111122 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 113\nHistory/PE\nUlcers are commonly seen in bedridden patients who lie in the same spot for\ntoo long. An underlying bony prominence or lack of fat â†‘ the likelihood of\nulcer formation (sacrum, heels). Patients with prolonged intensive care unit\n(ICU) stays or lacking mobility or cutaneous sensation are also at â†‘ risk.\nIncontinence of urine or stool may macerate the skin, facilitating ulceration.\nDiagnosis\nCharacteristic exam findings and history are sufficient. Occasionally, a biopsy\ncan be performed on a nonhealing ulcer to rule out cutaneous squamous cell\ncarcinoma, infection, and/or pyoderma gangrenosum. Bone biopsy to diag-\nnose osteomyelitis if bony exposure.\nTreatment\nâ–  Prevention is key: Routinely reposition bedridden patients (at least once\nevery 2 hours); special beds can distribute pressure. Nutritional optimiza-\ntion to promote wound healing.\nâ–  If an ulcer develops, low-grade lesions can be treated with routine wound\ncare, including hydrocolloid dressings. High-grade lesions require surgical\ndebridement.\nGANGRENE\nNecrosis of body tissue. There are three subtypes as follows:\nâ–  Dry gangrene: Due to insufficient blood flow to tissue, typically from\natherosclerosis.\nâ–  Wet gangrene: Involves bacterial infection, usually with skin flora.\nâ–  Gas gangrene: Due to C perfringens infection.\nHistory/PE\nâ–  Dry gangrene: Early signs are a dull ache, cold, and pallor of the flesh. As\nnecrosis sets in, the tissue (toes, fingers) becomes bluish-black, dry, and\nshriveled. Diabetes, vasculopathy, and smoking are risk factors.\nâ–  Wet gangrene: The tissue appears bruised, swollen, or blistered with pus.\nâ–  Gas gangrene: Occurs at sites of large trauma/surgery com",
      "char_start": 336000,
      "char_end": 338000
    },
    {
      "chunk_id": 169,
      "text": "promising\nblood flow to a region, bringing about an anaerobic environment. Bacte-\nria rapidly destroy tissue, producing gas that separates healthy tissue and\nexposes it to infection. Associated with dirty wounds contaminated with\ndirt or bowel/fecal matter. IV drug use is a risk factor. Presents with\nswelling and pale or dark-red skin around the injury. A medical\nemergency.\nDiagnosis\nCharacteristic exam findings and history are sufficient. Air in soft tissue on\nx-ray is very suggestive of necrosis (Fig. 2.2-32).\nTreatment\nFIGURE 2.2-32. Gas gangrene. X-ray of\nâ–  Emergency surgical debridement, with amputation if necessary, is the the foot showing gas tracking through\nmainstay of treatment. Antibiotics alone do not suffice by virtue of inade- soft tissues, most clearly seen overlying\nquate blood flow, but they should be given as an adjuvant to surgery. the calcaneus. (Reproduced with permission\nfrom Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine:\nâ–  Hyperbaric oxygen (toxic to the anaerobic C perfringens) can be used after\nA Comprehensive Study Guide, 7th ed. New York, NY:\ndebridement to help with treatment.\nMcGraw-Hill; 2011.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111133 1100//2211//2222 1122::1111 PPMM\n\n114 HIGH-YIELD FACTS IN DERMATOLOGY\nMISCELLANEOUS SKIN DISORDERS\nSTASIS DERMATITIS\nLower extremity dermatitis due to venous hypertension forcing blood from\nthe deep to the superficial venous system. Venous hypertension is often a\nresult of venous valve incompetence or flow obstruction. It commonly\ninvolves the medial ankle in patients with deep vein thrombosis (DVT) his-\ntory, chronic edema, and long periods of standing. If untreated, the area can\nbecome inflamed, exudative, and hyperpigmented from hemosiderin deposi-\ntion (Fig. 2.2-33). Stasis ulcers may develop. Treat early with leg elevation,\nFIGURE 2.2-33. Stasis dermatitis.\nVenous ulceration with stasis dermatitis, compression stockings, emollients, and topical ste",
      "char_start": 338000,
      "char_end": 340000
    },
    {
      "chunk_id": 170,
      "text": "roids.\nedema, and varicosities. (Reproduced with\npermission from Dr. Richard Usatine.)\nACANTHOSIS NIGRICANS\nâ–  A condition in which the skin in the intertriginous zones (neck folds, geni-\ntals, axillae) becomes hyperkeratotic and hyperpigmented with a velvety\nappearance (Fig. 2.2-34).\nâ–  Associated with DM (insulin resistance), Cushing disease, PCOS, and\nobesity. May also be a paraneoplastic sign of underlying adenocarcinoma\n(usually GI).\nâ–  Treatment: Typically not treated. The physician can encourage weight\nloss and treat the underlying endocrinopathy.\nLICHEN PLANUS\nA self-limited, recurrent, or chronic inflammatory disease affecting the skin,\noral mucosa, and genitalia. Lesions classically described using the 6 Ps (Pla-\nnar, Purple, Polygonal, Pruritic, Papules, and Plaques). It may be induced by\ndrugs (thiazides, quinines, Î²-blockers) and is associated with HCV infection.\nFIGURE 2.2-34. Acanthosis nigricans.\nVelvety, dark-brown epidermal thicken-\ning of the armpit is seen with prominent History/PE\nskinfold and feathered edges. (Reproduced\nPresents with violaceous, flat-topped, polygonal papules (Fig. 2.2-35). Wick-\nwith permission from Wolff K et al. Fitzpatrickâ€™s Color\nham striae (lacy white lines) may be present on the lesion. Lesions may dem-\nAtlas & Synopsis of Clinical Dermatology. 7th ed. New\nYork, NY: McGraw-Hill; 2013.) onstrate prominent Koebner phenomena (lesions that appear at the site of\ntrauma).\nTreatment\nMild cases are treated with topical corticosteroids. For severe disease, systemic\ncorticosteroids and phototherapy may be used.\nROSACEA\nA chronic disorder of pilosebaceous units of which the etiology is unclear.\nDiagnosis\nFIGURE 2.2-35. Lichen planus. Flat- Presentation can vary depending on the subtype as follows:\ntopped, polygonal, sharply defined\npapules of violaceous color are grouped â–  Erythematotelangiectatic rosacea: Presents with central facial erythema\nand confluent. The surface is shiny and with telangiectasias.\nreveals fine white lines (Wic",
      "char_start": 340000,
      "char_end": 342000
    },
    {
      "chunk_id": 171,
      "text": "kham striae). â–  Papulopustular rosacea: Develops papules and pustules.\n(Reproduced with permission from Wolff K et al.\nFitzpatrickâ€™s Dermatology in General Medicine. 7th ed.\nNew York, NY: McGraw-Hill; 2008.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111144 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 115\nâ–  Phymatous rosacea: Connective tissue overgrowth on the chin, forehead,\nand other areas of the face. May lead to severe overgrowth of nasal con-\nnective tissue known as rhinophyma (Fig. 2.2-36).\nâ–  Ocular rosacea: Can predispose to blepharitis, stye, and chalazion\nformation.\nHistory/PE\nâ–  Patients are middle-aged with fair skin and often have an abnormal flush-\ning response to hot drinks, spicy foods, alcohol, and sun. There is a female\npredominance.\nâ–  Often referred to as â€œadult acneâ€ because it can present similarly to acne\nbut involves an older age group.\nFIGURE 2.2-36. Rhinophyma. (Reproduced\nTreatment with permission from Wolff K et al. Fitzpatrickâ€™s Color\nAtlas & Synopsis of Clinical Dermatology. 7th ed. New\nâ–  Behavioral: sunlight and alcohol avoidance, skin hygiene, and emollient York, NY: McGraw-Hill; 2008.)\nuse\nâ–  Erythematotelangiectatic rosacea: topical brimonidine or laser therapy KEY FACT\nâ–  Papulopustular rosacea: topical metronidazole\nâ–  Phymatous rosacea: oral isotretinoin or laser therapy Pityriasis rosea spares palms and soles,\nâ–  Severe/ocular rosacea: oral doxycycline whereas secondary syphilis does not.\nPITYRIASIS ROSEA\nAn acute dermatitis of unknown etiology that has been hypothesized to repre-\nsent a reaction to a viral infection with HHV-7.\nHistory/PE\nâ–  Initial lesion is classically a herald patch that is erythematous with a\nperipheral scale.\nâ–  Days to weeks later, a secondary eruption appears: multiple scaling pap-\nFIGURE 2.2-37. Pityriasis rosea. The\nules and plaques with a fine â€œcigarette paperâ€ scale (Fig. 2.2-37). Papules\nround to oval erythematous plaques are\nare arranged along skin",
      "char_start": 342000,
      "char_end": 344000
    },
    {
      "chunk_id": 172,
      "text": " lines, giving a classic â€œChristmas treeâ€ pattern on often covered with a fine white scale (â€œciga-\nthe patientâ€™s back. rette paperâ€) and are often found on the\ntrunk and proximal extremities. Plaques\nare often preceded by a larger herald patch\nDiagnosis\n(inset). (Reproduced with permission from Tintinalli\nDiagnosis is clinical. Confirm with KOH exam to rule out fungus (the herald JE et al. Tintinalliâ€™s Emergency Medicine: A Comprehensive\npatch may be mistaken for tinea corporis). Consider testing for secondary Study Guide. 7th ed. New York, NY: McGraw-Hill; 2011.)\nsyphilis, which can present similarly.\nTreatment\nRash heals in 6 to 8 weeks without any treatment. Supportive therapy to man-\nage symptoms includes emollients and antihistamines.\nVITILIGO\nAutoimmune destruction of melanocytes leading to well-demarcated areas of\ndepigmentation. Frequently associated with other autoimmune diseases, such\nas hypothyroidism and type I DM.\nâ–  History/PE: Sharply demarcated, depigmented macules or patches on\notherwise normal skin, often on the hands, face, or genitalia (Fig. 2.2-38). FIGURE 2.2-38. Vitiligo of the hands.\nAreas of sharply demarcated depigmenta-\nVitiligo can present at any age and vary from small areas of involvement\ntion. (Reproduced with permission from Dr. Richard\nwith or without progression to large areas of depigmentation.\nUsatine.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111155 1100//2211//2222 1122::1111 PPMM\n\n116 HIGH-YIELD FACTS IN DERMATOLOGY\nâ–  Diagnosis: Often clinical. Many patients have serologic markers of auto-\nimmune disease (eg, antithyroid antibodies, type 1 DM, pernicious ane-\nmia) and occasionally present with these diseases. Histologic examination\ndemonstrates the absence of melanocytes and melanin pigment. Examina-\ntion of skin under Woodâ€™s lamp may be helpful for diagnosis.\nâ–  Treatment: For patients with rapidly progressive vitiligo, oral glucocorticoids\ncan be used to prevent further spread of lesions.",
      "char_start": 344000,
      "char_end": 346000
    },
    {
      "chunk_id": 173,
      "text": " Topical corticosteroids,\ntacrolimus ointment, JAK inhibitors, UV, and laser therapy can be used in\nstable vitiligo. Sunscreen prevents burns. Cover-up makeup can help with\ncosmetic concerns.\nFIGURE 2.2-39. Xanthelasma. (Repro-\nEYELID LESIONS\nduced with permission from Elgazi T & Zouheir H.\nXanthelasma. Pan Afr Med J. 2016;25:41. doi: 10.11604/\npamj.2016.25.41.10510.) â–  Xanthelasma: Soft yellow plaques seen on the medial aspects of the eye-\nlids bilaterally (Fig. 2.2-39), associated with hyperlipidemia and primary\nbiliary cirrhosis. Serum total cholesterol is often normal. Treatment is not\nnecessary.\nâ–  Hordeolum: Painful acute eyelid gland infection (stye), usually due to S\naureus and located on the edge of the lid. Most resolve spontaneously, but\nwarm, moist compresses may help.\nâ–  Chalazion: Chronic inflammatory painless cyst due to a blocked eyelid\ngland. Hordeolum can become a chalazion after the infection resolves.\nEPIDERMAL INCLUSION CYSTS\nâ–  Dome-shaped, firm or freely movable cyst often surrounding a hair follicle\n(Fig. 2.2-40). Erythema, mild tenderness, and cheeselike discharge may be\nFIGURE 2.2-40. Specimen of an epider-\nseen.\nmal inclusion cyst, with intact capsule.\nThe cyst is filled with keratin cells. (Repro- â–  Does not dimple when pinched (in contrast with dermatofibroma).\nduced with permission from Tsirevelou et al. Epider- â–  Usually resolves spontaneously, but can recur; thus excision of large cysts\nmoid cyst of the floor of the mouth: two case reports. is preferred.\nCases J. 2009;2:9360. doi: 10.1186/1757-1626-2-9360).\nDERMATOFIBROMA\nâ–  Dome-shaped, firm, brown-pink, nontender nodule often <1 cm in diam-\neter resulting from fibroblast proliferation (Fig. 2.2-41).\nâ–  Dimples when pinched (dimple or buttonhole sign).\nâ–  Benign. Treatment with excision for cosmetic reasons.\nHIDRADENITIS SUPPURATIVA\nâ–  Chronic inflammation of folliculopilosebaceous units causing inflamed,\nFIGURE 2.2-41. Dermatofibroma. painful nodules that may progress to form sinus tracts ",
      "char_start": 346000,
      "char_end": 348000
    },
    {
      "chunk_id": 174,
      "text": "and scars that\nDome-shaped, brown-pink nodule that\nsecrete a malodorous discharge (Fig. 2.2-42). It is more common in peo-\ndimples when pinched. A benign lesion\nple with family history, Black race, smoking history, diabetes, or obesity.\nthat can be excised for cosmetic reasons.\n(Reproduced with permission from Diluvio L, Torti C, â–  Common in intertriginous areas (axilla, groin) and often has a chronic\nTerrinoni A, et al. Dermoscopy as an adjuvant tool for relapsing course.\ndetecting skin leiomyomas in patient with uterine â–  Diagnosis: Clinical. No biopsy needed.\nfibroids and cerebral cavernomas. BMC Dermatol.\nâ–  Treatment: Oral antibiotics (topical clindamycin is often first line), drain-\n2014;14:7. doi:10.1186/1471-5945-14-7.)\nage, wound care, or surgical excision and skin grafting of affected areas.\nCould result in relapsing course despite medical and surgical manage-\nment. Weight loss and smoking cessation are recommended.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111166 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 117\nICHTHYOSIS VULGARIS\nâ–  Disorder of diffuse, dry dermal scaling that resembles fish scales (ichthyo-\nsis means â€œfishlikeâ€ in Greek; Fig. 2.2-43). Most often affects the extremi-\nties and trunk. Patients experience a worsening of symptoms in dry, cold\nweather.\nâ–  Inherited mutation in filaggrin gene; worse in homozygous individuals.\nFilaggrin plays a role in maintaining hydration of the skin with an epider-\nmal skin barrier.\nâ–  Diagnosis is clinical.\nâ–  Treat with emollients and moisturizers.\nFIGURE 2.2-42. Hidradenitis suppura-\ntiva. Draining sinus tracts present in the\naxilla. Associated infection and cellulitis\nAGE-RELATED SKIN CHANGES\nare common. (Reproduced with permission from\nAlharbi Z, Kauczok J, Pallua N. A review of wide surgi-\nThe elastic fibers in perivascular connective tissue deteriorate with age, causing cal excision of hidradenitis suppurativa. BMC Dermatol.\nwrinkles. The dermis a",
      "char_start": 348000,
      "char_end": 350000
    },
    {
      "chunk_id": 175,
      "text": "nd epidermis also thin, causing increased fragility of the 2012;12:9.)\nskin. Chronically photoaged skin will develop solar elastosis (thickened yellow\nskin with deep wrinkles). Botulinum toxin A may be used for cosmetic purposes\nto reduce development of wrinkles (paralysis of facial musculature). Senile pur-\npura (ecchymoses in older adult patients in areas exposed to repetitive trauma\nsuch as extensor surfaces) is a benign finding and does not warrant further\nworkup.\nSUN PROTECTION\nUV radiation from the sun causes hyperpigmentation and destruction of der-\nmal structural proteins, such as collagen and elastin. Sun avoidance is the\nFIGURE 2.2-43. Ichthyosis vulgaris.\nbest way to prevent sun-associated skin damage. Sunblock with a sun protec-\n(Reproduced with permission from Dr. Richard S.\ntion factor (SPF) of at least 30 applied 30 minutes prior to exposure provides a\nHibbets, Centers for Disease Control and Prevention,\nprotective film that prevents sunburn. SPF of greater than 50 has diminishing Atlanta, GA.)\nreturns on effective sun protection. Reapplication of sunblock should occur\nevery 2 hours, especially after swimming or sweating.\nSUNBURN\nSelf-limiting, inflammatory skin condition occurring in response to prolonged\nexposure to UV radiation. Vasodilation of dermal blood vessels causes an ery-\nthematous appearance to the skin and occasionally blistering lesions. Patients\nwith severe sunburn may exhibit symptoms of heat exhaustion such as fever,\nheadache, and vomiting. Mild sunburn may be treated with cool, moist com-\npresses and emollients with aloe vera for topical relief and NSAIDs for pain\nrelief. Consider hospitalization, IV fluids, and wound care for severe cases.\nNEOPLASMS OF THE SKIN\nSEBORRHEIC KERATOSIS\nA very common skin tumor in people older than 50 years of age. Unknown\netiology. Though lesions may appear similar to melanoma, they have no\nmalignant potential.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111177 1100/",
      "char_start": 350000,
      "char_end": 352000
    },
    {
      "chunk_id": 176,
      "text": "/2211//2222 1122::1111 PPMM\n\n118 HIGH-YIELD FACTS IN DERMATOLOGY\nHistory/PE\nâ–  Present as exophytic, waxy, brown papules and velvety or greasy plaques\nwith superficial keratin cysts (Fig. 2.2-44). Lesions may appear in great\nnumbers and have a â€œstuck onâ€ appearance.\nâ–  Lesions can become irritated either spontaneously or by external friction\ntrauma.\nDiagnosis\nClinical diagnosis. Malignancy can be ruled out with biopsy.\nTreatment\nCryotherapy, shave excision, or curettage.\nFIGURE 2.2-44. Seborrheic keratosis.\nWaxy brown papule with a â€œstuck onâ€ ACTINIC KERATOSIS\nappearance. (Reproduced with permission from\nDr. Richard Usatine.)\nFlat areas of erythema and scale caused by sun exposure in fair-skinned indi-\nviduals. These lesions have a 5% to 10% chance of developing into squamous\ncell carcinoma (SCC). Lesions must be treated before progression to\nmalignancy.\nKEY FACT\nâ–  Hx/PE: Lesions appear on sun-exposed areas (face, arms) and primarily\nLeser-Trelat sign is the sudden affect older patients, who often have multiple such lesions. They are ery-\nappearance of multiple seborrheic thematous with a sandpaper-like texture that can become thick and\nkeratoses in a â€œChristmas treeâ€ pattern crusted (Fig. 2.2-46).\non the back (Fig. 2.2-45). It is associated â–  Dx: Clinical. Biopsy may be indicated to differentiate from SCC.\nwith internal malignancy, most â–  Tx: Cryosurgery, topical 5-FU, or topical imiquimod can be used to\ncommonly gastric adenocarcinoma. destroy the lesion. Patients should be advised to use sun protection.\nCUTANEOUS SQUAMOUS CELL CARCINOMA\nThe second most common skin cancer, with locally destructive effects as well\nas the potential for metastasis and death. Sun exposure is the most common\ncausative factor, but exposure to chemical carcinogens, prior radiation ther-\napy, chronic inflammation and chronic wounds (eg, burns or draining infec-\ntious sinuses in osteomyelitis), and chronic immunosuppression (eg,\ntransplant recipients) also predispose patients to developing S",
      "char_start": 352000,
      "char_end": 354000
    },
    {
      "chunk_id": 177,
      "text": "CC. Keratoac-\nanthomas are a low-grade type of SCC.\nHistory/PE\nâ–  SCCs have many forms, and a single patient will often have multiple\nvariants.\nâ–  Most SCCs occur in older adults with sun-damaged skin arising from\nactinic keratoses and presenting as an erythematous, ulcerated papule or\nnodule (Fig. 2.2-47).\nâ–  Neurologic signs/symptoms may be due to perineural invasion.\nâ–  Marjolin ulcer is a type of rare SCC that arises in sites of scars, burns, or\nulcers. Marjolin ulcers typically take 5 to 10 years to develop after the ini-\ntial wound.\nâ–  Arsenic exposure is a rare cause of multiple SCCs in a palmoplantar\nFIGURE 2.2-45. Leser-Trelat sign. (Image distribution.\nmodified with permission from Ponti G, Luppi G, Losi\nâ–  SCC in situ is called Bowen disease and presents as a well-defined, ery-\nL, Giannetti A, Seidenari S. Leser-TrÃ©lat syndrome\nthematous, scaly plaque. When found on the penis, it is called erythropla-\nin patients affected by six multiple metachro-\nnous primitive cancers. J Hematol Oncol. 2010;3:2. sia of Queyrat and presents as red, velvetlike plaques.\ndoi:10.1186/1756-8722-3-2.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111188 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 119\nâ–  SCCs from actinic keratoses rarely metastasize, but those that arise on the\nlips and ulcers are more likely to do so. SCC occurs on the lower lip more\ncommonly than basal cell carcinoma (BCC).\nDiagnosis\nCharacteristic exam findings and history are sufficient. Confirm with shave\nbiopsy, which may show keratin pearls and full-thickness atypical keratino-\ncytes with invasion into the dermis.\nTreatment FIGURE 2.2-46. Actinic keratosis.\nThe discrete patch above has an erythem-\nSurgical excision or Mohs surgery (very thin slices are excised and examined atous base and a rough white scale. (Repro-\nwith a microscope via frozen section, ideally used for cosmetically sensitive duced with permission from Hurwitz RM. Pathology of\nareas such",
      "char_start": 354000,
      "char_end": 356000
    },
    {
      "chunk_id": 178,
      "text": " as face and distal extremities). Lesions with high metastatic poten- the Skin: Atlas of Clinical-Pathological Correlation. 2nd\ned. Stamford, CT: Appleton & Lange; 1998.)\ntial may need radiation or chemotherapy.\nBASAL CELL CARCINOMA\nThe most common malignant skin cancer, BCC is slow growing and locally\ndestructive but has virtually no metastatic potential. Cumulative sun exposure\nis the main risk factor. Most lesions appear on the face in fair-skinned individ-\nuals. Multiple BCCs appearing early in life and on nonâ€“sun-exposed areas\nare suggestive of inherited basal cell nevus syndrome (Gorlin syndrome).\nHistory/PE\nNodular subtype (Fig. 2.2-48) makes up 80% of BCC. Other types include super-\nficial and sclerosing. Pearly-white, translucent, dome-shaped nodule or papule\nthat may ulcerate, bleed, or crust in the center with overlying telangiectasias. FIGURE 2.2-47. Squamous cell carci-\nnoma. Note the crusting and ulceration of\nthis erythematous plaque. Most lesions are\nDiagnosis\nexophytic nodules with erosion or ulcer-\nConfirm with shave biopsy, which will show nests of basophilic cells invading ation. (Reproduced with permission from Hurwitz RM.\nPathology of the Skin: Atlas of Clinical-Pathological Corre-\ninto the dermis.\nlation. 2nd ed. Stamford, CT: Appleton & Lange; 1998.)\nTreatment\nExcision via curettage, cautery, cryotherapy, and superficial radiation. Mohs MNEMONIC\nsurgery can be used for cosmetically sensitive areas.\nThe ABCDEs of melanomaâ€”\nAsymmetric\nMELANOMA\nIrregular Border\nVariations in Color\nThe most common life-threatening dermatologic disease. Risk factors include Diameter >6 mm\nfair skin and a tendency to burn; intense bursts of sun exposure (especially in Evolution: changing or new lesions\nchildhood and with intermittent exposure); and the presence of large congen-\nital melanocytic nevi, an â†‘ number of nevi, or dysplastic nevi. Immunosup-\npression also â†‘ risk. Some patients inherit a predisposition to melanoma with\nthe familial atypical mole and melano",
      "char_start": 356000,
      "char_end": 358000
    },
    {
      "chunk_id": 179,
      "text": "ma (FAM-M) syndrome. There are sev-\neral subtypes (Table 2.2-5).\nA 72-year-old man presents to an\ninternist after moving to Florida. The\nHistory/PE internist notes a chronic wound on\nthe patientâ€™s right lower leg in the\nâ–  Malignant melanomas begin in the epidermal basal layer, where melano-\narea of a previous flame burn. The\ncytes are found.\npatient states that the wound has\nâ–  Malignant melanomas may metastasize anywhere in the body (eg, lung,\nbeen present for 5 years and has not\nliver, brain, fat). Three to five percent of patients with metastatic mela-\nhealed despite receiving dressings\nnoma have no known primary lesion.\nand topical treatment. What is the\nnext best step?\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 111199 1100//2211//2222 1122::1111 PPMM\n\n120 HIGH-YIELD FACTS IN DERMATOLOGY\nTABLE 2.2-5. Types of Melanoma\nTYPE PRESENTATION\nSuperficial 60% of all melanomas; incidence increases with age, but is also seen in young adults\nspreading Often presents on the trunk in men and on the legs in women\nA prolonged horizontal growth phase (see Image A) allows for early diagnosis when it is still confined to the epidermis\nNodular Lesions have a rapid vertical growth phase and appear as a fast-growing reddish-brown nodule with ulceration (see Image B)\nAcral Begins on the palms, soles (see Image C), and nailbed as a slowly spreading, pigmented patch\nlentiginous Most commonly seen in Asian and Black populations\nLentigo Arises in a solar lentigo\nmaligna Usually found on sun-damaged skin of the face (see Image D)\nAmelanotic Presents as a lesion without clinical pigmentation\nDifficult to identify; this variant of melanoma can be further classified into any of the above types\nA B C D\nImages reproduced with permission from Dr. Richard Usatine.\nDiagnosis\nâ–  Early recognition and treatment are essential. Screening exams using the\nABCDE criteria and dermoscopy may detect melanoma early when it is\ncurable (see Table 2.2-5). An excisional biops",
      "char_start": 358000,
      "char_end": 360000
    },
    {
      "chunk_id": 180,
      "text": "y should be performed on\nany suspicious lesion. Malignancy is determined histologically.\nâ–  A biopsy should be performed on a mole that is substantially different\nfrom nearby moles to assess for melanoma. This is the â€œugly duckling\nsignâ€ and has greater than 90% sensitivity for melanoma.\nâ–  Malignant melanomas are staged by Breslow thickness (depth of invasion\nin millimeters) and by tumor-node-metastasis (TNM) staging. Ulceration\nis a poor prognostic sign.\nFIGURE 2.2-48. Nodular basal cell car-\ncinoma. A smooth, pearly nodule with Treatment\ntelangiectasias. (Reproduced with permission\nfrom Wolff K et al. Fitzpatrickâ€™s Color Atlas & Synopsis of â–  Lesions confined to the skin are treated by excision with margins. Sentinel\nClinical Dermatology. 5th ed. New York, NY: McGraw- lymph node biopsy is useful for staging but does not â†‘ survival. Chemo-\nHill; 2005.) therapy, biologic therapy, and radiation therapy may be used for recurrent\nor metastatic melanoma.\nâ–  Patients with early melanoma are at low risk for recurrence but are at high\nrisk for the development of subsequent melanomas. More advanced mela-\nnomas may recur or metastasize at a higher rate. Patient surveillance is\nthus essential.\nThe next best step would be to\nperform a biopsy to rule out SCC.\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 112200 1100//2211//2222 1122::1111 PPMM\n\nDERMATOLOGY HIGH-YIELD FACTS IN 121\nKAPOSI SARCOMA\nA vascular proliferative disease that has been attributed to HHV-8, also called\nKaposi sarcomaâ€“associated herpesvirus (KSHV).\nHistory/PE\nâ–  Presents with multiple red to violaceous macules, papules, or nodules that\ncan progress to plaques on the lower limbs, back, face, mouth, and genita-\nlia (Fig. 2.2-49).\nâ–  Plaques can also be found in the GI tract and lung.\nâ–  HIV-associated (epidemic) Kaposi sarcoma is an aggressive form of the dis-\nease, and although less common since the advent of highly active antiret-\nroviral therapy (HAART), it remains the most com",
      "char_start": 360000,
      "char_end": 362000
    },
    {
      "chunk_id": 181,
      "text": "mon HIV-associated\nmalignancy.\nDiagnosis\nDiagnosed by history, clinical impression, and histology.\nFIGURE 2.2-49. Kaposi sarcoma. Note\nTreatment the multiple violaceous papules on the\nneck, back, and face. (Reproduced with per-\nStart HAART therapy if patient is HIVâŠ•. Small local lesions can be treated\nmission from Wolff K et al. Fitzpatrickâ€™s Color Atlas &\nwith radiation or cryotherapy. Widespread or internal disease is treated with Synopsis of Clinical Dermatology. 5th ed. New York, NY:\nsystemic chemotherapy (doxorubicin, paclitaxel, or interferon-Î± [IFN-Î±]). McGraw-Hill; 2005.)\nKEY FACT\nMYCOSIS FUNGOIDES (CUTANEOUS T-CELL LYMPHOMA)\nBacillary angiomatosis, caused by\nNot a fungus but a slow, progressive neoplastic proliferation of epidermo- Bartonella henselae and Bartonella\ntropic T cells. The disease is chronic and more common in men. quintana, can mimic Kaposi sarcoma\nand should be excluded in suspected\nHistory/PE Kaposi sarcoma patients; erythromycin\nâ–  Early lesions are nonspecific, psoriatic-appearing plaques or patches that is the treatment of choice.\nare often pruritic with a predilection for the trunk and buttocks. Later\nlesions are characterized by skin tumors with palpable lymph nodes (Fig.\n2.2-50).\nâ–  Patients may have dermatopathic lymphadenopathy without tumor\ninvolvement of the node. However, the internal organs can be involved,\nincluding the lymph nodes, liver, and spleen.\nâ–  SÃ©zary syndrome is the leukemic phase of cutaneous T-cell lymphoma,\ncharacterized by circulating SÃ©zary cells in the peripheral blood, erythro-\nderma, and lymphadenopathy.\nDiagnosis\nâ–  Diagnosed by clinical features and histology, with immunophenotypic\ncharacterization showing clonal T cells and electron microscopy showing\nthe typical SÃ©zary or Lutzner cells (cerebriform lymphocytes).\nâ–  Early lesions are clinically indistinguishable from dermatitis, so histologic\ndiagnosis is indicated for any dermatitis that is chronic and resistant to\ntreatment.\nTreatment\nFIGURE 2.2-50. Mycosis fu",
      "char_start": 362000,
      "char_end": 364000
    },
    {
      "chunk_id": 182,
      "text": "ngoides. Mas-\nPhototherapy and skin-directed topical treatments are the mainstay of treat- sive nodular infiltration of the face leads\nment for many patients. Early localized disease is amenable to total skin elec- to a leonine facies. (Reproduced with permission\ntron beam irradiation. For more extensive or advanced disease, radiation from Wolff K et al. Fitzpatrickâ€™s Dermatology in General\nMedicine. 7th ed. New York, NY: McGraw-Hill; 2008.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 112211 1100//2211//2222 1122::1111 PPMM\n\n122 HIGH-YIELD FACTS IN DERMATOLOGY\ntherapy is an effective option. Treatment modalities, including steroids, che-\nmotherapy, retinoids, monoclonal antibodies, and IFN-Î±, are often\ncombined.\nCHERRY ANGIOMAS (HEMANGIOMAS)\nSmall, vascular, red papules that can appear anywhere on the body (Fig. 2.2-\n51). It is the most common benign vascular tumor, and it often appears with\nage. No treatment is necessary, but it can be excised for cosmetic reasons.\nINFANTILE HEMANGIOMAS\nFIGURE 2.2-51. Cherry hemangioma.\n(Reproduced with permission from Dr. Richard Usatine.)\nSimilar to cherry angiomas, infantile hemangiomas (also called strawberry\nhemangiomas) are seen in infants during the first few weeks of life. They are\nalso benign and usually regress spontaneously after an initially rapid growth\nphase. Involution typically begins at 9 months to 1 year of age. Persistent\nlesions may be treated with topical or oral Î²-blockers.\nPYOGENIC GRANULOMA\nLobulated capillary hemangioma that typically occurs on the fingers, trunk\nand oral mucosa in young adults (Fig. 2.2-52). Ulcerates and bleeds profusely.\nAssociated with trauma and pregnancy likely due to increased vascular endo-\nthelial growth factor (VEGF) in pregnancy. Treated via surgical excision,\nlaser therapy, or topical silver nitrate. Lesions that occur during pregnancy\nmay regress spontaneously postpartum.\nFIGURE 2.2-52. Pyogenic granuloma.\n(Modified with permission from Dr. ",
      "char_start": 364000,
      "char_end": 366000
    },
    {
      "chunk_id": 183,
      "text": "Richard Ustaine.)\nNECROBIOSIS LIPOIDICA\nRed-brown to yellow annular plaques found on the lower extremities of\npatients with DM (Fig. 2.2-53). More common in women and classically\nfound on pretibial skin. Presents as multifocal lesions with dilated blood ves-\nsels and central epidermal atrophy that may ulcerate. Lesions may precede\nthe onset of diabetes; consequently, patients should be screened for DM.\nFIGURE 2.2-53. Necrobiosis lipoidica.\n(Reproduced with permission from Pathak R, Karm-\nacharya P, Aryal MR, Smith-Coleman KE. Necrobiosis\nlipoidica. J Community Hosp Intern Med Perspect.\n2013;3-4. doi:10.3402/jchimp.v3i3-4.22627.)\n22002222__0022..0022__SStteepp22CCKK__DDeerrmm__1111ee__008877--112222..iinndddd 112222 1100//2211//2222 1122::1111 PPMM\n\nH I G H - Y I E L D F A C T S I N\nENDOCRINOLOGY\nDisorders of Glucose Metabolism 124 Pituitary and Hypothalamic Disorders 141\nMetabolic SyndroMe 124 deficiency of pituitary HorMoneS 141\ndiabeteS MellituS 124 diabeteS inSipiduS 142\ndiabetic KetoacidoSiS and HyperglyceMic HyperoSMolar SyndroMe 127 exceSS of pituitary HorMoneS 144\nHypoglyceMia 129 HyperprolactineMia 146\nSyndroMe of inappropriate antidiuretic HorMone Secretion 147\nThyroid Disorders 130\ntHyroid pHySiology 130 Adrenal Gland Disorders 148\nHypertHyroidiSM and tHyrotoxicoSiS 130 adrenal inSufficiency 148\nHypotHyroidiSM 134 pHeocHroMocytoMa 150\ntHyroiditiS 135 cuSHing SyndroMe 151\ntHyroid neoplaSMS 136 HyperaldoSteroniSM 153\ncongenital adrenal HyperplaSia 154\nBone and Mineral Disorders 137\noSteoporoSiS 137 Multiple Endocrine Neoplasias 155\npaget diSeaSe of bone 139\nHyperparatHyroidiSM 139\n123\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112233 1100//2211//2222 1122::1188 PPMM\n\n124 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nDISORDERS OF GLUCOSE METABOLISM\nMETABOLIC SYNDROME\nMNEMONIC\nMetabolic syndrome refers to a constellation of findings suggestive of insulin\nWEIGHHT\nresistance that frequently develop in the setting of obesity. The often-a",
      "char_start": 366000,
      "char_end": 368000
    },
    {
      "chunk_id": 184,
      "text": "ssociated\nWaist Expanded, Impaired Glucose,\nhyperinsulinemia, hyperglycemia, and release of adipokines are thought to\nHypertension, HDL â†“, Triglycerides â†‘\nincrease risk for development of atherosclerotic cardiovascular disease and type\n2 diabetes mellitus (DM).\nHistory/PE\nAbdominal obesity (even in the setting of overall normal weight), acanthosis\nnigricans, and elevated blood pressure.\nDiagnosis\nAt least three of the following five criteria must be met:\nâ–  Abdominal obesity\nâ–  Elevated fasting glucose\nâ–  Hypertension\nâ–  Low HDL cholesterol\nâ–  Hypertriglyceridemia\nTreatment\nâ–  Best initial treatment is lifestyle modification.\nâ–  Mitigation of cardiovascular risk can occur with aggressive cholesterol\nmanagement and blood pressure (BP) control, as well as initiation of met-\nformin for prevention of diabetes in those with impaired fasting glucose.\nDIABETES MELLITUS\nDM refers to abnormal carbohydrate metabolism that leads to hyperglycemia\nthrough several mechanisms, including impairment of insulin secretion and\nresistance of peripheral tissues to the action of insulin.\nHistory/PE\nThe presentation of diabetes is variable (often asymptomatic), and it depends\non the specific etiology. Generally:\nâ–  Type 1 DM classically presents in children and young adults with symp-\ntoms of hyperglycemia (polyuria, polydipsia), polyphagia, unexplained\nweight loss, or ketoacidosis.\nâ–  Type 2 DM classically presents in older adults with obesity and other com-\nKEY FACT\nponents of metabolic syndrome, but it is increasingly diagnosed in chil-\ndren. Other risk factors include âŠ• family history, sedentary lifestyle,\nMicroalbuminuria cannot be\nincreasing age, and ethnicity (Asian, Hispanic, and African descent in the\ndetected on routine urinalysis (UA)\nUnited States). Although it may present with symptoms of hyperglyce-\nprotein dipstick. Instead, do a spot\nmiaâ€”in the same manner as type 1 DMâ€”it tends to be more insidious,\nurine albumin to creatinine ratio\nand patients frequently exhibit complications of l",
      "char_start": 368000,
      "char_end": 370000
    },
    {
      "chunk_id": 185,
      "text": "ong-term diabetes (see\n(microalbuminuria = 30 to 300 mg/g).\nTable 2.3-1) at time of diagnosis.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112244 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 125\nTABLE 2.3-1. Chronic Complications of Diabetes Mellitus\nCOMPLICATION DESCRIPTION, MANAGEMENT, AND PREVENTIVE CARE\nRetinopathy (non- Classically appears when diabetes has been present for at least 3â€“5 years (see Fig. 2.3-1). Preventive measures include\nproliferative, control of hyperglycemia and hypertension and annual eye exams. Treatment modalities include antiâ€“vascular endo-\nproliferative) thelial growth factor (VEGF) agents and laser photocoagulation therapy.\nDiabetic Characterized by glomerular hyperfiltration followed by microalbuminuria, macroproteinuria, and progression to chronic\nnephropathy kidney disease (CKD). Prevalence is estimated to be 20%â€“40% in those with DM. Preventive measures include glycemic\ncontrol, tight BP control (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin receptor blockers [ARBs]\nin the setting of proteinuria). Kimmelstiel-Wilson nodules are classically seen on kidney biopsy.\nNeuropathy Prevalence of diabetic neuropathy increases with longer duration/worsening severity of hyperglycemia. Can affect both\nsmall nerve fibers (pain, temperature) and large fibers (vibration, proprioception). Most commonly manifests as distal\nsymmetric polyneuropathy (â€œstocking and gloveâ€ numbness, tingling, burning pain). Can also present as autonomic\nneuropathy (postural hypotension, gastroparesis, diarrhea, neurogenic bladder, erectile dysfunction). Cranial mononeu-\nropathies can also occurâ€”cranial nerve (CN) III involvement is more common (ptosis, diplopia, preserved pupil response).\nEmphasize preventive foot care. Monofilament testing predicts ulcer risk. Neuropathic pain can be managed with tricy-\nclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), or gabapentino",
      "char_start": 370000,
      "char_end": 372000
    },
    {
      "chunk_id": 186,
      "text": "ids.\nGastroparesis with delayed gastric emptying can be managed with metoclopramide or erythromycin.\nMacrovascular Cardiovascular, cerebrovascular, and peripheral vascular disease. Cardiovascular disease is the most common cause of\ncomplications death in diabetic patients. See Table 2.3-2 for risk modification recommendations.\nHypoglycemia Inadequate autonomic response to hypoglycemia caused by insufficient release of stress hormones. It tends to develop in\nunawareness people who have frequent episodes of hypoglycemia, and it can lead to failure to recognize life-threatening hypoglycemia.\nA\nDiagnosis\nDiagnosis requires:\nâ–  A random plasma glucose level â‰¥200 mg/dL plus symptoms of hyperglycemia\nOR two abnormal results with any of the following tests:\nâ–  A fasting (>8-hour) plasma glucose level â‰¥126 mg/dL\nâ–  A 2-hour postprandial glucose level â‰¥200 mg/dL following an oral glucose\ntolerance test (OGTT)\nâ–  Hemoglobin A1c (HbA1c) >6.5%\nConsider screening for type 2 DM in: B\nâ–  Overweight adults with at least one risk factor for DM (hypertension, car-\ndiovascular disease [CVD], sedentary lifestyle, dyslipidemia, polycystic\novary syndrome [PCOS], first-degree relative with DM).\nâ–  Patients planning pregnancy.\nâ–  Patients on medications that increase risk for DM (chronic steroids, HIV\nmedications, antipsychotics).\nâ–  In all people aged 45 years or older, check HbA1câ€”if <5.7, recheck every\n3 years (unless other risk factors develop). If between 5.7 and 6.4, recheck\nyearly.\nFIGURE 2.3-1. Diabetic retinopathy. (A)\nPatients not meeting criteria for DM but with impaired fasting glucose (>100 Nonproliferative retinopathy presents\nbut <126 mg/dL) or impaired glucose tolerance on OGTT should also be with exudates, dot-blot hemorrhages, and\nmicroaneurysms. (B) Proliferative reti-\nrechecked yearly.\nnopathy presents with macular edema,\nvitreous traction, and neovascularization\nof the retinal vasculature. (Reproduced with\npermission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEn",
      "char_start": 372000,
      "char_end": 374000
    },
    {
      "chunk_id": 187,
      "text": "nddoo__1111ee__112233--115566..iinndddd 112255 1100//2211//2222 1122::1188 PPMM\n\n126 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nClassification\nType I DM is due to destruction of beta cells of the pancreas, which normally\nproduce insulin. This can be secondary to:\nâ–  Autoimmune diseaseâ€”characterized by the presence of autoantibodies\n(antiâ€“glutamic acid decarboxylase [GAD], anti-islet cell, anti-zinc trans-\nporter, anti-insulin antibodies). Associated with human leukocyte antigen\n(HLA)-DR3 and HLA-DR4.\nâ–  Acquired diseaseâ€”after pancreatitis, pancreatectomy, cystic fibrosis, or\nmalignancy.\nâ–  Idiopathic diseaseâ€”in the absence of antibodies or recognized destructive\ndisease.\nType II DM is due to relative insulin deficiency in the setting of peripheral\ninsulin resistance, leading to hyperglycemia. More than 90% of DM cases are\nclassified as type 2. Antibodies associated with type 1 DM will be negative.\nOther less common etiologies of DM include several genetic defects that\naffect beta-cell function. For example, several autosomal monogenetic defects\nhave been identified as causes of maturity-onset diabetes of the young\n(MODY), which typically presents in young people with a family history of\natypical diabetes.\nManagement\nâ–  Patient education and lifestyle modification are mainstays of management\n(see Table 2.3-2).\nTABLE 2.3-2. Diabetes Mellitus General Health Maintenance\nLIFESTYLE MODIFICATIONS RECOMMENDATION\nDiet Personalized diet to encourage weight loss; avoid saturated fats and\nadded sugars.\nExercise Moderate-intensity exercise for 30â€“60 minutes 5 days per week.\nCardiovascular risk The presence of diabetes is equivalent to the highest risk for cardio-\nmodification vascular disease regardless of all other risk factors.\nAll diabetic patients 40â€“75 years of age should be placed on a statin\nregardless of lipid levels. Use the AHA risk calculator to determine\nwhether moderate or high-intensity statin is recommended.a\nBlood pressure (BP) Strict BP control to <130/80 mm Hg; ACEIs/ARBs a",
      "char_start": 374000,
      "char_end": 376000
    },
    {
      "chunk_id": 188,
      "text": "re first-line agents\nmanagement when proteinuria is present.\nScreening exams Annual physical exam to screen for cardiovascular disease (BP\nand lipid monitoring), nephropathy (test for microalbuminuria),\nretinopathy (dilated-eye exams), and neuropathy (foot care\nevaluations).\nImmunizations In addition to routinely recommended immunizations based on\nage, all patients with diabetes >19 years of age should receive the\npneumonia vaccine.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112266 1100//2211//2222 1122::1188 PPMM\n\nâ–  Type 1 DM requires administration of insulin (see Fig. 2.3-2) to maintain\nblood glucose in the normal range (80â€“130 mg/dL preprandial levels,\n<180 mg/dL postprandial levels).\nâ–  Consider insulin infusion pump for patients with type 1 DM who are hav-\ning difficulty with intermittent dosing.\nâ–  Type 2 DM can be managed with nonpharmacologic interventions ini-\ntially. In the event of failure of lifestyle interventions, a number of medica-\ntion classes can be considered (see Table 2.3-3).\nâ–  All patients on insulin should participate in self-monitoring of blood glu-\ncose to detect hyperglycemia or hypoglycemia that can be corrected with\ndose modifications.\nâ–  Patients with DM should be encouraged to undergo routine HbA1c test-\ning every 3 months.\nâ–  Goal HbA1c <7% (<7.5% in children). Higher blood glucose and HbA1c\nlevels can be tolerated, particularly in the older adult population and in\nthose with multiple medical problems, considering the â†‘ risk for hypogly-\ncemia. Tight glucose control decreases the risk for microvascular compli-\ncations (nephropathy, retinopathy), but the effects on macrovascular\ncomplications (stroke, myocardial infarction) and all-cause mortality are\nunknown.\nDIABETIC KETOACIDOSIS AND HYPERGLYCEMIC HYPEROSMOLAR SYNDROME\nThese are two acute, life-threatening complications of diabetes that are char-\nacterized by hyperglycemia with fluid and electrolyte disturbances. Table\n2.3-4 outlines the individual c",
      "char_start": 376000,
      "char_end": 378000
    },
    {
      "chunk_id": 189,
      "text": "haracteristics of each.\nâ–  Diabetic ketoacidosis (DKA) is characterized by anion gap metabolic aci-\ndosis with elevated levels of ketoacids in serum and urine. Blood glucose\nlevel is usually between 250 and 500 mg/dL, but it can be higher.\nâ–  Hyperglycemic hyperosmolar syndrome (HHS) is characterized by\nextremely elevated blood glucose (frequently above 800â€“1000 mg/dL) and\nplasma hyperosmolality. Generally, there is no ketoacid accumulation and\ntherefore no anion gap acidosis.\n0 2\nlevel\nnilusni\namsalP\nENDOCRINOLOGY HIGH-YIELD FACTS IN 127\nLispro, aspart, glulisine\nRegular\nNPH\nDetemir\nGlargine\n4 6 8 10 12 14 16 18\nHours\nFIGURE 2.3-2. Pharmacokinetics of insulin preparations. Short acting (aspart, lispro, glulisine):\nonset in 5â€“20 minutes, peak in 0.5â€“3 hours, duration 3â€“8 hours. Regular: onset in 30 minutes, peak\nin 2â€“4 hours, duration 5â€“8 hours. Neutral Protamine Hagedorn (NPH) insulin: onset in 2â€“4 hours,\npeak in 6â€“10 hours, duration 18â€“28 hours. Long acting (detemir, glargine): onset in 2 hours, peak\nnone, duration 20â€“24 hours. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112277 1100//2211//2222 1122::1188 PPMM\n\n128 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nTABLE 2.3-3. Treatment of Type 2 Diabetes Mellitus\nPHARMACOTHERAPY (MONOTHERAPY OR COMBINATION THERAPY IF POOR GLYCEMIC CONTROL)\nDRUG MECHANISM ADVERSE EFFECTS NOTEWORTHY BENEFITS\nMetformin (first-line) Inhibits hepatic gluconeogenesis Gastrointestinal (GI) upset, lactic Weight loss, decrease in CVD events\nand â†‘ peripheral sensitivity to acidosis (rare)â€”avoid use in Expected decrease in A1c = 1.5%â€“2%\ninsulin renal insufficiency, hepatic\nfailure, or heart failure\nSulfonylureas (glipizide, gly- â†‘ endogenous insulin secretion Hypoglycemia and weight Decrease in microvascular events\nburide, glimepiride) gainâ€”avoid use in older Expected decrease in A1c = 1%â€“2%\npatients\nThiazolidinediones (rosigli- â†‘ insulin sensitivity Weight gain, edema (avoi",
      "char_start": 378000,
      "char_end": 380000
    },
    {
      "chunk_id": 190,
      "text": "d in Expected decrease in A1c =\ntazone, pioglitazone)a heart failure patients), hepa- 0.5%â€“1.5%\ntotoxicity, and bone loss\nDipeptidyl peptidase (DPP)-4 Inhibit degradation of glucagon-like Increased risk of infections, Expected decrease in A1c = 0.5%â€“1%\ninhibitors (sitagliptin, lina- peptide (GLP)-1; â†‘ insulin secre- rash\ngliptin, and other -gliptins) tion and â†“ glucagon secretion\nIncretins (exenatide, liraglu- GLP-1 agonists delay gastric emp- Injected subcutaneously; slow Decrease in CVD events and mortality\ntide, and other -tides) tying and decrease hunger; GI motility, nausea, and in high-risk patients (liraglutide)\nâ†‘ insulin secretion and â†“ glu- increased risk of pancreatitis Expected decrease in A1c = 0.5%â€“1%\ncagon secretion\nSodium-glucose trans- Inhibit SGLT2 in proximal tubule to Urinary tract infections (UTIs), Weight loss, decrease in CVD events\nporter (SGLT)2 inhibitors â†“ glucose reabsorption vulvovaginal candidiasis, and mortality in high-risk patients\n(empagliflozin and other Fournier gangrene, volume (empagliflozin), decreased risk\n-gliozins) depletion, and hypotension for development/worsening of\nnephropathy\nÎ±-glucosidase inhibitors â†“ intestinal absorption of Flatulence, diarrhea, and Potential decrease in CVD events in\n(acarbose, miglitol) carbohydrates hypoglycemia pre-DM\nExpected decrease in A1c = 0.5%â€“0.8%\nInsulin Given alone or in conjunction with Weight gain and Greatest potential A1c reduction\noral agents hypoglycemia\naIn September 2010, the US Food and Drug Administration restricted access to rosiglitazone because of concern for increased cardiovascular risks.\nThe drug is still available but is restricted to patients currently on the medication who acknowledge that they understand the risks and to patients\nwho cannot achieve adequate glycemic control with other medication.\nManagement\nTreatment of both entities is similar:\nâ–  Repletion of intravascular volume with infusion of normal saline. Patients\nwith DKA/HHS are typically very dehydrated due ",
      "char_start": 380000,
      "char_end": 382000
    },
    {
      "chunk_id": 191,
      "text": "to osmotic diuresis\nresulting from hyperglycemia.\nâ–  Frequent monitoring of serum electrolytes. Acidosis leads to extracellular\nshifting of potassium, which results in â€œnormalâ€ or â€œelevatedâ€ levels on ini-\ntial labs despite an actual total body deficit. As insulin is infused (and as\nthe acidosis is corrected), potassium shifts back into the intracellular\nspace, leading to frank hypokalemia.\nâ–  Infusion of regular insulin intravenously if serum potassium is >3.3\nmEq/L. Insulin should be infused until resolution of DKA/HHS (when\nanion gap closes and ketoacidosis is resolved in DKA, or until mental\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112288 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 129\nTABLE 2.3-4. Acute Complications of Diabetes Mellitus: Diabetic Ketoacidosis vs Hyperglycemic Hyperosmolar Syndrome\nDIABETIC KETOACIDOSIS HYPERGLYCEMIC HYPEROSMOLAR SYNDROME\nPatient characteristics Patients with type 1 diabetes > patients with type 2 diabetes Patients with type 2 diabetes\nPrecipitants Infections, trauma, alcohol, or nonadherence to insulin therapy Same as with DKA but includes dietary\nindiscretion\nSymptoms Abdominal pain; nausea; vomiting; Kussmaul respirations; mental Profound dehydration, mental status changes\nstatus changes; fruity, acetone breath odor (more prominent in HHS than in DKA)\nLab values Glucose >250 mg/dL Glucose >600 mg/dL\nMetabolic acidosis (bicarbonate <18 mEq/L) No acidosis (bicarbonate >18 mEq/L)\nâ†‘ urine and serum ketones No ketones\nâ†‘ anion gap Normal anion gap\nSerum osmolality normal Serum osmolality >320 mOsm/kg\nstatus improves to baseline in HHS). If potassium is <3.3mEq/L, insulin\nshould be held and potassium infused until potassium is >3.3 mEq/L). If\nserum glucose reaches <200 mg/dL before resolution of acidosis (or <250\nmg/dL in HHS), 5% dextrose can be administered intravenously to avoid\nstopping insulin infusion.\nHYPOGLYCEMIA\nSymptomatic hypoglycemia is very rare in people wh",
      "char_start": 382000,
      "char_end": 384000
    },
    {
      "chunk_id": 192,
      "text": "o are not on anti-\nhyperglycemic medications, even in the presence of a â€œlowâ€ blood sugar\n(<70 mg/dL). Further evaluation should only be carried out in patients who\nexhibit Whipple triad:\nâ–  Symptoms of hypoglycemia (tremor, anxiety, sweating, paresthesia, dizzi-\nness, weakness, confusion, loss of consciousness)\nâ–  A low plasma glucose concentration measured with a precise method\nwhile symptoms are present\nâ–  Relief of symptoms after blood glucose is raised\nCauses of hypoglycemia include:\nâ–  Medications (accidental or purposeful antihyperglycemic medication\noverdose)\nâ–  Critical illness\nâ–  Cortisol insufficiency\nâ–  Insulinoma or non-insulinoma islet cell hypertrophy\nâ–  Recent history of gastric bypass (dumping syndrome) A 10-year-old boy presents to the\nemergency department (ED) with\n2 weeks of polyuria and polydipsia\nDiagnosis\nand new-onset lethargy. Physical\nâ–  Obtaining a detailed history is crucial. Careful questioning can ascertain examination reveals signs of severe\ntiming of symptoms in relation to meals and medication administration. dehydration, and laboratory values\nreveal a blood glucose level of 500\nPatients with diabetes who are taking antihyperglycemics should have\nmg/dL. After being diagnosed with\ntheir medication regimen reviewed and medication doses reduced in cases\nDKA, the patient is started on insulin\nof persistent hypoglycemia.\nand nonâ€“dextrose-containing\nâ–  If patients report symptoms after prolonged fasting, the physician may order intravenous (IV) fluids. Glucose on\nan observed fast with periodic blood sugar assessment. Once symptoms\nrecheck is 250 mg/dL with an anion\narise, that is the time to obtain serum glucose, insulin, C-peptide, and anti- gap of 19. What is the next best step in\nhyperglycemic drug screen. management?\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 112299 1100//2211//2222 1122::1188 PPMM\n\n130 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nâ–  In patients who report symptoms shortly after meals, particularly in t",
      "char_start": 384000,
      "char_end": 386000
    },
    {
      "chunk_id": 193,
      "text": "hose\nwith a history of gastric bypass, mixed-meal testing (consumption of a non-\nliquid meal with subsequent observation and monitoring of labs) can eval-\nuate for dumping syndrome.\nâ–  If C-peptide levels are elevated, endogenous insulin is being produced. This is\nthe case with insulin-secreting tumors or islet cell hypertrophy, insulin auto-\nimmune hypoglycemia (in the presence of anti-insulin or anti-insulin receptor\nantibodies), or insulin secretagogue administration (âŠ• drug screen).\nâ–  If C-peptide levels are low, there is exogenous insulin administration (pos-\nsibly surreptitiously).\nManagement\nAfter the cause of hypoglycemia is identified, management will be specific\nto the underlying etiology. Acute or profound hypoglycemia can be life-\nthreatening, and it is most commonly seen in cases of overdosing of insulin\nor insulin secretagogues in people with diabetes. Rapid administration of\noral or intravenous carbohydrates is the first step in management. In those\nwith altered consciousness and no IV access, administer glucagon (intra-\nmuscular, intranasal, or subcutaneous formulations are available).\nTHYROID DISORDERS\nTHYROID PHYSIOLOGY\nSee Figure 2.3-3 for an overview of thyroid hormone synthesis and Figure\n2.3-4 for a review of the hypothalamic-pituitary-thyroid axis.\nâ–  The best initial test to screen for thyroid disease is thyroid-stimulating hor-\nmone (TSH) measurement alone. Suspicion of thyroid disease or detec-\ntion of a goiter on physical exam should always prompt a check of TSH.\nâ–  If there is known history (or suspicion) of hypothalamic or pituitary dis-\nease, measuring TSH and free T initially can guide more accurate assess-\n4\nment of thyroid function.\nâ–  Total T measurement is not an adequate screening test. Ninety-nine per-\n4\ncent of T is bound to thyroxine-binding globulin (TBG). Changes in levels\n4\nof TBG can occur in pregnancy, estrogen administration, and infection.\nâ–  In general, thyroid function testing should not be done in periods of acute\nillness,",
      "char_start": 386000,
      "char_end": 388000
    },
    {
      "chunk_id": 194,
      "text": " as many factors (medications, decreased binding protein levels,\ntransient central hypothyroidism) can alter thyroid function tests (TFTs).\nTFT patterns seen in selected diseases are included in Table 2.3-5.\nHYPERTHYROIDISM AND THYROTOXICOSIS\nEtiologies include:\nThe next best step is to add 5% â–  Graves disease: Most common cause of hyperthyroidism. Autoimmuneâ€”\ndextrose to the IV fluids. In the TSH receptor-stimulating autoantibodies â†‘ synthesis of T /T .\n3 4\nmanagement of DKA, it is important to\nâ–  Toxic adenoma/toxic multinodular goiter: Results in hyperthyroidism\nstart IV fluids and insulin immediately.\nsecondary to autonomous hyperactive thyroid nodules.\nInitially, the goal is to rehydrate the\nâ–  Thyroiditis: Caused by transient inflammation of the thyroid gland with\npatient and â†“ blood glucose, but as\nrelease of previously synthesized thyroid hormone; causes a temporary â†‘\nblood glucose reaches 250 to 300 mg/\nin circulating T /T . A hypothyroid phase may follow the hyperthyroid\ndL, it is important to add 5% dextrose 3 4\nto â†“ â†“ the risk for hypoglycemia, as the phase with eventual return to normal in many patients.\nanion gap acidosis is still being treated.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113300 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 131\nHypothalamus\nPeripheral tissue Blood Thyroid follicular epithelial cell Follicular lumen\nTRH\nTG TG\nTyrosine\nThyroglobulin\n+\nAnterior pituitary Iâ€“ Iâ€“ Oxidation I\n2\nSomatostatin Na+ Organification\nTSH Dopamine Downstream thyroid Thyroid\nGlucocorticoids function Deiodinase peroxidase MIT\nMIT\nPTU, TG\nDIT\nmethimazole\nMIT, DIT DIT\nThyroid follicular cells\nThyroid Coupling\nperoxidase reaction\nTSI\nT MIT MIT\nT, T 3\n3 4 T T T >T TG DDIITT TG DIT\n3 5'-deiodinase 4 (to circ 4 ulat 3 ion) Proteases T 3 Endocytosis T 3\nT T\n4 4\nPTU\nFIGURE 2.3-3. Overview of thyroid synthesis and mechanism of antithyroid medications. Iodide (Iâˆ’) is taken up from the bloodstream by\nfollicu",
      "char_start": 388000,
      "char_end": 390000
    },
    {
      "chunk_id": 195,
      "text": "lar thyroid cells, transported to the colloid of the follicle, and oxidized to iodine (I). I combines with thyroglobulin to form monoiodoty-\nrosine (MIT) and diiodotyrosine (DIT). Two DIT molecules combine to form T; MIT and DIT combine to form T. Iodinated thyroglobulin\n4 3\nis transported back to the follicular cells and is cleaved in lysosomes; T 4 and T 3 are then released into the circulation. (Modified with permission from\nScholarRx.com and USMLE-Rx.com.)\nGlucocorticoids,\ndopamine,\nHypothalamus\nsomatostatin\nand rexinoids\nTRH SS\nPosterior\npituitary\nAnterior\npituitary\nTSH\nTSI\nThyroid\nfollicular\ncells\nT,T\n3 4\nFIGURE 2.3-4. The hypothalamic-pituitary-thyroid axis. SS, Somatostatin;\nT, triiodothyronine; T, thyroxine; TSH, thyroid-stimulating hormone; TSI,\n3 4\nthyroid-stimulating immunoglobulin; TRH, thyrotropin-releasing hormone.\nEnd organs\n(Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113311 1100//2211//2222 1122::1188 PPMM\n\n132 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nTABLE 2.3-5. Thyroid Function Tests in Thyroid Disease\nDIAGNOSIS TSH T T CAUSES\n4 3\nPrimary â†“ â†‘ â†‘ Graves disease, toxic multinodular goiter, toxic adenoma, amiodarone, post-\nhyperthyroidism partum thyrotoxicosis, postviral thyroiditis\nSecondary Normal/â†‘ â†‘ â†‘ Rare; caused by TSH-producing pituitary adenoma; TSH often inappropriately\nhyperthyroidism normal (not suppressed)\nPrimary â†‘ â†“ â†“ Hashimoto thyroiditis, iatrogenic (radioactive ablation, excision), drugs (lithium,\nhypothyroidism amiodarone)\nSecondary â†“ â†“ â†“ Often caused by pituitary nonfunctioning macroadenomas, infiltrative diseases,\nhypothyroidism or postâ€“pituitary surgery; pituitary apoplexy (Sheehan syndrome) is a rare\ncause\nSubclinical â†‘ Normal Normal Often with mild elevations in TSH, asymptomatic\nhypothyroidism\nEuthyroid sick Normal/â†“ Normal/â†“ â†“ Caused by any serious illness; will have â†‘ reverse T (nonfunctional), as T is con-\n3 4\nsyndrome verted to rT instead of T; t",
      "char_start": 390000,
      "char_end": 392000
    },
    {
      "chunk_id": 196,
      "text": "hought to be protective (avoids excess catabolism\n3 3\nin acute illness); thyroid hormone supplementation is not indicated.\nKEY FACT â–  Fetal thyrotoxicosis: Classically presents as an irritable, tachycardic infant\nborn to a mother with Graves disease. Due to transplacental transfer of\nExophthalmos, pretibial myxedema, IgG TSH-stimulating antibodies.\nand thyroid bruits are specific for Graves\ndisease.\nHistory/PE\nâ–  Patient presents with weight loss, heat intolerance, anxiety, palpitations,\nâ†‘ bowel movement frequency, myopathy/proximal muscle weakness,\nA\ninsomnia, and/or menstrual abnormalities.\nâ–  Physical examination can reveal warm, moist skin; goiter; hypertension;\nsinus tachycardia or irregular heart rhythm (atrial fibrillation, other\ntachyarrhythmias); fine tremor; lid lag; and hyperactive reflexes.\nâ–  Exophthalmos (direct stimulation of orbital fibroblasts by antibodies), pre-\ntibial myxedema, acropachy (soft tissue swelling of the hands) (see\nFig. 2.3-5), and thyroid bruits are seen mainly in Graves disease.\nB\nâ–  Untreated long-standing hyperthyroidism can lead to decreased bone mass.\nDiagnosis\nâ–  Best initial test: Serum TSH level, followed by free T and T . May need\n4 3\nadditional information provided by RAI scans and thyroglobulin levels.\nâ–  Radioactive iodine uptake (RAIU) test and scan: Measures degree and dis-\ntribution of iodine uptake in the thyroid and can be used to differentiate\nbetween different causes of hyperthyroidism. Often used to differentiate\nfunctioning nodules (toxic adenomas, benign) from nonfunctioning nod-\nules (which require biopsy for malignancy workup). See Figure 2.3-6 and\nFIGURE 2.3-5. Physical signs of Graves\nTable 2.3-6.\ndisease. (A) Graves ophthalmopathy. (B)\nPretibial myxedema. (Reproduced with permis-\nsion from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113322 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 133\nA B\nFIGURE 2.3-6. Radioactive iodine uptake scans. ",
      "char_start": 392000,
      "char_end": 394000
    },
    {
      "chunk_id": 197,
      "text": "99m-Technetium pertechnetate thyroid scans showing (A) multinodular areas of increased\nuptake and (B) diffuse uptake as seen in Graves disease. (Image A reproduced with permission from Cho EA, et al. A case of masked toxic adenoma in a patient with\nnon-thyroidal illness. BMC Endocr Disord. 2014;14:1. Image B reproduced with permission from Coutinho E, et al. Gravesâ€™ disease presenting as pseudotumor cerebri: a case report. J Med\nCase Reports. 2011;5:68.)\nTABLE 2.3-6. Diagnoses Indicated by Radioactive Iodine Findings in Hyperthyroidism\nRADIOACTIVE IODINE THYROGLOBULIN (LEVEL\nDIAGNOSIS (RAI) % UPTAKE RAI SCAN FINDINGS IN BLOOD)\nGraves disease â†‘ Diffuse uptake N/A\nMultinodular goiter Normal/â†‘ Multiple nodules of N/A\nâ†‘ uptake\nToxic adenoma Normal/â†‘ One area of â†‘ uptake N/A\nThyroiditis, iodine â†“ Low uptake â†‘\nexposure,\nextraglandular\nproduction\nExogenous thyroid â†“ Low uptake â†“\nhormone\nTreatment\nâ–  Î²-Blockade is a mainstay of treatment for hyperthyroidism, regardless of\nthe cause. Î²-blockers can manage the symptoms of hyperthyroidism\ncaused by increased adrenergic tone (tachycardia, anxiety, tremulousness).\nâ–  Antithyroid medications inhibit the oxidation of iodide, thus impairing\nthyroid hormone synthesis. Methimazole is the first-line agent, except dur-\ning the first trimester of pregnancy, during which propylthiouracil (PTU)\nis preferred (methimazole is teratogenic).\nâ–  Definitive treatment: Radioactive I-131 thyroid ablation is generally pre-\nferred, unless there is a large, obstructive goiter or if there is Graves oph-\nthalmopathy (which can be worsened by radioactive iodine)â€”the\nalternative to ablation is thyroidectomy.\nâ–  Administration of levothyroxine (oral T replacement) prevents hypothy-\n4\nroidism in patients who have undergone ablation or surgery.\nâ–  Administering steroids can treat Graves ophthalmopathy if it is causing\ndiplopia or threatening vision.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113333 1100//2211//2222 1122::118",
      "char_start": 394000,
      "char_end": 396000
    },
    {
      "chunk_id": 198,
      "text": "8 PPMM\n\n134 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nTABLE 2.3-7. Adverse Reactions and Complications for Thyrotoxicosis Treatments\nDRUG/TREATMENT ADVERSE REACTIONS AND OTHER CONSIDERATIONS\nMethimazole Rash, agranulocytosis, liver dysfunction. Contraindicated during the\nfirst trimester of pregnancy.\nPropylthiouracil Rash, arthralgias, agranulocytosis, vasculitis, liver failure (black box\nwarning). Preferred agent in first trimester of pregnancy.\nRadioactive I-131 Most common side effect is subsequent hypothyroidism (most\nthyroid ablation common when treating patients with Graves disease). Contrain-\ndicated in pregnancy. Will initially worsen ophthalmopathy.\nThyroidectomy Hypothyroidism, hypoparathyroidism, damage to nearby structures\n(recurrent laryngeal nerve).\nâ–  See Table 2.3-7 for adverse drug reactions associated with antithyroid\nmedications.\nâ–  Thyroid storm is an acute, life-threatening form of thyrotoxicosis that may\npresent with tachyarrhythmia, fever, and delirium. It can be precipitated\nby acute illness, iodine load, or surgery.\nâ–  Treatment of thyroid storm essentially consists of the same measures noted\npreviously, but in rapid order. Begin with Î²-blockade, followed by antithy-\nroid medication (PTU preferred in this case due to peripheral inhibition\nof T â†’ T conversion) and glucocorticoids. After administration of anti-\n4 3\nthyroid medications, use of inorganic iodide (potassium iodide) blocks\nrelease and synthesis of thyroid hormone. Bile acid sequestrants (eg, cho-\nlestyramine) may be helpful, as thyroid hormone is excreted in bile and\nreabsorbed in the intestine.\nHYPOTHYROIDISM\nMost commonly caused by Hashimoto thyroiditis, but it can result from other\ncauses (see Table 2.3-7).\nâ–  Hashimoto thyroiditis (autoimmune hypothyroidism): Associated with\nâŠ• antithyroglobulin and antithyroid peroxidase (anti-TPO) antibodies that\nprecipitate thyroid destruction. Patients with Hashimoto thyroiditis have a\nhigher risk of developing thyroid lymphoma.\nâ–  Thyroiditis (postpartu",
      "char_start": 396000,
      "char_end": 398000
    },
    {
      "chunk_id": 199,
      "text": "m, postviral, subacute/de Quervain): Can have a\nhypothyroid phase that follows the hyperthyroid phase.\nâ–  Secondary hypothyroidism: Caused by pituitary tumors or pituitary\nsurgery.\nâ–  Congenital hypothyroidism: Most common etiology is thyroid dysgenesis.\nâ–  Generalized resistance to thyroid hormone: Rare. Elevated T /T , normal\n3 4\nto elevated TSH.\nHistory/PE\nâ–  Hypothyroidism classically presents with weakness, fatigue, cold intoler-\nance, constipation, weight gain, depression, hair loss, menstrual irregulari-\nties, and myopathy.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113344 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 135\nâ–  Exam reveals dry, cold, puffy skin accompanied by edema, bradycardia,\nand delayed relaxation of deep tendon reflexes.\nâ–  Congenital hypothyroidism presents with the â€œ6 Psâ€â€”Pot-bellied with a\nProtruding umbilicus, Pale, Puffy-faced, Protuberant tongue, and Poor\nbrain development. Jaundice (unconjugated hyperbilirubinemia) and\nenlarged fontanelles can also be seen. Features of hypothyroidism arise\nover the first few months of life, since maternal T crosses the placenta,\n4\nproviding somewhat adequate hormone levels at the time of birth.\nDiagnosis\nBest initial test: Serum TSH level, followed by free T levels (see Table 2.3-5).\n4\nOther common lab abnormalities include high LDL, â†‘ triglycerides, â†‘ cre-\natine kinase (CK), and hyponatremia.\nTreatment\nâ–  For frank hypothyroidism, administer levothyroxine. In subclinical hypo-\nthyroidism (â†‘ TSH, normal T ), treat with levothyroxine if TSH >10\n4\nmU/L.\nâ–  Myxedema coma is a state of severe hypothyroidism that can present with\nâ†“ mental status, hypothermia, hypotension, bradycardia, hypoglycemia,\nand hypoventilation. Mortality is 30% to 60%. Myxedema coma can be\ntriggered in a hypothyroid patient by acute events such as infections, myo-\ncardial infarction (MI), stroke, trauma, sedative drugs, surgery, and medi-\ncation nonadherence.\nâ–  To treat myxedema",
      "char_start": 398000,
      "char_end": 400000
    },
    {
      "chunk_id": 200,
      "text": " coma, admit to the intensive care unit (ICU) and\nurgently administer intravenous IV levothyroxine and IV hydrocortisone\n(unless adrenal insufficiency has already been excluded).\nTHYROIDITIS\nInflammation of the thyroid gland. Common subtypes include subacute gran-\nulomatous, radiation-induced, autoimmune, postpartum, infectious, and\ndrug-induced (eg, amiodarone).\nHistory/PE\nâ–  The subacute form presents with a tender thyroid, usually after an upper\nrespiratory tract infection.\nâ–  All other forms are associated with painless goiter.\nDiagnosis\nThyroid dysfunction (typically thyrotoxicosis followed by hypothyroidism),\nwith â†“ uptake on RAI scan during the hyperthyroid phase.\nTreatment\nâ–  Subacute thyroiditis is usually self-limited. Treatment calls for nonsteroi-\ndal anti-inflammatory drugs (NSAIDs) or oral prednisone for pain control.\nâ–  Î²-Blockers are appropriate for treating symptomatic hyperthyroidism. Anti-\nthyroid medications are generally not indicated. Levothyroxine is suitable A 24-year-old woman with\nfor management of hypothyroidism associated with thyroiditis if TSH hypothyroidism presents at 10 weeksâ€™\n>10 mU/L. gestation for a prenatal visit. Her only\nmedication is levothyroxine. What\nadjustment is probably needed to her\nlevothyroxine dose?\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113355 1100//2211//2222 1122::1188 PPMM\n\n136 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nTHYROID NEOPLASMS\nThyroid nodules are very common and show an â†‘ incidence with age. Most\n(~95%) are benign.\nHistory/PE\nâ–  Usually asymptomatic on initial presentation; discovered incidentally.\nâ–  Hyperfunctioning nodules may present with symptoms of hyperthyroidism.\nâ–  Large nodules adjacent to the trachea/esophagus may cause dysphagia,\ndyspnea, cough, and choking sensation.\nâ–  An â†‘ risk for malignancy is associated with a history of childhood neck\nirradiation, â€œcoldâ€ nodules (minimal uptake on RAI scan), female sex, age\n<20 or >70, firm and fixed solitary nodules, âŠ• famil",
      "char_start": 400000,
      "char_end": 402000
    },
    {
      "chunk_id": 201,
      "text": "y history, and rapidly\ngrowing nodules with hoarseness. Hyperfunctioning (â€œhotâ€) nodules are\ntypically benign.\nDiagnosis and Management\nSee Figure 2.3-7 for a diagnostic workup of thyroid nodules.\nâ–  Benign nodules: Physical exam/ultrasonography can assess for continued\nnodule growth or for development of suspicious characteristics (eg, micro-\ncalcifications, â†‘ vascular flow, nodules that are taller than they are wide).\nâ–  Malignant nodules: Surgical resection with hemithyroidectomy or total\nthyroidectomy is best initial treatment; adjunctive radioiodine ablation fol-\nlowing excision is appropriate for some high-risk patients.\nâ–  Indeterminate fine-needle aspiration (FNA): Initial management can be\nwatchful waiting vs hemithyroidectomy (10%â€“30% chance of malig-\nnancy). If resected, final pathology can guide further treatment.\nTable 2.3-8 summarizes the types of thyroid malignancy that can be diag-\nnosed after biopsy.\nThyroid nodule\n(found clinically or incidentally on imaging)\nClinical evaluation,\nTSH and ultrasound of neck\nTSH suppressed TSH normal or elevated\nThyroid scintigraphy\nHyperfunctional Hypofunctional â€˜coldâ€™ or\nâ€˜hotâ€™ nodule indeterminate nodule\nRadioiodine ablation or Meets sonographic criteria for FNA?\nsurgical excision Risk factors for malignancy,\nsuspicious ultrasound findings\nYes No\nFNA Monitor\nMalignant Benign\nThe patientâ€™s dose will probably have Thyroid surgery Close follow-up\nto be â†‘ (sometimes by up to 50%!).\nâ†‘ thyroxine-binding globulin (TBG) FIGURE 2.3-7. Diagnostic steps in the workup of a thyroid nodule. AUS, Atypia of undeter-\nlevels in pregnancy leads to â†“ free mined significance; FLUS, follicular lesion of undetermined significance; FNAC, fine-needle\nT/T levels and â†‘ TSH. aspiration cytology; Tc, technetium; US, ultrasound. (Reproduced with permission from USMLE-Rx.com.)\n3 4\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113366 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 137\nTABLE 2.3-",
      "char_start": 402000,
      "char_end": 404000
    },
    {
      "chunk_id": 202,
      "text": "8. Types of Thyroid Carcinoma\nTYPE CHARACTERISTICS PROGNOSIS\nPapillarya Represents 75%â€“80% of thyroid cancers. The female-to-male ratio Ninety percent of patients survive â‰¥10 years after diag-\nis 3:1; incidence peaks in the 30- to 50-year-old age group. Slow nosis; the prognosis is poorer in patients >45 years of\ngrowing. Derived from thyroid hormoneâ€“producing follicular age or those with large tumors.\ncells. Associated with psammoma bodies (round, microscopic\ncalcifications) and large, optically clear nuclei (â€œOrphan Annieâ€\nnuclei). Lymphatic spread.\nFolliculara Accounts for 17% of thyroid cancers. More common in females; Same as above.\nincidence peaks in the 40- to 60-year-old age group. Derived\nfrom thyroid hormoneâ€“producing follicular cells. Hemato-\nlogic spread with distant metastases.\nMedullary Represents 6%â€“8% of thyroid cancers. Derived from calcitonin- Age and stage at time of diagnosis, as well as degree of\nproducing C cells (frequently presents with elevated calcitonin). vascular invasion, are important prognostic factors;\nAssociated with multiple endocrine neoplasia type 2. 80% of patients survive at least 10 years after surgery.\nAnaplastic Accounts for <2% of thyroid cancers; rapidly enlarges and 10% of patients survive for >3 years.\nmetastasizes.\naTumors may contain mixed papillary and follicular pathologies.\nBONE AND MINERAL DISORDERS\nFigure 2.3-8 reviews calcium and phosphate regulation.\nKEY FACT\nOSTEOPOROSIS\nDo not confuse osteoporosis with\nosteomalaciaâ€”a mineralization defect\nA common metabolic bone disease characterized by low bone mass. It most\noften caused by severe vitamin D\noften affects thin postmenopausal females, especially those of White or Asian\ndeficiency that presents with bone\nethnicity or descent, with risk doubling after 65 years of age. Males are also at\npain, â†“ calcium/phosphate, and\nrisk for osteoporosis, but the diagnosis is often overlooked.\nsecondary hyperparathyroidism.\nHistory/PE\nâ–  Osteoporosis is commonly asymptomatic even i",
      "char_start": 404000,
      "char_end": 406000
    },
    {
      "chunk_id": 203,
      "text": "n the presence of a verte-\nbral fracture.\nâ–  Risk factors include smoking, advancing age, excessive alcohol intake, a\nhistory of estrogen-depleting conditions in women (eg, amenorrhea, eating\ndisorders, early menopause) or hypogonadism in men, physical inactivity,\nuncontrolled hyperthyroidism, hyperparathyroidism, chronic inflamma-\ntory disease, corticosteroid use, and Cushing syndrome.\nâ–  Exam may reveal hip fractures, vertebral compression fractures (loss of\nheight and progressive thoracic kyphosis), and/or distal radius fractures\n(Colles fracture) following minimal trauma (see Fig. 2.3-9).\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113377 1100//2211//2222 1122::1188 PPMM\n\n138 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nPTH activity\nionized Ca2+, PO\n4\n3â€“ , or 1,25-(OH)\n2\nD\n3\nFour\npara- Vitamin D activity\nthyroid\nFeedback glands 25-OH D\ninhibition 3\nof PTH\nsynthesis\nPTH released\nPO3â€“\ninto circulation 4\n1Î±-hydroxylase\n1,25-(OH) D\n2 3 1,25-(OH) D\n2 3\nRenal tubular cells\nIntestines/\nBone kidneys\n1,25-(OH) D synthesis Ca2+ and PO3â€“ absorption of\n2 3 4\nReabsorption: Ca2+, PO3â€“ released from bone Ca2+ and PO3â€“\n4 4\nUrine: Ca2+, PO3â€“\n4\nCa2+ and PO3â€“\n4\nCa2+ and PO3â€“\n4\nFIGURE 2.3-8. Overview of calcium and phosphate regulation. PTH, Parathyroid hormone.\n(Reproduced with permission from USMLE-Rx.com)\nKEY FACT\nOsteoporosis is the most common cause\nof pathologic fractures in women with Diagnosis\nlow body weight and men >60 years\nâ–  Diagnostic test: Dual-energy x-ray absorptiometry (DEXA) scan is the rec-\nof age.\nommended screening test for all women >65 years of age and men >70\nyears of age and those with other risk factors for osteoporosis.\nâ–  Osteoporosis: Bone mineral density (T-score) is 2.5 standard deviations\n(SDs) less than normal.\nâ–  Osteopenia: T-score is between 1 and 2.5 SDs below normal.\nâ–  Lab tests: Secondary causes reveal themselves through measurements of\ncalcium, phosphate, parathyroid hormone (PTH), TSH, free T , liver\n4\nenzymes, creatini",
      "char_start": 406000,
      "char_end": 408000
    },
    {
      "chunk_id": 204,
      "text": "ne, and electrolytes. If estrogen deficiency or hypogonad-\nism is suspected, laboratory tests should include follicle-stimulating hor-\nmone (FSH), luteinizing hormone (LH), estradiol, and testosterone.\nTreatment\nâ–  Lifestyle modifications: Adequate calcium and vitamin D intake (supple-\nmentation can be used for prevention), smoking cessation, avoiding heavy\nalcohol use, and weight-bearing exercises.\nFIGURE 2.3-9. Radiographic findings â–  Best initial treatment: Bisphosphonates (eg, alendronate, risedronate,\nin osteoporosis. Lateral thoracic spine ibandronate, zoledronic acid) used in the treatment of osteoporosis; treat-\nradiograph shows osteoporosis and an ment also offered to individuals with osteopenia who have a high calcu-\nanterior wedge deformity (red arrow) of a\nlated osteoporotic fracture risk based on the FRAX calculator.\nlower thoracic vertebral body with asso-\nciated kyphosis. This is a typical insuf- â–  Other medications: Teriparatide (PTH analogue), denosumab (a monoclo-\nficiency fracture in osteoporotic patients. nal antibody to RANK-L), and selective estrogen receptor modulators (eg,\n(Reproduced with permission from Fauci AS, et al. raloxifene).\nHarrisonâ€™s Principles of Internal Medicine. 17th ed. New\nYork, NY: McGraw-Hill; 2008.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113388 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 139\nComplications KEY FACT\nHip fracture is the most devastating consequence of low bone mineral density/\nUpper gastrointestinal side effects such\nosteoporosis, carrying a 50% â†‘ in mortality in the year following hip fracture.\nas reflux, esophagitis, and esophageal\nulcers are common reasons for oral\nPAGET DISEASE OF BONE bisphosphonate (alendronate and\nrisedronate) intolerance.\nCharacterized by an â†‘ rate of bone turnover with both excessive resorption\nand formation of bone. Suspected to be caused by the effects of latent viral\ninfection in genetically susceptible individuals.",
      "char_start": 408000,
      "char_end": 410000
    },
    {
      "chunk_id": 205,
      "text": " Associated with primary\nKEY FACT\nhyperparathyroidism and â†‘ risk for osteosarcoma. The disease can affect one\n(monostotic) or more (polyostotic) bones, with the skull, vertebral bodies, pel-\nIncreased serum alkaline phosphatase\nvis, and long bones most commonly affected.\nwith normal gamma-glutamyl\ntranspeptidase (GGT) points to bone\nHistory/PE\netiology, not liver etiology, as the cause\nâ–  Usually asymptomatic. of elevation.\nâ–  May present with aching bone or joint pain, bony deformities, fracture at a\npagetoid site, nerve entrapment, headaches, and hearing loss (latter two\noccur if involving the skull).\nDiagnosis\nâ–  Best initial test: Plain film x-rays (lytic and sclerotic lesions; see Fig. 2.3-\n10) usually diagnostic.\nâ–  Radionuclide bone scan necessary to characterize extent and sites of dis-\nease (see Fig. 2.3-11).\nâ–  Lab values: â†‘ serum alkaline phosphatase with normal calcium and phos-\nphate levels. Must be distinguished from metastatic bone disease.\nTreatment FIGURE 2.3-10. Radiographic findings\nin Paget disease. Pelvic radiograph\nâ–  Most patients are asymptomatic and require no treatment. demonstrates a thickened cortex (arrow),\nâ–  There is no curative treatment, but the goal is to reduce pain and disease thickened trabeculae (arrowhead), and\nprogression. expansion of the right femoral head, classic\nâ–  Pharmacologic: Bisphosphonates (first line), calcitonin (if intolerant to signs of Paget disease. (Reproduced with permis-\nsion from Fauci AS, et al. Harrisonâ€™s Principles of Internal\nbisphosphonates), calcium and vitamin D supplementation, analgesics\nMedicine. 17th ed. New York, NY: McGraw-Hill; 2008.)\n(NSAIDs and acetaminophen).\nâ–  Adjunctive therapy: Physiotherapy, occupational therapy.\nâ–  Surgery: If necessary, such as in the case of fractures, severe deformities, MNEMONIC\nand osteoarthritis.\nSymptoms and signs of Paget\ndisease of boneâ€”\nComplications PANICS\nOsteoarthritis, pathologic fractures, high-output cardiac failure (from atrio- Pain\nventricular [AV] connection",
      "char_start": 410000,
      "char_end": 412000
    },
    {
      "chunk_id": 206,
      "text": "s), and osteosarcoma (up to 1%). Arthralgia\nNerve compression/Neural deafness\nIncreased bone density\nHYPERPARATHYROIDISM\nCardiac failure\nSkull involvement/Sclerotic vertebra\nSee Figure 2.3-8 for the effects of PTH on serum calcium and phosphate reg-\nulation. For a more thorough review of hypocalcemia and hypercalcemia, see\nthe Renal/Genitourinary chapter. KEY FACT\nâ–  Primary hyperparathyroidism: Most cases (80%) caused by a single hyper- Bone pain and hearing loss â†’ think\nfunctioning adenoma, with the rest (15%) resulting from parathyroid\nPaget disease.\nhyperplasia and, rarely (5%), parathyroid carcinoma.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 113399 1100//2211//2222 1122::1188 PPMM\n\n140 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nâ–  Secondary hyperparathyroidism: A physiologic â†‘ of PTH in response to\nrenal insufficiency (caused by â†“ production of 1-25 dihydroxy vitamin D),\ncalcium deficiency, or vitamin D deficiency.\nâ–  Tertiary hyperparathyroidism: Seen in patients on dialysis with long-\nstanding secondary hyperparathyroidism, which leads to hyperplasia of the\nparathyroid glands. When one or more of the glands become autonomous,\ntertiary hyperparathyroidism results.\nâ–  Pseudohypoparathyroidism: PTH resistance. â†‘ PTH levels but ineffective\nat target organs, resulting in hypocalcemia and hyperphosphatemia. Asso-\nciated with Albright hereditary osteodystrophy (may have shortened fourth\nand fifth metatarsal or metacarpal bones).\nHistory/PE\nMost cases of primary hyperparathyroidism are asymptomatic but may show\nsigns and symptoms of hypercalcemia (see Renal/Genitourinary chapter).\nDiagnosis\nâ–  Lab results in primary hyperparathyroidism reveal hypercalcemia, hypo-\nphosphatemia, and hypercalciuria. Intact PTH is inappropriately â†‘ rela-\nFIGURE 2.3-11. Radionuclide bone scan tive to total and ionized calcium (see Table 2.3-9).\nin Paget disease. Dark areas represent â–  A 99mTc sestamibi scan, in conjunction with thyroid ultrasonography,\nincreased b",
      "char_start": 412000,
      "char_end": 414000
    },
    {
      "chunk_id": 207,
      "text": "one-seeking isotope uptake and\ncan help localize a solitary adenoma.\ndepicts severe disease in the left femur.\n(Reproduced with permission from Takigami I, et al. â–  DEXA may reveal low bone mineral density or frank osteoporosis in the\nFunctional bracing for delayed union of a femur fracture distal radius or other sites.\nassociated with Pagetâ€™s disease of the bone in an Asian â–  Renal imaging can look for nephrocalcinosis and nephrolithiasis.\npatient: a case report. J Orthop Surg Res. 2010;5:33.)\nTreatment\nKEY FACT\nâ–  Best initial treatment: For acute hypercalcemia, IV fluids and calcitonin.\nIV bisphosphonates suitable for long-term treatment.\nHypercalcemia is associated with\nâ€œstones, bones, moans, groans, and â–  Parathyroidectomy if the patient is symptomatic or if certain criteria are\nmet (â†‘ â†‘ calcium, â†‘ creatinine, â†“ bone mineral density, <50 years of\npsychiatric overtones.â€ Treatment:\nage). In the case of a solitary adenoma, 1 gland can be removed. In the set-\nIV fluids (first-line treatment) and\nting of hyperplasia, 3.5 glands must be removed.\ncalcitonin. If secondary to malignancy,\nadd bisphosphonates.\nKEY FACT\nTABLE 2.3-9. Lab Values in Hyperparathyroidism\nEtiologies of hypoparathyroidism\ninclude iatrogenic (postsurgical), PTH CALCIUM PO 4\nautoimmune, congenital (DiGeorge),\nPrimary â†‘ â†‘ â†“\nand infiltrative (hemochromatosis,\nWilson) diseases.\nSecondary â†‘â†‘ Nl/â†“ â†‘ (when etiology is\nrenal failure)\nTertiary â†‘ â†‘â†‘ â†‘\nEctopic PTHrP a â†“ â†‘â†‘ Normal/â†“\naPTH-related peptide (PTHrP) is a member of the PTH family and acts on the same PTH receptors.\nSome tumors (eg, breast, lung) produce PTHrP, causing hypercalcemia of malignancy.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114400 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 141\nâ–  In patients with chronic kidney disease, oral phosphate binders (calcium\nsalts, sevelamer hydrochloride, and lanthanum carbonate) and restriction\nof dietary phosphate intake to prevent secondary h",
      "char_start": 414000,
      "char_end": 416000
    },
    {
      "chunk_id": 208,
      "text": "yperparathyroidism.\nâ–  Cinacalcetâ€”a calcimimetic that acts to lower serum PTH levelsâ€”\napproved for use in hyperparathyroidism caused by renal failure or in\npatients who cannot undergo surgery.\nKEY FACT\nComplications\nHyperparathyroidism can be caused\nHypercalcemia is the most severe complication of primary hyperparathy-\nby ectopic PTH-related peptide\nroidism. Following parathyroidectomy, the physician should watch for hun-\n(PTHrP) production, particularly from\ngry bone syndrome (severe and prolonged hypocalcemia caused by acute\ncarcinomas of the breast, lung, and\nreversal of PTH and â†‘ in bone uptake of calcium, phosphate, and\nhead and neck.\nmagnesium).\nPITUITARY AND HYPOTHALAMIC DISORDERS\nFigure 2.3-12 illustrates the hypothalamic-pituitary axis. The following sec-\ntions outline the manner in which the components of this axis interact with\ntarget organs in various pathologic states.\nDEFICIENCY OF PITUITARY HORMONES\nHypopituitarism is the deficiency of anterior pituitary hormones. If the poste-\nrior pituitary hormones are also affected, it is known as panhypopituitarism.\nCommon causes include:\nâ–  Damage to pituitary gland/hypothalamus by surgery, radiation, mass lesions\n(tumors such as a nonfunctioning pituitary adenoma, craniopharyngioma)\nâ–  Sheehan syndrome (pituitary infarction seen in severe hemorrhage, classi-\ncally in postpartum patients)\nâ–  Pituitary apoplexy (hemorrhage)\nâ–  Infiltrative disorders (hemochromatosis)\nâ–  Infections\nHypothalamus CRH GnRH TRH GHRH DA\nAnterior\npituitary ACTH LH FSH TSH GH Prolactin\nSomatostatin\nBasophils (basophilic) Acidophils (eosinophilic)\nFIGURE 2.3-12. The hypothalamic-pituitary axis. ACTH, Adrenocorticotropic hormone;\nCRH, corticotropin-releasing hormone; DA, dopamine; FSH, follicle-stimulating hormone;\nGH, growth hormone; GHRH, growth hormone-releasing hormone; GnRH, gonadotropin-\nreleasing hormone; LH, luteinizing hormone; TRH, thyrotropin-releasing hormone; TSH,\nAn asymptomatic 36-year-old man\nthyroid-stimulating hormone. (Modifie",
      "char_start": 416000,
      "char_end": 418000
    },
    {
      "chunk_id": 209,
      "text": "d with permission from USMLE-Rx.com.)\npresents for his annual physical.\nRoutine labs reveal a serum calcium\nlevel of 11.3 mg/dL. He returns in 2\nweeks, and his serum calcium level\nremains elevated. Additional studies\nshow a normal serum PTH level and\na low 24-hour urinary calcium level.\nWhat is the most likely diagnosis?\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114411 1100//2211//2222 1122::1188 PPMM\n\n142 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nGonadotropins and growth hormone are often affected first; consequently,\nchildren first present with growth retardation, and adults present with hypogo-\nnadism. Pituitary hormone deficiencies include adrenocorticotropic hormone\n(ACTH) deficiency, secondary hypothyroidism, growth hormone (GH) defi-\nciency, gonadotropin deficiency, central diabetes insipidus (DI), and prolac-\ntin deficiency.\nHistory/PE\nSee Table 2.3-10 for a presentation of pituitary hormone deficiencies. Clini-\ncal manifestations may present suddenly (apoplexy, Sheehan syndrome) or\ngradually (radiation, infiltrative diseases).\nDiagnosis\nRoutine hypopituitarism testing includes 8 am cortisol (on at least two sepa-\nrate occasions), free T (TSH is not diagnostic), testosterone/estradiol levels,\n4\nurine, and plasma osmolality. After the diagnosis of a pituitary hormone defi-\nciency, a brain MRI can check for underlying causes. (See Table 2.3-10.)\nTreatment\nHormone replacement therapy and treatment of the underlying disorder.\nCorresponding sections outline treatments of specific hormone deficiencies.\nDIABETES INSIPIDUS\nInability to produce concentrated urine as a result of antidiuretic hormone\n(ADH) dysfunction, resulting in free water loss from the kidneys. The two\nsubtypes of diabetes insipidus (DI) are as follows:\nâ–  Central DI (ADH deficiency): The posterior pituitary gland fails to\nsecrete ADH. Causes include tumor, ischemia (Sheehan syndrome), pitu-\nitary hemorrhage, traumatic brain injury, infection, metastatic disease, and\nK",
      "char_start": 418000,
      "char_end": 420000
    },
    {
      "chunk_id": 210,
      "text": "EY FACT\nautoimmune disorders (see Fig. 2.3-13).\nIn patients with suspected DI, check â–  Nephrogenic DI (ADH resistance): The kidneys fail to respond to circu-\nserum or urinary glucose to rule out lating ADH. Causes include renal disease and drugs (eg, lithium,\ndiabetes mellitus. demeclocycline).\nï©serum\nï©serum osmolality\nosmolality Hypothalamus ï©serum volume\nï©urine osmolality\nADH\nCentral DI ï©urine volume\nSIADH\nThe patient most likely has familial Posterior Medullary collecting duct\nhypocalciuric hypercalcemia (FHH), pituitary Aquaporin channels\nADH\nan inherited disorder caused by (storage)\nmutations in a calcium-sensing\nADH antagonists\nreceptor present in the parathyroid Lithium\nand kidney, which presents with Nephrogenic DI\nelevated serum calcium levels.\nFIGURE 2.3-13. The hypothalamic-pituitary axis: Diabetes insipidus. In central DI, ADH is\nUnlike patients with primary\nnot secreted from the posterior hypothalamus. In nephrogenic DI, ADH is secreted from the\nhyperparathyroidism, these patients\nposterior hypothalamus, but its end-organ effects at the kidney are blocked. Both central and\nare asymptomatic and have low\nnephrogenic DI result in an increase in plasma osmolarity due to excessive free-water diuresis.\nurinary calcium levels. No treatment DI, Diabetes insipidus; SIADH, syndrome of inappropriate secretion of ADH. (Reproduced with\nis required. permission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114422 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 143\nTABLE 2.3-10. Pituitary Hormone Deficiencies\nDEFICIENT\nHORMONE CLINICAL MANIFESTATION DIAGNOSIS NOTES\nACTH Weakness, hypotension, hypona- Measure AM cortisol: Secondary adrenal insufficiency presents with\ntremia, hypoglycemia, weight <3 mcg/dL: Adrenal insufficiency predominant cortisol deficiency (aldosterone\nloss (AI) likely, confirm with ACTH is dependent on the renin-angiotensin system,\nmeasurement not ACTH)\n3-18 mcg/dL: ACTH stim",
      "char_start": 420000,
      "char_end": 422000
    },
    {
      "chunk_id": 211,
      "text": "ulation test No hyperpigmentation vs primary adrenal\n>18 mcg/dL: AI unlikely insufficiency\nTSH Cold intolerance, lethargy, con- Free T (TSH is not diagnostic) Secondary hypothyroidism; rule out ACTH\n4\nstipation, dry skin, delayed deficiency before starting on hormone\ndeep tendon reflex relaxation, replacement, as levothyroxine increases cor-\nweight gain tisol clearance and can precipitate adrenal\ncrisis\nGH Short stature in children; adults Deficiencies of various other pitu-\npresent with decreased bone itary hormones is suggestive\ndensity, muscle atrophy, Insulin-like growth factor (IGF)-1\nincreased fat mass and GH stimulation test\ndyslipidemia\nFSH/LH Females: primary amenorrhea, LH/FSH Hypogonadotropic hypogonadism\nsecondary amenorrhea, Testosterone Measurements of serum prolactin levels in\ninfertility Estrogen males can rule out hypogonadism secondary\nMales: decreased energy and to a prolactinoma\nlibido, infertility, loss of male\npattern hair, gynecomastia,\ntesticular atrophy\nADH Polyuria, polydipsia Urine osmolality and plasma Central diabetes insipidus\nosmolality\nIf abnormal, perform water depriva-\ntion test\nProlactin Failure to lactate after delivery Serum prolactin Usually occurs in conjunction with other pitu-\nitary hormone deficiencies\nHistory/PE\nâ–  DI presents with polydipsia, polyuria, and persistent thirst with dilute A 23-year-old man with a history\nof schizophrenia presents with\nurine.\ncomplaints of fatigue, weakness,\nâ–  If access to water is limited (eg, in people who are institutionalized or\ncramps, and headache for the\nolder adults), patients may present with dehydration and severe hyperna-\npast several days. He denies\ntremia, which lead to altered mental status, lethargy, seizures, and coma.\nany other symptoms, although\nhe had to urinate several times\nwhile in the office. Routine labs\nDiagnosis\nreveal hyponatremia. With water\nâ–  Lab tests: Serum osmolality > urine osmolality, â†“ urinary sodium, and deprivation, his urine osmolality â†‘.\npossible hypernatr",
      "char_start": 422000,
      "char_end": 424000
    },
    {
      "chunk_id": 212,
      "text": "emia. What is the most likely diagnosis?\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114433 1100//2211//2222 1122::1188 PPMM\n\nDehydration phase Desmopressin phase\nNormal\nCentral DI\nPrimary polydipsia\nPartial nephrogenic DI\nComplete nephrogenic DI\nTime (hours)\nFIGURE 2.3-14. Water deprivation test: DI; Diabetes insipidus. (Reproduced with permission from\nUSMLE-Rx.com.)\nTABLE 2.3-11. Water Deprivation Test\nCENTRAL DI NEPHROGENIC DI PRIMARY POLYDIPSIA\nSerum sodium High Normal Low\nResponse to water depriva- Mild â†‘ or no Mild â†‘ or no â†‘ >600 mOsmol/\ntion (urine osmolality) change change kg\nResponse to desmopressin â†‘ No response No response\n(urine osmolality)\nâ–  Water deprivation test: In psychogenic polydipsia and normal renal physi-\nology, water restriction will lead to more concentrated urine. In central\nand nephrogenic DI, patients excrete a high volume of inappropriately\ndilute urine (see Fig. 2.3-14, Table 2.3-11).\nâ–  Desmopressin acetate replacement test:\nâ–  Also known as vasopressin, a synthetic analogue of ADH.\nâ–  Central DI: â†“ urine output and â†‘ urine osmolarity (by 50%â€“100%).\nâ–  Nephrogenic DI: No effect on urine output or urine osmolarity.\nâ–  MRI may show a pituitary or hypothalamic mass in central DI.\nTreatment\nâ–  Treatment of underlying cause.\nâ–  Central DI: Administration of desmopressin intravenously, intranasally, or\norally.\nâ–  Nephrogenic DI: Salt restriction, hydrochlorothiazide, amiloride, low-\nThe most likely diagnosis is primary protein diet in adults.\n(psychogenic) polydipsia, a condition\nin which patients consume large\nvolumes of hypotonic fluid, resulting EXCESS OF PITUITARY HORMONES\nin polyuria. It most often occurs in\npatients with psychiatric disorders. Acromegaly\nPatients present with symptoms\nsimilar to DI, but following a water Elevated GH levels in adults, most commonly caused by a benign pituitary\ndeprivation test, urine osmolality â†‘ GH-secreting adenoma (see Fig. 2.3-15). Children with excess GH produc-\n(vs DI, ",
      "char_start": 424000,
      "char_end": 426000
    },
    {
      "chunk_id": 213,
      "text": "in which urine remains dilute). tion present with gigantism.\nytilalomso\nenirU\n144 HIGH-YIELD FACTS IN ENDOCRINOLOGY\n1000\n800\n600\n400\n200\n2 4 6 8 10 12\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114444 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 145\nSleep, hypoglycemia, stress, Aging, obesity,\npuberty, exercise hyperglycemia\nGHRH\nSomatostatin\nPosterior\nAnterior pituitary\npituitary\nGrowth\nhormone\nAmino acid uptake IGF-1 Amino acid uptake Glucose uptake\nProtein synthesis Protein synthesis Lipolysis\nDNA and RNA synthesis\nChondroitin sulfate\nCollagen\nCell size and number\nFIGURE 2.3-15. The hypothalamicâ€“anterior pituitary axis (hypophyseal portal system): acro-\nmegaly. GHRH, Growth hormone-releasing hormone; IGF-1, insulin-like growth factor 1.\n(Reproduced with permission from USMLE-Rx.com.)\nHistory/PE\nâ–  Pituitary adenoma may cause headache, cranial nerve defects, and bitem-\nporal hemianopsia due to compression of the optic chiasm.\nâ–  Systemic manifestations include:\nâ–  Increased skeletal and soft tissue growth manifesting as enlargement of the\nskull (frontal bossing, wide-spaced teeth) and hands and feet, malocclusion\nof the jaw, coarsening of facial features, and carpal tunnel syndrome\nâ–  Degeneration of cartilage resembling osteoarthritis\nâ–  Skin thickening and skin tags\nâ–  Hyperhidrosis\nâ–  Organomegaly (eg, tongue enlargement)\nâ–  Associated with an increased risk for:\nâ–  Obstructive sleep apnea\nâ–  Cardiovascular abnormalities such as hypertension, left ventricular\nhypertrophy, and cardiomyopathy with diastolic dysfunction (most\ncommon cause of death)\nâ–  Type 2 DM\nâ–  Diverticulosis\nâ–  Colon cancer\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114455 1100//2211//2222 1122::1188 PPMM\n\n146 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nFIGURE 2.3-16. Diagnostic algorithm for Clinical suspicion of acromegaly\nacromegaly. GH, Growth hormone; GHRH, (enlargement of nose, frontal bones and jaw)\ngrowth hormo",
      "char_start": 426000,
      "char_end": 428000
    },
    {
      "chunk_id": 214,
      "text": "ne-releasing hormone; IGF-1,\ninsulin-like growth factor 1. (Reproduced with per-\nmission from USMLE-Rx.com.) IGF-1 level\nNormal Elevated\nRules out acromegaly Oral glucose suppression test\nAdequate GH suppression Inadequate GH suppression\nRules out acromegaly MRI of brain\nNormal pituitary Pituitary mass\nEvaluate for extra pituitary Surgical vs\ncause of acromegaly medical management\n(eg, ectopic GH and\nGHRH-secreting tumors)\nDiagnosis\nâ–  Lab tests: Levels of IGF-1 increase with acromegaly; diagnosis can be con-\nfirmed with an oral glucose suppression test (GH levels will remain ele-\nvated despite glucose administration). Baseline GH is not a reliable test, as\nGH levels fluctuate widely throughout the day (see Fig. 2.3-16).\nâ–  Imaging: MRI shows a sellar lesion.\nTreatment\nâ–  Surgery: Trans-sphenoidal surgical resection.\nKEY FACT\nâ–  Medical therapy: Octreotide or lanreotide (somatostatin analogues) to\nsuppress GH secretion; pegvisomant (a GH receptor antagonist) to block\nMeasurement of IGF-1 levelsâ€”not GH\nthe peripheral actions of GH.\nlevelsâ€”can confirm acromegaly!\nâ–  Radiation: Effective when surgical and medical therapies fail.\nHYPERPROLACTINEMIA\nHyperprolactinemia refers to elevated prolactin levels, most commonly\ncaused by a pituitary adenoma (see Fig. 2.3-17). Prolactinoma is the most\ncommon functioning pituitary tumor. Other causes include physiologic ones\n(pregnancy, lactation); pituitary stalk compression from other masses (eg, cra-\nniopharyngioma, meningioma, nonsecreting pituitary tumor); hypothalamic\ndysfunction; drugs (eg, dopamine antagonists, selective serotonin reuptake\ninhibitors [SSRIs]); and systemic conditions such as renal failure, cirrhosis,\nand hypothyroidism.\nKEY FACT History/PE\nElevated prolactin inhibits GnRH secretion and consequently lowers LH and\nRule out pregnancy in all cases of\nFSH secretion, manifesting as infertility, galactorrhea, gynecomastia, impo-\nhyperprolactinemia!\ntence, and amenorrhea. Bitemporal hemianopsia may also be present.\nDiagn",
      "char_start": 428000,
      "char_end": 430000
    },
    {
      "chunk_id": 215,
      "text": "osis\nâ–  Serum prolactin level is typically >200 ng/mL.\nâ–  Pregnancy test to exclude pregnancy.\nâ–  MRI shows a sellar lesion.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114466 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 147\nMedications FIGURE 2.3-17. The hypothalamicâ€“anterior pitu-\nChest wall injury (via ANS) itary axis (hypophyseal portal system): Prolactin\nStimuli Nipple stimulation Primary hypothyroidism Pregnancy: Estrogen regulation. ANS, Autonomic nervous system; FSH,\nSight/cry of baby follicle-stimulating hormone; GnRH, gonadotropin-\nreleasing hormone; LH, luteinizing hormone; TRH,\nthyrotropin-releasing hormone. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nHypothalamus Dopamine TRH\nAnterior pituitary Prolactin\nGonadal axis\nPeripheral action\n(GnRH)\nOvulation Milk production\nSpermatogenesis\nTreatment\nâ–  Best initial treatment: Dopamine agonists (eg, cabergoline, bromocriptine).\nâ–  Trans-sphenoidal surgery: Indicated in adenomas refractory to medical\nmanagement or with compressive effects (eg, visual loss).\nâ–  Radiation: Rarely indicated.\nSYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION\nSyndrome of inappropriate antidiuretic hormone secretion (SIADH) is a\ncommon cause of euvolemic hyponatremia that results from persistent ADH\nrelease independent of serum osmolality.\nHistory/PE\nMay be associated with central nervous system (CNS) disease (eg, head\ninjury, tumor), pulmonary disease (eg, sarcoid, chronic obstructive pulmo-\nnary disease [COPD], pneumonia), ectopic tumor production/paraneoplastic\nsyndrome (eg, small cell lung carcinoma), and drugs (eg, antipsychotics, anti-\ndepressants, NSAIDs). Euvolemic on physical exam.\nDiagnosis\nâ–  Serum osmolality <280 mOsm/kg (hypotonic)\nâ–  Urine osmolality >100 mOsm/kg in the setting of serum hypo-osmolarity\nwithout a physiologic reason for â†‘ ADH (eg, congestive heart failure, cir-\nrhosis, hypovolemia)\nâ–  Urinary sodium level often â‰¥40 mEq/L\nTreatment\nKEY FACT\nâ–  E",
      "char_start": 430000,
      "char_end": 432000
    },
    {
      "chunk_id": 216,
      "text": "xploration of and addressing the underlying cause\nâ–  Best initial treatment: Restriction of fluid\nFluid restriction is the cornerstone of\nâ–  Persistent or symptomatic hyponatremia (<120 mEq/L): IV hypertonic\nSIADH treatment. Hyponatremia should\nsaline therapy\nbe corrected slowly to prevent osmotic\nâ–  Severe SIADH: ADH antagonists (eg, tolvaptan, conivaptan)\ndemyelination syndrome.\nâ–  Chronic SIADH: Demeclocycline\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114477 1100//2211//2222 1122::1188 PPMM\n\n148 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nKEY FACT ADRENAL GLAND DISORDERS\nDehydroepiandrosterone sulfate\nSee Figure 2.3-18 for an overview of adrenal anatomy, regulatory control, and\n(DHEAS) is produced only by the\nsecretory products.\nadrenal gland.\nADRENAL INSUFFICIENCY\nManifested by an inadequate production of adrenal hormones, including glu-\ncocorticoids and/or mineralocorticoids, AI may be primary, secondary, or ter-\ntiary. Etiologies are as follows:\nâ–  Primary: In the United States, most commonly caused by autoimmune\nadrenal cortical destruction (Addison disease). Other causes include infec-\nKEY FACT tions (tuberculosis [TB], HIV, histoplasmosis), congenital enzyme defi-\nciencies, and adrenal hemorrhage (Waterhouse-Friderichsen syndrome\nPrimary AI is associated with â†‘ skin\nfrom Neisseria meningitidis).\npigmentation, â†“ glucocorticoids, and\nâ–  Secondary/tertiary: Caused by â†“ ACTH production by the pituitary gland\nâ†“ mineralocorticoids. Secondary AI is\n(secondary) or â†“ CRH corticotropin-releasing hormone production by the\nonly associated with â†“ glucocorticoids\nhypothalamus (tertiary); most often caused by cessation of long-term glu-\nand does not have skin pigmentation or\ncocorticoid treatment (often with higher doses and longer duration of\nhyperkalemia.\ntherapy).\nHistory/PE\nâ–  Most symptoms are nonspecific.\nMNEMONIC â–  Common concerns include weakness, fatigue, anorexia with weight loss,\nand GI complaints (eg, nausea, abdominal pain).\nThe 4 Sâ€™s of",
      "char_start": 432000,
      "char_end": 434000
    },
    {
      "chunk_id": 217,
      "text": " adrenal crisis â–  Hyperpigmentation (caused by â†‘ ACTH secretion) and nonâ€“anion gap\nmanagementâ€”\nmetabolic acidosis (caused by â†“ aldosterone) occur in primary AI. Hyper-\nSalt: 0.9% saline pigmentation is not seen in secondary or tertiary AI due to a decrease in\nSteroids: IV hydrocortisone ACTH secretion.\nSupport (hemodynamic, glucose)\nâ–  Hypotension, confusion, and coma are seen in acute adrenal crisis (eg,\nSearch for the underlying illness\nstopping long-term steroids).\nDiagnosis\nâ–  Lab tests: Hypoglycemia, electrolyte imbalances (see Table 2.3-12).\nHORMONE 1Ëš HORMONE\nANATOMY HISTOLOGY 1Ëš REGULATION BY CLASS PRODUCED\nZona glomerulosa Angiotensin II Mineralocorticoids Aldosterone\nAdrenal gland\nCORTEX Zona fasciculata ACTH, CRH Glucocorticoids Cortisol\nCapsule\nACTH, CRH Androgens DHEA\nZona reticularis\nPreganglionic\nSuperior surface MEDULLA Chromaffin cells sympathetic fibers Catecholamines Epi, NE\nof kidney\nFIGURE 2.3-18. Overview of adrenal anatomy, regulatory control, and secretory products. ACTH, Adrenocorticotropic hormone; CRH, corti-\ncotropin-releasing hormone; DHEA, dehydroepiandrosterone; Epi, epinephrine; NE, norepinephrine. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114488 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 149\nTABLE 2.3-12. Laboratory Findings in Adrenal Insufficiency\nCORTISOL ALDOSTERONE ACTH SODIUM POTASSIUM\nPrimary adrenal â†“ â†“ â†‘ â†“ â†‘â†‘\ninsufficiency\nSecondary/ â†“ Normal â†“ Normal/â†“ Nl\ntertiary\nadrenal\ninsufficiency\nâ–  8 am plasma cortisol levels and ACTH levels (see Table 2.3-12, Fig. 2.3-\nKEY FACT\n19). An 8 am plasma cortisol level <3 Î¼g/dL in the absence of exogenous\nglucocorticoid administration is diagnostic of AI.\nDo not delay the administration of\nâ–  If morning cortisol levels are nondiagnostic, the test of choice is synthetic\nsteroids for diagnostic testing in a\nACTH stimulation (cosyntropin) test. Failure of cortisol to rise >20 Î¼g/dL\npati",
      "char_start": 434000,
      "char_end": 436000
    },
    {
      "chunk_id": 218,
      "text": "ent with suspected AI.\nfollowing ACTH administration confirms the diagnosis.\nTreatment\nâ–  Primary: Glucocorticoid and mineralocorticoid replacement\nâ–  Secondary/tertiary: Only glucocorticoid replacement necessary (mineralo-\ncorticoid production is not ACTH dependent)\nâ–  Acute adrenal crisis: IV steroids, correction of electrolyte abnormalities,\n50% dextrose to correct hypoglycemia, and initiation of aggressive volume\nresuscitation\nPrevention\nâ–  â†‘ steroids during periods of stress (eg, major surgery, trauma, infection).\nâ–  In patients on chronic steroid therapy, taper slowly to prevent secondary/\ntertiary AI.\nConcern for adrenal insufficiency\nCheck 8 AM cortisol\nIndeterminate\nNormal cortisol levels cortisol results Low cortisol levels\nNo adrenal insufficiency Cosyntropin stimulation\ntest with 30 minute cortisol levels\nNormal cortisol levels Minimal cortisol response\nNo adrenal insufficiency Adrenal insufficiency confirmed\nMeasure ACTH\nLow ACTH levels Elevated ACTH levels\nSecondary or tertiary Primary adrenal\nadrenal insufficiency insufficiency\nFIGURE 2.3-19. Diagnostic algorithm for adrenal insufficiency. (Modified with permission from USMLE-\nRx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 114499 1100//2211//2222 1122::1188 PPMM\n\n150 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nMNEMONIC PHEOCHROMOCYTOMA\nPheochromocytoma rule of 10â€™sâ€”\nA tumor of chromaffin tissue that secretes catecholamines and is found either\n10% Extra-adrenal\nin the adrenal medulla or in extra-adrenal sites. Most commonly associated with\n10% Bilateral\nmultiple endocrine neoplasia type 2A (MEN2A) and MEN type 2B (MEN2B).\n10% Malignant\n10% Occur in children\nHistory/PE\n>25% Familial (adults)\nâ–  Pheochromocytoma presents with paroxysmal tachycardia, palpitations,\nchest pain, diaphoresis, episodic or persistent hypertension, headache,\ntremor, anxiety, pallor, and weight loss. It may be misdiagnosed as anxiety/\npanic disorder.\nâ–  Obtaining a family history can rule out genetic cau",
      "char_start": 436000,
      "char_end": 438000
    },
    {
      "chunk_id": 219,
      "text": "ses of pheochromocy-\ntoma (eg, MEN2A/2B, von Hippelâ€“Lindau disease, neurofibromatosis\ntype 1).\nMNEMONIC\nDiagnosis\nThe 5 Ps of pheochromocytomaâ€”\nâ–  Best initial test: Indicated by â†‘ 24-hour urine metanephrines and cate-\nPressure (BP)\ncholamines or plasma-fractionated metanephrines.\nPain (headache)\nâ–  Helpful labs: Hyperglycemia Â± polycythemia (if EPO secreted).\nPerspiration\nPalpitations â–  Imaging (only after labs): CT or MRI of adrenal glands (see Fig. 2.3-20).\nA nuclear metaiodobenzylguanidine (MIBG) scan can localize extra-\nPallor\nadrenal lesions and metastatic disease.\nTreatment\nâ–  Surgical resection.\nâ–  Preoperatively, first Î±-adrenergic blockade (phenoxybenzamine) to control\nKEY FACT\nhypertension, followed by Î²-blockade to control tachycardia. Î²-Blockade\nshould never be given first, as unopposed Î±-adrenergicâ€“mediated vasocon-\nIn pheochromocytoma, administration\nstriction can lead to severe hypertension.\nof Î±-blockers should occur before\nâ–  If bilateral adrenalectomy, glucocorticoids to prevent acute adrenal\nÎ²-blockers to prevent hypertensive crisis.\ninsufficiency.\nA B\nFIGURE 2.3-20. Pheochromocy toma. (A) MRI showing left suprarenal mass (arrow). (B) Pheo-\nchromocytoma postsurgical resection. (Reproduced with permission from Roghi A, et al. Adrenergic myocarditis in\npheochromocytoma. J Cardiovasc Magn Reson. 2011;13:4.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115500 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 151\nCUSHING SYNDROME\nStress\nHypothalamus\nCircadian rhythm\nCushing syndrome is caused by elevated serum cortisol levels, and it most fre-\nquently develops secondary to prolonged treatment with exogenous cortico- CRH\nsteroids. The most common endogenous cause is hypersecretion of ACTH\nfrom a pituitary adenoma (known as Cushing disease; see Fig. 2.3-21). Other\nendogenous causes include excess adrenal secretion of cortisol (eg, bilateral\nadrenal hyperplasia, adrenal adenoma, adrenal cancer) and ectopic",
      "char_start": 438000,
      "char_end": 440000
    },
    {
      "chunk_id": 220,
      "text": " ACTH\nproduction from an occult neoplasm (eg, carcinoid tumor, medullary thyroid Anterior\npituitary\ncancer, small cell lung cancer).\nEndorphins\nHistory/PE MSH\nProopiomelanocortin ACTH\nSee Figure 2.3-22 for classic signs and symptoms of Cushing syndrome.\nCortisol\nMoon face\nPituitary tumor\nEmotional disturbances Hirsutism\nDownstream cortisol\nfunction\nBuffalo hump\nFIGURE 2.3-21. The hypothalamic-\nanterior pituitary axis (hypophyseal\nportal system): Cushing disease.\nCardiac hypertrophy ACTH, Adrenocorticotropic hormone;\nThin, wrinkled skin CRH, corticotropin-releasing hormone;\nMSH, melanocyte-stimulating hormone.\nObesity (Reproduced with permission from USMLE-Rx.com.)\nAbdominal striae\nInsulin resistance KEY FACT\nCushing syndrome: Too much cortisol.\nMuscle weakness Adrenal tumor Cushing disease: Too much cortisol\nor hyperplasia\nOsteoperosis from an ACTH-producing pituitary\nHypokalemia adenoma.\nHypertension\nPurpura MNEMONIC\nSkin ulcers Amenorrhea\n(poor healing) Cushing syndrome symptomsâ€”\nCUSHINGOID\nErectile dysfunction\nCataracts\nUlcers\nSkin (striae, bruising, thinning, ulcer)\nFIGURE 2.3-22. Physical findings in Cushing syndrome. (Modified with permission from USMLE-Rx.com.)\nHirsutism, hypertension\nInfections\nNecrosis (femur head)\nGlycosuria\nObesity, osteoporosis\nImmunosuppression\nDiabetes\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115511 1100//2211//2222 1122::1188 PPMM\n\n152 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nKEY FACT Diagnosis\nIn Cushing disease, cortisol secretion See Figure 2.3-23 for the diagnostic algorithm. Table 2.3-13 outlines impor-\nremains elevated with the low-dose tant lab findings that aid in diagnosis. Diagnosis follows a stepwise progression\n(1 mg) dexamethasone test but is of tests.\nsuppressed with the high-dose (8 mg)\ndexamethasone test. Treatment\nâ–  Exogenous: Gradual withdrawal and stoppage of glucocorticoids.\nâ–  Endogenous: Surgical resection of the source (pituitary, adrenal, ectopic\nneoplasm). Permanent hormone repl",
      "char_start": 440000,
      "char_end": 442000
    },
    {
      "chunk_id": 221,
      "text": "acement therapy to correct deficien-\ncies after treatment or resection of the primary lesion.\nClinical suspicion of Cushing syndrome\nPerform 24-hour urinary free cortisol or 1mg\novernight dexamethasone suppression of\nplasma cortisol or late night salivary cortisol\nNormal Abnormal\nNot Cushing syndrome Probable Cushing syndrome\nMeasure plasma ACTH\nLow or suppressed High or normal\nACTH-dependent\nProbable adrenal tumor\nCushing syndrome\nConfirm with adrenal CT MRI of the pituitary\n> 6 mm adenoma No adenoma or < 6 mm lesions\nPetrosal sinus sampling\nCushing disease\nwith CRH\n+ Central-peripheral No central-peripheral\nACTH gradient ACTH gradient\nEctopic ACTH-dependent\nCushing disease\nCushing syndrome\nFIGURE 2.3-23. Diagnostic algorithm for Cushing syndrome. ACTH, Adrenocorticotropic hormone; CRH, corti-\ncotropin-releasing hormone. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115522 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 153\nTABLE 2.3-13. Laboratory Findings in Cushing Syndrome\nCUSHING DISEASE ECTOPIC ACTH ADRENAL CORTISOL\n(PITUITARY HYPERSECRETION) EXOGENOUS STEROID USE SECRETION HYPERSECRETION\n24-hour urinary free â†‘ â†‘ â†‘ â†‘\ncortisol\nSalivary cortisol â†‘ â†‘ â†‘ â†‘\nACTH â†‘ â†“ â†‘ â†“\nDexamethasone\nsuppression test\nmorning cortisol level: N/Aa N/Aa\nLow dose â†‘ â†‘\nHigh dose â†“ â†‘\naA dexamethasone suppression test is not required once the diagnosis of ACTH-independent Cushing syndrome is made.\nHYPERALDOSTERONISM\nHyperaldosteronism results from excessive secretion of aldosterone from the\nzona glomerulosa of the adrenal cortex. It is usually caused by bilateral adre-\nnocortical hyperplasia (60%â€“70%) but can also result from unilateral adrenal\nadenoma (Conn syndrome).\nHistory/PE\nâ–  Presents with hypertension, headache, polyuria, muscle weakness (caused\nby hypokalemia), and constipation/paralytic ileus (particularly if\nhypokalemia).\nâ–  Consider hyperaldosteronism in younger adults who are d",
      "char_start": 442000,
      "char_end": 444000
    },
    {
      "chunk_id": 222,
      "text": "iagnosed with\nhypertension without risk factors or a family history of hypertension.\nDiagnosis\nâ–  Lab tests: Can confirm 1Âº hyperaldosteronism with â†‘ urinary aldosterone\nafter oral sodium loading or saline infusion test (ie, failure to suppress\naldosterone secretion). Hypokalemia, metabolic alkalosis, hypomagnese-\nmia, hyperaldosteronism, â†‘â†‘ aldosterone-to-plasma renin activity ratio\n(usually >30).\nâ–  Imaging: Only after labs. CT or MRI may reveal an adrenal mass.\nâ–  Adrenal venous sampling (will show â†‘ aldosterone) may be needed to\nlocalize the adenoma or to confirm bilateral adrenal hyperplasia.\nTreatment An asymptomatic 36-year-old woman\npresents with a 2 cm thyroid mass.\nâ–  Unilateral adenoma: Surgical resection (after correction of BP and TFTs are unremarkable, but FNA\npotassium). reveals medullary carcinoma. Total\nâ–  Bilateral hyperplasia: Aldosterone receptor antagonist (eg, spironolac- thyroidectomy with thyroid hormone\ntone). Switch to eplerenone if side effects. replacement is recommended. What\nare the most important screening\ntests to perform prior to surgery?\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115533 1100//2211//2222 1122::1188 PPMM\n\n154 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nTABLE 2.3-14. Overview of Congenital Adrenal Hyperplasia\nENZYME DEFICIENCY MINERALOCORTICOIDS CORTISOL SEX HORMONES BP [K+] LABORATORY TESTS PRESENTATION\n17Î±-hydroxylasea â†‘ â†“ â†“ â†‘ â†“ â†“ androstenedione XY: pseudohermaph-\nroditism (ambiguous\ngenitalia, unde-\nscended testes)\nXX: lack secondary\nsexual development\n21-hydroxylasea â†“ â†“ â†‘ â†“ â†‘ â†‘ renin activity Most common\nâ†‘ 17-hydroxyproges- Presents in infancy (salt\nterone wasting) or childhood\nâ†“ sodium (precocious puberty)\nâ†“ chloride XX: virilization\n11Î²-hydroxylasea â†“ aldosterone â†“ â†‘ â†‘ â†“ â†“ â†“ renin activity XX: virilization\nâ†‘ 11-deoxycorticosterone\n(results in â†‘ BP)\naAll congenital adrenal enzyme deficiencies are characterized by an enlargement of both adrenal glands caused by â†‘ ACTH stimulation (caused by",
      "char_start": 444000,
      "char_end": 446000
    },
    {
      "chunk_id": 223,
      "text": "\nâ†“ cortisol).\nAdapted with permission from Le T, Bhushan V. First Aid for the USMLE Step 1 2022. New York, NY: McGraw-Hill; 2022.\nMNEMONIC CONGENITAL ADRENAL HYPERPLASIA\nFor CAH, if the deficient enzyme begins Congenital adrenal hyperplasia (CAH) refers to genetic enzyme defects that\nwith 1 (11 and 17), mineralocorticoid\nimpair cortisol synthesis, resulting in glucocorticoid insufficiency and buildup\nactivity is high. If it ends with 1 (11 and\nof precursors. Most cases are caused by 21-hydroxylase deficiency (95%, autoso-\n21), androgen activity is high.\nmal recessive), but other causes include 11- and 17-hydroxylase deficiencies.\nKEY FACT History/PE\nSee Table 2.3-14.\nCongenital aromatase deficiency will\npresent similarly to CAH in female\nDiagnosis\nnewborns with external virilization and\nambiguous external genitalia. However, â–  Lab tests: Electrolyte abnormalities (see Table 2.3-14). In severe cases,\nthe patient will have no electrolyte or mineralocorticoid deficiency may lead to life-threatening salt wasting.\nblood pressure abnormalities. â–  Elevated serum 17-hydroxyprogesterone level is diagnostic of 21-hydroxy-\nlase deficiency.\nTreatment\nâ–  Immediate fluid resuscitation and salt repletion. Administer cortisol to\nThe most important screening tests\nâ†“ ACTH and adrenal androgens. Fludrocortisone is appropriate for severe\nto perform are vanillylmandelic acid\n21-hydroxylase deficiency.\n(VMA) and metanephrines. Medullary\nâ–  Possible surgical correction of ambiguous genitalia.\ncarcinoma of the thyroid is associated\nwith MEN type 2A/2B, an autosomal â–  Refer to the Gynecology chapter for information on the diagnosis and\ntreatment of late-onset CAH.\ndominant condition that predisposes\npatients not only to medullary carcino-\nma but also to pheochromocytomas.\nScreening for pheochromocytoma\nwith urine VMA and metanephrines\nprior to surgery can prevent potentially\nlife-threatening hypertensive crises\nduring thyroidectomy.\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__1122",
      "char_start": 446000,
      "char_end": 448000
    },
    {
      "chunk_id": 224,
      "text": "33--115566..iinndddd 115544 1100//2211//2222 1122::1188 PPMM\n\nENDOCRINOLOGY HIGH-YIELD FACTS IN 155\nMULTIPLE ENDOCRINE NEOPLASIAS\nA family of tumor syndromes with autosomal dominant inheritance (see Fig.\n2.3-24).\nMEN type 1 (formerly Wermer syndrome):\nâ–  Pancreatic islet cell tumors\nâ–  Gastrinomas: Zollinger-Ellison syndrome\nâ–  Insulinomas: Recurrent hypoglycemia with elevated insulin and\nC-peptide levels\nâ–  VIPomas: Watery diarrhea, hypokalemia, and hypochlorhydria\nâ–  Glucagonomas: New-onset diabetes, necrolytic migratory erythema\nâ–  Parathyroid adenomas\nâ–  Pituitary adenomas\nMEN type 2A (formerly Sipple syndrome): Medullary carcinoma of the thy-\nroid, pheochromocytoma, parathyroid hyperplasia/adenoma(s), parathyroid\nhyperplasia/adenoma(s). Caused by mutations in the RET proto-oncogene.\nMEN type 2B: Medullary carcinoma of the thyroid, pheochromocytoma,\noral and intestinal ganglioneuromatosis (mucosal neuromas), marfanoid habi-\ntus. Caused by mutations in the RET proto-oncogene.\nPituitary\nPancreas\nParathyroids\nThyroid\n(medullary carcinoma)\nPheochromocytomas\nMucosal neuromas\nMEN 1 = 3 Ps: Pituitary, Parathyroids,\nand Pancreas\nMEN 2A = 2 Ps: Parathyroids\nand Pheochromocytomas\nMEN 2 B = 1 P: Pheochromocytomas\nFIGURE 2.3-24. Multiple endocrine neoplasias (MEN). (Modified with permission from UMSLE-Rx.com.)\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115555 1100//2211//2222 1122::1188 PPMM\n\n156 HIGH-YIELD FACTS IN ENDOCRINOLOGY\nNOTES\n22002222__0022..0033__SStteepp22CCKK__EEnnddoo__1111ee__112233--115566..iinndddd 115566 1100//2211//2222 1122::1188 PPMM\n\nH I G H - Y I E L D F A C T S I N\nEPIDEMIOLOGY\nAssessment of Disease Frequency 158 Evaluating Clinical Studies 165\nBiaS 165\nPerson-Time Estimate 158\nStatiStical teSting 168\nAssessment of Diagnostic Studies 158 ScenarioS 168\nSenSitivity and Specificity 158 commonly uSed StatiStical teStS 169\npoSitive and negative predictive valueS 159\nPrevention 170\nlikelihood ratio 160\nVaccination 170\nMeasure",
      "char_start": 448000,
      "char_end": 450000
    },
    {
      "chunk_id": 225,
      "text": "s of Effect 160\ncovid-19 vaccineS 173\nTypes of Clinical Studies 161\nScreening Recommendations 174\ncroSS-Sectional Study 162\ncohort Study 162 Reportable Diseases 176\ncaSe-control Study 163\nrandomized controlled trial 164\nphaSeS of clinical trialS 164\n157\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 115577 1100//2211//2222 1122::2233 PPMM\n\nASSESSMENT OF DISEASE FREQUENCY\nKEY FACT The prevalence of a disease is the number of existing cases in the population\nat a specific moment in time.\nAs the mortality of a disease â†“, the\ntotalnumberofcasesinthepopulatiionatonepointintime\nprevalence of that disease â†‘ (eg, type 2 Prevalence=\ndiabetes mellitus), because the duration totalpopulation\nof disease has lengthened. Remember:\nThe incidence of a disease is the number of new cases in the disease-free pop-\nP = I Ã— D.\nulation (â€œpopulation at riskâ€) that develop over a period of time.\nnumberofnewcasesinthepopulationoveragiventimeperiod\nIncidence=\nKEY FACT totalpopulationatriiskduringthespecifiedtimeperiod\nPrevalence is directly related to incidence and duration of disease. It is\nIncidence can be measured in a cohort\ngiven by the following formula:\nstudy; prevalence can be measured in a\ncross-sectional study. Prevalence (P) = incidence (I) Ã— average duration of disease (D)\nFor example, a chronic disease such as type 2 diabetes mellitus (DM) is\ndiagnosed frequently, but due to improvements in treatment, people live lon-\nger with this disease. Thus the prevalence of type 2 DM increases daily as\nmore people are diagnosed and more people with the disease live for a longer\nperiod.\nFor incidence, remember to subtract any preexisting cases of the disease\nfrom the total population at risk, as these individuals are no longer at risk.\nPERSON-TIME ESTIMATE\nTo further estimate the actual time at risk that all patients contributed to a\nstudy, a person-time estimate is calculated. This is relevant in cohort studies,\nas this considers when a person enters the stu",
      "char_start": 450000,
      "char_end": 452000
    },
    {
      "chunk_id": 226,
      "text": "dy, leaves the study, or develops\ndisease by taking into consideration four major end points: presence of disease\nat the onset of the study, death of the subject being studied, loss to follow-up,\nand end of the study.\nASSESSMENT OF DIAGNOSTIC STUDIES\nSENSITIVITY AND SPECIFICITY\nPhysicians often use tests to narrow and confirm possible diagnoses. The sen-\nsitivity and specificity of these tests allow physicians to determine how often\nfalse âŠ• and false âŠ– results occur (Fig. 2.4-1). Both sensitivity and specificity\nare independent of disease prevalence.\nDisease\nTP FP\nFN\ntseT\nPPV\n= TP/(TP + FP)\nNPV\nTN\n= TN/(TN + FN)\nSensitivity Prevalence\nTP + FN\n= TP/(TP + FN) = TN/(TN + FP) (TP + FN + FP + TN)\nâ€“\nâ€“\n158 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nSpecificity\nFIGURE 2.4-1. Sensitivity, specificity, positive predictive value (PPV), and negative predic-\ntive value (NPV). Presence or absence of disease is typically assessed using a â€œgold standardâ€ test,\nor the most accurate test available for a given disease. TP, true positive; FP, false positive; FN, false\nnegative; TN, true negative. (Reproduced with permission USMLE-Rx.com.)\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 115588 1100//2211//2222 1122::2233 PPMM\n\nPossible cutoff values for vs test result\nDisease Disease A = 100% sensitivity cutoff value absent present\nB = practical compromise between specificity and sensitivity\nC = 100% specificity cutoff value\nTN TP\nLowering the cutoff value: â†‘ Sensitivity â†‘ NPV B A (â†‘ FP FN) Specificity PPV\nFN FP\nRaising the cutoff value:\nTest results\nâ–  Sensitivity: The probability that a patient with a disease will have a âŠ• test\nresult.\nâ–  A sensitive test rarely misses identifying people with the disease and is\ntherefore good at ruling out those who do not have the disease. A high\nMNEMONIC\nsensitivity means there is a low false âŠ– rate.\nâ–  High sensitivity is desirable early in a diagnostic workup or screening\nSNOUTâ€”SeNsitive tests rule OUT disease.\ntest, when it is",
      "char_start": 452000,
      "char_end": 454000
    },
    {
      "chunk_id": 227,
      "text": " necessary to reduce a broad differential diagnosis.\nSPINâ€”SPecific tests rule IN disease.\nâ–  Example: An initial enzyme-linked immunosorbent assay (ELISA) test\nfor HIV infection.\nFalse âŠ– rate = 1 â€“ sensitivity = 1 â€“ (TP/[TP + FN])\nâ–  Specificity: The probability that a patient without a disease will have a âŠ–\ntest result.\nâ–  A specific test rarely determines that someone has the disease when\nthey do not and is therefore good at ruling in those who have the dis-\nease. A high specificity means there is a low false âŠ• rate.\nâ–  High specificity is desirable when confirming a likely diagnosis.â†‘ speci-\nficity â†“ the number of false âŠ• results.\nâ–  Example: A Western blot confirmatory HIV test.\nFalse âŠ• rate = 1 â€“ specificity = 1 â€“ (TN/[TN + FP])\nâ–  The ideal test is both sensitive and specific, but a trade-off must often be\nmade between sensitivity and specificity (Fig. 2.4-2). For a given test,\nwhen sensitivity â†‘, specificity â†“ (and vice versa).\nâ–  Occasionally, the USMLE asks students to compare different diagnostic\ntests using receiver operating characteristic (ROC) curves, where sensitiv-\nity is plotted on the y-axis and 1 â€“ specificity is plotted on the x-axis\n(Fig. 2.4-3). The best diagnostic test will have a curve that â€œhugsâ€ the x-\nand y-axes (curve X).\nPOSITIVE AND NEGATIVE PREDICTIVE VALUES\nOnce a test has been administered and a patientâ€™s result has been made avail-\nable, that result must be interpreted through use of predictive values. Remem-\nber, unlike sensitivity and specificity, which refer to test characteristics, PPV\nand NPV depend both on the test characteristics and the underlying disease\nprevalence.\nâ–  PPV: The probability that a patient with a âŠ• test result truly has the dis-\nease. The higher the disease prevalence, the higher the PPV of the test for\nthat disease. A change in the test cutoff point that â†‘ false âŠ• will â†“ the\nPPV. This means that with an increase in the specificity of the test, there\nis an increase in the PPV, and vice versa.\nelpoep\nfo\nrebmuN\nA B C\nâ†‘",
      "char_start": 454000,
      "char_end": 456000
    },
    {
      "chunk_id": 228,
      "text": " â†‘ â†‘ â†‘\nâ†‘ Specificity â†‘ PPV\nB C (â†‘ FN FP) Sensitivity NPV â†‘ â†‘ â†‘ â†‘\nâ€“ Ideal test (AUC = 1)\nNo\npredictive\nvalue\n(AUC =\n0.5)\nFIGURE 2.4-2. Effect of cutoff values on sensitivity and specificity. FN, False negative; FP,\nfalse positive; TN, true negative; TP, true positive. (Reproduced with permission from USMLE-Rx.com.)\n)ytivitisnes(\netar\nPT\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 159\n1\nActual\ntest (0.5\n<\nAUC <\n1)\nFP rate (1 â€“ specificity) 1\nFIGURE 2.4-3. Receiver operating char-\nacteristic curves. The better performing\ntest will have a higher AUC, with the\ncurve closer to the upper left corner. (Repro-\nduced with permission of USMLE-Rx.com.)\n1\nWhat happens to the PPV and NPV\nwhen prevalence â†“?\n2\nA local child care center that was built\nbefore the 1950s was found to have\nelevated lead levels in its paint. A\nstudent organization at your medical\nschool is hosting a lead-screening\nevent to test all children at the center.\nWhich initial screening test would\nbe more appropriate: a test that has\nhigh sensitivity or one that has high\nspecificity?\n3\nYour hospital is considering\nadopting a new diagnostic test for\npheochromocytoma. In Figure 2.4-2,\nthe current diagnostic test (urinary\nmetanephrines) falls close to point B.\nThe new test falls closer to point A.\nHow will the false âŠ• and false âŠ– rates\nof this new test compare to urinary\nmetanephrines?\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 115599 1100//2211//2222 1122::2233 PPMM\n\n160 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nâ–  NPV: The probability that a patient with a âŠ– test result truly does not\nhave the disease. The lower the disease prevalence, the higher the NPV of\nthe test for that disease. A change in the test cutoff point that â†‘ false âŠ– will\nâ†“ the NPV. This means that with an increase in the sensitivity of a test,\nthere is an increase in the NPV, and vice versa.\nLIKELIHOOD RATIO\nThe likelihood ratio (LR) expresses the extent to which a given test result is\nlikely in diseased people as opposed to peopl",
      "char_start": 456000,
      "char_end": 458000
    },
    {
      "chunk_id": 229,
      "text": "e without disease:\nâ–  LR âŠ• shows how much the odds (or probability) of disease are â†‘ if the test\nresult is âŠ•.\nâ–  LR âŠ– shows how much the odds (or probability) of disease are â†“ if the test\nresult is âŠ–.\n1 LRâŠ• = sensitivity/(1 âˆ’ specificity)\nPPV â†“ and NPV â†‘. Remember that if LRâŠ– = (1 âˆ’ sensitivity)/specificity\nprevalence is low, even a test with\nhigh sensitivity or specificity will have Posttest odds = pretest odds Ã— LR\na low PPV.\nMEASURES OF EFFECT\nA central aim of epidemiology is to assess the relationship between an expo-\nsure event and an outcome measure. The likelihood or risk of observing an\noutcome following an exposure is quantified using measures of effect. Ways\n2 to express and compare risk include the following:\nâ–  Absolute risk: The incidence of disease.\nA test with high sensitivity, such\nâ–  Relative risk (or risk ratio; RR): Expresses how much more likely an\nas a fingerstick lead test (capillary\nexposed person is to get the disease in comparison to an unexposed per-\nblood), is preferred for initial\nson. This indicates the relative strength of the association between expo-\nscreening because it can ensure that\nsure and disease, making it useful when one is considering disease\nno children who might have the\ndiseaseâ€”and who might benefit etiology. This is used mostly in cohort studies.\nfrom further testing and treatmentâ€”\nincidenceinexposed\nwill be missed. The children with a âŠ• RR =\nfingerstick test should subsequently incidenceinunexposed\nhave a serum blood level drawn\nRR > 1 suggests â†‘ risk\n(higher specificity).\nRR < 1 suggests â†“ risk\nâ–  Attributable risk (or risk difference): The difference in risk between\nexposed and unexposed groups.\nAttributable risk = (incidence of disease in exposed âˆ’ incidence in unexposed)\n3 Attributable risk percentage = [(RR âˆ’ 1)/RR] Ã— 100%\nâ–  Absolute risk reduction (ARR): The difference in risk that is attributable\nThe false âŠ• rate will â†‘ (capturing to the intervention compared to a control. From the 2 Ã— 2 table (see exam-\nmore of the â€œ",
      "char_start": 458000,
      "char_end": 460000
    },
    {
      "chunk_id": 230,
      "text": "no diseaseâ€ cohort), but ple in Fig. 2.4-4), ARR is derived as:\nthe false âŠ– rate will â†“ (capturing the\nARR = (c/[c + d]) â€“ (a/[a + b])\nlittle tail of the â€œdiseaseâ€ cohort). In Fig.\n2.4-2, this translates to â†‘ sensitivity\nand â†“ specificity.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116600 1100//2211//2222 1122::2233 PPMM\n\nDisease No\ndevelops disease\na / (a + b) Absolute risk = (a + c) / (a + b + c + d)\nExposure a b RR =\nc / (c + d) Attributable risk = a / (a + b) âˆ’ c / (c + d)\nNo exposure c d OR = ad / bc Number needed to treat = 1/ARR\nFIGURE 2.4-4. Relative risk (RR) vs odds ratio (OR). (Adapted with permission from USMLE-Rx.com.)\nâ–  Number needed to treat (NNT): Number of individuals who need to be\ntreated for one patient to benefit.\nNNT = 1/absolute risk reduction\nâ–  Odds ratio (OR): An estimate of relative risk that is used in case-control\nstudies, ie, it represents the odds of exposure among cases vs odds of expo-\nsure among controls. The OR tells how much more likely it is that a per-\nson with a disease has been exposed to a risk factor than someone without\nthe disease. The lower the disease prevalence, the more closely it approxi-\nmates RR. In case-control studies, the OR also describes how many times\nmore likely an exposed individual is to have disease compared to an unex-\nposed individual (see Fig. 2.4-4).\noddsthatadiseasedpersonisexposed\nOR =\noddsthhatanondiseasedpersonisexposed\nOnce a diagnosis has been established, it is important to be able to describe\nthe associated prognosis. Survival analysis is used to summarize the average\ntime from one event (eg, presentation, diagnosis, or start of treatment) to any\noutcome that can occur only once during follow-up (eg, death or recurrence\nof cancer). The usual method is with a Kaplan-Meier curve (Fig. 2.4-5)\ndescribing the survival in a cohort of patients, with the probability of survival\nâ†“ over time as patients die or drop out from the study.\nâ–  Hazard ratio (HR): An estimate ",
      "char_start": 460000,
      "char_end": 462000
    },
    {
      "chunk_id": 231,
      "text": "of the chances that an event occurs in the\ntreatment arm of a trial vs the nontreatment arm. Used in prospective stud-\nies. Values <1 indicate that the treatment arm had a â†“ in the event rate,\nand values >1 indicate the event rate â†‘. A value of 1 suggests lack of\nassociation.\nHR = hazard in treatment arm/hazard in control arm\nTYPES OF CLINICAL STUDIES\nStudies are typically used to evaluate diagnosis, treatment, and screening for a\ndisease. Although the gold standard for such evaluation is a randomized, Assume that the data below are from\ndouble-blind controlled trial, other types of studies may be used as well (eg, a hypothetical case-control study.\nan observational study, in which the exposure in question is a therapeutic Calculate and interpret the OR.\nintervention). Figure 2.4-6 illustrates the level of evidence pyramid. At the\nEXPOSED\nbottom of the pyramid are low level of evidence studies, and at the top of the\npyramid are high level of evidence studies. In descending order of strength of YES NO\nDisease Cases 283 263\nStatus\nControls 182 210\nytilibaborp\nlavivruS\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 161\n1.0\n0.9 Drug\n0.8\n0.7\n0.6\nControl\n0.5\n0.4\n0.3\n0.2\nX Y Z\nTime\nFIGURE 2.4-5. Example of a Kaplan-\nMeier curve. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116611 1100//2211//2222 1122::2233 PPMM\n\n162 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nnce\ne\nd\nevi Clinical Synopses of syntheses\nof practice\nLevel guideline F\nin\nil\nf\nt\no\ne\nr\nr\nm\ned\nation\nMeta-analysis\nI Synthesis of studies\nn Systematic review\no\nmati\nof i\nnf\nor\nII\nRandomized controlled study\nQ\nuality Cohort study\nStudies\nCase-control study\nIII\nCross-sectional study, observational study Unfiltered\ninformation\nV\nI Case series or case report\nV Expert opinion, narrative review, or editorial\nAnimal or laboratory study\nFIGURE 2.4-6. Strength of evidence in increasing order. (Reproduced with permission from USMLE-Rx.\ncom.)\nevidence, published studie",
      "char_start": 462000,
      "char_end": 464000
    },
    {
      "chunk_id": 232,
      "text": "s regarding treatment options include randomized\ncontrolled trials (RCTs); observational studies like case-control, cohort, and\ncross-sectional studies; and case series/case reports. Meta-analyses are often\nused to systematically synthesize information across studies to help summa-\nrize the totality of the evidence. Randomization is successful when the base-\nline characteristics of patients in each group are statistically similar.\nCROSS-SECTIONAL STUDY\nA cross-sectional study is an observational study that assesses risk factors and\noutcomes at a snapshot in time (Fig. 2.4-7). This study does not prove tempo-\nKEY FACT ral relationships because it measures correlation, not causation. The most\ncommon example of this type of study would be a general survey or a census.\nA cross-sectional study that is\nAdvantages of cross-sectional studies include the following:\nundertaken to estimate prevalence is\ncalled a prevalence study. â–  They provide an efficient means of examining a population, allowing\nsimultaneous assessment of people with the disorder and those without it.\nâ–  They can give a basis for diagnostic testing.\nDisadvantages include the following:\nâ–  Cross-sectional studies only obtain information at a single point in time, so\nresearchers cannot determine causal relationships.\nâ–  Risk or incidence of disease cannot be directly measured.\nCOHORT STUDY\nOR = ad/bc\nIn a cohort study, a group of people sharing certain characteristics (eg, age,\n= (283 Ã— 210)/(263 Ã— 182) = 1.24\ngender, occupation, or date of birth) is assembled to study the relationships\nbetween exposures and outcomes of interest (see Fig. 2.4-7). For each possi-\nInterpretation: The exposed group had ble risk factor, the members of the cohort are classified as either exposed or\n1.24 times the odds of having disease\nunexposed. All the cohort members are then followed over time, and the inci-\ncompared to the unexposed group.\ndence of outcome events is compared in the two exposure groups.\n22002222__0022..0044__SStte",
      "char_start": 464000,
      "char_end": 466000
    },
    {
      "chunk_id": 233,
      "text": "epp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116622 1100//2211//2222 1122::2233 PPMM\n\nExample: The Framingham Heart Study followed a group of men and\nwomen over time to see how different exposures (eg, diet, exercise, aspirin) KEY FACT\naffected the incidence of heart disease.\nCohort studies are also known as\nAdvantages of cohort studies include:\nlongitudinal or prospective or incidence\nâ–  They provide the only way to directly determine incidence (because they studies, from which both OR and RR can\nfollow a cohort over time to assess disease development). be calculated.\nâ–  They let researchers assess the relationship of a given exposure to many\ndiseases.\nâ–  In prospective studies, exposure is elicited without bias from a known\noutcome.\nDisadvantages include the following:\nKEY FACT\nâ–  Cohort studies can be time-consuming and expensive.\nâ–  Studies only assess the relationship of the disease to the few exposures In cohort studies, the researcher\nidentified and measured as a part of the study.\nascertains who is exposed or\nâ–  The requirement for many subjects makes it difficult to study rare diseases. unexposed and follows them over time\nCohort studies can be either prospective, in which a cohort is assembled\nfor disease development.\nin the present and followed into the future, or retrospective, in which a cohort\nis identified from past records and is followed to the present.\nCASE-CONTROL STUDY\nIn a case-control study, a series of cases are identified and a set of controls is\nsampled from the underlying population to estimate the frequency of expo-\nsure in the population at risk for the outcome (see Fig. 2.4-7). In such a study,\na researcher compares the frequency of exposure to a possible risk factor\nbetween the case and control groups.\nExample: A study examines patients with heart disease (cases) and those\nwithout heart disease (controls) and compares exposures to red meat in both\ngroups. KEY FACT\nâ–  Validity depends on appropriate selection of cases and controls, the",
      "char_start": 466000,
      "char_end": 468000
    },
    {
      "chunk_id": 234,
      "text": " way Accuracy and validity measure\nexposure is measured, and the ways in which a researcher deals with con-\nbias. Accuracy requires correct\nfounding variables.\nmeasurements. Precision (and reliability)\nâ–  External validity (also known as generalizability) is the applicability of the measures random error. Precision â†‘\nresults to a new population.\nwith â†‘ sample size.\nâ–  Cases and controls should be comparable in terms of opportunity for expo-\nsure (ie, they should be members of the same base population with an\nequal opportunity of risk factor exposure).\ntsaP\ntneserP\nerutuF\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 163\nCross-sectional study Case-control study Retrospective cohort study Prospective cohort study\nCompare risk factor\nfrequency Risk factor Risk factor\nControls Compare disease\nRisk factor Risk factor Diseased\nwithout incidence cases\ndisease Risk factor Risk factor\nCompare disease Review previous\nprevalence records\nCompare disease\nincidence\nFIGURE 2.4-7. An overview of various observational studies. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116633 1100//2211//2222 1122::2233 PPMM\n\n164 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nâ–  â€œMatchingâ€ occurs when the researcher chooses controls that match cases\non a particular characteristic.\nKEY FACT\nâ–  Example: If matching on sex, female cases would be matched to\nIn case-control studies, the researcher female controls and male cases would be matched to male controls.\ncontrols the number of cases and â–  The purpose of matching is to â†“ confounding.\ncontrols. Only ORs can be calculated\nAdvantages of case-control studies are as follows:\nfrom case-control studies.\nâ–  They use smaller groups than cohorts, thereby reducing costs.\nâ–  They can be used to study rare diseases and can easily examine multiple\nrisk factors. This is because in case-control studies, the OR is a close\napproximation of RR, known as â€œrare disease assumption.â€\nDisadvantages include the followin",
      "char_start": 468000,
      "char_end": 470000
    },
    {
      "chunk_id": 235,
      "text": "g:\nâ–  Case-control studies cannot calculate disease prevalence or incidence, and\nthey cannot directly estimate the RR because the investigatorâ€”not\nnatureâ€”artificially determines the numbers of subjects with and without a\ndisease. However, an OR determined via a case-control study can be used\nto estimate a measure of RR if the prevalence is low.\nâ–  Retrospective data can be inaccurate because of recall or survivorship biases.\nRANDOMIZED CONTROLLED TRIAL\nKEY FACT\nAn RCT is an experimental, prospective study in which subjects are randomly\nRandomization minimizes bias and assigned to a treatment or control group. Random assignment helps remove\nconfounding; double-blind studies confounding and ensure that the two groups are truly comparable. The control\nprevent observation bias. group may be treated with a placebo or with the accepted standard of care.\nThe study can be masked in one of two ways: 1) single blind, in which\npatients do not know which treatment group they are in, or 2) double blind, in\nwhich neither the patients nor their physicians know who is in which group.\nâ–  Double-blind studies are the gold standard for studying treatment effects.\nâ–  Factorial design involves several rounds of randomization with two or\nmore variables.\nâ–  Example: A trial studies the role of aspirin and statins in preventing\nmyocardial infarction (MI) by creating four groups: one given aspirin\nonly, one given statin only, one given both aspirin and statin, and one\ngiven neither. The rates of MI are then measured.\nAdvantages of RCTs are as follows (see also Table 2.4-1):\nâ–  They minimize bias.\nâ–  They have the potential to demonstrate causal relationships because expo-\nsure is assigned randomly, which minimizes confounding.\nâ–  Exposure to the treatment is assigned randomly while other characteristics\nin the groups are all similar.\nDisadvantages include the following:\nâ–  RCTs are costly and time intensive.\nâ–  Some interventions (eg, surgery) are not amenable to blinding.\nKEY FACT\nPHASES OF CLINICAL",
      "char_start": 470000,
      "char_end": 472000
    },
    {
      "chunk_id": 236,
      "text": " TRIALS\nA drug is available in the market once it\npasses Phase 3. A new drug must undergo several phases of testing before being placed on the\nmarket for public use. The phases include testing in animals, healthy volun-\nteers, and small and large groups of patients with disease. Once the drug is on\nthe market, mandatory reporting of adverse events is required during postmar-\nketing surveillance. Table 2.4-2 lists details of these phases.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116644 1100//2211//2222 1122::2233 PPMM\n\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 165\nTABLE 2.4-1. Comparison of Study Designs\nVARIABLE RCT COHORT CROSS-SECTIONAL CASE CONTROL\nPurpose Tests causality through random Follows groups of patients Determines prevalence Tests association (usually\nassignment of exposure over a specified period in a snapshot of time retrospectively, but\nto capture the associa- outcome first, then\ntion of risk factors to the looks for risk factors)\ndevelopment of disease\nMeasures Varied, including response to RR, OR, incidence, Prevalence (not OR\ntreatment, adverse effects, sur- prevalence incidence)\nvival during follow-up\nDesign Subjects are randomly assigned Subjects are not assigned Determines disease Identifies cases (disease)\nto be in treatment or placebo to groups prevalence at one and controls (no\narms Determines if subjects are point in time; cannot disease) groups first and\nin exposed or unexposed determine the direc- then goes backward to\ngroups and follows them tionality of association determine if they are\nuntil they develop the between exposure exposed or not (the\ndisease (or do not) and outcome opposite of RCT and\ncohort studies)\nAdvantages Can determine causality; mini- Temporality can be deter- Less time-consuming Predetermined number\nmizes bias and confounding mined; incidence can be and costly of cases; less time-\ndetermined consuming and costly\nDisadvantages RCT is not possible when: Follows large groups over Direction",
      "char_start": 472000,
      "char_end": 474000
    },
    {
      "chunk_id": 237,
      "text": "ality of asso- Recall bias, selection bias\nâ–  Treatment has a known adverse long periods ciation cannot be\noutcome Selection bias in retrospec- determined\nâ–  Disease is very rare tive cohort studies Incidence cannot be\nâ–  Treatment is in widespread use determined\nor represents the best option\n(because it is unethical to\nwithhold treatment)\nEVALUATING CLINICAL STUDIES\nBIAS\nA bias in research is any process that causes results to systematically differ\nfrom the truth. Research can be biased before conduction, during conduc-\ntion, and after completion (during analysis) (Fig. 2.4-8.)\nâ–  Selection bias: Occurs when samples or participants are selected that dif-\nfer from the study population in a meaningful way. Example: Individuals\nconcerned about a family history of breast cancer may be more likely to\nself-select in entering a mammography program, giving the impression of\na prevalence that is higher than it is in reality.\nâ–  Example: If a substantial portion of subjects in one group are lost to\nfollow-up (attrition bias), the study may overestimate the association.\nThis is a special type of selection bias.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116655 1100//2211//2222 1122::2233 PPMM\n\n166 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nTABLE 2.4-2. Phases of Clinical Treatment Trials\nPHASE GOALS NUMBER OF PARTICIPANTS TYPE OF PARTICIPANTS\nPreclinical Understand mechanism of drug N/A Nonhuman\n0 Study pharmacokinetics of drug in human body Usually limited to 10 Healthy volunteers\n1 Establish safety range of drug dosing Anywhere from 20 to 100 Healthy volunteers\nparticipants\n2 Assess efficacy and adverse effects of drug Anywhere from 100 to 300 Patients with disease the drug is to treat\nparticipants\n3 Assess safety and efficacy of drug Anywhere from 300 to Patients with disease the drug is to treat\n3000 participants Compared to gold-standard treatment\n4 Postmarketing surveillance to see long-term All patients taking the drug Effects and adverse effects",
      "char_start": 474000,
      "char_end": 476000
    },
    {
      "chunk_id": 238,
      "text": " to be noted by\neffectiveness and adverse effects treating physician\n70% of drugs 33% of drugs 20-30% of drugs FDA approval\nadvance advance advance\nPreclinical Phase 1 Phase 2 Phase 3 Phase 4\nTest drug in lab animals Determine dosing and Assess effectiveness and Confirm effectiveness, monitor Post-marketing surveillance\nand in vitro experiments test effectiveness evaluate safety of drug side effects, and compare to to see long-term effects\ngold standard treatment and adverse effects\nSample size: 20-100 healthy 100-300 patients with 300-3000 patients with All patients with disease\nvolunteers disease of interest disease of interest of interest taking drug\n(Reproduced with permission from USMLE-Rx.com.)\nâ–  Measurement bias: Occurs when measurement or data-gathering meth-\nKEY FACT ods differ between groups.\nâ–  Example: One group is assessed by CT, while another group is assessed\nStudies that are masked and by MRI.\nrandomized are better protected\nfrom the effects of bias, whereas â–  Confounding bias: Occurs when a third variable is either positively or\nnegatively associated with both the exposure and outcome variables,\nobservational studies are particularly\ninducing an incorrect association.\nsusceptiwble to bias.\nâ–  Example: Fishermen in an area may experience a higher incidence of\nlung cancer than that found in the general population. If people who\nsmoke become fishermen, then by this logic they are also more likely\nto develop lung cancer than those who do not smoke (and yet become\nfishermen). So, in testing for an association between lung cancer and\nfishing, smoking would be a confounding variable.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116666 1100//2211//2222 1122::2233 PPMM\n\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 167\nTRIAL PROGRESSION\nTrial planning Trial implementation Data analysis and\npublication\nPre-trial bias Bias during trial\nFlawed study design Measurement bias Bias after trial\nSelection bias Recall bias Effect modification\nObse",
      "char_start": 476000,
      "char_end": 478000
    },
    {
      "chunk_id": 239,
      "text": "rver bias Confounding bias\nHawthorne effect Lead-time bias\nLength-time bias\nFIGURE 2.4-8. Major sources of bias in clinical trials. (Reproduced with permission from USMLE-Rx.com.)\nâ–  Effect modification: Occurs when a third variable disproportionately\naffects two groups. Effect modification shows a meaningful difference, KEY FACT\nwhereas confounding does not. This can be identified by use of stratified\nanalysis (ie, a subgroup analysis of the cohort). Confounding variables reduce the\nâ–  Example: A study shows that a new chemotherapeutic agent only mod- internal validity of a study.\nestly improves survival rates in some patients with non-Hodgkin lym-\nphoma. However, investigators noted that those patients >65 years of\nage had significant survival benefits, whereas those below the age of 65\nyears did not. In this case age is an effect modifier.\nâ–  Recall bias: Results from a difference in the retrospective recall of past fac-\ntors or outcomes.\nâ–  Example: A patient with cancer may be more motivated to recall past\nepisodes of chemical exposure than would a healthy individual.\nâ–  Example: A mother whose child has neural tube defects may likely\nrecall more about lack of folate supplementation during early preg-\nnancy than a mother with a healthy child.\nâ–  Observer bias: Results from investigatorâ€™s awareness of the population\nbeing studied and its exposure status.\nâ–  Example: A trial for new blood pressure management in the intensive\ncare unit (ICU) is biased when the attending physician knows which\npatients are enrolled in the treatment arm.\nâ–  Hawthorne effect: Results from study subjectsâ€™ awareness that they are\nbeing studied, causing them to change aspects of their behavior.\nâ–  Example: Employees at an automotive factory may work more produc-\ntively when they realize that their superiors are conducting random\naudits.\nâ–  Lead-time bias: Results from earlier detection of disease, giving an appear-\nance of prolonged survival when in fact the natural course is not altered.\nâ–  Exampl",
      "char_start": 478000,
      "char_end": 480000
    },
    {
      "chunk_id": 240,
      "text": "e: A new and widely used screening test that detects cancer 5\nyears earlier may yield the impression that patients are living longer\nwith the disease.\nâ–  Length bias: Occurs when screening tests detect a disproportionate num-\nber of slowly progressive diseases but miss rapidly progressive ones, leading\nto overestimation of the benefit of the screen.\nâ–  Example: A better prognosis for patients with cancer is celebrated, fol-\nlowing the implementation of a new screening program. However, this\ntest disproportionately detects slow-growing tumors, which generally A hypothetical study finds a âŠ•\ntend to be less aggressive. association between poor sleep habits\nand the risk for Parkinson disease. The\nRR is 10, and the P value is 0.4. How do\nyou interpret these results?\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116677 1100//2211//2222 1122::2233 PPMM\n\n168 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nSTATISTICAL TESTING\nEven with bias reduction, unsystematic random error is unavoidable because\nof chance variation in studied data. Types of errors are as follows:\nâ–  Type I (ð›‚) error:\nâ–  A type I/ð›‚ error is the probability of concluding that there is a differ-\nence in treatment effects between groups when in fact there is not (eg,\na false âŠ• conclusion)â€”in other words, rejecting the null hypothesis (of\nno effect) when it should not be rejected.\nâ–  The P value is an estimate of the probability that differences in treat-\nment effects in a study could have happened by chance alone if no\ntrue association exists. A P value of <0.05 is considered statistically sig-\nnificant in medical literature but may not always imply clinical signifi-\ncance (usually noted with meta-analysis where the sample size is large\nenough to identify a small but clinically insignificant difference in out-\ncome). A P value alone does not give any information about the direc-\ntion or size of the effect.\nâ–  Type II (ð›ƒ) error:\nâ–  A type II/ð›ƒ error is the probability of concluding that there is ",
      "char_start": 480000,
      "char_end": 482000
    },
    {
      "chunk_id": 241,
      "text": "no differ-\nence in treatment effects when in fact a difference exists (eg, a false âŠ–\nconclusion)â€”in other words, not rejecting the null hypothesis (of no\neffect) when it should be rejected.\nâ–  Power is the probability that a study will find a statistically significant\ndifference when one is truly there. Increasing the number of subjects\nin a study increases the power. A lower type II error leads to an increase\nin the power of the study. Similarly, larger effect size would lead to an\nincrease in power and a decrease in need of a large study sample.\nPower = 1 âˆ’ type II error (Î²)\nThe confidence interval (CI) is a way of expressing statistical significance\nthat shows the size of the effect and the statistical power (the narrower the CI,\nthe greater the statistical power). CIs are interpreted as follows:\nâ–  If one is using a 95% CI, there is a 95% chance that the interval contains\nthe true value.\nâ–  Larger sample sizes produce more power and narrower CIs. If the CI\nincludes the null value (RR of 1.0 or 0), the results are not statistically\nsignificant.\nâ–  Example: An RCT studying aspirin to prevent MI shows an RR of 0.9 with\na 95% CI of 0.85 to 0.95 in a sample of 3000 patients, whereas in a sample\nof 30 patients the 95% CI is 0.1 to 1.7. The first example shows a signifi-\ncant difference, whereas the second does not.\nSCENARIOS\nThere is no sufficient evidence\nIn a scenario where we are trying to study the effect of drug X on multiple\nto reject the null hypothesis, and\nsclerosis, the null hypothesis states that drug X is not effective for multiple\ntherefore there is insufficient evidence\nto support an association between sclerosis. If the statistical testing shows:\npoor sleep habits and the risk for\nâ–  P >0.05, the null hypothesis is not rejected (there is a risk of type II/ð›ƒ\nParkinson disease. Remember that the\nerror) ie, drug X is not effective.\nnull hypothesis always assumes that\nthere is no association between the\nexposure and outcome variables. If\nthe P value is >0.05, th",
      "char_start": 482000,
      "char_end": 484000
    },
    {
      "chunk_id": 242,
      "text": "en you cannot\nreject the null hypothesis.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116688 1100//2211//2222 1122::2233 PPMM\n\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 169\nâ–  P â‰¤0.05, the null hypothesis is rejected and statistical significance is\nreached (there is a risk of type I/ð›‚ error) ie, drug X is effective for multi-\nple sclerosis.\nImportant limitations of P value:\nâ–  It does not quantify the strength of benefit derived from or the effect size\nof an intervention or exposure on individual subjects.\nâ–  It is usually arbitrarily defined to be significant if it is less than or equal to\n0.05. This means that there is still a 5% risk of type I/Î± error even in a sta-\ntistically significant result.\nâ–  It does not tell whether an individual patient will derive the same benefit\nas the whole group.\nCOMMONLY USED STATISTICAL TESTS\nTests can be used to evaluate either categorical data or numerical data (see\nFig. 2.4-9). These are used to represent data and assess if there is any statisti-\ncally significant difference between two or more groups that are compared.\nâ–  Descriptive statistics: Includes common measures like mean, median,\nand mode as measures of central tendency and interquartile range, stan-\ndard deviation, and variance as measures of variability.\nâ–  t-test: Used to check the difference between means of two variables.\nâ–  Analysis of variance (ANOVA): Used to check the difference among\nmeans of three or more variables.\nâ–  Fisherâ€™s exact test: Used to assess differences between two categorical vari-\nables when the sample size is small.\nâ–  Chi-square (Ï‡2) test: Used to assess differences between two or more cate-\ngorical variables when the sample size is large. This test is only an approxi-\nmation (vs Fischerâ€™s exact test) in a large population.\nâ–  Correlation: Used to assess if change in one variable is directly linked to\nchange in another variable. Used mostly for continuous variables.\nâ–  Logistic regression: Used to describe data and explain ",
      "char_start": 484000,
      "char_end": 486000
    },
    {
      "chunk_id": 243,
      "text": "the relationship\nbetween one dependent categorical (binary) variable and one or more\nindependent variables.\nâ–  Linear regression: Used to predict the value of one dependent continuous\nvariable based on the value of one or more independent variables.\nVariables to be compared\nNumerical (means) Categorical (proportions)\n2 groups â‰¥ 3 groups Small sample size Large sample size\nt-test ANOVA Fisherâ€™s exact test Chi-square test\nFIGURE 2.4-9. Choosing statistical tests for numerical and categorical data. (Reproduced with permis-\nsion from USMLE-Rx.com.)\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 116699 1100//2211//2222 1122::2233 PPMM\n\n170 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nPREVENTION\nThere are three levels of prevention:\nâ–  Primary prevention: Includes preventive measures to â†“ the incidence of\ndisease in unaffected individuals.\nâ–  Secondary prevention: Focuses on identifying the disease early, when it is\nasymptomatic or mild, and implementing measures that can halt or slow\ndisease progression. Includes screening tests that are designed to identify\nsubclinical disease.\nâ–  Tertiary prevention: Includes measures that â†“ morbidity or mortality\nresulting from the presence of disease.\nKEY FACT\nâ–  Quaternary prevention: Includes measures to minimize harm from inci-\ndents during treatment.\nExamples of levels of prevention:\nPrimary: â†“ dietary fat/alcohol intake to Prevention may be accomplished by a combination of immunization, che-\nreduce risk for breast cancer. moprevention, behavioral counseling, and screening. A good screening test\nSecondary: Routine mammograms to has the following characteristics:\nscreen for breast cancer.\nTertiary: Adjuvant therapy with â–  High sensitivity and specificity (usually more important to have high sensi-\ntivity to rule out those who do not have the disease)\ntamoxifen for breast cancer.\nQuaternary: Identification of a â–  High NPV\npotential polypharmacy-induced â–  Inexpensive, easy to administer, and safe\ninteraction prior t",
      "char_start": 486000,
      "char_end": 488000
    },
    {
      "chunk_id": 244,
      "text": "o dispensing â–  Treatment after screening is more effective than subsequent treatment\nwithout screening\nmedications.\nVACCINATION\nVaccines work by mimicking infections and triggering an immune response\nin which memory cells are formed to recognize and fight any future infection.\nThey work as a mode of primary prevention. There are several different vac-\ncine formulations, as indicated in Table 2.4-3.\nRecommended vaccination schedules for children and adults are outlined\nin Figures 2.4-10 and 2.4-11.\nTABLE 2.4-3. Types of Vaccinations\nVACCINE TYPE TARGETED DISEASES\nLive attenuated Measles, mumps, rubella, polio (Sabin), yellow fever, influenza (nasal spray),\nvaricella\nInactivated (killed) Cholera, HAV, polio (Salk), rabies, influenza (injection)\nToxoid Diphtheria, tetanus\nSubunit HBV, pertussis, Streptococcus pneumoniae, HPV, meningococcus\nConjugate Hib, S pneumoniae\nRNA-based COVID-19 vaccines\nHAV, Hepatitis A virus; HBV, hepatitis B virus; Hib, Haemophilus influenzae B; HPV, human\npapillomavirus.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117700 1100//2211//2222 1122::2233 PPMM\n\nBirth 1 month 2 months 4 months 6 months 9 months 12 months 15 months 18 months 19-23 months 2-3 years 4-5 years 6 years 7-8 years 9-10 years 11-12 years 13-15 years 16 years 17-18 years\nHepatitis B (HepB)\nRotavirus (RV) RV1 (2-dose series); RV5 (3-dose series)\nDiphtheria, tetanus, and acellular\npertussis (DTaP: < 7 years)\nHaemophilus influenzae type B (Hib)\nPneumococcal conjugate (PCV13)\nInactivated poliovirus (IPV:\n< 18 years)\nInfluenza (IIV)\nInfluenza (LAIV4)\nMeasles, mumps, rubella (MMR)\nVaricella (VAR)\nHepatitis A (HepA)\nMeningococcal (MenACWY-D > 9 months; MenACWY-CRM > 2 months)\nTetanus, diphtheria, and acellular\npertussis (Tdap: > 7 years)\nHuman papillomavirus (HPV)\nMeningococcal B (MenB)\nPneumococcal polysaccharide\n(PPSV23)\nRange of recommended ages for all children:\nFirst dose Second dose Third dose Fourth dose Fifth dose Range of recommended ag",
      "char_start": 488000,
      "char_end": 490000
    },
    {
      "chunk_id": 245,
      "text": "es for Range of recommended ages for Recommended based on shared clinical decision-making Not routinely recommended\ncertain high-risk groups catch-up immunization and can be used in this age group\neniccaV\nAge\n1st dose 2nd dose 3rd dose\n1st dose 2nd dose\n1st dose 2nd dose 3rd dose 4th dose 5th dose\n1st dose 2nd dose 3rd dose\n1st dose 2nd dose 3rd dose 4th dose\n1st dose 2nd dose 3rd dose 4th dose\nAnnual vaccination 1 or 2 doses Annual vaccination 1 dose only\nor or\nAnnual vaccination 1 or 2 doses Annual vaccination 1 dose only\n1st dose 2nd dose\n1st dose 2nd dose\n2-dose series\n1st dose 2nd dose\nFIGURE 2.4-10. Recommended vaccinations for children 0â€“18 years of age. (Data collection courtesy of the Centers for Disease Control and Prevention, Atlanta, GA, https://www.cdc.gov/vaccines/schedules/downloads/child/0-\n18yrs-child-combined-schedule.pdf. Data from 2021.)\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd\n117711\n1100//2211//2222\n1122::2233\nPPMM\nEPIDEMIOLOGY\nHIGH-YIELD\nFACTS\nIN\n171\n\n19-23 years 24-26 years 27-45 years 46-49 years 50-65 years > 65 years\nInfluenza inactivated (IIV) or\n1 dose annually\nInfluenza recombinant (RIV4)\nor or\nInfluenza live, attenuated (LAIV4) 1 dose annually\n1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management\nTetanus, diphtheria, pertussis (Tdap or Td)\n1 dose Tdap + Td or Tdap booster every 10 years\nMeasles, mumps, rubella (MMR) 1 or 2 doses if indicated (born before 1957)\nVaricella (VAR) 2 doses (born after 1980) 2 doses\n2 or 3 doses depending\nHuman papillomavirus (HPV) on age of initial vaccination\nor conditions\nZoster recombinant (RZV) 2 doses\nPneumococcal (PCV15, PCV20, PPSV23) 1 dose PCV15 followed by PPSV23 OR 1 dose PCV20\nHepatitis A (HepA) 2 or 3 doses depending on vaccine\nHepatitis B (HepB) 2, 3, or 4 doses depending on vaccine or condition\nMeningococcal A, C, W, Y (MenACWY) 1 or 2 doses depending on indication, then booster every five years if risk remains\nMeningococcal B (MenB) 2 or 3 dos",
      "char_start": 490000,
      "char_end": 492000
    },
    {
      "chunk_id": 246,
      "text": "es depending on vaccine\nHaemophilus influenzae type B (Hib) 1 or 3 doses depending on indication\nRecommended for adults who meet the age requirement, Recommended for adults with other indications\nlack documentation of vaccination or lack evidence\nof past infections\nRecommended based on shared clinical decision-making No recommendation\nFIGURE 2.4-11. Recommended vaccinations for adults. (Data collection courtesy of the Centers for Disease Control and Prevention, Atlanta, GA, https://www.cdc.gov/\nvaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Data from 2021.)\neniccaV\n172 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nAge\n2 doses for immunocompromising conditions\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117722 1100//2211//2222 1122::2233 PPMM\n\nPregnancy ( c e o x i I m c n m l f u p e m d r c o u i t n i m n o g o n i s H - ) e I d V H < IV 1 5 in % f e o c r ti a o n n d C c D o 4 u n p t e > r 1 c 5 e % n t a a n g d e c d o e A m fi s c p p i l l e e e n n m c ia e ie , n s t r h e e E n m n a o d l o r - d d s o is i t a n a e l g a y e s s e is , H a e l d a c i r o s t h e o a o r s l i l e s u ; m ng Ch d ro is n e i a c s l e iver Diabetes H p e e a r l s t o h n c n a e r l e w M ha i e t v h n e w m s h e e x o n\n<200 mm3 >200 mm3\nInfluenza inactivated (IIV) or 1 dose annually\nInfluenza recombinant (RIV4)\nor or\nInfluenza live, attenuated (LAIV4) Contraindicated Precaution 1 dose annually\nTetanus, diphtheria, pertussis (Tdap or Td) ea 1 c h d o p s r e e g T n d a a n p cy 1 dose Tdap, then Td or Tdap booster every 10 years\nMeasles, mumps, rubella (MMR) Contraindicated Contraindicated 1 or 2 doses depending on indication\nVaricella (VAR) Contraindicated Contraindicated 2 doses\nHuman papillomavirus (HPV) Not 3 doses through age 26 years 2 or 3 doses through age 26 years depending on age at initial vaccination or condition\nrecommended\nZoster recombinant (RZV) 2 doses at age > 50 years\nPneumococcal (PCV15, PCV20, PPSV23)\n",
      "char_start": 492000,
      "char_end": 494000
    },
    {
      "chunk_id": 247,
      "text": "2 or 3 doses\nHepatitis A (HepA) 2 or 3 doses depending on vaccine depending on 2 or 3 doses depending on vaccine\nvaccine\nHepatitis B (HepB) 3 doses 2,3 or 4 doses depending on vaccine or condition\nMeningococcal A, C, W, Y (MenACWY) 1 or 2 doses depending on 1 or 2 doses depending on indication 1 or 2 doses depending on indication\nindication\nMeningococcal B (MenB) Precaution\nHaemophilus influenzae type B (Hib) 1 dose\nRecommended vaccination for adults who meet the age Recommended vaccination for adults with an additional Recommend vaccination based on shared clinical Contraindicated or not recommended- vaccine should\nrequirement, lack documentation of vaccination or lack risk factor or another indication decision-making not be administered\nevidence of past infections\nPrecaution- vaccination might be indicated if benefit of No recommendation/ Not applicable\nprotection outweighs risk of adverse reaction\nFIGURE 2.4-12. Recommended vaccines for special populations. (Data collection courtesy of the Centers for Disease Control and Prevention, Atlanta, GA, https://www.cdc.\ngov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Data from 2021.)\nLive vaccines should not be administered to patients with immunosup-\npression (Fig. 2.4-12). They are also contraindicated in pregnant patients,\nowing to a theoretical risk for maternal-fetal transmission. A possible excep-\ntion to this rule can be some asymptomatic HIV/AIDS patients who may be\ncandidates for the measles, mumps, and rubella (MMR) vaccine.\nCOVID-19 VACCINES\nAt the time of writing this book, in the light of the ongoing pandemic,\nCOVID-19 vaccines are recommended for everyone aged 6 months and\nolder. Number of doses, duration between doses, and need for booster doses\nvary by manufacturer. Three commonly available vaccines are Pfizer-BioN-\ntech, Moderna, and Janssen/Johnson & Johnson.\neniccaV\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 173\nMedical condition or other indication\n2 doses at age > 19 years\n1 dose PCV15 foll",
      "char_start": 494000,
      "char_end": 496000
    },
    {
      "chunk_id": 248,
      "text": "owed by PPSV23 or 1 dose PCV20\n2 or 3 doses depending on vaccine and indication\n3 doses HSCT recipients only\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117733 1100//2211//2222 1122::2233 PPMM\n\n174 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nSCREENING RECOMMENDATIONS\nTables 2.4-4 and 2.4-5 outline recommended healthcare screening measures\nby gender and age.\nTABLE 2.4-4. Health Screening Recommendations for Women by Age\nRECOMMENDATION\nAGE IN\nYEARS CARDIOVASCULAR BREAST/REPRODUCTIVE OTHER\n19â€“39 BP screening at least Pap test every 3 years starting at 21 years of age; Diabetes: Blood glucose or HbA screening\n1c\nonce every 2 years co-testing (Pap + HPV) may be done every 5 years starting if BP>135/80 mm Hg or taking medi-\nCholesterol screening starting at 30 years of age cation for hypertension\nstarting at 20 years Chlamydia test yearly until 24 years of age if sexually\nof age for patients active. Women â‰¥25 years of age should be tested\nat â†‘ risk of heart only if there is an â†‘ risk\ndisease HIV test at least once to ascertain status\nTest for gonorrhea and syphilis if at â†‘ risk\n40â€“49 BP screening at least Pap test every 3 years or co-testing every 5 years Diabetes: Blood glucose or HbA1c screening if\nonce every 2 years Pelvic exam yearly; chlamydia test if patient has new or BP >135/80 mm Hg or taking medication for\nCholesterol screening multiple partners hypertension\nfor women >45 HIV test at least once to ascertain status Colorectal: For patients >45 years with no\nyears of age Test for gonorrhea and syphilis if at â†‘ risk family history; FOBT yearly; flexible sigmoid-\noscopy every 5 years or colonoscopy every 10\nyears\n50â€“64 BP screening at least Mammogram once every 1â€“2 years (can start at 40 Diabetes: Blood glucose or HbA1c screening if\nonce every 2 years years of age, if patient chooses) BP >135/80 mm Hg or taking medication for\nCholesterol screening Pap test every 3 years hypertension\nfor women >45 Chlamydia test if patient has new or multipl",
      "char_start": 496000,
      "char_end": 498000
    },
    {
      "chunk_id": 249,
      "text": "e Bone: DEXA scan can be done in patients with\nyears of age partners other osteoporosis risk factors\nHIV test at least once to ascertain status Colorectal: FOBT yearly; flexible sigmoidoscopy\nTest for gonorrhea and syphilis if at â†‘ risk every 5 years or colonoscopy every 10 years\nâ‰¥65 BP screening at least Mammogram once every 1â€“2 years until 75 years of age Diabetes: Blood glucose or HbA1c screening\nonce every 2 years Discuss Pap test with physician or nurse if blood pressure higher than 135/80 or\nCholesterol screening Chlamydia test if patient has new or multiple partners taking medication for hypertension\nfor women >45 Discuss HIV test with physician or nurse Bone: DEXA scan at least once\nyears of age Test for gonorrhea and syphilis if at â†‘ risk Colorectal: Screening with FOBT, sigmoidos-\ncopy, or colonoscopy every 10 years until 75\nyears of age\nModified with permission from the U.S. Department of Health and Human Services, Washington, DC.\nBP, Blood pressure; DEXA, dual-energy x-ray absorptiometry; FOBT, fecal occult blood test; HbA1c, hemoglobin A1c; HPV, human papillomavirus.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117744 1100//2211//2222 1122::2233 PPMM\n\nEPIDEMIOLOGY HIGH-YIELD FACTS IN 175\nTABLE 2.4-5. Health Screening Recommendations for Men by Age\nRECOMMENDATION\nAGE IN\nYEARS CARDIOVASCULAR REPRODUCTIVE OTHER\n19â€“39 BP screening at least once every Both partners should be tested for STIs, N/A\n2 years including HIV, before initiating sexual\nCholesterol screening starting at intercourse\n20 years of age for patients at Test for syphilis if at â†‘ risk\nâ†‘ risk for heart disease. Screen\nall men >35 years of age\n40â€“49 BP screening at least once every Discuss DRE and PSA with physician or Diabetes: Blood glucose or HbA1c screening if\n2 years nurse BP >135/80 mm Hg or taking medication for\nCholesterol screening for all HIV test at least once to ascertain status hypertension\nmen >35 years of age Test for syphilis if at â†‘ risk Color",
      "char_start": 498000,
      "char_end": 500000
    },
    {
      "chunk_id": 250,
      "text": "ectal: For patients age >45 with no family\nhistory; FOBT yearly; flexible sigmoidoscopy\nevery 5 years or colonoscopy every 10 years\n50â€“64 BP screening at least once every Discuss DRE and PSA with physician or Diabetes: Blood glucose or HbA screening starting\n1c\n2 years nurse if BP >135/80 mm Hg or taking medication for\nCholesterol screening for all HIV test at least once to ascertain status hypertension\nmen >35 years of age Test for syphilis if at â†‘ risk Colorectal: Screening with FOBT yearly; flexible sig-\nmoidoscopy every 5 years or colonoscopy every\n10 years\nLung: Cancer screening with low-dose CT for indi-\nvidual with >20-year smoking history who are\npresently smoking or quit within the last 15 years\nâ‰¥65 BP screening at least once every Discuss DRE and PSA with physician or Diabetes: Blood glucose or HbA screening starting\n1c\n2 years nurse if BP >135/80 mm Hg or taking medication for\nCholesterol screening for all Discuss HIV test with physician hypertension\nmen >35 years of age Test for syphilis if at â†‘ risk Colorectal: Screening with FOBT; flexible sigmoidos-\ncopy every 5 years or colonoscopy every 10 years\nuntil age 75\nAbdominal aortic aneurysm: One-time screening\nfor men who have ever smoked or have a family\nhistory\nLung: Cancer screening with low-dose CT for indi-\nvidual age less than 81 with >20-year smoking\nhistory who are presently smoking or quit within\nthe last 15 years\nModified with permission from the US Department of Health and Human Services, Washington, DC.\nBP, Blood pressure; DRE, digital rectal exam; FOBT, fecal occult blood test; HbA1c, hemoglobin A1c; PSA, prostate-specific antigen; STIs, sexually\ntransmitted infections.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117755 1100//2211//2222 1122::2233 PPMM\n\n176 HIGH-YIELD FACTS IN EPIDEMIOLOGY\nREPORTABLE DISEASES\nBy law, disease reporting is mandated at the state level, and the list of diseases\nthat must be reported to public health authorities varies slightly ",
      "char_start": 500000,
      "char_end": 502000
    },
    {
      "chunk_id": 251,
      "text": "by state. The\nCenters for Disease Control and Prevention (CDC) has a list of nationally\nnotifiable diseases that states voluntarily report. These diseases include but are\nnot limited to those listed in Table 2.4-6.\nTABLE 2.4-6. Common Reportable Diseases\nDISEASE CATEGORY EXAMPLES\nSTIs HIV/AIDS, syphilis, gonorrhea, chlamydia, chancroid, HCV\nTick-borne disease Lyme disease, ehrlichiosis, Rocky Mountain spotted fever\nPotential bioweapons Anthrax, smallpox, plague\nVaccine-preventable Diphtheria, tetanus, pertussis, measles, mumps, rubella, polio, vari-\ndisease cella, HAV, HBV, H influenzae (invasive), meningococcal disease\nWater-/food-borne Cholera, giardiasis, Legionella, listeriosis, botulism, shigellosis,\ndisease Shiga toxinâ€“producing Escherichia coli, salmonellosis, trichinellosis,\ntyphoid\nZoonoses Tularemia, psittacosis, brucellosis, rabies\nMiscellaneous TB, leprosy, toxic shock syndrome, SARS, COVID-19, West Nile virus,\nVRSA, coccidioidomycosis, cryptosporidiosis; MRSA is reportable in\nseveral states\nHAV, Hepatitis A virus; HBV, hepatitis B virus; MRSA, methicillin-resistant Staphylococcus aureus;\nSARS, severe acute respiratory syndrome; STIs, sexually transmitted infections; TB, tuberculosis;\nVRSA, vancomycin-resistant S aureus.\n22002222__0022..0044__SStteepp22CCKK__EEppiidd__1111ee__115577--117766..iinndddd 117766 1100//2211//2222 1122::2233 PPMM\n\nH I G H - Y I E L D F A C T S I N\nHEALTH SYSTEMS SCIENCE\nHealth System Delivery 178 Competence and Decision-Making Capacity 186\nHealtH Insurance Plans 178 coMPetence 186\nMedIcare and MedIcaId 178 decIsIon-MakIng caPacIty 187\nPallIatIve care 179 InforMed consent 187\nCommunication 179 End-of-Life Issues 189\nPatIent-centered, evIdence-Based IntervIewIng 179 advance dIrectIves 189\nefforts to estaBlIsH raPPort 180 surrogate decIsIon MakIng 190\ncHallengIng conversatIons 181 wItHdrawal of lIfe-sustaInIng treatMent 190\ngender- and sexualIty-InclusIve HIstory takIng 181 eutHanasIa and clInIcIan-assIsted suIcIde 190\nculturally ",
      "char_start": 502000,
      "char_end": 504000
    },
    {
      "chunk_id": 252,
      "text": "InclusIve HIstory takIng 181 HosPIce care 191\nMotIvatIonal IntervIewIng 182 futIle treatMent 191\ncoMMunIcatIng wItH PatIents wItH dIsaBIlItIes 182\nComplementary and Alternative Medicine Therapy 191\nInterPreters 182\nBeHavIoral counselIng 182 Disclosure 191\nfull dIsclosure 191\nPatient Safety and Quality 182\nsettIng for delIverIng news 192\nsafety culture 182\nPdsa cycle 183 Confidentiality 193\nswIss cHeese Model 183\nClinical Research 194\nMeasurIng QualIty outcoMes 183\ncore PrIncIPles of clInIcal researcH 194\nerrors In HealtHcare 184 etHIcal concerns 194\nHealtHcare worker Burnout and fatIgue 184\nConflict of Interest 195\nanalyzIng MedIcal errors 185\ngIfts froM PatIents 195\nEthics and Legal Issues 185\ngIfts froM drug coMPanIes 195\ngeneral/core PrIncIPles 185\nMalpractice 196\ndoctor-PatIent ProfessIonal relatIonsHIP 186\ndoctor-PatIent sexual relatIonsHIP 186\ndefInIng MalPractIce 196\nIMPaIred PractIcIng clInIcIans 196\n177\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 117777 1100//2211//2222 1122::2288 PPMM\n\n178 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nHEALTH SYSTEM DELIVERY\nHEALTH INSURANCE PLANS\nPatients may receive insurance from various providers that reimburse the\ninsured patients based on the services they utilize. These services may provide\npayment to the clinician or organization in one of the following ways:\nâ–  Bundled payment: Organization receives set amount per service, regard-\nless of ultimate cost, with the received amount divided among all provid-\ners and facilities involved.\nâ–  Capitation: Clinicians receive a set amount per patient per period regard-\nless of the healthcare utilization. This is usually provided by health main-\ntenance organizations.\nâ–  Fee-for-service insurance: The patient or insurer pays for each individual\nservice.\nâ–  Discounted fee-for-service insurance: The patient or insurer pays for each\nutilized service at a discounted rate predetermined by providers and pay-\ners. This service is mostly used by preferred p",
      "char_start": 504000,
      "char_end": 506000
    },
    {
      "chunk_id": 253,
      "text": "rovider organizations.\nâ–  Global payment: The patient or insurer pays for all expenses for a single\nincident of care, with a single payment once the service is used. For exam-\nple, payment for elective surgeries may cover the cost of the surgery and\nthe necessary preoperative and postoperative visits.\nMEDICARE AND MEDICAID\nMany patients may have Medicare or Medicaid enrollment, and this may\naffect the services they choose to utilize (Table 2.5-1).\nTABLE 2.5-1. Medicare vs Medicaid\nMEDICARE MEDICAID\nAdministrating body Federal Federal and state\nType of program Insurance Assistance\nEligibility Patients â‰¥65 years of age, younger patients with disability, Low-income patient of any age\npatients undergoing dialysis\nBill payment Trust funds Patients do not pay any part of expenses\nCopays and Small monthly premiums for nonhospital coverage Small copayment (in some cases)\ndeductibles\nCoverage Part A: Hospital admissions including hospice, skilled nursing Basic healthcare and prescription drug costs,\nPart B: Basic medical bills (eg, clinician fees, diagnostic testing) long-term care, medical equipment, prescrip-\nPart C: Delivered by approved private companies (delivers all tion glasses, dental care, and more\nservices of parts A and B)\nPart D: Prescription drugs\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 117788 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 179\nPALLIATIVE CARE\nThis is an approach to improve the quality of life for patients experiencing\nlife-threatening illness and for their families. The goals of palliative care are to\nminimize suffering and to provide care that is consistent with the patientâ€™s val-\nues. This includes addressing symptoms such as pain, dyspnea, or any other\nphysical symptoms; psychological distress; and social issues. A palliative care\nteam also provides support to families during the patientâ€™s illness and their\nfamilyâ€™s subsequent bereavement. Care is provided via a team approach",
      "char_start": 506000,
      "char_end": 508000
    },
    {
      "chunk_id": 254,
      "text": " (eg,\nclinicians, nurses, social workers) to support patients and their caregivers. The\npalliative care approach has five stages:\n1. Stable: A treatment plan is created, and medical interventions are placed\nto control symptoms and enhance quality of life.\n2. Unstable: Existing symptoms worsen, or patients may have unexpected\nsymptoms, and the care of plan is changed. This stage requires provision\nof mental, emotional, and spiritual support.\n3. Deteriorating: Overall health and body functions of the patient gradually\ndecline, leading to mental and physical distress in the patient and for their\nfamily. Emotional support is key during this stage.\n4. Terminal: The patient may become bedridden, have loss of appetite, have\ndifficulty in swallowing, and may require daily medical interventions. A\nhospital setting may be needed for further care provision.\n5. Bereavement: This is the stage where the patient has died. The care plan\nfocuses on caring for the patientâ€™s loved ones and addressing their emo-\ntional needs, including connection with specific support groups; spiritual\nsupport, eg, via a pastor, priest, or rabbi; and psychosocial support to tackle\ngrief, loss, and adjustment.\nWhen the prognosis for the patient is less than 6 months, or when life-\nprolonging treatment is no longer beneficial, the patient may be referred to\nend-of-life care or hospice care.\nCOMMUNICATION\nPATIENT-CENTERED, EVIDENCE-BASED INTERVIEWING\nThere are certain key ways to make a patient feel comfortable being inter-\nviewed about their medical history. Following these steps can help obtain a\nreliable history. These steps are outlined here:\nâ–  Setting the stage: Welcome the patient and use the patientâ€™s preferred\nname or pronouns to address them directly. Introduce yourself and identify\nyour specific role. Ensure privacy and comfort for the patient. When\npatients are accompanied by a caregiver, let them introduce themselves and\nclarify with the patient if they would want their caregiver to be include",
      "char_start": 508000,
      "char_end": 510000
    },
    {
      "chunk_id": 255,
      "text": "d in\nthe discussion.\nâ–  Agenda of interview: Indicate the time available and obtain a list of issues\nthe patient wants to discuss. Let the patient understand how the interview\nwill proceed, and summarize the agenda for that interview.\nâ–  Nonfocused expression/reflection: Always start with open-ended ques-\ntions or requests and use nonverbal cues (eg, patient gestures) to obtain\nmore information.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 117799 1100//2211//2222 1122::2288 PPMM\n\n180 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nâ–  Focused expression/validation: Elicit further history with a focus on\ndescription of symptoms, with perspective of impact on the patientâ€™s per-\nsonal, psychosocial, and emotional contexts. Identify the patientâ€™s beliefs\nand attributions, while addressing feelings and emotions (Naming, Under-\nstanding, Respecting, Supporting, Exploring, or the NURSE technique).\nâ–  Recapitulate: Check accuracy by providing a brief summary of what has\nbeen dealt with and what needs further input.\nâ–  Facilitation: Encourage the patient to speak freely and ask questions\nthroughout the interview.\nâ–  Open-ended skills: Can be nonfocusing techniques like silence (to\nallow patient to speak), nonverbal encouragement, and prompting the\npatient to continue with their story, or focusing techniques like echo-\ning (repeating what the patient just said and asking if this is correct),\nrequesting, and summarizing.\nâ–  Emotion-seeking skills: Ask directly how this condition or situation\naffects the patientâ€™s emotions. Indirect assessment can include impact\nof condition on life, beliefs the patient has about their problems, and\nany triggers that relate to the problem.\nâ–  Empathy: Name, Understand, Respect, Support, Explore.\nEFFORTS TO ESTABLISH RAPPORT\nEstablishing rapport may be the most difficult part of the medical interview,\nbut there are certain steps to follow for this process as well. Establishing rap-\nport can be done by either the PEARLS model ",
      "char_start": 510000,
      "char_end": 512000
    },
    {
      "chunk_id": 256,
      "text": "(see Table 2.5-2) or the Ask-\nTell-Ask model.\nTABLE 2.5-2. PEARLS Model of Establishing Rapport\nKEY STEP DEFINITION EXAMPLE\nPartnership Working with the patient to identify primary problems and You may have difficult times ahead, but we will work\npreferred solutions together to provide you the best possible care consistent\nwith your goals, values, and beliefs.\nEmpathy Identifying emotions displayed and understanding why You appear sad. I understand that the news about your\nthe patient feels that way illness may have upset you, especially with your family so\nfar away right now.\nApology Taking personal responsibility when appropriate I am very sorry that I had to attend to personal business\nand you had to wait for me. However, I still would like to\nunderstand your concerns so that I can help you, if you\nchoose to allow me.\nRespect Positively encouraging patients, especially when they discuss I understand that you have had a tough time trying to stop\na difficult problem, helping them navigate through chal- drinking alcohol. I also know that you have given your best\nlenging circumstances, or other constructive behavior effort every time, and I appreciate the effort you put in.\nLegitimization Validating the patientâ€™s emotions and letting them know It is understandable to feel anxious about the uncertainty as\nthat feeling a certain way during challenging situations we move forward to identify the problem and complete\nis normal or common the workup.\nSupport Reassuring the patient about the presence of your continued I am here to support you through the process and answer\nsupport throughout the patientâ€™s time of need and offering any questions you may have along the way.\nthem appropriate resources to tackle such situations\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118800 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 181\nCHALLENGING CONVERSATIONS\nWhen delivering challenging or difficult-to-break news to pati",
      "char_start": 512000,
      "char_end": 514000
    },
    {
      "chunk_id": 257,
      "text": "ents, one\nshould think about the following (SPIKES):\nâ–  Setting: As with effective history taking, one should ensure a private envi-\nronment free from distractions when presenting news to the patient.\nâ–  Perception: Before proceeding with delivering the news, always ask first\nwhat the patient thinks about their illness and what their understanding of\ntheir current state of health is.\nâ–  Invitation: Ask the patient if they have any queries they would like\nanswered and the amount of information that they would like to obtain\nfrom the clinician before delivering the news.\nâ–  Knowledge: Educate the patient about the news in small pieces, allowing\ntime for them to process. Assess the patientâ€™s understanding of the news\nstep by step.\nâ–  Emotions: Acknowledge that the patient responds to the news in a certain\nway and acknowledge their emotions. When dealing with patientsâ€™ emo-\ntions, always be empathetic to their responses and listen to them without\ninterrupting.\nâ–  Strategy: Once the patient feels ready to further discuss treatment options\nor prognosis and goals of care, offer them an agenda about how to pro-\nceed, and schedule their appointments around these agendas.\nGENDER- AND SEXUALITY-INCLUSIVE HISTORY TAKING\nWhen interviewing the patient, always take into consideration the following\npoints:\nâ–  Avoid making assumptions about a patientâ€™s sexual orientation, gender\nidentity, gender expression, or sexual behavior without first asking the\npatient about these. If gender or sexuality is not relevant for the presenting\nillness, do not bring it up.\nâ–  Note that the patient may identify as a different gender than the sex\nassigned to them at birth.\nâ–  Try to use gender-neutral terms (eg, partner or spouse) rather than assum-\ning their gender.\nâ–  Always reassure the patient that whatever they share is confidential and\neven if they are not open about their sexual orientation or gender identity,\nthis information will not be revealed to anyone else without the patientâ€™s\nprior permission or ",
      "char_start": 514000,
      "char_end": 516000
    },
    {
      "chunk_id": 258,
      "text": "request.\nCULTURALLY INCLUSIVE HISTORY TAKING\nAs stressed earlier, patients have their own cultures and specific goals, values,\nor beliefs and may not accept the treatment plan proposed for them. Always KEY FACT\nnote the following points when interviewing patients:\nWhen treatment can save a childâ€™s\nâ–  Try to think about the illness from the patientâ€™s perspective. life, or if the outcome of treatment\nâ–  Try to understand what factors in the patientâ€™s cultures or background (or is a normal life with a reasonably\neven some past experiences) influences certain decisions they make. good quality of life, or if the medical\nâ–  Also note how their culture would affect future decisions for treatment. community is in agreement about the\ncourse of action and if the parent is\nFor example, note that patients who belong to the Jehovahâ€™s Witnesses\nrefusing to grant consent to proceed,\nmay refuse lifesaving blood transfusion for themselves (if adult and compe-\nthe healthcare decisions for that child\ntent), but they cannot do the same if their child (who is below the legal age\ncan be taken over by the State.\nand not an emancipated minor) because this amounts to child abuse.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118811 1100//2211//2222 1122::2288 PPMM\n\n182 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nMOTIVATIONAL INTERVIEWING\nMake sure to counsel the patient on every visit about improving their behavior to\nhelp treat their illness if these behaviors affect them directly or indirectly. For\nexample, if a patient smokes, mention smoking cessation at every visit. When the\npatient notes a desire to change their behavior, document this step and encourage\nthem. If the patient is not expressing such a desire, assess any barriers that may\nlead to difficulty in changing these behaviors. Expressing a desire to change their\nbehavior is the first step to changing the behavior itself. Once a patient has\nexpressed a desire to change, set goals for the patients to m",
      "char_start": 516000,
      "char_end": 518000
    },
    {
      "chunk_id": 259,
      "text": "eet. These goals should\nbe Specific, Measurable, Achievable, Relevant, and Time bound (SMART).\nCOMMUNICATING WITH PATIENTS WITH DISABILITIES\nWhen interviewing a patient who has a disability or disabilities, speak directly\nto the patient and ask them how they identify themselves: person first (ie, a\nperson with a disability) or identity first (ie, a disabled person). Obtain addi-\ntional information from caregivers when appropriate. Do not assume that\nthese patients cannot complete a certain task; rather, ask them if they require\nassistance.\nâ–  For patients with speech difficulties, provide extra time for an interview.\nâ–  For patients with cognitive impairment, use specific language and ask sim-\nple, direct questions.\nâ–  For patients who are hard of hearing ask them about their preferred mode\nof communication. Consider using an interpreter when necessary.\nâ–  Also, do not bring up a disability if it is not relevant to the presenting ill-\nness. Do not skip portions of the physical examination even if the disabil-\nity makes the exam challenging.\nINTERPRETERS\nWhen patients who do not speak English or have difficulty in conversing in\nthe language, always use a professionally trained medical interpreter for com-\nmunication unless the clinician is conversationally fluent in the patientâ€™s pre-\nferred language. If professional interpreters are unavailable or if you are\nworking with the patient outside service hours, a telephone or video call may\nprovide the same service. If the patient prefers to use a family member for\ninterpretation, this should be recorded in the chart. In emergencies, facilitate\ncommunication using any tools available (eg, friends, family, interpreter apps)\neven though this may not be standard procedure otherwise.\nBEHAVIORAL COUNSELING\nWhen offering counsel, clinicians should tailor their education and sugges-\ntions to the individual patient, as well as to their stage of change (see Table\n2.5-3 and Fig. 2.5-1).\nPATIENT SAFETY AND QUALITY\nSAFETY CULTURE\nThis is",
      "char_start": 518000,
      "char_end": 520000
    },
    {
      "chunk_id": 260,
      "text": " a part of an organizationâ€™s culture, which is a collection of the beliefs,\nperceptions, and values that the employees share in relation to risks within the\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118822 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 183\nTABLE 2.5-3. Stages of Change in Behavioral Counseling\nPrecontemplation\nSTAGE OF CHANGE CHARACTERIZATION EXAMPLE No intention of\nchanging behavior\nPrecontemplation Denial or ignorance of the A patient with a substance use disorder\nRelapse Contemplation\nproblem has not even thought about cessation pa F t a t l e l r b n a s c o k f i b n e to h a o v ld ior ackn P ow ro l b e l d e g m ment,\nno specific actions\nContemplation Ambivalence or conflicted A patient with a substance use dis-\nemotions; assessing bene- order considers treatment for his\nfits and barriers to change addiction Maintenance Preparation\nSustaining Made the decision to\nchange change, intent on\ntaking action\nPreparation Experimenting with small A patient with a substance use\nchanges; collecting infor- disorder visits his doctor to ask ques- Action\nActive modification\nmation about change tions about quitting of behavior\nAction Taking direct action toward A patient with a substance use disorder\nFIGURE 2.5-1. Stages of change model.\nachieving a goal enters a rehabilitation facility for (Reproduced with permission from USMLE-Rx.com.)\ntreatment of addiction\nMaintenance Maintaining a new behavior; A patient with a substance use disorder\navoiding temptation continues to visit recovery meetings\nto gain support and reinforcement\nagainst relapse\n1. Plan 2. Implement\nEstablish the objectives to Implement the plan\nbe achieved Execute the processes\nEstablish the processes Collect the data\nnecessary to deliver results\nDefine the expected output\nhealthcare sector. To note, the Institute of Medicine noted that the â€œfocus\nPlan Implem\nent\nmust shift from blaming individuals for past errors to a focus",
      "char_start": 520000,
      "char_end": 522000
    },
    {
      "chunk_id": 261,
      "text": " on preventing\nfuture errors by designing safety into the system.â€ So, patient safety includes\nthe process of amelioration, avoidance, and prevention of adverse injuries or\nImprove Evaluate\n4. Improve 3. Evaluate\noutcomes that arise because of the healthcare process.\nAssess the results from the Study the results of the\nevaluate stage implement stage\nDetermine the changes Gather the feedback\nPDSA CYCLE n t m h e e e e t d p e la d n i â€™ n s o o b rd je e c r t i t v o e e s n c s a u n r e b e C if o t r m h e e q p u p a i l r r a e e n m t â€™ h s e e o n r b t e s je s h u c a t lt i v v s e e t o s b a e s n e e n d e\nmet\nThe PDSA cycle involves four key processes (Plan, Do, Study, Act) that help\nidentify possible deficiencies in provisions of care, which when changed, can FIGURE 2.5-2. PDSA cycle. (Reproduced with\npermission from USMLE-Rx.com.)\naffect healthcare delivery and improve patient safety. This is a continuous\ncycle, and it requires reassessment of strategies after implementation of a plan\nfor a set time period (see Fig. 2.5-2).\nSWISS CHEESE MODEL\nPotential failures\nin defense strategy\nThis is a model of risk assessment that focuses on systems and conditions that\nmay align to lead to an adverse event. The Swiss cheese model tries to mitigate\nsuch threats at various levels. However, despite provisions of multiple safe-\nguards, an error may occur and lead to harm to the patient when the â€œholes in\nthe cheese line upâ€ (see Fig. 2.5-3). During a root cause analysis, the goal is to\nunderstand how the adverse event occurred, including by understanding how\neach of these safeguards may have failed. In doing so, efforts to add additional Defense\nsafeguards or revise prior safeguards can help minimize future adverse events. strategies\nFIGURE 2.5-3. Swiss cheese model of\nMEASURING QUALITY OUTCOMES safeguarding delivery of care. (Repro-\nduced with permission from USMLE-Rx.com.)\nDelivery of quality healthcare can be assessed by various processes that may\nevaluate the s",
      "char_start": 522000,
      "char_end": 524000
    },
    {
      "chunk_id": 262,
      "text": "tructure, process, outcome, and balance of any healthcare system:\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118833 1100//2211//2222 1122::2288 PPMM\n\n184 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nâ–  Structural: Assessment of physical equipment, resources, and facilities.\nExample: Machine used to evaluate the potassium levels of patients.\nâ–  Process: Assessment of function of the healthcare system as planned.\nExample: Number of patients undergoing dialysis utilizing the said\nfunction.\nâ–  Outcome: Measurement of the impact of the healthcare measure on\npatients. Example: Average levels of potassium of patients undergoing\ndialysis.\nâ–  Balancing: Assessment of impact on other systems or outcomes. Example:\nAverage drop in levels of potassium of patients who underwent dialysis\ncompared with the initial levels.\nERRORS IN HEALTHCARE\nAlthough a clinician may have no intention to bring about harm to the\npatient, certain processes may align to bring about errors in healthcare deliv-\nery (see Table 2.5-4). These are called adverse events (errors in medical or\nsurgical treatment that can potentially lead to patient harm, rather than as an\nimpact of the patientâ€™s previous underlying medical condition). The outcome\nof such events may be unintended injury to the patient, prolonged hospital-\nization, or even disability.\nHEALTHCARE WORKER BURNOUT AND FATIGUE\nThe leading causes of errors in provision of care include healthcare worker\nburnout and fatigue. Burnout may occur with prolonged, excessive stress and\nlead to reduced professional efficacy. Burnout can be due to intrinsic\nTABLE 2.5-4. Errors in Healthcare Delivery\nTYPE OF ERROR DESCRIPTION IMPACT\nActive error At the level of the front-line operator Immediate impact (eg, wrong intravenous [IV] dose or illegible hand-\nwriting on orders).\nLatent error Indirect processes that affect patient care Accident waiting to happen (eg, different types of IV pumps used\nwithin the same hospital).\nNever event Err",
      "char_start": 524000,
      "char_end": 526000
    },
    {
      "chunk_id": 263,
      "text": "ors that should never happen Major error that should never occur (eg, wrong foot amputated).\nNear miss Event that could have led to harm but did not Intervention by someone or something that led to prevention but\nshould have not happened (eg, medication interactions that may be\nrecognized by the pharmacist and corrected or cancelled).\nMedical error Failure to complete the intended plan of action Deviation from process of care. May lead to unintended consequence\nor implementation of wrong plan to achieve (eg, administration of a wrong dose of medication when a full stop was\ntreatment goal interpreted as a comma, ie, 100 U insulin when the order stated 10.0 U).\nNegligence Failure to meet expected standard of care May lead to direct harm to the patient (eg, missing the pathology\nreport of a cancer diagnosis).\nSentinel event Any unexpected occurrence involving death or When repeated, there is a significant chance for a serious adverse\nserious harm to the patient or the risk thereof outcome (eg, using the same bronchoscope for several patients and\nnot cleaning between the procedures due to miscommunication\nbetween staff).\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118844 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 185\ndemands of the job, individual susceptibility, and poor work organization.\nDeprivation of sleep or rest can lead to cognitive impairment and lead to\nmedical errors. This can be minimized by:\nâ–  Setting clear and consistent goals for the staff\nâ–  Providing training to increase coping strategies, increase role effectiveness,\nand nurture better conflict resolution strategies\nâ–  Encouraging support groups and resource exchange networks\nâ–  Organizing workload and working time, with regular breaks and flexible\nschedules\nâ–  Providing accommodation for health workers during emergency opera-\ntions with access to food services, sanitary facilities, and adequate recre-\national opportunities\nANALYZING MEDI",
      "char_start": 526000,
      "char_end": 528000
    },
    {
      "chunk_id": 264,
      "text": "CAL ERRORS\nWhen analyzing medical errors, two different models may be commonly\nused: (1) root cause analysis and (2) failure mode and effects analysis. The\nroot cause approach is applied after a system failure to find out what went\nwrong, whereas the failure mode and effects analysis is applied before an error\noccurs to prevent failure.\nâ–  Root cause analysis: Typically evaluates sentinel events to decrease the\nodds of repeating the same event. This process uses records and partici-\npant interviews (eg, five whys approach, fishbone diagrams, cause-effect\ndiagrams, process maps) to identify the underlying cause of error.\nâ–  Failure mode and effects analysis: Concludes that errors will occur even\nif healthcare professionals are careful. This process helps build redundan-\ncies that act as safety nets to trap errors. The process uses inductive reason-\ning to identify all the ways a system might fail and prioritizes them by their\nprobability of occurrence and impact on patients.\nETHICS AND LEGAL ISSUES\nGENERAL/CORE PRINCIPLES\nKEY FACT\nâ–  Respect for autonomy: This is absolute. Clinicians are obligated to\nrespect patients as individuals and to honor their preferences. In some cases (eg, psychiatric illness,\nâ–  Example: A pregnant patient has the right to refuse a cesarean section grave disability), the Baker Act allows\ndespite potential risk to the fetus. This is called the principle of mater- for the involuntary hospitalization of\nnal autonomyâ€”as long as the mother has capacity, she has ultimate patients against their will if they are\nrights over her unborn child (in the United States), as the fetus is con- deemed a threat to themselves or\nsidered a part of the mother. others and are neglectful.\nâ–  Beneficence: Clinicians have a responsibility to act in the patientâ€™s best\ninterest. Respect for patient autonomy may conflict with beneficence. In\ngeneral, if a patient is mentally competent, respect for patient autonomy\nsupersedes beneficence even if the clinician believes the pa",
      "char_start": 528000,
      "char_end": 530000
    },
    {
      "chunk_id": 265,
      "text": "tient is not act-\ning in their best interest.\nâ–  Example: The clinician has a responsibility to recommend a lifesaving\ntransfusion to a Jehovahâ€™s Witness (beneficence) and respect the patientâ€™s\nautonomy if they should refuse. However, when a parent who is a Jeho-\nvahâ€™s Witness refuses emergency medical treatment for their child\n(claiming the same status for the child), the clinician is not obliged to\nagree with the parent, but must instead provide the necessary treatment\nto save the life of the child (beneficence outweighs autonomy).\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118855 1100//2211//2222 1122::2288 PPMM\n\n186 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nâ–  Nonmaleficence: â€œDo no harm.â€ All medical interventions involve benefits\nand risks, and clinicians should generally only recommend treatments for\nwhich the likely benefits outweigh the known risks. Also, it should be made\nclear to the patient the consequences of refusing treatment if they were to\nchoose so. This category includes most medical and surgical interventions.\nâ€¢â–  Example: A surgeon declines to perform a procedure because they\nthink the patient will die intraoperatively.\nâ–  Justice: Healthcare is a scarce resource. Fairness and equality in distribu-\ntion and delivery of healthcare are ongoing challenges for health policy\nand in the clinical arena.\nâ–  Example: A state designs a program for homeless people.\nDOCTOR-PATIENT PROFESSIONAL RELATIONSHIP\nâ–  The doctor-patient relationship is a voluntary relationship. It occurs when\nthe patient agrees to seek medical attention with a specific doctor and\nKEY FACT when the doctor agrees to care for the patient.\nâ–  In a hospital setting, emergency management should be provided to all\nClinicians are not obligated to accept patients.\nevery person coming to them as a â–  In the absence of an emergent condition, the clinician is under no\npatient. Furthermore, clinicians have legal obligation to accept caring for patients.\nthe right to ",
      "char_start": 530000,
      "char_end": 532000
    },
    {
      "chunk_id": 266,
      "text": "end a doctor-patient â–  Example: If a pregnant patient is seeking to get an abortion, the clini-\nrelationship but must give the patient cian is under no legal obligation to perform the procedure if that goes\nthe resources and time to find another against their moral standards.\nclinician. â–  To end a doctor-patient relationship, the doctor should allow patients to\nhave adequate time to find an alternative clinician.\nDOCTOR-PATIENT SEXUAL RELATIONSHIP\nâ–  Sexual contact between clinicians and their patients is always inappropri-\nate, independent of who initiates contact.\nâ–  A patient and clinician should terminate their professional relationship\nbefore engaging in a sexual relationship.\nâ–  No clear recommendation exists as to when it is appropriate to initiate a\nsexual relationship after termination of the professional relationship.\nCOMPETENCE AND DECISION-MAKING CAPACITY\nCOMPETENCE\nâ–  A personâ€™s global and legal capacity to make decisions and to be held\naccountable in a court of law. All individuals are competent unless legally\nproven otherwise. Competence is assessed by the courts and is distinct\nfrom the term decision-making capacity.\nâ–  Incompetent patients, as assessed by the courts, or temporarily incapaci-\ntated patients may still be able to provide assent for treatment or refuse\ntreatment. However, the need to treat supersedes the refusal of an incapac-\nitated patient in emergency situations.\nâ–  Example: A severely hypoxic patient with altered mental status who is\nunable to accept treatment may receive respiratory supportive therapy,\nas this constitutes a medical emergency.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118866 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 187\nâ–  Incompetent patients can nonetheless have adequate decision-making capac-\nity to refuse treatment. In these cases, autonomy supersedes beneficence.\nâ–  Example: Patients living with a psychiatric illness, autism, or intellec-\ntual disa",
      "char_start": 532000,
      "char_end": 534000
    },
    {
      "chunk_id": 267,
      "text": "bilities may be deemed incompetent in managing their\nfinances, while maintaining adequate capacity to refuse treatment.\nDECISION-MAKING CAPACITY\nThe ability of a patient to understand relevant information, appreciate the severity\nof the medical situation and its consequences, communicate clear and consistent\nchoices, and deliberate rationally about their values in relation to the decision\nbeing made. This can be assessed by any clinician, based on a neurologic exami-\nnation evaluating memory, comprehension, reasoning, and judgment.\nâ–  Testing for decision-making capacity does not always require a psychiatric\nconsultation. It can be assessed by any clinician.\nâ–  Decision-making capacity is best understood as varying with the complex-\nity of the decision involved.\nâ–  Example: The level of capacity needed for a decision about liver trans-\nplantation is different from that needed to choose between two types of\npain medication for fracture-related pain.\nâ–  In general, patients who have decision-making capacity have the right to\nrefuse or discontinue treatment.\nâ–  Example: A patient living with cancer with decision-making capacity\ncan opt out of oncologic treatment.\nâ–  A patientâ€™s decision to refuse treatment can be overruled if the choice\nendangers the health and welfare of others.\nâ–  Example: A patient with active tuberculosis (TB) must undergo antibi-\notic treatment because not treating the patient would pose a public\nhealth threat.\nâ–  All suicidal patients are considered to lack capacity.\nâ–  Occasionally, psychiatric evaluation can be recommended when decision-\nmaking capacity is equivocal. In cases where capacity is clearly impaired\nor intact, there is no need for psychiatric evaluation.\n1\nINFORMED CONSENT A 47-year-old man is diagnosed with\npancreatic cancer. His diagnosis and\nâ–  Willing and voluntary acceptance of a specific medical intervention by a treatment options are discussed,\npatient after adequate discussion with a clinician about the nature of the but the patient do",
      "char_start": 534000,
      "char_end": 536000
    },
    {
      "chunk_id": 268,
      "text": "es not want any\nintervention. He states that he would\nintervention along with its indications, risks, benefits, and potential alter-\nlike to go home to his spouse and\nnatives (including no treatment).\nchildren to die peacefully. What is\nâ–  Informed consent should be obtained in the language the patient can clearly\nthe most appropriate next step in\ncommunicate and understand. If needed, an official translator should be used.\nmanagement?\nâ–  Informed consent is given for a specific procedure, so that autonomy\nsupersedes beneficence.\nâ–  Informed consent should be obtained by the doctor performing the\nprocedure. 2\nâ–  Patients may change their minds at any time even after agreeing to the\nprocedure. The healthcare team will honor the wishes of the patients and\nA 51-year-old man is brought to the\nsupport the decision. emergency department after he\nâ–  Informed consent is required for significant procedures except for the was struck by a motor vehicle while\nfollowing: crossing the street. He is unresponsive\nâ–  When emergency treatment is required. Example: An unconscious and in need of emergent surgery.\npatient presents with cerebral edema after a motor vehicle collision, or His spouse and children cannot be\na patient without previously indicated DNR/DNI (do not resuscitate/do reached. What is the most appropriate\nnext step in treatment?\nnot intubate) status undergoes cardiac arrest.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118877 1100//2211//2222 1122::2288 PPMM\n\n188 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nKEY FACT\nâ–  In the case a patient lost consciousness and no family member is\naround to provide consent for a procedure, a witnessed telephone con-\nPatients with psychiatric illness can\nsent is valid if that is the only way to obtain consent.\ngive consent if their decision-making\ncapacity is intact. â–  When a patient lacks decision-making capacity. In this case, consent is\nstill required but must be obtained from a surrogate decision maker.\n",
      "char_start": 536000,
      "char_end": 538000
    },
    {
      "chunk_id": 269,
      "text": "Example: Minors generally require surrogate decision makers until they\ndemonstrate adequate decision-making capacity or are of legal age.\nInformed Consent for Incapacitated Individuals\nWhen individuals lose consciousness, doctors and caregivers should respect\nthe patientâ€™s last known wishes, whether expressed orally or in writing. Oral\nwishes, however, are more difficult to prove.\nâ–  Example: If a patient repeatedly did not want a procedure performed, per-\nforming the surgery cannot be performed once the patient loses\nMNEMONIC\nconsciousness.\nBRAIN of informed consentâ€”\nInformed Consent in Reproductive Health\nBenefits\nRisks â–  The motherâ€™s autonomy supersedes the rights of the fetus.\nAlternatives â–  Except when acting as a surrogate decision maker for the pregnant patient,\nIndications the father has no legal right to provide informed consent on a pregnancy-\nNature related procedure.\nâ–  Adults have access to sterilization. Consent is needed from the patient\nonly and not the partner.\nInformed Consent for a Never-Competent Person\nIn the case informed consent should be obtained for a never-competent person\nbut no guardian is present, a court-designated third party should make a deci-\nsion for the medical intervention based on the best interests of the patient.\nInformed Consent for Minors\nâ–  In general, minors (people <18 years of age) cannot consent for their own\nmedical treatment and require parents or guardians to consent on their\nbehalf (one parent is sufficient as long as that parent has custody), except\nin the following situations:\nâ–  Life-threatening emergencies: When parents cannot be contacted,\n1\nparental consent is implied. A court order is not appropriate, as it\ndelays the urgent intervention.\nThe most appropriate next step in â–  Legal emancipation: Emancipated minors do not require parental\nmanagement is to respectfully ask consent for medical care. Although emancipation laws vary from state\nthe patient about his reasons for\nto state, in general minors are emancipated",
      "char_start": 538000,
      "char_end": 540000
    },
    {
      "chunk_id": 270,
      "text": " if they are married, are in\nnot wanting to pursue treatment.\nthe armed services, are the parent of a child that they themselves sup-\nPatients often need clarification and\nport, or are financially independent of their parents and have obtained\nreassurance. If he continues to decline\nlegal emancipation.\ntreatment, abide by his decision\n(respect for autonomy). â–  Sexually transmitted infections and substance abuse treatment:\nRules concerning contraception, pregnancy, HIV, and treatment for\ndrug and alcohol dependency vary across the United States.\nâ–  In cases discussed earlier, treating the patient without notifying the parents\n2 is acceptable.\nâ–  In cases where minors are seeking an abortion, encouraging patients to dis-\ncuss with and notify parents/guardians is likely the best answer. There is no\nThe most appropriate next step is to\nproceed with the surgery. A clinician national standard as to whether clinicians should notify parents themselves.\nmay give emergent treatment in the\nabsence of informed consent when\nimmediate intervention is necessary\nto prevent serious harm or death.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118888 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 189\nâ–  In some states, the clinician is left with the decision of informing parents\nabout adolescent use of confidential services in the interest of best serving\nthe patient; other states limit disclosure.\nRefusal of Treatment\nâ–  A parent has the right to refuse treatment for their child as long as those\ndecisions do not pose a serious threat to the childâ€™s well-being.\nâ–  In nonemergent situations, the clinician in charge is responsible of engag-\ning with the parents and care partners by providing education and clarifi-\ncation regarding the treatment.\nâ–  When faced with continued resistance despite discussions with the par-\nents, if the parental decision is not in the best interest of the child, the\nclinician should seek a court order (",
      "char_start": 540000,
      "char_end": 542000
    },
    {
      "chunk_id": 271,
      "text": "eg, refusing immunizations is not\nconsidered a serious threat; therefore the parent has the right to refuse).\nâ–  In an emergent situation, if a parental decision is not in the best interest of KEY FACT\nthe child, a clinician may provide treatment against parental wishes. As\nsuch, if withholding treatment jeopardizes the childâ€™s safety, treatment can Brain death is the irreversible loss of\nbe initiated on the basis of legal precedent. In the case a child presents to all brain activity and is equivalent to\nthe hospital with severe intra-abdominal hemorrhage and a blood transfu- cardiopulmonary death. If a patient is\nsion appears to be necessary and lifesaving, the clinician can override the brain dead, no consent is needed to\nrequest of parents not to transfuse in order to save the life of the patient. stop therapy. Two clinicians are required\nâ–  Example involving Jehovahâ€™s Witnesses: A clinician provides a blood to perform a brain death examination\ntransfusion to save the life of a 6-year-old child seriously injured in a motor to legally declare a patient brain dead.\nvehicle collision despite parental requests to withhold such a measure.\nEND-OF-LIFE ISSUES\nADVANCE DIRECTIVES\nAn advance directive is a way for patients to let their doctors know what the\npatientâ€™s wishes are in case they lose capacity. A formal advance directive,\nsuch as a living will or healthcare proxy, will override the wishes of the family.\nAdvance directives are legal documents that should be completed by any\ncompetent adult.\nâ–  Living will: A written advance directive outlining the patientâ€™s wishes. It\naddresses a patientâ€™s wishes to maintain, withhold, or withdraw life-\nsustaining treatment in the event of terminal disease or a persistent vege-\ntative state when the patient has lost the capacity to make decisions. A\nliving will can be a detailed document describing what tests and inter-\nventions the patient would refuse or consent to. If the living will is not\ndetailed, decision making can be more d",
      "char_start": 542000,
      "char_end": 544000
    },
    {
      "chunk_id": 272,
      "text": "ifficult (eg, a living will stating\nno extraordinary care). This advance directive does not provide enough\nclarification and medical guidance for clinicians to follow. The defini-\ntion of extraordinary care is subjective. It can mean no chemotherapy to\nsome patients, but for others it could mean no invasive blood draws.\nA 5-year-old girl with hydrocephalus\nâ–  Physician orders for life-sustaining treatment: POLST is a clinicianâ€™s needs another revision of her\norder that outlines a plan for end-of-life care that reflects both the patientâ€™s ventriculoperitoneal shunt. There are\npreferences concerning care at lifeâ€™s end and the clinicianâ€™s judgment, no satisfactory alternatives available\nbased on a medical evaluation. The POLST is not a replacement of an to relieve her symptoms. Her father\nadvance directive. consents, but her mother does not\nwant to proceed with the procedure,\nexplaining that she has been through\nenough procedures in her young life.\nWhat is the most appropriate next\nstep in management?\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 118899 1100//2211//2222 1122::2288 PPMM\n\n190 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nMNEMONIC SURROGATE DECISION MAKING\nIn the absence of a living will or\nWhen faced with an unconscious patient or a patient who cannot make a\ndurable power of attorney for\nhealthcareâ€” decision for themselves, surrogate decision making comes into play. The fol-\nlowing scenarios are examples of such:\nThe spouse CHIPS in For the\npatient â–  Durable power of attorney for healthcare or â€œhealthcare proxyâ€: Legally\nAdult CHIldren designates a surrogate healthcare decision maker if a patient lacks\nParent decision-making capacity. More flexible than a living will. Surrogates\nSibling should make decisions consistent with the personâ€™s stated wishes regarding\nFriend (in this order) medical care only. The healthcare proxy makes decisions based on the\npatientâ€™s verbal and written communicated wishes. The proxyâ€™s decision\noutwe",
      "char_start": 544000,
      "char_end": 546000
    },
    {
      "chunk_id": 273,
      "text": "ighs the family wishes.\nâ–  No living will: If no living will or durable power of attorney for healthcare\nexists, decisions should be made by close family members (spouse, adult\nchildren, parents, and adult siblings) or friends, in that order.\nâ–  When all are in agreement, decision making on an intervention is\nstraightforward.\nâ–  When family members disagree, the clinician should first encourage\ndiscussion. If no consensus is agreed upon, refer the case to the hospi-\ntalâ€™s ethics committee. Seek a court referral as a last resort.\nâ–  Ethics committees or court orders can be helpful when the patient lacks\ncapacity, when the patient has no proxy or advance directive and there is\ndisagreement among family members, or when there is disagreement\nbetween the family and healthcare team (eg, in cases of medical futility or\nparental refusal of necessary treatment for minors).\nKEY FACT Do not resuscitate (DNR)/do not intubate (DNI) orders:\nDo not resuscitate (DNR) and do not â–  DNR and DNI orders are based on patient preferences regarding cardio-\nintubate (DNI) orders do not mean â€œdo pulmonary resuscitation (CPR) and intubation only. Patients can refuse\nnot treat.â€ all nonpalliative treatments or specific therapies (eg, CPR, intubation,\nantibiotics, feeding tubes).\nâ–  A DNR/DNI order does not prevent people from getting other interven-\ntions (eg, dialysis, chemotherapy, blood transfusions).\nWITHDRAWAL OF LIFE-SUSTAINING TREATMENT\nâ–  Patients and their decision makers have the right to forego or withdraw\nlife-sustaining treatment. Also, the clinician should never use the term\nwithdrawal of care because healthcare staff do not stop caring for a patient.\nClinicians should seek to understand patients and their reasons for refus-\ning beneficial treatments.\nâ–  When a patient has full capacity and decides to withdraw life-sustaining\ntreatment, there is no need for a psychiatric evaluation. Psychiatric evalua-\ntions are only needed if the patientâ€™s capacity to understand is uncertain.\nâ–  No eth",
      "char_start": 546000,
      "char_end": 548000
    },
    {
      "chunk_id": 274,
      "text": "ical distinction is made between withholding a treatment and with-\ndrawing a treatment, because a patient may choose to refuse an interven-\ntion either before or after it is initiated. This can include ventilation,\nfluids, nutrition, and medications such as antibiotics.\nThe most appropriate next step in EUTHANASIA AND CLINICIAN-ASSISTED SUICIDE\nmanagement is to proceed with the\nshunt revision. The consent of one\nâ–  Euthanasia is the administration of a lethal agent by the healthcare pro-\nparent is sufficient to proceed with\nvider with the intent to end life.\nthe treatment of a minor, particularly\nwhen it is unequivocally clear that the â–  It is opposed by the American Medical Association (AMA) Code of\ndecision is in the childâ€™s best interest. Medical Ethics and is illegal in all states.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119900 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 191\nâ–  Patients who request euthanasia should be evaluated for inadequate\npain control and comorbid depression.\nâ–  Clinician-assisted suicide consists of prescribing a lethal agent to a patient\nwho will self-administer it to end his or her own life. This is currently ille-\ngal except in the states of Oregon, Washington, Vermont, Colorado, and\nCalifornia. This is also legal via court order in Montana.\nHOSPICE CARE\nâ–  Hospice care is a subtype of palliative care focused on palliation of symp-\ntoms for patients with a poor prognosis. The focus is on pain management,\nquality of life, and bereavement.\nâ–  If the intent is to relieve suffering and if the medications administered are\ntitrated for that purpose, it is considered ethical to provide palliative treat-\nment to relieve pain and suffering even if it may hasten a patientâ€™s death\n(principle of double effect).\nFUTILE TREATMENT\nClinicians are not ethically obligated to provide treatment and may refuse a\npatientâ€™s or family memberâ€™s request for further intervention on the grounds\nof ",
      "char_start": 548000,
      "char_end": 550000
    },
    {
      "chunk_id": 275,
      "text": "futility under any of the following circumstances:\nâ–  There is no evidence or pathophysiologic rationale for the treatment.\nâ–  The intervention has already failed.\nâ–  Maximal intervention is currently failing.\nâ–  Treatment will not achieve the goals of care.\nCOMPLEMENTARY AND ALTERNATIVE MEDICINE THERAPY\nComplementary and alternative medicine (CAM) represents medical services\nand practices that are not part of standard medical care. As the name indi-\ncates, this can include special diets, vitamins, dietary/herbal supplements,\nmeditation, yoga, and hypnosis, among others. These alternative treatments\nhelp patients cope with their disease and side effects of their disease such as\nnausea, fatigue, pain, and loss of appetite. If a patient is interested in alterna-\ntive/nontraditional treatment, the clinician should obtain more information\nas to why the patient is interested. The clinician should provide as much\ninformation as possible, and they should not dismiss the patient.\nDISCLOSURE\nFULL DISCLOSURE\nâ–  Disclosure is the act of making something known in its entirety. Medi-\ncally, patients have a right to know about their medical status, prognosis,\nand treatment options (full disclosure). They have the legal right to obtain\ncopies of their medical records within a specified timeframe.\nâ–  Per the right to autonomy, a patientâ€™s family cannot require that a clini-\ncian withhold information from the patient without the knowledge and\nconsent of the patient. When such a case arises, the clinician should\nexplore why the family member does not want the diagnosis revealed. Ulti-\nmately, however, the patient should be told.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119911 1100//2211//2222 1122::2288 PPMM\n\n192 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nâ–  A clinician may withhold information only if the patient requests not to be\ntold or in the rare and controversial case in which a clinician determines\nthat disclosure would cause severe and immediat",
      "char_start": 550000,
      "char_end": 552000
    },
    {
      "chunk_id": 276,
      "text": "e harm to the patient\n(therapeutic privilege). This may include any information that may lead to\ndepression, anxiety, or even resignation from a current job.\nâ–  Therapeutic privilege does not involve withholding medical information\nin emergency situations or reporting errors in patient care.\nâ–  Disclosure is to be done at the earliest time possible, and it is withheld\nonly if there are contraindications to communicating this information to\nthe patient (ie, if it might do more harm to the patient than good).\nâ–  If issues arise when information is being disclosed, this is handled by dis-\ncussing with the patientâ€™s family as to why they donâ€™t want disclosure with-\nout actually letting them know the details of the information being\ndisclosed. Alternatively, this can be discussed with the ethics committee if\nthere appears to be a conflict of interest (eg, debate between two siblings\nover what their parent would have wanted).\nSETTING FOR DELIVERING NEWS\nNews, good or bad, needs to be disclosed to the patient in a way that it is fully\nunderstood, without breach of privacy, and with empathy. A setup needs to be\ncreated whenever delivering news so that all these concerns, and more, can\nbe addressed directly.\nThe most commonly followed model is the SPIKES model. This includes\nthe following:\nâ–  Setup: This requires the area of news delivery to be in a private area, ide-\nally with everyone sitting down for the discussion. It is also important to\ninclude people who the patient thinks should hear the news (with consent\nby the patient first).\nâ–  Perception of the patient: The next step entails asking the patient what\nthey know so far about their illness. It is important to know what they\nthink that the news might be: good or bad?\nâ–  Invitation from the patient: Also, it is important to ask them what informa-\ntion they would like to hear and what they feel like they want to exclude.\nIf the patient thinks they do not want to include certain pieces of informa-\ntion in the discussion, they ",
      "char_start": 552000,
      "char_end": 554000
    },
    {
      "chunk_id": 277,
      "text": "should be asked why. However, it is important\nto remember that as much as the patient has the right to know, the patient\nalso has the right not to know.\nAfter this, the clinician should initiate discussion of the news in stages.\nâ–  Knowledge: This stage is when all the information about the patientâ€™s cur-\nrent condition is delivered. It is important to know the intellectual level of\nthe patient to make sure that the patient understands what information is\nbeing communicated to them. Special circumstances may require\ndetailed diagrams that are simplified for the patient.\nâ–  Always give information bit by bit, and make sure that you consider the\npatientâ€™s current emotional state prior to giving information.\nâ–  Always be gentle and caring. Examples include statements like: â€œI am\nsorry to let you know...â€, or â€œI think this piece of information may be\nparticularly disturbing for you...â€\nâ–  Emotions: Prepare to identify any emotion that the patient shows,\nacknowledge it, and respond in an empathetic manner. Examples include\nstatements such as â€œI know this might be difficult to hear...â€ or â€œI know\nthis might not be what you had anticipated...â€\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119922 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 193\nâ–  Strategy and summary: Let the patient know that the information you\nneeded to deliver, and that the patient wanted to hear, has now been com-\nmunicated. Ask the patient if they have any queries or if they have anything\nelse that they might want to hear. If not, ask them about when they may be\nready for the next meeting and briefly outline what will be discussed next.\nExamples include statements like: â€œAlthough this news might have come\nunexpectedly for you, we still need to discuss your care plan. While you pro-\ncess this information, we also need to discuss how to proceed further with\nyour care. If you want to discuss this further, then we can continue. Other-\nwise, plea",
      "char_start": 554000,
      "char_end": 556000
    },
    {
      "chunk_id": 278,
      "text": "se let me know when you would like to discuss this next.â€\nCONFIDENTIALITY\nMNEMONIC\nâ–  Patient security, privacy, and healthcare data protection fall within the\nauspices of the Health Insurance Portability and Accountability Act\nOverriding confidentialityâ€”\n(HIPAA). This law addresses three main issues: privacy (for use and disclo-\nWAITT a SEC before letting a\nsure of individualsâ€™ health information), security (to set national standards\npatient in danger go!\nfor protecting confidentiality, integrity, and availability of electronically\nprotected healthcare-related information), and breach rules (to notify WOUNDS\nAutomobile-driving impairment\naffected individuals, federal government, and media about unsecured pro-\nInfectious disease\ntected health information).\nTarasoff (violent crimes) and human\nâ–  Protected health information is any information that is transmitted or\nTrafficking\nmaintained in electronic media directly related to an individualâ€™s health-\nSuicide\ncare. This may also involve any verbal communications (eg, talk over cof-\nElder abuse and neglect\nfee or lunch) that discloses patientsâ€™ identifiable health information (eg, Child abuse\nname, patient number). This can also include bills, admission profile, pre-\nscription records, referral, discharge, and follow-up appointments.\nâ–  Information disclosed by a patient to their clinician and information about\na patientâ€™s medical condition are strictly confidential and should be dis-\ncussed and accessed only by those directly involved in the patientâ€™s care,\nwith few exceptions (described later). This may require disclosure to a\nhealthcare monitoring body like the Centers for Disease Control or Pre-\nKEY FACT\nvention (CDC), or even to the police.\nâ–  Who has access to medical records? This is typically reserved only for the Signs of suspected child abuse:\npatient or their authorized representatives. A patient may waive the obliga-\nHistory given not consistent with injury\ntion of the clinician to protect confidentiality (eg, ",
      "char_start": 556000,
      "char_end": 558000
    },
    {
      "chunk_id": 279,
      "text": "with insurance compa-\nUnusual child or parental behavior\nnies, authorized family members), preferably by way of written or verbal\nDelay in seeking medical care\nconsent. The clinician should disclose only the minimally necessary infor-\nSubdural hematomas\nmation to these personnel.\nRetinal hemorrhages\nSpiral, bucket-handle, or rib fractures\nIt is ethically and legally necessary to override confidentiality in the following\nInjuries in different stages of healing\nsituations:\nâ–  Patient intent to commit a crime against an identifiable victim\n(Tarasoff decision): Clinicians have a duty to protect the intended victim\nthrough reasonable means (eg, warn the victim, notify police).\nâ–  Suicidal patients. KEY FACT\nâ–  Child abuse/neglect and elder abuse/neglect.\nPotential signs of elder abuse and neglect:\nâ–  Reportable infectious diseases (eg, HIV, sexually transmitted infections,\nCuts, bruises, pressure ulcers, burns\nTB, polio, diphtheria, rabies, enteric fever, tetanus, COVID-19): There is\nUncommon fractures\na duty to warn public officials and identifiable people at risk. It is normally\nMalnutrition or dehydration\nbest to encourage patients themselves to inform sexual contacts who are at\nAnogenital injury or infection\nrisk for contracting the illness.\nEvidence of poor caretaking or financial\nâ–  Reportable noninfectious diseases: These include cancer, carbon monox-\nexploitation\nide poisoning, silicosis, and lead poisoning.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119933 1100//2211//2222 1122::2288 PPMM\n\n194 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nKEY FACT â–  Notifiable outbreaks: These include food- and water-borne disease outbreaks.\nCurrently patients affected by the COVID-19 pandemic are also reportable.\nGuiding principles for overriding\nâ–  Gunshot and knife wound (a duty to notify the police): Such instances\nconfidentiality:\nalso include emergency scenarios when the treating clinician is trying to\nThere is an identifiable third party at risk",
      "char_start": 558000,
      "char_end": 560000
    },
    {
      "chunk_id": 280,
      "text": "\nobtain consent over the phone because the patient cannot provide one.\nfor harm.\nâ–  The patient is a danger to others (eg, impaired automobile drivers): Cur-\nThe harm is significant and probable.\nrently, only six states have mandatory clinician reporting laws.\nDisclosure will help prevent or mitigate\nâ–  Example: A patient begins to drive 1 week after hospitalization for sei-\nthe harm.\nzures, although the department of motor vehicles in his state requires\nOther measures, such as convincing the\nthat licensed drivers be without seizures for at least 3 months.\npatient to self-disclose, have failed.\nCLINICAL RESEARCH\nThe formal definition of clinical research is any medical research that tests new\ninvestigations, treatments, and therapies on people or against a standard of care.\nâ–  The role of ethics in research is to ensure patient safety and integrity of\nresearch results. The Declaration of Geneva of the World Medical Associ-\nation (WMA) binds the clinician with the statement: â€œThe health of my\npatient will be my first consideration,â€ which implies that the patient\nshould be protected from harmful treatment at all times. As such, patients\nmay choose voluntarily to be research subjects, or they may be enrolled in\na therapeutic trial for a disease without any known cure to see if they may\nbenefit from the treatment.\nâ–  The Declaration of Helsinki addresses ethical concerns that arise from\nsuch studies. It also mentions that clinicians are obligated to inform\npatients considering involvement in a clinical research protocol about the\npurpose of the research study and the entire study design as it will affect\nthe patientâ€™s treatment. This includes the possible risks, benefits, and alter-\nnatives to the research protocol. Clinicians are also obligated to inform the\nparticipants that no patient identification label (eg, name, patient num-\nber) will be used in the research.\nCORE PRINCIPLES OF CLINICAL RESEARCH\nThe principles followed include the following:\nâ–  Ensuring compliance wi",
      "char_start": 560000,
      "char_end": 562000
    },
    {
      "chunk_id": 281,
      "text": "th clinical protocols, with repeated reviews con-\nfirming the same during the time of research\nâ–  Verification of scientific validity of results\nâ–  Ensuring a fair system of selecting treatment options, with removal of bias\nwhere possible\nâ–  Obtaining informed consent discussing benefit and harm prior to partici-\npation in research\nKEY FACT ETHICAL CONCERNS\nMandatory reporting of intimate\nâ–  Pregnant patients: Ensure no harm comes to both mother and child dur-\npartner violence is controversial and\ning research.\nvaries by state. Nonetheless, clinicians\nâ–  Children: It is important to obtain assent of the child, even though the\nshould document the encounter, offer\nconsent from the guardians is mandatory.\nsupport, and have resources available\nâ–  Incurable illness: The clinician should make sure the patient does not\nfor assistance.\nenroll only for anticipated personal benefit.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119944 1100//2211//2222 1122::2288 PPMM\n\nHEALTH SYSTEMS SCIENCE HIGH-YIELD FACTS IN 195\nâ–  Monetary compensation: Such compensation may provide undue influence\nfor accepting the risk for contracting a disease or being harmed in the pro-\ncess. Most trials provide only out-of-pocket expenses as compensation.\nâ–  Recruitment: The patient may be enrolled in multiple trials due to lack of\nvolunteers or due to rarity of disease. This may lead to bias in the results\nand to patient harm.\nâ–  Stem cell research: Such research has an intrinsic difficulty with maintaining\nanonymity of human tissue donors, ownership of tissue, long-term storage of\nsamples, and manipulation of genetic material to create new organisms.\nâ–  Inability for patient to consent: In this case, the clinician should obtain\nconsent from the legally authorized representative.\nâ–  Incarcerated patients: Incarceration does not change the process of con-\nsent or healthcare rights.\nCONFLICT OF INTEREST\nâ–  Occurs when clinicians find themselves having a personal interest in a\ngiven",
      "char_start": 562000,
      "char_end": 564000
    },
    {
      "chunk_id": 282,
      "text": " situation, which influences their professional obligations.\nâ–  Example: A clinician may own stock in a pharmaceutical company\n(financial interest) that produces a drug he is prescribing to his patient\n(patient care interest).\nâ–  Clinicians should disclose existing conflicts of interest to affected parties (eg,\npatients, institutions, audiences of journal articles or scientific meetings).\nâ–  Accepting gifts from pharmaceutical companies can influence a clini-\ncianâ€™s practice and should generally be avoided. Nonmonetary gifts\nshould be accepted only if they will directly benefit patient care and\nare of small monetary value. A clinician should never accept cash.\nGIFTS FROM PATIENTS\nâ–  A patient or patient party may offer to provide the treating healthcare team\nor a particular member in the team with a gift as an expression of gratitude\nor as a reflection of the patientâ€™s culture.\nâ–  Accepting gifts or cash to influence care or preferential treatment is unac-\nceptable. This can further harm the patient-doctor relationship.\nâ–  When accepting a gift, keep the following in mind:\nâ–  Do not allow the gift or offer to influence care.\nâ–  Decline gifts if acceptance may present financial or emotional hard-\nship to the gifting family.\nâ–  Be sensitive about the patientâ€™s emotions and be fair (accepting a gift\nmay lead to impaired relationship among team members if the gift is\nprovided disproportionately).\nGIFTS FROM DRUG COMPANIES\nâ–  Governed by the Sunshine Act, which requires clinicians to disclose any\nfinancial information or conflict of interest required by employers, advi-\nsory board, and institutions that provide research funding. A 35-year-old woman visits a primary\nâ–  Includes gifts that cost more than $10 or any small gifts that are worth care clinician after hurting her wrist.\nPhysical exam reveals circumferential\ncumulatively a sum of more than $100.\nbruises of her wrist, neck, and arms.\nâ–  Exemptions include certified and accredited continuing medical educa-\nThe patient admits t",
      "char_start": 564000,
      "char_end": 566000
    },
    {
      "chunk_id": 283,
      "text": "hat the injuries\ntion, buffet lunch and snacks at large-scale events, product samples not\nwere inflicted by her partner. What\nintended for sale, education material for patients, charitable items, or\nis the most appropriate next step in\nloaned devices for a trial period of less than 90 days.\nmanagement?\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119955 1100//2211//2222 1122::2288 PPMM\n\n196 HIGH-YIELD FACTS IN HEALTH SYSTEMS SCIENCE\nâ–  However, such gifts, or any advertisements, if received, should not alter the\nappropriate evidence-based practice of medicine on the clinicianâ€™s part.\nMALPRACTICE\nDEFINING MALPRACTICE\nMedical malpractice occurs when a hospital, doctor, or other healthcare pro-\nfessional causes injury or permanent harm to a patient as a result of a negli-\ngent act of carelessness. This may occur in two different ways: acts of omission\n(breach of duty to provide appropriate care to patients when capacity to con-\nsent was not determined) or acts of commission (doing something purpose-\nfully that leads to harm, despite being aware of possible outcomes without\nnotifying the patient of such outcomes).\nMNEMONIC The essential elements of a civil suit under negligence include:\nThe 4 Ds of malpracticeâ€” â–  The clinician has a Duty to the patient.\nâ–  Dereliction of duty occurs.\nDuty\nDereliction â–  There is Damage to the patient.\nDamage â–  Dereliction is the Direct cause of damage.\nDirect cause\nAn exception involves the â€œGood Samaritanâ€ laws, which protect those who\nhave completed basic first aid training and are certified by a healthcare organi-\nzation. These laws apply mostly to those people who may respond to victims in\ngood faith and in a rational manner, with the aim of preventing harm.\nUnlike a criminal suit, in which the burden of proof is â€œbeyond a reason-\nable doubt,â€ the burden of proof in a malpractice suit is â€œa preponderance of\nthe evidence.â€\nClinicians may refuse inappropriate requests, such as demanding to be seen\nafter ",
      "char_start": 566000,
      "char_end": 568000
    },
    {
      "chunk_id": 284,
      "text": "hours. The clinician should set clear limits and professional boundaries\nwhile remaining calm. If the patient has a nonurgent condition, the clinician\nshould not recommend that the patient visit the emergency department.\nIMPAIRED PRACTICING CLINICIAN\nImpairment does not only refer to aging. Per the AMA, an impaired clinician\nis one whose physical or mental health interferes with their ability to safely\nengage in professional activities. This can also involve anxiety (a major stress\nfactor that affects job performance and working memory), burnout (emotional\nexhaustion, depersonalization, reduced sense of personal accomplishment),\nand those clinicians with substance use disorder.\nA clinician has an obligation to protect patient interests and ensure appro-\npriate care and assistance to other clinicians/colleagues who may be impaired\nphysically or mentally. They should also report impaired colleagues to the\npeer review body of the hospital (eg, the program director or medical direc-\ntor) or the local or state medical board when the physician does not have hos-\npital privileges. When compromise of a patientâ€™s health and safety is an\nThe most appropriate next step\nwould be to offer support and immediate threat, report directly to the state licensing board. If the situation\nacknowledge the courage it takes does not change despite prior reporting, report to a higher authority.\nto discuss abuse. Assess the safety\nâ–  Example: A clinician notes that his colleague, a surgeon, gets repeatedly\nof the woman and of any children\ndrunk at parties throughout the week and comes late to work the next day.\ninvolved, introduce the concept of an\nA patient has recently filed a malpractice lawsuit, as the patient believes\nemergency plan, and encourage the\nuse of community resources. If the that the doctor operated on him in a drunken state. Your responsibility in\npatient consents, report the abuse to this case is to refer the clinician to a clinician health program for further\nrelevant author",
      "char_start": 568000,
      "char_end": 570000
    },
    {
      "chunk_id": 285,
      "text": "ities. evaluation and possible therapy.\n22002222__0022..0055__SStteepp22CCKK__HHSSSS__1111ee__117777--119966..iinndddd 119966 1100//2211//2222 1122::2288 PPMM\n\nH I G H - Y I E L D F A C T S I N\nGASTROINTESTINAL\nOral and Salivary Gland Disease 199 CarCinOid syndrOMe 224\nOral lesiOns 199 sMall BOwel OBstruCtiOn 224\nOrOpharyangeal CanCers 201 ileus 225\nsalivary gland disease 201 aCute aBdOMen 226\nduOdenal heMatOMa 228\nEsophageal Disease 203\nMesenteriC isCheMia 229\ndysphagia/OdynOphagia 203\naCute appendiCitis 230\ninfeCtiOus esOphagitis 204\npill (MediCatiOn-induCed) esOphagitis 205 Disorders of the Large Bowel 231\neOsinOphiliC esOphagitis 206 ClOstridiuM diffiCile COlitis 231\nesOphageal rings 207 divertiCular disease 232\npluMMer-vinsOn syndrOMe 207 large BOwel OBstruCtiOn 234\ndistal esOphageal spasM 207 irritaBle BOwel syndrOMe 234\naChalasia 208 COlOreCtal CanCer 236\nesOphageal divertiCula 209 COlOreCtal CanCer-assOCiated COnditiOns 237\ngastrOesOphageal reflux disease 209 isCheMiC COlitis 238\nhiatal hernia 211 MiCrOsCOpiC COlitis 240\nesOphageal CanCer 211\nAnorectal Disease 241\nGastrointestinal Bleeding 211 heMOrrhOid grading 241\nupper gi Bleeding 212\nInflammatory Bowel Disease 241\nDisorders of the Stomach and Duodenum 214\nHernias 243\ndyspepsia 214\nBiliary Disease 244\ngastritis 214\ngastriC CanCer 216 ChOlelithiasis and Biliary COliC 244\npeptiC ulCer disease 216 ChOleCystitis 244\nZOllinger-ellisOn syndrOMe 217 ChOledOChOlithiasis 246\ngastrOparesis 217 ChOlangitis 246\nMÃ©nÃ©trier disease 218 gallstOne ileus 246\ngastriC BeZOar 218 pOstChOleCysteCtOMy syndrOMe 247\nBariatriC surgery 219 Biliary Cyst 247\nChOlangiOCarCinOMa 247\nDisorders of the Small Bowel 220\nLiver Disease 248\ndiarrhea 220\nMalaBsOrptiOn/MaldigestiOn 223 aBnOrMal liver assOCiated enZyMes 248\nCarBOhydrate MaldigestiOn 224 hepatitis 249\n197\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 119977 1100//2211//2222 1122::5588 PPMM\n\nH I G H - Y I E L D F A C T S I N\nGASTROINTESTINAL\nC",
      "char_start": 570000,
      "char_end": 572000
    },
    {
      "chunk_id": 286,
      "text": "irrhOsis 252 hepatOCellular CarCinOMa 259\nspOntaneOus BaCterial peritOnitis 254 heMOChrOMatOsis 260\nisCheMiC hepatitis 256 wilsOn disease (hepatOlentiCular degeneratiOn) 261\naCute liver failure 256 liver transplantatiOn 261\nhepatOrenal syndrOMe 257 Benign liver lesiOns 262\nhepatOpulMOnary syndrOMe 257\nPancreatic Disease 264\nhepatiC hydrOthOrax 258\npanCreatitis 264\ntransjugular intrahepatiC pOrtOsysteMiC shunt prOCedure 258\npanCreatiC Cysts 264\npriMary sClerOsing ChOlangitis 259\npanCreatiC nOnendOCrine tuMOrs (pnets) 266\npriMary Biliary ChOlangitis 259 panCreatiC CanCer 267\nnOnalCOhOliC fatty liver disease 259\n198\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 119988 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 199\nORAL AND SALIVARY GLAND DISEASE\nORAL LESIONS\nTable 2.6-1 describes common benign oral lesions. Figure 2.6-1 depicts pre-\nmalignant oral lesions. Although these lesions are noncancerous, they can\ntransform into squamous cell carcinoma (SCC).\nTABLE 2.6-1. Selected Benign Oral Lesions\nCONDITION AND ETIOLOGY PRESENTATION DIAGNOSIS AND TREATMENT\nRecurrent aphthous stomatitis Recurrent aphthous stomatitis is the most Administering topical corticosteroids and systemic\ncommon cause of ulcerations in the mouth immunomodulators\nUlcers are painful, shallow, and round/oval with a Treating underlying systemic conditions\ncentral yellow exudate Avoiding mucosal trauma, correcting vitamin deficien-\nCondition begins in childhood or adolescence, cies, or excluding obvious dietary causes can help\noften resolving later in life\nDifferential includes underlying causes of recur-\nrent ulceration due to systemic conditions (eg,\ninflammatory bowel disease [IBD], celiac disease,\nsystemic lupus erythematosus [SLE])\nTorus palatinus Torus palatinus is a benign and asymptomatic Generally, no treatment is required; surgical excision\nmidline bony overgrowth of the hard palate can be considered if the lesion is causing signifi",
      "char_start": 572000,
      "char_end": 574000
    },
    {
      "chunk_id": 287,
      "text": "cant\nImaging and biopsy are required for fast- discomfort\ngrowing mass, atypical appearance, or if the\novergrowth is not in the midline\nPrevalence is up to 27% of the population\n(Image 1 adapted with permission from Peterson DE, Oâ€™Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of\nrapamycin inhibitors: Emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016;5[8]:1897-1907. Image 2 adapted\nwith permission from Chao PJ, Yang HY, Huang WH, et al. Oral tori in chronic hemodialysis patients. Bio-med Res Int. 2015;2015:897674.)\nA B C\nFIGURE 2.6-1. Premalignant lesions of the mouth. (A) Leukoplakia. (B) Erythroplakia. (C) Oral submucosal fibrosis. (Images A and B reproduced\nwith permission from van der Waal I. Oral leukoplakia, the ongoing discussion on definition and terminology. Med Oral Patol Oral Cir Bucal. 2015;20[6]:e685-e692. Image C reproduced with\npermission from Saravanan K, Narayanan V. The use of buccal fat pad in the treatment of oral submucous fibrosis: A newer method. Int J Dent. 2012;2012:935135.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 119999 1100//2211//2222 1122::5588 PPMM\n\n200 HIGH-YIELD FACTS IN GASTROINTESTINAL\nOral Leukoplakia\nGenerally asymptomatic, premalignant lesions that occur in 1.5% to 4.3% of\nthe normal population.\nKEY FACT\nHistory/PE\nOral hairy leukoplakia is a\nmanifestation of EBV seen in Patients present with white patches in the oral mucosa that cannot be scraped\nimmunocompromised patients. It off (Fig. 2.6-1A). The reported rates of transformation to SCC vary widely,\naffects the lateral portion of the tongue ranging from <1% to 36%.\nand presents with painless plaques that\nRisk Factors\nhave a feathery or hairy appearance\nand cannot be scraped off. There is â–  Tobacco use, alcohol use, and human papilloma virus (HPV) infection.\nno malignancy potential. â–  Risk factors for transformation to SCC: Nonhomogeneous lesions, large\nlesions (>4",
      "char_start": 574000,
      "char_end": 576000
    },
    {
      "chunk_id": 288,
      "text": " cm diameter), multiple anatomic sites, high-risk location (lateral\ntongue and floor of the mouth), and dysplasia on histologic examination.\nDiagnosis\nâ–  Definitive diagnosis is based on biopsy and histopathology.\nâ–  Histopathology may show hyperkeratosis, atrophy, inflammation, hyperpla-\nKEY FACT sia, or dysplasia. Occasionally there may be carcinoma in situ or invasive\ncarcinoma.\nOral candidiasis is an opportunistic,\nintraoral infection that most commonly Treatment\npresents with confluent white patches\nâ–  Options include surgical excision of smaller high-risk lesions. For larger\nand plaques in the oral mucosa. They\nlesions, risk factor modification (eg, cessation of smoking and alcohol use)\nare differentiated from leukoplakia\nand close clinical and histologic surveillance are indicated.\nbecause they can be scraped or\nâ–  Other options include destruction (with laser ablation or cryosurgery) and\nwiped off, exposing an erythematous\nmedical treatment (eg, retinoids, vitamin A).\nbase (see the Candidiasis section in the\nâ–  Lifelong follow-up is required due to high recurrence and development of\nDermatology chapter).\nsquamous cell carcinoma.\nErythroplakia\nRed, well-demarcated lesions commonly located on the floor of the mouth,\nthe ventral tongue, or soft palate that cannot be explained by another disease\n(Fig. 2.6-1B). An estimated 2.7% of cases annually transform to SCC.\nâ–  Hx/PE: Generally asymptomatic in patients\nâ–  Risk factors: Most often found in older adults who use tobacco and con-\nsume alcohol\nâ–  Dx: Definitive diagnosis based on biopsy and histopathology, which may\nshow dysplasia, carcinoma in situ, or even invasive SCC\nâ–  Tx: Similar to leukoplakia\nOral Submucosal Fibrosis\nSubmucosal fibrosis of the whole oral mucosa (Fig. 2.6-1C). The estimated\nannual rate of transformation to SCC is 2% to 8%.\nâ–  Hx/PE: Burning, ulceration, and pain of the oral mucosa\nâ–  Risk factors: Chewing araca nuts (including betel quid, paan)\nâ–  Dx: Based on history and biopsy findings\nâ–  Tx: Discon",
      "char_start": 576000,
      "char_end": 578000
    },
    {
      "chunk_id": 289,
      "text": "tinuing betel productsâ€”mainstay of treatment\nOral Lichen Planus\nInflammatory lesions of the skin and oral mucosa with a prevalence of 1% to\n3% (see the Miscellaneous Skin Disorders section in the Dermatology chapter\nfor more details). Oral lesions appear as reticular white plaques, mucosal\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220000 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 201\nerythema, or erosions most commonly affecting the buccal mucosa. The overall\ntransformation rate to SCC is 1% to 2%.\nâ–  Hx/PE: Reticular white plaques that are rarely symptomatic. Other lesions\ncan present with pain.\nâ–  Dx: Based on clinical evaluation and biopsy findings\nâ–  Tx: No treatment for asymptomatic disease. Treatment of symptomatic dis-\nease is with topical corticosteroids (first line). If ineffective, topical tacroli-\nmus or pimecrolimus can be used. Refractory disease may require oral\nglucocorticoids or systemic immunomodulators.\nOROPHARYNGEAL CANCERS\nOropharyngeal SCC is the most common oral cancer (up to 90% of all oral\nneoplasms). It most commonly arises from premalignant lesions such as leu-\nkoplakia, erythroplakia, or lichen planus.\nHistory/PE\nPatients may be initially asymptomatic. Most commonly, oral cancer presents\nas an ulcerated lesion with a central necrotic area with rolled-up borders. The\nmost common locations are the lateral and ventrolateral parts of the tongue,\nalthough other areas may also be affected.\nRisk Factors\nâ–  Smoking or use of smokeless tobacco\nâ–  Alcohol consumption\nâ–  Areca (betel) nut ingestion (more prevalent in developing countries)\nâ–  Sometimes associated with HPV-16 and chronic irritants (eg, certain\nmouthwashes)\nDiagnosis\nDiagnosis is based on biopsy and histopathology. Laryngoscopy, bronchoscopy,\nand esophagoscopy are required to rule out simultaneous second primary cancers.\nAfter diagnosis, head and neck CT and a x-ray of the chest (CXR) or positron MNEMONIC\nemission tomograph",
      "char_start": 578000,
      "char_end": 580000
    },
    {
      "chunk_id": 290,
      "text": "y (PET)/CT are done to determine extent of spread and\nThe RULE acronym helps physicians\nmetastasis.\ndecide which oral lesions to biopsy.\nRed/red-white lesions\nTreatment\nUlcers\nTreatment is initially surgical resection. Lymph node dissections are done with Lumps\nsignificant nodal disease or deep invasion. Surgical reconstruction is important Especially in combination or if indurated\nto reduce postsurgical disability. Postoperative chemotherapy or radiotherapy is\nused with high-risk or advanced disease. In many patients for whom surgical\nresection is challenging or overly morbid (or in certain subtypes [eg, HPV-asso-\nciated cancers]), chemotherapy and radiation will be used as the definitive\ntreatment with curative intent, with no surgery except in cases of relapse.\nSALIVARY GLAND DISEASE\nThe sublingual, submandibular, and parotid glands are the most prominent\nsalivary glands. Clinically, salivary gland swelling may be approached by iden-\ntification of chronicity (acute vs chronic) and distribution (unifocal [single\ngland] vs multifocal [multiple glands]) of swelling. Figure 2.6-2 shows an out-\nline of salivary gland pathologies based on this approach. Tables 2.6-2 and\n2.6-3 describe selected non-neoplastic and neoplastic conditions in detail.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220011 1100//2211//2222 1122::5588 PPMM\n\n202 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-2. Selected Non-neoplastic Causes of Salivary Gland Swelling\nCONDITION ETIOLOGY PRESENTATION DIAGNOSIS TREATMENT\nSialadenosis Noninflammatory, non- History compatible with Compatible history Management of underlying\ninfectious, and painless predisposing causes (eg, Physical examination: condition\nswelling of parotid glands diabetes or alcoholism) no signs of infection\nCommon causes: malnutrition, (eg, pain, fever, sup-\nbulimia, diabetes, alcoholism, purative discharge)\nobesity, and liver diseases Ultrasound Â± contrast\nCT to rule out other\ncauses of saliva",
      "char_start": 580000,
      "char_end": 582000
    },
    {
      "chunk_id": 291,
      "text": "ry\ngland swelling\nAcute sup- Bacterial infection of salivary Acute, unifocal salivary Initial testing: ultra- Hydration, sialagogues (eg, sour\nglands that most commonly gland swelling and pain sound Â± contrast candy), warm compresses, non-\npurative\naffects parotid Purulent secretions from CT to identify sup- steroidal anti-inflammatory\nsialadenitis\nMost commonly due to Staphylo- duct puration (diffuse vs drugs (NSAIDs)\ncoccus aureus Associated with fever, tender abscess), stones, or Initial empiric antibiotics (eg,\nMay be primary or secondary to lymphadenopathy strictures amoxicillin clavulanate), which\nobstruction (stone or stricture) When secondary to stone, Pus exuded intraorally may change later, according to\nRisk factors: dehydrated states pain and swelling occur from gland is sent culture and sensitivity\n(hospitalized/postoperative before fever develops for culture and If an abscess is present, it needs\npatients), chronic conditions sensitivity surgical drainage\n(hypothyroidism, renal failure),\ndrugs (anticholinergics)\nAcute non- Most common cause: viral par- Viral prodrome of fever, Real-time reverse Observation and supportive care\notitis due to mumps virus; malaise, headache transcriptaseâ€“ (hydration, pain control)\nsuppurative\nother viral causes include cox- Acute, multifocal parotid polymerase chain Prevention: vaccination (measles,\nsialadenitis\nsackie and cytomegalovirus gland swelling and pain reaction (RT-PCR) mumps, and rubella [MMR])\n(CMV) (ie, initially unilateral, pro- of samples (serum,\nMost common in children <15 gressing to bilateral) buccal, or oral\nyears of age May be associ- swabs)\nHighly contagious by airborne ated with aseptic Viral culture\ndroplets meningitis, encephalitis, Serology (positive IgM)\nor pancreatitis\nSialolithiasis Caused by stone in salivary duct Acute, unifocal salivary Ultrasound Initial: sialagogues (eg, sour candy),\nMost often affects sub- gland swelling and pain Noncontrast CT warm compress, hydration,\nmandibular gland (up",
      "char_start": 582000,
      "char_end": 584000
    },
    {
      "chunk_id": 292,
      "text": " to 90%), that are intermittent and massage of gland, and NSAIDS\nfollowed by parotid occur after meals (post- Antibiotics for infection\nMost common cause of acute, prandial pain) If conservative treatment is inef-\nunifocal salivary gland swelling fective, minimally invasive (eg,\nRisk factors: smoking, hypovo- sialoendoscopy) or surgical (eg,\nlemia, anticholinergics sialoadenectomy) treatment\nmay be indicated\nPrevention: risk factor modification\n(ie, stop smoking and using an-\nticholinergics; avoid dehydration)\nRanula Pseudocysts of the major salivary Translucent blue swelling in Diagnosis based on Generally, resolve spontaneously\nglands (sublingual or subman- floor of mouth lateral to clinical appearance Persistent, recurrent, or symptom-\ndibular ducts) midline Imaging (ultrasound atic lesions may be treated by\nMay be congenital or acquired sonography [USG], surgical excision, marsupializa-\n(due to oral trauma) CT, MRI) can help tion, or other techniques (eg,\nto assess cause laser ablation, cryotherapy,\nMucocele Pseudocysts of minor salivary Smooth swellings in the and extent and electrocautery)\nglands buccal mucosa on oc- determine surgical Aspiration is not effective due to\nclusive plane; not blue in approach high recurrence rates\nappearance\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220022 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 203\nTABLE 2.6-3. Selected Benign and Malignant Tumors of Salivary Glands\nCONDITION ETIOLOGY PRESENTATION DIAGNOSIS TREATMENT\nPleomorphic ade- Most common salivary gland Chronic, unifocal, painless, Ultrasonography, Surgical excisionâ€”mainstay of\nnomas (benign) tumor in adults slow-growing mass or CT, MRI, and treatment no matter if benign\nMajority in parotid gland, fol- swelling in malignant and sometimes or malignant\nlowed by submandibular benign disease PET-CT Postoperative radiation therapy in\nMay undergo malignant trans- Signs of malignancy: pain, Fine-needle aspi",
      "char_start": 584000,
      "char_end": 586000
    },
    {
      "chunk_id": 293,
      "text": "- select cases\nformation and recurrence facial paresis, fixed mass, and ration biopsy Cervical lymph node dissection\nAssociated with ionizing cervical lymphadenopathy or ultrasound- may be required in malignant\nradiation exposure, viral guided core disease or with presence of other\ninfection, smoking, and needle biopsy high-risk features (eg, high-grade\nexposure to chemicals (eg, can confirm tumors, facial nerve weakness)\nrubber manufacturers, diagnosis Important risks of surgery: facial\ncosmetics) nerve dysfunction and Frey syn-\ndrome (sweating when chewing)\nMucoepidermoid Most common malignant Painless, slow-growing mass Based on Surgical excision recommended\ncarcinoma salivary gland neoplasm that is firm or hard histologic for localized resectable disease\n(malignant) Commonly in parotid examination Postoperative or palliative radio-\nLow-grade with good prog- therapy may be used\nnosis if treated early\nAdenoid cystic Second most common Most commonly arises in the Based on Standard therapy includes surgical\ncarcinoma (ACC; malignant salivary gland salivary glands or other areas histologic removal of the malignancy and\nmalignant) neoplasm within the head and neck examination affected tissue followed by radia-\nMost common in sub- region; symptoms of ACC tion; if initial surgery is not an\nmandibular gland of the salivary glands may option due to the specific loca-\nInvades facial nerve early, thus include numbness of the tion and/or progression of the\nfacial weakness or paralysis lower lip and/or other facial malignancy, therapy may include\nLocal recurrence after excision areas, nerve impairment radiation alone\ncausing weakness of certain\nfacial muscles, ongoing pain,\nand/or other associated\nabnormalities\nSalivary gland swelling\nAcute Chronic/progressive\nUnifocal Multifocal Unifocal Multifocal\nBacterial sialadenitis Mumps Benign tumors Autoimmune\nSialolithiasis Drug side effects Malignant tumors Granulomatous\nInflammatory HIV-associated\nJuvenile recurrent parotitis Meta",
      "char_start": 586000,
      "char_end": 588000
    },
    {
      "chunk_id": 294,
      "text": "bolic sialosis\nFIGURE 2.6-2. Causes of salivary gland swelling. (Reproduced with permission from USMLE-Rx.com.)\nESOPHAGEAL DISEASE\nDYSPHAGIA/ODYNOPHAGIA KEY FACT\nIn an immunocompromised person\nDifficulty swallowing (dysphagia) or pain with swallowing (odynophagia)\nwith odynophagia, candidiasis should\ncaused by abnormalities of the oropharynx or esophagus. Figure 2.6-3 illus-\nbe one of the differential diagnoses.\ntrates approaches to the diagnosis of esophageal dysphagia.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220033 1100//2211//2222 1122::5588 PPMM\n\n204 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDysphagia description\nFood â€œstuckâ€ while swallowing Difficulty initiating swallowing\nEsophageal dysphagia Oropharyngeal dysphagia\nTrigger of dysphagia\nSolid food Solid food or liquids\nMechanical obstruction Neuromuscular etiology\nDysphagia timing Dysphagia timing\nIntermittent Progressive Intermittent Progressive\nEsophageal webs/rings/stricture Peptic stricture Achalasia\nDiffuse esophageal spasm\nEosinophilic esophagitis Esophageal mass Scleroderma\nFIGURE 2.6-3. Approach to differential diagnosis of esophageal dysphagia. (Reproduced with permission from USMLE-Rx.com.)\nOropharyngeal Dysphagia\nKEY FACT\nProblem with initiation of swallowing that may lead to aspiration of food into\nPatients who are immunocompromised the lungs or regurgitation of food.\n(eg, HIV) with odynophagia or\nâ–  Etiology: Neurologic or muscular, including stroke, Parkinson disease,\ndysphagia may be empirically treated\nmyasthenia gravis, prolonged intubation, and Zenker diverticula.\nfor candida esophagitis. EGD can be\nâ–  Usually more of a problem with liquids than with solids.\nconsidered if there is no response to\nâ–  History/PE: Rule out alternative syndromes such as xerostomia, globus,\ndiagnose other causes (eg, CMV or HSV\nand esophageal dysphagia through history and physical examination.\nesophagitis).\nâ–  Investigations: Consider specific laboratory tests to rule out myopat",
      "char_start": 588000,
      "char_end": 590000
    },
    {
      "chunk_id": 295,
      "text": "hies,\nmyasthenia, or other conditions. Consider brain imaging if central ner-\nvous system (CNS) tumor, stroke, or head trauma is suspected.\nâ–  Best initial test: Modified barium swallow (video fluoroscopic swallowing\nexam) Â± esophageal manometry. Esophagogastroduodenoscopy (EGD)\nmay also be appropriate to rule out structural disease (see Fig. 2.6-3).\nâ–  Treatment: Diet modification, swallowing therapy, and sometimes tempo-\nrary nonoral feeds. Severe dysphagia may require nonoral feeding (eg, per-\ncutaneous endoscopic gastrostomy) or tracheostomy. Structural causes\nmust be treated specifically (eg, cricopharyngectomy and diverticulectomy\nfor Zenker diverticula).\nEsophageal Dysphagia\nâ–  Generally, patients complain that food gets â€œstuckâ€ in the throat; however,\nthere is no issue initiating swallowing.\nâ–  Can be caused by an obstruction (eg, strictures, Schatzki rings, webs, carci-\nnoma) or motility disorder (eg, achalasia, scleroderma, esophageal spasm).\nâ–  Obstructions usually more of a problem with solids than with liquids;\nmotility disorders cause both solid and liquid food dysphagia.\nKEY FACT â–  Best initial test: EGD; consider pre-EGD barium swallow (aka esophagram)\nif history of esophageal radiation, caustic ingestion, esophageal or laryngeal\nEsophageal webs are associated with\ncancer surgery, or strictures, as these patients may be at higher risk for esoph-\niron-deficiency anemia and glossitis\nageal perforation; this may be followed by manometry in some cases.\n(Plummer-Vinson syndrome).\nINFECTIOUS ESOPHAGITIS\nInflammation of the esophageal lining. Seen in immunocompromised\npatients. Table 2.6-4 outlines the etiology, diagnosis, and treatment of infec-\ntious esophagitis.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220044 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 205\nTABLE 2.6-4. Causes of Infectious Esophagitis\nETIOLOGIC AGENT EXAM FINDINGS UPPER ENDOSCOPY TREATMENT\nCandida albicans Â± oral thrush Ye",
      "char_start": 590000,
      "char_end": 592000
    },
    {
      "chunk_id": 296,
      "text": "llow-white plaques adherent to the mucosa; Fluconazole PO (treat with\nbiopsy shows yeasts and hyphae invading more than a topical agent\nmucosal cells alone)\nHerpes simplex virus Oral ulcers Small, deep ulcerations with â€œvolcano-likeâ€ appear- Acyclovir IV or PO\nance; multinucleated giant cells with intranuclear\ninclusions on biopsy + Tzanck smear\nCytomegalovirus Retinitis, colitis Large, linear, superficial ulcerations; intranuclear and Ganciclovir IV\nintracytoplasmic inclusions on biopsy\nImage reproduced with permission from Kantarjian HM, et al. MD Anderson Manual of Medical Oncology. New York: McGraw-Hill; 2006.\nKEY FACT\nHistory\nCandida esophagitis is an AIDS-defining\nCommonly presents with odynophagia and/or dysphagia. illness, typically when CD4+ cell count\n<100 cells/ÂµL.\nPILL (MEDICATION-INDUCED) ESOPHAGITIS\nKEY FACT\nCaused by ingestion of medications that have a direct toxic effect on the High-risk factors for Candida\nmucosa of the esophagus through creation of a localized acidotic or alkaline esophagitis include broad-spectrum\nenvironment by the inciting medication. antibiotics, corticosteroids, treatment\nin an intensive care unit (ICU), cancer,\nRisk Factors\ndiabetes, organ transplant, mechanical\nâ–  Medication known to be associated with pill esophagitis (see related key fact) ventilation, and indwelling catheter.\nâ–  Taking medications without water or immediately before lying down\nâ–  Anything that might increase dwell time of medications in the esophagus (eg,\ngeriatric-related low saliva production, altered esophageal anatomy, drinking\ninsufficient water with medication, and motility disorders of the esophagus)\nHistory/PE\nâ–  Dysphagia/odynophagia\nâ–  Retrosternal burning\nâ–  Taking an offending medication\nDiagnosis\nâ–  Clinical diagnosis for patients with symptoms who took a medication FIGURE 2.6-4. An ulcer in the esophagus\nknown to cause pill esophagitis caused by nonsteroidal anti-inflamma-\nâ–  Upper endoscopic evaluation with biopsy for patients with severe symp- to",
      "char_start": 592000,
      "char_end": 594000
    },
    {
      "chunk_id": 297,
      "text": "ry drugs (NSAIDs). (Adapted with permis-\ntoms (hematemesis, abdominal pain, weight loss) or symptoms that donâ€™t sion from Hu S-W, Chen A-C, Wu S-F. Drug-induced\nesophageal ulcer in adolescent population: Experi-\nresolve after discontinuing the medication for at least 1 week\nence at a single medical center in central Taiwan.\nâ–  Endoscopic evaluation usually reveals a localized ulceration of the esoph- Medicina. 2021;57[12]:1286. https://doi.org/10.3390/\nagus with surrounding normal mucosa (see Fig. 2.6-4) medicina57121286.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220055 1100//2211//2222 1122::5588 PPMM\n\n206 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTreatment\nâ–  Discontinuing inciting medication (symptoms usually resolve in 7 to 10\ndays after discontinuation)\nâ–  If medication cannot be discontinued, switching to liquid formulation\nEOSINOPHILIC ESOPHAGITIS\nImmune-mediated disorder of the esophagus in which eosinophils are\nrecruited to the esophagus causing dysphagia or food impaction.\nHistory/PE\nâ–  Past medical history of seasonal allergies and asthma\nâ–  Presents with dysphagia, food impaction, centrally located chest pain not\nrelieved by proton pump prohibitors (PPIs)\nDiagnosis\nâ–  Diagnosis is based on clinical presentation and evaluation with EGD and\nesophageal biopsy\nâ–  EGD most commonly shows ringlike structures (44%) or thickened linear\nKEY FACT furrows (48%) (see Fig. 2.6-5)\nâ–  Biopsy is the most accurate test and will reveal esophageal inflammation\nCommon causes of pill esophagitis\nwith an eosinophilic-predominant infiltrate (â‰¥15 eosinophils per high-\ninclude antibiotics (especially\npowered field on light microscopy)\ntetracyclines), nonsteroidal\nanti-inflammatory drugs (NSAIDs),\nbisphosphonates, ascorbic acid, Treatment\npotassium chloride, ferrous sul- â–  Best initial treatment: PPIs and elimination of possible causes (ie, six-\nfate, acetaminophen, warfarin, and food elimination diet involving exclusion of wheat, milk, egg, nuts, s",
      "char_start": 594000,
      "char_end": 596000
    },
    {
      "chunk_id": 298,
      "text": "oy,\nchemotherapy regimens. and fish/shellfish).\nâ–  If initial treatment fails, swallowed inhalational steroids or swallowed topi-\ncal steroids are recommended for further management.\nâ–  Esophageal dilation may be required in refractory disease.\nA B\nFIGURE 2.6-5. Concentric rings. Mucosal irregularity (A: black arrow) and furrows (B: black arrowhead)\nseen in esophagus with eosinophilic esophagitis on fluoroscopic evaluation (A) and endoscopic evaluation\n(B). (Images modified with permission from Al-Hussaini A, AboZeid A, Hai A. How does esophagus look on barium esopha-\ngram in pediatric eosinophilic esophagitis? Abdom Radiol (NY). 2016;41[8]:1466-1473.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220066 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 207\nESOPHAGEAL RINGS\nConcentric â€œringâ€ of tissue protruding into the esophageal lumen. Most com-\nmonly seen in the distal esophagus. Often associated with another condition\n(eg, eosinophilic esophagitis and hiatal hernia). Schatzki rings are the most\ncommon type of esophageal ring. In Figure 2.6-5, rings are shown on fluoro-\nscopic evaluation (A) and endoscopic evaluation (B).\nHistory/PE\nPatients with esophageal rings are usually asymptomatic, but they may present\nwith dysphagia to solids. With more chewing, symptoms tend to be less\nsevere. Increased severity of symptoms is associated with internal diameter of\nesophageal lumen associated with ring.\nDiagnosis\nâ–  Barium swallow: Thin, symmetric, circumferential narrowing\nâ–  EGD and biopsy: Thin, smooth, circumferential membrane; biopsy used\nto evaluate for esophagitis\nFIGURE 2.6-6. Radiographic evaluation\nTreatment revealing an esophageal web. (Reproduced\nwith permission from Ohtaka M, Kobayashi S, Yoshida\nGoal of therapy is to relieve symptoms if present and prevent recurrent symptoms.\nT, et al. Use of Sato's curved laryngoscope and an\ninsulated-tip knife for endoscopic incisional therapy of\nâ–  Initial therapy: Es",
      "char_start": 596000,
      "char_end": 598000
    },
    {
      "chunk_id": 299,
      "text": "ophageal dilation followed by 6 weeks of PPI therapy\nesophageal web. Dig Endosc. 2015 May;27(4):522-526.\nâ–  Recurrent and refractory symptoms: Repetition of EGD to confirm doi: 10.1111/den.12334.)\nabsence of eosinophilic esophagitis (can be patchy) and repetition of\nesophageal dilation + addition of long-term PPI.\nKEY FACT\nSteakhouse syndrome refers to food\nPLUMMER-VINSON SYNDROME\nimpaction of the esophagus after\neating a piece of food without sufficient\nHistory/PE\nchewing. This most often involves a\nPlummer-Vinson syndrome presents with a classic triad of dysphagia, iron-defi- meat bolus. Steakhouse syndrome must\nciency anemia (fatigue and weakness), and esophageal webs. Additional find- be differentiated from other causes of\nings may include glossitis, angular cheilitis, koilonychia, splenomegaly, and dysphagia.\nthyromegaly. Figure 2.6-6 shows a radiographic view of an esophageal web.\nKEY FACT\nDiagnosis\nLaboratory testing reveals iron-deficiency anemia, and an esophageal web Esophageal webs are like esophageal\nappears on esophagram, videofluoroscopic evaluation, or upper endoscopy. rings, but they are noncircumferential\nand are associated with different\nTreatment conditions (eg, Plummer-Vinson\nsyndrome, which occurs in patients\nâ–  Iron repletion: Rapid resolution of dysphagia in some patients\nwith long-term iron-deficiency anemia).\nâ–  Esophageal dilation: May be necessary in those with significant esopha-\nEsophageal webs are often ruptured\ngeal lumen obstruction\nduring EGD and do not cause recurrent\nâ–  Annual upper endoscopy + biopsy: Recommended by some to watch for\nor refractory symptoms.\ndevelopment of SCC, although no change in outcomes has been observed\nin the literature with this screening\nMNEMONIC\nDISTAL ESOPHAGEAL SPASM Plumbers DIE from Plummer-Vinson\nsyndrome:\nMotility disorder in which normal peristalsis is periodically interrupted by Dysphagia\nhigh-amplitude, nonperistaltic contractions (see Fig. 2.6-7A). Iron-deficiency anemia\nEsophageal web\n22002222__002",
      "char_start": 598000,
      "char_end": 600000
    },
    {
      "chunk_id": 300,
      "text": "2..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220077 1100//2211//2222 1122::5588 PPMM\n\n208 HIGH-YIELD FACTS IN GASTROINTESTINAL\nA B\nFIGURE 2.6-7. Esophageal disease on bar-\nium esophagram. (A) Esophageal spasm.\n(B) Achalasia. Note the dilated esophagus\ntapering to a â€œbirdâ€™s beakâ€ narrowing (arrows)\nat the LES. (Image A reproduced with permission from\nUSMLE-Rx.com. Image B reproduced with permission from\nDoherty GM. Current Diagnosis & Treatment: Surgery. 13th ed.\nNew York, NY: McGraw-Hill; 2010.\nKEY FACT\nHistory/PE\nThe musculature of the upper one-third Presents with heartburn, chest pain, dysphagia, and odynophagia. Often pre-\nof the esophagus is skeletal, whereas cipitated by ingestion of hot or cold liquids; relieved by nitroglycerin.\nthat of the lower two-thirds is smooth\nmuscle. Diagnosis\nâ–  EGD with biopsy: Best initial test to rule out other esophageal disorders.\nâ–  Barium swallow: Shows a corkscrew-shaped esophagus. Done as initial\ntest prior to EGD in selected patients at risk of perforation (proximal\nesophageal lesion [eg, Zenker diverticulum, radiation therapy], known\ncomplex strictures [due to radiation exposure or caustic injury]).\nâ–  Most accurate test: Esophageal manometry, which allows for definitive\ndiagnosis. High-amplitude, simultaneous contractions shown in greater\nthan 20% of swallows.\nTreatment\nâ–  Symptomatic relief: Calcium channel blockers, tricyclic antidepressants\n(TCAs), or nitrates\nWet swallow â–  Severe, incapacitating symptoms: Growing evidence supporting peroral\n100\nendoscopic myotomy (POEM)\nLES pressure\n(mm Hg)\n0\nACHALASIA\n100\nProximal\nesophageal Motility disorder of the esophagus characterized by impaired relaxation of the\npressure\n(mm Hg) lower esophageal sphincter (LES) and loss of peristalsis in the distal two-thirds\n0\nof the esophagus.\n100\nEtiology\n0 Degeneration of the inhibitory neurons in the myenteric (Auerbach) plexus.\n100\nHistory/PE\nProgressive dysphagia (solids and liquids), chest pain, regurgitation of",
      "char_start": 600000,
      "char_end": 602000
    },
    {
      "chunk_id": 301,
      "text": " undi-\n0 gested food, weight loss, and nocturnal cough.\n100\nDistal\nesophageal Diagnosis\npressure\n(mm Hg) â–  Best initial test: EGD to rule out structural disorders, including mechani-\n0\ncal obstruction, pseudoachalasia, cancer.\n15 sec\nâ–  Most accurate test: High-resolution manometry, which shows increase in\nFIGURE 2.6-8. Achalasia. Manometry\nresting LES pressure, incomplete LES relaxation upon swallowing, and\nwith incomplete LES relaxation. (Repro-\ndecrease in peristalsis in the body of the esophagus (see Fig. 2.6-8).\nduced with permission from Farrokhi F, Vaezi MF.\nIdiopathic (primary) achalasia. Orphanet J Rare Dis. â–  Barium swallow is useful when manometric findings are equivocal. Will\n2007;2:38.) show esophageal dilation with â€œbirdâ€™s beakâ€ tapering of the distal esopha-\ngus (see Fig. 2.6-7B).\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220088 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 209\nTreatment A\nâ–  Definitive: First-line treatment options are laparoscopic Heller myotomy,\nPOEM, and less often, pneumatic dilation. Thyropharyngeus\nmuscle\nâ–  If first-line options are unsuitable, the physician may administer injection\nKillian triangle\nof botulinum toxin.\nCricopharyngeus\nâ–  Calcium channel blockers and phosphodiesterase inhibitors or nitrates may muscle\nprovide short-term relief. They are only used in patients who are not candi- Zenker\ndiverticulum\ndates for definitive therapy and have failed botulinum toxin injection.\nTrachea\nESOPHAGEAL DIVERTICULA\nB\nDiverticula can be present in any location in the esophagus or pharynx. Usu-\nally due to distal stricture/stenosis leading to increased pressure in the proxi-\nmal esophagus. Zenker diverticulum is a cervical outpouching through the\ncricopharyngeus muscle. It is a posterior, false diverticulum (outpouching\nonly through submucosa and mucosa). See Figure 2.6-9.\nâ–  Hx/PE: Chest pain, dysphagia, halitosis, and regurgitation of undigested\nfood.\nâ–  Dx: Barium sw",
      "char_start": 602000,
      "char_end": 604000
    },
    {
      "chunk_id": 302,
      "text": "allow to demonstrate outpouchings.\nâ–  Tx: If symptomatic, surgical excision of the diverticulum. For Zenker\ndiverticulum, myotomy of the cricopharyngeus required to relieve the\nhigh-pressure zone.\nGASTROESOPHAGEAL REFLUX DISEASE\nGastroesophageal reflux disease (GERD) is symptomatic reflux of gastric con- FIGURE 2.6-9. Illustration of a Zenker\ndiverticulum (A) and fluoroscopic eval-\ntents into the esophagus, most commonly from transient LES relaxation.\nuation revealing a Zenker diverticulum\nIncompetent LES, gastroparesis, or hiatal hernia can all contribute to GERD, (B). (Image A reproduced with permission from\nbut they are not the sole causes. Figure 2.6-10 depicts the general manage- USMLE-Rx.com. Image B reproduced with permis-\nment approach to GERD-like symptoms. sion from Dionigi G, Sessa F, Rovera F, et al. Ten year\nsurvival after excision of squamous cell cancer in\nZenker's diverticulum: report of a case. World J Surg\nOncol. 2006;4:17. doi:10.1186/1477-7819-4-17.)\nGERD-like symptoms\nAlarm symptoms for malignancy:\nweight loss, dysphagia, melena,\nhematemesis and/or anemia\nYes No\nPerform endoscopy\nTrial proton pump\ninhibitor for 8 weeks\nAssess for clinical response\nYes No\nContinue proton pump Increase proton pump inhibitor\ninhibitor to twice daily or change to\na different proton pump inhibitor\nClinical response\nYes No\nFIGURE 2.6-10. Management of GERD-like\nContinue current proton Perform endoscopy or\npump inhibitor pH manometry symptoms. (Reproduced with permission from USMLE-\nRx.com.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 220099 1100//2211//2222 1122::5588 PPMM\n\n210 HIGH-YIELD FACTS IN GASTROINTESTINAL\nHistory/PE\nâ–  Heartburn and/or regurgitation that commonly occurs 30 to 90 minutes\nafter a meal; worsens with reclining; and often improves with antacids, sit-\nting, or standing. Uncommon symptoms: sour taste, a globus sensation,\nunexplained cough, morning hoarseness, and chest pain mimicking coro-\nnary artery disease.\n",
      "char_start": 604000,
      "char_end": 606000
    },
    {
      "chunk_id": 303,
      "text": "â–  Normal unless a systemic disease (eg, scleroderma) is present.\nDiagnosis\nâ–  Primarily a clinical diagnosis, with empirical treatment first in patients\nwithout alarm symptoms (see later for lifestyle modification and medical\nFIGURE 2.6-11. Barrett esophagus on\nupper endoscopy. Shown is proximal treatment).\nextension of Z-line (squamocolumnar â–  Most accurate test: 24-hour pH monitoring with impedance; indicated if\njunction between esophagus and stom- the diagnosis is uncertain.\nach) caused by columnar metaplasia.\nâ–  EGD with biopsy: Performed in patients whose symptoms are the\nThe squamocolumnar junction must\nfollowing:\nextend at least 1 cm above the gastro-\nesophageal junction to diagnose Barrett's â–  Refractory to initial empiric therapy\nesophagus. (Reproduced with permission from â–  Long-standing (to rule out Barrett esophagus and adenocarcinoma; see\nFauci AS et al. Harrisonâ€™s Principles of Internal Medicine, Fig. 2.6-11)\n17th ed. New York, NY: McGraw-Hill; 2008.)\nâ–  Associated with alarm symptoms like hematemesis, weight loss, dysphagia/\nodynophagia, or chest pain. ECG (or cardiac referral) should be done first.\nKEY FACT â–  Other studies: Indicated for refractory symptoms or if concern for other\ncauses. May include esophageal manometry. Although barium swallow\nGERD can mimic angina or myocardial may demonstrate reflux, its role is limited due to a high prevalence of\ninfarction. physiologic reflux.\nTreatment\nâ–  Lifestyle modifications: Indicated for all patients, these modifications include\nweight loss; head-of-bed elevation; small meals; avoidance of nocturnal meals;\nKEY FACT avoidance of substances like alcohol, chocolate, or coffee that â†“ LES tone.\nâ–  An initial, empirical trial of pharmacotherapy (eg, 8 weeks of PPI) is indi-\nGERD is not a result of the presence of cated in patients with clinical features of GERD in the absence of alarm\nHelicobacter pylori. GERD arises from a symptoms.\ntransient relaxation of the LES. â–  In the presence of alarm symptoms (weight loss,",
      "char_start": 606000,
      "char_end": 608000
    },
    {
      "chunk_id": 304,
      "text": " dysphagia, and gastrointesti-\nnal [GI] bleeding) and in patients with multiple risk factors for Barrett\nesophagus, endoscopy should be performed initially (ie, before trial of PPI).\nâ–  Pharmacologic treatment:\nâ–  Mild/intermittent: Antacids\nâ–  Chronic/frequent: H -receptor antagonists (cimetidine, famotidine) or\n2\nPPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole, esomepra-\nzole, dexlansoprazole). Fundoplication surgery or other antireflux pro-\ncedures may benefit carefully selected patients.\nâ–  Severe/erosive: PPIs first; fundoplication surgery or other antireflux\nprocedures may benefit carefully selected patients.\nâ–  Complications: Erosive esophagitis, esophageal peptic stricture, aspiration\npneumonia, upper GI bleeding, Barrett esophagus, adenocarcinoma.\nâ–  Management of Barrett esophagus: Optimization of medical therapy\n(should be on chronic PPI therapy). Based on biopsy findings, manage-\nment calls for the following steps:\nâ–  No dysplasia: Repeat endoscopy every 3 to 5 years\nâ–  Indefinite dysplasia: Repeat endoscopy in 2 to 6 months\nâ–  Dysplasia or intramucosal carcinoma: Treat with endoscopic eradication\nâ–  Esophageal adenocarcinoma: See Esophageal Cancer section of this\nchapter for treatment.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221100 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 211\nHIATAL HERNIA A\nHerniated\ngastric cardia\nHerniation of stomach upward into the chest through the diaphragm. Com-\nmon types:\nâ–  Sliding hiatal hernia (95%): Gastroesophageal junction and a portion of\nthe proximal stomach are displaced above the diaphragm (see Fig. 2.6-12).\nâ–  Paraesophageal hiatal hernia (5%): Gastroesophageal junction remains\nbelow the diaphragm while the fundus herniates into the thorax (see Fig.\n2.6-12). B\nâ–  Hx/PE: Most are asymptomatic. Patients with sliding hernias may present\nwith GERD; paraesophageal hernias can cause strangulation. Herniated\ngastric fundus\nâ–  Dx: Incidental finding is ap",
      "char_start": 608000,
      "char_end": 610000
    },
    {
      "chunk_id": 305,
      "text": "parent on CXR; it is also frequently diagnosed\nby barium swallow or EGD.\nâ–  Tx:\nâ–  Sliding hernias: Medical therapy and lifestyle modifications to â†“\nGERD symptoms\nâ–  Paraesophageal hernias: Surgical gastropexy to prevent gastric volvu-\nlus in some cases\nFIGURE 2.6-12. (A) Sliding hiatal and (B)\nparaesophageal hiatal hernia. (Reproduced\nwith permission from USMLE-Rx.com.)\nESOPHAGEAL CANCER\nSCC is the most common type of esophageal cancer worldwide. Adenocarci-\nnoma is the most common type of esophageal cancer in the United States,\nEurope, and Australia.\nKEY FACT\nRisk Factors SCC of the esophagus tends to occur\nâ–  SCC: Alcohol use, tobacco use, and nitrosamines in the upper and middle thirds of the\nâ–  Adenocarcinoma: Barrett esophagus (intestinal metaplasia of the distal esophagus, whereas adenocarcinoma\nesophagus secondary to chronic GERD) occurs in the lower third.\nHistory/PE\nProgressive dysphagiaâ€”initially to solids and later to liquidsâ€”is common.\nWeight loss, odynophagia, GERD, GI bleeding, and vomiting are also seen.\nKEY FACT\nDiagnosis\nNo radiologic test can diagnose\nâ–  Best initial and most accurate test: EGD + biopsy; required to establish esophageal cancer. Diagnosis must be\ndiagnosis made with a tissue biopsy.\nâ–  CT and endoscopic ultrasound (EUS) for tumor staging\nKEY FACT\nTreatment\nEsophageal cancer metastasizes early,\nâ–  Best initial treatment: Chemoradiation and surgical resection. If there is\nbecause the esophagus lacks a serosa.\nmetastatic disease that is considered incurable, systemic therapy alone is\nused.\nâ–  Resection is also indicated in cases of high-grade Barrett dysplasia\nâ–  Has a poor prognosis\nKEY FACT\nResection is required for esophageal\ncancer treatment to be curative.\nGASTROINTESTINAL BLEEDING\nKEY FACT\nOvert GI bleeding presents as hematemesis, hematochezia, and/or melena.\nBleeding may be from the upper GI tract (ie, bleeding from lesions proximal\nOne unit of packed RBCs should â†‘\nto the ligament of Treitz, the anatomic boundary between the duodenum an",
      "char_start": 610000,
      "char_end": 612000
    },
    {
      "chunk_id": 306,
      "text": "d\nhemoglobin by 1 g/dL and hematocrit\njejunum) or from the lower GI tract. Table 2.6-5 presents the features of\nby 3 to 4 units.\nupper and lower GI bleeding, and this chapter discusses selected conditions.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221111 1100//2211//2222 1122::5588 PPMM\n\n212 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-5. Features of Upper and Lower GI Bleeding\nVARIABLE UPPER GI BLEEDING LOWER GI BLEEDING\nHistory/exam Hematemesis (â€œcoffee-groundâ€ emesis), melena > Hematochezia > melena, but can be either\nhematochezia, hypovolemia (eg, elevated blood\nurea nitrogen [BUN], tachycardia, lightheadedness,\nhypotension)\nDiagnosis Nasogastric (NG) tube and lavage (may be âŠ in 15% of Rule out upper GI hemorrhage with NG lavage if brisk\nupper GI bleeds); endoscopy is definitive Anoscopy/sigmoidoscopy for patients <45 years of\nage with small-volume bleeding\nColonoscopy if stable; arteriography or exploratory\nlaparotomy if unstable\nEtiologies Peptic ulcer disease ([PUD] most common), esophagitis/ Diverticulosis (60%), angiodysplasia, IBD, hem-\ngastritis, Mallory-Weiss tear, esophageal/gastric varices, orrhoids/fissures, neoplasm, arteriovenous\ngastric antral vascular ectasia, malignancy, Dieulafoy malformation\nlesions\nInitial management Protect the airway (intubation may be needed). Stabilize the patient with IV fluids and packed RBCs\nPlace two large-bore IVs; immediately administer fluids (hematocrit may be normal early in acute blood\nand transfusions if hemoglobin <8 g/dL (packed RBCs loss)\n[hematocrit may be normal early in acute blood loss],\nplatelets, or fresh frozen plasma as indicated)\nLong-term management Endoscopy followed by therapy directed at the under- Depends on the underlying etiology. Endoscopic\nlying cause therapy (eg, epinephrine injection, cauterization,\nor clip placement), intra-arterial vasopressin infu-\nsion or embolization, or surgery for diverticular\ndisease or angiodysplasia\nUPPER GI BLEEDING\n",
      "char_start": 612000,
      "char_end": 614000
    },
    {
      "chunk_id": 307,
      "text": "Esophageal and Gastric Varices\nEtiology\nâ–  Esophageal and gastric varices stem from increases in portal pressure,\nwhich result in collateral flow of blood from the portal circulation into the\nsystemic circulation via portosystemic shunts that increase esophageal\nvenous blood flow. This may result in dilated esophageal veins (ie, esopha-\ngeal varices) that are prone to bleeding.\nâ–  The most common reason for increased portal pressure is hepatic cirrhosis\nFIGURE 2.6-13. Esophageal varices seen (due to alcohol abuse or viral hepatitis). Other causal conditions include\non upper endoscopy. (Adapted with permis- right heart failure and hepatic vein obstruction (Budd-Chiari syndrome).\nsion from Akiyama T, Abe Y, Iida H, et al. Endoscopic See Figure 2.6-13 for endoscopic images of esophageal varices.\ntherapy using an endoscopic variceal ligation for\nminute cancer of the esophagogastric junction com-\nplicated with esophageal varices: A case report. J Med History/PE\nCase Rep. 2010;4:149.)\nâ–  Painless GI bleeding manifesting as hematemesis or melena (less com-\nmonly hematochezia)\nâ–  Possible signs and symptoms of cirrhosis such as jaundice, pruritis, hepatic\nencephalopathy (altered mental status), asterixis, palmar erythema, caput\nmedusa, and spider angiomas\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221122 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 213\nDiagnosis and Treatment\nâ–  Initial treatment for upper GI bleeding includes hemodynamic stabilization\nand transfusion (packed RBCs, fresh frozen plasma, or platelets as indicated).\nAdditionally, acid suppression (IV PPI reduces rebleeding rate and need for\nblood transfusion for ulcers) and prokinetic agents (erythromycin or metoclo-\npramide improve visualization when endoscopy is performed) are given.\nâ–  Treatment specific for suspected variceal bleeding includes antibiotic prophy-\nlaxis for spontaneous bacterial peritonitis (eg, ceftriaxone) and vasoactive\nagents ",
      "char_start": 614000,
      "char_end": 616000
    },
    {
      "chunk_id": 308,
      "text": "(octreotide).\nâ–  Control of bleeding may be achieved with upper GI endoscopy (endo- KEY FACT\nscopic variceal ligation or sclerotherapy), which should be performed\nwithin 12 hours. This also confirms the diagnosis. Although upper GI endoscopy may\nâ–  A transjugular intrahepatic portosystemic shunt (TIPS) may be required if confirm the diagnosis in acute upper\nendoscopic treatment fails or there is a high risk of rebleeding. Rarely, GI bleeding, the best initial step is to\ntemporary treatments may be used in the interim until TIPS can be done stabilize the patient hemodynamically\n(esophageal stent or balloon tamponade). Later sections of this chapter with fluids and transfusion, and ensure\ngive more information on TIPS. the airway is protected.\nOther Causes of Upper GI Bleeding\nMallory-Weiss tear: Forced retching causes longitudinal intramural lacera-\ntions of the esophagus resulting in bleeding from the submucosa. Common\ncauses: bulimia, alcohol use disorder, coughing, and hiccups.\nâ–  Dx/Tx: Diagnosis and treatment to stop bleeding are established on upper\nGI endoscopy. Many spontaneously resolve, and low-risk patients may be\ntreated as outpatients. They may require fluid resuscitation, antiemetics,\nand endoscopic hemostasis, depending on presentation.\nBoerhaave syndrome: Rupture of the esophagus causes vomiting or straining\n(increased intraesophageal pressure and decreased intrathoracic pressure).\nâ–  Hx/PE: Patients have retrosternal chest pain and crepitus. Sometimes\nthere may be neck or back pain, upper abdominal pain, hoarseness of\nvoice, dysphagia, or odynophagia. Patients deteriorate in hours and\ndevelop dyspnea, sepsis, and shock.\nâ–  Dx: Contrast esophagogram or CT scan confirm the diagnosis. CXR may\nshow mediastinal, subdiaphragmatic, or free peritoneal air; subcutaneous\nemphysema; pleural effusions; mediastinal widening; and other changes.\nHowever, it has low sensitivity.\nâ–  Tx:\nâ–  Nothing by mouth (NPO), IV fluids, nutritional support, broad-\nspectrum antibiotics, ",
      "char_start": 616000,
      "char_end": 618000
    },
    {
      "chunk_id": 309,
      "text": "PPI.\nâ–  Free or large perforations in high-risk patients are handled with surgery\nor esophageal stenting (if surgery contraindicated). Contained or small\nperforations may not require surgery.\nDieulafoy lesion: An anatomic variant of a submucosal arteriole in the stom-\nach wall. See Figure 2.6-14 for an endoscopic view of Dieulafoy lesion.\nâ–  Hx/PE: Patients will present with painless bleeding from an unidentifiable\nsource, and the condition can be either brisk or self-limited (yet prone to\nrecur). NSAID use is typical and may incite bleeding.\nâ–  Dx: EGD with visualization of bleeding or angiogram. FIGURE 2.6-14. Endoscopic image of\nâ–  Tx: Electrocoagulation during endoscopy is common, although many Dieulafoy lesion of the colon. (Adapted\nother options can effectively treat this condition (eg, clips or epinephrine with permission from Ma C, Hundal R, Cheng EJ.\ninjection). Colonic Dieulafoyâ€™s lesion: A rare cause of lower\ngastrointestinal hemorrhage and review of endo-\nscopic management. Case Rep Gastrointest Med.\n2014;2014:436293.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221133 1100//2211//2222 1122::5588 PPMM\n\n214 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDISORDERS OF THE STOMACH AND DUODENUM\nDYSPEPSIA\nCommonly experienced; range of symptoms typically characterized by upper\nabdominal discomfort and/or pain after eating.\nHistory/PE\nAfter eating or drinking, patients may experience early satiety, bloating, and/\nor epigastric pain or discomfort. Patient history suggests possible etiologies,\nalthough few patients will have an identifiable, underlying cause. However,\nhistory is important to consider when thinking of next best test.\nâ–  Malignancy: History of smoking and obstructive or constitutional symp-\ntoms (eg, weight loss, night sweats, chills)\nâ–  Peptic ulcer disease (PUD): Pain and discomfort localized to epigastric\narea\nâ–  Drug induced: Symptoms coinciding with initiation of new drug (eg,\nNSAIDs, bisphosphonates, antibiotics)\nâ–  Bil",
      "char_start": 618000,
      "char_end": 620000
    },
    {
      "chunk_id": 310,
      "text": "iary: Episodic pain localized to the right upper quadrant\nDiagnosis\nPer Rome IV criteria, the diagnosis of functional dyspepsia is made when\nthere is no evidence of structural disease and one or more of the following:\nâ–  Bothersome postprandial fullness or early satiety\nâ–  Bothersome epigastric pain or burning\nWhen ruling out secondary dyspepsia:\nâ–  If >60 years of age, all patients should undergo endoscopy\nKEY FACT\nâ–  If <60 years of age, only patients with â€œred flagâ€ symptoms should have\nRed flag symptoms of dyspepsia: endoscopy\nprogressive dysphagia, iron-deficiency\nanemia, odynophagia, palpable mass or Other etiologies should be pursued, based on patient-specific history. In\nlymphadenopathy, persistent vomiting, absence of symptoms specific to a discussed etiology, consider Helicobacter\nor a family history of GI malignancy. pylori testing.\nTreatment\nSecondary causes should be treated with their respective therapies. However,\nif an identifiable cause is not found and the patient is negative for H pylori,\npatients may start PPI.\nGASTRITIS\nInflammation of the gastric mucosa. See Figure 2.6-15 for general diagnostic\napproach to gastritis. Subtypes:\nâ–  Acute gastritis: Rapidly developing, superficial, or deep erosive lesions,\noften caused by NSAIDs, alcohol, H pylori infection, and stress from\nsevere illness (eg, burns, CNS injury). Toxic ingestion can also cause\nacute gastritis, along with possible gastric outlet stricture.\nâ–  Chronic gastritis:\nâ–  Type A (10%): Occurs in the fundus and is caused by autoantibodies\nto parietal cells. Causes pernicious anemia and is associated with other\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221144 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 215\nGastritis\nAcute gastritis Chronic gastritis\nType A (10%) Type B (90%)\nCan occur anywhere in the KEY FACT\nstomach due to NSAIDs,\nalcohol, H pylori, and/or Occurs in the fundus due Occurs in the antrum due Stress ulcers include C",
      "char_start": 620000,
      "char_end": 622000
    },
    {
      "chunk_id": 311,
      "text": "urling ulcers,\ntoxic ingestion to parietal cell antibodies to NSAIDs or H pylori\nwhich are associated with burn\ninjuries, and Cushing ulcers, which are\nassociated with traumatic brain injury.\nKEY FACT\nFIGURE 2.6-15. General diagnostic approach to gastritis. (Reproduced with permission from USMLE-Rx. Type A gastritis is associated with\ncom.) pernicious anemia caused by lack\nof intrinsic factor necessary for the\nautoimmune disorders and â†‘ risk for gastric adenocarcinoma and car- absorption of vitamin B .\n12\ncinoid tumors.\nâ–  Type B (90%): Occurs in the antrum and may be caused by NSAIDs\nor H pylori infection. Often asymptomatic but associated with â†‘ risk for\nKEY FACT\nPUD and gastric cancer. Note: H pylori infection can, but does not\nalways, cause gastritis. H pylori antibodies stay âŠ• even when\nthe infection is cleared. The urea breath\nHistory/PE test or a repeat stool antigen can serve\nas a test of cure.\nAsymptomatic or symptomatic with epigastric pain, nausea, vomiting,\nhematemesis, or melena.\nDiagnosis KEY FACT\nUpper endoscopy is required to diagnose gastritis. Different tests for H pylori Peptic ulcer disease and gastritis should\nare shown in Table 2.6-6. be considered in older adult patients\nwho are taking medications for arthritis\nTreatment or heart disease (eg, NSAIDs) and who\nâ–  Patient should stop intake of exacerbating agents such as NSAIDs or alcohol. present with abdominal pain or GI\nâ–  Antacids, sucralfate, H receptor blockers, and/or PPIs may help. bleeding.\n2\nTABLE 2.6-6. Tests for H pylori\nTEST DESCRIPTION TEST CHARACTERISTICS\nUrea breath test H pylori urease converts radio-labeled urea (C14 or C13) to High specificity, lower sensitivity\nCO and ammonia; this test detects CO formed from urea PPIs may cause false âŠ results\n2 2\nmetabolism\nStool antigen test Stool antigen test detects H pylori antigens in stool High specificity, high sensitivity\nCost-effective initial test for H pylori\nMust be off PPI Ã—2 weeks prior to testing\nEndoscopic biopsy Endoscopic biop",
      "char_start": 622000,
      "char_end": 624000
    },
    {
      "chunk_id": 312,
      "text": "sy detects H pylori on histology or culture; it Gold standard for diagnosis of gastritis and H pylori\ncan also detect intestinal metaplasia, mucosa-associated Most invasive test\nlymphoid tissue (MALT), or widespread gastritis Must be off PPI Ã—2 weeks prior to endoscopy\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221155 1100//2211//2222 1122::5588 PPMM\n\n216 HIGH-YIELD FACTS IN GASTROINTESTINAL\nKEY FACT â–  Bismuth quadruple therapy (PPI, bismuth subcitrate, tetracycline, and\nmetronidazole) can treat H pylori infection. Other quadruple regimens\nA gastric adenocarcinoma that\ninclude PPI, clarithromycin, amoxicillin, and metronidazole.\nmetastasizes to the ovary is called a\nKrukenberg tumor. â–  Patients at risk for stress ulcers (eg, intensive care unit [ICU] patients)\nshould receive prophylactic PPIs.\nKEY FACT\nGASTRIC CANCER\nMucosa-associated lymphoid tissue\n(MALT) lymphoma is a rare gastric Malignant tumor (mostly adenocarcinoma) with a poor prognosis that is par-\ntumor that presents in patients with ticularly common in Korea and Japan. See Fig. 2.6-16 for pathologic speci-\nchronic H pylori infection. It is the only mens of gastric cancer.\nmalignancy that can be cured with\nantibiotics. The physician should treat it â–  Risk factors: Diet high in nitrites and salt and low in fresh vegetables (anti-\noxidants), H pylori colonization, and chronic gastritis.\nwith triple therapy.\nâ–  Hx/PE: Early-stage disease usually asymptomatic, but may be associated\nwith indigestion and loss of appetite.\nKEY FACT â–  Late-stage disease indicated by alarm symptoms: abdominal pain,\nweight loss, and upper GI bleeding.\nGastric cancer may present with\na Virchow node (an enlarged left â–  Dx: Upper endoscopy with biopsy (most accurate test) to rule out other\nsupraclavicular lymph node) or a Sister etiologies and confirm the diagnosis.\nMary Joseph node (a palpable lymph â–  Tx: If detected early, surgical resection often with perioperative chemo-\nnode near the umbili",
      "char_start": 624000,
      "char_end": 626000
    },
    {
      "chunk_id": 313,
      "text": "cus). therapy. Most patients present with late-stage, incurable disease. Systemic\ntherapies are used for metastatic or incurable disease. Five-year survival\nrate is <10% for advanced disease.\nPEPTIC ULCER DISEASE\nâ–  Results from damage to the gastric or duodenal mucosa caused by\nimpaired mucosal defense and/or â†‘ acidic gastric contents.\nâ–  Risk factors: H pylori (>90% of duodenal ulcers and 70% of gastric\nulcers), NSAIDs, alcohol and tobacco use; concomitant use of corticoste-\nroids and NSAIDs; male sex\nFIGURE 2.6-16. Gastric ulcer subse-\nquently diagnosed as adenocarcinoma.\nHistory/PE\n(Adapted with permission from Kinoshita H, Yamagu-\nchi S, Sakata Y, et al. A rare case of xanthogranuloma â–  Presentation: Chronic or periodic dull, burning epigastric pain that is\nof the stomach masquerading as an advanced stage often related to meals and can radiate to the back; nausea; hematemesis\ntumor. World J Surg Oncol. 2011;9:67.)\n(â€œcoffee-groundâ€ emesis); or melena (blood in the stool)\nâ–  PE: Usually normal but may reveal epigastric tenderness and stool guaiac\nâ–  Risks: Acute perforation (rigid abdomen, rebound tenderness, and/or\nguarding)\nDiagnosis\nâ–  Most accurate test: Upper endoscopy with biopsy is the most accurate\ntest. It can also be used to test for H pylori infection and to rule out active\nbleeding or gastric adenocarcinoma (10% of gastric ulcers without\nperforation).\nâ–  H pylori testing. See Table 2.6-6.\nâ–  If perforation is suspected, perform upright CXR (see Fig. 2.6-17) to evalu-\nate air under the diaphragm or CT scan of the abdomen.\nâ–  In recurrent or refractory cases, serum gastrin levels can screen for\nFIGURE 2.6-17. Pneumoperito-\nZollinger-Ellison syndrome.\nneum. Upright chest x-ray (CXR) reveals\nfree air under the diaphragm. (Reproduced\nwith permission from USMLE-Rx.com.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221166 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 217\nTreatment\nAcute management:\nâ–  I",
      "char_start": 626000,
      "char_end": 628000
    },
    {
      "chunk_id": 314,
      "text": "f perforation is suspected: An upright x-ray of the abdomen (initial test)\nto rule out free air under the diaphragm. CT (definitive test) if x-ray of the\nabdomen shows no perforation but there is high clinical suspicion. Sur-\ngery if perforation is confirmed on CT.\nâ–  Ruling out active bleeding: Serial hemoglobin/hematocrits (initially),\nrectal vault exam, nasogastric (NG) suction. Monitoring blood pressure\n(BP) and treating with IV hydration, blood transfusion, and IV PPIs. An\nurgent EGD (definitive) to control suspected bleeding. If bleeding not\ncontrolled with EGD, may need surgery or coiling embolization to gastro-\nduodenal artery.\nLong-term management:\nâ–  Medical therapy goals: Protecting the mucosa, â†“ acid production, and\neradicating H pylori infection\nâ–  Mild disease: Treatment with antacids, PPIs, or H -blockers\n2\nâ–  H pylori infection: Triple therapy (omeprazole, clarithromycin, and\namoxicillin)\nKEY FACT\nâ–  Discontinuation of exacerbating agents (alcohol, tobacco)\nAnterior duodenal ulcers have a\nâ–  Endoscopy with targeted biopsy: Indicated in patients with symptoms\ntendency to perforate, whereas\nrefractory to medical therapy to rule out gastric cancer\nposterior duodenal ulcers have a\nâ–  Surgical therapy (eg, parietal cell vagotomy): Severe cases refractory to\ntendency to cause bleeding from\nmedical therapy\nerosion through the gastroduodenal\nartery.\nComplications\nHemorrhage (most likely from posterior ulcers that erode into the gastroduo-\nKEY FACT\ndenal artery), gastric outlet obstruction (presenting with succussion splash),\nperforation, and intractable pain. Uncomplicated, NSAID-induced\nulcers are treated with PPIs. However,\nproviders must routinely reassess for\nZOLLINGER-ELLISON SYNDROME\nthe need for NSAIDs and may consider\nswitching to a COX-2 selective NSAID.\nRare condition characterized by gastrin-secreting neuroendocrine tumors in\nthe duodenum and/or pancreas, leading to high serum gastrin and large,\nrecurrent or intractable ulcers in the duodenum or jejunum.",
      "char_start": 628000,
      "char_end": 630000
    },
    {
      "chunk_id": 315,
      "text": "\nâ–  Hx/PE: Recurrent, gnawing, burning abdominal pain; diarrhea; nausea;\nvomiting; fatigue; weakness; weight loss; and GI bleeding.\nâ–  Dx: Diagnosis of Zollinger-Ellison syndrome dependent on (1) fasting\nserum gastrin levels >1000 pg/mL and (2) increase in gastrin levels with\nthe administration of secretin; in addition, pH <2.\nâ–  CT indicated to characterize and stage disease\nâ–  Nuclear octreotide scan to facilitate localization of gastrinomas\nâ–  Tx: Moderate- to high-dose PPIs to control symptoms. Surgical resection KEY FACT\nof the gastrinoma if not metastatic. Somatostatin analogs have also been\nshown to be effective for symptom control. Zollinger-Ellison syndrome:\nâ–  Hypercalcemia from\nhyperparathyroidism\nGASTROPARESIS\nâ–  Epigastric pain (peptic ulcer)\nâ–  Diarrhea (caused by mucosal\nCommon cause of early satiety associated with delayed gastric emptying. Pri-\ndamage and pancreatic enzyme\nmarily caused by diabetes; other causes: idiopathy, viral infection, medication\ninactivation)\ninduction, and postsurgery status.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221177 1100//2211//2222 1122::5588 PPMM\n\n218 HIGH-YIELD FACTS IN GASTROINTESTINAL\nHistory/PE\nPatients typically have a long-term history of diabetes. Those who are insulin\ndependent experience nausea, vomiting, early satiety, and postprandial hypo-\nglycemia due to delayed glucose absorption.\nDiagnosis\nâ–  MRI or CT may help exclude other etiologies.\nâ–  Delayed gastric emptying on nuclear scan is diagnostic.\nâ–  Fluoroscopic upper GI evaluation can help rule out obstruction.\nâ–  An updated hemoglobin A1c (HbA1c) can assess glycemic control.\nTreatment\nFirst-line treatments are hydration and diet modifications. Glycemic control is\nkey. Pharmacologic treatments include prokinetics such as metoclopramide and\nmacrolides. Antiemetics relieve nausea. Patients should avoid pramlintide and\nglucagon-like peptide-1 (GLP1) agonists, which may worsen gastric emptying.\nMÃ‰NÃ‰TRIER DISEASE\nCharacterized",
      "char_start": 630000,
      "char_end": 632000
    },
    {
      "chunk_id": 316,
      "text": " by large gastric folds due to hyperplasia of gastric mucosa and\nreduced gastric acid secretion.\nHistory/PE\nTypically seen in adult males and presents with progressive weight loss, vomit-\ning, epigastric pain, and peripheral edema.\nDiagnosis\nLarge gastric folds revealed on endoscopy, but diagnosis made via gastric\nbiopsy. Laboratory evaluation may reveal hypobilirubinemia and anemia.\nTreatment\nNo definitive treatment available. Management is typically supportive and\nentails diet modification (ie, high protein) and use of PPIs if associated bleeding\nis present. Patients require yearly endoscopy to screen for associated carcinoma.\nGASTRIC BEZOAR\nâ–  Gastric bezoars are foreign bodies made up of ingested material most com-\nmonly found in the stomach.\nâ–  Their composition may include vegetable matter (phytobezoars), hair\n(trichobezoars, seen in patients with trichotillomania), and/or medications.\nHistory/PE\nâ–  Patients may be asymptomatic initially, but they may insidiously develop\nsymptoms such as abdominal pain, nausea, vomiting, early satiety,\nanorexia, and weight loss.\nâ–  Rare complications include gastric/small bowel obstruction (SBO), intus-\nsusception or perforation, peritonitis, protein-losing enteropathy, steator-\nrhea, obstructive jaundice, pancreatitis, appendicitis, constipation, and\npneumatosis intestinalis.\nâ–  Physical examination may show abdominal mass (occasionally) or alope-\ncia (trichobezoars).\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221188 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 219\nDiagnosis\nâ–  Gastric bezoars are generally found incidentally on imaging such as\nabdominal x-ray, barium swallow, abdominal ultrasound, or CT.\nâ–  Definitive diagnosis occurs with upper GI endoscopy.\nTreatment\nâ–  Treatment options include chemical dissolution (based on composition of\nbezoar) for mildly symptomatic bezoars.\nâ–  Endoscopic removal may be considered in more severe cases.\nâ–  Metoclopramide or othe",
      "char_start": 632000,
      "char_end": 634000
    },
    {
      "chunk_id": 317,
      "text": "r promotility drugs may be used as an adjuvant\ntreatment with chemical or endoscopic therapy.\nâ–  Surgery is considered if other treatment options fail.\nâ–  Good hydration, dietary modification, chewing or psychiatric evaluation\nmay be required to prevent recurrence.\nBARIATRIC SURGERY\nGenerally speaking, bariatric surgery is a procedure performed to promote\nweight loss. These surgeries promote weight loss through limiting caloric\nintake (by decreasing the size of the stomach) and through decreasing the\nability of the body to absorb nutrients (by shortening the length of the bowel).\nThere are several procedures with which to achieve these goals, a few of the\nmore common ones are discussed here.\nIndications for Bariatric Surgery\nMost bariatric surgeons encourage/require patients to utilize lifestyle changes\nbefore surgery in addition to satisfying the following criteria to show true com-\nmitment to weight loss:\n1. Body mass index (BMI) â‰¥40 kg/m2\n2. BMI 35 to 39.9 kg/m2 with at least one serious comorbidity (type 2 diabe-\ntes mellitus [DM], obstructive sleep apnea [OSA], Pickwickian syndrome,\nhypertension, hyperlipidemia, others)\n3. BMI 30 to 34.9 kg/m2 with uncontrolled type 2 DM or metabolic\nsyndrome\nTypes of Bariatric Surgery\n1. Roux-n-Y gastric bypass: Division of the proximal stomach from the distal\nstomach and division of the jejunum. The proximal portion of the stomach is\nthen surgically anastomosed to the distal limb (the â€œRoux limbâ€) of the jeju-\nnum (gastrojejunal anastomosis). The proximal portion of the jejunum is sur-\ngically anastomosed to a more distal portion of the jejunum (jejunojejunal\nanastomosis), which was previously anastomosed to the proximal stomach.\n2. Sleeve gastrectomy: Removal of one-third to two-thirds of the stomach\nsurgically.\n3. Adjustable gastric band: Placement of a silicone band around the stom-\nach with an attached under-skin port. The port is able to be accessed for\ninjections of saline to inflate/deflate the balloon, allowing adjustme",
      "char_start": 634000,
      "char_end": 636000
    },
    {
      "chunk_id": 318,
      "text": "nts to\nthe band, if necessary.\nCommon complications: Dependent on the specific type of bariatric surgery.\nCommon complications include acid reflux, cholelithiasis, malnutrition, leak\nat the surgical site, and dumping syndrome.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 221199 1100//2211//2222 1122::5588 PPMM\n\n220 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDumping Syndrome\nCaused by rapid emptying of food from the stomach into the small bowel. The\nhyperosmolar content osmotically pulls fluids from the plasma into the bowel,\ncausing hypotension and reflex activation of the sympathetic nervous system.\nâ–  Hx/PE: Colicky abdominal pain, diarrhea, tachycardia, and nausea\nâ–  Dx: Made clinically\nâ–  Tx: Avoiding simple sugars; increasing dietary fiber/protein; eating small,\nfrequent meals; separating consumption of solid from liquid foods by ~30\nminutes\nâ–  Px: Resolves on its own in 7 to 12 weeks\nDISORDERS OF THE SMALL BOWEL\nKEY FACT DIARRHEA\nCryptosporidium and Isospora are\nâ–  The most common mechanisms are malabsorption/osmotic, secretory,\nassociated with chronic diarrhea in\ninflammatory/infectious, and â†‘ motility (see Tables 2.6-7 and 2.6-8).\npatients with HIV/AIDS.\nâ–  Stool electrolytes: Primarily sodium and potassium (normal stool osmotic\ngap is 50â€“100 mOsm/kg). Stool osmotic gap = 290 â€“ 2 Ã— (stool Na + stool K).\nHistory/PE\nâ–  Acute diarrhea: Acute onset with a duration of <2 weeks; usually infec-\ntious and self-limited\nâ–  Possibility for multiple pathogens to be responsible (see Table 2.6-8)\nâ–  Common causes of pediatric diarrheaâ€”rotavirus, Norwalk virus, and\nenterovirus infection\nâ–  Chronic diarrhea: Often insidious onset with a duration of >4 weeks\nâ–  Secretory: Carcinoid tumors, vasoactive intestinal peptide (VIP)omas\nKEY FACT â–  Malabsorption/maldigestive/osmotic: Bacterial overgrowth, pancre-\natic insufficiency, mucosal damage, lactose intolerance, celiac disease,\nOrganisms that cause bloody\nlaxative abuse (presents with dark-brown colonic ",
      "char_start": 636000,
      "char_end": 638000
    },
    {
      "chunk_id": 319,
      "text": "discoloration), post-\ndiarrhea include Salmonella, Shigella,\nsurgical short bowel syndrome\nenterohemorrhagic Escherichia coli\nâ–  Inflammatory/infectious: IBD, giardiasis, amoebic dysentery\n(EHEC), and Campylobacter.\nâ–  Increased motility: Irritable bowel syndrome (IBS)\nDiagnosis\nâ–  Acute diarrhea: No further studies indicated unless the patient has a high\nfever, bloody diarrhea, or diarrhea lasting >4 to 5 days.\nâ–  Chronic diarrhea: History/physical examination to narrow the differential\ndiagnosis. Additional studies include the following:\nKEY FACT\nâ–  Secretory: Carcinoid tumors, VIPomas, bile acid diarrhea (Ileal malab-\nsoprtion of bile acids [due to ileal resection, ileal Crohn's disease]\nOrganisms that cause watery diarrhea\nresults in excess bile acids in colon. Bile acids increase colonic secre-\ninclude Vibrio cholerae, rotavirus,\ntion and motility)\nenteropathogenic E coli (ETEC),\nCryptosporidium, Giardia, and norovirus. â–  Stool analysis: Leukocytes, culture, Clostridioides difficile toxin, and\nova and parasite exam (O&P)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222200 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 221\nTABLE 2.6-7. Types of Stool Osmotic Gap\nSTOOL OSMOTIC GAP DESCRIPTION EXAMPLES\nLow osmotic gap (<50 mOsm/kg) Secretory diarrhea: â†‘ secretion or inhibi- Bacterial toxins (eg, cholera, Escherichia coli), vasoac-\ntion of absorption of water tive intestinal peptide tumor (VIPoma), gastrinoma,\nmedullary cancer of thyroid\nHigh osmotic gap (>100 mOsm/kg) Osmotic diarrhea: Osmotically active com- Celiac disease, Whipple disease, pancreatic insuf-\npounds in bowel draw in water ficiency, laxative abuse, and carbohydrate\nmaldigestion\nTABLE 2.6-8. Causes of Infectious Diarrhea\nINFECTIOUS EXAM AND TEST RESULTS (NOTE: ALL\nAGENT HISTORY HAVE FECAL RBCs AND WBCs) COMMENTS TREATMENT\nCampylobacter The most common Frequently presents with Rule out appendicitis and Supportive treatment first,\njejuni etiol",
      "char_start": 638000,
      "char_end": 640000
    },
    {
      "chunk_id": 320,
      "text": "ogy of bacterial bloody diarrhea IBD then fluoroquinolones\ndiarrhea (eg, ciprofloxacin) or\nCaused by ingestion of azithromycin\ncontaminated food or\nwater\nAffects young children\nand young adults; gen-\nerally lasts 7â€“10 days\nClostridioides Associated with recent Presents with fever, abdominal Most commonly causes Cessation of the inciting\ndifficile treatment with pain, and possible systemic colitis, but can involve antibiotic\nantibiotics (penicil- toxicity the small bowel Nonsevere: PO fidaxomicin\nlins, quinolones, Identify C difficile toxin in or vancomycin\nclindamycin) the stool Severe (first episode):\nAffects hospitalized adult Sigmoidoscopy shows PO fidaxomicin > PO\npatients vancomycin\npseudomembranes\nImportant to watch for Recurrent (first episode): PO\ntoxic megacolon (on fidaxomicin is preferred\nx-ray of the abdomen) over PO vancomycin\nRecurrent (second or sub-\nsequent recurrence):\nPO fidaxomicin > PO\nvancomycin\nFulminant without ileus: PO\nvancomycin + parenteral\nmetronidazole\nFulminant with ileus: PO or\nrectal vancomycin + par-\nenteral metronidazole\nEchinococcus Contracted from close â€œEggshell calcificationâ€ on CT scan Cyst aspiration may cause Surgical resection and\ngranulosus contact with dogs, Usually found incidentally, but cyst rupture and anaphy- albendazole\ndefinitive host for may cause mild right upper lactic shock\ntapeworm quadrant (RUQ) pain caused\nCauses simple liver cysts by compression of other\nstructures\n(continues)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222211 1100//2211//2222 1122::5588 PPMM\n\n222 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-8. Causes of Infectious Diarrhea (continued)\nINFECTIOUS EXAM AND TEST RESULTS (NOTE: ALL\nAGENT HISTORY HAVE FECAL RBCs AND WBCs) COMMENTS TREATMENT\nEntamoeba Caused by ingestion of Presents with severe abdominal Chronic amebic colitis Steroids can lead to fatal\nhistolytica contaminated food or pain and fever mimics IBD perforation\nwater Endoscopy shows â€œflask-sh",
      "char_start": 640000,
      "char_end": 642000
    },
    {
      "chunk_id": 321,
      "text": "apedâ€ Treat with metronidazole\nMay relate to possible ulcers\npatient history of trav-\neling in developing\ncountries\nIncubation period lasting\nup to 3 months\nEscherichia coli Caused by ingestion of Presents with severe abdominal It is important to rule out Antibiotic or antidiarrheal\ncontaminated food pain, low-grade fever, and GI bleeding and ischemic therapy to be avoided\n(raw meat) vomiting colitis because they â†‘ HUS risk\nAffects children and older Hemolytic uremic syndrome\nadults (HUS) is a potential com-\nGenerally lasts 5-10 days plication (especially for\nserotype O157:H7), pri-\nmarily in children\nSalmonella spp. Classically caused by Presents with a prodromal Sepsis is a concern, as First fluids; at-risk patients\ningestion of contami- headache, fever, myalgia, and 5%â€“10% of patients (eg, sickle cell patients)\nnated poultry or eggs, abdominal pain become bacteremic or those with bacte-\nbut many other foods Sickle cell patients are remia treated with\nmay be contaminated susceptible to invasive oral quinolone or\nAffects young children disease leading to trimethoprim-\nand the elderly; gener- osteomyelitis sulfamethoxazole\nally lasts 2-5 days (TMP-SMX)\nShigella spp. Extremely contagious; Presents with high fever, Shigella spp. May lead to A fluoroquinolone +\ntransmitted between abdominal pain, and severe dehydration azithromycin + third\npeople by the fecal-oral cramping It can also cause febrile sei- generation\nroute zures in the very young cephalosporin or\nAffects young children Diarrhea may initially be TMP-SMX + ampicillin\nand institutionalized watery and progress to to prevent person-to-\npatients become bloody/mucoid person spread\nTaenia solium Pork tapeworm Presents with signs of elevated T solium is diagnosed via CT Treatment with alben-\nAcquired by ingestion of intracranial pressure (head- or MRI showing several dazole and with\nundercooked pork aches, vomiting, seizures, cysts with edema symptomatic manage-\nvisual changes) ment of CNS symptoms\nTrichinella Acq",
      "char_start": 642000,
      "char_end": 644000
    },
    {
      "chunk_id": 322,
      "text": "uired by ingestion Classic triad of myositis, perior- Multiorgan involvement is Albendazole (or mebenda-\nspiralis of undercooked meat bital edema, and eosinophilia possible zole); corticosteroids in\n(primarily pork) in Possibility for migrating larvae severe cases\ndeveloping countries to cause vasculitis, leading to\n(especially Mexico and splinter hemorrhages\nThailand)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222222 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 223\nTreatment\nâ–  Acute diarrhea: Oral rehydration key. Antibiotics are not indicated KEY FACT\n(except in C difficile infection or in the epidemic setting) because they do\nDiarrhea after ingestion of raw eggs or\nnot shorten the course of illness.\ndairy: think Salmonella.\nâ–  Chronic diarrhea: Treatment specific to etiology.\nMALABSORPTION/MALDIGESTION\nâ–  Inability to absorb macronutrients and/or micronutrients. Presents with\nchronic diarrhea with weight loss, growth failure, and macronutrient and/\nor micronutrient deficiencies.\nâ–  Celiac disease: Characterized by mucosal inflammation, villous atrophy,\nand crypt hyperplasia in response to dietary gluten exposure. Celiac dis-\nease is associated with extraintestinal manifestations, including dermatitis\nherpetiformis (see Fig. 2.6-18) and autoimmune diseases of thyroid gland,\nliver, and type 1 diabetes.\nFIGURE 2.6-18. Dermatitis herpetifor-\nDiagnosis mis. Grouped, papulovesicular, pruritic\nskin lesions are shown. Lesions tend to\nâ–  Serologic testing is crucial for screening and diagnosis and includes antiâ€“ be symmetrically located on the extensor\ntissue transglutaminase-IgA (TTG-IgA) and endomysial IgA antibody surfaces of the elbows, knees, buttocks,\ntesting. and posterior scalp and are associated\nwith celiac disease. (Reproduced with permis-\nâ–  Histologic analysis of duodenal biopsies is gold standard for diagnosis and\nsion from Caproni M et al. Celiac disease and der-\ngrading based on Marsch classific",
      "char_start": 644000,
      "char_end": 646000
    },
    {
      "chunk_id": 323,
      "text": "ation.\nmatologic manifestations: many skin clues to unfold\nâ–  Celiac disease has a strong genetic component, but testing for HLA-DQ2/ gluten-sensitive enteropathy. Gastroenterol Res Pract.\nDQ8 has limited role in diagnosis. 2012;2012:952753.)\nManagement\nâ–  Lifelong adherence to gluten-free diet is the cornerstone of treatment and\nresults in symptom resolution and mucosal healing.\nâ–  Concomitant testing for micronutrient deficiencies (iron, folic acid, vita-\nmins D, B ) should be undertaken and repleted as needed.\n12\nâ–  Close monitoring for other autoimmune diseases (thyroid, liver, type 1\ndiabetes) and osteoporosis should be done.\nOther etiologies of malabsorption:\nâ–  Mucosal abnormalities: Whipple disease (also presents with arthritis,\nlymphadenopathy, cardiac issues, periodic acidâ€“Schiff [PAS]â€“positive\ngranules in lamina propria on biopsy), tropical sprue (chronic diarrhea\nand nutritional malabsorption [vitamin B and vitamin B ] and living >1\n12 9\nmonth in an endemic area)\nâ–  Bile salt deficiency: Ileal disease in Crohn disease or small bowel resec-\ntions (>100 cm of terminal ileum), bacterial overgrowth\nâ–  Short bowel syndrome: Caused by resection of small bowel; results in\nmalabsorption of both micronutrients and macronutrients; amount of KEY FACT\nbowel resection weakly correlated to likelihood/degree of symptoms\nThe initial tests specific for celiac\nâ–  Small intestinal bacterial overgrowth (SIBO): Bacterial overgrowth due\ndisease are IgA anti-transglutaminase\nto various causes, resulting in bloating or chronic watery diarrhea. Under-\nantibody or antiendomysial antibody.\nlying etiologies include abnormal motility, abnormal anatomy (eg, after\nThe gold standard is intestinal biopsy,\nabdominal surgery, GI cancer), metabolic and systemic disorders (eg, dia-\nwhich will show increased intraepi-\nbetes), and immune disorders (eg, IgA deficiency)\nthelial lymphocytes (>25 per 100\nâ–  Hx/PE: Presents with pale, foul-smelling, bulky stools (steatorrhea or\nenterocytes), crypt hyperpla",
      "char_start": 646000,
      "char_end": 648000
    },
    {
      "chunk_id": 324,
      "text": "sia, and\nfat maldigestion) associated with abdominal pain, flatus, bloating,\nvillous atrophy.\nweight loss, nutritional deficiencies, and fatigue.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222233 1100//2211//2222 1122::5588 PPMM\n\n224 HIGH-YIELD FACTS IN GASTROINTESTINAL\nâ–  Dx: Multiple laboratory tests based on clinical suspicion. Biopsy is\ndefinitive.\nâ–  Tx: Etiology dependent. In severe cases, patients may require total paren-\nteral nutrition (TPN), immunosuppressants, and anti-inflammatory medi-\ncations. Dapsone can be used for dermatitis herpetiformis.\nCARBOHYDRATE MALDIGESTION\nLactase Deficiency\nCan be primary (autosomal recessive) or secondary (acquired conditions that\naffect structural or functional integrity of small bowel).\nâ–  Common among populations of African, Asian, and Native American\ndescent, also transiently after an acute episode of gastroenteritis.\nâ–  Hx/PE: Presents with abdominal bloating, flatulence, cramping, and\nwatery diarrhea following dairy ingestion.\nâ–  Dx: Often treated empirically with lactose-free diet. Hydrogen breath test\nreveals â†‘ hydrogen following the ingestion of lactose.\nâ–  Tx: Avoidance of dairy products; oral lactase enzyme replacement.\nOther Forms of Carbohydrate Maldigestion\nâ–  Sucrase-isomaltase deficiency: Rare homozygous recessive disorder with\nsucrose maldigestion.\nâ–  Maltase-glucoamylase deficiency.\nâ–  Fructose intolerance: Can be hereditary (presents in infancy) or dietary\n(later in life). No standardized diagnostic tests are available, but fructose\nbreath test can be suggestive. Treatment involves restricting fructose in diet.\nKEY FACT\nCARCINOID SYNDROME\nPatients with carcinoid syndrome also\ndevelop niacin/vitamin B deficiency\n3 Carcinoid syndrome is caused by metastasis of carcinoid tumors, which most\n(pellagra) because tryptophan is\ncommonly arise from the ileum and appendix and produce serotonin. Prior to\nmetabolized into serotonin.\nmetastasis, most secreted hormones undergo first-pa",
      "char_start": 648000,
      "char_end": 650000
    },
    {
      "chunk_id": 325,
      "text": "ss metabolism by the liver\nand do not cause systemic symptoms.\nâ–  Hx/PE: Cutaneous flushing, watery diarrhea, abdominal cramps, wheezing,\nMNEMONIC and right-sided cardiac valvular lesions are the most common manifestations.\nâ–  Dx: High urine levels (elevated 24-hour urinary excretion) of the serotonin\nThe classic presentation of pellagra metabolite 5-hydroxyindoleacetic acid (5-HIAA) (best initial test) are diag-\n(deficiency in niacin/vitamin B) is the 4\n3 nostic. CT and In-111 octreotide scans are used to localize the tumor.\nDs: Diarrhea, Dementia, Dermatitis, and\nâ–  Tx: Treatment includes octreotide for symptomatic patients and surgery in\nDeath.\nresectable disease.\nSMALL BOWEL OBSTRUCTION\nKEY FACT\nâ–  Partial or complete blockage of passage of bowel contents through the\nsmall bowel.\nIn the United States, the leading cause\nof SBO in children is hernia. The leading â–  Etiologies: Adhesions (60% of cases), hernias (10%â€“20%), neoplasms\n(10%â€“20%), intussusception, gallstone ileus, stricture, and volvulus\ncause of SBO in adults is adhesions.\nâ–  Partial SBO: Continued passage of flatus, but no stool\nâ–  Complete SBO: No passage of flatus or stool (obstipation)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222244 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 225\nHistory/PE A\nâ–  History: Crampy abdominal pain at 4- to 5-minute intervals. Vomiting\ntypically follows the pain.\nâ–  Abdominal exam: Distention, tenderness, prior surgical scars, or her-\nnias; hyperactive bowel sounds (high-pitched tinkles and peristaltic\nrushes).\nâ–  Complications: Ischemic necrosis and bowel rupture with prolonged or\ncomplete obstruction. Patients present with peritonitis manifested by fever,\nhypotension, rebound tenderness, and tachycardia.\nDiagnosis\nâ–  Best initial test: Abdominal x-ray demonstrates a stepladder pattern of\ndilated small bowel loops, air-fluid levels (see Fig. 2.6-19), and a paucity of B\ngas in the colon.\nâ–  Most accurate test: CT",
      "char_start": 650000,
      "char_end": 652000
    },
    {
      "chunk_id": 326,
      "text": " scan of the abdomen further characterizes\nobstruction and evaluates for etiology.\nâ–  Complete blood cell count (CBC) may demonstrate leukocytosis if there\nis ischemia or necrosis of bowel.\nâ–  Lab tests often reveal dehydration. Lactic acidosis is a prognostic sign, as it\nsuggests necrotic bowel.\nTreatment\nâ–  Best initial treatment: Fluid resuscitation.\nâ–  Partial obstruction: Supportive care sufficient. It should include NPO\nstatus, NG suction, IV hydration, correction of electrolyte abnormali- FIGURE 2.6-19. Small bowel obstruc-\ntion. (A) Supine x-ray of the abdomen\nties, Foley catheterization to monitor fluid status, and pain manage-\nshows dilated air-filled small bowel loops\nment. Patient should avoid opioids and anticholinergics (slow GI\nwith relatively little gas in the colon. (B)\nmotility). Left lateral decubitus x-ray on the same\nâ–  Complete obstruction: Exploratory laparotomy indicated if there is pres- patient demonstrates multiple air-fluid\nence of bowel necrosis, perforation, ischemia, or a surgically correctable levels (arrows) at different levels. These\nare typical plain film findings of com-\ncause of complete SBO. Otherwise, nonoperative management can be uti-\nplete SBO. (Reproduced with permission from\nlized for a period of time if the patient is clinically stable.\nDoherty GM. Current Diagnosis & Treatment: Surgery,\n13th ed. New York, NY: McGraw-Hill; 2010.)\nILEUS KEY FACT\nGallstone ileus is a form of SBO that\nLoss of peristalsis without structural obstruction.\noccurs when a gallstone lodges at the\nileocecal valve after passing through a\nRisk Factors\ncholecystoenteric fistula.\nRecent surgery/GI procedures, severe medical illness, immobility, hypokale-\nmia or other electrolyte imbalances, hypothyroidism, DM, and medications\nthat slow GI motility (eg, anticholinergics, opioids).\nHistory/PE\nâ–  Diffuse, constant abdominal discomfort; nausea and vomiting; an absence A 53-year-old woman with a history\nof carcinoid tumor of the appendix\nof flatus or bowel movemen",
      "char_start": 652000,
      "char_end": 654000
    },
    {
      "chunk_id": 327,
      "text": "ts.\n(status post-resection) presents to\nâ–  Diffuse tenderness, abdominal distention, and â†“ or absent bowel sounds.\na local clinic with symmetric, dry,\nA rectal exam is required to rule out fecal impaction in older adult\nhyperpigmented skin lesions and\npatients.\npersistent diarrhea. Her husband\nexpresses concern that the patient\ndoes not seem to be herself anymore;\nhe reports that she has been irritable,\nconfused, and forgetful. What is the\nmost likely diagnosis?\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222255 1100//2211//2222 1122::5588 PPMM\n\n226 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDiagnosis\nKEY FACT\nâ–  Must consider clinical history in diagnosis.\nIn ileus, there is air present throughout â–  Best initial test: Abdominal film showing distended loops of small and\nthe small and large bowel on x-ray of large bowel, with air seen throughout the colon and rectum (SBO has no\nthe abdomen. air distal to the obstruction).\nâ–  Most accurate test: CT scan of the abdomen.\nTreatment\nâ–  â†“ or discontinue the use of narcotics and any other drugs that reduce\nbowel motility.\nâ–  Bowel rest: Temporarily â†“ or discontinue oral feeds.\nâ–  Bowel decompression: Initiate low, intermittent NG suctions and paren-\ntal feeds.\nâ–  Supportive care: Replete electrolytes as needed; hydrate with IV fluids.\nACUTE ABDOMEN\nAny condition that presents with new-onset, severe abdominal pain and ten-\nderness. These patients usually require surgery, but many nonsurgical mimics\nexist. A physician should always consider a gynecologic etiology in females\nand nonsurgical causes of acute abdomen (see Table 2.6-9) in all patients.\nHistory/PE\nIn general, four pathologies contribute to acute abdomen and present with\ncharacteristic symptoms. Considering these mechanisms along with location\nand associated history/physical examination findings may help delineate the\ndiagnosis.\nThe four pathologies are perforation/rupture, obstruction, inflammation,\nand ischemia.\nâ–  Perforation or rupture",
      "char_start": 654000,
      "char_end": 656000
    },
    {
      "chunk_id": 328,
      "text": ": Sudden onset of diffuse, excruciating pain.\nPatients will lie still to minimize pain. Peritoneal signs are prominent.\nâ–  Esophageal perforation (Boerhaave syndrome): Has been associated\nwith recurrent vomiting/hematemesis, but up to 45% of patients have\nno history of emesis. Esophageal perforation commonly presents with\nretrosternal and epigastric pain.\nâ–  Other GI perforation: Associated with PUD, cancer, diverticulitis, and\nIBD.\nâ–  Ruptured abdominal aortic aneurysm (AAA): Most common in male\nsmokers >65 years of age. Patient may describe periumbilical pain that\nradiates to the back. Abdominal exam may reveal pulsatile mass.\nTABLE 2.6-9. Nonsurgical Causes of Acute Abdomen\nETIOLOGY CAUSE\nPellagra, a deficiency of vitamin B\n3 Extra-abdominal Myocardial infarction (MI), pulmonary embolism, pneumonia\n(niacin), secondary to a recurrent\ncarcinoid tumor. Carcinoid tumors All of these cause right or left upper quadrant pain\nproduce serotonin, which is a\nderivative of tryptophan. However, Hematologic Sickle cell crisis, leukemia\ntryptophan is also the precursor of\nniacin. In patients with carcinoid Metabolic Diabetic ketoacidosis, uremia\ntumors, the tumor can be so active\nthat most tryptophan is used for Genetic/familial Familial Mediterranean fever, acute intermittent porphyria\nserotonin production, resulting in\nniacin deficiency. Toxic Lead and heavy metal poisoning, black widow spider bite\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222266 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 227\nâ–  Ruptured ectopic pregnancy/ovarian cyst: Presents with first-trimester KEY FACT\nbleeding, abdominal pain, and hypovolemic shock. Abdominal pain is\nÎ²-Human chorionic gonadotropin\nusually localized to the pelvis, but specific location and quality of pain\n(Î²-Hcg) is a vital sign in women with\nare variable.\nacute abdomen. âŠ• Î²-Hcg in the\nsetting of shock is a ruptured ectopic\nâ–  Obstruction: Sudden onset of severe, colicky, ",
      "char_start": 656000,
      "char_end": 658000
    },
    {
      "chunk_id": 329,
      "text": "intermittent pain. Patients\npregnancy until proven otherwise.\ncannot sit still. Peritoneal signs are usually absent.\nâ–  SBO: Most commonly from adhesions years after abdominal surgery,\nincarcerated hernias, or in patients with IBD or cancer. Patient may\ncomplain of obstipation (failure to pass stool or gas). Bowel sounds are\nhigh-pitched early in the disease process.\nâ–  Volvulus: Abdominal pain with insidious onset that is continuous, with\nintermittent exacerbations associated with peristalsis. Patients also com-\nplain of nausea, distention, and obstipation. Immediate surgery is pur-\nsued in the presence of peritonitis or perforation. Otherwise,\nendoscopic detorsion may be used for management of sigmoid volvu-\nlus. Cecal volvulus is mostly treated surgically.\nâ–  Ureteric/biliary obstruction: Nephrolithiasis causing colicky pain that KEY FACT\nusually radiates to the groin and may cause hematuria/pyuria. This\ncondition may also cause costovertebral angle tenderness (CVAT). Bil- Adhesions are the most common cause\niary colic is most common in multiparous, overweight women (female, of small bowel obstruction in patients\nforty, fertile, and fat). Fatty meals exacerbate pain. There are no signs with a history of abdominal surgeries.\nof peritoneal irritation.\nâ–  Inflammation: Gradual onset (over 10â€“12 hours) of constant, poorly local-\nized pain that later localizes to problem area. Patients lie still to minimize\npain. Peritoneal signs are prominent.\nâ–  Appendicitis: Detailed later.\nâ–  Cholecystitis: Same demographics as biliary colic. Pain is constant.\nPeritoneal irritation is evident. Murphy sign causes pain on inspiration.\nâ–  Diverticulitis: Prominent left lower quadrant (LLQ) pain, change in\nbowel habits, and Â± nausea/vomiting. Palpation or rectal exam may\nreveal mass (abscess).\nâ–  Pelvic inflammatory disease (PID): Associated with history of sexually\ntransmitted diseases or occurring in young females with unsafe sexual\npractices. Pelvic exam elicits cervical motion tenderness ",
      "char_start": 658000,
      "char_end": 660000
    },
    {
      "chunk_id": 330,
      "text": "and adnexal\ntenderness.\nâ–  Ischemia: Variable presentation, dependent on specific etiology.\nâ–  Acute mesenteric ischemia: Sudden onset of pain and hematochezia\nin a patient with history of atrial fibrillation.\nâ–  Ischemic colitis: Postprandial abdominal pain Â± hematochezia/\nmelena in a patient with significant atherosclerotic disease (prior myo-\ncardial infarction [MI]/stroke, peripheral artery disease).\nâ–  Strangulated hernia: Irreducible bulge in abdominal wall.\nâ–  Ovarian torsion: Sudden onset of adnexal pain Â± nausea/vomiting.\nCharacter of pain is variable. Palpation usually reveals a mass. Condi-\ntion has a high index of suspicion in females since clinical presentation\nis variable.\nKEY FACT\nDiagnosis\nAcute abdominal pain with blood per\nâ–  To rule out OB/GYN causes in women: Urine Î²-human chorionic rectum is acute mesenteric ischemia\ngonadotropin (Î²-Hcg) for ectopic pregnancy; pelvic ultrasound for ovarian\nuntil proven otherwise. Classically, an\ntorsion, ruptured cyst, or fibroids; pelvic exam Â± swab for PID\nolder adult patient with a history of\nâ–  To rule out extra-abdominal mimics in patients with upper abdominal atrial fibrillation or recent AAA repair\npain: Troponins and ECG for MI, d-dimer/CT angiogram for pulmonary\npresents with these findings.\nembolism, CXR for pneumonia\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222277 1100//2211//2222 1122::5588 PPMM\n\n228 HIGH-YIELD FACTS IN GASTROINTESTINAL\nâ–  To rule out nonsurgical abdominal causes, if appropriate: Amylase/lipase\nin patient consistent with pancreatitis (nausea/vomiting, epigastric pain,\nhunched over), CT abdomen without contrast in patient consistent with\nkidney stones/pyelonephritis (hematuria, flank pain, radiation to groin),\nparacentesis for patient consistent with systolic blood pressure (ascites, fever)\nâ–  Additional diagnostic tests to rule in surgical diagnoses:\nâ–  X-ray of the abdomen: Perforation (see Fig. 2.6-20), SBO, volvulus\nâ–  CT with contrast: Appendiciti",
      "char_start": 660000,
      "char_end": 662000
    },
    {
      "chunk_id": 331,
      "text": "s, diverticulitis, IBD, abscess, cancer, AAA\nâ–  Right upper quadrant (RUQ) ultrasound: Cholecystitis, biliary colic,\ncholedocholithiasis\nManagement\nA detailed approach to management is beyond the scope of this section, but\ngeneral concepts are as follows:\nFIGURE 2.6-20. Pneumoperitoneum.\nFree gas under the right and left hemi- â–  In the presence of peritoneal signs or shock: Exploratory laparotomy.\ndiaphragms visible in erect CXR. This â–  All unstable patients and those with suspected potential hemorrhage:\nmay occur due to small bowel perfora- Blood typing, cross-matching and transfusion as needed.\ntion. (Reproduced with permission from Buckle C, â–  Patients with perforation or signs of sepsis: Broad-spectrum antibiotics.\nHoldridge C, Xu T, et al. Acute abdominal pain and\nTreatment with these antibiotics is also indicated for patients with sus-\nradiological pneumoperitoneum: always an Indication\npected infectious processes (cholecystitis, diverticulitis, pyelonephritis).\nfor Laparotomy? J Clin Med Res 2013;5:2. doi: 10.4021/\njocmr929w.) â–  Stable patients: Expectant management, possibly including NPO status,\nNG tube placement (for decompression of bowel in the setting of obstruc-\ntion or acute pancreatitis), IV fluids, placement of a Foley catheter (to\nmonitor urine output and fluid status), and vital sign monitoring with\nserial abdominal exams and serial labs.\nDUODENAL HEMATOMA\nDuodenal injuries are rare and involve the second part of the duodenum\nmost commonly. Duodenal injuries are often accompanied by injuries to sur-\nrounding structures in the retroperitoneal region. Initial presentation can be\nnonspecific, and suspicion should arise in cases with direct blow or impact to\nthe mid-abdomen.\nEtiology\nâ–  In children, may result from a blunt trauma through bicycle handlebar or\nabuse.\nâ–  In adults, more often due to penetrating injuries (eg, gun shot, stabbing).\nNonpenetrating injuries with duodenal hematoma in adults are typically\ndue to steering wheel injuries.\nHistory/PE",
      "char_start": 662000,
      "char_end": 664000
    },
    {
      "chunk_id": 332,
      "text": "\nâ–  Typically, signs and symptoms are nonspecific. Patients may have signs\nand symptoms of GI obstruction such as bilious emesis, with an inability\nto tolerate oral intake.\nâ–  Presentation is often insidious, leading to delayed diagnosis. Some patients\ndevelop symptoms 48 hours after injury (due to gradual fluid shift into\nhyperosmotic hematoma).\nâ–  PE: Ecchymosis may be seen in the pattern of injury (crush injury with\nbicycle handlebar or seat belt sign), abdominal tenderness, peritonitis, or\npalpable upper abdominal mass.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222288 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 229\nDiagnosis\nâ–  Abdominal CT is the best initial test for duodenal injury in hemodynami-\ncally stable patients. Alternatively, upper GI series may be used (shows\ncoiled spring sign or obstruction).\nâ–  Patients who are hemodynamically unstable may be diagnosed during\nexplorative laparotomy.\nâ–  Pancreatic injury and other associated injuries should be excluded.\nTreatment\nâ–  For blunt duodenal injuries, nonsurgical management in hemodynami-\ncally stable patients is recommended. Patients receive NG suction and\nTPN. Patients are followed with upper GI series or ultrasound at 5-day to\n7-day intervals if signs of obstruction do not abate. Surgery may be consid-\nered if conservative management fails.\nâ–  For penetrating duodenal injury, conservative management is not recom-\nmended, and patients should undergo surgery (duodenal repair, decom-\npression, and other procedures).\nMESENTERIC ISCHEMIA\nInsufficient blood supply to the small intestine, resulting in ischemia and,\npotentially, necrosis. See Table 2.6-10 for clues to differentiating between\ntypes of ischemia. The most common causes are as follows:\nâ–  Embolism: Most commonly originates in the heart. Risk factors include\natrial fibrillation and stasis from â†“ ejection fraction.\nâ–  Acute arterial occlusion from thrombosis: Most commonly occurs in the\npro",
      "char_start": 664000,
      "char_end": 666000
    },
    {
      "chunk_id": 333,
      "text": "ximal superior mesenteric artery (SMA). The primary risk factor is\natherosclerosis.\nâ–  Other causes: Nonocclusive arterial disease (atherosclerosis of mesenteric\nvessels, arteriolar vasospasm), venous thrombosis (caused by hypercoagula-\nble states), or shock state.\nHistory/PE\nPresents with severe abdominal pain out of proportion to the examination,\nnausea, vomiting, diarrhea, bloody stools, prior episodes of abdominal pain\nafter eating (â€œintestinal anginaâ€).\nDiagnosis\nâ–  Best initial test: X-ray or CT scan of the abdomen may reveal bowel wall\nedema (â€œthumbprintingâ€) and air within the bowel wall (pneumatosis\nintestinalis).\nâ–  Most accurate test: Mesenteric/CT angiography is the gold standard for\ndiagnosis of arterial occlusive disease, but conventional angiography A 65-year-old male smoker is brought\nto the emergency department for\nallows for intervention of thrombosis/embolism.\nsudden-onset abdominal and back\npain. The anxious patient complains\nTreatment of â€œripping pain.â€ Physical examination\nreveals a large, pulsatile mass\nâ–  Best initial treatment: Volume resuscitation, broad-spectrum antibiotics\nbehind the umbilicus. BP is 80/50\nâ–  For acute arterial thrombosis or embolism: Anticoagulation and either mm Hg; heart rate 125 beats per\nlaparotomy or angioplasty\nminute (bpm). The physician begins\ncrystalloid and blood infusions. What\nis the most appropriate next step in\nmanagement?\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 222299 1100//2211//2222 1122::5588 PPMM\n\n230 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-10. Differentiating Types of Mesenteric Ischemia\nACUTE MESENTERIC ISCHEMIA ISCHEMIC COLITIS CHRONIC MESENTERIC ISCHEMIA\nSite Small intestine Large intestine, watershed zones Small and large intestine\n(splenic flexure and rectosigmoid\njunction)\nEtiology Thromboembolic (atherosclerosis, atrial fibril- Transient decrease in perfusion Fixed progressive obstruction\nlation, oral contraceptives) pressure due to decreased in bl",
      "char_start": 666000,
      "char_end": 668000
    },
    {
      "chunk_id": 334,
      "text": "ood flow (eg, atheroscle-\nCholesterol emboli after percutaneous vascular cardiac output (eg, dehydration, rosis of mesenteric vessels)\nprocedures shock)\nSymptoms Sudden-onset severe pain, diarrhea (bloody or Bloody diarrhea with abdominal Postprandial pain leading to\nnonbloody) pain fear of eating and weight loss\nPain â€œout of proportionâ€ to examination findings\nInvestigations X-ray: ileus, may show portal venous gas or gas X-ray: Thumbprinting of watershed Duplex ultrasonography\nwithin the walls (pneumatosis intestinalis) areas of colon\nCT angiogramâ€”investigational method of choice\nTreatment Supportive measures with fluids; antibiotic Optimization of cardiac output May require revasculariza-\ntherapy followed by surgery/embolectomy with fluids, treatment of shock tion, either surgical or\npercutaneous\nKEY FACT â–  For venous thrombosis: Anticoagulation\nâ–  Surgery: Resection of infarcted bowel\nCholesterol embolism may occur after\ncardiac catheterization, and ischemia\nComplications\nof multiple organs may be seen (bowel,\nSepsis/septic shock, multisystem organ failure, death\nkidney, pancreas, lower extremity skin\ncausing livedo reticularis).\nACUTE APPENDICITIS\nObstruction of the appendiceal lumen with subsequent inflammation and\ninfection. Rising intraluminal pressure leads to vascular compromising of the\nappendix, ischemia, necrosis, and possible perforation. Etiologies include\nhypertrophied lymphoid tissue (55%â€“65%), fecalith (35%), foreign body,\ntumor (eg, carcinoid tumor), and parasites. Incidence peaks in the early teens\n(most patients 10â€“30 years of age), and the male-to-female ratio is 2âˆ¶1.\nHistory/PE\nâ–  Classically presents with dull periumbilical pain lasting 1 to 12 hours with\nsubsequent migration to sharp right lower quadrant (RLQ) pain at McBur-\nBased on the clinical findings of\nney point.\nshock, abdominal pain, and a pulsatile\nmass, the patient has a ruptured â–  Can present with nausea, vomiting, anorexia, and low-grade fever.\nabdominal aortic aneurysm (AAA), â–  Ps",
      "char_start": 668000,
      "char_end": 670000
    },
    {
      "chunk_id": 335,
      "text": "oas, obturator, and Rovsing signs not sensitive tests, but their presence â†‘\nwhich is a surgical emergency. If the the likelihood of appendicitis. Psoas abscess can present similarly to\npatient is stable, ultrasonography\nor urgent CT are the next best\nsteps and inform intervention;\nhowever, immediate laparotomy or\nendovascular repair should not be\ndelayed in the unstable patient.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223300 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 231\nappendicitis, but with a more insidious onset over days. CT can distin-\nguish between the two.\nâ–  In perforated appendicitis, possibility of partial pain relief. Peritoneal signs\n(eg, rebound, guarding, hypotension, â†‘ WBC count, fever) will ultimately\ndevelop.\nâ–  Atypical presentations possible in children, older adults, pregnant patients,\nand those with retrocecal appendices. These may result in misdiagnosis\nand â†‘ mortality. Atypical or nonspecific features include indigestion, flatu-\nlence, diarrhea, bowel irregularity, and generalized malaise.\nDiagnosis\nâ–  Appendicitis is a clinical diagnosis in patients with classic history\n(described earlier), fever, and leukocytosis.\nâ–  Investigation can occur with CT IV contrast (see Fig. 2.6-21) or RLQ\nFIGURE 2.6-21. Acute appendicitis.\nultrasound (preferred in children and pregnant patients).\nContrast-enhanced CT demonstrating an\nenlarged, hyperenhancing appendix with\nan appendicolith visualized in the lumen\nTreatment\nand periappendiceal fat stranding located\nâ–  IV antibiotics with anaerobic and gram âŠ– coverage (eg, cefoxitin or anterior to the right posts muscle. (Repro-\ncefazolin plus metronidazole). The patient should be NPO and receive IV duced with permission from USMLE-Rx.com.)\nhydration, analgesia, and antiemetics.\nâ–  Uncomplicated appendicitis: Surgery or observation with antibiotics\ndepending on the clinical scenario. If appendicitis not found, complete\nexploration of the abdomen is",
      "char_start": 670000,
      "char_end": 672000
    },
    {
      "chunk_id": 336,
      "text": " performed. There is no need to administer KEY FACT\nantibiotics postoperatively.\nThe McBurney point is located one-\nâ–  Perforation: Perform immediate open or laparoscopic appendectomy.\nthird of the distance from the anterior\nAdminister antibiotics postoperatively until the patient is afebrile with a\nsuperior iliac spine to the umbilicus.\nnormalized WBC count. If open approach is used, the incision should be\nIt is an important part of a physical\nclosed by delayed primary closure.\nexamination because this location\nâ–  Abscess: Broad-spectrum antibiotics and CT-guided drainage. Interval\ncorresponds to the base of the\nappendectomy should be performed 6 to 8 weeks after resolution of\nappendix.\nabscess.\nKEY FACT\nDISORDERS OF THE LARGE BOWEL Surgical incisions can be closed by the\nfollowing:\nâ–  Primary closure (primary intent):\nCLOSTRIDIUM DIFFICILE COLITIS Surgical approximation using\nsutures or staples\nTraced to spore-forming, toxin-producing, gram-positive anaerobic bacteria that â–  Secondary closure (secondary\ncolonize the colon after normal gut flora are disrupted by antibiotics (penicil- intent): No approximation, typically\nlins, quinolones, cephalosporins, clindamycin). Infection with C difficile classi- packed with gauze, filled in with\ncally affects adult patients in hospitals and nursing homes, as well as those with granulation tissue\nsignificant risk factors (eg, IBD). â–  Delayed primary closure (tertiary\nintent): Similar to primary closure;\nHistory/PE occurs after several days of\nâ–  It is typically associated with recent antibiotic usage. observation to permit drainage\nâ–  Additional risk factors include age >65 years, recent hospitalization, and\nuse of PPIs.\nâ–  Symptoms range from asymptomatic carriage to profuse diarrhea (>3\nwatery loose stools in 24 hours), fever, abdominal pain, and possible sys-\ntemic toxicity.\nâ–  Infection with C difficile most commonly causes colitis, but it can involve\nthe small bowel.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__11",
      "char_start": 672000,
      "char_end": 674000
    },
    {
      "chunk_id": 337,
      "text": "9977--226688..iinndddd 223311 1100//2211//2222 1122::5588 PPMM\n\n232 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDiagnosis\nKEY FACT â–  C difficile toxin can be identified in the stool sample.\nâ–  Sigmoidoscopy may be normal or show patchy erythema in mild cases and\nLack of history of antibiotic usage does\npseudomembranes in severe cases.\nnot exclude the possibility of C. difficile\ncolitis. Leukocytosis in the absence of\nTreatment\ndiarrhea in a hospitalized patient can be\nrelated to C. difficile colitis. â–  Cessation of the inciting antibiotic\nâ–  Nonsevere (WBC <15k, Cr <1.5): PO fidaxomicin or PO vancomycin\nâ–  First severe (WBC >15k, Cr >1.5): PO fidaxomicin > PO vancomycin\nâ–  Recurrent (first, second, and subsequent episodes): PO fidaxomicin > PO\nvancomycin and consider fecal microbiota transplantation\nâ–  Fulminant without ileus: PO vancomycin + parenteral metronidazole\nâ–  Fulminant with ileus: PO and rectal vancomycin + parenteral\nmetronidazole\nComplications\nToxic megacolon presents with large bowel dilatation (>7 cm diameter in\ncolon or >12 cm in the cecum).\nDIVERTICULAR DISEASE\nâ–  Diverticula: Outpouching of mucosa and submucosa (false diverticula)\nthat herniate through the colonic muscle layers in areas of high intralumi-\nnal pressure; most commonly found in the sigmoid colon\nâ–  Diverticulosis: Presence of many diverticulaâ€”most common cause of\nacute lower GI bleeding in patients >40 years of age. Predominantly left-\nsided in Western countries. Bleeding usually results from weakened intes-\ntinal vasa recta vessels.\nKEY FACT\nâ–  Diverticulitis Inflammation following microperforations secondary to\nfecalith impaction and high luminal pressure.\nDiverticulosis is the most common\ncause of acute lower GI bleeding in â–  Risk factors: Diets that worsen constipation (eg, low fiber, red meat, and\nhigh-fat content), advanced age (65% occur in those >80 years of age),\npatients >40 years of age.\nand connective tissue disorders.\nHistory/PE\nâ–  Diverticulosis (see Fig. 2.6-22): Often asymptomatic unti",
      "char_start": 674000,
      "char_end": 676000
    },
    {
      "chunk_id": 338,
      "text": "l patients pres-\nent with sudden, intermittent, painless bleeding, which can cause symp-\ntoms of anemia when bleeding is severe. Diverticulosis is associated with\nchronic constipation, which increases intraluminal pressure of the colon\nand worsens outpouchings.\nâ–  Diverticulitis: LLQ abdominal pain, fever, nausea, and vomiting. Perfora-\ntion is a serious complication that presents with peritonitis and shock.\nDiagnosis\nâ–  Clinical history is important to diagnosis.\nâ–  CBC may show leukocytosis or anemia.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223322 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 233\nA B\nFIGURE 2.6-22. (A) An endoscopic view of diverticulosis. (B) An axial CT slice visualizing diver-\nticulosis. (Image A adapted with permission from USMLE-Rx.com. Image B adapted with permission from Sartelli M, Moore FA,\nAnsaloni L, et al. A proposal for a CT driven classification of left colon acute diverticulitis. World J Emerg Surg. 2015;10:3. https://doi.\norg/10.1186/1749-7922-10-3.)\nâ–  Most accurate test: Colonoscopy provides definitive diagnosis in divertic-\nular disease; however, sigmoidoscopy/colonoscopy should be avoided in L S\npatients with acute diverticulitis because of the risk for perforation.\nGB\nâ–  In acute diverticulitis, CT scan is the best test for diagnosis; it may reveal\ninflammation or abscess (see Fig. 2.6-23).\nTreatment\nâ–  Uncomplicated diverticulosis: Routine follow-up is indicated. Patient\nshould receive encouragement to follow a high-fiber diet or take fiber\nUB\nsupplements.\nâ–  Diverticular bleeding: Bleeding usually stops spontaneously; physician\nshould transfuse and hydrate patient as needed. If bleeding does not stop,\nFIGURE 2.6-23. Acute diverticulitis.\nhemostasis by colonoscopy, angiography with embolization, or surgery is\nCoronal reconstruction from a contrast-\nindicated. enhanced CT demonstrates sigmoid\nâ–  Diverticulitis: Treat with bowel rest (NPO), NG tube placement (if dive",
      "char_start": 676000,
      "char_end": 678000
    },
    {
      "chunk_id": 339,
      "text": "rticula with presigmoid inflammatory\nsevere), and broad-spectrum antibiotics (if complicated, metronidazole â€œfat stranding.â€ The area of abnormal-\nity is circled in red. GB, gallbladder; L,\nand a fluoroquinolone or a second- or third-generation cephalosporin).\nliver; S, stomach; UB, urinary bladder.\nUncomplicated, left-sided diverticulitis may initially be treated in the out-\n(Reproduced with permission from USMLE-Rx.com.)\npatient setting without antibiotics. Colonoscopy can occur after the initial\nstage.\nâ–  Hospitalization: If there is evidence of peritonitis or systemic signs of\nKEY FACT\ninfection.\nâ–  For perforation: Immediate surgical resection of diseased bowel via a Sigmoidoscopy should be avoided\nHartmann procedure with a temporary colostomy. when there is clinical and imaging\nevidence of diverticulitis because of the\nrisk for perforation.\nComplications\nDiverticulitis may cause fistulas in other organs, leading to pneumaturia, ster-\nile pyuria, fecaluria, or fecal discharge from the vagina. The physician should\ndiagnose with CT and treat with surgical resection.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223333 1100//2211//2222 1122::5588 PPMM\n\n234 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-11. Characteristics of Small and Large Bowel Obstruction KEY FACT\nVARIABLE SMALL BOWEL OBSTRUCTION LARGE BOWEL OBSTRUCTION Imaging allows identification of\nsmall and large bowels according to\nHistory Moderate to severe acute abdominal pain; copious emesis Constipation/obstipation, deep and cramping abdominal pain\nanatomic locations and appearance.\nCramping pain with distal SBO (less intense than SBO), nausea/vomiting (less than that of Small bowel: the plicae circularis\nFever, signs of dehydration, and hypotension possible SBO, but more commonly feculent) stand out due to their thin, circular,\ncircumferential mucosal folds. Large\nExamination Abdominal distention (distal SBO), abdominal tenderness, Significant distention, tympany,",
      "char_start": 678000,
      "char_end": 680000
    },
    {
      "chunk_id": 340,
      "text": " and tenderness bowel: characteristic haustral markings\nvisible peristaltic waves, fever, hypovolemia Examination for peritoneal irritation or mass formed by longitudinal and circular\nExamination for surgical scars/hernias; rectal examination Fever or signs of shock suggesting perforation/peritonitis or muscles.\nHigh-pitched â€œtinklyâ€ bowel sounds; later, absence of ischemia/necrosis\nbowel sounds High-pitched â€œtinklyâ€ bowel sounds; later, absence of bowel sounds\nEtiologies Adhesions (postsurgery), hernias, neoplasm, volvulus, Colon cancer, volvulus, diverticulitis, intussusception, fecal\nCrohn disease, intussusception, hematoma, foreign impaction, benign tumors\nbody, cystic fibrosis (CF), gallstone ileus Colon cancer assumed until proven otherwise\nDifferential LBO, paralytic ileus, gastroenteritis SBO, paralytic ileus, appendicitis, IBD, Ogilvie syndrome\n(pseudo-obstruction)\nDiagnosis CBC, electrolytes, lactic acid, x-ray of the abdomen, con- CBC, electrolytes, lactic acid, x-ray of the abdomen, CT scan,\ntrast studies (determine if it is partial or complete), CT water contrast enema (if perforation is suspected), endoscopic\nscan evaluation if stable and prior imaging equivocal for bowel\nperforation\nTreatment Hospitalize. Partial SBO can be treated conservatively with Hospitalize. Obstruction can be relieved with a Gastrografin\nNG decompression, IV fluids, and NPO status. enema, colonoscopy, or rectal tube; however, surgery is\nPatients with complete SBO should be managed aggres- usually required. Ischemic colon usually requires partial colec-\nsively with NPO status, NG decompression, IV fluids, tomy with a diverting colostomy.\nelectrolyte replacement, and surgical correction. Under- The physician should treat the underlying cause (eg, neoplasm).\nlying causes of obstruction (eg hernia or cancer) should\nbe treated as well, if present.\nMNEMONIC\nLARGE BOWEL OBSTRUCTION\n3-6-9 Rule of Bowel Dilation\nIn general, when the bowel is dilated Table 2.6-11 describes features that ",
      "char_start": 680000,
      "char_end": 682000
    },
    {
      "chunk_id": 341,
      "text": "distinguish SBO from large bowel\ngreater than the following dimensions,\nobstruction (LBO).\nphysicians consider it dilated.\nObstruction should be considered.\nSmall bowel: <3 cm IRRITABLE BOWEL SYNDROME\nLarge bowel/appendix: <6 cm/<6 mm\nCecum: <9 cm Among the most common GI conditions seen in primary care and GI clinics,\nwith a prevalence of 4% to 10%. IBS is an idiopathic functional disorder that\ncommonly affects women in their 20s to 30s. Often patients have comorbid\ndisorders such as depression, anxiety, and fibromyalgia.\nHistory/PE\nâ–  Patients with IBS present with abdominal pain that is related to bowel\nmovements, diarrhea and/or constipation, and abdominal distention.\nSymptoms often worsen with stress. It can be constipation predominant\n(IBS-C) or diarrheal predominant (IBS-D) or a combination of both.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223344 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 235\nA B KEY FACT\nImaging allows identification of\nsmall and large bowels according to\nanatomic locations and appearance.\nSmall bowel: the plicae circularis\nstand out due to their thin, circular,\ncircumferential mucosal folds. Large\nbowel: characteristic haustral markings\nformed by longitudinal and circular\nmuscles.\nFIGURE 2.6-24. Abdominal plain films. Supine (A) and upright (B) abdominal plain films\ndemonstrate multiple loops of dilated small bowel (arrows in A) with air/fluid levels (arrows in\nB) in the right abdomen, suggestive of small bowel obstruction; this finding can also be seen as\nan unusual sign of acute appendicitis. Intestinal malrotation was not considered at this time.\n(Reproduced with permission from Welte FJ, Grosso M. Left-sided appendicitis in a patient with congenital gastrointestinal\nmalrotation: A case report. J Med Case Rep. 2007;1:92..)\nâ–  No alarm symptoms: Rarely awakens patients from sleep. Vomiting, sig-\nnificant weight loss, hematochezia, and constitutional symptoms are\nuncommo",
      "char_start": 682000,
      "char_end": 684000
    },
    {
      "chunk_id": 342,
      "text": "n.\nâ–  PE: Usually unremarkable.\nDiagnosis\nâ–  Definition (per Rome IV diagnostic criteria): At least 4 days in 2 months\nof episodic abdominal discomfort that is (one or more of the following cri-\nteria): (1) related to defecation; (2) associated with a change in stool fre-\nquency or consistency; (3) associated with a change in stool appearance.\nMNEMONIC â–  There are no biomarkers or diagnostic tests currently available for IBS.\nLARGE BOWEL OBSTRUCTION Celiac disease should be ruled out in diarrhea-predominant IBS.\n3-6-9 Rule of Bowel Dilation\nâ–  In children, usually abdominal pain that is not resolved with resolution of\nIn general, when the bowel is dilated Table 2.6-11 describes features that distinguish SBO from large bowel constipation.\ngreater than the following dimensions,\nobstruction (LBO). â–  After appropriate evaluation, symptoms not fully explained by another\nphysicians consider it dilated.\nmedical condition.\nObstruction should be considered.\nSmall bowel: <3 cm IRRITABLE BOWEL SYNDROME\nLarge bowel/appendix: <6 cm/<6 mm Treatment\nCecum: <9 cm Among the most common GI conditions seen in primary care and GI clinics,\nâ–  Psychosocial: Patients benefit from a strong patient-physician relationship.\nwith a prevalence of 4% to 10%. IBS is an idiopathic functional disorder that\nPhysicians should offer reassurance and should not dismiss the symptoms.\ncommonly affects women in their 20s to 30s. Often patients have comorbid\nâ–  Lifestyle: Consistent physical activity in the form of exercise has been\ndisorders such as depression, anxiety, and fibromyalgia.\nshown to reduce severity of IBS-related symptoms.\nâ–  Diet: Patients should avoid insoluble fiber and supplement their diets with\nHistory/PE\nsoluble fiber (found in psyllium, oat bran, barley, and beans).\nâ–  Patients with IBS present with abdominal pain that is related to bowel â–  Chronic constipation may lead to anal fissures. Treat with topical anes-\nmovements, diarrhea and/or constipation, and abdominal distention. thetics and v",
      "char_start": 684000,
      "char_end": 686000
    },
    {
      "chunk_id": 343,
      "text": "asodilators.\nSymptoms often worsen with stress. It can be constipation predominant â–  Pharmacologic: Initial treatment includes soluble fiber and antispasmodics\n(IBS-C) or diarrheal predominant (IBS-D) or a combination of both. for global IBS symptoms. Symptomatic treatment of IBS-C may include\nuse of chloride channel activators (lubiprostone) or guanylate cyclase\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223355 1100//2211//2222 1122::5588 PPMM\n\n236 HIGH-YIELD FACTS IN GASTROINTESTINAL\nA\nactivators (linaclotide, plecanatide). Rifaximin may be used for treatment of\nIBS-D. Neuromodulators (eg, TCA/SNRI [serotonin-norepinephrine reup-\ntake inhibitor]) may be used to treat both IBS-C and IBS-D.\nCOLORECTAL CANCER\nThe second leading cause of cancer mortality in the United States. There is an\nâ†‘ incidence with age, with a peak incidence at 70 to 80 years of age. Risk factors\nand screening recommendations are summarized in Tables 2.6-12 and 2.6-13.\nHistory/PE\nMost patients are asymptomatic. In those who have symptoms, the location of\nB the lesion varies.\nâ–  Right-sided lesions: Often bulky, ulcerating, exophytic masses that lead to\nanemia from chronic occult blood loss. Patients may complain of weight\nloss, anorexia, diarrhea, weakness, or vague abdominal pain. Obstruction\nis rare. (Right colon has a larger diameter than left colon.)\nâ–  Left-sided lesions: Typically, â€œapple-coreâ€ obstructing masses (see Fig.\n2.6-25). Patients complain of obstruction, change in bowel habits (eg, â†“\nstool caliber, constipation, obstipation), and/or blood-streaked stools. (Left\nside has smaller diameter and thus is easier to obstruct.)\nâ–  Rectal lesions: Usually present with bright-red blood per rectum, often\nwith tenesmus and/or rectal pain. Rectal cancer must be ruled out in all\npatients with rectal bleeding. However, âŠ– fecal occult blood test (FOBT)\nhas insufficient sensitivity to exclude the possibility of cancer.\nFIGURE 2.6-25. A carcinoma seen in the\n",
      "char_start": 686000,
      "char_end": 688000
    },
    {
      "chunk_id": 344,
      "text": "ascending colon during colonoscopy (A)\nDiagnosis\nand apple-core lesion seen on contrast\nenema imaging (B). (Image A adapted with â–  Most accurate test: Colonoscopy with biopsy\npermission from Takiyama A, Nozawa H, Ishihara S, â–  Evaluation for metastases: CXR, liver function tests (LFTs), and an\net al. Secondary metastasis in the lymph node of the abdominal/pelvic CT\nbowel invaded by colon cancer: A report of three\nâ–  Staging based on the depth of tumor penetration into the bowel wall and\ncases. World J Surg Oncol. 2016;14[1]:273. Published\nthe presence of lymph node involvement and distant metastases\n2016 Oct 26. Image B reproduced with permission\nfrom USMLE-Rx.com.)\nTABLE 2.6-12. Risk Factors for Colorectal Cancer\nRISK FACTOR COMMENTS\nAge Risk â†‘ with age; peak incidence is at 70â€“80 years of age\nHereditary polyposis Familial adenomatous polyposis (FAP; 100% risk by 40 years\nsyndromes of age); hereditary nonpolyposis colorectal cancer (HNPCC,\nalso known as Lynch syndrome. Also risk for endometrial\nand ovarian cancers.)\nKEY FACT âŠ• Family history Especially first-degree relatives < 60 years of age\nIron-deficiency anemia in an older adult IBD Ulcerative colitis > Crohn disease\npatient indicates colorectal cancer until\nproven otherwise. Adenomatous polyps Villous > tubular; sessile > pedunculated\nHigh-fat, low-fiber diet, â€”\nalcohol, and sedentary\nlifestyle\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223366 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 237\nTABLE 2.6-13. Screening Recommendations for Colorectal Cancer\nRISK CATEGORY RECOMMENDATIONS\nNo past medical or family Starting at 45 years of age (U.S. Preventive Services Task\nhistory Force grade B):\nâ–  Annual fecal occult blood test (FOBT), fecal immunochemical\ntest (FIT) or DNA-based stool tests (eg, Cologuard; in certain\npatients)\nâ–  Colonoscopy every 10 years or\nâ–  Sigmoidoscopy every 5 years\nFirst-degree relative with Colonoscopy every 5 years, starting ",
      "char_start": 688000,
      "char_end": 690000
    },
    {
      "chunk_id": 345,
      "text": "at 40 years of age, or co-\ncolon cancer lonoscopy every 5 years, starting 10 years before the age\nof affected family member at time of diagnosis (whichever\ncomes first). Average-risk screening resumes at age 60.\nInflammatory bowel disease Colonoscopy every 1â€“2 years starting 8â€“10 years after diagnosis\nHereditary nonpolyposis Colonoscopy every 1â€“2 years starting at 25 years of age\ncolon cancer syndrome\nFamilial adenomatous Sigmoidoscopy every year starting at 12 years of age\npolyposis\nHigh-risk colonoscopy Colonoscopy every 3â€“5 years\nfindings (eg, high-grade\ndysplasia, >1 cm, and\nvillous component)\nTreatment\nâ–  Best initial treatment: Surgical resection of the tumor (colectomy of vary-\ning length depending on tumor size) Â± radiation for rectal cancer\nâ–  Neoadjuvant chemotherapy and/or radiotherapy usually administered to\nreduce tumor burden\nâ–  Follow-up with serial carcinoembryonic antigen (CEA) levels to detect\nrecurrence; colonoscopy 1 year after resection and every 3 to 5 years there-\nafter; LFTs, CXR, and abdominal CT to screen for metastases\nCOLORECTAL CANCER-ASSOCIATED CONDITIONS\nSeveral genetically linked diseases may increase the risk of lower intestinal\nmalignancy, including Lynch syndrome, Peutz-Jeghers syndrome, Gardner\nsyndrome, Turcot syndrome, and juvenile polyposis syndrome.\nA 60-year-old patient with no past\nLynch Syndrome medical history presents with fever,\ndyspnea, and orthopnea of 2 weeksâ€™\nAlso called hereditary nonpolyposis colorectal cancer (HNPCC). Autosomal duration. Physical examination reveals\ndominant disease that increases risk for Colorectal, Endometrial, Ovarian splinter hemorrhages and a new IV/\n(â€œCEOâ€) cancers due to a mismatch-repair gene deficiency (eg, MSH2, VI diastolic decrescendo murmur.\nMLH1, MSH6, PMS2, and EPCAM). Echocardiogram confirms aortic\nvalve endocarditis, and IV antibiotics\nâ–  Hx/PE: Patient aged <50 years with positive family history of colorectal are started. Blood cultures are âŠ• for\n(eg, three or more members) or assoc",
      "char_start": 690000,
      "char_end": 692000
    },
    {
      "chunk_id": 346,
      "text": "iated cancers Streptococcus bovis. What is the next\nâ–  Dx: Genetic testing for most commonly mutated genes (listed earlier) diagnostic step?\nâ–  Tx: Colonoscopy every 1 to 2 years starting at age 20 to 25 years or 5 years\nprior to earliest family Lynch diagnosis\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223377 1100//2211//2222 1122::5588 PPMM\n\n238 HIGH-YIELD FACTS IN GASTROINTESTINAL\nPeutz-Jeghers Syndrome\nAutosomal dominant disease that leads to benign, hamartomatous polyps.\nAlthough polyps are benign, patients remain at higher risk for GI, breast, and\ngynecologic cancers.\nâ–  Hx/PE: Numerous mucocutaneous pigmented macules and possibly a\nfamily history of the associated cancers\nâ–  Dx: Diagnosis with two of three clinical history criteria: family history of\nPeutz-Jeghers, presence of hyperpigmented macules (see Fig. 2.6-26), and/\nFIGURE 2.6-26. A classic finding of or hamartomatous polyps found in GI tract\nPeutz-Jeghers syndrome: pigmented â–  Tx: Requires GI cancer screening at diagnosis (EGD, video capsule\nmacules on oral mucosa. (Reproduced with\nendoscopy, and colonoscopy) with subsequent screening based on pres-\npermission from Gondak RO, da Silva-Jorge R, Jorge J,\nence of polyps\nLopes MA, Vargas PA. Oral pigmented lesions: Clinico-\npathologic features and review of the literature. Med\nOral Patol Oral Cir Bucal. 2012;17[6]:e919-e924.)\nGardner Syndrome\nFamilial adenomatous polyposis (FAP) + osteomas + fibromatosis\nâ–  Hx/PE: Painless bone growths typically on the skull or facial bones.\nUnerupted teeth. Dermal manifestations such as lipomas or fibromas.\nFundoscopy showing hypertrophy of retinal pigment epithelium.\nâ–  Dx: Occurs through genetic testing or presence of >100 colorectal polyps\nand classic skin and bone findings.\nâ–  Tx: Screening for GI cancer with sigmoidoscopy every year, starting at\n12 years of age (similar to that of FAP).\nTurcot Syndrome\nFAP + brain tumors (eg, medulloblastoma)\nâ–  Hx/PE: Signs of neurologic deficit in",
      "char_start": 692000,
      "char_end": 694000
    },
    {
      "chunk_id": 347,
      "text": " the setting of positive family history\nor >100 polyps found on colonoscopy\nâ–  Dx: Genetic testing for APC mutation or mismatch-repair gene mutations\n(eg, MLH1 and PMS2)\nâ–  Tx: Similar screening to FAP, as well as neurologic screenings (brain\nimaging for screening not typically done)\nJuvenile Polyposis Syndrome (JPS)\nAutosomal dominant condition causing numerous hamartomatous polyps in\nthe GI tract in young patients.\nâ–  Hx/PE: Most commonly presents in a young adult (<20 years) with rectal\nbleeding or signs of anemia. May also have signs of obstruction or frequent\ndiarrhea.\nâ–  Dx: Endoscopy revealing one or more of the following: single polyp in\nsomeone with family history of JPS, >5 polyps found in colorectum, or\nmultiple polyps anywhere else in GI tract.\nâ–  Tx: Colonoscopy every 1 to 3 years or yearly if polyps are found; upper\nendoscopy every 2 to 3 years or yearly if polyps are found.\nISCHEMIC COLITIS\nColonoscopy is the next diagnostic\nstep. Although the mechanism of\nassociation has yet to be determined, Insufficient blood supply to the colon that results in ischemia and, poten-\nthere is a well-established association tially, necrosis. Most commonly affects the left colon, particularly the\nbetween S. bovis and colon cancer. â€œwatershed areaâ€ at the splenic flexure (see Fig. 2.6-27 for anatomic illustra-\nClostridium septicum is also associated tion of watershed areas of the colon). Usually occurs in the setting of\nwith colon cancer. atherosclerosis.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223388 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 239\nAbdominal Superior and inferior\naorta mesenteric artery\nwatershed\nSuperior\nmesenteric Splenic flexure\nartery\nInferior mesenteric\nartery\nHypogastric artery\n(internal iliac artery) Inferior mesenteric\nand hypogastric\nartery watershed\nRectosigmoid junction\nFIGURE 2.6-27. Watershed areas of the GI tract. (Reproduced with permission from USMLE-Rx.com.)\nHistory/PE\nâ– ",
      "char_start": 694000,
      "char_end": 696000
    },
    {
      "chunk_id": 348,
      "text": " Presents with crampy lower abdominal pain followed by bloody diarrhea\nafter meals or exertion or in the heat. Fever and peritoneal signs suggest\nbowel necrosis.\nâ–  Risk factors: Surgery that may reduce blood flow to colon (eg, AAA repair,\ncoronary artery bypass), atherosclerosis risk factors (eg, diabetes and hyper-\ntension), hypercoagulability, and constipation.\nDifferential\nâ–  Acute mesenteric ischemia: History more suggestive of a thrombus or\nembolus in the setting of arrythmia or long-standing atherosclerosis.\nInfarction is not localized to watershed areas.\nâ–  Chronic mesenteric ischemia: Less acute presentation than ischemic coli-\ntis. Patient has history of food aversion due to postprandial pain.\nDiagnosis\nâ–  Best initial test: CT scan with contrast possibly showing thickened bowel\nwall, atherosclerosis\nâ–  Most accurate test: Angiography\nâ–  Colonoscopy possibly showing a pale mucosa with petechial bleeding\nTreatment\nâ–  Supportive therapy with bowel rest, IV fluids, and broad-spectrum\nantibiotics\nâ–  Surgical bowel resection indicated for infarction, fulminant colitis, or\nobstruction\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 223399 1100//2211//2222 1122::5588 PPMM\n\n240 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-14. Differentiating Anorectal Diseases\nDISEASE CLASSIC PRESENTATION RISK FACTORS TREATMENT\nExternal hemorrhoids Pruritic and painful Obesity, constipation, older High-fiber diet, sitz baths, stool soft-\n(below dentate May appear blue if thrombosed age, and pregnancy eners, topical analgesia\nline) Hemorrhoidectomy if refractory\nInternal hemorrhoids Painless, bright-red bleeding after defecation Obesity, sitting on toilet for High-fiber diet, sitz baths, stool soft-\n(above dentate or wiping extended times, older eners, topical analgesia\nline) age, and pregnancy Rubber band ligation if refractory\nRectal prolapse Protruding, erythematous mass with concentric Multiparity, prior pelvic Diet and lifestyle modifications\nrin",
      "char_start": 696000,
      "char_end": 698000
    },
    {
      "chunk_id": 349,
      "text": "gs seen when patient bears down surgery, older age, (increased fiber and water intake)\nMay have preceding discomfort, constipation, chronic constipation or If refractory and symptomatic, pos-\nincontinence diarrhea, or post-stroke sibly surgery (rectopexy)\nAnal fissure Intense pain lasting for hours typically following Constipation or diar- Diet and lifestyle modifications;\ndefecation Â± blood on toilet paper rhea, Crohn disease, or topical anesthetics and vasodilators\nClassically seen on examination at posterior malignancy If refractory, lateral sphincterotomy\nmidline of anal canal\nAbscess Tender, fluctuant mass at anal verge Constipation, DM, and Prompt incision and drainage fol-\nMay have fever or other systemic symptoms immunosuppression lowed by empiric antibiotics\nAnorectal fistula Intermittent, malodorous perianal drainage Perianal abscesses, Crohn Surgical closure (fistulotomy)\nand pain with defecation disease, and malignancy\nProctalgia fugax Recurrent rectal pain unrelated to defecation, Higher incidence among Reassurance, biofeedback therapy,\nlasting seconds to minutes females and age <45 or possibly inhaled albuterol when\nNo organic cause identifiable years symptomatic\nRadiation proctitis Acute: Within 3 months following pelvic Pelvic radiation in the Acute: May be self-limited\nradiation setting of rectal, prostate, Antidiarrheals and butyrate enema\nDiarrhea, mucus, and minimal bleeding or other malignancy Chronic: Sucralfate or steroid enemas\nChronic: Within 3 months to 2 years of pelvic Endoscopic thermal coagulation for\nradiation bleeding\nConstipation, rectal pain, and severe bleeding\nMICROSCOPIC COLITIS\nChronic, inflammatory cause of diarrhea subdivided into lymphocytic and\ncollagenous colitis.\nHistory/PE\nThe typical patient is a middle-aged adult with chronic, watery diarrhea who\nhas negative workup for other etiologies.\nDiagnosis\nEvaluation of other causes typically precedes the required colonic biopsy to\ndiagnose (eg, infectious, celiac, Crohn disease",
      "char_start": 698000,
      "char_end": 700000
    },
    {
      "chunk_id": 350,
      "text": "). Colonoscopy classically\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224400 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 241\nA\nshows normal mucosa. Biopsy will show subepithelial collagen if the patient\nhas a collagenous variant; alternatively, the biopsy will show intraepithelial\nlymphocytes if the lymphocytic variant.\nTreatment\nThe patient should avoid trigger medications (eg, NSAIDs, sertraline, PPIs).\nSupplemental antidiarrheals and short courses of glucocorticoids may be used\nif refractory.\nANORECTAL DISEASE\nThe rectum and anus have diverse pathology that can cause significant symp-\ntoms for patients, which can be distinguished based on presentation, exam,\nB\nand risk factors (Table 2.6-14).\nHEMORRHOID GRADING\nI â€“ Enlarged vasculature without prolapse\nII â€“ Reducible prolapse that occurs only with straining\nIII â€“ Manually reproducible prolapse that extends below the dentate line\nIV â€“ Prolapse that cannot be reduced\nINFLAMMATORY BOWEL DISEASE\nIncludes Crohn disease (see Fig. 2.6-28) and ulcerative colitis (see Fig. 2.6-29).\nSee Table 2.6-15 for differentiation between the two diseases. See Figure 2.6-30\nfor anatomic distribution of diseases. Most common in Caucasians and those of\nAshkenazi Jewish decent, with onset most frequently occurring in the teens to\nC\n50s. Table 2.6-9 summarizes the features of IBD. In patients with a history of\nCrohn disease and acute abdominal pain, the physician should suspect SBO,\nwhich is caused by transmural inflammation and stricture formation. Transmu-\nral inflammation in Crohn disease can also lead to fistula formation, abscesses,\nand draining sinuses. Ulcerative colitis does not cause fistulas.\nA B C\nFIGURE 2.6-29. Ulcerative colitis. (A)\nX-ray from a barium enema showing a\nfeatureless (â€œlead pipeâ€) colon with small\nmucosal ulcerations (arrow). Compare\nwith normal haustral markings in (B). (C)\nDiffuse mucosal ulcerations and exudates\nFIGURE 2.6-28. Crohn disease.",
      "char_start": 700000,
      "char_end": 702000
    },
    {
      "chunk_id": 351,
      "text": " (A) Small bowel follow-through (SBFT) barium study shows at colonoscopy in chronic ulcerative colitis.\nskip areas of narrowed small bowel with nodular mucosa (arrows) and ulceration. Compare (Image A reproduced with permission from Doherty\nwith normal small bowel (arrowhead). (B) Spot compression image from SBFT shows â€œstring GM. Current Diagnosis & Treatment: Surgery, 13th ed. New\nsignâ€ narrowing (arrow) caused by stricture. (C) Deep ulcers in the colon of a patient with York, NY: McGraw-Hill; 2010. Image B reproduced with\nCrohn disease, seen at colonoscopy. (Image A reproduced with permission from Chen MY et al. Basic Radiology. permission from Chen MY et al. Basic Radiology. New\nNew York, NY: McGraw-Hill; 2004. Image B reproduced with permission from USMLE-Rx.com. Image C reproduced with per- York, NY: McGraw-Hill; 2004. Image C reproduced with\nmission from Fauci AS et al. Harrisonâ€™s Principles of Internal Medicine, 17th ed. New York, NY: McGraw-Hill; 2008). permission from Fauci AS et al. Harrisonâ€™s Principles of\nInternal Medicine, 17th ed. New York, NY: McGraw-Hill;\n2008.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224411 1100//2211//2222 1122::5588 PPMM\n\n242 HIGH-YIELD FACTS IN GASTROINTESTINAL\nInvolvement in Involvement in a\na discontinuous continuous pattern\npattern\nRectum is spared Rectum involvement\nCrohnâ€™s disease Ulcerative colitis\nFIGURE 2.6-30. Crohn disease vs ulcerative colitis distribution throughout the GI tract. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nTABLE 2.6-15. Features of Ulcerative Colitis and Crohn Disease\nVARIABLE ULCERATIVE COLITIS CROHN DISEASE\nSite of Rectum always involved. May extend proximally in a contin- May involve any portion of the GI tract, particularly the\ninvolvement uous fashion. In most cases only involves the colon. ileocecal region, in a discontinuous pattern (â€œskip\nInflammation and ulceration limited to the mucosa and lesionsâ€); rectum is often spared\nsubmucosa Transmu",
      "char_start": 702000,
      "char_end": 704000
    },
    {
      "chunk_id": 352,
      "text": "ral inflammation is seen, sometimes leading to\nfistulas to other organs\nHistory/ Bloody diarrhea, lower abdominal cramps, tenesmus, urgency Abdominal pain, abdominal mass, low-grade fever, weight\nexamination Exam possibly revealing orthostatic hypotension, tachycardia, loss, watery diarrhea\nabdominal tenderness, frank blood on rectal exam, and Exam may reveal fever, abdominal tenderness or mass,\nextraintestinal manifestations perianal fissures or tags, fistulas, and extraintestinal\nToxic megacolon possibly presented (avoidance of tubes or manifestations\nscopes in view of the risk for perforation)\nExtraintestinal Aphthous stomatitis, episcleritis/uveitis, arthritis, primary Same as ulcerative colitis (UC) in addition to fistulas to the\nmanifesta- sclerosing cholangitis, erythema nodosum, and pyoderma skin, to the bladder, or between bowel loops\ngangrenosum\ntions\nDiagnosis CBC, x-ray of the abdomen, stool cultures, O&P, stool assay for Same lab workup as for UC; upper GI series with small\nC difficile bowel follow-through\nColonoscopy possibly showing diffuse and continuous rectal Colonoscopy possibly showing aphthoid, linear, or stellate\ninvolvement, friability, edema, and pseudopolyps ulcers; strictures; noncaseating granulomas, â€œcobble-\nDefinitive diagnosis with biopsy stoning,â€ and â€œskip lesionsâ€\nâ€œCreeping fatâ€ possibly present during laparotomy\nDefinitive diagnosis with biopsy\nTreatment 5-acetylsalicylic acid (ASA) agents (eg, sulfasalazine, mesa- Similar to UC: Corticosteroids for flare-ups. May require\nlamine), topical or oral; corticosteroids for flare-ups and biologics (eg, infliximab) (first-line) or immunomodula-\nimmunomodulators (eg, azathioprine) or biologics (eg, tors (eg, azathioprine) for refractory or moderate to\ninfliximab) for refractory or moderate to severe disease severe disease and for maintenance therapy\nTotal proctocolectomy possibly curative for long-standing or Surgical resection potentially necessary for suspected per-\nfulminant colitis or to",
      "char_start": 704000,
      "char_end": 706000
    },
    {
      "chunk_id": 353,
      "text": "xic megacolon; also â†“ cancer risk foration, stricture, fistula, or abscess\nIncidence of Markedly â†‘ risk for colorectal cancer in long-standing cases Incidence of secondary malignancy lower than that for UC\n(monitor with frequent FOBT and yearly colonoscopy with but greater than that of the general population\ncancer\nmultiple biopsies after 8 years of disease)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224422 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 243\nTABLE 2.6-16. Types of Hernias\nHERNIA\nTYPE LOCATION ETIOLOGY PREVALENCE\nIndirect Herniation of abdominal contents through both Results from congenital patent processus vaginalis Most common\nexternal and internal rings, lateral to inferior\nepigastric vessels (see Fig. 2.6-36)\nDirect Herniation through floor of Hesselbach triangle, Mechanical breakdown in transversalis fascia\nmedial to epigastric vessels (see Fig. 2.6-36) resulting from older age\nFemoral Herniation below inguinal ligament through Increased intra-abdominal pressure, weakened More common in\nfemoral canal, below and lateral to the pubic pelvic floor females than in\ntubercle males\nIncisional Herniation through the site of a previous surgical Localized, mechanical weakness of the abdominal Most commonly\nincision (incisional hernia) wall from prior abdominal incision occurs after\nRisk factors: Patient factors (older age, smoking, midline abdominal\nobesity, immunosuppression, connective tissue incisions\ndisease) and technical factors (wound infection,\nsuboptimal closure, fascial dehiscence, larger\nopen, as opposed to laparoscopic, surgeries)\nSpigelian Just lateral to the lateral border of the rectus Caused by a defect in the spigelian aponeurosis Usually occur in\nmuscle that is composed of the transversus the fifth or sixth\ndecades of life; rare\nUmbilical Center of the umbilical ring Typically caused by herniation of omentum or peri- More common in\ntoneal fat through the umbilical ring; bow",
      "char_start": 706000,
      "char_end": 708000
    },
    {
      "chunk_id": 354,
      "text": "el can females, but more\nherniate through here as well likely to present\nRisk factors: Obesity, abdominal distention, ascites, incarcerated in\npregnancy males\nEpigastric Midline between the umbilicus and the xiphoid Thought to be due to a congenitally weakened More common in\nprocess linea alba males; rare\nRisk factors: Extensive physical training, coughing,\nobesity, smoking, chronic steroid use, diabetes,\nolder age, and male sex\nKEY FACT\nHERNIAS\nEpigastric, umbilical, and anterior\nInguinal hernias are protrusions of abdominal contents (usually the small incisional hernias are all types of ventral\nintestine) into the inguinal region through a weakness or defect in the abdom- hernias.\ninal wall. See Table 2.6-16 for comparisons of several different types of com-\nmon hernias, including inguinal hernias.\nKEY FACT\nTreatment\nThe Hesselbach triangle is an area\nBecause of the risk for incarceration and strangulation, surgical correction is\nbounded by the inguinal ligament, the\nindicated.\ninferior epigastric artery, and the rectus\nabdominis.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224433 1100//2211//2222 1122::5588 PPMM\n\n244 HIGH-YIELD FACTS IN GASTROINTESTINAL\nBILIARY DISEASE\nL\nCHOLELITHIASIS AND BILIARY COLIC\nColic results from transient cystic duct blockage from impacted stones.\nAlthough risk factors include the four Fs (Female, Fat, Fertile, and Forty), the\ndisorder is common and can occur in any patient. Additional risk factors\ninclude use of oral contraceptive pills (OCPs), rapid weight loss, chronic hemo-\nlysis (pigment stones in sickle cell disease), small bowel resection (loss of\nFIGURE 2.6-31. Cholelithiasis. Ultra- enterohepatically circulated bile), and TPN. Table 2.6-17 details the forms of\nsound image of the gallbladder shows a\nbiliary disease and compares the laboratory findings associated with each one.\ngallstone (arrow) with posterior shadow-\ning. L, Liver. (Reproduced with permission from\nUSMLE-Rx.com.)\nHistory/P",
      "char_start": 708000,
      "char_end": 710000
    },
    {
      "chunk_id": 355,
      "text": "E\nâ–  Postprandial abdominal pain (usually in the RUQ) that radiates to the\nright subscapular area or the epigastrium, often associated with nausea and\nMNEMONIC vomiting, dyspepsia, and flatulence\nâ–  Gallstones: May have RUQ tenderness and a palpable gallbladder or be\nMDs donâ€™t Lie\nasymptomatic\nMedial to inferior epigastric vessel = Direct\nhernia\nDiagnosis\nLateral to epigastric vessel = Indirect hernia\nRUQ ultrasound is the best initial test and the most accurate test (see Fig. 2.6-31).\nTreatment\nKEY FACT\nâ–  Cholecystectomy is curative and recommended for patients with symp-\nImmunosuppressed patients (especially\ntomatic gallstones. Asymptomatic gallstones do not require treatment.\npatients with diabetes) are at risk for\nLifestyle modifications may help aid in asymptomatic gallstone elimina-\nemphysematous cholecystitis (infection\ntion (eg, reduced refined carbohydrates, adequate fiber intake, glycemic\nof the gallbladder with gas-forming\ncontrol in people with diabetes, weight loss at a modest pace).\nbacteria). This requires emergent chol-\necystectomy. â–  Porcelain gallbladder (PGB), characterized by gallbladder calcification, is\noften (but not always) asymptomatic and discovered incidentally. Risk of\ngallbladder adenocarcinoma is increased. Cholecystectomy is indicated if\nsymptomatic or asymptomatic with high-risk features (eg, spotty calcifica-\ntion) or low procedural risk (eg, young and fit).\nComplications\nPostcholecystectomy syndrome can stem from retained stones, strictures, or\nextrabiliary causes. Symptoms include early satiety, bloating, and dyspepsia\nafter cholecystectomy. Diagnosis is made with additional abdominal imaging\n(ultrasound, endoscopic retrograde cholangiopancreatography [ERCP], mag-\nnetic resonance cholangiopancreatography [MRCP]).\nCHOLECYSTITIS\nProlonged blockage of the cystic duct by a gallstone, which leads to progres-\nsive distention, inflammation, and infection. Acalculous cholecystitis occurs\nin the absence of cholelithiasis in patients who are c",
      "char_start": 710000,
      "char_end": 712000
    },
    {
      "chunk_id": 356,
      "text": "hronically debilitated or\ncritically ill.\nHistory/PE\nâ–  History: RUQ pain, nausea, vomiting, and fever. See Figure 2.6-32 for\nultrasound findings consistent with acute cholecystitis.\nâ–  Physical exam: RUQ tenderness, inspiratory arrest with deep palpation of\nthe RUQ (Murphy sign), and low-grade fever.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224444 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 245\nTABLE 2.6-17. Disorders Caused by Gallstones\nLABORATORY\nDISORDER DEFINITION PRESENTATION RESULTS DIAGNOSIS MANAGEMENT\nCholelithiasis Stones in the May be asymptomatic, or Normal total bili- Ultrasonography If asymptomatic,\ngallbladder may cause biliary colic; rubin/alkaline observation; if\ntransient RUQ pain com- phosphatase, symptomatic,\nmonly seen after eating serum amylase laparoscopic\nfatty meals; caused by cholecystectomy\ntemporary occlusion of\nthe cystic duct by a stone\nCholecystitis Inflammation of RUQ pain, fever (maybe), â†‘ WBC, normal Ultrasonography, Laparoscopic cho-\nthe gallbladder, Murphy sign (cessation total bilirubin/ hepato-iminodiacetic lecystectomy; if\ntypically of inspiration with pal- alkaline acid (HIDA) scan patient is too ill to\ncaused by pation of RUQ) phosphatase, undergo surgery,\nstone Tends to present in criti- amylase transcutaneous\noccluding the cally ill patients, typically drainage of\ncystic duct in the ICU gallbladder\nCholedocholithiasis Stone in the Jaundice, Â± RUQ pain, Normal/â†‘ WBC, Ultrasonography often Endoscopic\ncommon bile afebrile â†‘ total bili- does not show the retrograde\nduct (CBD) rubin/alkaline stone but may show cholangiopancre-\nphosphatase, dilated CBD. Magnetic atography (ERCP)\nâ†‘ amylase/ resonance cholan- to remove stone,\nlipase (if giopancreatography followed by\npancreatitis is (MRCP) and endoscopic cholecystectomy\npresent) retrograde cholangio-\npancreatography (ERCP)\nare definitive\nCholangitis Infection of the Charcot triad: RUQ pain, â†‘ WBC, â†‘ total bil- Cl",
      "char_start": 712000,
      "char_end": 714000
    },
    {
      "chunk_id": 357,
      "text": "inical diagnosis con- ERCP; surgery if\nCBD, usually fever, jaundice, Reynolds irubin/alkaline firmed by biliary dilation patient toxic\ncaused by pentad: Charcot triad phosphatase on imaging; or ERCP\nstone in the + shock and altered (both diagnostic and\nCBD mental status therapeutic)\nA 43-year-old patient presents to\nFIGURE 2.6-32. Cholecystitis. RUQ ultra-\nthe emergency department with\nsound imaging of acute cholecystitis reveal-\nnausea, vomiting, and epigastric\ning pericholecystic fluid with a gallstone\npain. They have complained of\nvisualized within the gallbladder lumen.\nintermittent RUQ pain for the past\n(Reproduced with permission from Nibhanipudi K, Al-\nHusaini A, Kahlon S, Stone RK. An unusual cause of vomit- several months. Physical examination\ning in an infant of 3 months of age. Case Rep Emerg Med. reveals marked epigastric tenderness.\n2012;2012:913481.) Labs show leukocytosis, â†‘ aspartate\naminotransferase (AST) and alanine\naminotransferase (ALT), and â†‘ lipase.\nX-ray of the abdomen is unremarkable.\nWhat is the most likely diagnosis?\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224455 1100//2211//2222 1122::5588 PPMM\n\n246 HIGH-YIELD FACTS IN GASTROINTESTINAL\nDiagnosis\nâ–  Best initial test: Ultrasound may reveal stones, bile sludge, pericholecystic\nfluid, a thickened gallbladder wall, gas in the wall of the gallbladder, and/\nor an ultrasonic Murphy sign.\nâ–  If ultrasound is equivocal, the next best step is a hepato-iminodiacetic acid\n(HIDA) scan. A nuclear imaging tool, it uses a radiotracer excreted\nthrough the biliary system. On HIDA, nonvisualization of the gallbladder\nsuggests acute cholecystitis.\nTreatment\nâ–  Broad-spectrum IV antibiotics and IV fluids\nâ–  Cholecystectomy indicated\nCHOLEDOCHOLITHIASIS\nGallstones in the common bile duct (CBD). Symptoms vary according to the\ndegree of obstruction, the duration of the obstruction, and the presence/sever-\nity of infection.\nâ–  Hx/PE: Biliary colic, jaundice, afebrile unless ",
      "char_start": 714000,
      "char_end": 716000
    },
    {
      "chunk_id": 358,
      "text": "current infection, and/or\npancreatitis\nâ–  Dx: â†‘ alkaline phosphatase and total and direct bilirubin (see Table 2.6-17)\nâ–  Tx: ERCP with sphincterotomy followed by cholecystectomy\nCHOLANGITIS\nâ–  An acute bacterial infection of the biliary tree that commonly occurs sec-\nondary to obstruction, usually from gallstones (choledocholithiasis).\nâ–  Other etiologies: Bile duct stricture, primary sclerosing cholangitis (PSC),\nand malignancy. Gram âŠ– enterics commonly identified pathogen.\nHistory/PE\nâ–  Charcot triadâ€”RUQ pain, jaundice, and fever/chillsâ€”is classic.\nâ–  Reynolds pentadâ€”Charcot triad plus septic shock and altered mental sta-\ntusâ€”may be present in acute suppurative cholangitis.\nDiagnosis\nâ–  Labs: Leukocytosis, â†‘ bilirubin, and â†‘ alkaline phosphatase (see Table\n2.6-17); blood cultures\nâ–  Best initial test: Ultrasound diagnostic for CBD dilation\nâ–  Most accurate test: ERCP diagnostic and therapeutic\nTreatment\nThe most likely diagnosis is gallstone â–  Patients often require ICU admission for monitoring, hydration, BP sup-\npancreatitis, which results from port, and broad-spectrum IV antibiotic treatment.\na gallstone that travels through â–  Patients with acute suppurative cholangitis require emergent bile duct\nthe common bile duct (CBD) and\ndecompression via ERCP/sphincterotomy, percutaneous transhepatic\nlodges at the ampulla of Vater,\ndrainage, or open decompression.\nthus obstructing the flow of both\npancreatic exocrine enzymes and\nbile. It most commonly occurs in GALLSTONE ILEUS\nfemales, who often report a history\nof biliary colic. Treatment involves\nMechanical obstruction resulting from the passage of a large (>2.5 cm) stone\nmanagement of the pancreatitis\ninto the bowel through a cholecystoduodenal fistula. Obstruction is often at\nwith supportive care and elective\nthe ileocecal valve.\ncholecystectomy.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224466 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 247\nâ–  Hx/PE: Class",
      "char_start": 716000,
      "char_end": 718000
    },
    {
      "chunk_id": 359,
      "text": "ic presentation is a subacute SBO in an older adult female.\nPatients may have no history of biliary colic.\nâ–  Dx: X-ray of the abdomen with characteristics of SBO and pneumobilia\n(gas in the biliary tree) confirming diagnosis. Upper GI barium contrast\nimages will demonstrate no contrast in the colon.\nâ–  Tx: Laparotomy with stone extraction; closure of the fistula and\ncholecystectomy\nPOSTCHOLECYSTECTOMY SYNDROME\nPersistent abdominal pain and dyspepsia in a patient who has had a chole-\ncystectomy. This syndrome may occur immediately after the procedure\n(early postcholecystectomy syndrome [PCS]) or months afterwards (late\nPCS). PCS can be caused by several conditions. One-half of patients have\nbiliary, pancreatic, or GI disorders, and the other half have extraintestinal\ndisease.\nâ–  Early PCS causes: Biliary injury, retained cystic duct, or CBD stones\nâ–  Late PCS causes: Recurrent CBD stones, bile duct stricture, inflamed\ncystic duct or gallbladder remnant, papillary stenosis, or biliary dyskinesia\n(motor forms of sphincter of Oddi dysfunction)\nâ–  Extrabiliary GI causes of PCS: IBS, pancreatitis, pancreatic tumors, pan-\ncreatic divisum, hepatitis, PUD, mesenteric ischemia, diverticulitis, or\nesophageal diseases\nâ–  Extraintestinal causes of PCS: Intercostal neuritis, wound neuroma, cor-\nonary artery disease (CAD), or psychomotor disorders\nâ–  Hx/PE: Postoperative persistent abdominal pain and dyspepsia\nâ–  Dx: Imaging (eg, ultrasound, CT, or MRCP) to determine underlying KEY FACT\ncause of PCS (eg recurrent stones, bile duct injury)\nBile acid diarrhea may be a part of\nâ–  Tx: Tailored to underlying cause of PCS postcholecystectomy syndrome. With\nâ–  Prevention: Careful selection of patients who would benefit from chole- the gallbladder no longer present,\ncystectomy, weighing the risks/benefits of surgery against each in the\nexcess bile acids can enter the colon\ncontext of underlying medical conditions and overall stability of the\nand continuous drainage can overcome\npatient\nthe termina",
      "char_start": 718000,
      "char_end": 720000
    },
    {
      "chunk_id": 360,
      "text": "l ileumâ€™s ability to reabsorb\nbile, causing diarrhea. Usually resolves\nBILIARY CYST on its own. Tx: cholestyramine or\ncolestipol.\nâ–  Hx/PE: Most patients with biliary cysts will present before the age of 10\nwith the triad of abdominal pain, jaundice, and a palpable mass (not all\nwill have all three in the triad). Other symptoms that may be seen include\nnausea/vomiting, pain, fever, and jaundice. Others may have cysts discov-\nered incidentally on imaging.\nâ–  Dx: Laboratory evaluation is often normal. If obstruction is present within\nthe biliary system, there may be transaminitis and hyperbilirubinemia.\nâ–  Prognosis: Biliary cysts are associated with an increased risk of cholangio-\ncarcinoma, and surgical resection via Roux-en-Y hepaticojejunostomy may\nbe indicated.\nCHOLANGIOCARCINOMA\nArise from squamous cells of the biliary epithelium. It has the potential to\nbe highly lethal due to an insidious presentation. Symptoms typically arise\nwhen obstruction ensues from the growing tumor. Cholangiocarcinoma\nmay be extrahepatic or intrahepatic, with intrahepatic cholangiocarcinoma\ntypically presenting even more insidiously (and often incidentally on\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224477 1100//2211//2222 1122::5588 PPMM\n\n248 HIGH-YIELD FACTS IN GASTROINTESTINAL\nimaging) than extrahepatic cholangiocarcinoma. Intrahepatic cholangiocar-\ncinoma will be discussed here.\nâ–  Risk factors: Patients may have history of PSC, fibropolycystic liver dis-\nease, chronic liver disease, or parasitic exposure to liver flukes.\nâ–  Hx/PE: Cholangiocarcinoma manifests itself with jaundice, pruritis, clay-\ncolored stools, and dark urine. Patients may also have a dull/achy RUQ\nabdominal pain and weight loss. Laboratory evaluation will typically reveal\nhyperbilirubinemia, elevated alkaline phosphatase, and either normal or\nslightly elevated transaminase levels.\nâ–  Dx: Tumor markers (CA 19-9, CEA, Î±-fetoprotein [AFP]), and abdominal\nimaging (ultrasound, CT",
      "char_start": 720000,
      "char_end": 722000
    },
    {
      "chunk_id": 361,
      "text": ", MRCP) raise suspicion for the diagnosis of\ncholangiocarcinoma. EUS with fine-needle aspiration (FNA) or ERCP\nallows for tissue sampling to confirm the diagnosis.\nâ–  Tx: Those with distal cholangiocarcinoma who meet criteria for surgical\nresection can have surgical resection performed via a pancreaticoduode-\nnectomy (Whipple procedure). Those who have evidence of metastasis\nmay require chemoradiation.\nLIVER DISEASE\nABNORMAL LIVER ASSOCIATED ENZYMES\nLiver diseases can be divided into several patterns, based on LFT results as follows:\nâ–  Hepatocellular injury: â†‘ aspartate aminotransferase (AST) and alanine\naminotransferase (ALT)\nâ–  Cholestasis: â†‘ alkaline phosphatase\nâ–  Mixed: Combination of hepatocellular and cholestatic picture\nâ–  Isolated hyperbilirubinemia: â†‘ bilirubin\nJaundice is a clinical sign that occurs when bilirubin levels exceed 2.5 mg/dL.\nFigures 2.6-33 and 2.6-34 summarize the clinical approach toward cholestasis\nand isolated hyperbilirubinemia.\nCholestasis ( alkaline\nphosphatase and bilirubin)\nDuctal dilation?\nNo Yes\nIntrahepatic cholestasis Biliary obstruction\nMedications Stone\nPost-op Stricture\nSepsis Cancer\nFIGURE 2.6-33. Approach to cholestasis. (Reproduced with per-\nmission from USMLE-Rx.com.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224488 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 249\nIsolated hyperbilirubinemia\n( bilirubin)\nUnconjugated Conjugated\nOverproduction Defective conjugation Defective excretion\nHemolytic anemia Gilbert syndrome (<5 mg/dL) Dubin-Johnson syndrome\nCrigler-Najjar syndrome Rotor syndrome\nFIGURE 2.6-34. Approach to isolated hyperbilirubinemia. (Reproduced with\npermission from USMLE-Rx.com.)\nHEPATITIS\nInflammation of the liver leading to cell injury and necrosis. Hepatitis can be\neither acute or chronic. KEY FACT\nâ–  Acute: Most common causes are viruses (hepatitis A virus [HAV], hepatitis Hepatitis C virus (HCV) is Chronic; 70%\nB virus [HBV], hepatitis C virus ",
      "char_start": 722000,
      "char_end": 724000
    },
    {
      "chunk_id": 362,
      "text": "[HCV], hepatitis D virus [HDV], hepati-\nto 80% of patients with HCV infection\ntis E virus [HEV]) and drugs (alcohol, acetaminophen, isoniazid [INH],\nwill develop chronic hepatitis.\nmethyldopa).\nâ–  Fulminant: This is also known as acute liver failure. Severe liver injury\nwith international normalized ratio (INR) >1.5 and hepatic encepha-\nlopathy in a patient without underlying chronic liver disease.\nâ–  Chronic: The most common causes are chronic viral infection (HCV MNEMONIC\nmost common in United States, HBV worldwide), alcohol, autoimmune\nHepatitis virusâ€”\nhepatitis, and metabolic syndromes (Wilson disease, hemochromatosis,\nÎ± -antitrypsin deficiency). A: Acute (up to 2 months of nausea/\n1\nvomiting, jaundice, fatigue, fever,\nabdominal pain)\nHistory/PE\nB: Body fluids (blood, sexual activity,\nvertical transmission, breastfeeding)\nâ–  Acute hepatitis:\nC: Chronic (becomes chronic for most)\nâ–  Acute hepatitis often begins with a nonspecific viral prodrome (mal-\nD: Double whammy (coinfection of\naise, fever, joint pain, nausea, vomiting, changes in bowel habits) fol-\nhepatitis B required)\nlowed by jaundice and RUQ tenderness. Exam often reveals jaundice,\nE: Expecting (pregnant patients)\nscleral icterus, and tender hepatomegaly.\nâ–  HAV and HEV have only a self-limited acute phase; HBV and HCV\nmay feature a mild acute phase or none at all. Acetaminophen toxicity\ncan cause a life-threatening hepatitis. Table 2.6-18 outlines further dis-\ntinctions among these.\nâ–  Chronic hepatitis: It may be asymptomatic, or it may cause fatigue and\njoint and muscle pains. Jaundice and complications of portal hypertension\ntypically occur only when the disease progresses to cirrhosis. At least 80%\nof those infected with HCV and 10% of those with HBV in adulthood will\ndevelop persistent infection with chronic active hepatitis.\nA 21-year-old college student in\nthe midst of final exams presents to\nDiagnosis a local clinic with â€œyellow eyes.â€ His\nâ–  Acute hepatitis: Labs reveal markedly â†‘ ALT and AST, â†‘ gamm",
      "char_start": 724000,
      "char_end": 726000
    },
    {
      "chunk_id": 363,
      "text": "a-glutamyl physical exam is unremarkable except\nfor scleral icterus, and a CBC and\ntransferase (GGT), â†‘ ferritin, and â†‘ bilirubin/alkaline phosphatase.\nblood smear show no abnormalities.\nA comprehensive metabolic profile\nreveals a normal AST and ALT but\nelevated unconjugated bilirubin. What\nis the most likely diagnosis?\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 224499 1100//2211//2222 1122::5588 PPMM\n\n250 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-18. Types of Hepatitis\nVIRUS MODE OF\nTYPE TRANSMISSION PRESENTATION NOTES\nHAV Fecal-oral Typically self-limited acute hepatitis Most common cause of acute viral hepatitis worldwide\nMay lead to fulminant hepatic failure\nHBV Bodily fluids/ May be asymptomatic, but may present as viral pro- <10% of infections in adults become chronic, while\nblood- drome (this is listed above) and/or jaundice most vertically transmitted become chronic\nborne May lead to fulminant hepatic failure and require Extremely high transmission rate\ntreatment with antivirals or liver transplant in severe\ncases\nHCV Bodily fluids Asymptomatic or viral prodrome and/or jaundice 80% become chronic\nLess likely to be sexually transmitted than HBV\nMay present with very mild acute phase\nVery rarely leads to acute liver failure\nIf palpable purpura, arthralgia, and low complement\nlevels, cryoglobulinemia a possibility\nHDV Bodily fluids Co-infection with HBV or superinfection in patient with Requires HBV surface antigen. HDV is Dependent on HBV\nprior HBV (more severe)\nHEV Fecal-oral Typically self-limited acute hepatitis similar to HAV High mortality rate in pregnant women\nMay become chronic in patients with immunosuppression\nMNEMONIC â–  Chronic hepatitis: ALT and AST are either mildly elevated or even nor-\nmal/low for >3 to 6 months, contrasting with the marked elevations of\nAn AST/ALT ratio >2 suggests alcohol\nacute hepatitis.\nhepatitis: youâ€™re Toasted.\nâ–  Diagnosis of viral hepatitis is made by hepatitis serology (see ",
      "char_start": 726000,
      "char_end": 728000
    },
    {
      "chunk_id": 364,
      "text": "Table 2.6-19\nand Fig. 2.6-35 for a description and timing of serologic markers). The\nphysician may require a liver biopsy if diagnosis is uncertain or to rule out\nother causes of liver disease in chronic or severe cases.\nâ–  Other diagnostic studies include the following:\nâ–  Autoimmune hepatitis: âŠ• Antiâ€“nuclear and antiâ€“smooth muscle anti-\nbodies (type 1) and antiâ€“liver-kidney microsomal-1 antibodies and\nantiâ€“liver cytosol antibodies (type 2). May also present with elevated\nserum gamma globulins (IgG) and perinuclear antineutrophil cytoplas-\nmic antibody (p-ANCA).\nâ–  Hemochromatosis: â†‘ ferritin and transferrin saturation >50%. Liver\nbiopsy showing high hepatic iron index.\nThe most likely diagnosis is Gilbert\nâ–  Wilson disease: â†“ ceruloplasmin, â†‘ urine copper, Kayser-Fleischer\nsyndrome, an autosomal recessive\nrings. Liver biopsy if diagnosis uncertain.\ndisorder of bilirubin glucuronidation\ncaused by â†“ activity of the enzyme\nTreatment\nglucuronyl transferase. Patients\npresent with unconjugated â–  Acute hepatitis: Generally supportive care. Possibility of acute HBV\nhyperbilirubinemia but have a normal requiring treatment with antivirals.\nCBC, blood smear, and LFTs. The\nâ–  Alcoholic hepatitis: Treatment of alcohol withdrawal with benzodiaze-\ncondition is benign, and no treatment\npines if showing signs of withdrawal, providing adequate hydration and\nis indicated.\nsupplementation to maintain nutritional status.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225500 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 251\nImportant Incubation Prodrome, Convalescence\ndiagnostic period acute disease Early Late\ntests\nHBsAg Anti- Anti-HBs\nHBsAg\n(anti-HBc) HBc (anti-HBc)\nAnti-HBc\nDNA\nRelative polymerase\nconcentration\nof reactants HBV particles\nHBsAg\nWindow period Anti-HBs\nHBeAg Anti-HBe\nLevel of\ndetection\nMonths after 0 1 2 3 4 5 6 7 8\nexposure\nSymptoms\nSGPT (ALT)\nFIGURE 2.6-35. Time course of hepatitis B with serologic markers. (R",
      "char_start": 728000,
      "char_end": 730000
    },
    {
      "chunk_id": 365,
      "text": "eproduced with permission from\nUSMLE-Rx.com.)\nTABLE 2.6-19. Key Hepatitis Serologic Markers\nSEROLOGIC\nMARKER DESCRIPTION\nIgM HAVAb IgM antibody to HAV; the best test to detect acute HAV\nHBsAg Antigen found on the surface of HBV; continued presence indicates carrier state\nHBsAb Antibody to HBsAg; indicates immunity to HBV\nHBcAb Antibody to HBcAg; IgM âŠ• during the window period\nIgG HBcAb is an indicator of prior or current infection\nHBeAg A different antigenic determinant in the HBV core\nAn important indicator of transmissibility (Beware!)\nHBeAb Antibody to e antigen; indicates low transmissibility\nâ–  Drug-induced hepatitis: General treatmentâ€”removal of offending agent\nwith exceptions, including use of N-acetylcysteine for acetaminophen\noverdose and l-carnitine in the treatment of valproic acid overdose.\nâ–  Chronic hepatitis: Etiology-specific treatment.\nâ–  Chronic HBV infection: Tenofovir and entecavir most commonly used, as\nthey have the highest barrier to resistance. Other agents, including telbivudine,\nadefovir, and lamivudine, are not recommended because of a high rate of\nresistance.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225511 1100//2211//2222 1122::5588 PPMM\n\n252 HIGH-YIELD FACTS IN GASTROINTESTINAL\nNormal liver Steatosis Nonalcoholic Cirrhosis*\nsteatohepatitis*\nKEY FACT\nHepatitis B postexposure prophylaxis:\nNonimmunized individuals require both\nvaccination and immunoglobulins.\nFat deposition Fat deposition and Fibrosis\nHepatitis Bâ€“immunized individuals and inflammation\nthose exposed to hepatitis C do not *Risk factor for hepatocellular carcinoma\nrequire any postexposure prophylaxis.\nFIGURE 2.6-36. Liver cirrhosis progression. (Reproduced with permission from USMLE-Rx.com.)\nâ–  Chronic HCV infection: Varying medications and treatment duration,\nKEY FACT\nbased on genotype, cirrhosis status, and history of prior treatment. Typi-\nThe sequelae of chronic hepatitis cally, either two direct-acting antivirals (DAAs) or one DAA ",
      "char_start": 730000,
      "char_end": 732000
    },
    {
      "chunk_id": 366,
      "text": "plus ribavirin.\ninclude cirrhosis, portal hypertension, Interferon is no longer used. This field is rapidly evolving.\nliver failure, and hepatocellular â–  Most definitive treatment: Liver transplantation for patients with end-\ncarcinoma. stage liver failure. Emergent transplantation indicated in cases of fulmi-\nnant hepatic failure.\nComplications\nCirrhosis, liver failure, hepatocellular carcinoma (3%â€“5%).\nCIRRHOSIS\nGenerally speaking, cirrhosis is progressive fibrosis of liver parenchyma caus-\ning pathologic dysfunction resulting from chronic injury, which may arise by\nvarious means.\nKEY FACT\nâ–  Pathophysiology involves bridging fibrosis and nodular regeneration result-\nSpontaneous bacterial peritonitis is a\ning from chronic hepatic injury.\ncommon complication in patients with\nâ–  Most common etiologies in the United States are alcohol, chronic HCV,\ncirrhosis and ascites, and if they present\nand nonalcoholic steatohepatitis. Cirrhosis occurs in a progressive pattern,\nwith signs and symptoms suggestive\nstarting at a normal liver and eventually resulting in liver cirrhosis (see\nof infection, paracentesis should be\nFig. 2.6-36 for progression and Fig. 2.6-37 for a visual representation). Eti-\nperformed. Spontaneous bacterial\nologies can be as follows:\nperitonitis is diagnosed by >250\nâ–  Etiology of all causes of chronic hepatitis: Biliary tract disease (primary bil-\npolymorphonuclear leukocytes (PMNs)/\niary cirrhosis, PSC); posthepatic causes, including right-sided heart failure,\nmm3 in the ascitic fluid.\nconstrictive pericarditis, and Budd-Chiari syndrome (hepatic vein throm-\nbosis secondary to hypercoagulability).\nHistory/PE\nâ–  May be asymptomatic, though may present with jaundice, easy bruising\n(coagulopathy), and complications of portal hypertension such as ascites,\nhepatic encephalopathy (asterixis, altered mental status; see Table 2.6-20\nfor hepatic encephalopathy grading), gastroesophageal varices, hepatic\nhydrothorax (transudative pleural effusion), and thrombocytope",
      "char_start": 732000,
      "char_end": 734000
    },
    {
      "chunk_id": 367,
      "text": "nia. Asci-\ntes can be complicated by spontaneous bacterial peritonitis. Tables 2.6-21\nand 2.6-22 help differentiate ascitic fluid characteristics and their associ-\nated differential diagnoses.\nâ–  May reveal an enlarged, palpable, or firm liver and other signs of portal\nhypertension and liver failure (Fig. 2.6-37).\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225522 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 253\nIntegumentary Neurologic\nJaundice Hepatic encephalopathy\nSpider angiomas Asterixis (â€flapping tremorâ€)\nPalmar erythema\nPurpura\nGastrointestinal\nPetechiae\nAnorexia\nNausea, vomiting\nEffects of portal Dull abdominal pain\nhypertension Fetor hepaticus\nEsophageal varices\n( hematemesis) Hematologic\nGastric varices Thrombocytopenia\n( melena) Anemia\nCoagulation disorders\nCaput medusae Splenomegaly\nAscites\nAnorectal varices Renal\nHepatorenal syndrome\nReproductive Metabolic\nTesticular atrophy Hyperbilirubinemia\nGynecomastia Hyponatremia\nAmenorrhea\nCardiovascular\nCardiomyopathy\nPeripheral edema\nFIGURE 2.6-37. Presentation of cirrhosis/portal hypertension. (Reproduced with permission from\nUSMLE-Rx.com.)\nTABLE 2.6-20. Grading of Encephalopathy by West Haven Criteria\nGRADE MENTAL STATUS ASTERIXIS ELECTROENCEPHALOGRAPHY (EEG)\nI â–  Euphoria/depression Possible Usually normal\nâ–  Mild confusion\nâ–  Slurred speech\nâ–  Disordered sleep\nII â–  Lethargy Yes Abnormal\nâ–  Moderate confusion\nIII â–  Marked confusion Yes Abnormal\nâ–  Incoherent\nâ–  Sleeping but arousable\nIV â–  Coma No Abnormal\nDiagnosis\nâ–  Most accurate diagnostic test: Liver biopsy showing bridging fibrosis and\nnodular regeneration\nâ–  Alternative diagnostic tests: Biochemical (eg, AST:ALT ratio, APRI, FIB-4,\nthrombocytopenia, other proprietary tests [fibroscan, fibrosure]), and elasto-\ngraphic measures of fibrosis (fibroscan, MR elastography, US elastography).\nâ–  Synthetic dysfunction: â†“ albumin, â†‘ prothrombin time (PT)/INR, and â†‘\nbilirubin\nâ–  Portal hypertension: Thromboc",
      "char_start": 734000,
      "char_end": 736000
    },
    {
      "chunk_id": 368,
      "text": "ytopenia (secondary to hypersplenism,\nsequestration of platelets in the liver, and â†“ thrombopoietin production),\nvarices, ascites (paracentesis)\nâ–  Etiology: Hepatitis serologies, autoimmune markers, serum ferritin, ceru-\nloplasmin, and Î± -antitrypsin\n1\nâ–  If ascites present, etiology of ascites determined by the serum-ascites albu-\nmin gradient (SAAG = serum albuminâ€“ascites albumin); see Table 2.6-20\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225533 1100//2211//2222 1122::5588 PPMM\n\n254 HIGH-YIELD FACTS IN GASTROINTESTINAL\nTABLE 2.6-21. Etiologies of Ascites by SAAG\nSAAG > 1.1 SAAG < 1.1\nRelated to portal hypertension: Not related to portal hypertension:\nâ–  Presinusoidal: Splenic or portal vein thrombosis, schistosomiasis â–  Nephrotic syndrome\nâ–  Sinusoidal: Cirrhosis â–  TB\nâ–  Postsinusoidal: Right heart failure, constrictive pericarditis, Budd-Chiari â–  Malignancy with peritoneal carcinomatosis (eg, ovarian\nsyndrome cancer)\nTABLE 2.6-22. Ascites Fluid Characteristics\nColor â–  Bloody: trauma, malignancy, TB (rare)\nâ–  Milky: chylous\nâ–  Turbid: possible infection\nâ–  Straw-colored: likely more benign causes\nNeutrophils â–  â‰¥250/mm3: peritonitis (secondary or spontaneous bacterial)\nTotal Protein â–  â‰¥2.5 g/dL (high-protein ascites)\nâ–  CHF, constrictive pericarditis, peritoneal carcinomatosis, TB, Budd-Chiari syndrome, fungal\nâ–  <2.5 g/dL (low-protein ascites)\nâ–  Cirrhosis, nephrotic syndrome\nSAAG â–  â‰¥1.1 g/dL (indicates portal hypertension)\nâ–  Cardiac ascites, cirrhosis, Budd-Chiari syndrome\nâ–  <1.1 g/dL (absence of portal hypertension)\nâ–  TB, peritoneal carcinomatosis, pancreatic ascites, nephrotic syndrome\nKEY FACT Treatment\nHepatic encephalopathy manifestations The goal is to treat and prevent the progression of cirrhosis and minimize factors\nrange from changes in behavior that can lead to decompensation (see Table 2.6-23). All cirrhotic patients should\nto coma. Hepatic encephalopathy receive vaccinations for hepatitis A, hepatitis B, and PPSV-23 ",
      "char_start": 736000,
      "char_end": 738000
    },
    {
      "chunk_id": 369,
      "text": "(pneumonia).\nis graded, based on degree of\nsymptomatology. Asterixis may be SPONTANEOUS BACTERIAL PERITONITIS\npresent.\nSpontaneous bacterial peritonitis (SBP) is defined as an infection of the ascitic\nfluid, typically presenting in patients with advanced cirrhosis. The higher the\nModel for End-stage Liver Disease (MELD) score, the higher the risk of SBP.\nHistory/PE\nâ–  SBP classically presents with fever, abdominal pain, chills, nausea, altered\nKEY FACT\nmental status, and vomiting.\nCommon causes of SBP include â–  Patients may be asymptomatic (~13%â€“30% of patients have no signs or\nsymptoms).\nperforation peritonitis (eg, perforated\npeptic ulcer), nonperforation â–  Altered mental status is seen in approximately one-half of patients and\ndoes not correlate with ammonia levels.\nperitonitis (eg, perinephric abscess), or\ntranslocation of GI flora. â–  Lab abnormalities may include subtle leukocytosis, metabolic acidosis,\nand azotemia.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225544 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 255\nTABLE 2.6-23. Complications of Cirrhosis\nCOMPLICATION MECHANISM/HISTORY MANAGEMENT\nAscites â†‘ portal hypertension results in transudative Sodium restriction and diuretics (furosemide, spironolactone);\neffusion large-volume paracentesis. TIPS (Transjugular Intrahepatic Por-\nPhysical exam reveals abdominal distention, fluid tosystemic Shunt)\nwave, and shifting dullness to percussion Treat underlying liver disease if possible\nSpontaneous Presents with fever, abdominal pain, chills, nausea, IV antibiotics acutely (third-generation cephalosporin), IV albumin;\nbacterial and vomiting prophylaxis with a fluoroquinolone to prevent recurrence\nperitonitis Treatment indicated if diagnostic paracentesis Development of SBP is associated with poor 1-year prognosis\nreveals >250 PMNs/mL\nHepatorenal Prerenal failure in the setting of severe liver disease Initially trial of volume repletion and rule out o",
      "char_start": 738000,
      "char_end": 740000
    },
    {
      "chunk_id": 370,
      "text": "ther causes of renal\nsyndrome A diagnosis of exclusion failure\nCaused by splanchnic vasodilation and decreased May use octreotide (decrease splanchnic vasodilation) and mido-\nblood flow to the kidneys drine (increase blood pressure)\nUrinary sodium <10 mEq/L May require dialysis\nâ€œHealthy kidneys in an unhealthy environmentâ€ Poor prognosis\nLiver transplantation can be curative\nHepatic enceph- â†“ clearance of ammonia; often precipitated by Lactulose and/or rifaximin\nalopathy dehydration, infection, electrolyte abnormalities, Correct underlying triggers\nand GI bleeding\nEsophageal Portal hypertension leads to â†‘ flow through porto- Endoscopic surveillance in all patients with cirrhosis; medical\nvarices systemic anastomoses prophylaxis with nonselective Î²-blockers or endoscopic band\nligation to prevent bleeding in patients with known varices\nFor acute bleeding, endoscopy with band ligation or sclerotherapy\nis indicated. Urgent TIPS in refractory cases (associated with high\nmortality)\nCoagulopathy Impaired synthesis of all clotting factors For acute bleeding, administer fresh frozen plasma\n(except VIII) Vitamin K will not correct coagulopathy\nCHF, Congestive heart failure; SAAG, serum ascites albumin gradient; SBP, spontaneous bacterial peritonitis; TB, tuberculosis.\nEtiologies\nMost common cause is Escherichia coli. Other organisms include Klebsiella\npneumonia, Streptococcus pneumonia, Enterobacteriaceae, and Staphylococcus.\nPathogenesis\nâ–  Disturbance in gut flora is related to overgrowth and extraintestinal\ntranslocation.\nâ–  It is thought cirrhosis predisposes to a bacterial overgrowth because of\naltered small intestinal motility.\nâ–  Bacterial seeding is secondary to urinary tract infections, pneumococcal\nsepsis, cellulitis, pharyngitis, and dental infections.\nRisk Factors\nâ–  Advanced cirrhosis\nâ–  Previous episode of SBP\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225555 1100//2211//2222 1122::5588 PPMM\n\n256 HIGH-YIELD FACTS IN GASTROINT",
      "char_start": 740000,
      "char_end": 742000
    },
    {
      "chunk_id": 371,
      "text": "ESTINAL\nâ–  Variceal hemorrhage\nâ–  Total protein concentration <1g/dL in ascites fluid\nâ–  Serum total bilirubin >2.5 mg/dL\nâ–  GI bleed\nâ–  Use of PPIs\nDiagnosis\nâ–  Paracentesis of ascitic fluid with analysis of cell count. Samples should be\ntaken before antibiotic administration.\nâ–  Ascitic, blood, and urine cultures indicated.\nâ–  Elevated ascitic fluid absolute PMN count (>250 PMNs/mm3) is\ndiagnostic.\nâ–  Evaluation needed for secondary causes of peritonitis.\nKEY FACT\nTreatment\nSBP prophylaxis is important in all\nâ–  IV antibiotics (third-generation cephalosporin)\ncirrhotic patients admitted for a GI\nâ–  IV albumin for patients with renal dysfunction\nbleed/variceal hemorrhage due to the\nâ–  Prophylaxis with a trimethoprim-sulfamethoxazole or a fluoroquinolone to\nincreased risk of bacterial translocation.\nprevent recurrence\nPrognosis\nâ–  Development of SBP is associated with poor 1-year prognosis due to its\nassociation with advanced cirrhosis\nâ–  Recurrence rates of SBP are close to 70%\nISCHEMIC HEPATITIS\nAlso called shock liver, hypoxic hepatitis, and hypoxic liver injury. Generally\nis diffuse hepatic injury resulting from acute hypoperfusion.\nâ–  Risk factors: Any type of shock.\nâ–  Hx/PE: History of shock (any kind of shock) or other acute causes of blood\nsupply interruption (eg, hepatic sickle cell crisis or hepatic artery thrombo-\nsis in those who have undergone liver transplantation or who have pre-\nexisting portal vein thrombosis).\nâ–  Dx: History of hypotensive episode followed by transaminitis with LFTs 25\nto 250 times the normal levels (usually with AST and ALT >1000 units/L)\nand a massive rise in lactate dehydrogenase (LDH).\nKEY FACT â–  Tx: Addressing underlying causes of ischemic insult.\nâ–  Prognosis: In the absence of continued ischemic insult, LFTs usually nor-\nThere are few causes of liver injury that\nmalize in 7 to 10 days. The mortality rates are around 25% in ischemic\ncause LFTs to rise above 1000 units/L.\nhepatitis with shock (although mortality is mostly due to underlying cau",
      "char_start": 742000,
      "char_end": 744000
    },
    {
      "chunk_id": 372,
      "text": "se\nThese include drug-induced hepatitis,\nof shock rather than hepatitis alone). Occasionally patients will progress to\nviral hepatitis, and ischemic hepatitis.\nacute liver failure, where mortality rates range from 60% to 100%.\nACUTE LIVER FAILURE\nAlso called fulminant hepatic failure, acute hepatic necrosis, fulminant\nhepatic necrosis, and fulminant hepatitis. Characterized by severe acute liver\ninjury, hepatic encephalopathy, and an elevated PT/INR (â‰¥1.5) that develops\nin less than 26 weeks (versus chronic liver failure). The diagnosis may also be\nmade in those with newly discovered Wilson disease, reactivation of chronic\nhepatitis B, or autoimmune hepatitis recognized in less than 26 weeks who\nalso have cirrhosis.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225566 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 257\nâ–  Etiology: Many different etiologies, the most common of which are due to\ndrug-induced and viral hepatitis\nâ–  Hx/PE: Fatigue/malaise, lethargy, anorexia, nausea/vomiting, RUQ pain,\npruritis, jaundice, abdominal distention (secondary to ascites), and hepatic\nencephalopathy\nâ–  Dx: Must have elevated transaminases, hepatic encephalopathy (any\ngrade), and prolonged PT (INR â‰¥1.5) KEY FACT\nâ–  Tx: Diagnosing and treating the underlying cause of acute liver failure,\nThose with acute severe alcoholic\ntransferring to ICU at a liver transplant center whenever possible, avoiding\nhepatitis, even if recognized in less than\nhepatotoxic medications, and addressing complications that can occur\n26 weeks, are considered to have acute-\nâ–  Complications: Hemodynamic derangement, bleeding, malnutrition,\non-chronic severe alcoholic hepatitis\nelectrolyte derangements (hypokalemia, hyponatremia, hypophosphate-\nas opposed to acute liver failure, since\nmia, and hypoglycemia), hepatic encephalopathy, cerebral edema with\nthere is usually a long history of alcohol\nassociated increased intracranial pressure elevation, seizu",
      "char_start": 744000,
      "char_end": 746000
    },
    {
      "chunk_id": 373,
      "text": "res, acute renal\nuse disorder.\nfailure, and pulmonary edema/infections\nHEPATORENAL SYNDROME\nAcute kidney injury caused by acute or chronic liver disease causing fulmi-\nnant renal failure.\nâ–  Pathogenesis: Arterial vasodilation in the splanchnic circulation (arteries\nsupplying visceral organs of the abdomen) secondary to portal hyperten-\nsionâ€“induced nitric oxide release. This is ultimately unable to be over-\ncome by the renin-angiotensin-aldosterone system (RAAS), leading to\nkidney injury.\nâ–  Hx/PE: Underlying liver disease accompanied by a progressive rise in\nserum creatinine.\nâ–  Type 1: More serious; at least a twofold increase in serum creatinine to\na level greater than 2.5 mg/dL in less than 2 weeks.\nâ–  Type 2: Kidney failure that is less severe than type 1 hepatorenal syn-\ndrome. The major clinical feature of type 2 hepatorenal syndrome is\nascites resistant to diuretics.\nâ–  Dx: One of exclusion, meaning other causes of potential kidney injury\nmust be ruled out.\nâ–  Tx: Addressing underlying liver pathology and treating appropriately (if\npossible) in addition to medical therapy/optimization. Those who do not\nrespond may benefit from a TIPS procedure.\nHEPATOPULMONARY SYNDROME\nHypoxemia secondary to ventilation/perfusion mismatch caused by acute or\nchronic liver disease.\nâ–  Pathogenesis: As with hepatorenal syndrome, this is thought to be due to\nincreased nitric oxide release due to portal hypertension. This results in\ndilation of pulmonary vasculature, leading to increased blood delivery to\npulmonary circulation without an equal increase in ventilation. This\nresults in blood being delivered to the left side of the heart that is inade-\nquately oxygenated\nâ–  Hx/PE: Underlying liver disease in addition to dyspnea (nonspecific),\nplatypnea (increased dyspnea while standing; relieved while recumbent),\northodeoxia (decreased oxygen saturation when moving from recumbent\nto standing position), and hypoxemia.\nâ–  Dx: One of exclusion, meaning other causes of hypoxemia and dyspnea\nsho",
      "char_start": 746000,
      "char_end": 748000
    },
    {
      "chunk_id": 374,
      "text": "uld be ruled out. In general, those with underlying liver disease with\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225577 1100//2211//2222 1122::5588 PPMM\n\n258 HIGH-YIELD FACTS IN GASTROINTESTINAL\nimpaired oxygenation (A-a gradient >20 mm Hg, PaO <70 mm Hg, and\n2\nidentified pulmonary vascular abnormalities identified on transthoracic\ncontrast echocardiography.\nâ–  Tx: Observation with pulse oximetry or arterial blood gases every 6 to 12\nmonths is adequate to monitor for worsening disease process; supplemen-\ntal oxygen may be required if symptomatic. In those with severe to very\nsevere disease, in addition to oxygen supplementation liver transplantation\nshould be considered as well as TIPS. Liver transplantation is curative.\nHEPATIC HYDROTHORAX\nGenerally speaking, hepatic hydrothorax is accumulation of ascitic fluid in\nthe pleural cavity in patients with underlying liver disease.\nâ–  Pathogenesis: Thought to be due to passage of ascitic fluid from the peri-\ntoneal cavity through diaphragm defects into the pleural cavity. Defects\nare usually <1 cm and associated with the tendinous portion of the dia-\nphragm. Most often, hepatic hydrothorax occurs on the right side of the\ndiaphragm due to the left side being more muscular and thicker.\nâ–  Hx/PE: Typically presents with dyspnea (nonspecific), a nonproductive\ncough, pleuritic chest pain, and hypoxemia in a patient with underlying\nliver disease and ascites.\nâ–  Dx: Identification of a pleural effusion on CXR and ruling out other\ncauses of pleural effusion. Further evaluation via a thoracentesis with fluid\nstudies revealing transudative fluid can be performed to further rule out\nother potential causes of plural effusion. Similar to evaluating SAAG in\nascitic fluid, evaluating the serum-pleural albumin gradient should reveal\na gradient of >1.1 g/dL because the fluid is ascitic fluid.\nâ–  Tx: Similar to the treatment of ascites (sodium restriction and diuretics.)\nAdditionally, therapeutic thora",
      "char_start": 748000,
      "char_end": 750000
    },
    {
      "chunk_id": 375,
      "text": "centesis can be performed for symptom\nrelief. In those with refractory hepatic hydrothorax, a TIPS procedure can\nbe considered. In those who are not good candidates for TIPS, pleurodesis\n(chemical or mechanical obliteration of the pleural space to prevent accu-\nmulation of fluid/air), surgical repair of diaphragm defects, and liver trans-\nplantation may be considered.\nTRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT PROCEDURE\nCreates a low-resistance channel between the portal circulation and systemic\ncirculation to reduce portal pressure and help treat sequalae of portal hyper-\ntension (eg, ascites, varices.) Generally speaking, this minimally invasive pro-\ncedure is performed under fluoroscopic guidance in an interventional\nradiology suite, using wires and catheters to ultimately place a stent connect-\ning a hepatic vein to a portal vein.\nKEY FACT â–  Indications: Bleeding related to portal hypertension (eg, esophageal, gas-\ntric, or ectopic varices), portal hypertensive gastropathy/intestineopathy,\nHepatopulmonary syndrome in\nBudd-Chiari syndrome, hepatorenal syndrome, hepatopulmonary syn-\nportal hypertension may be from\ndrome, hepatic hydrothorax, and refractory ascites\nâ†‘ nitric oxide production â†’ â†‘\nâ–  Absolute contraindications: Congestive heart failure (CHF), severe tri-\npulmonary vascular dilation and V/Q\ncuspid regurgitation, severe pulmonary hypertension, polycystic liver dis-\nmismatch. Blood that flows through\nease, active systemic infection/sepsis, and unrelieved biliary obstruction\nthe pulmonary vasculature does not\nâ–  Postprocedural complications: Hepatic encephalopathy (secondary to\nreceive proper oxygenation due to an\nincreased ammonia in circulation; typically managed with rifaximin or\nunchanged amount of ventilation from\nlactulose), recurrent bleeding due to shunt stenosis/thrombosis (typically\nthe lungs.\nmanaged with angioplasty), and heart failure due to increased preload.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndd",
      "char_start": 750000,
      "char_end": 752000
    },
    {
      "chunk_id": 376,
      "text": "dd 225588 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 259\nPRIMARY SCLEROSING CHOLANGITIS\nAn idiopathic disorder characterized by progressive inflammation and fibrosis\naccompanied by strictures of extrahepatic and intrahepatic bile ducts. The\ndisease usually presents in young males with ulcerative colitis. Patients are at\nincreased risk for cholangiocarcinoma.\nHistory/PE\nPresents with progressive jaundice, pruritus, and fatigue.\nDiagnosis\nâ–  Laboratory findings including â†‘ ALP and â†‘ bilirubin; PSC also associated\nwith p-ANCA antibodies\nâ–  Most accurate test: MRCP/ERCP showing multiple bile duct strictures and\ndilatations (â€œbeadingâ€). MRCP is preferred initially as it is noninvasive.\nâ–  Liver biopsy revealing periductal sclerosis (â€œonion skinningâ€)\nâ–  Colonoscopy for all newly diagnosed patients to evaluate for IBD\nKEY FACT\nTreatment\nPrimary sclerosing cholangitis is\nERCP with dilation and stenting of strictures. Liver transplantation is the\nstrongly associated with ulcerative\ndefinitive treatment. Ursodeoxycholic acid has been shown to improve the\ncolitis.\nliver function profile in some patients.\nPRIMARY BILIARY CHOLANGITIS\nAutoimmune disorder characterized by destruction of intrahepatic bile ducts.\nMost commonly presents in middle-aged females with other autoimmune\nconditions.\nKEY FACT\nâ–  Hx/PE: Presents with progressive jaundice, pruritus, and fat-soluble vita-\nmin deficiencies (A, D, E, K)\nPrimary biliary cholangitis is an\nâ–  Dx: Laboratory findings including â†‘ ALP, âŠ• antimitochondrial antibody, autoimmune disease that presents with\nand â†‘ cholesterol\njaundice and pruritus in middle-aged\nâ–  Tx: Ursodeoxycholic acid (slows progression of disease) or obeticholic acid females.\nfor those intolerant of or unresponsive to ursodeoxycholic acid; cholestyr-\namine for pruritus; liver transplantation\nNONALCOHOLIC FATTY LIVER DISEASE\nSteatosis of hepatocytes leading to liver injury. Some patients progress to non-\nalcoholic steatohepatitis (NASH) and are at ",
      "char_start": 752000,
      "char_end": 754000
    },
    {
      "chunk_id": 377,
      "text": "risk for liver fibrosis and cirrhosis.\nIt is associated with insulin resistance and metabolic syndrome.\nâ–  Dx: Largely a diagnosis of exclusion. Liver biopsy may show steatosis or\nsteatohepatitis.\nâ–  Tx: Weight loss, diet, and exercise. If NASH is present, the physician\nshould consider vitamin E and pioglitazone.\nHEPATOCELLULAR CARCINOMA\nHepatocellular carcinoma is one of the most common cancers worldwide\ndespite its relatively low incidence in the United States. Metastatic disease\n(especially from colon cancer) is much more common than primary hepatic\ncancer.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 225599 1100//2211//2222 1122::5588 PPMM\n\n260 HIGH-YIELD FACTS IN GASTROINTESTINAL\nRisk factors: In the United States, risk factors are cirrhosis (from alcohol,\nHCV, and NASH) and chronic hepatitis B (even without cirrhosis). In devel-\noping countries, HBV infection and aflatoxins (in various food sources) are\nmajor risk factors.\nHistory/PE\nâ–  Patients commonly present with RUQ tenderness, abdominal distention,\nand signs of chronic liver disease such as jaundice, easy bruising, and\ncoagulopathy. The disease may present as decompensation of previously\ncompensated cirrhosis.\nâ–  Exam may reveal tender hepatomegaly.\nDiagnosis\nHepatocellular carcinoma is often suggested by the presence of a mass on\nultrasound or CT, as well as by abnormal LFTs and significantly elevated\nAFP levels. Biopsy is required if diagnosis is uncertain, but can be deferred if\nimaging findings are highly suggestive of hepatocellular cancer.\nTreatment\nâ–  Surgical: Partial hepatectomy if technically feasible and synthetic func-\ntion preserved. An orthotopic liver transplantation in patients with cirrho-\nsis is preferred treatment if there are only a few small tumors (Milan\ncriteria: single lesion <5 cm or three lesions <3 cm).\nâ–  Nonsurgical: Transarterial chemoembolization (TACE) and/or radiofre-\nKEY FACT quency ablation. Tyrosine kinase inhibitors (eg, levatinib), i",
      "char_start": 754000,
      "char_end": 756000
    },
    {
      "chunk_id": 378,
      "text": "mmunother-\napy (eg, atezolizumab), and anti-VEGF antibodies (eg, bevacizumab) may\nHepatic adenomas (caused by oral\nbe indicated for advance metastatic disease.\ncontraceptives) are benign tumors and\nâ–  May monitor AFP levels (if previously elevated) and use serial surveillance\ndo not transform into malignancy.\nimaging (ultrasound, CT) to screen for recurrence.\nHEMOCHROMATOSIS\nA state of iron overload in which hemosiderin accumulates in the liver, pan-\ncreas (islet cells), heart, adrenal glands, and pituitary gland\nâ–  Primary hemochromatosis: An autosomal recessive disease characterized by\nmutations in the HFE gene that result in excessive absorption of dietary iron\nâ–  Secondary hemochromatosis: Occurs in patients receiving chronic trans-\nfusion therapy (eg, sickle cell disease or Î±-thalassemia)\nHistory/PE\nâ–  Presentation with abdominal pain, DM, hypogonadotropic hypogonadism\n(due to deposition of hemosiderin in the pituitary), arthropathy of the\nmetacarpophalangeal joints, heart failure, impotence, or cirrhosis.\nâ–  Bronze skin pigmentation, cardiac dysfunction (CHF), hepatomegaly, and\ntesticular atrophy. Labs may reveal evidence of DM.\nâ–  Lung, kidney, or eye unaffected.\nDiagnosis\nâ–  Best initial tests: Iron studies showing â†‘ serum iron, percent saturation of\niron, and ferritin with â†“ serum transferrin. A transferrin saturation (serum\niron divided by total iron-binding capacity [TIBC]) >45% is highly sug-\ngestive of iron overload.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226600 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 261\nâ–  Most accurate tests: HFE gene mutation screen (C282Y/H63D) and\nMRI; liver biopsy (most accurate test) to determine hepatic iron index.\nTreatment\nâ–  Weekly phlebotomy to normalize serum iron levels (target ferritin between\n50 and 100 mcg/L) and then maintenance phlebotomy every 2 to 4 months\nâ–  Iron-chelating agents such as deferoxamine, deferiprone, or deferasirox for\nmaintenance the",
      "char_start": 756000,
      "char_end": 758000
    },
    {
      "chunk_id": 379,
      "text": "rapy\nComplications\nCirrhosis, hepatocellular carcinoma, restrictive cardiomyopathy, arrhythmias,\nDM, impotence, arthropathy, and hypopituitarism. Patients with hemochro-\nmatosis (and all patients with cirrhosis) have increased susceptibility to Vibrio\nvulnificus, Listeria monocytogenes, and Yersinia enterocolitica infections.\nWILSON DISEASE (HEPATOLENTICULAR DEGENERATION)\nAn autosomal recessive disorder that results in defective copper transport and\nsubsequent accumulation and deposition of copper in the liver and brain.\nUsually occurs in patients <30 years of age.\nHistory/PE\nFIGURE 2.6-38. Kayser-Fleischer ring.\nâ–  Presentation with hepatitis/cirrhosis, neurologic dysfunction (ataxia, tremor), Note the brown ring encircling the\nand psychiatric abnormalities (psychosis, anxiety, mania, depression) iris. This is a result of copper deposits\nâ–  May reveal Kayser-Fleischer rings (green-to-brown copper deposits in the in the Descemet membrane and is\nDescemet membrane; see Fig. 2.6-38), as well as jaundice, hepatomegaly,\na classic finding in Wilson disease.\n(Reproduced with permission from van Dijk HA,\nasterixis, choreiform movements, and rigidity\nFred HL. Images of memorable cases: case 81.\nConnexions Web site. December 3, 2008. Avail-\nable at https://cnx.org/contents/KD3uzS6O@3/\nDiagnosis\nImages-of-Memorable-Cases-Case-9)\nâ–  Best initial test: Serum ceruloplasmin level is decreased.\nâ–  If ceruloplasmin level is low, then 24-hour urinary copper excretion\n(increased) and slit lamp exam (for Keyser-Fleischer rings) are done.\nâ–  Most accurate test: Liver biopsy with dry copper weight or ATP7B gene\ntesting.\nTreatment\nPenicillamine or trientine (copper chelators that â†‘ urinary copper excretion),\ndietary copper restriction (avoid shellfish, liver, legumes), and zinc (â†‘ fecal\nexcretion)\nLIVER TRANSPLANTATION\nA 36-year-old woman with\nIndications: a past medical history of\nâ–  Acute liver failure hypercholesterolemia and type\nâ–  Cirrhosis with portal hypertension or compromised hepatic f",
      "char_start": 758000,
      "char_end": 760000
    },
    {
      "chunk_id": 380,
      "text": "unction (eg, 2 DM presents with intermittent\nvariceal hemorrhage, ascites, encephalopathy, and hepatorenal syndrome) dull RUQ discomfort. The patient\nâ–  Primary liver neoplasms (hepatocellular carcinoma) that meet specific does not drink alcohol. Her physical\nexam is unremarkable. Lab studies\ncriteria:\nshow elevated AST and ALT but are\nâ–  Single lesion â‰¤5 cm\notherwise normal. Hepatitis serologies\nâ–  Up to three separate lesions â‰¤3 cm\nare âŠ–. What is the most likely\nâ–  No evidence of gross vascular invasion diagnosis?\nâ–  No regional or nodal metastasis\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226611 1100//2211//2222 1122::5588 PPMM\n\n262 HIGH-YIELD FACTS IN GASTROINTESTINAL\nA B C\nFIGURE 2.6-39. Contrast-enhanced arterial phase CT scan of focal nodular hyperplasia\n(FNH). (A) an axial view of the liver with FNH is seen during the arterial phase of contrast\nadministration. (B), the portal phase is seen of this same liver lesions demonstrating washout\n(loss of brightness) of this lesion. (C) delayed imaging (taken after the portal venous phase)\nrevealing further washout of the liver lesion. All three images reveal a hypodense, central, stel-\nlate-shaped region in this lesion.(Adapted with permission from Scialpi M, Pierotti L, Gravante S, et al. Split-bolus\nversus triphasic multidetector-row computed tomography technique in the diagnosis of hepatic focal nodular hyperplasia: A\ncase report. J Med Case Rep. 2014;8:425.)\nâ–  Metabolic disorders (eg, Wilson disease, Î±-1 antitrypsin deficiency, certain\nglycogen storage diseases, hemochromatosis, acute intermittent porphyria)\nContraindications:\nâ–  Uncorrectable cardiopulmonary disease\nâ–  Malignancy outside of liver not meeting oncologic criteria for cure\nâ–  Hepatocellular carcinoma with metastatic spread\nâ–  Intrahepatic cholangiocarcinoma\nâ–  Hemangiosarcoma\nâ–  Certain anatomic abnormalities\nâ–  Uncontrolled sepsis\nâ–  Acute liver failure with sustained intracranial pressure >50 mm Hg or\ncerebral perfus",
      "char_start": 760000,
      "char_end": 762000
    },
    {
      "chunk_id": 381,
      "text": "ion pressure <40 mm Hg\nâ–  Persistent nonadherence to medical care or lack of adequate social support\nBENIGN LIVER LESIONS\nFocal Nodular Hyperplasia\nSolitary liver lesion seen in females. Focal nodular hyperplasia (FNH) is the\nsecond most common benign liver lesion. It typically occurs in response to\na dystrophic artery, arteriovenous shunting, or congenital vascular malfor-\nmation. Fibrosis develops in the center of the lesion, creating the character-\nistic stellate central scar surrounded peripherally by hyperplastic\nhepatocytes.\nThe most likely diagnosis is\nnonalcoholic fatty liver disease â–  Hx/PE: Usually asymptomatic and found incidentally on imaging. Those\n(NAFLD), a condition that is associated with symptoms tend to have nonspecific abdominal pain, but this is less\nwith insulin resistance and metabolic common.\nsyndrome. â–  Dx: Seen on contrast-enhanced imaging as a peripherally enhancing\nlesion on arterial phase with characteristic central stellate appearance. On\nportal phase imaging, washout is visualized (see Fig. 2.6-39).\nâ–  Tx: In asymptomatic individuals, no intervention necessary. For those\nwho are symptomatic, recommendations for intervention may be made\n(eg, surgical resection, transarterial embolization, radiofrequency\nablation).\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226622 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 263\nHepatic Hemangioma\nAberrant collection of blood vessels within the liver. Pathogenesis not well\nunderstood, but thought to be due to congenital vascular lesions that develop\ninto hemangiomas through the process of ectasia over time. Generally asymp-\ntomatic. Most common benign liver lesion\nâ–  Hx/PE: Typically asymptomatic and discovered incidentally on contrast-\nenhanced imaging.\nâ–  Dx: Contrast-enhanced imaging revealing arterial phase enhancement\nwith heterogenous washout on portal phase imaging.\nâ–  Tx: No intervention required for lesions <5 mm that are asymptomati",
      "char_start": 762000,
      "char_end": 764000
    },
    {
      "chunk_id": 382,
      "text": "c.\nLesions >5 mm should have follow-up; MRI should be performed in 6 to\n12 months. If the lesion grows in size >3 mm per year on surveillance\nimaging, repeat surveillance imaging should be obtained in 6 to 12\nmonths. If it continues to show a growth rate >3 mm/year, multidisci-\nplinary evaluation for possible intervention should be obtained. If the\nlesion is stable (growth rate <3 mm/year), no further surveillance imaging\nis required.\nHepatic Adenoma (Hepatocellular Adenoma)\nRare benign liver tumor with risk of rupture and subsequent intraperitoneal\nhemorrhage. Associated especially with use of oral contraceptives, but also\nassociated with obesity, FAP, and glycogen storage diseases.\nâ–  Hx/PE: Tends to present asymptomatically in patients taking oral contra-\nceptive medications, but can also present with life-threatening intraperito-\nneal hemorrhage from adenoma rupture manifesting as sudden-onset\nsevere abdominal pain with signs of hypotension.\nâ–  Dx: May be discovered incidentally on imaging or in a patient with signs\nof hemorrhagic shock from adenoma rupture and subsequent intraperito-\nneal bleeding.\nâ–  Tx: For asymptomatic individuals with lesions <5 cm, discontinuation\nof oral contraceptives and weight loss/lifestyle modifications to achieve\nideal body weight in addition to 6-month surveillance imaging with con-\ntrast-enhanced MRI. If there is no increase in size on 6-month follow up,\nannual MRI surveillance imaging is recommended. If there is increase\nin size, surgical resection is recommend. For lesions >5 cm or symp-\ntomatic, surgical resection is recommended due to increased risk of\nhemorrhage.\nHepatic Abscess\nLiver abscesses are the most common visceral abscess. Most liver abscesses are\npolymicrobial, with most pathogens being mixed enteric facultative and\nanaerobic species.\nâ–  Risk factors: DM, underlying hepatobiliary/pancreatic disease, liver trans-\nplant, and regular use of PPIs.\nâ–  Hx/PE: Fever, abdominal pain, nausea/vomiting, anorexia, weight loss,\nand m",
      "char_start": 764000,
      "char_end": 766000
    },
    {
      "chunk_id": 383,
      "text": "alaise. FIGURE 2.6-40. CT of the abdomen\nâ–  Dx: Multiple space-occupying lesions on abdominal imaging. A CT of the with contrast enhancement revealing a\nabdomen and pelvis will typically reveal a well-defined lesion with periph- multiloculated, rim-enhancing hepatic\nabscess. (Adapted with permission from Casella\neral rim-enhancement and central hypoattenuation (see Fig. 2.6-40); how-\nF, Finazzi L, Repetti V, et al. Liver abscess caused by\never, they can be loculated with subcollections and have an irregular\nKlebsiella pneumoniae: Two case reports. Cases J.\nborder. Laboratory evaluation will likely reveal transaminitis and 2009;2:6879.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226633 1100//2211//2222 1122::5588 PPMM\n\n264 HIGH-YIELD FACTS IN GASTROINTESTINAL\nhyperbilirubinemia. Definitive diagnosis can be made with image-guided\naspiration and drainage revealing purulent material or bacteria identified\non Gram stain/culture of the aspirate material.\nâ–  Tx: Image-guided aspiration or drainage and empiric antibiotic therapy.\nHydatid Cyst\nTriggered by infection with Echinococcus granulosus, which causes cystic\nechinococcus infection (also called hydatid disease or hydatidosis).\nâ–  Risk factors: Exposure through ingestion of parasite egg in contaminated\nfood, water, soil or by direct contact with animal hosts (dogs are definitive\nhosts).\nâ–  Hx/PE: May cause asymptomatic incubation that lasts several years. Hyda-\ntid cysts only manifest with symptoms when they get large enough.\nPatients typically present with abdominal pain and nausea/vomiting.\nâ–  Dx: Imaging of the abdomen, typically by ultrasound revealing an\nanechoic, smooth, round cyst, typically with â€œdaughterâ€ cysts, which may\nhave echogenic material between the cysts. Imaging findings in combina-\ntion with laboratory evaluation via enzyme-linked immunosorbent assay\n(ELISA) serologic testing makes the diagnosis. In the absence of positive\nserologic tests, percutaneous aspiration ",
      "char_start": 766000,
      "char_end": 768000
    },
    {
      "chunk_id": 384,
      "text": "or biopsy may be required to con-\nfirm the diagnosis.\nâ–  Tx: Antiparasitic therapy in combination with either surgical resection or\ncyst aspiration.\nPANCREATIC DISEASE\nPANCREATITIS\nTable 2.6-24 outlines the features of acute and chronic pancreatitis.\nPANCREATIC CYSTS\nPancreatic cysts are common incidental findings on imaging in older popula-\ntions (>70 years of age).\nâ–  Hx/PE: Usually detected incidentally on imaging being performed for an\nunrelated reason.\nâ–  Dx: Most manageable with imaging surveillance. Some may require fur-\nther workup, based on presence/absence of â€œred flag featuresâ€ on radio-\nKEY FACT graphic evaluation.\nâ–  Red flag features include large size (>3 cm), solid components or cal-\nRed flag features of pancreatic cystic\ncifications, main pancreatic duct involvement (as evidenced by ductal\nlesions on radiography:\ndilation on imaging), or thickened/irregular cystic walls.\nâ–  Large size (>3 cm)\nâ–  The presence of these red flag signs increases risk of malignant trans-\nâ–  Solid components or calcifications\nformation of the pancreatic cystic lesion and requires further workup\nâ–  Main pancreatic duct involvement\nvia EUS-guided biopsy.\n(as evidenced by ductal dilation on\nâ–  Occasionally, a surgeon may opt to immediately resect the lesion with-\nimaging)\nout prior biopsy if the lesion identified is determined to be very high\nâ–  Thickened or irregular cystic wall\nrisk.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226644 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 265\nTABLE 2.6-24. Features of Acute and Chronic Pancreatitis\nVARIABLE ACUTE PANCREATITIS CHRONIC PANCREATITIS\nPathophysiology Leakage of activated pancreatic enzymes into pancreatic and peripan- Irreversible parenchymal destruction leading\ncreatic tissue to pancreatic dysfunction and insufficiency\nTime course Abrupt onset of severe pain Persistent, recurrent episodes of severe pain\nEtiology/risk Gallstones, alcohol abuse, hypercalcemia, hypert",
      "char_start": 768000,
      "char_end": 770000
    },
    {
      "chunk_id": 385,
      "text": "riglyceridemia, trauma Alcohol abuse (90%), gallstones, cystic fibrosis\nfactors (most common cause of acute pancreatitis in children), drug side CF, smoking, pancreatic divisum, family\neffects (thiazide diuretics), viral infections, post-ERCP, scorpion sting history autoimmune (IgG4) pancreatitis\nHistory/PE Severe epigastric pain (radiating to the back); nausea, vomiting, weakness, Recurrent episodes of persistent epigastric\nfever, shock, pleural effusions, acute respiratory distress syndrome (ARDS) pain; anorexia, nausea, constipation, flatu-\nFlank bruising (Grey Turner sign) and periumbilical discoloration (Cullen lence, steatorrhea, weight loss, DM\nsign) may be evident on exam\nDiagnosis â†‘ lipase (more sensitive and specific than amylase), â†‘ amylase, â†“ calcium if â†‘ to normal amylase and lipase, â†“ stool elastase,\nsevere; â€œsentinel loopâ€ or â€œcolon cutoff signâ€ on x-ray of the abdomen pancreatic calcifications (arrows in Image B),\nUltrasound of the abdomen or CT may show an enlarged pancreas with and alternating stenosis and dilation (arrow-\nperipancreatic fluid and fat stranding (arrows in Image A), abscess, head in Image B) of the main pancreatic duct\nhemorrhage, necrosis, or pseudocyst on CT or ultrasound (â€œchain of lakesâ€)\nTreatment Removal of the offending agent if possible Analgesia, pancreatic enzyme replacement,\nSupportive care, including IV fluids/electrolyte replacement, analgesia, avoidance of causative agents (EtOH), celiac\nbowel rest, NG suction, nutritional support, and O nerve block; endoscopic dilation of pan-\n2\nInfected pancreatic necrosis should be treated with antibiotics, though creatic duct; surgery for intractable pain or\nprophylactic antibiotics are not recommended structural causes\nEndoscopic, percutaneous, or surgical debridement may be considered\nPrognosis Roughly 85%â€“90% are mild and self-limited; 10%â€“15% are severe, Patients can have chronic pain and pancreatic\nrequiring ICU admission dysfunction\nMortality may approach 50% in severe cases\n",
      "char_start": 770000,
      "char_end": 772000
    },
    {
      "chunk_id": 386,
      "text": "Complications Pancreatic pseudocyst, fistula formation, hypocalcemia, renal failure, Chronic pain, opiate addiction, diabetes mel-\npleural effusion, chronic pancreatitis, sepsis, and ARDS litus, malnutrition/weight loss, splenic vein\nMortality secondary to acute pancreatitis can be predicted with Ranson thrombosis, pancreatic cancer\ncriteria\nA B\nP\nP, Pancreas. (Images reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226655 1100//2211//2222 1122::5588 PPMM\n\n266 HIGH-YIELD FACTS IN GASTROINTESTINAL\nPANCREATIC NEUROENDOCRINE TUMORS (PNETS)\nInsulinoma\nResults from insulin-producing tumor, associated with multiple endocrine\nneoplasia (MEN) type 1, usually benign.\nHistory\nHypoglycemia satisfying Whipple triad: (1) documented hypoglycemia on a\nvenipuncture; (2) associated symptoms, including sweating, palpitations, anxi-\nety, tremors, headache, and confusion; and (3) resolution of symptoms with\ncorrection of hypoglycemia\nDiagnosis\nâ–  Best initial test: Fasting serum insulin (elevated), C-peptide (elevated).\nâ–  Most accurate test: 72-hour fasting. Patient develops profound or symp-\ntomatic hypoglycemia after prolonged fast. Once hypoglycemia is\nreached, labs drawn to determine etiology include glucose, serum insu-\nlin level (elevated), C-peptide level (elevated), sulfonylurea screen (âŠ–),\nserum Î²-hydroxybutyrate level (low), and serum cortisol level (normal/\nelevated).\nTreatment\nSurgery to resect tumor.\nVIPoma\nResults from VIP-producing tumor; highly malignant.\nHistory\nWatery diarrhea, dehydration, muscle weakness, flushing.\nDiagnosis\nâ–  Stool sample: Low stool osmotic gap (ie, secretory diarrhea)\nâ–  Lab tests: High VIP levels, achlorhydria (since VIP inhibits gastrin secre-\ntion), hyperglycemia, hypercalcemia, hypokalemia\nâ–  CT scan: Localization of tumor\nTreatment\nInitially, replacement of fluid and electrolyte losses. Surgery to resect tumor.\nMay also consider octreotide.\nSomatostatinoma\nResults",
      "char_start": 772000,
      "char_end": 774000
    },
    {
      "chunk_id": 387,
      "text": " from somatostatin-producing tumor originating from D cells. May\noccur as part of MEN type 1 syndrome. Usually found in the pancreatic head\nbut may also be found in the duodenum.\nâ–  Hx/PE: Generally speaking, symptoms nonspecific. Presents with abdomi-\nnal pain and weight loss. Rarely, presents with somatostatinoma syndrome,\nwhich should be suspected in those who have the triad of cholelithiasis,\ndiarrhea/steatorrhea, and diabetes/glucose intolerance.\nâ–  Dx: Usually found on imaging incidentally through the evaluation of\nabdominal pain. The best test to establishing diagnosis: EUS with FNA.\nâ–  Tx: In those with nonmetastatic disease, surgical resection is the treatment\nof choice. Surgical resection is usually manageable with a pancreaticoduo-\ndenectomy (Whipple procedure). Treatment in those with metastatic\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226666 1100//2211//2222 1122::5588 PPMM\n\nGASTROINTESTINAL HIGH-YIELD FACTS IN 267\ndisease is dependent on the extent and location of metastasis. Symptom-\natic treatment with somatostatin analogs (eg, octreotide) to inhibit soma-\ntostatin secretion is also used.\nGastrinoma\nResults from gastrin-producing tumor originating from G cells. See\nâ€œZollinger-Ellison Syndromeâ€ for more information.\nPANCREATIC CANCER\nMost (75%) are adenocarcinomas in the head of the pancreas. Risk factors\ninclude smoking, chronic pancreatitis, and a first-degree relative with pancre-\natic cancer. Incidence â†‘ after 45 years of age; pancreatic cancer is slightly\nmore common in males.\nHistory/PE\nâ–  Abdominal pain radiating toward the back, obstructive jaundice, loss of\nappetite, nausea, vomiting, weight loss, weakness, fatigue, and indigestion.\nKEY FACT\nOften asymptomatic and thus presents late in the disease course. In some\npatients, depression most prominent symptom. The hallmark finding in pancreatic\ncancer is a nontender, palpable\nâ–  May reveal a palpable, nontender gallbladder (Courvoisier sign) or migra-\ngallb",
      "char_start": 774000,
      "char_end": 776000
    },
    {
      "chunk_id": 388,
      "text": "ladder and jaundice.\ntory thrombophlebitis (Trousseau syndrome).\nDiagnosis\nBest initial test: CT scan with contrast. Localization of the tumor and assess-\nment of the extent of local invasion and distant metastases. Ultrasound of the\nabdomen initial test of choice if the patient suspected of having pancreatic\ncancer also has jaundice. If mass not visualized on CT/ultrasound, ERCP\nindicated. CA-19-9 often elevated, but is neither sensitive nor specific.\nTreatment\nâ–  Locally advanced or metastatic disease: Most frequent presentation. Pal-\nliative chemotherapy or best supportive care.\nâ–  Small tumors in the pancreatic head with no metastasis or major vessel\ninvolvement: Whipple procedure (pancreaticoduodenectomy).\nâ–  Tumors in the body or tail of the pancreas with no metastasis or celiac\nartery involvement: Distal pancreatotomy and splenectomy. Chemother-\napy with fluorouracil (5-FU) and gemcitabine to possibly improve short-\nterm survival, but long-term prognosis poor (5%â€“10% 5-year survival).\nERCP with stenting to relieve patients presenting with obstructive\nsymptoms.\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226677 1100//2211//2222 1122::5588 PPMM\n\n268 HIGH-YIELD FACTS IN GASTROINTESTINAL\nNOTES\n22002222__0022..0066__SStteepp22CCKK__GGaassttrroo__1111ee__119977--226688..iinndddd 226688 1100//2211//2222 1122::5588 PPMM\n\nH I G H - Y I E L D F A C T S I N\nHEMATOLOGY\nCoagulation Disorders 270 autoimmuNe Hemolytic aNemia 292\nNormal Hemostasis 270 megaloblastic, macrocytic aNemia 293\ntraNsfusioN Products 274 PorPHyrias 294\nHemoPHilia 274 PolycytHemias 295\nVoN WillebraNd disease 276 blood traNsfusioN reactioNs 296\nHypercoagulable States 277 White Blood Cell Disorders 296\nactiVated ProteiN c (aPc) resistaNce/factor V leideN 278 NeutroPeNia 296\nHePariN-iNduced tHrombocytoPeNia (Hit) 279 lymPHoPeNia aNd eosiNoPeNia 298\naNtiPHosPHoliPid syNdrome 279 eosiNoPHilia 299\ndissemiNated iNtraVascular coagulatioN 280 leukemias 300\ncHroNic myelogeN",
      "char_start": 776000,
      "char_end": 778000
    },
    {
      "chunk_id": 389,
      "text": "ous leukemia 302\nPlatelet Disorders 281\nlymPHomas 304\ntHrombotic tHrombocytic PurPura 281\nHemolytic uremic syNdrome 282 Plasma Cell Disorders 307\nidioPatHic tHrombocytoPeNic PurPura (immuNe tHrombocytoPeNia) 284 multiPle myeloma 307\nWaldeNstrÃ¶m macroglobuliNemia 308\nRed Blood Cell Disorders 285\namyloidosis 308\naNemias 285\nmicrocytic aNemias 286 Transplant Medicine 309\nNoNHemolytic, Normocytic aNemias 289\nMultisystem Hematology 310\nHemolytic, Normocytic aNemias 290\nHemoPHagocytic lymPHoHistiocytosis 310\ng6Pd deficieNcy 291\nmastocytosis 311\nParoxysmal NocturNal HemoglobiNuria 291\nlaNgerHaNs cell Histiocytosis 311\nHereditary sPHerocytosis 291\n269\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 226699 1100//2211//2222 11::0099 PPMM\n\n270 HIGH-YIELD FACTS IN HEMATOLOGY\nCOAGULATION DISORDERS\nNORMAL HEMOSTASIS\nNormal hemostasis is a regulated, dynamic process between thrombin-\nstimulated fibrin clot formation and plasmin-induced clot lysis. It is divided\ninto three phases: vascular phase (spasm), platelet phase (plug), and coagula-\ntion phase.\nâ–  The vascular phase is a brief contraction of blood vessels at the site of ves-\nsel injury.\nâ–  The platelet phase is first activated at the site of vascular injury to form a\nplatelet plug. It can be further subdivided into:\nâ–  The adhesion of platelets to the disrupted endothelium, which is medi-\nated by the binding of the platelet surface receptor GPIb to von Wille-\nKEY FACT brand factor (vWF)\nâ–  The aggregation of platelets at the site of bleeding mediated by the\nTissue plasminogen activators are binding of the GPIIb/IIIa receptor on the platelet surface\ncontraindicated in: â–  Platelet function monitored by bleeding time\nâ–  Active bleeding or risk of bleeding\nâ–  A known intracranial lesion â–  The coagulation phase can be further subdivided based on commonly\nobtained laboratory tests into:\nâ–  Recent (<2 months) trauma or\nsurgery to the spine or brain â–  The extrinsic pathway (fewer factors [factor VII and tis",
      "char_start": 778000,
      "char_end": 780000
    },
    {
      "chunk_id": 390,
      "text": "sue factor] moni-\ntored by prothrombin time [PT]).\nâ–  History of a hemorrhagic stroke\nor evidence of a nonhemorrhagic â–  The intrinsic pathway (more factors [factors VIII, IX, XI, and XII] mon-\nitored by partial thromboplastin time [PTT]).\nstroke in the past 3 months\nâ–  Both of these pathways converge into the common pathway (factors I,\nII, X, XIII). See Figure 2.7-1.\nIn the setting of bleeding dysfunction, bleeding time PT and/or PTT may\nbe prolonged, depending on the causes of bleeding.\nKEY FACT Vascular injury leads to the release of vWF and tissue factor from suben-\ndothelial vessel walls.\nEnteric bacteria synthesize vitamin K.\nNeonates lack these bacteria and are â–  vWF facilitates adhesion and aggregation of platelets, forming a platelet\nprone to bleeding, which is why vitamin plug.\nK is given at birth. â–  Tissue factor triggers the coagulation cascade via the extrinsic pathway\nSimilarly, in children and adults, with factor VII.\nprolonged use of antibiotics could\nUltimately the platelet plug and coagulation cascade create a fibrin mesh,\naffect the normal flora, and therefore\nas shown in Figure 2.7-1. Common findings seen in platelet vs coagulation\nantibiotics could increase the bleeding\ndisorders can be found in Table 2.7-1. Drugs affecting the cascade are shown\ntendency.\nin Table 2.7-2.\nA heparin-to-warfarin bridge is necessary because the onset of anticoagula-\ntion with warfarin is slow. Concurrent initiation with heparin is needed until\nwarfarin dosing is adjusted to reach an international normalized ratio (INR)\nKEY FACT\nin the therapeutic range (2-3). In addition, proteins C and S have shorter half-\nlives than the other vitamin Kâ€“dependent factors (II, VII, IX, and X), leading\nThe liver is the machinery responsible\nto a transient period of paradoxical hypercoagulability before proper\nfor synthesizing the vitamin Kâ€“\nanticoagulation.\ndependent coagulation factors. Liver\nWarfarin vs DOAC pharmacology can be found in Table 2.7-3 and treat-\ndisease can therefore inc",
      "char_start": 780000,
      "char_end": 782000
    },
    {
      "chunk_id": 391,
      "text": "rease the\nment of a supratherapeutic INR secondary to warfarin use can be found in\nbleeding tendency.\nTable 2.7-4.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227700 1100//2211//2222 11::0099 PPMM\n\nCollagen, HMWK\nbasement membrane,\nKallikrein â†‘ Vasodilation\nactivated platelets\nContact Bradykinin â†‘ Permeability\nactivation\n(intrinsic) XII XIIa Kinin cascade â†‘ Pain\npathway\nXI XIa\nIX IXa\nTissue factor VIII\n* VIIIa\nwith vWF ANTICOAGULANTS: IIa (thrombin)\nTissue factor\nVII VIIa - heparin (greatest efficacy)\n(extrinsic)\n- LMWH (dalteparin, enoxaparin)\npathway X Xa\n- direct thrombin inhibitors (argatroban,\n* Va V bivalirudin, dabigatran)\nANTICOAGULANTS: factor Xa\n- LMWH (greatest efficacy) II IIa\n- heparin Prothrombin Thrombin\nPlasminogen\n- direct Xa inhibitors (apixaban, rivaroxaban) THROMBOLYTICS:\n- fondaparinux alteplase, reteplase,\nI Ia streptokinase, tenecteplase\ntPA\nFibrinogen Fibrin monomers\nAggregation Amicocaproic acid,\nHemophilia A: deficiency of factor VIII (XR) Plasmin tranexamic acid\nHemophilia B: deficiency of factor IX (XR) Combined\nHemophilia C: deficiency of factor XI (AR) pathway Ca2+ XIIIa XIII Fibrinolytic system\nNote: Kallikrein activates bradykinin; ACE inactivates bradykinin\n* = require Ca2+ , phospholipid Fibrin degradation\n= inhibited by vitamin K antagonist warfarin products\n= cofactor\nFibrin mesh stabilizes\n= activates but not part of coagulation cascade platelet plug\nLMWH, low-molecular-weight heparin\nFIGURE 2.7-1. Coagulation cascade. HMWK, High-molecular-weight kininogen; LMWH, low-molecular-weight heparin; vWF,\nvon Willebrand factor. (Reproduced with permission from USMLE-Rx.com.)\nâ€“\nâ€“\nâ€“\nHEMATOLOGY HIGH-YIELD FACTS IN 271\n*\n* *\n*\n*\nTABLE 2.7-1. Features of Bleeding Disorders\nPLATELET DISORDERS COAGULATION DISORDERS\nSite of bleeding Skin, mucous membranes Deep in soft tissues (joints,\n(epistaxis, gum, muscles)\ngastrointestinal tract)\nPetechiae Yes No\nEcchymosis Small, superficial Large, deep\nHemarthrosis/musc",
      "char_start": 782000,
      "char_end": 784000
    },
    {
      "chunk_id": 392,
      "text": "le No Yes\nbleeding\nBleeding onset after surge Immediate Delayed (1-2 days)\nor trauma\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227711 1100//2211//2222 11::0099 PPMM\n\n272 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-2. Coagulation Pharmacology\nMEDICATION MECHANISM LAB VALUES* MISCELLANEOUS\nUnfractionated heparin Activates antithrombin â†‘ partial thrombo- Antidoteâ€”protamine sulfate\nActivated antithrombin then inactivates plastin time (PTT) Safe to use in pregnancy\nfactor Xa, thrombin (IIa), and other Used as a bridge to warfarin\nproteases Causes heparin-induced thrombocytopenia\n(HIT)\nWarfarin Inhibits synthesis of vitamin Kâ€“dependent â†‘ prothrombin time For rapid reversal, prothrombin complex\ncoagulation factors (II, VII, IX, X, and to a (PT)/international concentrate (PCC); otherwise, vitamin K\nlesser extent proteins C and S) by blocking normalized ratio Teratogenic, LMWH can be given instead in\nvitamin K epoxide reductase (INR) pregnancy\nTissue plasminogen Aid conversion of plasminogen to plasmin, â†‘ PT, â†‘ PTT Toxicity (overdose) treated with aminoca-\nactivators (tPAs) which breaks down fibrin No change in proic acid, tranexamic acid, and fresh\nInclude alteplase, reteplase, and platelet count frozen plasma (FFP) to decrease bleeding\ntenecteplase risk\nPossibility of Tpa to cause angioedema\nFactor Xa inhibitors Directly inhibit factor Xa PT/PTT not Antidote/reversal agent to factor Xa inhib-\n(ApiXAban, Direct oral anticoagulant (DOAC) monitored itor is andexanet alfa\nRivaroXAban)\nLMWH (enoxaparin, Mainly inhibits factor Xa Antifactor Xa, Protamine used for reversal but less effec-\ndalteparin) although typically tive at reversing LMWH than heparin\nnot monitored Lower rate of HIT compared to UFH\nby PTT LMWHâ€”better bioavailability and two to\nfour times longer half-life than UFH\nUsually administered subcutaneously\nDirect thrombin Directly inhibit factor II (thrombin) PT/PTT not Antidote/reversal agent to\ninhibitors (dabi- DOAC monitored dab",
      "char_start": 784000,
      "char_end": 786000
    },
    {
      "chunk_id": 393,
      "text": "igatranâ€”idarucizumab\ngatran, argatroban, No reversal agent currently available for\nbivalirudin) other direct thrombin inhibitors\nArgatroban often used in the case of HIT for\nanticoagulation instead of heparin\nGlycoprotein IIb/IIIa Reversibly binds to the glycoprotein PT/PTT not Abciximab is made from monoclonal anti-\ninhibitors (abciximab, receptor IIb/IIIa on activated platelet, pre- monitored body fragments\neptifibatide, tirofiban) venting aggregation\n*No change in platelet count is observed with these drugs.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227722 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 273\nTABLE 2.7-3. Warfarin vs DOACs Pharmacology\nWARFARIN DOAC\nMechanism of action Inhibits vitamin K epoxide Inhibits Factor Xa or\nreductase thrombin\nLaboratory monitoring PT/INR Not needed\nAntidote Vitamin K, FFP, PCC Idarucizumab for dabigatran\nAndexanet alfa for factor Xa\ninhibitor\nHalf-life Long Short\nOnset Slow Rapid\nOffset Prolonged Short\nMetabolism Hepatic Renal\nSpecial populations Patients with mechanical Pregnant patients\nvalves (warfarin pre- Patients with cirrhosis\nferred), poor medication\nadherence (avoid\nwarfarin), CKD (avoid\nwarfarin)\nCost Low High\nDOAC, Direct oral anticoagulant.\nTABLE 2.7-4. Treatment of Supratherapeutic INR Due to Warfarin\nMANAGEMENT\nBleeding Discontinue warfarin, administer vitamin K IV and PCC.\nMonitor INR closely.\nINR >10 without bleeding Discontinue warfarin, administer oral vitamin K. Monitor\nINR closely.\nINR 4.5-10 without bleeding Hold warfarin temporarily for few doses; can administer\nlow-dose oral vitamin K.\nINR <4.5 without bleeding Hold the next dose of warfarin and readjust the mainte-\nnance dose of warfarin.\nAn 8-year-old boy from Eastern\nEurope presents with severe swelling\nand warmth of his knee several\nhours after a minor â€œbumpâ€ against a\nlamppost. What is the most accurate\ndiagnostic test for his presentation?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__111",
      "char_start": 786000,
      "char_end": 788000
    },
    {
      "chunk_id": 394,
      "text": "1ee__226699--331122..iinndddd 227733 1100//2211//2222 11::0099 PPMM\n\n274 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-5. Features of Blood Replacement Products\nFFP PCC CRYOPRECIPITATE PRBC PLATELETS\nClotting factor II, V, VII-XIII; fibrinogen II, VII, IX, X; protein High concentra- â€“ â€“\ncomposition at normal plasma C and S tion of VIII, vWF\nconcentration fibrinogen\nIndications Inherited coagulation Active bleeding Fibrinogen dis- Hb <7 g/dL or <8 g/dL Plt count <10,000 if\nfactor disorders due to vitamin orders, vWD, in patients with coro- nonbleeding\nOngoing bleeding due to K deficiency DIC, liver nary artery disease Plt count <20,000 if\nliver disease, vitamin K or warfarin disease, uremic Anemia and acute blood bleeding or planning\ndeficiency, or warfarin anticoagulation bleeding loss contributing to undergo procedure\nanticoagulation Warfarin anticoag- to hemodynamic OR\nulation reversal instability 50,000 prior to surgery\nmuch faster Each unit Hb by 1 g/dL Each unit â†‘ Plt count by\nthan FFP ~6000/Î¼l\nComplications TRALI or TACO Some complica- Some complica- Hemolytic reaction, Allergic reaction, TRALI,\ntions related to tions related TRALI, TACO TACO\nvolume over- to volume\nload, but overall overload, but\nless volume â†’ overall less\nfewer complica- volume â†’\ntions related to fewer compli-\nvolume com- cations related\npared to FFP to volume\nRisk of thrombosis compared to\nFFP\nABO- Yes No Yes Yes No\ncompatibility\nrequired\nCost High Low High Low Low\nDIC, Disseminated intravascular coagulation; FFP, fresh frozen plasma; Hb, hemoglobin; PCC, prothrombin complex concentrate; Plt, platelet; pRBCs,\npacked red blood cells; TACO, transfusion-associated circulatory overload; TRALI, transfusion-related acute lung injury; vWD, von Willebrand disease;\nvWF, von Willebrand factor.\nTRANSFUSION PRODUCTS\nMany different blood products are transfused for a variety of reasons. Com-\nmon blood replacement product composition, indications, and complications\nare discussed in Table 2.7-5.\nThis boy probab",
      "char_start": 788000,
      "char_end": 790000
    },
    {
      "chunk_id": 395,
      "text": "ly has (X-linked)\nHEMOPHILIA\nhemophilia A (most common), which\nis most accurately diagnosed with a\nClotting factor deficiencies of factors VIII (hemophilia A, 80% of cases); IX\nspecific factor VIII level.\n(hemophilia B); and XI (hemophilia C), which â†‘ tendency to bleed. Hemo-\nphilia A and B are X-linked recessive genetic disorders (1:10,000 male births).\nRarely, hemophilias can be acquired if antibodies against these factors are\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227744 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 275\nproduced as a result of autoimmune diseases, lymphoproliferative disorders, KEY FACT\nor postpartum states.\nHemophilia A and hemophilia B are\nX-linked recessive genetic disorders.\nHistory/PE\nHemophilia C is most common in\nâ–  Hemophilia presents in a young male (think child that is beginning to people with Ashkenazi Jewish heritage,\nwalk; 1â€“2 years of age) with spontaneous bleeding into the tissues, mus- and it is often autosomal recessive.\ncles, and joints (hemarthrosis) that, if untreated, can lead to irreversible\ndebilitating arthropathy and joint destruction caused by hemosiderin\ndeposition, destruction of the cartilage and synovium (the lining of the\njoint), and fibrosis. Joint x-ray will show calcifications.\nâ–  Spontaneous intracerebral, renal, retroperitoneal, and gastrointestinal (GI)\nhemorrhages are also seen.\nâ–  Mild cases may have major hemorrhage after surgery, trauma, or dental\nprocedures, but they are otherwise asymptomatic.\nDiagnosis\nâ–  Prolonged PTT (VIII, IX, and XI are all the factors of intrinsic pathway)\non basic bleeding workup. PT and bleeding time are normal. KEY FACT\nâ–  Best initial test: Mixing study. Mixing the patientâ€™s plasma with normal\nCryoprecipitate consists mainly of\nplasma will correct the PTT in hemophilia patients because normal\nfactor VIII and fibrinogen, with smaller\nplasma contains all clotting factors and will replace the missing clotting\nconcentrations of ",
      "char_start": 790000,
      "char_end": 792000
    },
    {
      "chunk_id": 396,
      "text": "factor XIII, Vwf, and\nfactor (Fig. 2.7-2).\nfibronectin. It is a more concentrated\nâ–  In cases of acquired hemophilia, adding the missing factor will not correct\nsource of factor VIII and fibrinogen\nthe PTT due to the presence of antibodies directed at the missing factor.\nthan FFP.\nâ–  Most accurate test: Specific factor assays for factors VII, VIII, IX, XI, and XII\nTreatment\nâ–  Cases in which bleeding is severe or the factor level is â‰¤1% of normal\n(severe) call for immediate transfusion with the missing factor; if that is\nunavailable, cryoprecipitate can be used.\nProlonged aPTT\nMixing test\n(control + pt plasma)\naPTT correction Weak/no aPTT correction\nMeasure FVIII, FIX, FXI, vWF Time/temperature Not time/temperature\ndependent dependent\nNormal Low\nMeasure FVIII and inhibitor Test for lupus anticoagulant\nFurther workup Factor deficiency\nneeded Negative Positive\nFVIII low Inhibitor detected\nLupus anticoagulant\nFVIII deficiency Inhibitor present\nFIGURE 2.7-2. Workup of prolonged PPT in patients with suspected factor deficiency. aPTT, Activated partial thromboplastin\ntime. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227755 1100//2211//2222 11::0099 PPMM\n\n276 HIGH-YIELD FACTS IN HEMATOLOGY\nClopidogrel, prasugrel,\nPlatelet\nticlopidine\nInside vWF\nAspirin platelets\nfibrinogen\nFibrinogen\nCOX\nArachidonic TXA\nADP (P2Y 12 ) receptor acid 2\nDeficiency: Glanzmann thrombasthenia\nGpIIb/IIIa\nActivated\nDeficiency: Bernard- GpIIb/IIIa Abciximab, Thrombin- Protein C protein C\nSoulier syndrome insertion eptifibatide, thrombomodulin Vascular endothelial cells\ntirofiban complex\nDeficiency: von\nWillebrand Inside (vWF + factor VIII)\nSubendothelial GpIb vWF disease endothelial thromboplastin\ncollagen cells tPA, PGI\n2\nFIGURE 2.7-3. Thrombogenesis deficiencies. ADP, Adenosine diphosphate; COX, cyclooxygenase; PGI 2 , prostacyclin; tPA, tissue plasmino-\ngen activator; TXA 2 , thromboxane A2; vWF, von Willebrand fact",
      "char_start": 792000,
      "char_end": 794000
    },
    {
      "chunk_id": 397,
      "text": "or. (Adapted with permission from USMLE-Rx.com.)\nâ–  If bleeding is not severe and factor level is >5% of normal (mild) or 1% to\n5% of normal (moderate), hemophilia A may be treated with desmopres-\nsin, which releases factor VIII from the endothelial cells.\nâ–  Genetic counseling may be required to screen other family members.\nâ–  Prophylactic administration of clotting factor concentrates is the basis of\nmodern treatment of severe hemophilia A.\nVON WILLEBRAND DISEASE\nVon Willebrand disease (vWD) is the most common inherited bleeding disor-\nder (1% of the population). It results from an autosomal dominant defect or a\ndeficiency in vWF with a potential decrease in the levels of factor VIII, which\nKEY FACT\nis carried by vWF (see Fig. 2.7-3). The three main roles of vWF are to (1)\nbring platelets to the exposed subendothelium, (2) aggregate platelets, and (3)\nvWD often presents with a positive\nbind to factor VIII. Symptoms of vWD are caused by platelet dysfunction and\nfamily history of bleeding tendency,\ndeficient factor VIII but are milder than in hemophilia.\nnormal platelet count, and clinical\nThe most common form of vWD is type 1 vWD (Mild to moderate quan-\nmanifestations of platelet dysfunction\ntitative deficiency in vWF). Type 2 vWD includes qualitative defects in vWF,\nsuch as epistaxis, menorrhagia, and\nand type 3 vWD is complete quantitative loss of vWF.\nothers.\nHeyde syndrome is a multisystem disorder characterized by the triad of\naortic stenosis (AS), GI bleeding, and acquired von Willebrand syndrome,\nwhich results from the increased circulatory shear forces and subsequent\nKEY FACT cleavage and loss of vWF.\nReduced agglutination is seen on the\nHistory/PE\nristocetin cofactor assay (detects vWF\ndysfunction); it is diagnostic of vWD â–  Often presents in childhood with recurrent and prolonged mucosal bleed-\ning (epistaxis, gums, gingival, menorrhagia) and bleeding after dental or\nand helps to distinguish it from other\nsurgical procedures\nplatelet disorders, such as Berna",
      "char_start": 794000,
      "char_end": 796000
    },
    {
      "chunk_id": 398,
      "text": "rd-\nSoulier syndrome. â–  Family history often present\nâ–  Worsening of symptoms with acetylsalicylic acid (ASA) use\nDiagnosis\nâ–  Best initial diagnostic test: Ristocetin cofactor assay of patient plasma\ndiagnostic. It measures the capacity of vWF to agglutinate platelets and\ndetects vWF dysfunction.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227766 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 277\nâ–  Additional diagnostic test: vWF antigen level. â†“ levels of antigen may be\npresent. Factor VIII levels can also be used to detect vWF dysfunction, but\nthis is less specific.\nâ–  Initial bleeding workup showing an â†‘ bleeding time in all vWD types. â†‘\nPTT as in hemophilia may be seen, which is caused by low factor VIII lev-\nels. PT and platelet count will be normal.\nTreatment\nKEY FACT\nâ–  Best initial treatment: Desmopressin for mild to moderate disease to\nrelease the endogenous vWF from storage sites in endothelial cells. For\nASA â†‘ the risk for bleeding in patients\nmore severe disease, for major bleeds and surgery, and for those who do\nwith vWD.\nnot respond to desmopressin such as type 2 vWD, patients should receive\nreplacement therapy of vWF/factor VIII concentrates.\nâ–  Antifibrinolytic agents such as aminocaproic acid and tranexamic acid can\nbe used as adjunct treatment for bleeding from mucosal sites such as the KEY FACT\nnose, oropharynx, and urogenital tract.\nâ–  Control menorrhagia with oral contraceptive pills (OCPs). Drugs to be VWD types 1 and 2 are generally\navoided are ASA, nonsteroidal anti-inflammatory drugs (NSAIDs), and inherited in an autosomal dominant\nplatelet function inhibitors. pattern. VWD type 3 is inherited in an\nautosomal recessive pattern.\nHYPERCOAGULABLE STATES\nHypercoagulable states (thrombophilias or prothrombotic states) are an all-\ninclusive term describing conditions that â†‘ a patientâ€™s risk for developing\nthrombosis, usually venous thromboembolism (VTE) disease.\nEtiology\nEtiologies can be genetic, ac",
      "char_start": 796000,
      "char_end": 798000
    },
    {
      "chunk_id": 399,
      "text": "quired, or physiologic (see Table 2.7-6).\nTABLE 2.7-6. Causes of Hypercoagulable States\nGENETIC ACQUIRED PHYSIOLOGIC\nAntithrombin III deficiency Surgery Pregnancy\nProtein C deficiency Trauma Age\nProtein S deficiency Sepsis\nFactor V Leiden OCPs/hormone replacement therapy (HRT)\nHyperhomocysteinemia (MTHFR Malignancy\ngene mutation) Immobilization\nDysfibrinogenemia Antiphospholipid syndrome\nPlasminogen deficiency Nephrotic syndrome\nProthrombin G20210A mutation Inflammatory bowel disease\nSmoking\nObesity\nVaricose veins\nParoxysmal nocturnal hemoglobinuria\nLiver disease (nonalcoholic fatty liver disease\n[NAFLD], decompensated cirrhosis)\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227777 1100//2211//2222 11::0099 PPMM\n\n278 HIGH-YIELD FACTS IN HEMATOLOGY\nHistory/PE\nThrombophilias can present with recurrent thrombotic complications: deep\nvenous thrombosis (DVT), pulmonary embolism, arterial thrombosis, myocar-\ndial infarction (MI), and stroke. Females may have recurrent miscarriages.\nDiagnosis\nâ–  Ruling out acquired causes of thrombosis before thrombophilia screening\nsuch as immobilization, surgery, OCPs, pregnancy, and hormone replace-\nment therapy\nâ–  Thrombophilia screening: To be considered only in patients with a his-\ntory of VTE in the absence of risk factors and in patients with a first-degree\nrelative who had VTE at <50 years of age or a first-degree relative with a\ndiagnosis of thrombophilia\nâ–  Hereditary abnormality confirmed with two abnormal values obtained\nwhile the patient is asymptomatic and untreated, with similar values\nobtained in two other family members\nâ–  Lab tests: Complete blood count (CBC), PT, thrombin time, PTT, fibrin-\nogen, and assays for antithrombin and protein C and S deficiency\nTreatment\nâ–  Patients with a hypercoagulable state with a provoked DVT or pulmonary\nembolism can be treated with heparin, low-molecular-weight heparin\n(LMWH), warfarin, or a DOAC for 3 to 6 months for the first VTE event\nand lifelong antico",
      "char_start": 798000,
      "char_end": 800000
    },
    {
      "chunk_id": 400,
      "text": "agulation for subsequent events.\nâ–  If anticoagulation is contraindicated (eg, recent trauma, hemorrhage,\nsevere uncontrolled hypertension) or if patients have recurrent DVTs on\ntherapeutic doses of anticoagulation, an inferior vena cava filter is the next\nbest step.\nACTIVATED PROTEIN C (APC) RESISTANCE/FACTOR V LEIDEN\nKEY FACT\nProtein C or S deficiency: The most common cause of inherited thrombophilia. A single-point mutation\nHypercoagulable state with skin or in factor V, rendering it resistant to being inactivated/broken down by acti-\ntissue necrosis following warfarin vated protein C. Risk for DVT or pulmonary embolism is â†‘ 5-fold if heterozy-\nadministration gous and 50-fold if homozygous.\nHistory/PE\nKEY FACT Factor V Leiden: Young, White patients (<45 years of age) with a personal\nand family history of thrombosis (eg, multiple VTEs, unusual location, atypi-\nThe liver is responsible for the synthesis\ncally young age)\nof proteins C and S. In cases of\ndecompensated cirrhosis, deficiency Diagnosis\nin protein C and S can cause a\nDisease-specific tests: Factor V Leiden (APC resistance test) functional assay\nhypercoagulable state.\nor genetic testing\nTreatment\nFactor V Leiden mutation: Direct oral anticoagulation without the need of\nmonitoring INR. Can use warfarin for 6 months with a target INR of 2 to 3 in\npatients who trigger concerns about compliance with medication, in individ-\nuals taking medications that can interact with direct oral anticoagulants\n(DOACs), or in individuals who have extreme body weight due to erratic\nabsorption. OCPs should be avoided in patients with factor V Leiden.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227788 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 279\nHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)\nA drop in platelet count more commonly observed due to unfractionated hep-\narin (UFH) than to LMWH. It can happen with heparin or enoxaparin.\nâ–  HIT type I: A mild, nonimmune-mediated transie",
      "char_start": 800000,
      "char_end": 802000
    },
    {
      "chunk_id": 401,
      "text": "nt decrease in platelet\ncount that occurs 1 to 4 days after heparin initiation. The platelet nadir is\ntypically ~100 k/ÂµL This type of HIT is benign and requires only observa-\nKEY FACT\ntion. No heparin interruption is required.\nâ–  HIT type II: An immunologic reaction due to the formation of platelet- Pulmonary embolism should be\nactivating antibodies against heparin-prostaglandin (PG)4 antigen, which suspected in a patient with rapid\nleads to the formation of blood clots and a drop in platelet count. It is usu- onset of dyspnea, pleuritic chest pain,\nally a severe and rapid (>50%) drop in platelet count that occurs 5 to 10 hypoxia, tachycardia, and an â†‘ alveolar-\ndays after starting heparin. HIT type II often presents as skin necrosis at arterial oxygen gradient without\nthe injection site of subcutaneous heparin. HIT rarely causes bleeding. another obvious explanation.\nVenous and arterial thromboses can occur; however, VTEs are more com-\nmon. Heparin discontinuation is required, and a nonheparin anticoagu-\nlant must be initiated. MNEMONIC\nAntiphospholipid syndrome\nDiagnosis effectsâ€”\nâ–  The 4Ts score helps differentiate thrombocytopenia due to HIT from CLOTS\nother causes. This score includes the platelet count fall (Thrombocytope- Coagulation defect\nnia), the Timing of platelet count fall, evidence of Thrombosis or skin Livedo reticularis\nnecrosis, and the probability of other causes for the Thrombocytopenia. Obstetric (recurrent miscarriage)\nâ–  Disease-specific tests: Thrombocytopenia (â†“ platelets)\nâ–  Best initial test: Evidence of the HIT platelet factor 4 antibody SLE (association)\nâ–  Most accurate test: Functional assay with the serotonin release assay\nTreatment\nDiscontinuing heparin immediately upon suspicion of diagnosis and starting 1\na direct thrombin inhibitor (eg, fondaparinux, argatroban, and bivalirudin).\nWarfarin should be commenced after a direct thrombin inhibitor is started A 65-year-old male was recently\nand once platelet count is >150,000. Starting nonhe",
      "char_start": 802000,
      "char_end": 804000
    },
    {
      "chunk_id": 402,
      "text": "parin anticoagulation is admitted to the hospital for\ncrucial to prevent arterial and venous clots. management of a DVT with heparin.\nTwo days after his admission, he was\nfound to have petechiae. Laboratory\nANTIPHOSPHOLIPID SYNDROME testing identified a drop in platelet\ncount from 180,000 to 50,000. What is\nAntiphospholipid syndrome (APS) is often associated with systemic lupus ery- the best next step in management of\nthematosus (SLE) (20%â€“30%) and rheumatoid arthritis (RA). The main APS his thrombo-cytopenia?\nantibodies are the lupus anticoagulant, anti-beta-2-glycoprotein, and anticar-\ndiolipin. APS predisposes to both arterial and venous thrombi formation and\nspontaneous abortion (particularly associated with anticardiolipin antibodies).\nLaboratory testing shows a paradoxically prolonged PTT (only thrombophilia\nwith an abnormality in the PTT).\n2\nHistory/PE\nA 33-year-old woman was admitted\nAPS: Most commonly in young and middle-aged females with recurrent mis- to the hospital for anticoagulation\ncarriages or thrombosis. Could have a history suggestive of SLE with photo- after a pulmonary embolism. On day\nsensitivity, oral ulcers, patchy hair loss, and Raynaud phenomenon. 4 of her stay, her platelet level â†“ from\n150,000 to 60,000/mm3, and her INR\nDiagnosis remains <2. What is the next best\nstep, and what complications can\nDiagnostic criteria for APS (at least one clinical and one laboratory criterion\nresult from this condition?\nneed to be met):\nâ–  Clinical criteria:\nâ–  Evidence of vascular thrombosis events\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 227799 1100//2211//2222 11::0099 PPMM\n\n280 HIGH-YIELD FACTS IN HEMATOLOGY\nâ–  Any of the following pregnancy complications:\n1. â‰¥1 spontaneous abortion of a normal fetus at or beyond 10 weeks gesta-\ntional age (GA)\n2. â‰¥1 premature births of a morphologically normal neonate before 34\nweeks GA\n3. Three or more unexplained consecutive spontaneous abortions before\n10 weeks GA unexplained by ",
      "char_start": 804000,
      "char_end": 806000
    },
    {
      "chunk_id": 403,
      "text": "any maternal or paternal causes (ana-\ntomic, chromosomal or hormonal)\nâ–  Laboratory criteria: Detection of lupus anticoagulant or anti-beta-2 glyco-\nprotein I antibody or anticardiolipin antibody on two or more occasions, at\nleast 2 weeks apart.\nLaboratory testing showing a paradoxically prolonged PTT and normal\nKEY FACT PT. PTT does not correct with a mixing study due to the presence of antibod-\nies. The addition of excess phospholipids can correct the prolonged PTT.\nIn patients with recent exposure Disease-specific tests for APS: Lupus anticoagulant and anticardiolipin\nto warfarin who are experiencing antibodies.\nwarfarin-induced skin necrosis, the\nphysician should suspect protein C or S Treatment\ndeficiency.\nâ–  For vascular events, treatment with LMWH or UFH and bridge to warfa-\nrin until the INR is in the therapeutic range. May require lifelong antico-\nagulation with warfarin. DOACs are less effective in APS.\nKEY FACT â–  Thromboprophylaxis is controversial in APS in the absence of vascular events.\nDIC is characterized by both thrombosis\nand hemorrhage. DISSEMINATED INTRAVASCULAR COAGULATION\nAn acquired coagulopathy caused by deposition of fibrin in small blood ves-\nsels, leading to thrombosis and end-organ damage. Depletion of clotting fac-\ntors and platelets leads to a bleeding diathesis. It is associated with many\nsevere illnesses and is often seen in hospitalized patients.\n1\nDisseminated intravascular coagulation (DIC) can be acute or chronic.\nThis patient has HIT type I. The best History/PE\nnext step is to discontinue heparin\nSome common causes of DIC can be found in Table 2.7-7.\nimmediately and treat the DVT with a\nClinical presentation:\ndirect thrombin inhibitor.\nâ–  Acute DIC is observed with a recent history of trauma or sepsis or in\npatients with a history of ABO-incompatible blood transfusions. It presents\nwith bleeding; low platelet count and plasma fibrinogen; and a prolonged\nPT, PTT, and d-dimer.\nTABLE 2.7-7. Common Etiologies for DIC\n2\nObstetric complic",
      "char_start": 806000,
      "char_end": 808000
    },
    {
      "chunk_id": 404,
      "text": "ations (eg, amni- Vascular disorders (aortic aneurysm)\notic fluid embolism, abruptio\nThis patient is experiencing HIT,\nplacentae)\nwhich occurs secondary to the\nformation of antibodies that\nMalignancy (acute promyelocytic Systemic disorders: sepsis, transfusion reactions, trans-\nactivate platelets. Because HIT\ncan lead to a hypercoagulable leukemia, pancreatic cancer) plant rejections, hemolysis, drug reactions, acidosis\nstate and subsequent thrombotic\ncomplications, heparin must be Acute respiratory distress syndrome Other: massive trauma, snake bites\nstopped immediately, and the patient (ARDS), pancreatitis, burns\nmust be switched to argatroban,\nbivalirudin, or fondaparinux.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228800 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 281\nâ–  Presents with shock and multiorgan dysfunction (renal dysfunction, KEY FACT\nhepatic dysfunction, and transient neurologic syndromes). Bleeding\nDIC is characterized by both thrombosis\nfrom venipuncture sites into organs, with ecchymoses and petechiae.\nand hemorrhage.\nâ–  Chronic DIC is observed in patients with a chronic history of cancer; nor-\nmal to low platelet count; normal to mildly high PT, PTT, and fibrinogen;\nand elevated d-dimer. It is often asymptomatic and can present with labo-\nratory changes only. It can also present with venous or arterial thrombo-\nembolism without an identifiable precipitating factor.\nDiagnosis\nâ–  Lab tests: â†‘ PT and PTT, â†“ platelets (thrombocytopenia), â†‘ d-dimer and\nfibrin, â†“ fibrinogen.\nâ–  Possibility for DIC to be confused with liver disease. Unlike liver disease,\nfactor VIII is depressed in DIC.\nTreatment\nTreatment of the underlying cause; transfusion of RBCs, platelets, and fresh\nfrozen plasma (FFP); and management of shock as necessary.\nPLATELET DISORDERS\nTHROMBOTIC THROMBOCYTOPENIC PURPURA\nThrombotic thrombocytopenic purpura (TTP) is a deficiency of the vWF-\ncleaving enzyme (ADAMTS-13), resulting in abnorma",
      "char_start": 808000,
      "char_end": 810000
    },
    {
      "chunk_id": 405,
      "text": "lly large vWF multim-\ners that aggregate platelets and create platelet microthrombi. These block\nsmall blood vessels, leading to end-organ damage. RBCs are fragmented by\ncontact with the microthrombi, leading to hemolysis (microangiopathic\nhemolytic anemia) and thrombocytopenia. TTP is a medical emergency and\ncan be immune-mediated or hereditary.\nHistory/PE\nTTP: Associated with SLE, malignancy, pregnancy, cyclosporine, quinidine,\nclopidogrel, ticlopidine, and AIDS. TTP can also be hereditary. Classic\ndescription involves a pentad of features. The physician should suspect TTP if\nthree of five of the following symptoms are present (LMNOP):\n1. Low platelet count (thrombocytopenia)\n2. Microangiopathic hemolytic anemia with schistocytes (severe, often\nwith jaundice)\n3. Neurologic changes (delirium, seizure, stroke, â†“ consciousness, â†“ vision)\n4. â€œObsoleteâ€ (impaired) renal function (acute kidney injury [AKI])\n5. Pyrexia (fever)\nDiagnosis\nGeneral workup for thrombocytopenia can be found in Figure 2.7-4.\nâ–  Lab tests: â†“ platelets, â†“ hemoglobin (Hb), â†‘ creatinine, normal clotting/\ncoagulation screen. PT, PTT, and fibrinogen are normal, which is differ-\nent from the coagulation profile observed in DIC.\nâ–  In addition, due to the hemolysis, lactate dehydrogenase (LDH) and indi-\nrect bilirubin are increased, while haptoglobin is decreased.\nâ–  Blood film: Presence of schistocytes (fragmented RBCs) (see Fig. 2.7-5)\nâ–  Most accurate diagnostic test: Measurement of ADAMTS-13 activity\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228811 1100//2211//2222 11::0099 PPMM\n\n282 HIGH-YIELD FACTS IN HEMATOLOGY\nThrombocytopenia\n(platelets <150,000)\nCheck CBC\nRBC and WBC normal ï© RBC and WBC\nEvaluate for hemolysis: Pursue bone marrow\nPeripheral smear biopsy\nfragmented RBCs\nLab work\nï¨ bilirubin, D-dimer, fibrinogen, PT/PTT, LDH\nï© haptoglobin\nYes No\nï¨ destruction ï¨ destruction\nMAHA (TTP/HUS/DIC), mechanical Antibody-mediated (ITP/HIT)\n(prosthetic valve, vegetation",
      "char_start": 810000,
      "char_end": 812000
    },
    {
      "chunk_id": 406,
      "text": ") ï© production\nNutritional deficiencies, medications\nRedistribution\nDilution, sequestration\nFIGURE 2.7-4. Thrombocytopenia workup. (Reproduced with permission from USMLE-Rx.com.)\nTreatment\nâ–  TTP: Plasma exchange is the best initial treatment. Steroids and rituximab\ncan be added to â†“ microthrombus formation.\nâ–  Platelet transfusion is contraindicated in TTP, as additional platelets are con-\nsumed by the disease process, potentially worsening the patientâ€™s condition.\nHEMOLYTIC UREMIC SYNDROME\nHemolytic uremic syndrome (HUS) and TTP have overlapping clinical man-\nifestations and are considered a spectrum of the same disease that is caused by\nADAMTS-13 deficiency, which is either inherited or often acquired second-\nary to infection. TTP is more common in adults, and HUS is frequently seen\nin children (associated with Escherichia coli 0157:H7).\nHUS: Can present similarly to TTP with the absence of neurologic features.\nâ–  >90% of cases in children are caused by E coli O157:H7 hemorrhagic\ndiarrhea, which precedes the syndrome. The E coli infection is triggered\nby eating undercooked, contaminated meat.\nâ–  Characterized by renal failure, microangiopathic hemolytic anemia, and\nlow platelets without neurologic symptoms.\nâ–  Abdominal pain, bloody diarrhea, and AKI often seen. Severe â†‘ in creati-\nnine levels is more typical of HUS than of TTP.\nâ–  Schistocytes (fragmented RBCs) seen in both HUS and TTP.\nDiagnosis\nFIGURE 2.7-5. Schistocytes. These frag- â–  Lab tests: â†“ platelets, â†“ Hb, â†‘ creatinine, normal clotting/coagulation\nmented RBCs (arrows) can be seen in screen. PT, PTT, and fibrinogen are normal, which is different from the\nmicroangiopathic hemolytic anemia and coagulation profile observed in DIC.\nin mechanical hemolysis such as that\nâ–  In addition, due to the hemolysis, LDH and indirect bilirubin are\ndue to an artificial heart valve. (Reproduced\nincreased, whereas haptoglobin is decreased.\nwith permission from Dr. Peter McPhedran, Yale\nDepartment of Hematology.) â–  Blood film: P",
      "char_start": 812000,
      "char_end": 814000
    },
    {
      "chunk_id": 407,
      "text": "resence of schistocytes (fragmented RBCs) (see Fig. 2.7-5).\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228822 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 283\nTreatment\nâ–  HUS: Dialysis for AKI may be needed. Plasma exchange is used for\nsevere, persistent disease. Antibiotics and antimotility drugs such as anti-\ncholinergics are not recommended, as they have been shown to increase\nthe likelihood of HUS resulting from E coli O157:H7.\nâ–  One other key point is that hydration can help reduce the risk of AKI.\nâ–  Platelet transfusion is contraindicated in HUS, as additional platelets are\nconsumed by the disease process, potentially worsening the patientâ€™s\ncondition.\nâ–  A summary of the clinical and laboratory findings seen in TTP, HUS and\nDIC can be found in Table 2.7-8 and the common laboratory features\nseen in different bleeding disorders can be seen in Table 2.7-9.\nTABLE 2.7-8. Summary of the Clinical and Laboratory Features of TTP, HUS, and DIC\nTTP HUS DIC\nPathogenesis Acquired or heredi- Toxin-induced endo- Uncontrolled\ntary deficient thelial damage, activation of\nvWF-cleaving often due to E coli coagulation and\nenzyme O157:H7 fibrinolysis â†’\n(ADAMTS-13) consumptive\ncoagulopathy\nAge group Adults 20â€“50 years of Children <5 years of Both\nage age\nPeripheral smear Schistocyte Schistocyte Schistocyte\nMAHA Yes Yes Yes\nPlatelets Low Low Low\nPT Normal Normal Prolonged\nPTT Normal Normal Prolonged\nFibrinogen Normal Normal Low\nd-dimer Normal Normal High\nCreatinine Increased (renal Increased (renal Normal to\ndysfunction) failure) increased\nSymptoms CNS yes (severe) CNS possible (mild) CNS possible\nFever Diarrhea Multiorgan failure\nAn 8-year-old girl presents to the\nManagement Plasma exchange and Supportive Treat underlying emergency department with 2\nsteroids cause (eg, sepsis) days of fever, vomiting, bloody\ndiarrhea, and irritability. She began\nCryoprecipitate\nfeeling unwell after attending a\ntransfusion and\nclassmateâ€™s birth",
      "char_start": 814000,
      "char_end": 816000
    },
    {
      "chunk_id": 408,
      "text": "day party. Laboratory\nsupportive care results reveal thrombocytopenia, â†‘\ncreatinine level, and schistocytes.\nCNS, Central nervous system; MAHA; microangiopathic hemolytic anemia. What is the next best step?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228833 1100//2211//2222 11::0099 PPMM\n\n284 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-9. Laboratory Features of Bleeding Disorders\nTHROMBOCYTOPENIA VWD HEMOPHILIA VITAMIN K DEFICIENCY LIVER DISEASE DIC\nPlatelet count Low Normal Normal Normal Low to normal Low\nBleeding time Prolonged Prolonged Normal Normal Normal Prolonged\nPT Normal Normal Normal Prolonged Prolonged Prolonged\nPTT Normal Normal to prolonged Prolonged Prolonged Prolonged Prolonged\nFibrinogen Normal Normal Normal Normal Normal Low\nd-dimer Normal Normal Normal Normal Normal High\nIDIOPATHIC THROMBOCYTOPENIC PURPURA (IMMUNE THROMBOCYTOPENIA)\nIgG antibodies are formed against the membrane protein Gp Iib/IIIa of plate-\nlets. The platelet-antibody complex is destroyed by the spleen. Bone marrow\nproduction of platelets is â†‘, with â†‘ megakaryocytes in the marrow. It is the\nmost common immunologic disorder in females of childbearing age.\nHistory/PE\nâ–  Patients often feel well with no systemic symptoms. They may have minor\nmucocutaneous bleeding, easy bruising, petechiae, hematuria, or melena.\nGenerally there is no splenomegaly. (Splenomegaly can also cause platelet\nsequestration resulting in thrombocytopenia, generally seen in myelopro-\nliferative disorders, infections like malaria, and visceral leishmaniasis.)\nâ–  Idiopathic thrombocytopenic purpura (ITP) is associated with a range of\nconditions, including malignancies (lymphoma, leukemia), autoimmune\ndisorders (SLE), and viral infections (HIV, hepatitis C virus [HCV]). It\ncan present acutely or as a chronic illness.\nâ–  Acute: Abrupt onset of hemorrhagic complications occurs after a viral ill-\nness with sudden, self-limiting purpura. It commonly affects children 2 to\n6 years of age, w",
      "char_start": 816000,
      "char_end": 818000
    },
    {
      "chunk_id": 409,
      "text": "ith boys and girls affected equally.\nâ–  Chronic: Insidious onset of symptoms occurs, or CBC shows incidental\nthrombocytopenia. There is a fluctuating course of bleeding, purpura, epi-\nstaxis, and menorrhagia. It affects adults 20 to 40 years of age and females\nmore than males.\nDiagnosis\nâ–  The diagnosis is one of exclusion. Once other causes of thrombocytopenia\nhave been ruled out, diagnosis can occur via history and PE, a CBC, and a\nperipheral blood smear showing megakaryocytes and normal RBC\nmorphology.\nHUS is the most common cause\nâ–  It is important to rule out pseudothrombocytopenia due to platelet\nof acute renal failure in children.\nclumping by ethylenediaminetetraacetic acid (EDTA) in test tubes.\nSupportive therapy includes\nintravenous (IV) fluids, blood pressure â–  Antiplatelet antibodies are often present.\n(BP) control, blood transfusion, and, â–  Bone marrow biopsy would also show â†‘ megakaryocytes but is done only\nif necessary, dialysis. Antibiotics are in atypical cases or patients >60 years of age.\nnot indicated, as they are thought to\nâ†“ expulsion of the toxin and may â†‘\ntoxin from the destruction of bacteria.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228844 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 285\nâ–  Additional tests for all patients with ITP include HIV (5%â€“10% of chronic\nHIV patients may present with isolated thrombocytopenia), hepatitis C,\nKEY FACT\nHelicobacter pylori, direct antiglobulin test, and blood type.\nAnti-D (Rh) immunoglobulin and\nTreatment rituximab are second-line therapies\nfor ITP. Anti-D (Rh) immunoglobulin\nâ–  Platelet count >30,000 and no bleeding: No treatment required\nand IVIG act as â€œdecoysâ€ so that WBCs\nâ–  Platelet count <30,000 or clinically significant bleeding symptoms: Corti-\nwill recognize them instead of IgG on\ncosteroids or intravenous immunoglobulin (IVIG)\nplatelets.\nâ–  If platelet count fails to improve or bleeding recurs, the physician should\nconsider splenectomy Â± ritu",
      "char_start": 818000,
      "char_end": 820000
    },
    {
      "chunk_id": 410,
      "text": "ximab Â± thrombopoietin (TPO) receptor ago-\nnist to â†‘ platelet production (romiplostim or eltrombopag).\nâ–  Platelet transfusions are not used (except during splenectomy or life- KEY FACT\nthreatening hemorrhage), as the platelets are quickly destroyed by\nSteroid-sparing therapies are generally\nautoantibodies.\nagents used as alternatives to avoid\nâ–  If caused by HCV or HIV, treatment of the underlying infection can\nsteroid-related adverse events such as\nimprove platelet count.\nhigh blood sugar and osteoporosis.\nâ–  In pregnant patients, severe thrombocytopenia may occur in the fetus.\nRED BLOOD CELL DISORDERS\nANEMIAS\nDisorders of low hematocrit (Hct) and Hb. Subtypes are classified according to\nRBC mean corpuscular volume (MCV) and reticulocyte count (see Fig. 2.7-6).\nAnemias\nMicrocytic Normocytic Macrocytic\n(MCV < 80 fL) (MCV 80â€“100 fL) (MCV > 100 fL)\nHemoglobin defects Megaloblastic Nonmegaloblastic\nDefective heme synthesis\nâ€¢Iron deficiency (late) Nuclear defects\nâ€¢Lead poisoning Defective DNA synthesis â€¢Diamond-Blackfan anemia\nâ€¢Sideroblastic anemia â€¢Folate deficiency â€¢Liver disease\nâ€¢Anemia of chronic disease â€¢Vitamin B 12 deficiency â€¢Alcoholism\nDefective globin chain â€¢Orotic aciduria\nâ€¢Thalassemias Defective DNA repair\nâ€¢Fanconi anemia\nNonhemolytic Hemolytic\n(reticulocyte count â‰¤ 2%) (reticulocyte count > 2%)\nâ€¢Iron deficiency (early)\nâ€¢Anemia of chronic disease\nâ€¢Aplastic anemia Intrinsic Extrinsic\nâ€¢Chronic kidney disease\nMembrane defects â€¢Autoimmune\nâ€¢Hereditary spherocytosis â€¢Microangiopathic\nâ€¢Paroxysmal nocturnal â€¢Macroangiopathic\nhemoglobinuria â€¢Infections\nEnzyme deficiencies\nâ€¢G6PD deficiency\nâ€¢Pyruvate kinase deficiency\nHemoglobinopathies\nâ€¢Sickle cell anemia\nâ€¢HbC disease\nFIGURE 2.7-6. Anemia algorithm. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228855 1100//2211//2222 11::0099 PPMM\n\n286 HIGH-YIELD FACTS IN HEMATOLOGY\nMICROCYTIC ANEMIAS\nIron Deficiency Anemia\nOccurs due to â†‘ demand (eg, gr",
      "char_start": 820000,
      "char_end": 822000
    },
    {
      "chunk_id": 411,
      "text": "owing period, pregnancy, erythropoietin\n[EPO] therapy) or â†“ iron due to chronic bleeding (menorrhagia, GI loss),\nmalnutrition/absorption disorders (eg, celiac disease), and GI surgery (eg, gas-\ntrectomy). Toddlers, adolescent females, and females of reproductive age con-\nFIGURE 2.7-7. Koilonychia (spoon nails).\nThe fingernail plate is concave. (Repro- stitute high-risk groups.\nduced with permission from Wolff K, et al. Fitzpatrickâ€™s\nColor Atlas and Synopsis of Clinical Dermatology. New History/PE\nYork, NY: McGraw-Hill; 2013.)\nâ–  Symptoms: Fatigue, dyspnea, tachycardia, angina, syncope, and pica (per-\nsistent craving and compulsive eating of nonfood substances).\nKEY FACT\nâ–  Physical findings: Glossitis, cheilosis, conjunctival pallor, and koilonychia\n(â€œspoon nails,â€ see Fig. 2.7-7), Plummer-Vinson syndrome (triad of iron\nMicrocytic anemias, or microcytosis,\ndeficiency anemia, esophageal webs, and dysphagia).\nhave a low MCV (<80 Fl) and generally\nhave a low reticulocyte count.\nDiagnosis\nâ–  Best initial test: CBC (â†“ MCV, â†“ mean corpuscular Hb [MCH], â†“ mean\ncorpuscular Hb concentration [MCHC]) with iron profile (see Table 2.7-\nKEY FACT\n10). Iron deficiency anemia should be distinguished from thalassemia and\nIron deficiency anemia in an older adult anemia of chronic disease.\npatient may be caused by colorectal â–  Most accurate test: Bone marrow iron stain (Prussian blue stain).\ncancer until proven otherwise and â–  Peripheral blood smear can show microcytic, hypochromic RBCs (see\nmust therefore be evaluated to rule out Fig. 2.7-8) with anisocytosis, poikilocytosis, and a low reticulocyte count.\nmalignancy.\nTreatment\nâ–  Iron supplementation. Oral iron is preferred over IV iron. Duration of oral\niron replacement to replenish stores depends on iron deficit (6 weeks to 6\nMNEMONIC months).\nâ–  Oral iron may lead to nausea, constipation, diarrhea, abdominal pain, and\nCauses of microcytic anemiaâ€” black stools. Alternate-day therapy can minimize GI adverse effects. Antac-\nIRON LAST ids m",
      "char_start": 822000,
      "char_end": 824000
    },
    {
      "chunk_id": 412,
      "text": "ay interfere with iron absorption.\nIRON deficiency\nLead poisoning\nAnemia of chronic disease TABLE 2.7-10. Iron Deficiency Anemia vs Anemia of Chronic Disease vs. Thalassemia\nSideroblastic anemia\nIRON DEFICIENCY CHRONIC DISEASE THALASSEMIA TRAIT\nThalassemia\nSerum iron â†“ â†“ â†‘\nTotal iron binding â†‘ â†“â†“ â†“\ncapacity\nFerritin â†“â†“ â†‘â†‘ â†‘\n% transferrin â†“â†“ Normal/â†“ â†‘â†‘\nsaturation\nRed cell distribution â†‘â†‘ Normal Normal\nwidth\nPeripheral smear Microcytosis, Â± target cells Â± target cells\nFIGURE 2.7-8. Iron deficiency anemia. hypochromia\nNote the microcytic, hypochromic RBCs\n(â€œdoughnut cellsâ€) with enlarged areas of\nResponse to iron â†‘ Hb No improvement No improvement\ncentral pallor (arrow). (Reproduced with per-\nmission from Dr. Peter McPhedran, Yale Department supplementation\nof Hematology.)\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228866 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 287\nâ–  IV iron is preferred if the oral route is ineffective (eg, gluten sensitivity,\ninflammatory bowel disease, GI malabsorption, postâ€“gastric bypass sur-\ngery, hyperemesis gravidarum, and a history of oral iron intolerance).\nâ–  IV iron is superior to oral iron in achieving a sustained Hb response;\nreducing the need for packed RBC transfusions; and improving the qual- KEY FACT\nity of life for patients with chronic heart failure, inflammatory bowel dis-\nAnemia secondary to end-stage renal\nease, chronic kidney disease and hemodialysis, and cancer-related\ndisease is caused by deficiency of EPO.\nanemia.\nTreatment with recombinant EPO is\nâ–  IV iron dextran is associated with a small risk for serious adverse effects,\neffective but often leads to worsening\nincluding anaphylaxis. Iron sucrose may be associated with a lower risk for\nof hypertension.\nallergy.\nAnemia of Chronic Inflammation/Disease\nTo limit bacterial proliferation, the body â€œhidesâ€ or â€œlocksâ€ its iron in situa-\ntions of chronic inflammation such as infection, malignancy, RA, or SLE.\nIron is trapp",
      "char_start": 824000,
      "char_end": 826000
    },
    {
      "chunk_id": 413,
      "text": "ed in macrophages or in ferritin (â†‘ in inflammation). This results\nin a microcytic or normocytic anemia with normal or â†‘ levels of iron storage\nin the form of ferritin but â†“ serum iron and â†“ total iron binding capacity\n(TIBC) (see Table 2.7-4). Treatment consists of treating the underlying dis-\nease. Anemia associated with end-stage renal disease (ESRD) responds to\nEPO replacement, once iron stores have been repleted.\nLead Poisoning\nInhibits ferrochelatase and Î´-aminolevulinic acid (ALA) dehydratase â†’ â†“ heme\nsynthesis and â†‘ RBC protoporphyrin. Also inhibits ribosomal RNA (Rrna) deg-\nradation â†’ RBCs retain aggregates of Rrna (basophilic stippling). Exposure risk\nâ†‘ in adults because of inhalation during industrial work (battery factory) and in\nchildren because of eating lead paint (old houses with chipped paint built\nA B\nbefore 1978).\nHistory/PE: Symptoms of LEAD poisoning include:\nâ–  Lead Lines on gingivae (Burton lines) and on metaphyses of long bones\non x-ray\nâ–  Encephalopathy and Erythrocyte basophilic stippling\nâ–  Abdominal pain (lead colic) and sideroblastic Anemia\nâ–  Dropsâ€”wrist and foot drops FIGURE 2.7-9. Pathogenic RBC forms.\n(A) Basophilic stippling. (B) Ringed\nLabs: â†“ Hb, â†“ MCV sideroblasts. (Image A reproduced courtesy of van\nTreatment: Removal from the exposure, chelation with succimer, EDTA, Dijk HA, Fred HL. Images of memorable cases: case 81.\nOpenStax website. June 18, 2018. Available at https://\ndimercaprol\ncnx.org/contents/57cfLKUe@7.2:MZa_Ph4e@4/Images-\nof-Memorable-Cases-Case. Image B reproduced with\nSideroblastic Anemia permission from Invernizzi R, Quaglia F, Porta MG.\nImportance of classical morphology in the diagnosis\nâ–  Occurs due to defective heme synthesis.\nof myelodysplastic syndrome. Mediterr J Hematol\nâ–  Causes: Genetic (eg, X-linked defect in ALA synthase gene); acquired Infect Dis. 2015 May 1;7(1):e2015035. doi: 10.4084/\n(myelodysplastic syndromes); and reversible (alcohol is most common and MJHID.2015.035.)\ncan suppress bone marrow; also le",
      "char_start": 826000,
      "char_end": 828000
    },
    {
      "chunk_id": 414,
      "text": "ad poisoning, vitamin B deficiency,\n6\ncopper deficiency, drugs [eg, isoniazid, linezolid]).\nâ–  Hx/PE/Labs: Presents with â†“ Hb, â†“ MCV. Iron studies show iron over-\nload (â†‘ serum iron, normal/â†“ TIBC, â†‘ ferritin). Peripheral blood smear\nshows basophilic stippling of RBCs (in lead poisoning). KEY FACT\nâ–  Dx: Presence of ringed sideroblasts (with iron-laden, Prussian blueâ€“stained Sideroblastic anemia is the only form of\nmitochondria) on bone marrow smear is diagnostic (see Fig. 2.7-9).\nmicrocytic anemia in which the serum\nâ–  Tx: Treatment of the underlying cause. Treatment of acquired causes with iron level is elevated.\npyridoxine (vitamin B , cofactor for ALA synthase).\n6\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228877 1100//2211//2222 11::0099 PPMM\n\n288 HIGH-YIELD FACTS IN HEMATOLOGY\nÎ±-thalassemias Î²-thalassemias\nMinima Î± Î± Minor Î± Î±\nÎ± Î± Î± Î±\nÎ² Î² Î² Î²\nMinor Î± Î± Î± Î± Major Î± Î±\nÎ± Î± Î± Î± Î± Î±\nÎ² Î² Î² Î² Î² Î²\nCis Trans\nHb H Î± Î±\nÎ± Î±\nÎ² Î²\nHb Barts Î± Î±\nNon-functional gene\nÎ± Î±\nFunctional gene\nÎ² Î²\nFIGURE 2.7-10. Gene function in Î±- and Î²-thalassemia. (Reproduced with permission from USMLE-Rx.com.)\nThalassemias\nHereditary disorders involving â†“ or absent production of normal globin\nchains of Hb. Î±-Thalassemia is caused by a gene deletion of one or more of\nthe four genes that encode Î±-hemoglobin. Î²-Thalassemia results from a point\nmutation of one or both of the two genes encoding Î²-hemoglobin.\nHistory/PE\nThalassemia is most common among people of African, Middle Eastern, and\nAsian descent. Disease presentation varies with the number of genes missing\n(see Table 2.7-11). A typical case can be an asymptomatic or fatigued individ-\nual with a microcytic anemia and normal iron studies.\nDiagnosis\nMost accurate test is Hb electrophoresis (normal in Î± trait, Î± silent carrier).\nFor Î±-thalassemia, genetic studies are the most accurate tests. All forms of\nthalassemia have a normal red cell distribution width (RDW). Only three-\nKEY FACT gene deletion Î±-thalassemia is",
      "char_start": 828000,
      "char_end": 830000
    },
    {
      "chunk_id": 415,
      "text": " associated with Hb H and â†‘ reticulocyte count.\nMentzer index: MCV divided by RBC Treatment\ncount (MCV/RBC). Can help distinguish\nâ–  Most patients do not require treatment (trait is not treated).\nbetween thalassemia and iron\nâ–  Those with Î²-thalassemia major and Hb H disease are often transfusion\ndeficiency anemia. Mentzer index <13\ndependent (chronic, lifelong transfusion) and require oral iron chelators\nsuggests thalassemia and >13 suggests\n(deferasirox or deferiprone) or a parenteral iron chelator (deferoxamine) to\niron deficiency anemia.\nprevent overload.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228888 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 289\nTABLE 2.7-11. Differential Diagnosis of Thalassemias\nNUMBER\nOF GENES\nSUBTYPE PRESENT CLINICAL FEATURES\nÎ²-thalassemia 0/2 Î² Patients develop severe microcytic anemia and failure to\nmajor (Cooley thrive during late infancy (6-12 months) due to HbF to\nanemia) HbA transition. Patients need lifelong chronic transfusions\nor marrow transplant to survive. Extramedullary hemo-\npoiesis occurs in response to anemia (eg, skull bossing,\nhepatosplenomegaly).\nÎ²-thalassemia 1/2 Î² Patients are asymptomatic with mild to moderate and\nminor well-tolerated anemia, but their cells are microcytic and\nhypochromic on peripheral smear.\nThis disease is often confused with iron deficiency anemia.\nIt is common among people of Mediterranean descent.\nHydrops 0/4 Î± Fetal demise in utero\nfetalis (Bartâ€™s\nhydrops)\nHb H disease 1/4 Î± Patients have severe hypochromic, microcytic anemia\nwith chronic hemolysis, splenomegaly, jaundice, and\ncholelithiasis\nThe reticulocyte count â†‘ to compensate, and one-third\nof patients have skeletal changes caused by expanded\nerythropoiesis\nÎ±-thalassemia 2/4 Î± Patients have low MCV but are usually asymptomatic\ntrait\nSilent carrier 3/4 Î± Patients have no signs or symptoms of disease. Normal clinical\nstate\nKEY FACT\nPatients with Fanconi anemia can be\nidentified on phys",
      "char_start": 830000,
      "char_end": 832000
    },
    {
      "chunk_id": 416,
      "text": "ical examination by\ncafÃ© au lait spots, short stature, and\nNONHEMOLYTIC, NORMOCYTIC ANEMIAS\nradial/thumb hypoplasia/aplasia.\nAplastic Anemia\nFailure of blood cell production (pancytopenia) caused by destruction of\nbone marrow cells. It may be hereditary, as in Fanconi anemia (genetic analy-\nsis will show chromosomal breaks); may have an autoimmune or viral etiology\n(HIV, parvovirus B19, Epstein-Barr virus [EBV], cytomegalovirus [CMV],\nhepatitis); or may result from exposure to toxins (cleaning solvents, insecti- A 30-year-old man from Greece\ncides, benzene), radiation, or drugs (sulfa, chloramphenicol, propylthiouracil, comes to the physicianâ€™s office,\ncarbamazepine, alcohol, methimazole, chemotherapy). complaining of chronic fatigue.\nHe has no significant past medical\nHistory/PE history and is on no medications. A\nCBC shows Hb of 10.4 and MCV of 71.\nPatients are pancytopenic, with symptoms resulting from a lack of RBCs,\nThe physician starts him on oral iron\nWBCs, and platelets: pallor, fatigue, weakness, a tendency to infection, pete-\nsupplements and sees him back in\nchiae, bruising, and bleeding.\n4 weeks with no change in the CBC.\nWhat is the most likely diagnosis?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 228899 1100//2211//2222 11::0099 PPMM\n\n290 HIGH-YIELD FACTS IN HEMATOLOGY\nDiagnosis\nâ–  Diagnosed by clinical presentation and CBC\nâ–  Most accurate test: Bone marrow biopsy revealing hypocellularity and\nspace occupied by fat\nTreatment\nâ–  Supportive therapy: Blood transfusion for anemia, antibiotics for infec-\ntion, platelets for bleeding\nâ–  Consideration of allogenic bone marrow transplantation (BMT) in\nyoung patients with a matched donor. Some severe casesâ€”patients with-\nout a stem cell donor or patients not suitable for BMT (>50 years of\nage)â€”call for immunosuppression with cyclosporine, antithymocyte\nFIGURE 2.7-11. Spherocytes. These globulin (ATG), and eltrombopag to prevent autoimmune marrow\nRBCs (arrows) lack areas of cent",
      "char_start": 832000,
      "char_end": 834000
    },
    {
      "chunk_id": 417,
      "text": "ral pal- destruction. Tacrolimus is an alternative to cyclosporine. Infections\nlor. Spherocytes are seen in autoimmune\nshould be treated aggressively.\nhemolysis and in hereditary spherocyto-\nsis. (Reproduced with permission from Bun HF, Aster\nJC. Pathophysiology of Blood Disorders. New York, NY:\nMcGraw Hill; 2011.) HEMOLYTIC, NORMOCYTIC ANEMIAS\nOccurs when bone marrow production is unable to compensate for â†‘ destruc-\nKEY FACT\ntion of circulating blood cells. Etiologies can be due to extrinsic and intrinsic\nDiamond-Blackfan syndrome hemolytic anemias as follows:\npresents with pure red cell aplasia\nâ–  Extrinsic hemolytic anemias: Autoimmune hemolytic anemia (AIHA),\nand congenital anomalies, such as\nmicroangiopathic hemolytic anemia (TTP, HUS, DIC), macroangio-\ntriphalangeal thumbs and cleft lip.\npathic hemolytic anemia (prosthetic heart valves, aortic stenosis), hemo-\nlytic anemia due to infection (eg, malaria, Babesia)\nâ–  Intrinsic hemolytic anemias: Glucose 6-phosphate dehydrogenase\n(G6PD) deficiency, paroxysmal nocturnal hemoglobinuria (PNH), heredi-\nMNEMONIC\ntary spherocytosis (see Fig. 2.7-11), sickle cell anemia.\nCauses of hemolytic anemiaâ€”\nMOM PASS me the GLUCOSE History/PE\nMicroangiopathic hemolytic anemia (TTP, â–  Present with pallor, fatigue, tachycardia, and tachypnea.\nHUS, DIC)\nâ–  Jaundice often present too. Hepatosplenomegaly, pigmented gallstones\nOther: malaria, hypersplenism\n(pigment caused by â†‘ indirect bilirubin), and leg ulcers (poor blood flow)\nMechanical hemolysis\nmay be noted.\nParoxysmal nocturnal hemoglobinuria\nAutoimmune anemia\nSickle cell disease Diagnosis\nSpherocytosis\nGLUCOSE 6-phosphate dehydrogenase â–  Lab tests: CBC, reticulocytes, electrolytes, liver function tests (LFTs),\ndeficiency haptoglobin, urinary urobilinogen\nâ–  â†“ Hct, â†‘ LDH, â†‘ Hct bilirubin, â†‘ reticulocyte count, â†“ haptoglobin are\ncommonly seen. Folate deficiency (folate is used from increased cell pro-\nduction) and hyperkalemia (â†‘ cell breakdown) may be seen. Urine is dark\nwith hemogl",
      "char_start": 834000,
      "char_end": 836000
    },
    {
      "chunk_id": 418,
      "text": "obinuria, and there is â†‘ excretion of urinary and fecal urobi-\nlinogen. A slight â†‘ MCV (macrocytosis) is caused by large reticulocytes.\nâ–  Blood films: Hypochromic microcytic anemia (thalassemia), sickle cells\nThe most likely diagnosis is\n(sickle cell anemia), schistocytes (microangiopathic hemolytic anemia),\nÎ²-thalassemia minor. The physician\nabnormal cells (hematologic malignancy), spherocytes (hereditary sphero-\nshould recognize that this patient\ncytosis or AIHA), Heinz bodies (seen with supravital staining), bite cells\nhas a microcytic anemia that did\nnot respond to iron supplements (G6PD deficiency).\n(probably has normal iron studies) â–  Direct antiglobulin (Coombs) test to identify AIHA.\nand is from the Mediterranean.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229900 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 291\nTreatment\nVaries with the cause of hemolytic anemia (see later) but often includes corti-\ncosteroids to address immunologic causes and iron supplementation to\nreplace losses. Splenectomy or transfusions are helpful in severe cases.\nG6PD DEFICIENCY\nAn X-linked recessive defect in G6PD, causing the inability to generate gluta-\nthione reductase, leaving RBCs susceptible to hemolytic anemia following\noxidant stress. KEY FACT\nâ–  History/PE: Patients are often males of Mediterranean or African descent A classic presentation of G6PD\nwho present with sudden anemia, episodic dark urine, and jaundice and\ndeficiency is a Black male patient\nwho have a normal-sized spleen with an infection or use drugs that induce\npresenting with fatigue, dark urine, and\noxidative damage to RBCs. Common triggers include infections (most\nshortness of breath (SOB) after taking\ncommon), fava beans, isoniazid, nitrofurantoin, dapsone, sulfa drugs (trim-\nTMP-SMX for a cold.\nethoprim-sulfamethoxazole [TMP-SMX]), and antimalarials (quinines).\nâ–  Diagnosis:\nâ–  Best initial test: CBC with smear showing features of hemolysis with\nbite cel",
      "char_start": 836000,
      "char_end": 838000
    },
    {
      "chunk_id": 419,
      "text": "ls and Heinz bodies\nâ–  Most accurate test: G6PD level 1 to 2 months after an episode (often MNEMONIC\nnormal during acute episode since G6PD-deficient RBCs are hemo-\nlyzed first) Causes of oxidative stress in G6PD\ndeficiencyâ€”\nâ–  Treatment: There is no reversal to the hemolysis. Avoiding triggers is the\nSell FAVA BEANS in INDIA\nmainstay of treatment.\nSulfa-drugs\nFAVA BEANS\nPAROXYSMAL NOCTURNAL HEMOGLOBINURIA Infections (most common cause)\nNitrofurantoin\nDapsone\nCD55 (complement decay-accelerating factor) and CD59 (membrane inhibi-\nIsoniazid\ntor of reactive lysis) proteins normally found on the RBC surfaces protect\nAntimalarials (quinines)\nthem from complement-mediated hemolysis. PNH is a deficiency in glyco-\nsylphosphatidylinositol-anchor molecules that inhibit CD55/CD59 attach-\nment or binding to RBCs, resulting in complement-mediated hemolysis and\nthrombosis.\nâ–  History/PE: PNH can manifest as iron deficiency anemia, episodic dark\nurine, venous thrombosis (most commonly mesenteric and hepatic vein\nthrombosis), pancytopenia, and abdominal pain.\nâ–  Diagnosis: Most accurate diagnostic test is CD55/CD59 absence via flow\ncytometry.\nâ–  Treatment: Prednisone is the best initial therapy. Allogeneic bone marrow\ntransplant is curative. Eculizumab, a complement inhibitor, can be used\nfor hemolysis and thrombosis. Vaccination for Neisseria meningitidis\nneeds to be administered for patients receiving eculizumab.\nHEREDITARY SPHEROCYTOSIS\nAutosomal dominant defect or deficiency in spectrin or ankyrin, an RBC\nmembrane protein, resulting in a loss of RBC membrane surface area and\ncharacteristic biconcave disc. RBCs are forced to take spherical shapes and\nare trapped and destroyed by the spleen.\nâ–  History/PE: Clinically presents as an extravascular hemolytic anemia with\nsplenomegaly and jaundice. Acute cholecystitis from pigmented gallstones\nis a common complication.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229911 1100//2211//2222 11::0099 PPMM\n\nPat",
      "char_start": 838000,
      "char_end": 840000
    },
    {
      "chunk_id": 420,
      "text": "ient component Result\n(no agglutination)\nRBCs +/â€“ anti-RBC Ab Result\nAnti-RBC Ab present\nPatient serum +/â€“ Anti-human globulin\nanti-donor RBC Ab (Coombs reagent)\nFIGURE 2.7-12. Direct and indirect Coombs tests. (Reproduced with permission from USMLE-Rx.com.)\nKEY FACT â–  Diagnosis:\nâ–  Best initial test: CBC with a normal to low MCV, â†‘ MCHC, and âŠ–\nPatients who had a splenectomy for\nCoombs test. A blood smear shows spherocytes (see Fig. 2.7-10).\nany reason are at an increased lifelong\nâ–  Most accurate test: Eosin-5 maleimide flow cytometry (replaced\nrisk for sepsis (for up to 30 years) from\nosmotic fragility test) and acidified glycerol lysis test.\nencapsulated bacteria and thus require\nâ–  Treatment: Manage with a splenectomy (stops hemolysis, but spherocytes\npneumococcal, meningococcal, and\nwill remain) and chronic folic acid replacement (assists in RBC produc-\nHaemophilus vaccinations before the\ntion). Patients with hereditary spherocytosis (HS) have a characteristically\noperation.\nincreased MCHC and RDW.\nAUTOIMMUNE HEMOLYTIC ANEMIA\nAutoantibodies against RBC membrane destroy blood cells, causing extravas-\ncular hemolysis.\nâ–  Two types:\nâ–  Warm: IgG, associated with SLE, chronic lymphocytic leukemia\n(CLL), lymphoma, penicillin, rifampin, phenytoin, and Î±-methyldopa\nâ–  Cold: IgM, associated with Mycoplasma pneumonia, EBV, and\nWaldenstrÃ¶m macroglobulinemia\nâ–  History/PE: Presents as a hemolytic anemia\nâ–  Diagnosis: Direct Coombs test (see Fig. 2.7-12). AIHA is also associated\nKEY FACT with spherocytes. Cold agglutinin is the most effective test in cold AIHA.\nâ–  Treatment: If AIHA is mild, no treatment is necessary. Warm AIHA is\nBoth AIHA and hereditary spherocytosis\ntreated with steroids; recurrent episodes respond to splenectomy. Severe,\ncan present with spherocytes and\nnonresponsive hemolysis is controlled with IVIG. Severe cold AIHA is\npositive osmotic fragility tests, but only\nmanaged by avoiding exposure to cold (keeping patient warm) Â± rituximab\nAIHA will have a âŠ• direct C",
      "char_start": 840000,
      "char_end": 842000
    },
    {
      "chunk_id": 421,
      "text": "oombsâ€™s test.\n(anti-CD20 antibody).\nsbmooC\ntceriD\nsbmooC\ntceridnI\n292 HIGH-YIELD FACTS IN HEMATOLOGY\nReagent(s) Result\n(agglutination)\nAnti-human globulin Result\n(Coombs reagent) Anti-RBC Ab absent\nDonor blood\nResult Result\nAntiâ€“donor RBC Ab present Antiâ€“donor RBC Ab absent\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229922 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 293\nMEGALOBLASTIC, MACROCYTIC ANEMIA\nImpaired DNA synthesis (due to vitamin B or folate deficiency, medications)\n12\nâ†’ delayed maturation of nucleus of precursor cells in bone marrow relative to\nmaturation of cytoplasm. Vitamin B deficiency caused by pernicious anemia,\n12\nmalabsorption (eg, Crohn disease), pancreatic insufficiency, gastrectomy, insuf-\nficient intake (eg, veganism), Diphyllobothrium latum (fish tapeworm), or drugs\n(eg, proton pump inhibitors [PPIs], antacids, metformin). Folate deficiency\ncaused by malnutrition (eg, chronic alcohol overuse), malabsorption, drugs (eg,\nmethotrexate, trimethoprim, phenytoin), â†‘ requirement (eg, hemolytic anemia, FIGURE 2.7-13. Hypersegmentation.\npregnancy). Drugs that interfere with DNA synthesis include chemotherapeutic The nucleus of this hypersegmented\nneutrophil has six lobes (six or more\nagents (methotrexate, 6-mercaptopurine).\nnuclear lobes are required). This is a\ncharacteristic finding of megaloblastic\nHistory/PE anemia. (Courtesy of Dr. Kristine Krafts.)\nKEY FACT\nâ–  Megaloblastic anemia presents with fatigue, pallor, glossitis, cheilosis, diar-\nrhea, loss of appetite, and headache.\nVitamin B deficiency can be\nâ–  Vitamin B 12 deficiency causes neurologic symptoms: reversible dementia caused by 1 2 infection by a tapeworm,\nand subacute combined degeneration of the spinal cord (vitamin B is\n12 Diphyllobothrium latum. Folate\nrequired in fatty acid pathways and myelin synthesis) involving the spino-\ndeficiency can occur secondary\ncerebellar tract, lateral corticospinal tract (causing motor and upper m",
      "char_start": 842000,
      "char_end": 844000
    },
    {
      "chunk_id": 422,
      "text": "otor\nto chronic phenytoin use, causing\nneuron [UMN] signs), and dorsal column (causing sensory and lower\nmalabsorption.\nmotor neuron [LMN] signs).\nâ–  Folate deficiency does not cause neurologic symptoms. Folate supplemen-\ntation in vitamin B deficiency can correct the anemia, but it worsens KEY FACT\n12\nneurologic symptoms.\nSubacute combined degeneration\nof the spinal cord seen in vitamin\nDiagnosis\nB deficiency presents as pe-\n12\nâ–  Best initial test: CBC (â†“ Hb, â†‘ MCV) with peripheral blood smear show- ripheral neuropathy, vibration and\ning RBC macrocytosis and hypersegmented (six or more lobes) neutro- proprioception dysfunction, dementia,\nphils (see Fig. 2.7-13). Vitamin B and folate deficiency are identical and spasticity.\n12\nhematologically and on blood smear.\nâ–  â†“ reticulocyte count, pancytopenia if severe, â†‘ LDH, â†‘ indirect bilirubin\nlevels. KEY FACT\nâ–  â†“ vitamin B and/or folate levels. If vitamin B and folate levels are non-\n12 12 Only megaloblastic anemia (eg, due\ndiagnostic and clinical suspicion persists, the following adjunctive tests\nto vitamin B or folic acid deficiency)\ncan be measured: 12\nis associated with hypersegmented\nâ–  Vitamin B deficiency: â†‘ methylmalonic acid (MMA) and â†‘\n12 neutrophils (not nonmegaloblastic\nhomocysteine\nanemia, eg, due to chronic alcohol\nâ–  Folate deficiency: Normal MMA and â†‘ homocysteine\noveruse, liver disease).\nâ–  Bone marrow sample revealing giant neutrophils and hypersegmented\nmature neutrophils.\nâ–  Anti-intrinsic factor and antiparietal cell antibodies in pernicious anemia. KEY FACT\nâ–  Schilling test, a test that determines if the cause is dietary insufficiency or\nmalabsorption. A Schilling test measures the absorption of cobalamin via Pernicious anemia increases the risk for\ningestion of radiolabeled cobalamin with and without intrinsic factor. This gastric cancer and is the most common\ntest is rarely performed. cause of vitamin B deficiency in\n12\nâ–  Radiolabeled vitamin B in urine: Dietary vitamin B deficiency. people of European ",
      "char_start": 844000,
      "char_end": 846000
    },
    {
      "chunk_id": 423,
      "text": "descent.\n12 12\nâ–  No radiolabeled vitamin B in urine: Pernicious anemia, bacterial\n12\novergrowth, or pancreatic enzyme deficiency. The hypothesis under-\ngoes testing with the addition of intrinsic factor, antibiotics, or pancre-\natic enzymes to radiolabeled B .\n12\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229933 1100//2211//2222 11::0099 PPMM\n\n294 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-12. Porphyria\nDISEASE AFFECTED ENZYME ACCUMULATED SUBSTRATE SYMPTOMS AND TREATMENT\nAcute intermittent Porphobilinogen Porphobilinogen, ALA Painful abdomen, port wineâ€“colored urine, polyneuropathy,\nporphyria deaminase psychiatric issues\nExacerbated by factors that increase ALA synthase â€“ drugs\n(CYP 450 inducers), alcohol, starvation\nTreated with hemin and glucose\nPorphyria cutanea Uroporphyrinogen Uroporphyrin causes Blistering cutaneous photosensitivity and\ntarda decarboxylase tea-colored urine hyperpigmentation\nMost common porphyria\nExacerbated by alcohol consumption\nCauses are familial and seen in hepatitis C\nTreated with phlebotomy, sun avoidance, and antimalarials\n(hydroxychloroquine)\nTreatment\nAddressing underlying cause. Intramuscular hydroxocobalamin (if vitamin B\n12\ndeficiency due to malabsorption), oral vitamin B supplementation (if due to\n12\ndietary causes).\nPORPHYRIAS\nPorphyrias are metabolic disorders caused by dysfunction in the enzymatic\nactivity of heme synthesis, which results in the abnormal accumulation of\nheme precursors.\nHistory/PE\nâ–  History reveals acute attacks.\nâ–  The physical examination can reveal signs specific to an enzymatic defi-\nciency such as neurovisceral manifestations (abdominal pain, peripheral\nneuropathy) and cutaneous photosensitivity (blistering). See Table 2.7-5.\nDiagnosis\nâ–  For suspected acute intermittent porphyria, measurement of porphobilin-\nogen (PBG) in the urine at the time of the attack (sensitive and specific)\ncan be diagnostic.\nâ–  For suspected blistering cutaneous porphyria, measurement of plasma o",
      "char_start": 846000,
      "char_end": 848000
    },
    {
      "chunk_id": 424,
      "text": "r\nurine porphyrins can help confirm the diagnosis.\nTreatment\nâ–  Supportive treatment (pain, nausea)\nâ–  Avoidance of triggering factors such as alcohol, smoking, OCPs\nâ–  Specific treatments in Table 2.7-12\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229944 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 295\nPOLYCYTHEMIAS\nErythrocytosis (an abnormal elevation of Hct) may be either absolute (â†‘\nRBC production) or relative (â†“ plasma volume and hemoconcentration).\nAbsolute polycythemia causes are primary (polycythemia rubra vera) or sec-\nondary (caused by hypoxia) or inappropriately â†‘ EPO secretion (EPO-\nproducing tumors).\nHistory/PE\nâ–  Polycythemias are characterized by â†‘ Hct, â†‘ blood viscosity, â†“ tissue KEY FACT\nblood flow and oxygenation, and â†‘ cardiac work.\nâ–  Absolute erythrocytosis is associated with hypoxia (lung disease, heavy Hemoglobinuria in a hemolytic transfusion\nsmoking, high altitudes, obstructive sleep apnea, cyanotic congenital heart reaction may lead to acute tubular necrosis\ndisease, or poor intrauterine environment); neoplasia (renal carcinoma, and subsequent renal failure.\nhepatocellular carcinoma); or polycythemia vera (PCV).\nâ–  A PCV is a myeloproliferative neoplasm that results from clonal prolifera-\ntion of a pluripotent marrow stem cell caused by a mutation in the JAK2, KEY FACT\nwhich regulates marrow production. There is excess proliferation of RBCs,\nWBCs, and platelets â†’ hyperviscosity and thrombosis, but RBCs are most Mutations in the JAK2 gene lead to PCV\nsignificantly affected. RBCs proliferate at an exceedingly high rate despite and account for 30% to 50% of the cases\na low level of EPO. of two other myeloproliferative disorders:\nâ–  Presentation: Hyperviscosity syndrome. Easy bleeding/bruising from Essential thrombocytopenia and\nengorged blood vessels, fatigue, hypertension, thrombosis (arterial and myelofigrosis.\nvenous), visual disturbance, neurologic deficits, headaches, dizziness,\ntinnitus, p",
      "char_start": 848000,
      "char_end": 850000
    },
    {
      "chunk_id": 425,
      "text": "ruritus after a warm bath, congestive heart failure (CHF),\nfacial plethora, and splenomegaly.\nKEY FACT\nâ–  Commonly affects older individuals (>60 years of age).\nâ–  Can convert to acute myeloid leukemia in a small proportion of patients. Myelodysplastic syndromes consist of\nstem cell disorders due to ineffective\nâ–  Relative erythrocytosis is associated with hypovolemia and dehydration:\nhematopoiesis â†’ â†‘ number of blasts\ndiuresis, gastroenteritis, alcohol, burns.\nin the bone marrow: <20% blasts\ncomparted to AML with >20% blasts.\nDiagnosis Myelodysplastic syndromes stem from\nde novo mutations or from exposures\nâ–  PCV: Best initial test is a CBC showing elevated RBCs/WBCs/platelets (â†‘\n(chemotherapy, radiation).\nreticulocyte, â†‘ Hb, â†‘ Hct, â†‘ packed cell volume) with an arterial blood\ngas (ABG) and EPO level. â†“ EPO, normal O , and Hct >60% (key find-\n2\ning) suggest packed cell volume. Most accurate test is the JAK2 mutation\n(present in 95% of patients).\nâ–  Relative erythrocytosis also has an â†‘ Hct and splenomegaly, but EPO is\nnormal or increased, and O 2 is often low compared to packed cell volume. KEY FACT\nPCV has low EPO and normal O levels.\nTreatment 2\nRelative erythrocytosis has normal or\nâ–  PCV: Target is hematocrit <45%. Phlebotomy and aspirin provide symp- increased EPO with low O 2 levels.\ntom relief and prevent thrombosis. Hydroxyurea reduces cell counts. Ele-\nvated uric acid levels are common due to increased cell turnover. This can\nlead to gout and kidney stones. Hydroxyurea-resistant disease is treated\nwith ruxolitinib (JAK inhibitor).\nâ–  Relative erythrocytosis: Treatment should address the underlying cause\nand treat symptoms with phlebotomy. A 49-year-old man comes into the clinic\ncomplaining of â€œtirednessâ€ over the last\nseveral months. His past medical history\nis significant for hypertension, diabetes\nmellitus, and alcohol overuse. A CBC\nreveals a low Hb and an MCV of 115\nFl. What is the most likely cause of his\nanemia?\n22002222__0022..0077__SStteepp22CCKK__HHeemma",
      "char_start": 850000,
      "char_end": 852000
    },
    {
      "chunk_id": 426,
      "text": "a__1111ee__226699--331122..iinndddd 229955 1100//2211//2222 11::0099 PPMM\n\n296 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-13. Transfusion Reactions\nFEBRILE NONHEMOLYTIC\nVARIABLE ALLERGIC REACTION ANAPHYLACTIC REACTION REACTION HEMOLYTIC TRANSFUSION REACTION\nMechanism Antibody formation Severe allergic reac- Cytokine formation during Acute (within the first hour post\nagainst donor plasma tion in IgA-deficient storage of blood transfusion) or delayed (within\nproteins, usually after individuals who must Host antibodies against 3â€“10 days post transfusion) due to\nreceiving plasma-con- receive blood prod- the donor HLA antigens recipient antibodies against donor\ntaining product ucts without IgA and WBCs erythrocytes\nType I hypersensitivity Type II hypersensitivity Intravascular hemolysis (ABO blood\nreaction reaction group incompatibility) or extra-\nvascular hemolysis (host antibody\nreaction against donor foreign\nantigen on donor RBCs)\nType II hypersensitivity reaction\nPresentation Prominent urticaria, pru- Dyspnea, broncho- Fever, headache, chills, Fever, hypotension, chills, nausea,\nritus, wheezing, fever spasm, respiratory flushing, rigors, and flushing, burning at the IV site, tachy-\narrest, hypotension, malaise 1â€“6 hours after cardia, tachypnea, flank pain/renal\nand shock transfusion failure, hemoglobinuria (intravascular\nhemolysis), jaundice (extravascular),\nduring or shortly after the transfusion\nTreatment Stop transfusion immedi- Should stop the trans- Should stop the trans- Should stop the transfusion\nately, independent of fusion and give fusion and give immediately!\nseverity of the reaction, epinephrine acetaminophen Vigorous IV fluids and maintain good\nGive antihistamines. Should treat ana- Leukoreduction of donor urine output\nGive epinephrine is phylactic shock as blood\nsevere reaction. If mild required\nreaction (urticaria\nwanes and there is no\nevidence of dyspnea,\nhypotension, or ana-\nphylaxis), can resume\ntransfusion.\nKEY FACT\nBLOOD TRANSFUSION REACTIONS\nPremed",
      "char_start": 852000,
      "char_end": 854000
    },
    {
      "chunk_id": 427,
      "text": "ication with acetaminophen\nand diphenhydramine is sometimes Transfusions are generally safe but may result in adverse reactions (see Table\nused to prevent minor transfusion 2.7-13). Febrile nonhemolytic and allergic reactions are the most common,\nreactions. occurring in 3% to 4% of all transfusions.\nWHITE BLOOD CELL DISORDERS\nThe patient has megaloblastic anemia\ncaused by either a vitamin B or\n12 NEUTROPENIA\nfolate deficiency. His history of alcohol\ndependence strongly suggests\nfolate deficiency, as that is the most An absolute neutrophil count (ANC) <1500 cells/mm3, where ANC = (WBC\ncommon cause of megaloblastic count) Ã— (% bands + % segmented neutrophils). Neutropenia may be caused\nanemia in people with a history of by a combination of â†“ production, migration away from the vascular space,\nacute/chronic alcohol overuse. and â†‘ destruction or utilization. It may be acquired or intrinsic. The most\ncommon causes of neutropenia in adults are infections and drugs. Other\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229966 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 297\ncommon causes include diseases that infiltrate the bone marrow such as leu-\nkemias or lymphomas, aplastic anemias, or vitamin B /folate deficiencies.\n12\nFelty syndrome: Neutropenia along with splenomegaly and rheumatoid\narthritis\nHistory/PE\nâ–  Patients are at â†‘ risk for infection. Severe infections are typical when\n<500 cells/mm3.\nâ–  Acute neutropenia: Associated with Staphylococcus aureus, Pseudomonas,\nE coli, Proteus, and Klebsiella sepsis.\nâ–  Chronic and autoimmune neutropenia: Presents with recurrent sinusitis,\nstomatitis, gingivitis, and perirectal infections rather than sepsis. Some\nchronic neutropenias are accompanied by splenomegaly (Felty syndrome,\nGaucher disease, sarcoidosis).\nâ–  The physician should look for drug or toxin exposure, infection, autoim-\nmunity, or neoplastic disease.\nDiagnosis\nâ–  Best initial test: CBC with a peripheral blood smear.",
      "char_start": 854000,
      "char_end": 856000
    },
    {
      "chunk_id": 428,
      "text": " Neutropenia is fol-\nlowed up with ANC and thrombocytopenia or anemia with bone marrow\naspiration and biopsy.\nâ–  Serum immunologic evaluation, antinuclear antibody (ANA) levels, and a\nworkup for collagen vascular disease may be merited.\nKEY FACT\nTreatment\nThe ANC (cells/mm3) can be obtained\nâ–  Infection management: Neutropenic patients cannot mount an effective by multiplying the total WBCs\ninflammatory response. found on CBC by percentage of\nâ–  It is important to discontinue drugs implicated in neutropenia. polymorphonuclear cells.\nâ–  Neutropenic fever: In the context of neutropenia, fever is a medical\nemergency that calls for immediate treatment with broad-spectrum\nantibiotics such as cefepime that provide Pseudomonas coverage. Sus-\npected fungal infections also call for appropriate treatment.\nâ–  Hematopoietic stem cell factors such as granulocyte colony stimulating\nfactor (G-CSF) (filgrastim) can be used to shorten the duration of neu-\ntropenia. Rarely, IVIG and allogeneic BMT may be used.\nNeutropenic Fever\nDefined as a single oral temperature of â‰¥38.3Â°C (â‰¥101Â°F) in a neutropenic\npatient or a temperature of â‰¥38Â°C (â‰¥100.4Â°F) for â‰¥1 hour in a neutropenic\npatient (ie, an ANC <500 cells/mm3).\nHistory/PE\nCommon in cancer patients undergoing chemotherapy (neutropenic nadir\n7â€“10 days postchemotherapy). Signs of infection may be minimal or absent.\nThorough physical examination but no rectal examination in light of the\nbleeding and infection risk.\nDiagnosis\nâ–  CBC with differential, serum creatinine, blood urea nitrogen (BUN), and\ntransaminases. Testing of blood, urine, lesion, sputum, and stool cultures.\nThe physician should also consider testing for viruses, fungi, and\nmycobacteria.\nâ–  X-ray of the chest (CXR) for patients with respiratory symptoms; a CT scan\nto evaluate for abscesses or other occult infection.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229977 1100//2211//2222 11::0099 PPMM\n\n298 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-14.",
      "char_start": 856000,
      "char_end": 858000
    },
    {
      "chunk_id": 429,
      "text": " Lymphopenia vs Eosinopenia\nLYMPHOPENIA EOSINOPENIA\nDefinition Absolute lymphocyte count (ALC) <1500/mm3 (<3000/mm3 in Absolute eosinophil count of <30 cells/mm3\nchildren)\nCauses HIV, congenital disorders like DiGeorge syndrome, SCID, sepsis, immu- Glucocorticoids, Cushing syndrome\nnosuppressive medications (glucocorticoids), SLE, chemotherapy,\nand radiation therapy\nBest initial test CBC with differential CBC with differential\nTreatment Asymptomatic: Monitor Asymptomatic: Monitor\nHIV ART, prophylactic antibiotics for opportunistic infections\nImmunodeficiency syndromes: Ig replacement\nNote: Corticosteroids cause neutrophilia despite causing eosinopenia and lymphopenia. Corticosteroids also impair neutrophil adhesion\nmolecules, limiting migration out of the vasculature to sites of inflammation. In contrast, corticosteroids sequester eosinophils in lymph nodes and\ncause apoptosis of lymphocytes.\nTreatment\nEmpiric antibiotic therapy immediately with antipseudomonal agent\n(cefepime, piperacillin-tazobactam) and vancomycin for methicillin-\nresistant S aureus (MRSA) coverage in patients with indwelling catheters,\npneumonia, or cutaneous abscess. Routine use of colony-stimulating factors\nis not indicated. If fevers persist after 72 hours despite antibiotic therapy, the\nphysician should start antifungal treatment (eg, amphotericin B or\ncaspofungin).\nLYMPHOPENIA AND EOSENOPENIA\nAn absolute lymphocyte count (ALC) <1500/mm3, where ALC (cells/\nmicroL) = WBC (cells/microL) Ã— percent lymphocytes Ã· 100. The most\ncommon causes of lymphopenia include viral infections such as HIV, con-\ngenital disorders like DiGeorge syndrome, severe combined immunodefi-\nciency (SCID), sepsis, immunosuppressive medications (glucocorticoids),\nSLE, chemotherapy, and radiation therapy. Table 2.7-14 presents lympho-\npenia versus eosinopenia.\nHistory/PE\nPatients are at â†‘ risk for recurrent infections (especially opportunistic bacte-\nrial and fungal infections in HIV) and autoimmune disorders.\nDiagnosis\nBes",
      "char_start": 858000,
      "char_end": 860000
    },
    {
      "chunk_id": 430,
      "text": "t initial test: CBC with a peripheral blood smear. Neutropenia is followed\nup with ANC and thrombocytopenia or anemia with bone marrow aspiration\nand biopsy.\nTreatment\nâ–  Asymptomatic lymphopenia is usually not treated, but is monitored.\nâ–  HIV is treated with antiretroviral therapy. Prophylactic antibiotics for\nopportunistic infections in HIV are the standard of care.\nâ–  In case of immunodeficiency syndromes, immunoglobulin replacement\nmay be considered.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229988 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 299\nTABLE 2.7-15. Etiologies of Hypereosinophilia\nINFECTIOUS AUTOIMMUNE NEOPLASM ALLERGIC MISCELLANEOUS\nHelminthic Eosinophilic granuloma- Primary hypereo- Asthma/atopy, allergic Adrenal insuffi-\nFungal tosis with polyangiitis sinophilic syndromes, bronchopulmonary ciency, cholesterol\nProtozoal (previously Churg- several different leuke- aspergillosis (ABPA), emboli syndrome,\nViral Strauss syndrome), mias and lymphomas acute interstitial nephritis acute arterial\ngraft-vs-host disease (AIN), drug reaction with thrombosis, radia-\n(GVHD) eosinophilia and systemic tion exposure\nsymptoms (DRESS) and\ndrugs\nEOSINOPHILIA\nMNEMONIC\nAn absolute eosinophil count â‰¥500/mm3. Eosinophilia as a primary disorder Causes of secondary\nis rare. The most common cause in the developed world is allergy, whereas in eosinophiliaâ€”\nthe developing world, it is parasitic infection. Table 2.7-15 summarizes the NAAACPDD\ndifferent etiologies of hypereosinophilia. Neoplasm\nAllergies\nCommon Presentations of Eosinophilia Asthma\nAtopy\nAllergic bronchopulmonary aspergillosis (ABPA): Allergic reaction in the\nCollagen vascular disease\nlungs due to Aspergillus fumigatus. Commonly observed in patients with\nParasites (eg Trichinella or Toxocara)\nasthma and cystic fibrosis. The chronic inflammation and mucoid impaction\nDrug\ncan result in lung damage, particularly bronchiectasis and fibrosis.\nEosinophilic granuloma",
      "char_start": 860000,
      "char_end": 862000
    },
    {
      "chunk_id": 431,
      "text": "tosis with polyangiitis (EGPA): A type of vascu-\nlitis also known as Churg-Strauss syndrome, which consists of chronic rhinosi-\nnusitis, asthma, and prominent peripheral blood eosinophilia\nChronic eosinophilic pneumonia (CEP): Idiopathic disorder caused by\nhigh accumulation of eosinophils in the interstitium of the lungs\nHistory/PE\nâ–  Procurement of travel, medication, and diet history.\nâ–  Inquiry into predisposing conditions, including atopy, asthma, sinus symp-\ntoms, cystic fibrosis, peripheral neuropathy, and lymphoma/leukemia.\nâ–  Examination directed toward cause. Patients with hypereosinophilic syn-\ndrome (HES) may present with fever, anemia, and prominent cardiac\nfindings (emboli from mural thrombi, abnormal ECGs, congestive heart\nfailure [CHF], murmurs).\nâ–  Eosinophils able to infiltrate and affect other organs as well (cutaneous,\nrespiratory, GI, and nervous systems).\nâ–  The absolute eosinophil count does not accurately predict organ damage.\nDiagnosis\nâ–  CBC with differential. Cerebrospinal fluid (CSF) analysis showing eosino-\nA 35-year-old man is airlifted to the\nphilia is suggestive of a drug reaction or infection with coccidioidomycosis\nemergency department after a motor\nor a helminth.\nvehicle accident. He requires multiple\nâ–  Hematuria with eosinophilia is a possible sign of schistosomiasis.\ntransfusions, which stabilize his blood\nâ–  ABPA: Serum IgE against A fumigatus or elevated total serum IgE pressure (BP) and Hb. The following\nconcentration.\nmorning, he is transferred to his hospital\nâ–  EGPA: Eosinophilia (â‰¥1500 cells/microL), asthma, rhinosinusitis, and room, where he begins to complain of\nevidence on histopathology of eosinophilic infiltration with or without numbness in his fingers. A prolonged\nvasculitis. QT interval is noted on an ECG. What is\nâ–  CEP: Bronchoalveolar lavage showing eosinophilia with CT chest imag- the most likely diagnosis?\ning findings of opacities.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 229999 ",
      "char_start": 862000,
      "char_end": 864000
    },
    {
      "chunk_id": 432,
      "text": "1100//2211//2222 11::0099 PPMM\n\n300 HIGH-YIELD FACTS IN HEMATOLOGY\nTreatment\nImmediate treatment: New-onset cardiac findings, eosinophilia >100,000/mm3,\nand drug reaction with eosinophilia and systemic symptoms (DRESS) must be\nspotted early and should be treated with steroids and discontinuation of offending\nagents.\nNonemergency treatment: Several steroid-sparing agents can be considered.\nâ–  Mepolizumab: A monoclonal antibody directed against IL-5, a growth\nfactor n eeded for the maturation of eosinophils and their activation\nâ–  Benralizumab: Monoclonal anti-IL-5 receptor alpha (IL-5R)\nâ–  Hydroxyurea: Works by suppressing eosinophilopoiesis\nâ–  Other treatments: Imatinib (features of myeloid disease), interferon alpha,\nalemtuzumab (anti-CD52 antibody), and JAK inhibitors (tofacitinib and\nruxolitinib)\nTreatment-specific indications:\nâ–  ABPA: Steroids are the mainstay of treatment. Antifungal therapy with\nitraconazole or voriconazole can be considered in addition to steroids dur-\ning an acute exacerbation.\nâ–  Omalizumab: Humanized monoclonal antibody can be considered in the\nsetting of poorly controlled asthma. Mepolizumab and benralizumab can\nKEY FACT\nbe considered in severe asthma and hypereosinophilia.\nA characteristic sign for AML subtype â–  EGPA: Steroids are the mainstay of treatment. During remission, steroid-\nM3 (APL) is the Auer rod seen in the sparing agents with azathioprine or methotrexate are considered. Mepoli-\nWBC cytoplasm (see Fig. 2.7-14), zumab and benralizumab can be considered.\nalthough Auer rods can be seen in â–  CEP: Steroids are the mainstay of treatment.\nother AML subtypes.\nLEUKEMIAS\nMalignant proliferations of hematopoietic cells, categorized by the type of\ncell involved and their level of differentiation\nAcute Leukemias\nAcute myelogenous and lymphocytic leukemias are clonal disorders of early\nhematopoietic stem cells (blasts), resulting in unregulated growth and differ-\nentiation of WBCs in bone marrow. As the bone marrow becomes replaced\nby leukemia",
      "char_start": 864000,
      "char_end": 866000
    },
    {
      "chunk_id": 433,
      "text": " cells, patients present with features of pancytopenia: anemia (â†“\nRBCs), infection (â†“ mature WBCs), and hemorrhage (â†“ platelets).\nFIGURE 2.7-14. Auer rod in AML. The Acute lymphocytic leukemia (ALL) and acute myelogenous leukemia\nred rod-shaped structure (arrow) in the (AML) are two subtypes that most commonly affect children and adults,\ncytoplasm of the myeloblast is pathogno- respectively.\nmonic. (Reproduced with permission from Dr. Peter\nMcPhedran, Yale Department of Hematology.) History/PE\nâ–  Rapid onset and progression. Patients present with signs and symptoms of\nanemia (pallor, fatigue), thrombocytopenia (petechiae, purpura, bleed-\ning), infections (ineffective and immature WBCs), and disseminated intra-\nvascular coagulation (DIC, most commonly seen in acute promyelocytic\nThis patient presents with symptoms leukemia [APL]). Medullary expansion into the periosteum may lead to\nof hypocalcemia following multiple\nbone pain (common in ALL).\nblood transfusions. Blood products\nâ–  Physical examination may show hepatosplenomegaly and swollen/bleed-\noften contain citrate, which binds\ning gums from leukemic infiltration and â†“ platelets. Leukemic cells also\nto serum calcium, leading to\ninfiltrate the skin and the central nervous system (CNS).\nhypocalcemia, which can cause\nprolonged QT intervals.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330000 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 301\nA\nDiagnosis\nâ–  Best initial test: CBC with smear showing blast cells.\nâ–  Most accurate test: Bone marrow biopsy with flow cytometry to classify\nleukemia type.\nâ–  Marrow that is infiltrated with blast cells is consistent with leukemia. In\nAML, the leukemic cells are myeloblasts; in ALL, they are lymphoblasts.\nThese cells can be distinguished by morphology (see Fig. 2.7-15), cytoge-\nnetics, and immunophenotyping (see Table 2.7-16).\nâ–  WBC count can be elevated, but the cells are dysfunctional, and\nB\npatients may be neutropenic with a hi",
      "char_start": 866000,
      "char_end": 868000
    },
    {
      "chunk_id": 434,
      "text": "story of frequent infection. If the\nWBC count is very high (eg, >100,000/mm3), there is a risk for leukosta-\nsis (blasts occluding the microcirculation, leading to pulmonary edema,\nCNS symptoms, ischemic injury, and DIC).\nTreatment\nâ–  In general, ALL and AML cases are treated with chemotherapy. Bone\nmarrow transplantation is considered in some patients, especially those\nwith higher risk cytogenetics and those who do not respond appropriately FIGURE 2.7-15. AML and ALL on periph-\neral smear. (A) AML. Large, uniform\nto upfront chemotherapy.\nmyeloblasts with round or kidney-shaped\nâ–  All-trans-retinoic acid (ATRA) combined with arsenic trioxide is highly nuclei and prominent nucleoli are char-\neffective in APL. acteristic. (B) ALL. Peripheral blood\nâ–  To prevent tumor lysis syndrome (hyperuricemia, hyperkalemia, hypocal- smear reveals numerous large, uniform\ncemia, renal insufficiency, as blasts are destroyed by chemotherapy), lymphoblasts, which are large cells with a\nhigh nuclear-to-cytoplasmic ratio. Some\npatients should be well hydrated. If WBC counts are â†‘, they may also be\nlymphoblasts have visible clefts in their\nstarted on allopurinol or rasburicase (often used in the pediatric popula-\nnuclei. (Reproduced with permission from Dr. Peter\ntion) to decrease serum uric acid as renal protection. Rasburicase is con-\nMcPhedran, Yale Department of Hematology.)\ntraindicated in G6PD deficiency.\nâ–  Leukostasis syndrome may be treated with hydroxyurea Â± leukapheresis to\nâ†“ WBC count.\nâ–  Indicators of poor prognosis:\nâ–  ALL: Age <1 year or >10 years; an â†‘ in WBC count to >50,000/mm3;\npresence of the Philadelphia chromosome t(9;22) (associated with\nB-cell cancer); CNS involvement at diagnosis\nâ–  AML: Age >60 years; elevated LDH; poor-risk or complex karyotype\nChronic Lymphocytic Leukemia\nA malignant, clonal proliferation of mature but functionally incompetent\nlymphocytes that accumulate in the bone marrow, peripheral blood, lymph\nnodes, spleen, and liver. All CLL cases involve well-d",
      "char_start": 868000,
      "char_end": 870000
    },
    {
      "chunk_id": 435,
      "text": "ifferentiated B lympho-\ncytes. Primarily affects older adults (median age 65 years); the male-to-female\nratio is 2:1.\nHistory/PE\nOften asymptomatic; patients present with fatigue, malaise, and infection.\nCommon physical findings are lymphadenopathy, hepatomegaly, and A 70-year-old woman with a history of\nsplenomegaly. hypertension and lymphoma presents\nwith nausea, vomiting, and fever of\nDiagnosis 2 daysâ€™ duration. She just completed\nher second cycle of high-dose\nâ–  Best initial test: CBC with differential and smear showing mature lym-\nchemotherapy. She has a temperature\nphocytosis (B cells >500/mm3) and characteristic smudge cells (fragile\nof 38.5Â°C (101.3Â°F). Her CXR is\nleukemia cells crushed by the slide). See Figure 2.7-16.\nunchanged, and her WBC count is 900/\nâ–  Most accurate test: Flow cytometry shows monoclonal B cells with CD5 mm3 with 25% neutrophils. After urine\nand CD23 markers. and blood cultures have been sent,\nwhat is the next step in management?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330011 1100//2211//2222 11::0099 PPMM\n\n302 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-16. Myeloblasts vs Lymphoblasts\nVARIABLE MYELOBLAST LYMPHOBLAST\nSize Larger (2â€“4 times RBC) Smaller (1.5â€“3.0 times RBC)\nAmount of cytoplasm More Less\nNucleoli Conspicuous Inconspicuous\nGranules Common, fine Uncommon, coarse\nFIGURE 2.7-16. CLL with characteristic\nAuer rods Present in 50% of cases Absent\nsmudge cells. The numerous small,\nmature lymphocytes and smudge cells\n(arrows; fragile malignant lymphocytes Myeloperoxidase âŠ• âŠ\nare disrupted during blood smear prepa-\nration) are characteristic. (Reproduced with Terminal âŠ âŠ•\npermission from Dr. Peter McPhedran, Yale Depart-\ndeoxynucleotidyltransferase (TdT)\nment of Hematology.)\nKEY FACT â–  Granulocytopenia, anemia, and thrombocytopenia are common as leuke-\nmic cells infiltrate bone marrow. Abnormal function by the leukemic cells\nThe presence of smudge cells may leads to hypogammaglobulinemia.\nindicate",
      "char_start": 870000,
      "char_end": 872000
    },
    {
      "chunk_id": 436,
      "text": " CLL. Smudge cells result â–  Bone marrow biopsy is rarely required for diagnosis but may provide prog-\nfrom the coverslip crushing the fragile nostic information.\nleukemia cells.\nTreatment\nâ–  CLL often does not require treatment due to its indolent natural history.\nDisease progression should be monitored every 3 to 6 months.\nâ–  Initial preferred agents are ibrutinib (BTK inhibitor), rituximab (anti-\nCD20 mAb therapy), venetoclax (anti-BCL2 therapy)\nâ–  Treatment, however, is palliative and is often withheld until patients are\nsymptomatic: recurrent infection, severe lymphadenopathy or splenomeg-\naly, anemia, or thrombocytopenia (poorest prognosis).\nâ–  Although CLL has a low likelihood of long-term cure, extended disease-\nfree intervals may be achieved with adequate treatment of symptoms. The\nclinical stage correlates with expected survival.\nCHRONIC MYELOGENOUS LEUKEMIA\nClonal expansion of myeloid progenitor cells, leading to leukocytosis with\nexcess granulocytes and basophils and sometimes â†‘ erythrocytes and platelets\nas well. To truly be CML, the BCR-ABL translocation must be present. In\n>95% of patients, this is reflected on conventional cytogenetic analysis by the\nPhiladelphia chromosome t(9;22). CML primarily affects middle-aged\npatients (median age 50 years).\nThe physician should admit the\npatient and begin IV antibiotics with\nHistory/PE\nan antipseudomonal Î²-lactam (eg,\ncefepime, piperacillin-tazobactam, â–  Many patients are asymptomatic at diagnosis. Typical signs and symptoms\nmeropenem, imipenem). Febrile, are those of anemia.\nneutropenic patients who are on\nâ–  Patients can have splenomegaly with left upper quadrant (LUQ) pain and\nhigh-dose chemotherapy, have a\nearly satiety. Constitutional symptoms of weight loss, anorexia, fever, and\nhematologic malignancy, or have\nchills may also be seen.\nbeen neutropenic for >14 days should\nbe admitted for empiric IV antibiotics.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330022 1100//2211//2",
      "char_start": 872000,
      "char_end": 874000
    },
    {
      "chunk_id": 437,
      "text": "222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 303\nTABLE 2.7-17. Leukemoid Reaction vs CML 19\nLEUKEMOID REACTION CML KEY FACT\nLeucocyte count 50,000/mm3 Often >100,000/mm3) The presence of smudge cells may\nindicate CLL. Smudge cells result\nCause Severe infection BCR-ABL fusion\nfrom the coverslip crushing the fragile\nleukemia cells.\nLAP score High Low\nNeutrophil precursors More mature (meta- Less mature (metamyelo-\nmyelocytes > cytes < myelocytes)\nKEY FACT\nmyelocytes)\nThe likely diagnosis of leukemia is based\nAbsolute basophilia Not present Present on age at presentation:\nâ–  ALL: <13 years (but can present in\nToxic granulation in neutrophils Present Not Present\nany age group)\nâ–  AML: 13 to 40 years (but can\npresent in any age group)\nâ–  CML: 40 to 60 years\nâ–  CLL: >60 years\nâ–  Patients with CML in the absense of treatment go through three disease\nphases: KEY FACT\nâ–  Chronic: Without treatment, this phase typically lasts 3.5 to 5 years.\nLymphocytosis is a common lab\nInfection and bleeding complications are rare.\nfinding of CLL (â†‘ B cells) vs CML, which\nâ–  Accelerated: This phase embodies a transition toward blast crisis, with\nshows granulocytosis (â†‘ granulocytes:\nan â†‘ in peripheral and bone marrow blast counts. It should be sus-\nneutrophils, eosinophils, or basophils).\npected when the differential shows an abrupt â†‘ in basophils and\nthrombocytopenia (platelet count <100,000/mm3).\nâ–  Blast crisis: A large percentage of untreated CML patients will eventu-\nally reach this phase. It resembles acute leukemia; survival is 3 to 6\n1\nmonths.\nA 40-year-old woman sees a physician\nDiagnosis\nfor a 6-month history of weight loss,\nâ–  Most accurate test: Philadelphia chromosome via polymerase chain reac- fevers, and abdominal discomfort.\ntion (PCR) or fluorescence in situ hybridization (FISH) analysis showing Her WBC count is 56,000/mm3. The\nthe t(9;22) translocation, although some cases lack the translocation. physician orders a leukocyte alkaline\nâ–  CBC often shows a very high WBC countâ€”oft",
      "char_start": 874000,
      "char_end": 876000
    },
    {
      "chunk_id": 438,
      "text": "en >100,000/mm3 at diag- phosphatase (LAP) to distinguish\nbetween a leukemoid reaction and\nnosis, sometimes reaching >500,000/mm3. The differential shows granu-\na hematologic malignancy. What is\nlocytes (predominantly neutrophils) in all stages of maturation. Rarely, the\nthe expected result in a leukemoid\nWBC count will be so elevated as to cause a hyperviscosity syndrome.\nreaction?\nâ–  CML can be confused clinically with a leukemoid reaction (acute inflam-\nmatory response to infection with â†‘ neutrophils and a left shift). Leuko-\ncyte alkaline phosphatase score is low in CML and other hematologic\nmalignancies, and LAP is high in leukemoid reactions. See Table 2.7-17.\nTreatment\nâ–  Chronic: Tyrosine kinase inhibitors (eg, imatinib). Young patients may be 2\ncandidates for allogeneic stem cell transplantation if a matched sibling\ndonor is available. A 41-year-old man is diagnosed with\nâ–  Blast crisis: Same as that for acute leukemia, or second-generation tyro- AML. Fluorescence in situ hybridization\nsine kinase inhibitors (eg, dasatinib, nilotinib) plus hematopoietic stem (FISH) analysis reveals that he has APL,\ncell transplantation or a clinical trial. M3 subtype (FAB classification). What is\nthe preferred therapy for this subtype\nof AML?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330033 1100//2211//2222 11::0099 PPMM\n\n304 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-18. Non-Hodgkin vs Hodgkin Lymphoma\nNON-HODGKIN LYMPHOMA HODGKIN LYMPHOMA\nMany peripheral nodes involved; Single group of localized nodes, spreads contiguously\nextranodal, noncontiguous and rarely involves extranodal sites\nspread\nMainly B cells, sometimes T cells Reed-Sternberg cells: distinct CD15+ and CD30+ B cells\nFIGURE 2.7-17. Hairy cell leukemia. Peak incidence 65â€“75 years of age Bimodal: young and old\nNote the hairlike cytoplasmic projections\nfrom neoplastic lymphocytes. Villous\nHIV and autoimmune association EBV association\nlymphoma can also have this appear-\nance. (Re",
      "char_start": 876000,
      "char_end": 878000
    },
    {
      "chunk_id": 439,
      "text": "produced with permission from Dr. Peter\nMcPhedran, Yale Department of Hematology.) Adapted with permission from Le T, et al. First Aid for the USMLE Step 1 2018. New York, NY: McGraw-\nHill; 2018.\nKEY FACT Hairy Cell Leukemia\nImatinib is a selective inhibitor of the A malignant disorder of well-differentiated B lymphocytes. Hairy cell leuke-\nBCR-ABL tyrosine kinase, the product of mia (HCL) is a rare disease that accounts for 2% of adult leukemia cases and\nthe t(9;22) translocation, or Philadelphia most commonly affects older males (median age 50â€“55 years).\nchromosome.\nHistory/PE\nâ–  Typically presents with pancytopenia, bone marrow infiltration, and\nsplenomegaly.\nâ–  Patients complain of weakness, fatigue, petechiae, bruising, infection\n(especially with atypical mycobacteria such as Mycobacterium aviumâ€“\nintracellulare), abdominal pain, early satiety, and weight loss. Presentation\nis similar to that of CLL except that patients rarely have\nlymphadenopathy.\nDiagnosis\nâ–  Best initial test: CBC with smear showing pathognomonic â€œhairy cellsâ€\n(mononuclear cells with many cytoplasmic projections; see Fig. 2.7-17)\nthat stain with tartrate-resistant acid phosphatase (TRAP). Leukopenia can\nsometimes be seen as well.\nâ–  Most accurate test: Flow cytometry identifying the â€œhairy cellsâ€\nTreatment\n1\nâ–  Best initial treatment: Cladribine.\nThe LAP score would be â†‘ . â–  Alternative treatment options: Pentostatin, rituximab, and interferon\n(IFN)-Î±.\nHematologic malignancies, in\ncontrast, have â†“ LAP score. â–  Median survival without treatment is 5 years. If left untreated, most\npatients will develop progressive pancytopenia and splenomegaly, eventu-\nally requiring therapy.\nLYMPHOMAS\n2\nMalignant transformations of lymphoid cells residing primarily in lymphoid\ntissues, especially the lymph nodes. Classically organized into Hodgkin lym-\nAPL has a favorable prognosis, phoma (HL) and non-Hodgkin lymphoma (NHL). See Table 2.7-18.\nbecause it is responsive to ATRA\ntherapy. This AML subtype is also Non-Ho",
      "char_start": 878000,
      "char_end": 880000
    },
    {
      "chunk_id": 440,
      "text": "dgkin Lymphoma\nassociated with an â†‘ incidence of DIC\nand a chromosomal translocation NHL represents a diverse group of mature B- and T-cell neoplasms. Most\ninvolving chromosomes 15 and 17. NHLs (almost 85%) are of B-cell origin. NHL is the most common hemato-\npoietic neoplasm and is five times more common than HL.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330044 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 305\nTABLE 2.7-19. Non-Hodgkin Lymphoma Types\nTYPE OCCURS IN GENETICS/ETIOLOGY COMMENTS\nB-CELL NEOPLASMS\nFollicular Adults (mean t(14;18)â€”translocation of Indolent course or low grade\nlymphoma age 55 heavy-chain Ig (14) and Painless waxing and waning adenopathy\nyears) BCL-2 (18) Localized disease (15%) may be cured with radiation therapy\nDiffuse large B-cell Usually Mutations in BCL-2, BCL-6, Intermediate grade\nlymphoma middle-aged and MYC Most common NHL in adults\nand elderly Often presents with single rapidly growing mass\nHigh cure rate with R-CHOP therapy (rituximab, cyclophosphamide,\ndoxorubicin, vincristine, and prednisone)\nBurkitt lymphoma Children and t(8;14)â€”translocation of High grade, â€œstarry skyâ€ appearance on lesion biopsy\nadolescents c-myc (8) and heavy- Jaw lesion in Africa, abdominal lesion in Americas\nchain Ig (14) Associated with EBV and t(8;14) translocation\nAggressive treatment with chemotherapy\nMantle cell Older adult t(11;14)â€”translocation CD5+\nlymphoma Males of cyclin D1 (11) and Rarest form of NHL\nheavy-chain Ig (14),\nCD5+\nPrimary CNS Adults EBV related; associated An AIDS-defining illness\nlymphoma with HIV/AIDS Variable presentation: confusion, memory loss, seizures\nCNS mass (often single, ring-enhancing lesion on MRI) in immunocom-\npromised patients\nDistinguished from toxoplasmosis via CSF analysis or other lab tests\nT-CELL NEOPLASMS\nAdult T-cell Adults Caused by HTLV (associ- High grade, can progress to ALL\nlymphoma ated with IV drug use) Presents with cutaneous lesions\nCaused by HTL",
      "char_start": 880000,
      "char_end": 882000
    },
    {
      "chunk_id": 441,
      "text": "V, associated with IVDA\nMycosis fun- Adults Mycosis fungoides is a T-cell lymphoma of the skin\ngoides/SÃ©zary Cutaneous eczema-like lesions and pruritus are common presentations\nsyndrome On skin biopsy see lymphoid cells with â€œcerebriformâ€ nuclei\nCan progress to SÃ©zary syndrome (T-cell leukemia) with characteristic\nSÃ©zary cells seen on blood smear\nAdapted with permission from Le T et al. First Aid for the USMLE Step 1 2022. New York, NY: McGraw-Hill; 2022.\nHistory/PE\nThe median patient age is >50 years, but NHL may also be found in chil-\ndren, who tend to have more aggressive, higher-grade disease. Patient presen-\ntation varies with disease (see Table 2.7-19), but often includes painless\nperipheral lymphadenopathy, â€œBâ€ symptoms (fevers, night sweats, weight\nloss), and masses on examination.\nDiagnosis\nâ–  Best initial test: Excisional lymph node biopsy\nâ–  A CSF exam should be done in patients with HIV, neurologic symptoms,\nor primary CNS lymphoma.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330055 1100//2211//2222 11::0099 PPMM\n\n306 HIGH-YIELD FACTS IN HEMATOLOGY\nA B\nFIGURE 2.7-18. Hodgkin lymphoma. (A) CXR of a 27-year-old man presenting with several\nweeks of fevers and night sweats shows bulky bilateral hilar (arrows) and right paratracheal lymph-\nadenopathy (arrowhead). (B) Lymph node sampling shows a mixed inflammatory infiltrate and a\nclassic binucleate Reed-Sternberg cell (circle) consistent with Hodgkin lymphoma. (Image A adapted\nwith permission from Harrison NK. Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations. Cough.\n2013;9(1):9. Published 2013 Mar 6. doi:10.1186/1745-9974-9-9. Image B courtesy of Dr. Andrea Subhawong.)\nKEY FACT\nThe treatment of high-grade NHL Treatment\nmay be complicated by tumor lysis\nâ–  Radiation and/or chemotherapy can be used as a therapy.\nsyndrome, in which rapid cell death\nâ–  Low-grade indolent NHL treatment is generally palliative.\nreleases intracellular contents and l",
      "char_start": 882000,
      "char_end": 884000
    },
    {
      "chunk_id": 442,
      "text": "eads\nâ–  High-grade aggressive NHL treatment is aggressive chemotherapy with a\nto hyperkalemia, hyperphosphatemia,\ncurative approach. A common regimen is rituximab, cyclophosphamide,\nhyperuricemia, and hypocalcemia.\ndoxorubicin, vincristine, and prednisone (R-CHOP).\nHodgkin Lymphoma\nA predominantly B-cell malignancy associated with EBV. HL has a bimodal\nage distribution: 30 years of age (primarily the nodular sclerosing type) and 60\nyears of age (mainly the lymphocyte-depleted type). It has a male predomi-\nKEY FACT\nnance in childhood.\nOn physical examination, lymph nodes\nsuspicious for malignancy are generally History/PE\ndescribed as firm, fixed, nontender, â–  HL commonly presents above the diaphragm (classically as cervical ade-\ncircumscribed, rubbery, and >1 cm in nopathy; see Fig. 2.7-18A). Infradiaphragmatic involvement suggests dis-\ndiameter. Benign nodes (usually from seminated disease.\ninfection) are generally described as â–  Patients can have systemic B symptoms, pruritus, and hepatosplenomegaly.\nbilateral, <1 cm, mobile, and nontender Pel-Ebstein fevers (1â€“2 weeks of high fever alternating with 1â€“2 afebrile\n(viral) or tender (bacterial). weeks) and alcohol-induced pain at nodal sites are rare signs specific for HL.\nDiagnosis\nKEY FACT â–  Best initial step: Excisional lymph node biopsy shows the classic Reed-\nSternberg cells (giant abnormal B cells with bilobar nuclei and huge,\nChemotherapy and radiation can eosinophilic nucleoli, which create an â€œowlâ€™s-eyeâ€ appearance; see Fig.\nlead to secondary neoplasms such as 2.7-18B).\nAML, NHL, breast cancer, and thyroid â–  Staging is based on the number of lymph node groups involved, the pres-\ncancer. Preventive measures such as ence of B symptoms, and whether the disease involves lymph nodes (both\nmammography are warranted. sides of the diaphragm) and extranodal sites (eg, bone marrow).\nTreatment\nâ–  Treatment is stage dependent, involving chemotherapy and/or radiation\n(in early stage disease). A common chemotherapy regimen i",
      "char_start": 884000,
      "char_end": 886000
    },
    {
      "chunk_id": 443,
      "text": "s Adriamycin\n(doxorubicin), bleomycin, vinblastine, and dacarbazine (ABVD).\nâ–  Radiation increases the risk for premature coronary artery disease, solid\ntumors (eg, breast, lung, thyroid), and hypothyroidism.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330066 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 307\nâ–  Five-year survival rates are 90% for stage I and II disease (nodal disease\nM spike\nlimited to one side of the diaphragm), 84% for stage III, and 65% for stage\nIV. Lymphocyte-predominant HL has the best prognosis.\nPLASMA CELL DISORDERS\nAlbumin Î±1 Î±2 Î² Î³\nFIGURE 2.7-19. Multiple myeloma.\nMULTIPLE MYELOMA\nSerum protein electrophoretic tracing\nshowing M protein spike IgG/A (diag-\nClonal proliferation of malignant plasma cells with excessive production of nostic of MM). Note that M protein\nspike IgM indicates WaldenstrÃ¶m macro-\nmonoclonal immunoglobulins (typically ineffective IgA or IgG) and/or\nglobulinemia. (Reproduced with permission from\nimmunoglobulin fragments (kappa/lambda light chains). Multiple myeloma\nUSMLE-Rx.com.)\n(MM) primarily affects older adults, peaking in the seventh decade. Risk fac-\ntors include radiation exposure and monoclonal gammopathy of undeter-\nmined significance (MGUS).\nKEY FACT\nHistory/PE\nâ–  Patients present with bone pain or with a pathologic fracture (MM cells Chemotherapy often induces nausea\ninfiltrate bone marrow, where they activate osteoclasts, creating lytic in cancer patients and should be\nlesions, weak bones, and hypercalcemia). managed with ondansetron, a\nâ–  Patients are prone to infection (IgG and IgA produced by myeloma cells serotonin 5-hydroxytryptamine (5-HT3)\nare monoclonal, thus making them ineffective) and have elevated mono- receptor antagonist.\nclonal (M) proteins in serum and/or urine.\nDiagnosis\nMNEMONIC\nâ–  Best initial test: Serum protein electrophoresis showing IgG or IgA mono-\nclonal spikes (see Fig. 2.7-19), and/or serum free light chains. Clinical features of mu",
      "char_start": 886000,
      "char_end": 888000
    },
    {
      "chunk_id": 444,
      "text": "ltiple\nâ–  Most accurate test: Bone marrow biopsy shows >10% monoclonal myelomaâ€”\nCD138+ plasma cells. CRAB\nâ–  CBC with smear may show rouleaux formation, whereas urine protein Cooselycemia\nelectrophoresis may show Bence Jones protein (paraprotein). Gamma gap Renal involvement/Recurrent infections\n(total serum protein â€“ serum albumin) is often elevated. Anemia/Amyloidosis\nâ–  M protein alone is insufficient for the diagnosis of MM, as MGUS, CLL, Bone lytic lesions/Back pain\nlymphoma, WaldenstrÃ¶m macroglobulinemia, and amyloidosis can also â†‘\nM protein.\nKEY FACT\nSimilar to MM, MGUS is a monoclonal\nA B\nexpansion of plasma cells that is\nasymptomatic and may eventually lead\nto multiple myeloma (1%-2% per year).\nNo â€œCRABâ€ findings.\nFIGURE 2.7-20. Multiple myeloma skeletal survey. Characteristic lytic bony lesions of mul-\ntiple myeloma involving the tibia and fibula (A) and the skull (B) are seen. (Image A reproduced\nwith permission from Lichtman MA et al. Williams Hematology. 8th ed. New York, NY: McGraw-Hill; 2010. Image B reproduced\nwith permission from Kantarjian HM, Wolff RA, Koller CA. MD Anderson Manual of Medical Oncology. 2nd ed. New York, NY:\nMcGraw-Hill; 2011.)\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330077 1100//2211//2222 11::0099 PPMM\n\n308 HIGH-YIELD FACTS IN HEMATOLOGY\nKEY FACT â–  Patients should also be evaluated for anemia, hypercalcemia, and renal\nfailure. Bone lesions are also seen with imaging such as a skeletal survey\nMM damaging renal tubules can\n(see Fig. 2.7-20).\nproduce adult Fanconi syndrome.\nTreatment\nKEY FACT â–  Patients who are candidates can be treated with chemotherapy and autolo-\ngous bone marrow transplant. Common chemotherapeutic agents are\nAs MM is an osteoclastic process, a\ncyclophosphamide, bortezomib, daratumumab (anti-CD138 mAb), dexa-\nbone scan, which detects osteoblastic\nmethasone, and lenalidomide.\nactivity, may be âŠ–.\nâ–  Patients who are not candidates for bone marrow transplantation can be\ntreated w",
      "char_start": 888000,
      "char_end": 890000
    },
    {
      "chunk_id": 445,
      "text": "ith daratumumab, lenalidmoide, dexamethasone, cyclophospha-\nmide and/or bortexomib.\nWALDENSTRÃ–M MACROGLOBULINEMIA\nKEY FACT\nCryoglobulinemia and cold agglutinins A clonal disorder of B cells that leads to malignant monoclonal gammopathy. â†‘\nare different disorders caused by IgM levels of IgM result in hyperviscosity syndrome, coagulation abnormalities, cryo-\nantibodies. Cryoglobulinemia is most globulinemia, cold agglutinin disease (leading to AIHA), and amyloidosis. Tis-\noften seen in hepatitis C virus (HCV) sue is infiltrated by IgM and neoplastic plasma cells. A chronic, indolent\nand has systemic signs such as joint disease of older adults.\npain and renal involvement. Cold\nagglutinins may cause finger or toe History/PE\nnumbness and hemolytic anemia\nâ–  Presents with nonspecific symptoms: Lethargy, weight loss, and Raynaud\nupon cold exposure and are seen\nphenomenon from cryoglobulinemia. Organomegaly and organ dysfunc-\nwith EBV, mycoplasmal infection, and\ntion can be present.\nWaldenstrÃ¶m macroglobulinemia.\nâ–  Neurologic problems ranging from mental status changes to sensorimotor\nperipheral neuropathy and blurry vision (engorged blood vessels can be\nnoted on eye exam) are also seen.\nâ–  As with MM, MGUS is a precursor to disease.\nDiagnosis\nâ–  Most accurate test: Bone marrow biopsy and aspirate. Marrow shows\nabnormal plasma cells, classically with Dutcher bodies (periodic acidâ€“\nSchiff [PAS]âŠ• IgM deposits around the nucleus). Serum and urine pro-\ntein electrophoresis and immunofixation are also used.\nâ–  Nonspecific findings include â†‘ erythrocyte sedimentation rate (ESR), uric\nacid, LDH, and alkaline phosphatase.\nTreatment\nRituximab and chemotherapy for patients with symptomatic disease. Plasma-\npheresis can remove excess immunoglobulin for patients who present with\nsigns or symptoms of hyperviscosity.\nAMYLOIDOSIS\nExtracellular deposition of amyloid protein fibrils resulting from a variety of\ncauses (see Table 2.7-20). Classically a disease of older adults.\nHistory/PE\nâ–  Clinic",
      "char_start": 890000,
      "char_end": 892000
    },
    {
      "chunk_id": 446,
      "text": "al presentation depends on the type, amount, and tissue distribution\nof amyloid. In the most common forms of systemic amyloidosis, primary\n(AL) and secondary (AA), the major sites of clinically important amyloid\ndeposition are in the kidneys, heart, and liver.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330088 1100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 309\nTABLE 2.7-20. Types of Amyloidosis\nAMYLOID CAUSE\nAL A plasma cell dyscrasia with deposition of monoclonal light-chain\nfragments\nAssociated with multiple myeloma and WaldenstrÃ¶m macroglobulinemia\nAA Deposition of the acute-phase reactant serum amyloid A\nAssociated with chronic inflammatory diseases (eg, rheumatoid arthritis),\ninfections, and neoplasms\nDialysis related Deposition of Î²-microglobulin, which accumulates in patients' joints\n2\n(scapulohumeral joint and carpal tunnel) on long-term dialysis.\nHeritable Deposition of abnormal gene products (eg, transthyretin, also known as\nprealbumin). A heterogeneous group of disorders\nSenile-systemic Deposition of otherwise normal transthyretin\nAA, Secondary amyloidosis; AL, primary amyloidosis.\nâ–  In some disorders, amyloid deposition is limited to one organ (eg, cerebral\namyloid angiopathy in Alzheimer disease).\nDiagnosis\nMost accurate test: Tissue biopsy with Congo red staining showing apple-\ngreen birefringence under polarized light.\n1\nTreatment\nA 45-year-old woman presents to the\nâ–  Primary amyloidosis is treated with chemotherapy and/or autologous stem emergency department with fever,\ncell transplant. Chemotherapy agents are similar to those used in MM. chills, nausea, vomiting, and severe\nâ–  Secondary amyloidosis is treated by addressing the underlying condition. flank pain. She has a history of multiple\nurinary tract infections (UTIs) and was\nrecently hospitalized for pyelonephritis.\nUrinalysis (UA) reveals pyuria and\nTRANSPLANT MEDICINE bacteriuria. Ultrasound performed in\nthe emergency department shows\nwhat ap",
      "char_start": 892000,
      "char_end": 894000
    },
    {
      "chunk_id": 447,
      "text": "pears to be a perinephric\nâ–  Three types of tissue transplantation are increasingly used to treat diseases: abscess. What is the next most\nâ–  Autologous: Transplantation from the patient to himself or herself appropriate step in management?\nâ–  Allogeneic: Transplantation from a donor to a genetically different\npatient\nâ–  Syngeneic: Transplantation between identical twins (from a donor to a\ngenetically identical patient)\nâ–  With allogeneic donation, efforts are made to ABO- and HLA-match the\n2\ndonor and recipient. Despite matching and immunosuppression, however,\ntransplants may be rejected. There are three types of solid organ rejection:\nAn 80-year-old man is seen in clinic\nhyperacute, acute, and chronic (see Table 2.7-21).\nafter an incidental finding of elevated\nâ–  Graft-vs-host disease (GVHD) is a complication specific to allogeneic\nIgG on a recent hospital admission for\nBMT in which donated T cells attack host tissues, especially the skin,\npneumonia. He has no signs of kidney\nliver, and GI tract. It may be acute (<100 days posttransplant) or chronic\ndamage, anemia, or bone lesions.\n(>100 days afterward).\nThe IgG level is 2100 mg/dL, and a\nâ–  Minor histocompatibility antigens are thought to be responsible for subsequent bone marrow biopsy\nGVHD, which presents with skin changes, cholestatic liver dysfunc- shows 3% plasma cells. What is the next\ntion, obstructive lung disease, or GI problems. best step?\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 330099 1100//2211//2222 11::0099 PPMM\n\n310 HIGH-YIELD FACTS IN HEMATOLOGY\nTABLE 2.7-21. Types of Solid Organ Transplant Rejection\nVARIABLE HYPERACUTE ACUTE CHRONIC\nTiming after Within minutes Between 5 days and 3 months Months to years\ntransplant (intraopera-\ntively)\nPathogenesis Preformed Mixed T-cell and B-cell mediated Chronic immune\nantibodies response against mismatched reaction causing\nHLA class I and class II fibrosis\nantigens\nTissue findings Vascular thrombi; Laboratory evidence of tissu",
      "char_start": 894000,
      "char_end": 896000
    },
    {
      "chunk_id": 448,
      "text": "e Gradual loss of\ntissue ischemia destruction such as â†‘ gamma- organ function\nglutamyl transferase (GGT),\nalkaline phosphatase, LDH,\nBUN, or creatinine\nPrevention Check ABO N/A N/A\ncompatibility\nTreatment Cytotoxic agents Confirmation with sampling No treatment;\nof transplanted tissue; biopsy to rule\ninitial treatment with out treatable\ncorticosteroids. acute reaction\nAdditional immunosuppressive\ntherapy can include antilym-\nphocyte antibodies (OKT3),\ntacrolimus, or mycophenolate\nmofetil (MMF)\n1\nâ–  Patients are treated with high-dose corticosteroids.\nPatients with multiple â–  Typical posttransplant immunosuppression regimens include prednisone;\nmyeloma frequently have renal mycophenolate mofetil (MMF); FK506 (tacrolimus) to suppress immune-\ndysfunction secondary to urinary mediated rejection; and TMP-SMX, ganciclovir, and fluconazole to pre-\nimmunoglobulins (also known as vent subsequent infection in the immunosuppressed host.\nBence Jones protein) that have the â–  A variant of GVHD is the graft-vs-leukemia effect, in which leukemia\nability to form casts, leading to cast patients who are treated with an allogeneic bone marrow transplant have\nnephropathy.\nsignificantly lower relapse rates of leukemia than those treated with an\nautologous transplant. This difference is thought to be caused by a recog-\nnition of leukemia cells by the donor T cells.\n2 MULTISYSTEM HEMATOLOGY\nThis patient has MGUS, as seen by the\nHEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS\nelevated IgG in the absence of other\nclinical abnormalities or symptoms.\nNo treatment is required, but because Life-threatening state of severe immune system activation due to overactive\nMGUS can progress to MM, this patient macrophages and lymphocytes with phagocytosis of blood cells. This com-\nshould be seen regularly for signs of monly occur in infants 0 to 18 months but can be seen in adults of all ages.\nrenal failure, anemia, or bone pain.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 331100 1",
      "char_start": 896000,
      "char_end": 898000
    },
    {
      "chunk_id": 449,
      "text": "100//2211//2222 11::0099 PPMM\n\nHEMATOLOGY HIGH-YIELD FACTS IN 311\nHistory/PE\nPresents with fever, rash, hepatosplenomegaly, neurologic disturbances (sei-\nzures, mental status changes, ataxia), multiorgan dysfunction, cytopenias,\ncoagulopathies, and hemodynamic instability.\nDiagnosis\nâ–  Clinical findings as mentioned: â†‘ inflammatory markers (ferritin, Scd25,\nCXCL9)â†‘\nâ–  Bone marrow aspirate demonstrating hemophagocytosis\nTreatment\nAcutely ill: dexamethasone and etoposide. Supportive care (blood transfusion\nfor anemia and thrombocytopenia), antibiotics for infection due to pancytope-\nnia, immunosuppressive/cytotoxic therapy (eg, dexamethasone and etoposide).\nMASTOCYTOSIS\nRare disorder involving excessive release and accumulation of mastocytes in\nthe skin (cutaneous mastocytosis) or other tissues (systemic mastocytosis).\nHistory/PE\nPhysical examination demonstrating skin findings: diffuse red-brown cutane-\nous maculopapular lesions and splenomegaly.\nDiagnosis\nâ–  Skin or bone marrow biopsy with KIT stain (mast cell specific) with â†‘\nmast cell concentration, KIT mutation, serum tryptase >20.\nâ–  Bone marrow biopsy can also show cytopenia due to crowding of the bone\nmarrow by mastocytosis.\nTreatment\nAimed at preventing mast cell degranulation with antihistamines, cromolyn,\nand antileukotrienes.\nLANGERHANS CELL HISTIOCYTOSIS\nProliferative disorders of Langerhans cells characterized by histiocyte infiltra-\ntion of tissue, commonly due to BRAF V600E mutation.\nHistory/PE\nâ–  Langerhans cell histiocytosis can present with multisystem involvement\n(eg, skin, lymph nodes, liver, lung, CNS).\nâ–  Skin or oral mucosa: Can present with eczematous rash (resembles Can-\ndida infection) and/or brown, purplish papules.\nâ–  Lung: Can present with nonproductive cough, dyspnea, chest pain, con-\nstitutional symptoms (eg, fever, weight loss).\nâ–  Bone: Can present with localized bone pain due to osteolytic lesions.\nâ–  CNS: Can manifest as cognitive dysfunction and ataxia.\nâ–  Diabetes insipidus: Present with po",
      "char_start": 898000,
      "char_end": 900000
    },
    {
      "chunk_id": 450,
      "text": "lyuria, nocturia, and polydipsia due to\nhypothalamic-pituitary axis (HPA) involvement. May also have associated\nendocrinopathies (hypogonadism, growth failure, impaired glucose toler-\nance/diabetes mellitus, and thyroid enlargement).\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 331111 1100//2211//2222 11::0099 PPMM\n\n312 HIGH-YIELD FACTS IN HEMATOLOGY\nDiagnosis\nBone or skin biopsy, pathology demonstrating collections of histiocytes and\nLangerhans cells (large ovoid mononuclear cells).\nTreatment\nTreatment depends on the organ involved in the disease. Bone disease can be\ntreated with curettage or radiotherapy. Skin involvement can be treated with\ntopical steroids or methotrexate. Lymph node involvement can be treated\nwith vinblastine chemotherapy. Steroids can also be considered when the\nlungs are involved, along with smoking cessation.\n22002222__0022..0077__SStteepp22CCKK__HHeemmaa__1111ee__226699--331122..iinndddd 331122 1100//2211//2222 11::0099 PPMM\n\nH I G H - Y I E L D F A C T S I N\nMUSCULOSKELETAL\nWhole Body 314 Upper Extremity 339\nCommon Adult orthopediC injuries 314 Adhesive CApsulitis 339\nottAwA Ankle rules 319 rotAtor CuFF injuries 340\nsAlter-hArris pediAtriC FrACture ClAssiFiCAtion 319 CompArtment syndrome 340\nCommon peripherAl nerve injuries 320 rhAbdomyolysis 341\nComplex regionAl pAin syndrome 322 CArpAl tunnel syndrome 342\nosteosArComA 323 gAnglion Cyst 342\nseptiC Arthritis 325 dupuytren ContrACture 343\nosteomyelitis 326 AvAsCulAr neCrosis 343\nosteoArthritis 327 rAynAud phenomenon 344\nosteoporosis 329 hAnd inFeCtion And bite wounds 344\nrheumAtoid Arthritis 329\nLower Extremity 345\nseronegAtive spondyloArthropAthy 330\nosteoChondritis disseCAns 345\npolymyositis And dermAtomyositis 332\nbursitis 345\ntemporomAndibulAr joint disorders 333\npes Anserinus pAin syndrome 345\nmyoFAsCiAl pAin syndrome 334\npAtelloFemorAl pAin syndrome 346\nsystemiC sClerosis 334\nmorton neuromA 346\nsystemiC lupus erythemAtosus 335\ngout 346\nserum siCknes",
      "char_start": 900000,
      "char_end": 902000
    },
    {
      "chunk_id": 451,
      "text": "sâ€“like reACtion 336\npseudogout 348\ngiAnt Cell Arteritis 336\ntAkAyAsu Arteritis 337 Trunk 348\nbehÃ§et syndrome 338 low bACk pAin 348\nFibromyAlgiA 338 herniAted disk 349\npolymyAlgiA rheumAtiCA 339 spinAl stenosis 349\nspondylolisthesis And spondylosis 350\n313\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331133 1100//2211//2222 11::5500 PPMM\n\n314 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nWHOLE BODY\nKEY FACT COMMON ADULT ORTHOPEDIC INJURIES\nâ–  Posterior hip dislocation: Shortened,\nOrthopedic injuries affect all populations and often present as a result of trauma\ninternally rotated leg\nor a fall. Understanding the presenting features, diagnostic findings, and man-\nâ–  Anterior hip dislocation:\nagement of these common injuries is critical for developing clinical knowledge.\nLengthened, externally rotated leg\nThe most commonly tested and seen conditions are discussed here.\nâ–  Hip fracture: Shortened, externally\nTable 2.8-1 outlines the presentation and treatment of orthopedic injuries\nrotated leg\nthat commonly affect adults.\nTABLE 2.8-1. Common Adult Orthopedic Injuries\nUPPER EXTREMITY\nINJURY PRESENTATION TREATMENT\nShoulder and Upper Arm\nClavicle fracture Occurs after trauma (typically a fall). Sling if uncomplicated. Surgery if fracture open,\nA Pain with possible skin tenting due to fracture angula- displaced with skin tenting, or neurovascular\ntion, proximal fragment will be elevated, distal will be compromise.\ndepressed due to muscular pull. There may be accom-\npanying snapping or clicking.\nShoulder dislocation Anterior dislocation: Most common (95%); risk for axillary Reduction followed by a sling and swath. Recur-\nB nerve injury. Patients hold arm in slight abduction and rent dislocations may need surgery.\nexternal rotation (see Image B).\nPosterior dislocation: Rare; associated with seizure and\nelectrocution. Patients hold arm in adduction and\ninternal rotation.\nAcute rotator cuff tear Acute-onset anterior shoulder pain and weakness with Rest an",
      "char_start": 902000,
      "char_end": 904000
    },
    {
      "chunk_id": 452,
      "text": "d nonsteroidal anti-inflammatory drugs\nabduction or external rotation of the humerus after fall (NSAIDs) for minor injury.\non outstretched arm or in young athletes. Surgery if loss of active range of motion with pre-\nSignificant shoulder stiffness in patients with served passive range of motion.\ndermatomyositis.\nDiagnosis can be made clinically, and it is confirmed with\nMRI.\nHumerus fracture Direct trauma. May lead to nerve injury if fractured proxi- Coaptation splint if uncomplicated. Surgery if\nmally (axillary), mid-shaft (radial), or distally (median fracture open or significantly displaced.\nor ulnar).\n(continues)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331144 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 315\nTABLE 2.8-1. Common Adult Orthopedic Injuries (continued)\nUPPER EXTREMITY\nINJURY PRESENTATION TREATMENT\nForearm\nC Radius\nCarpal bones Ulna Humerus\nGaleazzi Monteggia\nDistal radius fracture Proximal ulnar fracture\nUlnar dislocation Radius dislocation\nâ€œNightstick fractureâ€ Ulnar shaft fracture from direct trauma, often in Conservative therapy if uncomplicated. Surgery if\nself-defense. open or significant displacement.\nMonteggia fracture Diaphyseal fracture of the proximal ulna with subluxation Open reduction and internal fixation (ORIF) of the\nD of the radial head. Results from fall on pronated and shaft fracture and closed reduction of the radial\noutstretched arm or in self-defense similar to â€œnight- head.\nstick fractures.â€\nGCaleazzi fracture Diaphyseal fracture of the radius with dislocation of the ORIF of the radius and casting of the fractured\nE distal radioulnar joint. Results from a direct blow to the forearm in supination to reduce the distal radio-\nradius. ulnar joint.\nD\nWrist and Hand\nColles fracture Distal radius fracture. Results from a fall onto an out- Closed reduction followed by application of a\nF stretched hand (FOOSH) that is in dorsiflexion, leading short arm cast; open reduction ",
      "char_start": 904000,
      "char_end": 906000
    },
    {
      "chunk_id": 453,
      "text": "if the fracture is\nto a dorsally displaced, dorsally angulated fracture. open or intra-articular and displaced.\nCommonly seen in older adults (osteoporosis) and\nchildren.\nE\n(continues)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331155 1100//2211//2222 11::5500 PPMM\n\n316 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-1. Common Adult Orthopedic Injuries (continued)\nUPPER EXTREMITY\nINJURY PRESENTATION TREATMENT\nScaphoid fracture Most commonly fractured carpal bone. Results from a Thumb spica cast, monitor with serial x-rays. If\nG FOOSH. displacement or nonunion present, treatment\nMay take 2 weeks for x-rays to show fracture. Can assume with ORIF if >1 mm displacement.\na fracture if there is tenderness in anatomic snuffbox. Possibility for avascular necrosis (AVN) to result\nfrom disruption of retrograde blood flow. Risk\nfactors: Proximal, displaced, or comminuted\nfracture, smoker status.\nBFoxerâ€™s fracture Fracture of the fifth metacarpal neck. Caused by forward Closed reduction and splint; surgery if excessively\nH trauma of a closed fist (eg, punching a wall). angulated/rotated, unstable, or more than one\nmetacarpal is fractured.\nDe Quervain tenosynovitis New parent holding infant with outstretched thumb or NSAIDs, ice, and thumb spica splint. Corticosteroid\nI Extensor retinaculum Extensor frequent use of handheld device. injection if refractory.\npollicis\nbrevis Pain on Finkelstein test (flexing thumb across palm and\nplacing the wrist in ulnar deviation).\nInflamed Abductor\ntendon sheaths pollicis longus\nLOWER EXTREMITY\nINJURY PRESENTATION TREATMENT\nHip and Thigh\nHip dislocation (see image J) Posterior dislocation: Emergent closed reduction unless concomitant\nâ–  Most common (>90%). pathology requiring open reduction.\nâ–  Occurs via a posteriorly directed force on an internally Evaluation with CT scan after reduction.\nrotated, flexed, adducted hip (â€œdashboard injuryâ€). J Anterior hip dislocation Posterior hip dislocation\nâ–  Associated with",
      "char_start": 906000,
      "char_end": 908000
    },
    {
      "chunk_id": 454,
      "text": " risk for sciatic nerve injury, AVN.\nAnterior dislocation: Direct blow to an externally rotated,\nabducted thigh (eg, fall); can injure the obturator nerve.\nAbduction, extension, Adduction, slight flexion,\nexternally rotated internally rotated\n(continues)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331166 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 317\nTABLE 2.8-1. Common Adult Orthopedic Injuries (continued)\nLUOPWPEERR EEXXTTRREEMMIITTYY\nINJURY PRESENTATION TREATMENT\nHip fracture â†‘ risk with osteoporosis. Presents with shortened and ORIF. Increased likelihood for displaced femoral\nexternally rotated leg. neck fracture to require hip hemiarthroplasty or\nCan be radiographically occult, so a good clinical history total arthroplasty.\nwith âŠ– x-rays warrants further evaluation with CT or MRI. Anticoagulation to â†“ the likelihood of DVT.\nDisplaced femoral neck fractures associated with an â†‘\nrisk for AVN and nonunion.\nAssociated with deep venous thrombosis (DVT).\nInvolves acetabulum and/or proximal intracapsular femur.\nFemoral fracture Direct trauma. â†‘ risk with long-term bisphosphonate use. ORIF.\nK\nComplicated by fat emboli: presents with fever, changes Irrigation and debridement of open fractures.\nin mental status, dyspnea, hypoxia, petechiae, and â†“\nplatelets.\nKnee and Leg\nL M N O r In o t t e a r ti n o a n l V fo a r r c u e s V f a o l r g c u e s\n90Â° of 90Â° of\nflexion flexion External\nrotation\n20â€“30Â°\nof flexion McMurray test McMurray test\nAnterior drawer test Posterior drawer test (lateral meniscus) (medial meniscus)\n(ACL tear) Lachman test (PCL tear)\n(ACL tear)\nKnee ligament injuries Present with immediate pain, significant swelling, insta- ACL tear: ACL tear is the most commonly repaired\nbility, and hematoma. ligament in the knee, which is done in symp-\nAnterior cruciate ligament (ACL) injury: tomatic, young patients. Older patients often\nâ–  Results from a noncontact twisting mechanism, forced treated nonope",
      "char_start": 908000,
      "char_end": 910000
    },
    {
      "chunk_id": 455,
      "text": "ratively.\nhyperextension, or impact to an extended knee. Meniscus tear: Repair for younger patients with\nâ–  âŠ• anterior drawer and Lachman tests. reparable tears or removal (meniscectomy)\nâ–  Ruling out of a meniscal or medial collateral ligament if repair fails. Removal in older patients with\n(MCL) injury (MCL injury = âŠ• valgus stress test; lateral mechanical symptoms who do not respond to\ncollateral ligament [LCL] injury = âŠ• varus stress test). conservative treatment.\nPosterior cruciate ligament (PCL) injury:\nâ–  Results from a posteriorly directed force on a flexed\nknee (eg, dashboard injury).\nâ–  âŠ• posterior drawer test.\nMeniscal tears:\nâ–  Result from an acute twisting injury or a degenerative\ntear in older adult patients.\nâ–  Clicking, catching, or locking possibly present.\nâ–  Exam showing joint line tenderness and a âŠ• McMurray\ntest.\nâ–  MRI diagnostic test of choice.\n(continues)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331177 1100//2211//2222 11::5500 PPMM\n\n318 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-1. Common Adult Orthopedic Injuries (continued)\nLUOPWPEERR EEXXTTRREEMMIITTYY\nINJURY PRESENTATION TREATMENT\nTibial stress fracture Point tenderness that worsens with activity. Associated Nonoperative: Activity modification and casting.\nwith malalignment, foot arch issues, and female athlete Operative: Intramedullary nailing versus ORIF (due\ntriad. Differential diagnosis: Shin splints (medial tibial to increased risk of non-union).\nstress syndrome), which are seen in more casual, over-\nweight athletes and compartment syndrome.\nInitial x-rays can be negative.\nAchilles tendon rupture Presents with a sudden â€œpopâ€ in back of calf. In elite athletes: Surgery followed by casting (for\nMore likely with â†“ physical conditioning and ciproflox- quicker return to activity).\nacin use. Other cases: Conservative management with\nLimited plantar flexion and a âŠ• Thompson test (pressure casting.\non the gastrocnemius leading to absent foot plantar\nflexio",
      "char_start": 910000,
      "char_end": 912000
    },
    {
      "chunk_id": 456,
      "text": "n).\nPopliteal (Baker) cyst Caused by extrusion of synovial fluid into gastrocnemius Ultrasound to rule out DVT; NSAIDS and activity\nrupture or semimembranosus bursa in patients with under- modification, surgery if remains symptomatic\nP lying arthritis.\nMay present with painless bulge in popliteal space, acute\nPatella\nFemur Popliteal cyst calf pain, tibial nerve palsy, or â€œcrescent signâ€ (ecchy-\nTibia Synovial space mosis at medial malleolus).\nAnkle and Foot\nAnkle fracture Falling onto inverted or everted foot. Differential diag- ORIF if open, displaced, or unstable.\nnosis: Ankle sprain. Ottawa ankle rules to determine if\nx-ray is necessary.\nCalcaneal stress fracture Pain at the base of posterior foot, reproducible with com- Conservative, including activity modification.\npression of the calcaneus.\nMetatarsal stress fracture Increased risk with repetitive activities, female athlete Conservative treatment unless fifth metatarsal\ntriad, or rapid increase in activity (eg, military recruits). injured. Due to increased nonunion risk, treated\nSecond metatarsal most commonly injured. with ORIF or casting.\nImage A reproduced with permission from Paladini P, Pellegrini A, Merolla G, et al. Treatment of clavicle fractures. Transl Med UniSa. 2012 Jan\n18;2:47-58. Images D and E reproduced with permission from Knoop K et al., editors. The Atlas of Emergency Medicine, 3rd ed. New York: McGraw-\nHill, 2009, Figs. 11.16, 11.17. Image F reproduced with permission from Usatine RP et al., editors. The Color Atlas of Family Medicine, 2nd ed. New\nYork: McGraw-Hill, 2013, Fig. 103-1. Image H modified with permission from Bohr S, Pallua N. Early Functional Treatment and Modern Cast Making\nfor Indications in Hand Surgery. Adv Orthop. 2016;2016:5726979. doi: 10.1155/2016/5726979. Images B, C, G, and I-P reproduced with permission\nfrom USMLE-Rx.com.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331188 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD ",
      "char_start": 912000,
      "char_end": 914000
    },
    {
      "chunk_id": 457,
      "text": "FACTS IN 319\nValgus force\nPCL ACL\nLCL\nMM\nKEY FACT\nMCL LM\nThe classic unhappy triad of knee\nAnterior view of left knee\ninjury involves the ACL, the MCL, and\nFIGURE 2.8-1. The unhappy triad involving the anterior cruciate ligament (ACL), medial the medial meniscus. However, lateral\nmeniscus (MM), and medial collateral ligament (MCL) is classically caused by a valgus meniscal tears are more commonly seen\nforce at the knee on a planted foot. LCL, Lateral collateral ligament; LM, lateral meniscus; in acute ACL injuries (see Fig. 2.8-1).\nPCL, posterior cruciate ligament. (Reproduced with permission from USMLE-Rx.com.)\nOTTAWA ANKLE RULES\nA guide for knowing when patients should get an x-ray for their ankle pain vs\njust â€œwalking it offâ€:\nâ–  If patient cannot walk four steps â†’ x-ray\nOr:\nâ–  X-ray if pain with palpation at the malleolar zone and medial or lateral\nmalleolus (see Fig. 2.8-2)\nâ–  X-ray of foot if pain at the midfoot and the navicular or proximal metatarsal\nSALTER-HARRIS PEDIATRIC FRACTURE CLASSIFICATION\nA method for grading fractures in pediatric populations that aids in assessing\nprognosis of a given fracture in terms of growth arrest (see Fig. 2.8-3):\nâ–  Type I: Fracture line is within the growth plate (physis) but has not com-\npressed it (eg, slipped capital femoral epiphysis [SCFE]).\nLateral view Medial view\nMalleolar zone\nPosterior edge of\nMidfoot zone medial malleolus\nPosterior edge of\nlateral malleolus\nNavicular\nBase of 5th\nmetatarsal\nFIGURE 2.8-2. Zones of the foot and ankle. The highlighted malleolar and lateral midfoot\nzones are common locations of pain in those who may require an x-ray of their ankle. (Repro-\nduced with permission from USMLE-Rx.com.)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 331199 1100//2211//2222 11::5500 PPMM\n\n320 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nNormal Type I Type II Type III Type IV Type V\nS A L T R\nStraight Above Lower Through Rammed\nacross growth (below) growth ERased growth\nplate/joint plate",
      "char_start": 914000,
      "char_end": 916000
    },
    {
      "chunk_id": 458,
      "text": "/towards plate\nspace joint space\nFIGURE 2.8-3. The five Salter-Harris fracture classifications are determined by the fracture in\nMNEMONIC relation to the physis. Prognosis differs among the fracture types. (Reproduced with permission from\nUSMLE-Rx.com.)\nâ€œSALTERRâ€\nâ–  Type II: Fracture extends through both the metaphysis and physis (most\nSlipped\ncommon).\nAbove\nâ–  Type III: Fracture extends through both the physis and epiphysis.\nLower\nâ–  Type IV: Fracture extends through all three: metaphysis, physis, and\nThrough\nepiphysis.\nERased or Rammed\nâ–  Type V: The physis is compressed or crushed (worst prognosis, but very rare).\nCOMMON PERIPHERAL NERVE INJURIES\nThe brachial plexus and its many nerves are high yield, both as clinical knowl-\nedge and commonly tested concepts. Often you will be required to trace symp-\ntoms to nerve lesions based on symptoms and exam alone. Table 2.8-2 presents\ncharacteristic clinical presentations with their associated nerves.\nTABLE 2.8-2. Common Peripheral Nerve Injuries\nNERVE MOTOR DEFICIT SENSORY DEFICIT COMMON CAUSES CLINICAL FINDINGS\nLong thoracic Abduction of None Axillary lymphadenectomy, chest Lifting of scapula off thorax\narm above 90 tube placement, or stab wound when pressing hands\ndegrees to axilla against wall, â€œwinged\nscapulaâ€ (Image A)\nRadial Wrist, finger, and Dorsal forearm and hand Midshaft humeral fracture Wrist drop and sensory defi-\nthumb exten- (first three and a half Prolonged compression at level cits (proximal)\nsion (Fig. 2.8-4) fingers) of humerus (â€œSaturday night Finger drop without sensory\npalsyâ€) (proximal) deficits (distal)\nRadial head subluxation\nand repetitive pronation/\nsupination (distal)\nMedian Forearm pronation, Palmar surface (first three Supracondylar fracture (proximal) Weak wrist flexion and flat\nwrist and finger and a half fingers) Carpal tunnel (distal) thenar eminence\nflexion, thumb Benediction sign or OK sign\nopposition (proximal; Fig. 2.8-5)\nMedian claw (distal) when\nextending fingers\n(continues)\n22002222__",
      "char_start": 916000,
      "char_end": 918000
    },
    {
      "chunk_id": 459,
      "text": "0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332200 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 321\nTABLE 2.8-2. Common Peripheral Nerve Injuries (continued)\nNERVE MOTOR DEFICIT SENSORY DEFICIT COMMON CAUSES CLINICAL FINDINGS\nUlnar Finger abduction Palmar and dorsal surface Hook of hamate fracture or Ulnar claw (distal) when\n(last two and a half Guyon canal syndrome (distal) extending fingers\nfingers) Elbow dislocation, or entrapment Lack of finger adduction\nat medial epicondylar groove and abduction\nof humerus (proximal)\nMusculocutaneous Elbow flexion, Lateral forearm Shoulder dislocation, trauma to Absent biceps reflex\nforearm anterior biceps Weak elbow and shoulder\nsupination flexion\nAxillary Arm abduction â†“ sensation over the deltoid Anterior shoulder dislocation Difficult abduction beyond\n(regimental badge area) Fracture of the surgical neck of 15 degrees and flattened\nthe humerus deltoid\nCommon peroneal Dorsiflexion, Dorsal foot and lateral leg Knee dislocation, prolonged Foot drop\neversion (Image B) immobilization (crossed legs),\ntrauma to the fibula\nSuperior gluteal Hip abduction None Weakness of gluteus medius or Dropping of contralateral\nminimus muscles pelvis below horizontal\nwhile walking (Trendelen-\nburg sign [Image C])\nTibial Foot inversion, Sole of foot (Image D) Trauma to the knee, Baker cysts Tarsal tunnel syndrome\nplantar flexion (distal lesion)\nPositive Tinel sign at tarsal\ntunnel\nObturator Thigh adduction Distal, medial thigh Pelvic lymph node dissection or Wide-based gait\n(Image E) tumors\nFemoral Hip flexion, knee Anteromedial thigh and Direct injury (trauma), pro- Abnormal knee reflex\nextension medial side of leg and longed pressure on nerve (eg,\nfoot (saphenous nerve; lithotomy positioning)\nImage F)\nLateral femoral None Lateral thigh (meralgia Iatrogenic compression (surgeries, Abnormal thigh sensation\ncutaneous paresthetica) IVC filter replacement), obesity\nor tight clothing\nC\nA\nB D E F\nTrende",
      "char_start": 918000,
      "char_end": 920000
    },
    {
      "chunk_id": 460,
      "text": "lenburg\nNormal sign\nImage A reproduced with permission from Boukhris J, Boussouga M, Jaafar A, Bouslmame N. Stabilisation dynamique dâ€™un winging scapula (Ã \npropos dâ€™un cas avec revue de la littÃ©rature) [Dynamic stabilization of a winging scapula (about a case with review of the literature)]. Pan Afr Med J.\n2014;19:331. doi:10.11604/pamj.2014.19.331.3429. Images Bâ€“F reproduced with permission from USMLE-Rx.com.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332211 1100//2211//2222 11::5500 PPMM\n\n322 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nRadial nerve Ulnar nerve Median nerve\nMotor exam\nThumb extension Finger flexion An OK sign\nagainst resistance Abduct fingers Anterior\nagainst resistance interosseous nerve\nSensory exam\nPalmar Dorsal Palmar Dorsal Palmar Dorsal\nFIGURE 2.8-4. Nerve injuries and their respective motor and sensory exam findings. Radial, median, and ulnar nerve lesions can\nbe distinguished by sensory and motor examinations. (Adapted with permission from USMLE-Rx.com.)\nKEY FACT\nCOMPLEX REGIONAL PAIN SYNDROME\nMedian nerve injury leads to the\nâ€œbenediction signâ€ caused by an A pain syndrome accompanied by loss of function and autonomic dysfunc-\ninability to close the first through third tion, usually occurring after trauma. Not linked with true nerve injury.\ndigits. Ulnar nerve injury leads to the The disease has three phases:\nâ€œclaw handâ€ caused by an inability to 1) Acute/traumatic: Development of pain â†’ 2) Dystrophic: Progression of\nopen the fourth to fifth digits. soft tissue edema, muscle wasting â†’ 3) Atrophic: Limited movement, con-\ntracted digits, trophic skin. Radiograph shows severe demineralization of bones.\nHistory/PE\nâ–  Diffuse pain occurs out of proportion to the initial injury, often in a non-\nanatomic distribution. Pain is also unrelated to timing of initial injury.\nâ–  Loss of function of the affected limb is seen.\nâ–  Sympathetic dysfunction occurs and may be documented by skin, soft tis-\nsue, or blood flow changes.\nâ– ",
      "char_start": 920000,
      "char_end": 922000
    },
    {
      "chunk_id": 461,
      "text": " Skin temperature, hair growth, and nail growth may â†‘/â†“. Edema may be\npresent.\nDiagnosis\nA clinical diagnosis, but objective evidence of changes in skin hypersensitivity\nto touch, temperature, changes in color, hair growth, or nail growth.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332222 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 323\nC5\nC6\nAxillary nerve C7\nC8\nT1 Median nerve\nAxillary nerve\nMusculocutaneous nerve\nUlnar nerve\nIntercostobrachial\nRadial nerve nerve\nRadial nerve Radial nerve\nMedial brachial\nRadial nerve in\ncutaneous nerve Palm of hand\nspiral groove\nMusculocutaneous\nMedian nerve Ulnar nerve\nnerve Medial antebrachial\ncutaneous nerve Median nerve\nRadial nerve\nUlnar nerve\nRadial nerve\nRecurrent branch\nRadial nerve\nof median nerve\nDorsum of hand\nFIGURE 2.8-5. Comparison of median and ulnar nerve lesions. Median and ulnar nerve injuries can be distinguished from each other on exam-\nination of range of motion. Digit flexion and extension will display classic symptoms for each nerve injury. (Adapted with permission from USMLE-Rx.com.)\nTreatment\nâ–  Initial treatment consists of a trial of nonsteroidal anti-inflammatory drugs\n(NSAIDs) along with physical and occupational therapies.\nâ–  Other adjuvant medications include oral corticosteroids, low-dose tricyclic\nantidepressants, gabapentin, pregabalin, and calcitonin (no oral medica-\ntions are consistently effective).\nâ–  Chemical sympathetic blockade may relieve symptoms.\nâ–  Referral to a chronic pain specialist is appropriate for complicated cases.\nOSTEOSARCOMA\nAlthough a rare tumor, osteosarcoma is the most common primary malig-\nnancy of bone in children and adolescents (Table 2.8-3). It tends to occur in\nthe metaphyseal regions of the distal femur, proximal tibia, and proximal\nhumerus, and it often metastasizes to the lungs. Bimodal age distribution\noccurs in young adults and patients >65 years of age. Risk factors for older\npatients are radiation, Paget",
      "char_start": 922000,
      "char_end": 924000
    },
    {
      "chunk_id": 462,
      "text": " disease, Li-Fraumeni syndrome, and familial\nretinoblastoma.\nHistory/PE\nâ–  An osteosarcoma manifests with progressive and eventually intractable\npain that worsens at night.\nâ–  Constitutional symptoms such as fever, weight loss, and night sweats may\nbe present.\nâ–  Erythema and enlargement over the site of the tumor may be seen.\nA 55-year-old man with a history of\nprostate cancer presents with low\nback pain (LBP) and bilateral leg\nweakness. On examination, he is\nfound to have point tenderness on\nthe lumbar spine and â†“ sensation in\nhis legs. What is the best next step?\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332233 1100//2211//2222 11::5500 PPMM\n\n324 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-3. Common Bone Tumors\nBENIGN TUMORS\nDISEASE CLASSIC FINDINGS KEY HISTORY FINDINGS TREATMENT\nEnchondroma Imaging via x-ray of lytic lesion on Young adult with family history of Monitoring with serial x-rays\nhand or foot Ollier disease or Maffucci syndrome\nGiant cell tumor â€œSoap bubbleâ€ finding on x-ray Young adult, Paget disease of bone Denosumab\nOsteoblastoma Typically spinal lesions and >2 cm Pain that does not improve with Resection with or without chemo-\nâ€œblasted in the backâ€ NSAIDs therapy/radiation, depending on\nmargins\nOsteochondroma Projects out of the growth plate Young males (<25 years of age) Monitoring with serial x-rays\nMay be incidental finding\nOsteoid osteoma Fibula, tibia, or other long bones Young males (<25 years of age) Conservative management, resection\nTypically small, <2 cm and no improvement in pain with if refractory or patient cannot tol-\nNSAIDs erate NSAIDs\nMALIGNANT TUMORS\nEwing sarcoma Large, permeative lesions that Adolescent males (<15 years of age) Resection with possible radiation or\nappear aggressive with lamel- chemotherapy\nlated periosteal reactions\nLong bones or pelvis\nChondrosarcoma â€œMoth-eatenâ€ finding on x-ray May be malignant transformation of Resection with possible radiation or\nesteochondroma or ench",
      "char_start": 924000,
      "char_end": 926000
    },
    {
      "chunk_id": 463,
      "text": "ondroma chemotherapy\nOsteosarcoma Codman triangle or sunburst Teenager or older adult and history of Resection and chemotherapy\nappearance on x-ray Paget disease of bone, radiation\nKEY FACT Diagnosis\nâ–  Best initial test: X-rays. These can show a Codman triangle (formation of\nThe most common benign bone tumor\nperiosteal new bone at the diaphyseal end of the lesion) or a â€œsunburstâ€\nis an osteochondroma. It commonly\npattern of the osteosarcoma (see Fig. 2.8-6) in contrast with both the mul-\npresents as a painless mass and does\ntilayered â€œonion skinningâ€ that is classic for Ewing sarcoma and the â€œsoap\nnot typically require treatmentâ€”just\nbubbleâ€ appearance of giant cell tumor of bone (see Fig. 2.8-7).\nserial monitoring with x-rays.\nâ–  Most accurate test: Bone biopsy.\nâ–  MRI and positron emission tomography (PET)/CT or bone scan for stag-\ning and workup.\nTreatment\nThe best next step would be to obtain â–  Limb-sparing surgical procedures and preoperative and postoperative che-\nan MRI. MRI is the best study, but motherapy (eg, methotrexate, doxorubicin, cisplatin, ifosfamide)\npreventing permanent neurologic â–  Amputation possibly necessary\ndisability is the priority. Remember\nto consider multiple myeloma,\nwhich can present almost identically.\nTreatment is to administer steroids\nto relieve spinal cord compression\nresulting from likely bone metastasis.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332244 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 325\nSEPTIC ARTHRITIS A B\nAn infection of the joint space that typically occurs after open injury or\nbacteremia.\nHistory/PE\nPresents as a warm, red, immobile joint. Palpable effusions may also be pres-\nent. Fevers and chills can be seen if the patient is bacteremic. Intense pain\nwith brief joint movement (short arc sign) is pathognomonic. Typically\nunable to bear weight. Prosthetic joints greatly â†‘ risk. Other risk factors\nA B\ninclude recent trauma, underlying joint disease (eg,",
      "char_start": 926000,
      "char_end": 928000
    },
    {
      "chunk_id": 464,
      "text": " gout, rheumatoid arthri- FIGURE 2.8-6. Malignant bone tumors.\ntis, or osteoarthritis), older age, recent articular injection, and bacteremia (A) Osteosarcoma. X-ray of the femur\nshows the typical â€œsunburstâ€ appearance\nfrom endocarditis or intravenous (IV) drug use.\n(arrows). (B) Ewing sarcoma. X-ray of\nthe left hip shows characteristic â€œonion\nDiagnosis skinningâ€ in proximal femur (arrowhead).\nâ–  Most accurate test: Joint aspiration. See Table 2.8-4 and Figure 2.8-8 (Reproduced with permission from Kantarjian HM, et al.\nMD Anderson Manual of Medical, 1st ed. New York, NY:\nâ–  Septic arthritis: WBC count >50,000/mm3, âŠ• gram stain, or âŠ• fluid culture\nMcGraw-Hill; 2006.)\nâ–  Most common organisms: Staphylococcus, Streptococcus, and gram âŠ–\nrods (see Table 2.8-5)\nTreatment\nEmpiric ceftriaxone and vancomycin initially until culture test results; then\nmodification of therapy for specific organisms. Septic arthritis is considered a\nsurgical emergency. Septic joints are considered surgical emergencies and are\ntreated with joint drainage or debridement. Delay in treatment may lead to\npermanent joint destruction.\nTABLE 2.8-4. Synovial Fluid Analysis\nNORMAL NONINFLAMMATORY INFLAMMATORYa SEPTIC\nColor Clear Yellow Yellow Yellow-green FIGURE 2.8-7. Giant cell tumor of the\nbone. Note the â€œsoap bubbleâ€ appear-\nance at the proximal end of the tibia.\nViscosity High High Low Variable\n(Reproduced with permission from Skinner HB. Current\nDiagnosis & Treatment in Orthopedics, 4th ed. New\nWBC <200 0â€“1000 1000â€“10,000 (up 10,000â€“100,000 York, NY: McGraw-Hill; 2006.)\n(per mm3) to 100,000)\nPolymorphonuclear <25 <25 â‰¥50 â‰¥75\nKEY FACT\n(PMN) leukocytes\n(%) Any patient presenting with a red, hot,\nand swollen joint should have joint\nGlucose (mg/dL) = serum = serum >25 (crystal <25 aspiration/arthrocentesis to rule out\nanalysis septic arthritis.\nfor gout vs\npseudogout)\naA joint affected by inflammatory arthritis can become secondarily infected.\nA 15-year-old youth presents with\nseveral monthsâ€™ history of ",
      "char_start": 928000,
      "char_end": 930000
    },
    {
      "chunk_id": 465,
      "text": "pain in the\nupper part of his thigh. The pain is\nworse at night. A plain film shows a\nsmall lucent nidus. What over-the-\ncounter (OTC) remedy is indicated?\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332255 1100//2211//2222 11::5500 PPMM\n\n326 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nArthrocentesis\nCrystals WBC <2,000 WBC 2,000-10,000 WBC >10,000 Hemorrhagic fluid or fat droplets\nPolarized light Noninflammatory Inflammatory arthritis Culture Fracture\narthritis (eg, (eg, rheumatoid\nmicroscopy\nosteoarthritis) arthritis)\nSeptic arthritis\nRhomboids, blue Needle-shaped, yellow\n(positive birefringence) (negative birefringence)\nPseudogout Gout\nFIGURE 2.8-8. Synovial fluid characteristics. Diagnosis of inflammatory pathology can be done utilizing arthrocentesis and fluid\nanalysis. Color, crystal content, and the quantity of WBCs can determine the appropriate diagnosis. (Reproduced with permission from\nUSMLE-Rx.com.)\nTABLE 2.8-5. Common Septic Arthritis Etiologies\nBACTERIA RISK FACTORS/HISTORY TREATMENT\nStaphylococcus aureus Middle-aged or older adult Vancomycin\nNeisseria gonorrhoeae Young adult, sexually active; Third-generation\ndue to disseminated cephalosporin\ngonococcal infection via\nhematogenous spread\nâ€œSTDâ€ â€” synovitis, tenosyno-\nKEY FACT\nvitis, and dermatitis\nIn sexually active individuals with\nHaemophilus influenzae Age <2 years of age, sickle Third-generation\njoint pain, consider the diagnosis of\ngonococcal septic arthritis. Neisseria cell cephalosporin\ngonorrhoeae septic arthritis can\nSalmonella Sickle cell Third-generation\npresent with asymmetric oligoarthritis,\ntenosynovitis, and skin rash. cephalosporin\nKEY FACT\nOSTEOMYELITIS\nOsteomyelitis in patients with diabetes\nshould be treated with antibiotics Bone infection caused by direct spread from a soft tissue infection (80% of\ntargeting gram âŠ• organisms and cases) is most common in adults, whereas infection caused by hematoge-\nanaerobes. nous seeding (20% of cases) is more common in c",
      "char_start": 930000,
      "char_end": 932000
    },
    {
      "chunk_id": 466,
      "text": "hildren (metaphysis of the\nlong bones) and patients who use injectable drugs (vertebral bodies). Com-\nmon pathogens are outlined in Table 2.8-6. Patient characteristics are\nimportant to keep in mind, as they can clue you in to commonly associated\npathogens.\nHistory/PE\nThis adolescent patient is likely\npresenting with osteoid osteoma, Presents with localized bone pain and tenderness along with warmth, swell-\na benign bone-forming tumor ing, erythema, and limited motion of the adjacent joint. Systemic symptoms\ncharacterized by prostaglandin (fevers, chills) and purulent drainage may be present.\nformation. Relief of pain is thus often\nachieved with NSAIDs. Tumors may Diagnosis\nresolve on their own, but surgical\nremoval of the nidus may be â–  Labs: â†‘ WBC count; â†‘ erythrocyte sedimentation rate (ESR) and C-reac-\nnecessary for symptom relief. tive protein (CRP) levels in most cases. Blood cultures may be âŠ•.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332266 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 327\nTABLE 2.8-6. Common Pathogens in Osteomyelitis\nIF... THINK...\nNo risk factors Staphylococcus aureus\nIV drug use S aureus or Pseudomonas\nSickle cell disease Salmonella\nHip replacement Staphylococcus epidermidis (coagulase âŠ– staphylococcus)\nFoot puncture wound Pseudomonas\nChronic S aureus, Pseudomonas, Enterobacteriaceae\nDiabetes mellitus Polymicrobial, Pseudomonas, S aureus, streptococci, anaerobes\nFIGURE 2.8-9. Diskitis/osteomyelitis.\nSagittal contrast-enhanced MRI shows\ndestruction of a lower thoracic interver-\nâ–  Imaging:\ntebral disk with abnormal enhancement\nâ–  X-rays are often âŠ initially but may show periosteal elevation within 10 throughout the adjacent vertebral bodies\nto 14 days. Bone scans are sensitive for osteomyelitis but lack (arrows) and a posterior rim-enhancing\nspecificity. epidural abscess (arrowhead) in the\nâ–  MRI (the test of choice) will show â†‘ signal in the bone marrow and spinal canal. (Reprodu",
      "char_start": 932000,
      "char_end": 934000
    },
    {
      "chunk_id": 467,
      "text": "ced with permission from\nTintinalli JE et al. Tintinalliâ€™s Emergency Medicine: A\nassociated soft tissue infection (see Fig. 2.8-9).\nComprehensive Study Guide, 6th ed. New York, NY:\nâ–  Most accurate test: Bone aspiration with Gram stain and culture. McGraw-Hill; 2004.)\nHowever, clinical diagnosis made by probing through the soft tissue to\nbone is usually sufficient, as aspiration carries a risk for infection.\nTreatment KEY FACT\nâ–  Most accurate treatment: Surgical debridement of necrotic, infected Penicillin and cephalosporins have\nbone followed by IV antibiotics for 4 to 6 weeks. Empiric antibiotic selec- minimal cross-reactivity. If a patient\ntion is based on the suspected organism and Gram stain. had an allergic rash to penicillin,\nâ–  The physician should consider clindamycin plus ciprofloxacin, ampicil- cephalosporins are considered safe. If\nlin/sulbactam, or oxacillin/nafcillin (for methicillin-sensitive Staphylococ- a patient had an anaphylactic reaction\ncus aureus); vancomycin (for methicillin-resistant S aureus [MRSA]); or or developed angioedema while\nceftriaxone or ciprofloxacin (for gram âŠ bacteria). on penicillin, use a nonâ€“Î²-lactam\nantibiotic.\nComplications\nChronic osteomyelitis, sepsis, septic arthritis. Long-standing chronic osteomy-\nelitis with a draining sinus tract may eventually lead to squamous cell carci-\nnoma (Marjolin ulcer).\nOSTEOARTHRITIS An 11-year-old boy with a history\nof multiple hospitalizations for\nA common chronic, noninflammatory arthritis of the synovial joints. Charac- pain crises, all related to his sickle\ncell anemia, presents with fever\nterized by deterioration of the articular cartilage and osteophyte bone forma-\nand severe pain in his right hand.\ntion at the joint surfaces. Risk factors include age, female sex, prior joint\nPhysical examination shows an area\ntrauma, malalignment, sedentary lifestyle, âŠ• family history, obesity, and a his-\nof redness, tenderness, and swelling\ntory of joint trauma. Osteoarthritis (OA) is considered pr",
      "char_start": 934000,
      "char_end": 936000
    },
    {
      "chunk_id": 468,
      "text": "imary if no underly-\nnear the right second metacarpal.\ning etiology is found. Secondary OA may be due to prior trauma, avascular\nLaboratory results show leukocytosis\nnecrosis (AVN), inflammatory arthritis, osteochondritis dissecans, and more. and an elevated erythrocyte\nTable 2.8-7 contrasts OA with rheumatoid arthritis (RA). sedimentation rate (ESR). MRI shows\nan area of â†‘ intensity in the painful\narea. What pathogen is the most likely\ncause of his condition?\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332277 1100//2211//2222 11::5500 PPMM\n\n328 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-7. Osteoarthritis vs Rheumatoid Arthritis KEY FACT\nVARIABLE OSTEOARTHRITIS RHEUMATOID ARTHRITIS There is a minimal role for opioids in\nthe treatment of osteoarthritis because\nHistory Affects older adults Affects the young\npotential risks outweigh benefits. If\nSlow onset Prolonged morning stiffness that\npatients have refractory, severe pain\nPain that worsens with use improves with use\nand are unwilling or unable to undergo\nsurgical treatment, opioids may be\nJoint Affects the distal interphalangeal (DIP) joint, proximal inter- Affects the wrists, metacarpophalangeal (MCP) joint, ankles,\nconsidered. Weak opioids (eg, tramadol)\ninvolvement phalangeal (PIP) joint, first carpometacarpal (CMC) joint, knees, shoulders, hips, and elbows (see Images C and D)\nare preferred for initial treatment.\nhips, and knees (see Images A and B) Symmetric distribution\nSymmetric if affecting hands but classically asymmetric C D\nelsewhere\nA B\nSynovial fluid WBC count <2000 cells/mm3; osteophytes WBC count between 2000 and 50,000 cells/mm3\nanalysis and X-ray showing joint space narrowing (see Image E) (see Image F)\nimaging\nOsteoarthritis Normal Rheumatoid arthritis\nE Thickened Joint capsule F\ncapsule and synovial Pannus\nlining Synovial proliferation\nThinned and\nHypervascularity\nfibrillated\ncartilage Synovial cavity Dense inflammatory\ninfiltrate\nOsteophyte Cartilage\nLoose",
      "char_start": 936000,
      "char_end": 938000
    },
    {
      "chunk_id": 469,
      "text": " bodies ï¨ synovial fluid\nSubchondral\nsclerosis Eroding cartilage\nSubchondral Bone\nbone cyst Bone erosion\nTreatment Physical therapy, NSAIDs, intra-articular corticosteroid injec- Disease-modifying antirheumatic drugs (DMARDs) with\ntions, and surgery NSAIDs or glucocorticoids for symptom flares or while\nbridging to DMARD therapy\nArthritis illustration and Image A reproduced with permission from USMLE-Rx.com. Image B reproduced with permission from Clement ND,\nBreusch SJ, Biant LC. Lower limb joint replacement in rheumatoid arthritis. J Orthop Surg Res. 2012;7:27. Published 2012 Jun 14. doi:10.1186/1749-\n799X-7-27. Images C, D, E, and F reproduced with permission from Dr. Richard Usatine.\nKEY FACT History/PE\nPresents with crepitus, â†“ range of motion (ROM), and initially pain that wors-\nSGalelmnoohnuelmlae isra tlh oes tmeooastr tlhikreitliys of the\nens with activity and weight-bearing but improves with rest. Morning stiffness\npshaothuoldgeern c caanu psrinesge tnhte s ipmatiliaernlyt â€™sto\ngenerally lasts for <30 minutes. Stiffness is also experienced after periods of\ncrootnadtoitri ocnu.ff S itmapphinylgoecomcecnustâ€” aupreauins is\nrest (â€œgellingâ€). Bony nodes occurring on distal interphalangeal (DIP) joints\ntwhieth m aobsdtu ccotmionm aonnd c eaxutseer nina lp raottiaetniotsn .\nin the hands are called â€œHeberden nodes,â€ and the ones on the proximal\nwAnit hx-oruayt swicokuleld c eblel dainse eaassey awnady i sto t he\nsdeectoernmd imneo wsth caotmâ€™s wmhoant oorng atensits mda tyh, at interphalangeal (PIP) joints are referred to as â€œBouchard nodes.â€\ncauses osteomyelitis in patients with\nbut if this isnâ€™t in the question stem,\nsickle cell disease.\nremember that rotator cuff pathology\nhas more classic night pain, and\nglenohumeral osteoarthritis is gradual-\nonset â€œdeep shoulderâ€ or anterior pain\nwith movement.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332288 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 329\nKEY FAC",
      "char_start": 938000,
      "char_end": 940000
    },
    {
      "chunk_id": 470,
      "text": "T\nThere is a minimal role for opioids in\nthe treatment of osteoarthritis because\npotential risks outweigh benefits. If\npatients have refractory, severe pain\nand are unwilling or unable to undergo\nsurgical treatment, opioids may be\nconsidered. Weak opioids (eg, tramadol)\nare preferred for initial treatment.\nFIGURE 2.8-10. Osteoarthritis. Plain x-rays show joint space narrowing, osteophytes, and sub-\nchondral degenerative cysts involving the DIP and PIP joints, with sparing of the MCP. (Repro-\nduced with permission from USMLE-Rx.com.)\nDiagnosis\nâ–  X-rays show joint space narrowing, osteophytes, subchondral sclerosis, and\nsubchondral bone cysts (see Fig. 2.8-10). X-ray severity does not correlate\nwith symptomatology.\nâ–  Laboratory tests, including inflammatory markers, are typically normal.\nTreatment\nâ–  Best initial treatment: Physical therapy, weight reduction (if comorbid\nobesity present), and NSAIDs. Intra-articular corticosteroid injections may\nprovide temporary relief.\nâ–  Most definitive treatment: Surgeryâ€”consider joint replacement (eg, total\nhip/knee/shoulder arthroplasty) in advanced cases. Patients are at higher\nrisk for developing osteoporosis.\nOSTEOPOROSIS\nRefer to Endocrinology chapter.\nRHEUMATOID ARTHRITIS\nKEY FACT\nA systemic autoimmune disorder characterized by chronic, destructive,\ninflammatory arthritis with symmetric joint involvement resulting in synovial\nKeratoconjunctivitis sicca secondary to\nhypertrophy and pannus formation, ultimately leading to erosion of adjacent\nSjÃ¶gren syndrome is a common ocular\ncartilage, bone, and tendons. Risk factors include female sex, 35 to 50 years of\nmanifestation of RA.\nage, smoking, and human leukocyte antigen (HLA)â€“death receptor (DR)4.\nKEY FACT History/PE History/PE\nPresents with crepitus, â†“ range of motion (ROM), and initially pain that wors- â–  Insidious onset of prolonged morning stiffness (>30 minutes) occurs\nGlenohumeral osteoarthritis of the\nens with activity and weight-bearing but improves with rest. Morning sti",
      "char_start": 940000,
      "char_end": 942000
    },
    {
      "chunk_id": 471,
      "text": "ffness along with painful, warm swelling of polyarticular symmetric joints (wrists;\nshoulder can present similarly to\ngenerally lasts for <30 minutes. Stiffness is also experienced after periods of metacarpophalangeal [MCP] joints; PIP joints of hands, ankles, knees,\nrotator cuff impingementâ€”pain\nrest (â€œgellingâ€). Bony nodes occurring on distal interphalangeal (DIP) joints shoulders, hips, and elbows) for >6 weeks.\nwith abduction and external rotation.\nin the hands are called â€œHeberden nodes,â€ and the ones on the proximal â–  Rheumatoid nodules may form at bony prominences and near joints\nAn x-ray would be an easy way to\ninterphalangeal (PIP) joints are referred to as â€œBouchard nodes.â€ affected by the disease.\ndetermine whatâ€™s what on test day,\nbut if this isnâ€™t in the question stem,\nremember that rotator cuff pathology\nhas more classic night pain, and\nglenohumeral osteoarthritis is gradual-\nonset â€œdeep shoulderâ€ or anterior pain\nwith movement.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 332299 1100//2211//2222 11::5500 PPMM\n\n330 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nKEY FACT â–  In advanced disease, ulnar deviation of the fingers is seen with MCP joint\nhypertrophy.\nRA-Associated Syndromes â–  RA also presents with ligament and tendon deformations (eg, swan-neck and\nFelty syndrome: RA, splenomegaly, and boutonniÃ¨re deformities), vasculitis, atlantoaxial subluxation (â†‘ intubation\nneutropenia risk), and keratoconjunctivitis sicca (if accompanying Sjogren syndrome is\nCaplan syndrome: RA, pneumoconiosis, present). RA typically spares the lumbosacral spine.\nand lung nodules\nDiagnosis\nâ–  Diagnostic criteria (need â‰¥6 points):\nâ–  â†‘ rheumatoid factor (RF) (IgM antibodies against Fc IgG) or the pres-\nKEY FACT ence of anti-CCP (cyclic citrullinated peptide) antibodies (1 point)\nâ–  â†‘ ESR or CRP (1 point)\nThe DIP joint is spared in RA compared\nâ–  Inflammatory arthritis of three or more joints (up to 5 points)\nto OA and psoriatic arthritis, where the\nâ–  Sy",
      "char_start": 942000,
      "char_end": 944000
    },
    {
      "chunk_id": 472,
      "text": "mptom duration >6 weeks (1 point)\nDIP is involved.\nâ–  Exclusion of diseases with similar clinical presentations such as psori-\natic arthritis, gout, pseudogout, and systemic lupus erythematosus (SLE)\nâ–  Labs:\nâ–  â†‘ ESR and CRP (nonspecific signs of inflammation); anemia of\nchronic disease is common.\nâ–  Synovial fluid aspirate showing turbid fluid, â†“ viscosity, and an â†‘ WBC\ncount (2000â€“50,000 cells/Î¼L)\nâ–  X-rays (not necessary to confirm RA):\nâ–  Early: Soft tissue swelling and juxta-articular demineralization\nâ–  Late: Symmetric joint space narrowing and erosions\nKEY FACT\nTreatment\nHydroxychloroquine causes irreversible\nâ–  Disease-modifying antirheumatic drugs (DMARDs) should be started\nretinal toxicity. Patients must undergo\nearly. They include methotrexate (initial drug of choice), hydroxychloro-\nregular screening while taking this\nquine, and sulfasalazine. Second-line agents include tumor necrosis factor\nmedication for long periods (>5 years)\n(TNF) inhibitors, rituximab (anti-CD20), and leflunomide.\nto look for findings indicative of toxicity\nâ–  NSAIDs or glucocorticoids can be used for symptom flares or while bridg-\n(â€œbullâ€™s-eyeâ€ appearance).\ning to DMARD therapy.\nComplications\nâ–  Articular manifestations: Joint deformation, osteopenia, OA\nâ–  Extra-articular manifestations: Anemia, rheumatoid nodules, scleritis,\namyloidosis, cardiovascular disease, vasculitis, lung fibrosis, Caplan syn-\ndrome, carpal tunnel syndrome, SjÃ¶gren syndrome, and Felty syndrome\nSERONEGATIVE SPONDYLOARTHROPATHY\nAnkylosing Spondylitis\nA chronic inflammatory disease of the spine and pelvis that leads to erosion\nand fusion of the sacroiliac joint. Strongly associated with HLA-B27. Risk fac-\ntors include male sex and a âŠ• family history.\nHistory/PE\nâ–  Typical onset is in the late teens and early 20s. It presents with fatigue,\nintermittent hip pain, and low back pain that worsens with inactivity and\nat night and improves with activity.\nâ–  â†“ spine flexion (âŠ• Schober test), loss of lumbar lordosis, hip pain, an",
      "char_start": 944000,
      "char_end": 946000
    },
    {
      "chunk_id": 473,
      "text": "d\nstiffness increase as the disease progresses. Vertebral fracture may occur\nafter minimal trauma.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333300 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 331\nâ–  Ankylosing spondylitis (AS) can also be associated with anterior uveitis,\naortic insufficiency, psoriasis, inflammatory bowel disorder (IBD), and\nheart block.\nâ–  Approximately 30% of AS cases are associated with enthesitis (pain at\ninsertion of tendons/ligaments) at the heel (Achilles tendon involvement) KEY FACT\nand dactylitis (diffuse swelling of toes/fingers, named â€œsausage digitsâ€).\nKeratoderma blennorrhagica (skin\nâ–  Other seronegative spondyloarthropathies must be ruled out (also associ-\nlesions on palms and soles) and\nated with HLA-B27), including the following:\ncircinate balanitis (painless ulcerative\nâ–  Reactive arthritis: A disease of young adults. The characteristic arthritis,\nlesion on glans penis) are characteristic\nuveitis, conjunctivitis, and urethritis usually follow an infection with\ncutaneous features of reactive arthritis.\nCampylobacter (especially C jejuni), Shigella, Salmonella, Yersinia,\nChlamydia, or Ureaplasma.\nâ–  Psoriatic arthritis: An oligoarthritis that can include the DIP joints.\nMNEMONIC\nAssociated with psoriatic skin changes and sausage-shaped digits (dacty-\nlitis). X-rays show a classic erosion and resorption of periarticular bone, Reactive arthritisâ€”\nalso called a â€œpencil-in-cupâ€ deformity (arrows in Fig. 2.8-11).\nâ€œCanâ€™t see (uveitis), canâ€™t pee (urethritis),\nâ–  Enteropathic spondylitis: An AS-like disease characterized by sacroili- canâ€™t climb a tree (arthritis).â€\nitis that is usually asymmetric and is associated with IBD.\nDiagnosis\nBest initial test: X-rays may show erosion, ankylosis, fusion, or sclerosis of sac-\nroiliac joints; squaring of the lumbar vertebrae; development of vertical syndes-\nmophytes (ossification of spinal ligament); and bamboo spine (see Fig. 2.8-12).\nLaborat",
      "char_start": 946000,
      "char_end": 948000
    },
    {
      "chunk_id": 474,
      "text": "ory values:\nâ–  âŠ• HLA-B27 found in 85% to 95% of cases\nâ–  ESR or CRP â†‘ in 85% of cases\nâ–  âŠ– RF; âŠ– antinuclear antibody (ANA)\nFIGURE 2.8-12. Ankylosing spondylitis.\nFrontal view of the thoracolumbar spine\nFIGURE 2.8-11. In those with psoriatic shows the classic â€œbambooâ€ appearance\narthritis, the middle phalanx may be of the spine, which results from fusion\npointed on x-ray and appear to be rub- of the vertebral bodies and posterior ele-\nbing away at the distal phalanx, giving an ments. (Reproduced with permission from Chen MY\nappearance of a pencil in a cup. (Repro- et al. Basic Radiology, 2nd ed. New York, NY: McGraw-\nduced with permission from Dr. Richard Usatine.) Hill; 2011.)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333311 1100//2211//2222 11::5500 PPMM\n\n332 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-8. Polymyositis vs Dermatomyositis\nPOLYMYOSITIS DERMATOMYOSITIS\nPhysical exam signs Symmetric, progressive proximal muscle weakness Polymyositis muscle weakness\nA and/or pain âŠ• rash\nDifficulty getting up from a seat or climbing stairs Heliotrope rash: A violaceous periorbital rash (see\nDifficulty breathing or swallowing (advanced Image A)\ndisease) â€Shawl signâ€: A rash involving the shoulders, upper\nchest, and back\nGottron papules: Papular rash with scales on the\ndorsa of the hands, over bony prominences (see\nImage B)\nB\nBiopsy Endomysial inflammatory infiltrate surrounding Perifascicular inflammatory infiltrates\nmuscle fibers\nImages reproduced with permission from Dr. Richard Usatine.\nTreatment\nâ–  Best initial therapy: NSAIDs for pain; exercise to improve posture and\nbreathing\nâ–  TNF inhibitors, interleukin (IL)-17 inhibitors, or sulfasalazine in refrac-\ntory cases\nPOLYMYOSITIS AND DERMATOMYOSITIS\nBoth diseases are progressive immune-mediated myopathies characterized by\nstriated muscle inflammation manifesting as symmetric proximal muscle\nweakness. Polymyositis presents with muscle weakness; dermatomyositis is dif-\nferentiated by c",
      "char_start": 948000,
      "char_end": 950000
    },
    {
      "chunk_id": 475,
      "text": "utaneous involvement. They most often affect patients 50 to\n70 years of age; the male-to-female ratio is 1:2. Black individuals are affected\nmore often than White individuals (see Table 2.8-8).\nHistory/PE\nSee Table 2.8-8.\nâ–  Ten percent of polymyositis/dermatomyositis cases are associated with\ninterstitial lung disease (ILD).\nâ–  Esophageal involvement presents as dysphagia.\nâ–  Cardiac involvement presents as myocarditis and cardiac conduction deficits.\nâ–  Polymyositis/dermatomyositis can be associated with an underlying malig-\nnancy, especially lung, breast, and ovarian carcinoma. Dermatomyositis is\nassociated with â†‘ rate of malignancy compared with PM.\nDiagnosis\nâ–  Based on characteristic clinical presentation and laboratory values\nâ–  Best initial test: â†‘ serum creatine kinase and anti-Jo-1 antibodies (see\nTable 2.8-9)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333322 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 333\nTABLE 2.8-9. Common Antibodies and Their Autoimmune Disease Associations\nANTIBODY DISEASE ASSOCIATION\nANA Systemic lupus erythematosus (SLE)\nAnti-CCP RA\nAnticentromere CREST syndrome\nAnti-dsDNA SLE\nAnti-histone Drug-induced SLE\nAnti-Jo-1 Polymyositis/dermatomyositis\nAnti-Ro/anti-La SjÃ¶gren syndrome\nAnti-Scl-70/antitopoisomerase-I Systemic sclerosis\nAnti-Sm SLE\nAntiâ€“smooth muscle Autoimmune hepatitis\nc-ANCA Vasculitis, especially granulomatosis with polyangiitis\n(formerly Wegener syndrome)\np-ANCA Vasculitis, microscopic polyangiitis\nRF RA\nU1 RNP antibody Mixed connective tissue disease\nANA, Antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies (c, cytoplasmic; p,\nKEY FACT\nperinuclear); CCP, cyclic citrullinated peptide; ds, double stranded; RF, rheumatoid factor; RNP,\nribonucleoproteins; Sm, Smith.\nAldolase, lactate dehydrogenase (LDH),\naspartate aminotransferase (AST),\nand alanine aminotransferase (ALT)\nâ–  Most accurate test: Muscle biopsy to differentiate between polymyositis are also ",
      "char_start": 950000,
      "char_end": 952000
    },
    {
      "chunk_id": 476,
      "text": "muscle enzymes. In patients\nand dermatomyositisin atypical presentations\nwith unexplained elevation of AST and\nALT (not due to alcohol abuse or liver\nTreatment\ndisease) and especially if AST > ALT,\nâ–  Best initial treatment: High-dose corticosteroids (eg, prednisone) with creatine kinase (CK) should be checked\ntaper after 4 to 6 weeks to â†“ the maintenance dose to evaluate for myopathy.\nâ–  Azathioprine and/or methotrexate used in steroid-resistant or intolerant\ncases\nTEMPOROMANDIBULAR JOINT DISORDERS\nSeveral factors contribute to the development of temporomandibular joint\n(TMJ) disorders, including joint trauma (eg, bruxism) and history of psychiat-\nric illness (eg, depression, anxiety).\nHistory/PE/Diagnosis\nâ–  Patients present with unilateral morning heading and with waxing and\nwaning facial pain that worsens with jaw motion. The pain can be accom-\npanied by tinnitus and may radiate to the ear and periorbital region and\ndown the mandible.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333333 1100//2211//2222 11::5500 PPMM\n\n334 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nâ–  On physical examination, muscles of mastication may be tender, tooth\nwear from bruxism can be present, and jaw movement may result in click-\ning or even locking that limits jaw opening.\nâ–  The diagnosis of TMJ disorders is primarily based on history and physical\nexamination findings.\nTreatment\nâ–  Patient education and self-care measures: Avoidance of triggers and con-\nsumption of a soft diet\nâ–  Pharmacology: NSAIDs and corticosteroid injections\nâ–  Dental splints if bruxism is suspected\nMYOFASCIAL PAIN SYNDROME\nMyofascial pain syndrome shares some clinical features with fibromyalgia. It\nis characterized as a regional pain disorder having trigger points within fascia\nand muscles.\nHistory/PE\nâ–  Patients complain of a deep aching pain, often accompanied by a burning\nsensation and restricted active motion in the affected area.\nâ–  Physical examination reveals indurated regions known as t",
      "char_start": 952000,
      "char_end": 954000
    },
    {
      "chunk_id": 477,
      "text": "rigger points.\nPalpating a trigger point reproduces pain in another location known as\nthe â€œtarget zone.â€ Myofascial pain syndrome differs from fibromyalgia, as\nthe latter does not have indurated trigger points and the tender points are\nlocated within tissues other than muscles.\nTreatment\nMultidisciplinary patient education, sleep hygiene, low-impact exercise, phys-\nical therapy, non-narcotic pain medications, antidepressants, gabapentin, and\nmuscle relaxants.\nMNEMONIC SYSTEMIC SCLEROSIS\nCREST syndromeâ€”\nAlso called scleroderma; characterized by chronic inflammation leading to\nCalcinosis progressive tissue fibrosis through excessive deposition of types I and III colla-\nRaynaud phenomenon\ngen. Commonly manifests as CREST syndrome (limited form, 80% of cases),\nEsophageal dysmotility\nbut can also occur in a diffuse form (20% of cases) involving the skin and\nSclerodactyly\nmultiple organ systems. Risk factors include female sex and age between 35\nTelangiectasias\nand 50 years.\nHistory/PE\nâ–  Examination that may reveal symmetric thickening of the skin of the face\nand/or distal extremities\nâ–  Limited cutaneous: Head, neck, distal upper extremities (earliest areas\nof involvement)\nâ–  Diffuse cutaneous: Torso, abdomen, proximal upper extremity/\nshoulder\nâ–  CREST syndrome: Associated with limited cutaneous type\nâ–  Diffuse form: Leading to gastrointestinal (GI) dysmotility, pulmonary\nfibrosis, cor pulmonale, acute renal failure (scleroderma renal crisis),\nRaynaud phenomenon, and malignant hypertension\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333344 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 335\nâ–  Scleroderma renal crisis is characterized by an abrupt onset of hyper-\ntension and acute renal failure in patients with scleroderma. Early rec-\nognition is crucial, as scleroderma renal crisis has a high mortality rate\nif not treated.\nDiagnosis\nKEY FACT\nâ–  Diagnosis and categorization depend on constellation of symptoms.\nâ–  RF and ",
      "char_start": 954000,
      "char_end": 956000
    },
    {
      "chunk_id": 478,
      "text": "ANA may be âŠ•. Ninety-five percent of patients will have âŠ• ANA. Presence of anti-RNA polymerase III\nantibody in scleroderma is a risk factor\nâ–  Antiscleroderma (anti-Scl)-70/antitopoisomerase-I is highly specific\nfor renal crisis.\n(>99%) but only has âˆ¼20% to 45% sensitivity. These antibodies are asso-\nciated with diffuse disease and poor prognosis.\nâ–  RF may also be âŠ•.\nâ–  Anticentromere antibodies are specific for CREST syndrome (see Table\n2.8-9). MNEMONIC\nSevere disease may cause microangiopathic hemolytic anemia with Criteria for SLEâ€”\nschistocytes.\nDOPAMINE RASH\nDiscoid rash\nTreatment\nOral ulcers\nâ–  Organ-based treatment that includes frequent monitoring for progressive Photosensitivity\ndamage and symptomatic support where necessary Arthritis (nondeforming)\nâ–  Corticosteroids for acute flares (but they increase the patientâ€™s risk for Malar rash (see Fig. 2.8-13)\nrenal crisis); methotrexate for limited scleroderma Immunologic criteria: anti-dsDNA, anti-Sm\nâ–  Calcium channel blockers (dihydropyridine) such as amlodipine for Rayn- proteins, antiphospholipids\nNeurologic symptoms (lupus cerebritis,\naud phenomenon\nseizures)\nâ–  Angiotensin-converting enzyme inhibitors for treatment of renal crisis\nElevated ESR\nRenal disease\nComplications\nANA âŠ•\nMortality is most commonly caused by complications of ILD/pulmonary Serositis (pleural or pericardial effusion)\nfibrosis, pulmonary hypertension, and resulting renal or cardiac disease. Hematologic abnormalities\nSYSTEMIC LUPUS ERYTHEMATOSUS\nA chronic multisystem autoimmune disorder related to antibody-mediated\ncellular attack and deposition of antigen-antibody complexes in any organ sys-\ntem, resulting in variable clinical manifestations and presentations. Black\nwomen are at highest risk. SLE usually affects women of childbearing age.\nHistory/PE\nPresents with nonspecific symptoms such as fever, anorexia, weight loss, and\nsymmetric joint pain. Clinical heterogeneity and nonspecific symptoms pres-\nent a diagnostic difficulty in many patients",
      "char_start": 956000,
      "char_end": 958000
    },
    {
      "chunk_id": 479,
      "text": ", making SLE a diagnosis of\nexclusion.\nDiagnosis\nâ–  The mnemonic DOPAMINE RASH summarizes the criteria for diagnos-\ning SLE, an adaptation of the American College of Rheumatology (ACR)\ncriteria. Patients must have four of the criteria to consider a diagnosis of\nSLE (96% sensitive and specific). FIGURE 2.8-13. Systemic lupus\nâ–  A âŠ• ANA is highly sensitive (present in 95%â€“99% of cases). If âŠ• ANA, the erythematosus (SLE). The malar rash\nphysician should test for other antibodies, mainly anti-dsDNA and anti- of SLE is red to purple with a continuous\nplaque extending across the bridge of\nSm. Both are highly specific but not as sensitive (see Table 2.8-9).\nthe nose and to both cheeks. It typically\nâ–  Drug-induced SLE: âŠ• antihistone antibodies are seen in 100% of spares the nasolabial folds. (Reproduced with\ncases but are nonspecific. Common medications include hydralazine,\npermission from Bondi EE. Dermatology: Diagnosis and\nprocainamide, and isoniazid. Therapy. Stamford, CT: Appleton & Lange; 1991.)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333355 1100//2211//2222 11::5500 PPMM\n\n336 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nâ–  Neonatal SLE: It is associated with âŠ• anti-Ro antibodies transmitted\nfrom mother to neonate. The presence of anti-Ro antibodies may cause\nheart block.\nâ–  The following may also be seen:\nKEY FACT\nâ–  Low complement levels during acute flares\nThe lupus anticoagulant â–  Antiphospholipid antibodies (antibodies to anticardiolipin, antiâ€“\nÎ² -glycoprotein, or lupus â€œanticoagulantâ€). All cause a hypercoagulable\n(antiphospholipid antibodies) occurs 2\nstate and may cause thromboembolism and recurrent spontaneous\nin 5% to 10% of SLE cases. IgM or IgG\nabortion.\nbinds proteins in a clinical assay test\nand prolongs partial thromboplastin â–  Raynaud phenomenon\ntime (PTT). â–  Anemia, leukopenia, and/or thrombocytopenia\nâ–  Proteinuria and/or casts\nTreatment\nKEY FACT\nâ–  NSAIDs for mild joint symptoms.\nLibman-Sacks Endocarditis: â–  Corticosteroids ",
      "char_start": 958000,
      "char_end": 960000
    },
    {
      "chunk_id": 480,
      "text": "for acute exacerbations. Be wary of Cushing syndrome and\nNoninfectious vegetations often seen possible AVN from chronic use.\non the mitral valve in association with â–  Corticosteroids, hydroxychloroquine, cyclophosphamide, mycophenolate,\nSLE and antiphospholipid syndrome. and azathioprine for progressive or refractory cases. A few have specific uses:\nNote L-S Endocarditis corresponds with â–  Hydroxychloroquine: Can be used for isolated skin and joint involvement.\nS-L-E. â–  Cyclophosphamide or mycophenolate: Used for severe cases of lupus\nnephritis. The physician should be sure to get a renal biopsy for patients\nwith nephritic symptoms.\nComplications\nKEY FACT\nCommon causes of morbidity and mortality are important to know for SLE,\nSLE can cause a false âŠ• Venereal including renal failure, cardiovascular disease, and infections.\nDisease Research Laboratory (VDRL)\ntest or rapid plasma reagin (RPR) test!\nSERUM SICKNESSâ€“LIKE REACTION\nSelf-limited fever, urticarial rash, arthralgia, lymphadenopathy, and protein-\nuria within 1 to 2 weeks of exposure to a Î²-lactam antibiotic (eg, penicillin,\nKEY FACT\namoxicillin) or sulfa drug (eg, trimethoprim-sulfamethoxazole). Symptoms\nSLE and RA both affect the MCP and resolve upon discontinuation of the drug.\nPIP joints; the difference is that in SLE,\nthe joint disease is nondeforming and GIANT CELL ARTERITIS\nnonerosive, a pattern called Jaccoud\narthropathy.\nMost common of the systemic vasculitides. Formerly called temporal arteritis.\nCaused by subacute granulomatous inflammation of the large vessels, includ-\ning the aorta, external carotid (especially the temporal branch), and vertebral\narteries (see Fig. 2.8-14). Risk factors include polymyalgia rheumatica (affects\nalmost one half of patients), >50 years of age, and female sex.\nHistory/PE\nâ–  Presents with new headache (unilateral or bilateral), scalp pain, temporal\ntenderness, and jaw claudication\nâ–  Fever, permanent monocular blindness, transient monocular vision loss,\naortic aneurysm, wei",
      "char_start": 960000,
      "char_end": 962000
    },
    {
      "chunk_id": 481,
      "text": "ght loss, and myalgias and/or arthralgias (especially of\nthe shoulders and hips) also seen\nDiagnosis\nâ–  Best initial test: ESR >50 mm/hr (influenced by age).\nâ–  Most accurate test: Temporal artery biopsy. The physician should look for\nthrombosis; necrosis of the media; and the presence of lymphocytes,\nplasma cells, and giant cells.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333366 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 337\nGiant cell arteritis\nTakayasu arteritis\nGranulomatous arteritis\nCapillaries\nLarge vessel vasculitis\nArterioles\nVenules\nAorta Veins\nArteries\nMedium vessel vasculitis Small vessel vasculitis\nPaucity of vascular Ig Immune complex\nNecrotizing arteritis\n(often with ANCA) mediated\nPolyarteritis nodosa Microscopic polyangiitis SLE\nKawasaki disease Granulomatosis with Mixed cryoglobulinemia\npolyangiitis IgA vasculitis\n(Wegener granulomatosis) (Henoch-SchÃ¶nlein purpura)\nEosinophilic granulomatosis Anti-GBM vasculitis\nwith polyangiitis (Goodpasture disease)\n(Churg-Strauss syndrome)\nNote: BehÃ§et is an inflammatory vasculitis that can affect blood vessels of any size.\nFIGURE 2.8-14. Classification of vasculitis acoording to vessel size. (Reproduced with permission from\nUSMLE-Rx.com.)\nTreatment\nâ–  Best initial treatment: High-dose prednisone immediately to prevent ocu-\nlar involvement (or involvement of the remaining eye after onset of mon-\nocular blindness). If suspected as contribution to vision loss, give\npulse-dose steroids.\nâ–  A temporal artery biopsy to confirm diagnosis. However, do not delay treat-\nment. Conduct a follow-up eye examination.\nComplications\nThe most feared manifestation is blindness from anterior ischemic optic neu-\nropathy (AION) secondary to occlusion of the posterior ciliary artery, a\nbranch of the ophthalmic artery, which itself is a branch of the internal\ncarotid artery. Central retinal artery (a branch of the internal carotid artery) A 55-year-old woman presents to\nocclu",
      "char_start": 962000,
      "char_end": 964000
    },
    {
      "chunk_id": 482,
      "text": "sion is less common; however, if affected it may initially present as tran- the clinic with a chief complaint\nsient vision loss. of â€œblindness.â€ She states that she\nexperienced a temporary loss of\nvision in her left eye. She has also\nTAKAYASU ARTERITIS\nbeen experiencing new headaches\nand soreness in her jaw. Her vision\nLarge-vessel autoimmune vasculitis affecting the aorta and primary branches. exam is unremarkable. What\nCommon in Asian females <40 years of age. Diagnosis made through clinical diagnostic exam should be ordered?\npresentation and imaging. Classic symptoms include aortic claudication,\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333377 1100//2211//2222 11::5500 PPMM\n\n338 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-10. Fibromyalgia vs Polymyalgia Rheumatica\nCHARACTERISTIC FIBROMYALGIA POLYMYALGIA RHEUMATICA\nAge and sex Females 30â€“50 years of age Females >50 years of age\nLocation Various Shoulder and pelvic girdle\nESR Normal Markedly â†‘ (>100 mm/hr)\nCK Normal Normal\nMuscle biopsy Normal Normal\nClassic findings Anxiety, stress, point tenderness, Temporal arteritis; response to\nâŠ– workup steroids\nTreatment Antidepressants, NSAIDs, rest Low-dose prednisone\ndifferential blood pressure in both upper extremities, and the absence of pal-\npable pulses (pulseless disease). ESR and CRP are often highly elevated.\nImaging (magnetic resonance angiography [MRA] or computed tomography\nangiography [CTA]) will show narrowing of aorta or its primary branches.\nTreatment calls for oral high-dose steroids.\nBEHÃ‡ET SYNDROME\nAutoimmune vasculitis common in males of Turkish or Middle Eastern\ndescent. Characterized by recurrent, painful oral and genital ulcers and uve-\nitis. Thrombosis is a common cause of morbidity. To prevent recurrence,\npatients should be treated with colchicine. Topical steroids can treat oral and\ngenital ulcers, with ophthalmic steroids treating ocular involvement.\nFIBROMYALGIA\nA chronic musculoskeletal pain disorder that ",
      "char_start": 964000,
      "char_end": 966000
    },
    {
      "chunk_id": 483,
      "text": "primarily affects young females\nand is characterized by soft tissue and axial skeletal pain in the absence of\njoint pain. Inflammation is notably absent (see Table 2.8-10). Fibromyalgia\nmay be difficult to distinguish from myofascial pain (<11 painful areas).\nâ–  Hx/PE: Most common in females 30 to 50 years of age; associated with\ndepression, anxiety, sleep disorders, irritable bowel syndrome (IBS), and\ncognitive disorders (â€œfibro fogâ€).\nâ–  Dx: Multiple painful areas over all four body quadrants and the axial skel-\neton for more than 3 months. The absence of any other pathology suggests\na diagnosis of fibromyalgia.\nâ–  Tx: Initial nonpharmacologic approach, including multidisciplinary\npatient education regarding disease process, good sleep hygiene, low-\nimpact exercise with psychotherapy, and physical therapy (stretching,\nheat, hydrotherapy). Next step: Pharmacologic options, including antide-\npressants (tricyclic antidepressant or serotonin-norepinephrine reuptake\ninhibitors), gabapentin, pregabalin, or muscle relaxants. Avoidance of\nMonocular amaurosis fugax is\nnarcotics.\nassociated with giant cell (temporal)\narteritis and may progress to\ncomplete vision loss. A temporal\nartery biopsy should be obtained.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333388 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 339\nPOLYMYALGIA RHEUMATICA\nAn inflammatory rheumatic condition characterized by aching and stiffness\nin the shoulders, hips, and neck. Associated with temporal arteritis. Risk fac-\ntors include female sex and >50 years of age (see Table 2.8-10).\nHistory/PE\nâ–  Patient presents with pain and stiffness of the shoulder and pelvic girdle mus-\nculature with difficulty getting out of a chair or lifting arms above the head.\nâ–  Other symptoms include fever, malaise, and weight loss. Weakness is gen-\nerally not appreciated on examination.\nDiagnosis\nAn elevated ESR and/or CRP, normal creatine kinase (CK).\nTreatment\nLow-dose pred",
      "char_start": 966000,
      "char_end": 968000
    },
    {
      "chunk_id": 484,
      "text": "nisone (10â€“20 mg/day).\nUPPER EXTREMITY\nADHESIVE CAPSULITIS\nAdhesive capsulitis (â€œfrozen shoulderâ€) is a pathology of the glenohumeral\njoint in which the shoulder loses its normal ROM. This condition can be\neither idiopathic or result from several predisposing conditions such as shoul-\nder injury (eg, rotator cuff tear, humeral fracture, or surgery), subacromial\nbursitis, diabetes mellitus, hypothyroidism, Dupuytren contracture, or para-\nlytic stroke.\nHistory/PE\nâ–  Adhesive capsulitis presents in middle-aged and older individuals.\nâ–  Patients complain of gradual onset of poorly localized, nagging shoulder\npain that is worse at night.\nâ–  The pain is accompanied by a significant reduction in both active and pas-\nsive shoulder ROM. Patients may particularly complain of their inability\nto reach overhead or difficulty in back scratching or putting on a coat.\nDiagnosis\nClinical diagnosis. Based on demonstration of both active and passive shoul-\nder mobility reduction in multiple planes. Imaging is not typically required\nunless to rule out another shoulder pathology.\nTreatment\nâ–  Most cases are managed with ROM exercises and physical therapy.\nâ–  Cases having limited success with ROM exercises may be treated with cor-\nticosteroid injections, as well as arthroscopic distention and surgical\nrelease and NSAIDs.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 333399 1100//2211//2222 11::5500 PPMM\n\n340 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-11. Physical Examination Maneuvers for Shoulder Pathology\nDISEASE TEST DESCRIPTION\nImpingement Neer Positive if pain upon passively raising an internally rotated\narm (thumb pointing toward the floor). Arm should be\nhalfway between forward elevation and abduction while\nbeing raised.\nHawkins Positive if pain upon internally rotating an arm that is\n90 degrees flexed at the shoulder and elbow\nRotator cuff tear Drop arm Positive if patient drops their arm (due to pain or weakness)\nwhile slowly lowering it from 90 ",
      "char_start": 968000,
      "char_end": 970000
    },
    {
      "chunk_id": 485,
      "text": "degrees of abduction\nKEY FACT ROTATOR CUFF INJURIES\nTendinitis is a slight misnomer, as a\nRotator cuff pathology is a common cause of pain in older adults, and it typi-\nclassic cellular inflammatory response\ncally relates to impingement, glenohumeral OA, or an acute traumatic event.\nis absent or minimal in cases of\nThe supraspinatus is most commonly torn, but the subscapularis, infraspina-\noveruse tendinopathy. Tendinosis is\ntus, or teres minor may also be involved. Sports that require overhand motion\na more appropriate term referring\n(eg, baseball, swimming) may cause tears in young adults. Impingement or\nto chronic tendinopathy without\ntendinopathy may precede a full rotator cuff tear.\ncellular inflammation (eg, rotator cuff\ntendinopathy).\nHistory/PE\nâ–  Impingement: Normal ROM but painful abduction and external rota-\ntion. Neer sign and Hawkins test for impingement may be positive (see\nKEY FACT Table 2.8-11).\nâ–  Tear: Painful and weak abduction and external rotation. Drop arm sign\nRotator cuff tears can be acute or\nmay be positive if supraspinatus is torn. Risk factors include trauma, dislo-\nchronic. Chronic tears cause gradual\ncation, and age >40 years.\npain and typically are seen in older\nadults. Impingement syndrome\nDiagnosis\ninvolves pain caused by compression of\nsoft tissue structures, and it may have a â–  Impingement: X-ray\nmore insidious onset. â–  Tear: If suspicion high (eg, preceding trauma, weakness, and âŠ• drop\narm), MRI best next test\nTreatment\nMany patients improve with conservative management (eg, physical therapy).\nThe physician may consider repair if patient is refractory or fails physical\ntherapy.\nCOMPARTMENT SYNDROME\nâ†‘ pressure within a confined space that compromises nerve, muscle, and soft\ntissue perfusion. Occurs most commonly in the anterior compartment of the\nlower leg and in forearm secondary to trauma to the affected limb (fracture or\nmuscle injury). Compartment syndrome can also occur due to nontraumatic\ncauses such as (1) thrombosis leading t",
      "char_start": 970000,
      "char_end": 972000
    },
    {
      "chunk_id": 486,
      "text": "o ischemia-reperfusion injury or (2)\nprolonged limb compression (eg, in a patient who overuses alcohol or drugs).\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334400 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 341\nHistory/PE\nâ–  Symptoms develop acutely over several hours. Patient presents with Pain\nOut Of Proportion (POOP) to physical findings; Pain with passive motion\nof the fingers and toes; and Paresthesias, Pallor, Poikilothermia, Pulseless-\nKEY FACT\nness, and Paralysis (the six Ps).\nâ–  Paralysis and pulselessness occur as late signs of compartment syndrome. Volkmann contracture of the wrist and\nfingers is caused by compartment\nDiagnosis syndrome, which is associated with\nBased on history, serial examinations, and elevated compartment pressure supracondylar humerus fractures. These\n>30 mm Hg (although not necessary). The physician should calculate delta fractures may affect the brachial artery\npressure (diastolic pressure â€“ compartment pressure); the diagnosis is âŠ• if and radial nerve. Ischemia results in\ndelta pressure â‰¤30 mm Hg. fibrosis of dead muscle.\nTreatment\nâ–  Emergent fasciotomy to â†“ pressures and â†‘ tissue perfusion. KEY FACT\nâ–  Time to fasciotomy is one of the most important prognostic factors.\nTimeline of the six Ps in compartment\nâ–  If <6 hours from symptom onset, limb recovery approaches âˆ¼100%.\nsyndrome:\nâ–  If >6 hours from symptom onset, residual nerve dysfunction, muscle\nEarly (nerve dysfunction) â€” Pain out of\ndeath, and need for amputation likelihood increase.\nproportion, paresthesia\nLate (vascular insufficiency) â€” Pallor,\nRHABDOMYOLYSIS\npoikilothermia â†’ Paralysis,\npulselessness\nCaused by muscle necrosis and subsequent release of byproducts into sys-\ntemic circulation. Hallmark finding is elevated CK. Etiologies include direct\nmuscle damage (trauma, compression, compartment syndrome), extreme\nexertion (power lifters, marathon runners), toxins, or a syndrome such as KEY FACT\nmalignant hyperther",
      "char_start": 972000,
      "char_end": 974000
    },
    {
      "chunk_id": 487,
      "text": "mia.\nOpen fractures are an orthopedic\nHistory/PE emergency. Closed tibia and forearm\nfractures have higher rates of\nâ–  Commonly presents with muscle pain and weakness; however, can be\ncompartment syndrome. Patients\nasymptomatic\nshould be taken to the operating room\nâ–  Dark or â€œbloodyâ€ urine secondary to myoglobinuria\nwithin 8 to 24 hours for irrigation and\ndebridement followed by fracture\nDiagnosis\nrepair. The physician should reduce\nâ–  â†‘â†‘ serum CK, usually >1500 U/L or five times the upper limit of normal infection risk with antibiotics and\nâ–  Urinalysis âŠ• for myoglobin, minimal RBCs, possibility of acute kidney tetanus prophylaxis.\ninjury (AKI)\nâ–  Hyperkalemia, hyperphosphatemia\nTreatment\nâ–  IV fluid resuscitation and correction of electrolyte abnormalities\nâ–  Treatment of etiology if applicable (compartment syndrome, malignant\nhyperthermia)\nComplications\nAKI occurs in 15% to 50% with rhabdomyolysis due to volume depletion and\ndirect nephron injury from myoglobin acting as a direct toxin. A 37-year-old man is seen after a\nmotorcycle accident. He complains\nof intense leg pain, tingling in his\nfoot, and inability to move his toes.\nA physical examination reveals pain\nwith passive motion of his toes and\npalpable dorsalis pedis pulses. An\nx-ray film confirms a tibial fracture.\nWhat is the best treatment?\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334411 1100//2211//2222 11::5500 PPMM\n\n342 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nKEY FACT CARPAL TUNNEL SYNDROME\nPronator syndrome (PS) is due to\nEntrapment of the median nerve at the wrist caused by â†“ size or space of the\ncompression of the median nerve\ncarpal tunnel, leading to paresthesia, pain, and occasionally paralysis. Can be\nat the elbow. Symptoms include\nprecipitated by overuse of wrist flexors; associated with pregnancy, diabetes\nparesthesia in a similar distribution\nmellitus, hypothyroidism, acromegaly, RA, and amyloidosis\nto carpal tunnel syndrome. Patients\nalso have fewer night symptom",
      "char_start": 974000,
      "char_end": 976000
    },
    {
      "chunk_id": 488,
      "text": "s and\nHistory/PE\nmay have a positive Tinel sign at the\nproximal, anterior forearm. One risk â–  Difficulty with daily activities such as typing, turning doorknobs, opening\na bottle cap, and driving\nfactor: Hypertrophic forearm muscles.\nâ–  Presents with aching over the thenar area of the hand and proximal forearm\nâ–  Paresthesia or numbness seen in a median nerve distribution (first three\nKEY FACT and a half digits)\nâ–  Symptoms that worsen at night and awaken patient from sleep\nSensory loss in carpal tunnel syndrome\nâ–  Examination that shows thenar eminence atrophy (if disease is\nis a late finding that spares the thenar\nlong-standing)\neminence, as this area is supplied by\nâ–  Phalen maneuver and Tinel test âŠ• (see Fig. 2.8-15). Durkan test (carpal\nthe palmar sensory cutaneous nerve,\ncompression test) is another provocative method to diagnose carpal tunnel\nwhich arises proximal to the carpal\nsyndrome.\ntunnel and passes over it.\nDiagnosis\nA â–  Usually a clinical diagnosis from symptoms and signs\nâ–  Electrodiagnostic tests: Nerve conduction studies and electromyography\nTreatment\nâ–  Best initial treatment: Splinting the wrist in a neutral position at night\nand during the day if possible\nA â–  Medical treatment: Corticosteroid injection of the carpal canal and\nB NSAIDs\nâ–  Most definitive treatment: Surgical decompression of the tunnel, a\nwidely accepted treatment, particularly for fixed sensory loss, thenar\nweakness, or intolerable symptoms with no improvement after splinting\nand/or glucocorticoids\nComplications\nPermanent loss of sensation, hand strength, and fine motor skills.\nGANGLION CYST\nB\nFIGURE 2.8-15. Carpal tunnel syndrome.\n(A) The Tinel test is performed by tap- Fluid-filled cyst arising from tendon sheaths, ligaments, or joint connective\nping the volar surface of the wrist over\ntissue. Most commonly arises in the dorsum of the wrist (see Fig. 2.8-16)\nthe median nerve. (B) The Phalen\nmaneuver is performed by compressing\nthe opposing dorsal surfaces of the hand History/PE\nwith th",
      "char_start": 976000,
      "char_end": 978000
    },
    {
      "chunk_id": 489,
      "text": "e wrists flexed together as shown.\nâ–  A ganglion cyst commonly presents with a slowly growing mass overlying\nThis causes tingling over the median\nthe joint and causing wrist pain.\nnerve distribution. (Modified with permission\nfrom USMLE-Rx.com.) â–  The mass will be rubbery, round, and firm. It will be relatively immobile\ndue to association with joint connective tissue.\nDiagnosis\nThe best treatment is immediate Transillumination will show a fluid-filled structure, and it can guide diagno-\nfasciotomy for compartment sis. Ultrasound may differentiate a simple from a multiloculated cyst or a solid\nsyndrome (within 6 hours to prevent\nstructure (eg, lipoma, tumor, nodule).\nmuscle necrosis) followed by\nfracture stabilization. Remember that\nnonpalpable pulses are a late finding.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334422 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 343\nTreatment\nâ–  Observation. Up to 50% of ganglion cysts spontaneously regress.\nâ–  Surgical excision for ganglion cysts that do not regress, are symptomatic,\nor have features concerning for malignancy. The recurrence rate is âˆ¼10%.\nDUPUYTREN CONTRACTURE\nDue to disorder in fibroblastic proliferation and deposition of collagen in the\npalmar fascia of the hand with progressive fibrosis. Dupuytren contracture\noften presents after the fifth decade of life, predominantly in White males.\nHistory/PE\nâ–  Often begins as a painless nodule in the palm with progressive thickening\nand development of palmar cords FIGURE 2.8-16. Ganglion cyst. (Reproduced\nâ–  Eventually advances to a permanent contracture and flexion of the digits with permission from Vaishya R, Kapoor C, Agarwal\nAK, Vijay V. A rare presentation of ganglion cyst of\nwith inability to extend\nthe elbow. Cureus. 2016 Jul 1;8(7):e665. doi: 10.7759/\nâ–  Mostly affects ulnar aspect of hands, with MCP and PIP joints of the cureus.665.)\nfourth and fifth digits most commonly affected\nDiagnosis\nâ–  Characteristic pal",
      "char_start": 978000,
      "char_end": 980000
    },
    {
      "chunk_id": 490,
      "text": "mar nodules or cords, depending on clinical stage\nâ–  Physical examination demonstrating inability to extend the fingers or\njoints\nTreatment\nâ–  Surgical correction with fasciotomy (transection) or fasciectomy (excision)\nof cords\nâ–  Percutaneous needle aponeurotomy less invasive but less effective in\nrelieving contracture\nComplications\nHigh recurrence rate, even after surgical correction.\nAVASCULAR NECROSIS\nAVN, also known as osteonecrosis or ischemic necrosis, is caused by disrup-\ntion of proximal blood supply, leading to death of bone (see Fig. 2.8-17). Two\ncommonly tested concepts are AVN of the scaphoid bone (after a fall onto an\noutstretched hand [FOOSH]) and AVN of the femoral head (associated with\na variety of conditions).\nHistory/PE\nâ–  Scaphoid necrosis: Pain at the anatomic snuff box after a FOOSH\nâ–  Femoral head necrosis: Dull or sharp pain in the affected hip\nâ–  Children: Idiopathic AVN (Legg-Calve-Perthes disease) or slipped capital\nfemoral epiphysis\nâ–  Sickle cell disease, prolonged glucocorticoid or bisphosphonate use, femo- FIGURE 2.8-17. Femoral head AVN.\nral fracture\n(Reproduced with permission from Bilge O, Doral MN,\nYel M, Karalezli N, Miniaci A. Treatment of osteonecro-\nDiagnosis sis of the femoral head with focal anatomic-resurfac-\ning implantation (HemiCAP): Preliminary results of an\nâ–  X-ray of the affected wrist or hip. MRI is gold standard for those with nega- alternative option. J Orthop Surg Res. 2015;10:56. Pub-\ntive x-ray and high suspicion for AVN. lished 2015 Apr 28. doi:10.1186/s13018-015-0199-3.)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334433 1100//2211//2222 11::5500 PPMM\n\n344 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nâ–  In scaphoid fractures, x-rays possibly negative for 2 to 6 weeks after a fall. It\nis important to get delayed follow-up imaging to rule out necrosis or\ndisplacement.\nTreatment\nâ–  Scaphoid AVN: Wrist splints after fall; surgical referral for displaced frac-\ntures or those with neurovascular com",
      "char_start": 980000,
      "char_end": 982000
    },
    {
      "chunk_id": 491,
      "text": "promise\nâ–  Femoral head AVN: Total hip replacement\nRAYNAUD PHENOMENON\nAbnormal vasoconstriction of peripheral arteries in response to cold, leading\nto characteristic progression of digit color changes reflecting pathologic\nprocess.\nâ–  Ischemia: Vasospasm of artery causing occlusion and pallor â†’ pale\nâ€œwhiteâ€ digits\nâ–  Cyanosis: Dilation of capillaries and filling of deoxygenated blood â†’\nâ€œblueâ€ digits\nKEY FACT\nâ–  Rubor: Resolution of arterial vasospasm and reperfusion â†’ â€œredâ€ digits\nRaynaud phenomenon may be May be primary or associated with other autoimmune conditions. Test\ntriggered by cold temperatures and for ANA and RF to lead to diagnosis. First-line treatment is general avoid-\nstress. Keeping the bodyâ€™s core warm ance of triggers. Pharmacologic treatment calls for calcium channel block-\nis essential. It can be treated with ers (eg, amlodipine, nifedipine).\ncalcium channel blockers (CCBs) such\nas nifedipine or amlodipine.\nHAND INFECTIONS AND BITE WOUNDS\nAcute hand infections and bites should be promptly evaluated and treated.\nBoth animal and human bites should be empirically treated. A â€œfight biteâ€ is a\nlaceration from striking anotherâ€™s mouth and should be carefully examined\ndue to high mouth colonization and possibility for progression to a septic joint.\nSurgical debridement should be done by an orthopedic or hand specialist.\nHistory/PE\nâ–  Presents with hand pain and erythema, often with loss of ROM due to\nedema\nâ–  Alarm signs: Crepitus, indicating possible necrotizing infection, and skin\ndiscoloration, indicating necrosis or ischemia\nDiagnosis\nâ–  Laboratory studies: Leukocytosis may assess severity of infection and help\nmonitor progression. Cultures of wounds can help guide antibiotic\ntreatment.\nâ–  Imaging: Plain radiographs should be first-line to evaluate bones for possi-\nble fracture or osteomyelitis, foreign bodies, affected joints, or subcutane-\nous gas.\nTreatment\nâ–  Broad-spectrum antibiotics should be first-line until cultures can guide\ntherapy.\nâ–  Treatment sho",
      "char_start": 982000,
      "char_end": 984000
    },
    {
      "chunk_id": 492,
      "text": "uld be based on source of bite. Dog and catsâ€”Pasteurella,\nStaphylococcus, Streptococcus. Humanâ€”Eikenella, group A Streptococcus.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334444 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 345\nâ–  Necrotizing infections and severe infections require surgical debridement\nand source control to prevent permanent compromise.\nâ–  Septic arthritis requires joint aspiration and urgent surgical debridement.\nComplications\nProgression of infection can require emergent surgical intervention, and with-\nout proper treatment can lead to loss of digits, limb, or permanent disfigure-\nment and disability.\nLOWER EXTREMITY\nOSTEOCHONDRITIS DISSECANS\nOsteochondritis dissecans (OCD) often presents in adolescent children in\nwhich a part of the subchondral bone detaches from the underlying bone\n(see Fig. 2.8-18). OCD has a propensity to affect boys. It results from\nrepeated trauma in highly active children. The most common joints\ninvolved include the knee, elbow, and ankle (often with a history of ankle\ninversion).\nâ–  Hx: Patients complain of dull, poorly localized joint pain that worsens\nwith activity. Accompanying swelling, stiffness, crepitus, and tenderness\nmay be present. In advanced stages of the disease, patients can have an\nantalgic gait (patients rotate the affected limb laterally to reduce pain from\nweight-bearing) and complain of a catching and locking sensation. FIGURE 2.8-18. Osteochondritis dis-\nâ–  Dx: Based on visualization of subchondral bone fragment on plain radio- secans. Subchondral bone detaches\nfrom the underlying bone. (Reproduced with\ngraph. In case of high suspicion and normal radiograph, an MRI can be\npermission from Kanto R, Nakayama H, Iseki T, Yoshiya\nobtained.\nS. Juvenile osteochondritis dissecans in the lateral\nâ–  Tx: Rest, physical therapy, and surgery (in severe disease). femoral condyle requiring osteochondral autograft\nas a revision procedure: A case report. J Med Cas",
      "char_start": 984000,
      "char_end": 986000
    },
    {
      "chunk_id": 493,
      "text": "e Rep.\n2016;10:3 doi:10.1186/s13256-015-0795-1.)\nBURSITIS\nInflammation of the joint bursa by repetitive use, trauma, infection, systemic\ninflammatory disease (eg, autoimmune disease), or crystalline disorders (eg,\ngout). Common sites of bursitis include subacromial, olecranon, trochanteric,\npopliteal fossa (Baker cyst), prepatellar (housemaidâ€™s knee), and infrapatellar\nbursae.\nâ–  Hx/PE: Presents as pain, tenderness, swelling, and reduction on active\nROM but with limited impact on passive ROM. Presence of abrasion,\noverlying cellulitis, or puncture wound/history of bursal injection with\naccompanying fever and chills suggests a septic etiology (often due to S\naureus).\nâ–  Dx: Based on history and PE. In case of suspected septic or crystalline eti-\nology, aspiration should be performed.\nâ–  Tx: Activity modification and NSAIDs for nonseptic cases. In case of sep-\ntic etiology, systemic antibiotics are required, with surgical debridement in\nselected cases. A 23-year-old man presents to the\nemergency department with a\nswollen and erythematous right\nPES ANSERINUS PAIN SYNDROME hand following an altercation at a\nbar a few days ago. The dorsum of\nAlso called anserine bursitis. Common in young adults active in sports, over- the hand shows abrasions, and x-ray\nweight middle-aged females, and older adults with OA. Presents with films reveal a fracture of the fifth\nmetacarpal. What is the next step in\nmanagement?\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334455 1100//2211//2222 11::5500 PPMM\n\n346 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nlocalized pain at the anteromedial tibia at the insertion of the pes anserinus\n(just below the joint line) that is aggravated by overuse, obesity, knee OA, and\npressure from the opposite knee while lying on the side. Pain typically devel-\nops over weeks and worsens overnight. Valgus stress test will not aggravate the\npain, and x-rays will also be normal. Treatment includes NSAIDs and\nstrengthening of quadricep muscle",
      "char_start": 986000,
      "char_end": 988000
    },
    {
      "chunk_id": 494,
      "text": "s.\nPATELLOFEMORAL PAIN SYNDROME\nAnterior knee pain caused by overuse. Common in females, runners, cyclists,\nand athletes. Pain can be reproduced with knee extension or using stairs.\nTreatment calls for activity modification (often rest) and NSAIDs.\nHistory/PE\nPresents with localized tenderness, â†“ ROM, edema, and erythema; possible\nKEY FACT\nhistory of trauma or inflammatory disease. Pain is reproducible with squat-\nInfection of the superficial bursae ting, and it worsens with ascending or descending stairs. Diagnosis can occur\noccurs after trauma to the skin. with patellar tendonitis (localized pain directly beneath patella).\nInfection of deep bursae is often\niatrogenic following injections or Diagnosis\naspirations.\nâ–  Mainly a clinical diagnosis based on symptoms and physical exam findings.\nâ–  Needle aspiration indicated if septic bursitis is suspected. No labs or imag-\ning is needed.\nTreatment\nâ–  Best initial treatment: Rest, heat and ice, elevation, and NSAIDs. Patient\nshould increase quadriceps strength with physical therapy.\nKEY FACT â–  An intrabursal corticosteroid injection can be considered, but it is contra-\nindicated if septic bursitis is suspected.\nIn a child with gout and inexplicable\nâ–  Septic bursitis should be treated with 7 to 10 days of antibiotics.\ninjuries, consider Lesch-Nyhan\nsyndrome (hypoxanthine-guanine\nphosphoribosyltransferase [HGPRT] MORTON NEUROMA\ndeficiency).\nNeuropathic degeneration of nerves (most commonly between the third and\nfourth toes) that causes numbness, pain, and paresthesia. Often associated\nwith a â€œclicking sensationâ€ when palpating this joint space. Morton neuroma\noccurs in runners, and symptoms worsen when metatarsals are squeezed\ntogether (eg, from wearing high-heeled shoes or walking on hard surfaces).\nTreatment requires padded shoe inserts to decrease pressure on metatarsal\nheads or surgical removal.\nKEY FACT GOUT\nGout crystals appear yeLLow when\nRecurrent attacks of acute monoarticular arthritis resulting from intra-\nparaLLe",
      "char_start": 988000,
      "char_end": 990000
    },
    {
      "chunk_id": 495,
      "text": "l to the condenser.\narticular deposition of monosodium urate crystals caused by disorders of urate\nmetabolism (â†‘ production or â†“ excretion). Risk factors include male sex, obe-\nsity, postmenopausal status in women, and binge drinking.\nHistory/PE\nâ–  Presents with sudden onset of excruciating joint pain. Gout is associated\nIf skin is broken in a boxerâ€™s fracture,\nwith erythema, warmth, swelling, and decreased ROM. Fever and mild\nassume infection by human oral\nleukocytosis can be present.\npathogens and treat with surgical\nirrigation, debridement, and IV\nantibiotics to cover Eikenella.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334466 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 347\nTABLE 2.8-12. Gout vs Pseudogout\nCRYSTAL\nDISORDER HISTORY JOINTS AFFECTED CRYSTAL SHAPE BIREFRINGENCE\nGout (uric acid) Male sex, binge First big toe Needle shaped âŠ–\ndrinking, (podagra) (see Fig.\nrecent surgery, and other 2.8-20)\nhyperuricemia joints\nFIGURE 2.8-19. Tophaceous gout. Note\nPseudogout, also Hemochromatosis Wrists and Rhomboid (see âŠ•\nthe slowly enlarging nodule of the right\ncalled calcium or hyperpara- knees Fig. 2.8-20) second toe in a 55-year-old man who is\npyrophosphate thyroidism hypertensive, takes hydrochlorothiazide,\nand overuses alcohol. (Reproduced with per-\ndeposition\nmission from USMLE-Rx.com.)\ndisease (CPPD)\nâ–  Eighty percent of cases are monoarticular. Gout most commonly affects\nthe first metatarsophalangeal (MTP) joint (podagra) and the midfoot,\nknees, ankles, and wrists; the hips and shoulders are generally spared.\nâ–  Tophi (urate crystal deposits in soft tissue) can be seen with chronic dis-\nease and are associated with tissue destruction (see Fig. 2.8-19). Tophi are\nvirtually pathognomonic for gout and are painless and nontender. They\ncan ulcerate and discharge a chalky white substance.\nâ–  Uric acid kidney stones are seen with chronic disease.\nKEY FACT\nDiagnosis\nCauses of hyperuricemia:\nâ–  Diagnosis requires ",
      "char_start": 990000,
      "char_end": 992000
    },
    {
      "chunk_id": 496,
      "text": "joint synovial fluid aspiration because septic arthritis\nâ–  â†‘ cell turnover (hemolysis, blast\ncan present similarly. Aspirate shows needle-shaped, negatively birefrin-\ncrisis, tumor lysis, myelodysplasia,\ngent crystals (vs pseudogout; see Table 2.8-12).\npsoriasis)\nâ–  Lab tests and imaging:\nâ–  Drugs: Cyclosporine, diuretics, low-\nâ–  Serum uric acid is usually elevated (â‰¥7.5 mg/dL), but patients may\ndose salicylates\nhave normal or even decreased levels during an acute attack of gout.\nâ–  Physiologic states: Dehydration,\nESR and CRP are typically elevated, and joint fluid aspiration and\nstarvation, obesity\nanalysis are required to clarify the diagnosis.\nâ–  Disease: DI, HGPRT deficiency, G6P\nâ–  X-rays may show punched-out erosions with overhanging cortical bone\ndeficiency\n(â€œrat-biteâ€ erosions, see Fig. 2.8-21) that are seen in advanced gout.\nâ–  Diet (eg, â†‘ red meat, alcohol)\nâ–  Diuretics\nâ–  Lead poisoning\nA B\nâ–  Lesch-Nyhan syndrome\nâ–  Salicylates (low dose)\nA 49-year-old man presents with a\npainful, swollen big toe after a night\nof heavy drinking. How does alcohol\nFIGURE 2.8-20. Gout and pseudogout crystals. Gout (A) has negatively birefringent needle-\naffect uric acid metabolism?\nshaped crystals, but pseudogout (B) has rhomboid crystals under light microscopy. (Image A repro-\nduced with permission from Manhas A, Kelkar P, Keen J, et al. Recurrent craniocervical pseudogout: indications for surgical\nresection, surveillance imaging, and craniocervical fixation. Cureus, 8(2): e511. doi:10.7759/cureus.511. Image B adapted with\npermission from Zhang Y, Lee SY, Zhang Y, et al. Wide-field imaging of birefringent synovial fluid crystals using lens-free\npolarized microscopy for gout diagnosis. Sci Rep, 2016;6:28793. doi:10.1038/srep28793.)\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334477 1100//2211//2222 11::5500 PPMM\n\n348 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nFIGURE 2.8-22. Chondrocalcinosis. Punctate and\nlinear lesions that correlate with the depositio",
      "char_start": 992000,
      "char_end": 994000
    },
    {
      "chunk_id": 497,
      "text": "n of\ncalcium-containing crystals in articular cartilage.\n(Reproduced with permission from Hahn M, Raithel M, Hagel A,\nBiermann T, Manger B. Chronic calcium pyrophosphate crystal\ninflammatory arthritis induced by extreme hypomagnesemia in\nshort bowel syndrome. BMC Gastroenterol. 2012;12:129. Published\n2012 Sep 22. doi:10.1186/1471-230X-12-129.)\nTreatment\nâ–  Acute attacks:\nâ–  High-dose NSAIDs (eg, indomethacin) are first-line. NSAIDs should\nbe avoided in cases of congestive heart failure (CHF), chronic kid-\nFIGURE 2.8-21. Rat-bite lesions.\nney disease (CKD), peptic ulcer disease, and for anticoagulated\nPunched-out erosions with overhanging\ncortical bone, seen in patients with gout. patients. Colchicine may also be used; it is most effective when used\n(Reproduced with permission from Girish G, Melville within 24 hours of attack onset.\nDM, Kaeley GS, et al. Imaging appearances in gout. â–  Steroids are used when NSAIDs are ineffective or contraindicated (eg,\nArthritis. 2013;2013:673401. doi:10.1155/2013/673401.)\nrenal insufficiency).\nâ–  Intra-articular steroid injection is preferable if only one or two joints\nKEY FACT are involved. Otherwise, systemic steroids should be used.\nAllopurinol and febuxostat are both â–  Maintenance therapy is indicated in case of two or more attacks annually,\nxanthine oxidase inhibitors. Allopurinol presence of tophi, or structural joint damage. Maintenance medications\nand febuxostat decrease metabolism include:\nof azathioprine or 6-mercaptopurine, â–  Xanthine-oxidase inhibitors: Allopurinol and febuxostat. Can â†‘ inci-\nleading to profound toxicities, and they dence of urate nephropathy\nshould be avoided in patients who are â–  Uricosuric agents: Probenecid. Contraindicated in patients with tophi,\non azathioprine or mercaptopurine nephrolithiasis, or CKD\n(6-MP).\nâ–  Weight loss and avoidance of triggers (eg, binge drinking, red meat) will\nprevent recurrent attacks in many patients.\nKEY FACT\nPSEUDOGOUT\nColchicine inhibits neutrophil\nPseudogout is acute sy",
      "char_start": 994000,
      "char_end": 996000
    },
    {
      "chunk_id": 498,
      "text": "novitis presenting similarly to gout attacks. Flares are\nchemotaxis and is most effective\ncommon in a setting of recent surgery or medical illness. It is a disease of\nin pseudogout when used within\nolder adults, characterized by calcium pyrophosphate crystal deposition into\n24 hours of flare onset. However, it\nthe joint space. Peripheral joints are most commonly involved, classically the\ncan cause diarrhea, neuromyopathy,\nknee joint. Risk factors include hemochromatosis, hypothyroidism, and\nand bone marrow suppression\nhypercalcemia.\n(neutropenia).\nâ–  Hx/PE: Same as gout (see previous section).\nâ–  Dx: Based on joint aspiration showing rhomboid-shaped birefringent crys-\ntals. Imaging classically reveals chondrocalcinosis (see Fig. 2.8-22).\nâ–  Tx: Intra-articular steroids, NSAIDs, and colchicine.\nTRUNK\nAlcohol is a source of purines, which\nLOW BACK PAIN\nare metabolized into uric acid,\nincreasing serum concentrations and\npredisposing patients to gout flares. Low back pain (LBP) is the second-leading symptom-related cause for office\nvisits in the United States. Although often self-limited, it can also be a sign of\nmore severe disease, including infection, malignancy, or abdominal aortic\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334488 1100//2211//2222 11::5500 PPMM\n\nMUSCULOSKELETAL HIGH-YIELD FACTS IN 349\naneurysm (AAA). Routine imaging studies are not indicated in the majority of KEY FACT\npatients with acute LBP unless alarming symptoms are present.\nMost LBP is mechanical, so bed rest is\nRed Flag Symptoms contraindicated.\nPatient histories involving back pain that would warrant further imaging include:\nâ–  Constitutional symptoms (eg, fever, chills, night sweats)\nâ–  Sensory or motor deficits (eg, paresthesia or urine retention)\nâ–  Suspicion of infection (eg, immunosuppressive drugs, recent spinal proce-\ndure, endocarditis) KEY FACT\nâ–  Risk factors for compression fracture (eg, glucocorticoid use, older age,\nRed flags for LBP include >50 ye",
      "char_start": 996000,
      "char_end": 998000
    },
    {
      "chunk_id": 499,
      "text": "ars of\nosteoporosis)\nage, >6 weeks of pain, previous cancer\nâ–  History of drug abuse or malignancy\nhistory, severe pain, constitutional\nsymptoms, neurologic deficits, and loss\nHERNIATED DISK of anal sphincter tone.\nCauses include degenerative changes, trauma, or neck/back strain or sprain.\nA herniated disk most commonly occurs (95%) in the lumbar region, espe-\ncially at L5â€“S1 (most common site) and L4â€“L5 (second most common site).\nHistory/PE KEY FACT\nâ–  Presents with sudden onset of severe, electricity-like LBP, usually pre- Bowel or bladder dysfunction (urinary\nceded by several months of aching, â€œdiskogenicâ€ pain overflow incontinence), impotence, and\nâ–  Common among middle-aged and older males saddle-area anesthesia are consistent\nâ–  Exacerbated by â†‘ intra-abdominal pressure (eg, coughing, sneezing) or with cauda equina syndrome, a surgical\nValsalva (eg, coughing) emergency.\nâ–  Associated with sciatica, paresthesia, muscle weakness, atrophy, contrac-\ntions, or spasms\nâ–  A contralateral (crossed) straight-leg raise â†‘ pain (highly specific but not\nsensitive)\nâ–  Large midline herniations can cause cauda equina syndrome\nDiagnosis\nâ–  Diagnosed with a âŠ• passive straight-leg raise with increased pain (sensi-\ntive, not specific).\nâ–  Imaging: MRI (see Fig. 2.8-23) is the preferred test. It is necessary for\ncauda equina syndrome or for a severe or rapidly progressing neurologic\ndeficit.\nâ–  Additional tests: ESR and plain x-ray if other causes of back pain are sus-\npected (eg, infection, trauma, compression fracture).\nTreatment\nâ–  Best initial treatments: NSAIDs in scheduled doses, physical therapy, and\nlocal heat. The physician should not prescribe bed rest; continuation of\nregular activities is preferred.\nâ–  Epidural steroid injection or nerve block: Patients who do not respond to\ninitial treatment.\nâ–  Most definitive treatment: Surgeryâ€”only in focal neurologic deficits,\ncauda equina syndrome, and in cases of persistent pain for at least 6 weeks.\nFIGURE 2.8-23. Disk herniation. Sagitta",
      "char_start": 998000,
      "char_end": 1000000
    },
    {
      "chunk_id": 500,
      "text": "l\nT2-weighted MRI of the lumbar spine\nSPINAL STENOSIS shows posterior herniation of the L5-S1\ndisk. (Reproduced with permission from Fauci AS\nNarrowing of the lumbar or cervical spinal canal, leading to compression of et al. Harrisonâ€™s Principles of Internal Medicine, 17th ed.\nNew York, NY: McGraw-Hill; 2008.)\nthe nerve roots and spinal cord. Most commonly caused by degenerative joint\ndisease; typically occurs in middle-aged or older adult patients\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 334499 1100//2211//2222 11::5511 PPMM\n\n350 HIGH-YIELD FACTS IN MUSCULOSKELETAL\nTABLE 2.8-13. Motor, Reflex, and Sensory Deficits in Back Pain\nASSOCIATED DEFICIT\nNERVE ROOT MOTOR REFLEX SENSORY\nL2â€“L4 Hip flexion (psoas), knee extension (quadriceps), Patellar Anterior thigh and medial aspect of the lower leg\nand foot dorsiflexion (tibialis anterior)\nL5 Big toe dorsiflexion (extensor hallucis longus), foot None Dorsum of the foot and lateral aspect of the lower\neversion (peroneus muscles) leg\nS1 Plantarflexion (gastrocnemius/soleus), hip exten- Achilles Lateral aspects of the foot and little toe\nsion (gluteus maximus)\nS2â€“S4 Incontinence and sexual dysfunction Anocutaneous Posterior, medial thigh, and perianal\nHistory/PE\nâ–  Spinal stenosis presents with neck pain, back pain that radiates to the arms\nKEY FACT or the buttocks and legs bilaterally, and leg numbness/weakness.\nâ–  In lumbar stenosis, leg cramping is worse with standing and with walking\nNeurogenic claudication or\ndownhill.\npseudoclaudication is an important\nâ–  In lumbar stenosis, symptoms improve with flexion at the hips and bending\nfeature of lumbar spinal stenosis and is\nforward, which relieves pressure on the nerves, aka, the â€œshopping cart sign.â€\ncharacterized by worsening symptoms\nwith walking and relief with sitting or\nDiagnosis\nlying down.\nMRI is the main imaging modality to use.\nTreatment\nâ–  Mild to moderate: Treatments include NSAIDs, weight loss, and abdomi-\nnal muscle strengtheni",
      "char_start": 1000000,
      "char_end": 1002000
    },
    {
      "chunk_id": 501,
      "text": "ng.\nâ–  Advanced: Epidural corticosteroid injections can provide relief.\nâ–  Refractory: Surgical laminectomy is needed in 75% of patients with\nrefractory symptoms.\nTable 2.8-13 outlines the motor, reflex, and sensory deficits with which\nLBP is associated.\nSPONDYLOLISTHESIS AND SPONDYLOSIS\nSpondylosis is a common cause of LBP in preadolescent children and ath-\nletes with repetitive back extension and rotation (divers, gymnasts). It repre-\nsents a bilateral fracture of the posterior arch, whereas spondylolisthesis\ninvolves the anterior displacement of vertebrae (usually L5, S1) due to a\ndefect in the posterior arch.\nâ–  Hx/PE: Presents as chronic back pain exacerbated with lumber extension.\nBoth spondylolisthesis and spondylosis may be accompanied by neuro-\nlogic dysfunction and palpable step-off in the lumbosacral area.\nâ–  Dx: Primarily based on history/PE. Patients can follow prescribed bed rest\nfor 2 weeks to see if there is a resolution of symptoms. If symptoms persist\nor if LBP danger signs are present (eg, night pain, neurologic symptoms),\nimaging should be sought.\nâ–  Tx: Mainly centered around rest, symptom control (eg, stretching exercises),\nand close follow-up. However, if patients start to exhibit signs of neurologic\ninjury (eg, radiculopathy), a spine surgery consult should be obtained.\nâ–  Prognosis/complications: Usually complete recovery. Long-term complica-\ntions from surgery include spinal canal stenosis and disk degeneration.\n22002222__0022..0088__SStteepp22CCKK__MMuusscc__1111ee__331133--335500..iinndddd 335500 1100//2211//2222 11::5511 PPMM\n\nH I G H - Y I E L D F A C T S I N\nNEUROLOGY\nClinical Neuroanatomy 353 Vertigo 377\nBrain 353 Benign paroxysMal positional Vertigo 377\nCirCle of Willis and arterial supply/Venous drainage of Brain 354 aCute peripheral VestiBulopathy\nMeninges 355 (laByrinthitis or VestiBular neuritis) 378\nluMBar punCture 356 MÃ©niÃ¨re disease 378\nperipheral and Cranial nerVes 356\nCNS Infections 379\nreflexes 358\nMeningitis 379\nSpinal Cord 358 ",
      "char_start": 1002000,
      "char_end": 1004000
    },
    {
      "chunk_id": 502,
      "text": "CryptoCoCCal Meningitis 381\ntoxoplasMosis 381\nHeadaches 361\nenCephalitis 382\nMigraine headaChe 361\nBrain aBsCess 383\nCluster headaChe 362\ntension-type headaChe 363 Disorders of Neuromuscular Junction 384\nseCondary headaChes 363 Myasthenia graVis 384\ntrigeMinal neuralgia 364 laMBert-eaton MyastheniC syndroMe 385\nBotulisM 386\nVascular Disorders 364\ntransient isCheMiC attaCk 364 Demyelinating Disorders 387\nstroke 365 Multiple sClerosis 387\nsuBaraChnoid heMorrhage 368 guillian-BarrÃ© syndroMe 388\nintraCereBral heMorrhage 369\nNeurodegenerative Disorders 388\nsuBdural and epidural heMorrhage 369\ndeMentia 390\nCaVernous sinus throMBosis 369\nalzheiMer disease 390\nComa and Encephalopathy 371 VasCular deMentia 392\nfrontoteMporal deMentia (piCk disease) 393\nAphasia 372\nnorMal-pressure hydroCephalus 393\nBroCa/expressiVe aphasia 372\nCreutzfeldt-JakoB disease 394\nWerniCke/reCeptiVe aphasia 373\nleWy Body deMentia 395\nSeizure Disorders 373\nMovement Disorders 396\nClassifiCation of seizure 374\nhuntington disease 396\nstatus epileptiCus 376\nparkinson disease and parkinsonisM 397\n351\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335511 1100//2211//2222 22::1188 PPMM\n\nH I G H - Y I E L D F A C T S I N\nNEUROLOGY\naMyotrophiC lateral sClerosis 399 ContaCt lens keratitis 415\nrestless legs syndroMe 400 uVeitis 416\ntreMors 401 refraCtiVe errors 416\nWilson disease or hepatolentiCular degeneration 401 presByopia 416\nglauCoMa 417\nNeoplasms 403\nCataraCt 417\nNeurocutaneous Disorders 406 age-related MaCular degeneration 418\nneurofiBroMatosis 406 retinal VasCular oCClusion 419\ntuBerous sClerosis 407 optiC neuritis 419\nsturge-WeBer syndroMe 408 retinal detaChMent 421\nVon hipple-lindau syndroMe 409 diaBetiC retinopathy 421\nataxia-telangieCtasia 410 hypertensiVe retinopathy 421\nOther Neurologic Diseases 410\nretinitis pigMentosa 421\nnutritional defiCienCies 410\npapilledeMa 422\nidiopathiC intraCranial hypertension 410\nleukoCoria 422\nrelatiVe afferent pupillary defeCt 422\n",
      "char_start": 1004000,
      "char_end": 1006000
    },
    {
      "chunk_id": 503,
      "text": "Ophthalmology 412\nhorner syndroMe 422\nVisual field defeCts 412\norBital BloWout fraCture 422\nhordeoluM 412\nCaVernous sinus syndroMe 422\nChalazion 412\nintranuClear ophthalMoplegia 423\nBlepharitis 413\nOtology 423\nCorneal aBrasion 413\npreseptal (periorBital) Cellulitis 413\notitis Media 423\norBital (postseptal) Cellulitis 413\notitis externa 424\nConJunCtiVitis 414\nMalignant otitis externa 424\naCute daCryoCystitis 414\nsensorineural hearing loss 425\nherpes siMplex keratitis 415\nConduCtiVe hearing loss 426\n352\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335522 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 353\nCLINICAL NEUROANATOMY\nBRAIN\nThe brain is organized into diverse areas that allow it to carry out a wide vari-\nety of specific functions. Most of the sensory areas are located posterior to the\ncentral sulcus, whereas the motor areas are located anterior to the central sul-\ncus. The visual cortex is in the occipital lobe, and the auditory cortex is in the\ntemporal lobe. Further details are shown in Figure 2.9-1.\nThe primary motor and somatosensory cortices can also be mapped to rep-\nresent specific parts of the body. This is called the homunculus. Note the dis-\nproportionate representation of various areas of the body, based on the\ninnervation density of nerve cells to these areas and the complexity of their\nfunctions (Fig. 2.9-2).\nNeuroimaging helps assess complications of intracranial pathology such as\nherniation syndromes, as shown in Figure 2.9-3. The most common types of\nbrain herniation include:\nâ–  Cingulate (subfalcine) herniation under the falx cerebri, which can com-\npress the anterior cerebral artery.\nâ–  Central/downward transtentorial herniation that leads to brainstem dis-\nplacement with rupture of paramedian basilar artery branches and Duret\nhemorrhages in the brainstem. It is usually fatal.\nâ–  Uncal transtentorial herniation, or herniation of the medial temporal lobe:\nEarly herniation leads to ipsilateral b",
      "char_start": 1006000,
      "char_end": 1008000
    },
    {
      "chunk_id": 504,
      "text": "lown pupil (secondary to ipsilateral\ncranial nerve [CN] III compression) and contralateral hemiparesis. Late\npresentation leads to coma and Kernohan phenomenon (ipsilateral hemi- KEY FACT\nparesis due to contralateral compression against the Kernohan notch and a\nA â€œblown pupilâ€ suggests ipsilateral third\nsubsequent misleading contralateral blown pupil).\nnerve compression secondary to uncal\nâ–  Cerebellar tonsillar herniation into the foramen magnum, which com-\nherniation.\npresses the brainstem and may lead to coma and death.\nPremotor Central sulcus Somatosensory\ncortex association cortex\nF\nP\nro\nre\nn\nf\nt\nr\na\no\nl\nfi\nn\ne\ne\nt\ny\nl\na\nd\ne\nl\nFr l o o n b t e al\nPri\nmary\nmotor\nPri m\nso\na m r a y\ntosensory\nPa lo ri b e e tal\ncortex\nArcuatefasciculus\nBroca area Wernicke area\nOccipital\nTemporal lobe\nlobe Primary\nSylvian fissure visual cortex\nLimbic Primary\nassociation area auditorycortex\nFIGURE 2.9-1. Cortical map of the brain. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335533 1100//2211//2222 22::1188 PPMM\n\nMotor homunculus Sensory homunculus\nAnterior\ncerebral pi H artery Leg Middle cerebral artery Posterior cerebral\nartery\nCIRCLE OF WILLIS AND ARTERIAL SUPPLY/VENOUS DRAINAGE OF BRAIN\nThere are three major blood vessels arising from the circle of Willis to supply\nthe brain, and the respective cortical territories supplied by them are shown in\nFigure 2.9-4.\nThe various branches of the circle of Willis and their divisions into the\nanterior and posterior circulations are shown in Figure 2.9-5.\nThe most common sites of aneurysm are in the anterior circulation. The\nthree most common sites (âˆ¼85% of all intracranial aneurysms) are the junc-\ntion of the anterior communicating artery with the anterior cerebral artery\n(35%), junction of the posterior communicating artery with the internal\ncarotid artery (30%), and bifurcation of the middle cerebral artery (22%).\npiH knurT\n354 HIGH-YIELD FACTS IN NEUROLO",
      "char_start": 1008000,
      "char_end": 1010000
    },
    {
      "chunk_id": 505,
      "text": "GY\nN T e I h n c M u d k m R i e d i x L b d n i l g t e H tle an W d rist F Elb i o n w g Sho e uld r er s k n urT A K n ne k T e l o e es F T G o o e o e n s t itals Neck He S a h d oul F de i r A n r E m g lb F e o o w r r e s ar m Wr L is i t R t M t i l n i T e I d n g h d d u l e e m x b\nBrow Eye\nEyelid Nose\nFace\nLips\nJaw\nUpper lip\nTongue\nLower lip\nTeeth, gums\nPharynx, upper esophagus Intra-abdominal Tongue\nPharynx\nFIGURE 2.9-2. Homunculus. (Modified with permission from USMLE-Rx.com.)\nAnterior cerebral artery (supplies anteromedial surface)\nMiddle cerebral artery (supplies lateral surface)\nLacunar vessels (supply subcortical structures)\nPosterior cerebral artery (supplies posterior and inferior surfaces)\nFalx cerebri\nAnterior\nLateral\nventricles Anterior\nSupratentorial\nmass\nUncus\nTentorium\ncerebelli\nKernohan\nDuret notch Posterior\nhemorrhage Posterior\nFIGURE 2.9-3. Herniation syndromes. FIGURE 2.9-4. Cortical blood supply by various arteries. (Reproduced with permission from USMLE-Rx.\n(Reproduced with permission from USMLE-Rx.com.) com.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335544 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 355\nAnterior\nACom\ncommunicating Optic chiasm\nA2\nAnterior\nACA\ncerebral A1 Internal carotid ICA\nACA\nAnterior\ncirculation MCA Middle Lenticulo- MCA\ncerebral\nACA striate PCA\nICA\nM1\nOF\nMCA Posterior\nPCom Anterior\nPosterior communicating choroidal BA\ncirculation P2 P1\nPCom\nPosterior\nPCA\ncerebral ICA\nECA\nCCA VA\nSuperior\nSCA Pontine\ncerebellar Brachio-\ncephalic\nSub-\nclavian\nAnterior inferior\nAICA cerebellar Basilar BA\nAorta\nPosterior inferior Vertebral VA\nPICA\ncerebellar OBLIQUE-LATERAL VIEW\nINFERIOR VIEW\nAnterior spinal ASA\nFIGURE 2.9-5. Circle of Willis. (Reproduced with permission from USMLE-Rx.com.)\nMENINGES\nBridging veins Arachnoid\nDura mater mater\nThe brain and the spinal cord are protected by layers of membranous cover- Subarachnoid\ning (meninges) that protect them from mechanica",
      "char_start": 1010000,
      "char_end": 1012000
    },
    {
      "chunk_id": 506,
      "text": "l damage and help provide space\nPia mater\na structural framework for the vasculature. There are three layers of meninges:\nBrain\nthe outermost dura mater, the innermost pia mater, and the one in between\ncalled the arachnoid mater, as shown in Figure 2.9-6.\nâ–  Dura mater: Two-layered thick connective tissue sheath that houses the\ndural venous sinuses, which empty into the internal jugular veins. Blood FIGURE 2.9-6. Different layers of\nsupply comes from the middle meningeal artery and vein. Nerve supply is meninges. (Modified with permission from\nfrom CN V (anterior and middle cranial fossa), CN X (posterior fossa), USMLE-Rx.com.)\nsympathetics, and C1â€“C3 cervical nerves.\nâ–  Arachnoid mater: Avascular middle layer that gives rise to small projec-\ntions called arachnoid granulations, which allow cerebrospinal fluid\n(CSF) to re-enter the circulation. CSF is present underneath this layer of\nthe meninges in a space called the subarachnoid space.\nâ–  Pia mater: Innermost layer of the meninges that is very thin and tightly\nadhered to the surface of the brain and spinal cord.\nThe pia mater and the arachnoid mater are commonly referred to collec-\ntively as the leptomeninges. Meningitis refers to inflammation of these layers.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335555 1100//2211//2222 22::1188 PPMM\n\n356 HIGH-YIELD FACTS IN NEUROLOGY\nLUMBAR PUNCTURE\nLumbar punctures are one of the most commonly used examinations to diagnose\na central nervous system (CNS) problem. They are commonly performed distal\nQ\nR to the inferior tip of the spinal cord, below the level of the lumbar (L)1â€“L2 verte-\nbrae in adults (L3â€“4 and L4â€“5 are common locations) and below the L4 vertebra\nS in children. Lumbar puncture entails piercing the subarachnoid space (which\nT extends to the lower border of the sacral [S2] vertebra and contains the CSF).\nU\nThe layers pierced by the needle to enter this space are shown in Figure 2.9-7.\nV\nW\nX\nPERIPHERAL AND CRANIAL NERVES\nY\nSo",
      "char_start": 1012000,
      "char_end": 1014000
    },
    {
      "chunk_id": 507,
      "text": "me commonly tested CN lesions appear in Table 2.9-1.\nTABLE 2.9-1. Cranial Nerve Lesions\nCRANIAL\nNERVE FEATURES\nCN III CN III nerve comprises both motor (centrally located) and parasympathetic\n(peripherally located) components. Common causes include:\nâ–  Ischemia â†’ pupil sparing (motor fibers affected more than parasympathetic fibers)\nâ–  Uncal herniation â†’ coma\nâ–  Posterior communicating (PCom) artery aneurysm â†’ sudden-onset headache\nNeedle passes through:\nâ–  Cavernous sinus thrombosis â†’ proptosis, involvement of CNs IV, V1/V2, VI\nSkin\nâ–  Midbrain stroke â†’ contralateral hemiplegia\nFascia and fat\nMotor output to extraocular muscles and levator palpebrae superiorisâ€”affected\nSupraspinous ligament\nInterspinous ligament primarily by vascular disease (eg, diabetes mellitus) due to â†“ diffusion of oxygen\nLigamentum flavum and nutrients to the interior fibers from compromised vasculature on the\nEpidural space (epidural anes- outside of the nerve. Signs: ptosis, â€œdown-and-outâ€ gaze.\nthesia needle stops here) For parasympathetic outputâ€”fibers on the periphery first affected by compres-\nDura mater\nsion (eg, posterior communicating artery aneurysm, uncal herniation). Signs:\nArachnoid mater\ndiminished or absent pupillary light reflex, â€œblown pupil,â€ often with â€œdown-and-\nSubarachnoid space (CSF col-\noutâ€ gaze.\nlection occurs here)\nFIGURE 2.9-7. Structures pierced during CN IV Pupil higher in the affected eye. Characteristic head tilt to contralateral/unaffected\nlumbar puncture. (Modified with permission side to compensate for lack of intorsion in affected eye.\nfrom USMLE-Rx.com.)\nPatient has diplopia, most severe when attempting to look down and in (eg, going\ndownstairs, reading).\nCN V Deviation of jaw toward the side of the lesion due to unopposed actions of oppo-\nsite pterygoid muscle.\nCN VI Affected eye unable to abduct and is displaced medially in primary position of gaze.\nCN X Deviation of uvula away from side, dysarthria due to unilateral paralysis of vocal\ncord.\nCN XI Weakness tu",
      "char_start": 1014000,
      "char_end": 1016000
    },
    {
      "chunk_id": 508,
      "text": "rning head away from side of lesion (sternocleidomastoid) with\ndrooped shoulder (trapezius).\nCN XII Deviation of tongue toward side of the lesion due to strong action of contralateral\ngenioglossus overpowering the weak muscles on the affected side.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335566 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 357\nFacial Nerve Palsy\nFacial weakness is broadly categorized into either upper or lower motor neu-\nron weakness. UMN facial weakness is most often due to a stroke in the con-\ntralateral hemisphere while LMN facial weakness is most often due to a lesion\nof the facial nerve itself (Table 2.9-2).\nUMN vs LMN\nWhen differentiating upper versus lower motor neuron symptoms, remember\nthat with an upper motor neuron (UMN) type lesion, everything goes â€œup.â€\nHowever, with a lower motor neuron (LMN) type lesion, everything goes\nâ€œdown.â€ See Table 2.9-3 for differentiating features.\nTABLE 2.9-2. Facial Nerve Lesions TABLE 2.9-3. UMN vs LMN Lesions\nTYPE DESCRIPTION UMN LMN\nSIGNS LESION LESION\nUpper motor neuron Lesion of the motor cortex: contralateral paralysis of the lower\n(UMN) lesion face only. Atrophy of âˆ’ +\nmuscle groups\nLower motor neuron (LMN) Peripheral ipsilateral facial paralysis with inability to close the\nlesion eye on the involved side. Bell palsy is usually due to herpes Fasciculations âˆ’ +\nsimplex reactivation. Gradual recovery occurs in most cases;\nReflexes â†‘ â†“\nhowever, prednisone speeds recovery.\nTone â†‘ â†“\nOther causes Can be congenital but may also appear in adults. Facial nerve\npalsy may develop slowly when due to facial nerve schwan-\nBabinski sign + âˆ’\nnoma. It also is seen as a complication in AIDS, Lyme disease,\nSarcoidosis, parotid Surgery, Tumors, and Diabetes. Spastic weakness + âˆ’\nRamsay Hunt syndrome â€“ facial palsy with rash in the ipsilateral\nFlaccid weakness âˆ’ +\near or mouth caused by varicella zoster virus. Treat this with\nacyclovir or famciclovir.\nFace area Fa",
      "char_start": 1016000,
      "char_end": 1018000
    },
    {
      "chunk_id": 509,
      "text": "ce area Face area Face area\nof motor of motor of motor of motor\ncortex cortex cortex cortex\nCorticobulbar tract\n(UMN lesionâ€“central) Upper Upper\ndivision Facial division Facial\nLower nucleus Lower nucleus\ndivision division\nCN VII\n(LMN lesionâ€“peripheral)\nFacial nerve palsy: upper motor neuron lesion (left) and lower motor\nneuron lesion (right).\nAdapted with permission from Le T et al. First Aid for the USMLE Step 1 2022. New York, NY: McGraw-\nHill Education; 2022. Images reproduced with permission from USMLE-Rx.com.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335577 1100//2211//2222 22::1188 PPMM\n\n358 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-4. Commonly Tested Reflexes\nThe most important reflexes count up in Reflex grading:\norder. The main nerve roots are given in 0 = absent\nC5, 6 bold: 1+ = hypoactive\nC6, 7, 8\nâ–  Achilles reflex: S1, S2 2+ = normal\nâ–  Patellar reflex: L2â€“L4 3+ = hyperactive\nL2, 3, 4\nâ–  Biceps and brachioradialis reflexes: C5, C6 4+ = clonus\nS1, 2 â–  Triceps reflex: C6, C7, C8\nImportant reflexes Additionally, the following reflexes can be\nassessed:\nâ–  Cremasteric reflex: L1, L2\nâ–  Anal wink reflex: S3, S4\nImage reproduced with permission from USMLE-Rx.com.\nREFLEXES\nTo identify lesions in various spinal segments, reflexes are tested clinically.\nReflexes can act as a guide to assess the level of spinal cord injury. Some\nimportant reflexes are given in Table 2.9-4.\nSPINAL CORD\nTables 2.9-5 and 2.9-6 highlight critical aspects of clinical neuroanatomy,\nincluding the clinical presentation of common spinal cord lesions. The align-\nment of these tracts in a spinal cord, when examined on a cross-section, is\nshown in Figure 2.9-8.\nTABLE 2.9-5. Spinal Tract Functions\nTRACT FUNCTION CLINICAL EFFECTS OF LESION\nLateral corticospinal Movement of ipsilateral limbs Ipsilateral paresis below level\nand body of lesion\nDorsal column Fine touch, two-point discrimi- Ipsilateral loss of fine touch,\nnation, vibration, conscious vibration, and",
      "char_start": 1018000,
      "char_end": 1020000
    },
    {
      "chunk_id": 510,
      "text": " propriocep-\nproprioception tion below level of lesion\nSpinothalamic Pain, temperature Contralateral loss of pain and\ntemperature below level of\nlesion\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335588 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 359\nTABLE 2.9-6. Spinal Cord Lesions\nAREA AFFECTED DISEASE CHARACTERISTICS\nPoliomyelitis and LMN lesions only, caused by destruction of anterior horns; presents with flaccid paralysis.\nspinal mus- Poliomyelitis is caused by enterovirus (picornavirus, RNA), transmitted via fecal-oral route. Similar\ncular atrophy lesions and symptoms may occur with West Nile virus infection. Lumbar puncture (LP) shows\npleocytosis (neutrophils first and then lymphocytes) with slightly elevated protein and normal\nglucose. Treatment calls for supportive therapy and rehabilitation.\nSpinal muscular atrophy (SMA) is due to mutation in SMN1 and SMN2 genes. It presents with weak-\nness and muscle wasting in limbs, respiratory, or brainstem muscles. Diagnosis relies on genetic\ntesting (prenatal and postnatal); normal CSF findings and normal creatine kinase (CK) levels.\nSupportive therapy is the mainstay of treatment.\nMultiple sclerosis Can be caused by infections (Epstein-Barr virus [EBV]), immune disorders, environmental factors\n(eg, vitamin D deficiency), and genetic factors. Leads to focal inflammation and macroscopic\nplaques with injury to the blood-brain barrier (BBB) and subsequent neurodegeneration.\nFeatures: Demyelination involves patchy areas of the subcortical white matter, brainstem, and\nspinal cord, mostly cervical region. Optic nerve demyelination leads to monocular vision loss.\nDiagnosis: Clinical + MRI + to rule out other causes. Lesions are disseminated in space and time.\nTreatment: Glatiramer acetate, fingolimod, interferon-beta preparations, and dimethyl fumarate\nmodify disease course. Treat underlying cause for relapse and symptoms of neurologic issues-\ncourse of IV steroids (m",
      "char_start": 1020000,
      "char_end": 1022000
    },
    {
      "chunk_id": 511,
      "text": "ethylprednisolone) can hasten recovery from flare or relapse.\nTransverse Can be an acquired, focal, inflammatory disorder that usually is a part of multiple sclerosis. However,\nmyelitis it can occur with infections by enterovirus, HIV, Mycoplasma, Treponema pallidum, and others.\nPresentation: Most commonly in thoracic levels, leads to paraplegia with loss of bladder/bowel\nfunction. It can have both UMN and LMN signs.\nPathology: Perivascular infiltration, demyelination, and axonal injury.\nDiagnosis: Exclude cord compression first with MRI and then do LP.\nTreatment: High-dose intravenous (IV) glucocorticoids, pain management.\nBrown-SÃ©quard Caused most commonly by trauma to the spinal cord.\nRight Left hemisection Leads to contralateral loss of pain and temperature sensation one to two levels below the lesion\nand ipsilateral hemiparesis and diminished dorsal column sensation (vibration and propriocep-\ntion) below the level of the lesion.\nLesion\nAmyotrophic Commonly known as Lou Gehrig disease in the United States and motor neuron disease in the\nlateral scle- United Kingdom.\nrosis (ALS) Combined UMN and LMN deficits with no sensory or oculomotor deficits; both UMN and LMN signs.\nCommonly presents as asymmetric painless weakness, fasciculations, and eventual atrophy and\nweakness of arms and legs; fatal. Riluzole treatment has modest benefit by â†“ presynaptic gluta-\nmate release. For Lou Gehrig disease, give riluzole.\n(continues)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 335599 1100//2211//2222 22::1188 PPMM\n\n360 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-6. Spinal Cord Lesions (continued)\nAREA AFFECTED DISEASE CHARACTERISTICS\nPosterior spinal arteries Complete Also called anterior cord syndrome. Spares dorsal columns. Acute onset of sensory-motor dissociation.\nocclusion of Location of infarct often at T1â€“L2 levels, leading to lateral horn injury and associated autonomic\nanterior spinal dysfunctions such as neurogenic bowel/bladder, ort",
      "char_start": 1022000,
      "char_end": 1024000
    },
    {
      "chunk_id": 512,
      "text": "hostatic hypotension, or sexual dysfunction.\nartery Associated with abdominal aortic surgery with injury to artery of Adamkiewicz.\nDiagnosis: MRI.\nTreatment: Correct aortic dissection or treat vasculitis.\nAnterior spinal artery\nSyringomyelia Syrinx (CSF-filled cavity within spinal cord) expands and damages anterior white commissure of\nspinothalamic tract. Can arise from trauma or tumors; seen in 35% of Chiari malformations.\nResults in a capelike, bilateral loss of pain and temperature in upper extremities (likely to have\npainless burn injuries).\nCentral cord Weakness more pronounced in upper extremities than lower extremities, as the arm/trunk fibers\nsyndrome are located more medially within the corticospinal tract and are preferentially affected. Affected\nsensory losses are due to effect on the decussating spinothalamic tract fibers (bilateral loss of\npain and temperature at level of lesion).\nCaused by hyperextension injuries in individuals >50 years of age or secondary to spinal cord\ntumors (eg, astrocytomas, ependymomas).\nTabes dorsalis Caused by tertiary syphilis. Results from degeneration (demyelination) of dorsal columns and roots\n(especially at lumbosacral levels) â†’ impaired sensation and proprioception, sharp fleeting pain\nin the legs, progressive sensory ataxia (inability to sense or feel the legs) â†’ poor coordination.\nAssociated with Charcot joints (repeated unknowing trauma to joint caused by lack of pain),\nshooting pain, Argyll Robertson pupils.\nExamination will demonstrate absence of deep tendon reflex and âŠ• Romberg sign.\nVitamin B Subacute combined degenerationâ€”demyelination of dorsal columns, lateral corticospinal tracts,\n12\ndeficiency and spinocerebellar tracts; ataxic gait, paresthesia, impaired position and vibration sense.\nCauda equina Neurosurgical emergency. Compression of spinal roots L2 and below, most likely caused by disc\nsyndrome herniation, epidural abscess, trauma, or metastatic cancer.\nClinical: Saddle anesthesia, loss of bladder and ana",
      "char_start": 1024000,
      "char_end": 1026000
    },
    {
      "chunk_id": 513,
      "text": "l sphincter control, and absent knee and ankle\nCompressed jerk reflexes.\ncauda\nDiagnosis: MRI and surgical evaluation (in that order).\nequina\nT12 Conus medullaris Similar to cauda equina with robust parasympathetic dysfunction, but with symmetric weakness.\nL1 UMN signs will be present (eg, Babinski reflex).\nL2\nConus Treatment: Same as cauda equina.\nmedullaris L3\nCauda\nequina L4\nL5\nS1\nS2\nS3\nS4\nS5\nTable modified with permission from Le T et al. First Aid for the USMLE Step 1 2022. New York, NY: McGraw-Hill Education; 2022. Illustrations reproduced\nwith permission from USMLE-Rx.com. MRI adapted with permission from Dooley MC, Foroozan R. Optic neuritis. J Ophthalmic Vis Res. 2010;5(3):182-187.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336600 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 361\nASCENDING\nDorsal column\n(pressure, vibration, fine touch, [conscious]\nCentral canal\nproprioception)\nâ€¢ Fasciculus graciLis (Lower body, legs)\nPosterior horn\nâ€¢ Fasciculus cUneatus (Upper body, arms)\nDESCENDING S a cr\nal\nL u m b\nar\nh or a ci\nc\nervical Gray matter\nT C\nLateral corticospinal tract\nIntermediate horn (sympathetic)\n(voluntary motor)\n(T1â€“L2/L3)\nâ€¢ Sacral\nâ€¢ Cervical\nASCENDING\nAnterior corticospinal tract\nLateral spinothalamic tract (pain, temperature)\n(voluntary motor)\nâ€¢ Sacral\nWhite matter â€¢ Cervical\nAnterior spinothalamic tract (crude touch, pressure)\nAnterior horn\nFIGURE 2.9-8. Cross-section of spinal cord (thoracic) showing arrangement of various tracts. (Reproduced with permission from USMLE-Rx.com.)\nHEADACHES\nHeadaches can either be primary/idiopathic (eg, migraine, cluster, tension\ntype) or secondary (resulting from underlying disease, such as tumor or intra-\ncranial hemorrhage). The differences in these types of headaches are dis-\ncussed in Table 2.9-7.\nMIGRAINE HEADACHE\nRecurrent headache disorder with attacks that last 4 to 72 hours. Headache\ntypically unilateral, pulsating, and moderate or severe in intensity a",
      "char_start": 1026000,
      "char_end": 1028000
    },
    {
      "chunk_id": 514,
      "text": "nd aggra-\nvated by routine physical activity. Usually preceded by auras (auditory or\nvisual most common). Affects women more than men; often familial; onset\nusually by teens to early 20s, but peak age is 30 to 39 years. Linked to changes\nin vascular tone and neurotransmitters (especially calcitonin gene-related pep-\ntide [CGRP]). Triggers: Certain foods (eg, red wine, cheese), fasting, stress,\nmenses, oral contraceptive pills (OCPs), bright light, and disruptions in nor-\nmal sleep patterns, among others. Increased stroke risk in women with classic\nmigraine headaches who take OCPs and smoke.\nTABLE 2.9-7. Common Types of Headache\nMIGRAINE HEADACHE CLUSTER HEADACHE TENSION-TYPE HEADACHE\nPattern Typically unilateral, usually Severe pain behind the eye, usually Bandlike tightening or pressing, typically\nthrobbing unilateral, and usually in smokers bilateral\nOnset Preceded by aura in classical type Without preceding aura and 15- to Without aura, usually at the end of the day;\n180-minute headaches that cluster patient can function during headache\nTreatment Abortive therapy (best initial treat- Best initial treatment: 100% oxygen Best initial treatment: NSAIDs,\nment): Triptans, nonsteroidal for 15 minutes acetaminophen\nanti-inflammatory drugs (NSAIDs) Next step: Prevention with verapamil Relaxation therapy, ice packs potentially\nNext step: Prevention with propran- helpful\nolol, topiramate, or nortriptyline\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336611 1100//2211//2222 22::1188 PPMM\n\n362 HIGH-YIELD FACTS IN NEUROLOGY\nDiagnosis\nâ–  Based on history and recognition of pattern of headache (usually preceded\nby an aura and a trigger). Physician should query about past events that\nmay have started the headache at first.\nâ–  Recognition of associated features such as nausea, dizziness, light sensitiv-\nity, smell changes, and disturbed bowel movements. Headaches typically\nlast 4 to 72 hours (untreated or successfully treated), with two of four",
      "char_start": 1028000,
      "char_end": 1030000
    },
    {
      "chunk_id": 515,
      "text": " char-\nacteristics (unilateral, pulsating, moderate/severe pain intensity, aggravated\nby routine physical activity) and association with nausea/vomiting or pho-\ntophobia/phonophobia.\nâ–  At least five attacks needed for migraine diagnosis.\nTreatment\nâ–  Avoidance of known triggers\nâ–  Abortive therapy, including triptans (after over-the-counter [OTC] nonste-\nroidal anti-inflammatory drugs [NSAIDs] have failed), alone or in addition\nto other analgesics such as naproxen. The physician should consider symp-\ntomatic treatment for nausea. IV metoclopramide can be used for abortive\ntherapy in the ED. Other treatments include ergots or CGRP antagonists\n(rimegepant, ubrogepant).\nâ–  Prophylaxis for frequent or severe migraines, including anticonvulsants\n(eg, valproate, topiramate), tricyclic antidepressants ([TCAs], eg, amitripty-\nline), and Î²-blockers (propranolol; first-line prevention in pregnant\npatients). Erenumab blocks CGRP action and has a prophylactic role.\nChronic cases may benefit from injection of botulinum toxin.\nâ–  Routine aerobic exercise and good sleep hygiene.\nCLUSTER HEADACHE\nMen are affected more often than women; average age of onset is 25 years.\nPatients who smoke have a higher risk of this type of headache.\nHistory/PE\nâ–  Presents as a brief, excruciating, unilateral, periorbital headache that lasts\nKEY FACT\nfrom 30 minutes to 3 hours, during which time the patient tends to be\nextremely restless. Patients do not have auras (vs migraine headache).\nIf a 25-year-old man wakes up\nrepeatedly during the night with â–  Tends to occur in clusters of time, affecting the same part of the head at\nthe same time of day (commonly during sleep) during a certain season of\nunilateral periorbital pain associated\nthe year.\nwith ipsilateral lacrimation, think cluster\nheadache. â–  Associated autonomic symptoms include ipsilateral lacrimation, conjunc-\ntival injection, Horner syndrome, and nasal stuffiness.\nDiagnosis\nClassic presentations with a history of repeated attacks over an extend",
      "char_start": 1030000,
      "char_end": 1032000
    },
    {
      "chunk_id": 516,
      "text": "ed\nperiod do not need imaging. First episodes require a workup (eg, MRI,\ncarotid artery ultrasound) to exclude structural brain lesion or disorders associ-\nated with Horner syndrome (eg, carotid artery dissection, cavernous sinus\ninfection).\nTreatment\nâ–  Acute therapy: High-flow O or sumatriptan injection\n2\nâ–  Prophylactic therapy: Verapamilâ€”first-line treatment, typically pre-\nscribed with prednisone (10-day course); alternatives include lithium, val-\nproic acid, and topiramate\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336622 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 363\nTENSION-TYPE HEADACHE KEY FACT\nIf a 30-year-old woman complains of\nâ–  Hx: Presents with tight, bandlike pain around the head that is triggered by\nheadaches at the end of the day that\nfatigue or stress. Nonspecific symptoms (eg, anxiety, poor concentration,\nworsen with stress and improve with\ndifficulty sleeping) may also be seen.\nrelaxation or massage, think tension-\nâ–  Dx: Must have at least two of the following characteristics: bilateral loca-\ntype headache.\ntion, pressing/tightening quality, mild to moderate intensity, and not aggra-\nvated by routine physical activity. The physician should rule out giant cell\narteritis in patients >65 years of age with new headaches (usually accom-\npanied by jaw claudication) by obtaining an erythrocyte sedimentation\nrate (ESR), even if headaches are mild with no associated constitutional or\nvascular symptoms.\nâ–  Tx: Relaxation, massage, hot baths, and avoidance of exacerbating factors.\nNSAIDs and acetaminophen are first-line abortive therapy.\nSECONDARY HEADACHES\nThe physician should consider secondary headaches when â€œred flagsâ€ (eg,\nsudden onset, great severity, nocturnal presentation, age >65 years of age,\nwith focal neurologic symptoms, postâ€“head trauma) are present.\nHistory/PE\nâ–  Significant findings include fever or rash (consider meningitis or other\ninfectious causes), jaw claudication (specific for te",
      "char_start": 1032000,
      "char_end": 1034000
    },
    {
      "chunk_id": 517,
      "text": "mporal arteritis), or con-\nstitutional symptoms such as weight loss (associated with neoplastic,\nKEY FACT\ninflammatory, or infectious conditions).\nâ–  Photophobia, nausea, vomiting, and neck stiffness can be associated with Headache red flagsâ€”First, worst,\naneurysmal subarachnoid hemorrhage (SAH) and meningitis caused by\nsudden onset of most severe headache\nmeningeal irritation.\never; neurologic sequelae; nocturnal\nâ–  Full general and neurologic examinations, including a funduscopic exam- headache; morning vomiting; onset\nination, should occur.\nof headache >65 or <10 years of age;\nâ–  Neurologic sequelae: The physician should look for diplopia, altered focal neurologic signs or symptoms;\nmental status or associated symptoms (numbness, weakness, dizziness,\npapilledema; headache subsequent to\nataxia, visual disturbances), papilledema, or pupillary abnormalities (par-\nhead trauma.\ntial CN III palsy or Horner syndrome).\nDiagnosis\nBased on the etiology.\nâ–  If SAH is suspected: Procure a head CT without contrast. If CT is nega-\ntive, perform a lumbar puncture to look for xanthochromia, which, if posi-\ntive, supports the diagnosis of SAH.\nâ–  In the emergency room, when SAH is suspected:\nâ–  Check ABCs and Glasgow Coma Scale (GCS). Consider early intuba-\ntion if required.\nâ–  Treat seizures with benzodiazepines and start fluid infusion to main-\ntain intravascular volume.\nâ–  Obtain a complete blood cell count (CBC) to check for systemic A 28-year-old woman with no\ninfections. prior medical history presents with\nâ–  If temporal arteritis is suspected, obtain an ESR. throbbing, unilateral headache that\nis exacerbated by menstruation and\nCT of the head is indicated for â€œred flagâ€ symptoms. minimally relieved by acetaminophen\nand lying in a dark room. She would\nlike something that would provide\nmore symptomatic relief. What\nabortive therapy should the physician\nprescribe?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336633 1100//2211//2222 22::1188 PPMM\n\n",
      "char_start": 1034000,
      "char_end": 1036000
    },
    {
      "chunk_id": 518,
      "text": "364 HIGH-YIELD FACTS IN NEUROLOGY\nTreatment\nâ–  Directed toward underlying cause of headaches. Some conditions such as\nSAH may require emergency surgery, whereas cases of temporal arteritis\nmay require steroid use.\nâ–  Analgesics administered for pain relief as search for underlying disorders\nbegins.\nTRIGEMINAL NEURALGIA\nRecurrent, severe, and shocklike shooting or stabbing pain along distributions\nof the trigeminal nerve (CN V), often triggered by cold, minor trauma, or\neven chewing food or brushing teeth. The pain is often unilateral. It lasts a\nmaximum of 2 minutes.\nâ–  Pathophysiology: Compression of trigeminal nerve root most common\ncause. Demyelination occurs in multiple sclerosis.\nâ–  Dx: Clinical, with precipitation by innocuous stimulus and not accounted\nfor by another diagnosis. If bilateral, the physician should suspect multiple\nsclerosis.\nâ–  Ddx: Herpes zosterâ€“induced trigeminal neuropathy, postherpetic\nneuropathy.\nâ–  Tx: First line with carbamazepine or oxcarbazepine. Surgery (microvascu-\nlar decompression and rhizotomy, among various options) is required for\nrefractory cases only.\nVASCULAR DISORDERS\nTRANSIENT ISCHEMIC ATTACK\nA transient ischemic attack (TIA) is a transient episode of neurologic dysfunc-\ntion caused by focal brain, spinal cord, or retinal ischemia, without acute\ninfarction. Most TIAs last 5 to 10 minutes, but can rarely last up to 24 hours.\nThe highest risk for stroke is on the day following the TIA, a risk estimated\nwith the ABCD2 score.\nPathophysiology\nEmbolism, lacunar, or small-vessel obstruction; low flow in a large vessel.\nDiagnosis\nBased on clinical features of transient attack (transient monocular blindness,\naphasia/dysarthria, hemianopia, hemiparesis, or sensory loss).\nTreatment\nâ–  If symptoms are ongoing and potentially disabling: Emergency evaluation\nfor intravenous (IV) thrombolysis + thrombectomy\nâ–  If symptoms resolve or are ongoing but nondisabling: Evaluation with\nMRI or neurovascular imaging to rule out stroke\nâ–  Once cause is ident",
      "char_start": 1036000,
      "char_end": 1038000
    },
    {
      "chunk_id": 519,
      "text": "ified, a plan is implemented to reduce the risk of\nfuture stroke by use of medications (antiplatelet therapy), modification of\nstroke risk factors (eg, hypertension, diabetes), or carotid endarterectomy\nThis patientâ€™s symptoms are\nconsistent with migraine headaches.\nThe physician should prescribe a\ntriptan for abortive therapy.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336644 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 365\nSTROKE TABLE 2.9-8. Modifiable and\nNonmodifiable Risk Factors for Stroke\nDisruption of cerebral blood flow leads to death of brain cells, resulting in MODIFIABLE RISK NONMODIFIABLE\nacute onset of focal neurologic deficits. A stroke can be ischemic (80%) or FACTORS RISK FACTORS\nhemorrhagic (20%). Table 2.9-8 contrasts modifiable and nonmodifiable risk\nâ€œLive the way FAME:\nfactors associated with stroke. Common etiologies are listed later.\na COACH Family history\nâ–  Atherosclerosis of the extracranial (carotid and vertebral) and intracranial\nSHoulDDâ€: of myocardial\nvessels (internal carotid, cerebral, basilar, and vertebral arteries)\nCAD infarction (MI)\nâ–  Chronic hypertension, hypercholesterolemia, and diabetesâ€”conditions\nObesity or stroke\nthat can damage perforating vessels supplying deep regions of the brain,\nleading to lacunar infarcts Atrial fibrillation Age >60\nâ–  Cardiac or aortic emboli Carotid stenosis Male sex\nâ–  Other causes: Hypercoagulable states, craniocervical dissection, venous Hypercholesterol- Ethnicity (Black,\nsinus thrombosis, sickle cell anemia, vasculitis (eg, giant cell arteritis) emia Hispanic, Asian)\nSmoking\nHistory/PE Hypertension\nSymptoms are dependent on the vascular territory affected (see Table 2.9-9). (highest risk\nfactor)\nDiagnosis Diabetes\nâ–  Best initial step: Head CT without contrast (see Fig. 2.9-9A) to differenti- Drug use\nate ischemic from hemorrhagic stroke and identify potential candidates for (cocaine, IV\nthrombolytic therapy. Ischemic strokes <6 hours old a",
      "char_start": 1038000,
      "char_end": 1040000
    },
    {
      "chunk_id": 520,
      "text": "re usually not visi- drugs)\nble on CT scan.\nTABLE 2.9-9. Common Stroke Symptoms by Vessel Territory\nVESSEL TERRITORY DISTINGUISHING SYMPTOMS\nMiddle cerebral artery Contralateral paresis and sensory loss in the face and arm; gaze (eyes deviated towards the lesion); contra-\nlateral homonymous hemianopsia\nNondominant hemisphereâ€”neglect\nDominant hemisphere (90% left side)â€”aphasia\nAnterior cerebral artery Contralateral paresis and sensory loss in the leg; cognitive or personality changes; urinary incontinence\nPosterior cerebral artery Contralateral homonymous hemianopia with macular sparing. Alexia without agraphia is seen in left PCA\nstrokes\nWeber syndrome: Occlusion of branch of posterior cerebral artery leading to ipsilateral CN III palsy, contra-\nlateral hemiparesis, and parkinsonian rigidity (may not be present if substantia nigra is spared)\nLacunar Symptoms are pure motor, pure sensory, ataxic hemiparesis, dysarthria, or clumsy hand\nUnderlying pathology includes formation of microatheromas and lipohyalinosis, commonly secondary to\nhypertension, diabetes, hyperlipidemia, or smoking\nStrokes affecting the thalamus may cause thalamic pain syndrome several weeks after the event, with\nhypersensitive pain response over the contralateral affected area of the body\nPosterior inferior cerebral artery Loss of pain and temperature sensation on ipsilateral face and contralateral body\n(PICA) stroke/vertebral (Wal- Ipsilateral bulbar weakness/dysarthria\nlenberg syndrome) Ipsilateral Horner syndrome (ptosis, miosis, and seldom with facial anhidrosis)\nVertigo, nystagmus, hiccups\nCarotid artery dissection Sudden headache, neck pain, Horner syndrome\nCaused by oropharyngeal injury (most common)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336655 1100//2211//2222 22::1188 PPMM\n\n366 HIGH-YIELD FACTS IN NEUROLOGY\nA B C â–  Assessment of blood glucose levels and treatment to keep levels between\n140 and 180 mg/dL.\nâ–  IV alteplase indicated in patients with",
      "char_start": 1040000,
      "char_end": 1042000
    },
    {
      "chunk_id": 521,
      "text": "out contraindications; consideration\nof mechanical thrombectomy. Give alteplase even if thrombectomy is\nbeing considered (especially for anterior large vessel occlusions within\n24 hours of presentation).\nâ–  Thrombolytics (tissue plasminogen activators [tPAs]) if <3 to 4.5 hours\nsince onset of stroke and no bleeding or absolute contraindications. Per-\nmissive hypertension is allowed in stroke for perfusion of ischemic area,\nbut patientâ€™s systolic blood pressure (SBP) must be <185 and diastolic\nblood pressure (DBP) <110 mm Hg for tPA.\nâ–  Acetylsalicylic acid (ASA) if >3 hours since onset of stroke/TIA.\nA B C â–  If BP is high but patient is eligible for alteplase, lowering of BP to\nFIGURE 2.9-9. Acute ischemic stroke. Acute left hemiparesis in a 62-year-old woman. <185/110 mm Hg slowly before therapy initiation. Use labetalol, nicardip-\n(A) Noncontrast head CT with loss of gray and white matter differentiation, cortical efface- ine, or clevidipine.\nment, and asymmetrically decreased size of the right lateral ventricle in a right middle cere-\nâ–  Treatment of high (>200 mm Hg SBP or >120 mm Hg DBP) or low BP\nbral artery (MCA) distribution (indicating mass effect). (B) Diffusion-weighted MRI with\nprior to initiating treatment for stroke. Raised BP can lead to further injury\nreduced diffusion in the same distribution, consistent with an acute infarct. Diffusion-weighted\nsequences are the most sensitive modality for diagnosing an acute ischemic infarct. (C) Mag- (cerebral edema, hemorrhagic transformation, or expansion of hema-\nnetic resonance angiography (MRA) shows the cause: an abrupt occlusion of the proximal right toma), whereas a low BP can lead to further infarction and perihematomal\nMCA (red arrow) Compare with the normal left MCA (yellow arrowhead). Note pronounced ischemia. Treatment goals include:\nmidline shift evident on both MRI and MRA. (Reproduced with permission from USMLE-Rx.com.)\nâ–  Before tPA: <185/110 mm Hg\nâ–  After and within 24 hours of tPA administration or",
      "char_start": 1042000,
      "char_end": 1044000
    },
    {
      "chunk_id": 522,
      "text": " during and after\n24 hours of endovascular treatment: <185/105 mm Hg\nâ–  Check blood glucose first. Labs to draw immediately, in case thrombolytic â–  Failed reperfusion: Maintenance of SBP >150 mm Hg\ntherapy or intervention may be required, include CBC, prothrombin time â–  Successful reperfusion or hemorrhagic conversion: SBP <140 mm Hg\n(PT)/partial thromboplastin time (PTT), cardiac enzymes and troponin, â–  If BP >220/120 mm Hg, lowering of BP by 15% in first 24 hours after\nand blood urea nitrogen (BUN)/creatinine. stroke\nâ–  Diffusion-weighted MRI (follow-up to CT) (see Fig. 2.9-9B) to identify â–  If BP >140/90 mm Hg and neurologically stable, commencement of anti-\nearly ischemic changes not detected on CT. hypertensive therapy during hospitalization\nâ–  Determine underlying cause of stroke: â–  Check of baseline ECG, troponin\nMNEMONIC\nâ–  Cardioembolic: ECG; echocardiogram; Holter monitor if initial ECG â–  Investigation for cause of hyperthermia (>38Â°C)\nContraindications to tPA therapy normal. â–  Monitor for signs and symptoms of brain swelling, â†‘ intracranial pressure\n(major ones italicized)â€” â–  Thrombotic: Carotid ultrasonography; MRA; CT angiography (CTA); (ICP), and herniation. Treat by elevating head-end of the bed to 30Â°, start-\nSAMPLE STaGES transcranial Doppler; conventional angiography (see Fig. 2.9-9C). ing hypertonic saline or mannitol, and hyperventilating the patient.\nâ–  Other potential causes that should be worked up if there is a high â–  Prevention and treatment of poststroke complications, such as aspiration\nStroke or head trauma within the last\nindex of suspicion: Hypercoagulable states; sickle cell disease; pneumonia, urinary tract infection (UTI), and deep vein thrombosis (DVT)\n3 months\nvasculitis.\n*Anticoagulation with INR >1.7 or\nprolonged PTT Preventive and Long-Term Treatment\nAcute Treatment\nMI in past 3 months â–  Hypertension management (DBP <80 mm Hg)\nPrior intracranial hemorrhage Hemorrhagic stroke: See intracerebral hemorrhage discussion. â–  Diabetes manage",
      "char_start": 1044000,
      "char_end": 1046000
    },
    {
      "chunk_id": 523,
      "text": "ment (blood sugar level approximately 100 mg/dL)\nLow platelet count (<100,000/mm3)\n*Elevated BP: Systolic >185 mm Hg or Ischemic stroke, prehospital: Assessment by first-aid providers and informa- â–  Blood lipids management with a statin\ndiastolic >110 mm Hg tion provided to health care providers in a timely manner prevent â–  ASA or clopidogrel\nMajor Surgery in the past 14 days complications. â–  Diet, exercise\nTIA (mild symptoms or rapid improvement â–  For cardioembolic strokes, anticoagulation. In new atrial fibrillation (AF)\nof symptoms) within 6 months Ischemic stroke, hospital (emergency department): or hypercoagulable states, the target international normalized ratio (INR)\nGI or urinary bleeding in the past 21 days or â–  Airway support for patients with low GCS (<8) or with bulbar is 2 to 3. In cases involving a prosthetic valve, the target INR is 2.5 to 3.5\nglucose <50 mg/dL dysfunction. â–  For vascular pathology (pipe failure), antiplatelet medication\n*Elevated (>400 mg/dL) or â†“ (<50 mg/dL) â–  Supplemental oxygen to keep SpO >94% only in hypoxic patients. â–  Carotid endarterectomy: If stenosis is >60% in symptomatic patients or\nblood glucose 2 >70% in asymptomatic patients (contraindicated in 100% occlusion; see\nâ–  Treatment of hypotension for adequate organ perfusion.\nSeizures present at onset of stroke Fig. 2.9-10). Benefits may also occur in lower absolute percent stenosis; the\nâ–  Use of National Institutes of Health Stroke Scale (NIHSS) for diagnosis\n*If values can be corrected using appropriate physician should use clinical judgment when answering these questions\nand assessment.\ntreatment before the 3- to 4.5-hour period,\nconsider tPA treatment. â–  Emergency brain imaging on hospital arrival: Noncontrast computed\ntomography (NCCT) head is investigation of choice.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336666 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 367\nâ–  Assessment of blood glucose levels and treatmen",
      "char_start": 1046000,
      "char_end": 1048000
    },
    {
      "chunk_id": 524,
      "text": "t to keep levels between\n140 and 180 mg/dL.\nâ–  IV alteplase indicated in patients without contraindications; consideration\nof mechanical thrombectomy. Give alteplase even if thrombectomy is\nbeing considered (especially for anterior large vessel occlusions within\n24 hours of presentation).\nâ–  Thrombolytics (tissue plasminogen activators [tPAs]) if <3 to 4.5 hours A\nsince onset of stroke and no bleeding or absolute contraindications. Per-\nmissive hypertension is allowed in stroke for perfusion of ischemic area,\nbut patientâ€™s systolic blood pressure (SBP) must be <185 and diastolic\nblood pressure (DBP) <110 mm Hg for tPA.\nâ–  Acetylsalicylic acid (ASA) if >3 hours since onset of stroke/TIA.\nâ–  If BP is high but patient is eligible for alteplase, lowering of BP to\n<185/110 mm Hg slowly before therapy initiation. Use labetalol, nicardip-\nine, or clevidipine.\nâ–  Treatment of high (>200 mm Hg SBP or >120 mm Hg DBP) or low BP\nprior to initiating treatment for stroke. Raised BP can lead to further injury\n(cerebral edema, hemorrhagic transformation, or expansion of hema-\ntoma), whereas a low BP can lead to further infarction and perihematomal\nischemia. Treatment goals include:\nâ–  Before tPA: <185/110 mm Hg\nâ–  After and within 24 hours of tPA administration or during and after\n24 hours of endovascular treatment: <185/105 mm Hg\nâ–  Failed reperfusion: Maintenance of SBP >150 mm Hg\nâ–  Successful reperfusion or hemorrhagic conversion: SBP <140 mm Hg A\nB\nâ–  If BP >220/120 mm Hg, lowering of BP by 15% in first 24 hours after\nstroke\nâ–  If BP >140/90 mm Hg and neurologically stable, commencement of anti-\nhypertensive therapy during hospitalization\nâ–  Check of baseline ECG, troponin\nMNEMONIC\nâ–  Investigation for cause of hyperthermia (>38Â°C)\nContraindications to tPA therapy â–  Monitor for signs and symptoms of brain swelling, â†‘ intracranial pressure\n(major ones italicized)â€” (ICP), and herniation. Treat by elevating head-end of the bed to 30Â°, start-\nSAMPLE STaGES ing hypertonic saline or mannitol, an",
      "char_start": 1048000,
      "char_end": 1050000
    },
    {
      "chunk_id": 525,
      "text": "d hyperventilating the patient.\nâ–  Prevention and treatment of poststroke complications, such as aspiration\nStroke or head trauma within the last\npneumonia, urinary tract infection (UTI), and deep vein thrombosis (DVT)\n3 months\n*Anticoagulation with INR >1.7 or\nprolonged PTT Preventive and Long-Term Treatment\nMI in past 3 months â–  Hypertension management (DBP <80 mm Hg)\nPrior intracranial hemorrhage\nâ–  Diabetes management (blood sugar level approximately 100 mg/dL)\nLow platelet count (<100,000/mm3)\nâ–  Blood lipids management with a statin\n*Elevated BP: Systolic >185 mm Hg or\nâ–  ASA or clopidogrel\ndiastolic >110 mm Hg\nMajor Surgery in the past 14 days â–  Diet, exercise F B IGURE 2.9-10. Vascular studies\nTIA (mild symptoms or rapid improvement â–  For cardioembolic strokes, anticoagulation. In new atrial fibrillation (AF) preendarterectomy and postend-\nof symptoms) within 6 months or hypercoagulable states, the target international normalized ratio (INR) arterectomy. (A) Carotid arteriogram\nGI or urinary bleeding in the past 21 days or is 2 to 3. In cases involving a prosthetic valve, the target INR is 2.5 to 3.5 showing stenosis of the proximal internal\nglucose <50 mg/dL â–  For vascular pathology (pipe failure), antiplatelet medication carotid artery. (B) Postoperative arterio-\n*Elevated (>400 mg/dL) or â†“ (<50 mg/dL) â–  Carotid endarterectomy: If stenosis is >60% in symptomatic patients or gram with restoration of the normal\nluminal size following endarterectomy.\nblood glucose >70% in asymptomatic patients (contraindicated in 100% occlusion; see\nSeizures present at onset of stroke Fig. 2.9-10). Benefits may also occur in lower absolute percent stenosis; the (Reproduced with permission from Way LW. Current\nSurgical Diagnosis & Treatment. 10th ed. Stamford, CT:\n*If values can be corrected using appropriate physician should use clinical judgment when answering these questions Appleton & Lange; 1994.)\ntreatment before the 3- to 4.5-hour period,\nconsider tPA treatment.\n22002222__0",
      "char_start": 1050000,
      "char_end": 1052000
    },
    {
      "chunk_id": 526,
      "text": "022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336677 1100//2211//2222 22::1188 PPMM\n\n368 HIGH-YIELD FACTS IN NEUROLOGY\nSUBARACHNOID HEMORRHAGE\nEtiologies of SAH include ruptured saccular aneurysms (berry aneurysms),\narteriovenous malformation (AVM), and trauma.\nHistory/PE\nâ–  Aneurysmal SAH presents with an abrupt-onset, intensely painful â€œthun-\nderclapâ€ headache, often followed by neck stiffness (caused by meningeal\nirritation). Other signs of meningeal irritation, including photophobia,\nKEY FACT nausea/vomiting, and meningeal stretch signs (Kernig and Brudzinski\nsigns), can also be seen.\nSAH = â€œthe worst headache of my lifeâ€ â–  More than one third of patients will give a history of a â€œsentinel bleedâ€\nwith sudden onset. (â€œwarning leakâ€) days to weeks before presentation.\nMigraine = a gradually worsening â–  In the absence of neurosurgical intervention, rapid development of\nheadache (peak intensity >30 minutes) obstructive hydrocephalus or seizures often leads to â†“ arousal or frank\ncoma and death.\nKEY FACT Diagnosis\nXanthochromia (blood on an LP) is seen â–  Immediate head CT without contrast subarachnoid space (greatest sensi-\nin two situationsâ€”herpes simplex virus tivity with 6 hours of symptoms; see Fig. 2.9-11A). to look for blood in the\n(HSV) encephalitis and SAH. subarachnoid space.\nâ–  Lumbar puncture if CT is âŠ– to look for RBCs, xanthochromia (yellowish\nCSF caused by breakdown of RBCs), â†‘ protein (from the RBCs), and\nMNEMONIC â†‘ ICP a few hours after onset of thunderclap headache.\nâ–  Four-vessel angiography (or equivalent noninvasive angiography such as\nConditions associated with berry CTA with three-dimensional reconstructions) once SAH has been con-\naneurysms that can MAKE an SAH\nfirmed (see Fig. 2.9-11Bâ€“D) to identify source of bleeding. Invasive CTA\nmore likelyâ€”\nis warranted in high-risk cases and in those with high clinical suspicion\nMarfan syndrome even if CT and LP are unrevealing.\nAortic coarctation\nKidney disease (autosomal dominant,\n",
      "char_start": 1052000,
      "char_end": 1054000
    },
    {
      "chunk_id": 527,
      "text": "Treatment\npolycystic)\nEhlers-Danlos syndrome â–  Most definitive treatment: Neurosurgery. May perform angiographic coil-\nSickle cell anemia; Smoking tobacco ing and/or stenting to stabilize aneurysm first.\nAtherosclerosis â–  Prevention of rebleeding (most dreaded complication and most likely to\nHistory (familial); Hypertension; occur in the first 24 hours) by maintenance of SBP <150 mm Hg until\nHyperlipidemia the aneurysm has been coiled or clipped. Choice between coiling and\nclipping dependent on site of lesion, neck of aneurysm, and availability.\nGenerally, coiling is preferred.\nA\nC D\nB\nA B C D\nFIGURE 2.9-11. Subarachnoid hemorrhage. Noncontrast CT (A) showing SAH filling the basilar cisterns and sylvian fissures (straight\narrows). The curved arrow shows the dilated temporal horns of the lateral ventricles/hydrocephalus. Images from a catheter angiogram (B),\na CT angiogram (C), and an MRA (D) show a saccular aneurysm arising from the anterior communicating artery (arrows in B, C, and D).\n(Image A reproduced with permission from Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine: A Comprehensive Study Guide. 6th ed. New York, NY: McGraw-Hill; 2004. Images B, C, and D\nreproduced with permission from Doherty GM. Current Diagnosis & Treatment: Surgery. 13th ed. New York, NY: McGraw-Hill; 2010.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336688 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 369\nâ–  Prevention of vasospasm (a major cause of delayed morbidity and mortal-\nity) and subsequent ischemic stroke (most likely to occur up to 12 days\nafter SAH) by administration of calcium channel blockers (CCBs), such as\nnimodipine.\nâ–  â†“ ICP by raising the head of the bed and instituting hyperventilation in an\nacute setting (<30 minutes after onset). C\nâ–  Treatment of hydrocephalus through a lumbar drain, serial LPs, or ven-\ntriculoperitoneal shunt. P H\nT\nINTRACEREBRAL HEMORRHAGE\nBleeding within brain parenchyma. Commonly affects",
      "char_start": 1054000,
      "char_end": 1056000
    },
    {
      "chunk_id": 528,
      "text": " deep brain regions\nsuch as the basal ganglia, internal capsule, thalamus, pons, and cerebellum.\nSome risk factors include hypertension, tumor, and illicit drug use. Hyperten-\nsion is the most common cause of intracerebral hemorrhage, followed by\namyloid angiopathy (in older adults). FIGURE 2.9-12. Intracerebral hemor-\nrhage. Noncontrast head CT shows an\nHistory/PE intraparenchymal hemorrhage (H) and\nsurrounding edema (arrows) centered in\nâ–  Early symptoms/signs: Focal motor or sensory deficits that often worsen as the left putamen, a common location for\nthe hematoma expands hypertensive hemorrhage. C, P, and T\nâ–  Late symptoms/signs: Features of increased ICP (eg, vomiting and head- denote the normal contralateral caudate,\nputamen, and thalamus, respectively.\nache, bradycardia, reduced alertness)\n(Reproduced with permission from Fauci AS et al. Har-\nrisonâ€™s Principles of Internal Medicine. 17th ed. New York,\nDiagnosis NY: McGraw-Hill; 2008.)\nImmediate noncontrast head CT (see Fig. 2.9-12). The physician should look\nfor hyperdense areas, mass effect, or edema that may predict herniation.\nTreatment\nâ–  Monitor for signs of rebleed, shift, and possible herniation.\nâ–  Suspect herniation if patient develops Cushing triad (hypertension, brady-\ncardia, irregular respirations), fixed pupils, or loss of consciousness.\nâ–  Herniation is a medical emergency. Treat initially with mannitol or hyper- KEY FACT\ntonic saline in all patients, followed with emergency decompressive crani-\nectomy to allow edema to expand outward. Altered mental status associated with\nan expanding epidural hematoma\noccurs within minutes to hours and\nSUBDURAL AND EPIDURAL HEMORRHAGE classically includes acute loss of\nconsciousness â†’ lucid interval â†’\nPatients who present after head trauma with headache, focal neurologic defi- gradual loss of consciousness. With a\ncits, and confusion should always be assumed to have a subdural or epidural subdural hematoma, such changes can\nhematoma and are in need of urgent neur",
      "char_start": 1056000,
      "char_end": 1058000
    },
    {
      "chunk_id": 529,
      "text": "oimaging. Overall, subdural hema- occur within days to weeks.\ntomas are more common in the elderly, whereas epidural hematomas are\nmore common in younger individuals. See Table 2.9-10.\nCAVERNOUS SINUS THROMBOSIS\nThe cavernous sinus is a blood-filled collection of venous sinuses on either\nside of the pituitary gland. Common etiologies involve uncontrolled infec-\ntions of central facial skin, the orbit, or nasal sinuses that lead to septic throm-\nbosis of the cavernous sinus. Staphylococcus aureus is the most common\ncausative agent. Current antimicrobials have greatly â†“ both incidence and\nmortality. However, this can also occur in the setting of trauma or postsurgery\nin patients with thrombophilia.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 336699 1100//2211//2222 22::1188 PPMM\n\n370 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-10. Subdural vs Epidural Hemorrhage\nACUTE SUBDURAL CHRONIC SUBDURAL EPIDURAL\nCommon etiology Head trauma â†’ rupture of bridging veins â†’ accumulation of blood Head trauma â†’ lateral skull fracture\nbetween dura and arachnoid membranes â†’ tear of middle meningeal artery\nâ†’ accumulation of blood between\nskull and dura mater\nEpidemiology Older adults, patients who overuse alcohol Severe trauma\nHistory/PE Within 24 hours with Headache; altered mental status; Immediate loss of consciousness fol-\ndecreased GCS, pupil contralateral hemiparesis; focal lowed by a lucid interval (minutes to\ninequality, and motor neurologic findings; altered hours)\ndeficits mental status in older adults\nDiagnosis CT findings: Crescent shaped, concave hyperdensity acutely CT findings: Lens-shaped, biconvex\n(isodense subacutely; hypodense chronically) hyperdensity\nTreatment Neurosurgical evacuation Neurosurgical evacuation if Emergent neurosurgical evacuation\nregardless of symptoms symptomatic Can quickly evolve to brain herniation\nSubdural hematomas that may and death secondary to the arterial\nregress spontaneously source of bleeding\nNote In the",
      "char_start": 1058000,
      "char_end": 1060000
    },
    {
      "chunk_id": 530,
      "text": " setting of mild traumatic brain injury without vomiting, headache, and loss of consciousness and a normal\nhead CT, observe for 4â€“6 hours. If observation period is unremarkable, the patient can be sent home with\nextensive return precautions.\nImages reproduced with permission from Aminoff MJ. Clinical Neurology, 3rd ed. Stamford, CT: Appleton & Lange; 1996: 296.\nHistory/PE\nâ–  Headache is the most common presenting symptom.\nâ–  Patients may present with orbital pain, edema, diplopia, other CN signs\nsecondary to oculomotor, abducens, trigeminal, or trochlear involvement.\nOn examination, they typically appear ill and have a fever.\nâ–  Late findings: Altered mental status such as confusion, drowsiness, or\ncoma suggests spread to the CNS or sepsis.\nDiagnosis\nâ–  MRI (with gadolinium and magnetic resonance [MR] venography) is the\nmain method for diagnosis, but CTA and CT venography are also often\nused for diagnosis.\nâ–  Lab studies show â†‘ WBC count.\nâ–  Blood cultures reveal the causative agent in up to 50% of cases.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337700 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 371\nTreatment\nâ–  Cavernous sinus thrombosis calls for aggressive and empirical treatment\nwith broad-spectrum antibiotics: vancomycin + third- or fourth-generation\ncephalosporin (eg, ceftriaxone or cefepime).\nâ–  Metronidazole covers anaerobic infection from sinus or dental sources.\nâ–  Antifungal therapy is required for fungal cases.\nâ–  IV antibiotics are recommended for at least 3 to 4 weeks.\nâ–  Anticoagulation with unfractionated heparin or low-molecular-weight hep-\narin may be used to decrease mortality. This may be required for several\nmonths.\nâ–  Surgical drainage may be necessary if there is no response to antibiotics\nwithin 24 hours.\nKEY FACT\nCOMA AND ENCEPHALOPATHY\nProcurement of a head CT without\nA state of â€œunarousable unresponsiveness,â€ ie, unconsciousness marked by contrast before other imaging to\nlimited to no respons",
      "char_start": 1060000,
      "char_end": 1062000
    },
    {
      "chunk_id": 531,
      "text": "e to stimuli. Lesser states of impaired arousal are known evaluate for hemorrhage or structural\nas â€œobtundationâ€ or â€œstupor.â€ Coma is caused by dysfunction of both cerebral changes. Imaging should precede LP in\nhemispheres or the brainstem (pons or higher), which stems from structural light of the risk for herniation.\nor toxic-metabolic insults.\nCommon causes may include encephalopathy (hypoxic/ischemic), diffuse\naxonal injury, brainstem herniation, electrolyte disturbances (eg, hypoglyce-\nmia), toxins, and central pontine myelinolysis.\nHistory/PE\n1\nâ–  Obtain a complete medical history from witnesses, including current med-\nications (eg, sedatives).\nâ–  Conduct thorough medical and neurologic examinations, including A 68-year-old man presents to\nassessments of mental status, spontaneous motor activity, muscle tone, the emergency department with\nnumbness and droop on the right\nbreathing pattern, fundoscopy (to look for papilledema), pupillary resting\nside of the face, inability to speak,\ndiameters and responses to light response, eye movements, corneal reflex,\nand numbness and weakness in the\ngag reflex, and motor or autonomic responses to noxious stimuli applied to\nright arm that began 2 hours ago.\nthe limbs, trunk, and face (eg, retromandibular pressure, nasal tickle).\nWhere is this lesion, and what is the\nnext best step in management?\nDiagnosis\nTypically made by a combination of the history/physical examination and lab-\noratory tests or neuroimaging: 2\nâ–  Best initial step: Check of glucose, electrolytes, calcium; procurement of\nA 59-year-old man with prior medical\nrenal panel, liver function tests (LFTs), arterial blood gases (ABGs), a toxi-\nhistory of polycystic kidney disease\ncology screen, and blood and CSF cultures.\nwas admitted for treatment of\nâ–  Next step: Vital signs, ventilatory pattern, neurologic examination. The SAH. Four days after admission, he\nphysician can identify treatable conditions such as infection, metabolic\ndeveloped weakness in his right arm.\nc",
      "char_start": 1062000,
      "char_end": 1064000
    },
    {
      "chunk_id": 532,
      "text": "onditions, seizures, intoxications/overdose, and surgical lesions. What could have prevented this?\nâ–  Test of choice: CT head. MRI is superior for encephalitis, early strokes,\ndiffuse axonal injury (DAI), and multiple small hemorrhages. LP and elec-\ntroencephalography (EEG) should also be part of the diagnostic workup 3\nwhen neuroimaging and metabolic studies have not disclosed the etiology.\nâ–  Procurement of an MRI to exclude structural changes and ischemia (eg, A 59-year-old man with prior medical\nbrainstem).\nhistory of polycystic kidney disease is\nadmitted for treatment of SAH. Four\nhours after admission, he develops\nweakness in his left arm. What is the\ncause of this new finding?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337711 1100//2211//2222 22::1188 PPMM\n\n372 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-11. Differential Diagnosis of Minimally Conscious State KEY FACT\nVARIABLE â€œLOCKED-INâ€ SYNDROME PERSISTENT VEGETATIVE STATE COMA BRAIN DEATH Broca aphasia = motor aphasia,\nexpressive aphasia, or nonfluent\nAlertness Wakeful and aware with Awake but not aware; eyes Unconscious, eyes closed; no Unconscious; no\naphasia\nretained cognitive abilities open and closedâ€”sleep- sleep-wake cycles sleep-wake cycles\nWernicke aphasia = sensory aphasia,\nwake cycles present\nreceptive aphasia, or fluent aphasia\nMost common Central pontinemyelinolysis Diffuse cortical injury or Diffuse hypoxic encephalopathy, Same as coma\ncauses (after rapid sodium cor- hypoxic ischemic injury widespread infection, electro-\nrection), brainstem stroke, lyte disturbances, toxins\nadvanced ALS\nVoluntary motor Eyes and eyelids None None None\nability\nRespiratory drive Yes Yes Yes None\nKEY FACT â–  Rule out catatonia, conversion unresponsiveness, â€œlocked-inâ€ syndrome,\nor persistent vegetative state (PVS), all of which can be confused with true\nArtificial life support can be\ncoma (see Table 2.9-11).\ndiscontinued only after two physicians\nhave declared the patient legally b",
      "char_start": 1064000,
      "char_end": 1066000
    },
    {
      "chunk_id": 533,
      "text": "rain\nTreatment\ndead.\nInitial treatment should consist of the following measures:\nâ–  Stabilize the patient: Attend to ABCs.\n1 â–  Reverse the reversible: Administer DONTâ€”Dextrose, Oxygen, Nalox-\none, and Thiamine.\nâ–  Identify and treat the underlying cause and associated complications.\nOcclusion of the left middle cerebral\nâ–  Prevent further damage.\nartery (MCA) is suspected, as aphasia\nand contralateral sensory loss and\nweakness are part of the description.\nCT of brain without contrast should APHASIA\nbe done to rule out hemorrhage\nand assess whether tPA should be\nA general term for speech and language disorders. Usually results from lesions\ninitiated.\n(eg, strokes, tumors, abscesses) in the â€œdominant hemisphere.â€ The left hemi-\nsphere is dominant in >95% of right-handed people and in 60% to 80% of\nleft-handed people.\n2\nThis patientâ€™s focal weakness is BROCA/EXPRESSIVE APHASIA\nprobably caused by ischemia\nsecondary to vasospasm, so A disorder of spoken and/or written language production with intact compre-\nnimodipine administration could hension. Caused by an insult to the Broca area in the posterior inferior frontal\nprevent this adverse event. cortex (see Fig. 2.9-13). Often secondary to a left superior middle cerebral\nartery (MCA) stroke. Also known as motor aphasia.\n3 History/PE\nPresents with impaired speech production, frustration with awareness of defi-\nNew onset of neurologic symptoms\ncits, arm and facial hemiparesis, hemisensory loss, and apraxia of the oral\nwithin 24 hours following an SAH\nmuscles. Speech is described as â€œtelegraphicâ€ with few words and frequent\nis most likely caused by rebleeding\npauses.\nof the aneurysm (as opposed to\nischemia days after, which is caused\nby vasospasm).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337722 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 373\nKEY FACT\nPremotor\ncortex\nBroca aphasia = motor aphasia,\nexpressive aphasia, or nonfluent\nFrontal Parietal aphasia\nlobe lobe Wer",
      "char_start": 1066000,
      "char_end": 1068000
    },
    {
      "chunk_id": 534,
      "text": "nicke aphasia = sensory aphasia,\nA\nrcuate f\nasciculus receptive aphasia, or fluent aphasia\nBroca area Wernicke area\nOccipital KEY FACT\nTemporal lobe\nlobe In true Broca and Wernicke aphasia,\nrepetition is impaired. If repetition is\nPrimary intact, the deficit is called transcortical\nauditory cortex motor aphasia (TMA) or transcortical\nsensory aphasia (TSA), and it is caused\nby a lesion around either the Broca area\nor the Wernicke area, respectively. Also\nFIGURE 2.9-13. Cerebral cortex with Broca and Wernicke areas highlighted. (Reproduced with called secondary aphasia.\npermission from USMLE-Rx.com.)\nKEY FACT â–  Rule out catatonia, conversion unresponsiveness, â€œlocked-inâ€ syndrome,\nor persistent vegetative state (PVS), all of which can be confused with true Treatment\nArtificial life support can be\nGood comprehension Poor comprehension\ncoma (see Table 2.9-11).\ndiscontinued only after two physicians Speech therapy (varying outcomes with intermediate prognosis).\nhave declared the patient legally brain Wernicke\nTreatment aphasia\ndead. Fluent Conduction\nWERNICKE/RECEPTIVE APHASIA speech aphasia\nInitial treatment should consist of the following measures: Transcortical\nsensory aphasia\nâ–  Stabilize the patient: Attend to ABCs. A disorder of language comprehension with intact yet nonsensical produc-\nâ–  Reverse the reversible: Administer DONTâ€”Dextrose, Oxygen, Nalox- tion. Caused by an insult to the Wernicke area in the left posterior superior Broca\none, and Thiamine. temporal (perisylvian) lobe. Often secondary to left inferior/posterior MCA Nonfluent aphasia Transcortical\nâ–  Identify and treat the underlying cause and associated complications. embolic stroke (see Fig. 2.9-13). speech mixed aphasia\nTranscortical\nâ–  Prevent further damage. motor aphasia\nâ–  Hx/PE: Presents with preserved fluency of language with impaired repeti-\nAPHASIA t f p i o a o l r n l a o p w a h n c a d o s i m c c o m e m r a r p o n r r d e s s h ( , e w m n o s a r i d k o e n s , u f r b l e e s q a t u i ",
      "char_start": 1068000,
      "char_end": 1070000
    },
    {
      "chunk_id": 535,
      "text": "d t e u in n ti g t o u n to s s e ), â€œ o w a f n o n d rd e s o h s l a o o l g w a i d s l m . a â€ c s P k ( a m o ti f e a a n d w e ts - a u r a e p r n e w e u s o s n r d o a s b f ) l d e a e n fi t d o - Poo G r o r o e d p e r t e it p\nio\net\nn\nition\ncits (see Fig. 2.9-14).\nFIGURE 2.9-14. Aphasia classification.\nA general term for speech and language disorders. Usually results from lesions â–  Tx: Treatment of underlying etiology and institution of speech therapy. (Reproduced with permission from USMLE-Rx.com.)\n(eg, strokes, tumors, abscesses) in the â€œdominant hemisphere.â€ The left hemi-\nsphere is dominant in >95% of right-handed people and in 60% to 80% of\nleft-handed people.\nSEIZURE DISORDERS\nMNEMONIC\nBROCA/EXPRESSIVE APHASIA Sudden changes in neurologic activity caused by abnormal electrical activity\nBROca is BROken and Wernicke is Wordy.\nin the brain that can often be detected on EEG. See Table 2.9-12 for com-\nA disorder of spoken and/or written language production with intact compre- mon etiologies by age. Etiologies of seizures, and their distinguishing features,\nhension. Caused by an insult to the Broca area in the posterior inferior frontal include the following:\ncortex (see Fig. 2.9-13). Often secondary to a left superior middle cerebral\nâ–  Idiopathic epilepsy (recurrent, unprovoked seizures): May be caused by\nartery (MCA) stroke. Also known as motor aphasia.\ngenetics, developmental factors, early life brain injuries, and so on.\nâ–  Causes of acquired epilepsy: An 82-year-old woman presents to\nHistory/PE the emergency department with a\nâ–  Structural brain lesion (tumor, stroke, AVM hemorrhage, or devel-\nPresents with impaired speech production, frustration with awareness of defi- opmental abnormality): tend to have focal onset or focal postictal defi- 2-day history of difficulty speaking\nand weakness in her right face\ncits, arm and facial hemiparesis, hemisensory loss, and apraxia of the oral cit, suggesting focal CNS pathology.\nand arm. During the interv",
      "char_start": 1070000,
      "char_end": 1072000
    },
    {
      "chunk_id": 536,
      "text": "iew, she\nmuscles. Speech is described as â€œtelegraphicâ€ with few words and frequent â–  Nonneurologic etiologies (ie, provoked seizures): Hypoglycemia, speaks in two- to three-word choppy\npauses. hyponatremia, hypocalcemia, hyperosmolar states, hepatic encepha-\nsentences and can follow commands.\nlopathy, uremia, porphyria, drug overdose (cocaine, antidepressants, She cannot repeat what you say.\nneuroleptics, methylxanthines, lidocaine), drug withdrawal (alcohol Where is her lesion?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337733 1100//2211//2222 22::1188 PPMM\n\n374 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-12. Causes of Seizure by Age Group\nINFANTS CHILDREN ADOLESCENTS ADULTS ADULTS\n(<2 YEARS) (2â€“10 YEARS) (10â€“18 YEARS) (18â€“35 YEARS) (>35 YEARS)\nPerinatal injury Idiopathic Idiopathic Trauma Trauma\nInfection Infection Trauma Alcoholism Stroke\nMetabolic Trauma Drug withdrawal Brain tumor Metabolic disorders\nKEY FACT Genetic Febrile Arteriovenous mal- Alcoholism\nformations (AVMs) Brain tumor\nBoth simple partial and complex partial\nseizures may evolve into secondary\ngeneralized seizures.\nand other sedatives), eclampsia, hyperthermia, hypertensive encepha-\nlopathy, head trauma, and cerebral hypoperfusion.\nKEY FACT\nFocal seizures can change into bilateral\nCLASSIFICATION OF SEIZURE\ntonic-clonic type and may have\nassociated loss of consciousness and\nA seizure is classified as partial (focal) or generalized (see Fig. 2.9-15).\npostictal confusion.\nHistory/PE\nâ–  Focal (partial): Abnormal electrical activity arises from a discrete region\nKEY FACT\n(or multiple discrete regions) of the brain. It can involve motor, sensory,\nIf an adult patient presents with an autonomic, or psychic features (eg, fear, dÃ©jÃ  vu, hallucinations). Aura is\nepisode of lip smacking associated with common (auditory, visual, olfactory, or tactile hallucinations). Automa-\nan impaired level of consciousness and tisms like lip smacking, picking, and swallowing are common. A ",
      "char_start": 1072000,
      "char_end": 1074000
    },
    {
      "chunk_id": 537,
      "text": "postictal\nfollowed by confusion, think complex focal neurologic deficit (eg, hemiplegia/hemiparesis, or Todd paralysis) is\npartial seizures. possible and usually resolves within 24 hours. It can be simple or complex.\nâ–  Aware: Previously called simple partial seizures. No impaired level of\nconsciousness.\nâ–  Impaired awareness: Previously called complex partial seizures. Typi-\nKEY FACT\ncally start on one side of the brain, often involving the temporal lobe\nIf a patient presents with uncontrollable (70%â€“80%) with bilateral spread of the aberrant electrical discharge,\ntwitching of their thumb and is fully leading to impaired level of consciousness. Postictal confusion, disori-\naware of their symptoms, think simple entation, and amnesia are characteristic.\npartial seizures. â–  Generalized seizure: Seizure activity that involves both cerebral hemi-\nspheres, resulting in impaired level of consciousness. Classified as motor\n(tonic-clonic, other motor) or nonmotor (absence) type.\nKEY FACT â–  Tonic-clonic seizure: Sudden loss of consciousness with extension of the\nback and contraction of muscles (chest and extremities); repetitive, sym-\nIf a patient presents with clonic metric clonic (alternation between muscle contraction and relaxation)\nmovements associated with loss of movements. Etiology often idiopathic. Simple and complex partial sei-\nconsciousness and incontinence, think zures may evolve into secondary generalized tonic-clonic seizures.\ntonic-clonic (grand mal) seizures. â–  Marked by incontinence and tongue biting.\nâ–  Patients may appear cyanotic during the ictal period.\nâ–  Postictal confusion and drowsiness. Muscle aches and headaches may\nalso be present.\nâ–  Absence seizure: A form of generalized seizure. Presents with brief (5- to\nThis patient presents with Broca or 10-second), often unnoticeable episodes of impaired consciousness (petit\nexpressive aphasia. In Broca aphasia,\nmal seizures) occurring up to hundreds of times per day. Patient can\nthe lesion is in the posterior ",
      "char_start": 1074000,
      "char_end": 1076000
    },
    {
      "chunk_id": 538,
      "text": "frontal\nappear to be daydreaming or staring. Symptoms may include sudden stops\ncortex of the dominant side of the\nin motion, lip smacking, eyelid fluttering, and chewing motions. It can be\nbrain. In this case, the lesion also\ntriggered by hyperventilation. There is no postictal phase. Absence seizure\ninvolves the face and arm regions\nbegins in childhood and subsides before adulthood. It is often familial.\nof the motor cortex, which are\nimmediately adjacent to Broca area â–  Unknown seizure: Generalized or focal. Often the beginning of seizure is\non the left hemisphere. not clear.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337744 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 375\nSeizure\nPartial (focal) seizures Generalized seizures\n2Â° generalized\nImpaired consciousness?\nTonic-clonic Absence\nSimple partial Complex partial Tonic Myoclonic Atonic\n(grand mal) (petit mal)\nAlternating Quick Blank stare\nDrop seizure\nstiffening and Stiffening and repetitive no postictal\n(falls to floor)\nmovement jerks confusion\nTonic phase\nDrop\nClonic phase\nFIGURE 2.9-15. Classification of seizures. (Reproduced with permission from USMLE-Rx.com.)\nDiagnosis\nâ–  Clinical history by a bystander and physical examination are always clues\nto the diagnosis and differentiation among similarly appearing clinical\nsymptoms. The history should look for brain trauma, infection, neoplasm,\nstroke, or developmental issues.\nâ–  Best initial step: EEG. Brain MRI is considered for focal seizures.\nâ–  Focal seizure: Search for epileptogenic focus (CT or contrast MRI).\nâ–  Absence seizure: EEG shows three-per-second spike-and-wave discharges\n(remember classic EEG findings, but do not worry about learning how to\nread them!). EEG changes can be triggered by hyperventilation.\nâ–  Tonic-clonic seizure: EEG typically shows 10-Hz activity during the tonic\nphase and slow waves during the clonic phase (normal = pseudoseizures).\nâ–  Serum prolactin levels may be elevated in the i",
      "char_start": 1076000,
      "char_end": 1078000
    },
    {
      "chunk_id": 539,
      "text": "mmediate postictal period\nof generalized and complex-partial seizures (vs pseudoseizures).\nâ–  To rule out: Systemic causes with a CBC, electrolytes, calcium, fasting\nglucose, LFTs, a renal panel, ESR, and a toxicology screen.\nTreatment\nâ–  Secure airway when appropriate.\nâ–  For acute seizures lasting longer than 5 minutes, see treatment of status\nepilepticus later in chapter.\nâ–  In cases of systemic secondary seizures, treat the underlying cause (eg, low\nblood sugar, alcohol withdrawal, or fever in children).\nâ–  Anticonvulsants for partial and tonic-clonic seizures: levetiracetam, phe-\nnytoin, carbamazepine, and valproic acid have similar efficacy and can be\nA 40-year-old man presents to the\nused as chronic monotherapy.\nemergency department with a single\nâ–  In children, levetiracetam is the first-line anticonvulsant. If fever is pres-\nsimple partial seizure of 1 minute but\nent, treat fever but also give lorazepam.\nis no longer symptomatic. He also\nâ–  If a certain antiepileptic is ineffective as monotherapy, try an alternative. If complains of 2 months of morning\nthe alternative is ineffective, try a regimen of multiple antiepileptics. headaches and one episode of\nâ–  Other treatment options include gabapentin, topiramate, and oxcarbazepine. vomiting in the past week. What is the\nâ–  Absence seizure: First-line is ethosuximide; second-line is valproic acid. next step in management?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337755 1100//2211//2222 22::1188 PPMM\n\n376 HIGH-YIELD FACTS IN NEUROLOGY\nâ–  Intractable temporal lobe seizure: Consider anterior temporal lobectomy\n(epilepsy surgery) and/or vagal nerve stimulator.\nâ–  Treatment is not necessary for a single episode of seizure.\nSTATUS EPILEPTICUS\nA medical emergency consisting of prolonged seizures (usually >5 minutes)\nor two or more seizures that occur without a return to baseline consciousness\nwithin 30 minutes or continuous clinical and/or electrographic seizure\nactivity\nâ–  Common causes",
      "char_start": 1078000,
      "char_end": 1080000
    },
    {
      "chunk_id": 540,
      "text": " include anticonvulsant withdrawal/noncompliance,\nanoxic brain injury, EtOH/sedative withdrawal or other drug intoxication,\nand metabolic disturbances (eg, hyponatremia), head trauma, and\ninfection.\nâ–  Mortality is 10% to 20%.\nDiagnosis\nâ–  Treatment and diagnostic workup should be initiated simultaneously.\nâ–  Determination of the underlying cause should entail collateral history,\nphysical exam, CBC, electrolytes, calcium, glucose, ABGs, LFTs, BUN/\nKEY FACT\ncreatinine, ESR, antiepileptic drug levels, and a toxicology screen.\nAlthough status epilepticus is â–  Continuous EEG monitoring is indicated if nonconvulsive status epilepti-\ncus is suspected or if patient is not waking up after clinically obvious sei-\ntraditionally defined as seizures lasting\nzures stop.\n>5 minutes, treatment should begin\nfor any seizure lasting >5 minutes â–  If intracranial pathology is suspected, the physician should obtain a stat\nhead CT.\nto prevent brain-induced cardiac,\npulmonary, and other complications. â–  An LP should be procured in the setting of fever or meningeal signs, but\nonly after a CT scan has been obtained to assess the safety of the LP.\nTreatment\nâ–  Best initial step: Like in all emergencies, treatment starts with the ABCs.\nDuring the stabilization phase, the following interventions usually occur\nsimultaneously:\nâ–  Stabilization of the airway for breathing and circulation\nâ–  Check of oxygen saturation and use of supplemental oxygen or consid-\neration of intubation\nMNEMONIC\nâ–  Connection of ECG monitor\nWithdrawal from ABBA can cause â–  Determination of capillary blood glucose reading and treatment if it is\nseizuresâ€” less than 60 mg/dL\nâ–  Procurement of IV access to collect blood for electrolytes, hematologic\nAlcohol\nworkup, toxicology screen, and anticonvulsant levels (if already on\nBenzodiazepines\nmedications)\nBarbiturates\nAnticonvulsants â–  Best initial therapy: Benzodiazepines are given intravascularly: IV loraze-\npam or IV diazepam. These steps (from ABCs to IV benzodiazepines) are\ncarri",
      "char_start": 1080000,
      "char_end": 1082000
    },
    {
      "chunk_id": 541,
      "text": "ed out between 5 and 20 minutes of resuscitation:\nâ–  This is given if the seizure persists after 5 minutes (ie, the stabilization\nphase) or recurs when the patient is being treated.\nâ–  Alternatives include phenobarbital, rectal diazepam for children, and\nintranasal midazolam.\nThe next step in management is\nâ–  Next step in management: If seizure persists despite these treatments, the\nto order a CT of the brain because\nphysician should consider IV fosphenytoin, IV valproic acid, or IV\nthe history is suggestive of a brain\nlevetiracetam.\ntumor and the patient is no longer\nsymptomatic. If seizures recur, â–  Last-resort options include repetition of second-line drugs or induction of\nconsider beginning anticonvulsant coma by use of general anesthetics (eg, propofol).\ntherapy.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337766 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 377\nVERTIGO\nBefore discussing conditions that cause vertigo, it is worth defining vertigo\nand differentiating it from lightheadedness. â€œDizzinessâ€ is often used to\ndescribe vertigo and lightheadedness. Vertigo feels as if one or oneâ€™s surround-\nings are moving when there is no actual movement. Lightheadedness feels as\nif one is about to faint or â€œpass out.â€ Conscious sensation of vertigo occurs in\nthe cerebral cortex as a result of an error signal of observed over expected\nfrom the vestibular apparatus in the inner ear and brainstem, or in response to\nimbalances in vestibular input between left and right sides.\nVertigo can be divided into central and peripheral vertigo. Central vertigo\nis caused by lesions in the CNS. Common characteristics include severe pos-\ntural and gait instability, purely vertical or purely torsional nystagmus, and\nother focal neurologic signs. Peripheral vertigo is caused by lesions in the\ninner ear. Common characteristics include deafness, tinnitus, horizontal tor-\nsional nystagmus, and absent focal neurologic signs.\nBENIGN PAROXYS",
      "char_start": 1082000,
      "char_end": 1084000
    },
    {
      "chunk_id": 542,
      "text": "MAL POSITIONAL VERTIGO\nA common cause of recurrent peripheral vertigo resulting from displacement\nof otoliths (â€œear stonesâ€), which lead to disturbances in the semicircular\ncanalsâ€”the parts of the ear responsible for detecting head rotation. The pos-\nterior canal is the most common site. KEY FACT\nProgressive bilateral (high-frequency)\nHistory/PE\nsensorineural hearing loss and\nPatients present with transient, episodic vertigo (lasting <1 minute) and nys-\noccasional tinnitus are normal\ntagmus triggered by changes in head position (eg, while turning in bed, get-\n(presbycusis). They are typically noticed\nting in and out of bed, or reaching overhead). Benign paroxysmal positional\nby 60 years of age.\nvertigo (BPPV) may be accompanied by nausea and vomiting.\nDiagnosis\nâ–  Dix-Hallpike maneuver (used primarily to identify posterior canal BPPV):\nThe patient should turn their head 45 degrees right or left and go from a\nsitting to a supine position. If vertigo and the typical nystagmus (rotatory\nnystagmus with the fast phase toward the affected side) are reproduced,\nBPPV is the likely diagnosis. If positive, the test should be repeated. In\nBPPV, the vertigo fatigues with the second attempt due to washout of the\notoconia.\nâ–  Nystagmus that persists for >1 minute, is not suppressed by visual fixation,\nand lacks fatigability along with gait disturbance should raise concern for a\ncentral lesion.\nTreatment\nâ–  Epley maneuver (an extended version of the Dix-Hallpike maneuver used\nas treatment) resolves 85% of cases.\nâ–  BPPV usually subsides spontaneously in weeks to months, but up to 30%\nrecur within 1 to 3 years. Long-term use of antivertigo medications (eg,\nmeclizine) are generally contraindicated, as they have limited efficacy,\nthey are sedating, and they inhibit vestibular compensation, which may\nlead to chronic unsteadiness.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337777 1100//2211//2222 22::1188 PPMM\n\n378 HIGH-YIELD FACTS IN NEUROLOGY\nACUTE",
      "char_start": 1084000,
      "char_end": 1086000
    },
    {
      "chunk_id": 543,
      "text": " PERIPHERAL VESTIBULOPATHY (LABYRINTHITIS OR VESTIBULAR\nNEURITIS)\nHistory/PE\nâ–  Presents with acute onset of severe vertigo, head motion intolerance, and\ngait unsteadiness accompanied by nausea, vomiting, and nystagmus. Often\npreceded by viral infection.\nâ–  Labyrinthitis: Inflammation of the labyrinth, which contains organs of\nboth hearing and equilibrium. Auditory or aural symptoms (tinnitus, ear\nfullness, or hearing loss) present. Lateral pontine/cerebellar stroke (anterior\ninferior cerebellar artery territory) may present with similar symptoms but\nKEY FACT\nmay have additional occipital headache, ataxia, nystagmus, and somatosen-\nsory deficits (supplies spinal tract of CN V and spinothalamic tract).\nIf a patient complains of vertigo and\nvomiting without hearing loss for 1 â–  Vestibular neuritis: Inflammation of the vestibular nerve, responsible for\nbalance and equilibrium. Lacks auditory or aural symptoms. Lateral med-\nweek after having been diagnosed with\nullary/cerebellar stroke (posterior inferior cerebellar artery territory) can\na viral infection, think acute vestibular\npresent with similar symptoms, but patients have focal findings on exam\nneuritis.\n(ie, ataxia, sensory loss, dysphagia, Horner syndrome).\nDiagnosis\nâ–  A diagnosis of exclusion once the more serious causes of vertigo (eg, cere-\nbellar/brainstem stroke) have been ruled out. Acute peripheral vestibulop-\nathy presents with vertigo over minutes to hours, but the onset of vertigo\ndue to a vascular event is more hyperacute.\nâ–  Acute peripheral vestibulopathy demonstrates the following:\nâ–  An abnormal vestibulo-ocular reflex, as determined by a bedside head\nimpulse test (ie, patient not able to maintain visual fixation during\nrapid head rotation toward side of the lesion, followed by a compensa-\ntory saccade once the head stops moving)\nâ–  A predominantly horizontal nystagmus that always beats in one direc-\ntion, towards the opposite side of the lesion\nâ–  No vertical eye misalignment by alternate cover testing\n",
      "char_start": 1086000,
      "char_end": 1088000
    },
    {
      "chunk_id": 544,
      "text": "â–  If patients are â€œhigh riskâ€ (ie, atypical eye findings or neurologic symptoms\nor signs; cannot stand independently; have a new-onset headache, head, or\nneck pain; are >50 years of age; or have one or more stroke risk factors),\nMRI with diffusion-weighted imaging and MRA are indicated.\nTreatment\nAcute treatment consists of corticosteroids given <72 hours after symptom\nonset, antivertigo agents (eg, meclizine), and antiemetics. The condition usu-\nally subsides spontaneously within weeks to months.\nMÃ‰NIÃˆRE DISEASE\nA cause of recurrent vertigo with unilateral auditory symptoms that affects at\nleast 1 in 500 individuals in the United States. More common among\nwomen. This disorder of the inner ear is characterized by â†‘ volume of endo-\nlymph (endolymphatic hydrops).\nHistory/PE\nPresents with the classic tetrad of episodic vertigo, tinnitus, aural fullness, and\nhearing loss. Episodes often last minutes to hours. Nausea and vomiting are\ntypical. Patients progressively lose low-frequency hearing over years and may\nbecome deaf on the affected side.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337788 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 379\nDiagnosis\nUsually clinical. Based on the following:\nâ–  Two episodes lasting â‰¥20 minutes with remission of symptoms between\nepisodes\nâ–  Hearing loss documented at least once with audiometry\nKEY FACT\nâ–  Tinnitus or aural fullness\nThe incidence of Haemophilus\nMRI of the temporal bone often helpful to rule out other causes that present\ninfluenzae type B meningitis has greatly\nsimilarly (eg, tumors, aneurysms, multiple sclerosis)\nâ†“ over the past 10 to 15 years as a result\nof routine vaccination.\nTreatment\nâ–  Acute: Meclizine or benzodiazepines to control spinning sensation during\nacute attacks; antiemetics for nausea/vomiting.\nKEY FACT\nâ–  Chronic: Dietary/lifestyle changes that limit salt, caffeine, nicotine, and\nalcohol intake to avoid fluid retention. Betahistine (vasodilator that\nA pet",
      "char_start": 1088000,
      "char_end": 1090000
    },
    {
      "chunk_id": 545,
      "text": "echial or purpuric rash is\nimproves circulation in the inner ear) or diuretics can be used for patients\ncharacteristic of meningococcal\nwith refractory symptoms not amenable to lifestyle changes.\nmeningitis. Waterhouse-Friderichsen\nâ–  For severe unilateral cases, intratympanic injection of gentamicin into the syndrome (acute adrenal insufficiency\nmiddle ear (absorbed by the inner ear) is shown to reduce the frequency\ncaused by adrenal gland hemorrhage)\nand severity of vertigo attacks.\nis characterized by profound\nhypotension and has a high mortality.\nCNS INFECTIONS\nMENINGITIS\nAcute bacterial meningitis is a life-threatening emergency. Viral (also called\nâ€œasepticâ€) meningitis is more common and clinically less morbid. Risk factors\nfor meningitis include recent ear infection, sinusitis, immunodeficiencies,\nrecent neurosurgical procedures, crowded living conditions (ie, college\ndorms, military), and sick contacts. Commonly encountered causative organ-\nisms are listed in Table 2.9-13.\nHistory/PE\nâ–  Classic triad of fever, headache, and neck stiffness in one half of patients\nâ–  Other symptoms include malaise, photophobia, altered mental status,\nnausea/vomiting, seizures, or signs of meningeal irritation (âŠ• Kernig\n[thigh flexion â†’ pain/resistance with knee extension] and Brudzinski\n[neck flexion â†’ knee and hip flexion] signs).\nTABLE 2.9-13. Common Pathogens Causing Meningitis\nVIRAL\nBACTERIAL (ASEPTIC) HIV\nStreptococcus pneumoniae (#1 in adults) Enteroviruses: Cryptococcus neoformans,\nNeisseria meningitidis (#1 in teens) â–  Echovirus cytomegalovirus (CMV),\nGroup B Streptococcus (GBS) and Esch- â–  Coxsackie HSV, varicella zoster virus\nerichia coli (in neonates) â–  HSV-2 (VZV), tuberculosis (TB),\nHaemophilus influenzae serotype b, Lis- toxoplasmosis, and John\nteria (see Fig. 2.9-16) Cunningham (JC) virus FIGURE 2.9-16. Listeria. These numerous\ngram-positive, rod-shaped bacilli were\n(progressive multifocal leu-\nisolated from the blood of a patient with\nkoencephalopathy [PML]) Liste",
      "char_start": 1090000,
      "char_end": 1092000
    },
    {
      "chunk_id": 546,
      "text": "ria meningitis. (Reproduced with permis-\nsion from USMLE-Rx.com.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 337799 1100//2211//2222 22::1188 PPMM\n\n380 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-14. CSF Profiles\nOPENING GAMMA\nGLUCOSE PROTEIN PRESSURE GLOBULIN\nRBCS (PER MM3) WBCS (PER MM3) (MG/DL) (MG/DL) (CM HO) APPEARANCE (% PROTEIN)\n2\nNormal <10 <5 >2/3 of serum 15â€“45 10-20 Clear 3â€“12\nBacterial â†” â†‘ (>1000 poly- â†“ â†‘â†‘ â†‘ Cloudy/purulent â†” or â†‘\nmeningitis morphonuclear\n[PMN] cells)\nViral/aseptic â†” â†‘ (monos/lymphs) â†” â†” or â†‘ â†” or â†‘ Most often clear â†” or â†‘\nmeningitis\nSubarachnoid â†‘â†‘ â†‘ â†” â†‘ â†” or â†‘ Yellow/red â†” or â†‘\nhemorrhage\nGuillain-BarrÃ© â†” â†” â†” or â†‘ â†‘â†‘ â†” Clear or yellow â†”\nsyndrome (high protein)\nMultiple sclerosis â†” â†” or â†‘ â†” â†” â†” Clear â†‘â†‘\nIdiopathic â†” â†” â†” â†” â†‘â†‘â†‘ Clear â†”\nintracranial\nhypertension\nDiagnosis\nâ–  Best initial test: An LP for CSF analysis, Gram stain, and culture, ideally\nbefore initiation of antibiotics and procurement of glucose, protein, WBC\ncount plus differential, RBC count, and opening pressure (in the absence\nof papilledema or focal neurologic deficits) information.\nâ–  Viral polymerase chain reactions ([PCRs]; eg, herpes simplex virus\n[HSV]); cryptococcal antigen (for HIV patients).\nâ–  CT or MRI indicated in a minority of patients before LP, in particular\nthose with altered mental status, papilledema, or focal neurologic deficits\nto exclude a mass lesion or â†‘ ICP. If CT is being obtained, empiric antibi-\notics should be started beforehand. Obtain blood cultures. CBC may\nreveal leukocytosis. CSF findings vary (see Table 2.9-14).\nTreatment\nâ–  Most accurate treatment: Rapid administration of antibiotics for bacterial\nmeningitis (see Table 2.9-15).\nâ–  Most cases of viral meningitis can be treated with supportive care and\nclose follow-up.\nâ–  Close contacts of patients with meningococcal meningitis should receive\nrifampin or ceftriaxone (preferred during pregnancy) or ciprofloxacin\n(avoid for those pregnant or <18 years of age) an",
      "char_start": 1092000,
      "char_end": 1094000
    },
    {
      "chunk_id": 547,
      "text": "d the meningococcal\nvaccine.\nâ–  Dexamethasone â†“ mortality, hearing loss, and short-term neurologic com-\nplications in bacterial meningitis caused by S pneumoniae in adults, if\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338800 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 381\nTABLE 2.9-15. Empiric Treatment of Bacterial Meningitis\nAGE CAUSATIVE ORGANISM TREATMENT\n<1 month GBS, E coli/gram âŠ– bacilli, Ampicillin + cefotaxime or\nListeria gentamicin\n1â€“3 months S pneumoniae, N meningitidis, Vancomycin IV + ceftriaxone\nH influenzae type b or cefotaxime\n3 months to adulthood N meningitidis, S pneumoniae Vancomycin IV + ceftriaxone\nor cefotaxime\n>50 years/alcohol use S pneumoniae, gram Ampicillin + vancomycin +\ndisorder/chronic illness/ âŠ– bacilli, Listeria, cefotaxime or ceftriaxone\nimmunocompromise N meningitidis\ngiven 15 to 20 minutes before antibiotics and â†“ hearing loss in children,\nparticularly those with H influenzae type b (Hib) meningitis.\nâ–  If immunocompromised, >50 years of age, or neonate, add ampicillin for\nListeria.\nComplications\nSensorineural hearing loss, mental impairment, seizures, cerebral edema,\nâ†‘ ICP, brain abscess, ventriculitis/hydrocephalus, focal neurologic deficits\n(eg, cranial nerve palsies), hyponatremia, coma, and death.\nCRYPTOCOCCAL MENINGITIS\nKEY FACT\nâ–  Risk factors: AIDS, exposure to pigeon droppings\nThe CSF antigen test for cryptococcal\nâ–  Hx/PE: Subacute onset of headache, fever, impaired mentation, signs of\nmeningitis is highly sensitive and\nincreased ICP, and absent meningeal signs. The differential diagnosis\nspecific.\nincludes toxoplasmosis, lymphoma, tuberculosis (TB) meningitis, AIDS\ndementia complex, progressive multifocal leukoencephalopathy (PML),\nHSV encephalitis, and other fungal disease.\nâ–  Dx: LP (â†“ CSF glucose, â†‘ protein, â†‘ leukocyte count with monocytic pre-\ndominance, â†‘â†‘ opening pressure), âŠ• cryptococcal antigen testing in CSF\nand/or blood, CSF India ink stain, and fungal cul",
      "char_start": 1094000,
      "char_end": 1096000
    },
    {
      "chunk_id": 548,
      "text": "ture.\nâ–  Tx:\nâ–  Induction phase: Amphotericin B (IV) + flucytosine (PO) for\nâ‰¥2 weeks\nA 19-year-old college student\nâ–  Consolidation phase: Fluconazole (PO) for â‰¥8 weeks\nis brought to the emergency\nâ–  Maintenance phase: Fluconazole â‰¥1 year; can thereafter discontinue\ndepartment from her dorm room,\nif on antiretroviral therapy (ART) with CD4+ cell count >100/mm3\nwhere she was found by her\nand viral load undetectable for >3 months\nroommate in a confused state. She\nâ–  â†‘ opening pressure may require serial LPs or a ventriculoperitoneal shunt complains of fever, nausea, vomiting,\nfor management. and pain in her neck and head. She\nhas a petechial rash on her legs.\nCSF examination reveals a glucose\nTOXOPLASMOSIS\nlevel of 22 mg/dL, a protein level\nof 140 mg/dL, and a WBC count\nRisk factors include ingesting raw or undercooked meat, eating contaminated of 1400/mm3. What is the most\nfruits or vegetables, exposure to cat feces, and drinking unpasteurized milk. likely organism responsible for her\ncondition?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338811 1100//2211//2222 22::1188 PPMM\n\n382 HIGH-YIELD FACTS IN NEUROLOGY\nHistory/PE\nâ–  Primary infection is usually asymptomatic.\nâ–  Reactivated toxoplasmosis occurs in immunosuppressed patients and may\npresent in specific organs (brain, lung, and eye > heart, skin, gastrointesti-\nnal [GI] tract, and liver).\nâ–  Encephalitis is common in seropositive AIDS patients. Classically, CNS\nlesions present with fever, headache, altered mental status, seizures, and\nfocal neurologic deficits.\nDiagnosis\nâ–  Serology, PCR (indicates exposure and risk for reactivation), and occasion-\nally tissue exam for histology.\nâ–  In the setting of CNS involvement, CT scan (toxoplasmosis indicated by\nmultiple isodense or hypodense ring-enhancing mass lesions) or an MRI\n(has a predilection for the basal ganglia; more sensitive).\nKEY FACT\nTreatment\nRing-enhancing lesions in patients\nâ–  Most accurate treatment: Induction with high-dose ",
      "char_start": 1096000,
      "char_end": 1098000
    },
    {
      "chunk_id": 549,
      "text": "PO pyrimethamine\nwith AIDS should always prompt\n+ sulfadiazine and leucovorin (a folic acid analog to prevent hematologic\nconsideration of toxoplasmosis and\ntoxicity) for 4 to 8 weeks; maintenance with a low-dose regimen until the\nCNS lymphoma.\ndisease has resolved clinically and radiographically\nâ–  Use of trimethoprim-sulfamethoxazole ([TMP-SMX], eg, Bactrim DS) or\npyrimethamine + dapsone for prophylaxis in patients with a CD4+ cell\nKEY FACT count <100/mm3 and a âŠ• toxoplasmosis IgG\nThe presence of RBCs in CSF (pink-\nENCEPHALITIS\ncolored CSF) without a history of\ntrauma is highly suggestive of HSV\nencephalitis. HSV and arboviruses are the most common causes of encephalitis. Rarer eti-\nologies include CMV, toxoplasmosis, West Nile virus, varicella zoster virus\n(VZV), Borrelia, Rickettsia, Legionella, enterovirus, Mycoplasma, and cere-\nbral malaria. Children and older adults are the most vulnerable.\nKEY FACT\nHistory/PE\nCNS infections key words:\nPhotophobia, nuchal rigidity = â–  Altered consciousness, headache, fever, seizures.\nmeningitis â–  Lethargy, confusion, coma, focal neurological deficits may also be present.\nFocal neurologic deficits = brain â–  Differentials include brain abscess, malignancy, SDH, SAH, toxic-meta-\nabscess bolic encephalopathy.\nConfusion, altered mental status =\nencephalitis Diagnosis\nâ–  The physician should procure a CT immediately to rule out other life-\nthreatening conditions that cause neurologic symptoms and may demon-\nstrate characteristic temporal lobe signal abnormalities in HSV\nencephalitis (see Fig. 2.9-17).\nâ–  CSF shows lymphocytic pleocytosis and moderately â†‘ protein. The glu-\ncose level is low in tuberculous, fungal, bacterial, and amebic infections.\nâ–  Perform CSF Gram stain (bacteria); acid-fast stain (mycobacteria); India\nink stain (Cryptococcus); cultures for all organism types; and PCR for\nNeisseria meningitidis is the most\nHSV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), VZV, and\nlikely organism responsible for her\ncondition. Th",
      "char_start": 1098000,
      "char_end": 1100000
    },
    {
      "chunk_id": 550,
      "text": "e physician should enterovirus. Obtain West Nile IgM serologies and consider a wet prepara-\nsuspect meningococcal meningitis in tion (free-living amebae) and a Giemsa stain (trypanosomes) if the history\na very ill patient with fever, headache, is suggestive.\naltered mental status, a petechial\nrash in the lower extremities, and\na CSF profile indicative of bacterial\nmeningitis.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338822 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 383\nFIGURE 2.9-18. Brain abscess. Post-\ncontrast MRI of the brain shows ring-\nenhancing lesions in the lateral right\nFIGURE 2.9-17. HSV encephalitis. Coronal fluid-attenuated inversion recovery (FLAIR) image frontal lobe, with â€œdaughterâ€ lesions\nof a young man with HSV encephalitis shows the characteristic MRI pattern within the cortex (smaller adjacent rings of enhancement)\nof the right temporal lobe (circle). The left temporal lobe is also involved (arrow), but to a lesser also noted. (Reproduced with permission from\nextent. (Reproduced with permission from Fauci AS et al. Harrisonâ€™s Principles of Internal Medicine, 17th ed. New York, NY: USMLE-Rx.com.)\nMcGraw-Hill; 2008.)\nTreatment\nâ–  HSV encephalitis: Immediate IV acyclovir, foscarnet if resistant\nâ–  CMV encephalitis: IV ganciclovir Â± foscarnet\nâ–  Suspected Rocky Mountain spotted fever or ehrlichiosis: Doxycycline\nâ–  Lyme encephalitis: Ceftriaxone\nBRAIN ABSCESS\nKEY FACT\nA focal suppurative infection of the brain parenchyma, usually with a â€œring-\nenhancingâ€ appearance caused by a fibrous capsule (see Fig. 2.9-18). The The classic clinical triad of headache,\nmost common pathogens are Streptococci, Staphylococci, and anaerobes; 80% fever, and a focal neurologic deficit\nto 90% are polymicrobial. Nonbacterial causes include Toxoplasma and Can- is present in 50% of cases of brain\ndida; Aspergillus and zygomycosis should be considered in immunocompro- abscess.\nmised hosts, and neurocysticercosis should",
      "char_start": 1100000,
      "char_end": 1102000
    },
    {
      "chunk_id": 551,
      "text": " be considered in relevant\nepidemiologic settings (Central and South America, sub-Saharan Africa and\nAsia). Modes of transmission include the following:\nâ–  Direct spread (25â€“50% of cases): Caused by paranasal sinusitis (fre-\nquently affects young men and is often caused by Streptococcus milleri [of\nthe Î±-hemolytic viridans streptococcus]), otitis media, mastoiditis, or den-\ntal infection\nâ–  Direct inoculation: History of head trauma or neurosurgical procedures\nâ–  Hematogenous spread (25% of cases): Often shows an MCA distribution\nwith multiple abscesses that are poorly encapsulated and located at the\ngray-white junction\nHistory/PE\nHeadache (most common), drowsiness, inattention, confusion, and seizures\nare early symptoms, followed by signs of increasing ICP and focal neurologic\ndeficits.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338833 1100//2211//2222 22::1188 PPMM\n\n384 HIGH-YIELD FACTS IN NEUROLOGY\nKEY FACT Diagnosis\nIn general, LP is contraindicated for â–  CT scan will show a ring-enhancing lesion with a low-density core.\na patient with a mass lesion in the â–  Most accurate test: MRI has a higher sensitivity for early abscesses and\nposterior fossa lesions.\nbrain because of the potential but life-\nthreatening risk for uncal or cerebellar â–  CSF analysis is not necessary and may precipitate brainstem herniation.\nherniation. â–  Lab values may show peripheral leukocytosis, â†‘ ESR, and â†‘ C-reactive\nprotein (CRP).\nTreatment\nâ–  IV antibiotics: Metronidazole + a third-generation cephalosporin Â± van-\ncomycin for 6 to 8 weeks. The physician should obtain serial CT/MRIs to\nfollow resolution. Lesions <2 cm can often be treated medically.\nâ–  Surgical drainage (aspiration or excision) may be necessary for diagnostic\nand/or therapeutic purposes.\nâ–  Dexamethasone with taper may be used in severe cases to â†“ cerebral\nedema; IV mannitol may be used to â†“ ICP. Prophylactic anticonvulsants\nshould be given.\nDISORDERS OF THE NEUROMUSCULAR JUNCTION\nMYASTHENI",
      "char_start": 1102000,
      "char_end": 1104000
    },
    {
      "chunk_id": 552,
      "text": "A GRAVIS\nMyasthenia gravis (MG) is an autoimmune neuromuscular junction disorder\ncaused by nicotinic acetylcholine receptor autoantibodies. These autoantibod-\nies bind to nicotinic acetylcholine receptors on the postsynaptic neuromuscu-\nlar membrane, which results in a fatiguing muscular weakness syndrome with\na sex-specific age distribution (women aged 20â€“30 years; men aged 60â€“80\nA\nyears). Seventy-five percent of patients have thymic disease (85% thymic\nhyperplasia; 15% thymoma; Fig. 2.9-19).\nHistory/PE\nâ–  Hallmark: Muscle fatigability. Small, often-used muscles (eyelid, jaw\nmuscles) are more sensitive to AChR-Ab interference, which results in\nocular symptoms (most common initially: ptosis, diplopia), facial weak-\nness, bulbar symptoms (chewing fatigue, dysphagia, dysarthria), and\nupper/lower extremity muscle weakness notably worse at the end of the\nday and with sustained activity.\nB\nâ–  Other distinguishing features: Absence of autonomic symptoms (only a\nneuromuscular junction disorder) along with normal pupillary responses,\nsensations, and deep tendon reflexes. Progressive muscle weakness occurs\nwith increased use. See Table 2.9-16.\nâ–  Myasthenic crisis: Rapid worsening of muscular weakness that is life\nthreatening because it can lead to respiratory distress and airway obstruc-\ntion due to respiratory and bulbar muscle fatigue, respectively. Precipitat-\ning factors include infection (most common), surgery, and drugs. Notably,\nantibiotics (aminoglycosides, fluoroquinolones), hydroxychloroquine, and\nÎ²-blockers can precipitate crisis and/or worsen symptoms. Avoid if\nFIGURE 2.9-19. CT image of an encapsu-\nlated thymoma (arrow) in a 61-year-old possible.\nfemale with myasthenia gravis set to\nundergo surgical resection. (Reproduced Diagnosis\nwith permission from Lee JH, Park CM, Park SJ, et al.\nValue of computerized 3D shape analysis in differen- â–  Best initial test: Acetylcholine receptor autoantibodies (AChR-Ab). If\ntiating encapsulated from invasive thymomas. PLoS serone",
      "char_start": 1104000,
      "char_end": 1106000
    },
    {
      "chunk_id": 553,
      "text": "gative for AChR-Ab and symptoms suggest MG, the case calls for\nOne. 2015;10[5]:e0126175. Published 2015 May 4. muscle-specific kinase (MuSK) autoantibodies.\ndoi:10.1371/journal.pone.0126175.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338844 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 385\nTABLE 2.9-16. Myasthenia Gravis vs Lambert-Eaton Myasthenic Syndrome\nLAMBERT-EATON\nKEY FEATURES MYASTHENIA GRAVIS MYASTHENIC SYNDROME\nCause Acetylcholine receptor (AChR) VGCC autoantibodies that bind\nautoantibodies that bind to to presynaptic VGCCs on the\nthe postsynaptic nicotinic NMJ + autonomic nervous\nACh-Rs on the neuromus- system\nMNEMONIC\ncular junction (NMJ)\nBecause patients with myasthenic\nUsing muscles Worsens symptoms Temporarily improves symp- gravis characteristically lack\n(muscle fatigability) toms (muscle usability) autonomic symptoms, the presence\nof autonomic symptoms suggests\ntreatment (anticholinesterase)\nTesting deep tendon Initially normal â†’ Initially diminished/absent â†’\ntoxicityâ€”\nreflexes Worsen with repeated testing Improve with repeated testing\nDUMBELLS signs/symptoms:\nEye symptoms Common Less common Diarrhea\nUrination\nMiosis\nAutonomic dysfunction Absent Present\nBradycardia + Bronchorrhea +\nBronchospasms\nEmesis\nLacrimation\nLethargy\nSalivation\nâ–  Most accurate test: Electromyography (EMG). It shows muscle fatigabil-\nity with a decremental response to repetitive nerve stimulation. This\noccurs as endogenous acetylcholine (ACh) stores are depleted and AChR-\nAb outcompete endogenous ACh for nicotinic receptors.\nâ–  Best initial imaging test: Contrast CT or MRI of the chest to evaluate the\nKEY FACT\nanterior mediastinum for thymic disease.\nâ–  Bedside tests: Application of ice for 1 to 2 minutes on the eyelid to relieve Myasthenia gravis presents with eye/\nptosis by decreasing acetylcholinesterase activity and increasing endoge-\nbulbar muscle symptoms that worsen\nnous ACh in the synapse. Edrophonium is a short-act",
      "char_start": 1106000,
      "char_end": 1108000
    },
    {
      "chunk_id": 554,
      "text": "ing acetylcholines-\nwith use, initially normal reflexes that\nterase antagonist that raises endogenous ACh in the synapse to briefly\nworsen with testing, with no autonomic\nimprove motor symptoms.\ndysfunctionâ€”classically in a patient\nwith an anterior mediastinal mass\nTreatment\n(thymic hyperplasia/thymoma).\nâ–  Acute exacerbations/myasthenia crisis: Plasmapheresis/exchange or intra-\nvenous immunoglobulin (IVIG) Â± steroids. Monitoring vital capacity,\nmaximum inspiratory pressure, and airway patency can call attention to\ninvasive or noninvasive ventilation needs.\nâ–  Chronic drug therapies: Acetylcholinesterase inhibitors (best initial treat-\nment; pyridostigmine) Â± glycopyrrolate (antimuscarinic drug used to con-\ntrol autonomic side effects of anticholinesterase treatment). Most need\nimmunotherapy initially with steroids, followed by a transition to nonste-\nroidal immunosuppressants such as azathioprine.\nâ–  Anticholinesterase drug toxicity: Because patients with MG lack auto-\nnomic symptoms, alertness is required for patients presenting with wide-\nspread cholinergic activation.\nâ–  Surgery: Thymectomy indicated for all patients with thymomas and for all\npatients <60 years of age with mild to moderate disease.\nLAMBERT-EATON MYASTHENIC SYNDROME\nLambert-Eaton myasthenic syndrome (LEMS) is an autoimmune neuromus-\ncular junction disorder caused by voltage-gated calcium channel (VGCC)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338855 1100//2211//2222 22::1188 PPMM\n\n386 HIGH-YIELD FACTS IN NEUROLOGY\nautoantibodies. These autoantibodies bind to VGCCs on the presynaptic neu-\nromuscular membrane and other presynaptic terminals located throughout\nthe autonomic nervous system â†’ â†“ ACh release. This results in a muscular\nweakness syndrome with autonomic dysfunction. It can occur as a non-para-\nneoplastic syndrome or a paraneoplastic syndrome (more common) that is\nclassically associated with small cell lung carcinoma (62% of cases).\nKEY FACT History/PE",
      "char_start": 1108000,
      "char_end": 1110000
    },
    {
      "chunk_id": 555,
      "text": "\nRepetitive nerve stimulation reveals a â–  Hallmark: Muscle usability. LEMS is characterized by slow-onset proxi-\ncharacteristic incremental response in mal muscle weakness (difficulty rising from chair, walking, combing hair,\nLambert-Eaton myasthenic syndrome reaching upward on shelves) that is distinguished from myositis as creatine\n(muscle usability) but shows a kinase (CK) levels are normal and myalgia is absent. The symptoms of\ndecremental response in myasthenia LEMS improve with activity (muscle usability) as repeated depolarizations\ngravis (muscle fatigability). of presynaptic terminals help overcome the autoantibody blockade of pre-\nsynaptic VGCCs.\nâ–  Other distinguishing features: Presence of autonomic dysfunction. Auto-\nantibodies to presynaptic VGCCs impair Ach release in the neuromuscu-\nlar junction and throughout the autonomic nervous system. This results in\nautonomic dysfunction, including xerostomia, erectile dysfunction, consti-\npation, and impaired pupillary light response. Initial deep tendon reflexes\nare diminished/absent but increase with repeated testing due to â€œmuscle\nusability.â€\nDiagnosis\nâ–  Best initial test: Anti-P/Qâ€“type VGCC autoantibodies.\nâ–  Most accurate test: EMG. Shows muscle usability with an incremental\nresponse to repetitive nerve stimulation as repeated depolarizations of pre-\nsynaptic terminals helps overcome the autoantibody blockade of presynap-\ntic VGCCs.\nâ–  Best initial imaging test: CT or MRI facilitates evaluation for underlying\nmalignancy, classically small cell lung cancer (contrast CT chest).\nKEY FACT Treatment\nLambert-Eaton myasthenic syndrome â–  Paraneoplastic LEMS â†’ treatment of underlying malignancies (classically\nsmall cell lung carcinoma).\npresents with proximal muscle\nweakness that briefly improves with â–  Amifampridine (3,4-diaminopyridine [3,4-DAP]) or guanidine. Both\nâ†“ potassium efflux from presynaptic neurons â†’ prolonged depolarization\nuse, initially diminished/absent\nâ†’ â†‘ ACh release. Acetylcholinesterase inhibitors ",
      "char_start": 1110000,
      "char_end": 1112000
    },
    {
      "chunk_id": 556,
      "text": "(pyridostigmine) are also\nreflexes that improve with testing, and\nused to â†‘ ACh.\nautonomic dysfunctionâ€”classically in a\npatient with a lung mass on imaging. â–  IVIG followed by oral immunosuppressive agents if persistent disease\ndespite medical therapy and treatment of underlying malignancy.\nBOTULISM\nSymmetric descending paralysis caused by ingestion of Clostridium botulinum\nspores or exposure to spores in soil of endemic regions (California, Utah).\nDisease calls for IV botulism IG and respiratory support. Consider in any\ninfant with bulbar palsies, ptosis, constipation, or hypotonia. Avoid honey to\nprevent exposure in young infants (see Table 2.9-17).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338866 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 387\nTABLE 2.9-17. Types of Botulism\nFOODBORNE INFANT WOUND\nEtiology Ingestion of pre- Ingestion of spores Spores in contaminated\nformed toxin wounds (eg, IV drug use)\nIncubation 12â€“36 hours Days to 4 weeks 4â€“14 days\nTreatment Equine botulinum Human botulism Equine botulinum antitoxin\nantitoxin immunoglobulin Surgical debridement\nPrevention Sterilize food Avoid giving honey to Avoid using IV drugs\n(autoclaving) infants <12 months Follow medically sound\nBoil food twice wound care\nbefore canning\nDEMYELINATING DISORDERS\nMULTIPLE SCLEROSIS\nMultiple sclerosis (MS) is a demyelinating disorder of the CNS of unclear eti-\nology, but it is thought to be immune mediated. The female-to-male ratio is\n2:1, and it is typically diagnosed between 20 and 40 years of age. MS becomes\nmore common with increasing distance from the equator during childhood\nand in patients with a history of autoimmune disease. MS has been associated\nwith the HLA-DRB1 locus. Subtypes are relapsing remitting (most common),\nprimary progressive, secondary progressive, and progressive relapsing.\nHistory/PE\nâ–  Multiple neurologic complaints that are separate in time and space and\nare not explained by a single lesion. ",
      "char_start": 1112000,
      "char_end": 1114000
    },
    {
      "chunk_id": 557,
      "text": "As the disease progresses, permanent\ndeficits accumulate.\nâ–  Bilateral internuclear ophthalmoplegia caused by bilateral medial longitu-\ndinal fasciculus (MLF) lesions is classic for MS.\nâ–  Limb weakness, gait unsteadiness, paresthesias, Lhermitte sign (electric\nshock sensation that radiates down the spine or limbs), blurry vision, ver-\ntigo, nystagmus, urinary retention, sexual and bowel dysfunction, depres-\nKEY FACT\nsion, and cognitive impairment are also seen. Symptoms classically worsen\ntransiently with hot showers.\nPregnancy may be associated with\nâ–  Attacks are unpredictable but on average occur every 1.5 years, lasting for a â†“ in MS symptoms, but this comes\n2 to 8 weeks.\nwith increased risk of exacerbation\nâ–  Neurologic symptoms can come and go or be progressive. Those with a postpartum.\nrelapsing and remitting history have the best prognosis.\nDiagnosis\nâ–  Thorough history and physical examination are important.\nâ–  Most accurate tests: Use MRI and LP for definitive diagnosis.\nâ–  MRI (diagnostic test of choice for MS) shows multiple asymmetric, often\nperiventricular, white matter lesions (Dawson fingers), especially in the\ncorpus callosum. Active lesions are enhanced with gadolinium.\nâ–  CSF reveals â†‘ IgG index or at least two oligoclonal bands not found in the\nserum (nonspecific).\nâ–  LP is only indicated for atypical cases where the diagnosis is unclear clini-\ncally and by MRI.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338877 1100//2211//2222 22::1188 PPMM\n\n388 HIGH-YIELD FACTS IN NEUROLOGY\nTreatment\nâ–  Acute exacerbations: High-dose IV corticosteroids. Plasma exchange in\npatients who do not respond to corticosteroids\nâ–  Disease-modifying medications: Natalizumab and ocrelizumab are highly\neffective in patients who havenâ€™t responded to other therapies. Risk of PML\nwith natalizumab. Patients with less active disease can be started on oral\nmedications, such as dimethyl fumarate or fingolimod. Beta-interferon\ntherapy and glatiramer ha",
      "char_start": 1114000,
      "char_end": 1116000
    },
    {
      "chunk_id": 558,
      "text": "ve the highest safety profiles but decreased\neffectiveness.\nâ–  Symptomatic therapy includes baclofen for spasticity, cholinergics for uri-\nnary retention, anticholinergics for urinary incontinence, carbamazepine\nor amitriptyline for painful paresthesias, and antidepressants for clinical\ndepression.\nGUILLAIN-BARRÃ‰ SYNDROME\nMNEMONIC\nAn acute, rapidly progressive demyelinating autoimmune disorder of the\nThe 4 As of Guillain-BarrÃ© peripheral and cranial nerves that results in weakness. Associated with recent\nsyndromeâ€”\nCampylobacter jejuni infection, viral infection, or influenza vaccine (in\nAcute inflammatory demyelinating extremely rare cases). This preceding infection triggers an autoimmune\npolyradiculopathy response against the myelin or axon of peripheral nerves. Approximately 85%\nAscending paralysis\nof patients make a complete or near-complete recovery (may take up to\nAutonomic neuropathy\n1 year). The most common type is called acute inflammatory demyelinating\nAlbuminocytologic dissociation (increased\npolyneuropathy. Another subtype is Miller Fisher syndrome, characterized by\nalbumin in CSF)\nophthalmoplegia, ataxia, and absent reflexes.\nHistory/PE\nâ–  Classically presents with progressive (hours to days), symmetric, ascending\nparalysis (distal to proximal) and areflexia. Paralysis can progress to involve\nthe trunk, diaphragm, and cranial nerves. Twenty-five percent of patients\nexperience respiratory failure and may require intubation.\nâ–  Autonomic and sensory nerves may also be affected, leading to glove-and-\nstocking distribution paresthesias and autonomic dysregulation (eg, ortho-\nstatic hypotension, bladder dysfunction, arrhythmias).\nâ–  Increased risk of hyponatremia (poor prognostic factor).\nKEY FACT\nDiagnosis\nRemember that ascending paralysis\nwith normal CSF findings and without â–  Evidence of diffuse demyelination is seen on nerve conduction studies,\nautonomic dysfunction is characteristic which show â†“ nerve conduction velocity.\nof tick-borne paralysis, not Guillai",
      "char_start": 1116000,
      "char_end": 1118000
    },
    {
      "chunk_id": 559,
      "text": "n-BarrÃ© â–  Diagnosis is supported by an elevated CSF protein level >55 mg/dL and\nsyndrome. normal WBC count (albuminocytologic dissociation).\nTreatment\nâ–  Frequent monitoring of maximal negative inspiratory force (NIF) and vital\ncapacity can determine whether the patient should be admitted to the\nintensive care unit (ICU) for impending respiratory failure.\nâ–  Plasmapheresis and IVIG are first-line. Corticosteroids are not indicated.\nâ–  Aggressive physical rehabilitation is imperative.\nNEURODEGENERATIVE DISORDERS\nNeurodegenerative disorders commonly present with cognitive complaints.\nEarly on, it can be difficult to determine whether this is due to normal aging\nor mild or major neurocognitive impairment (see Table 2.9-18).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338888 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 389\nTABLE 2.9-18. Clinical Approach to Neurocognitive Disorders\nCONDITION CRITERIA\nNormal aging Age >60 years, normal MMSE (>27/30)\nExecutive function issues in attention span, problem solving, acquiring new information\nWord-finding difficulties (expressive aphasia)\nAdvanced sleep-wake cycle (eg, go to sleep 7 pM, wake at 3 aM)\nGenerally, no loss of functional ability of daily living occurs (ADLs, IADLs)\nMild neurocognitive disorder Deficit in at least one neurocognitive domain (executive function, perceptual-motor function, language,\nlearning + memory, social cognition, complex attention) that cannot be related to normal aging\nAbnormal MMSE (23â€“27/30)\nGenerally, some functional ability is lost, but patient can still function in daily living (ADLs) with certain\nconstraints (IADLs)\nMajor neurocognitive disorder = Significant decline in one or more neurocognitive domains\ndementia Abnormal MMSE (usually <24/30)\nFunctional ability is lost + assistance with ADLs/IADLs is needed\nMost important risk factor is age\nClassic 4 As of dementia:\n1. Amnesia (forgetting)\n2. Aphasia (forgetting words, struggling to comm",
      "char_start": 1118000,
      "char_end": 1120000
    },
    {
      "chunk_id": 560,
      "text": "unicate, comprehension issues [nods to pretend])\n3. Apraxia (cannot perform preprogrammed motor tasks) â†’ cannot do job/ADLs/IADLs â†’ eating,\ndressing, using a TV remote, driving a car, mobility (walking) issues\n4. Agnosia (struggling to interpret senses): Visual (cannot recognize people), auditory (cannot recognize\na voice as familiar), alexia (inability to read or comprehend written language), sensing full bladder â†’\nincontinence, painâ†’ general irritability\nContrast delirium (acute, level-of-consciousness changes, cognition waxes/wanes, usually reversible, EEG\nabnormal with â€œacutely sick brainâ€) versus dementia (exhibits no changes in level of consciousness,\nusually irreversible, chronic + gradually progressive cognitive decline, EEG normal)\nRuling out reversible causes via history (especially medications, social history for depression [loss of\nspouse] â†’ pseudodementia), physical examination, and laboratory (CBC + differential, thyroid func-\ntion tests, vitamin levels (B/B ), chemistry panel, infection diseases (VDRL [syphilis] + HIV screening)\n9 12\nÂ± imaging (CT/MRI)\nREVERSIBLE CAUSES OF DEMENTIA IRREVERSIBLE CAUSES OF DEMENTIA\nHypothyroidism Alzheimer disease (overall 66% of cases)\nNeurosyphilis/HIV dementia Vascular (multi-infarct dementia; overall 5%â€“10% cases)\n(depending on stage/treatment) Parkinson disease dementia, Lewy body dementia (20%)\nVitamin B , B deficiencies Huntington disease, frontotemporal dementia\n12 9\nThiamine deficiency (alcohol Unresectable brain neoplasm, Wilson disease, PML\noveruse â†’ Wernicke aphasia) Prion diseases (Creutzfeldt-Jakob disease)\nMedications (eg, benzodiazepines, Neurosyphilis/HIV dementia (depending on stage/treatment)\nanticholinergics) Thiamine deficiency (alcohol abuse â†’ Korsakoff)\nNormal-pressure hydrocephalus\nPseudodementia\nChronic subdural hematoma (fall\nâ†’ bridging veins tear)\nADLs, Activities of daily living; IADLs, instrumental activities of daily living; MMSE, Mini Mental State Examination (score range depends on\neducat",
      "char_start": 1120000,
      "char_end": 1122000
    },
    {
      "chunk_id": 561,
      "text": "ion level).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 338899 1100//2211//2222 22::1188 PPMM\n\n390 HIGH-YIELD FACTS IN NEUROLOGY\nKEY FACT DEMENTIA\nIn HIV-associated neurocognitive\nDementias are progressive, chronic diseases characterized by the continuous\ndisorder (HAND) can occur in HIV/AIDS\ndegeneration of neurons. So focus on the onset of early presenting features to\npatients regardless of HIV treatment\ndiagnose them in vignettes, as middle-to-late findings can overlap. Table 2.9-\nstatus. HAND is partly caused by HIV-\n19 and the sections that follow contrast the time course, diagnostic criteria,\ninfected microglia in the CNS. Dx:\nand treatment of common types of dementia.\nDiagnosis of exclusion; early findings\ninclude mild cognitive impairment\nALZHEIMER DISEASE\nthat can progress to HIV-associated\ndementia. Tx: antiretroviral therapy;\navoid efavirenz due to CNS side effects. Alzheimer disease (AD) is a chronic, progressive neurodegenerative disease that\nrepresents the most common cause of dementia (66%). Degeneration of cholin-\nergic circuits â†’ diffuse atrophy of cortex + subcortex (hippocampus = hall-\nmark of recent memory impairment). Age is the most important risk factor for\nsporadic AD, as 95% of patients present at age >65. The apolipoprotein E gene\nTABLE 2.9-19. Types of Dementia\nTIME COURSE,\nTYPE KEY EARLY PRESENTATION PATHOLOGIC FINDINGS IMAGING/STUDIES\nAlzheimer Gradual, early memory Extracellular neuritic plaques (Image A, MRI/CT â†’ diffuse cortical atrophy (especially in\ndisease impairment red arrows: amyloid Î² trapping neuritic temporal/parietal lobes) + hippocampal atrophy\nprocesses) + intracellular neurofibril- â†’ hydrocephalus ex vacuo = ventriculomegaly,\nlary tangles (Image B, black arrow: which is in proportion to increased sulcal size\nhyperphosphorylated tau proteins) +\nintracellular Hirano bodies (rod-shaped\naggregates actin/associated proteins,\nespecially in hippocampus)\nVascular Stepwise, abrupt Strokes in ",
      "char_start": 1122000,
      "char_end": 1124000
    },
    {
      "chunk_id": 562,
      "text": "multiple areas of cerebral Brain imaging revealing evidence of old infarctions\ndementia decline after each cortex and subcortical regions (including lacunes) or extensive deep white-\novert/subclinical matter changes secondary to chronic ischemia\nstroke\nFrontotemporal Gradual, early person- Neuronal intracellular accumulations of MRI revealing unilateral or bilateral frontal and/or\ndementia (Pick ality Â± language ubiquitinated TDP-43 proteins Â± Pick temporal lobe atrophy â†’ hydrocephalus ex vacuo\ndisease) changes bodies Fluorodeoxyglucose-positron emission\ntomography (FDG-PET) â†’ frontotemporal hypo-\nperfusion + hypometabolism\nNormal-pressure Gradual, early gait â†“ CSF absorption â†’ â†‘ CSF â†’ lateral MRI > CT â†’ ventriculomegaly without cortical\nhydrocephalus ataxia ventricles expand â†’ stretch corona atrophy = without sulcal enlargement\nradiata â†’ Wobbly, Wet, Wacky\nCreutzfeldt-Jakob Abrupt, rapidly pro- Real-time quaking-induced conversion MRI (diffusion-weighted imaging) â†’ â†‘ T2 + FLAIR\ndisease gressive dementia + (RT-QuIC) detection of prions, spongi- intensity in the putamen + caudate\nstartle myoclonus form degeneration EEG â†’ periodic sharp, triphasic synchronous dis-\ncharge complexes\n(continues)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339900 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 391\nTABLE 2.9-19. Types of Dementia (continued)\nTIME COURSE,\nTYPE KEY EARLY PRESENTATION PATHOLOGIC FINDINGS IMAGING/STUDIES\nDementia with Gradual, more rapid Round, eosinophilic inclusions of MRI â†’ cortical atrophy with limited hippocampal\nLewy bodies than Alzheimer Î±-synuclein in cerebral cortex (Image atrophy (vs Alzheimer disease)\ndisease; hallu- C) (dementia with Lewy bodies [DLB])\ncinations, daily or subcortical (basal ganglia)/midbrain\nfluctuations in regions (Parkinson disease dementia)\ncognition; parkin-\nsonism; REM sleep\nbehavior disorder\nA B C\nImage A reproduced with permission from USMLE-Rx.com. Image B reproduced with",
      "char_start": 1124000,
      "char_end": 1126000
    },
    {
      "chunk_id": 563,
      "text": " permission from Dr. Kristine Krafts. Image C Modified with\npermission from Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci,\n2008;6:8. doi:10.1186/1477-5956-6-8.\ncan be harmful or protective (Îµ4 allele â†’ amyloid precursor protein [APP] â†’\npromotes formation of amyloid Î² [pathologic]). Îµ2 allele â†’ APP â†’ promotes\nformation of amyloid Î± (nonpathologic). â†‘ number = â†‘ risk. Early-onset AD\n(5% cases, <65 years of age) is familial (APP + presenilin 1,2 gene mutations)\nand associated with Down syndrome (APP on chromosome 21).\nHistory/PE\nâ–  Neurocognitive dysfunction: Degeneration of cholinergic circuits to hip-\npocampus â†’ declarative episodic recent memory impairment = earliest,\nmost important clinical finding. Continued degeneration of cortex + sub-\ncortex â†’ progressive memory impairments (eg, long-term memories) later\nin the disease. Other early-to-intermediate findings include executive dys-\nfunction with judgment/problem solving (poor work performance) + MNEMONIC\nvisuospatial impairments (getting lost in familiar places) + language defi-\ncits (naming, comprehension, fluency). Other cognitive domains = inter- Symptom onset distinguishes\nAD from normal-pressure\nmediate-to-late findings.\nhydrocephalus (NPH):\nâ–  Behavioral + psychiatric: Middle to late in the course of AD. Patients\nexhibit personality changes and can become apathetic, socially disen- Alzheimer (DUM): Dementia (early, short-\nterm memory) > Urinary incontinence\ngaged, irritable, aggressive, and psychotic.\n> Motor\nâ–  Incontinence + motor: Bowel/bladder incontinence + motor dysfunc-\nNPH (MUD): Motor (early, gait ataxia) >\ntion (eg, apraxia for learned motor tasks) are not present in the early-to-\nUrinary incontinence > Dementia\nintermediate course of AD (mainly late findings).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339911 1100//2211//2222 22::1188 PPMM\n\n392 HIGH-YIELD FACTS IN NEUROLOGY\nDiagn",
      "char_start": 1126000,
      "char_end": 1128000
    },
    {
      "chunk_id": 564,
      "text": "osis\nClinical diagnosis:\nâ–  Imaging: MRI/CT reveals diffuse cortical (especially temporal/parietal\nlobes) + hippocampal atrophy â†’ hydrocephalus ex vacuo\nâ–  Pathologic examination reveals extracellular neuritic plaques (amyloid Î²\nentrapping neuritic processes â†’ cerebral amyloid angiopathy â†’ lobar\nhemorrhage) + intracellular neurofibrillary tangles (hyperphosphorylated\ntau proteins) + intracellular Hirano bodies (rod-shaped aggregates actin/\nassociated proteins, especially in hippocampus)\nTreatment\nâ–  Best first-line treatment of mild to moderate AD: Acetylcholinesterase\ninhibitors. Degeneration of cholinergic neurons â†’ widespread choliner-\ngic deficiency â†’ treatment with acetylcholinesterase inhibitors (donepe-\nzil, galantamine, rivastigmine) â†’ modest improvement in cognitive +\nglobal functioning. No evidence for altering disease progression. Adverse\neffects include nausea, dizziness, and insomnia, among other cholinergic\nside effects.\nâ–  Avoid anticholinergic medications!\nâ–  Vitamin E can be supplemented for its antioxidant role in mild to moder-\nate dementia. Although evidence is inconclusive, it is often prescribed due\nto its good safety profile.\nâ–  Moderate to severe AD â†’ add memantine â†’ N-methyl-d-aspartate\n(NMDA) receptor antagonist â†’ â†“ glutamate excitotoxicity â†’ neuroprotec-\ntive â†’ modifies progressive symptomatic decline. Adverse effects include diz-\nziness, confusion, and hallucinations.\nVASCULAR DEMENTIA\nDementia associated with a history of stroke and cerebrovascular disease. Vas-\ncular dementia is the second most common type of dementia.\nHistory/PE\nâ–  Stepwise decline in cognitive ability, with impaired executive function\noften preceding memory deficits\nKEY FACT\nâ–  May be associated with other symptoms of stroke, such as sensory or motor\nIf a patient shows abrupt changes in deficits\nsymptoms (especially motor symptoms) â–  Risk factors include age, hypertension, diabetes, coronary artery disease,\nover time rather than a steady decline, embolic sources, and a histor",
      "char_start": 1128000,
      "char_end": 1130000
    },
    {
      "chunk_id": 565,
      "text": "y of stroke\nthink vascular dementia.\nDiagnosis\nThe diagnosis is made when there is dementia or mild cognitive impairment\nand all of the following:\nâ–  Cerebrovascular disease as evidenced by history/PE or neuroimaging\nâ–  Clinical course that is abrupt, stepwise, or related to stroke\nâ–  Symptoms not better explained by other disorders such as progressive non-\nvascular dementia\nTreatment\nProtocols for the prevention and treatment of vascular dementia are the same\nas those for stroke, including treatment of risk factors for atherosclerotic car-\ndiovascular disease (ASCVD).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339922 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 393\nFRONTOTEMPORAL DEMENTIA (PICK DISEASE)\nA rare progressive, irreversible neurodegeneration of mainly the frontal and/or\ntemporal lobes. Frontotemporal dementia (FTD) manifests as early-onset\ndementia (50s to 60s) and encompasses a spectrum of subtypes that present\nwith predominately frontal lobe (Pick personality/behavioral changes/possibly\nmotor) and/or temporal lobe (aphasia) features.\nHistory/PE\nâ–  Behavioral variant FTD (most common) is characterized by early pro-\ngressive changes in behavior that represent a dramatic, persistent shift in\npredisease personality. Representing degeneration of the frontal cortex,\npresentations include disinhibition, socially inappropriate behavior, apa-\nthy, loss of empathy/sympathy, hyperorality (binge eating, putting objects\nin mouth), compulsive behaviors, and depending on subtype/locations of\ndegeneration, motor symptoms.\nâ–  Primary progressive aphasia represents an aphasia subtype of FTD that\npresents with an insidious onset and gradual progression of speech/lan-\nguage impairment such as speech apraxia Â± word finding/usage/compre-\nhension difficulties. Early in the disease, other cognitive domains remain\nintact.\nDiagnosis\nâ–  Clinical diagnosis\nâ–  Imaging:\nâ–  MRI reveals unilateral or bilateral frontal and/or temporal ",
      "char_start": 1130000,
      "char_end": 1132000
    },
    {
      "chunk_id": 566,
      "text": "lobe atrophy\nâ†’ hydrocephalus ex vacuo\nâ–  FDG-PET reveals frontotemporal hypoperfusion + hypometabolism\nâ–  Pathologic examination reveals neuronal intracellular accumulations of\nubiquitinated TDP-43 proteins Â± Pick bodies (spherical [round] aggre-\ngates of hyperphosphorylated tau proteins)\nTreatment\nNo disease-modifying therapies exist. Supportive care only (eg, for depression,\nagitation, insomnia).\nNORMAL-PRESSURE HYDROCEPHALUS\nA relatively rare, potentially reversible form of dementia that arises in adults\nage >60. Normal-pressure hydrocephalus (NPH) is a form of chronic com-\nmunicating hydrocephalus: â†“ CSF absorption â†’ â†‘ CSF â†’ enlargement of\nventricles â†’ lateral ventricles expand â†’ stretching of the corona radiata â†’\ngait ataxia (early, altered corticospinal tract) + urinary urgency/frequency/\nincontinence (loss detrusor inhibition) + dementia. NPH can be idiopathic\nor arise secondarily from damage to the arachnoid granulations (impairs CSF\nabsorption) triggered by inflammatory (meningitis) and hemorrhage-induced\n(intraventricular/subarachnoid) causes. A 71-year-old woman is brought to\nher primary care physicianâ€™s office by\nHistory/PE her son, who is concerned that she\nhas had worsening recent memory,\nPressures: NPH is characterized by a normal opening pressure on LP. Con-\ndifficulty participating in her daily\ntinuous ICP monitoring in studies shows normal or episodically â†‘ ICP. As\nactivities, restlessness, and difficulty\nsuch, NPH is a form of hydrocephalus that occurs in the absence of diffusely\nsleeping for the past year. She scores\nâ†‘ ICP symptoms (papilledema, headaches, nausea/vomiting, vision loss). The\na 22 on the Mini-Mental State Exam\n(MMSE). What is the most likely\ndiagnosis?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339933 1100//2211//2222 22::1188 PPMM\n\n394 HIGH-YIELD FACTS IN NEUROLOGY\nâ†‘ CSF in NPH causes regional, not diffuse, â†‘ ICP via the stretching of the\nlateral ventricles â†’ stretching of the corona radiata â†’",
      "char_start": 1132000,
      "char_end": 1134000
    },
    {
      "chunk_id": 567,
      "text": " classic triad of gait\nataxia (wobbly), urinary incontinence (wet), and dementia (wacky).\nâ–  Gait ataxia (wobbly) is an early hallmark sign. The magnetic gait is like\nthe shuffling gait seen with Parkinson disease (PD) (slow, wide based). It is\ndistinguished by arm swing preservation + lack of other motor findings\n(tremor).\nâ–  Urinary incontinence (wet). Early in disease, urinary urgency/frequency\nis more common. Later in disease, urinary incontinence is more common\nand is accompanied by apathy.\nâ–  Dementia (wacky) evolves over months to years after gait dysfunction with\npsychomotor delay, decreased concentration/attention, executive dysfunc-\ntion, and apathy.\nDiagnosis\nâ–  Clinical: Patients do not need to have the complete triad of gait ataxia,\nurinary incontinence, and dementia.\nFIGURE 2.9-20. Normal-pressure hydro- â–  Gait dysfunction is key, as it can be the only symptom and must be pres-\ncephalus. T2-weighted MRI from a ent for the diagnosis. The physician should establish the presence of uri-\n60-year-old woman with early gait ataxia,\nnary urgency/frequency/incontinence via history and dementia via\nslowly developing urinary incontinence,\ncognitive testing.\nand dementia shows marked dilation of\nthe lateral ventricles (red arrow). This is â–  Best initial imaging test: MRI > CT and shows ventriculomegaly without\nout of proportion to the sulcal enlarge- cortical atrophy = without sulcal enlargement (see Fig. 2.9-20).\nment (ie, without sulcal enlargement) â–  Best confirmatory test: Improvement of symptoms following LP (opening\n(yellow arrow). (Reproduced with permission pressure is normal/slightly â†‘).\nfrom USMLE-Rx.com.)\nTreatment\nKEY FACT Definitive treatment: Ventriculoperitoneal (VP) shunting. A lumbar drainage\ntrial, over the course of 2 to 7 days, can be used to determine potential\nClassic triad of NPH in order of onset =\nresponse to VP shunting. Predominant gait symptoms indicate a favorable sur-\nâ€œWobbly (gait ataxia), Wet (urgency/\ngical response, while the presence",
      "char_start": 1134000,
      "char_end": 1136000
    },
    {
      "chunk_id": 568,
      "text": " of moderate to severe dementia does not.\nincontinence), and Wacky (dementia).â€\nCREUTZFELDT-JAKOB DISEASE\nKEY FACT\nAlthough it is the most common prion disease, Creutzfeldt-Jakob disease\nCJDâ€™s rapid progression and presence (CJD) remains an extremely rare form of dementia. CJD occurs when an\nof myoclonus distinguish it from other abnormal protease-resistant prion protein accumulates in the brain, causing\ndementias. spongy degeneration, neuronal loss, and astrocytic proliferation.\nHistory/PE\nâ–  CJD causes a subacute dementia with ataxia and/or startle-induced myo-\nclonic jerks, with rapid clinical progression that is noted weeks to months\nafter symptom onset.\nâ–  New-variant CJD (mad cow disease) is a more slowly progressive prion dis-\nease seen in younger people with a history of eating contaminated beef or\ncontaminated human brains (kuru).\nâ–  Iatrogenic CJD can be seen after ophthalmologic or neurosurgical proce-\nAlzheimer disease is the likely\ndures such as corneal transplant due to poor equipment sterilization.\ndiagnosis. The key differences\nbetween Alzheimer disease and\nDiagnosis\nnormal aging are that in normal\naging, patients can perform their â–  Definitive diagnosis can be made only by brain biopsy or autopsy, but clin-\nactivities of daily living, complain of ical features, imaging, and lab results are sufficient to make a probable\nmemory loss yet provide detailed diagnosis.\ninformation about their forgetfulness,\nand have a score >27 on the MMSE.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339944 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 395\nâ–  â†‘ 14-3-3 protein in CSF and periodic sharp wave complexes on EEG.\nâ–  Real-time quaking-induced conversion (RT-QuIC) is a new method to\ndetect real-time protein misfolding within CSF samples.\nâ–  Brain MRI may show hyperintensity in the caudate and putamen (â€œhockey\nstick signâ€) or a cortical ribboning pattern.\nâ–  Differential diagnosis includes paraneoplastic syndromes, dr",
      "char_start": 1136000,
      "char_end": 1138000
    },
    {
      "chunk_id": 569,
      "text": "ug induced, and\nautoimmune encephalitis. Probable diagnosis of CJD is made when there is a\nrapid progression of symptoms with no other cause identified by MRI, EEG,\nor CSF samples, plus corroborating findings as listed in this section.\nTreatment\nSymptomatic management. Most patients die within 1 year of symptom onset\nas there is no cure and progression cannot be halted.\nLEWY BODY DEMENTIA\nLewy body dementia is an umbrella term for PD (Lewy body) dementia and\ndementia with Lewy bodies (DLB)â€”distinguished by the 1-year rule (see\nDiagnosis). DLB is the second most common cause of dementia (10%â€“20%\nof cases) and classically presents in patients age >65 and classically presents\nin patients age >65 with associated depression and suicidality.\nHistory/PE\nClassic triad of dementia + parkinsonism + visual â€œhallewynations.â€\nâ–  Dementia is characterized by executive and visuospatial dysfunction.\nâ–  Parkinsonism = extrapyramidal motor symptoms = TRAP (Tremor,\nRigidity, Akinesia/bradykinesia, Postural instability).\nâ–  Visual hallucinations are well-formed + detailed (animals, people,\nabstract shapes/colors).\nâ–  Fluctuations are present in cognition, arousal, and attention (range from\nbaseline to brief decline to strokelike).\nâ–  Rapid eye movement (REM) sleep behavior disorder â†’ recurrent dream-\nrelated vocalizations/motor behaviors.\nDiagnosis\nClinical diagnosis. One-year rule distinguishes PD dementia from DLB:\nâ–  DLB is diagnosed when cognitive impairment occurs with parkinsonism\nor within <1 year before parkinsonism.\nâ–  Parkinson disease dementia (PDD) is diagnosed when cognitive impair-\nment occurs >1 year after parkinsonism.\nâ–  Imaging: MRI can show cortical atrophy with limited hippocampal atro-\nphy (vs AD).\nâ–  Pathology: PD, PDD, and Lewy body dementia all have round, eosino-\nphilic inclusions of Î±-synuclein (Lewy bodies) on pathologic examination\nand represent a disease spectrum. Inclusions are found in cortical cells\n(Lewy body dementia) and basal ganglia (PD, PDD).\nTreatment\nâ–  Ac",
      "char_start": 1138000,
      "char_end": 1140000
    },
    {
      "chunk_id": 570,
      "text": "etylcholinesterase inhibitors for dementia: Donepezil, galantamine,\nrivastigmine. Only used in AD + Lewy body dementias\nâ–  Parkinsonian symptoms: Similar to PD treatment with an emphasis on\nlower doses/slower titration to avoid exacerbating psychotic symptoms and\nhallucinations via â†‘ dopamine\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339955 1100//2211//2222 22::1188 PPMM\n\n396 HIGH-YIELD FACTS IN NEUROLOGY\nMOVEMENT DISORDERS\nHUNTINGTON DISEASE\nAn autosomal dominant neurodegenerative disorder caused by excessive tri-\nnucleotide (CAG) repeats on chromosome 4 during spermatogenesis â†’\nabnormally long huntingtin protein â†’ glutamate excitotoxicity via the\nNMDA-Râ†’ degeneration of cerebrum + striatum (caudate + putamen) â†’\nloss of gamma-aminobutyric acid (GABA)/ACh, unbalanced dopamine (DA)\nactivity â†’ triad of motor (chorea), memory (executive dysfunction), and\nmood (irritability) symptoms. Huntington disease (HD) is slowly progressive,\nwith only symptomatic treatments, and results in death in 10 to 20 years.\nHistory/PE\nA\nTypically presents at 30 to 50 years of age with a family history that is indica-\ntive of anticipation (worsening/earlier symptoms in successive generations)\nand/or with relatives being misdiagnosed with psychiatric conditions/suicide.\nHD is characterized by a triad of motor, memory, and mood symptoms:\nâ–  Motor: Hyperkinetic early in disease (chorea, hyperreflexia, â†‘ urine flow\n[incontinence], hyperhidrosis) early in disease â†’ hypokinetic late in dis-\nease (rigidity, dystonia, bradykinesia, dysphagia, dysarthria). Chorea refers\nto random, brief, and irregular involuntary movements of the face, trunk,\nand limbs that flow between muscle groups. Early in the disease, chorea\nmay manifest as restlessness/fidgetiness with delayed saccades.\nâ–  Memory: Cognitive impairment (executive dysfunction) + dementia.\nâ–  Mood: Symptoms of irritability, depression, and disruption of relationships\nprecede chorea. Other psychiatric symptoms i",
      "char_start": 1140000,
      "char_end": 1142000
    },
    {
      "chunk_id": 571,
      "text": "nclude obsessive-compulsive\ntendencies, aggression, anxiety, paranoia, delusions, hallucinations, suicid-\nality, and psychosis, which may be mistaken for substance abuse.\nB\nDiagnosis\nâ–  Clinical features (motor, memory, mood) + family history (look for antici-\npation and misdiagnosed parents/grandparents with psychiatric conditions/\nsuicide). Test creators may obscure these details in adopted children +\ngenetic confirmation (CAG trinucleotide repeat expansions â‰¥36 repeats).\nâ–  Imaging:\nâ–  FDG-PET early in disease shows altered glucose metabolism in stria-\ntum (caudate + putamen).\nâ–  CT/MRI is important in diagnosing + assessing severity of disease\n(mainly). Late disease findings are marked atrophy of the cerebrum\nand the striatum (caudate + putamen). Atrophy, especially head of the\ncaudate nuclei, â†’ dilation of the lateral ventricles (hydrocephalus ex\nvacuo; see Fig. 2.9-21).\nFIGURE 2.9-21. Atrophy of the head of the\nTreatment\ncaudate nuclei in Huntington Disease.\n(A) Noncontrast CT in a 54-year-old â–  No cure exists, and disease progression cannot be halted. Genetic counsel-\npatient with Huntington disease shows ing is recommended. Medical treatment is symptomatic and aimed at\natrophy of the cerebrum and caudate\nmotor and associated psychiatric features. Mood disorders such as\nnuclei (arrows) â†’ dilation of the lateral\npsychosis/agitation (atypical neuroleptics) and depression/anxiety (first-line\nventricles (hydrocephalus ex vacuo). (B)\nA normal 54-year-old patient with normal treatment: selective serotonin reuptake inhibitors [SSRIs]) should be\ncerebral mass, caudate nuclei (arrows), treated. When approaching treatment, it is important to consider the pres-\nand lateral ventricles. (Modified with permis- ence of chorea that interferes with functioning, as it guides drug selection.\nsion from Ropper AH, Samuels MA. Adams & Victorâ€™s\nâ–  Chorea + psychiatric features result from unbalanced DA (loss of GABA/\nPrinciples of Neurology, 9th ed. New York, NY: McGraw-\nACh) in brain:\n",
      "char_start": 1142000,
      "char_end": 1144000
    },
    {
      "chunk_id": 572,
      "text": "Hill; 2009.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339966 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 397\nâ–  Chorea + comorbid depression, agitation Â± psychosis â†’ atypical neu-\nroleptics (â†“ risk of parkinsonism versus typical psychotics; monitor for\nadverse effects on motor function).\nâ–  Chorea without comorbid depression, agitation, and/or psychosis â†’\ninhibit vesicular monoamine transporter 2 (VMAT2) (tetrabenazine or\ndeutetrabenazine) = monoamine depleting agents â†’ inhibit VMAT2\nâ†’ â†“ DA packing into vesicles â†’ â†“ DA release.\nPARKINSON DISEASE AND PARKINSONISM\nA progressive neurodegenerative disorder characterized by the loss of\nneuromelanin-containing dopaminergic neurons of the substantia nigra pars\ncompacta (part of the basal ganglia). Pathologic examination reveals round,\neosinophilic inclusions of alpha-synuclein in degenerating neurons. Typical\nage at presentation is >50 years, and risk factors include older age and family\nhistory of PDâ€”with smoking being protective. PD is the most common hypo-\nkinetic movement disorder and is characterized by a unilateral hand tremor\n(â€œpill rollingâ€), oscillating rigidity (cogwheel), akinesia/bradykinesia (shuffling\ngait), and postural instability (frequent falls). PD is an idiopathic condition,\nKEY FACT\nbut the motor symptoms (parkinsonism) can occur secondary to other neuro-\ndegenerative disorders, trauma, and medications. Treatment aims to â†‘ dopa-\nThe gaits of NPH and PD are similar. A\nminergic activity (mainly) + â†“ cholinergic activity.\nsignificant difference between them, for\ndiagnostic purposes, is the arm swing:\nHistory/PE\nâ–  PD gait = Reduced arm swing\nPreclinical stage: Characterized by nonmotor signs of constipation, anosmia, â–  NPH gait = Preservation of arm\nsleep disturbances (REM disorders, restless leg syndrome, excessive sleepi- swing\nness) and by mood disorders (depression, apathy, anxiety) that predate motor\nsymptoms by up to 20 years.\nClinical: Charac",
      "char_start": 1144000,
      "char_end": 1146000
    },
    {
      "chunk_id": 573,
      "text": "terized by motor signs (mainly), autonomic dysfunction, and\nneuropsychiatric features:\nâ–  Motor signs: Unilateral at onset with possible progression to the contralat-\neral side. Asymmetric (worse on one side). See the TRAPSS mnemonic to\nrecall the following motor signs = parkinsonism:\nâ–  Tremor: Unilateral resting (4â€“6 Hz) tremor that improves with move-\nment and worsens with distraction. â€œPill-rollingâ€ quality arises from\n4- to 6-Hz frequency of thumb and finger movements.\nâ–  Rigidity: Increased resistance to passive movement that can be uniform\n(lead pipe) but is classically cogwheeled, resulting in oscillating\n(â€œratchet-likeâ€) joint movements.\nâ–  Akinesia/bradykinesia: Lack of or slowness of movements that can man-\nifest as a narrow-based Shuffling gait with shortened strides + lack of\narm swing; Small handwriting (micrographia); hypomimia (masked\nfaces/limited facial expressions); hypophonia (soft speech).\nâ–  Postural instability: Characterized by a flexed axial posture, loss of bal- MNEMONIC\nance with stopping/turning, and an increased risk for frequent falls.\nâ–  Autonomic dysfunction: Neurogenic orthostatic hypotension (supine Parkinson disease TRAPSS the\nbodyâ€”\nhypertensive and/or orthostatic hypotension), increased sweating, oily skin,\nconstipation, sexual dysfunction, urinary urgency, dysphagia. Tremor (â€œpill rollingâ€)\nâ–  Neuropsychiatric: Dementia (advanced disease, see â€œDiagnosisâ€), execu- Rigidity (cogwheeling)\nAkinesia/bradykinesia\ntive/visuospatial dysfunction, visual hallucinations, delusions, sleep disor-\nPostural instability\nders (insomnia, restless leg syndrome, REM disorders, daytime sleepiness\nShuffling gait\nwith sleep attacks, vivid dreams, sleep fragmentation [night awakenings]),\nSmall handwriting (micrographia)\ndepression, anxiety, apathy, anosmia.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339977 1100//2211//2222 22::1188 PPMM\n\n398 HIGH-YIELD FACTS IN NEUROLOGY\nDiagnosis\nSymptoms of parkinsonism (TRAPSS) may be",
      "char_start": 1146000,
      "char_end": 1148000
    },
    {
      "chunk_id": 574,
      "text": " present in other conditions\n(secondary). Clinical suspicion for alternative causes â†‘ when there is lack of\nresponse to levodopa and and the following findings: a lack of adequate\nresponse to levodopa and the following findings:\nParkinsonism + ...\nâ–  Dysautonomia (mainly orthostasis) = multisystem atrophy-Parkinsonian\nType (MSA-P) (Shy-Drager syndrome)\nâ–  Cerebellar ataxia = multisystem atrophy-cerebellar type (MSA-C)\nâ–  Oculomotor deficits (vertical gaze palsy) with no tremor = progressive\nsupranuclear palsy (PSP)\nâ–  Impaired cognition, dystonia, sensory deficits, myoclonus = corticobasal\ndegeneration\nâ–  Certain patient drugs (drug-induced â†“ dopamine activity):\nâ–  Common causes: Typical > atypical antipsychotics, antiemetics (meto-\nclopramide), vesicular dopamine depleters (tetrabenazine, reserpine),\nCCBs (flunarizine, cinnarizine).\nâ–  Infrequent causes: Atypical antipsychotics (clozapine and quetiapine\n[itâ€™s â€œquietâ€ so use in PD psychosis]), mood stabilizer (lithium), antiepi-\nleptics (valproic acid, phenytoin), antiarrhythmic (amiodarone), MPTP\n(used in illegal drugs â†’ destruction of substantia nigra â†’ PD).\nâ–  Liver findings: Consider Wilson disease or hemochromatosis.\nâ–  Dementia = PDD or Lewy body dementia (see â€œDementiaâ€ section).\nTreatment\nKEY FACT\nâ–  General guidelines: With the loss of dopaminergic neurons in the sub-\nTreatment of Parkinson disease is\nstantia nigra pars compacta, cholinergic circuits operate relatively unop-\nbased on â†‘ dopaminergic activity +\nposed. Treatment aims to restore balance by â†‘ dopaminergic activity +\nâ†“ cholinergic activity as these circuits\nâ†“ cholinergic activity (see Fig. 2.9-22). General side effects of agents that\nbecome unbalanced with the loss of\nâ†‘ DA activity include nausea/vomiting, orthostatic hypotension, sleepi-\ndopaminergic neurons in the substantia\nness, dyskinesias, and confusion/hallucinations. Initial treatment, if possi-\nnigra pars compacta.\nble, involves agents other than levodopa-carbidopa (especially in patients\nâ–  Dopami",
      "char_start": 1148000,
      "char_end": 1150000
    },
    {
      "chunk_id": 575,
      "text": "ne activates the direct\nage <65), as long-term use limits utility â†’ â€œon-offâ€ phenomena.\npathway and inhibits the indirect\nâ–  Mild symptoms + minimal impact on daily living:\npathway to promote movement.\nâ–  Initial therapy for any age: MAO-B inhibitors (selegiline, rasagiline,\nâ–  Acetylcholine inhibits the direct\nsafinamide) â†’ â†“ MAO-Brain activity â†’ â†‘ CNS dopamine, or DA.\npathway and activates the indirect\nTyramine-containing foods (cheese) â†’ hypertensin (HTN) (â†“ risk ver-\npathway to inhibit movement.\nsus MAO-A inhibitors).\nâ–  Tremor-dominant: M1 muscarinic ACh receptor antagonists (trihexy-\nphenidyl, benztropine), with cautious use in older adults or amanta-\ndine (â†‘ DA activity/anticholinergic).\nâ–  Mild to moderate symptoms + impact daily living:\nKEY FACT â–  Best therapy: Nonergot DA receptor agonists (pramipexole, ropinirole,\nrotigotine) â†’ useful as monotherapy in younger patients (age <65).\nIn a patient with severe Parkinson\nâ–  Moderate to severe symptoms + significant impact on daily living:\ndisease who develops psychosis, the\nâ–  Best and most effective therapy at any age: Levodopa-carbidopa. Typi-\npatient should not stop PD medications\ncally, it is the first-line treatment in patients age >65 years. Carbidopa\n(this would lead to severe akinesia);\nblocks peripheral dihydroxyphenylalanine (DOPA) decarboxylase â†’ â†‘\ninstead, the patient should use\nCNS bioavailability of levodopa + â†“ peripheral adverse effects. Long-\nquetiapine (which is the antipsychotic\nterm use â†’ â†“ endogenous DA â†’ dependence â†’ â€œon (increased\nwith the least amount of movement\nresponse, dyskinesias) \"on-off\" phenomena (\"on\" = increased response,\nside effectsâ€”itâ€™s â€œquietâ€).\ndyskenesias; \"off\" = loss of response, akinesias).\nâ–  Levodopa-carbidopa â€œboosting agentsâ€: MAO-B inhibitors or COMT\ninhibitors (â†‘ CNS bioavailability of DA, lessening â€œoff periodsâ€).\nCOMT inhibitors are only used in combination with levodopa-\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339988 1100//221",
      "char_start": 1150000,
      "char_end": 1152000
    },
    {
      "chunk_id": 576,
      "text": "1//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 399\nDOPA KEY FACT\nDECARBOXYLASE Dopamine CIRCULATION 3-OMD\nINHIBITOR â€“ L-DOPA COMT INHIBITORS Anticholinergic side effects:\nCarbidopa DDC COMT â€“\n(peripheral) Blind as a bat (mydriasis + impaired\nBLOOD- Entacapone lens accommodation), mad as a hatter\nBRAIN\nBARRIER Tolcapone (altered mental status), red as a beet\n(flushing), hot as a hare (hyperthermia),\ndry as a bone (dry mucosae + skin),\nL-DOPA\nthe bowel and bladder lose their tone\nDDC COMT INHIBITOR (organ paralysis), and the heart runs\n(central)\nPRESYNAPTIC alone (tachycardia).\nTERMINAL FROM THE Dopamine COMT â€“ Tolcapone\nSUBSTANTIA NIGRA\n3-MT\nDOPAC\nâ€“\nAutoregulatory MAO TYPE B\nreceptor INHIBITORS KEY FACT\nReuptake\nSelegiline\nPathology determines phenotype:\nRasagiline\nâ–  Parkinson disease â†’ loss of\nDOPAMINE dopaminergic neurons in basal\n+\nAVAILABILITY\nganglia â†’ extrapyramidal motor\nAmantadine symptoms.\nâ–  Alzheimer disease â†’ loss of\ncholinergic circuits in cortex/\nDopaminereceptors + DOPAMINE AGONISTS\nPOSTSYNAPTIC subcortex â†’ dementia.\nTERMINAL IN\nTHE STRIATUM Pramipexole (non-ergot) â–  Amyotrophic lateral sclerosis â†’ loss\nRopinirole (non-ergot)\nBromocriptine (ergot) of UMNs/LMNs â†’ UMN/LMN signs\nonly.\nâ–  Myasthenia gravis â†’ loss of\nFIGURE 2.9-22. Mechanism of action for Parkinson disease drugs. (Reproduced with permission from acetylcholine receptor function â†’\nUSMLE-Rx.com.)\nfatigability.\nâ–  Huntington disease â†’ loss of\ncarbidopa and include entacapone (more common) and tolcapone GABA/ACh activity in degenerated\n(hepatotoxic). Istradefylline (adenosine A antagonist) can also be used cerebrum + striatum â†’ unbalanced\n2\nto â†“ â€œoffâ€ phenomena. dopamine activity â†’ motor,\nâ–  Surgery: Patients refractory to medical treatment and those who develop memory, and mood findings.\nsevere disease or are younger (<40 years old) should be considered for\nimplantation of a deep brain stimulator to suppress neural activity of the\nsubthalamic nucleus/globus pallidus internus.\nâ–  Caution with s",
      "char_start": 1152000,
      "char_end": 1154000
    },
    {
      "chunk_id": 577,
      "text": "pecific drugs: Caution using drugs with antidopaminergic\nactivity such as metoclopramide, prochlorperazine, and antipsychotics.\nQuetiapine is â€œquietâ€ and has the least movement side effects of the anti-\npsychotics. It is first line in PD patients who develop psychosis. Pimavan-\nserin is an antipsychotic that inhibits 5-hydroxytryptamine (5HT), not DA,\nand can also be used.\nKEY FACT\nAMYOTROPHIC LATERAL SCLEROSIS\nIf a 55-year-old man presents with\nslowly progressive weakness with\nAlso known as â€œLou Gehrig diseaseâ€ and â€œmotor neuron disease,â€ amyo-\nincreased reflexes in his left upper\ntrophic lateral sclerosis (ALS) is a chronic, progressive disease characterized\nextremity and later in his right (upper\nby loss of upper and lower motor neurons. It is often sporadic (90% of cases)\nmotor neuron signs) associated with\nbut can also be genetic. Age, family history, and cigarette smoking are risk fac-\nfasciculations and atrophy (lower motor\ntors. ALS has an unrelenting course and almost always progresses to respira-\nneuron signs) but without bladder\ntory failure and death, usually within 5 years of diagnosis. Men are more\ndisturbance and with a normal cervical\ncommonly affected than women, and onset is generally between 40 and\nMRI, think amyotrophic lateral sclerosis.\n80 years of age.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 339999 1100//2211//2222 22::1188 PPMM\n\n400 HIGH-YIELD FACTS IN NEUROLOGY\nKEY FACT History/PE\nâ–  Presents with asymmetric, slowly progressive weakness (over months to\nAbout 20% of people have â€œbulbar\nyears) affecting the arms, legs, diaphragm, and lower cranial nerves. Initial\nonsetâ€ ALS, which means patients first\npresentation is often asymmetric extremity weakness, but can also present\npresent with speech and swallowing\nwith fasciculations (muscle twitching). Weight loss is common.\nsymptoms (eg, dysarthria, dysphagia,\nâ–  Associated with UMN and/or LMN UMN and/or LMN signs (Table 2.9-3).\nloss of tongue mobility). Pa",
      "char_start": 1154000,
      "char_end": 1156000
    },
    {
      "chunk_id": 578,
      "text": "tients may\nâ–  Sensation, eye movements, and sphincter tone are generally spared.\nalso have pseudobulbar affect (sudden\nâ–  Emotional lability is a common feature.\ninappropriate laughing or crying\nâ–  Differences in symptom onset and spread cause a variable disease presen-\nepisodes).\ntation in individuals.\nDiagnosis\nDiagnosis is usually clinical and follows these criteria:\nâ–  Progressive motor dysfunction preceded by previously normal motor\nfunction\nKEY FACT â–  Evidence of UMN and LMN involvement in one body segment or evi-\ndence of LMN involvement in at least two body segments\nBulbar involvement (involvement of\nâ–  Investigations excluding other diseases that explain these symptoms\nthe tongue [CN XII] or oropharyngeal\nâ–  EMG/nerve conduction studies revealing widespread denervation and\nmuscles [CN IX, X]) suggests pathology\nspontaneous action potentials (fibrillation potentials). Such studies are\nabove the foramen magnum, which\nprincipally performed to exclude other demyelinating motor neuropathies\ndistinguishes ALS from cervical\nâ–  CT/MRI of the cervical spine often performed to exclude structural\nspondylosis with compressive\nlesions, such as cervical spondylosis with compressive myelopathy. Espe-\nmyelopathy as the cause of symptoms.\ncially useful in those without bulbar involvement\nTreatment\nâ–  Supportive measures and patient education.\nâ–  Baclofen can be used for spasticity\nâ–  Serial pulmonary assessments beginning at diagnosis. Patients with ALS\nmost commonly die from respiratory failure. First-line treatment for respi-\nratory insufficiency is noninvasive positive-pressure ventilation (PPV).\nâ–  Supportive measures and patient education. Riluzole may delay disease\nprogression by 2â€“3 months by decreasing glutamate-induced excitotoxic-\nity. Edaravone, although new, is a medication used for advanced ALS.\nRESTLESS LEGS SYNDROME\nâ–  Hx/PE: A common disorder characterized by leg dysesthesias (abnormal\nsensations of crawling/itching) and an irresistible urge to move the legs\nwhen at res",
      "char_start": 1156000,
      "char_end": 1158000
    },
    {
      "chunk_id": 579,
      "text": "t, especially when lying flat. These symptoms are partially\nrelieved with movement, and they typically occur with inactivity, classi-\ncally in the evening/night at bedtime and while sleeping (bed partner may\nreport being kicked at night).\nâ–  Causes: Classified as primary (idiopathic) or secondary if it occurs in asso-\nciation with the following conditions: iron-deficiency anemia (misuse of\niron in CNS â†’ impairs CNS dopaminergic pathways), located near circa-\ndian control centers), uremia (end-stage renal disease [ESRD]/chronic\nkidney disease [CKD]), cancer (especially colon cancer), pregnancy, dia-\nbetes, MS, PD, drugs (eg, antidepressants, metoclopramide).\nâ–  Dx: Clinical + serum iron studies in all patients.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440000 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 401\nâ–  Tx:\nâ–  Iron supplementation with deficient or low to normal serum ferritin\n(â‰¤75Î¼g/L)\nâ–  If symptoms are mild/intermittent: Addition of supportive measures\n(leg massage, heating pads, exercise) + avoid aggravating factors (caf-\nfeine, sleep deprivations, certain medications)\nâ–  If symptoms are persistent/moderate to severe: Dopamine agonists\n(pramipexole, ropinirole); neuropathic pain agents (gabapentin,\npregabalin)\nTREMORS KEY FACT\nA tremor is an involuntary, rhythmic, oscillatory movement of one or more Lesions to the superior colliculus can\nparts of the body. Tremors represent a diverse set of movement disorders as result in Parinaud syndrome: paralysis of\nFigure 2.9-23 and Table 2.9-20 explore. conjugate vertical gaze.\nTremor\nOther\nTiming Functional asterixis\nOccurs Occurs with\nat rest voluntary movement\nResting tremor Action tremor\nPostural:\noccurs when body Kinetic:\nParkinson tremor part is voluntarily occurs with any\nheld against gravity voluntary movement\nPhysiologic tremor Essential tremor Intention tremor\nFIGURE 2.9-23. Tremor workup. (Reproduced with permission from USMLE-Rx.com.)\nWILSON DISEASE OR H",
      "char_start": 1158000,
      "char_end": 1160000
    },
    {
      "chunk_id": 580,
      "text": "EPATOLENTICULAR DEGENERATION\nThis is an autosomal recessive disorder that leads to accumulation of copper\nin various tissues. Mutation in intracellular copper transporter ATP7B leads to\nimpaired biliary copper excretion and accumulation of copper in the liver,\nbrain, kidneys, and cornea.\nClinical Features\nPatients usually develop liver disease before 40 years of age: jaundice, hepati-\ntis, ascites, and cirrhosis. Associated neurologic disease (eg, dysarthria, dysto-\nnia, tremor, parkinsonism) may manifest early in the course of the disease.\nProximal tubular dysfunction leading to Fanconi syndrome can present with\nglucosuria, aminoaciduria, hypouricemia, and proximal renal tubular acido-\nA 65-year-old man presents to his\nsis. Kayser-Fleischer rings due to copper deposition in the Descemet mem-\ninternist with 10 years of bilateral\nbrane of the peripheral cornea may be noted on slit-lamp examination.\nhand tremors. His mother and\nolder brother have similar tremors.\nHe denies difficulty concentrating,\ntrouble with rising from seated\npositions, or recent falls. What is the\nmost likely diagnosis?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440011 1100//2211//2222 22::1188 PPMM\n\n402 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-20. Classification of Tremors\nTREMOR TYPE TREMOR SUBTYPE FEATURES ETIOLOGIES IMPROVE TREATMENT\nResting tremor Parkinsonian Unilateral â€œpill-rollingâ€ tremor (4â€“6 Hz) occur- PD or neuroleptics Action Dopami-\nOccurs without tremor ring at rest (move- nergic /\nmovement â€œRest in the parkâ€ ment) anticho-\n(rest) linergic\nagents\nAction tremor Postural tremor Physi- Bilateral, fine (10â€“12 Hz) â†‘ sympathetic â†“ sympa- Treat cause\nOccurs with Occurs when ologic activity thetic (anxiety,\nvoluntary appendage is tremor activity glucose)\nmovement voluntarily held\n(action) against gravity\nKinetic tremor Essential Bilateral, fine (6â€“12 Hz), Familial (AD Alcohol + Propran-\nOccurs with any tremor worsens by certain pos- inheritance) no ac",
      "char_start": 1160000,
      "char_end": 1162000
    },
    {
      "chunk_id": 581,
      "text": "tion olol +\nvoluntary â€œBenign tures (outstretched hands) (rest) primidone\nmovement familial + voluntary movement\ntremorâ€ (kinetic)\nIntention Asymmetrical, coarse Cerebellar outflow No action Cerebellar\ntremor (2â€“4 Hz), worsens as hand disease (rest) disease\napproaches target (inten- causes\ntion) â†’ zigzag motion â†’\novershoots/undershoots\ntarget = dysmetria on\nfinger-to-nose testing\nOther â€œFlapping Bilateral; variable frequency/amplitude; â†‘ ammonia (renal â†“ ammonia Underlying\ntremorâ€: asynchronous inability to maintain out- causes; hepatic renal/liver\nAsterixis stretched hand posture â†’ loss of tone â†’ encephalopathy cause(s)\n*Negative involuntary corrective reflex movement = = â€œliver flapâ€)\nmyoclonus* â€œflapping hand tremorâ€\nFunctional Changing, multiple tremor types; abrupt Psychogenic Distraction Psycho-\nâ€œpsychogenicâ€ onset; observation worsens; no known (history of therapy\ntremor neurologic cause trauma)\nDiagnosis\nEssential tremor (â€œbenign familial trem-\norâ€) is the most likely diagnosis. Unlike â–  Initial test: LFT (look for aspartate aminotransferase [AST]: alanine ami-\nthe unilateral resting tremor generally notransferase [ALT] ratio >2); CBC (look for anemia).\nseen in Parkinson disease that improves â–  Diagnostic test: Ceruloplasmin level (<20 mg/dL) and urinary copper\nwith movement, essential tremors are levels (>100 mcg/dL) with Kayser-Fleischer rings confirm diagnosis.\nusually bilateral action tremors that are\nâ–  Most specific test: Liver biopsy.\nworsened by movements. Understand\nthat unilateral tremors are classic for\nTreatment\nParkinson disease but can progress\nto bilateral tremors with other motor Penicillamine is commonly used for chelation, but trientine has fewer side\nsymptoms (not present in patient his- effects. Oral zinc can also be considered as an alternative. A diet low in cop-\ntory). Patients classically self-medicate per with avoidance of mushrooms, chocolate, nuts, dried fruit, liver, and shell-\nessential tremors with alcohol. First-line fish is gen",
      "char_start": 1162000,
      "char_end": 1164000
    },
    {
      "chunk_id": 582,
      "text": "erally advised.\ntreatment of essential tremors is with\npropranolol or primidone.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440022 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 403\nNEOPLASMS\nIntracranial neoplasms may be primary (30%) or metastatic (70%).\nKEY FACT\nâ–  Of all primary brain tumors, 40% are benign, and these rarely spread\nMost CNS tumors are metastatic.\nbeyond the CNS.\nThe most common primary CNS\nâ–  Metastatic tumors are most often from primary lung, breast, kidney, and\ntumors in adults are glioblastoma\nGI tract neoplasms and melanoma. They occur at the gray-white junction;\nmultiforme and meningiomas. The\nmay be multiple discrete nodules; and are characterized by rapid growth,\nmost common primary CNS tumors in\ninvasiveness, necrosis, and neovascularization.\nchildren are astrocytomas, followed by\nâ–  Neoplasms are more common in males than in females, except for\nmedulloblastomas.\nmeningiomas.\nHistory/PE\nâ–  Symptoms depend on tumor type and location (see Table 2.9-21), local\ngrowth and resulting mass effect, cerebral edema, or â†‘ ICP secondary to\nventricular obstruction.\nâ–  Seizures or slowly progressive focal motor deficits are the most common MNEMONIC\npresenting features.\nMost common cancers that\nâ–  Although headaches are often thought of as the main presenting symptom,\nmetastasize to the brainâ€”\nonly 31% of patients present with headache at diagnosis, and only 8% have\nLung and Skin Go to the BRain\nheadache as the sole presenting feature.\nâ–  When â†‘ ICP is the presenting feature, symptoms include headache, Lung\nnausea/vomiting, and diplopia (false localizing CN VI palsies). In the era Skin\nof neuroimaging, it is relatively rare for patients to present with â†‘ ICP. GI\nBreast\nâ–  Other presenting symptoms: Visual field abnormalities, neurologic defi-\nRenal\ncits, psychiatric symptoms.\nDiagnosis\nâ–  Best initial test: CT and MRI with and without contrast to localize and\ndetermine the extent of the lesion.\nâ–  Gadolinium",
      "char_start": 1164000,
      "char_end": 1166000
    },
    {
      "chunk_id": 583,
      "text": "-enhanced MRI is generally better for visualizing soft tis-\nsue tumors and vascularity.\nKEY FACT\nâ–  CT is preferred for evaluating skull base lesions and for emergencies\n(eg, obstructive hydrocephalus) when an MRI cannot be rapidly Two thirds of primary brain tumors in\nacquired. adults are supratentorial. One third of\nâ–  Histologic diagnosis via CT-guided biopsy or surgical biopsy. those in children are supratentorial.\nTreatment\nâ–  Consider resection (if possible), radiation, and chemotherapy after appro-\npriate consultation with medical and surgical oncology teams.\nâ–  Therapy is highly dependent on tumor type, histology, progression, and\nsite (see Table 2.9-21).\nâ–  If ICP is â†‘, management of ICP calls for the following:\nKEY FACT\nâ–  Head elevation (â†‘ venous outflow from brain)\nâ–  Hyperventilation (â†“ CO 2 leads to cerebral vasoconstriction resulting in Symptoms of â†‘ ICP:\nâ†“ vasogenic edema)\nâ–  Nausea\nâ–  Corticosteroids (â†“ vasogenic edema) â–  Vomiting\nâ–  Mannitol and hypertonic saline (extraction of free water from brain via â–  Diplopia\nosmotic diuresis)\nâ–  Headache that is worse in the\nâ–  Removal of CSF morning, with bending over, or\nâ–  Automated external defibrillators (AEDs) can be used in patients who with recumbency\nhave had a seizure.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440033 1100//2211//2222 22::1188 PPMM\n\n404 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-21. Common Primary Neoplasms in Adults\nTUMOR AND APPEARANCE BENIGN VS MALIGNANT PRESENTATION TREATMENT\nAstrocytoma (diffuse, anaplastic, Low grade: diffuseâ€” Presentation of astrocytomas depends on Surgical removal/resection\ngrade IV/glioblastoma) benign, or high location of tumor. Some symptoms include Radiation and chemo-\nHistology shows astrocyte origin grade headache, seizures, or focal deficits. therapy have variable\nwith glial fibrillary acid protein Anaplastic: malignant Glioblastoma is the most common malignant results\n(GFAP) âŠ• staining (Image A). Glioblastoma: primary brain tu",
      "char_start": 1166000,
      "char_end": 1168000
    },
    {
      "chunk_id": 584,
      "text": "mor. It progresses rapidly\nâ€œPseudopalisadingâ€ pleomor- malignant and has a poor prognosis (<1 year from time\nphic tumor cells border central of diagnosis).\nareas of necrosis, hemorrhage,\nand/or microvascular prolif-\neration. It is associated with\namplification.\nOligodendroglioma Low grade: benign, Oligodendroglioma most commonly presents Surgical resection is fol-\nMRI brain reveals a mass in the slow growing as seizures, but may be silent. Age of onset is lowed by radiation and\nleft frontal lobe High grade: anaplastic usually between 25 and 45 years. chemotherapy, as these\nHistologically has appearance oligodendroglioma It is most often in frontal lobes and is com- tumors are often very\nof â€œfried eggâ€ cells (Image monly calcified. chemosensitive.\nC)â€”round nuclei with clear\ncytoplasm. There is a â€œchicken-\nwireâ€ capillary pattern.\nMeningioma Generally benign Presentation depends on location. Meningioma Surgical resection; radiation\nMRI brain reveals a meningioma is often related to cranial neuropathy or is an for unresectable tumors\nwith associated dural tails. incidental finding.\nHistology shows spindle cells A classic imaging finding is extension of the\n(Image D), which are concen- tumor along the dura known as a dural tail.\ntrically arranged in a whorled The origin of the meningioma is an arach-\npattern, as well as psam- noid cell.\nmoma bodies (laminated\ncalcifications).\nHemangioblastoma Generally benign A hemangioblastoma is most often cerebellar. Surgical resection; radiation\nMRI brain reveals a hemangioblas- It is associated with von Hippel-Lindau syn- therapy is sometimes\ntoma (Image E, white arrow). drome when found with retinal angiomas. used in recurrent cases.\nHistologically has closely It can produce erythropoietin â†’ secondary\narranged, thin-walled capillaries polycythemia.\nand minimal intervening paren-\nchyma (Image F).\nPituitary adenoma Generally benign May be nonfunctioning (silent) or hyperfunc- Workup for suspected pitu-\nMRI of the brain revealing tio",
      "char_start": 1168000,
      "char_end": 1170000
    },
    {
      "chunk_id": 585,
      "text": "ning (hormone producing). Nonfunctional itary adenoma includes\nmass in the pituitary gland tumors present with mass effect (eg, bitem- brain MRI with gadolinium\n(Image G) poral hemianopia) due to pressure on optic contrast and measure-\nHistology shows hyperplasia of chiasm. Pituitary apoplexy hyperpituitarism ments of serum prolactin,\nonly one type of endocrine cells or hypopituitarism is present. IGF-1, ACTH, and 24-hour\nfound in pituitary. Prolactinoma classically presents as galactor- urinary free cortisol. Addi-\nrhea, amenorrhea, â†“ bone density due to tional tests for TSH, LH, and\nsuppression of estrogen in females and â†“ FSH are obtained based on\nlibido, infertility in males. clinical presentation.\n(continues)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440044 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 405\nTABLE 2.9-21. Common Primary Neoplasms in Adults (continued)\nTUMOR AND APPEARANCE BENIGN VS MALIGNANT PRESENTATION TREATMENT\nMost commonly from lactotrophs (prolactin- Lactotroph adenomas are\nproducing cells), which cause hyperprolac- initially managed using\ntinemia. Less commonly, from somatotrophs dopamine agonists (eg,\n(GH-producing cells) â†’ acromegaly, gigan- bromocriptine, cabergo-\ntism; corticotrophs (ACTH-producing cells) line), while most other\nâ†’ Cushing disease. Rarely, from thyrotrophs subtypes require trans-\n(TSH-producing cells), gonadotrophs (FSH-, sphenoidal resection.\nLH-producing cells).\nVestibular schwannoma (also Generally benign Classically at the cerebellopontine angle. Surgical resection, focal\nknown as acoustic neuroma) Earlyâ€”compresses CN VIII, VII. Lateâ€”can com- radiation, or monitoring\nHead CT reveals a vestibular press CNs V, IX, X. Cranial nerve compression\nschwannoma (Image H, red may cause facial numbness, weakness, uni-\narrows). lateral hearing loss, tinnitus, vertigo, and loss\nSchwann cell origin, S-100 âŠ•. of balance.\nBiphasic, dense, hypercellular Vestibular schwannomas a",
      "char_start": 1170000,
      "char_end": 1172000
    },
    {
      "chunk_id": 586,
      "text": "re bilateral in NF2.\nareas containing spindle cells\nalternating with hypocellular,\nmyxoid areas.\nA B C D\nE G H\nF\nImage A reproduced with permission from Lim SM, Choi J, Chang JH, et al. Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme. PLoS\nOne. 2015;10(9):e0137678. doi:10.1371/journal.pone.0137678. Image B reproduced with permission from Kao HW, Chiang SW, Chung HW, et al.\nAdvanced MR imaging of gliomas: an update. Biomed Res Int. 2013;2013:970586. doi:10.1155/2013/970586. Image E reproduced with permission\nfrom Park DM, Zhuang Z, Chen L, et al. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells.\nPLoS Med. 2007;4(2):e60. doi:10.1371/journal.pmed.0040060. Image F reproduced with permission from Zywicke H, Palmer CA, Vaphiades MS,\nRiley KO. Optic nerve hemangioblastoma: a case report. Case Rep Pathol. 2012;2012:915408. doi:10.1155/2012/915408. Image G reproduced with\npermission from Wang CS, Yeh TC, Wu TC, Yeh CH. Pituitary macroadenoma co-existent with supraclinoid internal carotid artery cerebral aneurysm:\na case report and review of the literature. Cases J. 2009;2:6459. doi:10.4076/1757-1626-2-6459. Images C, D, and H reproduced with permission\nfrom USMLE-Rx.com.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440055 1100//2211//2222 22::1188 PPMM\n\n406 HIGH-YIELD FACTS IN NEUROLOGY\nNEUROCUTANEOUS DISORDERS\nNEUROFIBROMATOSIS\nThe most common neurocutaneous disorder. There are two major types: neu-\nrofibromatosis 1 (NF1, or von Recklinghausen syndrome) and neurofibroma-\ntosis 2 (NF2). Both are autosomal dominant diseases caused by mutations to\ntumor suppressor genes.\nHistory/PE\nDiagnostic criteria for NF1 include two or more of the following:\n1. Six cafÃ© au lait spots (flat, uniformly hyperpigmented macules).\n2. Two neurofibromas (benign peripheral nerve sheath tumors) of any type\n(see Fig. 2.9-24).\n3. Freckling in the axillary or inguinal area.\n4. Optic glioma (mainly pat",
      "char_start": 1172000,
      "char_end": 1174000
    },
    {
      "chunk_id": 587,
      "text": "ients under age 6 years).\n5. Two Lisch nodules (pigmented iris hamartomas). These are the most spe-\ncific clinical features of NF1.\nFIGURE 2.9-24. Neurofibromas associ-\n6. Bone abnormality (eg, kyphoscoliosis).\nated with neurofibromatosis. (Reproduced\nwith permission from USMLE-Rx.com.) 7. A first-degree relative with NF1.\nDiagnostic criteria for NF2 are as follows:\nâ–  Bilateral vestibular schwannomas (also known as acoustic neuromas)\nâ–  First-degree relative with NF2 and either:\nâ–  Unilateral acoustic neuromas, or\nâ–  Two of any of the following tumor types: neurofibroma, meningioma,\nglioma, or schwannoma\nâ–  Other features, including seizures, skin nodules, and cafÃ© au lait spots\nDiagnosis\nâ–  Usually clinical.\nâ–  MRI of the brain, brainstem, and spine with gadolinium.\nKEY FACT â–  A complete dermatologic examination, ophthalmologic examination,\nbone evaluation, and family history. Auditory testing is recommended.\nVestibular schwannomas (also known\nGenetic testing is often not required for diagnosis.\nas acoustic neuromas) present with\nâ–  Evaluation for renal artery stenosis. Patients with NF1 are at increased risk\nipsilateral tinnitus, hearing loss, and\nof hypertension due to renovascular lesions, developing as early as\nvertigo. The treatment of choice is\nchildhood.\nsurgical resection.\nâ–  Carefully screen patients under age of 6 years for optic nerve glioma.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440066 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 407\nTreatment\nâ–  There is no cure; treatment is symptomatic (eg, surgery for kyphoscoliosis\nor debulking of tumors).\nâ–  Vestibular schwannomas (see Table 2.9-21) and optic gliomas can be\ntreated with surgery or radiosurgery. Rapidly growing meningiomas can be\nresected.\nâ–  Mutation in NF1 tumor suppressor gene causes increased signal transduc-\ntion through the Ras/Raf/MEK/MAPK pathway. Use of MEK or MAPK\ninhibitors (ie, selumetinib) can be used to induce tumor regression.\nTUBERO",
      "char_start": 1174000,
      "char_end": 1176000
    },
    {
      "chunk_id": 588,
      "text": "US SCLEROSIS\nAutosomal dominant disorder that affects many organ systems, including the\nCNS, skin, heart, retina, lungs, and kidneys. A mutation in the tuberous scle-\nrosis complex (TSC) gene leads to this disorder. TSC1 codes for the tumor\nsuppressor gene hamartin, and TSC2 codes for the tumor suppressor gene\ntuberin. Mutations in TSC2 are more common than in TSC1.\nHistory/PE\nâ–  Seizures are the most frequent presenting symptom, with infantile spasms\nbeing the most common type. Tuberous sclerosis also presents with â€œash-\nleafâ€ hypopigmented lesions (Fig. 2.9-25A) on the trunk and extremities\nand with mental disability (â†‘ likelihood with early age of onset).\nâ–  Other skin manifestations include angiofibromas (small red nodules on\nthe nose and cheeks in the distribution of a butterfly Fig. 2.9-25B),\nshagreen patch (a rough papule in the lumbosacral region with an orange-\npeel consistency), and periungual fibromas.\nâ–  Other symptoms are secondary to small benign tumors that grow on the\nface, eyes, brain, kidney, and other organs. For example:\nâ–  Congestive heart failure (CHF) from cardiac rhabdomyoma; renal dis-\nease from renal cysts, angiomyolipomas, or carcinomas\nâ–  Developmental disability from brain lesions (eg, subependymal\nnodules)\nâ–  Lymphangioleiomyomatosis (LAM) is cystic lung disease that is also due\nto a mutation in the TSC. LAM can present as a late manifestation of\nA B\nFIGURE 2.9-25. Tuberous sclerosis. (A) â€œAsh-leafâ€ macules on a patient with tuberous sclero-\nsis and (B) angiofibromas in a butterfly distribution. (Image A reproduced with permission from Falsafi P,\nTaghavi-Zenouz A, Khorshidi-Khiyavi R, et al A case of tuberous sclerosis without multiorgan involvement. Glob J Health Sci.\n2015 Feb 24;7(5):124-31. doi: 10.5539/gjhs.v7n5p124. Image B adapted with permission from Fred H, van Dijk H. Images of\nmemorable cases: Case 143. Connexions Website. December 4, 2008. Available at: http://cnx.org/content/m14923/1.3/.)\n22002222__0022..0099__SStteepp22CCKK__NNee",
      "char_start": 1176000,
      "char_end": 1178000
    },
    {
      "chunk_id": 589,
      "text": "uurroo__1111ee__335511--442266..iinndddd 440077 1100//2211//2222 22::1188 PPMM\n\n408 HIGH-YIELD FACTS IN NEUROLOGY\nKEY FACT tuberous sclerosis, often in the third or fourth decade, or it can occur spo-\nradically. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor,\nInfantile spasms occur in children has been found to slow disease progression.\n<3 years of age and can consist\nof head bobbing, flexor spasms, Diagnosis\nextensor spasms, or movements that\nâ–  Usually clinical\nmimic the startle response. They may\nâ–  Ash-leaf lesions enhanced by a Woodâ€™s ultraviolet (UV) light lamp\nbe associated with psychomotor\nâ–  Imaging:\nregression or behavioral changes.\nâ–  MRI of brain: Evaluate for subependymal giant cell astrocytoma and\ncalcified tubers (potato-like nodules) within the cerebrum in the peri-\nventricular area. If lesions obstruct CSF outflow, obstructive hydro-\ncephalus can develop.\nâ–  Ophthalmic exam: Evaluate for retinal hamartomas and eyelid\nangiofibromas.\nâ–  Echocardiography: Evaluate for rhabdomyoma of the heart, especially\nin the apex of the left ventricle (affects >50% of patients).\nâ–  MRI of abdomen: Evaluate for renal disease (cysts, angiomyolipoma,\nand/or carcinoma).\nâ–  EEG: Evaluate for seizure activity.\nTreatment\nâ–  Treatment should be based on symptoms (eg, cosmetic surgery for facial\nsebaceous adenomas).\nâ–  Seizures should be treated.\nâ–  When standard epileptic medications fail, mTOR inhibitors (eg, evero-\nlimus) can help reduce seizures.\nâ–  If infantile spasms are present, first-line treatment is with vigabatrin,\nwhich enhances GABA transmission. Adrenocorticotropic hormone\n(ACTH) can be used as an alternative/adjunctive.\nâ–  Surgical intervention may be indicated in the setting of â†‘ ICP from\nobstructive hydrocephalus or for seizures associated with an epileptogenic\nfocus or severe developmental delay.\nSTURGE-WEBER SYNDROME\nSturge-Weber syndrome is due to a somatic mosaic mutation in the GNAQ\ngene, and therefore is not an inheritable disease.\nHistory/PE\nFacial ca",
      "char_start": 1178000,
      "char_end": 1180000
    },
    {
      "chunk_id": 590,
      "text": "pillary malformation (port wine stain) is usually in a V1 distribution.\nThis finding in isolation does not qualify for the diagnosis of Sturge-Weber\nsyndrome since GNAQ mutations constitute a spectrum disorder with isolated\nport wine stain as the mildest form. Twenty percent have a leptomeningeal\ncapillary-venous malformation of the brain and eye that is adjacent to the port\nwine stain and are thus diagnosed as having Sturge-Weber syndrome. The\nbrain parenchyma may be atrophic and contain calcific deposits. Seizures,\nstrokelike episodes, hemiparesis, and mental retardation commonly occur.\nDiagnosis\nPreferred diagnostic test is brain MRI with contrast. The image may reveal\nintracranial calcifications that resemble a â€œtramline.â€\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440088 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 409\nTreatment\nâ–  Photothermolysis can be used for treatment of port wine stains.\nâ–  Low-dose aspirin beginning in infancy may decrease the frequency and\nduration of seizures.\nâ–  Anticonvulsant medications are first line for management of seizures.\nVON HIPPLE-LINDAU SYNDROME\nVon Hipple-Lindau (VHL) syndrome is an inherited autosomal dominant\ncondition characterized by the presence of benign and malignant tumors in\nmany organ systems, including the retina, CNS, pancreas, kidneys, and adre-\nnals. It is caused by a mutation in the VHL tumor suppressor gene. Patients\nwith type 1 VHL have a very low risk of developing pheochromocytoma, but\npatients with type II VHL (caused by missense mutations) have a higher risk\nfor pheochromocytoma.\nHistory/PE\nâ–  Hemangioblastomas are the hallmark tumors of VHL. When they occur\nin the CNS, especially the cerebellum and spinal cord, they can cause\nataxia and headaches. Retinal hemangioblastomas may cause vision loss,\nand they are often identified on fundoscopy.\nâ–  One half of all cases of pheochromocytomas under the age of 18 years are\ndue to VHL, and they result in epi",
      "char_start": 1180000,
      "char_end": 1182000
    },
    {
      "chunk_id": 591,
      "text": "sodes of palpitations, hypertension, and\nsweating.\nâ–  Other VHL-associated tumors include:\nâ–  Renal cell carcinoma (clear cell type) and renal cysts\nâ–  Serous cystadenoma of the pancreas\nâ–  Endolymphatic sac tumor\nâ–  Papillary cystadenoma of epididymis and broad ligament\nâ–  Epididymal cysts\nDiagnosis\nâ–  Genetic testing for individuals with manifestations of VHL disease or fam-\nily history\nâ–  MRI of the brain and spinal cord to evaluate for lesions\nâ–  Levels of catecholamines to evaluate for presence of pheochromocytoma\nâ–  Complete audiologic exam to evaluate for hearing loss (can be caused by\nendolymphatic sac tumors)\nTreatment\nâ–  Routine surveillance of the abdomen can check for renal cell carcinoma,\npheochromocytomas, and pancreatic tumors. Annual retinal exams should\nbe done to evaluate for retinal hemangioblastomas.\nâ–  For patients with symptomatic hemangioblastomas, surgical intervention\nshould be considered. If unresectable or if there are contraindications to\nsurgery, treatment with belzutifan (hypoxia-inducible factor [HIF]-2 alpha\ninhibitor) can be considered. In VHL disease, levels of HIF-1A and HIF-2A\ntranscription factors are elevated, causing an increase in physiologic angio-\ngenesis via upregulation of vascular endothelial growth factor (VEGF) and\nplatelet-derived growth factor (PDGF).\nâ–  Patients with renal cell carcinoma >3 cm should undergo surgical inter-\nvention rather than routine surveillance.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 440099 1100//2211//2222 22::1188 PPMM\n\n410 HIGH-YIELD FACTS IN NEUROLOGY\nATAXIA-TELANGIECTASIA\nAutosomal recessive disease caused by a mutation in the ATM gene, which\nencodes DNA repair enzymes. Leads to aberrant repair of double-stranded\nDNA breaks, causing cell death (eg, Purkinje cells in the cerebellum are par-\nticularly susceptible).\nHistory/PE\nâ–  Cerebellar ataxia is often the first presenting symptom in infancy or early\nchildhood. Patients may also present with ocular apraxia (inab",
      "char_start": 1182000,
      "char_end": 1184000
    },
    {
      "chunk_id": 592,
      "text": "ility to con-\ntrol purposeful eye movements), cognitive impairment, extrapyramidal\nsymptoms, and peripheral neuropathy.\nâ–  Telangiectasias are common, most often in the face, eyes, and ears.\nâ–  Immune deficiency (especially IgA) predisposes patients to recurrent sino-\npulmonary infections, which may lead to interstitial lung disease.\nâ–  Up to one fourth of patients will develop a malignancy, most often lym-\nphomas or leukemias.\nDiagnosis\nâ–  Usually clinical, but genetic testing supportive of diagnosis\nâ–  Low IgA\nâ–  Elevated levels of Î±-fetoprotein (AFP) often seen\nâ–  Imaging studies involving ionizing radiation to be minimized\nTreatment\nNo specific treatment exists for progressive ataxia and cerebellar degenera-\ntion. Infections should be treated with antibiotics. Prophylactic antibiotics\ncan be considered.\nOTHER NEUROLOGIC DISEASES\nNUTRITIONAL DEFICIENCIES\nTable 2.9-22 describes neurologic syndromes commonly associated with nutri-\ntional deficiencies.\nIDIOPATHIC INTRACRANIAL HYPERTENSION\nA disorder characterized by raised ICP with neurologic manifestations such as\nheadaches, papilledema (most common), and vision loss, without any indica-\ntion toward another cause of raised ICP on neuroimaging. The disease has no\nproven etiology (idiopathic), but is believed to be either due to decreased\nresorption and/or increased production of CSF. Other proposed mechanisms\ninclude vascular (transverse sinus stenosis), hormonal (aldosterone excess),\nand cellular (increased outflow resistance to CSF). Risk factors include\nfemale sex, obesity, use of tetracyclines, and hypervitaminosis A.\nHistory/PE\nâ–  Patients usually have bilateral, frontal (retrobulbar) headache, more pro-\nnounced in the mornings and on Valsalva; transient visual loss; diplopia;\npulsatile tinnitus.\nâ–  Sixth nerve (abducens) palsy may be a nonlocalizing sign of raised ICP.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441100 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN ",
      "char_start": 1184000,
      "char_end": 1186000
    },
    {
      "chunk_id": 593,
      "text": "411\nTABLE 2.9-22. Neurologic Syndromes Associated With Nutritional Deficiencies\nVITAMIN SYNDROME SIGNS/SYMPTOMS CLASSIC PATIENTS TREATMENT\nThiamine (vitamin B) Wernicke Classic triad consisting of Patients with acute/ Reversible almost\n1\nencephalopathy encephalopathy, ophthal- chronic alcohol immediately with thi-\nmoplegia, and ataxia overuse (toxin effect amine administration\non cerebellar Purkinje Always give thiamine\nfibers), hyperemesis, before glucose\nstarvation, renal dialysis,\nAIDS. Usually brought\non or exacerbated by\nhigh-dose glucose\nadministration\nKorsakoff dementia Above plus anterograde Same as above; usually Irreversible\nand retrograde amnesia, occurs in Wernicke syn-\nhorizontal nystagmus, and drome that was treated\nconfabulations too late or inadequately\nCobalamin (vitamin B )a Peripheral neu- Gradual, progressive gait dis- Patients with pernicious B injections or large\n12 12\nSubacute combined degeneration ropaTtahbeys ;d soursablisacute order due to profound loss of anemia; strict vegetar- oral doses\ncombined degen- proprioception ians; status postgastric\neration (SCD) Symmetric paresthesia, or ileal resection; ileal\nstocking-glove sensory disease (eg, Crohn);\nneuropathy, leg stiffness, patients with acute/\nspasticity, paraplegia, bowel chronic alcohol\nSubacute combined degeneration Tabes dorsalis and bladder dysfunction, overuse or others with\nsore tongue, and dementia malnutrition\nAssociated with elevated meth-\nylmalonic acid levels\nFolatea Folate deficiency Irritability; personality changes Patients with acute/ Reversible if corrected\nwithout the neurologic chronic alcohol overuse early\nsymptoms of SCD\naAssociated with â†‘ homocysteine and an â†‘ risk for vascular events. (Images reproduced with permission from USMLE-Rx.com.)\nDiagnosis\nâ–  Neuroimaging (MRI with venography) is preferred to rule out other causes\nof raised ICP. CT done when MRI contraindicated.\nâ–  CSF opening pressure >25 cm H O in adults is suggestive of diagnosis.\n2\nâ–  Ophthalmologic eval",
      "char_start": 1186000,
      "char_end": 1188000
    },
    {
      "chunk_id": 594,
      "text": "uation is mandatory to rule out papilledema (see\nOphthalmology section).\nTreatment A 61-year-old man presents to the\nemergency department with a\nâ–  Goals of therapy include alleviation of symptoms and preservation of 6-month history of progressively\nvision.\nworsening nausea and morning\nâ–  Best first treatment when patients have minimal symptoms is to address headache. The patient is in no\nrisk factors/comorbidities and advise weight loss. apparent acute distress. What is the\nâ–  Carbonic anhydrase inhibitor, acetazolamide, is best first medication to preferred diagnostic study?\nuse in these patients.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441111 1100//2211//2222 22::1188 PPMM\n\n412 HIGH-YIELD FACTS IN NEUROLOGY\nâ–  When medical therapy fails, the physician should consider topiramate and\nserial LPs (not preferred, as CSF reforms within 6 hours) prior to surgery.\nâ–  Surgery is advised when patients have worsening visual defects despite\nmedical therapy, and presence of visual acuity loss is secondary to papill-\nedema. Performed procedures include optic nerve sheath fenestration\n(ONSF) and CSF-shunting procedures.\nOPHTHALMOLOGY\nVISUAL FIELD DEFECTS\nFigure 2.9-26 illustrates common visual field defects and the anatomic areas\nwith which they are associated.\nHORDEOLUM\nPainful abscess of the eyelid, also called a stye, caused by inflammation or\ninfection of a sebaceous gland located around the eyelash (Zeis and Moll) or\ninner lid margin (meibomian). S aureus is the most common pathogen. Hor-\ndeolum presents with localized swelling and erythema. Initial management\nconsists of warm, moist compresses, topical antibiotic/steroids ointment, and\nlid massage several times a day to facilitate drainage. Refractory hordeola may\nbe referred to ophthalmologists for incision and drainage.\nCHALAZION\nGranulomatous lesion of the eyelid that presents with localized swelling and a\nnontender, hard nodule. Differentiated from a hordeolum by a comparative\nlac",
      "char_start": 1188000,
      "char_end": 1190000
    },
    {
      "chunk_id": 595,
      "text": "k of erythema and pain. Management includes warm compress, topical\nantibiotic/steroid combination, and possible incision and drainage (refractory\nlesions).\nL eye R eye\n1 Macula\nCentral scotoma\n(macular degeneration)\n2 Optic nerve\nLeft anopia\nL R\n3 Optic chiasm\nBitemporal hemianopia\n4 Optic tract\nRight homonymous hemianopia\n5 Meyer loop\nRight upper quadrantanopia\n(left parietal lesion)\n6 Dorsal optic radiation\nRight lower quadrantanopia\n(left temporal lesion)\nThis patient presents with symptoms 7 (if PCA infarct) Visual cortex\nthat are concerning for increased Right hemianopia with macular sparing\nICP. As he is not in acute distress, MRI\nis the preferred study because it is FIGURE 2.9-26. CNS lesions cause characteristic visual field defects. (Reproduced with permission\nbetter for visualizing soft tissue and from USMLE-Rx.com.)\nvascularity.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441122 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 413\nA\nFIGURE 2.9-27. Blepharitis. (Left image reproduced with permission from USMLE-Rx.com. Right image reproduced\nwith permission from Vanzzini Zago V, Alcantara Castro M, Naranjo Tackman R. Support of the laboratory in the diagnosis of B\nfungal ocular infections. Int J Inflam. 2012;2012:643104. doi:10.1155/2012/643104.)\nBLEPHARITIS\nA chronic inflammatory condition of the eyelash follicles (anterior) or Meibo-\nmian glands (posterior) of the eyelid, producing lid irritation that may lead to\nerythema and pruritis of the eyelid or conjunctiva (Fig. 2.9-27), excessive tear\nproduction, eyelash crusting, and light sensitivity. Initial treatment is with\nwarm compresses, lid hygiene, and lubricating drops to prevent corneal dry-\nness. Patients who do not respond to initial therapy are treated with topical\nFIGURE 2.9-28. (A) Corneal abrasion; (B)\nerythromycin. Oral antibiotics (doxycycline, azithromycin) may be used for Woodâ€™s lamp examination with corneal\nrefractory cases. Lid hygiene, in",
      "char_start": 1190000,
      "char_end": 1192000
    },
    {
      "chunk_id": 596,
      "text": "cluding washing, and avoidance of irritants abrasion. (Image A reproduced with permission\nsuch as smoke, eye makeup, or contact lenses is emphasized to prevent future from Gilani CJ, Yang A, Yonkers M, Boysen-Osborn\nM. Differentiating urgent and emergent causes of\nsymptoms.\nacute red eye for the emergency physician. West\nJ Emerg Med. 2017;18[3]:509-517. doi:10.5811/\nCORNEAL ABRASION westjem.2016.12.31798. Image B reproduced with\npermission from USMLE-Rx.com.)\nDamage to the corneal epithelium (Fig. 2.9-28A) caused by trauma (includ-\ning from foreign bodies or contact lenses). Patients report severe eye pain, for-\neign body sensation, and photophobia. Diagnosis is made by fluorescein\nexamination, where there is increased uptake of fluorescein stain in the area\nof abrasion under a Woodâ€™s lamp (Fig. 2.9-28B). Treatment consists of remov-\ning any retained foreign body, pain control, and topical antibiotic therapy.\nFluoroquinolone drops are used for contact lens wearers due to risk of\nPseudomonas infection, whereas erythromycin ointment or polymyxin/\ntrimethoprim drops are suitable for patients who do not wear contact lenses.\nPRESEPTAL (PERIORBITAL) CELLULITIS\nInfection of the eyelid and surrounding soft tissue anterior to the orbital sep-\ntum. Presents with painful erythema and edema of the eyelid. S aureus is the\nmost common pathogen. Patients with no skin trauma are treated with\namoxicillin-clavulanic acid, whereas patients with skin trauma are covered for\nA 24-year-old female with a body\nmethicillin-resistant S aureus (MRSA) with the addition of trimethoprim-\nmass index (BMI) of 33 presents with\nsulfamethoxazole or clindamycin. This condition is differentiated from the a 3-week history of constant retro-\nmore serious orbital (postseptal) cellulitis by lack of ophthalmoplegia, pain orbital headache with occasional\nwith eye movement, or proptosis. CT of the orbit can be used to differentiate nausea, vomiting, and tinnitus. She\nthe site of infection in unclear cases. als",
      "char_start": 1192000,
      "char_end": 1194000
    },
    {
      "chunk_id": 597,
      "text": "o developed new-onset diplopia\n2 hours before presentation. On\nphysical examination, she is noted to\nORBITAL (POSTSEPTAL) CELLULITIS\nhave papilledema. What is the most\nlikely diagnosis, and what are the risk\nInfection of the ocular muscles or orbital fat, sparing the globe, that may lead factors for this condition?\nto vision loss or death if left untreated. Commonly caused by direct spread of\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441133 1100//2211//2222 22::1188 PPMM\n\n414 HIGH-YIELD FACTS IN NEUROLOGY\ninfection from the paranasal sinuses. Other causes include trauma, ophthal-\nmic surgeries, dental infections, and dacryocystitis. It is usually caused by\nstaphylococci (including MRSA), streptococci, and H influenzae (in chil-\ndren). In patients with diabetes and immunocompromise, Mucor and Rhizo-\npus must be included in the differential diagnosis.\nHistory/PE\nPresents with acute-onset fever, proptosis, â†“ extraocular movement, ocular\npain, and â†“ visual acuity. The physician should look for a history of ocular\ntrauma/surgery or sinusitis. Palatal or nasal mucosal ulceration with coexisting\nmaxillary and/or ethmoid sinusitis suggests mucormycosis or Rhizopus.\nFIGURE 2.9-30. Conjunctivitis. (Reproduced\nwith permission from USMLE-Rx.com.) Diagnosis\nKEY FACT Mostly clinical. Best initial test: Blood and tissue fluid culture. CT scan or\nMRI of the orbit and sinuses to rule out orbital abscess and intracranial\nOrbital cellulitis can be distinguished from involvement.\npreseptal cellulitis by the presence of the\nfollowing clinical features: restricted or Treatment\npainful eye movements, â†“ visual acuity,\nâ–  The patient should be admitted and administered broad-spectrum IV anti-\ndiplopia, proptosis, and presence of a\nbiotics such as vancomycin and ceftriaxone. Metronidazole is added for\nrelative afferent pupillary defect.\nintracranial extension; case requires an ophthalmologic/ear, nose, throat\n(ENT) consult.\nKEY FACT\nâ–  Abscess formation",
      "char_start": 1194000,
      "char_end": 1196000
    },
    {
      "chunk_id": 598,
      "text": " or a worsening condition may necessitate surgery.\nNeisseria conjunctivitis is an ocular â–  Patients with diabetes or immunocompromise should be treated with\namphotericin B and surgical debridement (often associated with cavern-\nemergency often requiring inpatient\nous sinus thrombosis) if Mucor or Rhizopus is diagnosed.\nparenteral antibiotic therapy.\nCONJUNCTIVITIS\nInflammation of the conjunctiva producing a red-appearing eye (Fig. 2.9-30).\nIt is most often allergic, viral, or bacterial but can also be fungal, parasitic, or\nchemical. It is essential to differentiate potentially vision-threatening infec-\ntious etiologies from allergic or other causes of conjunctivitis and to identify\nother vision-threatening conditions that may mimic conjunctivitis.\nTable 2.9-23 lists the common etiologies of infectious conjunctivitis.\nâ–  Allergic conjunctivitis: Bilateral predominantly itchy eyes. Treat with\nantihistamine (olopatadine) eye drops.\nâ–  Bacterial conjunctivitis: Purulent discharge. Treat with erythromycin\nFIGURE 2.9-31. Dacryocystitis. (Reproduced ointment or fluoroquinolone drops in contact lens wearers.\nwith permission from USMLE-Rx.com.) â–  Viral conjunctivitis: Watery discharge, often bilateral. Self-limiting. Treat\nwith antihistamine (olopatadine) or lubricating eye drops for symptomatic\nrelief.\nGiven this patientâ€™s symptoms\nand risk factors, she probably has ACUTE DACRYOCYSTITIS\npseudotumor cerebri, also known as\nidiopathic intracranial hypertension Infection of the lacrimal sac, usually by Staphylococcus or Streptococcus spp.\n(IIH). In IIH, symptoms are suggestive May progress to orbital cellulitis or meningitis if left untreated. Congenital\nof a brain tumor, and CSF pressure will nasolacrimal duct stenosis and dacryocystocele (nasolacrimal duct cyst) are\nbe â†‘; however, neuroimaging will be\npredisposing conditions.\nnormal. Obesity, tetracycline, growth\nâ–  Hx/PE: Presentation with purulent eye discharge, as well as inflammation\nhormone, and excess vitamin A are\noverlyi",
      "char_start": 1196000,
      "char_end": 1198000
    },
    {
      "chunk_id": 599,
      "text": "ng the lacrimal system and medial eyelids (medial canthal region)\nrisk factors for the disease. Treatment\n(Fig. 2.9-31). Less commonly fever and â†‘ WBC.\nis with acetazolamide, topiramate,\noptic nerve fenestration, and â–  Dx: Clinical diagnosis.\nventriculoperitoneal shunt if needed. â–  Tx: If mild, oral anti-staphylococcus/streptococcus agents. If serious,\nimmediate empiric broad-spectrum antibiotics to prevent orbital cellulitis.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441144 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 415\nTABLE 2.9-23. Common Causes of Infectious Conjunctivitis\nPATHOGEN CHARACTERISTICS DIAGNOSIS TREATMENT\nBacterial Staphylococci, Foreign body sensation, purulent discharge Gram stain Antibiotic drops/ointment\nstreptococci, and culture\nHaemophilus, Pseu- if severe\ndomonas, Moraxella\nNeisseria gonorrhoeae An emergencyâ€”corneal involvement can lead to Gram stain IM or IV ceftriaxone;\nperforation and blindness showing inpatient treatment if\ngram âŠ– complicated. Contact\nintracellular tracing/treat sexual\ndiplococci partners.\nChlamydia tracho- Recurrent epithelial keratitis in childhood, trichiasis, Clinical (most Azithromycin (single oral\nmatis Aâ€“C corneal scarring, and entropion often), PCR dose) in mass treatment\nTrachoma (global) Leading cause of preventable blindness world wide\nChlamydia tracho- Ophthalmia neonatorum: Mucopurulent conjuncti- Ophthalmia Ophthalmia neonatorum:\nmatis Dâ€“K vitis in neonates neonatorum: Erythromycin (first line),\nAdult inclusion conjunctivitis: Chronic conjunctivitis Giemsa azithromycin\nwith mild mucopurulent discharge in adults stain, PCR Adult inclusion conjunc-\nAdult inclu- tivitis: Azithromycin\nsion (single oral dose),\nconjuncti- screening for gonorrhea\nvitis: PCR and contact tracing\nViral Adenovirus (most Copious watery discharge, severe ocular irritation, Contagious; self-limited\ncommon) preauricular lymphadenopathy, pharyngitis (with\nadenovirus, â€œpharyngoconjun",
      "char_start": 1198000,
      "char_end": 1200000
    },
    {
      "chunk_id": 600,
      "text": "ctival feverâ€)\nOccurs in epidemics\nHERPES SIMPLEX KERATITIS\nViral infection of the cornea. Common cause of visual impairment in the\nUnited States.\nâ–  Hx/PE: Presents with pain, blurred vision, tearing, and redness. The virus\nremains dormant along the trigeminal nerve and may reactivate during\nperiods of immunocompromise such as illness.\nâ–  Dx: Typically clinical. However, dendritic ulcers (Fig. 2.9-32) are charac-\nteristic. Epithelial scrapings show multinucleated giant cells. PCR of con-\njunctival/corneal swab for confirmation.\nâ–  Tx: Oral or topical antiviral therapy.\nCONTACT LENS KERATITIS\nFIGURE 2.9-32. Herpes simplex kerati-\nMedical emergency, often caused by Pseudomonas infection. tis with dendritic ulcer. (Reproduced with\nâ–  Hx/PE: Typically presents with painful, red eye and opacification and permission from Gilani CJ, Yang A, Yonkers M, Boysen-\nOsborn M. Differentiating urgent and emergent\nulceration of the cornea. Most patients report a history of improper con-\ncauses of acute red eye for the emergency physician.\ntact lens hygiene, such as reusing lens solution or showering/swimming\nWest J Emerg Med. 2017;18[3]:509-517. doi:10.5811/\nwith lenses in. Severe disease can cause corneal perforation and perma- westjem.2016.12.31798.)\nnent vision loss.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441155 1100//2211//2222 22::1188 PPMM\n\n416 HIGH-YIELD FACTS IN NEUROLOGY\nâ–  Dx: Clinical. Corneal scrape and bacterial culture are usually performed\nfor antibiotic sensitivity.\nâ–  Tx: Immediate removal of the contact lens and administration of topical\nbroad-spectrum antibiotics.\nUVEITIS\nInfectious or noninfectious inflammation of the uveaâ€”specific name is based\non location within the affected eye. Anterior uveitis: iritis; posterior uveitis:\nchoroiditis and/or retinitis. Associated with systemic inflammatory disorders\n(eg, sarcoidosis, inflammatory bowel disease, rheumatoid arthritis, juvenile\nidiopathic arthritis, human leukocyte antigen (",
      "char_start": 1200000,
      "char_end": 1202000
    },
    {
      "chunk_id": 601,
      "text": "HLA)-B27â€“associated\nconditions)\nFIGURE 2.9-33. Uveitis. (Reproduced with History/PE\npermission from Barut K, Rzayev T, Canpolat N, et\nâ–  Patients with anterior uveitis may have pain and redness of the eyeâ€”often\nal. Acute granulomatous iridocyclitis in a child with\nworse at the limbus (corneal-scleral junction) (Fig. 2.9-33). They may\ntubulointerstitial nephritis and uveitis syndrome. J\nOphthalmic Inflamm Infect. 2015;5:3. Published 2015 have hypopyon (accumulation of pus in anterior chamber).\nFeb 13. doi:10.1186/s12348-015-0035-2. â–  Posterior uveitis presents with visual changes such as decreased visual acu-\nity or floaters in the visual fields.\nDiagnosis\nDiagnosis is made by slitlamp examination showing leukocytes in the anterior\nchamber, vitreous humor, or other signs of inflammation of the retina.\nTreatment\nâ–  Treatment of infectious uveitis is targeted toward the specific pathogen.\nâ–  Noninfectious uveitis is treated with topical glucocorticoids. Oral or intra-\nocular glucocorticoids are used for refractory cases.\nREFRACTIVE ERRORS\nCommon cause of impaired vision, correctable with glasses, contact lenses, or\nrefractive surgery.\nâ–  Hyperopia, also called â€œfarsightedness.â€ Eye too short for refractive power\nof cornea and lens â†’ light focused behind retina. Correct with convex\n(converging) lenses.\nâ–  Myopia, also called â€œnearsightedness.â€ Eye too long for refractive power of\ncornea and lens â†’ light focused in front of retina. Correct with concave\n(diverging) lens.\nâ–  Astigmatism, irregular curvature of cornea â†’ different refractive power at\ndifferent axes. Correct with cylindrical lens.\nPRESBYOPIA\nAging-related impaired accommodation (focusing on near objects), primarily\ndue to â†“ lens elasticity, changes in lens curvature, and â†“ strength of the ciliary\nmuscle. Patients often need â€œreading glassesâ€ (magnifiers).\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441166 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 417\nGLAUCO",
      "char_start": 1202000,
      "char_end": 1204000
    },
    {
      "chunk_id": 602,
      "text": "MA KEY FACT\nClosed-angle glaucoma headaches\nIn the eye, aqueous humor produced by the ciliary body behind the iris trav-\nare triggered by darkness (caused by\nels through the pupil into the anterior chamber and is then drained back into\npupillary dilation). Migraine headaches\nthe bloodstream via the trabecular meshwork in the angle of the anterior\nare triggered by bright lights.\nchamber.\nâ–  Any process that disrupts this natural flow (Fig. 2.9-34) can â†‘ intraocular KEY FACT\npressure (IOP), damaging the optic nerve head and causing visual field\ndeficits. Glaucoma is the result of such damage to the nerve. Open-angle glaucoma generally occurs\nâ–  Open-angle glaucoma is much more common in the United States than bilaterally, but closed-angle glaucoma\nclosed-angle glaucoma (see Fig. 2.9-35 and Table 2.9-24). usually presents unilaterally.\nCATARACT\nâ–  Lens opacification resulting in obstructed passage of light (Fig. 2.9-36).\nAssociated with diabetes, HTN, advanced age, and exposure to radiation or\ncorticosteroids. Congenital risk factors: classic galactosemia, galactokinase\ndeficiency, trisomies (13, 18, 21), TORCH infections (eg, rubella), Marfan\nsyndrome, Alport syndrome, myotonic dystrophy, and neurofibromatosis 2.\nâ–  Hx/PE: Presents with reduced visual acuity, especially at night, and loss of\nthe red reflex.\nâ–  Tx: Surgical lens removal and replacement.\nOpen-angle glaucoma Angle-closure glaucoma\nNormal aqueous flow Obstruction of drainage\npathways by the iris\nAbnormal aqueous flow\nï¨ trabecular\noutflow resistance\nPupillary block\nFIGURE 2.9-34. Aqueous humor flow in glaucoma. (Reproduced with permission from USMLE-Rx.com.)\nA B\nA 39-year-old man presents to\nthe emergency department with\nsevere eye pain, photophobia, and a\npersistent sensation that something is\nNormal Cupping in his eye. The physician is suspicious\nof a corneal abrasion. What are the\nFIGURE 2.9-35. Findings in open- and closed-angle glaucoma. (A) Normal optic disc. (B) risk factors for this condition, and\nCuppi",
      "char_start": 1204000,
      "char_end": 1206000
    },
    {
      "chunk_id": 603,
      "text": "ng (increased cup-to-disc ratio) seen in open-angle glaucoma. (Reproduced with permission from what diagnostic test can you do to\nEyeRounds.) confirm your suspicion?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441177 1100//2211//2222 22::1188 PPMM\n\n418 HIGH-YIELD FACTS IN NEUROLOGY\nTABLE 2.9-24. Closed-Angle vs Open-Angle Glaucoma\nCLOSED-ANGLE GLAUCOMA OPEN-ANGLE GLAUCOMA\nEtiology Disrupted flow of aqueous humor into the anterior chamber Diseased trabecular meshwork results in â†“ drainage,\nresults in â†‘ pressure in the posterior chamber, leading to leading to gradual â†‘ in IOP and progressive vision loss.\nangle closure that â†“ drainage. This ophthalmic emergency can\ncause blindness. Although this disease usually presents unilat-\nerally, it often affects both eyes sequentially.\nRisk factors Family history, older age (55â€“70 years), Asian descent, hyper- Age >40 years, family history of open-angle glaucoma,\nopia, prolonged pupillary dilation (prolonged time in a dark Black ethnicity, diabetes, and myopia.\narea, stress, medications), anterior uveitis, and lens dislocation.\nHistory/PE Extreme, sudden-onset eye pain, blurred vision, headache, Usually asymptomatic until late in the clinical course,\nnausea, and vomiting. when it can cause gradual loss of peripheral vision if\nA hard, red eye is seen; the pupil is dilated and nonreactive to left untreated.\nlight. Cupping of the optic nerve head is seen on funduscopic\nexam.\nDiagnosis Best initial test: Ocular tonometry (to measure IOP) can quickly Best initial test: Tonometry.\nprovide additional information. Best diagnostic test: Ophthalmoscopic visualization of\nBest diagnostic test: Assessing the corneal angle with gonios- the optic nerve head (enlarged cup-to-disc ratio) and\ncopy is the gold standard. visual field testing.\nTreatment Treatment to â†“ IOP uses a combination of topical and systemic Topical medications such as prostaglandins (latanoprost)\ntherapy as follows: and cholinergic agoni",
      "char_start": 1206000,
      "char_end": 1208000
    },
    {
      "chunk_id": 604,
      "text": "sts (pilocarpine) â†‘ aqueous\nâ–  Eye drops (timolol, apraclonidine, pilocarpine, dorzolamide, outflow, whereas Î²-blockers (timolol, betaxolol) and\nlatanoprost) carbonic anhydrase inhibitors (acetazolamide) â†“\nâ–  Systemic medications (oral or IV acetazolamide, or IV aqueous production. Alpha-agonists (apraclonidine,\nmannitol) brimonidine) work via both mechanisms.\nâ–  Laser peripheral iridotomy, which creates a hole in Prostaglandins or Î²-blockers are chosen as first-line\nthe peripheral iris, is curative, and can be performed therapy. If medication fails, laser trabeculoplasty or a\nprophylactically trabeculectomy can improve aqueous drainage.\nThe patient should not have any medications that cause\npupillary dilation (atropine or other medications with anticho-\nlinergic activity such as antihistamines and antidepressants).\nAGE-RELATED MACULAR DEGENERATION\nAge-related macular degeneration (AMD) is more common among White\nindividuals, females, people who smoke, and those with a family history.\nRisk factors for corneal abrasion\ninclude trauma, foreign body, and History/PE\ncontact lens use. Use a penlight to\nâ–  Presents with painless loss of central vision. Early signs include distortion\ndocument pupillary function and the\nof straight lines (metamorphopsia) and loss of other aspects of fine visual\npresence/absence of a foreign body.\nacuity.\nA fluorescein examination can be\ndiagnostic and will show a corneal\nstaining defect. Pain persists even\nafter departure of foreign body due to\ndamage and sensitization of corneal\nnerves.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441188 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 419\nâ–  Atrophic (â€œdryâ€) macular degeneration: Responsible for 80% of cases. It\ncauses gradual vision loss.\nâ–  Exudative or neovascular (â€œwetâ€) macular degeneration: Much less\ncommon but associated with more rapid and severe vision loss.\nDiagnosis\nâ–  Atrophic (â€œdryâ€) macular degeneration: Fundoscopy reveals drusen\n(",
      "char_start": 1208000,
      "char_end": 1210000
    },
    {
      "chunk_id": 605,
      "text": "accumulation of white/yellow extracellular material) and/or pigmentary\nchanges (Fig. 2.9-37). FIGURE 2.9-36. Cataract. (Reproduced with\npermission from Roshan M, Kabekkodu SP, Vijaya\nâ–  Exudative or neovascular (â€œwetâ€) macular degeneration: Hemorrhage PH, et al. Analysis of mitochondrial DNA variations\nand subretinal fluid are present.\nin Indian patients with congenital cataract. Mol Vis.\n2012;18:181â€“193.)\nTreatment\nâ–  Atrophic AMD: No treatment is currently available, although a combina-\ntion of vitamins (vitamin C, vitamin E, beta-carotene, and zinc) has been\nfound to slow disease progression. The physician should be cautious about\ngiving high doses of vitamin E and beta-carotene to patients who smoke,\nas there is an association of â†‘ mortality rate from lung cancer in people\ntaking high doses of these supplements.\nâ–  Exudative AMD: Intravitreal injections of VEGF inhibitors have been\nshown to improve vision (aflibercept, ranibizumab, bevacizumab) or slow\nvisual loss in patients with exudative AMD.\nRETINAL VASCULAR OCCLUSION\nOccurs in older adult patients and is strongly related to cardiovascular disease\n(see Table 2.9-25).\nFIGURE 2.9-37. Macular degeneration\nwith evidence of drusen and fibrosis on\nOPTIC NEURITIS fundoscopic exam. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nInflammation of the optic nerve that is commonly associated with MS. Other\noptic neuropathies may be caused by ischemia, infection/postinfection (men-\ningitis, encephalitis), vasculitis, connective tissue disease (systemic lupus ery-\nthematosus [SLE], SjÃ¶gren), genetic conditions, and drugs (eg, methanol,\nethambutol, linezolid, infliximab).\nHistory/PE/Diagnosis\nâ–  Optic neuritis produces painful vision loss that is often unilateral. It causes\nKEY FACT\nrelative afferent pupillary defect (Marcus-Gunn pupil).\nâ–  Fundoscopy may show disc swelling that looks similar to papilledema; For optic neuritis, give IV, not oral,\nhowever, fundoscopy is normal in two thirds of patients because the\ncorticostero",
      "char_start": 1210000,
      "char_end": 1212000
    },
    {
      "chunk_id": 606,
      "text": "ids.\ninflammation is posterior to the optic nerve head.\nâ–  The diagnosis is clinical, based on history and physical exam. Diagnosis\nmay be confirmed with MRI of the orbits.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 441199 1100//2211//2222 22::1188 PPMM\n\n420 HIGH-YIELD FACTS IN NEUROLOGY\nTreatment\nMethylprednisolone IV for 3 days, followed by oral steroids. Oral steroids\nalone may increase risk of recurrence. Most patients gradually recover vision\neven without treatment, although IV methylprednisolone increases the rate of\nrecovery.\nTABLE 2.9-25. Central Retinal Artery vs Central Retinal Vein Occlusion\nCENTRAL RETINAL ARTERY OCCLUSION CENTRAL RETINAL VEIN OCCLUSION\nHistory/PE Presents with sudden, painless, unilateral vision loss (eg, Presents with rapid, painless vision loss of variable\nscotoma), as well as relative afferent pupillary defect severity; associated with hypertension\nPatients present with a cherry-red spot on the fovea (blue arrow A swollen optic disc with hemorrhages, venous stasis\nin image), retinal swelling (whitish appearance to the nerve retinal hemorrhages, cotton-wool spots, and macular\nfiber layer), and retinal arteries that may appear bloodless edema may be seen on funduscopic exam\nTransient occlusion is comparable to transient ischemic attack\nand is known as amaurosis fugax\nEtiology Atherosclerosis is the biggest risk factor; other risk factors Hypertension is the biggest risk factor; other risk factors\ninclude cardioembolism (atrial fibrillation, endocarditis), giant include conditions that cause hypercoagulability (factor\ncell arteritis, Behcet syndrome, and sickle cell disease V Leiden, proteins C and S deficiency, antithrombin [AT]\nIII deficiency, anti-phospholipid antibody syndrome,\nmonoclonal gammopathies)\nWorkup Diagnosis is based on history and fundoscopy Hypercoagulability testing should be performed if there is\nThe next best tests to order after diagnosis are a carotid duplex a suggestive histo",
      "char_start": 1212000,
      "char_end": 1214000
    },
    {
      "chunk_id": 607,
      "text": "ry or other causes have been excluded\n+ echocardiogram to evaluate for atherosclerotic disease and\ncardioembolic sources\nGiant cell arteritis is ruled out using erythrocyte sedimentation\nrate and C-reactive protein in patients over 50 years who have\nno visualized retinal emboli\nTreatment Ocular massage with high-flow oxygen administration; intra- Laser photocoagulation for ischemic central retinal vein\narterial thrombolysis within 8 hours occlusion (CRVO) to reduce risk of neovascularization\nOther treatments target the specific etiology and may include VEGF inhibitors treat macular edema (cause of vision loss\nanticoagulation, carotid endarterectomy, and secondary pre- in CRVO); optimization of risk factor treatment ([HTN,\nvention of vascular events such as stroke or MI diabetes mellitus [DM]) should occur\nImage A reproduced with permission from USMLE-Rx.com. Image B reproduced with permission from Alasil T, Rauser ME. Intravitreal bevacizumab\nin the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report. Cases J. 2009;2:176.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442200 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 421\nRETINAL DETACHMENT\nSeparation of the retina from the underlying retinal pigment epithelium\n(RPE) and choroid. May be caused by retinal tears, proliferative diabetic reti-\nnopathy, or trauma. High myopia (>6 diopters of correction required) is a risk\nfactor.\nHistory/PE\nâ–  Sudden-onset painless monocular vision loss is often associated with float-\ners and flashes of light.\nâ–  Visual field defect may resemble a curtain ascending or descending over\nthe eye.\nFIGURE 2.9-38. Retinal detachment on\nâ–  Retinal detachment and other trauma may cause vitreous hemorrhage, fundoscopic examination. (Reproduced with\nwhere the vitreous humor fills with blood. This complication presents permission from USMLE-Rx.com.)\nwith black spots and cobweb shapes in the visual field.\nDiag",
      "char_start": 1214000,
      "char_end": 1216000
    },
    {
      "chunk_id": 608,
      "text": "nosis KEY FACT\nâ–  All patients should have visual field and acuity testing. Retinal detachment presents with\nâ–  The detached retina can be seen floating in the posterior chamber on sudden-onset flashing lights and\nultrasound.\nblurred vision. Patients typically\nâ–  Definitive diagnosis requires a dilated funduscopic exam, where the describe a curtain coming down over\ndetached retina can be directly visualized (Fig. 2.9-38).\ntheir eye. Ophthalmoscopy shows a\ngray, elevated retina.\nTreatment\nTamponading of the retina via surgery (vitrectomy or scleral buckle).\nDIABETIC RETINOPATHY\nRetinal damage due to chronic hyperglycemia. Two types:\nâ–  Nonproliferativeâ€”Damaged capillaries leak blood â†’ lipids and fluid seep\ninto retina causing hemorrhages and macular edema. Treatment: Blood\nsugar and blood pressure control.\nâ–  Proliferativeâ€”Chronic hypoxia results in new blood vessel formation with\nresultant traction on retina â†’ retinal detachment. Treatment: Anti-VEGF\ninjections, peripheral retinal photocoagulation, or surgery.\nHYPERTENSIVE RETINOPATHY\nâ–  Chronic uncontrolled HTN â†’ endothelial disruption â†’ fibrinoid necro-\nsis â†’ retinal damage.\nâ–  Flame-shaped retinal hemorrhages, arteriovenous nicking, microaneu-\nrysms, macular star, cotton-wool spots (blue arrow in Fig. 2.9-43). Presence\nof papilledema in a hypertensive patient is indicative of malignant hyper-\ntension and requires immediate lowering of BP.\nâ–  Associated with risk of stroke, CAD, and kidney disease.\nRETINITIS PIGMENTOSA\nInherited progressive dystrophy of RPE and photoreceptors. It may be associ-\nated with abetalipoproteinemia. Early findings include nyctalopia (night\nblindness) and peripheral vision loss. Fundoscopy may show triad of optic disc\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442211 1100//2211//2222 22::1188 PPMM\n\n422 HIGH-YIELD FACTS IN NEUROLOGY\npallor, retinal vessel attenuation, and retinal pigmentation with bone spicule-\nshaped deposits (Fig. 2.9-39).\nPAPILLEDEMA\nOpti",
      "char_start": 1216000,
      "char_end": 1218000
    },
    {
      "chunk_id": 609,
      "text": "c disc swelling with blurred disc margins and dilated/tortuous retinal\nveins (usually bilateral) due to â†‘ ICP (eg, secondary to mass effect). Enlarged\nblind spot and elevated optic disc (Fig. 2.9-40) with blurred margins.\nLEUKOCORIA\nFIGURE 2.9-39. Retinitis pigmentosa on Loss (whitening) of the red reflex (Fig. 2.9-41). Important causes in children\nfundoscopic exam. (Modified with permission include retinoblastoma and congenital cataract.\nfrom USMLE-Rx.com.)\nRELATIVE AFFERENT PUPILLARY DEFECT\nAlso called Marcus-Gunn pupil. When the light shines into a normal eye,\nconstriction of the ipsilateral (direct reflex) and contralateral pupil (consen-\nsual reflex) is observed. When the light is then swung to the affected eye (side\nof optic nerve defect), both pupils dilate instead of constricting due to\nimpaired conduction of a light signal along the injured optic nerve. It is asso-\nciated with optic neuritis (eg, MS) and optic neuropathies (eg, giant cell\narteritis).\nHORNER SYNDROME\nSympathetic denervation of face causing:\nFIGURE 2.9-40. Papilledema on fundo-\nscopic exam. (Modified with permission from â–  Ptosis (slight drooping of eyelid: superior tarsal muscle)\nUSMLE-Rx.com.) â–  Anhidrosis (absence of sweating) and flushing of affected side of face\nâ–  Miosis (pupil constriction)\nAssociated with lesions along the sympathetic chain (Fig. 2.9-42):\nâ–  First neuron: Pontine hemorrhage, lateral medullary syndrome, spinal cord\nlesion above T1 (eg, Brown-SÃ©quard syndrome, late-stage syringomyelia)\nâ–  Second neuron: Stellate ganglion compression by Pancoast tumor\nFIGURE 2.9-41. Leukocoria with loss of â–  Third neuron: Carotid dissection (painful); anhidrosis usually absent\nred reflex. (Reproduced with permission from\nAerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al.\nORBITAL BLOWOUT FRACTURE\nRetinoblastoma. Orphanet J Rare Dis. 2006;1:31. Pub-\nlished 2006 Aug 25. doi:10.1186/1750-1172-1-31.)\nOrbital floor fracture; usually caused by direct trauma to eyeball or intraor-\nbital rim. ",
      "char_start": 1218000,
      "char_end": 1220000
    },
    {
      "chunk_id": 610,
      "text": "â†‘ risk of inferior rectus muscle and/or orbital fat entrapment. It may\nHypothalamus Ophthalmic division\nof trigeminal nerve lead to infraorbital nerve injury.\nLong ciliary nerve\nTo sweat glands\nof forehead\nCAVERNOUS SINUS SYNDROME\nTo smooth muscle of eyelid\nTo pupillary dilator\nInternal\ncarotid To sweat glands of face\nartery External carotid artery Cavernous sinus syndrome presents with variable ophthalmoplegia (CNs III\nThird neuron and VI involved most frequently), â†“ corneal sensation, Horner syndrome, and\nFirst neuron\nSuperior cervical ganglion decreased maxillary sensation. Secondary to pituitary tumor mass effect,\nSynapse in carotid-cavernous fistula, or cavernous sinus thrombosis related to infection\nlateral horn\nSecond neuron\nSpinal cord\nFIGURE 2.9-42. Sympathetic chain anat-\nomy in Horner syndrome. (Reproduced with\npermission from USMLE-Rx.com.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442222 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 423\nINTRANUCLEAR OPHTHALMOPLEGIA Right frontal\neye field\nVoluntary gaze\nâ–  MLF: Pair of tracts that interconnect CN VI and CN III nuclei to left\n(Fig. 2.9-43). Coordinates both eyes to move in same horizontal direc- L R\nLateral Medial\ntion. When patient looks left, the left nucleus of CN VI fires, which con- rectus rectus\ntracts the left lateral rectus and stimulates the contralateral (right)\nCN VI CN III\nnucleus of CN III via the right MLF to contract the right medial rectus.\nLesions may be unilateral or bilateral (latter classically seen in MS,\nOculomotor\nstroke). Midbrain (CN III) nucleus\nâ–  Lesion in MLF: Internuclear ophthalmoplegia (INO), a conjugate hori-\nzontal gaze palsy. Lack of communication occurs so that when CN VI Right MLF\nnucleus activates ipsilateral lateral rectus, the contralateral CN III Paramedian pontine\nreticular formation (PPRF)\nnucleus does not stimulate the medial rectus to contract. Abducting eye Pons Abducens\n(CN VI) nucleus\ndisplays nystagmus",
      "char_start": 1220000,
      "char_end": 1222000
    },
    {
      "chunk_id": 611,
      "text": " (CN VI overfires to stimulate CN III). Convergence\nis normal.\nâ–  Directional term (eg, right INO, left INO) refers to the eye that is unable Medulla\nto adduct.\nFIGURE 2.9-43. Neural pathways associ-\nated with intranuclear ophthalmople-\ngia. (Reproduced with permission from USMLE-Rx.\nOTOLOGY\ncom.)\nOTITIS MEDIA\nMNEMONIC\nAcute Otitis Media\nINOâ€”\nHistory/PE\nIpsilateral adduction failure,\nPain in the ear, redness, decreased hearing, and fever. On otoscopy, bulging,\nNystagmus Opposite.\nhypomobile, and decreased light reflex of tympanic membrane are seen.\nDiagnosis\nBest initial test: Usually empirically treated with antibiotics. Consider tympa-\nnocentesis with culture in case of recurrent infections.\nTreatment\nInitial best treatment: Amoxicillin for 10 days. If no response, the patient has\nbeen treated with amoxicillin recently, or symptoms return within 1 month,\namoxicillin-clavulanate should be used.\nChronic Suppurative Otitis Media\nSimilar to acute otitis media except:\nâ–  Continuous suppuration for >6 weeks with tympanic membrane\nperforation\nâ–  Prolonged duration of symptomsâ€”drainage, pain, and hearing loss\nâ–  Absence of systemic symptoms such as fever\nOtitis Media With Effusion/Serous Otitis Media/Glue Ear\nFluid in the middle ear for >3 months without an infection.\nA 55-year-old man presents to the\nHistory/PE\nemergency department with sudden-\nâ–  May be asymptomatic. Painless pressure in the ear postâ€“acute otitis media onset headache and a dilated pupil\nin children. in his right eye that is nonreactive\nâ–  Otoscopy shows air-fluid level behind the bulging tympanic membrane to light. His right eye is hard to\nand hypomobility. the touch. What is the most likely\ndiagnosis, and what medications\nshould be avoided in this patient?\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442233 1100//2211//2222 22::1188 PPMM\n\n424 HIGH-YIELD FACTS IN NEUROLOGY\nTreatment\nMonitoring for 3 months. If hearing impairment is resulting in speech impair-\nment, tymapn",
      "char_start": 1222000,
      "char_end": 1224000
    },
    {
      "chunk_id": 612,
      "text": "ostomy tubes may be considered.\nOTITIS EXTERNA\nInflammation of the external auditory canal, also known as â€œswimmerâ€™s ear.â€\nPseudomonas and Staphylococcus are the most common etiologic agents.\nBoth grow in the presence of excess moisture. Necrotizing (malignant) otitis\nexterna (Pseudomonas in >95%) can lead to osteomyelitis of the skull base.\nHistory/PE\nPresents with pain, pruritus, hearing loss, and possible purulent discharge.\nExamination reveals pain with movement of the tragus/pinna (unlike otitis\nmedia), an edematous and erythematous ear canal, and granulation tissue if\nnecrotizing type. Cranial nerve palsies may be visible in the necrotizing type.\nSee the Pediatrics chapter for a discussion of otitis media.\nDiagnosis\nA clinical diagnosis. A culture for severe or refractory cases. CT scan if the\npatient appears toxic.\nTreatment\nâ–  Best initial treatment: Aural toilet (clean and dry ear [eg, using wick and/\nor astringents]).\nâ–  Mild otitis externa can be treated with topical acetic acid (7â€“10) days.\nâ–  Moderate otitis externa is treated with topical antibiotics (ofloxacin or cip-\nrofloxacin) and steroid ear drops.\nâ–  Older adults with diabetes and individuals who are immunocompromised\nare at risk for necrotizing otitis externa and may require IV antibiotics\n(usually a fluoroquinolone or fourth-generation cephalosporin).\nâ–  Consider wick placement if occlusion of canal.\nâ–  To prevent, patients should avoid getting moisture in the ear and should\nthoroughly dry their ears after swimming,\nMALIGNANT OTITIS EXTERNA\nHistory/PE\nâ–  Severe infection of the external auditory meatus occurs with ear pain and\nsuppurative drainage. Granulation tissue is seen on otoscopy. Malignant\notitis externa is commonly seen in patients with poorly controlled diabetes\nand individuals who are immunosuppressed.\nâ–  Complications include cranial osteomyelitis and facial nerve palsy.\nâ–  The cause is Pseudomonas infection.\nTreatment\nâ–  Drug of choiceâ€”IV ciprofloxacin. Other IV antibiotics against Pseudomo-",
      "char_start": 1224000,
      "char_end": 1226000
    },
    {
      "chunk_id": 613,
      "text": "\nnas can also be used (eg, ceftazidime, cefepime, quinolones, aztreonam,\npiperacillin/tazobactam).\nThis patientâ€™s presentation is\nconsistent with closed-angle â–  Surgical debridement and biopsy are required with failure to respond to\nantibiotics.\nglaucoma. The physician should\navoid pupil-dilating medications such\nas atropine, which will â†‘ IOP and\nprevent drainage of aqueous humor.\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442244 1100//2211//2222 22::1188 PPMM\n\nNEUROLOGY HIGH-YIELD FACTS IN 425\nSENSORINEURAL HEARING LOSS\nEtiology\nâ–  MÃ©niÃ¨re diseaseâ€”hearing loss, tinnitus, vertigo, and aural fullness due to\nexcessive endolymph in the inner ear.\nâ–  Presbycusisâ€”bilateral, symmetric age-related hearing loss to high-\nfrequency sounds due to degenerative changes in inner ear and CN VIII.\nHearing is worse in noisy environments.\nâ–  Drug-induced hearing loss\nâ–  Noise-induced hearing loss\nâ–  Acoustic neuroma\nDiagnosis\nSee Figure 2.9-44.\nâ–  Rinne test: Reduced bilaterally\nâ–  Weber test: Localized to normal ear\nâ–  Pure tone audiometry: Increased auditory threshold in air and bone\nconduction\nâ–  Other tests include impendence audiometry and otoscopy for visual\nassessment\nTympanic\nmembrane CN VII\nSemicircular canals\nAuricle (pinna) CN VIII\nVestibule\nOval window\nExternal\nCochlea\nauditory canal\nOssicles\nPharyngotympanic\n(eustachian) tube\nSensoriNeural\nConductive hearing loss\nhearing loss\nRinne: abnormal Rinne: Normal\nWeber: affected ear Weber: Normal ear\nExternal (outer) ear Middle ear Internal (inner) ear\nOsteoma Cholesteatoma Presbycusis*\nCerumen impaction Tympanic MÃ©niereâ€™s disease\nOtitis membrane Acoustic neuroma\nperforation\nOtotoxic drugs\nOtosclerosis\nCochlear nerve damage*\n*normal Weber and Rinne\nFIGURE 2.9-44. Diagnosing hearing loss. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442255 1100//2211//2222 22::1188 PPMM\n\n426 HIGH-YIELD FACTS IN NEUROLOGY\nCONDUCTIVE",
      "char_start": 1226000,
      "char_end": 1228000
    },
    {
      "chunk_id": 614,
      "text": " HEARING LOSS\nEtiology\nâ–  Otitis media: Acute, chronic suppurative, serous\nâ–  Wax impaction\nâ–  Cholesteatoma: Growth of keratinizing squamous epithelium, which\nerodes ear ossicles; on otoscopy, discrete white plaque is seen on the tym-\npanic membrane\nâ–  Otosclerosis: Sclerotic changes in the ear ossicles\nDiagnosis\nSee Figure 2.9-44.\nâ–  Rinne test: Bone > air\nâ–  Weber test: Localized to affected ear\nâ–  Pure tone audiometry: Increased auditory threshold in air conduction only\n22002222__0022..0099__SStteepp22CCKK__NNeeuurroo__1111ee__335511--442266..iinndddd 442266 1100//2211//2222 22::1188 PPMM\n\nH I G H - Y I E L D F A C T S I N\nOBSTETRICS\nThe Basics of Pregnancy 428 Normal Labor and Delivery 454\ndefinition and staGes of laBor 454\nDiagnosis of Pregnancy 428\noBstetriC examination 454\nBeta-Human CHorioniC Gonadotropin (Î²-HCG) 428\nfetal Heart rate monitorinG 455\nultrasonoGrapHy 428\noBstetriC analGesia and anestHesia 455\nPhysiologic Changes in Pregnancy 429\nAbnormal Labor and Delivery 457\nPrenatal Care and Diagnostic Testing 430 indiCations for C-seCtion 457\nGroup B streptoCoCCus testinG and treatment 431 preterm laBor 457\nprenatal diaGnostiC testinG 431 rupture of memBranes 458\nTeratology 434 failure to proGress 459\nintra-amniotiC infeCtion 460\nCongenital Infections 435\nfetal malpresentation 460\nAbortion 436 umBiliCal Cord prolapse 461\nspontaneous aBortion 436 sHoulder dystoCia 461\neleCtive termination of preGnanCy 438 episiotomy 461\nCompliCations of aBortion 438 uterine inversion 462\nuterine rupture 462\nMaternal Complications of Pregnancy 438\nHyperemesis Gravidarum 438 Puerperium 462\ndiaBetes 439 postpartum HemorrHaGe 462\nHypertensive disease of preGnanCy 441 postpartum infeCtion 462\nurinary traCt infeCtions and asymptomatiC BaCteriuria 444 peripartum CardiomyopatHy 464\nintraHepatiC CHolestasis 444 sHeeHan syndrome (postpartum pituitary neCrosis) 464\naCute fatty liver in preGnanCy 445 Lactation and Breastfeeding 464\nObstetric Complications of Pregnancy 445 pHysioloGy 464\neCtop",
      "char_start": 1228000,
      "char_end": 1230000
    },
    {
      "chunk_id": 615,
      "text": "iC preGnanCy 445 ContraindiCations to BreastfeedinG 465\nGestational tropHoBlastiC disease 446 mastitis/Breast aBsCess 465\nantepartum HemorrHaGe and aBnormal plaCentation 446 Breast enGorGement 466\nmultiple Gestation 448 nipple injury 466\nfetal GrowtH restriCtion 449 loCalized pluGGed duCt 466\nfetal maCrosomia 449 GalaCtoCele 466\npolyHydramnios 450\noliGoHydramnios 450\nrH isoimmunization 451\nantepartum fetal surveillanCe 451\n427\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 442277 1100//2211//2222 11::5555 PPMM\n\n428 HIGH-YIELD FACTS IN OBSTETRICS\nTHE BASICS OF PREGNANCY\nThe terms and concepts that follow are central to an understanding of the\nphysiologic processes of pregnancy:\nGravidity: Number of times a woman has been pregnant\nParity: Number of pregnancies that led to a birth beyond 20 weeksâ€™ gesta-\ntional age or an infant weighing >500 g (1 lb, 2 oz).\nâ–  In prenatal assessment, TPAL expresses the number of term deliveries (T),\nthe number of preterm deliveries (P), the number of abortuses (A), and the\nnumber of living children (L).\nEmbryonic age: Number of weeks + days since fertilization; usually\nunknown\nGestational age (GA): The number of weeks and days measured from the\nfirst day of the last menstrual period (LMP). GA can also be determined by\nthe following:\nâ–  Fundal height: Reaches umbilicus (approximately 22 cm) at 20 weeks; +1\ncm/week of gestational age thereafter\nâ–  Fetal heart tones (Doppler): Typically, 10 to 12 weeks\nâ–  Quickening or appreciation of fetal movement: Occurs at 16 weeks for\nmultiparas and 20 weeks for primiparas at the earliest\nKEY FACT â–  Ultrasonography:\nA G3P1 patient has had three â–  Most accurate dating method in early pregnancy: Fetal crown-rump\nlength (CRL) at 6 to 12 weeks\npregnancies but only one birth beyond\n20 weeks and/or an infant who weighs â–  Preferred measurement from 13 weeks+: Biometry using biparietal\ndiameter (BPD), femur length (FL), and abdominal circumference\nat least 500 g.\n(AC",
      "char_start": 1230000,
      "char_end": 1232000
    },
    {
      "chunk_id": 616,
      "text": ")\nDIAGNOSIS OF PREGNANCY\nKEY FACT ð›ƒâˆ’HUMAN CHORIONIC GONADOTROPIN (ð›ƒ-hCG)\nGet a quantitative serum Î²-hCG:\nâ–  To help diagnose ectopic â–  The standard for diagnosing pregnancy. Can be detected in serum or\nurine.\npregnancy and follow the trend for\nresolution after treatment â–  Serum Î²-hCG more sensitive and preferred if menstrual period is\n<1 week late.\nâ–  To help diagnose miscarriage\nâ–  To monitor after treatment of â–  Produced by the placenta; peaks at 100,000 mIU/mL by 10 weeks.\ntrophoblastic disease (rising levels â–  â†“ throughout the second trimester; plateaus in the third trimester.\nconcerning for choriocarcinoma) â–  Î²-hCG levels double approximately every 48 hours during early preg-\nnancy; failure of hCG levels to double every 48 hours concerning for mis-\nâ–  To screen for fetal aneuploidy\ncarriage or ectopic pregnancy.\nULTRASONOGRAPHY\nâ–  Used to confirm an intrauterine pregnancy\nâ–  Gestational sac visible on transvaginal ultrasonography by:\nâ–  5 weeks\nâ–  A Î²-hCG in the range of 1500 to 3500 mIU/mL\nâ–  Transabdominal ultrasound (US) typically reserved for second-/third-\ntrimester measurements\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 442288 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 429\nPHYSIOLOGIC CHANGES IN PREGNANCY\nTable 2.10-1 describes the physiologic changes seen in pregnancy, as well as\ntheir mechanisms. These changes occur to increase perfusion to the fetus, opti-\nmize materno-fetal gas exchange, and alter the maternal pelvis to aid in delivery.\nTABLE 2.10-1 Physiologic Changes in Pregnancy\nSYSTEM CHANGES MECHANISMS\nCardiovascular Stroke volume increases to maximum at 19 weeks and then plateaus Stroke volume + â†‘ heart rate â†’ â†‘ cardiac\nHeart rate gradually increases 20% output\nCardiac output rises rapidly by 20% and then gradually increases an addi- â†‘ progesterone â†’ â†“ peripheral vascular\ntional 10% by 26 weeks resistance â†’ â†“ blood pressure\nPeripheral vascular resistance progressively decreases to term",
      "char_start": 1232000,
      "char_end": 1234000
    },
    {
      "chunk_id": 617,
      "text": "\nBlood pressure gradually decreases 10% by 34 weeks and then increases\nto prepregnancy values\nPeripheral venous distention progressively increases to term\nThe increase in stroke volume may cause physiologic systolic flow murmur\nCirculatory Blood volume â†‘ by 50% in the second trimester â†‘ fibrinogen, factor VII and VIII + â†“ protein S\nFibrinogen â†‘ â†’ hypercoagulable state (â†“ intrapartum\nHematocrit â†“ slightly blood loss risk)\nâ†“ platelet count Plasma volume â†‘â†‘ > â†‘ RBC â†’ â†“ hemato-\ncrit (dilutional anemia)\nPulmonary Tidal volume â†‘â†‘ Dyspnea (due to pressure from uterus)\nRespiratory rate, vital capacity: Unchanged Respiratory alkalosis with metabolic com-\nExpiratory reserve: Gradual decline pensation (progesterone mediates an\nincrease in tidal volume and alveolar\nventilation)\nRenal Renal flow â†‘ 25%â€“50%\nGlomerular filtration rate (GFR) â†‘ early and then plateaus\nâ†“ serum creatinine (Cr) and blood urea nitrogen (BUN)\nHyponatremia 4â€“5 mEq/L below prepregnancy levels (due to dilution and\nincreased antidiuretic hormone secretion)\nâ†‘ urinary frequency\nGlucosuria\nGastrointestinal â†“ esophageal sphincter tone + â†‘ gastric emptying time â†’ reflux\nâ†“ gastrointestinal (GI) motility â†’ constipation\nâ†“ gallbladder motility â†’ gallstones\nâ†“ venous return â†’ hemorrhoids\nMusculoskeletal Low back pain common in third trimester, caused by â†‘ pressure from the\nuterus and laxity of muscles and joints\nSkin Chloasma (melasma): patchy brown discoloration of the face\nLinea nigra\nNipple hyperpigmentation\n(continues)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 442299 1100//2211//2222 11::5555 PPMM\n\n430 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-1 Physiologic Changes in Pregnancy (continued)\nSYSTEM CHANGES MECHANISMS\nEndocrine Progressive â†‘ in estrogen, progesterone, and prolactin Thyroid-binding globulin (TBG) levels â†‘ in\nâ†‘ in Î²-hCG, peak at 12 weeks, and â†“ until plateau reached at about 24 response to estrogen in pregnancy. Most\nweeks T and T circulate bound to TBG,",
      "char_start": 1234000,
      "char_end": 1236000
    },
    {
      "chunk_id": 618,
      "text": " so the\n3 4\nâ†‘ in total T and T and â†“ in thyroid-stimulating hormone (TSH) due to â†‘ T and total T will also â†‘, but the levels of\n3 4 3 4\nnegative feedback (see Fig. 2.10-1) free T and T will not change.\n3 4\nPRENATAL CARE AND DIAGNOSTIC TESTING\nThe goal of prenatal care is to prevent, diagnose, and treat conditions that can\nlead to adverse fetal or maternal outcomes in pregnancy. Expected weight\ngain, nutrition, and exercise recommendations are outlined in Table 2.10-2.\nMaternal failure to gain appropriate weight is associated with fetal growth\nThyrotropic restriction (FGR), whereas excess weight gain is associated with diabetes.\nactivity\nAnterior\nhCG\npituitary\nTSH\nTABLE 2.10-2. Recommendations for Standard Prenatal Care\nCATEGORY RECOMMENDATIONS\nThyroid\ngland\nWeight gain Guidelines for weight gain according to prepregnancy body mass index (BMI):\nâ–  Underweight (BMI <18.5): 12â€“18 kg (28â€“40 lb)\ntotal T3/T4\nâ–  Acceptable (BMI 18.5â€“24.9): 11â€“16 kg (25â€“35 lb)\nâ–  Overweight (BMI 25â€“29.9): 7â€“11 kg (15â€“25 lb)\nestrogen TBG\nâ–  Obese (all classes, BMI >30): 5â€“9 kg (11â€“20 lb)\nFIGURE 2.10-1. Effect of pregnancy on\nNutrition Guidelines for nutritional supplementation:\nthe pituitary-thyroid axis. hCG, Human\nchorionic gonadotropin; TBG, thyroid- â–  An additional 100â€“300 kcal/day; additional 500 kcal/day during\nbinding globulin; TSH, thyroid-stimulat- breastfeeding\ning hormone. (Reproduced with permission from\nâ–  Folic acid supplements 400 mcg daily or 4000 mcg if previous neural\nUSMLE-Rx.com.)\ntube defect or maternal use of valproate or carbamazepine (folate\nsupplementation â†“ neural tube defects for all reproductive-age women)\nâ–  Iron\nâ–  Calcium\nâ–  Additional guidelines for vegans and others limiting meat/dairy intake:\nâ–  Vitamin D\nâ–  Vitamin B 12\nExercise Thirty minutes of moderate exercise daily, while avoiding contact sports\nHarmful â–  Avoid fish with high mercury levels\nsubstances â–  Moderate caffeine intake\nâ–  Avoid uncooked meat, fish, eggs\nâ–  Avoid unpasteurized dairy\n22002222__0022..1100__S",
      "char_start": 1236000,
      "char_end": 1238000
    },
    {
      "chunk_id": 619,
      "text": "Stteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443300 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 431\nGROUP B STREPTOCOCCUS TESTING AND TREATMENT\nScreening for group B streptococcus (GBS): Rectovaginal swab at 36 to 38\nweeks.\nIndications for intrapartum prophylaxis:\nâ–  GBS-positive rectovaginal swab at 36 to 38 weeks\nâ–  GBS bacteriuria/urinary tract infection (UTI) any time during pregnancy\nâ–  Prior infant with early-onset GBS sepsis\nâ–  Unknown GBS status with any of the following: labor at <37 weeks, intra-\npartum fever, rupture of membranes >18 hours\nIntrapartum prophylaxis: Intravenous (IV) penicillin (regardless of mode\nof birth); first-generation cephalosporins for patients with low-risk penicillin\nallergy; clindamycin or vancomycin for high risk of anaphylaxis\nPRENATAL DIAGNOSTIC TESTING\nTable 2.10-3 outlines a typical prenatal diagnostic testing schedule by week.\nThe sections that follow describe each recommended screening modality.\nTABLE 2.10-3. Prenatal Visit and Diagnostic Testing Schedule\nPRENATAL DIAGNOSTIC TESTING\nPrenatal visits Weeks 0â€“28: Every 4 weeks\nWeeks 29â€“35: Every 2 weeks\nWeeks 36â€“birth: Every week\nInitial visit Heme: Complete blood cell count (CBC); type and screen (important for determining Rh status)\nInfectious disease: Urinalysis (UA) and culture; rubella antibody titer; hepatitis B surface antigen (HBsAg); Hepatitis C antigen;\nrapid plasma reagin (RPR)/Venereal Disease Research Laboratory (VDRL); cervical gonorrhea and chlamydia; purified\nprotein derivative (PPD); HIV; tuberculosis (TB) testing (or Mycobacterium tuberculosis [M.tb]); Pap smear (to check for dys-\nplasia); consideration of hepatitis C vaccine (HCV) and varicella vaccine, based on history\nIf indicated: Hemoglobin (Hb)A1c, sickle cell screening\nDiscussion of genetic screening: Tay-Sachs disease, cystic fibrosis, spinal muscular atrophy\n10â€“22 weeks Aneuploidy screening: Multiple options are possible:\nâ–  Cell-free DNA screening most sensitiv",
      "char_start": 1238000,
      "char_end": 1240000
    },
    {
      "chunk_id": 620,
      "text": "e and specific screening tool available for trisomies 13, 18, and 21 (see Table 2.10-4).\nIt is accepted as a primary screening option\nâ–  Full integrated test: Serum pregnancy-associated plasma protein A (PAPP-A) collected 11â€“14 weeks; crown-rump length\nmeasured 10â€“14 weeks, + quadruple screen in second trimester (hCG, inhibin A, alpha-fetoprotein, unconjugated estriol)\nâ–  Combined test: Î²-hCG, PAPP-A, measure of nuchal translucency 10â€“14 weeks\n18â€“20 weeks Ultrasonography for full anatomic screen\n24â€“28 weeks 1-hour 50-gram glucose challenge test for gestational diabetes screen; if positive: 3-hour 100-gram glucose challenge test\n28â€“30 weeks Rh (D antigena) immune globulin for RhâŠ– women (after antibody screen)\n35â€“37 weeks GBS culture; repeat CBC\n34â€“40 weeks In high-risk patients, cervical chlamydia and gonorrhea cultures, HIV, RPR\naRh immune globulin to treat any unsensitized RhâŠ– woman during any occasion of fetal-maternal blood mixing (eg, spontaneous abortion [SAB],\nplacental abruption, abdominal trauma) even if <28 weeksâ€™ gestation\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443311 1100//2211//2222 11::5555 PPMM\n\n432 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-4. Quadruple Screening for Fetal Aneuploidy\nMSAFP ESTRIOL INHIBIN A Î²-HCG\nTrisomy 18 â†“ â†“â†“ â†“â†“ â†“â†“\nTrisomy 21 â†“ â†“ â†‘ â†‘\nQuadruple Screening\nQuadruple screening consists of four elements (see Table 2.10-4): maternal\nserum Î±-fetoprotein (MSAFP), inhibin A, estriol, and Î²-hCG.\nâ–  MSAFP: Produced by the fetus and enters the maternal circulation.\nResults are reported as multiples of the median (MoMs).\nâ–  Measurement results depend on accurate gestational dating. Multiple\ngestations and uterine leiomyomata (fibroids) may cause size/date\ndiscrepancy.\nâ–  MSAFP is rarely tested alone, as quad screening has â†‘ sensitivity for\ndetecting chromosomal abnormalities.\nâ–  â†‘ MSAFP (>2.5 MoMs) is associated with the following:\nKEY FACT\nâ–  Open neural tube defects (anencephaly, spina bifida)\nSti",
      "char_start": 1240000,
      "char_end": 1242000
    },
    {
      "chunk_id": 621,
      "text": "ll UNDER age at 18: trisomy 18 = â†“ â–  Abdominal wall defects (gastroschisis, omphalocele)\nAFP, â†“ estriol, â†“â†“ Î²-hCG, â†“ inhibin A â–  Multiple gestation\nâ–  Incorrect gestational dating\nâ–  Fetal death\nKEY FACT â–  Placental abnormalities (eg, placental abruption)\n2 up, 2 down: trisomy 21 = â†“ AFP, â†“ â–  â†“ MSAFP (<0.5 MoMs) is associated with the following:\nestriol, â†‘ Î²-hCG, â†‘ inhibin A â–  Trisomies 21 and 18\nâ–  Incorrect gestational dating\nNuchal Translucency\nâ–  Recommended at weeks 9 to 14\nâ–  PAPP-A + nuchal translucency + free Î²-hCG can detect âˆ¼91% of cases of\nDown syndrome and âˆ¼95% of cases of trisomy 18\nâ–  Advantages:\nâ–  Available earlier than chorionic villus sampling (CVS) and less inva-\nsive than CVS (see following section on CVS)\nChorionic Villus Sampling\nTable 2.10-5 outlines the relative advantages and disadvantages of CVS, cell-\nfree fetal DNA, and amniocentesis (see Fig. 2.10-2).\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443322 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 433\nTABLE 2.10-5. Prenatal Screening for Fetal Genetic Abnormalities\nVARIABLE CELL-FREE FETAL DNA CHORIONIC VILLUS SAMPLING AMNIOCENTESIS\nGA 10 weeks 10â€“12 weeks 15â€“20 weeks\nProcedure Isolation of fetal DNA from Transcervical or transabdominal aspiration of Transabdominal aspiration of amniotic\nblood sample obtained placental tissue fluid, using an ultrasound-guided\nfrom pregnant patient needle\nAdvantages Noninvasive Genetically diagnostic Genetically diagnostic\nAvailable at an earlier GA than amniocentesis\nDisadvantages May be limited because Risk for fetal loss relatively high (1%) Premature rupture of membranes\nof low concentration of Cannot detect open neural tube defects (PROM), chorioamnionitis, fetal-\nfetal DNA in maternal Limb defects associated with CVS at maternal hemorrhage\ncirculation <9 weeks\nCatheter\nUltrasound\ntaking tissue\ntransducer\nsamples\nUterus\nPlacenta\nCatheter\nFetus\nPlacental\ntissue\nFIGURE 2.10-2. Chorionic villous ",
      "char_start": 1242000,
      "char_end": 1244000
    },
    {
      "chunk_id": 622,
      "text": "sampling. (Reproduced with permission from USMLE-Rx.com.)\nAmniocentesis\nIndicated for the following:\nâ–  Concern for fetal genetic disease based on abnormal aneuploidy screening\nand/or ultrasound findings.\nâ–  Rh-sensitized pregnancy to obtain fetal blood type or to detect fetal\nhemolysis.\nâ–  Evaluation of fetal lung maturity. Lecithin-to-sphingomyelin ratio â‰¥2.5 or\npresence of phosphatidylglycerol (performed during the third trimester)\nindicates lung maturity.\nâ–  Assess for intraamniotic infection with Gram stain, culture.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443333 1100//2211//2222 11::5555 PPMM\n\n434 HIGH-YIELD FACTS IN OBSTETRICS\nTERATOLOGY\nMajor defects are apparent in about 3% of births and in roughly 4.5% of chil-\ndren by 5 years of age. Table 2.10-6 outlines common teratogenic agents.\nTABLE 2.10-6. Common Teratogenic Agents and Their Associated Defects\nDRUGS AND CHEMICALS DEFECTS\nAngiotensin-converting enzyme Fetal renal tubular dysplasia and neonatal renal failure, oligohydramnios, FGR, lack of cranial ossification\n(ACE) inhibitors\nAlcohol Fetal alcohol syndrome (growth restriction before and after birth, intellectual disability, midfacial hypo-\nplasia, smooth philtrum, renal and cardiac defects)\nConsumption of >6 drinks per day is associated with a 40% risk for fetal alcohol syndrome\nAmphetamines Preterm delivery, placental abruption, preeclampsia, FGR, fetal demise\nAndrogens Virilization of female fetuses; advanced genital development in male fetuses; most commonly caused by\nmaternal luteomas\nCarbamazepine Neural tube defects, fingernail hypoplasia, microcephaly, developmental delay, FGR\nCocaine Bowel atresias; congenital malformations of the heart, limbs, face, and genitourinary (GU) tract; micro-\ncephaly; FGR; cerebral infarctions\nDiethylstilbestrol (DES) Clear cell adenocarcinoma of the vagina or cervix, vaginal adenosis, abnormalities of the cervix and\nuterus or testes, possible infertility\nLead â†‘ SAB r",
      "char_start": 1244000,
      "char_end": 1246000
    },
    {
      "chunk_id": 623,
      "text": "ate; stillbirth\nLithium Congenital heart disease (Ebstein anomaly)\nMethotrexate â†‘ SAB rate\nOrganic mercury Cerebral atrophy, microcephaly, intellectual disability, spasticity, seizures, blindness\nPhenytoin FGR, intellectual disability, microcephaly, dysmorphic craniofacial features, cardiac defects, fingernail\nhypoplasia\nRadiation Microcephaly, intellectual disability\nMedical diagnostic radiation delivering <50 mGy to the fetus no teratogenic risk\nStreptomycin and kanamycin Hearing loss; cranial nerve (CN) VIII damage\nTetracyclines Permanent yellow-brown discoloration of deciduous teeth; hypoplasia of tooth enamel (effects are rare\nwith doxycycline, generally considered safe to use in pregnancy)\nThalidomide Bilateral limb deficiencies, anotia and microtia, cardiac and GI anomalies\nTrimethadione and Cleft lip or cleft palate, cardiac defects, microcephaly, intellectual disability\nparamethadione\nValproic acid Neural tube defects (spina bifida), minor craniofacial defects\nVitamin A and derivatives â†‘ SAB rate, microtia, thymic agenesis, cardiovascular defects, craniofacial dysmorphism, microphthalmia,\ncleft lip or cleft palate, intellectual disability\nWarfarin (wages war on the fetus) Nasal hypoplasia and stippled bone epiphyses, developmental delay, fetal growth restriction, ophthal-\nmologic abnormalities\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443344 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 435\nMNEMONIC\nCONGENITAL INFECTIONS\nToRCHHeS\nCan occur at any time during pregnancy, labor, and delivery. Common\nToxoplasmosis\nsequelae include the following abnormalities:\nRubella\nâ–  Premature delivery Cytomegalovirus\nâ–  Central nervous system (CNS) abnormalities HIV\nHerpes viruses (herpes simplex virus,\nâ–  Anemia\nvaricella zoster virus)\nâ–  Jaundice\nSyphilis\nâ–  Hepatosplenomegaly\nâ–  Growth restriction\nKEY FACT\nThe most common pathogens involved in congenital infections can be\nremembered through use of the ToRCHHeS",
      "char_start": 1246000,
      "char_end": 1248000
    },
    {
      "chunk_id": 624,
      "text": " mnemonic (see Table 2.10-7). Pregnant patients should not change\na catâ€™s litterbox to prevent exposure to\ntoxoplasma.\nTABLE 2.10-7. Diagnosis and Treatment of Common Congenital Infections\nDISEASE TRANSMISSION SYMPTOMS DIAGNOSIS TREATMENT PREVENTION\nToxoplasmosis Transplacental; Hydrocephalus Serologic testing Pyrimethamine + Avoiding exposure\nprimary infection Intracranial calcifications Ring-enhancing sulfadiazine to cat feces or\nvia consumption of Chorioretinitis lesions on MRI uncooked meat\nraw meat or contact during pregnancy\nwith cat feces\nRubella Transplacental in the Purpuric â€œblueberry muffinâ€ Serologic testing Symptomatic Immunization before\nfirst trimester rash pregnancy; vaccina-\nCataracts tion of mother after\nIntellectual disability delivery if serologic\nHearing loss titers remain âŠ–\nPatent ductus arteriosus (PDA)\nCMV Primarily Petechial rash Urine culture; poly- Postpartum N/A\ntransplacental Periventricular calcifications merase chain ganciclovir\nreaction (PCR) of\namniotic fluid\nHSV Intrapartum transmis- Skin, eye, and mouth Serologic testing Acyclovir at C-section if lesions are\nsion if the mother infections 36 weeks until present at delivery\nhas active lesions; Life-threatening CNS/ delivery\ntransplacental systemic infection\ntransmission rare\nHIV In utero, at delivery, or Often asymptomatic Enzyme-linked Highly active Azidothymidine (AZT)\nvia breast milk Failure to thrive immunosorbent antiretro- or nevirapine in\nBacterial infections assay (ELISA), viral therapy pregnant women\nâ†‘ incidence of upper and Western blot (HAART) with HIV; elective\nlower respiratory diseases C-section if viral\nload is >1000\nTreatment of infants\nwith prophylactic\nAZT; avoidance of\nbreastfeeding\n(continues)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443355 1100//2211//2222 11::5555 PPMM\n\n436 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-7. Diagnosis and Treatment of Common Congenital Infections (continued)\nDISEASE TRANSMISSION SYMPT",
      "char_start": 1248000,
      "char_end": 1250000
    },
    {
      "chunk_id": 625,
      "text": "OMS DIAGNOSIS TREATMENT PREVENTION\nSyphilis Intrapartum; transpla- Maculopapular skin rash Dark-field micros- Penicillin (if Penicillin in pregnant\ncental transmission Lymphadenopathy copy, VDRL/ allergic, patients who test âŠ•\npossible Hepatomegaly RPR, fluorescent should desen-\nâ€œSnufflesâ€: Mucopurulent treponemal anti- sitize and give\nrhinitis body absorption penicillin)\nOsteitis (FTA-ABS)\nLate congenital syphilis:\nSaber shins\nSaddle nose\nCNS involvement\nHutchinson triad: Peg-\nshaped central incisors,\ndeafness, interstitial\nkeratitis\nZika virus Transplacental Microcephaly Zika RNA detection None Avoidance of tropical\ntransmission Craniofacial disproportion mosquito-infested\nNeurologic and ocular regions\nabnormalities\nABORTION\nSPONTANEOUS ABORTION\nThe loss of gestation before 20 weeksâ€™ gestation. More than 80% of cases\noccur in the first trimester. Associations are as follows:\nâ–  Maternal factors:\nâ–  Inherited thrombophilia: Factor V Leiden, prothrombin, antithrom-\nbin, protein C and S deficiencies, methylene tetrahydrofolate reduc-\ntase deficiency (hyperhomocysteinemia)\nâ–  Immunologic issues: Antiphospholipid antibodies; alloimmune factors\nâ–  Anatomic issues: Uterine and cervical abnormalities, cervical insuffi-\nciency, cervical conization or loop electrosurgical excision procedure\n(LEEP), cervical injury, diethylstilbestrol (DES) exposure\nâ–  Endocrinologic issues: Diabetes mellitus (DM), hypothyroidism, pro-\ngesterone deficiency\nâ–  Genetics: Osteogenesis imperfecta type II; this is severe and lethal; infants\npresent with multiple fractures and die in utero or shortly after birth.\nâ–  Other: Maternal trauma, â†‘ maternal age, infection, dietary deficiencies\nâ–  Environmental factors: Tobacco, alcohol, excessive caffeine (>500 mg/\nday), toxins, drugs, radiation\nâ–  Fetal factors:\nâ–  Anatomic malformation\nâ–  Chromosomal abnormalities: A factor in approximately 50% of spon-\ntaneous abortions (SABs) in the first trimester, 20% to 30% in second-\ntrimester losses, and 5% to 10% in third-",
      "char_start": 1250000,
      "char_end": 1252000
    },
    {
      "chunk_id": 626,
      "text": "trimester losses\nâ–  Recurrent SAB: Two or more consecutive SABs or three SABs in 1 year;\ncauses dependent on timing; determining possible causes requires karyo-\ntyping of both parents, workup of mother for hypercoagulability, and eval-\nuation of uterine anatomy\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443366 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 437\nâ–  Early (<12 weeks): Chromosomal abnormalities likely cause\nâ–  Late (12â€“20 weeks): Hypercoagulable states (eg, antiphospholipid syn-\ndrome, systemic lupus erythematosus [SLE], factor V Leiden, protein S\ndeficiency), cervical insufficiency\nIf antiphospholipid antibodies are detected, false âŠ• Venereal Disease\nResearch Laboratory (VDRL) and falsely prolonged partial thromboplastin\ntime (PTT) may be seen. Low-molecular-weight heparin and low-dose aspirin\nprovide prophylaxis against recurrent SAB.\nHistory/PE\nSAB can be categorized by visual examination of the cervical os (open vs\nclosed) and the presence or status of the fetus and products of conception.\nSee Table 2.10-8 for types of SAB.\nTABLE 2.10-8. Types of Spontaneous Abortion\nTYPE SYMPTOMS/SIGNS DIAGNOSIS TREATMENT\nComplete Cessation of bleeding and cramping Closed os None\nExpulsion of products of conception Ultrasonography showing no POC\n(POC)\nThreatened Uterine bleeding Â± abdominal pain Closed os + intact membranes + Follow-up ultrasonography to assess\n(often painless) fetal cardiac motion on viability of fetus\nNo POC expulsion ultrasonography\nIncomplete Partial POC expulsion; bleeding/mild Visible tissue on examination Manual uterine aspiration (MUA) if\ncramping Open os POC present on ultraso- <12 weeks or dilation and curettage\nnography Treatment (D&C); may also use misoprostol or\nexpectant management in inevitable\nand missed SAB\nVisible tissue on Open os POC present on ultrasonography\nexamination\nInevitable Uterine bleeding and cramps Open os Â± rupture of membranes\nNo POC expulsion (ROM)\nPOC",
      "char_start": 1252000,
      "char_end": 1254000
    },
    {
      "chunk_id": 627,
      "text": " present on ultrasonography\nMissed Asymptomatic Â± cramping Closed os\nNo bleeding No fetal cardiac activity; POC\npresent on ultrasonography\nSeptic Foul-smelling discharge, abdominal Hypotension, hypothermia, â†‘ WBC Manual uterine aspiration or D&C and IV\npain, fever, and cervical motion count antibiotics\ntenderness; Â± POC expulsion Blood cultures\nMaternal mortality 10%â€“15%\nStillbirth Absence of fetal cardiac activity Uterus small for GA; no fetal If <24 weeks, dilation and evacuation (D&E)\n>20 week heart tones or movement on If >24 weeks, induction of labor within\nultrasonography 1â€“2 weeks, based on patient preference\nOffer autopsy to attempt to determine\ncause of death\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443377 1100//2211//2222 11::5555 PPMM\n\n438 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-9. Elective Abortion\nTRIMESTER PROCEDURE GESTATIONAL AGE\nFirst (90% of abortions) Medical management: oral mifepristone (low dose) + oral/ <10 weeks\nvaginal misoprostol\nSurgical management: >10 weeks\nâ–  Manual uterine aspiration\nâ–  Dilation and curettage (D&C) with vacuum aspiration\nSecond (10% of abortions) Obstetric management: induction of labor (typically with 13â€“24 weeks (depending on state laws)\nprostaglandins, amniotomy, and oxytocin)\nSurgical management: Dilation and evacuation (D&E) Same as above\nDiagnosis\nâ–  Diagnosis by clinical presentation and physical examination\nâ–  Nonviable pregnancy: Gestational sac >25 mm without a fetal pole or\nabsence of fetal cardiac activity when CRL >7 mm on transvaginal\nultrasonography\nâ–  Best initial test: Ultrasonography can identify the following:\nâ–  Gestational sac 5 to 6 weeks from the LMP\nâ–  Fetal pole at 6 weeks\nâ–  Fetal cardiac activity at 6 to 7 weeks\nâ–  Next best test: Serum Î²-hCG\nKEY FACT\nTreatment\nIf fever, vomiting, purulent discharge, â–  See Table 2.10-8 for treatment specific to the type of SAB.\nand/or hemodynamic instability are â–  Administer Rh immune globulin if the mother is Rh âŠ–",
      "char_start": 1254000,
      "char_end": 1256000
    },
    {
      "chunk_id": 628,
      "text": ".\nseen after a spontaneous or elective\nabortion, septic abortion should be\nELECTIVE TERMINATION OF PREGNANCY\nsuspected. This is a medical emergency\nthat requires broad-spectrum\nIt has been estimated that 50% of all pregnancies in the United States are\nantibiotics and immediate surgery to\nunintended. About 25% of all pregnancies end in elective abortion. Options\nremove infected tissue.\nfor elective abortion depend on GA and patient preference (see Table 2.10-9).\nCOMPLICATIONS OF ABORTION\nMNEMONIC\nThe Iâ€™s are open. â–  Septic abortion\nFindings in cervical exam during SAB: â–  Retained products of conception â†’ disseminated intravascular coagula-\nInevitable and Incomplete show tion (DIC)\nopen os. â–  Endometritis\nMATERNAL COMPLICATIONS OF PREGNANCY\nHYPEREMESIS GRAVIDARUM\nPersistent vomiting not related to other causes, leading to starvation ketosis\nand weight loss (usually at least a 5% â†“ from prepregnancy weight).\nâ–  More common in first pregnancies, multiple gestations, and molar\npregnancies\nâ–  â†‘ Î²-hCG and â†‘ estradiol have been implicated in pathophysiology\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443388 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 439\nHistory/PE KEY FACT\nDistinguished from nausea and vomiting of pregnancy (NVP) by severity\nRule out trophoblastic disease with US\n(presence of weight loss and ketosis) and timing. Acid reflux, gastroenteritis,\nin a pregnant patient who presents\nhyperthyroidism, and neurologic conditions can also cause NVP and should\nwith severe nausea and vomiting.\nbe on the differential diagnosis.\nDiagnosis\nClinical diagnosis.\nâ–  Best initial test: Ultrasonography; evaluation for trophoblastic disease or\nmultiple gestation.\nâ–  Evaluation for electrolyte abnormalities (eg, hypokalemia), abnormal liver\nenzymes, amylase, and lipase.\nâ–  Wernicke encephalopathy from vitamin B deficiency possible in severe\n1\ncases. The physician can look for gait ataxia and oculomotor dysfunction.\nTre",
      "char_start": 1256000,
      "char_end": 1258000
    },
    {
      "chunk_id": 629,
      "text": "atment\nâ–  Best initial treatment:\nâ–  Dietary changes and doxylamine-pyridoxine\nâ–  If no response, discontinue doxylamine-pyridoxine and use metoclo-\npramide, promethazine, or prochlorperazine\nâ–  Consider ondansetron if vomiting is not resolved with treatments men-\ntioned earlier\nâ–  If dehydrated, administration of IV fluids, IV nutritional supplementation,\nand ondansetron IV\nDIABETES\nDiabetes in pregnancy is divided into the following two categories: pregesta-\ntional DM and gestational DM.\nâ–  Pregestational DM: Onset before pregnancy (Type 1 or Type 2 DM)\nâ–  Gestational DM: Onset during pregnancy\nConsider early screening (fasting glucose, first-trimester HbA1c, or early\nglucose tolerence test) for the following risk factors:\nâ–  Overweight or obese (BMI >25)\nâ–  Physical inactivity\nâ–  First-degree relative with DM\nâ–  Have previously given birth to an infant weighing 4000 g (approximately\n9 lb) or more\nâ–  Previous gestational DM\nâ–  Women with polycystic ovarian syndrome\nâ–  Hemoglobin A1c (HbA1c) â‰¥5.7%, impaired glucose tolerance, or\nimpaired fasting glucose on previous testing\nâ–  History of cardiovascular disease\nâ–  Other clinical conditions associated with insulin resistance (eg, metabolic\nsyndrome, acanthosis nigricans)\nPregestational Diabetes\nObserved in 1% of all pregnancies. Insulin requirements may â†‘ as much as KEY FACT\nthreefold. Poorly controlled DM is associated with an â†‘ risk for congenital\nGreater than 8, investigate! If HbA1c is\nmalformations, fetal loss, and maternal/fetal morbidity during labor and\n>8%, look for congenital abnormalities.\ndelivery.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 443399 1100//2211//2222 11::5555 PPMM\n\n440 HIGH-YIELD FACTS IN OBSTETRICS\nTesting and Treatment\nMother:\nâ–  Renal, ophthalmologic, and cardiac evaluation to assess for end-organ\ndamage.\nâ–  Best initial treatment: Lifestyle modification with diet and exercise. Addi-\ntion of insulin therapy if poor response.\nâ–  Strict glucose control is impor",
      "char_start": 1258000,
      "char_end": 1260000
    },
    {
      "chunk_id": 630,
      "text": "tant to minimize fetal defects:\nâ–  Fasting morning: â‰¤95 mg/dL\nâ–  2-hour postprandial: <120 mg/dL\nâ–  Delivery and postpartum:\nâ–  Maintain normoglycemia (80â€“100 mg/dL) during labor with an IV\ninsulin drip and hourly glucose measurements.\nâ–  Consider delivery in the setting of poor maternal glucose control, pre-\neclampsia, macrosomia, or evidence of fetal lung maturity (preferably\nafter 32 weeks).\nâ–  Consider C-section in the setting of an estimated fetal weight (EFW)\n>4500 g.\nFetus:\nâ–  16â€“24 weeks:\nâ–  Ultrasonography to determine fetal anatomy (18â€“20 weeks)\nâ–  32â€“34 weeks:\nâ–  Antepartum fetal surveillance (eg, nonstress test [NST], contraction\nstress test [CST], biophysical profile [BPP]) if poor glucose control or\nsmall vessel disease\nâ–  Hospitalization if maternal DM has been poorly controlled or fetal\nparameters are a concern\nâ–  Serial ultrasonograms for fetal growth\nKEY FACT Complications\nPregestational DM is a risk factor for a variety of antepartum, intrapartum,\nHyperglycemia in the first trimester\nand postpartum maternal and fetal complications (Table 2.10-10). Tight gly-\nsuggests preexisting DM and should be\ncemic control is the best way to prevent these complications\nmanaged as pregestational DM.\nGestational Diabetes\nCarbohydrate intolerance of variable severity first diagnosed during preg-\nnancy. Occurs in 3% to 5% of all pregnancies and is usually diagnosed in the\nsecond trimester (24â€“28 weeks).\nTABLE 2.10-10. Complications of Pregestational Diabetes Mellitus\nMATERNAL COMPLICATIONS FETAL COMPLICATIONS\nDiabetic ketoacidosis ([DKA], type 1) or hypergly- Small left colon syndrome\ncemic hyperosmolar nonketotic coma (type 2) Macrosomia or FGR\nPreeclampsia/eclampsia Cardiac and renal defects\nCephalopelvic disproportion (from macrosomia) Neural tube defects (eg, sacral agenesis)\nand need for C-section Hypocalcemia\nPreterm labor Polycythemia\nInfection Hyperbilirubinemia\nPolyhydramnios Hypoglycemia from hyperinsulinemia\nPostpartum hemorrhage Respiratory distress syndrome (RDS)\n",
      "char_start": 1260000,
      "char_end": 1262000
    },
    {
      "chunk_id": 631,
      "text": "Maternal mortality Birth injury (eg, shoulder dystocia)\nPerinatal mortality\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444400 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 441\nHistory/PE\nâ–  Typically asymptomatic\nâ–  May present with edema, polyhydramnios, or a large-for-gestational-age\ninfant (>90th percentile)\nDiagnosis\nâ–  Best initial test: Routine screening with a 1-hour 50-g glucose challenge\ntest\nâ–  Venous plasma glucose measured 1 hour later\nâ–  Performed at 24 to 28 weeks\nâ–  Values â‰¥140 mg/dL considered abnormal\nâ–  Confirmation with an oral 3-hour (100-g) glucose tolerance test (GTT;\nnext test if âŠ• screening test) showing any two of the following:\nâ–  Fasting: >95 mg/dL\nâ–  1 hour: >180 mg/dL\nâ–  2 hours: >155 mg/dL\nâ–  3 hours: >140 mg/dL\nTreatment\nMother:\nâ–  Best initial treatment: American Diabetes Association (ADA) diet, regular KEY FACT\nexercise, and strict glucose monitoring (four times per day).\nâ–  Insulin is the gold standard if dietary control is insufficient. Tight maternal Keys to the management of gestational\nglucose control (fasting â‰¤95 mg/dL; 1 hour postprandial â‰¤140 mg/dL; diabetes: (1) ADA diet, (2) insulin\n2 hours postprandial â‰¤120 mg/dL) improves outcomes. if needed, (3) ultrasonography for\nâ–  Intrapartum insulin and dextrose to maintain tight control during delivery. fetal growth, and (4) antepartum\nsurveillance if requiring insulin or an\nFetus:\noral hypoglycemic agent.\nâ–  Periodic ultrasonography and NSTs to assess fetal growth and well-being\nâ–  Recommended induction of labor at 39 to 40 weeks in patients with gesta-\ntional diabetes controlled on insulin\nComplications\nMore than 50% of patients with gestational diabetes develop glucose intoler-\nance and/or type 2 DM later in life. At 6 to 12 weeks postpartum, the physi-\ncian should screen for DM (75-g 2-hour GTT) and repeat testing every\n3 years if normal results.\nHYPERTENSIVE DISEASE IN PREGNANCY\nChronic and Gestational Hypertension\nDefined as ",
      "char_start": 1262000,
      "char_end": 1264000
    },
    {
      "chunk_id": 632,
      "text": "follows:\nâ–  Chronic hypertension:\nâ–  Presents before conception or at <20 weeks\nâ–  Can be diagnosed postpartum if increased blood pressure (BP) persists\nfor >12 weeks postpartum\nâ–  Possibility for up to one third of patients with chronic hypertension to\ndevelop superimposed preeclampsia\nâ–  Gestational hypertension:\nâ–  Idiopathic hypertension (systolic BP â‰¥140 mm Hg or diastolic BP\nâ‰¥90 mm Hg measured twice >4 hours apart) without significant pro-\nteinuria (<300 mg/L)\nâ–  Develops at â‰¥20 weeks\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444411 1100//2211//2222 11::5555 PPMM\n\n442 HIGH-YIELD FACTS IN OBSTETRICS\nâ–  Possibility for up to 25% of patients with gestational hypertension to\ndevelop preeclampsia\nâ–  Must normalize within 12 weeks after pregnancy\nTreatment\nâ–  Close monitoring of BP\nâ–  Best initial treatment: Treatment with appropriate antihypertensives (eg,\nmethyldopa, labetalol, nifedipine)\nâ–  If systolic BP â‰¥160 mm Hg or diastolic BP â‰¥110 mm Hg, this is a hyper-\ntensive crisis that calls for labetalol, hydralazine, or nifedipine because of\nshort onset of action\nâ–  The patient should not take angiotensin-converting enzyme (ACE) inhibi-\ntors or diuretics\nâ–  ACE inhibitors are known to lead to uterine ischemia and fetal renal\ndamage/defects\nâ–  Diuretics can aggravate low plasma volume to the point of uterine\nischemia\nComplications\nSimilar to those of preeclampsia (see next).\nPreeclampsia\nâ–  New-onset hypertension (systolic BP â‰¥140 mm Hg or diastolic BP\nâ‰¥90 mm Hg) and proteinuria (>300 mg of protein in a 24-hour period or\nelevated urine or protein/creatinine ratio of 0.3 or more) occurring at >20\nweeks gestation up to 6 weeks postdelivery\nâ–  Preeclampsia with severe features defined as new-onset hypertension with\nnew onset of any of the following features (with or without proteinuria):\nâ–  Platelet count <100,000/Î¼L\nâ–  Serum creatinine >1.1 mg/dL or doubling of creatinine concentration\nin the absence of other renal disease\nâ–  Liver transa",
      "char_start": 1264000,
      "char_end": 1266000
    },
    {
      "chunk_id": 633,
      "text": "minases at least twice the upper limit of normal\nâ–  Pulmonary edema\nâ–  Neurologic or visual symptoms\nâ–  New-onset headache unresponsive to medication and not accounted\nfor by alternative diagnoses\nâ–  HELLP syndrome: A variant of severe preeclampsia with severe features\nMNEMONIC\nâ–  Consists of hemolytic anemia, elevated liver enzymes, and low platelets.\nHELLP syndromeâ€” â–  Etiology unknown. Clinical manifestations are explained by vasospasm\nleading to distention of hepatic capsule, hemorrhage, and organ necrosis.\nHemolysis\nâ–  Risk factors: Nulliparity, extremes of age (<20 or >35 years), multiple ges-\nElevated liver function tests (LFTs)\ntation, molar pregnancy, renal disease (caused by SLE or type 1 DM), a\nLow Platelets\nfamily history of preeclampsia, and chronic hypertension.\nâ–  Indication for delivery\nHistory/PE\nSee Table 2.10-11 for the signs and symptoms of preeclampsia.\nTreatment\nâ–  Recommend low dose aspirin daily during pregnancy\nâ–  Delivery of the fetus is the only cure for preeclampsia.\nâ–  Close-to-term or worsening preeclampsia: Induce delivery with IV oxyto-\ncin, prostaglandin, or amniotomy.\nâ–  Delivery should occur no later than 37 weeks.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444422 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 443\nTABLE 2.10-11. Presentation of Preeclampsia and Eclampsia\nDISEASE SEVERITY SIGNS AND SYMPTOMS DELIVERY\nPreeclampsia Usually asymptomatic Delivery at 37 weeks\nBP â‰¥140/90 mm Hg on two occasions >4 hr apart\nand\nProteinuria (>300 mg/24 hours or two âŠ• urine\ndipsticks)\nPreeclampsia Any one of the following: Hospitalization\nwith severe BP â‰¥160/110 mm Hg on two occasions >4 hr BP control\nfeatures apart Delivery by 34 weeks,\nCerebral changes: Severe headache, somnolence must balance\nVisual changes: Blurred vision, scotomata maternal risk with\nOther: Progressive renal insufficiency, pulmonary risks of prematu-\nedema; right upper quadrant (RUQ) pain, hemo- rity in the infant\nlysi",
      "char_start": 1266000,
      "char_end": 1268000
    },
    {
      "chunk_id": 634,
      "text": "s, elevated liver enzymes, thrombocytopenia\n(HELLP syndrome)\nEclampsia Most common signs preceding an eclamptic Immediate delivery\nattack: Headache, visual changes, and RUQ/\nepigastric pain\nSeizures severe if not controlled with anticonvul-\nsant therapy\nâ–  Far from term (<34 weeks): Provide expectant management with close\nsurveillance; hospital admission for uncontrolled severe-range blood\npressures.\nâ–  Prevent intrapartum seizures with a continuous magnesium sulfate drip.\nâ–  Continue seizure prophylaxis for 24 hours postpartum.\nâ–  Treat magnesium toxicity with IV calcium gluconate.\nâ–  Preeclampsia with severe features: KEY FACT\nâ–  Control BP with labetalol and/or hydralazine (goal <160/110 mm Hg Watch for signs of magnesium toxicity\nwith a diastolic BP of 90â€“100 mm Hg to maintain fetal blood flow)\n(loss of deep tendon reflexes [DTRs],\nâ–  Provide a continuous magnesium sulfate drip respiratory paralysis, coma).\nâ–  Deliver by induction or C-section once term\nComplications\nPrematurity, fetal distress, stillbirth, placental abruption, seizure, DIC, cere-\nbral hemorrhage, serous retinal detachment, and fetal/maternal death.\nEclampsia\nNew-onset grand mal seizures in a patient with preeclampsia. A 36-year-old G1P0 woman with a\nhistory of SLE at 36 weeks presents\nHistory/PE with headache and RUQ pain. She is\nadmitted and found to have BPs of\nSee Table 2.10-11 for the signs and symptoms of eclampsia.\n165/100 and 170/105 mm Hg when\ntested twice 6 hours apart. She has\nTreatment\n3+ protein on urine dipstick. Once\nâ–  Delivery of the fetus is the only cure for eclampsia her BP has been controlled with\nâ–  Management of maternal hypertension with labetalol or hydralazine labetalol, what are the next steps in\nmanagement?\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444433 1100//2211//2222 11::5555 PPMM\n\n444 HIGH-YIELD FACTS IN OBSTETRICS\nâ–  Seizure control/prophylaxis with magnesium\nâ–  If seizures recur, give IV diazepam\nâ–  Monitor for clinical ma",
      "char_start": 1268000,
      "char_end": 1270000
    },
    {
      "chunk_id": 635,
      "text": "gnesium toxicity; there is no need to routinely\nmonitor magnesium blood levels if renal function is normal\nâ–  Monitor fetal status\nâ–  Control BP\nâ–  Limit fluids; use urinary Foley catheter for strict intake and output\n(I/Os)\nâ–  Initiate emergent delivery once the patient is stable and convulsions are\ncontrolled\nâ–  Postpartum management is the same as that for preeclampsia\nâ–  Seizures may occur antepartum (25%), intrapartum (50%), or postpartum\n(25%); most occur within 48 hours after delivery\nComplications\nCerebral hemorrhage, aspiration pneumonia, hypoxic encephalopathy,\nthromboembolic events, and fetal/maternal death.\nURINARY TRACT INFECTION AND ASYMPTOMATIC BACTERIURIA\nAsymptomatic bacteriuria occurs in up to 7% of pregnant patients, and\n30% to 40% will subsequently develop cystitis or pyelonephritis if untreated.\nPersistent untreated bacteriuria places the patient at a higher risk for preterm\nlabor, low birth weight, and perinatal mortality. Escherichia coli is responsible\nfor 70% to 90% of infections.\nHistory/PE\nâ–  Asymptomatic bacteriuria: Screening 12 to 16 weeks, âŠ• urine culture on\nfirst-trimester screen (â‰¥105 colony-forming units [CFUs])\nâ–  Urinary tract infection (UTI): Dysuria, urinary urgency, and frequency\nâ–  Pyelonephritis: Same as UTI + fever and costovertebral angle tenderness\nDiagnosis\nBest initial test: Urinalysis and âŠ• urine culture\nTreatment\nâ–  Asymptomatic bacteriuria and UTI: 3 to 7 days nitrofurantoin (avoid in\nfirst trimester if possible), cephalexin, amoxicillin-clavulanate, or fosfomy-\ncin. No fluoroquinolones or TMP-SMX in first or third trimester. Do a\nfollow-up culture at 1 week as test of cure.\nâ–  Pyelonephritis: Admittance to hospital, IV fluids, IV third-generation\ncephalosporins, suppressive antibiotics based on culture susceptibility for\nremainder of pregnancy, and follow-up culture for test of cure.\nâ–  GBS prophylaxis during time of delivery if GBS UTI at any time during\npregnancy\nThe patient has preeclampsia with\nINTRAHEPATIC CHOLESTASIS\nsever",
      "char_start": 1270000,
      "char_end": 1272000
    },
    {
      "chunk_id": 636,
      "text": "e features. The next steps\nin management are to start a\nmagnesium sulfate drip for seizure â–  Symptoms: Maternal pruritis, mainly on palms and soles. Can also pres-\nent with right upper quadrant (RUQ) pain, sleep deprivation, and\nprophylaxis, give antihypertensive\nmedications, and deliver by induction steatorrhea.\nor C-section. The physician should â–  Labs: Raised serum bile acids (most sensitive), increased aminotransfer-\ncheck for end-organ involvement ases, alkaline phosphatase, and total/direct bilirubin (less specific).\nwith labs (platelets, liver enzymes, and\ncreatinine).\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444444 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 445\nâ–  Risk: Stillbirth, preterm delivery, and meconium-stained amniotic fluid. A\nâ–  Management: Ursodeoxycholic acid and consideration of delivery at\n36 weeks.\nACUTE FATTY LIVER IN PREGNANCY\nRare, life-threatening complication in the third trimester of pregnancy\nâ–  Symptoms: Nausea, vomiting, RUQ/epigastric pain, fulminant liver fail-\nure, scleral icterus\nâ–  Labs: Aminotransferases two times normal, increased bilirubin, thrombo- B\ncytopenia, DIC, acute kidney injury, profound hypoglycemia\nâ–  Management: Immediate delivery due to high fetal and maternal\nmortality\nOBSTETRIC COMPLICATIONS OF PREGNANCY\nCM\nECTOPIC PREGNANCY\nFIGURE 2.10-3. Normal intrauterine\npregnancy and ectopic pregnancy.\nMost often tubal (95%), but can be abdominal, ovarian, or cervical\nTransvaginal ultrasonograms showing\n(A) a normal intrauterine pregnancy\nHistory/PE with a gestational sac containing a yolk\nsac within the uterine cavity and (B) a\nâ–  Presents with unilateral lower abdominal pain and vaginal spotting/\ncomplex mass (CM)/ectopic pregnancy\nbleeding, although some patients are asymptomatic\nadjacent to an empty uterus. (Reproduced\nâ–  Associated with etiologies that cause damage to the fallopian tubes, includ- with permission from Tintinalli JE et al. Tintinalliâ€™s E",
      "char_start": 1272000,
      "char_end": 1274000
    },
    {
      "chunk_id": 637,
      "text": "mer-\ning a history of pelvic inflammatory disease (PID), pelvic surgery, DES gency Medicine: A Comprehensive Study Guide, 6th ed.\nuse, or endometriosis New York, NY: McGraw-Hill; 2004.)\nâ–  Differential diagnosis includes SAB, ovarian torsion, PID, and ruptured\novarian cyst\nDiagnosis\nâ–  Evaluate for ectopic pregnancy in all females of reproductive age present- MNEMONIC\ning with abdominal pain and positive pregnancy test\nThese symptoms PAVE the way for\nâ–  Best initial test: Transvaginal ultrasonogram (see Fig. 2.10-3). a diagnosis of ectopic pregnancyâ€”\nâ–  Next best test: Serial serum Î²-hCG may be used to stratify hemodynami-\nPain (abdominal)\ncally stable patients in whom transvaginal US is nondiagnostic:\nAmenorrhea OR\nâ–  <3500 IU/L â†’ serial Î²-hCG until levels reach 3500 IU/L (which is Vaginal bleeding\nwhen an intrauterine pregnancy should be seen)\nEctopic pregnancy\nâ–  Levels in viable intrauterine pregnancy usually rise 50% to 100% in\n48 hours\nâ–  >3500 IU/L â†’ repeat Î²-hCG and US in 2 days KEY FACT\nTreatment Unstable patients or those with signs\nof peritoneal irritation (eg, rebound\nâ–  Medical treatment (methotrexate) is sufficient for small, unruptured tubal tenderness) require emergent surgical\npregnancies.\nintervention regardless of US findings\nâ–  Surgical options include salpingectomy or salpingostomy with evacuation and hCG levels.\n(laparoscopy vs laparotomy).\nComplications\nTubal rupture and hemoperitoneum (a surgical emergency).\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444455 1100//2211//2222 11::5555 PPMM\n\n446 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-12. Complete vs Partial Moles\nVARIABLE COMPLETE PARTIAL\nMechanism Sperm fertilization of an empty Normal ovum fertilized by two\novum sperm\nKaryotype 46,XX 69,XXY\nFetal tissue No fetal tissue Contains fetal tissue\nGESTATIONAL TROPHOBLASTIC DISEASE\nA range of proliferative trophoblastic abnormalities that can be benign or\nmalignant\nâ–  Benign gestational trophoblastic disease ",
      "char_start": 1274000,
      "char_end": 1276000
    },
    {
      "chunk_id": 638,
      "text": "(GTD): It includes complete\nand partial molar pregnancies (see Table 2.10-12).\nâ–  Malignant GTD: Molar pregnancy may progress to malignant GTD,\nincluding the following:\nâ–  Invasive hydatidiform moles (10%â€“15%)\nâ–  Choriocarcinoma (2%â€“5%)\nâ–  Complications of malignant GTD include pulmonary or CNS metastases\nand trophoblastic pulmonary emboli.\nHistory/PE\nâ–  GTD presents with first-trimester uterine bleeding, hyperemesis gravidarum,\npreeclampsia/eclampsia at <24 weeks, and uterine size greater than dates.\nâ–  Risk factors include extremes of age (<20 or >40 years) and a diet defi-\ncient in folate or Î²-carotene.\nDiagnosis\nâ–  Initial test: Pelvic examination may reveal enlarged ovaries (bilateral\ntheca-lutein cysts) or expulsion of grapelike molar clusters into the vagina.\nâ–  Next best/most accurate test: Pelvic ultrasonography reveals a â€œsnow-\nstormâ€ appearance with no gestational sac or fetus present (see\nFig. 2.10-4).\nâ–  Labs show markedly â†‘ serum Î²-hCG (usually >100,000 mIU/mL).\nâ–  X-ray of the chest (CXR) may show lung metastases.\nFIGURE 2.10-4. Molar pregnancy.\nTransvaginal ultrasonogram shows a â–  D&C reveals â€œcluster-of-grapesâ€ tissue.\nlarge, complex intrauterine mass with\ncystic regions that have the characteris- Treatment\ntic appearance of grapes, also known as\nâ€œsnowstormâ€ appearance. (Reproduced with â–  Best initial treatment: Evacuate the uterus with D&C.\npermission from Tintinalli JE et al. Tintinalliâ€™s Emergency â–  Follow with weekly Î²-hCG to undetectable (or negative) weekly, and then\nMedicine: A Comprehensive Study Guide, 6th ed. New monthly for 6 months. Contraception for at least 6 months.\nYork, NY: McGraw-Hill; 2004.) â–  Treat malignant disease with chemotherapy (methotrexate or dactinomycin).\nâ–  Treat residual uterine disease with hysterectomy.\nâ–  Chemotherapy and irradiation are highly effective for metastases.\nANTEPARTUM HEMORRHAGE AND ABNORMAL PLACENTATION\nâ–  Any bleeding that occurs after 20 weeks\nâ–  Complicates 3% to 5% of pregnancies\nâ–  Most common causes: Placental",
      "char_start": 1276000,
      "char_end": 1278000
    },
    {
      "chunk_id": 639,
      "text": " abruption and placenta previa (see\nTable 2.10-13 and Figs. 2.10-5 and 2.10-6)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444466 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 447\nTABLE 2.10-13. Placental Abruption vs Placenta Previa vs Vasa Previa\nVARIABLE PLACENTAL ABRUPTION PLACENTA PREVIA VASA PREVIA\nPathophysiology Premature (before delivery) separa- Abnormal placental location: Velamentous umbilical cord\ntion of normally implanted placenta Total: Placenta covers the cervical os insertion and/or bilobed\nMarginal: Placenta extends to the margin of placenta causing vessels to\nthe os pass over the internal os\nLow lying: Placenta is in close proximity to\nthe os\nIncidence 1 in 100 1 in 200 1 in 2500\nRisk factors Hypertension, abdominal/pelvic Prior C-sections, uterine surgeries, grand Multiple gestation, in vitro\ntrauma, tobacco or cocaine use, multiparity, advanced maternal age, mul- fertilization (IVF), accessory\nprevious abruption, rapid decom- tiple gestation, prior placenta previa placental lobes, single umbil-\npression of an overdistended ical artery, placenta previa,\nuterus, excessive stimulation low-lying placenta\nSymptoms Painful vaginal bleeding that does not Painless, bright red bleeding that often Painless bleeding at rupture\nspontaneously cease ceases in 1â€“2 hours with or without of membranes with fetal\nAbdominal pain; uterine hypertonicity uterine contractions bradycardia\nFetal distress Usually no fetal distress\nDiagnosis Primarily clinical Transabdominal/transvaginal ultrasonog- Transvaginal ultrasonography\nTransabdominal/transvaginal ultraso- raphy sensitivity >95%; the physician with color Doppler showing\nnography sensitivity only 50%; the should look for an abnormally positioned vessels passing over the\nphysician should look for a retropla- placenta. Partial previa can resolve as internal os\ncental clot; most useful for ruling the lower uterine segment expands with\nout previa pregnan",
      "char_start": 1278000,
      "char_end": 1280000
    },
    {
      "chunk_id": 640,
      "text": "cy progression.\nManagement Stabilize patients with mild abruption Do not perform a transvaginal exam or US Acute bleeding = emergency\nand a premature fetus; manage Stabilize patients with a premature fetus; C-section delivery\nexpectantly (hospitalize; start IV provide active surveillance Diagnosis before bleeding: Ste-\nand fetal monitoring; type and Give tocolytics roids at 28â€“32 weeks to help\ncross-match blood) Use serial ultrasonograms to assess fetal with fetal lung maturity, hos-\nModerate to severe abruption: Imme- growth, resolution of partial previa pitalization at 30â€“32 weeks\ndiate delivery is indicated (vaginal Administer betamethasone at 28â€“32 weeks for close monitoring and\ndelivery with amniotomy if mother to help with fetal lung maturity scheduled C-section delivery\nand fetus are stable and delivery Deliver by C-section as clinically indicated\nis expected soon; C-section for Indications for delivery include labor,\nmaternal or fetal distress) life-threatening bleeding, fetal distress,\ndocumented fetal lung maturity, and 36\nweeks\nComplications Hemorrhagic shock Risk for placenta accreta Fetal exsanguination\nDIC in 10% of patients Vasa previa\nRecurrence risk: 5%â€“15% Preterm delivery, PROM, FGR, congenital\nFetal hypoxia anomalies\nRecurrence risk: 4%â€“8%\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444477 1100//2211//2222 11::5555 PPMM\n\n448 HIGH-YIELD FACTS IN OBSTETRICS\nMyometrium Normal placenta Placenta previa Vasa previa Placental abruption\nSerosa Endometrium\nNormal\nplacenta\nPlacenta\naccreta\nFIGURE 2.10-6 Placental Implantation. (Reproduced with permission from USMLE-Rx.com.)\nPlacenta\nincreta\nâ–  Other causes: Other forms of abnormal placentation (see later), ruptured\nuterus, genital tract lesions, and trauma\nPlacenta\npercreta â–  Abnormal placental implantation (Figs. 2.10-5 and 2.10-6) results from\nan abnormality of the decidua basalis and is an important risk factor for\npostpartum maternal hemorrhage.\nâ–  Placent",
      "char_start": 1280000,
      "char_end": 1282000
    },
    {
      "chunk_id": 641,
      "text": "a accreta: Abnormal implantation of the placenta such that the\nPlacenta placental vili are attached to the myometrium.\nFIGURE 2.10-5. Placenta accreta spec- â–  Placenta increta: Abnormal implantation of the placenta such that the\ntrum. (Reproduced with permission from USMLE-Rx. placental vili penetrate into the myometrium\ncom.) â–  Placenta percreta: Abnormal implantation of the placenta such that\nthe placental villi penetrate through the myometrium and into the\nserosa.\nKEY FACT\nâ–  Risk factors: Prior uterine incisions (C-section, fibroid removal), low-lying\nplacentation, placenta previa, fetal Down syndrome\nWith third-trimester bleeding, think\nanatomically: â–  Complications: Maternal hemorrhage, fetal asphyxiation, death.\nâ–  Vagina: vaginitis, vaginal lesion/\ntrauma MULTIPLE GESTATION\nâ–  Cervix: bloody show (labor), cervical\nlesion/trauma Affects 3% of all live births. Since 1980, the incidence of monozygotic (identi-\nâ–  Placenta: Placental abruption, cal) twins has remained steady, whereas the incidence of dizygotic (fraternal)\nplacenta previa and higher-order births has â†‘.\nâ–  Fetus: Fetal bleeding\nHistory/PE\nCharacterized by rapid uterine growth, excessive maternal weight gain, and\npalpation of three or more large fetal parts on Leopold maneuvers.\nDiagnosis\nâ–  Ultrasonography\nâ–  Î²-hCG, human placental lactogen, and MSAFP elevated for GA\nTreatment\nâ–  Multifetal reduction and selective fetal termination options for higher-\norder multiple pregnancies\nâ–  Antepartum fetal surveillance for FGR\nComplications\nâ–  Maternal: Patients six times more likely to be hospitalized with complica-\ntions of pregnancy. â†‘ incidence of placenta previa and need for C-section\ndelivery.\nâ–  Fetal: Twin-to-twin transfusion syndrome (most common in monochori-\nonic twins), cord entanglement (commonly in monoamniotic twins),\nFGR, preterm labor, and â†‘ incidence of congenital malformations.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444488 1100//2211//2222 11::5",
      "char_start": 1282000,
      "char_end": 1284000
    },
    {
      "chunk_id": 642,
      "text": "555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 449\nFETAL GROWTH RESTRICTION\nAn EFW less than 10th percentile for GA.\nHistory/PE\nRisk factors include:\nâ–  Maternal systemic disease leading to uteroplacental insufficiency (intra-\nuterine infection, hypertension, anemia).\nâ–  Maternal substance use.\nâ–  Placenta previa.\nâ–  Multiple gestation.\nâ–  Symmetric FGR results from aneuploidy, congenital anomalies, and intra-\nuterine infection. This usually occurs in the first trimester.\nâ–  Asymmetric FGR (â€œhead-sparing growth lagâ€) results from uteroplacental\ninsufficiency, maternal hypertension, or other maternal chronic disease.\nThis usually occurs in the second/third trimester.\nDiagnosis\nâ–  Best initial test: US to confirm GA and fetal weight.\nâ–  Antepartum serial fundal height measurements with ultrasonography and\nweekly biophysical profiles; umbilical artery Doppler velocimetry.\nTreatment\nâ–  Explore the underlying etiology and correct if possible.\nâ–  If the patient is near due date, administer steroids (eg, betamethasone) to\naccelerate fetal lung maturity; this treatment is required 48 hours before\ndelivery.\nâ–  Perform antepartum fetal monitoring.\nâ–  A nonreassuring status near term may prompt delivery.\nComplications\nâ†‘ perinatal morbidity and mortality.\nFETAL MACROSOMIA\nA birth weight >95th percentile. A common sequela of gestational diabetes\ndue to fetal hyperglycemia.\nDiagnosis\nâ–  Best initial test: US to estimate fetal size\nâ–  Most accurate test: Weighing the newborn at birth (prenatal diagnosis is\nimprecise)\nTreatment\nConsideration of planned C-section delivery for an EFW >5000 g in a preg-\nnant patient without DM and for an EFW >4500 g in a pregnant patient\nwith DM.\nComplications\nâ†‘ risk for shoulder dystocia (leading to brachial plexus injury and Erb-\nDuchenne palsy) as birth weight â†‘.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 444499 1100//2211//2222 11::5555 PPMM\n\n450 HIGH-YIELD FACTS IN OBSTETRICS\nPOLYHYDRAMNIOS\nAn amniotic fluid index (A",
      "char_start": 1284000,
      "char_end": 1286000
    },
    {
      "chunk_id": 643,
      "text": "FI) â‰¥24 or single deepest pocket â‰¥8 cm on ultra-\nsonography. May be present in normal pregnancies, but fetal chromosomal\ndevelopmental abnormalities must be considered.\nEtiologies\nâ–  Maternal DM\nâ–  Multiple gestation\nâ–  Isoimmunization\nâ–  Pulmonary abnormalities (eg, cystic lung malformations)\nâ–  Fetal gastrointestinal (GI) tract anomalies (eg, duodenal atresia, tracheo-\nesophageal fistula, anencephaly)\nâ–  Twin-twin transfusion syndrome\nHistory/PE\nUsually asymptomatic.\nDiagnosis\nSonographic documentation of excessive amniotic fluid volume defined as an\nAFI greater than or equal to (symbol) 24 cm or a single deepest pocket greater\nthan or equal to (symbol) 8 cm. Additional evaluation should include ultraso-\nnography for fetal anomalies, glucose testing for DM, and Rh screen. May\nnote fundal height greater than expected for GA.\nTreatment\nTherapeutic serial amniocentesis to remove fluid for severe symptomatic poly-\nhydramnios with shortness of breath; treatment of underlying cause if possible\nComplications\nPreterm labor, fetal malpresentation, cord prolapse\nOLIGOHYDRAMNIOS\nAn AFI <5 on US or largest visible pocket <2 cm. Oligohydramnios is usu-\nally asymptomatic, but FGR or fetal distress may be present.\nEtiologies\nâ–  Fetal urinary tract abnormalities (eg, renal agenesis, gastrourinary [GU]\nobstruction)\nâ–  Chronic uteroplacental insufficiency\nâ–  Postterm pregnancy (>41 weeks)\nâ–  Rupture of membranes\nDiagnosis\nThe sum of the deepest amniotic fluid pocket in all four abdominal quadrants\non ultrasonography.\nTreatment\nRule out rupture of membranes.Treat the underlying cause if possible.\nComplications\nâ–  Associated with a 40-fold â†‘ in perinatal mortality\nâ–  Other complications: Musculoskeletal abnormalities (eg, clubfoot, facial\ndistortion), pulmonary hypoplasia, umbilical cord compression, and FGR\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445500 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 451\nAgglutination of\nfetal ",
      "char_start": 1286000,
      "char_end": 1288000
    },
    {
      "chunk_id": 644,
      "text": "RhâŠ•\nFetal RhâŠ• red blood cells\nred blood cell in the leads to HDN\nMaternal maternal circulation\nRhâŠ–\nred blood cell\nAnti-Rh\nantibodies\nA B C D\nFIGURE 2.10-7. Maternal antibodies, from Rh isoimmunization at the time of the previous delivery, cross the placenta and cause hemoly-\nsis of RBCs in the fetus. (A) Rh âŠ– mother before pregnancy. (B) Rh âŠ• fetus in Rh âŠ– mother. (C) After delivery, the mother develops antibod-\nies to Rh antigen. (D) Rh âŠ• fetus in the next pregnancy. HDN, Hemolytic disease of the newborn. (Reproduced with permission from USMLE-Rx.com.)\nRH ISOIMMUNIZATION\nFetal RBCs leak into the maternal circulation, and maternal anti-Rh IgG anti-\nbodies form that can cross the placenta, leading to hemolysis of fetal RhâŠ•\nRBCs (erythroblastosis fetalis; see Fig. 2.10-7). Rh isoimmunization occurs\nonly in RhâŠ– women; â†‘ risk with previous SAB or therapeutic abortion (TAB)\nor previous delivery with no Rho (D antigen) immune globulin given.\nDiagnosis\nSensitized RhâŠ– pregnant patients with titers >1âˆ¶16. Anti-D antibody titers\nshould be closely monitored for evidence of fetal hemolysis.\nTreatment\nIn severe cases, the physician should initiate preterm delivery. Before delivery,\nintrauterine blood transfusions can be given to correct a low fetal hematocrit.\nPrevention\nâ–  If the patient is RhâŠ– and the other parent is RhâŠ• (or the status is\nunknown), give Rh immune globulin at 28 weeks.\nâ–  If the baby is RhâŠ•, give the mother Rh immune globulin postpartum. The\ndose is based on the Kleihauer-Betke test. Inadequate dosing can lead to\nalloimmunization.\nâ–  Give Rh immune globulin to RhâŠ– mothers who undergo abortion or who\nhave had an ectopic pregnancy, amniocentesis, vaginal bleeding, or pla-\ncenta previa/placental abruption. Type and screening are critical.\nComplications\nâ–  Hydrops fetalis when fetal hemoglobin is <7 g/dL\nâ–  Fetal hypoxia and acidosis, kernicterus, prematurity, death\nANTEPARTUM FETAL SURVEILLANCE\nIn general, antepartum fetal surveillance should occur in pregnancies in\nwh",
      "char_start": 1288000,
      "char_end": 1290000
    },
    {
      "chunk_id": 645,
      "text": "ich the risk for antepartum fetal demise is â†‘. Testing is initiated in most at-\nrisk pregnant patients at 32 to 34 weeks (or 26â€“28 weeks if there are multiple\nworrisome risk factors). The following assessments take place:\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445511 1100//2211//2222 11::5555 PPMM\n\n452 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-14. Nonstress Test Interpretation\nReactive NST (normal Two accelerations in FHR over 20-minute period (see Fig. 2.10-8):\nresponse) â–  >10 bpm for 10 seconds if <32 weeks\nâ–  >15 bpm for 15 seconds above baseline for >32 weeks\nNonreactive NST Insufficient accelerations over a 40-minute period\nPossibility for FHR accelerations to not occur because of any of the\nfollowing reasons:\nFetal sleeping (most common); can use vibroacoustic stimulation to\nwake up fetus\n<32 weeks\nFetal CNS anomalies\nMaternal sedative or narcotic administration\nFollow up a nonreactive stress test with contraction stress test (CST)\nor biophysical profile (BPP)\nâ–  Fetal movement assessment:\nâ–  Assessed by mother as the number of fetal movements over 1 hour\nâ–  On average, 2 hours required for a mother to register 10 fetal\nmovements\nâ–  Maternal reports of â†“ fetal movements should be evaluated by means\nof various tests\nâ–  NST:\nâ–  Performed with the mother resting in the lateral tilt position (to prevent\nsupine hypotension)\nâ–  Fetal heart rate (FHR) monitored externally by Doppler along with a\ntocodynamometer to detect uterine contractions\nâ–  If NST nonreactive, acoustic stimulation used to wake up the fetus\nâ–  See Table 2.10-14 for NST interpretation\n190 190\nAcceleration\nDoppler\n160 160\n130 130\n120 120\n90 90\n60 60\n30 30\n100 100\nFetal movement\n75 75\n50 50\n25 25\n0 0\nFIGURE 2.10-8. Reactive nonstress test. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445522 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 453\nTABLE ",
      "char_start": 1290000,
      "char_end": 1292000
    },
    {
      "chunk_id": 646,
      "text": "2.10-15. Contraction Stress Test Interpretation\nPositive CST Late decelerations after 50% or more of contractions in a 10-minute\nwindow. Raises concerns about fetal compromise. Delivery is warranted.\nNegative CST No late or significant variable decelerations within 10 minutes and at least\nthree contractions.\nEquivocal CST Intermittent late decelerations or significant variable decelerations.\nTABLE 2.10-16. Biophysical Profile Scoring\nCOMPONENT NORMAL FINDING SCORE\n1. Nonstress test Two accelerations â‰¥15 bpm lasting at least 15 2 â€“ normal\nseconds over a 20-minute period 0 â€“ abnormal\n2. Amniotic fluid Single fluid pocket â‰¥2 Ã— 1 cm or amniotic fluid 2 â€“ normal\nvolume index >5 0 â€“ abnormal\n3. Fetal movements Three or more general body movements 2 â€“ normal\n0 â€“ abnormal\n4. Fetal tone One or more episodes of flexion/extension of fetal 2 â€“ normal\nlimbs or spine 0 â€“ abnormal\n5. Fetal breathing One or more breathing episodes â‰¥30 seconds 2 â€“ normal\nmovements 0 â€“ abnormal\nâ–  CST:\nâ–  Performed in the lateral recumbent position\nâ–  FHR monitored during spontaneous or oxytocin-induced contractions\nâ–  Contraindicated in pregnant patients with preterm membrane rupture\nor known placenta previa, those with a history of uterine surgery, and\nin those who are at high risk for preterm labor\nâ–  See Table 2.10-15 for CST interpretation\nâ–  Biophysical profile (BPP): Uses real-time ultrasonography to assign a\nscore of 2 (normal) or 0 (abnormal) to five parameters: fetal tone, breath-\ning, movement, amniotic fluid volume, and NST (Table 2.10-16)\nâ–  8 to 10: Reassuring for fetal well-being\nâ–  6: Considered equivocal; test repeated in 24 hours if fetus <36 weeks or\ndelivery initiated if fetus is at term\nâ–  0 to 4: Extremely worrisome for fetal asphyxia; strong consideration\nshould be given to immediate delivery if no other explanation is found\nâ–  AFI: Sum of the measurements of the deepest cord-free amniotic fluid\nmeasured in each of the abdominal quadrants:\nâ–  <5 cm: Oligohydramnios\nâ–  â‰¥24 cm: Polyhydramnio",
      "char_start": 1292000,
      "char_end": 1294000
    },
    {
      "chunk_id": 647,
      "text": "s\nâ–  Umbilical artery Doppler velocimetry:\nâ–  Used only when FGR is suspected\nâ–  Normal: High-velocity diastolic flow in the umbilical artery\nâ–  Abnormal: Decreased, absent, or reversed end-diastolic flow in umbili-\ncal artery\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445533 1100//2211//2222 11::5555 PPMM\n\n454 HIGH-YIELD FACTS IN OBSTETRICS\nKEY FACT â–  With FGR, there is a reduction and even a reversal of umbilical artery\ndiastolic flow\nA âŠ– CST is good; a âŠ• one is bad.\nâ–  With oligohydramnios (AFI <5 cm), further workup is always warranted\nMNEMONIC\nNORMAL LABOR AND DELIVERY\nWhen performing a BPPâ€”\nTest the Baby, MAN!\nDEFINITION AND STAGES OF LABOR\nFetal Tone\nFetal Breathing\nLabor is the process whereby contractions of the uterus are accompanied by\nFetal Movement\nprogressive effacement (thinning) and dilation of the cervix, resulting in deliv-\nAmniotic fluid volume\nery of the fetus and placenta through the birth canal (Table 2.10-17).\nNonstress test\nOBSTETRIC EXAMINATION\nKEY FACT\nâ–  Leopold maneuvers are used to determine fetal lie (longitudinal or trans-\nBraxton Hicks contractions: Irregular\nverse) and, if possible, fetal presentation (breech or cephalic).\nlow-intensity contractions of the uterus\nâ–  Cervical exam:\nwithout effacement or dilation of cervix.\nâ–  Evaluate dilation, effacement, station, cervical position, and cervical\nconsistency.\nâ–  Confirm or determine fetal presentation.\nTABLE 2.10-17. Stages of Labor\nDURATION\nSTAGE STARTS/ENDS NULLIPAROUS MULTIPAROUS COMMENTS\nFirst\nLatent Onset of labor to â‰¤20 h â‰¤14 h Prolongation seen with\n6-cm dilation excessive sedation/\nhypotonic uterine\ncontractions\nActive 6-cm dilation to 4â€“6 h 2â€“3 h Prolongation seen\ncomplete cer- (1.2 cm/h) (1.5 cm/h) with cephalopelvic\nvical dilation disproportion\n(10 cm)\nSecond Complete cer- 0.5â€“3.0 h 5â€“30 minutes Neonate going through all\nvical dilation cardinal movements of\nto delivery of delivery\ninfant\nThird Delivery of infant 0â€“0.5 h 0â€“0.5 h Uteru",
      "char_start": 1294000,
      "char_end": 1296000
    },
    {
      "chunk_id": 648,
      "text": "s contraction and\nto delivery of placental separation to\nplacenta establish hemostasis\nFourth Delivery of the 1â€“2 h Tone of the uterus rees-\nplacenta to tablished, expelling any\n1â€“2 h after remaining contents\nAugmented by\nbreastfeeding\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445544 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 455\nâ–  Determine fetal position through palpation of the fetal sutures and\nfontanelles.\nâ–  Conduct a sterile speculum exam if rupture of membranes (ROM) is\nsuspected.\nâ–  Determine station or engagement of the fetal head relative to a line\nthrough the ischial spines of the maternal pelvis. âŠ– station = fetal\nhead superior to this line; âŠ• station = fetal head inferior to this line.\nâ–  Oxytocin and misoprostol are often used as aids in the delivery process\n(for contraction augmentation and cervical softening).\nâ–  Adverse Effects of Oxytocin:\nâ–  Hyponatremia\nâ–  Tachysystole\nâ–  Hypotension\nFETAL HEART RATE MONITORING\nMonitoring can be performed noninvasively with Doppler US or invasively\nwith an electrode attached to the fetal scalp (a method that yields more precise\nresults but can only be used with ruptured membranes).\nContinuous electronic FHR monitoring has not been shown to be more\neffective than appropriate intermittent monitoring in low-risk patients.\nComponents of FHR evaluation\nâ–  Rate (normal = 110â€“160 bpm):\nâ–  FHR <110 bpm: Bradycardia. Can be caused by congenital heart mal-\nformations or by severe hypoxia (secondary to uterine hyperstimula-\ntion, cord prolapse, or rapid fetal descent).\nâ–  FHR >160 bpm: Tachycardia. Causes include hypoxia, maternal fever,\nintra-amniotic infection, and fetal anemia.\nâ–  Variability: Fluctuations in the baseline FHR that are irregular in fre-\nquency and amplitude. Related to fetal cerebral activity.\nâ–  Absent variability: Indicates severe fetal acidemia.\nâ–  Minimal variability: <6 bpm. Indicates fetal hypoxia or the effects of\nopioids, magnesium, or sle",
      "char_start": 1296000,
      "char_end": 1298000
    },
    {
      "chunk_id": 649,
      "text": "ep cycle.\nâ–  Normal variability: 6 to 25 bpm. MNEMONIC\nâ–  Marked variability: >25 bpm. May indicate fetal hypoxia; may occur\nVEAL CHOP\nbefore a â†“ in variability.\nâ–  Sinusoidal variability: Concerning for serious fetal anemia; a pseudo- Variable deceleration = Cord compression\nsinusoidal pattern may also occur during maternal meperidine use. Early deceleration = Head compression\nâ–  Accelerations: Onset of an â†‘ in FHR >15 beats above baseline to a peak Accelerations = OK!\nLate deceleration = Placental insufficiency\nin <30 seconds. Reassuring because they indicate proper function of fetal\nNote: Interventions include maternal\nautonomic nervous system.\nrepositioning, amnioinfusion, or delivery.\nâ–  Decelerations: See Table 2.10-18.\nOBSTETRIC ANALGESIA AND ANESTHESIA\nUterine contractions and cervical dilation result in visceral pain (T10â€“L1).\nDescent of the fetal head and pressure on the vagina and perineum result in\nsomatic pain (pudendal nerve [S2â€“4]).\nâ–  Pudendal block:\nâ–  Bilateral transvaginal injection of local anesthetic in and around\npudendal nerve as it passes around ischial spine\nâ–  Provides perineal anesthesia; can be used in second stage of labor\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445555 1100//2211//2222 11::5555 PPMM\n\n456 HIGH-YIELD FACTS IN OBSTETRICS\nTABLE 2.10-18. Types of Fetal Deceleration\nTYPE DESCRIPTION ETIOLOGY SCHEMATIC\nEarly A visually apparent, gradual (onset to nadir in Head compression\n>30 seconds) â†“ in FHR with a return to baseline from the uterine\nthat mirrors the uterine contraction contraction\n(normal)\nLate A visually apparent, gradual (onset to nadir in Uteroplacental insuf-\n>30 seconds) â†“ in FHR with return to baseline ficiency and fetal\nwhose onset, nadir, and recovery occur after the hypoxemia\nbeginning, peak, and end of uterine contraction,\nrespectively\nVariable An abrupt (onset to nadir in <30 seconds), visually Umbilical cord\napparent â†“ in FHR 15 bpm below baseline lasting compression\nâ‰¥",
      "char_start": 1298000,
      "char_end": 1300000
    },
    {
      "chunk_id": 650,
      "text": "15 seconds but <2 minutes\nIllustrations reproduced with permission from Cunningham FC et al. Williams Obstetrics, 23rd ed. New York, NY: McGraw-Hill; 2010.\nâ–  Epidural block:\nâ–  Injection of local anesthetic in epidural space that blocks lumbosacral\nnerve roots\nâ–  Can be used for either vaginal delivery or C-section\nComplications\nâ–  Transient hypotension from sympathetic blockade is a common complica-\ntion and does not require treatment unless there are signs of shock.\nâ–  Spinal headache is another common complication if there is a dural\npuncture.\nâ–  Epidural anesthesia can cause postpartum urinary retention. Urethral\ncatheterization is diagnostic and therapeutic.\nâ–  Absolute contraindications to regional anesthesia (epidural, spinal, or\ncombination) include the following:\nâ–  Refractory maternal hypotension\nâ–  Maternal coagulopathy\nâ–  Maternal use of a once-daily dose of low-molecular-weight heparin\nwithin 12 hours\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445566 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 457\nâ–  Untreated maternal bacteremia\nâ–  Skin infection over the site of needle placement\nâ–  â†‘ ICP caused by a mass lesion\nABNORMAL LABOR AND DELIVERY\nINDICATIONS FOR C-SECTION\nSee Table 2.10-19 for indications. For both elective and indicated C-section\ndeliveries, an agent such as sodium citrate, H blockers, or PPIs should be\n2\nused in the pregnant patient to â†“ gastric acidity and prevent acid aspiration\nsyndrome.\nPRETERM LABOR\nOnset of labor between 20 and 37 weeks. The primary cause of neonatal mor-\nbidity and mortality.\nâ–  Risk factors include previous preterm delivery (greatest risk factor), multi-\nple gestation, infection, ROM, uterine anomalies (eg, prior surgery, bicor-\nnuate uterus), polyhydramnios, placental abruption, poor maternal KEY FACT\nnutrition, and low socioeconomic status (SES).\nPreterm labor = Regular uterine\nâ–  Patients found to have a short cervix at <24 weeks are at high risk for pre- con",
      "char_start": 1300000,
      "char_end": 1302000
    },
    {
      "chunk_id": 651,
      "text": "tractions + concurrent cervical\nterm labor.\nchange at <37 weeks.\nâ–  Most patients have no identifiable risk factors.\nHistory/PE\nPresents with menstrual-like cramps, onset of low back pain, pelvic pressure,\nand new vaginal discharge or bleeding.\nDiagnosis\nâ–  Requires the following:\nâ–  Regular uterine contractions (three or more contractions of 30 seconds\neach over a 30-minute period)\nâ–  Concurrent cervical change at <37 weeks\nâ–  Assessment for contraindications to tocolysis such as infection, nonreassur-\ning fetal testing, and/or placental abruption\nâ–  Sterile speculum exam to rule out ROM\nâ–  Ultrasonography to rule out fetal or uterine anomalies, verify GA, and\nassess fetal presentation and amniotic fluid volume\nâ–  Cultures for chlamydia, gonorrhea, and group B streptococcus (GBS);\nalso, a urinalysis (UA) and urine culture\nTABLE 2.10-19. Indications for C-section\nMATERNAL FACTORS FETAL AND MATERNAL FACTORS FETAL FACTORS\nPrior classical C-section (vertical incision predisposes Cephalopelvic disproportion (the most Fetal malposition (eg, breech presentation,\nto uterine rupture with vaginal delivery) common cause of primary C-section) shoulder presentation)\nActive genital herpes infection Placenta previa/placental abruption Nonreasuring fetal heart rate pattern\nCervical carcinoma Failed operative vaginal delivery Cord compression/prolapse\nMaternal trauma/demise\nHIV infection with viral load >1000 copies/mL\nPrior transverse C-section (relative indication)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445577 1100//2211//2222 11::5555 PPMM\n\n458 HIGH-YIELD FACTS IN OBSTETRICS\nTreatment\nâ–  Tocolytic therapy (Î²-agonists, MgSO , calcium channel blockers [CCBs],\n4\nprostaglandin inhibitors) if <34 weeks' gestation, unless contraindicated\nâ–  Magnesium for cerebral palsy prophylaxis if <32 weeks\nâ–  Steroids to accelerate fetal lung maturity\nâ–  Penicillin or ampicillin for GBS prophylaxis if preterm delivery likely\nComplications\nRespiratory distr",
      "char_start": 1302000,
      "char_end": 1304000
    },
    {
      "chunk_id": 652,
      "text": "ess syndrome, intraventricular hemorrhage, apnea of prema-\nturity, patent ductus arteriosus, necrotizing enterocolitis, retinopathy of pre-\nmaturity, bronchopulmonary dysplasia, and death.\nRUPTURE OF MEMBRANES\nDistinguished as follows:\nâ–  Spontaneous ROM: Occurs after or at the onset of labor.\nâ–  Premature ROM (PROM): Occurs >1 hour before onset of labor. This is\na variant of normal at term or may be precipitated by vaginal or cervical\ninfections, abnormal membrane physiology, or cervical insufficient.\nâ–  Preterm PROM (PPROM): ROM occurring at <37 weeks.\nâ–  Prolonged ROM: ROM occurring >18 hours before delivery. Risk fac-\ntors: Young maternal age, smoking, and sexually transmitted infections\n(STIs).\nHistory/PE\nPatients often report a â€œgushâ€ of clear or blood-tinged amniotic fluid. Uterine\ncontractions may be present.\nDiagnosis\nâ–  Sterile speculum examination reveals pooling of amniotic fluid in the vag-\ninal vault.\nâ–  Nitrazine paper test is âŠ• (paper turns blue, indicating alkaline pH of\namniotic fluid).\nâ–  Fern test is âŠ• (a ferning pattern is seen under a microscope after amniotic\nfluid dries on a glass slide).\nâ–  Ultrasonography assesses amniotic fluid volume.\nâ–  If diagnosis is uncertain, ultrasonography-guided transabdominal instilla-\ntion of indigo carmine dye can check for leakage (unequivocal test).\nKEY FACT â–  Minimize infection risk; do not perform digital vaginal examinations on\npregnant patients who are not in labor or for whom labor is not planned\nTo minimize the risk for infection, limit\nimmediately.\ndigital vaginal examinations on women\nwith PROM. â–  Check fetal heart tracing, maternal temperature, WBC count, and uterine\ntenderness for evidence of intrauterine infection.\nTreatment\nâ–  Depends on GA:\nâ–  Term: First check GBS status and fetal presentation, then labor may\nbe induced, or the patient can be observed for 6 hours.\nâ–  34 to 36 weeks: Labor induction may be considered.\nâ–  <32 weeks: Institute expectant management and hospitalization for close\nobservation of fe",
      "char_start": 1304000,
      "char_end": 1306000
    },
    {
      "chunk_id": 653,
      "text": "tal well-being and monitoring for signs of infection.\nâ–  Antibiotics: To prolong the latency period in the absence of infection.\nâ–  Antenatal corticosteroids:\nâ–  Give betamethasone or dexamethasone for 48 hours, which promote\nfetal lung maturity in the absence of intra-amniotic infection before 32\nto 36 weeks.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445588 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 459\nâ–  If signs of infection or fetal distress develop, the physician should give anti-\nbiotics (ampicillin and gentamicin) and induce labor.\nComplications\nPreterm labor and delivery, intrauterine infection, placental abruption, and\ncord prolapse.\nFAILURE TO PROGRESS\nAssociated with intrauterine infection, occiput posterior position, nulliparity,\nelevated birth weight, and maternal obesity.\nDiagnosis\nâ–  First-stage protraction or arrest: Labor that fails to produce adequate rates\nof progressive cervical change.\nâ–  Prolonged second stage or arrest: Protraction or arrest of fetal descent.\nMost commonly caused by malposition. See Table 2.10-20 for definitions\nbased on parity and anesthesia.\nTreatment\nSee Table 2.10-20.\nComplications\nâ–  Intrauterine infections may lead to fetal infection, pneumonia, and\nbacteremia.\nâ–  The risk for postpartum hemorrhage is 11%; that of fourth-degree lacera-\ntion is 3.8%.\nTABLE 2.10-20. Failure to Progress\nSTAGE DEFINITION TREATMENTa\nFirst Stage: Failure to Have Progressive Cervical Change\nLatent Primiparous: >20 h Therapeutic rest via parenteral analgesia; oxytocin; amni-\nMultiparous: >14 h otomy; cervical ripening\nActive Dilation of at least 6 cm and either: Amniotomy; oxytocin; C-section if the previous interventions\nNo change in dilation with 4 h of adequate contractions are ineffective\nor\nNo change in dilation with 6 h of inadequate contractions\nSecond Stage: Arrest of Fetal Descent\nPrimiparous: >2 h; >3 h with epidural Close observation with a â†“ in epidural rate and continue",
      "char_start": 1306000,
      "char_end": 1308000
    },
    {
      "chunk_id": 654,
      "text": "d\nMultiparous: >1 h; >2 h with epidural oxytocin\nAssisted vaginal delivery (forceps or vacuum)\nC-section\naAugmentation with oxytocin should be considered when contraction frequency is <3 in a 10-minute period or intensity of contraction is\n<25 mm Hg above baseline.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 445599 1100//2211//2222 11::5555 PPMM\n\n460 HIGH-YIELD FACTS IN OBSTETRICS\nINTRA-AMNIOTIC INFECTION\nIntrauterine infections occur via ascending polymicrobial disease from the\nvagina through the amnion, placenta, and uterus. Less commonly, hematoge-\nnous transplacental seeding from a specific systemic maternal infection (eg,\nListeria) can also occur. The following sections refer only to ascending infec-\ntions, often called chorioamnionitis.\nâ–  Risk factors: PPROM, prolonged rupture of membranes, prolonged labor,\ninternal fetal/uterine monitoring devices, repeated vaginal examinations\nâ–  Complications: Postpartum hemorrhage, endometritis, preterm birth,\nneonatal pneumonia, and encephalopathy\nâ–  Tx: Broad-spectrum IV antibiotics (ampicillin, gentamicin, clindamycin)\nand augmentation of labor\nFETAL MALPRESENTATION\nAny presentation other than vertex (ie, head closest to birth canal, chin to\nchest, occiput anterior). Risk factors include prematurity, prior breech deliv-\nery, uterine anomalies (eg, fibroids), polyhydramnios or oligohydramnios,\nmultiple gestation, PPROM, hydrocephalus, anencephaly, and placenta\nprevia.\nHistory/PE\nBreech presentations are the most common form and involve presentation of\nthe fetal lower extremities or buttocks into the maternal pelvis (see\nFig. 2.10-9). Subtypes include the following:\nKEY FACT â–  Frank breech (50%â€“75%): The thighs are flexed, and the knees are\nextended.\nBreech presentation is the most\ncommon fetal malpresentation. â–  Footling breech (20%): One or both legs are extended below the buttocks.\nâ–  Complete breech (5%â€“10%): The thighs and knees are flexed.\nTreatment\nâ–  Follow: Up to 75% s",
      "char_start": 1308000,
      "char_end": 1310000
    },
    {
      "chunk_id": 655,
      "text": "pontaneously change to vertex by week 38.\nâ–  External cephalic version: If the fetus has not reverted spontaneously, a\nversion may be attempted by applying directed pressure to the maternal\nabdomen to turn the infant to vertex. The success rate is roughly 50%.\nRisks of version are placental abruption and cord compression, so the phy-\nsician should be prepared for an emergency C-section if needed.\nFrank breech Single footling breech Complete breech\nFIGURE 2.10-9. Types of breech presentations. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446600 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 461\nâ–  Trial of breech vaginal delivery: Attempt trial only if delivery is immi-\nnent. Complications include cord prolapse and/or head entrapment.\nâ–  Elective C-section: Recommended given the lower risk for fetal morbidity.\nUMBILICAL CORD PROLAPSE\nOccurs when cord presents ahead of fetal parts and protrudes through cervix.\nConsidered an obstetric emergency. Risk factors include rupturing mem-\nbranes without engaged fetal head part, malpresentation, prolonged labor,\nand polyhydramnios.\nâ–  Dx: Visualization or palpation of the umbilical cord ahead of fetal present-\ning part. Can be accompanied by abrupt, severe prolonged decelerations.\nâ–  Tx: Manual elevation of presenting part, call for assistance, and prepara-\ntion for emergency delivery.\nSHOULDER DYSTOCIA\nAffects 0.6% to 1.4% of all deliveries in the United States. Risk factors include\nobesity, diabetes, suspected fetal macrosomia, a history of an infant with mac-\nrosomy, postterm pregnancy, and a history of prior shoulder dystocia.\nDiagnosis\nDiagnosed by a prolonged second stage of labor, retraction of the head from\nthe perineum (â€œturtle signâ€).\nTreatment\nâ–  In the event of dystocia, the following maneuvers may be attempted:\nâ–  McRoberts maneuver (see Fig. 2.10-10)\nâ–  Application of suprapubic pressure (Fig. 2.10-10)\nâ–  Interna",
      "char_start": 1310000,
      "char_end": 1312000
    },
    {
      "chunk_id": 656,
      "text": "l rotational maneuvers: Used if external maneuvers have failed\nto reduce the dystocia. These maneuvers reduce the diameter of the\nfetal shoulder girdle through abduction of the anterior shoulder toward\nthe fetal back (Woods screw) or adduction of the anterior shoulder\ntoward the fetal chest (Rubin) by the fingers of one hand introduced\nintravaginally. FIGURE 2.10-10. Leg elevation (McRob-\nerts maneuver) and application of\nâ–  Delivery of posterior arm\nsuprapubic pressure. Flexing the hips\nâ–  Intentional fracture of fetal clavicle against the abdomen. The leg positioning\nâ–  Procto-episiotomy illustrated here can be used to assist in\nâ–  Zavanelli maneuver (manually pushing delivered fetal head into uterus a delivery where the infant is at risk for\nand taking patient for C-section) shoulder dystocia. Suprapubic pressure\nmay cause reduction of a shoulder dys-\nâ–  Excessive traction on the fetal head to deliver the anterior shoulder can\ntocia through adduction of the anterior\nresult in â€œstretchâ€ injuries to the C8 to T1 brachial plexus, including\nshoulder. Fundal pressure should be\nHorner syndrome, Erb-Duchenne palsy, or Klumpke palsy. These brachial avoided in shoulder dystocia as it may\nplexus injuries usually resolve spontaneously. cause further impaction of the anterior\nshoulder against the pubic bone. (Repro-\nduced with permission from Cunningham FG et al.\nEPISIOTOMY Williams Obstetrics, 23rd ed. New York, NY: McGraw-\nHill; 2010.)\nSurgical extension of the vaginal opening into the perineum. Can be median\n(midline) or mediolateral.\nComplications\nâ–  Extension to the anal sphincter (third degree) or rectum (fourth\ndegree): More common with midline episiotomy\nâ–  Others: Bleeding, infection, dyspareunia, rectovaginal fistula formation\nâ–  Routine use of episiotomy not recommended\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446611 1100//2211//2222 11::5555 PPMM\n\n462 HIGH-YIELD FACTS IN OBSTETRICS\nUTERINE INVERSION\nAn uncommon cause of",
      "char_start": 1312000,
      "char_end": 1314000
    },
    {
      "chunk_id": 657,
      "text": " postpartum hemorrhage. This occurs when the uter-\nine fundus prolapses through the cervix and vagina and can often be visible as\na shaggy mass protruding from the vagina. The fundus is no longer palpable,\nand the patient is usually experiencing severe abdominal pain. Causes\ninclude excessive fundal pressure and traction on the umbilical cord. Treat-\nment involves discontinuation of uterotonics, manually replacing the uterus,\nand monitoring hemodynamic status.\nUTERINE RUPTURE\nVery rare but life-threatening complication that may occur in pregnant\npatients with a history of C-section (especially vertical C-section) or other\nuterine surgeries. May result in postpartum bleeding. Loss of fetal station is\npathognomonic for this condition, and fetal parts may be palpable in the\nabdomen but not in the vagina. Treatment involves emergent laparotomy.\nPUERPERIUM\nâ–  Normal changes after delivery include lochia (vaginal bleeding), uterine\ncontraction, and uterine involution.\nâ–  The superficial layers of the endometrial decidua shed through the vagina\nfor the first 3 postpartum weeks. This is called lochia.\nâ–  For the first few days, lochia is red in color (lochia rubra), and then it\nchanges to pink in color (lochia serosa). Lochia changes to white color\n(lochia alba) by the end of the second week.\nâ–  Postpartum urinary retention is also common, and it is caused by bladder\natony. This can be managed with catheterization and encouragement of\nambulation, and it usually resolves spontaneously.\nâ–  Radiating suprapubic pain exacerbated by weight-bearing may occur\nbecause of diastasis of the pubic symphysis (separation of the pubic\nbones). This is more common after a traumatic delivery, and treatment is\nwith supportive care.\nPOSTPARTUM HEMORRHAGE\nA loss of â‰¥1000 mL in the first 24 hours after C-section or vaginal delivery.\nTable 2.10-21 summarizes common causes.\nSigns of delayed postpartum hemorrhage:\nâ–  Saturating more than one pad per hour for 2 consecutive hours\nâ–  Passing large clots\nâ–  Si",
      "char_start": 1314000,
      "char_end": 1316000
    },
    {
      "chunk_id": 658,
      "text": "gns and symptoms of anemia (low hemoglobin [Hb], dizziness,\nlightheadedness)\nComplications\nâ–  Anemia caused by chronic blood loss (predisposes to puerperal infection)\nâ–  Sheehan syndrome (discussed later)\nPOSTPARTUM INFECTION\nA temperature â‰¥38Â°C for at least 2 of the first 10 postpartum days (not includ-\ning the first 24 hours).\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446622 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 463\nTABLE 2.10-21. Common Causes of Postpartum Hemorrhage\nVARIABLE UTERINE ATONY (80%) GENITAL TRACT TRAUMA (15%) RETAINED PLACENTAL TISSUE (5%)\nRisk factors Uterine overdistention (multiple gestation, Precipitous labor Placenta accreta/increta/percreta\nmacrosomia, polyhydramnios) Operative vaginal delivery Placenta previa\nExhausted myometrium (rapid or prolonged (forceps, vacuum extraction) Uterine leiomyomas\nlabor, oxytocin stimulation) Macrosomia Preterm delivery\nUterine infection Inadequate episiotomy repair Previous C-section/curettage\nConditions interfering with contractions\n(anesthesia, myomas, MgSO)\n4\nDiagnosis Palpation of a soft, enlarged, â€œboggyâ€ uterus Manual and visual inspection of Manual and visual inspection of the pla-\nMost common cause of postpartum the lower genital tract for any centa and uterine cavity for missing\nhemorrhage laceration >2 cm long cotyledons\nUS to look for retained intrauterine tissue\nTreatmenta Bimanual uterine massage (usually Surgical correction of the phys- Manual removal of remaining placental\nsuccessful) ical defect tissue\nOxytocin infusion Curettage with suctioning (carries risk for\nMethylergonovine if not hypertensive uterine perforation or scarring [Ash-\nPGFÎ± erman syndrome])\n2\naFor all uterine causes, when bleeding persists after conventional therapy, uterine/internal iliac artery ligation, uterine artery embolization, or\nhysterectomy can be lifesaving.\nOther rare causes of postpartum hemorrhage are disseminated intravascular coagulation",
      "char_start": 1316000,
      "char_end": 1318000
    },
    {
      "chunk_id": 659,
      "text": " and uterine inversion.\nâ–  Risk factors for postpartum endometritis: Emergent C-section, PROM, KEY FACT\nprolonged labor, multiple intrapartum vaginal exams, intrauterine manip-\nPostpartum endometritis:\nulations, emergent delivery, low SES, young age, invasive fetal monitor-\nâ–  Fever >38Â°C\ning, prolonged ROM, bacterial colonization, and corticosteroid use.\nâ–  Uterine tenderness\nâ–  Dx: Diagnose with blood cultures and CT, looking for a pelvic abscess. â–  Malodorous lochia\nâ–  Tx: Broad-spectrum antibiotics and anticoagulation with heparin for 7 to\n10 days.\nTreatment\nBroad-spectrum empiric IV antibiotics (eg, clindamycin and gentamicin)\nuntil patient has been afebrile for 48 hours (24 hours for intrauterine infec-\ntions). Add ampicillin for complicated cases.\nComplications\nSeptic pelvic thrombophlebitis:\nâ–  Pelvic infection leads to infection of the vein wall and intimal damage,\nleading in turn to thrombogenesis. The clot is then invaded by\nmicroorganisms.\nâ–  Suppuration follows, with liquefaction, fragmentation, and, finally, septic\nembolization.\nâ–  Septic pelvic thrombophlebitis presents with abdominal and back pain\nand a â€œpicket-fenceâ€ fever curve (â€œhecticâ€ fevers) with wide swings from\nnormal to as high as 41Â°C (105.8Â°F) that does not resolve despite antibi-\notic treatment.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446633 1100//2211//2222 11::5555 PPMM\n\n464 HIGH-YIELD FACTS IN OBSTETRICS\nMNEMONIC â–  The physician should diagnose with blood cultures and CT, looking for a\npelvic abscess.\nThe seven Ws of postpartum fever â–  Treatment calls for broad-spectrum antibiotics and anticoagulation with\n(10 days postdelivery)â€” heparin for 7 to 10 days.\nWomb (endomyometritis)\nWind (atelectasis, pneumonia)\nPERIPARTUM CARDIOMYOPATHY\nWater (UTI)\nWalk (DVT, pulmonary embolism)\nWound (incision, episiotomy) Peripartum cardiomyopathy and hypertensive disorders of pregnancy are a ris-\nWeaning (breast engorgement, abscess, ing cause of maternal mor",
      "char_start": 1318000,
      "char_end": 1320000
    },
    {
      "chunk_id": 660,
      "text": "tality in high-income countries. This topic is dis-\nmastitis) cussed in detail in the Cardiology chapter.\nWonder drugs (drug fever)\nSHEEHAN SYNDROME (POSTPARTUM PITUITARY NECROSIS)\nPituitary ischemia and necrosis that lead to anterior pituitary insufficiency\nsecondary to massive obstetric hemorrhage and shock\nHistory/PE\nâ–  The primary cause of anterior pituitary insufficiency in adult females\nâ–  Most common presenting symptom: Failure to lactate (caused by â†“ prolac-\ntin levels)\nâ–  Other symptoms: Hypotension, weakness, lethargy, cold intolerance, geni-\ntal atrophy, and menstrual disorders\nDiagnosis\nâ–  Best initial test: Adrenocorticotropic hormone (ACTH) stimulation test\nâ–  Most accurate test: MRI of the pituitary gland and hypothalamus to rule\nout tumor or other pathology\nTreatment\nReplacement of all deficient hormones. Some patients may recover thyroid-\nstimulating hormone (TSH) and even gonadotropin function after cortisol\nreplacement alone.\nLACTATION AND BREASTFEEDING\nHypothalamus\nPHYSIOLOGY\nâ–  During pregnancy, â†‘ estrogen and progesterone result in breast hypertro-\nphy and inhibition of the action of prolactin on the breast.\nâ–  After delivery of the placenta, hormone levels â†“ markedly, and prolactin\nAnterior Posterior stimulates the alveolar epithelial cells, activating milk production. â†‘ pro-\npituitary pituitary\nlactin will â†“ luteinizing hormone (LH) and follicle-stimulating hormone\n(FSH), causing anovulation and amenorrhea during breastfeeding.\nSuckling at â–  Periodic infant suckling leads to further release of prolactin and oxytocin.\nlactating breast Oxytocin\nOxytocin stimulates myoepithelial cell contraction and milk ejection (â€œlet-\ndown reflexâ€) and promotes greater involution of the uterus postpartum\n(Fig. 2.10-11).\nâ–  Colostrum (early breast milk) contains protein, fat, secretory IgA, and\nContraction of minerals.\nmyoepithelial cells\nâ–  Within 1 week postpartum, mature milk with protein, fat, lactose, and\nwater is produced.\nFIGURE 2.10-11 Physiology of breast-\nmilk",
      "char_start": 1320000,
      "char_end": 1322000
    },
    {
      "chunk_id": 661,
      "text": " production. (Reproduced with permission â–  High IgA levels in colostrum provide passive immunity for the infant and\nprotect against enteric bacteria.\nfrom USMLE-Rx.com.)\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446644 1100//2211//2222 11::5555 PPMM\n\nOBSTETRICS HIGH-YIELD FACTS IN 465\nTABLE 2.10-22. Contraindications to Breastfeeding\nINFECTIOUS NONINFECTIOUS\nMaternal HIV (not a contraindication in Chemotherapy\nresource-poor countries) Radiation therapy\nActive untreated TB Active substance use (eg, cannabis,\nActive varicella cocaine, PCP)\nActive herpes on breasts Certain medications (eg, tetracy-\ncline, chloramphenicol)\nInfant Galactosemia\nPCP, Phencyclidine hydrochloride piperdine; TB, tuberculosis.\nâ–  Other potential benefits of breastfeeding include the following:\nâ–  â†“ incidence of infant allergies\nâ–  â†“ incidence of early infant upper respiratory infections (URIs) and GI\ninfections\nâ–  Facilitation of mother-child bonding\nâ–  Maternal weight loss\nâ–  Females who desire to suppress lactation should wear a supportive bra,\navoid nipple stimulation, apply ice packs to the breasts, and use nonsteroi-\ndal anti-inflammatory drugs (NSAIDs) to reduce pain. Breast binding\nshould be avoided, as it â†‘ risk for mastitis.\nCONTRAINDICATIONS TO BREASTFEEDING\nBreastfeeding has many benefits and should be encouraged when possible.\nContraindications to breastfeeding are rare (see Table 2.10-22).\nMASTITIS/BREAST ABSCESS\nCellulitis of the periglandular tissue caused by nipple trauma from breastfeed-\ning coupled with the introduction of bacteria, usually Staphylococcus aureus,\ninto the nipple ducts.\nHistory/PE\nSymptoms often begin 2 to 4 weeks postpartum, are usually unilateral, and\ninclude:\nâ–  Breast tenderness\nâ–  Erythema, edema, warmth, and possible purulent nipple drainage\nâ–  Significant fever, chills, and malaise can also be seen\nDiagnosis\nâ–  Differentiate mastitis from simple breast swelling\nâ–  Infection is suggested by focal symptoms, an â†‘ WBC",
      "char_start": 1322000,
      "char_end": 1324000
    },
    {
      "chunk_id": 662,
      "text": " count, and fever\nTreatment\nâ–  Continuation of breastfeeding to prevent the accumulation of infected mate-\nrial (or use of a breast pump in patients who are no longer breastfeeding)\nâ–  Oral antibiotics (dicloxacillin, cephalexin, amoxicillin/clavulanate, azithro-\nmycin, clindamycin), antipyretics, and NSAIDs to reduce inflammation\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446655 1100//2211//2222 11::5555 PPMM\n\n466 HIGH-YIELD FACTS IN OBSTETRICS\nâ–  If no clinical improvement within 48 to 72 hours, evaluation with breast\nultrasonography to assess for abscess; if present, treat abscess with incision\nand drainage\nBREAST ENGORGEMENT\nOccurs when milk production exceeds removal â†’ bilateral firmness, fullness,\ntenderness, and warmth. Management calls for frequent breastfeeding, com-\npresses (warm before and cold between feeds), and mild analgesics. If patient\nis not breastfeeding, management calls for suppression of lactation (described\nearlier).\nNIPPLE INJURY\nDue to poor latch/infant positioning, infection, and vasospasm. Presents with\npain, bruises, cracks, blisters, and bleeding. Management with nursing tech-\nnique counseling, analgesia, and compresses.\nLOCALIZED PLUGGED DUCT\nStasis in milk ducts â†’ painful, tender lump. Clinical diagnosis. Most cases\nresolve on their own.\nGALACTOCELE\nMilk retention cyst due to duct obstruction. Presents as a soft, cystic,\nmobile, nontender, subareolar mass on examination. Mainly clinical diag-\nnosis. Milky fluid on fine-needle aspiration ([FNA], diagnostic and thera-\npeutic), complex mass on US, and indeterminate or fat-fluid level on\nmammography (rarely indicated). Most cases resolve by themselves; treat-\nment is usually not needed.\n22002222__0022..1100__SStteepp22CCKK__OObbsstteettrriiccss__1111ee__442277--446666..iinndddd 446666 1100//2211//2222 11::5555 PPMM\n\nH I G H - Y I E L D F A C T S I N\nGYNECOLOGY\nMenarche and Normal Female Development 468 Benign Breast Disorders 492\nnonProliferat",
      "char_start": 1324000,
      "char_end": 1326000
    },
    {
      "chunk_id": 663,
      "text": "ive breast lesions 492\nNormal Menstrual Cycle 468\nProliferative breast lesions Without atyPia 493\nAbnormalities of the Menstrual Cycle 469 intraDuctal PaPilloma 493\nPrecocious Puberty 469 PhylloDes tumor 494\nPrimary amenorrhea/DelayeD Puberty 470 atyPical hyPerPlasia 494\nseconDary amenorrhea 473\nBreast Cancer 494\nPrimary Dysmenorrhea 474\nseconDary Dysmenorrhea 474 Benign Gynecologic Disorders 497\nabnormal uterine bleeDing 476 uterine leiomyomas (fibroiDs) 497\nnonneoPlastic ovarian cysts 498\nContraception 478\nGynecologic Neoplasms 498\nReproductive Endocrinology 481\nenDometrial cancer 498\ncongenital aDrenal hyPerPlasia 481\ncervical cancer 499\nPolycystic ovarian synDrome 483\nvulvar cancer 502\ninfertility 484\nvaginal cancer 503\nMenopause 486 ovarian cancer 503\nGynecologic Disorders 487 Urologic Gynecology 506\ncyst anD abscess of the bartholin Duct 487 Pelvic organ ProlaPse 506\nvaginitis 487\nSexual Disorders 507\ncervicitis 489\ngenitoPelvic Pain DisorDer (vaginismus) 507\nPelvic inflammatory Disease 489\nvulvoDynia 507\novarian torsion 490\nfemale sexual interest/arousal DisorDer 507\nPeDiatric vaginal Discharge 491\ntoxic shock synDrome 491\n467\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 446677 1100//2211//2222 44::1177 PPMM\n\nKEY FACT\nMENARCHE AND NORMAL FEMALE DEVELOPMENT\nNormal male development is later in\nonset with a different order: testicular â–  Thelarche (breast development, onset 8â€“13 years of age) â†’ pubarche (pubic\nenlargement (onset 9â€“14 years of hair growth) â†’ growth acceleration â†’ menarche (onset 10â€“16 years of age)\nage) â†’ penile growth â†’ pubarche â†’ â–  Ages for these stages of development vary by race/ethnicity\ngrowth acceleration â†’ facial hair.\nNORMAL MENSTRUAL CYCLE\nThe progression of a normal menstrual cycle is detailed here. Figure 2.11-1\nshows the cyclic events in the ovary (follicular and luteal phases) and the cor-\nresponding events in the uterus (proliferative and secretory) levels throughout\na typical 28-day cycle.\nFIGURE",
      "char_start": 1326000,
      "char_end": 1328000
    },
    {
      "chunk_id": 664,
      "text": " 2.11-1 The phases of the ovarian and uterine cycles. (Reproduced with permission from USMLE-Rx.com.)\nnoitaluvO\nnoitaluvO\nMature\n(Graafian)\nPrimordial Developing Corpus\nfollicle\nfollicles follicle luteum\nProduces\nsetalumitS\nsecudorP\n468 HIGH-YIELD FACTS IN GYNECOLOGY\nPHASES OF OVARIAN CYCLE: FOLLICULAR PHASE LUTEAL PHASE\nLH\nFSH\nAnterior\nHypothalamus GnRH pituitary LH FSH\nCorpus\nalbicans\nOvary\nProgesterone\nEstrogen\nEndometrium\nPHASES OF UTERINE CYCLE: Menses Proliferative Secretory Menses\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 446688 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 469\nMenstruation and follicular phase (days 1â€“13):\nâ–  Starts with menstruation and ends at luteinizing hormone (LH) surge/\novulation\nâ–  May vary but typically lasts âˆ¼13 days\nâ–  â†‘ frequency of gonadotropin-releasing hormone (GnRH) pulse â†’â†‘ follicle-\nstimulating hormone (FSH) â†’ growth of follicles â†’â†‘ estrogen production\nâ–  Results in the development of straight glands and thin secretions of the\nuterine lining (proliferative phase)\nâ–  By late follicular phase: Dominant follicle is selected and â†‘ in size; uter-\nine endometrium has thickened; and cervical mucus is becoming copious,\nthin, and stretchy\nOvulation (day 14):\nâ–  Estradiol reaches a peak â†’ positive feedback to the pituitary gland â†’ LH KEY FACT\nsurge (smaller FSH rise) â†’ rupture of the ovarian follicle and release of a\nâ€œLH surgeâ€ triggers ovulation and\nmature ovum â†’ travels to oviduct/uterus\ninitiates production of progesterone.\nâ–  Ruptured follicular cells differentiate into the corpus luteum\nLuteal phase (days 15â€“28):\nâ–  Length of time (10â€“14 days) that the corpus luteum can survive without\nfurther LH or human chorionic gonadotropin (hCG) stimulation\nâ–  Change from estrogen to progesterone predominance; corpus luteum pro-\nduces progesterone and some estradiol, allowing the endometrial lining to\ndevelop thick and tortuous endometrial glands with thick secretions\n(secretory phase)\nâ–  In the",
      "char_start": 1328000,
      "char_end": 1330000
    },
    {
      "chunk_id": 665,
      "text": " absence of fertilization and implantation, â†“ LH â†’ â†“ progesterone\nand estradiol by the corpus luteum â†’ sloughing of the endometrial lining\nâ–  With â†“ estrogen and progesterone, there is no longer negative feedback to\nFSH, which then increases and restarts the menstruation/follicular phase\nABNORMALITIES OF THE MENSTRUAL CYCLE KEY FACT\nIf onset of secondary sexual\nPRECOCIOUS PUBERTY characteristics is seen before 8 years of\nage, work up for precocious puberty by\nOnset of secondary sexual characteristics in a child <8 years of age. Subtypes determining bone age and conducting\nare as follows (see Table 2.11-1): a GnRH stimulation test to distinguish\ncentral from peripheral precocious\nâ–  Central precocious puberty: Early activation of hypothalamic GnRH puberty.\nproduction\nTABLE 2.11-1. Causes of Precocious Pubertal Development\nCENTRAL (GnRH DEPENDENT) PERIPHERAL (GnRH INDEPENDENT)\nConstitutional (idiopathic) Congenital adrenal hyperplasia\nHypothalamic lesions (hamartomas, tumors, Adrenal tumors\ncongenital malformations) McCune-Albright syndrome (polyostotic\nDysgerminomas fibrous dysplasia)\nHydrocephalus Gonadal tumors (especially a granulosa cell\nCentral nervous system (CNS) infections tumor, which secretes estrogen)\nCNS trauma/irradiation Exposure to exogenous estrogen\nPineal tumors (rare) Ovarian cysts (females)\nNeurofibromatosis with CNS involvement Hypothyroidism\nTuberous sclerosis\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 446699 1100//2211//2222 44::1177 PPMM\n\n470 HIGH-YIELD FACTS IN GYNECOLOGY\nKEY FACT â–  Peripheral precocious puberty: Results from GnRH-independent\nmechanisms\nA patient with McCune-Albright\nsyndrome presents with precocious History/PE\npuberty, cafÃ© au lait spots, and bony\nâ–  Risk factors: smoking, immunosuppression, HPV infection.\nabnormalities (polyostotic fibrous\nâ–  Signs of estrogen excess (breast development and possibly vaginal bleed-\ndysplasia).\ning) suggest ovarian cysts or tumors.\nâ–  Signs of androgen excess (",
      "char_start": 1330000,
      "char_end": 1332000
    },
    {
      "chunk_id": 666,
      "text": "pubic and/or axillary hair, enlarged clitoris, and/\nor acne) suggest adrenal tumors or congenital adrenal hyperplasia (CAH).\nKEY FACT\nDiagnosis\nCentral precocious puberty: â†‘ estradiol,\nâ†‘ LH, â†‘ FSH Workup for precocious puberty includes the following:\nPeripheral precocious puberty: â†‘ â–  Bone age:\nestradiol, â†“ LH, â†“ FSH â–  Within 1 year of chronologic age: puberty either has not started or has\njust begun.\nâ–  >2 years ahead of chronologic age: puberty either started >1 year ago\nor recently started with rapid progression.\nâ–  GnRH agonist (leuprolide) stimulation test:\nâ–  Increased LH: Central precocious puberty â†’ CNS tumor (may be\ndetected on MRI) vs constitutional precocious puberty.\nâ–  No increase in LH: Peripheral precocious puberty â†’ ovarian cyst/adre-\nnal or gonadal tumor (may be detected on ovarian, gonadal, and/or\nadrenal ultrasound) vs exogenous estrogen or CAH.\nTreatment\nâ–  Central precocious puberty: Leuprolide is first-line therapy; physical\nchanges regress or cease to progress.\nâ–  Peripheral precocious puberty: The physician should treat the cause.\nâ–  Ovarian cysts: No intervention is necessary, as cysts will usually regress\nspontaneously.\nâ–  Congenital adrenal hyperplasia (CAH): Treatment with glucocorticoids.\nDepending on the enzyme deficiency, mineralocorticoid and sodium\nchloride supplementation may be necessary.\nâ–  Adrenal or ovarian tumors: These require surgical resection.\nâ–  McCune-Albright syndrome: Estrogen blockers such as tamoxifen or\ndrugs that decrease estrogen synthesis such as aromatase inhibitors (eg,\nanastrozole) or other synthesis blockers (ketoconazole or testolactone)\nmay be effective.\nPRIMARY AMENORRHEA/DELAYED PUBERTY\nPrimary amenorrhea is the absence of menses by 15 years of age with second-\nary sexual development present. Delayed puberty is the absence of secondary\nsexual characteristics by 13 years of age.\nHistory/PE\nAbsence of secondary sexual characteristics (no estrogen production):\nâ–  Primary ovarian insufficiency: Most common cause (âˆ¼50%). ",
      "char_start": 1332000,
      "char_end": 1334000
    },
    {
      "chunk_id": 667,
      "text": "Depletion\nof ovarian follicles and oocytes most commonly from Turner syndrome\n(45,XO). The physician should consider a history of radiation therapy and\nchemotherapy or gonadal dysgenesis.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447700 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 471\nâ–  Central hypogonadism: Can be caused by a variety of factors, including\nthe following:\nâ–  Undernourishment, stress, hyperprolactinemia, or exercise\nâ–  Central nervous system (CNS) tumor (consider prolactin-secreting\npituitary adenoma if galactorrhea) or cranial irradiation\nâ–  Kallmann syndrome (isolated gonadotropin deficiency) associated with\nanosmia\nâ–  Constitutional growth delay\nPresence of secondary sexual characteristics (estrogen production but\nother anatomic or genetic problems): Etiologies include the following: KEY FACT\nâ–  MÃ¼llerian agenesis: XX genotype with normal female testosterone levels. For Turner syndrome, think streak\nAbsence of upper two thirds of the vagina; uterine abnormalities gonads, shield chest, amenorrhea,\nâ–  Imperforate hymen: Presents with hematocolpos (blood in the vagina) webbed neck, aortic coarctation, and\nthat cannot escape, along with a bulging hymen bicuspid aortic valve.\nâ–  Complete androgen insensitivity: XY genotype with elevated testosterone\nlevels. Presents with breast development (aromatization of testosterone to\nKEY FACT\nestrogen) but amenorrhea and lack of pubic hair\nâ–  CAH: Can present as virilization with amenorrhea or oligomenorrhea; The first step in the workup of\noften presents in infancy with ambiguous genitalia primary or secondary amenorrhea is a\npregnancy test!\nPE: Pubertal development, genital exam, signs of androgen excess, physi-\ncal features of Turner syndrome\nDiagnosis\nPerform pregnancy test.\nAssess for anatomic abnormalities (eg, imperforate hymen): Physical\nexamination, ultrasonography:\nâ–  Uterus absent: Obtain karyotype and serum testosterone levels to assess if\npatient has abn",
      "char_start": 1334000,
      "char_end": 1336000
    },
    {
      "chunk_id": 668,
      "text": "ormal MÃ¼llerian development (46,XX, normal female tes-\ntosterone levels) or androgen insensitivity (46,XY, normal male testoster-\none levels).\nâ–  Uterus present: Check FSH, LH levels.\nâ–  â†‘ FSH: Primary ovarian insufficiency. Obtain karyotype for Turner\nsyndrome (45,XO).\nâ–  Normal/â†“ FSH: Central hypogonadism, constitutional growth delay.\nMeasure serum prolactin and thyrotropin, especially if galactorrhea is\npresent.\nIf signs of hyperandrogenism: Consider androgen-secreting neoplasm or\nCAH. Check serum testosterone, dehydroepiandrosterone-sulphate (DHEAS).\nIf hypertensive: Evaluate for CAH (17-hydroxylase and 11-hydroxylase\ndeficiencies).\nSee Table 2.11-2 for etiologies and Figure 2.11-2 for workup of primary\namenorrhea.\nTreatment\nâ–  Constitutional growth delay: No treatment is necessary.\nâ–  Hypogonadism: Begin hormone replacement therapy (HRT) with estro-\ngen alone at the lowest dose. Begin cyclic estrogen/progesterone therapy\n12 to 18 months later (if the uterus is present).\nâ–  Anatomic: Requires surgical intervention.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447711 1100//2211//2222 44::1177 PPMM\n\n472 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-2. Etiologies of Primary Amenorrhea\nGNRH LH/FSH ESTROGEN/PROGESTERONE ETIOLOGY\nConstitutional growth â†“ â†“ â†“ (prepuberty levels) Start of puberty behind schedule\ndelay\nHypogonadotropic â†“ â†“ or normal â†“ Hypothalamic or pituitary problem, low caloric intake,\nhypogonadism excessive exercise\nHypergonadotropic â†‘ â†‘ â†“ Ovaries have failed to produce estrogen\nhypogonadism\nAnovulatory problem â†‘ or â†“ Normal â†‘ estrogen/â†“ progesterone Problem with estrogen receptors, immature hypothalamic-\npituitary-ovarian axis (adolescents only)\nAnatomic problem Normal Normal Normal Menstrual blood unable to get out\nHistory and physical examination completed\nfor a patient with primary amenorrhea\nPresence of secondary\nsexual characteristics?\nYes No\nUterus present? Measure FSH/LH\nYes No\nOutflow obstruction Low FSH and LH High ",
      "char_start": 1336000,
      "char_end": 1338000
    },
    {
      "chunk_id": 669,
      "text": "FSH and LH\nYes No\nImperforate hyman Evaluate as Hypogonadotropic Hypergonadotropic\nor transverse for secondary hypogonadism hypogonadism\nvaginal septum amenorrhea\nKarotype analysis Karotype analysis\n46,XY 46,XX 46,XY 46,XX 45,XO\nAndrogen ..\nMullerian Swyer Premature Turner\ninsensitivity\nagenesis syndrome ovarian failure syndrome\nsyndrome\nFIGURE 2.11-2. Workup of primary amenorrhea. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447722 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 473\nProgestin challenge\nWithdrawal bleed No withdrawal bleed\nFSH or normal FSH\nHypergonadotropic\nb P y C L O H: S F S (s H u g ra g t e io st â‰¥ ed 2) hypogonadism Cyclic estrogen/\nPremature menopause progesterone test\nIdiopathic anovulation\nPrimary ovarian insufficiency\nWithdrawal No withdrawal\nbleed bleed\nHypogonadotropic Endometrial or\nhypogonadism anatomic problem\nFIGURE 2.11-3. Workup of secondary amenorrhea. (Reproduced with permission from USMLE-Rx.com.)\nSECONDARY AMENORRHEA\nThe absence of menses for 6 consecutive months in females who have passed\nmenarche. Etiologies include:\nâ–  Pregnancy\nâ–  Ovary: Polycystic ovarian syndrome (PCOS), premature ovarian insuffi-\nciency, chemotherapy, radiation\nâ–  Hypothalamus: Neoplasm, functional hypothalamic amenorrhea (poor\nnutrition, exercise, and stress), systemic illness (type 1 diabetes mellitus\n[DM], celiac disease)\nâ–  Pituitary gland: Adenoma (eg, prolactin secreting), sellar masses, Shee-\nhan syndrome\nâ–  Thyroid gland: Hypothyroidism, hyperthyroidism\nâ–  Uterus: Asherman syndrome, cervical stenosis\nDiagnosis\nâ–  History and physical examination\nâ–  Exclusion of pregnancy with a pregnancy test\nâ–  If âŠ–, measurement of FSH, thyroid-stimulating hormone (TSH), and\nprolactin\nâ–  â†‘ FSH indicates primary ovarian insufficiency.\nâ–  â†‘ TSH indicates hypothyroidism.\nâ–  â†‘ prolactin (inhibits the release of GnRH and thus LH and FSH)\npoints to a pituitary pathology. An MRI of ",
      "char_start": 1338000,
      "char_end": 1340000
    },
    {
      "chunk_id": 670,
      "text": "the pituitary gland should be\nordered to look for a prolactin-secreting pituitary adenoma.\nâ–  Initiation of a progestin challenge (10 days of progestin). See Figure 2.11-3\nfor an algorithm of the diagnostic workup.\nâ–  âŠ• progestin challenge (withdrawal bleed): Anovulation that is proba-\nbly caused by noncyclic gonadotropin secretion, pointing to PCOS or\nidiopathic anovulation\nâ–  âŠ– progestin challenge (no bleed): Uterine abnormality or estrogen A 16-year-old girl presents with â†“\ndeficiency\nappetite, insomnia, and amenorrhea\nâ–  Signs of hyperglycemia (polydipsia, polyuria) or hypotension: A 1-mg over- for 3 months. What is the most likely\nnight dexamethasone suppression test to distinguish CAH (21-hydroxylase diagnosis, and how should the\ndeficiency), Cushing syndrome, and Addison disease physician confirm it?\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447733 1100//2211//2222 44::1177 PPMM\n\n474 HIGH-YIELD FACTS IN GYNECOLOGY\nâ–  Clinical hyperandrogenism: If present, check testosterone, DHEA-S, and\nKEY FACT 17-hydroxyprogesterone levels\nâ–  Hirsutism = Male hair pattern (hair â–  Mild pattern: PCOS, CAH, or Cushing syndrome\nin face, chest, back) â–  Moderate-to-severe pattern (virilization, eg, deepening voice, male\npattern baldness, clitoromegaly): Concerning for ovarian or adrenal\nâ–  Virilization = male pattern baldness\ntumor\n(frontal balding), muscularity,\nclitoromegaly, and deepening of\nTreatment\nthe voice\nâ–  Defeminization = â†“ breast size; loss â–  Hypothalamic-pituitary-ovarian axis: Reversal of underlying cause. Induc-\nof feminine adipose tissue tion with fertility medications if trying to conceive. If not, use oral\ncontraceptives.\nâ–  Tumors: Excision; medical therapy for prolactinomas (eg, cabergoline,\nbromocriptine).\nâ–  Premature ovarian insufficiency (<40 years of age): If the uterus is pres-\nent, treatment with combined oral contraceptives or estrogen plus proges-\ntin replacement therapy.\nPRIMARY DYSMENORRHEA\nMenstrual pain associated wit",
      "char_start": 1340000,
      "char_end": 1342000
    },
    {
      "chunk_id": 671,
      "text": "h ovulatory cycles in the absence of pathologic\nfindings. Caused by uterine vasoconstriction, anoxia, and sustained contrac-\ntions mediated by an excess of prostaglandin F Î± (PGF Î±).\n2 2\nHistory/PE\nâ–  Presents with low, midline, spasmodic pelvic pain that often radiates to the\nback or inner thighs\nâ–  Cramps that occur in the first 1 to 3 days of menstruation possibly associ-\nated with nausea, diarrhea, headache, and flushing\nâ–  No pathologic findings on pelvic examination\nDiagnosis\nA diagnosis of exclusion. Rule out secondary dysmenorrhea (see next section).\nTreatment\nNonsteroidal anti-inflammatory drugs (NSAIDs), topical heat therapy, com-\nbined hormonal contraception, progestin intrauterine device (IUD).\nSECONDARY DYSMENORRHEA\nMenstrual pain for which an organic cause exists. Common causes include\nendometriosis, adenomyosis, fibroids, adhesions, and pelvic inflammatory dis-\nease (PID).\nHistory/PE\nâ–  Patients may have a palpable uterine mass, cervical motion tenderness,\nadnexal tenderness, or vaginal or cervical discharge. However, normal\nabdominal and pelvic exams do not rule out pathology.\nâ–  See Table 2.11-3 for distinguishing features of endometriosis vs\nadenomyosis.\nDiagnosis\nThe most likely diagnosis is\npregnancy. It can be confirmed with â–  Obtain a Î²-hCG test to exclude ectopic pregnancy.\na Î²-human chorionic gonadotropic â–  Perform a pelvic examination to assess uterine size, tenderness, and consis-\n(Î²-hCG) test.\ntency and to evaluate for ovarian masses.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447744 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 475\nâ–  Order the following:\nâ–  Complete blood cell (CBC) count with differential to rule out\ninfection\nâ–  Urinalysis (UA) to rule out urinary tract infection (UTI)\nâ–  Gonococcal/chlamydial swabs to rule out sexually transmitted diseases\n(STDs)/PID KEY FACT\nâ–  Consider ultrasound to assess endometrium, uterus, and ovaries (look for Polyps are not associated with pain.\npel",
      "char_start": 1342000,
      "char_end": 1344000
    },
    {
      "chunk_id": 672,
      "text": "vic pathology causing pain [see Table 2.11-3]).\nTreatment\nTreatment is etiology specific.\nTABLE 2.11-3. Endometriosis vs Adenomyosis\nVARIABLE ENDOMETRIOSIS ADENOMYOSIS\nDefinition Functional endometrial glands and Endometrial tissue in the myo-\nstroma outside the uterus metrium of the uterus\nHistory/PE Cyclic pelvic and/or rectal pain and Classic triad of pain; heavy\ndyspareunia menstrual bleeding; and an\nUterus is not enlarged but on exam may enlarged, boggy, symmetric\nbe fixed in place; tender nodules may uterus\nbe palpated in posterior cul-de-sac\nDiagnosis Endometriosis requires direct visualiza- MRI can aid in diagnosis but\ntion by laparoscopy or laparotomy with can be costly\ntissue biopsy Ultrasonography is useful but\nClassic lesions have a blue-black cannot always distinguish\n(â€œraspberryâ€) or dark brown (â€œpowder- between leiomyoma and\nburnedâ€) appearance adenomyosis\nThe ovaries may have endometriomas Ultimately, adenomyosis is a\n(â€œchocolate cystsâ€) pathologic diagnosis\nTreatment Pharmacologic: Inhibition of ovulation; Pharmacologic: Largely\ncombination hormonal contraception symptomatic relief; NSAIDs\n(first-line), GnRH analogues (leuprolide), (first-line) plus combined\ndanazol, NSAIDs, or progestins hormonal contraception or\nConservative surgical treatment: Excision, progestins\ncauterization, or ablation of the lesions Conservative surgical treat-\nand lysis of adhesions ment: Endometrial ablation;\nDefinitive surgical treatment: Hysterec- however, complete eradica-\ntomy/bilateral salpingo-oophorectomy tion of deep adenomyosis is\n(TAH/BSO) Â± lysis of adhesions difficult and usually results\nin treatment failure\nDefinitive surgical treatment: A 28-year-old woman presents for\nHysterectomy is the only a wellness exam. She reports that\napproximately 2 weeks after her\ndefinitive treatment\nmenses, she experiences intense,\nsharp lower quadrant abdominal pain\nComplications Infertility (the most common cause Abnormal uterine bleeding,\nthat lasts a couple of hours. The pai",
      "char_start": 1344000,
      "char_end": 1346000
    },
    {
      "chunk_id": 673,
      "text": "n\namong menstruating women painful menses varies from the right to the left side\n>30 years of age) each cycle. What is the name of this\nphenomenon?\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447755 1100//2211//2222 44::1177 PPMM\n\n476 HIGH-YIELD FACTS IN GYNECOLOGY\nABNORMAL UTERINE BLEEDING\nâ–  Normal menstrual bleeding ranges from 2 to 7 days. Abnormal uterine\nbleeding (AUB) refers to alterations in quantity, duration, or frequency.\nClassified by the acronym PALM-COEIN.\nKEY FACT â–  PALM refers to structural causesâ€”Polyp, Adenomyosis, Leiomyoma,\nand Malignancy/hyperplasia.\nPostmenopausal vaginal bleeding is\ncancer until proven otherwise. â–  COEIN refers to nonstructural causesâ€”Coagulopathy, Ovulatory dys-\nfunction, Endometrial, Iatrogenic, and Not yet classified.\nHistory/PE\nâ–  Assess the extent of bleeding:\nâ–  Oligomenorrhea: An â†‘ length of time between menses (35â€“90 days\nbetween cycles)\nâ–  Polymenorrhea: Frequent menstruation (<21-day cycle)\nâ–  Heavy menstrual bleeding (previously termed menorrhagia): â†‘\namount of flow (>80 mL of blood loss per cycle) or prolonged bleeding\n(flow lasting >8 days). Heavy menstrual bleeding may lead to anemia.\nâ–  Intermenstrual bleeding (previously termed metrorrhagia): Bleeding\nbetween periods.\nâ–  Heavy prolonged menstrual bleeding (previously termed menome-\ntrorrhagia): Excessive and irregular bleeding.\nâ–  On pelvic examination, the physician should evaluate the uterus and the\ncervix for a potential etiology of the bleeding. An enlarged uterus may be\nsuggestive of pregnancy or uterine myomas. A cervical mass or other cervi-\ncal abnormalities are concerning for cervical malignancy, infection, or an\nendocervical or prolapsed endometrial polyp.\nDiagnosis\nâ–  Î²-hCG test to rule out pregnancy\nâ–  CBC to evaluate for anemia\nâ–  Pap smear to rule out cervical cancer\nâ–  Gonorrhea/chlamydia probe to rule out cervical bleeding from cervicitis\nâ–  Thyroid function tests and prolactin to rule out hyperthyroidism/hypothy-\nroidism",
      "char_start": 1346000,
      "char_end": 1348000
    },
    {
      "chunk_id": 674,
      "text": " and hyperprolactinemia\nâ–  Platelet count, prothrombin time (PT)/partial thromboplastin time (PTT)\nto rule out von Willebrand disease and factor XI deficiency, primarily in\nadolescent patients\nâ–  Ultrasonography to look for uterine masses and polycystic ovaries and to\nassess thickness of the endometrium\nâ–  Indications for an endometrial biopsy:\nâ–  If the endometrium is â‰¥4 mm in a postmenopausal woman or if the\npatient is >45 years of age.\nâ–  If the patient is >35 years of age with risk factors for endometrial\nhyperplasia (eg, obesity, diabetes).\nâ–  See Figure 2.11-4 for guidance on which premenopausal patients should\nhave an endometrial biopsy as part of their workup for AUB.\nâ–  See Figure 2.11-5 for guidance on management of endometrial biopsy\nresults.\nTreatment\nAcute heavy bleeding:\nThis is called mittelschmerz, pain at\novulation caused by progesterone â–  High-dose estrogen intravenously stabilizes the endometrial lining and\nproduction. It can switch sides,\ntypically stops bleeding within 1 hour. When bleeding stabilizes, the phy-\ndepending on which ovary ovulates\nsician can transition patient to combined oral contraceptive or add\nin a given cycle.\nprogestin.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447766 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 477\nâ–  If estrogen is contraindicated, the physician can give high-dose progestin KEY FACT\ntherapy alone.\nFor acute life-threatening AUB:\nâ–  If bleeding is not controlled within 12 to 24 hours, dilation and curettage â–  IV estrogen best for adolescent/\n(D&C) may be indicated.\nyounger patients\nOvulatory bleeding (excessive bleeding associated with normal men- â–  Consider surgical management\nstrual cycles): (D&C) as first-line treatment for\npatients >45 years of age for whom\nâ–  NSAIDs â†“ blood loss. thorough endometrial sampling\nâ–  Tranexamic acid can be given for 5 days during menses. is indicated and/or in whom the\nâ–  If the patient is hemodynamically stable, the physician can",
      "char_start": 1348000,
      "char_end": 1350000
    },
    {
      "chunk_id": 675,
      "text": " prescribe oral cardiovascular risk of systemic\ncontraceptive pills (OCPs), oral or injectable progestin, or insertion of a\nintravenous (IV) estrogen is high.\nprogestin IUD.\nAnovulatory bleeding:\nâ–  Goal: Convert proliferative endometrium to secretory endometrium (to â†“\nthe risk for endometrial hyperplasia/cancer)\nKEY FACT\nâ–  Progestins for 10 days to stimulate withdrawal bleeding\nâ–  Combined hormonal contraception Combined hormonal contraception\nâ–  Progestin IUD and the progesterone-containing IUD\nare highly effective treatment options\nIf medical management fails:\nfor non-life-threatening menorrhagia.\nâ–  D&C\nâ–  Hysteroscopy to identify endometrial polyps or to perform directed uterine\nbiopsies\nAbnormal uterine bleeding (AUB)\nHistory and physical exam\nPregnancy test, Abnormal Manage other\nTSH and prolactin levels cause of AUB\nRule out other causes:\nSystemic disease\nMedication effects\nCervical pathology\nInfection\nConcern for endometrial\npathology\nAge <35\nAge <35 Age â‰¥35\nRisks of\nNo risks of endometrial cancer* Suspected anovulation\nendometrial cancer*\nTrial of combination oral Continued irregular\nbleeding\ncontraceptives, cyclic progestin Endometrial biopsy\nor medroxyprogesterone acetate\n*Risk factors for endometrial cancer: chronic anovulatory cycles, obesity, nulliparity,\ndiabetes mellitus, tamoxifen therapy\nFIGURE 2.11-4. Evaluation of abnormal uterine bleeding. (Reproduced with permission from USMLE-Rx.\ncom.)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447777 1100//2211//2222 44::1177 PPMM\n\n478 HIGH-YIELD FACTS IN GYNECOLOGY\nEndometrial biopsy\nNormal endometrium Hyperplasia without atypia Hyperplasia with atypia Endometrial carcinoma\nCombination oral contraceptive Medroxyprogesterone\npills, cyclic progestin, or acetate, megestrol Refer to gynecologic oncologist\nmedroxyprogesterone acetate or levonorgestrel IUD\nRepeat endometrial If continued irregular bleeding\nBleeding resolves Bleeding continues\nbiopsy in 3â€“6 months\nTransvaginal ultr",
      "char_start": 1350000,
      "char_end": 1352000
    },
    {
      "chunk_id": 676,
      "text": "asound\nand surgical therapy\n(ablation, myomectomy\nor hysterectomy)\nFIGURE 2.11-5. Management of endometrial biopsy results. (Reproduced with permission from USMLE-Rx.com.)\nKEY FACT â–  Uterine artery embolization, hysterectomy, or endometrial ablation appro-\npriate for females:\nComplications of AUB include anemia.\nPresence of AUB raises concern for â–  For whom hormonal treatment fails\nunderlying endometrial hyperplasia â–  Who no longer desire fertility\nand/or carcinoma. â–  Who have symptomatic anemia and/or who experience a disruption in\ntheir quality of life from persistent, unscheduled bleeding\nKEY FACT\nCONTRACEPTION\nMultiple sexual partners and nulliparity\nare not absolute contraindications to\nEighty-five percent of sexually active women with no contraception will\nIUD use.\nbecome pregnant within 1 year. Table 2.11-4 describes the effectiveness of con-\ntraceptive methods along with their relative advantages and disadvantages. See\nTable 2.11-5 for contraindications to common methods of contraception. Emer-\nKEY FACT gency contraception (EC) methods prevent pregnancy after unprotected sex or\ncontraceptive failure. Table 2.11-6 describes the various methods of EC.\nCombined hormonal methods of\ncontraception decrease the risk for\nendometrial and ovarian cancers.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447788 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 479\nTABLE 2.11-4. Contraceptive Methods\nMETHOD MECHANISM ADVANTAGES DISADVANTAGES\nMOST EFFECTIVE: >99%\nCopper intrauterine Foreign body results in Effective for up to 10 years â†‘ cramping and heavier bleeding (5%â€“10%)\ndevice (IUD) inflammation; copper has Immediate fertility once removed Risk for uterine perforation (1/100)\na spermicidal effect No hormonal exposure â†‘ risk for ectopic pregnancy (rare)\nSafe with breastfeeding\nImplant (progestin-only Inhibits ovulation; â†‘ cervical Effective for up to 3 years Irregular periods, scarring at site of insertion\nimplant) mucus v",
      "char_start": 1352000,
      "char_end": 1354000
    },
    {
      "chunk_id": 677,
      "text": "iscosity Immediate fertility once removed (upper arm)\nSafe with breastfeeding\nLighter periods\nIUD with progestin Progesterone leads to Effective for 3â€“8 years depending Spotting (up to 6 months), acne\ncervical mucus thick- on type of P4-IUD Risk for uterine perforation (1/100)\nening and endometrial Immediate fertility once removed â†‘ risk for ectopic pregnancy (rare)\ndecidualization Safe with breastfeeding\nLighter periods; less cramping\nSurgical sterilization Permanently effective; safe with Tubal ligation: Irreversible; â†‘ risk for ectopic\n(vasectomy, tubal breastfeeding pregnancy (rare)\nligation) Vasectomy: Most failures result from not\nwaiting for two âŠ– semen samples\nVERY EFFECTIVE: 90%â€“99%\nOCPs (combina- Inhibit FSH/LH, suppressing â†“ risk for ovarian and endometrial Requires daily compliance\ntion estrogen and ovulation; thicken cer- cancersa Breakthrough bleeding (10%â€“30%)\nprogestin) vical mucus; decidualize Predictable, lighter, less painful Thromboembolism risk (especially in\nendometrium menses smokers >35 years of age)\nCan improve acne Cannot be used in patients of any age who\nhave migraines with aura\nHTN, gastroesophageal reflux disease (pro-\ngesterone relaxes the lower esophageal\nsphincter)\nTransdermal patch (â€œthe Same as OCPs Predictable, lighter, less painful Thromboembolism risk (especially in\npatchâ€) menses smokers >35 years of age, patients with\nWeekly administration chronic hypertension [HTN])\nVaginal ring Same as OCPs Can make periods more regular May â†‘ vaginal discharge\nCan be placed intravaginally for Spotting (first 1â€“2 months)\n3 weeks; removed for 1 week Thromboembolism risk (especially in\n(menses will occur during this smokers >35 years of age, patients with\ntime) chronic HTN)\nMedroxyprogesterone Intramuscular (IM) injection Lighter or no periods Irregular bleeding, weight gain\n(progestin) Each shot works for 3 months Decreases in bone mineral density ([BMD],\nSuppresses ovulation reversible)\nand decidualizes Delayed fertility after discontinuation",
      "char_start": 1354000,
      "char_end": 1356000
    },
    {
      "chunk_id": 678,
      "text": " (up to\nendometrium 10 months)\nProgestin-only â€œminipillsâ€ Thicken cervical mucus Safe with breastfeeding Requires strict compliance with daily timing\n(continues)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 447799 1100//2211//2222 44::1177 PPMM\n\n480 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-4. Contraceptive Methods (continued)\nMETHOD MECHANISM ADVANTAGES DISADVANTAGES\nMODERATELY EFFECTIVE: 75%â€“90%\nMale condoms A latex sheath covering the The only method that effectively Possible allergy to latex or spermicides\npenis protects against pregnancy and\nSTDs, including HIV\nDiaphragm with A barrier inserted over the Some protection against STDs Must be fitted by the provider\nspermicide cervix to prevent entry of\nsperm\nFemale condom A barrier sheath that is Some protection against STDs Can be difficult to use\ninserted into the vagina\nFertility awareness Sexual intercourse is No adverse effects Not reliable for patients with irregular\nmethods (natural avoided on days during menses\nfamily planning) the menstrual cycle on Requires close monitoring of ovulation\nwhich conception is indicators (cervical mucus, basal body\nlikely (near the time of temperature, cycle length)\novulation) No STD/HIV protection\nLESS EFFECTIVE: 68%â€“74%\nWithdrawal Removal of the penis before No adverse effects No STD/HIV protection\nejaculation Not recommended as a primary method\nSpermicide A substance that inhibits May be used as a secondary Not recommended as a primary method\nsperm motility method\naOther combined hormonal methods (eg, patch, ring) may also protect against endometrial and ovarian cancers; however, data are still lacking,\ngiven their relatively recent introduction.\nTABLE 2.11-5. Contraindications to Common Methods of Contraception\nESTROGEN-CONTAINING HORMONAL METHODSa IUDS (PROGESTERONE AND COPPER)\nPregnancy/breastfeeding Severe uterine structural abnormality\nHistory of stroke, hypertension, deep venous (bicornuate, septate)\nthrombosis/pulmonary embolism ",
      "char_start": 1356000,
      "char_end": 1358000
    },
    {
      "chunk_id": 679,
      "text": "Known or suspected pregnancy\nUnexplained vaginal/uterine bleeding Active gynecologic infection (within\nEstrogen-dependent (eg, breast) cancer 3 months)\nBenign or malignant liver neoplasm Unexplained vaginal/uterine bleeding\nAbnormal liver function Suspected gynecologic malignancy\nCurrent tobacco use and >35 years of age Copper IUD alone:\nMigraine with visual aura â–  Copper intolerance (allergy, Wilson\nDiabetic retinopathy or neuropathy disease)\nâ–  Severe dysmenorrhea and/or\nmenorrhagia\nProgestin IUD alone:\nâ–  Levonorgestrel allergy\nâ–  Breast cancer\nâ–  Acute liver disease or liver tumor\naIncludes OCPs, vaginal ring, and transdermal patch.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448800 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 481\nTABLE 2.11-6. Emergency Contraceptive Methods\nMETHOD AND MECHANISM ADVANTAGES DISADVANTAGESa\nUlipristal: Selective progesterone receptor Does not disrupt embryo postimplantation Expensive\nantagonist; delays ovulation; can be used up to Safe for all patients Requires a prescription\n120 hours after intercourse Very effective\nCan be used in active pelvic infection\nCan be used longer after intercourse\nMore effective due to 2 mechanisms of\naction\nPreferred in patients with higher BMI\nLevonorgestrel: A progestin-only pill that delays Fewer nausea/vomiting adverse effects than Less effective than other methods\novulation; must be used within 72 hours of an oral contraceptive taper Shorter window after intercourse for\nintercourse Available without a prescription efficacy\nOral contraceptive taper: Delays ovulation; Useful for patients who have OCPs at home Nausea, vomiting, fatigue, headache,\nmost effective within 72 hours of inter- dizziness, breast tenderness\ncourse but can be used up to 120 hours after Requires a prescription\nintercourse\nCopper IUD: Copper particles disrupt sperm The most effective emergency contraceptive High initial cost of insertion\nand ovum function, preventing fusion; ma",
      "char_start": 1358000,
      "char_end": 1360000
    },
    {
      "chunk_id": 680,
      "text": "y method (99% effective) Must be inserted by the provider\nprevent implantation; can be used up to 7 days Can be used as emergency contracep- Should test for pregnancy and STIs before\nafter intercourse tive and continued for up to 10 years of insertion\ncontraception Cannot be placed during active infection\naNone of these methods provides protection from or treatment for HIV or other sexually transmitted infections.\nKEY FACT\nREPRODUCTIVE ENDOCRINOLOGY\nIn CAH, .if the first number in the name\nof the deficient enzyme is a 1, it is\nCONGENITAL ADRENAL HYPERPLASIA\nassociated with hypertension. If the\nsecond number is a 1, it is associated\nCAH is a deficiency of at least one enzyme required for the biochemical syn-\nwith hyperandrogenism.\nthesis of cortisol from cholesterol (see Fig. 2.11-6 and Table 2.11-7). Includes\nthe following:\nâ–  21-Hydroxylase deficiency: Accounts for âˆ¼90% of CAH cases. â€œClassicâ€\nform is most severe and presents as a newborn female with ambiguous genita-\nlia and adrenal insufficiency (with or without life-threatening salt wasting).\nâ€œNonclassicâ€ is a late-onset form that presents with androgen excess, or it\ncould be asymptomatic. Cannot convert 17-hydroxyprogesterone to\n11-deoxycortisol â†’ â†“ cortisol synthesis â†’ â†‘ adrenal stimulation â†’ â†‘ ACTH\nand androgens.\nâ–  11Î²-Hydroxylase deficiency: Second most common cause of adrenal\nhyperplasia. Cannot convert 11-deoxycortisol to cortisol or 11-deoxycorti-\ncosterone to corticosterone, also leading to â†‘ ACTH and androgens.\nHistory/PE\nAndrogen excess: Genital ambiguity, premature pubarche, menstrual irregu-\nlarity, infertility, hirsutism, acne, and, rarely, a palpable abdominal mass.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448811 1100//2211//2222 44::1177 PPMM\n\n482 HIGH-YIELD FACTS IN GYNECOLOGY\nCholesterol (via StARa)\nCholesterol desmolase\n17Î±-hydroxylase 17Î±-hydroxylase\nPregnenolone 17-hydroxypregnenolone Dehydroepiandrosterone (DHEA)\n3Î²-hydroxysteroid\ndehydrogenase\n17Î±-hydr",
      "char_start": 1360000,
      "char_end": 1362000
    },
    {
      "chunk_id": 681,
      "text": "oxylase 17Î±-hydroxylase\nAromatase\nProgesterone 17-hydroxyprogesterone Androstenedione Estrone\nAnastrozole,\n21-hydroxylase\nexemestane\nAromatase\n11-deoxycorticosterone 11-deoxycortisol Testosterone Estradiol\n11Î²-hydroxylase\n5Î±-reductase\nCorticosterone Cortisol Dihydrotestosterone\n(DHT)\nAldosterone synthase Glycyrrhetinic acid\nFinasteride\nAldosterone Cortisone\nAngiotensin II\nZONA GLOMERULOSA ZONA FASCICULATA ZONA RETICULARIS PERIPHERAL TISSUE\nMineralocorticoids Glucocorticoids Androgens Estrogens, DHT\nCapsule Medulla\nAdrenal gland\nCortex\n*StAR: Steroidogenic acute regulatory protein. Rate limiting step in steroid synthesis.\nFIGURE 2.11-6. Glucocorticoid biosynthesis pathway. (Modified with permission from USMLE-Rx.com.)\nDiagnosis\nâ–  Physical examination\nâ–  21-Hydroxylase deficiency: â†‘17-OH progesterone levels (a substrate for\n21-hydroxylase). This is part of the newborn screen. Cosyntropin (ACTH)\nstimulation testâ€”gold standard but not necessary if â†‘â†‘ 17-OH.\nâ–  11ð›ƒ-Hydroxylase deficiency: â†‘ serum 11-deoxycortisol and\n11-deoxycorticosterone.\nâ–  Both: Next, assessment of the following levels:\nâ–  Cortisol â†’ decreased.\nKEY FACT\nâ–  Androstenedione â†’ elevated in 21-hydroxylase and 11Î²-hydroxylase\ndeficiency [right arrow] elevated. Also consider adrenal/ovarian\n21-Hydroxylase deficiency can\nneoplasm.\npresent with hypotension, whereas\n11Î²-hydroxylase and 17-hydroxylase â–  Dehydroepiandrosterone ([DHEA]) â†’ elevated in 21-hydroxylase and\n11Î²-hydroxylase deficiency [right arrow] elevated. Also consider adre-\ndeficiencies can present with\nnal neoplasm, Cushing syndrome.\nhypertension caused by accumulation\nof deoxycorticosterone. â–  If salt wasting: Will also have â†“ aldosterone, â†“ sodium, â†‘ potassium, and\nâ†‘ renin associated with hypovolemia.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448822 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 483\nTABLE 2.11-7. Overview of Congenital Adrenal Hyperplasia\nSEX\nENZYME DEFICIENCY MINERALOCORTICOIDS ",
      "char_start": 1362000,
      "char_end": 1364000
    },
    {
      "chunk_id": 682,
      "text": "CORTISOL HORMONES BP [K+] LABS PRESENTATION\n17Î±-hydroxylasea â†‘ â†“ â†“ â†‘ â†“ â†“ androstenedione XY: Ambiguous geni-\ntalia, undescended\ntestes\nXX: Lacks sec-\nondary sexual\ndevelopment\n21-hydroxylasea â†“ â†“ â†‘ â†“ â†‘ â†‘ renin activity Most common\nâ†‘ 17-hydroxypro- Presents in infancy\ngesterone (salt wasting) or\nchildhood (preco-\ncious puberty)\nXX: Virilization\n11Î²-hydroxylasea â†“ aldosterone â†“ â†‘ â†‘ â†“ â†“ renin activity XX: Virilization\nâ†‘ 11-deoxycortico-\nsterone (results\nin â†‘ BP)\naAll congenital adrenal enzyme deficiencies are characterized by an enlargement of both adrenal glands and hyperpigmentation caused by â†‘\nACTH stimulation (caused by â†“ cortisol).\nModified with permission from Le T et al. First Aid for the USMLE Step 1 2022. New York, NY: McGraw-Hill; 2022.\nTreatment\nâ–  Glucocorticoids (eg, dexamethasone). Medical therapy for adrenal and\novarian disorders prevents new terminal hair growth but does not resolve\nhirsutism.\nâ–  Addition of mineralocorticoid therapy (eg, fludrocortisone) if salt wasting\nor hypotension is present.\nâ–  Laser ablation, electrolysis, or conventional hair removal techniques for\nremoval of unwanted hair.\nPOLYCYSTIC OVARIAN SYNDROME\nA syndrome of excess testosterone and excess estrogen, PCOS has a preva-\nlence of 6% to 10% among U.S. females of reproductive age and is the most MNEMONIC\ncommon cause of infertility in females. Diagnosis requires fulfillment of two\nThe most severe form of PCOS is\nof the following three (Rotterdam criteria):\nHAIR-AN syndrome:\nâ–  Polycystic ovaries (via ultrasonography) HyperAndrogenism, Insulin\nâ–  Oligo-ovulation and/or anovulation Resistance, and Acanthosis\nâ–  Clinical and/or biochemical evidence of hyperandrogenism Nigricans.\nHistory/PE\nâ–  Common presentation: Obesity (body mass index [BMI] >30 kg/m2),\nmenstrual cycle disturbances, infertility, acne, androgenic alopecia, and\nhirsutism from hyperandrogenism\nâ–  Females with PCOS also at â†‘ risk for the following:\nâ–  DM type 2: Acanthosis nigricans possibly seen on examination\nâ–  Metabolic sy",
      "char_start": 1364000,
      "char_end": 1366000
    },
    {
      "chunk_id": 683,
      "text": "ndrome: Insulin resistance, atherogenic dyslipidemia,\nand hypertension\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448833 1100//2211//2222 44::1177 PPMM\n\n484 HIGH-YIELD FACTS IN GYNECOLOGY\nDiagnosis\nâ–  Biochemical testing of hyperandrogenemia: â†‘ testosterone\nâ–  â†‘ free testosterone more sensitive than total testosterone (total can be\nnormal) because of low sex hormoneâ€“binding globulin\nâ–  Excluding other causes of hyperandrogenism: DHEAS to rule out adre-\nnal tumor\nâ–  Pelvic ultrasound to rule out androgen-secreting ovarian tumor\nâ–  17-Hydroxyprogesterone to rule out nonclassical CAH\nâ–  Screening in the setting of clinical signs of Cushing syndrome (eg, moon\nfacies, buffalo hump, abdominal striae) or acromegaly (eg, â†‘head size)\nâ–  Evaluation for metabolic abnormalities:\nFIGURE 2.11-7. Polycystic ovary with\nâ–  Two-hour oral glucose tolerance test\nprominent multiple cysts. (Reproduced with\npermission from DeCherney AH, Nathan R. Current â–  Fasting lipid and lipoprotein levels (total cholesterol, HDL, LDL,\nDiagnosis & Treatment: Obstetrics & Gynecology, 10th ed. triglycerides)\nNew York, NY: McGraw-Hill; 2007.) â–  Optional tests: Not necessary if both oligomenorrhea and signs of hyper-\nandrogenism are present\nâ–  Transvaginal ultrasonography: Look for more than 11 small\n(2â€“9 mm), subcapsular follicles forming a â€œpearl necklaceâ€ sign (see\nFig. 2.11-7). Seen in roughly two thirds of females with PCOS.\nâ–  Gonadotropins: â†‘ LH/FSH ratio (>2:1)\nâ–  24-hour urine for free cortisol: Adult-onset CAH or Cushing syndrome\nTreatment\nâ–  Females who are not attempting to conceive: The physician can treat\nthese patients with combined hormonal contraception or progestin Â± an\nantiandrogen like spironolactone if there are symptoms of hyperandrogen-\nism. Patients with metabolic syndrome or insulin resistance may benefit\nfrom the addition of metformin.\nâ–  Females who are attempting to conceive: Letrozole (aromatase inhibitor)\nÂ± metformin is first-line treatment for ovulato",
      "char_start": 1366000,
      "char_end": 1368000
    },
    {
      "chunk_id": 684,
      "text": "ry stimulation. Clomiphene\n(selective estrogen receptor modulator) is second-line.\nâ–  Symptom-specific treatment:\nâ–  Hirsutism: Combination OCPs first line; antiandrogens (spironolac-\ntone, finasteride) and metformin\nâ–  Obesity, cardiovascular risk factors, lipid levels: Diet, weight loss (can\nalso help regulate ovulation), and exercise plus potentially lipid-\ncontrolling medication (eg, statins)\nComplications\nKEY FACT\nâ–  Infertility\nCombined hormonal contraception â–  Miscarriage\nor progestin â†“ the risk for endometrial â–  Type 2 DM\nhyperplasia/carcinoma among women â–  Metabolic syndrome\nwith PCOS. â–  â†‘ long-term risk for breast and endometrial cancers because of unopposed\nestrogen secretion\nINFERTILITY\nKEY FACT\nFemale causes of infertility are more â–  Definition:\ncommon than male causes. An â–  The inability to conceive after 12 months of regular, unprotected sex-\ninvestigation should begin with history ual intercourse in women <35 years of age\n(including menstrual) and physical â–  The inability to conceive after 6 months of regular, unprotected sexual\nexamination of the female and then intercourse in women â‰¥35 years of age\nprogress to semen analysis before â–  Primary infertility characterized by no prior pregnancies; secondary infer-\nfurther workup in the female, as semen tility distinguished by at least one prior pregnancy. Etiologies are shown in\nanalysis is simple and noninvasive. Figure 2.11-8 and Table 2.11-8.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448844 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 485\nPrimary hypogonadism\n(â†‘ FSH)\n30%â€“40%\nSecondary hypogonadism\n(â†“ FSH, â†“ LH)\nMale causes 25% 2%\nDisordered sperm transport\n10%â€“20%\nUnknown\nHypothalamic/\n40%â€“50%\npituitary causes\n51%\nInfertility Unexplained 17%\nPolycystic ovary syndrome\nAmenorrhea/ 30%\novulatory dysfunction\n46%\nPremature ovarian failure\n12%\nTubal defect\n38%\nFemale causes 58% Uterine or outflow\ntract disorders\nEndometriosis 7%\n9%\nOther\n7%\nFIGURE 2.11-8.",
      "char_start": 1368000,
      "char_end": 1370000
    },
    {
      "chunk_id": 685,
      "text": " Causes of infertility. (Reproduced with permission from USMLE-Rx.com.)\nTABLE 2.11-8. Infertility Workup\nETIOLOGY HISTORY/PE DIAGNOSIS TREATMENT\nMale factors Testicular injury or infection Semen analysis Treatment of hormonal deficiency\nMedications (corticosteroids, cimeti- TSH Intrauterine insemination (IUI)\ndine, spironolactone) Prolactin Donor insemination\nPituitary, thyroid, or liver disease Karyotyping (to rule out Klinefelter In vitro fertilization (IVF)\nSigns of hypogonadism syndrome) Intracytoplasmic sperm injection\nVaricocele\nOvulatory â†‘ incidence with age Menstrual history Treatment depends on the etiology\nfactors Symptoms of hyperthyroidism/ Basal body temperature (eg, levothyroxine, dopamine)\nhypothyroidism Ovulation predictor Induction of ovulation with clomi-\nGalactorrhea Midluteal progesterone phene, gonadotropins\nMenstrual cycle abnormalities Early follicular FSH Â± estradiol level (ovarian IUI\nPituitary tumors reserve) IVF\nTSH, prolactin, androgens\nOvarian sonography (antral follicle count)\nEndometrial biopsy (luteal-phase defect)\nTubal/pelvic History of PID, appendicitis, endo- Hysterosalpingogram Laparoscopic resection or ablation of\nfactors metriosis, pelvic adhesions, tubal Potential laparoscopy endometriomas or fibroids\nsurgery IVF\nCervical Cryotherapy, conization, or diethyl- Physical exam IUI\nfactors stilbestrol (DES) exposure in utero IVF\nUterine Polyps Ultrasound Surgical treatment\nfactors Fibroids Hysterosalpingogram\nCongenital anomalies\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448855 1100//2211//2222 44::1177 PPMM\n\n486 HIGH-YIELD FACTS IN GYNECOLOGY\nMENOPAUSE\nCessation of menses for a minimum of 12 months as a result of follicular\ndepletion.\nHistory/PE\nâ–  The average age of onset is 51 years.\nâ–  Symptoms include hot flashes, pruritus, vaginal dryness caused by vaginal\natrophy, insomnia, anxiety/irritability, poor concentration, mood changes,\ndyspareunia, and loss of libido.\nâ–  â€œPremature menopauseâ€ (als",
      "char_start": 1370000,
      "char_end": 1372000
    },
    {
      "chunk_id": 686,
      "text": "o known as premature ovarian insufficiency)\nis cessation of menses before 40 years of age.\nDiagnosis\nA clinical diagnosis. The following studies are not routine but may be helpful:\nâ–  Labs: â†‘ FSH\nâ–  Serum TSH should be measured because of overlap of symptoms and\ncommon age of presentation of hypothyroidism and menopause\nTreatment\nâ–  Best initial treatment: HRT (combination estrogen and progestin) in\nsymptomatic patients without contraindications <60:\nâ–  Short-term use associated with a decrease in all-cause mortality.\nRisk:benefit ratio changes based on individual risk factors when consid-\nering continuing therapy long-term\nâ–  May â†‘ the incidence of breast cancer with long-term use at high doses\nâ–  May â†‘ cardiovascular mortality if initiated at age >60 and/or greater\nthan 10 years from the menopausal transition\nâ–  Contraindications: Vaginal bleeding, breast cancer (known or sus-\npected), untreated endometrial cancer, history of thromboembolism,\nchronic liver disease, hypertriglyceridemia, known coronary artery\ndisease\nâ–  Non-HRT (for those with contraindications to HRT listed earlier):\nSelective serotonin reuptake inhibitors (SSRIs)/serotonin-norepinephrine\nreuptake inhibitors (SNRIs), clonidine, and/or gabapentin to â†“ the fre-\nquency of hot flashes\nâ–  Topical estrogen preparation: Useful for vaginal atrophy; topical estro-\nKEY FACT gen preparation does NOT have the same contraindications as systemic\nHRT\nPostmenopausal women should be\nroutinely screened for osteoporosis, â–  Calcium supplements Â± bisphosphonates: Useful for osteoporosis; dual-\nenergy x-ray absorptiometry (DEXA) scan is used to measure bone mineral\nstarting at 65 years of age or earlier if\ndensity (BMD); supplemental treatment includes daily calcium/vitamin D\nthere are additional risk factors.\nand weight-bearing exercise\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448866 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 487\nGYNECOLOGIC DISORDERS\nCYST AND ABSCESS",
      "char_start": 1372000,
      "char_end": 1374000
    },
    {
      "chunk_id": 687,
      "text": " OF THE BARTHOLIN DUCT\nObstruction of the Bartholin duct may lead to cyst formation, as mucus con-\ntinues to accumulate behind the obstruction, causing cystic dilation. An\nobstructed Bartholin duct that becomes infected can develop a polymicrobial\nabscess.\nHistory/PE\nâ–  Cysts: 1 to 3 cm in size, unilateral, and often asymptomatic. Larger cysts\nlead to periodic, painful swelling and dyspareunia.\nâ–  Clinical diagnosis: Mass at medial labia majora or lower vestibular area\non physical examination.\nâ–  Abscess: Extremely painful, warm, fluctuant mass at medial labia majora\nor lower vestibule with possible cellulitis and fever.\nTreatment\nâ–  Asymptomatic cysts: No therapy Â± warm soaks. The physician can con-\nsider drainage and biopsy if patient >40 years of age to exclude\ncarcinoma.\nâ–  Abscess: Aspiration or incision and drainage to prevent reaccumulation.\nThe physician should order tests for gonorrhea and chlamydia and other\npathogens.\nâ–  Antibiotics are unnecessary unless cellulitis or sexually transmitted infec-\ntion (STI) is present.\nVAGINITIS\nA spectrum of conditions that cause vulvovaginal symptoms such as itching,\nburning, irritation, and abnormal discharge. The most common causes are\nbacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis (see\nTable 2.11-9).\nHistory/PE\nâ–  Presents with a change in discharge, malodor, pruritus, irritation, burning,\nswelling, dyspareunia, and dysuria\nâ–  Normal secretions as follows:\nâ–  Midcycle estrogen surge: Clear, elastic, mucoid secretions\nâ–  Luteal phase/pregnancy: Thick and white secretions that adhere to the\nvaginal wall\nâ–  A thorough examination of the vulva, vaginal walls, and cervix\nâ–  Many WBCs and no organism on saline smearâ€”suspect Chlamydia tra-\nchomatis, an intracellular organism\nA 56-year-old woman presents with\npresents with insomnia, vaginal\ndryness, and lack of menses for\n13 months. What is the most likely\ndiagnosis?\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448877 1100//2211//22",
      "char_start": 1374000,
      "char_end": 1376000
    },
    {
      "chunk_id": 688,
      "text": "22 44::1177 PPMM\n\n488 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-9. Causes of Vaginitis\nVARIABLE BACTERIAL VAGINOSIS TRICHOMONIASIS CANDIDIASIS\nIncidence 15%â€“50% (most common) 5%â€“50% 15%â€“30%\nEtiology Not an infection: shift in vaginal flora Protozoal flagellates (an STD) Usually Candida albicans\n(â†‘ anaerobes such as Gardnerella\nvaginalis, â†“ lactobacilli)\nRisk factors Pregnancy, multiple sexual partners, Unprotected sex with multiple DM, antibiotic use, pregnancy, corti-\nfemale sexual partner, frequent partners costeroids, HIV, OCP use, frequent\ndouching intercourse, tight-fitting clothing\nHistory â€œFishyâ€ odor, thin homogenous white â†‘ yellow-green discharge, odor, Pruritus, dysuria, burning, cottage\nor gray discharge pruritus, dysuria cheese discharge\nExamination Mild vulvar irritation, thin homog- â€œStrawberry petechiaeâ€ in the Erythematous, excoriated vulva/vagina\nenous white or gray discharge; pH upper vagina/cervix; pH >4.5 with cottage cheese discharge; pH\n>4.5 <4.5 (normal)\nDischarge Homogeneous, grayish-white with Profuse, malodorous, yellow- Thick, white, curdy texture without\nâ€œfishyâ€/stale odor green, frothy odor\nWet mount â€œClue cellsâ€ (epithelial cells coated with Motile trichomonads (flagellated Budding yeast or hyphae\nbacteria [see red arrows in Image A]) organisms slightly larger than\nWBCs [see Image B])\nKOH prep âŠ• â€œWhiffâ€ test (â€œfishyâ€ odor) N/A Pseudohyphae (see Image C)\nTreatment Oral (PO) or vaginal metronidazole or Single-dose PO metronidazole or Topical azole or PO fluconazole\nvaginal clindamycin tinidazole for both partners\nTreatment of partners; otherwise,\na â€œping-pong effectâ€\nComplications Chorioamnionitis/endometritis, infec- Same as for bacterial vaginosis\ntion, preterm delivery, PID\nA B C\nA B C\nImage A reproduced with permission from USMLE-Rx.com. Image B adapted with permission from the US Department of Health and Human Services.\nImage C reproduced with permission from Wolff K et al. Fitzpatrickâ€™s Color Atlas & Synopsis of Clinical Dermatology",
      "char_start": 1376000,
      "char_end": 1378000
    },
    {
      "chunk_id": 689,
      "text": ", 5th ed. New York, NY: McGraw-Hill; 2005.\nThe most likely diagnosis is\nmenopause. Menopause is a clinical\ndiagnosis determined retrospectively\nafter 12 months of amenorrhea Diagnosis/Treatment\nwithout any other obvious physiologic\nor pathologic cause. However, a â–  Vaginal fluid for vaginal pH, amine (\"whiff\") test, wet mount (with saline),\nand 10% potassium hydroxide (KOH) microscopy (Fig. 2.11-9).\nphysician trying to rule out menopause\nas a cause of secondary amenorrhea â–  If purulent discharge, numerous leukocytes on wet prep, cervical friability,\nmay consider ordering an FSH level. and any symptoms of PID: Nucleic acid amplification testing (NAAT) or\nElevation is suggestive of menopause.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448888 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 489\nVaginal pH\npH >4.5 Normal pH (4.0â€“4.5)\nKOH prep KOH prep\nNegative amine\nPositive amine Negative amine (whiff) test\n(whiff) test (whiff) test\nWet mount Wet mount Wet mount\nClue cells compose Motile\n>20% of epithelial cells trichomonads Pseudohyphae Normal KEY FACT\nBacterial Trichomaniasis Vulvovaginal Normal fluid Criteria for the clinical diagnosis of\nvaginosis candidiasis\nbacterial vaginosis (three of four are\nrequired):\nFIGURE 2.11-9. Using vaginal pH and wet mount to diagnose common vaginal infections.\nâ–  Abnormal whitish-gray discharge\n(Reproduced with permission from USMLE-Rx.com.)\nâ–  Vaginal pH >4.5\nâ–  âŠ• amine (\"whiff\") test\ncultures for Neisseria gonorrhoeae or C trachomatis to rule out cervicitis.\nâ–  Clue cells composing >20% of\nNAAT is the gold-standard test.\nepithelial cells on wet mount\nâ–  Treatment: Etiology specific (see Table 2.11-9).\nCERVICITIS\nInflammation of the uterine cervix. Etiologies are as follows:\nâ–  Infectious (most common):\nâ–  C trachomatis and N gonorrhoeae are most common.\nâ–  C trachomatis is more common than N gonorrhoeae in mucopurulent\ncervicitis. KEY FACT\nâ–  Trichomonas and herpes simplex virus (HSV) are ",
      "char_start": 1378000,
      "char_end": 1380000
    },
    {
      "chunk_id": 690,
      "text": "less common causes\nGenital ulcers:\nof cervicitis.\nâ–  Noninfectious: Trauma, radiation exposure, malignancy â–  Treponema pallidum causes single\npainless chancres.\nâ–  All sexually active women <25 years of age should undergo yearly screening\nfor C trachomatis and N gonorrhoeae because of increased rates of asymp- â–  Haemophilus ducreyi (dooÂ·krayÂ·ee)\ncauses deep painful ulcers with\ntomatic infection and increased risk for infertility in untreated infections.\nirregular borders (you â€œdo cryâ€).\nHistory/PE â–  HSV causes multiple shallow\npainful ulcers.\nMucopurulent discharge; âŠ• cervical motion tenderness; absence of other\nsigns of PID\nDiagnosis and Treatment\n1\nRelevant discussion of STIs in the Renal/Genitourinary chapter. If mucopuru-\nlent discharge is present, empiric treatment for both C trachomatis and N\nA 20-year-old woman is diagnosed\ngonorrhoeae is warranted.\nwith trichomoniasis and prescribed\nan antibiotic. She calls her physician,\nPELVIC INFLAMMATORY DISEASE reporting of flushing, nausea, and\nemesis. What antibiotic was the\npatient prescribed, and what should\nPID is a polymicrobial infection of the upper genital tract associated with\nshe have been warned of?\nN gonorrhoeae (one third of cases), C trachomatis (one third of cases), and\nendogenous aerobes/anaerobes. Risk factors include uterine instrumentation\nor procedure, douching, smoking, multiple sex partners, and prior STDs and/\n2\nor PID. Most cases are not secondary to STDs.\nA 23-year-old woman presents\nHistory/PE\nwith fever and abdominal pain of 2\nâ–  Presents with lower abdominal pain, fever, chills, menstrual disturbances, daysâ€™ duration. She has a âŠ• cervical\nand purulent cervical discharge motion tenderness. Antibiotics are\nâ–  Cervical motion tenderness and adnexal tenderness started. What is the next step in\nâ–  Orogenital contact that can cause gonococcal pharyngitis along with PID management?\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 448899 1100//2211//2222 44::1177 PPMM\n\n490",
      "char_start": 1380000,
      "char_end": 1382000
    },
    {
      "chunk_id": 691,
      "text": " HIGH-YIELD FACTS IN GYNECOLOGY\nDiagnosis\nâ–  Diagnosed by the presence of acute lower abdominal or pelvic pain plus\none of the following:\nâ–  Uterine tenderness\nâ–  Adnexal tenderness\nMNEMONIC â–  Cervical motion tenderness\nâ–  First, a Î²-hCG test to rule out pregnancy\nAcute causes of pelvic painâ€”\nâ–  Best test: NAAT for N gonorrhoeae and C trachomatis\nA ROPE â–  A WBC count >10,000 cells/Î¼L: Poor positive and negative predictive val-\nAppendicitisâ€”Periumbilical â†’ right lower ues for PID\nquadrant (RLQ) pain, fever, nausea, â–  Ultrasonography (not sensitive or specific): Possibly showing thickening or\nvomiting dilation of the fallopian tubes, fluid in the cul-de-sac, a multicystic ovary,\nRuptured ovarian cystâ€”Recent strenuous or tubo-ovarian abscess\nphysical activity\nOvarian torsion or abscessâ€”Torsion: severe\nTreatment\nunilateral pain (may be colicky), nausea,\nvomiting; abscess: gradual onset of â–  Antibiotic treatment should not be delayed while awaiting culture results.\nfever, vaginal discharge, respectively All sexual partners should be examined and treated appropriately.\nPIDâ€”Gradual onset of fever, vaginal â–  Outpatient regimens:\ndischarge â–  Regimen A: Ceftriaxone IM for one dose + doxycycline PO for 14 days\nEctopic pregnancyâ€”To be ruled out with Â± metronidazole PO for 14 days (metronidazole covers anaerobic\nÎ²-hCG test infections).\nâ–  Regimen B: Ofloxacin or levofloxacin for 14 days Â± metronidazole for\n14 days. This is only in special cases because there is an increase in\nquinolone-resistant N gonorrhoeae.\nâ–  Treatment should not be delayed for NAAT.\nâ–  Inpatient antibiotic regimens:\nâ–  Cefoxitin or cefotetan plus doxycycline for 14 days\nâ–  Clindamycin plus gentamicin for 14 days\nâ–  Additional intervention:\nâ–  Drainage of a tubo-ovarian/pelvic abscess is appropriate if mass persists\nafter antibiotic treatment, abscess is >4 to 6 cm, or mass is in the cul-\nKEY FACT de-sac in the midline and drainable through the vagina.\nMild and subclinical PID are major â–  If the patientâ€™s condition dete",
      "char_start": 1382000,
      "char_end": 1384000
    },
    {
      "chunk_id": 692,
      "text": "riorates, the case calls for exploratory laparos-\ncopy or laparotomy.\ncauses of tubal factor infertility, ectopic\npregnancy, and chronic pelvic pain â–  Surgery may range from total hysterectomy and bilateral oophorectomy\nwith lysis of adhesions in severe cases to conservative surgery for females\ncaused by pelvic scarring.\nwho desire to maintain fertility.\nComplications\nâ–  Repeated episodes of infection, chronic pelvic pain, dyspareunia, and\nectopic pregnancy\nâ–  Infertility (10% after the first episode, 25% after the second episode, and\n1 50% after a third episode)\nâ–  Fitz-Hughâ€“Curtis syndrome (presents with associated perihepatitis, right\nupper quadrant [RUQ] pain, abnormal liver function, and referred right\nShe was prescribed metronidazole.\nshoulder pain)\nShe should have been warned to\nabstain from alcohol while taking it, as\nmetronidazole causes a disulfiramlike\nOVARIAN TORSION\nreaction.\nTwisting of the ovarian vascular pedicle that occludes venous and/or arterial\nflow to the ovary, leading to ischemia.\n2\nHistory/PE\nThe next step in management is\npelvic ultrasonography to rule out â–  Colicky, lower quadrant abdominal pain of acute onset with peritoneal\ntubo-ovarian abscess. signs, nausea, and vomiting.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449900 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 491\nâ–  Risk factors, including PCOS and ovarian tumors and cysts.\nâ–  Most common times for torsion in pregnancy: 18 weeksâ€™ gestation, when\nthe uterus is rising over the pelvic brim or immediately postpartum with\nuterine involution. The increased motion of the uterus at these times\nincreases the risk for torsion.\nDiagnosis\nBest initial test:\nâ–  Ultrasound with Doppler may show ovarian abnormal venous or arterial flow.\nâ–  CT can help with visualization of an ovarian mass or cyst but will not pro-\nvide information on blood flow to the ovary.\nâ–  False negatives are possible due to intermittent torsion. If suspicion persists\nfollowi",
      "char_start": 1384000,
      "char_end": 1386000
    },
    {
      "chunk_id": 693,
      "text": "ng a negative ultrasound, surgical evaluation is indicated.\nTreatment\nLaparoscopy or laparotomy with detorsion if the ovary is still viable or oopho-\nrectomy if not viable\nPEDIATRIC VAGINAL DISCHARGE\nEtiologies of vaginal discharge in pediatric patients include the following:\nâ–  Foreign objects: Most common cause of vaginal discharge in pediatric\npatients\nâ–  Infectious vulvovaginitis: May present with a malodorous, yellow-green,\npurulent discharge. Causes include the following:\nâ–  Group A Streptococcus: The most common infectious cause\nâ–  Candida: Recent antibiotic therapy, immunosuppression (eg, diabe-\ntes); rare in children KEY FACT\nâ–  STIs: Typically from sexual abuse Pediatric vaginal discharge may be\nâ–  Noninfectious vulvovaginitis: Potential causes include poor hygiene, con- normal, but STDs resulting from sexual\ntact dermatitis, and eczema\nabuse must be ruled out and, if found,\nâ–  Sarcoma botryoides (rhabdomyosarcoma): A malignancy with lesions reported to Child Protective Services.\nthat have the appearance of â€œbunches of grapesâ€ within the vagina\nTOXIC SHOCK SYNDROME\nCaused by a reaction to toxic shock syndrome toxin 1 (TSST-1), a preformed\nStaphylococcus aureus toxin. Menstrual cases occur due to retained tampons\n(used for longer than recommended). Nonmenstrual cases are nearly as com-\nmon as menstrual cases and occur in the setting of surgical wounds and\nburns.\nHistory/PE\nâ–  Presents with abrupt onset of fever, vomiting, and watery diarrhea KEY FACT\nâ–  A diffuse macular erythematous rash involving the palms and soles Toxic shock syndrome (TSS) is a rare\nâ–  Nonpurulent conjunctivitis common but potentially fatal reaction to S aureus\nâ–  Desquamation, especially of the palms and soles, generally occurring dur- toxin, not to the bacterium itself.\ning recovery within 1 to 2 weeks of illness\nDiagnosis\nâ–  Based on clinical presentation: Fever >102Â°F (38.9Â°C), hypotension, skin\nfindings, involvement of three or more organ systems\nâ–  âŠ– blood cultures, given that TSS is caused b",
      "char_start": 1386000,
      "char_end": 1388000
    },
    {
      "chunk_id": 694,
      "text": "y a preformed toxin and not\ninvasive properties of the organism\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449911 1100//2211//2222 44::1177 PPMM\n\n492 HIGH-YIELD FACTS IN GYNECOLOGY\nTreatment\nâ–  Rapid rehydration, examination for foreign objects in vaginal canal, drain-\nage if localized infection found\nâ–  Empiric antibiotics: Clindamycin + vancomycin; clindamycin is used for\nits antitoxin properties\nâ–  If methicillin-sensitive S aureus isolated in wound, clindamycin + oxacil-\nlin OR nafcillin\nâ–  If methicillin-resistant S aureus isolated, clindamycin + vancomycin OR\nlinezolid\nComplications\nâ–  Mortality rate associated with TSS is 3% to 6%.\nâ–  Causes of death include cardiac arrhythmias, cardiomyopathy, respiratory\nfailure caused by acute respiratory distress syndrome (ARDS), and coagu-\nlopathy caused by disseminated intravascular coagulation (DIC).\nBENIGN BREAST DISORDERS\nNONPROLIFERATIVE BREAST LESIONS\nGenerally, no increased risk for breast cancer. Simple breast cysts are the most\ncommon; they are fluid-filled masses stemming from an exaggerated stromal\ntissue response to hormones and growth factors.\nâ–  Fat necrosis of the breast:\nâ–  Benign condition that presents radiographically like breast cancer, but\nthe breast biopsy reveals fat globules. No further workup indicated.\nâ–  Secondary to trauma to the breast or caffeine use.\nâ–  Typically, females 30 to 50 years of age develop nonproliferative breast\nlesions (postmenopausal females rarely develop them).\nâ–  Provide reassurance and pain control.\nâ–  Fibrocystic changes of the breast:\nâ–  Benign condition that presents as bilateral breast tenderness with dif-\nfuse, cordlike thickening of the breasts with no discharge\nâ–  Tenderness worsens during menstruation\nâ–  Fibroadenoma:\nKEY FACT â–  Benign condition that presents as solitary, mobile, well-circumscribed\nnodule\nThe differential diagnosis of a breast\nmass includes fibrocystic disease, breast â–  Tenderness and size increase during menstruation\ncyst f",
      "char_start": 1388000,
      "char_end": 1390000
    },
    {
      "chunk_id": 695,
      "text": "ibroadenoma, mastitis/abscess, fat â–  Classically seen in women <30 years of age\nnecrosis, and breast cancer. â–  Provide reassurance and pain control\nâ–  Discussed more later\nHistory/PE\nâ–  Cyclic bilateral mastalgia and swelling, most prominent just before\nmenstruation\nâ–  Rapid fluctuation in size of massesâ€”a common finding\nDiagnosis\nâ–  See Figure 2.11-10 for an algorithm of a breast mass workup.\nâ–  First, have patient return after menstruation, because symptoms fluctuate\nwith hormones.\nâ–  Best initial test: If unchanged on follow-up, perform ultrasonography to\ndifferentiate a mass from a fluid-filled one vs a solid one.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449922 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 493\nBreast mass\nHistory and breast examination to assess risk*\nNot suspicious Indeterminate Suspicious for\nfor cancer lesion cancer\nAge <30 Age >30\nUltrasound Â± Diagnostic mammogram Diagnostic mammogram\nUltrasound\ndiagnostic mammogram Â± ultrasound + core or excisional biopsy\n*Suspicious features: age > 35, family history of cancer, firm nonmobile mass,\naxillary adenopathy, skin changes, size does not change with menstrual cycle\nUltrasound\nSimple cyst Compl L e e x s c io y n st n o o r t s v o is li u d a m liz a e s d s\nFine-needle aspiration Biopsy (fine-needle aspiration\nFollow-up in 2-3 months or core needle) and cytology\nInad s e a q m u p at l e e Benign Atypical cells ma D lig C n IS a c o y r\nReassurance Treatment as\nRepeat biopsy Excisional biopsy\nRoutine follow-up indicated\nFIGURE 2.11-10. Workup of a breast mass. (Reproduced with permission from USMLE-Rx.com.)\nâ–  Subsequent test: Fine-needle aspiration (FNA) of a discrete mass that is\nsuggestive of a cyst is indicated to alleviate pain and to confirm the cystic\nnature of the mass.\nâ–  Most accurate test: Excisional biopsy is indicated if no fluid is obtained or\nif the fluid is bloody on aspiration.\nâ–  Mammography is of limited use (especially if <35 yea",
      "char_start": 1390000,
      "char_end": 1392000
    },
    {
      "chunk_id": 696,
      "text": "rs of age because of KEY FACT\ndensity of breast tissue).\nIntraductal papilloma and mammary\nâ–  There is no â†‘ risk for breast cancer if patient has a simple cyst, but there is duct ectasia are common causes of\nâ†‘ risk if patient has a complex cyst (ductal epithelial hyperplasia or cellu-\nbloody nipple discharge.\nlar atypia), which is rare.\nPROLIFERATIVE BREAST LESIONS WITHOUT ATYPIA\nInclude intraductal papillomas, sclerosing adenosis, and usual ductal hyper-\nplasia. Associated with a small increased risk for breast cancer. An intraductal\npapilloma is composed of papillary cells growing from the wall of a cyst into 1\nthe lumen.\nâ–  Dx: These lesions are diagnosed with core needle biopsy. Surgical excision A 30-year-old woman was in a\nis required to exclude atypia or ductal carcinoma in situ (DCIS). car accident 1 week ago and\nâ–  Tx: Sclerosing adenosis and usual ductal hyperplasia require no treatment. subsequently notices a hardened\nbump in the left breast. What is this\nlikely to be, and what can be found\nINTRADUCTAL PAPILLOMA\non biopsy?\nPapillary tumor affecting a single lactiferous duct. It is the most common\ncause of blood discharge in middle-aged women.\n2\nâ–  Hx/PE: Presents as unilateral bloody discharge from nipple in 40- to\n50-year-old females.\nA 27-year-old woman palpates a\nâ–  Dx: Obtain breast ultrasound or mammography (decision based on age of\n1 cm Ã— 1 cm new breast mass on\npatient). Obtain a needle biopsy or FNA.\nself-examination. What is the first step\nâ–  Tx: Excision is curative. in the workup of the mass?\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449933 1100//2211//2222 44::1177 PPMM\n\n494 HIGH-YIELD FACTS IN GYNECOLOGY\nPHYLLODES TUMOR\nCan sometimes be difficult to distinguish from a fibroadenoma. It is generally\nlarger with greater metastatic ability, and the differentiating features are the\npapillary projections of the stroma, lined with epithelium and associated with\nhyperplasia and atypia. Phyllodes tumors should be compl",
      "char_start": 1392000,
      "char_end": 1394000
    },
    {
      "chunk_id": 697,
      "text": "etely excised; axil-\nlary lymph node dissection is not necessary (see Fig. 2.11-11).\nATYPICAL HYPERPLASIA\nFIGURE 2.11-11. Phyllodes tumor with Atypical hyperplasia (AH) can be ductal or lobular, filling part of but not the\nclassic â€œleaflikeâ€ appearance. (Reproduced entire duct or lobule.\nwith permission from Crenshaw SA et al. Immediate\nbreast reconstruction with a saline implant and Allo- â–  Similar to a low-grade DCIS or lobular carcinoma in situ (LCIS) with a\nDerm, following removal of a Phyllodes tumor. World J moderately increased risk for breast cancer\nSurg Oncol. 2011;9:34.) â–  Found incidentally in biopsy done after a suspicious mammogram\nâ–  Requires risk reduction, which involves yearly mammograms and tamoxi-\nfen or aromatase inhibitor (if postmenopausal)\nMNEMONIC\nBREAST CANCER\nCommon metastases to boneâ€”\nBLT and Kosher Pickle on top\nThe most common cancer (affects one in eight women) and the second most\nBreast\ncommon cause of cancer death in females (after lung cancer) in the United\nLung\nStates. Sixty percent occur in the upper outer quadrant. One half of newly\nThyroid\ndiagnosed patients have risk factors. Risk factors include the following:\nKidney\nProstate â–  Female sex; older age (above 40 years of age)\nâ–  A personal history of breast cancer; family history in a first-degree relative;\ngenetic factors (BRCA1 and BRCA2 mutations: associated with early onset)\nKEY FACT â–  Alcohol; cigarettes (controversial)\nâ–  Exposure to radiation\nHormone-containing contraception\nâ–  A history of fibrocystic change with cellular atypia\nis contraindicated in patients with\nâ–  â†‘ exposure to estrogen (nulliparity, early menarche, late menopause, first\nbreast cancer. The safest option for\nfull-term pregnancy after 35 years of age, PCOS, HRT)\ncontraception is a copper IUD.\nHistory/PE\nClinical manifestations include the following:\n1\nâ–  Early findings: Single, nontender, immovable, firm-to-hard mass with ill-\nThis is fat necrosis of the breast. This defined margins or mammographic abnormalitie",
      "char_start": 1394000,
      "char_end": 1396000
    },
    {
      "chunk_id": 698,
      "text": "s on routine screening\ncommonly occurs after trauma that â–  Later findings/locally advanced:\nis not always remembered. It is a â–  Axillary lymphadenopathy, breast enlargement, pain, peau dâ€™orange skin\nmimicker of breast cancer in terms findings suggesting inflammation (redness, thickening, dimpling), fixa-\nof presentation and radiographic\ntion of the mass to the skin or chest wall\nfindings. Biopsy results differentiate\nâ–  Prolonged unilateral scaling erosion (with eczematous rash) of the nip-\nthe two and reveal coarse (not\nple that spreads to the areola with or without discharge (Paget disease\nmicro) calcifications and foamy\nof the nipple, specific for DCIS)\nmacrophages.\nâ–  Late findings: Ulceration, supraclavicular lymphadenopathy, edema of\nthe arm\n2 â–  Metastatic disease:\nâ–  Metastases to the bone (pain), lung (dyspnea, cough), and liver\n(abdominal pain, nausea, jaundice)\nUltrasonography. The patient is\nâ–  A firm or hard axillary node >1 cm\n<30 years of age, so ultrasonography\nis the preferred means of â–  Axillary nodes that are matted or fixed to the skin (stage III); ipsilateral\nsupraclavicular or infraclavicular nodes (stage IV)\ndistinguishing a solid mass from a\ncyst.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449944 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 495\nA B C\nA B\nFIGURE 2.11-12. Breast cancer. Mediolateral oblique (A) and craniocaudal (B) views from a mammogram demonstrate a spiculated mass with\na satellite mass (circles in A and B) in the central and outer upper right breast. A targeted breast ultrasonogram (C) in a different patient dem-\nonstrates a hypoechoic mass (arrow) that is taller than it is wide and exhibits dense posterior acoustic shadowing. (Reproduced with permission from\nUSMLE-Rx.com.)\nKEY FACT\nDiagnosis\nThe first step in the workup of a\nMajority of breast cancers diagnosed from mammography.\nsuspicious mass in postmenopausal\nâ–  Screening: females and in those >30 years of age\nâ–  Postmenop",
      "char_start": 1396000,
      "char_end": 1398000
    },
    {
      "chunk_id": 699,
      "text": "ausal women: Mammography. The physician should look is a mammogram. For premenopausal\nfor â†‘ density with microcalcifications, irregular borders, and spiculated females <30 years of age, the first step\nmass. Mammography can detect lesions roughly 2 years before they should be an ultrasound.\nbecome clinically palpable (see Fig. 2.11-14A).\nâ–  Premenopausal women: Ultrasonography for females <30 years of age\nbecause of density of breast tissue; can distinguish a solid mass from a\nbenign cyst (see Fig. 2.11-14C).\nâ–  Women with the following risk factors are recommended by the American\nCancer Society to undergo annual MRI screening:\nâ–  Known BRCA mutation\nâ–  First-degree relative who is a BRCA carrier\nâ–  Lifetime risk for breast cancer that is 20% to 25% or greater\nâ–  Biopsy of suspicious lesions on mammography:\nâ–  A mammography-guided FNA or core needle biopsy. A full-thickness\nskin biopsy should be done if signs of inflammation are present.\nâ–  FNA: A good initial biopsy, especially for lesions close to the skin; how-\never, it is a small sample with a high false-âŠ– rate. FNA may also be\nused to follow response to treatment.\nâ–  Core needle biopsy: A larger sample that allows testing for receptor\nstatus.\nâ–  Open biopsy: Less commonly used. It provides tissue for a more accu-\nrate diagnosis and allows immediate resection of tumor; however, an\nopen biopsy requires taking the patient to the operating room.\nâ–  Receptor status of tumor: Determination of estrogen receptor (ER), proges-\nterone receptor (PR), and human epidermal growth factor 2 (HER2) status\nâ–  Tumor markers for recurrent breast cancer: Typically used for metastatic\ndisease as a proxy to monitor treatment response. Include carcinoembry-\nonic antigen (CEA) and cancer antigen (CA) 15-3 or CA 27-29.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449955 1100//2211//2222 44::1177 PPMM\n\n496 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-10. Breast Cancer Stages\nPRIMARY TUMOR (T) REGIONAL LYMPH NODES (N) ",
      "char_start": 1398000,
      "char_end": 1400000
    },
    {
      "chunk_id": 700,
      "text": "METASTASIS (M)\n1: Tumor size <2 cm 0: No nodal involvement 0: No distant metastases\n2: Tumor size 2â€“5 cm 1: Movable ipsilateral axillary lymph 1: Distant metastases\n3: Tumor size >5 cm node (LN)\n4: Extension: Chest wall, 2: Fixed ipsilateral axillary LN\nskin 3: Ipsilateral infra/supraclavicular\nLN or clinically detected LN with\naxillary LN\nâ–  Metastatic disease:\nâ–  Imaging: X-ray of the chest (CXR); CT of the chest, abdomen, and\npelvis; brain MRI. Positron emission tomography (PET) and bone\nscans can also be useful.\nTreatment\nâ–  Early stage:\nâ–  Breast-conserving surgery + radiation or mastectomy Â± radiation (if\ncancer in deep margins or axillary lymph nodes). In both cases, the sit-\nuation also calls for sentinel node biopsy for evaluation of axillary\nlymph nodes.\nâ–  Adjuvant therapy as indicated.\nâ–  Locally advanced:\nâ–  Neoadjuvant chemotherapy + HER2-directed therapy to reduce size of\ntumor to allow for breast-conserving therapy as opposed to mastectomy\nâ–  Breast conservation surgery or mastectomy with sentinel lymph node\nKEY FACT biopsy\nâ–  Adjuvant therapy as indicated\nIn a postmenopausal woman with a\nâ–  Adjuvant therapy:\nnew breast lesion, the physician should â–  All ER/PR âŠ• patients should receive tamoxifen (a selective estrogen\nmaintain a high degree of clinical\nreceptor modulator [SERM] that competitively antagonizes the ER,\nsuspicion for breast cancer.\ninhibiting the growth of breast cancer cells) or an aromatase inhibitor\nif postmenopausal (inactivates aromatase that converts peripheral\nandrogens to estrogens).\nKEY FACT â–  All HER2âŠ• patients should receive HER2-directed therapies such as\ntrastuzumab, a monoclonal antibody that binds to HER2 receptors on\nTamoxifen use is associated with hot\nthe cancer cell (watch for cardiotoxicity).\nflashes, endometrial cancer, and venous\nâ–  ER, PR, and HER2âŠ– patients should receive chemotherapy if tumor\nthromboembolism because it has\n>0.5 cm.\nmixed antagonist (breast) and agonist\nâ–  Contraindications to breast-conserving therapy (lumpec",
      "char_start": 1400000,
      "char_end": 1402000
    },
    {
      "chunk_id": 701,
      "text": "tomy): Large\n(endometrium) activity on estrogen\ntumor size, subareolar location, multifocal tumors, fixation to the chest\nreceptors.\nwall, prior radiation to the chest wall, or involvement of the nipple or over-\nlying skin.\nKEY FACT â–  Stage IV disease: Treated with radiation therapy, hormonal therapy, and\nbiologic therapy (depending on the receptor status of the tumor).\nStage II of breast cancer is associated â–  Table 2.11-10 describes the breast cancer stages.\nwith tumor size >2 cm, stage III is\nassociated with nodal involvement, and Prognosis\nstage IV is associated with metastases.\nâ–  TNM staging (Iâ€“IV) is the most reliable indicator of prognosis.\nâ–  âŠ• ER status and PR status are associated with a favorable prognosis.\nâ–  Cancer localized to the breast has a 75% to 90% cure rate. With spread to\nthe axilla, the 5-year survival rate is 40% to 50%.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449966 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 497\nComplications KEY FACT\nPleural effusion is common in patients with metastatic breast cancer; edema Inflammatory breast carcinoma is\nof the arm is common secondary to nodal involvement. rare, but it is an aggressive cancer\nthat presents with peau dâ€™orange skin\n(edematous cutaneous thickening)\nBENIGN GYNECOLOGIC DISORDERS along with a red and painful breast\nmass. Axillary lymphadenopathy is\ntypically present.\nUTERINE LEIOMYOMAS (FIBROIDS)\nFibroids are the most common benign neoplams of the female genital tract.\nThey present as singular or multiple discrete, round, and firm tumors. Com-\nposed of smooth muscle and connective tissue, fibroids may cause infertility\nor menorrhagia.\nâ–  Fibroids are hormone sensitive; size will â†‘ in pregnancy and â†“ after KEY FACT\nmenopause.\nAn irregular and mobile uterus is the\nâ–  Malignant transformation to leiomyosarcoma is rare (0.1%â€“0.5%). key physical examination finding for\nâ–  Prevalence: More common in Black females (50%) than in White females fib",
      "char_start": 1402000,
      "char_end": 1404000
    },
    {
      "chunk_id": 702,
      "text": "roids.\n(25%)\nHistory/PE\nâ–  Majority of cases are asymptomatic.\nâ–  Symptomatic patients may present with the following:\nâ–  Bleeding: Longer, heavier periods; anemia\nâ–  Mass effect: Pelvic/rectal pressure, constipation, and urinary frequency\nor retention KEY FACT\nâ–  Pain: Secondary dysmenorrhea, dyspareunia If a uterine mass continues to grow\nâ–  Pelvic symptoms: A firm, nontender, irregular, enlarged (â€œlumpy- after menopause, suspect malignancy.\nbumpyâ€), or cobblestone uterus may be felt on physical examination.\nDiagnosis\nâ–  Physical examination\nâ–  Ultrasonography (transvaginal): To look for uterine myomas; can also\nexclude ovarian masses. Calcification indicates necrosis.\nâ–  MRI: Can delineate intramural, subserosal, and submucous myomas. The\nbest modality for visualization, MRI is usually reserved in preparation for\nsurgery or if there is concern for leiomyosarcoma (a new or growing mass\nin a postmenopausal female).\nâ–  CBC: To assess for anemia.\nTreatment\nâ–  If asymptomatic, expectant management with annual pelvic exams and\nCBCs as needed\nâ–  Pharmacologic:\nâ–  Combined hormonal contraception\nâ–  Medroxyprogesterone acetate or danazol to slow or stop bleeding\nâ–  GnRH analogues (leuprolide or nafarelin) to â†“ the size of myomas,\nsuppress further growth, and â†“ surrounding vascularity. These also may\nbe used before surgery to decrease uterine size, help with anemia, and\nallow a minimally invasive approach to hysterectomy.\nâ–  NSAIDs for pain.\nâ–  Surgery:\nâ–  Females of childbearing years: Abdominal or hysteroscopic\nmyomectomy\nâ–  Females who have completed childbearing: Hysterectomy.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449977 1100//2211//2222 44::1177 PPMM\n\n498 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-11. Common Benign Ovarian Cysts (Nonneoplastic)\nTYPE INFORMATION\nFollicular ovarian cysts Occurs when follicle develops into maturity and does not\n(physiologic cysts) rupture to release ovum\nCorpus luteal cyst Corpus luteum fails to involute and contin",
      "char_start": 1404000,
      "char_end": 1406000
    },
    {
      "chunk_id": 703,
      "text": "ues enlarging\npostovulation\nTheca lutein cyst Occurs from overstimulation from hormones (hCG)\nLuteoma Nonneoplastic ovarian mass\nAssociated with pregnancy, maternal hirsutism/virilization\nâ–  Uterine artery embolization (âˆ¼25% will need further invasive\ntreatment)\nâ–  Emergent surgery may be required if torsion of a pedunculated myoma\noccurs\nComplications\nInfertility may be caused by a myoma that distorts the uterine cavity and plays\na role similar to that of an IUD.\nNONNEOPLASTIC OVARIAN CYSTS\nNonneoplastic cysts are the most common cause of ovarian enlargement (see\nTable 2.11-11). Ovarian lesions are more likely to be benign if unilateral, sim-\nple, smaller than 8 cm, and in women <45 years of age. Malignant ovarian\nlesions are discussed in detail later in this chapter.\nKEY FACT\nGYNECOLOGIC NEOPLASMS\nVaginal bleeding is present in 80% of\nwomen with endometrial carcinoma, Gynecologic cancers include uterine, endometrial, ovarian, cervical, and vul-\nbut only 5% to 10% of women with var neoplasms. Ovarian cancer carries the highest mortality.\nabnormal vaginal bleeding have\nendometrial cancer.\nENDOMETRIAL CANCER\nType I endometrioid adenocarcinomas derive from atypical endometrial\nhyperplasia and are the most common female reproductive cancer in the\nUnited States. Type II cancers derive from serous or clear cell histology (see\nTable 2.11-12). Although type II cancers tend to be more aggressive, diagnosis\nand management are similar for both types. Type 1 is the most curable gyne-\ncologic cancer.\nHistory/PE\nâ–  Vaginal bleeding (early finding)\nâ–  Pain (late finding)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449988 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 499\nTABLE 2.11-12. Types of Endometrial Cancer\nVARIABLE TYPE I: ENDOMETRIOID TYPE II: SEROUS\nEpidemiology 75% of endometrial cancers 25% of endometrial cancers\nEtiology Unopposed estrogen stimulation Unrelated to estrogen; p53\n(eg, obesity, tamoxifen use, exog- mutatio",
      "char_start": 1406000,
      "char_end": 1408000
    },
    {
      "chunk_id": 704,
      "text": "n present in 90%\nenous estrogen-only therapy) of cases KEY FACT\nHormonal contraceptives reduce the\nPrecursor lesion Hyperplasia and atypical hyperplasia None\nrisk for endometrial cancer.\nMean age at diagnosis 55 years 67 years\nPrognosis Favorable Poor\nKEY FACT\nWhen to perform a biopsy for\nendometrial cancer:\nâ–  Postmenopausal: Endometrial\nDiagnosis stripe >4 mm or any recurrent\nâ–  First, physical examination and pregnancy test if premenopausal. or persistent bleeding, spotting\nâ–  Second, ultrasonography. If postmenopausal, can do transvaginal and eval- regardless of ultrasound results\nuate endometrial stripe (<4 mm unlikely to be endometrial cancer). â–  Premenopausal: Sustained\nUltrasonography shows thickened endometrium with hypertrophy and intermenstrual bleeding,\nneoplastic change in very advanced cases (Fig. 2.11-13). menorrhagia, or amenorrhea after\nâ–  Finally, endometrial biopsy. If patient is postmenopausal with recurrent or initial workup and in the setting of\npersistent bleeding, a biopsy is necessary, regardless of ultrasonography results. unopposed estrogen (obesity, DM)\nTreatment\nâ–  High-dose progestins for women who desire future fertility A\nâ–  Hysterectomy and BSO Â± radiation for postmenopausal women\nâ–  Hysterectomy and BSO with adjuvant chemotherapy and/or radiation for\nadvanced-stage cancer F\nCERVICAL CANCER\nThe endocervix lies proximal to the external os, is nonvisible, and is com-\nposed of columnar cells (similar to the lower uterine segment). The ectocer- A\nB\nvix is visible and composed of squamous cells (similar to the vagina). The\nexposure of columnar cells to an acidic vaginal pH results in metaplasia to\nsquamous cells. The normal squamocolumnar junction (transformation zone)\nis in the ectocervix and can be exposed to carcinogens, resulting in cervical\nintraepithelial neoplasia (CIN), an abnormal proliferation or overgrowth of\nthe basal cell layer.\nâ–  Human papillomavirus (HPV) DNA is found in 99.7% of all cervical car-\ncinomas. HPV 16 is the most preva",
      "char_start": 1408000,
      "char_end": 1410000
    },
    {
      "chunk_id": 705,
      "text": "lent type in squamous cell carcinoma;\nHPV 18 is most prevalent in adenocarcinoma. B\nâ–  Additional risk factors include immunosuppression; infection with HIV; or FIGURE 2.11-13. Endometrial cancer.\n(A) Sagittal endovaginal ultrasonogram\na history of STIs, tobacco use, or high parity.\ndemonstrates a mass (arrow) in the lower\nâ–  HPV vaccine protects against nine different pathogenic strains, including uterine segment of the endometrial\nHPV types 6 and 11 (cause 90% of genital warts) and 16 and 18 (causes canal, with fluid (F) distending the canal\n70% of cervical cancer). The vaccine is recommended for males and in the fundus. (B) Gross specimen from a\nfemales 11 to 26 years of age and may be considered in certain high-risk different patient shows a large mass fill-\ning the endometrial canal and invading\npatients up to age 45.\nthe myometrium. (Image A reproduced with\npermission from USMLE-Rx.com. Image B reproduced\nwith permission from Schorge JO et al. Williams Gyne-\ncology. New York, NY: McGraw-Hill; 2008.)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 449999 1100//2211//2222 44::1177 PPMM\n\n500 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-13. Classification of Pap Smears\nCIN BETHESDA SYSTEM\nBenign Negative\nBenign with inflammation ASC-US\nASC-H\nCIN I LSIL\nCIN II HSIL\nCIN III HSIL\nInvasive cancer Invasive cancer\nCervical intraepithelial neoplasia (CIN) is the histologic classification. The\nBethesda system is used for reporting cytologic diagnoses.\nHistory/PE\nâ–  Intermenstrual bleeding, postcoital spotting, and cervical ulceration are\nthe most common signs.\nâ–  Bloody or purulent, malodorous, nonpruritic discharge may appear after\ninvasion.\nScreening\nâ–  The American College of Obstetricians and Gynecologists (ACOG) cur-\nrently recommends that screening for cervical cancer begin at 21 years of\nage regardless of onset of sexual activity.\nâ–  Screening recommendations for females with previously normal\nexaminations:\nâ–  21 to 29 years of age: Pap smear",
      "char_start": 1410000,
      "char_end": 1412000
    },
    {
      "chunk_id": 706,
      "text": " (cytology) every 3 years\nâ–  30 to 65 years of age: Pap smear every 3 years or cotesting (Pap smear +\nHPV test) every 5 years\nâ–  65 years of age: Stoppage of screening if prior tests were negative\nâ–  See Table 2.11-13 for classification systems of Pap smears\nâ–  Alternative screening strategy using primary HPV testing to triage who\nshould have a Pap smear (see Fig. 2.11-14)\nâ–  Females with diethylstilbestrol (DES) exposure (risk for clear cell cancer)\nand/or immunocompromised status (including HIV positivity) should con-\ntinue to be screened as long as they do not have a life-limiting condition.\nâ–  Females with HIV should be screened with cytology twice in their first\nyear after diagnosis and then annually.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550000 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 501\n<21 yr 21â€“29 yr 30â€“65 yr >65 yr\nUSPSTF\nNothing Pap smear Pap smear every Stop if and\nrecommended every 3 years 3 years (preferred) nothing > CIN2 within AAFP\nregardless of OR co-test* every 5 years 25 years and negative guidelines\nsexual activity OR HPV test every 5 years screening in prior 10 years\n*co-test = HPV test + Pap smear\nFIGURE 2.11-14. Pap smear recommendations by age and HPV screening strategy. AAFP, American Academy of\nFamily Physicians; USPSTF, U.S. Preventive Services Task Force. (Reproduced with permission from USMLE-Rx.com.)\nDiagnosis\nSee algorithm in Figure 2.11-14. Applications of the information determine\nmanagement.\nâ–  Low-grade squamous intraepithelial lesion (LSIL): Repeat Pap smear at 12\nmonths. If âŠ– Ã—2, then routine screening.\nâ–  Atypical squamous cells of undetermined significance (ASC-US):\nDepends on cotesting; colposcopy if positive high-risk HPV.\nâ–  High-grade squamous intraepithelial lesion (LSIL): Colposcopy.\nTreatment\nFor noninvasive disease, treatment is based on likelihood of progression to cer-\nvical cancer and patientâ€™s age/desire for future childbearing is as follows:\nâ–  CIN I: Observa",
      "char_start": 1412000,
      "char_end": 1414000
    },
    {
      "chunk_id": 707,
      "text": "tion with yearly Pap smears vs ablative therapy when done\nwith childbearing\nâ–  CIN II: Observation or ablative/excisional therapy depending on child-\nbearing status\nâ–  CIN III: Excisional therapy\nâ–  Postablative or excisional therapy follow-up:\nâ–  CIN I, or CIN II or III with negative margins:: Pap smear at 12 months\nand/or HPV testing\nâ–  CIN II or III with âŠ• margins: Pap smear at 6 months; consider a repeat\nendocervical curettage\nâ–  Treatment based on biopsy results for invasive disease is as follows (for\nstaging, see Fig. 2.11-15):\nâ–  Microinvasive carcinoma (stage IA1): Treat with cone biopsy and close\nfollow-up or simple hysterectomy.\nâ–  Stages IA2, IB1, IB2, IIA: May be treated either with radical hysterec-\ntomy or with radiation therapy plus chemotherapy.\nâ–  Stages IIB, III, IV: Treat with radiation therapy plus concurrent\ncisplatin-based chemotherapy.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550011 1100//2211//2222 44::1177 PPMM\n\n502 HIGH-YIELD FACTS IN GYNECOLOGY\nSTAGE 0 STAGE 1 STAGE 2 STAGE 3 STAGE 4\nExtent of Carcinoma Confined to cervix Spreads beyond uterus Spreads to pelvic sidewall Invades bladder, rectum,\ntumor in-situ and/or uterus but not to pelvic wall or lower 1/3 of vagina or distant metastasis\nor lower 1/3 of vagina beyond true pelvis\n5-year 93% IA 93% IIA 63% IIIA 35% 16% IVA\nsurvival IB 80% IIB 58% IIIB 32% 15% IVB\nStage at 47% 28% 21% 4%\npresentation\nFundus\nUterine Fallopian Pelvic side\ncavity tube wall\nUterine\nwall Corpus\nInternal os IVA\nCervix IIA IIB IIIA\nExternal os IB\nIIIB\nIA\nVagina\nIVB\nFIGURE 2.11-15. Staging of cervical cancer. Anatomic display of the stages of cervical cancer, defined by location, extent of tumor, fre-\nquency of presentation, and 5-year survival. (Reproduced with permission from USMLE-Rx.com.)\nPrognosis\nFive-year survival rates are inversely proportionate to the stage of cancer, with\nstate 1A having more than 95% survival and state IV having <20% survival.\nVULVAR CANCER\nRisk factors inc",
      "char_start": 1414000,
      "char_end": 1416000
    },
    {
      "chunk_id": 708,
      "text": "lude HPV (types 16, 18, and 31), lichen sclerosus, diabetes,\nobesity, hypertension, cardiovascular disease, smoking, high-risk sexual behav-\nior, and immunosuppression. Vulvar intraepithelial neoplasia (VIN) is pre-\ncancerous and is more commonly found in premenopausal women.\nHistory/PE\nâ–  Presents with pruritus, pain, or ulceration of the mass\nâ–  Additional symptoms that include the following:\nâ–  Early: Lesions that appear white, pigmented, raised, thickened, nodu-\nlar, or ulcerative\nâ–  Late: Presents with a large and cauliflowerlike or hard and ulcerated\narea in the vulva\nDiagnosis\nVulvar punch biopsy for any suspicious lesions or persistent vulvar pruritus,\nespecially in postmenopausal patients\nTreatment\nâ–  High-grade VIN: Topical chemotherapy, laser ablation, wide local exci-\nsion, skinning vulvectomy, and simple vulvectomy\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550022 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 503\nâ–  Invasive:\nâ–  Radical vulvectomy and regional lymphadenectomy\nâ–  Wide local excision of the primary tumor with inguinal lymph node\ndissection Â± preoperative radiation, chemotherapy, or both\nVAGINAL CANCER\nAccounts for 1% to 2% of all gynecologic malignancies. Risk factors include\nimmunosuppression, chronic irritation (eg, long-term pessary use or prolapse\nof female organs), low socioeconomic status, radiation for cervical cancer,\nhysterectomy for dysplasia, multiple sexual partners, and DES exposure. Etiol-\nogies are as follows:\nâ–  Postmenopausal females: Usually squamous cell carcinoma\nâ–  Younger females: Usually other histologic types (eg, adenocarcinoma,\nclear cell adenocarcinoma from DES)\nHistory/PE\nâ–  Presents with abnormal vaginal bleeding, abnormal discharge, or postco-\nital bleeding\nâ–  Found in the upper third of the vagina in 75% of patients\nDiagnosis\nDefinitive diagnosis is with biopsy and staging.\nTreatment\nâ–  Local excision of involved areas when they are few and small\nâ–  Partial or complet",
      "char_start": 1416000,
      "char_end": 1418000
    },
    {
      "chunk_id": 709,
      "text": "e vaginectomyâ€”if extensive involvement of the vaginal\nmucosa\nâ–  Radiation therapy or radical surgeryâ€”if invasive disease\nOVARIAN CANCER\nMost ovarian tumors are benign, but malignant tumors are the leading cause\nof death from reproductive tract cancer. There is no screening test for ovarian\ncancer. Risk factors include the following:\nâ–  Age, low parity, â†“ fertility, or delayed childbearing.\nâ–  âŠ• family history: Patients with one affected first-degree relative have a 5%\nlifetime risk. With two or more affected first-degree relatives, the risk is 7%.\nKEY FACT\nâ–  Genetics: The BRCA1 mutation carries a 45% lifetime risk for ovarian\ncancer. The BRCA2 mutation is associated with a 25% lifetime risk. Frequency of female genital tract\nâ–  Lynch II syndrome: Also known as hereditary nonpolyposis colorectal can- cancers: Endometrial > ovarian >\ncer (HNPCC), it is associated with an â†‘ risk for colon, ovarian, endome- cervical\ntrial, and breast cancers. Number of deaths: Ovarian >\nendometrial > cervical\nOCPs taken for 5 years or more â†“ risk by 29%.\nHistory/PE\nâ–  Both benign and malignant ovarian neoplasms are generally asymptomatic.\nâ–  Mild, nonspecific gastrointestinal (GI) symptoms or pelvic pressure/pain\nmay be seen.\nâ–  Early disease is typically not detected on routine pelvic exam.\nâ–  Some 75% of women present with advanced malignant disease, as evidenced\nby abdominal pain and bloating, a palpable abdominal mass, and ascites.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550033 1100//2211//2222 44::1177 PPMM\n\n504 HIGH-YIELD FACTS IN GYNECOLOGY\nTABLE 2.11-14. Benign vs Malignant Pelvic Masses\nFINDING BENIGN MALIGNANT\nEXAMINATION: PELVIC MASS\nMobility Mobile Fixed\nConsistency Cystic Solid or firm\nCul-de-sac Smooth Nodular\nTRANSVAGINAL ULTRASONOGRAPHY: ADNEXAL MASS\nSize <8 cm >8 cm\nConsistency Cystic Solid or cystic and solid\nSeptations Unilocular Multilocular\nLocation Unilateral Bilateral\nOther Calcifications Ascites\nâ–  Table 2.11-14 differentiates the ",
      "char_start": 1418000,
      "char_end": 1420000
    },
    {
      "chunk_id": 710,
      "text": "benign and malignant characteristics of\npelvic masses.\nDiagnosis\nâ–  Tumor markers (see Table 2.11-15): â†‘ CA-125 is associated with epithelial\ncell cancer (90% of ovarian cancers), but is used only as a marker for pro-\ngression and recurrence.\nâ–  Premenopausal women: â†‘ CA-125 may point to benign disease such\nas endometriosis or a tubo-ovarian abscess (TOA).\nKEY FACT â–  Postmenopausal women: â†‘ CA-125 (>35 units) indicates an â†‘ likeli-\nhood that the ovarian tumor is malignant.\nGranulosa cell tumors predispose to\nendometrial hyperplasia and carcinoma â–  Transvaginal ultrasonography: Used to screen high-risk patients and as\nthe first step in the workup of symptomatic females (eg, pelvic fullness,\nbecause of unopposed estrogen\npelvic pain). A solid mass with thick septations Â± ascites on ultrasound is\nsecretion.\nhighly suggestive of neoplasm.\nKEY FACT Treatment\nOvarian masses in premenarchal females: Masses >2 cm in diameter require\nAny ovarian or adnexal mass in a\nclose clinical follow-up and often surgical removal.\npremenarchal or postmenopausal\nOvarian masses in premenopausal females:\npatient is suggestive of an ovarian\nneoplasm. â–  Observation is appropriate for asymptomatic, mobile, unilateral, simple\ncystic masses <8 to 10 cm in diameter. Most resolve spontaneously.\nâ–  Surgical evaluation of masses >8 to 10 cm in diameter and those that are\ncomplex and/or unchanged on repeat pelvic examinations and\nultrasonography.\nOvarian masses in postmenopausal females:\nâ–  Closely follow with ultrasonography asymptomatic, unilateral simple cysts\n<5 cm in diameter with a normal CA-125.\nâ–  Surgically evaluate palpable masses.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550044 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 505\nTABLE 2.11-15. Ovarian Tumor Characteristics\nTUMOR MARKER CHARACTERISTICS\nEpithelial CA-125 Serous adenocarcinomaâ€”the most common. A\ntumor may present with abdominal distention,\nbowel obstruction, and adnexal mass.\n",
      "char_start": 1420000,
      "char_end": 1422000
    },
    {
      "chunk_id": 711,
      "text": "Endodermal sinus Î±-Fetoprotein Very aggressive. An endodermal sinus may be seen\n(yolk sac) (AFP) in ovaries and/or sacrococcygeal area in young\nchildren; gross examination shows a yellow,\nfriable, solid mass.\nEmbryonal AFP, Î²-hCG Very rare. Embryonal carcinoma may be seen in ado-\ncarcinoma lescents; it may present with precocious puberty\nand abnormal uterine bleeding.\nChoriocarcinoma Î²-hCG Can develop during or after pregnancy and after\nmolar pregnancies. This is a malignancy of tropho-\nblastic tissue. Choriocarcinoma may be associated\nwith bilateral theca-lutein cysts. It spreads\nhematogenously.\nDysgerminoma Lactate dehydro- Most commonly seen in adolescents with sheets of\ngenase (LDH) uniform â€œfried eggâ€ cells.\nGranulosa cell Inhibin Most common malignant stromal tumor. Granulosa\ncells are often seen in females in their 50s; produc-\ntion of estrogen and/or progesterone may lead to\npostmenopausal bleeding, Call-Exner bodies on\nhistology.\nOvarian cancer treatment:\nâ–  Surgery:\nâ–  Surgical staging: Hysterectomy/BSO with omentectomy and pelvic and\nparaaortic lymphadenectomy\nâ–  Benign neoplasms warrant tumor removal or unilateral oophorectomy\nâ–  Perioperative chemotherapy: Routine except for females with early-stage\nor low-grade ovarian cancer\nâ–  Radiation therapy: Reserved for advanced germ cell tumors, in particular\ndysgerminomas (not effective in epithelial ovarian cancer)\nPrevention\nâ–  Females with the BRCA1 gene mutation should be screened every 6\nmonths with ultrasonography and CA-125 testing. Prophylactic oophorec-\ntomy is recommended by 40 years of age or whenever childbearing is\ncompleted.\nâ–  OCP use â†“ the risk for ovarian cancer.\nâ–  There is no routine screening for ovarian cancer.\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550055 1100//2211//2222 44::1177 PPMM\n\n506 HIGH-YIELD FACTS IN GYNECOLOGY\nUROLOGIC GYNECOLOGY\nPELVIC ORGAN PROLAPSE\nRisk factors for pelvic organ prolapse include multiple vaginal deliveries,\ngenetic predisposi",
      "char_start": 1422000,
      "char_end": 1424000
    },
    {
      "chunk_id": 712,
      "text": "tion, advancing age, prior pelvic surgery (hysterectomy),\nconnective tissue disorders, and â†‘ intra-abdominal pressure associated with\nobesity or straining with chronic constipation.\nHistory/PE\nâ–  Presents with the sensation of a bulge or protrusion in the vagina (see\nFig. 2.11-16).\nâ–  Urinary or fecal incontinence, a sense of incomplete bladder emptying,\nand/or dyspareunia are also seen.\nDiagnosis\nThe degree of prolapse can be evaluated by having the patient perform the\nValsalva maneuver while in the lithotomy position.\nTreatment\nâ–  Supportive measures include a high-fiber diet, weight reduction in obese\npatients, and limitations on straining and lifting.\nâ–  Pessaries may reduce prolapse and are helpful in patients who do not wish\nto undergo surgery or in those for whom surgery is contraindicated.\nâ–  Surgical procedure depends on where the prolapse is located:\nâ–  Uterine prolapse is treated by a hysterectomy with vaginal vault\nsuspension.\nâ–  Anterior/posterior vaginal wall: A prolapse here calls for repair of the\nanterior or posterior wall (colporrhaphy).\nNormal Uterine prolapse\nSlight prolapse\nMarked prolapse\n(procidentia)\nFIGURE 2.11-16. Uterine prolapse. Diagrams depicting different degrees of uterine prolapse.\n(Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550066 1100//2211//2222 44::1177 PPMM\n\nGYNECOLOGY HIGH-YIELD FACTS IN 507\nSEXUAL DISORDERS\nGENITOPELVIC PAIN DISORDER (VAGINISMUS)\nInvoluntary spasm of outer one third of the vagina\nHistory/PE\nâ–  Some caused by situational/psychosocial causes\nâ–  Can be associated with gynecologic disorders, chronic medical conditions,\nor certain medications\nTreatment\nâ–  Most effectiveâ€”cognitive and behavioral psychotherapy with systematic\ndesensitization\nâ–  Deep muscle relaxation techniques and dilators\nVULVODYNIA\nLocalized pain of the vulva, usually pain with insertion/at introitus.\nHistory/PE\nTypically chronic and idiopathic\nTreatment\nâ–  At start of treatm",
      "char_start": 1424000,
      "char_end": 1426000
    },
    {
      "chunk_id": 713,
      "text": "ent: Detailed history and physical examination\nâ–  Multidisciplinary treatment with pelvic floor physical therapy and\ncounseling\nFEMALE SEXUAL INTEREST/AROUSAL DISORDER\nInability to complete sexual activity\nHistory/PE\nâ–  Common in patients with depression or chronic disease\nâ–  Common in younger patients due to situational circumstances or\ndepression\nTreatment\nâ–  Usually resolves when underlying condition or medication is adjusted\nâ–  Individual or couples psychotherapy\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550077 1100//2211//2222 44::1177 PPMM\n\n508 HIGH-YIELD FACTS IN GYNECOLOGY\nNOTES\n22002222__0022..1111__SStteepp22CCKK__GGyynnoo__1111ee__446677--550088..iinndddd 550088 1100//2211//2222 44::1177 PPMM\n\nH I G H - Y I E L D F A C T S I N\nPEDIATRICS\nChild Development 511 Pediatric Urology 540\nDevelopmental milestones 511 vesiCoureteral reflux 540\nprimitive reflexes 511 CryptorChiDism 541\nGrowth 511 inGuinal hernia 541\nsexual Development 514 hypospaDias anD epispaDias 542\nGenetic Disease 514 Pediatric Immunology 542\nCystiC fibrosis 514 immunoDefiCienCy DisorDers 542\nkawasaki Disease 546\nNeonatology 520\nJuvenile iDiopathiC arthritis 547\napGar sCorinG 520\nConGenital malformations 520 Pediatric Infectious Disease 548\nneonatal JaunDiCe 520 aCute otitis meDia 548\nrespiratory Distress synDrome 524 bronChiolitis 549\nGerminal matrix hemorrhaGe 526 Croup (larynGotraCheobronChitis) 550\napnea of prematurity 526 epiGlottitis 551\nneonatal extraCranial inJuries 526 meninGitis 552\nConGenital hypothyroiDism 526 oCular infeCtions of the neonate 553\nbeniGn neonatal rashes 527 pertussis (whoopinG CouGh) 554\nneonatal abstinenCe synDrome 527 viral exanthems 555\ntorCh infeCtions 555\nCongenital Heart Disease 528\npinworm infeCtion 555\naCyanotiC ConGenital heart left-to-riGht shunts 529\nneonatal fever (<28 Days olD) 555\nseptal DefeCts 529\nfever of unknown oriGin 555\npatent DuCtus arteriosus 531\nCoarCtation of the aorta 531 Pediatric Neurologic Disease 557\nCya",
      "char_start": 1426000,
      "char_end": 1428000
    },
    {
      "chunk_id": 714,
      "text": "notiC ConGenital heart riGht-to-left shunts 532 Cerebral palsy 557\ntransposition of the Great arteries 532 febrile seizures 558\ntetraloGy of fallot 533 infantile hypotonia 559\nCommon brain neoplasms in ChilDren 560\nPediatric Gastrointestinal Disease 534\nspinal Dysraphism 561\npyloriC stenosis 534\nbreath-holDinG spells 562\nintussusCeption 535\nrett synDrome 562\nmalrotation with volvulus 536\nChiari malformations 563\nmeCkel DivertiCulum 536\nbeniGn familial miCroCephaly anD maCroCephaly 563\nhirsChsprunG Disease 537\nneCrotizinG enteroColitis 538 Pediatric Hematology 564\nfooD proteinâ€“inDuCeD allerGiC proCtoColitis 538 DiamonD-blaCkfan anemia 564\npeDiatriC Constipation 539 fanConi anemia 565\n509\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 550099 1100//2211//2222 44::2211 PPMM\n\nH I G H - Y I E L D F A C T S I N\nPEDIATRICS\nCyCliC neutropenia 566 metatarsus aDDuCtus 575\nthromboCytopenia absent raDius synDrome 566 Clubfoot (talipes equinovarus) 575\nkasabaCh-merritt synDrome 567 Developmental Dysplasia of the hip 575\nsiCkle Cell Disease 567 leGG-CalvÃ©-perthes Disease 576\nslippeD Capital femoral epiphysis 576\nPediatric Oncology 569\nsColiosis 577\nleukemia 569\nneuroblastoma 570 Child Abuse 577\nwilms tumor 571\nWell-Child Care 579\nChilDhooD bone tumors 571\nantiCipatory GuiDanCe 579\nlanGerhans histioCytosis 571\nhearinG anD vision sCreeninG 579\nPediatric Musculoskeletal Disorders 572 ChilDhooD vaCCinations 580\nCommon peDiatriC orthopeDiC inJuries 572 leaD poisoninG 580\nDuChenne musCular Dystrophy 572 perianal Dermatitis 582\nmyotoniC Dystrophy 574 piGmenteD lesions in ChilDhooD 583\nsponDylolisthesis 574\n510\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551100 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 511\nCHILD DEVELOPMENT\nPediatric development and growth are very important factors that strongly influ-\nence the well-being of the future adult. Although each child may develop differ- KEY FACT\nen",
      "char_start": 1428000,
      "char_end": 1430000
    },
    {
      "chunk_id": 715,
      "text": "tly, certain milestones and growth standards are applicable to most children.\nSome signs that may be concerning\nfor autism spectrum disorder include\nDEVELOPMENTAL MILESTONES\nfailure to achieve certain language\nmilestones (eg, babbling/gesturing\nAssessed at routine well-child visits through age 6 years. Within each type of\nby 12 months of age, use of two-word\nmilestone (Table 2.12-1), two or more delays indicate a developmental delay\nphases by 24 months of age), impaired\nof that type (eg, language delay). Delays in two or more types of development\nsocial interaction, restricted interest\nindicate a â€œglobal developmental delay.â€ Table 2.12-1 highlights major devel-\nin objects/activities, and insistence on\nopmental milestones. If isolated language delay is present, audiology should\nroutine.\nbe considered.\nLanguage disorder:\nâ–  Developmental disorder characterized by difficulty comprehending or pro-\nducing language. Patients have a limited vocabulary for their age, use\nincorrect tenses, lack the ability to synthesize simple sentences, and may\nhave word-finding difficulties.\nâ–  Inability to communicate their needs verbally may lead to temper tan-\ntrums or physical aggression. An undetected language disorder increases\nthe risk of developing specific learning disorders in a school-age child.\nEarly recognition and intervention improve outcomes. Table 2.12-2 lists\nsimilar conditions that must be differentiated.\nToilet training:\nâ–  Most children start toilet training at 2 years of age.\nâ–  Bedwetting (primary nocturnal enuresis) is normal until 5 years of age. If it\npersists at age 6 years or older, positive reinforcement (eg, bedwetting\nalarms) may be considered. Desmopressin (ADH analog) and anticholiner-\ngic medications (imipramine) may be provided for refractory cases. Be sure\nto rule out medical conditions such as bladder dysfunction, urinary tract\ninfection, and diabetes insipidus.\nPRIMITIVE REFLEXES\nReflexes that are present during infancy and disappear with frontal lobe dev",
      "char_start": 1430000,
      "char_end": 1432000
    },
    {
      "chunk_id": 716,
      "text": "el-\nopment. Persistence of these reflexes indicates impairment of brain develop-\nment. Return of these reflexes in an adult indicates frontal lobe lesions.\nTable 2.12-3 outlines commonly tested reflexes.\nGROWTH\nAt each well-child checkup, height and weight Â± head circumference are\nplotted on growth charts specific for sex and age:\nâ–  Head circumference: Measured routinely in the first 2 years. â†‘ head cir-\ncumference greater than the 97th percentile is macrocephaly and may\nindicate hydrocephalus or tumor (may be evaluated with brain imaging);\nâ†“ head circumference less than the 3rd percentile is microcephaly (eg,\nTORCH infections, fetal alcohol syndrome).\nâ–  Height and weight: Measured routinely until adulthood. The pattern of\ngrowth is more important than the raw numbers. Infants may lose 5% to\n10% of birth weight (BW) over the first few days but should return to their\nBW by 14 days. Infants can be expected to double their BW by 4 to\n5 months of age, triple it by 1 year of age, and quadruple it by 2 years of age.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551111 1100//2211//2222 44::2211 PPMM\n\n512 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-1. Developmental Milestones\nAGEa GROSS MOTOR FINE MOTOR LANGUAGE SOCIAL/COGNITIVE\n2 months Lifts head/chest when Tracks objects past Alerts to sound; coos Recognizes parent; exhibits\nprone midline social smile\n4â€“5 months Begins rolling Grasps rattle Squeals; orients to voice; begins Enjoys looking around; laughs\nto make consonant sounds\n6 months Sits unassisted Transfers objects from one Babbles; responds to name Demonstrates stranger anxiety\nhand to another; dem-\nonstrates raking grasp\n9â€“11 months Crawls; cruises; pulls Uses three-finger (imma- Says â€œmama/dadaâ€ (nonspecific); Waves bye-bye; plays pat-a-cake\nto stand ture) pincer grasp says first word at 11 months\n12 months Walks alone; throws Uses two-finger (mature) Uses one to three words; follows Imitates actions\nobject pincer grasp one-step",
      "char_start": 1432000,
      "char_end": 1434000
    },
    {
      "chunk_id": 717,
      "text": " commands Exhibits separation anxiety\nFollows one-step commands\n18 months Runs Builds tower of 2â€“4 cubes Uses 10â€“50 words Participates in pretend play\n2 years Walks up/down steps; Builds tower of six cubes Uses two-word phrases; follows Follows two-step commands;\njumps two-step commands removes clothes; participates\nSpeech 50% (one-half) intelli- in parallel play; starts toilet\ngible; vocabulary >50 words training\n3 years Rides a tricycle; Copies a circle; uses Forms sentences of three to four Brushes teeth with help; washes/\nclimbs stairs with utensils words dries hands\nalternating feet Speech 75% (three-fourths) Understands gender\n(3â€“4 years) intelligible Participates in imaginative play\n4 years Hops Copies a cross (square at Knows colors and some numbers Exhibits cooperative play; plays\n4.5 years of age) Speech 100% intelligible board games\n5 years Skips; walks backward Copies a triangle; ties Can form complex sentences Wants to please others and\nfor long distances shoelaces; knows left and use multiple sentence be liked\nand right; prints letters types (eg, with conjunctions, Understands rules; begins to\nquestions); knows opposites show independence\nCompletes toilet training\naFor premature infants <2 years of age, chronologic age must be adjusted for gestational age (GA). For example, an infant born at 7 monthsâ€™ GA\n(2 months early) would be expected to perform at a 4-month-old level at the chronologic age of 6 months. However, vaccines should be\nadministered based on chronologic age despite prematurity.\nâ–  Variants of normal growth:\nâ–  Constitutional growth delay: A normal variant and the most common\ncause of delayed puberty. The growth curve for such children lags\nbehind that of others of the same age but remains consistent. There is\noften a âŠ• family history, and children ultimately achieve target height\npotential. The key distinguishing feature is delayed bone age until\n11 years of age in girls and 13 years of age in boys.\n22002222__0022..1122__SStteepp22CCKK__PP",
      "char_start": 1434000,
      "char_end": 1436000
    },
    {
      "chunk_id": 718,
      "text": "eeddiiaa__1111ee__550099--558844..iinndddd 551122 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 513\nTABLE 2.12-2. Differential Diagnoses of Language Disorder\nDISORDER NOTES\nChildhood-onset fluency Dysfunctional speech fluency presenting as stuttering\ndisorder\nSpeech sound disorder Dysfunctional speech articulation presenting as difficulty\narticulating certain sounds\nSpecific learning disorder Difficulty acquiring academic skills that are appropriate for\ndevelopmental age (eg, reading [dyslexia], writing, math-\nematics [dyscalculia]); diagnosed via standardized testing\nSocial (pragmatic) communi- Dysfunctional verbal and nonverbal communication; differen-\ncation disorder tiate from autism spectrum disorder, as these patients do\nnot have restricted interests or repetitive behaviors\nTABLE 2.12-3. Primitive Reflexes\nREFLEX DESCRIPTION\nMoro reflex Startling causes extension and abduction of arms followed by flexion\nRooting reflex Stroking the cheek causes head to turn toward ipsilateral side (nipple seeking)\nSucking reflex Touching the roof of the mouth causes a sucking response\nGalant reflex Stroking infant along one side of spine in prone position causes flexion of\nlower body toward ipsilateral side\nPalmar grasp Stroking palm causes fingers to curl\nPlantar reflex Stroking the sole causes dorsiflexion of big toe and fanning out of the other\ntoes; it is normal through age 12 months\nBabinski sign: Persistence after age 12 months or reappearance indicates an\nupper motor neuron (UMN) issue\nâ–  Familial short stature: Short stature (height < second percentile)\nwhen one or both parents also have short stature. Growth curve shows\na low-to-normal height velocity. Bone age corresponds with chrono-\nlogic age, and puberty is not delayed. Adult height remains low.\nâ–  Failure to thrive (FTT): Persistent weight for age and/or length for age\nless than the fifth percentile, or â€œfalling off the growth curveâ€ (ie, crossing\ntwo major percentile lines on a growth chart). FTT ",
      "char_start": 1436000,
      "char_end": 1438000
    },
    {
      "chunk_id": 719,
      "text": "is classified as follows:\nâ–  Organic: Caused by an underlying medical condition such as cystic\nfibrosis, congenital heart disease (CHD), milk-protein allergy,\nchronic infection (eg, HIV), hypothyroidism, or gastroesophageal\nreflux disease (GERD)\nâ–  Nonorganic: Primarily caused by psychosocial factors such as low\nmilk supply/breastfeeding problems, inaccurate mixing of formula\n(too much water mixed in), maternal postpartum depression,\nneglect, or abuse\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551133 1100//2211//2222 44::2211 PPMM\n\n514 HIGH-YIELD FACTS IN PEDIATRICS\nKEY FACT â–  Critical to diagnosis: A careful dietary history and close observation of\nparent-infant interactions. Practitioner should inquire about preparation of\nInfants with FTT will first fall off the formula and feeding practices.\nweight curve, then the height curve, â–  Diagnostic testing: Targeted to suspected etiologies when indicated and\nand finally the head circumference no improvement occurs after ensuring adequate nutrition. Imaging modal-\ncurve. ities include echocardiogram for congenital heart defects and upper gas-\ntrointestinal (GI) series for GI causes.\nâ–  Children may need to be hospitalized if there is evidence of neglect or\nKEY FACT severe malnourishment. Calorie counts and supplemental nutrition (if\nbreastfeeding is inadequate) are mainstays of treatment for nonorganic\nNewborns can lose up to 10% of their\ncauses.\nbirth weight but should regain the\nweight by 2 weeks of life.\nSEXUAL DEVELOPMENT\nâ–  Tanner staging: Performed to assess sexual development in boys and girls.\nKEY FACT Figure 2.12-1 illustrates the stages, Figure 2.12-2 illustrates patterns of sex-\nual development.\nAndrogen insensitivity syndrome (AIS)\nis a genetic disorder characterized by â–  Variants of normal sexual development are as follows:\nan X-linked mutation of the androgen â–  Precocious puberty: Any sign of secondary sexual maturation in girls\n<8 years of age or boys <9 years of age. Of",
      "char_start": 1438000,
      "char_end": 1440000
    },
    {
      "chunk_id": 720,
      "text": "ten idiopathic; may be cen-\nreceptor leading to a phenotypically\ntral or peripheral (see the Gynecology chapter)\nfemale appearance in a 46,XY individual.\nAffected individuals will have breast â–  Delayed puberty: No testicular enlargement in boys by 14 years of age\nor no breast development or pubic hair in girls by 13 years of age\ndevelopment, cryptorchidism, and no\npubic hair. Perform a gonadectomy â–  Pathologic puberty delay: Caused by systemic disease (eg, inflamma-\ntory bowel disease [IBD]), malnutrition (eg, anorexia nervosa), gonadal\nafter puberty to prevent testicular\ndysgenesis (eg, Klinefelter syndrome, Turner syndrome), or endocrine\ncancer.\nabnormalities (eg, hypopituitarism, hypothyroidism, Kallmann syn-\ndrome, androgen insensitivity syndrome, Prader-Willi syndrome)\nMNEMONIC\nGENETIC DISEASE\nTrisomiesâ€”\nTables 2.12-4 to 2.12-7 outline common childhood-onset genetic diseases and\n21â€”Age to Drink (Down syndrome)\ntheir associated abnormalities.\n18â€”Age to vote in Elections (Edwards\nsyndrome)\n13â€”Age of Puberty (Patau syndrome)\nCYSTIC FIBROSIS\nAutosomal recessive disorder. Mutation in cystic fibrosis transmembrane con-\nductance regulator (CFTR) gene (chloride channel) on chromosome 7.\nCharacterized by widespread exocrine gland dysfunction. Cystic fibrosis (CF)\nis the most common severe genetic disease in the United States and is most\nfrequently found in Northern European ancestry.\nHistory/PE\nâ–  Most patients are diagnosed on newborn screening.\nâ–  Presentation:\nâ–  Neonates: Meconium ileus (obstruction of the distal ileum caused by\nabnormally thick meconium; 15% of presenting cases).\nâ–  Patients <1 year of age: Cough, wheezing, or recurrent respiratory\ninfections. Patients may also have steatorrhea and/or FTT.\nâ–  Most patients >1 year of age: FTT (caused by pancreatic insuffi-\nciency) or chronic sinopulmonary disease/sputum production.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551144 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YI",
      "char_start": 1440000,
      "char_end": 1442000
    },
    {
      "chunk_id": 721,
      "text": "ELD FACTS IN 515\nStage I Stage II Stage III Stage IV Stage V\nNo sexual hair Pubic hair appears Coarsening of pubic Coarse hair across pubis, Coarse hair across pubis and\nFlat-appearing chest with (pubarche) hair sparing thigh medial thigh\nraised nipple Testicular enlargement Penis size/length(cid:31) Penis width/glans(cid:31) Penis and testis enlarge to\nBreast bud forms Breast enlarges Breast enlarges, raised adult size\n(thelarche), mound forms areola, mound on mound Adult breast contour, areola\nflattens\nPrepubertal ~ 8â€“11.5 years ~ 11.5â€“13 years ~ 13â€“15 years Usually >15 years\nFIGURE 2.12-1. Tanner stages. The first sign of puberty in females is breast bud development; testicular enlargement is the first sign in\nmales. (Reproduced with permission from USMLE-Rx.com.)\nThelarche Menarche\n(breast buds) Growth spurt (menses)\nFemale\ndevelopment\nPubarche\n(pubic hair)\nMale\ndevelopment\nGonadarche Adrenarche Growth spurt\n(testicles enlarge) (axillary/facial\nhair, voice changes)\nFIGURE 2.12-2. Patterns of sexual development in females vs males. (Reproduced with permission\nfrom USMLE-Rx.com.)\nâ–  Affected individuals exhibit recurrent pulmonary infections (especially\nwith Pseudomonas as adults and Staphylococcus aureus as children) with\nsubsequent cyanosis, digital clubbing, chronic cough (the most common\npulmonary symptom), dyspnea, bronchiectasis, hemoptysis, chronic sinus-\nitis, rhonchi, rales, and nasal polyposis.\nâ–  Patients with pancreatic insufficiency usually have greasy stools and flatu-\nlence; other prominent GI symptoms include pancreatitis, rectal prolapse,\nhypoproteinemia, biliary cirrhosis, jaundice, and esophageal varices.\nâ–  Patients who present later in childhood or adulthood are likely to have pan-\ncreatic manifestations predominant and have a milder pulmonary course.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551155 1100//2211//2222 44::2211 PPMM\n\n516 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-4. Autosomal Chromosome Abnorm",
      "char_start": 1442000,
      "char_end": 1444000
    },
    {
      "chunk_id": 722,
      "text": "alities (Trisomies)\nDISEASE GENETIC ABNORMALITY PRESENTATION/FEATURES ASSOCIATED DISEASES OTHER FACTS\nDown Trisomy 21, which Presents with intellectual dis- Atlantoaxial instability (can lead to spinal The most common\nsyndrome occurs due to abilities, a flat facial profile, cord compression), duodenal atresia, chromosomal dis-\nmeiotic nondis- upward slanted eyes with Hirschsprung disease, CHD order and cause\njunction (95%), epicanthal folds, single Most common cardiac malformation: of intellectual\nRobertsonian palmar crease, general Complete AV canal defect (both sys- disabilities\ntranslocation hypotonia, and extra neck tolic ejection murmur and holosystolic Associated with\n(4%), or mosa- folds (nuchal folds are murmur present) (60%); ASDs, VSDs, advanced maternal\nicism (1%) sometimes seen on prenatal PDA, and complex CHD make up the age\nultrasound) remainder\nGI anomalies (duodenal atresia or stenosis,\nimperforate anus, and esophageal atresia)\nOphthalmologic disorders (refractive errors,\nstrabismus, nystagmus, cataracts, and\nkeratoconus)\nEndocrine disorders (type 1 DM,\nhypothyroidism)\nRisk for ALL, hypothyroidism, and early-\nonset Alzheimer disease\nEdwards Trisomy 18, Presents with severe intel- CHD (most often VSD, PDA) Second most common\nsyndrome which occurs lectual disabilities, rocker GI involvement common (Meckel diver- autosomal trisomy\ndue to meiotic bottom feet, low-set ears, ticulum, malrotation) Death usually occurs\nnondisjunction micrognathia, clenched Renal involvement (eg, horseshoe within 1 year of birth\nhands (overlapping of the kidneys, vesicoureteral reflux, and other Associated with\nindex finger over the third anomalies) advanced maternal\nfinger and the pinky over age\nthe fourth finger), and a 3:1 female-to-male ratio\nprominent occiput\nPatau Trisomy 13, Presents with classic triad CHD: VSD, PDA, ASD Death usually occurs\nsyndrome which occurs of microphthalmia/ CNS: Holoprosencephaly with incomplete within 1 year of birth\ndue to meiotic anophthalmi",
      "char_start": 1444000,
      "char_end": 1446000
    },
    {
      "chunk_id": 723,
      "text": "a/microcephaly; development of forebrain and olfactory Associated with\nnondisjunction cleft lip/palate; postaxial and optic nerves, intellectual disabilities advanced maternal\npolydactyly; other features age\nare holoprosencephaly,\nâ€œpunched-outâ€ scalp lesions,\nand omphalocele\nALL, Acute lymphocytic leukemia; ASD, atrial septal defect; AV, atrioventricular; CHD, congenital heart disease; CNS, central nervous system;\nDM, diabetes mellitus; PDA, patent ductus arteriosus; VSD, ventricular septal defects.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551166 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 517\nTABLE 2.12-5. Sex Chromosome Abnormalities\nDISEASE GENETIC ABNORMALITY PRESENTATION/FEATURES ASSOCIATED DISEASES OTHER FACTS\nKlinefelter 47,XXY, which Presents with testicular Most common cause of Characterized by the presence of\nsyndrome occurs due to atrophy, a eunuchoid body primary hypogonadism an inactivated X chromosome\n(male) nondisjunction of shape, tall stature, long in males (Barr body)\nsex chromosomes extremities, gynecomastia, â†‘ risk for breast cancer, psychi-\n(maternal or and female hair distribution atric disorders, autosomal\npaternal origin) Male newborns: Normal in spectrum disorders, and social\nphenotype with no dysmor- problems\nphic features Associated with advanced\nmaternal age\nSex chromosome karyotyping\nused to diagnose\nTreated with testosterone\n(prevents gynecomastia;\nimproves secondary sexual\ncharacteristics)\nTurner syndrome 45,XO Presents with short stature, The most common cause Missing one X chromosome; no\n(female) shield chest, widely spaced of primary amenor- Barr body\nnipples, a webbed neck, rhea; caused by ovarian Sex chromosome karyotyping\npubertal delay (due to dysgenesis (treat with used to diagnose\novarian failure), coarcta- estrogen) Not associated with advanced\ntion of the aorta (â†“ femoral May have horseshoe maternal age\npulses), and/or bicuspid kidney\naortic valve\nMay present with ",
      "char_start": 1446000,
      "char_end": 1448000
    },
    {
      "chunk_id": 724,
      "text": "lymphedema\nof the hands and feet in the\nneonatal period\nDouble Y males 47,XYY Often look normal; some Observed with â†‘ frequency\npatients very tall with severe among inmates of penal\nacne (seen in 1%â€“2% of XYY institutions\nmale patients) Sex chromosome karyotyping\nused to diagnose\nTABLE 2.12-6. Inherited Metabolic Disorders\nDISEASE ETIOLOGY MODE OF INHERITANCE/NOTES\nPhenylketonuria Caused by â†“ phenylalanine hydroxylase or â†“ tetrahydrobiopterin cofactor Autosomal recessive\n(PKU) Tyrosine becomes essential, and phenylalanine accumulates and is subsequently converted PKU screened for at birth\nto its ketone metabolites\nNot apparent at birth; presents within the first few months of life\nIf not treated at birth, presents with intellectual disabilities, fair hair and skin, eczema, blue\neyes, and a musty urine odor\nAssociated with â†‘ risk for heart disease\nDuring infancy, the patient will need special infant formula containing â†“ phenylalanine\n(artificial sweeteners) and â†‘ tyrosine (should not breastfeed)\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551177 1100//2211//2222 44::2211 PPMM\n\n518 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-6. Inherited Metabolic Disorders (continued)\nDISEASE ETIOLOGY MODE OF INHERITANCE/NOTES\nFabry disease Deficiency of Î±-galactosidase A that leads to accumulation of ceramide trihexoside in the X-linked recessive\nheart, brain, and kidneys\nFirst sign is severe neuropathic limb pain; also presents with joint swelling\nSkin involvement characterized by angiokeratomas and telangiectasias\nIf untreated, findings may include chronic kidney disease presenting as proteinuria and\nincreased risk for stroke and myocardial infarction (thromboembolic events)\nKrabbe disease Deficiency of galactosylceramide and galactoside (caused by galactosylceramidase defi- Autosomal recessive\nciency), leading to the accumulation of galactocerebroside in the brain\nCharacterized by progressive CNS degeneration, optic atrophy, spasti",
      "char_start": 1448000,
      "char_end": 1450000
    },
    {
      "chunk_id": 725,
      "text": "city, and death within\nthe first 3 years of life\nGaucher disease Deficiency of glucocerebrosidase (also known as acid Î²-glucosidase) that leads to the accu- Autosomal recessive\nmulation of glucocerebroside in the brain, liver, spleen, and bone marrow\nMay present with anemia and thrombocytopenia\nInfantile form manifested by early, rapid neurologic decline; adult form (more common) not\nmanifested by brain defects; compatible with normal life span\nNiemann-Pick Deficiency of sphingomyelinase that leads to the buildup of sphingomyelin cholesterol in Autosomal recessive\ndisease reticuloendothelial and parenchymal cells and tissues No man Picks his nose\nMay present with a cherry-red spot and hepatosplenomegaly with his sphinger\nTay-Sachs disease Deficiency of hexosaminidase A that leads to GM ganglioside accumulation Autosomal recessive\n2\nCould have normal appearance until 3â€“6 months of age, when weakness begins and devel- Tay-SaX lacks heXosa-\nopment slows and regresses minidase A\nAn exaggerated startle response possible\nPresents with a cherry-red spot but no hepatosplenomegaly\nMore prevalent in people of Jewish European descent\nMetachromatic Deficiency of arylsulfatase A that leads to the accumulation of sulfatide in the brain, kidney, Autosomal recessive\nleukodystrophy liver, and peripheral nerves\nDemyelination leading to progressive ataxia and dementia\nHurler syndrome Deficiency of Î±-l-iduronidase Autosomal recessive\nLeads to corneal clouding, intellectual disabilities, and gargoylism\nHunter syndrome Deficiency of iduronate sulfatase\nA mild form of Hurler syndrome with no corneal clouding and mild intellectual disabilities\nHomocystinemia Deficiency of cystathionine synthase Autosomal recessive\nCauses downward lens subluxation, marfanoid body habitus, hypercoagulability, and intel-\nlectual disability\nTreat with anticoagulation\nâ–  Additional symptoms include diabetes mellitus, â€œsalty-tastingâ€ skin, male\nKEY FACT\ninfertility (agenesis of the vas deferens), and hyponatremia",
      "char_start": 1450000,
      "char_end": 1452000
    },
    {
      "chunk_id": 726,
      "text": ".\nAlmost all cases of meconium ileus are â–  Patients are at risk for fat-soluble vitamin deficiency (vitamins A, D, E, and\nK) secondary to malabsorption and may present with manifestations of\ncaused by CF.\nthese deficiencies (eg, night blindness, rickets, neuropathy, coagulopathy).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551188 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 519\nTABLE 2.12-7. Other Genetic Diseases\nDISEASE FEATURES/PRESENTATION MODE OF INHERITANCE/NOTES\nFragile X syndrome Caused by a defect affecting the methylation and expres- X-linked dominant\nsion of the FMR1 gene The second most common genetic cause\nA triplet repeat disorder that may show genetic of intellectual disabilities\nanticipation\nPresents in childhood; features include long and narrow\nface, prominent forehead and chin, large ears, testicular\nenlargement, and autistic behaviors\nFriedrich ataxia Caused by a loss-of-function mutation in frataxin (FXN) Autosomal recessive degenerative disorder\ngene â†’ trinucleotide repeat expansion of GAA â†’â†“ The most common hereditary ataxia\nexpression of frataxin protein\nPresents in adolescence primarily with neurologic dys-\nfunction (limb, gait ataxia) and cardiomyopathy; other\nfeatures: optic atrophy, dysphagia, dysarthria, motor\nweakness, loss of distal proprioception, deafness, â†“\nvisual acuity, kyphoscoliosis, diabetes mellitus\nPrader-Willi syndrome Presents with hypotonia, hyperphagia, obesity, hypogo- Deletion of paternal 15q11-q13 (imprinting\nnadism, almond-shaped eyes, â†“ cognition disorder)\nCauses sleep apnea, DM type 2, gastric distention and Paternal deletion â†’ Prader-Willi\nrupture, and obesity-related complications Most common syndromic form of obesity\nClassic galactosemia Caused by a deficiency of galactose-1-phosphate uridyl Autosomal recessive inheritance\ntransferase (GALT) Most common and severe type of\nIf not treated shortly after birth, will present in infancy galactosemia\nwith jaundic",
      "char_start": 1452000,
      "char_end": 1454000
    },
    {
      "chunk_id": 727,
      "text": "e, vomiting, and hepatomegaly after Tested in newborn screening\nfeeding. Exclude galactose and lactose (galactose +\nglucose) from diet\nLate findings include cataract deposition and neurologic\nimpairment\nHereditary fructose Deficiency in aldolase B Autosomal recessive inheritance\nintolerance Presents with hypoglycemia, jaundice; cirrhosis; and vom- Urine dipstick will be âŠ\niting following consumption of fruit, juice, or honey\nMay also present with hepatomegaly, lactic acidosis, and\nfailure to thrive\nDiagnosis\nDiagnostic criteria of CF include at least one of the following:\nâ–  â‰¥1 phenotypic feature(s) of CF\nA newborn girl presents with\nâ–  Chronic pulmonary disease\nlymphedema of the hands and feet,\nâ–  Chronic sinusitis\nâ†“ femoral pulses, a webbed neck,\nâ–  GI and nutritional abnormalities widely spaced nipples, short fourth\nâ–  Salt loss syndromes metacarpals, and nail dysplasia.\nâ–  Obstructive azoospermia What form of hormone replacement\nâ–  History of CF in sibling therapy will the child need in the\nâ–  Positive newborn screening test future?\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 551199 1100//2211//2222 44::2211 PPMM\n\n520 HIGH-YIELD FACTS IN PEDIATRICS\nPLUS at least one of the following:\nâ–  â†‘ sweat chloride concentration\nâ–  Two CFTR gene mutations\nâ–  Abnormal nasal potential difference (NPD) test\nTreatment\nâ–  Pulmonary manifestations are managed with chest physical therapy, bron-\nchodilators, corticosteroids, antibiotics (should cover Pseudomonas and\nS. aureus; S. aureus is the main colonizer until 20 years of age), and deoxy-\nribonuclease (DNase).\nâ–  Administer pancreatic enzymes at mealtimes, as well as supplemental fat-\nsoluble vitamins (A, D, E, and K) due to malabsorption.\nâ–  Nutritional counseling and support with a high-calorie and high-protein\ndiet are essential for health maintenance.\nâ–  Patients who have severe disease but can tolerate surgery may be candidates\nfor a lung or pancreas transplant. Life expectancy was once âˆ¼20 years of",
      "char_start": 1454000,
      "char_end": 1456000
    },
    {
      "chunk_id": 728,
      "text": "\nage, but with newer treatments it is increasing to past 40 years of age.\nâ–  Ivacaftor, a drug that enhances CFTR membrane localization, was\nrecently approved to treat CF.\nNEONATOLOGY\nKEY FACT APGAR SCORING\nOmphalocele can be associated with\nA rapid scoring system that helps evaluate the need for neonatal resuscitation\nother congenital anomalies (Beckwith-\n(Table 2.12-8). Each of five parameters is assigned a score of 0 to 2 at 1 and\nWiedemann syndrome, trisomies 13\n5 minutes after birth.\nand 18); gastroschisis is not.\nâ–  Scores of 8 to 10: Typically reflect good cardiopulmonary adaptation\nâ–  Scores of 4 to 7: Indicate possible need for resuscitation; infants should be\nobserved, stimulated, and possibly given ventilatory support\nKEY FACT â–  Scores of 0 to 3: Indicate the need for immediate resuscitation\nDistinguishing between gastroschisis\nand omphalocele:\nCONGENITAL MALFORMATIONS\nâ–  Gastroschisis: GI contents are\noutside the â€œGâ€ to represent lack of\nTable 2.12-9 describes selected congenital malformations.\nperitoneal covering.\nâ–  Omphalocele: GI contents sealed\nwithin the â€œOâ€ to represent the NEONATAL JAUNDICE\npresence of peritoneal covering\nAn elevated serum bilirubin concentration (>5 mg/dL) caused by â†‘ hemoly-\nsis or â†“ excretion. Subtypes are as follows:\nâ–  Conjugated (direct) hyperbilirubinemia: Always pathologic.\nâ–  Unconjugated (indirect) hyperbilirubinemia: May be physiologic or\npathologic. See Table 2.12-10 and Figure 2.12-3 for differentiating\ncharacteristics.\nThis newborn has Turner syndrome.\nBecause of ovarian dysgenesis, â–  Kernicterus: A complication of unconjugated hyperbilirubinemia that\nthe patient will require estrogen results from irreversible bilirubin deposition in the basal ganglia, pons,\nreplacement therapy in the future. and cerebellum. It typically occurs at levels of >25 to 30 mg/dL and can\nThis newborn will need exogenous be fatal. Risk factors include prematurity, asphyxia, and sepsis.\nestrogen to support pubertal\ndevelopment and to prevent\nosteop",
      "char_start": 1456000,
      "char_end": 1458000
    },
    {
      "chunk_id": 729,
      "text": "orosis later in life.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552200 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 521\nTABLE 2.12-8. Apgar Scale (evaluated at 1 and 5 minutes postpartum)\nSIGN 2 POINTS 1 POINT 0 POINTS\nActivity (muscle tone) Active movement Arms and legs flexed Absent\nPulse â‰¥100 beats per minute (bpm) <100 bpm Absent\nGrimace (reflex irritability) Active (sneezes, coughs, pulls away) Some flexion of extremities Flaccid\nAppearance (skin color) Completely pink Pink body with blue extremities Blue/pale all over\nRespirations Vigorous cry Slow, irregular respirations Absent\nTABLE 2.12-9. Selected Congenital Malformations\nMALFORMATION PRESENTATION DIAGNOSIS TREATMENT\nChoanal atresia â†‘ nasal choanae occlusion by soft tissue, bone, CT scan of and enlargement Establishment of oral airway\nor combination of the vomer Surgical transnasal repair or\nChronic, recurrent purulent nasal discharge Flexible nasal endoscopy stenting\nIf unilateral, obstruction of affected side showing point of obstruc-\nIf bilateral, patient unable to breathe; patient is tion in the nasal passage\na neonatal ears, nose, and throat (ENT) emer-\ngency (baby wonâ€™t be able to feed)\nMay be associated with other anomaliesâ€”\nCHARGE syndrome: Coloboma, Heart disease,\nAtresia of the choanae, Retarded growth and\nmental development, Genital hypoplasia, and\nEar anomalies\nTracheoesophageal Tract between the trachea and esophagus X-ray of the chest (CXR) Surgical correction\nfistula Associated with defects such as esophageal showing a nasogastric\natresia and VACTERL (Vertebral, Anal, (NG) tube coiled in the\nCardiac, TracheoEsophageal, Renal, Limb) proximal atretic portion\nanomalies of the esophagus; this\nPolyhydramnios in utero, oral secretions, finding identifies esopha-\ninability to feed, gagging, aspiration pneu- geal atresia\nmonia, respiratory distress Presence of air in the GI tract\nsuggestive; confirmation\nwith bronchoscopy\nCongenital diaphrag",
      "char_start": 1458000,
      "char_end": 1460000
    },
    {
      "chunk_id": 730,
      "text": "- GI tract segments protruding through the dia- Ultrasound in utero; con- High-frequency ventilation or\nmatic hernia phragm into the thorax; 90% are posterior left firmed by postnatal CXR extracorporeal membrane\n(Bochdalek) oxygenation to manage\nRespiratory distress (from pulmonary hypo- pulmonary hypertension;\nplasia and pulmonary hypertension); sunken surgical correction\nabdomen; bowel sounds over the left\nhemithorax\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552211 1100//2211//2222 44::2211 PPMM\n\n522 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-9. Selected Congenital Malformations (continued)\nMALFORMATION PRESENTATION DIAGNOSIS TREATMENT\nGastroschisis Herniation of the intestine only through the Diagnosis made clinically Wrapping exposed bowel\nabdominal wall next to the umbilicus (usually with saline-soaked gauze\non the right) with no sac (GI tract is exposed) and securing it with plastic\nGastroschisis is commonly associated with oli- immediately after birth;\ngohydramnios, fetal growth restriction, and surgical correction needed;\nprematurity; gastroschisis is less commonly when primary closure is not\nassociated with polyhydramnios possible immediately, a silo\nAssociated with GI stenoses or atresia bag can be placed to gradu-\nPresents with erythematous; matted bowel ally reduce bowel contents\ninto the abdomen until\nsurgery can be performed\nOmphalocele Herniation of abdominal viscera through the Diagnosis made clinically C-section to prevent sac rupture;\nA abdominal wall at the umbilicus into a sac if the sac is intact, postpone\ncovered by peritoneum and amniotic mem- surgical correction until the\nbrane (see Image A) patient is fully resuscitated\nPolyhydramnios in utero; often premature; asso- Keeping sac covered/stable with\nciated with other GI and cardiac defects petroleum and gauze\nSeen in Beckwith-Wiedemann syndrome and Intermittent NG suction to\ntrisomies prevent abdominal distention\nDuodenal atresia Complete or",
      "char_start": 1460000,
      "char_end": 1462000
    },
    {
      "chunk_id": 731,
      "text": " partial failure of the duodenal X-ray of abdomen (see Surgical correction\nB lumen to recanalize during gestational Image B) showing â€œdouble\nweeks 8â€“10 bubbleâ€ sign (air bubbles\nPolyhydramnios in utero; bilious emesis within in the stomach [2] and\nhours after the first feeding duodenum [1]) proximal\nAssociated with Down syndrome and other to the site of the atresia\ncardiac/GI anomalies (eg, annular pancreas,\nmalrotation, imperforate anus)\nJejunal atresia Vascular accident in utero that prevents canali- â€œTriple bubble signâ€ (dilated Surgical correction\nzation of the jejunum stomach, duodenum, and\nCaused by prenatal exposure to cocaine and proximal jejunum) may\nother vasoconstrictive substances be seen\nImages reproduced with permission from Brunicardi FC et al. Schwartzâ€™s Principles of Surgery, 9th ed. New York, NY: McGraw-Hill; 2010.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552222 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 523\nTABLE 2.12-10. Physiologic vs Pathologic Jaundice MNEMONIC\nPHYSIOLOGIC JAUNDICE PATHOLOGIC JAUNDICE\nCrigler-Najjar and Gilbert have\nproblems with CoNjuGation of\nNot present in the first 24 hours of life Present in the first 24 hours of life\nbilirubin, while Dubin-Johnson and\nRotor have a defective DooR for\nBilirubin â†‘ <5 mg/dL/day Bilirubin â†‘ >5 mg/dL/day secretion of bilirubin.\nBilirubin peaking at <14â€“15 mg/dL Bilirubin peaks at >15 mg/dL\nDirect bilirubin <10% of total Direct bilirubin >10% of total\nResolves by 2â€“3 weeks in term infants Persists beyond 2â€“3 weeks in term infants\nKEY FACT\nUNCONJUGATED Breast milk jaundice and\nbreastfeeding jaundice both cause\nBreastfeeding increased enterohepatic circulation\njaundice of unconjugated bilirubin. It is\nBreast milk jaundice\nhypothesized that factors found in\nbreast milk may inhibit hepatic enzyme\nImpaired conjugation\nUGT1A1. Breastfeeding jaundice\nBilirubin production\nis due to inadequate milk, â†’ â†‘ in\nenterohepatic circulation. Breastfee",
      "char_start": 1462000,
      "char_end": 1464000
    },
    {
      "chunk_id": 732,
      "text": "ding\njaundice occurs in the first week of life,\nwhereas breast milk jaundice peaks in\nthe second week of life. Treatment of\nbreastfeeding jaundice is hydration.\nCONJUGATED\nBreast milk jaundice does not require\ntreatment, as it resolves with time.\nBiliary obstruction\nImpaired uptake or\nsecretion\nFIGURE 2.12-3. Conjugated vs unconjugated hyperbilirubinemia. (Reproduced with permission from\nUSMLE-Rx.com.)\nHistory/PE\nSee Table 2.12-11.\nâ–  History should focus on diet (breast milk or formula), intrauterine drug\nexposure, and family history (hemoglobinopathies, enzyme deficiencies,\nRBC defects).\nâ–  PE may reveal signs of hepatic or GI dysfunction (abdominal distention,\ndelayed passage of meconium, light-colored stools, dark urine), infection,\nor birth trauma (cephalohematomas, bruising, pallor, petechiae).\nâ–  Kernicterus presents with lethargy, poor feeding, a high-pitched cry, hyper-\ntonicity, and seizures. A 3-day-old boy born at\nâ–  Jaundice may follow a cephalopedal progression as bilirubin concentra- 39 weeksâ€™ gestational age via normal\ntions â†‘. spontaneous vaginal delivery has\nfailed to pass meconium and today\ndisplays abdominal distention and\nfive episodes of bilious vomiting.\nRectal examination shows no stool in\nthe rectal vault. Air contrast enema\nshows an obstruction at the ileum.\nWhat is the most likely cause of this\npatientâ€™s symptoms?\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552233 1100//2211//2222 44::2211 PPMM\n\n524 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-11. Mechanisms of Neonatal Jaundice\nMECHANISM EXAMPLE(S) PREDOMINANT BILIRUBIN SPECIES\nâ†‘ bilirubin production; mechanism Hemolysis (ABO or Rh incompatibility) â†‘ unconjugated bilirubin\nis via hemolysis Erythrocyte enzyme deficiency (glucose-6-phosphate\ndehydrogenase [G6PD] and pyruvate kinase deficiency)\nErythrocyte structural defects (sickle cell anemia, hereditary\nspherocytosis)\nIneffective erythropoiesis (thalassemias)\nSepsis with disseminated intravascular coagulati",
      "char_start": 1464000,
      "char_end": 1466000
    },
    {
      "chunk_id": 733,
      "text": "on (DIC)\nImpaired conjugation of bilirubin Gilbert syndrome â†‘ unconjugated bilirubin\nCrigler-Najjar syndrome\nNewborn physiologic jaundice\nImpaired bilirubin uptake and Dubin-Johnson syndrome â†‘ conjugated bilirubin\nsecretion from the liver Rotor syndrome\nâ†‘ enterohepatic circulation Poor feeding/breastfeeding jaundice â†‘ unconjugated bilirubin\nBreast milk jaundice\nDehydration\nObstruction of biliary tree and â†“ Biliary/choledochal cyst â†‘ conjugated bilirubin\nexcretion Biliary atresia\nAlagille syndrome (ie, too few bile ducts for adequate bile\ndrainage)\nDiagnosis\nâ–  For indirect hyperbilirubinemia, complete blood cell count (CBC) with\nperipheral blood smear (abnormal RBCs and signs of hemolysis); blood\ntyping of mother and infant (ABO or Rh incompatibility); Coombs test\nand bilirubin levels\nâ–  For direct hyperbilirubinemia, liver function tests (LFTs), bile acids, assess\nliver anatomy and biliary tract via ultrasound and/or hydroxy iminodiacetic\nacid (HIDA) scan can confirm suspected cholestatic disease\nâ–  A jaundiced neonate who is febrile, hypotensive, and/or tachypneic needs\na full sepsis workup and intensive care unit (ICU) monitoring\nTreatment\nâ–  Treat underlying causes (eg, infection).\nâ–  Treat unconjugated hyperbilirubinemia with phototherapy (for mild eleva-\ntions) or exchange transfusion (for severe elevations >20 mg/dL). Start pho-\nThis infant most likely has meconium\ntotherapy earlier (10â€“15 mg/dL) for preterm infants. Phototherapy is not\nileus resulting from CF; however,\nindicated for conjugated hyperbilirubinemia and can lead to skin bronzing.\nHirschsprung disease should remain\non the differential diagnosis, as it\nalso can cause delayed meconium RESPIRATORY DISTRESS SYNDROME\npassage. Meconium ileus causes\nobstruction at the level of the ileum,\nRespiratory distress syndrome ([RDS]; also known as neonatal respiratory dis-\nwhereas Hirschsprung disease causes\nKEY FACT\ntress syndrome [NRDS]) is the most common cause of respiratory failure in\nrectosigmoid obstruction, a",
      "char_start": 1466000,
      "char_end": 1468000
    },
    {
      "chunk_id": 734,
      "text": "nd a rectal\nDexiraemct m(caoyn rjuesgualtte idn) e hxyppuelsrbioilnir uobf sintoeoml.ia\npreterm infants (affects >70% of infants born at 28 to 30 weeks GA); it was\nis always pathologic.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552244 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 525\nformerly known as hyaline membrane disease. Surfactant deficiency leads to\npoor lung compliance, alveolar collapse, and atelectasis. Risk factors include\nC-section, maternal diabetes mellitus (DM), male sex, and the second born of\ntwins.\nHistory/PE\nPresents in the first 48 to 72 hours of life with a respiratory rate >60/min, pro-\ngressive hypoxemia, cyanosis, nasal flaring, intercostal retractions, and expira-\ntory grunting\nDiagnosis\nâ–  Arterial blood gases (ABGs), CBC, and blood cultures to rule out\ninfection\nâ–  Clinical diagnosis confirmed with characteristic findings on x-ray of the\nchest (CXR); see Table 2.12-12.\nTreatment\nâ–  Continuous positive airway pressure (CPAP) or intubation and mechani-\ncal ventilation\nâ–  Artificial surfactant administration â†“ mortality\nâ–  Pretreatment of mothers at risk for preterm delivery (24 weeks to 336/ 7\nweeks) in the next 7 days with corticosteroids\nTABLE 2.12-12. X-ray of the Chest Findings in Neonatal Lung Pathology\nDISEASE PROCESS KEY FINDINGS\nNRDS Ground-glass appearance (see Image A), air\nbronchograms, and lack of focal opacities\nTransient tachypnea of the newborn (retained Perihilar streaking (see Image B) in inter-\namniotic fluid in respiratory tract) lobular fissures\nMeconium aspiration Coarse, irregular infiltrates, lung hyperex-\npansion, and pneumothorax\nCongenital pneumonia Nonspecific patchy infiltrates\nA B\nImage A reproduced with permission from Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine: A\nComprehensive Study Guide, 7th ed. New York, NY: McGraw-Hill; 2010. Image B reproduced with\npermission from Alorainy IA, Barlas NB, Al-Boukai AA. Pictorial essay: Infants of diabetic mothe",
      "char_start": 1468000,
      "char_end": 1470000
    },
    {
      "chunk_id": 735,
      "text": "rs.\nIndian J Radiol Imaging. 2010;20(3):174â€“181.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552255 1100//2211//2222 44::2211 PPMM\n\n526 HIGH-YIELD FACTS IN PEDIATRICS\nComplications\nPersistent patent ductus arteriosus (PDA), bronchopulmonary dysplasia, reti-\nnopathy of prematurity, barotrauma from positive pressure ventilation, intraven-\ntricular hemorrhage, and necrotizing enterocolitis (NEC) are complications of\ntreatment.\nGERMINAL MATRIX HEMORRHAGE\nOften occurs in preterm infants or low-BW infants due to the fragility of their\ngerminal matrix, a highly vascular region important for fetal neural develop-\nment. Caused by decreased cerebral blood flow leading to ischemia and\nreperfusion injury. Many cases (up to 50%) are asymptomatic. More severe\ncases can be characterized by hypotonia, decreased level of consciousness, sei-\nzures, and irregular respirations. Germinal matrix hemorrhage can be diag-\nnosed with head ultrasound. Management is often supportive.\nAPNEA OF PREMATURITY\nIntermittent cessation of respiration for >20 seconds in premature infants\n(gestational age <37 weeks) due to immaturity of the central respiratory cen-\nters. Affects almost all infants with a gestational age <28 weeks. Presents with\nepisodes of intermittent apnea with bradycardia and desaturation in a prema-\nture infant who is healthy and well between episodes. Diagnosis is clinical,\nand alternative causes should be ruled out. Treatment involves noninvasive\nventilation and methylxanthines such as caffeine, which stimulate the respira-\ntory drive. Apnea of prematurity resolves with maturity (by 37 weeks in an\ninfant born >28 weeks).\nNEONATAL EXTRACRANIAL INJURIES\nExtracranial injuries in the newborn often occur secondary to instrumenta-\ntion injury during delivery. The layers of the head from outermost to inner-\nmost are skin, epicranial aponeurosis, periosteum, bone, dura mater, and\narachnoid mater. Table 2.12-13 shows the commonly tested extracranial\nin",
      "char_start": 1470000,
      "char_end": 1472000
    },
    {
      "chunk_id": 736,
      "text": "juries.\nCONGENITAL HYPOTHYROIDISM\nThyroid hormone deficiency in the neonate, often asymptomatic at birth due\nto transplacental transfer of maternal thyroxine. Most commonly due to thy-\nroid dysgenesis in the United States. Other causes include thyroid agenesis,\niodine deficiency (most common cause in underdeveloped countries), dyshor-\nmonogenesis (autosomal recessive), and transfer of maternal antibodies.\nHistory/PE\nâ–  Usually asymptomatic at birth; may cause delayed passage of meconium\ndue to decreased intestinal motility\nâ–  Manifestations after decrease of maternal thyroid hormone, including leth-\nargy, hypotonia, large protruding tongue, umbilical hernia, enlarged fonta-\nnelle, constipation, jaundice, pale dry skin, and intellectual disability\nDiagnosis\nNewborn screening mandatory with thyroid-stimulating hormone (TSH) lev-\nels 24 to 48 hours. Increased TSH levels indicate hypothyroidism.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552266 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 527\nTABLE 2.12-13. Neonatal Extracranial Injuries\nTYPE OF INJURY DESCRIPTION\nCaput succedaneum Edema or hematoma of the scalp that commonly occurs secondary to\nvacuum extraction\nLocated above the periosteum and crosses suture lines; resolves\nspontaneously without treatment\nCephalhematoma Hematoma that forms below the periosteum commonly over the\nparietal or occipital bone and does not cross suture lines; resolves\nspontaneously without treatment\nComplications: Infection and infant jaundice (due to breakdown of a\nlarge hematoma)\nSubgaleal Bleeding into the subgaleal space between the periosteum and epi-\nhemorrhage cranial aponeurosis (galea aponeurotica) due to injury to emissary\nveins by traction during delivery; presents as a fluctuant diffuse\nswelling that can shift with movement and crosses suture lines; the\nsubgaleal space extends from orbital ridges anteriorly to the nape\nof the neck posteriorly and can hold 40% of a neonateâ€™s",
      "char_start": 1472000,
      "char_end": 1474000
    },
    {
      "chunk_id": 737,
      "text": " total blood\nvolume, resulting in significant volume depletion and hemorrhagic\nshock; treatment is by volume resuscitation and correction of\ncoagulopathy\nMNEMONIC\nTreatment\nâ–  Levothyroxine; avoid coadministration with soy, calcium, and iron due to 6Ps of congenital\ndecreased absorption hypothyroidismâ€”\nâ–  Untreated or delayed treatment of disease causes decreased neurocognitive Potbellied\nfunction (eg, decreased intelligence quotient) Pale\nPuffy face\nProtruding umbilicus\nBENIGN NEONATAL RASHES\nProtruding tongue\nPoor brain development\nTable 2.12-14 lists the common benign neonatal rashes.\nNEONATAL ABSTINENCE SYNDROME\nWithdrawal symptoms in neonates born to females with narcotic dependence\nduring pregnancy. Newborns at high risk include those born to females with\npoor social support, poor mental health, no prenatal care, intravenous drug\nuse (IVDU) infections (eg, hepatitis C), or mothers requiring chronic pre-\nscription opioids.\nHistory/PE\nâ–  It usually presents >24 hours after birth due to withdrawal from transpla-\ncental opiates. It may present earlier if mother used heroin (short half-life).\nâ–  Central nervous symptoms (CNS) symptoms include shortened sleep-\nwake cycles, hypertonia, tremor, and suck-swallow incoordination.\nâ–  Autonomic symptoms include diaphoresis, sneezing, and yawning.\nâ–  Other symptoms include irritability, vomiting, and diarrhea.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552277 1100//2211//2222 44::2211 PPMM\n\n528 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-14. Benign Neonatal Rashes MNEMONIC\nRASH DESCRIPTION MANAGEMENT\nCyanotic heart shuntsâ€”\nErythema toxicum Onset within first 3 days of life Observation; resolves in The 5 Ts\nneonatorum Presents as erythematous pustules on the 1 week Truncus arteriosus\ntrunk and proximal extremities Transposition\nTricuspid atresia\nMilia Presents at birth Observation; resolves in Tetralogy of Fallot (TOF)\nTotal anomalous pulmonary venous return\nPresents as white, firm papules on ",
      "char_start": 1474000,
      "char_end": 1476000
    },
    {
      "chunk_id": 738,
      "text": "the face 1 month\n(TAPVR)\nMilia rubra Not present at birth, can develop any time Prevent overheating\n(heat rash) afterward Topical corticosteroids if KEY FACT\nPresents as erythematous papules on severe\nVSD is the most common type of CHD.\noccluded and intertriginous areas due\nVentricular septal defects occur most\nto blockage of eccrine sweat ducts in\ncommonly in the membranous septum,\nthe setting of increased heat\nand most resolve without intervention.\nNeonatal pustular Presents at birth Observation, as pustules\nmelanosis Presents as diffuse, nonerythematous pus- resolve within days\nMNEMONIC\ntules that evolve into hyperpigmented Possible for hyperpig-\nmacules with a scale mentation to take VACTERL-H includes:\nMay involve the palms and soles months to resolve\nVertebral anomalies\nAnal atresia\nNeonatal cephalic Onset around 3 weeks of age Observation immediately after birth. It usually requires urgent surgical treatment and/\nCardiac anomalies (ASD, VSD, PDA)\npustulosis Presents as erythematous papules and May take weeks to or maintenance of PDA. Tracheal-esophageal fistula\n(neonatal acne) pustules only on the face and scalp months to resolve Esophageal atresia\nRenal structural anomalies\nTopical corticosteroids or ACYANOTIC CONGENITAL HEART LEFT-TO-RIGHT SHUNTS\nLimb anomalies, essentially radii and/or\nketoconazole if severe\nthumbs\nMay be asymptomatic at birth. The severity of clinical presentation varies\nHydrocephalus\nwith defect size. Each has a characteristic murmur. Ventral septal defect\n(VSD) is the most common. PDA is less common overall but most common\nin prematurity. Uncorrected clinically significant left-to-right shunts â†’ â†‘ pul- KEY FACT\nDiagnosis/Treatment monary blood flow â†’ pathologic remodeling of vasculature â†’ pulmonary\nâ–  Clinical diagnosis; confirmation with drug testing of umbilical cord blood, arterial hypertension and right ventricular hypertrophy (RVH) â†’ right-left The size of the VSD is inversely\nurine, or stool shunt reversal (Eisenmenger syndrome). p",
      "char_start": 1476000,
      "char_end": 1478000
    },
    {
      "chunk_id": 739,
      "text": "roportional to the intensity of the\nmurmur. The smaller the VSD, the more\nâ–  Mild withdrawal treated with nonpharmacologic approach: Quiet environ-\nintensely the murmur will be heard.\nment, swaddling, small frequent feeding\nSEPTAL DEFECTS\nâ–  Severe withdrawal treated with morphine and methadone followed by\ntapering and support\nKEY FACT\nA condition in which a defective opening in the atrial (ASD) or ventricular\n(VSD) septum allows blood to flow between the atria or ventricles, leading to ASD has a fixed, widely split S.\n2\nleft-to-right shunting (left-side pressures > right-side pressures). VSD is the\nCONGENITAL HEART DISEASE\nmost common type of CHD.\nKEY FACT\nIntrauterine risk factors for CHD include maternal illness (DM, phenylketon- Presentation and Diagnosis\nuria [PKU]), drug use (alcohol, lithium, thalidomide, phenytoin, retinoic acid), A venous hum is a benign murmur\nSee Table 2.12-16.\nand infections (rubella). CHD can also be associated with fetal genetic syn- that can be present in childhood. The\ndromes. See Table 2.12-15 for a list of common associations with cardiac defects. Treatment murmur is a low-pitched, vibratory\nMNEMONIC CHD is classified by the presence or absence of cyanosis at birth or shortly murmur that is heard near the\nafter: â–  Most small ASDs/VSDs close spontaneously and do not require treatment. clavicle throughout the cardiac cycle.\nNoncyanotic heart shuntsâ€” Follow-up echocardiography is scheduled based on size of ASD/VSD and\nUnlike the murmur of hypertrophic\nThe 3 Ds â–  Acyanotic CHD (â€œpink babiesâ€): Have left-to-right shunts (oxygenated physical examination. cardiomyopathy, a venous hum\nblood is shunted back into the pulmonary circulation) or no shunt (eg, â–  Antibiotic prophylaxis is generally not needed before procedures.\nVSD murmur is loudest when sitting and\nbefore congenital obstruction). â–  If congestive heart failure (CHF) develops, best initial treatment involves\nASD disappears with supine position or neck\nâ–  Cyanotic CHD (â€œblue babiesâ€):",
      "char_start": 1478000,
      "char_end": 1480000
    },
    {
      "chunk_id": 740,
      "text": " Have right-to-left shunts (deoxygenated medical management of CHF, using the following:\nPDA rotation.\nblood is shunted into the systemic circulation). Diagnosed prenatally or â–  Diuretics\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552288 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 529\nTABLE 2.12-15. Congenital Cardiac Defect Associations MNEMONIC\nDEFECT ASSOCIATION\nCyanotic heart shuntsâ€”\nAV septal defect (endocardial cushion defect), Down syndrome The 5 Ts\nVSD, ASD Truncus arteriosus\nTransposition\nPDA, pulmonary artery stenosis, septal defects Congenital rubella Tricuspid atresia\nTetralogy of Fallot (TOF)\nCoarctation of the aorta, bicuspid aortic valve Turner syndrome Total anomalous pulmonary venous return\n(TAPVR)\nDiGeorge syndrome Truncus arteriosus, tetralogy of Fallot\nSupravalvular aortic stenosis Williams syndrome KEY FACT\nVSD is the most common type of CHD.\nEbstein anomaly (apical displacement of the tricuspid Prenatal lithium exposure\nVentricular septal defects occur most\nvalve leading to atrialization of the right ventricle)\ncommonly in the membranous septum,\nand most resolve without intervention.\nVSD, PDA, ASD, tetralogy of Fallot Prenatal alcohol exposure\nVSD and transposition of the great arteries Maternal diabetes during pregnancy\nMNEMONIC\nVACTERL-H includes:\nVertebral anomalies\nAnal atresia\nimmediately after birth. It usually requires urgent surgical treatment and/\nCardiac anomalies (ASD, VSD, PDA)\nor maintenance of PDA.\nTracheal-esophageal fistula\nEsophageal atresia\nRenal structural anomalies\nACYANOTIC CONGENITAL HEART LEFT-TO-RIGHT SHUNTS\nLimb anomalies, essentially radii and/or\nthumbs\nMay be asymptomatic at birth. The severity of clinical presentation varies\nHydrocephalus\nwith defect size. Each has a characteristic murmur. Ventral septal defect\n(VSD) is the most common. PDA is less common overall but most common\nin prematurity. Uncorrected clinically significant left-to-right shunts â†’ â†‘ pul- ",
      "char_start": 1480000,
      "char_end": 1482000
    },
    {
      "chunk_id": 741,
      "text": "KEY FACT\nmonary blood flow â†’ pathologic remodeling of vasculature â†’ pulmonary\narterial hypertension and right ventricular hypertrophy (RVH) â†’ right-left The size of the VSD is inversely\nshunt reversal (Eisenmenger syndrome). proportional to the intensity of the\nmurmur. The smaller the VSD, the more\nintensely the murmur will be heard.\nSEPTAL DEFECTS\nKEY FACT\nA condition in which a defective opening in the atrial (ASD) or ventricular\n(VSD) septum allows blood to flow between the atria or ventricles, leading to ASD has a fixed, widely split S.\n2\nleft-to-right shunting (left-side pressures > right-side pressures). VSD is the\nmost common type of CHD.\nKEY FACT\nPresentation and Diagnosis\nA venous hum is a benign murmur\nSee Table 2.12-16.\nthat can be present in childhood. The\nTreatment murmur is a low-pitched, vibratory\nMNEMONIC murmur that is heard near the\nâ–  Most small ASDs/VSDs close spontaneously and do not require treatment.\nclavicle throughout the cardiac cycle.\nNoncyanotic heart shuntsâ€” Follow-up echocardiography is scheduled based on size of ASD/VSD and\nUnlike the murmur of hypertrophic\nphysical examination.\nThe 3 Ds cardiomyopathy, a venous hum\nâ–  Antibiotic prophylaxis is generally not needed before procedures.\nVSD murmur is loudest when sitting and\nâ–  If congestive heart failure (CHF) develops, best initial treatment involves\nASD disappears with supine position or neck\nmedical management of CHF, using the following:\nPDA rotation.\nâ–  Diuretics\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 552299 1100//2211//2222 44::2211 PPMM\n\n530 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-16. Presentation and Diagnosis of ASD vs VSD\nASD (SEE IMAGE A) VSD (SEE IMAGE B)\nAssociated syndromes Holt-Oram syndrome (absent radii, ASD, first-degree Holt-Oram syndrome\nheart block) Fetal alcohol syndrome\nFetal alcohol syndrome Toxoplasmosis, other agents (syphilis, varicella, and\nTrisomies (13, 18, 21) zika virus), rubella, cytomegalovirus, herpes simplex\nTu",
      "char_start": 1482000,
      "char_end": 1484000
    },
    {
      "chunk_id": 742,
      "text": "rner syndrome (TORCH infections)\nCri du chat syndrome\nTrisomies (13, 18, and 21)\nTurner syndrome\nPresentation Small defects: Asymptomatic Small defects: Asymptomatic\nLarge defects: Easy fatiguability, FFT, recurrent respira- Large defects: Easy fatiguability, FFT, recurrent respi-\ntory infections, CHF ratory infections, CHF\nAuscultation findings Wide and fixed split S Harsh holosystolic murmur at lower-left sternal border\n2\nSystolic ejection murmur at the upper left sternal (louder for small defects)\nborder (â†‘ flow across pulmonary valve) Narrow S with â†‘ P (large defect)\n2 2\nMid-diastolic ruble at the left sternal border (caused by Mid-diastolic apical rumble (caused by increased flow\nincreased flow across tricuspid valve) across mitral valve)\nCXR findings Cardiomegaly Cardiomegaly\nâ†‘ pulmonary vascular markings â†‘ pulmonary vascular markings\nEchocardiogram findings Right ventricular hypertrophy Left ventricular hypertrophy (LVH)\nRight atrial enlargement RVH may be found in large defects\nDefect and blood flow across atrial septum Defect and blood flow across ventricular septum\nA Pulmonary artery B Pulmonary artery\nAtrial septal\nPulmonary\ndefect\nveins\nVentricular\nseptal defect\nImages reproduced with permission from USMLE-Rx.com.\nâ–  Then positive inotropes and angiotensin-converting enzyme inhibitors\nâ–  Surgical correction is indicated in symptomatic patients who:\nâ–  Fail in medical management\nâ–  <1 year of age with signs of pulmonary hypertension\nâ–  Older children with large defects that have not â†“ in size over time\nâ–  Early correction prevents complications such as arrhythmias, right ventric-\nular dysfunction, and Eisenmenger syndrome\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553300 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 531\nPATENT DUCTUS ARTERIOSUS\nPDA (Fig. 2.12-4) is a failure of the ductus arteriosus to close completely post-\nnatally â†’ left-to-right shunt from the aorta to the pulmonary artery. PDA is\nasso",
      "char_start": 1484000,
      "char_end": 1486000
    },
    {
      "chunk_id": 743,
      "text": "ciated with prematurity and congenital rubella syndrome.\nHistory/PE\nâ–  Patients with large defects may present with FTT, recurrent lower respira-\ntory tract infections, and CHF.\nâ–  Examination reveals a continuous â€œmachinery murmurâ€ at the second left\nintercostal space at the sternal border, a loud S , a wide pulse pressure,\n2\nand bounding peripheral pulses.\nâ–  Uncorrected PDA can eventually result in cyanosis (blue toes, normal fin-\ngers) through an Eisenmenger syndrome. FIGURE 2.12-4. Patent ductus arteriosus\nwith resultant left-to-right shunting\n(arrow). Ao, Aorta; PA, pulmonary artery;\nDiagnosis\nPDA, patent ductus arteriosus; LPA,\nâ–  Best initial test: Echocardiogram will demonstrate the defect. Large PDAs left pulmonary artery; LV, left ventricle.\nwill show left atrial and left ventricular enlargement. (Reproduced with permission from Henjes CR, Nolte I,\nâ–  Doppler color flow will demonstrate blood shunting from the aorta into Wesfaedt P. Multidetector-row computed tomography\nof thoracic aortic anomalies in dogs and cats: patent\nthe pulmonary artery.\nductus arteriosus and vascular rings. BMC Vet Res.\nâ–  ECG may show left ventricular hypertrophy (LVH), and CXR may reveal 2011;7:57. DOI: 10.1186/1746-6148-7-57.)\ncardiomegaly with large PDAs.\nTreatment MNEMONIC\nâ–  Best initial treatment: Indomethacin (a nonsteroidal anti-inflammatory Come IN and CLOSE the door. Give\ndrug [NSAID]) unless the PDA is needed for survival (eg, transposition of INdomethacin to CLOSE a PDA.\nthe great arteries, tetralogy of Fallot [TOF], hypoplastic left heart), or if\nindomethacin is contraindicated (eg, intraventricular hemorrhage).\nâ–  If indomethacin fails or if the infant is >2 weeks of age, surgical closure is KEY FACT\ntypically required.\nCoarctation of the aorta and bicuspid\naortic valve are associated with Turner\nCOARCTATION OF THE AORTA syndrome.\nAortic narrowing near insertion of ductus arteriosus (â€œjuxtaductalâ€), just dis-\ntal to the left subclavian artery â†’ â†‘ flow proximal to and â†“ flow",
      "char_start": 1486000,
      "char_end": 1488000
    },
    {
      "chunk_id": 744,
      "text": " distal to the KEY FACT\ncoarctation (Fig. 2.12-5). Associated with Turner syndrome, bicuspid aortic\nIn infants presenting in shock within\nvalve (found in more than two out of three cases), and intracranial aneu-\nthe first few weeks of life, look for:\nrysms. More common among male sex. Complications include heart failure\nâ–  Sepsis\n(HF), aortic rupture, endocarditis, and cerebral hemorrhage (due to berry\nâ–  Inborn errors of metabolism\naneurysms).\nâ–  Ductal-dependent CHD, usually left-\nsided lesions\nHistory/PE\nâ–  Congenital adrenal hyperplasia\nâ–  If not detected on newborn screening, then will next present in childhood\nwith asymptomatic hypertension (upper extremity hypertension); classic\nPE findings are systolic hypertension in upper extremities, low blood pres-\nsure (BP), and weak or delayed pulse (brachiofemoral delay) in lower\nextremities; the difference in BP between the left and right arm can indi-\ncate the point of coarctation.\nâ–  A systolic ejection or continuous murmur may be heard in the interscapu-\nA 2-year-old boy is brought to the\nlar region.\npediatrician because of shortness of\nâ–  Lower extremity claudication, syncope, epistaxis, and headache may be breath and easy fatigability during\npresent. play. Physical examination is notable\nâ–  In infancy, critical coarctation requires a PDA for survival. Such infants for tachypnea and a harsh 2/6\nmay present in the first few days of life with poor feeding, lethargy, tachy- holosystolic murmur over the lower\npnea, and an eventual shocklike state when the PDA closes. During the left sternal border. What is the most\nnewborn screening for coarctation of aorta, differential cyanosis may be likely cause of the boyâ€™s symptoms?\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553311 1100//2211//2222 44::2211 PPMM\n\n532 HIGH-YIELD FACTS IN PEDIATRICS\nA B History/PE\nCoarctation\nLigamentum Axillary â–  Transposition of the great arteries typically presents within the first few\nartery\narteriosum hours af",
      "char_start": 1488000,
      "char_end": 1490000
    },
    {
      "chunk_id": 745,
      "text": "ter birth. It is not affected by exertion or supplemental oxygen use.\nReverse differential cyanosis (higher postductal saturations than preductal\nsaturations) may be seen if left ventricular outflow tract obstruction (eg,\ncoarctation, aortic stenosis) is also present.\nAscending\naorta â–  Physical examination reveals tachypnea, progressive hypoxemia, and\nextreme cyanosis. Patient may have CHF, single loud S , and a systolic\nPulmonary 2\nartery Intercostal murmur (only if coexisting with VSD).\nDescending arteries\naorta\nInternal Diagnosis\nthoracic\nFIGURE 2.12-5. Coarctat a io rt n er o y f the aorta, â–  Best initial test: Echocardiography showing abnormal formation of the\ncausing severe obstruction of flow to great arteries\nFIGURE 2.12-6. Coarctation of the aorta. (A) Magnified view of the left upper thorax of a\nthe descending thoracic aorta. (Repro- patient with aortic coarctation showing multiple areas of rib notching (arrows). (B) Postero- â–  Classic CXR may show a heart with an â€œegg on a stringâ€ appearance\nduced with permission from USMLE-Rx.com.)\nanterior view of another patient with aortic coarctation showing the â€œ3 signâ€ of the deformed\ndescending aorta and â€œE signâ€ on the barium-filled esophagus (upper arrow). The lower arrow Treatment\nmarks the apex of the enlarged left ventricle. The arrow on the patientâ€™s right indicates the\ndilated ascending aorta. (Reproduced with permission from Fuster V et al. Hurstâ€™s The Heart, 13th ed. New York, NY: â–  Best initial treatment: Intravenous PGE 1 to maintain or open the PDA\nMcGraw-Hill; 2011.) â–  To allow some time for growth for a more successful surgical outcome, a\nballoon atrial septostomy is performed to create a shunt that is not reliant\non the PDA and prostaglandin infusion\nMNEMONIC\nseen with lower O saturation in the lower extremities (postductal areas) as â–  Most definitive treatment: Surgical correction (arterial switch operation)\n2\ncompared with the right arm (preductal area). DiGeorge syndromeâ€”\nMNEMONIC\nTETRALOGY OF FA",
      "char_start": 1490000,
      "char_end": 1492000
    },
    {
      "chunk_id": 746,
      "text": "LLOT\nCATCH 22\nCyanotic heart defectsâ€” Diagnosis\nCardiac abnormalities (TOF, VSD)\nConsists of right ventricular outflow tract (RVOT) obstruction, overriding\nThe five Ts that have right-to- â–  Best initial test: Echocardiography with Doppler color flow. Abnormal facies (retrognathia/\naorta, RVH, and VSD (see Fig. 2.12-8). Among the more common cyanotic\nleft shunts: â–  If presenting late in childhood or young adulthood untreated, CXR will micrognathia, long face, short philtrum,\nCHDs in children. Early cyanosis results from right-to-left shunting across the\nTruncus arteriosus (1 arterial vessel demonstrate cardiomegaly and pulmonary congestion (in infants) and rib low-set ears)\noverriding ventricles) notching of the chest (see Fig. 2.12-6A) due to enlarged intercostal arteries VSD due to high right-sided pressures from RVOT obstruction. As right-sided Thymic aplasia\npressures â†“ in the weeks after birth, the shunt direction reverses and cyanosis Cleft palate\nTransposition of the great arteries and the classic â€œ3â€ sign (see Fig. 2.12-6B) created by aortic wall indenta-\nresolves. If the degree of pulmonary stenosis is severe, the right-sided pressures Hypocalcemia (secondary to\n(2 arteries switched) tion with pre- and post-stenotic dilatation (in older children and adults).\nmay remain high and cyanosis may persist. Risk factors include trisomy 21 hypoparathyroidism)\nTricuspid atresia (3) â–  In older children, compensatory LVH may be seen on ECG.\nTetralogy of Fallot (4) and DiGeorge syndrome. 22q11 deletion\nTotal anomalous pulmonary venous return\nTreatment\n(5 words) History/PE\nâ–  Best initial treatment: If severe coarctation in infancy, prostaglandin E\n1 â–  TOF presents in infancy or early childhood with dyspnea and fatigability.\n(PGE ) to maintain ductus arteriosus patency prior to surgical repair\n1 Cyanosis is frequently absent at birth but develops over the first 2 years of\nâ–  Surgical repair in infants or toddlers or balloon angioplasty in older chil- KEY FACT\nlife; the degr",
      "char_start": 1492000,
      "char_end": 1494000
    },
    {
      "chunk_id": 747,
      "text": "ee of cyanosis often reflects the extent of RVOT obstruction.\ndren, with or without stent placement\nâ–  Infants are often asymptomatic until 4 to 6 months of age, when CHF may Both transposition of the great arteries\nKEY FACT â–  Monitoring for persistent hypertension, restenosis, aneurysm development, develop and manifest as diaphoresis with feeding or tachypnea. and tetralogy of Fallot are initially\nand aortic dissection\nâ–  Children often squat for relief during hypoxemic episodes called â€œtet treated with PGE 1 but are definitively\nCyanotic CHD does not respond to\nspells,â€ which â†‘ systemic vascular resistance, thus increasing blood flow to treated with surgical correction.\n100% oxygen challenge (minimal\nCYANOTIC CONGENITAL HEART RIGHT-TO-LEFT SHUNTS the pulmonary vasculature and improving oxygenation.\neffect on Pao), whereas most lung\n2 â–  Hypoxemia may lead to FTT and/or cognitive or developmental delays.\npathologies will respond to 100%\nPatients typically present with central cyanosis soon after birth. â–  PE may reveal a systolic ejection murmur at the left upper sternal border\noxygen administration.\ndue to pulmonic stenosis and/or a harsh holosystolic murmur at the left\nlower sternal border due to VSD.\nTRANSPOSITION OF THE GREAT ARTERIES\nDiagnosis\nAmong the more common cyanotic congenital heart conditions in new-\nborns (see Fig. 2.12-7). The aorta arises from the right ventricle (anterior), â–  Best initial tests: Echocardiography and catheterization.\nand the pulmonary trunk arises from the left ventricle (posterior) â†’ separa- â–  CXR shows a â€œboot-shapedâ€ heart with â†“ pulmonary vascular markings.\nThis boy probably has a large, Remember that an isolated VSD, without RVOT, may result in â†‘ pulmo-\ntion of pulmonary and systemic circulations. Life is incompatible unless a\nuntreated VSD that is presenting with nary vascular markings.\nshunt is present to allow mixing of blood (VSD, PDA, or patent foramen\nCHF. There is less turbulence across\novale). A PDA alone is usually not su",
      "char_start": 1494000,
      "char_end": 1496000
    },
    {
      "chunk_id": 748,
      "text": "fficient to allow adequate mixing of â–  ECG shows right-axis deviation and RVH.\na large defect (compared with a\nsmall one), leading to a lower-grade blood. Risk factors include mothers with preexisting diabetes and, rarely,\nmurmur. DiGeorge syndrome.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553322 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 533\nHistory/PE\nâ–  Transposition of the great arteries typically presents within the first few\nhours after birth. It is not affected by exertion or supplemental oxygen use.\nReverse differential cyanosis (higher postductal saturations than preductal\nsaturations) may be seen if left ventricular outflow tract obstruction (eg,\ncoarctation, aortic stenosis) is also present.\nâ–  Physical examination reveals tachypnea, progressive hypoxemia, and\nextreme cyanosis. Patient may have CHF, single loud S , and a systolic\n2\nmurmur (only if coexisting with VSD).\nDiagnosis\nâ–  Best initial test: Echocardiography showing abnormal formation of the\ngreat arteries\nFIGURE 2.12-7. Complete transposi-\nâ–  Classic CXR may show a heart with an â€œegg on a stringâ€ appearance tion of the great arteries. Deoxygenated\nblood from the right ventricle is directed\nTreatment to the aorta, and oxygenated blood is\ndirected back to the pulmonary artery.\nâ–  Best initial treatment: Intravenous PGE to maintain or open the PDA\n1 (Reproduced with permission from USMLE-Rx.com.)\nâ–  To allow some time for growth for a more successful surgical outcome, a\nballoon atrial septostomy is performed to create a shunt that is not reliant\non the PDA and prostaglandin infusion\nMNEMONIC\nâ–  Most definitive treatment: Surgical correction (arterial switch operation)\nDiGeorge syndromeâ€”\nTETRALOGY OF FALLOT\nCATCH 22\nCardiac abnormalities (TOF, VSD)\nConsists of right ventricular outflow tract (RVOT) obstruction, overriding\nAbnormal facies (retrognathia/\naorta, RVH, and VSD (see Fig. 2.12-8). Among the more common cyanotic\nmicrognathia, long face,",
      "char_start": 1496000,
      "char_end": 1498000
    },
    {
      "chunk_id": 749,
      "text": " short philtrum,\nCHDs in children. Early cyanosis results from right-to-left shunting across the\nlow-set ears)\nVSD due to high right-sided pressures from RVOT obstruction. As right-sided Thymic aplasia\npressures â†“ in the weeks after birth, the shunt direction reverses and cyanosis Cleft palate\nresolves. If the degree of pulmonary stenosis is severe, the right-sided pressures Hypocalcemia (secondary to\nmay remain high and cyanosis may persist. Risk factors include trisomy 21 hypoparathyroidism)\nand DiGeorge syndrome. 22q11 deletion\nHistory/PE\nâ–  TOF presents in infancy or early childhood with dyspnea and fatigability.\nCyanosis is frequently absent at birth but develops over the first 2 years of\nKEY FACT\nlife; the degree of cyanosis often reflects the extent of RVOT obstruction.\nâ–  Infants are often asymptomatic until 4 to 6 months of age, when CHF may Both transposition of the great arteries\nKEY FACT develop and manifest as diaphoresis with feeding or tachypnea. and tetralogy of Fallot are initially\nâ–  Children often squat for relief during hypoxemic episodes called â€œtet treated with PGE 1 but are definitively\nCyanotic CHD does not respond to\nspells,â€ which â†‘ systemic vascular resistance, thus increasing blood flow to treated with surgical correction.\n100% oxygen challenge (minimal\nthe pulmonary vasculature and improving oxygenation.\neffect on Pao), whereas most lung\n2 â–  Hypoxemia may lead to FTT and/or cognitive or developmental delays.\npathologies will respond to 100%\nâ–  PE may reveal a systolic ejection murmur at the left upper sternal border\noxygen administration.\ndue to pulmonic stenosis and/or a harsh holosystolic murmur at the left\nlower sternal border due to VSD.\nDiagnosis\nâ–  Best initial tests: Echocardiography and catheterization.\nâ–  CXR shows a â€œboot-shapedâ€ heart with â†“ pulmonary vascular markings.\nRemember that an isolated VSD, without RVOT, may result in â†‘ pulmo-\nnary vascular markings.\nâ–  ECG shows right-axis deviation and RVH.\nFIGURE 2.12-8 Tetralogy of Fall",
      "char_start": 1498000,
      "char_end": 1500000
    },
    {
      "chunk_id": 750,
      "text": "ot. (Repro-\nduced with permission from USMLE-Rx.com.)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553333 1100//2211//2222 44::2211 PPMM\n\n534 HIGH-YIELD FACTS IN PEDIATRICS\nTreatment\nâ–  Best initial treatment: If there is severe RVOT obstruction or atresia, one\nmust emergently administer PGE1 to keep the PDA open. This should be\ndone in conjunction with surgical consultation.\nâ–  Treatment of cyanotic â€œtet spellsâ€ may be treated with supplemental oxy-\ngen and placing the patient in a knee-chest position. If further treatment is\nneeded, IV fluids, opioid analgesia, Î²-blockers, or Î±-agonists can be con-\nsidered, depending on the context.\nâ–  Temporary palliation can be achieved through the creation of an artificial\nshunt (eg, balloon atrial septotomy) before beginning the multistep surgical\nmanagement (modified Blalock-Thomas-Taussig shunt is often the first\nstep).\nPEDIATRIC GASTROINTESTINAL DISEASE\nPYLORIC STENOSIS\nHypertrophy of the pyloric sphincter, leading to gastric outlet obstruction.\nMore common in first-born infant boys; can be associated with tracheoesoph-\nageal fistula, formula feeding, and maternal erythromycin ingestion.\nHistory/PE\nâ–  Nonbilious emesis typically begins around 3 to 6 weeks of age and pro-\ngresses to projectile nonbilious emesis after most or all feedings.\nâ–  Infants are hungry after episodes of vomiting; they initially feed well but\neventually suffer from dehydration and malnutrition.\nâ–  PE may reveal a palpable, olive-shaped, mobile, nontender epigastric mass\nand visible gastric peristaltic waves.\nDiagnosis\nâ–  Best initial test: Abdominal ultrasound will reveal a thickened, elongated\npylorus (see Fig. 2.12-9).\nâ–  Emesis results in loss of HCl and activation of the renin-angiotensin-\naldosterone system (RAAS).\nA\nEsophagus Stomach\nB\nL\nGB\nHypertrophic\npyloric\nstenosis\nDuodenum\nFIGURE 2.12-9. Hypertrophic pyloric stenosis. (A) Schematic representation of a hypertro-\nphied pylorus. (B) Longitudinal ultrasound of the",
      "char_start": 1500000,
      "char_end": 1502000
    },
    {
      "chunk_id": 751,
      "text": " pylorus showing a thickened pyloric muscu-\nlature (Xs) over a long pyloric channel length (plus signs). GB, Gallbladder; L, liver. (Reproduced\nwith permission from USMLE-Rx.com.)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553344 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 535\nA\nLarge\nB\nintestine\nIntussusception\nSmall\nintestine\nAppendix\nFIGURE 2.12-10. Intussusception. (A) Ileocolic intussusception, the most common location in\nchildren. (B) Transabdominal ultrasound showing the classic â€œtarget signâ€ of intussusception in\ncross-section. (Image A reproduced with permission from USMLE-Rx.com. Image B reproduced with permission from Ma\nOJ et al. Emergency Ultrasound, 2nd ed. New York, NY: McGraw-Hill; 2008.)\nâ–  Activation of the RAAS enhances renal K+ and H+ secretion in the collect-\ning duct. The resulting lab abnormalities include hypochloremic, hypoka-\nlemic metabolic alkalosis.\nTreatment\nâ–  Best initial treatment: Keeping the patient NPO (nothing by mouth),\nestablishing IV access, and correcting dehydration and acid-base/electro-\nlyte abnormalities\nâ–  Definitive treatment: Surgical correction with pyloromyotomy\nINTUSSUSCEPTION\nA condition in which a portion of the bowel invaginates, or â€œtelescopes,â€ into an\nadjacent segment, usually proximal to the ileocecal valve (see Fig. 2.12-10).\nThe most common cause of bowel obstruction in children between 6 months\nand 3 years of age (boys > girls). Etiology is unclear in most children. Risk fac-\ntors include conditions with potential lead points, including Meckel diverticu-\nlum, intestinal lymphoma (>6 years of age), submucosal hematoma (as in\nHenoch-SchÃ¶nlein purpura), polyps, and CF (lead point is inspissated stool).\nAn antecedent viral GI illness or upper respiratory infection (URI) is seen in\nmany children, which may cause formation of a lead point through enlarge-\nment of Peyer patches (lymphatic tissue in the bowel). There is a small risk of\nA 4-week-old boy, born ",
      "char_start": 1502000,
      "char_end": 1504000
    },
    {
      "chunk_id": 752,
      "text": "at term,\nintussusception after the oral rotavirus vaccine.\nis brought to the emergency\ndepartment after experiencing\nHistory/PE\nvomiting of increasing frequency\nâ–  Intussusception presents with abrupt-onset, episodic abdominal pain in appar- and intensity for the past week. His\nently healthy children, often accompanied by flexed knees and vomiting. The parents state that he now vomits\nforcefully after every meal and\nchild may appear well between episodes if intussusception is released.\nenthusiastically attempts to eat\nâ–  The classic triad involves severe abdominal pain, vomiting (initially non-\nimmediately after vomiting. The\nbilious and then bilious as obstruction develops), and bloody mucus in\ninfant appears lethargic, with sunken\nstool (â€œcurrant jelly stool,â€ a late finding). However, this classic triad is\nfontanelles and decreased skin turgor.\nonly present in one third of patients.\nThe abdomen is soft, nontender, and\nâ–  During examination, the physician should look for abdominal tenderness, nondistended; no masses are felt.\na âŠ• stool guaiac test, a palpable â€œsausage-shapedâ€ right upper quadrant What is the most likely cause of this\n(RUQ) abdominal mass, and â€œemptyâ€ right lower quadrant (RLQ) on pal- infantâ€™s symptoms?\npation (Dance sign).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553355 1100//2211//2222 44::2211 PPMM\n\n536 HIGH-YIELD FACTS IN PEDIATRICS\nDiagnosis/Treatment\nâ–  Ultrasonography is the initial test of choice and may show a â€œtarget signâ€\n(see Fig. 2.12-10B). An ultrasound must be conducted during a painful\nepisode to diagnose intussusception.\nâ–  X-rays of the abdomen are often normal early in the disease, but later they\nmay show small bowel obstruction, perforation, or a soft tissue mass.\nâ–  The physician should correct any volume or electrolyte abnormalities,\ncheck CBC for leukocytosis, and consider placement of a nasogastric\n(NG) tube for decompression.\nâ–  High clinical suspicion calls for an air insufflation enema ",
      "char_start": 1504000,
      "char_end": 1506000
    },
    {
      "chunk_id": 753,
      "text": "without delay, as\nit is diagnostic and curative in the vast majority of patients.\nâ–  Surgical resection is indicated if the child has peritoneal signs, air insufflation\nenema reduction is unsuccessful, or a pathologic lead point is identified.\nâ–  Air insufflation enema is preferred over water or barium-contrast enema\nfor diagnosis and management of intussusception, as it is faster and carries\na lower risk for complications.\nMALROTATION WITH VOLVULUS\nLiver\nStomach\nLadd\nbands\nC\nsm\no\na\nn\nl\ng\nl\ne\nin\nni\nt\nt\ne\na\ns\nl\nt in\nm\ne\na l\n(\nr\nc\no\ne\nt\nc\na\nu\nti\nm\non\ni n\no f\nt h\nth\ne\ne\nr i\nm\ngh\nid\nt\ng\nh\nu\ny\nt\np o\nre\nc\ns\nh\nu\no\nlt\nn\ns\nd\ni\nr\nn\niu\na\nm\nbn\n)\no\na\nr\nn\nm\nd\na\nf\nl\no r\np\nm\nos\na\ni\nt\nt\ni\ni\no\no\nn\nn i\no\nn\nf\ng\nfi\no\nb\nf\nr o\nth\nu\ne\ns\nbands known as Ladd bands (Fig. 2.12-11), which predispose to obstruction\nand volvulus with constriction of blood flow.\nSmall\nbowel History/PE\nColon â–  Often presents in the first month of life with bilious emesis, crampy\nabdominal pain, distention, and passage of blood or mucus in the stool.\nFIGURE 2.12-11. Ladd bands. (Reproduced â–  Postsurgical adhesions can lead to obstruction and volvulus at any point in\nwith permission from USMLE-Rx.com.) life.\nDiagnosis\nâ–  Barium contrast enema may reveal the characteristic narrowed â€œbird-beakâ€\nappearance and air-fluid levels, but may also appear normal.\nâ–  Upper GI series is the study of choice if the patient is stable and shows an\nUmbilicus abnormal location of the ligament of Treitz. Ultrasound may be used, but\nsensitivity depends on the userâ€™s experience.\nMeckel Treatment\ndiverticulum\nâ–  NG tube insertion to decompress the intestine; IV fluid hydration\nSmall â–  Emergent surgical correction is needed when there is ischemic bowel/GI\nintestine tract; definitive management is surgical (Laddâ€™s procedure)\nFIGURE 2.12-12. Meckel diverticulum.\nMECKEL DIVERTICULUM\n(Modified with permission from USMLE-Rx.com.)\nCaused by failure of the omphalomesenteric (or vitelline) duct to obliterate,\nresulting in the formation of a true diverti",
      "char_start": 1506000,
      "char_end": 1508000
    },
    {
      "chunk_id": 754,
      "text": "culum containing all three layers of\nthe small intestine (Fig. 2.12-12). Some Meckel diverticula have heterotopic\ngastric tissue, which places patients at risk for intestinal ulceration and pain-\nThis infant is most likely suffering\nfrom pyloric stenosis, an obstruction less hematochezia. This is the most common congenital abnormality of the\nof the gastric outlet secondary to small intestine, affecting up to 2% of children (boys > girls).\nhypertrophy and hyperplasia of\nthe muscular layers of the pylorus. History/PE\nNote that some infants, but not all,\nmay present with an olive-shaped â–  Typically asymptomatic and often discovered incidentally. Patients most\ncommonly symptomatic <2 years of age.\nabdominal mass.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553366 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 537\nâ–  Classically presents with painless rectal bleeding MNEMONIC\nâ–  Complications: Intestinal perforation or obstruction, diverticulitis (which\ncan mimic acute appendicitis), and intussusception Meckel rule of 2sâ€”\nOccurs in 2% of the population\nDiagnosis 2 times more common in boys\nContains 2 types of tissue (gastric and\nâ–  A Meckel scintigraphy scan (technetium-99m pertechnetate; detects ecto-\npancreatic)\npic gastric tissue) is diagnostic.\n2 inches long\nâ–  X-rays have limited value, but can be useful in diagnosing obstruction or Found within 2 feet of the ileocecal valve\nperforation.\nTreatment\nKEY FACT\nâ–  Definitive treatment: Surgical excision of the diverticulum together with\nthe adjacent ileal segment, which may be ulcerated Bleeding is the most common\nâ–  Indications for urgent/emergent surgery include hemorrhage, diverticuli- complication of Meckel diverticulum;\ntis, intestinal perforation, and obstruction/intussusception it may be minimal or severe enough to\ncause hemorrhagic shock.\nHIRSCHSPRUNG DISEASE\nCharacterized by congenital lack of ganglion cells in the distal colon. This\nleads to decreased motility ca",
      "char_start": 1508000,
      "char_end": 1510000
    },
    {
      "chunk_id": 755,
      "text": "used by unopposed smooth muscle tone in the\nabsence of enteric relaxing reflexes and uncoordinated peristalsis (see\nFig. 2.12-13). Associated with male sex, Down syndrome, Waardenburg syn-\ndrome, and multiple endocrine neoplasia type 2 (RET gene mutation).\nHistory/PE\nâ–  Presentation depends on the extent of the aganglionic segment.\nâ–  Neonates present with failure to pass meconium within 48 hours of birth,\naccompanied by bilious vomiting and FTT; children with less severe\nlesions may present later in life with chronic constipation.\nâ–  PE may reveal abdominal distention and explosive discharge of stool after\na rectal examination; lack of stool in the rectum; and/or abnormal sphinc-\nter tone.\nDiagnosis\nâ–  Best initial test: X-rays reveal distended bowel loops with a paucity of air\nin the rectum.\nFIGURE 2.12-13. Hirschsprung disease.\nâ–  Barium enema is the imaging study of choice and reveals a narrowed dis- Retrograde barium enema shows small\ntal colon with proximal dilation (rectosigmoid transition zone). This test caliber of the left colon (yellow arrow)\ndifferentiates Hirschsprung disease from meconium ileus (seen in CF and rectum in comparison to the more\ndilated transverse colon (red arrow). Fill-\npatients), which would show a microcolon on barium enema testing.\ning defects in the descending/sigmoid\nâ–  Anorectal manometry detects failure of the internal sphincter to relax after colon represent feces (blue arrow). (Repro-\ndistention of the rectal lumen. It is typically used in atypical presentations\nduced with permission from USMLE-Rx.com.)\nor older children.\nâ–  Most accurate test: Rectal suction biopsy confirms the diagnosis and\nKEY FACT\nreveals absence of the myenteric (Auerbach) plexus and submucosal\n(Meissner) plexus along with hypertrophied nerve trunks enhanced with Definitive diagnosis of Hirschsprung\nacetylcholinesterase stain. disease requires a rectal suction biopsy.\nTreatment\nTraditionally a two-stage surgical correction is used, involving the creation of\na div",
      "char_start": 1510000,
      "char_end": 1512000
    },
    {
      "chunk_id": 756,
      "text": "erting colostomy at the time of diagnosis, followed several weeks later by\na definitive â€œpull-throughâ€ procedure connecting the remaining colon to the\nrectum.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553377 1100//2211//2222 44::2211 PPMM\n\n538 HIGH-YIELD FACTS IN PEDIATRICS\nNECROTIZING ENTEROCOLITIS\nA condition in which a portion of the bowel (most commonly the terminal\nileum/proximal colon) undergoes necrosis. NEC is the most common GI\nemergency in neonates; it is most frequently seen in premature infants, but\ncan rarely occur in full-term infants as well. Risk factors include low BW,\nhypotension, and enteral feeding (especially formula) in the context of a pre-\nmaturity or compromised enteral blood flow.\nHistory/PE\nâ–  Symptoms usually present within the first few days or weeks of life and are\nnonspecific. They include feeding intolerance, delayed gastric emptying,\nFIGURE 2.12-14. Pneumatosis intestina- abdominal distention, and bloody stools.\nlis. Arrows highlight pneumatosis intesti-\nâ–  Symptoms can rapidly progress to intestinal perforation, peritonitis,\nnalis on an abdominal x-ray of a patient\nabdominal erythema, and shock. The physician should maintain a high\nwith necrotizing enterocolitis. Intramural\nair bubbles shown in the image repre- index of suspicion.\nsent gas produced by bacteria within the\nbowel wall. (Reproduced with permission from Diagnosis\nBrunicardi FC et al. Schwartzâ€™s Principles of Surgery, 9th\ned. New York, NY: McGraw-Hill; 2010.) â–  Lab findings are nonspecific and may show hyponatremia, metabolic (lac-\ntic) acidosis, leukopenia or leukocytosis with left shift, thrombocytopenia,\nand coagulopathy (disseminated intravascular coagulation [DIC] with pro-\nlonged prothrombin time/activated partial thromboplastin time [PT/aPTT]\nand a âŠ• d-dimer).\nâ–  X-rays of the abdomen are the imaging modality of choice and may show\ndilated bowel loops, pneumatosis intestinalis (â€œtrain track lucencyâ€; see Fig.\nKEY FACT 2.12-14),",
      "char_start": 1512000,
      "char_end": 1514000
    },
    {
      "chunk_id": 757,
      "text": " portal venous gas, or abdominal free air (in the case of bowel perfo-\nration). Serial x-rays of the abdomen should be taken every 6 hours.\nPneumatosis intestinalis on x-rays is\npathognomonic for NEC in neonates. â–  Ultrasound may also be helpful in discerning free air, areas of loculation,\nand bowel necrosis.\nTreatment\nâ–  Best initial treatment: Initiate supportive measures, including NPO, an\nNG tube for gastric decompression, correction of dehydration and electro-\nlyte abnormalities, total parenteral nutrition (TPN), and IV antibiotics.\nâ–  Indications for surgery are perforation (free air under the diaphragm) or\nworsening radiographic signs on serial abdominal x-rays. An ileostomy with\nmucous fistula is typically performed, with a reanastomosis at a later time.\nâ–  Complications include formation of intestinal strictures and short-bowel\nsyndrome.\nFOOD PROTEINâ€“INDUCED ALLERGIC PROCTOCOLITIS\nFood proteinâ€“induced allergic proctocolitis (FPIAP) is a condition whereby\nspecific food proteins (most commonly cowâ€™s milk or soy) cause inflammation\nof the colon via a non-IgE-mediated allergic reaction. This can occur in both\nbreastfed and formula-fed infants and usually presents within the first few\nmonths of life.\nHistory/PE\nâ–  Patients presents with increased volume of loose stools with mucus and\npainless hematochezia.\nâ–  Examination shows an afebrile, well-appearing infant, with blood- or\nmucus-streaked stools, and when the condition is severe, the patient may\nshow impaired growth or failure to thrive.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553388 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 539\nEvaluation/Treatment\nâ–  Diagnosis is clinical, based on history, PE, and successful treatment.\nThere should be notable absence of symptoms such as fever, lethargy,\nabdominal pain, or physical examination findings such as anal fissures or\nabdominal masses.\nâ–  Symptoms will resolve after removal of the antigen from the diet. In a\n",
      "char_start": 1514000,
      "char_end": 1516000
    },
    {
      "chunk_id": 758,
      "text": "breastfed baby, the mother has to eliminate ingestion of cowâ€™s milk, soy, or\nother suspected antigens. A formula-fed infant can switch to a hydrolyzed,\nhypoallergenic formula.\nPEDIATRIC CONSTIPATION\nPassage of hard stool less frequently than is appropriate for age. Bowel move-\nments may be difficult or painful to pass. Neonates should pass meconium\nwithin 48 hours of birth. Pediatric constipation can be divided into functional\nand pathologic constipation. Functional constipation is responsible for 95%\nof cases in healthy children greater than 1 year of age.\nHistory/PE\nâ–  Painful passage of hard, large-caliber stools or pelletlike stools. May have\nencopresis (involuntary leakage of soft stool around retained hard stool)\nâ–  Abdominal distention, bowel sounds hyperactive or hypoactive, depending\non the underlying cause\nâ–  Stool withholding\nâ–  Associated enuresis and urinary frequency if bladder is compressed by\nenlarged rectum\nâ–  Palpation of hard mass of stool possible if fecal impaction occurs\nDifferential Diagnosis\nâ–  Functional constipation: Constipation in the absence of an anatomic\nabnormality or disease. Risk factors include initiation of solid food/cowâ€™s\nmilk, periods of transition such as toilet training, and starting school.\nâ–  Hirschsprung disease: Delayed passage of meconium; may present later in\nchildhood with chronic constipation\nâ–  CF: Inspissated meconium and chronic constipation\nâ–  Infant dyschezia: Failure to relax pelvic muscles and coordinate defecation. It\npresents as prolonged straining and crying with delayed passage of soft stools\nin an infant younger than 9 months. It resolves spontaneously with maturity.\nâ–  Spinal dysraphism and hypothyroidism.\nDiagnosis\nâ–  It is important to get a thorough history regarding passage of meconium,\ndietary habits, onset of toilet training, and schooling. A 4-day-old boy born at 31 weeks for\nâ–  Organic causes of constipation should be ruled out to diagnose functional intrauterine growth restriction has\nconstipation. If alarm ",
      "char_start": 1516000,
      "char_end": 1518000
    },
    {
      "chunk_id": 759,
      "text": "signs are present, the physician should further evalu- experienced frequent bilious vomiting\nate the patient, based on suspected etiology. after formula feeding for the past 24\nâ–  Alarm signs include delayed passage of meconium, fever, ribbon stools, hours and has passed stool mixed\npoor growth, severe abdominal distention, abnormal examination such as with bright red blood twice today.\nHe was initially tolerating his NG\ntuft at gluteal cleft, and increased sphincter tone.\nfeeds well, but he now demonstrates\nlethargy, abdominal distention, and\nTreatment decreased bowel sounds. What is the\nmost likely diagnosis, and what would\nâ–  The mainstay of treating pediatric constipation is prevention, including\nthe physician expect to see on x-rays\nadequate fiber and water intake, as well as using a child-oriented approach\nof the abdomen?\nto toilet training.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 553399 1100//2211//2222 44::2211 PPMM\n\n540 HIGH-YIELD FACTS IN PEDIATRICS\nKEY FACT â–  Patients with episodic constipation, including stool withholding, may be\ntreated with dietary changes and osmotic laxatives such as polyethylene gly-\nPosterior urethral valves are the col. Chronic functional constipation is treated with a combination of dietary\nmost common congenital urethral changes, laxatives, and bowel retraining until laxative doses can be tapered.\nobstruction in newborn males. Classic â–  Therapies for organic constipation are targeted to the specific cause.\nfindings are a male infant with a\ndistended, palpable bladder; low urine\noutput; and/or a weak urinary stream.\nSevere in-utero cases may lead to PEDIATRIC UROLOGY\noligohydramnios with resultant Potterâ€™s\nsequence.\nVESICOURETERAL REFLUX\nRetrograde projection of urine from the bladder to the ureters and kidneys.\nMay be primary reflux (from abnormal/insufficient insertion of ureter into the\nbladder) or secondary reflux (from congenital bladder outlet obstruction, such\nas posterior urethral ",
      "char_start": 1518000,
      "char_end": 1520000
    },
    {
      "chunk_id": 760,
      "text": "valves, or from neurogenic bladder). Classified as follows:\nâ–  Mild reflux (grades Iâ€“II): Reflux into one or both ureters (I) or kidneys\n(II) but no ureteral or renal pelvic dilation. It often resolves spontaneously.\nâ–  Moderate to severe reflux (grades IIIâ€“V): Ureteral dilation (III), renal pel-\nvis and calyceal dilation (IV) with associated calicyeal blunting (V) and\npossible nephropathy (impaired renal function in severe cases.\nHistory/PE\nMay present in infancy or childhood with febrile urinary tract infections\n(UTIs) with particular concern for vesicoureteral reflux (VUR) if recurrent\nfebrile UTIs. Prenatal ultrasonography may identify hydronephrosis.\nDiagnosis\nVCUG is diagnostic test of choice to detect abnormalities at ureteral insertion\nsites and to classify the grade of reflux (see Fig. 2.12-15).\nKEY FACT\nChildren 2 to 24 months of age\nTreatment\nwith a febrile UTI should first have\nan ultrasound exam to evaluate the â–  The physician should have a low threshold to treat UTIs with prompt initi-\nanatomy of the urinary tract. A VCUG ation of antibiotics.\nis indicated for recurrent febrile UTIs â–  Surgery (ureteral reimplantation) is generally reserved for children with\nand abnormalities on ultrasound. For symptomatic high-grade (IIIâ€“V) reflux.\nchildren <2 months, imaging is also â–  In children with recurrent febrile UTIs and VUR, daily antibiotic prophy-\nrecommended but evidence is limited. laxis has been shown to reduce the number of febrile UTIs but not prevent\nrenal scarring. This benefit has not been demonstrated for children with\nrecurrent febrile UTIs without VUR.\nThis infant most likely has necrotizing\nenterocolitis, given his presentation\nand risk factors (prematurity, formula\nfeeding). This is a serious diagnosis FIGURE 2.12-15. Vesicoureteral reflux.\nwith up to 40% mortality. X-ray Frontal x-ray from a voiding cystourethro-\ngram shows reflux to the left ureter and\nfindings can include pneumatosis\nintrarenal collecting system with hydro-\nintestinalis, air in",
      "char_start": 1520000,
      "char_end": 1522000
    },
    {
      "chunk_id": 761,
      "text": " the portal venous\nnephrosis. Note the absence of reflux\nsystem, and free air under the\non the normal right side. (Reproduced with\ndiaphragm (in case of bowel\npermission from Doherty GM. Current Diagnosis &\nperforation).\nTreatment: Surgery, 13th ed. New York, NY: McGraw-\nHill; 2010.)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554400 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 541\nCRYPTORCHIDISM\nFailure of one or both testes to fully descend into the scrotum. Prematurity is\na risk factor.\nHistory/PE\nRisk factors for cryptorchidism include prematurity, congenital urinary tract\nabnormalities, and certain syndromes (eg, Prader-Willi, Noonan syndromes).\nIf not treated, it is associated with oligospermia and infertility, as well as\nmalignancy.\nDiagnosis\nThe testes cannot be manipulated into the scrotal sac with gentle pressure (vs\nretractile testes) and can be palpated anywhere along the inguinal canal.\nTreatment\nOrchiopexy for prepubertal boys; orchiectomy vs close observation if discov-\nered after puberty to minimize the risk for testicular cancer. If the condition is\ndiscovered in a newborn, surgery should be performed as soon as possible\nafter 4 months of ageâ€”imperatively before 2 years of age and ideally before\n1 year of age. Earlier treatment has been found to improve fertility and\ndecrease the risk of testicular cancer and testicular torsion.\nKEY FACT\nINGUINAL HERNIA\nIn cryptorchidism, bringing the testes\ninto the scrotum may lower, but not\nHistory/PE\neliminate, the risk for testicular cancer.\nInguinal hernia is most commonly indirect in children. The condition has\na prevalence of 1% to 5% in newborns and almost double that in prema-\nture newborns. The prevalence is three to four times higher in male\nnewborns.\nDiagnosis\nâ–  Hernia: Intermittent protrusion of abdominal contents through an abdom-\ninal wall opening. Can be either direct or indirect.\nâ–  Direct inguinal hernia: passes medial to the epigastric vesse",
      "char_start": 1522000,
      "char_end": 1524000
    },
    {
      "chunk_id": 762,
      "text": "ls, behind\nthe superficial inguinal ring and rarely enters the scrotum.\nâ–  Indirect inguinal hernia: passes through the inguinal canal, lateral to\nthe epigastric vessels.\nâ–  Incarceration: Entrapment of hernia that is not reducible.\nâ–  Strangulation: Ischemia and possible necrosis of the contents of the her-\nnia, resulting in intestinal perforation.\nTreatment\nReduction of the hernia and timely referral to a surgeon. Risk of incarceration\nand strangulation are high, especially under 1 year of age.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554411 1100//2211//2222 44::2211 PPMM\n\n542 HIGH-YIELD FACTS IN PEDIATRICS\nA TABLE 2.12-17. Comparison of Hypospadias and Epispadias\nPARAMETERS HYPOSPADIAS (SEE FIG. 2.12-16 [A]) EPISPADIAS (SEE FIG. 2.12-16 [B])\nDefinition Abnormal opening of penile urethra Abnormal opening of penile\nB ventrally urethra dorsally\nPathophysiology Abnormality of the fusion of urethral Growth of genital tubercule\nfolds in the cranial instead of\ncaudal direction\nFIGURE 2.12-16 Hypospadias (A) and\nepispadias (B). (Reproduced with permission\nfrom USMLE-Rx.com.) Risk factors Low androgen levels\nHigher maternal age\nFamily history\nMaternal exposure to environmental toxins causing hormonal\ndisturbances\nManagement Surgical correction within first 2 years of life\nCircumcision should not be performed; the foreskin may be used for\nKEY FACT\nsurgical reconstruction\nCircumcision refers to the removal of\nthe prepuce of the penis.\nâ–  Newborn circumcision generally\nHYPOSPADIAS AND EPISPADIAS\nhas fewer complications and\na shorter recovery period than\nBoth conditions are congenital malformations of the male urethra resulting in an\ncircumcision beyond the neonatal\nabnormal opening. See Table 2.12-17 and Figure 2.12-16. Immunodeficiencies\nperiod.\ncan also increase susceptibility to opportunistic infections (see Figure 2.12-17.)\nâ–  Circumcision has several potentilal\nbenefits, eg, reduction in UTIs, STIs,\nand penile malignancy.\nâ–  Complicat",
      "char_start": 1524000,
      "char_end": 1526000
    },
    {
      "chunk_id": 763,
      "text": "ions (rare) include PEDIATRIC IMMUNOLOGY\nbleeding, infection, ulceration,\ncosmetic issues, and stenosis.\nIMMUNODEFICIENCY DISORDERS\nCongenital immunodeficiencies are rare and often present with chronic or\nrecurrent infections (eg, chronic thrush), unusual or opportunistic organisms,\nincomplete treatment response, or FTT. Categorization is based on the single\nKEY FACT\nimmune system component that is abnormal (see Table 2.12-18).\nEnuresis:\nâ–  Involuntary voiding of urine.\nâ–  This can be primary, caused by Phagocytic cell deficiencies\nMucous membrane infections\nimmaturity of the reflex to awaken\nin response to a full bladder.\nViruses\nâ–  Evaluation for secondary causes can Fungi\nbecome necessary (UTI, anatomic Catalase (âŠ•) organisms\nabnormality of the urinary tract). Gram (âŠ–) enteric organisms\nâ–  Treatment is not always necessary,\nAspergillus Staphylococci\nbut enuresis alarms are generally\nconsidered the first-line option in\nViruses\nprimary enuresis. H influenzae\nFungi\nEnteroviruses S pneumoniae\nP jirovecii\nN meningitidis\nIntracellular bacteria\nT-cell deficiencies B-cell deficiencies\nOpportunistic and Encapsulated organisms\nlow-grade infections\nFIGURE 2.12-17. Infection Susceptibility According to Immune Cell Deficiency (Reproduced with\npermission from USMLE-Rx.com.)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554422 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 543\nTABLE 2.12-18. Pediatric Immune Disorders\nDISORDER DESCRIPTION INFECTION RISK/TYPE DIAGNOSIS/TREATMENT\nB-CELL DISORDERS\nBruton agamma- An X-linked recessive B-cell deficiency Life-threatening; characterized Quantitative Ig levels: If low, confir-\nglobulinemia found only in boys by encapsulated Pseudomonas, mation with B- and T-cell subsets\nSymptoms begin after 6 months of age, Streptococcus pneumoniae, and (B cells absent; T cells often high)\nwhen maternal IgG (transferred trans- Haemophilus infections after Absent tonsils and other lymphoid\nplacentally) di",
      "char_start": 1526000,
      "char_end": 1528000
    },
    {
      "chunk_id": 764,
      "text": "minishes in titer 6 months of age tissue may provide a clue\nTreat with prophylactic antibiotics\nand IVIG\nCommon variable Usually a combined B- and T-cell defect â†‘ pyogenic upper and lower respi- Quantitative Ig levels; confirmation\nimmunodeficiency All Ig levels are low (in the 20s and 30s) ratory infections with B- and T-cell subsets\n(CVID) Patient has normal B-cell numbers and â†‘ risk for lymphoma and autoim- Treat with IVIG\nâ†“ plasma cells mune disease\nSymptoms usually present later in life\n(15â€“35 years of age)\nIgA deficiency Mild; the most common Usually asymptomatic; possibility Quantitative IgA levels; treatment of\nimmunodeficiency for patients to develop recur- infections\nâ†“ IgA levels only rent respiratory or GI infections Be careful giving IVIG, as it can lead\n(Giardia) to the production of anti-IgA anti-\nAnaphylactic transfusion reaction bodies and cause severe allergic\ncaused by anti-IgA antibodies is reactions; if IVIG is necessary, give\na commonly tested presentation IgA-depleted IVIG\nHyper-IgM syndrome An X-linked recessive disease; absence Severe, recurrent sinopulmonary Treatment with antibiotic prophy-\nof CD40 ligand that allows class- infections caused by impaired Ig laxis and IVIG\nswitching from IgM to other Ig classes\nâ†‘ IgM levels, low levels of all other Ig,\nand normal numbers of lymphocytes\nT-CELL DISORDERS\nThymic aplasia See the mnemonic CATCH 22 Variable risk for infection Absolute T-lymphocyte count;\n(DiGeorge Presents with tetany (secondary to â†‘â†‘â†‘ infections with viruses, fungi, mitogen stimulation response;\nsyndrome) hypocalcemia) in the first days of life and pneumocystis pneumonia delayed hypersensitivity skin\nAutosomal dominant (PCP) testing\nX-ray possibly showing absent Treatment with bone marrow\nthymic shadow transplantation (BMT) and IVIG\nfor antibody deficiency; PCP\nprophylaxis\nThymus transplantation an\nalternative\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554433 1100//2211//2222 44:",
      "char_start": 1528000,
      "char_end": 1530000
    },
    {
      "chunk_id": 765,
      "text": ":2211 PPMM\n\n544 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-18. Pediatric Immune Disorders (continued)\nDISORDER DESCRIPTION INFECTION RISK/TYPE DIAGNOSIS/TREATMENT\nCOMBINED DISORDERS\nAtaxia- Progressive cerebellar ataxia and oculo- Triad: cerebellar defects (ataxia), No specific treatment; may require\ntelangiectasia cutaneous telangiectasias spider angiomas (telangiectasia), IVIG, depending on the severity of\nCaused by an autosomal-recessive IgA deficiency the Ig deficiency\nmutation in the gene responsible for â†‘ incidence of malignancies,\nrepair of dsDNA breaks including non-Hodgkin lym-\nphoma, leukemia, and gastric\ncarcinoma\nSevere combined Most commonly X-linked recessive Severe, frequent bacterial infec- Treatment with bone marrow or\nimmunodeficiency Severe lack of B and T cells caused by a tions; chronic candidiasis; stem cell transplantation and IVIG\ndefect in stem cell maturation and â†“ opportunistic organisms for antibody deficiency\nadenosine deaminase Requires PCP prophylaxis\nReferred to as â€œbubble boy disease,â€\nbecause children historically have\nbeen confined to an isolated, sterile\nenvironment\nWiskott-Aldrich An X-linked recessive disorder seen only â†‘â†‘ risk for atopic disorders, Treatment supportive (IVIG and\nsyndrome in male patients lymphoma/leukemia, and antibiotics)\nSymptoms usually present at birth infection from S pneumoniae, Patients are at â†‘ risk for devel-\nPatients have â†‘ IgE/IgA, â†“ IgM, and S. aureus, and H. influenzae oping autoimmune diseases and\nthrombocytopenia type b (encapsulated organ- malignancies\nThe classic presentation involves isms; think back to how IgM Patients rarely survive to adulthood\nbleeding, eczema, and recurrent otitis functions) Patients with severe infections may\nmedia be treated with BMT\nRemember the mnemonic WIPE:\nWiskott-Aldrich, Infections, Purpura\n(thrombocytopenic), Eczema\nPEDIATRIC PHAGOCYTIC DEFICIENCIES\nChronic granuloma- An X-linked (two-thirds) or autosomal Chronic skin, lymph node, pul- Absolute neutrophil count w",
      "char_start": 1530000,
      "char_end": 1532000
    },
    {
      "chunk_id": 766,
      "text": "ith\ntous disease (CGD) recessive (one-third) disease with monary, GI, and urinary tract neutrophil assays\ndeficient superoxide production by infections; osteomyelitis and The dihydrorhodamine (DHR) test\npolymorphonuclear leukocytes and hepatitis is diagnostic for CGD; nitroblue\nmacrophages Infecting organisms are catalase tetrazolium test is the previous\nAnemia, lymphadenopathy, and hyper- âŠ• (S aureus, Escherichia coli, gold standard and still occasion-\ngammaglobulinemia may be present Candida, Klebsiella, Pseudo- ally used\nmonas, Aspergillus) Treat with daily trimethoprim-\nPatients may have granulomas of sulfamethoxazole (TMP-SMX);\nthe skin and GI/genitourinary make judicious use of antibiotics\n(GU) tracts during infections.\nInterferon (IFN)-Î³ can â†“ the inci-\ndence of serious infection\nBMT and gene therapy are new\ntherapies\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554444 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 545\nTABLE 2.12-18. Pediatric Immune Disorders (continued)\nDISORDER DESCRIPTION INFECTION RISK/TYPE DIAGNOSIS/TREATMENT\nLeukocyte adhesion A defect in the chemotaxis of Recurrent skin, mucosal, and pul- No pus with minimal inflammation\ndeficiency leukocytes monary infections in wounds (caused by a chemo-\nâ†“ phagocytic activity Deficiency may present as ompha- taxis defect)\nlitis in the newborn period with Laboratory results show leukocy-\ndelayed separation of the umbil- tosis (particularly neutrophilia)\nical cord (>14 days postbirth) BMT is curative\nChÃ©diak-Higashi An autosomal recessive disorder that â†‘â†‘ incidence of overwhelming Giant granules in neutrophils\nsyndrome leads to a defect in neutrophil che- pyogenic infections with S pyo- BMT is the treatment of choice\nmotaxis/microtubule polymerization genes,\nThe syndrome includes partial ocu- S aureus, and Pneumococcus\nlocutaneous albinism, peripheral species\nneuropathy, and neutropenia\nJob syndrome A defect in neutrophil chemotaxis Rec",
      "char_start": 1532000,
      "char_end": 1534000
    },
    {
      "chunk_id": 767,
      "text": "urrent S aureus infections and Treatment with penicillinase-resis-\n(hyperimmuno- Remember the mnemonic FATED: abscesses tant antibiotics and IVIG\nglobulin E Coarse Facies\nsyndrome) Abscesses (S aureus)\nRetained primary Teeth\nHyper-IgE (eosinophilia)\nDermatologic (severe eczema)\nCOMPLEMENT DISORDERS\nC1 esterase inhibitor An autosomal dominant disorder with Can lead to life-threatening airway Total hemolytic complement (CH50)\ndeficiency (heredi- recurrent episodes of angioedema edema to assess the quantity and func-\ntary angioedema) lasting 2â€“72 hours and provoked by tion of complement\nstress or trauma Purified C1 inhibitor (C1INH) con-\ncentrate and fresh frozen plasma\n(FFP) can be used before surgery\nTerminal comple- Inability to form membrane attack Recurrent Neisseria infections, Meningococcal vaccine and appro-\nment deficiency complex meningococcal, or gonococcal priate antibiotics\n(C5â€“C9) Rarely, patients have lupus or\nglomerulonephritis\nâ–  B-cell deficiencies: Most common (50%). Typically present after 6 months\nof age with recurrent sinopulmonary, GI infections, and/or with encapsu-\nlated organisms (Haemophilus influenzae, Streptococcus pneumoniae, Neis-\nseria meningitidis). Treatment calls for intravenous immunoglobulin (IVIG),\nexcept for cases of IgA deficiency.\nâ–  Bruton agammaglobulinemia can be confused with transient hypogam-\nmaglobulinemia of infancy (THI), as both are characterized by â†‘ sus-\nceptibility to infections at âˆ¼6 months of age, when transplacental\nmaternal IgG is no longer active. B cells are â†“ in Bruton, whereas\nthose in THI are normal.\nâ–  Bruton agammaglobulinemia and common variable immunodefi-\nciency (CVID) also have similar symptoms. However, the former is\nfound in boys âˆ¼6 months of age, whereas CVID is seen in older males\nand females (15â€“35 years of age), and its symptoms are less severe.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554455 1100//2211//2222 44::2211 PPMM\n\n546 HIGH-YIELD FACTS IN PEDIATRIC",
      "char_start": 1534000,
      "char_end": 1536000
    },
    {
      "chunk_id": 768,
      "text": "S\nKEY FACT\nâ–  T-cell deficiencies: Tend to present earlier (1â€“3 months of age) with\nFlashback to immunology:\nopportunistic and low-grade fungal, viral, and intracellular bacterial infec-\nâ–  B cells make immunoglobulins tions (eg, mycobacteria). Secondary b-cell dysfunction can also be seen.\nand are responsible for immunity\nâ–  Phagocyte deficiencies: Characterized by mucous membrane infections,\nagainst extracellular bacteria.\nabscesses, and poor wound healing. Infections with catalase âŠ• organisms\nâ–  T cells are responsible for immunity (eg, S. aureus), fungi, and gram âŠ– enteric organisms are common.\nagainst intracellular bacteria,\nâ–  Complement deficiencies: These deficiencies are characterized by recur-\nviruses, and fungi.\nrent bacterial infections with encapsulated organisms.\nKAWASAKI DISEASE\nComplications: Untreated children may develop coronary artery aneurysms\nMNEMONIC (25%); all patients should be assessed by echocardiography at diagnosis.\nKawasaki disease symptomsâ€” An acute multisystem medium-vessel vasculitis that primarily affects young\nCRASH and BURN children. Usually affects children age <5 years (â†‘ incidence in people of Jap-\nanese and Korean descent). Kawasaki disease is divided into acute, subacute,\nConjunctivitis (without discharge)\nand convalescent phases.\nRash\nAdenopathy (unilateral and >1.5 cm)\nStrawberry tongue History/PE\nHands and feet (red, swollen, flaky skin)\nFive days of fever and at least four of the following five criteria:\nBURN (fever >40Â°C [>104Â°F] for â‰¥5 days)\n1. Conjunctivitis: Bilateral, nonexudative, painless with limbal sparing\n(acute phase)\n2. Oral mucosal changes: Erythematous mouth/pharynx, â€œstrawberry tongue,â€\nKEY FACT and/or cracked lips (acute phase)\n3. Rash: Primarily truncal, polymorphous, erythematous (acute phase)\nUntreated Kawasaki disease can lead\nto coronary aneurysms in up to 25% of 4. Peripheral extremity changes: Edema of hands and feet, palmar erythema\npatients. (acute phase), and desquamating palms and soles (convalescent",
      "char_start": 1536000,
      "char_end": 1538000
    },
    {
      "chunk_id": 769,
      "text": " phase)\n5. Cervical lymphadenopathy (>1.5 cm): Generally painful and unilateral\n(acute phase)\nKEY FACT Other manifestations (not required for diagnosis) include sterile pyuria, gall-\nbladder hydrops, hepatitis, and arthritis, hyponatremia, and hypoalbuminemia\nKawasaki disease and scarlet fever may\nboth present with â€œstrawberry tongue,â€\nDiagnosis\nrash, desquamation of the hands and\nfeet, and erythema of the mucous â–  Laboratory workup: Normochromic anemia, leukocytosis with left shift,\nmembranes. However, children with thrombocytosis, increased erythrocyte sedimentation rate (ESR) and\nscarlet fever have normal lips and no C-reactive protein (CRP).\nconjunctivitis. â–  The physician should obtain a baseline echocardiogram at diagnosis for lon-\ngitudinal follow-up of coronary artery morphology. Follow-up of uncompli-\ncated cases should occur at 2 weeks and 6 to 8 weeks after diagnosis.\nKEY FACT Treatment\nASA is used for Kawasaki disease in â–  Best initial treatment: High-dose aspirin (acetylsalicylic acid [ASA]), for\nthe pediatric population, despite anti-inflammatory, antipyretic, and antithrombotic effects and IVIG to\nfear of Reye syndrome, a rare but reduce the risk of coronary artery aneurysms from 25% to <5%.\nserious condition. Although the exact â–  Low-dose ASA is then continued until normalization of laboratory inflam-\nmechanism is unclear, Reye syndrome matory markers. Aspirin is continued if children develop coronary aneu-\nresults from mitochondrial injury rysms. Although young children taking ASA are at risk for Reye syndrome,\nand fatty degenerative liver failure, the risk/benefit favors treatment with ASA to prevent coronary artery\nwhich leads to hyperammonemia and aneurysms.\nultimately encephalopathy. â–  Corticosteroids may be used in IVIG-refractory cases, but routine use is\nnot recommended.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554466 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 547\nTABLE 2.12-19. Ju",
      "char_start": 1538000,
      "char_end": 1540000
    },
    {
      "chunk_id": 770,
      "text": "venile Idiopathic Arthritis Subtypes\nSUBTYPE PRESENTATION RF AND ANA STATUS NOTES\nOligoarthritis JIA Involves four or fewer joints (usually weight- Antinuclear antibody (ANA) âŠ• This is the most common\nbearing); large joints commonly affected; no Rheumatoid factor (RF) âŠ– presentation of JIA\nsystemic symptoms Oligoarthritis is usually\nUveitis common; requires slitlamp examination diagnosed in young\nfor diagnosis girls\nPolyarthritis JIA Present in five or more joints; generally RF positivity rare (indicates severe Rheumatoid nodules may\nsymmetric disease) be seen in children with\nSystemic symptoms rare Young children with milder disease may RF-positive disease\nbe ANA âŠ• though this is associated\nwith â†‘ risk of developing uveitis\nSystemic JIA Involves one or more joints; recurrent, quo- ANA âŠ– Joint inflammation may\ntidian high fever (>39Â°C [>102.2Â°F]) RF âŠ– not occur for months\nHepatosplenomegaly to years after systemic\nLymphadenopathy symptoms appear\nSalmon-colored macular rash\nEnthesitis-related Macrophage activation syndrome: A common ANA âŠ– Onset occurs in boys\narthritis life-threatening complication RF âŠ– >6 years of age\nPsoriatic arthritis Presents with arthritis and/or enthesitis ANA âŠ• Females are commonly\nSacroiliac joint tenderness or lumbosacral RF âŠ– affected\ninflammatory pain\nAcute anterior uveitis\nHistory of human leukocyte antigen (HLA)-\nB27â€“associated disease\nUndifferentiated Children with psoriasis and arthritis OR\narthritis Children with arthritis and two of the fol-\nlowing: Psoriasis in a first-degree relative,\ndactylitis, and nail pitting or onycholysis\nDoes not meet/overlap criteria of any of the\nsubtypes\nA 2-year-old boy is brought to the\nJUVENILE IDIOPATHIC ARTHRITIS pediatrician for a skin infection that\nstarted on his chin and rapidly spread\nAn autoimmune disorder manifesting as arthritis with â€œmorning stiffnessâ€ and to involve much of his face and neck.\ngradual loss of motion that is present for at least 6 weeks in a patient This is his third such in",
      "char_start": 1540000,
      "char_end": 1542000
    },
    {
      "chunk_id": 771,
      "text": "fection this\nyear, and he is constantly plagued\n<16 years of age. Formerly known as juvenile rheumatoid arthritis (JRA).\nby sinus infections and bouts of\nApproximately 95% of cases are resolved by puberty. This disorder is more\npneumonia. There is no family\ncommon in girls than in boys. The most common clinical and laboratory\nhistory of recurrent infections. The\nfindings of different subtypes of juvenile idiopathic arthritis (JIA) are\npatient appears uncomfortable, and\ndescribed in Table 2.12-19.\ndermatologic exam is notable for\nerosions coated in yellow crust that\nDiagnosis are widespread across the patientâ€™s\nface and neck. He also has patchy\nSee Table 2.12-19.\nwhite pigmentation of the skin, light\nblonde hair, and blue eyes. What is\nthe most likely diagnosis?\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554477 1100//2211//2222 44::2211 PPMM\n\n548 HIGH-YIELD FACTS IN PEDIATRICS\nTreatment\nâ–  Best initial treatments: NSAIDs and strengthening exercises\nâ–  Corticosteroids (for myocarditis) and immunosuppressive medications\n(methotrexate, antiâ€“tumor necrosis factor agents such as etanercept) are\nsecond-line agents\nPEDIATRIC INFECTIOUS DISEASE\nACUTE OTITIS MEDIA\nA suppurative infection of the middle ear cavity that is common in children.\nSixty percent of children will develop one or more episodes of AOM before 4\nyears of age. Common pathogens include S pneumoniae; nontypeable H\ninfluenzae; Moraxella catarrhalis; and viruses such as influenza A, respiratory\nsyncytial virus (RSV), and parainfluenza virus.\nHistory/PE\nSymptoms include ear pain, fever, crying, irritability, difficulty feeding or\nsleeping, vomiting, and diarrhea. Young children may tug on their ears.\nRisk Factors\nâ–  Family history, day care, and tobacco smoke and air pollution exposure.\nRate peaks between 6 and 12 months of age.\nâ–  Protective factors: Breastfeeding, oral xylitol.\nDiagnosis\nDiagnosis is made clinically.\nâ–  Otoscopic examination reveals an erythematous tympanic me",
      "char_start": 1542000,
      "char_end": 1544000
    },
    {
      "chunk_id": 772,
      "text": "mbrane\n(TM) effusion, bulging, or retraction of the TM and â†“ TM mobility (test\nwith an insufflator bulb). Viral causes may result in serous otitis media\nwith blue-gray bulging membranes.\nâ–  Serous otitis media is the presence of effusion without active infection.\nExamination shows a dull TM.\nTreatment\nâ–  Best initial treatment: For mild cases of unilateral otitis media in children\n>6 months of age, treatment options include supportive care (pain and\nfever control) and close follow-up rather than antibiotics.\nThis child most likely has ChÃ©diak- â–  If antibiotics are used, the physician can prescribe high-dose amoxicillin\nHigashi syndrome, caused by (80â€“90 mg/kg/day) for 10 days for empiric therapy. Patients with recent\nautosomal recessive defects in the amoxicillin use and those with resistant or recurrent cases may require\nsynthesis/maintenance of storage amoxicillin/clavulanic acid. If patient is allergic to penicillin, the physi-\ngranules in a number of cell types cian can consider cephalosporin (mild delayed reaction) or azithromycin\n(including leukocytes, platelets,\n(immediate serious or delayed reaction).\nneutrophils, and melanocytes). In\nâ–  Complications include TM perforation, mastoiditis, meningitis, cholestea-\naddition to partial oculocutaneous\ntomas, and chronic otitis media. Recurrent otitis media can cause hearing\nalbinism, these patients experience\nloss with resultant speech and language delay. Chronic otitis media may\nhepatosplenomegaly and recurrent,\nrequire tympanostomy tubes.\nserious infections of the skin\nand respiratory tract by S aureus,\nStreptococcus pyogenes, and\nPneumococcus species. ChÃ©diak-Higashi\nsyndrome is often fatal in childhood\nbecause of overwhelming infection.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554488 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 549\nBRONCHIOLITIS KEY FACT\nToddlers and older infants are at risk\nAn acute inflammatory illness of the small airways of the lower",
      "char_start": 1544000,
      "char_end": 1546000
    },
    {
      "chunk_id": 773,
      "text": " respiratory\nfor foreign body aspiration. Sudden-\ntract that primarily affects infants and children <2 years of age, often in the\nonset wheezing or respiratory distress\nfall or winter. RSV is the most common cause; others include parainfluenza,\nare often characteristic. Objects that\ninfluenza, metapneumovirus, and other viruses. Progression to respiratory fail-\ncause airway compromise or that\nure is a potentially fatal complication. Risk factors for severe RSV infection\ncause mucosal damage (batteries)\ninclude <6 months of age, prematurity, heart or lung disease, neuromuscular\nshould be removed immediately with\ndisease, and immunodeficiency.\nbronchoscopy.\nHistory/PE\nâ–  Presentation:\nâ–  Days 1 to 3: Low-grade fever, rhinorrhea, cough. Young infants might\nhave apnea. This is believed to be due to impaired central respiratory\ncenter function in the setting of the stress of infection. KEY FACT\nâ–  Days 4 to 6: Respiratory distress, tachypnea, hypoxia. RSV is the most common cause of\nâ–  PE: Tachypnea, hypoxia, intercostal retractions, crackles or coarse breath bronchiolitis. Parainfluenza is the most\nsounds (â€œwashing machine soundsâ€), Â± wheezing\ncommon cause of croup.\nâ–  An â†‘ respiratory rate: Earliest and most sensitive vital sign change\nDiagnosis\nâ–  Bronchiolitis is predominantly a clinical diagnosis. Routine cases do not\nneed any laboratory or radiologic workup.\nâ–  In severe cases, a CXR can be obtained to rule out pneumonia. The x-ray\nmay show hyperinflation of the lungs with a flattened diaphragm, intersti-\ntial infiltrates, and/or atelectasis. KEY FACT\nâ–  Nasopharyngeal aspirate to test for RSV and other viruses is highly sensi- Young infants are at risk for apnea as a\ntive and specific but has little effect on management (infants should be\nresult of RSV bronchiolitis.\ntreated for bronchiolitis whether or not a virus is identified).\nTreatment\nâ–  Treatment for bronchiolitis is primarily supportive with hydration, suction-\ning, and supplemental O .\n2\nâ–  For patients with a hist",
      "char_start": 1546000,
      "char_end": 1548000
    },
    {
      "chunk_id": 774,
      "text": "ory or strong family history of asthma, treatment\nwith bronchodilators may be considered, and if symptoms improve, may\nbe continued.\nâ–  Hospitalization of patient is necessary if infantâ€™s hypoxia and/or tachypnea\ninterfere with feeding or if signs of severe illness are present.\nâ–  Corticosteroids are not indicated.\nâ–  Ribavirin is an antiviral drug sometimes used in high-risk infants with\nunderlying heart, lung, or immune disease. The American Academy of\nPediatrics recommends against the use of ribavirin in otherwise healthy\nchildren.\nâ–  RSV prophylaxis with injectable monoclonal antibodies (palivizumab) is\nrecommended in the fall/winter for high-risk patients â‰¤2 years of age (eg,\nthose with a history of prematurity, chronic lung disease, or CHD).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 554499 1100//2211//2222 44::2211 PPMM\n\n550 HIGH-YIELD FACTS IN PEDIATRICS\nCROUP (LARYNGOTRACHEOBRONCHITIS)\nAn acute viral inflammatory disease of the larynx, primarily within the sub-\nglottic space. Pathogens include parainfluenza virus types 1 (most common),\n2, and 3; RSV; influenza; and adenovirus. Rarely, bacterial superinfection\nmay develop, causing tracheitis.\nHistory/PE\nProdromal URI symptoms are typically followed by low-grade fever, mild dys-\npnea, inspiratory stridor that worsens with agitation, a hoarse voice, and a\nFIGURE 2.12-18. Croup. Anteroposterior characteristic barking cough that worsens at night.\nx-ray of the neck in this 1-year-old child\nwith inspiratory stridor and cough shows Diagnosis\nthe classic â€œsteeple signâ€ (arrow) con-\nsistent with the subglottic narrowing of â–  Croup is diagnosed by clinical impression. The diagnosis is often based on\nlaryngotracheobronchitis. (Reproduced with the degree of stridor and respiratory distress.\npermission from Stone CK, Humphries RL. Current â–  An anteroposterior x-ray of the neck may show the classic â€œsteeple signâ€\nDiagnosis & Treatment: Emergency Medicine, 6th ed.\nfrom subglottic narrowi",
      "char_start": 1548000,
      "char_end": 1550000
    },
    {
      "chunk_id": 775,
      "text": "ng (see Fig. 2.12-18), but this finding is neither\nNew York, NY: McGraw-Hill; 2008.)\nsensitive nor specific.\nâ–  Table 2.12-20 and Figure 2.12-19 differentiate croup from epiglottitis and\ntracheitis.\nTreatment\nâ–  Mild cases: Outpatient management with cool-mist therapy and fluids\nâ–  Moderate cases: May require supplemental O , oral or intramuscular\n2\n(IM) corticosteroids, and nebulized racemic epinephrine\nâ–  Severe cases (eg, respiratory distress at rest, inspiratory stridor, accessory neck\nmuscle use): Hospitalization and nebulized racemic epinephrine. The phy-\nsician should consider intubation if there is danger of airway compromise.\nTABLE 2.12-20. Characteristics of Croup, Epiglottitis, and Tracheitis\nVARIABLE CROUP (MOST COMMON) EPIGLOTTITIS TRACHEITIS\nAge group affected 3 months to 3 years 3â€“7 years 3 months to 2 years\nAnatomic structures affected Larynx Epiglottis Trachea\n(see Fig.2.12-19). Subglottic airway Aryepiglottic folds\nPathogen Parainfluenza virus H influenzae type B, S pneumoniae Often S aureus; follows viral URI\nOnset Prodrome (1â€“7 days) Rapid (4â€“12 hours) Prodrome (3 days) leading to acute\ndecompensation (10 hours)\nFever severity Low grade and often High grade High grade\nafebrile\nAssociated symptoms Barking cough, inspiratory Respiratory distress: Acute decom- Acute and severe respiratory distress\nstridor, hoarseness pensation, toxic appearance, but slower onset than epiglottitis;\ninspiratory stridor, muffled voice, presence of pseudomembranes or\ndrooling, tripoding purulent secretions on examination\nResponse to racemic Stridor improves None None\nepinephrine\nFindings on x-ray of neck â€œSteeple signâ€ on antero- â€œThumbprint signâ€ on lateral film Subglottic narrowing in anteroposte-\nposterior x-ray rior x-ray\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555500 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 551\nEPIGLOTTITIS\nH influenzae type B\nStreptococcus\nStaphylococcus Nasal cavity\nViral agents\nPharynx",
      "char_start": 1550000,
      "char_end": 1552000
    },
    {
      "chunk_id": 776,
      "text": "\nCROUP Epiglottis\nParainfluenza types\n1, 2, 3 Larynx\nRSV Trachea\nInfluenza\nLung\nBRONCHIOLITIS\nRSV Bronchioles\nRhinovirus\nParainfluenza\nInfluenza\nMetapneumovirus\nFIGURE 2.12-19. Epiglottis, croup, and bronchiolitis: Anatomy. (Reproduced with permission from\nUSMLE-Rx.com.)\nEPIGLOTTITIS\nA serious and rapidly progressive infection of supraglottic structures (eg, the\nepiglottis and aryepiglottic folds). Before immunization, H influenzae type b\nwas the primary pathogen. Common causes now include Streptococcus spe-\ncies, nontypeable H influenzae, and viral agents, but this is now a very rare\ninfection in the postvaccine era.\nHistory/PE\nâ–  Epiglottitis presents with acute-onset high fever (39â€“40Â°C [102â€“104Â°F]),\ndysphagia, drooling, a muffled voice, inspiratory retractions, cyanosis, and\nsoft stridor.\nâ–  Patients sit with the neck hyperextended and the chin protruding (â€œsniffing\ndogâ€ position) and lean forward in a â€œtripodâ€ position to maximize air\nentry.\nâ–  Untreated infection can rapidly lead to life-threatening airway obstruction\nand respiratory arrest.\nDiagnosis\nâ–  Epiglottitis is diagnosed by clinical impression. The differential diagnosis\nmust include diffuse and localized causes of airway obstruction (see\nTable 2.12-21).\nâ–  The airway must be secured before a definitive diagnosis can be made. In\nlight of potential laryngospasm and airway compromise, an examination of\nthe throat should only be done in the presence of an anesthesiologist or\notolaryngologist.\nâ–  Definitive diagnosis is made via direct fiberoptic visualization of cherry-\nred, swollen epiglottis and arytenoids.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555511 1100//2211//2222 44::2211 PPMM\n\n552 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-21. Additional Differential Diagnosis of Epiglottitis: Retropharyngeal vs Peritonsillar Abscess\nVARIABLE RETROPHARYNGEAL ABSCESS PERITONSILLAR ABSCESS\nAge group affected From 6 months to 6 years of age Usually >10 years of age\nHistory/PE Ac",
      "char_start": 1552000,
      "char_end": 1554000
    },
    {
      "chunk_id": 777,
      "text": "ute-onset high fever with sore throat, a muffled Sore throat, a muffled â€œhot potatoâ€ voice, trismus,\nâ€œhot potatoâ€ voice, trismus, drooling, and cervical drooling, uvula displaced to opposite side\nlymphadenopathy\nPresentation is usually unilateral; a mass may be seen in the\nposterior pharyngeal wall on visual inspection\nPathogen Group A streptococcus (most common), S aureus, Bacte- Group A streptococcus (most common), S aureus, S\nroides; often polymicrobial in origin pneumoniae, anaerobes\nPreferred position Sitting up or flexion of neck (supine position with the neck None\nextended worsens symptoms)\nDiagnosis On lateral x-ray of the neck, soft tissue plane should be Usually clinical\nâ‰¤50% of the width of the corresponding vertebral body\nContrast CT of the neck helps differentiate abscess from\nphlegmon (soft tissue infection)\nTreatment Aspiration or incision and drainage of abscess; antibiotics Incision and drainage Â± tonsillectomy; antibiotics\nâ–  Lateral x-ray shows a swollen epiglottis obliterating the valleculae\n(â€œthumbprint signâ€; see Fig. 2.12-20).\nTreatment\nRemember the ABCs. Secure the airway first with endotracheal intubation or\ntracheostomy and then give IV antibiotics (ceftriaxone or cefuroxime).\nFIGURE 2.12-20. Epiglottitis. Lateral MENINGITIS\nx-ray of the neck shows a markedly swol-\nlen epiglottis (arrows) demonstrating the\nBacterial meningitis most often occurs in children <3 years of age; common\nclassic â€œthumbprint sign,â€ with near-\norganisms include S pneumoniae, N meningitidis, and Escherichia coli.\ncomplete airway obstruction. (Reproduced\nEnteroviruses are the most common agents of viral meningitis, and they infect\nwith permission from Stone CK, Humphries RL. Current\nDiagnosis & Treatment: Emergency Medicine, 6th ed. children of all ages. Risk factors for bacterial meningitis include sinofacial\nNew York, NY: McGraw-Hill; 2008.) infections, trauma, immunodeficiency, and sepsis.\nMost common causes of bacterial meningitis by age are as follows:\nKEY FACT â–  N",
      "char_start": 1554000,
      "char_end": 1556000
    },
    {
      "chunk_id": 778,
      "text": "eonates: Group B Streptococcus (GBS), E coli, Listeria\nâ–  Infants/children: S pneumoniae, N meningitidis, H influenzae\nEpiglottitis is a true emergency and â–  Adolescents: N meningitidis, S pneumoniae\ncan lead to life-threatening airway\nobstruction. Time should not be wasted History/PE\non ordering an x-ray. â–  Bacterial meningitis in older children classically presents with the triad of\nheadache, high fever, and nuchal rigidity. Infants can present with fever\nand irritability.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555522 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 553\nâ–  Viral meningitis is typically preceded by a prodromal illness that includes\nfever, upper respiratory symptoms, and fatigue.\nâ–  Kernig sign (reluctance of knee extension when the hip is flexed) and\nBrudzinski sign (hips are flexed in response to forced flexion of the neck) KEY FACT\nare nonspecific signs of meningeal irritation in older children, but not in\nDonâ€™t be fooledâ€”infants rarely have\ninfants.\nmeningeal signs such as Kernig or\nâ–  Additional PE findings may include signs of â†‘ intracranial pressure ([ICP]\nBrudzinski signs or nuchal rigidity\npapilledema, cranial nerve palsies) or a petechial rash (N meningitidis).\nbecause of their open fontanelle, which\nSigns in neonates include lethargy, hyperthermia or hypothermia, poor\nhelps relieve the increased ICP.\ntone, a bulging fontanelle, and vomiting.\nDiagnosis\nâ–  The physician should obtain a CT scan of the head to rule out â†‘ ICP (risk\nfor brainstem herniation) if the patient is at high risk (eg, exhibits neuro-\nlogic deficits or has papilledema on funduscopic exam); however, this is\nnot typically needed in infants because the open fontanelle makes an\nincrease of ICP less of an issue.\nâ–  The physician should arrange for a lumbar puncture (LP) and send diag-\nnostic testing, including cell count with differential, glucose and protein\nlevels, Gram stain, and culture.\nâ–  In bacterial meningitis, findi",
      "char_start": 1556000,
      "char_end": 1558000
    },
    {
      "chunk_id": 779,
      "text": "ngs include high WBC, low glucose, high\nprotein, âŠ• Gram stain, and âŠ• culture.\nâ–  In viral meningitis, the patient may just have a high WBC level with nor-\nmal to high protein.\nTreatment\nâ–  Treat neonates with ampicillin and cefotaxime or gentamicin. Consider KEY FACT\nacyclovir if there is concern for herpes encephalitis (eg, if the mother had\nherpes simplex virus [HSV] lesions at the time of the infantâ€™s birth or if the Neonates should not be given\ninfant has an extremely bloody, nontraumatic LP). ceftriaxone in light of the â†‘ risk for\nâ–  Give older children ceftriaxone and vancomycin. biliary sludging and kernicterus.\nOCULAR INFECTIONS OF THE NEONATE\nInfectious conjunctivitis is transmitted as the neonate passes through the birth\ncanal during labor, and the infection often presents during the first weeks of\nlife. The most common causative agents include Chlamydia trachomatis and\nHSV (usually HSV-2). Neisseria gonorrhoeae was much more common before\nthe routine use of prophylaxis. Now it causes <1% of cases of neonatal con-\njunctivitis in the United States. Erythromycin ointment is recommended as\nfirst-line prophylaxis. Silver nitrate is more effective for penicillinase-productive\nN gonorrhoeae.\nHistory/PE\nTable 2.12-22 summarizes the clinical presentation of common neonatal ocu-\nlar infections.\nDiagnosis\nâ–  Bacterial cultures and Gram stain represent the gold standard for sus-\npected gonococcal or chlamydial conjunctivitis.\nâ–  HSV polymerase chain reaction (PCR) is the diagnostic standard for chil-\ndren with corneal ulceration or for those with a vesicular eruption any-\nwhere on the body.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555533 1100//2211//2222 44::2211 PPMM\n\n554 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-22. Ocular Infections in the Neonatal Period\nCAUSATIVE AGENT CHARACTERISTICS TREATMENT\nChlamydia trachomatis Symptoms appear 1â€“2 weeks after birth Topical erythromycin ointment and oral\nPresents with eyelid swelling and ",
      "char_start": 1558000,
      "char_end": 1560000
    },
    {
      "chunk_id": 780,
      "text": "relatively scant erythromycin\nwatery discharge Topical antibiotics alone are insufficient, as sys-\ntemic infection is often present\nNeisseria gonorrhoeae Symptoms appear within 1 week of birth IV/IM third-generation cephalosporin\nBilateral purulent conjunctivitis and marked Gonococcal coverage is crucial if the causative\neyelid edema agent is unknown, as corneal ulceration (and\nTends to be more severe than chlamydial resultant scarring) can occur within 24â€“48 hours\nconjunctivitis\nHerpes simplex virus Symptoms appear within 2 weeks of birth IV acyclovir for 14- to 21-day course, along with a\nPresents with conjunctival injection, watery/ topical agent (such as vidarabine)\nserosanguineous eye discharge, and vesicular\neruptions surrounding the eyes\nâ–  The neonateâ€™s mother should undergo cervical Gram stain and culture if a\nsexually transmitted infection is the suspected cause of conjunctivitis.\nTreatment\nâ–  Empiric treatment can start before culture results are known.\nâ–  Specific treatments are listed in Table 2.12-22.\nPERTUSSIS (WHOOPING COUGH)\nA highly infectious form of bronchitis caused by the encapsulated gram âŠ–\nbacillus Bordetella pertussis. The diphtheria, tetanus, acellular pertussis\n(DTAP) vaccine (given in five doses in early childhood) is protective, but\nimmunity wanes by adolescence, and so booster vaccination is recom-\nmended every 10 years. Adolescents and young adults serve as the primary\nreservoir for pertussis; a physician should not exclude it as a diagnosis in\nyoung adults with paroxysms of cough. Transmission is through aerosol\ndroplets and requires airborne precautions with a mask. Pertussis can be life-\nthreatening for young infants but is generally a milder infection in older\nchildren and adults.\nKEY FACT History/PE\nThe classic presentation of pertussis â–  Has the following three stages:\nis an infant <6 months of age with â–  Catarrhal (mild URI symptoms; lasts 1â€“2 weeks)\nparoxysmal coughing, post-tussive â–  Paroxysmal (paroxysms of cough with inspirator",
      "char_start": 1560000,
      "char_end": 1562000
    },
    {
      "chunk_id": 781,
      "text": "y whoop and post-\ntussive emesis; lasts 2â€“3 months)\nemesis, and apnea. The typical\nâ€œwhoopingâ€ cough is usually absent at â–  Convalescent (symptoms wane)\nthis age. â–  Patients most often present in the paroxysmal stage, but are most conta-\ngious in the catarrhal stage\nDiagnosis\nâ–  Labs show an elevated WBC count with lymphocytosis (often â‰¥70%)\nâ–  Most accurate test: Nasopharyngeal culture or PCR\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555544 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 555\nTreatment\nâ–  Hospitalize infants <6 months of age.\nâ–  Give azithromycin for 10 days to patients. Exposed newborns are at high\nrisk irrespective of their immunization status because they may not be\nentirely protected by maternal transplacental immunoglobulins.\nâ–  Close contacts (including day care contacts) should receive prophylactic\nantibiotics (azithromycin for 5 days).\nVIRAL EXANTHEMS\nTable 2.12-23 outlines the clinical presentation of common viral exanthems.\nTORCH INFECTIONS\nRefer to the Obstetrics chapter.\nPINWORM INFECTION\nCaused by Enterobius vermicularis. Pinworm is a parasitic infection that causes\nperianal pruritus, which is more pronounced at night. Diagnosis is made with\nthe tape test (clear tape is pressed to the anal region in the morning and\nobserved under the microscope for pinworm eggs). The patient and all house-\nhold contacts should be treated with albendazole or pyrantel pamoate.\nNEONATAL FEVER (<28 DAYS OLD)\nâ–  Fever is defined as a rectal temperature â‰¥38Â°C (â‰¥100.4Â°F)\nâ–  One of the most common indications for hospitalization\nâ–  Neonates have a high risk of invasive bacterial infection (IBI) or a viral\ninfection; most severe is HSV\nâ–  Presentation of illness can be subtle with history of poor feeding, lethargy,\nand decreased activity\nDiagnosis\nCBC with differential; complete metabolic panel; cultures of blood, urine,\nand cerebrospinal fluid (CSF)\nMost common bacterial pathogens:\nâ–  Early onset (< 30 days): Predomi",
      "char_start": 1562000,
      "char_end": 1564000
    },
    {
      "chunk_id": 782,
      "text": "nantly GBS infection, followed by\ngram âŠ– organisms (predominantly E coli), and Listeria\nâ–  Late onset (>30 days): Predominantly GBS infection, followed by gram\nâŠ– organisms (predominantly E coli)\nTreatment\nBroad-spectrum antibiotic coverage with ampicillin and cefotaxime\nFEVER OF UNKNOWN ORIGIN\nâ–  Refers to children with a fever â‰¥38.3Â°C (>101Â°F) for at least 8 days with-\nout apparent diagnosis after a careful history, physical examination, and\nlaboratory assessment\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555555 1100//2211//2222 44::2211 PPMM\n\n556 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-23. Viral Exanthems\nDISEASE CAUSE SYMPTOMS COMPLICATIONS\nErythema infectiosum Parvovirus B19 Prodrome: None; fever often absent or low Arthropathy in children and adults\n(fifth disease) grade Congenital infection is associated with fetal\nA Rash: â€œSlapped-cheek,â€ pruritic, maculopapular, hydrops and death\nerythematous rash (see Image A); rash Aplastic crisis may be precipitated in children\nstarts on the arms and spreads to the trunk with â†‘ RBC turnover (eg, sickle cell anemia,\nand legs; rash worsens with fever and sun hereditary spherocytosis) or in those with â†“\nexposure RBC production (eg, severe iron-deficiency\nanemia)\nMeasles Paramyxovirus Prodrome: Fever (can be as high as 40Â°C Common: Otitis media, pneumonia,\nB [104Â°F]) with Cough, Coryza, and Conjuncti- laryngotracheitis\nvitis (the â€œ3 Csâ€); Koplik spots (small irregular Rare: Subacute sclerosing panencephalitis\nred spots with central gray specks) appear on Airborne infectious precautions are needed\nthe buccal mucosa after 1â€“2 days because of high level of contagiousness\nRash: An erythematous maculopapular rash\nthat spreads from head to toe (see Image B)\nTreatment with vitamin A may improve\nsymptoms\nRubella (â€œ3-day Rubella virus Prodrome: Asymptomatic or tender, general- Encephalitis, thrombocytopenia (a rare compli-\nmeaslesâ€) ized lymphadenopathy (clue: posterior cation of postnatal infec",
      "char_start": 1564000,
      "char_end": 1566000
    },
    {
      "chunk_id": 783,
      "text": "tion)\nC auricular lymphadenopathy) Congenital infection is associated with con-\nRash: An erythematous, tender maculopapular genital anomalies (PDA, deafness, cataracts,\nrash that also spreads from head to toe (see intellectual disabilities)\nImage C)\nIn contrast to measles, children with rubella\noften have only a low-grade fever and do not\nappear as ill\nPolyarthritis may be seen in adolescents\nRoseola infantum Human Prodrome: Acute onset of high fever (>40Â°C Febrile seizures that may result from rapid fever\nherpes virus [>104Â°F]); no other symptoms for 3â€“4 days onset\n(HHV)-6 and Rash: A maculopapular rash that appears as\nHHV-7 fever breaks (begins on the trunk and quickly\nspreads to the face and extremities) and\noften lasts <24 hours\nVaricella (chickenpox) Varicella-zoster Prodrome: Mild fever, anorexia, and malaise Progressive varicella with meningoen-\nD virus (VZV) that precede the rash by 24 hours cephalitis, pneumonia, and hepatitis in the\nRash: Generalized, pruritic, â€œteardropâ€ vesicles immunocompromised\non red base; lesions are often at different Skin lesions may develop secondary bacterial\nstages of healing (see Image D); rash usually infections\nappears on the face and spreads to the rest Reye syndrome may occur if a child takes\nof the body, sparing the palms and soles aspirin to address the fever\nInfectious from 24 hours before eruption until Varicella may be prevented with vaccine or with\nlesions crust over postexposure prophylaxis for nonimmunized\npatients >1 year of age (immunoglobulin for\nthe immunocompromised and vaccine for\nthe immunocompetent)\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555566 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 557\nTABLE 2.12-23. Viral Exanthems (continued)\nDISEASE CAUSE SYMPTOMS COMPLICATIONS\nVaricella zoster VZV Prodrome: Reactivation of varicella infection; Encephalopathy, aseptic meningitis, pneumo-\ndisease starts as pain along an affected nitis, thrombo",
      "char_start": 1566000,
      "char_end": 1568000
    },
    {
      "chunk_id": 784,
      "text": "tic thrombocytopenic purpura\nsensory nerve (TTP), Guillain-BarrÃ© syndrome, cellulitis,\nRash: Pruritic â€œteardropâ€ vesicular rash in a arthritis\ndermatomal distribution; rash is uncommon\nunless the patient is immunocompromised\nHand-foot-and-mouth Coxsackie A Prodrome: Fever, anorexia, oral and throat pain Aseptic meningitis, encephalitis, pneumonia,\ndisease Rash: Oral ulcers; maculopapular vesicular rash myopericarditis\non the hands and feet and sometimes on the\nbuttocks\nImage A reproduced with permission from Wolff K, Johnson RA. Fitzpatrickâ€™s Color Atlas & Synopsis of Clinical Dermatology, 6th ed. New York:\nMcGraw-Hill; 2009. Image B reproduced with permission from Wolff K, et al. Fitzpatrickâ€™s Dermatology in General Medicine, 7th ed. New York:\nMcGraw-Hill; 2008. Image C adapted with permission from the Centers for Disease Control and Prevention. Image D reproduced with permission\nfrom the Centers for Disease Control and Prevention and Dr John Noble, Jr.\nâ–  Should include an extensive workup of infections, connective tissue dis-\nease, fever, CNS dysfunction, and oncologic disease, especially leukemia\nâ–  Often a common disorder with an uncommon presentation\nPEDIATRIC NEUROLOGIC DISEASE\nCEREBRAL PALSY\nA group of nonhereditary, nonprogressive disorders of muscle tone; the most\ncommon movement disorder in children. Often results from prenatal, perina-\ntal, or neonatal neurologic insult, but in most cases stems from unknown\ncause. Risk factors of cerebral palsy (CP) include low BW, intrauterine expo-\nsure to maternal infection, prematurity, perinatal asphyxia, trauma, brain mal-\nformation, and neonatal cerebral hemorrhage. Pregnant patients at risk for\npreterm birth are given IV magnesium sulfate to decrease incidence of CP.\nCategories include the following:\nâ–  Pyramidal (spastic): A result of damage to the motor cortex. This type\npresents with spastic paresis of any or all limbs and accounts for 75% of\ncases. Intellectual disabilities are also present in up to 90% of cases",
      "char_start": 1568000,
      "char_end": 1570000
    },
    {
      "chunk_id": 785,
      "text": ".\nâ–  Extrapyramidal (dyskinetic): A result of damage to extrapyramidal tracts.\nSubtypes are choreoathetoid and dystonic (uncontrollable jerking, writh-\ning, or posturing). Abnormal movements worsen with stress and disappear\nduring sleep.\nâ–  Ataxic: A result of damage to the cerebellum. This type of CP often pres-\nents with a lack of body coordination and hypotonia.\nHistory/PE\nâ–  May be associated with seizure disorders, behavioral disorders, hearing or\nvision impairment, learning disabilities, speech deficits, GI disorders, or\nother associated complications of prematurity.\nâ–  Delayed achievement of gross motor and fine motor developmental mile-\nstones. Affected limbs may show hyperreflexia, pathologic reflexes (eg,\nBabinski), â†‘ tone/contractures, weakness, and/or underdevelopment. Defi-\nnite hand preference before 1 year of age is a red flag.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555577 1100//2211//2222 44::2211 PPMM\n\n558 HIGH-YIELD FACTS IN PEDIATRICS\nKEY FACT â–  Toe walking and scissor gait common. Hip dislocations and scoliosis may\nbe seen.\nThe most common presenting\nsymptom of cerebral palsy is delayed\nDiagnosis\nmotor development.\nâ–  Diagnosis is often clinical.\nâ–  Imaging can be used to determine the underlying cause of CP in some\ncases. Ultrasonography may be useful in infants to identify intracranial\nhemorrhage or structural malformations. MRI can be diagnostic. Elec-\ntroencephalography (EEG) may be useful in patients with suspected\nseizures.\nâ–  A full evaluation of hearing, vision, and developmental milestones (espe-\ncially motor) should be done if there is suspicion of CP.\nTreatment\nâ–  There is no cure for CP. Multidisciplinary treatment is required. Special\neducation, physical therapy, braces, and surgical release of contractures\nmay help.\nâ–  Spasticity can be treated with baclofen, diazepam, or dantrolene. Botuli-\nnum toxin can be helpful for localized spasticity. Baclofen pumps and pos-\nterior rhizotomy (nerve destructi",
      "char_start": 1570000,
      "char_end": 1572000
    },
    {
      "chunk_id": 786,
      "text": "on for pain relief) may alleviate severe\ncontractures.\nFEBRILE SEIZURES\nUsually occur in children between 6 months and 5 years of age who have no\nevidence of intracranial infection or other causes. Risk factors include a rapid\nâ†‘ in temperature and a history of febrile seizures in a close relative. Febrile\nseizures recur in approximately one in three patients.\nHistory/PE\nâ–  Seizures usually occur during the onset of fever and may be the first sign\nof an underlying illness (eg, otitis media, roseola).\nâ–  Classified as simple or complex:\nâ–  Simple: A short (<15 minutes), generalized tonic-clonic seizure with\none seizure in a 24-hour period and return to neurologic baseline\nshortly afterward. A high fever (>39Â°C [>102.2Â°F]) within hours of\nthe seizure is typical.\nâ–  Complex: A long (>15 minutes) seizure, focal seizure, or multiple sei-\nzures in a 24-hour period or no return to neurologic baseline. A low-\ngrade fever for several days before seizure onset may be present.\nâ–  Febrile status epilepticus: Prolonged continuous seizures (30 minutes) or\nintermittent seizures without return to baseline in between.\nDiagnosis\nâ–  Often a clinical diagnosis, with exclusion of CNS abnormalities, inflam-\nmation, or metabolic dysfunction that can account for the seizure.\nâ–  Focus on finding source of infection. LP and CSF studies are indicated if\nthere are concerns for clinical signs of CNS infection (eg, altered con-\nKEY FACT\nsciousness, meningismus, a tense/bulging anterior fontanelle) after ruling\nout â†‘ ICP.\nOnly perform an LP if CNS infection is\nsuspected in a patient with a febrile â–  No workup necessary for first-time simple febrile seizures, and no labora-\ntory studies needed if consistent with febrile seizures. Infants <6 months\nseizure. Keep in mind that if a patient is\nof age need a sepsis workup (CBC; urinalysis [UA]; and blood, urine, and\non antibiotics, it can mask symptoms of\nCSF culture).\nan infection.\nâ–  For atypical presentations, electrolytes, serum glucose, blood cultures, UA,",
      "char_start": 1572000,
      "char_end": 1574000
    },
    {
      "chunk_id": 787,
      "text": "\nand CBC with differential and additional studies as applicable to concerns.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555588 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 559\nTreatment\nâ–  First-time febrile seizures can be managed with observation and parental\ncounseling.\nâ–  Seizures >5 minutes should be treated with anticonvulsant medications\n(eg, benzodiazepines). Febrile status epilepticus can be treated with\nfosphenytoin.\nâ–  Patient can be treated with antipyretics (acetaminophen; avoid ASA in\nlight of the risk for Reye syndrome, acute liver failure, and encephalopa-\nthy), and any underlying illness should be addressed. Note that antipyretic\ntherapy does not â†“ the recurrence of febrile seizures.\nâ–  For complex seizures, the physician should conduct a thorough neuro-\nlogic evaluation, including EEG and MRI. Chronic anticonvulsant ther-\napy (eg, diazepam or phenobarbital) is only needed if abnormalities are\nfound; usually not necessary.\nKEY FACT\nComplications\nSimple febrile seizures do not cause\nâ–  The risk for recurrence is about 30% to 35% and is highest within 1 year of brain damage, do not â†‘ risk for\nthe initial episode. For simple febrile seizures, there is no â†‘ risk for devel-\ndevelopmental abnormalities, recur\nopmental abnormalities and only slight association with this being an early\nin about 30%â€“35% of cases, and only\nmanifestation of an underlying epilepsy.\nslight association with this being an\nâ–  Risk factors for the development of epilepsy include complex febrile sei- early manifestation of an underlying\nzures (âˆ¼10% risk), âŠ• family history of epilepsy, an abnormal neurologic\nepilepsy.\nexamination, and developmental delay.\nINFANTILE HYPOTONIA\nThe lack of tone or resistance of muscle movement. It differs from weakness,\nwhich is the decrease in active muscle contraction. Common causes of infan-\ntile hypotonia are listed in Table 2.12-24.\nTABLE 2.12-24. Common Causes of Infantile Hypotonia\nDISORDER ETIOL",
      "char_start": 1574000,
      "char_end": 1576000
    },
    {
      "chunk_id": 788,
      "text": "OGY PRESENTATION TREATMENT\nBotulism Caused by Clostridium botulinum toxin, Constipation sometimes the first presenting Supportive care\nwhich prevents presynaptic release of sign Botulism immunoglobulin\nacetylcholine (ACh) Symmetric, descending paralysis\nSpores found in honey or soil Occurs before 12 months of age\nSpinal muscular Mutation in SMN1 gene Progressive muscle weakness and atrophy Supportive care\natrophy Infantile type (type 1; also known as Presents with tongue fasciculation and sym- No cure\nWerdnig-Hoffman disease) metric proximal muscle weakness, greater\nLeads to anterior horn cell and motor in the lower than the upper extremities\nnuclei degeneration\nMyotonic dystrophy Trinucleotide repeat disorder (CTG) on Increasing loss of muscle tone and weak- Supportive care\n(type 1) DMPK gene ness, especially in the facial muscles\nAutosomal dominant disorder that is Can present in infancy as hypotonia\ncommonly inherited through the Most common onset in 20sâ€“40s\nmother Associated with mental retardation, cata-\nracts, and arrhythmias\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 555599 1100//2211//2222 44::2211 PPMM\n\n560 HIGH-YIELD FACTS IN PEDIATRICS\nCOMMON BRAIN NEOPLASMS IN CHILDREN\nTable 2.12-25 outlines pediatric cranial neoplasms.\nTABLE 2.12-25. Common Primary Neoplasms in Children\nTUMOR PATHOLOGY PRESENTATION TREATMENT\nPilocytic astrocytoma Generally benign, well-circumscribed Most common CNS tumor in children Resection if possible;\n(Images A and B) tumor of astrocyte origin; stains Presents with drowsiness, headache, ataxia, radiation\nâŠ• for glial fibrillary acidic protein nausea, vomiting, cranial neuropathy\n(GFAP) Slow growing with protracted course and favor-\nPosterior fossa/infratentorial tumor able prognosis\nBipolar neoplastic cells with hairlike projections;\nassociated with microcysts and Rosenthal\nfibers (eosinophilic, corkscrew fibers); cystic +\nsolid mass (gross)\nMedulloblastoma\nA primitive neuroectodermal tumor Hig",
      "char_start": 1576000,
      "char_end": 1578000
    },
    {
      "chunk_id": 789,
      "text": "hly malignant but radiosensitive; may seed Surgical resection\n(Image C)\n(PNET) of the posterior fossa/ the subarachnoid space or spread â€œdrop coupled with\ninfratentorial region metastasesâ€ to the spinal cord radiation and\nArises from the fourth ventricle or cer- May cause obstructive hydrocephalus by com- chemotherapy\nebellar vermis pressing the fourth ventricle â†’ headaches,\nHomer-Wright rosettes, small blue cells papilledema, vomiting\nSynaptophysin âŠ• Truncal ataxia caused by involvement of cer-\nebellar vermis\nEpendymoma Ependymal cell tumor most commonly Causes obstructive hydrocephalus by com- Surgical resection fol-\nfound in the fourth ventricle, but pressing the fourth ventricle â†’ headaches, lowed by radiation\nmay present as primary spinal cord papilledema, vomiting or chemotherapy\ntumors Myelopathy and radiculopathy possible pre-\nCharacteristic perivascular pseudoro- senting symptoms with involvement of spinal\nsettes; rod-shaped blepharoplasts cord\n(basal ciliary bodies) found near the\nnucleus\nCraniopharyngioma The most common suprasellar tumor Benign Surgical resection\n(Images D and E) in children Most commonly causes bitemporal hemianopsia\nCalcification common (distinguishes it due to compression of the optic chiasm\nfrom pituitary adenoma) Associated with a high recurrence rate\nDerived from remnants of Rathke\npouch (ectoderm); cholesterol crys-\ntals found in â€œmotor oilâ€â€“like fluid\nwithin tumor\n(continues)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556600 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 561\nTABLE 2.12-25. Common Primary Neoplasms in Children (continued)\nTUMOR PATHOLOGY PRESENTATION TREATMENT\nPinealoma Germ cell tumor of pineal gland; similar Malignant Radiation therapy Â±\nto other germ cell tumors (eg, tes- Can cause Parinaud syndrome (compression of chemotherapy\nticular seminoma) tectum â†’ vertical gaze palsy); obstructive\nMass arising in the third ventricle hydrocephalus (compression of cer",
      "char_start": 1578000,
      "char_end": 1580000
    },
    {
      "chunk_id": 790,
      "text": "ebral aque-\nduct); precocious puberty in males (human\nchorionic gonadotropin [hCG] production)\nA B C D E\nImage A modified with permission from Hafez, R.F. Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary\nresult. World J Surg Onc 5, 39 (2007). https://doi.org/10.1186/1477-7819-5-39. Image D reproduced with permission from Garnett, M.R., Puget, S., Grill, J. et al.\nCraniopharyngioma. Orphanet J Rare Dis 2, 18 (2007). https://doi.org/10.1186/1750-1172-2-18. Images B, C, and E reproduced with permission from USMLE-Rx.\ncom.\nSPINAL DYSRAPHISM\nA type of neural tube defect (NTD) caused by improper closure of the neural\ntube, leading to a potentially exposed spine or spinal cord. An important risk\nfactor is due to folate deficiency during pregnancy.\nHistory/PE\nâ–  Patients have varying clinical presentations, depending on the type of spi-\nnal dysraphism.\nâ–  Closed spinal dysraphism includes:\nâ–  Spina bifida occulta: Most common type. Caused by a defect in the\nvertebrae with intact meninges or spinal cord. Patients are usually\nasymptomatic with a tuft of hair or dimple at the level of the defect.\nâ–  Open spinal dysraphism includes:\nâ–  Meningocele: The meninges protrude through the vertebral defect.\nThe spinal cord is often undamaged.\nâ–  Myelomeningocele: This is the most severe variation. A portion of the\nspinal cord herniates through the vertebral defect.\nDiagnosis\nOpen spinal dysraphism is often detected by an elevated level of Î±-fetoprotein\n(AFP) in a quad screen during pregnancy. Ultrasound can then be used to\nrule out other causes of elevated AFP (eg, multifetal gestation).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556611 1100//2211//2222 44::2211 PPMM\n\n562 HIGH-YIELD FACTS IN PEDIATRICS\nTreatment\nClosed spinal dysraphism can be treated with monitoring, as patients are often\nasymptomatic. Open spinal dysraphism is more severe and should be treated\nwith surgery within 3 days of birth to",
      "char_start": 1580000,
      "char_end": 1582000
    },
    {
      "chunk_id": 791,
      "text": " reduce any chances of infection. Long-\nterm management includes multidisciplinary and interdisciplinary teams to\noptimize neuromuscular function.\nBREATH-HOLDING SPELLS\nKEY FACT\nBreath-holding spells are nonepileptic paroxysmal episodes that typically\nBreath-holding spells are triggered by\noccur between 6 months and 6 years of age. The spells are brief periods when\nan emotional trigger and may result\nyoung children stop breathing for up to 1 minute. The spells can cause the\nin loss of consciousness or cyanosis.\nchild to lose consciousness and often occur when a young child is angry, frus-\nAlthough they may be alarming to the\ntrated, in pain, or afraid, but the spell is a reflex. There is a significant associa-\nparents, these are benign episodes\ntion between breath-holding spells and certain types of anemia, particularly\nand not cardiac related. They typically\niron-deficiency anemia. A family history of breath-holding spells is also pres-\nresolve by 5 years of age.\nent in a significant portion of patients.\nHistory/PE\nCyanotic variant: Most common. The episode is generally preceded by an\nupsetting event such as a reprimand or temper tantrum. A stereotypical\nsequence ensues with a period of crying followed by forced apnea and loss of\ntone and consciousness. Cyanosis is very marked.\nPallid variant: More often in response to a very mild trauma to the head\nor upper body. The child then becomes pale and diaphoretic with loss of tone\nand consciousness.\nDiagnosis\nThe diagnosis is a clinical one. The episode must be distinguished from a sei-\nzure by careful history taking. A workup to identify anemia is recommended\nwith hemoglobin and ferritin. The prognosis is excellent, with a complete res-\nolution of spells in the vast majority of children by 8 years of age.\nTreatment\nTreatment is limited to correcting an iron-deficiency anemia; correcting this\ncan reduce the frequency of spells in some children. Antiepileptics are not\nrecommended, and seizures generally resolve over time.",
      "char_start": 1582000,
      "char_end": 1584000
    },
    {
      "chunk_id": 792,
      "text": "\nRETT SYNDROME\nRett syndrome is a neurodevelopmental disorder. It is due to a mutation in\nthe MECP2 gene on the X chromosome and is most commonly sporadic. It is\nalmost exclusively seen in females, as males with the condition die almost\nimmediately after birth. Manifestations begin around 6 to 18 months of age\nin girls.\nHistory/PE\nClinically, signs and symptoms typically begin after a period of normal growth\nand development. The earliest sign is the deceleration of head growth. Subse-\nquently, patients will progressively lose communication skills, fine motor\nskills, and intellectual abilities. A distinctive feature of the condition is the\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556622 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 563\nA\ndevelopment of stereotypical hand movements such as grasping of hair or\nclothing and episodes of inconsolable irritability.\nAdditional manifestations include the following:\nâ–  Loss of spoken language\nâ–  Motor dysfunction\nâ–  Scoliosis\nâ–  Growth failure (head circumference first and then height and weight)\nâ–  Epilepsy\nâ–  Decreased bone mineral density\nâ–  Cardiac defects/autonomic dysfunction\nâ–  Sleep dysfunction\nâ–  Abnormal breathing during wakefulness\nDiagnosis B\nThe clinical suspicion of Rett syndrome is confirmed by a DNA analysis\nshowing mutations in the MECP2 gene.\nTreatment\nTreatment is largely supportive. Currently no disease-modifying treatments\nare routinely used. Patients are usually managed by a multidisciplinary team\nwith physical, occupational, and communication therapy. Growth, nutrition,\ncardiac function, sleep, and neurologic function should be monitored.\nCHIARI MALFORMATIONS\nCongenital malformations are due to underdevelopment of the posterior\nFIGURE 2.12-21. Chiari malformations.\nfossa. There are two main types: Chiari I and Chiari II:\n(A) outlines the herniation of the tonsils\nonly (white arrows) in Chiari I. (B) out-\nâ–  Chiari I: Herniation of the cerebellar tonsils t",
      "char_start": 1584000,
      "char_end": 1586000
    },
    {
      "chunk_id": 793,
      "text": "hrough the foramen mag-\nlines the herniation of the medulla (thin\nnum (I structure) (Fig. 2.12-21A). Typically presents after childhood with\nwhite arrow), tonsils (transparent white\noccipital headaches and cerebellar symptoms (ataxia, dizziness). Head- arrow), and vermis (thick white arrow) in\naches are worse with Valsalva maneuver (eg, cough). Chiari I is associated Chiari II. (Image A adapted with permission from\nwith syringomyelia. Toldo I, De Carlo D, Mardari R, et al. Short lasting activ-\nâ–  Chiari II: Herniation of cerebellar tonsils, vermis, and medulla through ity-related headaches with sudden onset in children: a\ncase-based reasoning on classification and diagnosis.\nthe foramen magnum (Fig. 2.12-21B). Presents at birth with apnea, stri-\nJ Headache Pain. 2013;14[1]:3 doi:10.1186/1129-2377-\ndor, dysphagia due to medullary compression, and noncommunicating\n14-3. Image B reproduced with permission from\nhydrocephalus due to aqueductal stenosis. Chiari II is associated with lum- Geerdink N, van der Vliet T, Rotteveel JJ, et al. Essential\nbosacral myelomeningocele, which can cause lower limb motor weakness/ features of Chiari II malformation in MR imaging: an\nsensory loss. interobserver reliability studyâ€”part 1. Childs Nerv Syst.\n2012;28[7]:977-985. doi:10.1007/s00381-012-1761-5.)\nBENIGN FAMILIAL MICROCEPHALY AND MACROCEPHALY\nMicrocephaly is defined as head circumference >2 standard deviations below\nthe mean, whereas macrocephaly entails head circumference >2 standard\ndeviations above the mean. Diagnosed in normal, healthy children with a\nnormal parent with a similar-sized head. Development and examination will\nbe normal with no syndromic features.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556633 1100//2211//2222 44::2211 PPMM\n\n564 HIGH-YIELD FACTS IN PEDIATRICS\nPEDIATRIC HEMATOLOGY\nDIAMOND-BLACKFAN ANEMIA\nA congenital form of pure red cell aplasia (causes isolated anemia versus Fan-\nconi anemia, which causes pancytopenia; s",
      "char_start": 1586000,
      "char_end": 1588000
    },
    {
      "chunk_id": 794,
      "text": "ee Table 2.12-26). It is due to an\nintrinsic defect in erythroid progenitor cells, leading to macrocytic normo-\nchromic anemia. Patients have an increased malignancy risk (acute myeloge-\nnous leukemia [AML], myelodysplastic syndrome [MDS)], and solid tumors,\neg, colon cancer). Other long-term complications include endocrine dysfunc-\ntion (short stature, adrenal insufficiency, hypogonadism, hypothyroidism, vita-\nmin D deficiency) and hemosiderosis.\nHistory/PE\nâ–  Progressive anemia within first year of life â†’ signs and symptoms of\nimpaired oxygen-carrying capacity (eg, pallor, tachycardia, apnea, leth-\nargy). Low BW, growth restriction usually present.\nâ–  Associated with congenital abnormalities (up to 50% cases, mainly in head\nand upper limb). Craniofacial (low-set ears, micrognathia, cleft palate,\nbroad nasal bridge), ophthalmologic (congenital cataracts or glaucoma),\ncardiac (ASD, VSD), upper extremity malformations (triphalangeal\nthumbs), intellectual disability, hypogonadism, and short stature.\nDiagnosis\nâ–  CBC: â†“ hemoglobin (Hb), â†‘ mean corpuscular volume (MCV), normal\nWBC and platelet count; reticulocytopenia: â†‘ %HbF (but â†“ total Hb)\nâ–  Normal bone marrow cellularity with markedly decreased or absent ery-\nthroid precursors\nâ–  Specific testing: â†‘ erythrocyte adenosine deaminase (eADA) activity\nTABLE 2.12-26. Congenital Anemias\nDIAMOND-BLACKFAN ANEMIA FANCONI ANEMIA\nInheritance pattern Autosomal dominant Autosomal recessive or X-linked\nGene mutation effect Impaired ribosome synthesis Chromosome fragility\nType of anemia Macrocytic-normochromic\nAnemia age of onset Classically presents in infancy Around 8 years\nCongenital anomalies Present Present\nMalignancy risk Present Present\nCBC findings Isolated macrocytic anemia Pancytopenia\nSpecific testing Elevated erythrocyte adenosine Chromosome breakage assay\ndeaminase, elevated hemo-\nglobin F\nTreatment Corticosteroids, blood transfu- Androgens, blood transfusions,\nsions, stem cell transplant stem cell transplant\n22002222__002",
      "char_start": 1588000,
      "char_end": 1590000
    },
    {
      "chunk_id": 795,
      "text": "2..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556644 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 565\nâ–  Four diagnostic criteria (all must be present):\nâ–  Onset of anemia at age <1 year\nâ–  Macrocytic anemia without cytopenias\nâ–  Reticulocytopenia\nâ–  Normal marrow cellularity with a paucity of erythroid precursors\nTreatment\nâ–  Corticosteroids (children â‰¥1 year old), RBC transfusions (infants <1 year\nold or steroid-refractory patients), stem cell transplant (steroid-refractory\npatients)\nâ–  Corticosteroids avoided in infants due to â†‘ risk of adverse effects\nâ–  Monitoring for development of malignancies and iron overload, hemosid-\nerosis (among patients who received chronic transfusion therapy)\nFANCONI ANEMIA\nAutosomal recessive or X-linked disorder of chromosomal fragility. People of\nAshkenazi Jewish descent â†‘ carrier frequency. Genetic mutation of multiple\nDNA cross-link repair genes â†’ impaired cellular repair of DNA cross-links â†’\nimpaired cell cycle regulation, genomic instability â†’ increased sensitivity\nto cytotoxic therapies and a predisposition for blood/solid malignancies\n(eg, AML, MDS, squamous cell cancers) and hematopoietic stem cell loss\n(â†’ bone marrow failure â†’ macrocytic-normochromic anemia, pancytopenia).\nThere are many other causes of bone marrow failure, which are described in\nTable 2.12-27.\nHistory/PE\nâ–  Usually present within first 8 years of life. Pancytopenia: Neutropenia â†’\nlife-threatening infections; thrombocytopenia â†’ bleeding risk, bruising,\nanemia â†’ signs and symptoms of impaired oxygen-carrying capacity (eg,\npallor, tachycardia, apnea, lethargy).\nâ–  Associated with congenital abnormalities: Short stature, microcephaly,\ndevelopmental delay, cafÃ© au lait skin lesions, and malformations belong-\ning to the VACTERL-H association. For an explanation of VACTERL-H,\nsee the Mnemonic box.\nDiagnosis\nâ–  CBC (â†“ Hb, â†“ absolute neutrophil count, â†“ platelet count); â†“ absolute\nreticulocyte count\nâ–  Hypocellular bone marrow\nâ–  Speci",
      "char_start": 1590000,
      "char_end": 1592000
    },
    {
      "chunk_id": 796,
      "text": "fic testing: Chromosome breakage assay\nTABLE 2.12-27. Causes of Bone Marrow Failure\nINHERITED BONE MARROW FAILURE SYNDROMES ACQUIRED BONE MARROW FAILURE\nFanconi anemia Acquired aplastic anemia (due to drugs,\nShwachman-Diamond syndrome chemicals, radiation)\nDiamond-Blackfan anemia Acquired aplastic anemia (associated with\nThrombocytopenia absent radius viral infections such as parvovirus, immune\nSevere congenital neutropenia disorders)\nAmegakaryocytic thrombocytopenia Myelodysplastic syndromes\nParoxysmal nocturnal hemoglobinuria\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556655 1100//2211//2222 44::2211 PPMM\n\n566 HIGH-YIELD FACTS IN PEDIATRICS\nTreatment\nâ–  Allogeneic hematopoietic cell transplantation (HCT) (curative therapy for\nFanconi anemiaâ€“associated bone marrow failure, MDS, and leukemia).\nâ–  Androgen therapy (eg, oxymetholone), growth factors (eg, granulocyte col-\nony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating\nfactor [GM-CSF]), blood transfusion (leukoreduced, irradiated packed cell\nor platelet) therapy.\nâ–  Screening, monitoring for malignancies. First-degree relatives of affected\npatient should be tested and provided genetic counseling.\nCYCLIC NEUTROPENIA\nCyclic neutropenia is a rare genetic disorder characterized by consistent,\nsymptomatic, and recurrent neutropenia (usually every 3 weeks). Associated\nwith mutation of ELANE gene (encodes neutrophil elastase). Commonly\naffects children (equal sex predisposition). Cyclic neutropenia causes death,\nusually due to NEC, peritonitis, or sepsis. It is not associated with malignant\ntransformation to MDS or AML.\nTHROMBOCYTOPENIA ABSENT RADIUS SYNDROME\nThrombocytopenia absent radius (TAR) syndrome is an autosomal recessive\ndisorder that is caused by a deletion and/or mutation in the RBM8A gene.\nCharacterized by hypomegakaryocytic thrombocytopenia and bilateral radial\nbone aplasia in the presence of thumbs (usually absent or hypoplastic in Fan-\nconi anemia).",
      "char_start": 1592000,
      "char_end": 1594000
    },
    {
      "chunk_id": 797,
      "text": " TAR can be precipitated by stress, infection, or allergy to cowâ€™s\nmilk. Intracranial hemorrhage results in increased mortality.\nHistory/PE\nâ–  Presents with frequent nosebleeds or GI bleeding, bruising, life-threatening\nhemorrhages (due to thrombocytopenia), and radial aplasia. Ninety percent\nof individuals present with symptomatic thrombocytopenia by age 4 months,\nbut patients improve with age.\nâ–  Frequent cowâ€™s milk allergy (â†’ vomiting, bloody diarrhea, and failure to\nthrive).\nâ–  Associated with cardiac defects (ASD, VSD, TOF), facial defects (micro-\ngnathia; tall, broad forehead, hypertelorism), and lower extremity defects\n(hip dislocation, femoral and tibial torsion).\nDiagnosis\nâ–  CBC: Thrombocytopenia is present. â†‘ eosinophil count may be found\n(50% of cases). â†‘ WBC or â†“ Hb may also be found.\nâ–  X-ray of the forearm: Imaging shows characteristic absent radii and pres-\nence of thumbs.\nâ–  Bone marrow biopsy: This is not required for diagnosis but can help\nexclude other differentials.\nâ–  Molecular testing: Deletion or duplication analysis of RBM8A gene can\nconfirm diagnosis.\nTreatment\nâ–  Platelet transfusion, hematopoietic stem cell transplantation (persistent\nbleeding despite platelet transfusion)\nâ–  Splinting of the hands\nâ–  Avoiding trauma, antiplatelet drugs, or prolonged pressure on injection sites\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556666 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 567\nKASABACH-MERRITT SYNDROME\nA life-threatening coagulopathy of infancy classically characterized by throm-\nbocytopenia, microangiopathic hemolytic anemia, and consumptive coagu-\nlopathy. Occurs as a complication of a rapidly growing vascular tumor\n(kaposiform hemangioendothelioma and tufted angioma). Intravascular coag-\nulation with platelet trapping â†’ thrombocytopenia, fibrinogen consumption\nand degradation, consumption of coagulation factors â†’ disseminated intra-\nvascular coagulation (DIC). These benign vascular tumors a",
      "char_start": 1594000,
      "char_end": 1596000
    },
    {
      "chunk_id": 798,
      "text": "re aggressive. FIGURE 2.12-22. Large abdominal capil-\nlary hemangioma in an infant (Reproduced\nComplications include reactive hemarthrosis (â†’ hemophilia-like arthropa-\nwith permission from Abass K, Saad H, Kherala M,\nthy), congestive cardiac failure, and GI bleeding. Kasabach-Merritt syndrome\net al. Successful treatment of Kasabach-Merritt syn-\nhas a high mortality rate due to life-threatening bleeding, cardiac failure, and/ drome with vincristine and surgery: a case report and\nor local invasion into structures. review of literature. Cases J. 2008;1[9]:393. https://doi.\norg/10.1186/1757-1626-1-9.)\nHistory/PE\nâ–  Kasabach-Merritt syndrome presents in infancy with an enlarging, firm,\npurpuric cutaneous or soft tissue lesion, as shown in Figure 2.12-22. Most\ncommonly in the trunk, extremities, or retroperitoneum. It may be associ-\nated with overlying hypertrichosis or hyperhidrosis.\nâ–  Cutaneous lesions (10% of cases) present with a rapidly enlarging lesion\nthat turns painful, swollen, and/or purpuric or ecchymotic. Retroperito-\nneal lesions are often missed on physical examination and thus are diag-\nnosed late.\nDiagnosis\nâ–  CBC: â†“ Hb, â†“ platelets. Burr cells and schistocytes may be present on\nperipheral blood film (PBF) in microangiopathic hemolytic anemia.\nâ–  Prolonged PT, aPTT, â†“ fibrinogen, â†‘ d-dimer, â†‘ fibrin degradation prod-\nucts ([FDPs] in severe DIC)\nâ–  Ultrasound, CT scan, or MRI of suspected tumor can be performed to\nassess extent of the visible lesion or to evaluate visceral lesions. Tumor\nbiopsy is contraindicated due to bleeding risk.\nTreatment\nâ–  Definitive treatment is surgical resection of the tumor.\nâ–  If the tumor is not amenable to surgery, various other modalities with vary-\ning efficacy are available: systemic corticosteroids, radiation therapy, pneu-\nmatic compression, embolization and/or pharmacotherapy (eg, Î±-interferon,\nplatelet aggregation inhibitors, chemotherapy, particularly vincristine).\nSICKLE CELL DISEASE\nAn autosomal recessive disorder caused ",
      "char_start": 1596000,
      "char_end": 1598000
    },
    {
      "chunk_id": 799,
      "text": "by a mutation of adult hemoglobin KEY FACT\n(the Î²-chain has Glu replaced by Val, causing production of an abnormal\nSickling occurs with dehydration and\nÎ² globin chain), resulting in the production of HbS rather than HbA. HbA\n2 deoxygenation and at high altitude.\nand HbF are still produced. It is common in patients of sub-Saharan African\nAs it happens in the vasa recta (vessels\ndescent. The homozygote (SS) has sickle cell anemia (HbSS), and the hetero-\nsupplying the inner medulla of the\nzygote (HbAS) has sickle cell trait, which causes no disability (it does\nkidneys), sickle cell patients have â†“\nuniquely protect against Plasmodium falciparum malaria). Signs and symp-\nability to concentrate urine, presenting\ntoms of sickle cell disease are caused by â†“ RBC survival and a tendency of\nas polyuria or nocturia.\nsickled cells to aggregate and cause vaso-occlusion.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556677 1100//2211//2222 44::2211 PPMM\n\n568 HIGH-YIELD FACTS IN PEDIATRICS\nHistory/PE\nâ–  Classic presentation of pain crisis: Patient of sub-Saharan African descent\nwith sudden onset of severe chest pain, back pain, or thigh pain. Pain may\nbe accompanied by fever.\nâ–  Acute chest syndrome: Pulmonary infiltrations involving complete lung\nsegments and causing chest pain, fever, wheezing, coughing, and tachy-\npnea. Chief causes of infiltration are fat embolism from bone marrow or\ninfection with S pneumoniae, Mycoplasma, Chlamydia, or viruses.\nâ–  May first present with dactylitis in childhood (bilateral hand/foot swelling).\nâ–  Lifelong hemolysis results in anemia, jaundice, pigmented cholelithiasis, â†‘\ncardiac output ([CO] murmur, eventual CHF), and delayed growth.\nâ–  Chronic hemolysis is usually well tolerated, except in an acute, painful\nvaso-occlusive crisis ([VOC], commonly caused by microvascular occlu-\nFIGURE 2.12-23. Acute chest syndrome.\nsion), which stems from infection/fever, hypoxia, dehydration, and cold\nFrontal CXR of a 19-year-old",
      "char_start": 1598000,
      "char_end": 1600000
    },
    {
      "chunk_id": 800,
      "text": " woman\nwith sickle cell disease and acute chest temperatures.\npain. Note the bilateral lower and mid- â–  Other VOC: Dactylitis (occurs <3 years of age), mesenteric ischemia\nlung opacities and mild cardiomegaly. (mimics acute abdomen), CNS infarction (leads to stroke, cognitive\n(Reproduced with permission from USMLE-Rx.com.) defects, or seizures), priapism, and avascular necrosis (AVN) of the femo-\nral head. Leads to ischemic organ damage, especially splenic infarction\n(typically occurs <2 years of age), which predisposes to infection from\nencapsulated organisms, particularly pneumococcal sepsis and acute chest\nsyndrome (pneumonia and/or pulmonary infarction; see Fig. 2.12-23).\nPatient is also susceptible to osteomyelitis and to chronic kidney disease\n(sickle cell nephropathy).\nâ–  Other complications: Splenic sequestration (sudden pooling of blood into\nthe spleen resulting in hypovolemia) and aplastic crisis (secondary to\ninfection with viruses such as parvovirus B19). Both complications present\nKEY FACT\nwith â†“ hematocrit but are distinguished clinically by â†“ reticulocytes in\naplastic crisis (secondary to bone marrow involvement) and â†‘ reticulocytes\nThe most common cause of\nin splenic sequestration.\nosteomyelitis in patients with sickle\ncell disease is Staphylococcus aureus; â–  Sickle cell trait (HbAS) is relatively benign. Patients have normal Hb and\nRBC morphology. However, renal complications include hematuria (renal\nSalmonella is the second most common\npapillary necrosis), defect in the ability to concentrate urine (hyposthenu-\ncause. Patients are also at â†‘ risk for\nria), and â†‘ risk for UTIs.\navascular necrosis of the femoral head.\nDiagnosis\nMNEMONIC â–  Best initial test: CBC (â†‘ reticulocytes, â†‘ indirect bilirubin) with periph-\neral smear showing sickle cells and Howell-Jolly bodies (see Fig. 2.12-24)\nCauses/triggers of acute VOC in\nâ–  Most accurate test: Hemoglobin electrophoresis\nsickle cell diseaseâ€”\nHIDe in the COLD\nTreatment\nHypoxia\nInfections/fever â–  Management o",
      "char_start": 1600000,
      "char_end": 1602000
    },
    {
      "chunk_id": 801,
      "text": "f chronic disease:\nDehydration â–  Treat with hydroxyurea, which stimulates the production of fetal hemo-\nCOLD temperatures globin and helps prevent the recurrence of sickle cell crises. Hydroxy-\nurea is teratogenic and may cause mild myelosuppression (important to\nmonitor WBCs).\nâ–  If hydroxyurea does not prove effective, chronic transfusion therapy,\nwhich carries the risk for iron overload, can be attempted.\nâ–  Folic acid supplementation is often required to prevent macrocytic\nanemia caused by frequent RBC turnover.\nâ–  The risk exists for septicemia in febrile patients or in leukocytosis. Have\nlow threshold to give antibiotics (use ceftriaxone, levofloxacin, or\nmoxifloxacin).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556688 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 569\nA B\nFIGURE 2.12-24. Sickle cell disease. (A) Sickle-shaped RBCs (arrow) are almost always seen\non blood smear, regardless of whether the patient is having a sickle cell crisis. (B) Howell-Jolly\nbodies, which suggest functional hyposplenia or asplenia. (Image A reproduced with permission from Dr.\nPeter McPhedran, Yale Department of Hematology. Image B reproduced with permission from Serio B, Pezzullo L, Giudice V,\net al. OPSI threat in hematological patients. Transl Med UniSa. 2013;6:2-10.)\nâ–  Patients with autosplenectomy benefit from prophylactic pneumococ-\ncal vaccination and antibiotics (penicillin in patients <5 years of age)\nsince they are at â†‘ risk for infection from encapsulated bacteria. Treat\nrecurrent cholelithiasis with cholecystectomy.\nâ–  Management of sickle cell crises:\nâ–  Patients with VOC require pain to be treated with adequate analgesia\n(pain management), O therapy, IV fluid rehydration, and antibiotics\n2\n(if infection is suspected to be the trigger).\nâ–  If there is concern of a VOC progressing to acute chest syndrome, initi-\nate aggressive hydration, antibiotics, and incentive spirometry. Keep\nthe sickle variant <40%. This can b",
      "char_start": 1602000,
      "char_end": 1604000
    },
    {
      "chunk_id": 802,
      "text": "e done with simple transfusions or,\nif necessary, exchange transfusion in an intensive care unit (ICU) set-\nting. Bronchodilators may be helpful.\nâ–  No treatment is required for sickle cell trait (HbAS).\nPEDIATRIC ONCOLOGY\nLEUKEMIA\nA hematopoietic malignancy of lymphocytic or myeloblastic origin. The most\ncommon childhood malignancy; 97% of cases are acute leukemias (acute\nlymphocytic leukemia [ALL] > AML). ALL is most common in non-\nHispanic White males between 2 and 5 years of age, whereas AML is seen KEY FACT\nmost frequently in Black boys throughout childhood. Associated with trisomy\nALL is the most common childhood\n21, Fanconi anemia, prior radiation, severe combined immunodeficiency\nmalignancy, followed by CNS tumors\n(SCID), and congenital bone marrow failure states, ALL in children has a\nand lymphomas.\ngood prognosis, with a 5-year survival rate >85%.\nHistory/PE\nâ–  Symptoms are abrupt in onset. They are initially nonspecific (anorexia,\nfatigue) and are accompanied by bone pain with a limp or refusal to bear\nweight and fever (from neutropenia).\nâ–  CNS metastases may be associated with headache, vomiting, and\npapilledema.\nâ–  AML can present with a chloroma, a greenish soft tissue tumor of leuke-\nmic cells on the skin or spinal cord.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 556699 1100//2211//2222 44::2211 PPMM\n\n570 HIGH-YIELD FACTS IN PEDIATRICS\nDiagnosis\nâ–  Physical examination: Ecchymoses, petechiae (thrombocytopenia), pal-\nlor (anemia), and/or hepatosplenomegaly and lymphadenopathy may be\npresent.\nâ–  Laboratory studies: CBC (pancytopenia), coagulation studies, and periph-\neral blood smear are included. The blood work frequently shows high\nnumbers of blasts (lymphoblasts [ALL] or myeloblasts [AML] are found in\n90% of cases). WBC counts can be low, normal, or high.\nâ–  A bone marrow aspirate and biopsy for immunophenotyping (terminal\ndeoxynucleotidyl transferase [TdT] assay and a panel of monoclonal anti-\nbodies to T- and B-cel",
      "char_start": 1604000,
      "char_end": 1606000
    },
    {
      "chunk_id": 803,
      "text": "l antigens) and genetic analysis are necessary to con-\nfirm the diagnosis and assess the risk status to inform treatment. The\ndiagnosis is made if bone marrow is hypercellular with â†‘ lymphoblasts.\nâ–  A CXR can rule out a mediastinal mass (usually thymus).\nTreatment\nKEY FACT â–  Chemotherapy based, including induction, consolidation, and mainte-\nnance phases. Intrathecal chemotherapy for neurologic prophylaxis is gen-\nWatch for tumor lysis syndrome at the erally added to the treatment regimen.\nonset of any chemotherapy regimen. â–  Tumor lysis syndrome is common during the initiation of treatment of\ncancers with high cell turnover (such as leukemias and lymphomas).\nâ–  Caused by the lysis of many neoplastic cells in a short period, resulting\nMNEMONIC in the release of cell contents into the bloodstream.\nâ–  Characterized by hyperkalemia, hyperphosphatemia, hyperuricemia,\nElectrolytes affected by tumor lysis\nand hypocalcemia (as calcium is bound by phosphate released from\nsyndromeâ€”\nthe neoplastic cells). It can result in renal failure, arrhythmias, and\nPUKE Calcium\ndeath.\nPhosphorus â–  Treatment with fluids, diuretics, and rasburicase (which reduces the\nUric acid\nrisk for urate-induced nephropathy). Allopurinol can be used as\nK (potassium)\na preventive therapy, but rasburicase has been shown to be more\nElevated\neffective in treatment. Corticosteroids may precipitate tumor lysis\nCalcium (decreased)\nsyndrome.\nNEUROBLASTOMA\nAn embryonal tumor of neural crest origin, similar to pheochromocytoma.\nMore than one half of patients are <2 years of age, and 70% have distant\nmetastases at presentation. Neuroblastomas are associated with neurofibroma-\ntosis, Hirschsprung disease, Beckwith-Wiedemann syndrome, and the N-myc\noncogene.\nHistory/PE\nâ–  Tumors can be located anywhere along the sympathetic chain, but are\nmost commonly abdominal (in the adrenal medulla, followed by the para-\nspinal region), thoracic, and cervical (in descending order).\nâ–  Symptoms may vary with location and may include",
      "char_start": 1606000,
      "char_end": 1608000
    },
    {
      "chunk_id": 804,
      "text": " abdominal disten-\ntion with a firm and irregular abdominal mass (may cross the midline),\nHorner syndrome, hypertension, opsoclonus myoclonus ataxia (â€œdancing\neyesâ€“dancing feet syndromeâ€), or cord compression (from a paraspinal\ntumor).\nâ–  Patients may have anemia, FTT, and fever.\nâ–  More than 50% of patients will have metastases at diagnosis. Signs include\nbone marrow suppression, proptosis, hepatomegaly, subcutaneous nod-\nules, and opsoclonus/myoclonus.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557700 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 571\nDiagnosis\nâ–  Biopsy of tumor. Histologically appears as small, round, blue tumor cells\nwith a characteristic rosette pattern (see Fig. 2.12-25). Bombesin +.\nâ–  Elevated 24-hour urinary catecholamines (vanillylmandelic acid and\nhomovanillic acid), CT scan or MRI of suspected tumor.\nâ–  Metaiodobenzylguanidine (MIBG) scan and bone marrow aspirate for\nstaging.\nTreatment\nLocal excision plus postsurgical chemotherapy and/or radiation\nFIGURE 2.12-25. Neuroblastoma. (Repro-\nduced with permission from Suffia C, Sorrentino S,\nWILMS TUMOR\nVetrella S, et al. Neuroblastoma presenting with symp-\ntoms of epidural compression at birth: a case report.\nA renal tumor of embryonal origin (metanephros) that is most commonly seen Ital J Pediatr. 2016 May 21;42(1):52. doi: 10.1186/\nin children 2 to 5 years of age. Associated with Beckwith-Wiedemann syndrome s13052-016-0263-6.)\n(hemihypertrophy, macroglossia, visceromegaly), and WAGR syndrome. Risk\nfactors also include âŠ• family history and horseshoe kidney.\nMNEMONIC\nHistory/PE\nâ–  Presents as an asymptomatic, nontender, smooth abdominal mass that WAGR Syndrome\ndoes not usually cross the midline\nWilms tumor\nâ–  Abdominal pain, fever, hypertension, and microscopic or gross hematuria Aniridia\npossible symptoms\nGenitourinary abnormalities\nMental Retardation [now called\nâ€œintellectual disabilitiesâ€]\nDiagnosis\nâ–  Most accurate test: Biopsy of tumor for",
      "char_start": 1608000,
      "char_end": 1610000
    },
    {
      "chunk_id": 805,
      "text": " definitive diagnosis\nâ–  Best initial test: Abdominal ultrasonography\nâ–  CT scans of the chest and abdomen are used to detect metastases\nTreatment\nLocal resection and nephrectomy with postsurgical chemotherapy and radia-\ntion, depending on stage and histology.\nCHILDHOOD BONE TUMORS\nBone tumors can be either primary or secondary. Primary bone tumors are most\ncommon in the pediatric population. They can also be either benign or malig-\nnantâ€”the malignant tumors are important to recognize and treat promptly.\nIt is critical to distinguish between Ewing sarcoma and osteosarcoma (see\nTable 2.12-28).\nLANGERHANS HISTIOCYTOSIS\nA 14-month-old girl is brought to\nLangerhans histiocytosis is a rare pediatric malignancy that results from\nthe pediatrician by her mother for\nabnormal proliferation of histiocytes (activated dendritic cells and macro-\nincreasing irritability and a 4-pound\nphages). The disease can present with a single or multiple lesions. A common weight loss in the last month. PE is\npresentation is a solitary, painful lytic bone lesion surrounded by edema. notable for an ill-appearing child with\nâ€œTennis racketâ€ granules may be seen on pathology. Single bone lesions are a well-defined, nodular mass in the\ntypically treated with surgery alone. left flank that crosses the midline.\nWhat is the most likely diagnosis?\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557711 1100//2211//2222 44::2211 PPMM\n\n572 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-28. Ewing Sarcoma vs Osteosarcoma\nVARIABLE OSTEOSARCOMA EWING SARCOMA\nOrigin Osteoblasts (mesenchyme) Sarcoma (neuroectoderm); association with chro-\nmosome 11:22 translocation\nEpidemiology Commonly seen in Hispanic and White male Commonly seen in White males between 10 and\nadolescents; peak incidence is between 20 years of age\n13 and 16 years of age\nHistory/PE Local pain and swelling Local pain and swelling\nSystemic symptoms are rare Systemic symptoms (fever, anorexia, fatigue)\ncommon\nLocation Me",
      "char_start": 1610000,
      "char_end": 1612000
    },
    {
      "chunk_id": 806,
      "text": "taphyses of long bones (distal femur, prox- Diaphysis of long bones (femur, pelvis, fibula,\nimal tibia, proximal humerus) humerus)\nMetastases to lungs in 20%\nDiagnosis â†‘ alkaline phosphatase, â†‘ â€œsunburstâ€ lytic bone Leukocytosis, â†‘ ESR\nA B lesions (see Image A); Lytic bone lesion with â€œonion skinâ€ periosteal\nCodman triangle possibly found as well reaction on x-ray (see Image B)\nMRI of the entire length of the affected bone CT of the chest to rule out pulmonary metastases\nCT of the chest to rule out pulmonary Radionuclide technetium bone scanning to\nmetastases assess the rest of the skeleton for lesions\nRadionuclide technetium bone scanning to\nassess the rest of the skeleton for lesions\nTreatment Local excision, chemotherapy Local excision, chemotherapy, and radiation\nImages reproduced with permission from Kantarjian HM et al. MD Anderson Manual of Medical Oncology. New York, NY: McGraw-Hill; 2006.\nPEDIATRIC MUSCULOSKELETAL DISORDERS\nCOMMON PEDIATRIC ORTHOPEDIC INJURIES\nTable 2.12-29 outlines the presentation and treatment of common pediatric\northopedic injuries.\nDUCHENNE MUSCULAR DYSTROPHY\nAn X-linked recessive disorder resulting from a deficiency of dystrophin, a\nThis patient most likely has a cytoskeletal protein. Onset is usually at 3 to 5 years of age. Female carriers can\nneuroblastoma arising from the left be symptomatic, depending on severity of disease.\nadrenal gland. It is the most common\nsolid tumor of childhood and is History/PE\nderived from neural crest cells. Unlike\nâ–  Affects axial and proximal muscles more than distal muscles\nWilms tumor (nephroblastoma),\nneuroblastoma is accompanied by â–  May present with progressive clumsiness, fatigability, difficulty standing or\nwalking, increased toe walking, Gowers maneuver (using the hands to\nsystemic symptoms and often crosses\nthe midline. The majority of children push off the thighs when rising from the floor), and waddling gait\nhave metastases at the time of â–  Pseudohypertrophy (fibrofatty replacement of muscle",
      "char_start": 1612000,
      "char_end": 1614000
    },
    {
      "chunk_id": 807,
      "text": ") of the gastrocne-\ndiagnosis. mius muscles also seen\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557722 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 573\nTABLE 2.12-29. Orthopedic Injuries in Children\nINJURY MECHANICS TREATMENT\nClavicular fracture The most commonly fractured long bone in children; Middle third: Rest and ice, sling\nmay be birth related (especially in large infants); Distal third: Open reduction and\ncan be associated with brachial plexus palsies or internal fixation\nsubclavian artery injury (if concerned, angiog-\nraphy may be done to confirm)\nUsually involves the middle third of the clavicle, with\nthe proximal fracture end displaced superiorly as a\nresult of the pull of the sternocleidomastoid\nGreenstick fracture Incomplete fracture involving the cortex of only one Reduction with casting\nside (tension/trauma side) of the bone X-rays at 10â€“14 days\nTorus fracture Buckling of the compression side of the cortex sec- Cast immobilization for 3â€“5 weeks\nondary to trauma\nUsually occurs in the distal radius or ulna from a fall\nNursemaidâ€™s elbow Radial head subluxation secondary to being pulled Manual reduction by gentle forearm\nor lifted by the hand hyperpronation; alternatively, supi-\nPain, pronation, and refusal to bend the elbow; no nation of the forearm at 90 degrees\nsensory deficits or wrist drop of flexion\nNo immobilization\nSupracondylar humerus fracture The most common pediatric elbow fracture Cast immobilization; closed reduction\nTends to occur at 5â€“8 years of age after a fall on an with percutaneous pinning if signifi-\noutstretched hand cantly displaced\nInjury to median nerve or brachial artery\nCompartment syndrome possible as pain increases\ndespite analgesics\nProximity to the brachial artery increases the risk\nof Volkmann contracture; the physician should\nbeware of brachial artery entrapment (check radial\npulse)\nOsgood-Schlatter disease Overuse apophysitis of the tibial tubercle; causes Decrease",
      "char_start": 1614000,
      "char_end": 1616000
    },
    {
      "chunk_id": 808,
      "text": "d activity for 2â€“3 months or\nlocalized pain, especially with quadriceps contrac- until asymptomatic\ntion, in adolescent athletes Brace for symptomatic relief\nSalter-Harris fracture Fractures of the growth plate in children. Classified Closed vs. open reduction to obtain\nby fracture pattern (SALTER): appropriate alignment, followed by\nI: Physis (growth plate) (Straight across) immobilization\nII: Metaphysis and physis (Above)\nIII: Epiphysis and physis (Lower)\nIV: Epiphysis, metaphysis, and physis (Through)\nV: Crush injury of the physis (cRush)\nImage reproduced with permission from USMLE-Rx.com.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557733 1100//2211//2222 44::2211 PPMM\n\n574 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-30. Duchenne Muscular Dystrophy vs Becker Muscular Dystrophy\nCHARACTERISTIC DUCHENNE MUSCULAR DYSTROPHY BECKER MUSCULAR DYSTROPHY\nAge of onset 3â€“5 years 5â€“15 years and beyond\nLife expectancy Teens 30sâ€“40s\nIntellectual disabilities Common Uncommon\nWestern blot Dystrophin is markedly Dystrophin levels are normal,\ndecreased or absent but protein is abnormal\nSerum creatine kinase (CK) â†‘ 10â€“20Ã— normal â†‘ 5Ã— normal\nâ–  Intellectual disabilities commonly present\nTable 2.12-30 outlines the differences between Duchenne muscular dys-\ntrophy (DMD) and Becker muscular dystrophy (BMD).\nDiagnosis\nâ–  Creatine kinase (CK) levels >10 to 20 times normal suggest DMD.\nâ–  Confirmation is made with genetic testing.\nâ–  If genetic testing is inconclusive, muscle biopsy shows replacement of\nmuscle by fat and fibrotic tissue.\nâ–  Immunostaining is âŠ– and CK is â†‘.\nâ–  Electromyography (EMG) shows polyphasic potentials and â†‘ recruitment.\nâ–  Screening with ECG and echocardiogram can detect dilated cardiomyop-\nKEY FACT\nathy or conduction abnormalities.\nA child with a neck mass and head\ntilt to one side likely has congenital Treatment\ntorticollis, caused by fibrosis or spasm Glucocorticoids and physical therapy are necessary to maintain ambulation\nof the ",
      "char_start": 1616000,
      "char_end": 1618000
    },
    {
      "chunk_id": 809,
      "text": "sternocleidomastoid muscle. and to prevent contractures. Liberal use of tendon release surgery may pro-\nFirst-line treatment involves physical long ambulation.\ntherapy and improved positioning.\nPlagiocephaly may result if left Complications\nuntreated or if child does not have\nDeath occurs by 20 to 30 years of age due to dilated cardiomyopathy leading\nadequate â€œtummy time.â€\nto heart failure or respiratory failure.\nMYOTONIC DYSTROPHY\nAutosomal dominant disorder causing impaired muscle relaxation (look for\nâ€œabnormally long handshakeâ€ on USMLE). Onset later in life compared to\nDMD and BMD. Symptoms include difficulty relaxing muscles (myotonia),\ndysphagia, balding, testicular atrophy, cataracts, and cardiac conduction\nabnormalities. Type 1 is caused by trinucleotide repeat disorder (CTG) on the\nDMPK gene (Cataracts, Toupee, Gonads).\nSPONDYLOLISTHESIS\nForward slipping of vertebrae (L5 over S1) due to hyperextension of the spine,\ncommon in children and adolescents (eg, gymnasts, weightlifters). Presents\nwith bowel and bladder symptoms, lower back pain, and a palpable â€œstep-offâ€\non PE. Associated with congenital malformation of the lumbosacral joints\nand spondylolysis (pars interarticularis defects).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557744 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 575\nMETATARSUS ADDUCTUS\nCongenital deformity of the lower extremity, where the forefoot is turned\ninward. If the foot is flexible, no surgical treatment is indicated, and the con-\ndition is treated with physical therapy and support for spontaneous resolution.\nCLUBFOOT (TALIPES EQUINOVARUS)\nCongenital deformity of the lower extremity, presenting with forefoot adduc-\ntion and varus of the calcaneum, talus, and midfoot. In contrast to metatarsus\nadductus, the foot is not flexible and requires immediate treatment with serial\ncasting. Surgical correction within 3 to 6 months if it does not resolve.\nDEVELOPMENTAL DYSPLASIA OF THE HI",
      "char_start": 1618000,
      "char_end": 1620000
    },
    {
      "chunk_id": 810,
      "text": "P\nAlso called congenital hip dislocation. Excessive hip flexion in utero (eg,\nbreech presentation) leads to excessive stretching of the posterior hip capsule,\ncausing lax musculature and contractures. Developmental dysplasia of the\nhip can result in subluxation or dislocation of femoral heads and acetabular\ndysplasia, leading to early degenerative joint disease.\nHistory/PE\nâ–  Most commonly found in firstborn girls born in the breech position. â†‘ risk\noccurs with family history.\nBarlow test\nâ–  Barlow maneuver: Posterior pressure is placed on the flexed hip, and then (hip initially reduced)\nthe hip is adducted, leading to an audible â€œclunkâ€ as the femoral head dis-\nlocates posteriorly. Unilateral extension\nof inguinal fold\nâ–  Ortolani maneuver: Thighs are gently abducted from the midline with\nanterior pressure on the greater trochanter. A soft click signifies a reduc-\ntion of the femoral head into the acetabulum.\nâ–  Allis (Galeazzi) sign: The knees are at unequal heights when the hips and\nknees are flexed in the supine position (the dislocated side is lower).\nAnal aperture\nâ–  Asymmetric inguinal skinfolds that extend beyond the anus and limited\nabduction of the affected hip are also seen. Ortolani teesstt\n(hip initially dislooccaatteedd))\nâ–  If not treated in infancy, older children present with hip pain and leg\nlength discrepancy, causing a waddling or Trendelenburg gait.\nâ–  Figure 2.12-26 outlines the clinical tests and asymmetric skinfolds.\nDiagnosis\nâ–  Early detection with PE is critical to allow for proper hip development.\nâ–  Performing ultrasonography before 4 months of age is recommended,\nFIGURE 2.12-26. Developmental dys-\ngiven lack of ossification of the femoral head.\nplasia of the hip. (Reproduced with permission\nâ–  X-rays are appropriate at >4 months of age. from USMLE-Rx.com.)\nTreatment\nTreatment should begin early even though the condition may resolve on its\nown before 2 weeks of age.\nâ–  <6 months: Rigid brace, splint with a Pavlik harness (maintains the hip as\nflexe",
      "char_start": 1620000,
      "char_end": 1622000
    },
    {
      "chunk_id": 811,
      "text": "d and abducted); to prevent AVN, the hips should not be flexed\n>60 degrees\nâ–  6 to 18 months: Spica cast\nâ–  >18 months: Open reduction followed by spica cast\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557755 1100//2211//2222 44::2211 PPMM\n\n576 HIGH-YIELD FACTS IN PEDIATRICS\nComplications\nâ–  Joint contractures and AVN of the femoral head\nâ–  Without treatment, significant disability\nAA LEGG-CALVÃ‰-PERTHES DISEASE\nIdiopathic AVN and osteonecrosis of the femoral head (see Fig. 2.12-27).\nMost common in boys 4 to 10 years of age. Can be a self-limited disease in\nyounger patients, with symptoms lasting <18 months.\nHistory/PE\nâ–  Generally asymptomatic at first. Patients can develop a painless limp, anta-\nlgic gait, and thigh muscle atrophy.\nâ–  Pain sometimes present. If it is present, it can be in the groin or anterior\nthigh, or it may be referred to the knee.\nâ–  Limited abduction and internal rotation; atrophy of the affected leg.\nâ–  Usually unilateral (85%â€“90%).\nDiagnosis\nInitial x-rays can be normal but later can show a flattened and fragmented\nfemoral head.\nTreatment\nâ–  Observation is sufficient if limited femoral head involvement or if full\nrange of motion (ROM) is present.\nâ–  If extensive necrosis or â†“ ROM, the physician can consider bracing, hip\nabduction with a Petrie cast, or an osteotomy.\nâ–  The prognosis is favorable if the patient is <6 years of age and has full\nFIGURE 2.12-27. Legg-CalvÃ©-Perthes\nROM, â†“ femoral head involvement, and a stable joint.\ndisease. Avascular necrosis of the femoral\nhead showing fragmentation with loss of\nspherical contour. (Reproduced with permission SLIPPED CAPITAL FEMORAL EPIPHYSIS\nfrom Skinner HB. Current Diagnosis & Treatment in Ortho-\npedics, 2nd ed. Stamford, CT: Appleton & Lange; 2000.)\nPoor endochondral ossification of the growth plate during a growth spurt and\nKEY FACT increased shear force cause displacement of the femoral epiphysis from the\nfemoral neck, through the growth plate. The name slipped c",
      "char_start": 1622000,
      "char_end": 1624000
    },
    {
      "chunk_id": 812,
      "text": "apital femoral\nLegg-CalvÃ©-Perthes disease typically\nepiphysis (SCFE) is misleading because the epiphysis remains within the ace-\npresents as painLESS, whereas slipped\ntabulum while the metaphysis moves anteriorly and superiorly. Presents in\ncapital femoral epiphysis (SCFE) can be\nobese children 10 to 16 years of age; most common hip disorder in adoles-\npainFULL.\ncence. Associated with trauma, hypothyroidism, and other endocrinopathies.\nMNEMONIC History/PE\nâ–  Insidious onset of dull hip pain, or referred knee pain, and a painful limp\nDifferential diagnosis of pediatric\nlimpâ€” â–  Restricted ROM and inability to bear weight (differentiates unstable from\nstable SCFE)\nSTARTSS HOT\nâ–  Bilateral in 40% to 50% of cases\nSeptic joint â–  Limited internal rotation and abduction of the hip; patients hold hip in\nTumor\npassive external rotation\nAvascular necrosis (Legg-CalvÃ©-Perthes)\nRheumatoid arthritis/JIA\nDiagnosis\nTrauma\nSickle cell disease â–  X-rays of both hips in anteroposterior and frog-leg lateral views reveal pos-\nSCFE terior and inferior displacement of the femoral head (see Fig. 2.12-28).\nHenoch-SchÃ¶nlein purpura â–  In patients under the 10th percentile of height, the physician can rule out\nOsteomyelitis\nhypothyroidism with thyroid-stimulating hormone (TSH).\nToxic synovitis\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557766 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 577\nTreatment\nâ–  The disease is progressive, so treatment should begin promptly.\nâ–  Immediate surgical screw fixation can reduce the risk for AVN.\nâ–  No weight-bearing should be allowed until the defect is surgically\nstabilized.\nComplications\nChondrolysis, AVN of the femoral head, and premature hip osteoarthritis\nrequiring arthroplasty.\nFIGURE 2.12-28. Slipped capital femoral\nepiphysis. Frog-leg anteroposterior x-ray\nSCOLIOSIS\ndemonstrates medial and inferior dis-\nplacement of the right femoral epiphysis\nA lateral curvature of the spine >10 degrees (Cobb angle",
      "char_start": 1624000,
      "char_end": 1626000
    },
    {
      "chunk_id": 813,
      "text": "). It is sometimes (red arrow) relative to the femoral neck.\nassociated with kyphosis or lordosis. Most commonly idiopathic. Develops in In comparison, the left side (blue arrow)\nearly adolescence. Other etiologies are congenital or associated with neuro- is normal. (Reproduced with permission from\nUSMLE-Rx.com.)\nmuscular, vertebral, or spinal cord disease. The male-to-female ratio is 1:7 for\ncurves that progress and require treatment.\nHistory/PE\nâ–  Idiopathic disease is usually identified during school physical screening.\nâ–  Vertebral and rib rotation deformities are accentuated by the Adams for-\nward bending test.\nDiagnosis\nX-rays of the spine (posterior, anterior, and full-length views).\nTreatment\nâ–  Monitoring every 6 months for 10 to 30 degrees of curvature.\nâ–  Spinal bracing for â‰¥30 degrees of curvature in patients with remaining\ngrowth. Curvature may progress even with bracing.\nâ–  Surgical correction for â‰¥40 to 50 degrees of curvature.\nComplications\nSevere scoliosis can create restrictive lung disease.\nCHILD ABUSE\nAlso known as nonaccidental trauma (NAT); includes neglect and physical, sex-\nual, and psychological maltreatment of children. The physician should suspect\nabuse if the history is discordant with physical findings or if there is a delay in\nobtaining appropriate medical care. Certain injuries in children, such as retinal\nhemorrhages and specific fracture types, are highly suspicious for abuse.\nHistory/PE KEY FACT\nâ–  Abuse should be suspected if the history is not consistent with the injury\nSuspect sexual abuse if there is\npattern or with the childâ€™s developmental ageâ€”for example, if parents\ngenital trauma, bleeding, discharge,\nclaim their 2-month-old child â€œrolled off the couchâ€ (developmentally,\nor if children have an excessive\n2-month-olds cannot roll yet). Abuse also should be suspected if the his-\npreoccupation with or knowledge of\ntory continually changes or is vague.\nadult sexual behavior. Vaginal foreign\nâ–  Look for skin bruising patterns (indicative",
      "char_start": 1626000,
      "char_end": 1628000
    },
    {
      "chunk_id": 814,
      "text": " of the object used), bruises of\nbody may be an alternative diagnosis.\ndifferent ages and color, and burns that are well circumscribed.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557777 1100//2211//2222 44::2211 PPMM\n\n578 HIGH-YIELD FACTS IN PEDIATRICS\nTABLE 2.12-31. Common Presentations and Mimics of Child Abuse\nTYPE OF ABUSE PRESENTATION/IMAGING FINDINGS MIMICS\nBruises Most common physical finding Congenital dermal melanocytosis, formerly called\nOften located on head and torso â€œMongolian spotsâ€\nMay be in pattern reflecting implement (hand, belt) Coining/cupping (a therapy used in certain cultures\nwhere suction cups are attached to the skin)\nBleeding diathesis\nBurns Contact burns: Cigarette/curling iron Scalded skin syndrome, severe contact dermatitis,\nImmersion burns: Hot water; on buttocks, with sparing accidental burn injury\nof flexor surfaces, or stocking-glove distribution with\nsharp lines of demarcation and uniform burn depth\nFractures Spiral fractures: Humerus/femur (in children not yet Osteogenesis imperfecta (blue sclerae, hearing loss,\nwalking); epiphyseal-metaphyseal â€œbucketâ€ fractures opalescent teeth)\nPosterior rib fractures: Indication of squeezing\nAbusive head trauma Lethargy, feeding difficulty, apnea, seizures, retinal Accidental head trauma\nhemorrhage, subdural/epidural hematoma\nImage reproduced with permission from Wolff K et al. Fitzpatrickâ€™s Dermatology in General Medicine, 7th ed. New York, NY: McGraw-Hill; 2008.\nâ–  Injuries with high specificity for child abuse include posterior rib frac-\ntures, metaphyseal corner â€œbucket handleâ€ fractures, and spiral fractures of\nKEY FACT long bones such as the femur (but only before the child can walk, as a spi-\nral fracture may be developmentally appropriate in a walking child).\nOsteogenesis imperfecta (OI) is a great\nmimicker of child abuse and is often â–  Risk factors: These include parents with a history of abuse as a child,\npartner violence, and/or a history of alc",
      "char_start": 1628000,
      "char_end": 1630000
    },
    {
      "chunk_id": 815,
      "text": "ohol or drug use; premature chil-\ntested. It is a genetic disease that\ndren; children with complex medical problems; infants with colic\naffects type I collagen. Those with OI\n(excessive crying for >3 hours per day for >3 days per week); and\ncan present with a broad spectrum\nrepeated hospitalizations\nof clinical featuresâ€”most classically\nblue sclera, easy bruising, opalescent â–  Infants: Abuse or neglect in infants may present as apnea, seizures, feed-\ning intolerance, excessive irritability, somnolence, or FTT.\nteeth, conductive hearing loss, skeletal\nanomalies, and easily fractured bones. â–  Older children: Neglect in older children may present as poor hygiene or\nbehavioral abnormalities.\nâ–  See Table 2.12-31 for exam findings.\nKEY FACT\nDiagnosis\nIn infants, Neisseria gonorrhoeae isolated â–  An x-ray skeletal survey can show fractures in various stages of healing.\non a vaginal culture is definitive X-rays may not show fractures until 1 to 2 weeks after injury (although they\nevidence of sexual abuse. Chlamydia is may show evidence of prior trauma in children <3 years of age). Radionu-\nnot, because it can be acquired from cleotide bone scans (bone scintigraphy) are sometimes used, as they are\nthe mother during delivery and can more sensitive and may show fractures before they are detectable on\npersist for up to 3 years. x-rays; however, they are less specific than plain films.\nâ–  If sexual abuse is suspected, the physician should request tests for gonor-\nrhea, syphilis, chlamydia, HIV, and sperm (within 72 hours of assault).\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557788 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 579\nâ–  Abusive head trauma (formerly referred to as shaken baby syndrome) can\nbe ruled out by an ophthalmologic exam for retinal hemorrhages and a\nnoncontrast CT for subdural hematoma. Infants with abusive head trauma\noften do not exhibit external signs of abuse.\nâ–  An MRI can visualize white-matter cha",
      "char_start": 1630000,
      "char_end": 1632000
    },
    {
      "chunk_id": 816,
      "text": "nges associated with violent shak-\ning and the extent of intracranial and extracranial bleeds.\nTreatment\nâ–  Document and photograph findings, including location; size; shape; color;\nand the nature of all lesions, bruises, or burns.\nâ–  Notify child protective services for evaluation of safety of the child in their\ncurrent home.\nâ–  Hospitalize if necessary to stabilize injuries or to protect the child.\nâ–  Administer antibiotics and high-dose oral contraceptives for victims of sex-\nual abuse.\nWELL-CHILD CARE\nANTICIPATORY GUIDANCE\nAn important aspect of every well-child visit. Commonly discussed advice\nincludes the following:\nâ–  Keep the water heater at <48.8Â°C (<120Â°F).\nâ–  Babies should sleep on their backs without any stuffed animals, toys, or KEY FACT\nbottles in the crib (to â†“ the risk for sudden infant death syndrome [SIDS]).\nSIDS: Sudden infant death syndrome.\nâ–  Car safety seats should be rear facing and should be placed in the back of\nMost common cause of unexplained\nthe car (seats can face forward if the child is >2 years of age and weighs\ndeath in children <1 year of age.\n>18 kg [>40 lb]).\nUnknown pathogenesis.\nâ–  No solid foods should be given before 6 months of age; solid foods should\nBRUE: Brief resolved unexplained\nthen be introduced gradually and one at a time. Do not give cowâ€™s milk\nevent. <1 minute in duration with\nbefore 12 months of age (increases risk of iron-deficiency anemia).\nno known cause. May present with\nâ–  Syrup of ipecac (an emetic) is no longer routinely recommended for acci-\nan abrupt change in respiration,\ndental poisoning. Poison control should be contacted immediately for\nâ†“ responsiveness, cyanosis, and\nassistance.\nchange in muscle tone. No longer\nâ–  Other guidance important to mention in a well-child visit includes the\nthought to be a precursor of SIDS.\nfollowing:\nâ–  Children should wear helmets when riding bicycles.\nâ–  Parents should ensure that firearms are not loaded and are locked away.\nâ–  Smoke detectors should be present and in working order.\n",
      "char_start": 1632000,
      "char_end": 1634000
    },
    {
      "chunk_id": 817,
      "text": "â–  Intake of sugar-sweetened drinks and juices is strongly discouraged;\njuice should be avoided before 12 months of age.\nâ–  Safe sex education should be provided for adolescents.\nâ–  Screen time should be limited for children, as hands-on learning is\nessential for children younger than 24 months.\nA mother presents with her previously\nhealthy 3-month-old infant boy,\nHEARING AND VISION SCREENING stating that he has been increasingly\ndifficult to rouse for the past 4 hours\nâ–  Objective hearing screening (otoacoustic emissions and/or auditory brain- and has lost interest in feeding; she\nstem response) for newborns before discharge is a standard of care. Chil- left the baby alone with her boyfriend\nwhile she ran errands. While en route\ndren who fail these screening tests require further diagnostic workup.\nto the hospital, the baby stopped\nâ–  Objective hearing screening is indicated for children with a history of\nbreathing. PE is notable for occipital\nmeningitis, TORCH infections, measles and mumps, and recurrent otitis\nbruising. What is the most likely cause\nmedia. The most common cause of childhood conductive hearing loss is\nof this childâ€™s apnea?\nrepeated ear infections.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 557799 1100//2211//2222 44::2211 PPMM\n\n580 HIGH-YIELD FACTS IN PEDIATRICS\nâ–  The red reflex should be checked at birth. Leukocoria is the lack of a red\nreflex and can indicate the presence of retinoblastoma. It can also be an\nincidental finding in a babyâ€™s first photos.\nâ–  Vision screening to detect strabismus (ocular misalignment), amblyopia\n(suppression of retinal images in a misaligned eye, leading to permanent\nKEY FACT vision loss), and other conditions should be performed at all health visits\nin children <5 years of age.\nLeukocoria indicates retinoblastoma,\ncongenital cataracts, or retinopathy â–  Strabismus is normal until 3 months of age; beyond 3 months of age, chil-\ndren should be evaluated by a pediatric ophthalmologist ",
      "char_start": 1634000,
      "char_end": 1636000
    },
    {
      "chunk_id": 818,
      "text": "and may require\nof prematurity. All cases of leukocoria\ncorrective lenses, occlusion, and/or surgery to prevent amblyopia. Treat-\nrequire immediate ophthalmologic\nment of strabismus includes occluding the normal eye with an eye patch\nworkup.\nto strengthen the muscles and use of the abnormal eye.\nCHILDHOOD VACCINATIONS\nThe Epidemiology chapter summarizes Centers for Disease Control and Pre-\nvention (CDC)â€“recommended vaccinations for the pediatric population.\nContraindications and precautions in this population are as follows.\nContraindications:\nâ–  Severe allergy to a vaccine component or a prior dose of vaccine. Patients\nwho have life-threatening allergies to eggs may receive measles, mumps,\nand rubella (MMR) and influenza vaccinations under observation. The\nphysician should exercise caution in administering yellow fever vaccina-\ntions to those with egg allergies.\nâ–  Encephalopathy within 7 days of prior pertussis vaccination.\nâ–  Personal history of intussusception and SCID contraindications for the\nrotavirus vaccine.\nâ–  Live vaccines (rotavirus, oral polio vaccine, varicella, MMR, intranasal\ninfluenza, yellow fever) to be avoided in immunocompromised and preg-\nnant patients (exception: HIV patients with CD4+ cell count >200 copies/\nmm3 may receive MMR and varicella).\nPrecautions:\nâ–  Current moderate to severe illness (with or without fever)\nâ–  Prior reactions to pertussis vaccine (fever >40.5Â°C [>104.9Â°F]), a shock-\nlike state, persistent crying for >3 hours within 48 hours of vaccination, or\nseizure within 3 days of vaccination\nâ–  History of receiving IVIG in the past year\nThe following are not contraindications to vaccination:\nâ–  Mild illness and/or low-grade fever\nâ–  Current antibiotic therapy\nâ–  Prematurityâ€”all vaccines should be given, based on the childâ€™s chrono-\nlogic age, even if the child is premature\nThe most likely cause of this infantâ€™s\napnea is abusive head trauma,\nwhich is most common in 3- to LEAD POISONING\n4-month-old infants and presents\nearly with nonspecifi",
      "char_start": 1636000,
      "char_end": 1638000
    },
    {
      "chunk_id": 819,
      "text": "c symptoms\nMost exposure in children is caused by lead-contaminated household dust\n(lethargy, irritability, poor feeding,\nfrom lead paint. Screening should be routinely performed at 12 and\nvomiting) and later with seizures or\n24 months of age for patients living in high-risk areas (pre-1970s homes or zip\napnea. There is generally no reported\ncodes with high percentages of elevated blood lead levels). Universal screen-\nhistory of head trauma. Subdural\ning is not recommended.\nhematoma and edema account for\nmost neurologic findings. In babies\nwith abusive head trauma, there is a\n50%â€“70% chance of prior abuse.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 558800 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 581\nFIGURE 2.12-29. Basophilic stippling (arrows) in lead poisoning. (Reproduced courtesy of van Dijk HA,\nFred HL. Images of memorable cases: case 81. Connexions Web site. December 3, 2008. Available at https://cnx.org/contents/\nMZa_Ph4e@4/Images-of-Memorable-Cases-Case.)\nHistory/PE\nâ–  Children are usually asymptomatic. Children <6 years are most suscepti-\nble to the effects of lead because of an immature blood-brain barrier. KEY FACT\nâ–  Common symptoms include peripheral neuropathy (wrist and foot drop), New evidence has shown impaired\ncognitive impairment, colicky abdominal pain, constipation, headache,\nintelligence and neurodevelopmental\nhyperactivity or apathy, and anorexia.\noutcomes among children exposed to\nâ–  Acute encephalopathy (usually with levels >70 Î¼g/dL) is characterized by lead levels as low as 10 Î¼g/dL.\nâ†‘ ICP, vomiting, confusion, seizures, and coma.\nDiagnosis\nâ–  The physician should do a fingerstick test as an initial screen at 1 or\n2 years of age; if elevated, then a serum venous blood lead level should be\nobtained.\nâ–  CBC and peripheral blood smear show microcytic, hypochromic anemia\nand basophilic stippling (see Fig. 2.12-29). Sideroblastic anemia may\nalso be present. Note that concurrent iron-defic",
      "char_start": 1638000,
      "char_end": 1640000
    },
    {
      "chunk_id": 820,
      "text": "iency anemia may also\nbe present, as both lead poisoning and iron deficiency share similar risk\nfactors.\nâ–  X-ray of the abdomen may be useful in assessing for ingestion of objects\ncontaining lead.\nTreatment\nBlood lead levels (see Fig. 2-12-30):\nâ–  <5 Î¼g/dL: Family education and annual test of blood lead levels\nâ–  5 to 14 Î¼g/dL: Retest at 1 to 3 months; remove sources of lead\nâ–  15 to 44 Î¼g/dL: Retest within 1 to 4 weeks; remove sources of lead\nexposure\nVenous blood lead concentration (Î¼g/dL)\n<5 5-14 15-44 45-69 >70\nFamily education Retest at 1-3 months Retest at 1-4 weeks Retest within 48 hours Retest within 24 hours\nAnnual blood lead test Remove exposure Remove exposure Further workup Hospitalization\nBegin oral succimer Begin succimer +\nCaNaEDTA\n2\nFIGURE 2.12-30. Treatment based on venous blood lead levels. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 558811 1100//2211//2222 44::2211 PPMM\n\n582 HIGH-YIELD FACTS IN PEDIATRICS\nâ–  45 to 69 Î¼g/dL: Retest within 48 hours, further workup (eg, x-ray of the\nabdomen, electrolytes), commencement of chelation therapy (oral suc-\ncimer is recommended)\nâ–  >70 Î¼g/dL: Retest within 24 hours; urgent evaluations, hospitalization,\nand chelation therapy (succimer + edetate calcium disodium\n[CaNa EDTA])\n2\nPERIANAL DERMATITIS\nThe commonly tested perianal dermatoses are listed in Table 2.12-32.\nTABLE 2.12-32. Perianal Dermatoses\nDIAGNOSIS DESCRIPTION TREATMENT\nIrritant contact dermatitis Most common in infants. Presents as erythematous rash that Topical barrier ointment (eg, zinc oxide,\nspares the skinfolds. Classically due to skin breakdown by petrolatum)\nexposure to urine or stool.\nCandida diaper dermatitis Second most common in infants. Presents as beefy red, confluent Topical antifungal (eg, nystatin)\nplaques with satellite lesions. Does not spare the skinfolds.\nPerianal streptococcus Occurs in school-aged children in addition to infants. Presents Oral Î²-",
      "char_start": 1640000,
      "char_end": 1642000
    },
    {
      "chunk_id": 821,
      "text": "lactam antibiotics\nas a red, sharply demarcated perianal rash with associated\npruritis and pain. May have blood-streaked stools or constipa-\ntion from withholding stool due to pain. Diagnosis can be\nconfirmed with perianal bacterial culture.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 558822 1100//2211//2222 44::2211 PPMM\n\nPEDIATRICS HIGH-YIELD FACTS IN 583\nPIGMENTED LESIONS IN CHILDHOOD\nThe commonly tested lesions are listed in Table 2.12-33.\nTABLE 2.12-33. Pigmented Lesions in Childhood\nLESION DESCRIPTION\nCongenital melanocytic nevus Benign proliferation of melanocytes with an increased density of hair follicles. They present as solitary\nhyperpigmented lesions with coarse hair (Image A). The melanocytes may enlarge during infancy;\nlarge lesions are often surgically removed due to increased risk of transformation to melanoma.\nCongenital dermal melanocytosis Multiple poorly circumscribed, nontender, flat, blue-gray patches that do not blanch (Image B). They are\n(CDM) (Mongolian spot) often located on the lower back and sacral region and fade spontaneously during childhood. More\ncommon in people of Asian and Black descent. Congenital dermal melanocytosis may be mistaken for\nbruises due to abuse; however, bruises are tender, show color variation, and fade quickly. Presence of\nCDM should be documented on initial evaluation.\nCafÃ© au lait spots Flat, hyperpigmented patches having â€œcoffee with milkâ€ appearance (Image C). Isolated spots are most\noften idiopathic/benign, but multiple spots may be associated with McCune-Albright syndrome and\nneurofibromatosis.\nA B C\nImage A reproduced with permission from Kinsler VA, Oâ€™Hare P, Jacques T, Hargrave D, Slater O. MEK inhibition appears to improve symptom\ncontrol in primary NRAS-driven CNS melanoma in children. Br J Cancer. 2017;116(8):990-993. doi:10.1038/bjc.2017.49. Image B reproduced with\npermission from Thomas AC et al. Mosaic activating mutations in GNA11 and GNAQ are associated with p",
      "char_start": 1642000,
      "char_end": 1644000
    },
    {
      "chunk_id": 822,
      "text": "hakomatosis pigmentovascularis and\nextensive dermal melanocytosis. J Invest Dermatol. 2016;136(4):770-778. doi:10.1016/j.jid.2015.11.027. Image C reproduced with permission from\nKhalil J, Afif M, Elkacemi H, et al. Breast cancer associated with neurofibromatosis type 1: a case series and review of the literature. J Med Case Rep.\n2015;9:61 doi:10.1186/s13256-015-0533-8.\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 558833 1100//2211//2222 44::2211 PPMM\n\n584 HIGH-YIELD FACTS IN PEDIATRICS\nNOTES\n22002222__0022..1122__SStteepp22CCKK__PPeeddiiaa__1111ee__550099--558844..iinndddd 558844 1100//2211//2222 44::2211 PPMM\n\nH I G H - Y I E L D F A C T S I N\nPSYCHIATRY\nChildhood and Adolescent Disorders 586 Personality Disorders 607\nAttention-Deficit/HyperActivity 586\nSubstance Use Disorders 610\nAutism spectrum DisorDer 587\nAlcoHol use DisorDer 613\nDisruptive BeHAviorAl DisorDers 587\nmAnAGement of DruG WitHDrAWAl 614\nintellectuAl DevelopmentAl DisorDer/intellectuAl DisABility 588\ntourette synDrome 589 Eating Disorders 614\nsepArAtion Anxiety DisorDer 589 AnorexiA nervosA 614\nBulimiA nervosA 616\nPsychotic Disorders 590\nscHizopHreniA 590 Sexual Disorders 616\nscHizopHreniform 591 sexuAl cHAnGes WitH AGinG 616\npArApHilic DisorDers 616\nDissociative Disorders 593\nGenDer DyspHoriA 616\nAnxiety Disorders 594 sexuAl Dysfunction 617\nGenerAlizeD Anxiety DisorDer 594\nSleep Disorders 618\npAnic DisorDer 595\nprimAry insomniA 618\npHoBiAs (sociAl AnD specific) 596\nprimAry HypersomniA 618\nObsessive-Compulsive Disorder and Related Disorders 597 nArcolepsy 618\noBsessive-compulsive DisorDer 597 sleep ApneA 619\noBsessive-compulsiveâ€“relAteD DisorDers 597 circADiAn rHytHm sleep DisorDer 619\nTrauma and Stressor-Related Disorders 598 Somatic Symptom and Related Disorders 620\nposttrAumAtic stress DisorDer 598 somAtic symptom DisorDer 620\nillness Anxiety DisorDer 620\nNeurocognitive Disorders 599\nconversion DisorDer 620\nDementiA (mAjor neurocoGnitive DisorDer) 599\nDelirium",
      "char_start": 1644000,
      "char_end": 1646000
    },
    {
      "chunk_id": 823,
      "text": " 601 Factitious Disorders and Malingering 621\nMood Disorders 602 Sexual and Physical Abuse 621\nmAjor Depressive DisorDer 602 sexuAl AssAult 622\npersistent Depressive DisorDer (DystHymiA) 604\nSuicidality 622\nADjustment DisorDer 605\nBipolAr AnD relAteD DisorDers 605\n585\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 558855 1100//2211//2222 22::4466 PPMM\n\n586 HIGH-YIELD FACTS IN PSYCHIATRY\nCHILDHOOD AND ADOLESCENT DISORDERS\nATTENTION-DEFICIT/HYPERACTIVITY DISORDER\nA persistent pattern of excessive inattention and/or hyperactivity/impulsivity.\nTypically presents between 3 and 13 years of age; more common in males;\noften shows a familial relationship\nHistory/PE\nAttention-deficit/hyperactivity disorder (ADHD) presents with core symptoms\nthat can be divided into the following two categories:\nâ–  Inattention: Exhibits a poor/short attention span in schoolwork/play; dis-\nplays poor attention to detail or careless mistakes; has difficulty following\ninstructions or finishing tasks; is forgetful and easily distracted\nâ–  Hyperactivity/impulsivity: Fidgets; leaves seat in classroom; runs around\ninappropriately; cannot play quietly; talks excessively; does not wait for\ntheir turn; interrupts others\nDiagnosis\nâ–  Symptoms must be present and cause an impairment in functioning for\nâ‰¥6 months in at least two independent settings (eg, home and school).\nâ–  Age <17 years: Diagnosis requires six or more symptoms from either cate-\ngory of core symptoms (inattention and/or hyperactivity/impulsivity)\nâ–  Age â‰¥17 years: Diagnosis requires five or more symptoms from either cate-\ngory of core symptoms\nâ–  Symptoms must be present before 12 years of age\nâ–  Alternative causes of inattention and/or hyperactivity must be considered\n(such as substance abuse, organic reasons [eg, lead toxicity], hearing/visual\nimpairment, thyroid disorders, sleep disorders, absence seizures)\nTreatment\nFour to five years of age:\nâ–  Best initial treatment: Behavior therapy. The physici",
      "char_start": 1646000,
      "char_end": 1648000
    },
    {
      "chunk_id": 824,
      "text": "an can add medica-\ntion if behaviors do not improve.\nSix years of age or older:\nâ–  Best initial treatment: Pharmacologic therapy + behavior therapy\nâ–  First line: Central nervous system (CNS) stimulants (eg, methylphenidate,\nKEY FACT dextroamphetamine, amphetamine salts [dextroamphetamine and\namphetamine combo])\nUse of stimulants is contraindicated for\nindividuals with illicit substance abuse â–  Adverse effects: Weight loss (â†“ appetite), insomnia, anxiety, irritability,\nheadache, tic exacerbation, and â†“ growth velocity (normalizes when medi-\nat risk for addiction and those whose\ncation is stopped)\nparent/legal guardian is against their\nuse. â–  Because of stimulantsâ€™ potential for causing weight loss, it is recommended\nto give them after meals\nâ–  Alternatives: Nonstimulants\nâ–  Atomoxetine (norepinephrine reuptake inhibitor; second-line treat-\nment): Can be tried first because of the negative side-effect profile of\nCNS stimulants\nKEY FACT\nâ–  Third-line treatments: clonidine/guanfacine (Î± -agonist), bupropion,\n2\nChildren must exhibit ADHD symptoms and tricyclic antidepressants (TCAs)\nin two or more settings (eg, home and\nAll ages: Continuation of regular diet. Sugar and food additives are not con-\nschool).\nsidered etiologic factors.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 558866 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 587\nAUTISM SPECTRUM DISORDER\nDevelopmental disorder characterized by impairments in two major domains:\n(1) social interaction and communication and (2) repetitive/restricted behav-\nior, interests, or activities. Autism spectrum disorder (ASD) is more common\nin males. Severity is based on the level of support required for each domain.\nThe Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 does\nnot distinguish among the pervasive developmental disorders.\nHistory/PE\nâ–  Deficits in social interaction and communication: Reduced interest in\nsocialization, reduced empathy, inability t",
      "char_start": 1648000,
      "char_end": 1650000
    },
    {
      "chunk_id": 825,
      "text": "o form relationships, impaired\nlanguage development, inability to understand social cues, poor eye\ncontact\nâ–  Prognosis is best determined by language development because its\ndevelopment is based on social interaction\nâ–  Restricted/repetitive patterns of behavior, interests, or activities: Highly fix-\nated or restricted interests, inflexibility to change, hand flapping or other\nstereotypies, increased/decreased response to sensory input (eg, indiffer-\nence to temperature, excessive touching/smelling, adverse responses to\nsounds)\nâ–  Symptoms must impair function (eg, academic, social)\nâ–  Symptoms must be present in the early developmental period (typically\n<3 years of age)\nâ–  Conditions that produce symptoms suggestive of ASD must be excluded:\nâ–  Intellectual disability or global developmental delay\nâ–  Hearing impairment: Ruled out with audiometry before making\ndiagnosis\nâ–  Selective mutism: Refusal to speak only in social situations\nâ–  Rett syndrome: Similar to ASD; X-linked disorder characterized by\nmarked physical and psychomotor regression at approximately\n6 months of age after normal development. Predominantly seen in\nfemales; patients have classic hand-wringing movements\nâ–  Fragile X syndrome: X-linked dominant disorder caused by hypermeth-\nylation of FMR1 gene; most common cause of inherited intellectual\ndisability and autism; presents with the following characteristics:\nmacro-orchidism, long face, prominent jaw and forehead, high arched\npalate, large and everted ears, autism, connective tissue laxity, and /or\nmitral valve prolapse\nTreatment\nâ–  Intensive special education, behavioral management (specifically applied KEY FACT\nbehavior analysis therapy), and symptom-targeted medications (eg, stimu-\nIn patients with ASD, think about\nlants or Î± -agonists for ADHD; neuroleptics for aggression and mood insta-\n2 associated congenital conditions, such\nbility; selective serotonin reuptake inhibitors [SSRIs] for stereotypical\nas Rett syndrome, tuberous sclerosis,\nbehavior, anxiety",
      "char_start": 1650000,
      "char_end": 1652000
    },
    {
      "chunk_id": 826,
      "text": ", and mood)\nand fragile X syndrome.\nâ–  Family support and counselingâ€”crucial components of treatment\nDISRUPTIVE BEHAVIORAL DISORDERS\nIncludes conduct disorder, oppositional defiant disorder (ODD), and disrup-\ntive mood dysregulation disorder (DMDD). More common in males and in\npatients with a history of abuse. Psychiatric comorbidities are common (eg,\npost-traumatic stress disorder [PTSD], depression, substance abuse, somato-\nform conditions, personality disorders).\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 558877 1100//2211//2222 22::4466 PPMM\n\n588 HIGH-YIELD FACTS IN PSYCHIATRY\nHistory/PE\nâ–  ODD: A pattern of negative, defiant, disobedient, and hostile behavior\ntoward authority figures (eg, losing temper, arguing) for â‰¥6 months. May\nprogress to conduct disorder.\nâ–  Conduct disorder: A repetitive, persistent pattern of violating the basic\nrights of others or age-appropriate societal norms/rules for â‰¥1 year in chil-\ndren <18 years of age. Behaviors can be aggressive (eg, rape, robbery, ani-\nmal cruelty) or nonaggressive (eg, destruction of property, stealing, lying,\nrunning away, and truancy). After 18 years of age, conduct disorder is con-\nsidered antisocial personality disorder.\nâ–  DMDD: A pattern of severe, recurrent verbal (eg, screaming) or behav-\nioral (eg, physical aggression) outbursts that are out of proportion to the sit-\nuation and a persistently irritable or angry mood between outbursts.\nâ–  Symptoms must occur for â‰¥1 year; they may progress to depression in\nKEY FACT adulthood.\nâ–  DMDD should not be diagnosed before 6 years of age or after 18 years\nConduct disorder is diagnosed in of age.\nChildren. Antisocial personality disorder\nis diagnosed in Adults. Treatment\nPsychotherapy is the first-line treatment for all disruptive behavioral disorders.\nINTELLECTUAL DEVELOPMENTAL DISORDER/INTELLECTUAL DISABILITY\nDisorder of cognitive, social, and practical functioning. Associated with male\nsex, chromosomal abnormalities",
      "char_start": 1652000,
      "char_end": 1654000
    },
    {
      "chunk_id": 827,
      "text": ", congenital infections, teratogens (including\nalcohol/illicit substances), and inborn errors of metabolism. Most often no\nidentifiable cause is found in most patients with intellectual disability.\nHistory/PE\nâ–  Patients have deficiencies in multiple domains as follows:\nâ–  Intellectual deficits: Poor reasoning, problem solving, planning, and\nperformance on standardized testing\nâ–  Adaptive functioning deficits: Poor hygiene, social functioning, activi-\nties of daily living (ADLs)\nâ–  Onset: During developmental period (<18 years of age)\nâ–  Severity of intellectual disability: Determined by level of support\nrequired to address impaired adaptive functioning (IQ cutoffs for severity\nare no longer used with the DSM-5)\nâ–  Mild (independent in ADLs); moderate (some teaching and support\nfor ADLs); severe (significant support for ADLs); profound (dependent\non support for all ADLs)\nâ–  Differential diagnosis: Specific learning disorder (reading, math, or writ-\ning skills that are significantly lower than expected for age and\nKEY FACT intelligence)\nâ–  Reading disorder is the most common\nâ–  Down syndrome (trisomy 21): The\nmost common chromosomal cause Treatment\nof intellectual disability\nâ–  Fetal alcohol syndrome (FAS): The â–  Primary prevention: Educating the public about possible causes of intel-\nlectual disability and providing optimal prenatal screening and care to\nmost common preventable cause\npregnant patients\nof intellectual disability\nâ–  Fragile X syndrome: The most â–  Treatment measures: Family counseling and support, speech and lan-\nguage therapy, occupational/physical therapy, behavioral intervention,\ncommon inherited form of\neducational assistance, and social skills training\nintellectual disability\nâ–  Learning disorder: Remedial therapy directed toward patientâ€™s deficiency\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 558888 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 589\nTOURETTE SYNDROME\nDisorder characterized by b",
      "char_start": 1654000,
      "char_end": 1656000
    },
    {
      "chunk_id": 828,
      "text": "oth motor and vocal tics. More common in males;\nshows a genetic predisposition. Associated with ADHD, learning disorders,\nand obsessive-compulsive disorder (OCD). Symptoms can be temporarily\nsuppressed with effort or exacerbated by stress and fatigue.\nHistory/PE\nSymptoms begin <18 years of age and cause social or occupational\nimpairment.\nDiagnosis\nDiagnosis requires the following:\nâ–  Multiple motor tics (eg, blinking, grimacing)\nâ–  One or more vocal tics (eg, grunting, coprolalia, echolalia, throat clearing,\ncoughing)\nâ–  Tics present for >1 year\nâ–  Tics recurrent (occur many times per day and/or nearly every day)\nTreatment\nBest initial treatment: Behavior therapy; habit reversal therapy is most effec-\ntive. If behavior therapy fails or tics are severe/disabling, the next step is phar-\nmacologic management.\nâ–  Antidopaminergic agents:\nâ–  Dopamine-depleting agents (eg, tetrabenazine [vesicular monoamine\ntransporter (VMAT)-2 inhibitor; results in â†“ uptake of monoamines]):\nPreferred over dopamine-blocking agents; does not cause tardive dyski-\nnesia (TD)\nâ–  Dopamine-blocking agents: Antipsychotics (eg, fluphenazine, risperi-\ndone, haloperidol, pimozide)\nâ–  For severe, refractory tics: Typical antipsychotics (eg, haldol, pimozide)\nâ–  ð›‚ -agonists (eg, clonidine, guanfacine): Less effective at tic reduction; KEY FACT\n2\nmore favorable side-effect profile\nCoprolalia = Repetition of obscene\nDifferential Diagnosis words\nEcholalia = Repetition of words spoken\nPersistent (chronic) tic disorder consisting of either motor or vocal tics (but\nby others\nnot both) which last >1 year.\nSEPARATION ANXIETY DISORDER\nDisorder characterized by fear of separation from an attachment figure (eg,\nparent) or home. Separation anxiety normally begins at about 1 year of age\nand peaks at 18 months. Considered pathologic if it becomes extreme or per-\nsists. May be precipitated by a stressful event.\nHistory/PE\nFear of separation from an attachment figure or home lasting for â‰¥4 weeks in\nchildren or â‰¥6 months in a",
      "char_start": 1656000,
      "char_end": 1658000
    },
    {
      "chunk_id": 829,
      "text": "dults. May present as complaints of somatic symp-\ntoms to avoid school or work.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 558899 1100//2211//2222 22::4466 PPMM\n\n590 HIGH-YIELD FACTS IN PSYCHIATRY\nDiagnosis\nExcessive fear of separation from attachment figures and three of the\nfollowing:\nâ–  Separation that leads to extreme distress\nâ–  Separation that leads to social, academic, or occupational dysfunction\nâ–  Excessive worry about losing attachment figure\nâ–  Reluctance to leave home, sleep alone, or be alone\nâ–  Nightmares of separation\nâ–  Physical symptoms (eg, a stomachache) when separated\nTreatment\nCognitive-behavioral therapy (CBT), family therapy, SSRIs as an adjunct to\ntherapy.\nPSYCHOTIC DISORDERS\nSCHIZOPHRENIA\nDisorder of thought process characterized by psychotic symptoms that are fur-\nther divided into positive symptoms (hallucinations, delusions, disorganized\nthought/behavior) and negative symptoms (flat affect, social withdrawal,\napathy).\nKEY FACT â–  Epidemiology: Prevalence is ~1% (males > females). Peak onset is ear-\nlier in males (18â€“25 years of age) than in females (25â€“35 years of age).\nPsychosis (hallucinations and/\nSchizophrenia in first-degree relatives â†‘ risk. Up to 50% of patients\nor delusions without insight) â‰ \nattempt suicide; 10% of patients with schizophrenia complete suicide.\nschizophrenia. Differential diagnosis\nmust also include organic diseases, â–  Etiology: Unknown. Theories focus on neurotransmitter abnormalities\nsuch as dopamine dysregulation (frontal hypoactivity and limbic hyperac-\nother psychiatric illnesses, and\ntivity) and brain abnormalities on CT and MRI (enlarged ventricles and\nsubstance-induced psychosis.\nâ†“ cortical volume).\nHistory/PE\nâ–  Schizophrenia presents with chronic or recurrent psychosis, disorganiza-\ntion, and/or negative symptoms.\nâ–  Cognitive impairment in multiple areas (eg, processing speed, working\nmemory, attention, social cognition) may be present.\nâ–  Mood and anxiety symptom",
      "char_start": 1658000,
      "char_end": 1660000
    },
    {
      "chunk_id": 830,
      "text": "s are common.\nDiagnosis\nRequires two or more of the following symptoms for â‰¥6 months with social or\noccupational dysfunction; at least one of the symptoms must be hallucina-\ntions, delusions, or disorganized speech:\nâ–  Hallucinations (most often auditory)\nMNEMONIC â–  Delusions\nâ–  Disorganized speech\nFive As of schizophrenia\nâ–  Disorganized or catatonic behavior\ndiagnosisâ€”Affect (flat), Avolition,\nAsociality, Anhedonia, Apathy â–  Negative symptoms: Flattened affect, social withdrawal, anhedonia, apa-\nthy, â†“ emotion; may mimic depression\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559900 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 591\nSCHIZOPHRENIFORM\nDisorder of thought process. Presentation similar to schizophrenia, but psy- KEY FACT\nchotic symptoms are present for 1 to 6 months only.\nSee Table 2.13-1 for the differential diagnosis of psychosis. In addition to psychotic symptoms, a\npatient must have mood symptoms\nPrognosis present the majority of the time for a\nphysician to differentiate schizoaffective\nBetter prognosis:\ndisorder from schizophrenia.\nâ–  Acute onset with positive manifestations (hallucinations and delusions)\nâ–  No family history KEY FACT\nâ–  Rapid symptom resolution with treatment initiation\nTerms used to describe components of\nPoor prognosis: psychosis are as follows:\nâ–  Delusion: A fixed false idiosyncratic\nâ–  Symptoms arise before 13 years of age\nbelief\nâ–  Insidious course with depressive states\nâ–  Hallucination: Perception without\nâ–  Developmental delay; timid, introverted, and uncommunicative before\nan existing external stimulus\nmanifesting symptoms\nâ–  Illusion: Misperception of an actual\nexternal stimulus\nTreatment\nâ–  Treatment is usually lifelong and often involves a combination of medica-\nKEY FACT\ntions, psychotherapy, social skills training, and coordinated specialty care\nservices. In those with poor medication\nâ–  Pharmacologic intervention with antipsychotic medications can be used to adhere",
      "char_start": 1660000,
      "char_end": 1662000
    },
    {
      "chunk_id": 831,
      "text": "nce or noncompliance, depot\ntreat the acute symptoms of psychosis, as well as for long-term manage- (injectable) is preferred because they\nment and prevention of symptoms (see Table 2.13-2). are longer-acting medications.\nKEY FACT\nTABLE 2.13-1. Differential Diagnosis of Psychosis\nAtypical antipsychotics (olanzapine,\nDISORDER DURATION/CHARACTERISTICS risperidone, quetiapine) are preferred\nto typical antipsychotics (haloperidol,\nPsychotic Brief psychotic disorder: 1 day to 1 month\nthioridazine, chlorpromazine), given\ndisorders Schizophreniform disorder: 1â€“6 months\nfewer EPSs and anticholinergic effects.\nNote: Both present similarly to schizophrenia but are differentiated by dura-\ntion of illness; can be preceded by stressor(s), are less likely to have negative\nKEY FACT\nsymptoms, and have a better lifetime prognosis than schizophrenia\nSchizophrenia: >6 months Resistance is considered when a\nSchizoaffective disorder: Psychosis + mood disorder (mania or depression); minimum of two drugs have been\nattempted previously without\nRequires history/presence of:\nimprovement of symptoms.\nâ–  Psychosis + mood episode AND\nâ–  Psychosis for â‰¥2 weeks without mood episode\nPersonality Schizotypal: â€œMagical thinkingâ€\ndisorders Schizoid: â€œLonersâ€\nA 24-year-old woman presents to the\nDelusional Persistent delusions (often nonbizarre) without disorganized thought process,\nclinic. She has been â€œhearing voicesâ€\ndisorder hallucinations, or negative symptoms of schizophrenia; subtypes are and has isolated herself from her\njealous, paranoid, somatic, erotomanic, or grandiose friends and family. She first noticed\nSymptoms must be present â‰¥1 month the voices about 2 months ago when\nshe was feeling sad and reported\nDay-to-day functioning is mostly unaffected\nsleeping poorly. She reports that her\nFolie Ã  deux: A shared delusion (commonly between parent and child); the\nmood has since improved and denies\nbest course of action is to separate the patient pair and treat individually any current sleep disturb",
      "char_start": 1662000,
      "char_end": 1664000
    },
    {
      "chunk_id": 832,
      "text": "ances but\nis still hearing the voices. What is her\nmost likely diagnosis?\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559911 1100//2211//2222 22::4466 PPMM\n\n592 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-2. Antipsychotic Medications\nDRUG CLASS MECHANISM EXAMPLES INDICATIONS ADVERSE EFFECTS\nTypical anti- D antagonist Haloperidola, Psychotic disorders, acute agitation, EPSs (see Table 2.13-3) > anticholin-\n2\npsychotics (high potency) fluphenazinea acute mania, Tourette syndrome ergic symptoms (dry mouth, urinary\nThought to be more effective for posi- retention, constipation)\ntive symptoms of schizophrenia QTc prolongation and torsades\nIf compliance is a major issue, the phy- de pointes, especially with IV\nsician can consider antipsychotics haloperidol\navailable in long-acting depot forma Neuroleptic malignant syndrome\nD antagonist Thioridazine, Same as high potency Anticholinergic > EPSs\n2\n(low potency) chlorpromazine More sedating\nGreater risk for orthostatic hypotension\nThioridazine causes QTc prolongation\nand irreversible retinal pigmentation\nAtypical anti- D antago- Risperidonea, First-line treatment for schizophrenia,\n2\npsychotics nist, 5-HT quetiapine, given fewer EPSs and anticholinergic\n2A\nantagonist olanzapinea, effects\npaliperidonea, Clozapine is reserved for severe treat- â†“ EPSs (due to 5- HT antagonism)\n2A\nziprasidone, ment resistance and severe tardive Weight gain, dyslipidemia, type 2 DM,\nclozapine dyskinesia somnolence, sedation, and QTc\nprolongation (ziprasidone); hyperp-\nD partial agonist, Aripiprazolea Same as other atypicals, except it does\n2 rolactinemia (risperidone)\n5-HT partial not cause hyperprolactinemia due\n1A Clozapine can cause agranulocytosis;\nagonist, 5-HT to its ability to act as a D receptor\n2A 2 its use requires weekly CBC moni-\nantagonist agonist under hypodopaminergic\ntoring during first 6 months\nconditions and as a D receptor\n2\nantagonist during hyperdopami-\nnergic conditions\naAlso ava",
      "char_start": 1664000,
      "char_end": 1666000
    },
    {
      "chunk_id": 833,
      "text": "ilable as a long-acting depot injection. CBC, Complete blood cell count; DM, diabetes mellitus; EPS, Extrapyramidal symptom; HT,\nhydroxytryptamine; IV, intravenous.\nâ–  Supportive psychotherapy, training in social skills, vocational rehabilita-\ntion, and illness education may help. In particular, family psychoeduca-\ntion/therapy decreases the risk for relapse.\nâ–  Negative symptoms may be more difficult to treat than positive symptoms;\natypical antipsychotics are the drug of choice.\nâ–  Catatonia (awkward posturing, mutism, and immobility) may be seen in\nsevere disease; this can be treated with benzodiazepine challenge and\nThis patient most likely has\nelectroconvulsive therapy (ECT). Find a description of ECT in the Major\nschizoaffective disorder, which is\nDepressive Disorder section later in this chapter.\ncharacterized by psychosis and\nintermittent mood symptoms. The\ndiagnosis requires (1) psychotic\nsymptoms AND mood symptoms and\n(2) at least 2 weeks when psychotic\nsymptoms are present WITHOUT\nmood symptoms. Patients often have\nchronic psychotic symptoms, even\nafter mood symptoms have resolved.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559922 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 593\nTABLE 2.13-3. Extrapyramidal Symptoms and Treatment MNEMONIC\nTIME OF\nEvolution of extrapyramidal\nSUBTYPE DESCRIPTION ONSET TREATMENT symptomsâ€”\n4 and A\nAcute Prolonged, painful tonic Hours Anticholinergics (benztropine or\ndystonia muscle contraction or diphenhydramine) for acute 4 hours: Acute dystonia\n4 days: Akinesia\nspasm (eg, torticollis, therapy\n4 weeks: Akathisia\noculogyric crisis) Patients who are prone to dystonic\n4 months: Tardive dyskinesia (often\nreactions may need regular pro- permanent)\nphylactic dosing (eg, benztropine)\nAkathisia Subjective/objective Weeks â†“ dose of neuroleptic; Î²-blockers\nrestlessness that is (propranolol)\nperceived as being Benzodiazepines (lorazepam) or anti-\ndistressing cholinergics ",
      "char_start": 1666000,
      "char_end": 1668000
    },
    {
      "chunk_id": 834,
      "text": "(benztropine)\nDyskinesia Pseudo-parkinsonism Weeks â†“ dose of neuroleptic or discontinue\n(eg, tremor, shuffling (if tolerated)\ngait, cogwheel rigidity) Anticholinergics (benztropine) or\ndopamine agonist (amantadine)\nTardive Stereotypic, involuntary, Months Discontinue or â†“ dose of neuroleptic;\ndyskinesia painless oral-facial possibly change neuroleptic (eg,\nmovements to clozapine or quetiapine)\nProbably from dopamine Anticholinergics or â†“ neuroleptic\nreceptor sensitization dose may initially worsen tardive\nfrom chronic dopa- dyskinesia\nmine blockade If discontinuing or â†“ neuroleptic\nOften irreversible (50%) dose is ineffective, try valbenazine\nor deutetrabenazine\nNeuroleptic Fever, muscle rigidity, Any Discontinue medication; provide\nmalignant autonomic instability, time supportive care in the intensive\nsyndrome elevated creatine care unit (ICU); administer dan-\nkinase and white blood trolene or bromocriptine\ncells, delirium\nDISSOCIATIVE DISORDERS\nIncludes dissociative identity disorder, depersonalization/derealization disor-\nder, and dissociative amnesia. Symptoms are not better explained by sub-\nstance use, another medical condition, or another mental disorder.\nSee Table 2.13-4 for an overview of the dissociative disorders.\nTreatment\nâ–  Best initial treatment: Psychotherapy\nâ–  Appropriate pharmacologic treatment (eg, SSRIs) can be added to address\ncomorbidities (eg, depression, anxiety, substance abuse, PTSD)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559933 1100//2211//2222 22::4466 PPMM\n\n594 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-4. Overview of Dissociative Disorders\nDISORDER CHARACTERISTICS\nDissociative identity Presence of two or more distinct personalities or identities with\ndisorder (formerly separate memories and behavior patterns that dominate at\nmultiple personality different times. Patients are usually unaware of the other per-\ndisorder) sonalities and complain of frequent gaps in recall and memory\nlapses",
      "char_start": 1668000,
      "char_end": 1670000
    },
    {
      "chunk_id": 835,
      "text": ". Dissociative identify disorder is more common in females.\nAssociated with history of trauma, child abuse, PTSD, borderline\npersonality disorder, somatic symptom disorder, and major\ndepressive disorder.\nDepersonalization/ Recurrent or persistenta experiences of one or more of the\nderealization following:\ndisorder â–  Depersonalization: Feeling of detachment from oneâ€™s body,\nactions, thoughts, and perceptions Patient may feel like an\noutside observer or have â€œout-of-bodyâ€ experience\nâ–  Derealization: Experiencing oneâ€™s surroundings as unreal\nâ–  Still able to identify reality, has insight into the distinction\nbetween internal and external reality, unlike in patients with\npsychosis\nDissociative amnesia Inability to recall memories or important personal information,\nusually after a traumatic or stressful event; procedural memory is\npreserved.\nDissociative fugue: Subtype of dissociative amnesia characterized\nby sudden, unexpected travel in a dissociated state and subse-\nquent amnesia of the travel.\nIncreased risk for suicide as amnesia resolves and memories of\ntrauma return.\naTransient depersonalization/derealization may occur during times of severe stress; this does not\nmeet diagnostic criteria for DDD.\nANXIETY DISORDERS\nGENERALIZED ANXIETY DISORDER\nUncontrollable, excessive anxiety or worry about multiple topics that leads to\nsignificant impairment or distress.\nHistory/PE\nClinical onset is usually in the early 20s. Generalized anxiety disorder (GAD)\nis more common in females.\nDiagnosis\nâ–  GAD is diagnosed when excessive anxiety or worry about multiple activi-\nties is experienced on most days for â‰¥6 months.\nâ–  Symptoms of anxiety/worry are associated with three or more somatic\nsymptoms (only one required in children): restlessness, easy fatigue, diffi-\nculty concentrating, irritability, muscle tension, sleep disturbances.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559944 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD F",
      "char_start": 1670000,
      "char_end": 1672000
    },
    {
      "chunk_id": 836,
      "text": "ACTS IN 595\nâ–  Symptoms cause a clinically significant impairment (eg, social, MNEMONIC\noccupational).\nâ–  Disturbances are not caused by substances (eg, drug of abuse [eg, The diagnosis of GAD in an adult\nrequires the presence of three\ncocaine], medication [eg, amphetamines]).\nor more of the Worry WARTS\nâ–  Disturbance is not better explained by another psychiatric disorder (eg, symptoms:\nexcessive worry about panic attacks).\nWound up (irritability)\nWorn out (fatigue)\nTreatment\nAbsent-mindedness (difficulty\nâ–  Best initial treatment (first-line): Psychotherapy (CBT, applied relax- concentrating)\nation, biofeedback) + SSRIs (eg, fluoxetine, sertraline, escitalopram) or Restlessness\nserotonin norepinephrine reuptake inhibitors (SNRIs, eg, venlafaxine, Tension in muscles\nduloxetine). See Table 2.13-5. Sleep disturbance\nâ–  Alternative treatment (second-line): Buspirone, TCAs, benzodiazepines\n(short-term treatment).\nKEY FACT\nLike SSRIs, buspirone should not be\nPANIC DISORDER\nused in conjunction with monoamine\noxidase inhibitors. (See Tables 2.13-5\nCharacterized by recurrent, unexpected periods of intense fear that last for\nand 2.13-11.)\nseveral minutes and cause excessive worry about having another panic attack.\nHistory/PE\nâ–  Recurrent episodes of intense fear and discomfort. Symptoms usually last\nâ‰¤30 minutes.\nâ–  Associated with agoraphobia, increased risk of suicide.\nâ–  More common in females; may occur at any age. There is a strong genetic\ndisposition.\nTABLE 2.13-5. Anxiolytic Medications\nDRUG CLASS INDICATIONS ADVERSE EFFECTS\nSSRIs (eg, fluoxetine, sertraline, par- First-line treatment for GAD, OCD, panic Nausea, GI upset, somnolence, sexual dys-\noxetine, citalopram, escitalopram) disorder function, agitation\nSNRIs (eg, venlafaxine, duloxetine) First-line treatment for GAD Hypertension, stimulant effects\n5-HT partial agonist (eg, buspirone) Second-line treatment for GAD, social Headaches, dizziness, nausea\nphobia No tolerance, dependence, or withdrawal\nUsed if sexual dysfuncti",
      "char_start": 1672000,
      "char_end": 1674000
    },
    {
      "chunk_id": 837,
      "text": "on experienced with\nSSRIs\nÎ²-Blocker (propranolol) Performance-only social anxiety disorder Bradycardia, hypotension\nBenzodiazepines (eg, clonazepam, Anxiety (short-term), insomnia, alcohol â†‘ sleep duration; risk for abuse, tolerance,\nalprazolam) withdrawal, muscle spasm, night terrors, and dependence; disinhibition in young or\nsleepwalking older patients; confusion\nAbruptly stopping a short-acting benzo-\ndiazepine (eg, alprazolam) can result in\nseizures\nGAD, Generalized anxiety disorder; GI, gastrointestinal; OCD, obsessive-compulsive disorder.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559955 1100//2211//2222 22::4466 PPMM\n\n596 HIGH-YIELD FACTS IN PSYCHIATRY\nDiagnosis\nâ–  Panic attacks: Discrete periods of intense fear or discomfort in which four\nor more of the following symptoms develop abruptly and peak within 10\nminutes:\nâ–  Tachycardia or palpitations, diaphoresis, chest pain, shortness of\nbreath, nausea, trembling, dizziness, fear of dying or â€œgoing crazy,â€\ndepersonalization, hot flashes, chills or heat sensation, paresthesia\nâ–  Increased sensitivity to lactate infusion, which may precipitate an\nKEY FACT attack in the susceptible\nDifferential diagnosis for panic â–  Panic disorder:\ndisorders: â–  Recurrent, unexpected panic attacks\nâ–  Medical conditions: Angina, â–  Attacks followed by â‰¥1 month of at least one of the following\nmyocardial infarction (MI), â–  Persistent worry/concern of having additional attacks\narrhythmias, hyperthyroidism, â–  Maladaptive change in behavior (eg, avoidance of unfamiliar\nsituations)\npheochromocytoma, hypoglycemia\nâ–  Psychiatric conditions: Substance- â–  Worry about consequences of attack (eg, losing control)\ninduced anxiety, GAD, PTSD â–  Not explained by substances, medications, or another medical\ncondition\nTreatment\nâ–  See Table 2.13-5 for medications.\nâ–  Acute, initial treatment: Benzodiazepines (eg, clonazepam). Long-term\nuse should be avoided due to concerns of potential dependence and\nabuse. Be",
      "char_start": 1674000,
      "char_end": 1676000
    },
    {
      "chunk_id": 838,
      "text": "nzodiazepines should be tapered as soon as long-term treatment\nis effective.\nâ–  Long-term treatment: SSRIs (eg, sertraline).\nâ–  Psychotherapy: CBT; higher rates of response and sustained effects com-\npared with placebo and pharmacotherapy alone\nPHOBIAS (SOCIAL AND SPECIFIC)\nDisorders characterized by excessive fear that is unreasonable and stimulated\nby the presence or anticipation of a specific object or situation. Patients recog-\nnize the fear is excessive. Symptoms are persistent, usually lasting â‰¥6 months.\nHistory/PE\nâ–  Social anxiety disorder: Presents with excessive fear of criticism, humilia-\ntion, and embarrassment in multiple situations requiring social interac-\ntion. Patients may have anxiety in anticipation of the event, palpitations\nand sweating during the event, and they may avoid triggers (eg social\nevents, parties, school).\nâ–  Performance-only subtype: Symptoms provoked only by performance\nsituations (eg, public speaking, test taking, sexual intercourse).\nâ–  Specific phobia: Excessive anxiety and fear provoked by exposure to a\nKEY FACT feared object or situation (eg, animals, heights, airplanes). Most cases\nbegin in childhood.\nAgoraphobia is defined as fear of\nbeing alone in public places. Literally â–  Agoraphobia: Fear/anxiety of developing paniclike symptoms in two or\nmore situations from which it may be difficult to escape or get help, result-\ntranslated, it means â€œfear of the\ning in avoidance of those situations. Patients may become completely con-\nmarketplace.â€\nfined to the home. Agoraphobia is associated with panic disorder.\nTreatment\nâ–  Social anxiety disorder: Both CBT and SSRIs are first line, and the\nchoice of treatment is dependent on patient preference. CBT involves\ndesensitization through incremental exposure to the feared object or\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559966 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 597\nsituation along with relaxation techniques. Secon",
      "char_start": 1676000,
      "char_end": 1678000
    },
    {
      "chunk_id": 839,
      "text": "d-line treatment includes\nbenzodiazepines (if no history of substance use disorder) or phenelzine (if\npatient has a history of or risk factors for substance use disorder).\nâ–  Performance-only subtype: First-line treatment with Î²-blockers (eg, KEY FACT\npropranolol) before the event or as needed. Second-line treatment\nIn patients with a history of substance\nincludes CBT, benzodiazepines, and/or SSRIs.\nabuse, benzodiazepines should be\nâ–  Specific phobia: First-line treatment is CBT. Second-line treatment avoided due to their high potential for\nincludes SSRIs, benzodiazepines.\naddiction.\nâ–  Agoraphobia: CBT, SSRIs.\nOBSESSIVE-COMPULSIVE DISORDER AND RELATED DISORDERS\nKEY FACT\nAbnormalities on brain imaging\nOBSESSIVE-COMPULSIVE DISORDER\nare common in patients with OCD,\nspecifically in the orbitofrontal cortex\nCharacterized by obsessions and/or compulsions that lead to significant dis-\nand basal ganglia. The cortico-striatoâ€“\ntress and dysfunction in social or personal areas. Compulsions are typically\nthalamo-cortical (CSTC) circuits have\ntime-consuming, often requiring >1 hour daily. OCD typically presents in\nbeen implicated in the pathophysiology\nlate adolescence or early adulthood; prevalence is equal in male and female\nof the disorder.\npatients. It is often chronic and difficult to treat.\nHistory/PE KEY FACT\nâ–  Obsessions: Persistent, unwanted, and intrusive ideas, thoughts, impulses, Many patients with OCD initially\nor images that lead to marked anxiety or distress (eg, fear of contamina- present to a non-psychiatrist (eg, they\ntion, fear of harming oneself or loved ones) may consult a dermatologist with a skin\nâ–  Compulsions (or rituals): Repeated mental acts or behaviors that neutral- complaint secondary to overwashing\nize anxiety from obsessions (eg, handwashing, elaborate rituals for ordinary their hands).\ntasks, counting, excessive checking)\nâ–  Patients recognize their behaviors as excessive and irrational (vs obsessive-\ncompulsive personality disorder [OCPD]; see Table",
      "char_start": 1678000,
      "char_end": 1680000
    },
    {
      "chunk_id": 840,
      "text": " 2.13-6)\nâ–  Patients wish they could get rid of obsessions and/or compulsions\nTreatment\nâ–  Best initial treatment: SSRIs (high dose)\nâ–  Alternative: Clomipramine (TCA)\nâ–  CBT using exposure and desensitization relaxation techniques\nâ–  Patient education is imperative\nOBSESSIVE-COMPULSIVEâ€“RELATED DISORDERS\nObsessive-compulsive-related disorders are characterized by unwanted,\nintrusive, recurrent, and persistent thoughts, urges, or images, as well as\nrepetitive behaviors or mental acts in response to those preoccupations.\nTABLE 2.13-6. Obsessive-Compulsive Disorder vs Obsessive-Compulsive Personality\nDisorder A 22-year-old man presents to a\nphysicianâ€™s office. He frequently\nOBSESSIVE-COMPULSIVE DISORDER OBSESSIVE-COMPULSIVE PERSONALITY DISORDER washes his hands, refuses to sit on\nchairs in public places, and will not\nCharacterized by obsessions and/or Patients are excessively conscientious and\nuse public transportation for fear of\ncompulsions. inflexible.\ncontracting diseases. He does not\nthink his behaviors are abnormal, nor\nPatients recognize the obsessions/compulsions Patients do not recognize their behavior does he think his behaviors interfere\nand want to be rid of them (ego dystonic). as problematic (ego syntonic). with his daily activities. What is the\ndiagnosis?\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559977 1100//2211//2222 22::4466 PPMM\n\n598 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-7. Obsessive-Compulsiveâ€“Related Disorders\nDISORDER CHARACTERISTICS\nBody dysmorphic Preoccupation with imagined or slight defects in physical appearance\ndisorder that are usually imperceptible to others, leading to significant distress/\nimpairment\nThe physician should suspect body dysmorphic disorder in patients with\nan extensive history of cosmetic procedures\nTherapeutic approach: Acknowledge distress; avoid referring to com-\nplaints as imagined; evaluate level of insight; encourage patients to\navoid unnecessary cosmetic, surgical, o",
      "char_start": 1680000,
      "char_end": 1682000
    },
    {
      "chunk_id": 841,
      "text": "r medical treatments\nHoarding disorder Difficulty discarding possessions, regardless of value; attempts at dis-\ncarding objects causes significant distress; hoarding disorder results in\naccumulation of objects and can lead to an unsafe living environment\nExcoriation (skin Recurrent skin picking resulting in skin lesions\npicking) disorder Excoriation disorder causes clinically significant distress or impairment\nin social functioning; patient may report repeated attempts to stop or\ndecrease skin picking\nDifferential diagnosis: Pruritus caused by a medical condition (eg,\nprimary biliary cholangitis [PBC])\nTrichotillomania Recurrent hair pulling leading to hair loss\n(hair-pulling Trichotillomania causes clinically significant distress or impairment in\ndisorder) social functioning; patients may report repeated attempts to stop or\ndecrease the behavior; clinically, hair follicles in different stages of\ngrowth and hair of different lengths will be found\nDifferential diagnosis: Tinea capitis, alopecia\nKleptomania Persistent and recurrent impulse to steal items without motivators such\nas financial gain or personal need\nRegularly associated with other psychiatric disorders such as OCD,\nanxiety, eating disorders, and alcohol and substance abuse\nSome obsessive-compulsiveâ€“related disorders are primarily body-focused (eg,\nhair pulling, skin picking) with repeated attempts to decrease or stop the\nbehaviors. Others involve mental acts that an individual feels driven to per-\nform in response to an obsession or according to a rigid set of self-defined\nâ€œrulesâ€ (see Table 2.13-7).\nAll OCD-related disorders can be treated with CBT and SSRIs.\nTRAUMA AND STRESSOR-RELATED DISORDERS\nThis person suffers from obsessive-\ncompulsive personality disorder\n(OCPD). These patients are\nPOST-TRAUMATIC STRESS DISORDER\nperfectionists, are preoccupied\nwith rules and order, and are often\ninflexible. Unlike patients with Disorder characterized by clinically significant distress or impairment in daily\nobses",
      "char_start": 1682000,
      "char_end": 1684000
    },
    {
      "chunk_id": 842,
      "text": "sive-compulsive disorder, those functioning caused by exposure to an extreme, life-threatening traumatic\nwith OCPD typically are not disturbed event (eg, war, assault, injury, rape, accident, violent crime). Event can be\nby their disease. either directly experienced or witnessed.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559988 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 599\nHistory/PE KEY FACT\nâ–  Patients experience severe psychological distress when exposed to stimuli\nTop causes of PTSD in male patients are\nthat remind them of the event, resulting in avoidance of situations where\n(1) sexual assault and (2) war.\nexposure to triggers is possible\nTop causes of PTSD in female patients\nâ–  High incidence of substance abuse, anxiety, and/or depression\nare (1) childhood abuse and (2)\nsexual assault.\nDiagnosis\nâ–  Exposure to a traumatic event and the presence of one or more of the\nfollowing:\n1. Intrusive symptoms: Re-experiencing the event through nightmares,\nflashbacks, or intrusive memories\n2. Avoidance of stimuli associated with the trauma\n3. Negative alterations in mood and cognition: Numbed responsiveness\n(eg, detachment, anhedonia), guilt, blaming of oneself\n4. Changes in arousal and reactivity: â†‘ arousal (eg, hypervigilance, exag-\ngerated startle response), sleep disturbances, aggression/irritability, and\npoor concentration\nâ–  Symptoms lead to significant distress or impairment in functioning\nâ–  Symptoms must persist for >1 month\nâ–  Acute stress disorder: Diagnosed if symptoms are present for â‰¤1 month\nâ–  Clinical presentation is the same as PTSD\nâ–  Symptoms last â‰¥3 days but <1 month\nâ–  Symptoms present within 1 month of experiencing the traumatic event\nTreatment\nâ–  Best initial treatment:\nâ–  PTSD: CBT + SSRIs or SNRIs MNEMONIC\nâ–  Acute stress disorder: Trauma-focused CBT or eye movement desensiti-\nCauses of dementiaâ€”\nzation and reprocessing therapy\nDEMENTIASS\nâ–  Pharmacotherapy: SSRIs or SNRIs as a second-line",
      "char_start": 1684000,
      "char_end": 1686000
    },
    {
      "chunk_id": 843,
      "text": " option\nâ–  Prazosin (Î± -blocker) is used to treat PTSD-related nightmares Degenerative diseases (Parkinson,\n1\nâ–  CBT alone, SSRIs alone, or a combination of both have been found to be Huntington, dementia with Lewy bodies\nsimilarly effective [DLB])\nEndocrine (thyroid, parathyroid, pituitary,\nadrenal)\nMetabolic (alcohol, electrolytes, vitamin\nB deficiency, glucose, hepatic, renal,\nNEUROCOGNITIVE DISORDERS 12\nWilson disease)\nExogenous (heavy metals, carbon\nDisorders that affect memory, orientation, judgment, and attention. monoxide, drugs)\nNeoplasia\nTrauma (subdural hematoma)\nDEMENTIA (MAJOR NEUROCOGNITIVE DISORDER) Infection (meningitis, encephalitis,\nendocarditis, syphilis, HIV, prion\nA decline in cognitive functioning with global deficits. Level of consciousness diseases, Lyme disease)\nAffective disorders (pseudodementia)\nis stable (vs delirium). Prevalence is highest among those >85 years of age.\nStroke/Structure (vascular dementia,\nThe course is persistent and progressive. The most common causes are\nischemia, vasculitis, normal-pressure\nAlzheimer disease (65%) and vascular dementia (20%). Other causes are out-\nhydrocephalus)\nlined in the mnemonic DEMENTIASS.\nHistory/PE\nâ–  Patients with dementia are usually not concerned about their cognitive\ndecline and are often accompanied to the doctor visit by a family member\nor friend (vs major depressive disorder [MDD]/pseudodementia).\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 559999 1100//2211//2222 22::4466 PPMM\n\n600 HIGH-YIELD FACTS IN PSYCHIATRY\nâ–  Dementia is characterized by progressive memory impairment that can be\nclassified into the following four stages:\nâ–  Preclinical: Slight forgetfulness, fully oriented, and capable of caring\nfor oneself.\nâ–  Mild: Moderate memory loss, impaired executive function, impaired\nfunction at home but capable of maintaining most chores. Personal\nhygiene may need prompting.\nâ–  Moderate: Severe memory loss, inability to recognize friends (agnos",
      "char_start": 1686000,
      "char_end": 1688000
    },
    {
      "chunk_id": 844,
      "text": "ia),\nimpaired social judgement; requires assistance with dressing and per-\nsonal hygiene.\nâ–  Severe: Severe memory loss, oriented only to person, completely\ndependent on others for ADLs; may develop aphasia and become\nincommunicable.\nâ–  Personality, mood, and behavior changes are common (eg, wandering and\naggression).\nDiagnosis\nâ–  Diagnosis is clinical. History, PE, and Mini-Mental State Examination\n(MMSE) <24 or Montreal Cognitive Assessment (MoCA) <26\nâ–  The physician should rule out treatable causes of dementia. Obtain a\nurinalysis (UA), complete blood cell count (CBC), erythrocyte sedimenta-\ntion rate (ESR), vitamin B , folate, comprehensive metabolic panel\n12\n(CMP), thyroid function tests (TFTs), HIV, rapid plasma reagin (RPR),\nand a head CT/MRI.\nâ–  Definitive diagnosis requires autopsy and histopathologic exam (rarely\nperformed).\nâ–  Table 2.13-8 outlines key characteristics distinguishing dementia from\ndelirium.\nTABLE 2.13-8. Delirium vs Dementia\nCHARACTERISTIC DELIRIUM DEMENTIA\nLevel of attention Impaired (fluctuating) Usually alert\nOnset Acute Gradual\nCourse Fluctuating from hour to hour, â€œsundowningâ€ Progressive deterioration\nConsciousness Clouded Intact\nHallucinations Present (often visual or tactile) Occur in ~30% of patients in highly advanced\ndisease\nEEG changes Diffuse background slowing None\nPrognosis Reversible Largely irreversible, but up to 15% of cases are a\nresult of treatable causes and are reversible\nTreatment Treat underlying causes Cholinesterase inhibitors; low-dose antipsy-\nEnvironmental changes (eg, â†“ stimuli, providing frequent chotics (primarily for behavior disturbances)\norientation to day/time, keeping shades up during Environmental changes\ndaytime to reestablish circadian rhythm)\nLow-dose antipsychotics for disruptive behaviors (agita-\ntion, combativeness)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660000 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 601\nTreatment\nâ–  Pharmaco",
      "char_start": 1688000,
      "char_end": 1690000
    },
    {
      "chunk_id": 845,
      "text": "therapy:\nâ–  Best initial treatment: Cholinesterase inhibitors (donepezil, rivastig-\nmine, galantamine)\nâ–  Moderate/severe Alzheimer dementia: Addition of memantine\nKEY FACT\n(N-methyl-d-aspartate [NMDA] antagonist)\nâ–  Aggression/psychosis: Low-dose antipsychotics (use with caution in Confusion Assessment Method (CAM):\nolder adults; black box warning for increased mortality)\nEvidence-based tool used by medical\nâ–  Avoidance of benzodiazepines, which may exacerbate disinhibition personnel to help diagnose delirium.\nand confusion\nDiagnosis can be made if both 1 and 2\nâ–  Provide environmental cues and a rigid structure for the patientâ€™s daily life are present + either 3 or 4:\nâ–  Family, caregiver, and patient education and support are imperative 1. Acute onset or fluctuating course\n2. Inattention\nDELIRIUM 3. Disorganized thinking\n4. Altered level of consciousness\nAn acute disturbance of consciousness with altered cognition that develops over Questions on the CAM are designed\na short period (usually hours to days). Children, older adults, and hospitalized to confirm whether these features are\npatients (eg, intensive care unit [ICU] psychosis) are particularly susceptible. present or absent.\nSymptoms are potentially reversible if the underlying cause can be treated.\nHistory/PE\nâ–  Delirium presents with acute onset of waxing and waning consciousness\nwith lucid intervals and perceptual disturbances (hallucinations, illusions,\ndelusions).\nâ–  Patients may be combative, anxious, paranoid, or stuporous. MNEMONIC\nâ–  Patients have â†“ attention span and short-term memory, a reversed sleep-\nMajor causes of deliriumâ€”\nwake cycle, and â†‘ symptoms at night (sundowning).\nâ–  Procure history and conduct physical and neurologic examinations. I WATCH DEATH\nâ–  Check vital signs, pulse oximetry, electrolytes, glucose, CBC, and UA. Infection\nWithdrawal\nDiagnosis Acute metabolic/substance Abuse\nTrauma\nâ–  Best initial test: Investigate common causes of delirium.\nCNS pathology\nâ–  A urinary tract infection (UTI) i",
      "char_start": 1690000,
      "char_end": 1692000
    },
    {
      "chunk_id": 846,
      "text": "s a common cause of delirium in older\nHypoxia\nadults.\nDeficiencies\nâ–  Note recent medication additions/changes (eg, narcotics, anticholinergics, Endocrine\nsteroids, benzodiazepines).\nAcute vascular/MI\nâ–  Evaluate for substance abuse and medical problems (eg, renal failure, liver Toxins/drugs\nfailure). Heavy metals\nTreatment\nâ–  A combination of pharmacologic and nonpharmacologic interventions is\noften necessary (see Table 2.13-9).\nTABLE 2.13-9 Management of Delirium Symptoms\nNonpharmacologic Environment: Noise reduction, intervention grouping\nSleep facilitation: Bright day/dim night lighting\nPersonal interaction: Reassurance, physical touch\nConstant observation: Family, professional sitters\nMobilization: Out of bed, restraint avoidance\nPharmacologic Pain management: Nonopioid when possible\nAntipsychotics: Off-label indication\nBenzodiazepines: Antipsychotic/withdrawal symptoms\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660011 1100//2211//2222 22::4466 PPMM\n\n602 HIGH-YIELD FACTS IN PSYCHIATRY\nKEY FACT â–  Treat underlying causes (delirium is often reversible).\nâ–  Normalize fluids and electrolytes.\nIt is common for delirium to be â–  Optimize the sensory environment and provide necessary visual and hear-\nsuperimposed on dementia. ing aids.\nâ–  Use low-dose antipsychotics (eg, haloperidol) for agitation and psychotic\nsymptoms.\nMNEMONIC\nâ–  Conservative use of physical restraints may be necessary to prevent harm\nSymptoms of a depressive to the patient or others.\nepisodeâ€”\nSIG E CAPS\nSleep (hypersomnia or insomnia) MOOD DISORDERS\nInterest (loss of interest or pleasure in\nactivities)\nAlso known as affective disorders.\nGuilt (feelings of worthlessness or\ninappropriate guilt)\nEnergy (â†“) or fatigue MAJOR DEPRESSIVE DISORDER\nConcentration (â†“)\nAppetite (â†‘ or â†“) or weight (â†‘ or â†“)\nA mood disorder characterized by one or more major depressive episodes\nPsychomotor agitation or retardation\n(MDEs). The male-to-female ratio is 1:2; lifetime prevale",
      "char_start": 1692000,
      "char_end": 1694000
    },
    {
      "chunk_id": 847,
      "text": "nce ranges from\nSuicidal ideation\n15% to 25%. Onset is usually in the mid-20s; in older adults, prevalence â†‘\nwith age. Chronic illness and stress â†‘ risk. Approximately 2% to 9% of patients\nKEY FACT die by suicide.\nMajor depressive episodes can be\nTable 2.13-10 outlines differential diagnosis of conditions that can be mis-\npresent in major depressive disorder or\ntaken for depression.\nin bipolar disorder types I and II.\nSubtypes include the following:\nKEY FACT\nâ–  Psychotic features: Generally mood-congruent delusions/hallucinations.\nMinors with suicidal ideation should Psychosis only occurs during the MDD episode (distinguished from\nbe hospitalized involuntarily with or schizoaffective disorder).\nwithout parental consent (although â–  Postpartum: Occurs within 1 to 3 months postpartum; has a 10% inci-\nparental consent is preferred). dence and a high risk for recurrence. Psychotic symptoms are common\n(see Table 2.13-11).\nâ–  Atypical: Characterized by weight gain, hypersomnia, and rejection\nsensitivity.\nTABLE 2.13-10. Differential Diagnosis of Major Depressive Disorder\nDISORDER DESCRIPTION AND EXAMPLES\nMood disorder caused by a Hypothyroidism, Parkinson disease, CNS neoplasm, other neoplasms (eg, pancreatic cancer), stroke\nmedical condition (especially anterior cerebral artery stroke), dementias, parathyroid disorders\nSubstance-induced mood disorder Illicit drugs, alcohol, antihypertensives, corticosteroids, oral contraceptive pills (OCPs)\nAdjustment disorder with A constellation of symptoms that resemble an MDE but does not meet the criteria for MDE\ndepressed mood Occurs within 3 months of an identifiable stressor\nNormal bereavement Occurs after the loss of a loved one; involves no severe impairment/suicidality; â€œwavesâ€ of grief at\nreminders of loved one\nUsually lasts <6 months; should resolve within 1 year\nMay lead to MDD that requires treatment\nIllusions/hallucinations of the deceased can be normal as long as the person recognizes them as such\nDysthymia Milder, chronic d",
      "char_start": 1694000,
      "char_end": 1696000
    },
    {
      "chunk_id": 848,
      "text": "epression with depressed mood (two or more depressive symptoms) present most of\nthe time for â‰¥2 years; often resistant to treatment\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660022 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 603\nTABLE 2.13-11. Differential Diagnosis of Postpartum Disorders\nSUBTYPE TIME OF ONSET SYMPTOMS\nPostpartum â€œbluesâ€ Within 2 weeks of Sadness, moodiness, emotional lability\ndelivery No thoughts about hurting self or baby\nPostpartum 1â€“3 months Same as earlier plus sleep disturbances and\ndepression postdelivery anxiety\nMay have thoughts about hurting self and/or\nbaby\nMNEMONIC\nPostpartum psychosis 2â€“3 weeks Delusions, disorganized behavior\nTCA toxicityâ€”\npostdelivery May have thoughts about hurting baby\nTri Cs\nConvulsions\nComa\nâ–  Seasonal: Depressive episodes occurring during a specific season (most Cardiac arrhythmias\ncommonly winter). This subtype responds well to light therapy with or\nKEY FACT\nwithout antidepressants.\nIt is important to rule out bipolar\nDiagnosis\ndisorder before treating major\nDiagnosis requires depressed mood or anhedonia (loss of interest/pleasure) depressive disorder because SSRIs\nand five or more signs/symptoms from the SIG E CAPS mnemonic for can cause mania in those with bipolar\nâ‰¥2 weeks. disorder.\nTreatment\nKEY FACT\nâ–  Pharmacotherapy: Best initial treatment is with an SSRI (eg, fluoxetine\n[drug of choice], sertraline, paroxetine, citalopram, escitalopram). A par- Those with two or more episodes\ntial response to SSRIs can be augmented with bupropion or aripiprazole. should be prescribed maintenance\nâ–  Allow 2 to 6 weeks for medication to take effect. Dose can be adjusted antidepressant therapy for 1 to 3 years.\nas needed. Those with three or more episodes\nâ–  The patient should continue taking the medication for at least 6 months should have indefinite therapy\n(at the same effective dose) beyond the time of achieving full remission. prescribed.\nâ–  If a patient",
      "char_start": 1696000,
      "char_end": 1698000
    },
    {
      "chunk_id": 849,
      "text": " fails to respond to the initial antidepressant, they can be\nswitched to another first-line agent (SSRI). Agents alternatively used,\nbased on patient comorbidities and second-line treatment, include KEY FACT\nthose listed in Table 2.13-12.\nDiscontinue SSRIs at least 2 weeks\nâ–  Most effective treatment: Psychotherapy + antidepressants are more\nbefore starting an MAOI. Wait 5 weeks if\neffective than either treatment alone.\nthe patient was on fluoxetine due to its\nâ–  ECT: A small electrical current is used to induce a generalized seizure\nlong half-life.\nunder anesthesia. It is a safe and highly effective treatment option for\nsevere depression. ECT usually requires two to three treatments per week\nfor a total of 6 to 12 treatments. Indications are as follows:\nâ–  Refractory or treatment-resistant depression\nâ–  MDD with psychotic features\nâ–  Need for rapid improvement: Actively suicidal, refusal to eat/drink,\ncatatonia, pregnancy\nâ–  Bipolar depression or mania\nA 23-year-old woman complains of\nâ–  No absolute contraindications. Relative contraindications include\ndifficulty falling asleep and worsening\nrecent myocardial infarction (MI)/stroke, intracranial mass, and high\nanxiety that began 2 months earlier\nanesthetic risk\nafter she was involved in a minor\nâ–  Adverse effects: Anterograde amnesia, postictal confusion, arrhyth- biking accident (bike vs car) in which\nmias, and headache\nshe did not suffer any injuries. Since\nâ–  Phototherapy: This is effective for depression with seasonal pattern. the accident, she has refused to\nparticipate in any outdoor activities.\nWhat is her most likely diagnosis?\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660033 1100//2211//2222 22::4466 PPMM\n\n604 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-12. Indications and Side Effects of Common Antidepressants\nDRUG CLASS EXAMPLES INDICATIONS ADVERSE EFFECTS\nSSRIs Fluoxetine, sertra- Depression, anxiety Sexual side effects, GI distress, agitation, insomnia, tremor, d",
      "char_start": 1698000,
      "char_end": 1700000
    },
    {
      "chunk_id": 850,
      "text": "iarrhea\nline, paroxetine, Serotonin syndrome (fever, myoclonus, hyperreflexia, altered mental\ncitalopram, status, cardiovascular collapse) can occur if SSRIs are used with\nescitalopram, MAO inhibitors, illicit drugs, or herbal medications\nfluvoxamine Paroxetine should be avoided during pregnancy; it can cause cardiac\ndefects (first trimester) and pulmonary HTN (third trimester) in the\nfetus\nDiscontinuation syndrome (flulike symptoms, nausea, insomnia,\nsensory disturbances) occurs with abrupt cessation of shorter-\nacting agents\nAtypical antide- Bupropion, Depression, anxiety Bupropion: â†“ seizure threshold; minimal sexual side effects\npressants mirtazapine, Smoking cessation Contraindicated in patients with eating disorders and seizure\ntrazodone (bupropion) disorders\nMirtazapine: Weight gain, sedation, minimal sexual side effects\nTrazodone: Highly sedating; priapism\nSNRIs Venlafaxine, Depression, anxiety, neu- Noradrenergic side effects at higher doses\nduloxetine ropathic pain Venlafaxine: Diastolic HTN\nTCAs Nortriptyline, Depression, anxiety, neu- Antihistaminic effects: Sedation, weight gain\ndesipramine, ropathic pain, migraine Anticholinergic effects: Dry mouth, tachycardia, urinary retention\namitriptyline, headaches, enuresis Antiadrenergic effects: Orthostatic hypotension\nimipramine, clo- (imipramine), OCD TCA overdose can be lethal and cause convulsions (seizures), coma,\nmipramine (clomipramine) cardiotoxicity (prolonged conduction through AV node, prolonged\nQRS), hyperpyrexia, and respiratory depression\nTreatment for TCA overdose: Sodium bicarbonate if prolonged QRS\n(>100 msec), hypotensive, or ventricular arrhythmia; sodium\nbicarbonate alleviates depressant effect of TCA on cardiac fast Na+\nchannels\nMAO inhibitors Phenelzine, tranylcy- Depression, especially Hypertensive crisis if taken with foods high in tyramine (eg, aged\npromine, selegiline atypical cheese, red wine)\n(also available in Sexual side effects, orthostatic hypotension, weight gain\npatch form)\nAV",
      "char_start": 1700000,
      "char_end": 1702000
    },
    {
      "chunk_id": 851,
      "text": ", Atrioventricular; HTN, hypertension; MAO, monoamine oxidase.\nPERSISTENT DEPRESSIVE DISORDER (DYSTHYMIA)\nHistory/PE\nAdjustment disorder, which consists\nâ–  Persistent depressive disorder refers to a chronic depressed mood including\nof emotional and behavioral\nat least two depressive symptoms (one in children) present on most days\nsymptoms that develop in response\nfor >2 years with no symptom-free periods lasting more than 2 months.\nto an identifiable stressor, lasts\n>1 month and <6 months, and does â–  Patients often have felt depressed for as long as they can remember.\nnot have five or more symptoms of â–  Double depression: Diagnosed if patient meets criteria for MDD during\nmajor depressive disorder. dysthymic periods.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660044 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 605\nTreatment\nâ–  Psychotherapy is the most effective treatment.\nâ–  Persistent depressive disorder is often resistant to treatment. Treatments to\nconsider are antidepressants (eg, SSRIs) and ECT.\nADJUSTMENT DISORDER\nClinically significant distress following a profound life change (eg, divorce,\nunemployment, financial issues, romantic breakup); it is not severe enough to\nmeet criteria for another mental disorder.\nHistory/PE\nâ–  Patients develop anxiety or depressive symptoms (eg, anhedonia, depressed\nmood, weight loss) following a stressful life event (eg, divorce, death of\nfamily member, change in school/work).\nâ–  Event is not life-threatening.\nâ–  Symptoms present within 3 months after onset of the stressor. Adjust-\nment disorder resolves within 6 months after event is over.\nâ–  Adjustment disorder causes social or occupational dysfunction, as KEY FACT\nopposed to a normal stress reaction.\nPremenstrual dysphoric disorder\nTreatment (PMDD) presents the same as\ndysthymia, but the symptoms in PMDD\nâ–  Best initial treatment: Psychotherapy focusing on coping skills and sup- are cyclic, whereas dysthymia is pres",
      "char_start": 1702000,
      "char_end": 1704000
    },
    {
      "chunk_id": 852,
      "text": "ent\nportive counseling\nall the time.\nâ–  No pharmacologic treatment\nBIPOLAR AND RELATED DISORDERS\nPsychiatric illnesses characterized by episodes of mania or hypomania Â±\nMDE. A family history significantly â†‘ risk. The average age of onset is\n20 years, and the frequency of mood episodes tends to â†‘ with age. Up to 10%\nto 15% of those affected complete suicide. Bipolar and related disorders are\nclassified into the following subtypes: bipolar I, bipolar II, or cyclothymic\ndisorder.\nMNEMONIC\nHistory/PE\nSymptoms of maniaâ€”\nâ–  The mnemonic DIG FAST outlines the clinical presentation of mania. DIG FAST\nSee Table 2.13-13 to differentiate mania from hypomania. May report\nDistractibility\nexcessive engagement in pleasurable activities (eg, excessive spending or\nInsomnia (â†“ need for sleep)\nsexual activity), reckless behaviors, and/or psychotic features. Grandiosity (â†‘ self-esteem)/Goal directed\nâ–  Patients may or may not have history of a major depressive episode (see Flight of ideas (or racing thoughts)\nSIG E CAPS mnemonic). Activities/psychomotor Agitation\nSexual indiscretions/other pleasurable\nactivities\nTalkativeness/pressured speech\nTABLE 2.13-13. Mania vs Hypomania\nMANIA HYPOMANIA\nMore severe symptoms Less severe symptoms\nSymptoms present for â‰¥1 week, or if hospi- Symptoms present for â‰¥4 days; no hospi-\ntalization is necessary talization is required\nSignificant impairment in social/occupational No significant impairment in social/\nfunctioning occupational functioning\nMay develop psychotic features No psychotic features\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660055 1100//2211//2222 22::4466 PPMM\n\n606 HIGH-YIELD FACTS IN PSYCHIATRY\nâ–  Antidepressants may trigger manic episodes (without a mood stabilizer).\nRopinirole and other dopamine agonists can also cause manialike\nsymptoms.\nDiagnosis\nFigure 2.13-1 outlines different psychiatric disorders and the duration of\nsymptoms as part of their respective diagnostic criteria in the DSM",
      "char_start": 1704000,
      "char_end": 1706000
    },
    {
      "chunk_id": 853,
      "text": "-5.\nâ–  Symptoms must not be caused by substance abuse or a medical condition.\nâ–  Bipolar I:\nâ–  Manic episode\nâ–  Major depressive episode not required for diagnosis\nâ–  Bipolar II:\nâ–  Hypomanic episode\nâ–  One or more MDEs\nâ–  Cyclothymic disorder: Alternating periods of the following symptoms for\nat least 2 years:\nâ–  Hypomanic symptoms that do not meet criteria for hypomania\nâ–  Depressive symptoms that do not meet criteria for MDE\nTreatment\nâ–  Bipolar I and bipolar II:\nâ–  Maintenance therapy: Mood stabilizers (see Table 2.13-14). Most\npatients require lifelong mood stabilizer treatment.\nâ–  Best initial treatment: Lithium\nTABLE 2.13-14. Mood Stabilizers\nDRUG CLASS INDICATIONS ADVERSE EFFECTS\nLithium First-line mood stabilizer Narrow therapeutic window (0.8â€“1.2 mEq/L)\nUsed for acute mania (in combination with Thirst, polyuria, diabetes insipidus, tremor, weight gain, hypothyroidism,\nantipsychotics), for prophylaxis in bipolar nausea, diarrhea, seizures, teratogenicity (if used in the first trimester,\ndisorder, and for augmentation in depres- 0.1% risk for Ebstein anomaly), acne, vomiting, hyperparathyroidism\nsion treatment (with hypercalcemia)\nAlso â†“ suicide risk Lithium toxicity (blood level >1.5 mEq/L): Presents with ataxia, dysarthria,\ndelirium, and acute renal failure\nContraindicated in patients with â†“ renal function, sodium depletion, dehy-\ndration, and significant cardiovascular disease\nLamotrigine Second-line mood stabilizer; anticonvulsant Blurred vision, GI distress, Stevens-Johnson syndrome; dose slowly to\nmonitor for rashes\nCarbamazepine Alternative mood stabilizer; anticonvulsant; Nausea, skin rash, leukopenia, AV block Teratogenicity (0.5%â€“1% neural\ntrigeminal neuralgia tube defect) and hyponatremia (due to increased ADH release)\nRarely, aplastic anemia (monitor CBC biweekly), Stevens-Johnson\nsyndrome\nValproic acid Bipolar disorder; anticonvulsant GI side effects (nausea, vomiting), tremor, sedation, alopecia, weight gain,\nteratogenicity (3%â€“5% risk for neural tube defec",
      "char_start": 1706000,
      "char_end": 1708000
    },
    {
      "chunk_id": 854,
      "text": "t)\nRarely, pancreatitis, thrombocytopenia, fatal hepatotoxicity, and\nagranulocytosis\nContraindicated in patients with hepatic disease\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660066 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 607\nSLEEP DISORDERS\nNarcolepsy\n> 3 mo\nCHILDHOOD DISORDERS\nTic disorder\nDisruptive mood dysregulation\n> 1 yr\nADHD\nSpecific learning\nOppositional defiant\n> 1 mo\nSelective mutism > 6 mo\nSeparation anxiety\nANXIETY DISORDERS\nPhobias\nAdjustment Generalized anxiety\n> 1 mo\n< 6 mo > 6 mo\nPanic\nAcute stress Post-traumatic stress\n< 1 mo\nPSYCHOTIC DISORDERS\n> 1 mo\nDelusional\nBrief psychotic Schizophreniform Schizophrenia\n< 1 mo\n1-6 mo > 6 mo\nMOOD DISORDERS\nDysthymic\nCyclothymic\n> 2 yr\n> 2 wk\nMajor depressive\n> 1 wk\nManic sx of bipolar\n0 1wk 2wk 1mo 3mo 6mo 1yr 2yr\nFIGURE 2.13-1. Diagnostic criteria by symptom duration. Psychiatric conditions have overlapping symptoms and pre-\nsentations; therefore, emphasis is placed on symptom duration as part of the diagnostic criteria of most conditions in the\nDSM-5. (Adapted with permission from USMLE-Rx.com.)\nâ–  Acute mania: Considered a psychiatric emergency because of impaired\njudgment and risk for harm to self or others\nâ–  Mild to moderate mania: Atypical antipsychotics (olanzapine, quetiapine)\nâ–  Severe mania: Mood stabilizer (lithium/valproate) + antipsychotic\nâ–  Refractory mania: ECT\nâ–  Mania/hypomania in pregnancy: Antipsychoticsâ€”typical antipsychotics\n(eg, haloperidol) are generally first line and have fewer risks to the devel-\noping fetus than mood stabilizers. ECT can be used for severe or refrac-\ntory mania in pregnancy\nâ–  Bipolar depression: Mood stabilizers with or without antidepressants. The\npatient should begin taking the mood stabilizer first to avoid inducing\nmania. The physician may also try a combination of mood stabilizer and\nantipsychotic if monotherapy fails\nPERSONALITY DISORDERS\nPersonality can be defined as an individualâ€™s set of",
      "char_start": 1708000,
      "char_end": 1710000
    },
    {
      "chunk_id": 855,
      "text": " emotional and behavioral\ntraits, which are generally stable and predictable. Personality disorders are\ndefined when oneâ€™s traits become chronically rigid and maladaptive, leading\nto social or occupational dysfunction. Disorders are outlined in Table 2.13-15.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660077 1100//2211//2222 22::4466 PPMM\n\n608 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-15. Signs and Symptoms of Personality Disorders\nDISORDER CHARACTERISTICS CLINICAL PRESENTATION\nCLUSTER A: â€œWEIRDâ€\nParanoid Distrustful, suspicious; interprets othersâ€™ motives A 59-year-old man who lives alone constantly feels that his neighborâ€™s\nas malevolent children are spying on him and plotting to break into his home. He has\nNote: These patients commonly use projection as installed security cameras all around his property to obtain proof. He feels\na defense mechanism he cannot trust the police to do a good job because they will probably\ntake the side of his neighbors.\nSchizoid Isolated, detached â€œlonersâ€ who prefer to be A 66-year-old man who moves to Thailand alone after retirement, has\nalone no desire to remain in contact with his family, and is very distant in his\nRestricted emotional expression interactions. He stays in his remote accommodations without unneces-\nsary travel and does not crave interaction with the locals.\nSchizotypal Odd behavior, perceptions, and appearance A 35-year-old man with very strange ideas regarding the importance of\nMagical thinking; ideas of reference crystals and their effects on health. He meticulously mines and collects\ncrystals, feeling that they will one day prevent him from acquiring cancer.\nCLUSTER B: â€œWILDâ€\nBorderline Unstable mood, relationships, and self-image; A 28-year-old woman presents to the clinic after having praised her new\nfeelings of emptiness clinician as better than all the others. She reveals that she fired her last\nImpulsive therapist, as he was not really helping. The physicia",
      "char_start": 1710000,
      "char_end": 1712000
    },
    {
      "chunk_id": 856,
      "text": "n notices she has\nHistory of suicidal ideation or self-harm fresh cuts in a row on her forearm.\nNote: These patients often employ splitting as a\ndefense mechanism (see Table 2.13-16)\nHistrionic Excessively emotional and attention seeking A 35-year-old woman presents to clinic wearing a very low-cut blouse\nSexually provocative; theatrical and adjusting her position to draw attention to herself. When she does\nnot get attention, she breaks into tears, saying that no one notices her,\nnot even her friends.\nNarcissistic Grandiose; needs admiration; has sense of A 45-year-old man impatiently taps his foot in the waiting room of the office.\nentitlement He approaches the receptionist, demands to know where the doctor is,\nLack of empathy and tells her that he will have her fired and the doctor reported if he is not\nseen shortly as he believes his time is being wasted in a queue.\nAntisocial Violates rights of others, social norms, and laws; A 22-year-old man who has committed a brutal assault is at a court-ordered\nimpulsive; lacks remorse psychiatry appointment. When a teenager, he was in juvenile detention for\nMust be >18 years of age theft. He says he does not need to be seen by a \"shrink,\" and that because\nEvidence of conduct disorder before 15 years of age he was offended by the victim, they deserved to be assaulted.\nCLUSTER C: â€œWORRIED AND WIMPYâ€\nObsessive- Preoccupied with perfection, order, and control A 35-year-old woman presents to the office at the request of her boss,\ncompulsive at the expense of efficiency who feels she is too focused on minute details on team projects and\nInflexible morals and values does not allow others to participate for fear of unwanted errors. She\nNote: Remember, in contrast to obsessive- does not see anything wrong with this style of work, as she believes\ncompulsive disorder, patients with her coworkers cannot be trusted to pay adequate attention to detail.\nobsessive-compulsive personality disorder do\nnot feel their behavior is problematic (",
      "char_start": 1712000,
      "char_end": 1714000
    },
    {
      "chunk_id": 857,
      "text": "ego-syn-\ntonic); they also do not have true obsessions\nand compulsions\n(continues)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660088 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 609\nTABLE 2.13-15. Signs and Symptoms of Personality Disorders (continued)\nDISORDER CHARACTERISTICS CLINICAL PRESENTATION\nAvoidant Socially inhibited, sensitive to rejection A 33-year-old man stays at home to avoid an office party, as he fears\nFear of being disliked or ridiculed, yet desires to having to make small talk. He wants to go, but he is more afraid that he\nhave friends and social interactions will be inadequate or rejected by others.\nDependent Submissive, clingy; feels a need to be taken care A 30-year-old woman presents to the physicianâ€™s office in crisis, saying that\nof her parents just kicked her out of their house and that she is struggling\nHas difficulty making decisions to survive on her own. She says she cannot make her own choices at the\nFeels helpless grocery store, as her mother would always care for her, and now these\ndecisions are overwhelming. She has been sitting outside of their house\ndaily, hoping they will let her live there again.\nDefense mechanisms are methods of dealing with anxiety or conflicts of\nthe ego (eg, anger, guilt, inadequacy, grief). These can be immature (more\nprimitive) or mature (more sophisticated). Immature defense mechanisms are\ncommon in personality disorders. Important defense mechanisms are out-\nlined in Table 2.13-16.\nTABLE 2.13-16. Defense Mechanisms\nIMMATURE\nActing out Expressing unacceptable feelings and thoughts through actions\nDenial Acting as if an aspect of reality does not exist; refusing to accept the situation\nDisplacement Transferring feelings or impulses to a more neutral object\nIntellectualization Using facts and logic to avoid stressful thoughts or emotions\nPassive aggression Demonstrating hostile feelings in a nonconfrontational manner\nProjection Attributing a",
      "char_start": 1714000,
      "char_end": 1716000
    },
    {
      "chunk_id": 858,
      "text": "n unacceptable internal impulse to others (vs displacement)\nAssociated with paranoid personality disorder\nRationalization Explaining unacceptable behaviors in a rational or logical manner\nReaction formation Behaving in a manner opposite to oneâ€™s true feelings and thoughts\nRegression Involuntarily reverting to an earlier developmental stage\nAssociated with dependent personality disorder\nSplitting Believing that people are either all bad or all good\nAssociated with borderline personality disorder\nMATURE\nSublimation Channeling an unacceptable thought/wish into a socially acceptable outlet or behavior\nAltruism Coping with difficult stressors by meeting the needs of others\nSuppression Intentionally avoiding unwanted thoughts or feelings to deal with reality\nHumor Joking about an uncomfortable or anxiety-provoking situation\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 660099 1100//2211//2222 22::4466 PPMM\n\n610 HIGH-YIELD FACTS IN PSYCHIATRY\nMNEMONIC Diagnosis\nDiagnosis is clinical, and detailed history taking is imperative. Collateral\nCharacteristics of personality\ninformation may be helpful. Patients typically deny or do not realize they\ndisordersâ€”\nhave a problem (ego syntonic).\nMEDIC\nMaladaptive Treatment\nEnduring\nDeviate from cultural norms â–  Best initial treatment: Psychotherapy\nInflexible â–  Pharmacotherapy is reserved for cases with comorbid mood, anxiety, or\nCause impairment in social or occupational psychotic signs/symptoms\nfunctioning\nSUBSTANCE USE DISORDERS\nSubstance use disorder is a maladaptive pattern of substance use that leads to\nclinically significant impairment. It can be applied to most substances of\nabuse. The patient must meet â‰¥2 of the 11 criteria within a 1-year period for\ndiagnosis. The criteria can be grouped into four categories of symptoms and\nare as follows:\nâ–  Impaired control:\n1. Consumption of greater amounts of the substance than intended\n2. Failed attempts to cut down use or abstain from the sub",
      "char_start": 1716000,
      "char_end": 1718000
    },
    {
      "chunk_id": 859,
      "text": "stance\n3. Increased amount of time spent acquiring the substance, using it, or\nrecovering from effects\n4. Craving\nâ–  Social impairment:\n5. Failure to fulfill responsibilities at work, school, or home\n6. Continued substance use despite recurrent social or interpersonal\nproblems secondary to the effects of such use (eg, frequent arguments\nwith spouse over the substance use)\n7. Isolation from life activities\nâ–  Risky use:\n8. Use of substances in physically hazardous situations (eg, driving while\nintoxicated)\n9. Continued substance abuse despite recurrent physical or psychological\nproblems secondary to the effects of the substance use\nKEY FACT\nâ–  Pharmacologic:\n10. Tolerance and use of progressively larger amounts to obtain the same\nPinpoint pupils are not always a reliable\ndesired effects\nsign of opioid ingestion, because\n11. Withdrawal symptoms when not taking the substance\nco-ingestions can lead to normal or\nenlarged pupils. Also look for a Tolerance and withdrawal are not needed to make the diagnosis.\nâ†“ respiratory rate, track marks, and\nâ†“ breath sounds. â–  Withdrawal:\nâ–  Physiologic syndrome that occurs when concentrations of a substance\ndecline in an individual who has had prolonged heavy use of that\nKEY FACT substance\nâ–  Symptoms vary greatly across substances, but when they occur, the\nAcute pain management is the same for individual is likely to consume the substance again in order to relieve\nall patients with severe pain refractory the symptoms\nto NSAIDs regardless of a history of â–  For most substances, a history of withdrawal is usually associated with a\nsubstance abuse. In the appropriate more severe clinical course\nclinical setting, prior substance abuse\nis not a contraindication to the use Diagnosis/Treatment\nof opioids in pain management and\nâ–  Diagnosis is typically clinical, and detailed history-taking is imperative\nrequires a nonjudgmental environment\nâ–  Lab tests: Urine and blood toxicology screens, liver function tests (LFTs),\nand shared decision making.\nand ",
      "char_start": 1718000,
      "char_end": 1720000
    },
    {
      "chunk_id": 860,
      "text": "serum ethanol (EtOH)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661100 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 611\nâ–  Severity is determined by number of symptoms present\nâ–  Mild: Two to three; moderate: four to five; severe: six or more\nâ–  Symptoms of intoxication and withdrawal from selected drugs are\ndescribed in Table 2.13-17.\nTABLE 2.13-17. Signs and Symptoms of Substance Abuse\nDRUG INTOXICATION WITHDRAWAL\nDEPRESSANTS\nAlcohol Disinhibition, emotional lability, slurred speech, ataxia, 6â€“24 hours: Anxiety, tremor, tachycardia, HTN\naggression, blackouts, hallucinations, memory impairment, 12â€“24 hours: Hallucinations\nimpaired judgment, stupor, coma 12â€“48 hours: Seizures\n48â€“96 hours: DTs, fever, agitation, HTN,\nhallucinations\nOpioids Euphoria leading to apathy, CNS depression, constipation, Dysphoria, insomnia, anorexia, myalgias, fever,\npupillary constriction, respiratory depression (life- lacrimation, diaphoresis, dilated pupils, rhi-\nthreatening in overdose), bradycardia norrhea, piloerection, tachycardia, nausea,\nAcute reversal of opioid intoxication: Naloxone (short acting vomiting, stomach cramps, diarrhea, yawning\nso repeat dosing needed) Opioid withdrawal is not life-threatening, â€œhurts\nTo prevent relapse: Naltrexone (longer acting) all over,â€ and does not cause seizures; it can be\ntreated with buprenorphine or methadone\nSynthetic opioids Contains MPTP (synthetic heroin) leading to Parkinson-like dis- None\norder and loss of pigmented neurons in the substantia nigra\nBarbiturates Low safety margin; respiratory depression Anxiety, seizures, delirium, life-threatening car-\ndiovascular collapse\nBenzodiazepines Interactions with alcohol, amnesia, ataxia, somnolence, mild Rebound anxiety, seizures, tremor, insomnia,\nrespiratory depression HTN, tachycardia, death\nShould not be used for insomnia in older adults; can cause\nparadoxical agitation even in relatively low doses\nInhalants (solvents, glue,",
      "char_start": 1720000,
      "char_end": 1722000
    },
    {
      "chunk_id": 861,
      "text": " Tachycardia; nystagmus; tremor; ataxia; slurred speech; uncon- Dysphoria, headache, irritability\nfuels) sciousness followed by drowsiness and headache; perioral\nrash, common among adolescents\nShort duration of action\nLong-term use can lead to irreversible CNS damage and poly-\nneuropathy (due to vitamin B deficiency)\n12\nSTIMULANTS\nAmphetamines Psychomotor agitation, impaired judgment, HTN, pupillary Postuse â€œcrashâ€ with anxiety, lethargy, head-\ndilation, tachycardia, fever, diaphoresis, anxiety, angina, ache, stomach cramps, â†‘ appetite, fatigue,\neuphoria, grandiosity, prolonged wakefulness/attention, depression/dysphoria, sleep disturbance,\narrhythmias, delusions, seizures, hallucinations, skin excoria- nightmares\ntions, poor dentition (â€œmeth mouthâ€)\nHaloperidol can be given for severe agitation and symptom-\ntargeted medications (eg, antiemetics, NSAIDs)\n(continues)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661111 1100//2211//2222 22::4466 PPMM\n\n612 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-17. Signs and Symptoms of Substance Abuse (continued)\nDRUG INTOXICATION WITHDRAWAL\nCocaine Psychomotor agitation, euphoria, impaired judgment, Postuse â€œcrashâ€ with hypersomnolence, depres-\ntachycardia, pupillary dilation, HTN, paranoia, sion, malaise, â†‘ appetite, angina, suicidality,\nhallucinations, â€œcocaine bugsâ€ (the feeling of bugs crawling nightmares\nunder oneâ€™s skin), sudden death\nChronic use causes â†“ appetite, weight loss, erythema of the\nnasal turbinates and septum perforation\nECG changes from ischemia are often seen (â€œcocaine chest painâ€)\nTx: Benzodiazepines, nonselective Î±-/Î²-blockers (eg, labetalol)\nCaffeine Restlessness, insomnia, diuresis, muscle twitching, arrhyth- Headache, lethargy, depression, weight gain,\nmias, tachycardia, flushed face, psychomotor agitation irritability, craving\nNicotine Restlessness, insomnia, anxiety, arrhythmias Irritability, headache, anxiety, weight gain,\ncraving, bradycardia, difficulty c",
      "char_start": 1722000,
      "char_end": 1724000
    },
    {
      "chunk_id": 862,
      "text": "oncentrating,\ninsomnia\nHALLUCINOGENS\nPhencyclidine hydrochlo- Assaultive/combative, belligerence, psychosis, violence, Recurrence of intoxication symptoms caused by\nride (PCP) impulsiveness, psychomotor agitation, fever, tachycardia, reabsorption in the GI tract; sudden onset of\nvertical/horizontal nystagmus, HTN, impaired judgment, severe, random violence\nataxia, seizures, delirium\nBenzodiazepines or haloperidol can treat severe symptoms;\notherwise, physician should offer reassurance\nGastric lavage can help eliminate the drug\nLysergic acid diethyl- Marked anxiety or depression, delusions, visual hallucina- None\namide (LSD) tions, flashbacks, pupillary dilation, impaired judgment,\ndiaphoresis, tachycardia, HTN, heightened senses (eg, colors\nbecome more intense)\nTx: supportive counseling, traditional antipsychotics for psy-\nchotic symptoms, benzodiazepines for anxiety\nMarijuana (tetrahydro- Euphoria, laughter, slowed sense of time, impaired judgment, Irritability, anxiety, â†“ appetite, insomnia\ncannabinol [THC], social withdrawal, appetite, dry mouth, conjunctival injec-\ncannabis) tion, hallucinations, anxiety, paranoia, â†“ motivation\nBath salts (synthetic Stimulant drug that causes agitation, combativeness, delirium, Anxiety, depression, insomnia\ncathinones) and psychosis that may last for weeks; not detected on\nroutine urine toxicology screens\nGamma-hydroxybutyric Hypotension, bradycardia, respiratory depression, disinhibi- Irritability, anxiety, tremor, autonomic instability\nacid (GHB) tion, â†‘ libido, seizures\nMDMA (ecstasy) Amphetamine derivative with hallucinogenic properties; Depression, anxiety, difficulty concentrating\npopular at dance parties or â€œravesâ€\nIntoxication: HTN, euphoria, perceptual changes, bruxism,\nhyperthermia, heat exhaustion, hyponatremia; may also\nprecipitate serotonin syndrome\nDTs, Delirium tremens; HTN, hypertension; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NSAIDs, nonsteroidal anti-inflammatory drugs.\n22002222__0022..1133__SStteep",
      "char_start": 1724000,
      "char_end": 1726000
    },
    {
      "chunk_id": 863,
      "text": "p22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661122 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 613\nALCOHOL USE DISORDER\nOccurs more often in males (4:1) and in those 21 to 34 years of age, although\nthe incidence in females is rising. Alcohol use disorder is associated with a\npositive family history.\nHistory/PE\nMNEMONIC\nSee Table 2.13-17 for the symptoms of intoxication and withdrawal. The phy-\nsician should look for palmar erythema or telangiectasias and for other signs CAGE questionnaire:\nand symptoms of end-organ complications. Patients often present with sleep\n1. Have you ever felt the need to Cut\ndisturbances or anxiety symptoms caused by mild withdrawal.\ndown on your drinking?\n2. Have you ever felt Annoyed by\nDiagnosis\ncriticism of your drinking?\nâ–  Screening can be done with the CAGE questionnaire. The physician 3. Have you ever felt Guilty about\ndrinking?\nshould monitor vital signs for evidence of withdrawal.\n4. Have you ever had to take a morning\nâ–  Labs may reveal â†‘ LFTs (classically aspartate aminotransferase [AST]:\nEye opener?\nalanine aminotransferase [ALT] ratio >2:1), â†‘ lactate dehydrogenase\nMore than one â€œyesâ€ answer makes\n(LDH), â†‘ carbohydrate-deficient transferrin, and â†‘ mean corpuscular\nalcohol use disorder likely.\nvolume.\nTreatment\nâ–  Abstinence: KEY FACT\nâ–  Best initial treatment: Naltrexone (Î¼-opioid receptor blocker) â†“ crav- Naltrexone is a first-line\nings; can start while patient is still drinking\npharmacotherapy to reduce the craving\nâ–  Long-term rehabilitation (eg, Alcoholics Anonymous) for alcohol. It works by blocking the\nâ–  Aversion: Disulfiram (acetaldehyde dehydrogenase inhibitor): Produces Î¼-opioid receptor and can be given to\nan unpleasant response (eg, flushing, nausea, vertigo, palpitations) when\npatients who are still drinking.\nEtOH is consumed\nâ–  Withdrawal:\nâ–  Stabilization of vital signs; correction of electrolyte abnormalities\nâ–  Thiamine (administer before glucose to prevent Wernicke encephalop-\nat",
      "char_start": 1726000,
      "char_end": 1728000
    },
    {
      "chunk_id": 864,
      "text": "hy), glucose, and folic acid\nâ–  Medium-length benzodiazepine taper (eg, lorazepam, diazepam,\nchlordiazepoxide)\nâ–  Addition of haloperidol for hallucinations and psychotic symptoms\nComplications\nâ–  Gastritis (gastrointestinal [GI] bleeds, ulcers), varices, or Mallory-Weiss\ntears\nâ–  Pancreatitis, liver disease, delirium tremens (DTs), alcoholic hallucinosis\nAlcoholic hallucinosis\n(see Table 2.13-18, Fig. 2.13-2), peripheral neuropathy, Wernicke enceph-\n(usually visual)\nalopathy, Korsakoff psychosis, fetal alcohol syndrome, cardiomyopathy,\nanemia, aspiration pneumonia, â†‘ risk for sustaining trauma (eg, subdural Withdrawal seizures\nhematoma) Tremors, insomnia,\nDelirium\ndiaphoresis, agitation,\ntremens\nGI upset\nTABLE 2.13-18. Alcoholic Hallucinosis vs Delirium Tremens\n0 3 6 12 24 36 48 96\nALCOHOLIC HALLUCINOSIS DELIRIUM TREMENS\nTime from last drink (hours)\n12â€“24 hours since last drink 48â€“96 hours since last drink\nFIGURE 2.13-2. Alcohol withdrawal\nVisual, auditory, and tactile hallucinations Autonomic instability (hyperadrenergic state; timeline. Alcohol withdrawal can have\nâ†‘ blood pressure [BP], â†‘ heart rate [HR]) overlapping symptoms. Time from last\ndrink is important to delineate the type\nDisorientation, agitation\nof withdrawal and subsequent manage-\nHallucinations ment. (Reproduced with permission from USMLE-\nRx.com.)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661133 1100//2211//2222 22::4466 PPMM\n\n614 HIGH-YIELD FACTS IN PSYCHIATRY\nTABLE 2.13-19. Symptoms and Treatment of Drug Withdrawal\nDRUG WITHDRAWAL SYMPTOMS TREATMENT\nAlcohol Life-threatening (mortality up to 5%) Benzodiazepines (can require massive doses); thia-\nMild withdrawal: Tremor (first symptom); tachy- mine, folate, multivitamin replacement (banana\ncardia, HTN, agitation (within 48 hours) bagâ€”does not affect withdrawal, people with\nAlcoholic hallucinations: Visual hallucinations alcoholics use disorder)\nwithout delirium (12â€“48 hours)\nDelirium tremens: Visual ha",
      "char_start": 1728000,
      "char_end": 1730000
    },
    {
      "chunk_id": 865,
      "text": "llucinations with severe\nautonomic instability, delirium, seizures, and\npossibly death (within 2â€“7 days)\nBenzodiazepines and Life-threatening (mortality is rare) Benzodiazepine taper\nbarbiturates Tremor, rebound anxiety, insomnia, delirium/hal-\nlucinations, seizures\nMay mimic alcohol withdrawal, but HTN/\ntachycardia usually absent\nCocaine/amphetamines Not life-threatening IV benzodiazepines and supportive treatment\nDepression, hyperphagia, hypersomnolence, con- Avoidance of pure Î²-blockers (lead to unopposed Î±\nstricted pupils activity, causing hypertensive crisis)\nOpioids Not life-threatening Mild: Ondansetron, loperamide, benzodiazepines,\nAnxiety, insomnia, flulike symptoms, piloerection, NSAIDs\nfever, rhinorrhea, lacrimation, yawning, nausea, Severe: Clonidine for autonomic symptoms;\nstomach cramps, diarrhea, dilated pupils buprenorphine or methadone for craving\nKEY FACT MANAGEMENT OF DRUG WITHDRAWAL\nNeonatal abstinence syndrome occurs\nTable 2.13-19 summarizes common drug withdrawal symptoms and\nwhen a neonate suffers symptoms of\ntreatment.\nsubstance withdrawal because of in\nutero exposure to that substance on a\nconsistent basis.\nEATING DISORDERS\nANOREXIA NERVOSA\nRisk factors include female sex, low self-esteem, and high socioeconomic sta-\ntus. Associated with OCD; MDD; anxiety; and careers/hobbies such as mod-\neling, gymnastics, ballet, and running\nHistory/PE\nâ–  Patients are often perfectionists and high achieving. They have a distorted\nbody image and fear of gaining weight. Anorexia nervosa is divided into\ntwo subtypes:\nâ–  Restrictive: Severe restriction of food intake is primary method of\nweight loss.\nâ–  Binge eating/purging: Food intake is compensated by purging (eg,\nexcessive exercise, vomiting, laxative/diuretic abuse).\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661144 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 615\nâ–  Signs and symptoms: Cachexia, body mass index (BMI) <18.5 kg/m2,\nlanugo, dry",
      "char_start": 1730000,
      "char_end": 1732000
    },
    {
      "chunk_id": 866,
      "text": " skin, bradycardia, lethargy, hypotension, cold intolerance, and\nhypothermia (as low as 35Â°C [95Â°F]).\nâ–  See Table 2.13-20 to differentiate anorexia nervosa from bulimia nervosa.\nDiagnosis\nâ–  Measure height and weight; check BMI; check CBC, electrolytes, endo-\ncrine levels, and ECG.\nâ–  Perform a psychiatric evaluation to screen patients for comorbid conditions.\nTreatment\nSee Table 2.13-20.\nComplications\nSee Table 2.13-20 and Table 2.13-21. Mortality from suicide or medical com-\nplications is >10%.\nTABLE 2.13-20. Anorexia Nervosa vs Bulimia Nervosa\nCHARACTERISTIC ANOREXIA NERVOSA BULIMIA NERVOSA\nPresentation Persistent restriction of caloric intake resulting in low body Episodes of binge eating followed by compensa-\nweight; intense fear of gaining weight; distorted body tory behaviors (eg, purging, fasting, excessive\nimage (patients perceive themselves as overweight or exercise)\nobese) Episodes occur at least once a week for â‰¥3 months\nWeight Patients are underweight (BMI <18.5 kg/m2) Patients are of normal weight or are overweight\n(BMI >18.5 kg/m2)\nAttitude toward illness Patients are typically not distressed by their illness and may Patients are typically distressed about their symp-\nthus be resistant to treatment toms and are thus easier to treat\nTreatment Monitor calorie intake and weight gain; hospitalize if Psychotherapy Â± antidepressants (SSRIs)\nnecessary Treat comorbidities; avoid bupropion because of\nWatch for refeeding syndrome (electrolyte abnormalities [â†“ risk for seizure\nphosphate], arrhythmias, respiratory failure, and seizures\nafter sudden increase in caloric intake)\nPsychotherapy: Address maladaptive family dynamics\nAntidepressants (SSRIs): Note that these are not effective\nuntil weight is restored\nTreat comorbidities; avoid bupropion because of risk for\nseizure\nTABLE 2.13-21. Medical Complications of Eating Disorders\nCONSTITUTIONAL CARDIAC GASTROINTESTINAL GENITOURINARY OTHER\nCachexia Arrhythmias Dental erosions and Amenorrhea Dermatologic: Lanugo\nHypoth",
      "char_start": 1732000,
      "char_end": 1734000
    },
    {
      "chunk_id": 867,
      "text": "ermia Sudden death decay Nephrolithiasis Hematologic: Leukopenia\nFatigue Hypotension Abdominal pain Neurologic: Seizures\nElectrolyte abnormalities Bradycardia Delayed gastric Musculoskeletal: Osteoporosis,\n(hypokalemia, pH Prolonged QT interval emptying stress fractures\nabnormalities)\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661155 1100//2211//2222 22::4466 PPMM\n\n616 HIGH-YIELD FACTS IN PSYCHIATRY\nBULIMIA NERVOSA\nEating disorder characterized by recurrent episodes of binge eating and com-\npensatory purging behavior (eg, vomiting, laxative/diuretic abuse, excessive\nexercise). More common in females; associated with low self-esteem, mood\ndisorders, and OCD.\nHistory/PE\nâ–  Patients often have a long history of other comorbid psychiatric conditions\n(eg, anxiety, depression) and are concerned about their behaviors.\nâ–  Signs: Dental enamel erosion, enlarged parotid glands, scars on the dorsal\nhand surfaces (if there is a history of repeated induced vomiting), and BMI\n>18.5 kg/m2 are signs of bulimia nervosa.\nâ–  See Table 2.13-20 to differentiate anorexia nervosa from bulimia nervosa.\nTreatment\nSee Table 2.13-20.\nComplications\nSee Table 2.13-21 for a summary of complications related to eating disorders.\nSEXUAL DISORDERS\nSEXUAL CHANGES WITH AGING\nâ–  Interest in sexual activity usually does not â†“ with aging.\nâ–  Males usually require â†‘ stimulation of the genitalia for longer periods of\ntime to reach orgasm; intensity of orgasm â†“, and the length of the refrac-\ntory period before the next orgasm â†‘.\nâ–  In females, estrogen levels â†“ after menopause, leading to vaginal dryness\nand thinning, which may result in discomfort during coitus. The patient\nmay be treated with hormone replacement therapy, estrogen vaginal sup-\npositories, or other vaginal creams.\nPARAPHILIC DISORDERS\nâ–  Preoccupation with or engagement in unusual sexual fantasies, urges, or\nbehaviors for >6 months with clinically significant impairment of oneâ€™s\nlife. There are eig",
      "char_start": 1734000,
      "char_end": 1736000
    },
    {
      "chunk_id": 868,
      "text": "ht classified disorders, characterized by disordered court-\nship (voyeurism, exhibitionism, and frotteurism), disordered preferences\n(pedophilia, transvestic fetishism, fetishism), and pleasure in inflicting/\nreceiving pain (sadism, masochism). See Table 2.13-22.\nâ–  Tx: Includes insight-oriented psychotherapy and behavioral therapy. Anti-\nandrogens (eg, a medroxyprogesterone injection) have been used for\nhypersexual paraphilic activity.\nGENDER DYSPHORIA\nSignificant incongruence between one's gender identity and one's gender\nassigned at birth, lasting >6 months and leading to persistent distress. Individ-\nuals experience marked discomfort with assigned gender, which interferes\nwith social, academic, and other areas of function. More common in males\nthan females.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661166 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 617\nHistory/PE\nMore common in males than in females. Gender dysphoria is associated with\ndepression, anxiety, substance abuse, and personality disorders.\nâ–  Some individuals who are transgender will experience gender dysphoria.\nNonconformity to one's assigned gender itself is not a mental disorder.\nGender dysphoria is associated with depression, anxiety, substance abuse,\nand personality disorders.\nTreatment\nâ–  Address comorbid psychiatric conditions. If the patient is interested, dis-\ncuss options for gender-affirming surgery or hormonal treatment.\nâ–  In teens, hormone suppression therapy can be offered to delay puberty,\nbut this decision should be made with support from family, if possible.\nOne should also assess safety and multidisciplinary specialist services.\nSEXUAL DYSFUNCTION\nHistory/PE\nâ–  Problems in sexual arousal, desire, or orgasm or pain with sexual intercourse\nâ–  Prevalence: 30%; one-third of cases are attributable to biologic factors,\nand another third to psychological factors\nTreatment\nDepends on the condition. Pharmacologic strategies inclu",
      "char_start": 1736000,
      "char_end": 1738000
    },
    {
      "chunk_id": 869,
      "text": "de phosphodiester-\nase type 5 (PDE5) inhibitors (eg, sildenafil, tadalafil). If dysfunction is caused\nby antidepressants (SSRIs), the physician can institute a switch to bupropion.\nPsychotherapeutic strategies include sensate focusing.\nTABLE 2.13-22. Features of Common Paraphilic Disorders\nDISORDER CLINICAL MANIFESTATIONS\nExhibitionistic Sexual arousal from exposing oneâ€™s genitals to a stranger\nPedophilic Urges or behaviors involving sexual activities with children\nVoyeuristic Observing unsuspecting people unclothed or involved in sex\nFetishistic Use of nonliving objects (often clothing) for sexual arousal\nTransvestic Cross-dressing for sexual arousal\nFrotteuristic Touching or rubbing oneâ€™s genitalia against a nonconsenting person\n(common in crowded places)\nSexual sadism Sexual arousal from inflicting suffering on sexual partner\nSexual masochism Sexual arousal from being hurt, humiliated, bound, or threatened\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661177 1100//2211//2222 22::4466 PPMM\n\n618 HIGH-YIELD FACTS IN PSYCHIATRY\nSLEEP DISORDERS\nUp to one-third of all American adults suffer from some type of sleep disorder\nduring their lives. Dyssomnia describes any condition that leads to a distur-\nbance in the normal rhythm or pattern of sleep. Insomnia is the most com-\nmon example. Risk factors include female sex, the presence of mental and\nmedical disorders, substance abuse, and advanced age.\nNormal age-related sleep changes include more frequent waking, decreased\ntotal time asleep, and increased napping.\nPRIMARY INSOMNIA\nKEY FACT\nSleep hygiene measuresâ€”stimulus Affects up to 30% of the general population; causes sleep disturbance that is not\ncontrol therapy to reestablish a 24-hour attributable to physical or mental conditions. Insomnia is often exacerbated by\nsleep/wake cycle: anxiety, and patients may become preoccupied with getting enough sleep.\nâ–  Establish a sleep schedule\nâ–  Limit caffeine intake History/PE\nâ–  Avoi",
      "char_start": 1738000,
      "char_end": 1740000
    },
    {
      "chunk_id": 870,
      "text": "d naps Patients present with a history of nonrestorative sleep or difficulty initiating or\nâ–  Take warm baths in the evening maintaining sleep that is present at least three times per week for 1 month.\nâ–  Use the bedroom for sleep and\nsexual activity only Treatment\nâ–  Exercise early in the day\nâ–  Employ relaxation techniques â–  Best initial treatment: Initiate good sleep hygiene measures.\nâ–  Avoid large meals near bedtime â–  Next best treatment: Psychotherapy, specifically CBT for insomnia\n(CBTi). Pharmacotherapy can be initiated with care for short periods of\ntime (<2 weeks). Pharmacologic agents include diphenhydramine, zolpi-\ndem, zaleplon, and trazodone.\nPRIMARY HYPERSOMNIA\nDiagnosis\nDiagnosed when a patient complains of excessive daytime sleepiness or night-\ntime sleep that occurs for >1 month. The excessive somnolence cannot be\nattributable to medical or mental illness, medications, poor sleep hygiene,\ninsufficient sleep, or narcolepsy.\nTreatment\nâ–  Best initial treatment: CNS stimulants (eg, amphetamines)\nâ–  Antidepressants such as SSRIs may be useful in some patients\nNARCOLEPSY\nOnset typically occurs by young adulthood, generally before 30 years of age.\nSome forms of narcolepsy may have a genetic component.\nDiagnosis\nâ–  Manifestations include excessive daytime somnolence and â†“ rapid eye\nmovement (REM) sleep latency at least three times a week for at least\n3 months. Hypocretin deficiency (confirmed by cerebrospinal fluid [CSF]\nsampling) is also diagnostic of this condition. Sleep attacks are the classic\nsymptom; patients cannot avoid falling asleep.\nâ–  Characteristic excessive sleepiness may be associated with the following:\nâ–  Cataplexy: Sudden loss of muscle tone that leads to collapse\nâ–  Hypnagogic hallucinations: Occur as the patient is falling asleep\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661188 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 619\nâ–  Hypnopompic hallucinations: Occur as the patient aw",
      "char_start": 1740000,
      "char_end": 1742000
    },
    {
      "chunk_id": 871,
      "text": "akens MNEMONIC\nâ–  Sleep paralysis: Brief paralysis upon awakening\nHypnaGOgic = hallucinations while GOing\nto bed\nTreatment\nHypnoPOMPic = hallucinations while\nA regimen of scheduled daily naps plus stimulant drugs such as amphet- POMPing out of bed\namines or modafinil; SSRIs for cataplexy.\nSLEEP APNEA\nâ–  Sleep apnea occurs secondary to disturbances in breathing during sleep\nthat lead to excessive daytime somnolence and sleep disruption. Etiologies\ncan be either central or peripheral.\nâ–  Central sleep apnea (CSA): A condition in which both airflow and\nrespiratory effort cease. CSA is linked to morning headaches, mood\nchanges, and repeated awakenings during the night.\nâ–  Obstructive sleep apnea (OSA): A condition in which airflow ceases\nas a result of obstruction along the respiratory passages. OSA is strongly\nassociated with snoring. Risk factors: Male sex, obesity, prior upper air-\nway surgeries, a deviated nasal septum, a large uvula or tongue, and ret-\nrognathia (recession of the mandible).\nâ–  In both forms, arousal results in cessation of the apneic event.\nâ–  Sleep apnea is associated with sudden death in infants and older adults,\nheadaches, depression, â†‘ systolic blood pressure (BP), and pulmonary\nhypertension.\nDiagnosis\nSleep study (polysomnography) to document the number of arousals, obstruc-\ntions, and episodes of â†“ O saturation; distinguish OSA from CSA; and iden-\n2\ntify possible movement disorders, seizures, or other sleep disorders.\nTreatment\nâ–  OSA: Nasal continuous positive airway pressure (CPAP). Weight loss if\nobese. In children, most cases are caused by tonsillar/adenoidal hypertro-\nphy, which is corrected surgically.\nâ–  CSA: Mechanical ventilation (eg, bilevel positive airway pressure [BiPAP])\nwith a backup rate for severe cases.\nCIRCADIAN RHYTHM SLEEP DISORDER\nA spectrum of disorders characterized by a misalignment between desired and\nactual sleep periods. Subtypes include jet lag, shift work, delayed sleep phase\n(â€œnight owlsâ€), advanced sleep phase (â€œearly ",
      "char_start": 1742000,
      "char_end": 1744000
    },
    {
      "chunk_id": 872,
      "text": "birdsâ€), and unspecified causes.\nTreatment\nâ–  Jet-lag type usually resolves within 2 to 7 days without specific treatment. A 57-year-old morbidly obese\nâ–  Shift-work and delayed sleep-phase types may respond to light therapy. man presents to his physician\nModafinil is approved for shift-work sleep disorder. with concerns about â†‘ daytime\nâ–  Oral melatonin may be useful if given 30 minutes before the desired sleepiness and â†“ work productivity.\nbedtime. His wife adds that he has excessive\nsnoring that sounds like â€œthe snort\nof a steam engine.â€ What long-term\ncomplications are of concern for this\npatient?\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 661199 1100//2211//2222 22::4466 PPMM\n\n620 HIGH-YIELD FACTS IN PSYCHIATRY\nSOMATIC SYMPTOM AND RELATED DISORDERS\nSOMATIC SYMPTOM DISORDER\nPatients often present with excessive thoughts, anxiety, and behaviors driven by\nthe presence of somatic symptoms that are distressing and negatively affect daily\nlife. Somatic symptom disorder may occur with or without any medical illness\npresent. High health care utilization is often present. Disorder may present with\nmultiple recurrent somatic symptoms that may be specific (eg, localized pain)\nor nonspecific (eg, fatigue). Even normal bodily symptoms can be perceived as\nunduly threatening, even when there is evidence to the contrary.\nTreatment\nâ–  Scheduling regular appointments with one clinician as primary caregiver\nâ–  Avoiding unnecessary diagnostics but legitimizing symptoms\nâ–  Psychotherapy focused on reducing psychosocial stressors\nILLNESS ANXIETY DISORDER\nFormerly known as hypochondria. For at least 6 months, patients have anxiety\nabout and preoccupation with acquiring a serious medical illness despite hav-\ning no somatic symptoms (or mild somatic symptoms), a normal physical\nexamination, negative tests, and reassurance from a health care provider. The\npatientâ€™s preoccupation with illness is not better explained by another disor-\nder. In ad",
      "char_start": 1744000,
      "char_end": 1746000
    },
    {
      "chunk_id": 873,
      "text": "dition to the aforementioned, patients must have one of the follow-\ning: excessive health behaviors (eg, repeated checking for signs of an illness)\nor maladaptive avoidance of situations (eg, health care settings, visiting sick\nfamily members).\nKEY FACT\nTreatment\nPsychogenic/nonepileptic spells can\nco-occur with a seizure disorder. â–  CBT (first line)\nâ–  Another type of psychotherapy (second line)\nâ–  Antidepressant medication (third line)\nCONVERSION DISORDER\nAlso known as functional neurologic symptom disorder. Characterized by\nsymptoms or deficits of voluntary motor or sensory function (eg, blindness,\nseizurelike movements, paralysis) incompatible with medical processes. Close\ntemporal relationship to stress or intense emotion.\nDiagnosis\nâ–  Symptoms unexplained by other medical or neurologic causes\nâ–  Signs during physical examination suggesting nonorganic cause of\nsymptoms:\nâ–  Presence of Hoover sign (extension of affected leg when asked to raise\nthe unaffected contralateral leg) when attempting to rule out leg\nparalysis\nâ–  Eyes closed and resistant to opening during seizure; negative simulta-\nneous EEG\nThis patient has obstructive sleep\nâ–  Disappearance of tremors with distraction\napnea. Serious consequences\ninclude leg swelling, hypertension, â–  La belle indifference: Patients are strangely indifferent to their symptoms;\ncommonly associated but not required for the diagnosis\ncor pulmonale, stroke, and clinical\ndepression.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 662200 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 621\nTreatment\nâ–  Psychotherapy, physical therapy (PT)/occupation therapy (OT), treating\ncomorbid psychiatric issues (anxiety, depression, trauma)\nâ–  Goal: Improve function\nFACTITIOUS DISORDERS AND MALINGERING\nDiagnosis\nâ–  Factitious disorder (formerly Munchausen syndrome): Characterized by\nthe fabrication of symptoms or self-injury to assume the sick role (primary\ngain)\nâ–  Factitious disorder impo",
      "char_start": 1746000,
      "char_end": 1748000
    },
    {
      "chunk_id": 874,
      "text": "sed on another (formerly Munchausen by KEY FACT\nproxy): Caregiver exaggerates or falsifies medical/psychiatric symptoms or\nFactitious disorders and malingering\nintentionally induces illness in someone else to receive benefit by taking\nare distinct from somatoform disorders\non the role of concerned caregiver\nin that they involve conscious and\nâ–  Malingering: Patients intentionally cause or feign symptoms for secondary intentional processes.\ngain (eg, financial, housing, legal)\nTreatment\nâ–  Psychotherapy\nâ–  Minimal diagnostics and treatment to avoid reinforcement of behaviors\nâ–  Contacting appropriate legal authorities (factitious disorder imposed on\nanother)\nSEXUAL AND PHYSICAL ABUSE\nâ–  Most frequently affects females <35 years of age who:\nâ–  Are experiencing marital discord and have a personal history of, or a\npartner with, substance abuse\nâ–  Are pregnant, have low socioeconomic status, or have obtained a\nrestraining order\nâ–  Victims of childhood abuse are more likely to become adult victims of\nabuse\nHistory/PE\nâ–  Patients typically have multiple somatic complaints, frequent emergency\ndepartment visits, and unexplained injuries with delayed medical treat-\nment. They may also avoid eye contact or act afraid or hostile.\nâ–  Children may exhibit precocious sexual behavior, genital or anal trauma,\nsexually transmitted diseases (STDs), UTIs, and/or psychiatric/behavioral\nproblems (see Pediatrics chapter).\nâ–  Other clues include a partner who answers questions for the patient or\nrefuses to leave the examination room.\nTreatment\nâ–  Perform a screening assessment of the patientâ€™s safety domestically and in\ntheir close personal relationships.\nâ–  Provide medical care, emotional support, and counseling. KEY FACT\nâ–  Educate the patient about support services and refer the patient Sexual abusers are usually male and\nappropriately.\nare often known to the victim (and are\nâ–  Documentation is crucial. Know local laws for reporting suspected child/ often family members).\nelder abuse.\n22002222__0022..",
      "char_start": 1748000,
      "char_end": 1750000
    },
    {
      "chunk_id": 875,
      "text": "1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 662211 1100//2211//2222 22::4466 PPMM\n\n622 HIGH-YIELD FACTS IN PSYCHIATRY\nSEXUAL ASSAULT\nAny sexual act performed on another individual without their consent.\nDiagnostic Evaluation and Testing\nâ–  Assessment for physical injury with focus on genital trauma\nâ–  Psychological evaluation\nâ–  Pregnancy test\nâ–  Testing for sexually transmitted infections\nâ–  Smear/culture for chlamydia and gonorrhea\nâ–  Wet mount and culture for trichomonas\nâ–  Consideration of testing for HIV, herpes simplex virus (HSV), hepatitis\nB virus (HBV), syphilis, and cytomegalovirus (CMV)\nâ–  Forensic evaluation with detailed history and samples from buccal\nmucosa, vagina, rectum, fingernail scraping and clippings, blood samples,\nand saliva samples\nâ–  Important historical details include contraceptive use, last time of\ncoitus, condom use before the assault, drug or alcohol use, history of\nSTDs, description of the assailant, location and time of the assault, cir-\ncumstances of the assault (eg, penile penetration, use of condoms,\nextragenital acts, use or display of weapons), and the patientâ€™s actions\nsince the assault (eg, douching, bathing, brushing teeth, urination/def-\necation, changing clothes).\nPostexposure Prophylaxis and Evaluation\nâ–  Follow-up medical visit within 1 to 2 weeks\nâ–  Ceftriaxone plus azithromycin Â± metronidazole for prophylaxis against\ngonorrhea and chlamydia\nâ–  Hepatitis B booster vaccination if unknown vaccination and immune sta-\ntus or if unvaccinated\nâ–  HIV: Antiretroviral drug offered within 72 hours of assault; options are\ntenofovir-emtricitabine + raltegravir\nâ–  Human papillomavirus (HPV) vaccination recommended at time of initial\nevaluation in female survivors ages 9 to 26 years and male survivors ages\n9 to 21 years\nContraception\nâ–  Emergency contraception: Progestin/antagonist/agonist ulipristal or levonorg-\nestrel or combination ethinyl estradiol and levonorgestrel (Yuzpe regimen)\nâ–  Offer for mental health serv",
      "char_start": 1750000,
      "char_end": 1752000
    },
    {
      "chunk_id": 876,
      "text": "ices\nMNEMONIC\nSUICIDALITY\nRisk factors for suicide attemptsâ€”\nSAD PERSONS\nAccounts for 45,000 deaths per year in the United States; the 10th overall\nSex (male) cause of death in the United States. Approximately one suicide occurs every\nAge (older) 11 minutes.\nDepression\nPrevious attempt (greatest risk) â–  Risk factors: Previous suicide attempt (primary risk factor), male sex,\nEthanol/substance abuse >45 years of age, psychiatric disorders (eg, MDD, presence of psychotic\nRational thinking loss symptoms), history of psychiatric hospitalization, history of violent behav-\nSickness (chronic illness) ior, ethanol or substance abuse, recent severe stressors, poor social support,\nOrganized plan/access to weapons and a family history of suicide (see SAD PERSONS mnemonic).\nNo spouse\nâ–  Females are more likely to attempt suicide. Men use more lethal methods\nSocial support lacking\n(eg, firearms) and are more likely to complete suicide.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 662222 1100//2211//2222 22::4466 PPMM\n\nPSYCHIATRY HIGH-YIELD FACTS IN 623\nâ–  Adults aged 45 to 64 have higher rates of death from suicides than other KEY FACT\nage groups. However, young adults aged 18 to 25 are at higher risk for sui-\ncidal thoughts and attempts than other age groups. Suicide is the second leading cause\nâ–  Protective factors: Social support, family connectedness, religiosity, preg- of death (after unintentional injury)\nnancy, and parenthood. among 15- to 24-year-olds in the\nUnited States.\nDiagnosis\nâ–  Perform a comprehensive psychiatric evaluation. KEY FACT\nâ–  Ask about family history, previous attempts, ambivalence toward death, Emergent inpatient hospitalization\nand hopelessness.\nis required for patients with suicidal\nâ–  Ask directly about suicidal ideation, intent, and plan, and look for avail- intentions.\nable means.\nTreatment\nâ–  A patient who endorses suicidality requires emergent inpatient hospitaliza-\ntion even against their will.\nâ–  Suicide",
      "char_start": 1752000,
      "char_end": 1754000
    },
    {
      "chunk_id": 877,
      "text": " risk may increase after antidepressant therapy is initiated and is\nconsidered an adverse effect of the medication. There is a black box warn-\ning on all antidepressant medications when used in those <24 years of\nage.\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 662233 1100//2211//2222 22::4466 PPMM\n\n624 HIGH-YIELD FACTS IN PSYCHIATRY\nNOTES\n22002222__0022..1133__SStteepp22CCKK__PPssyycchhiiaattrryy__1111ee__558855--662244..iinndddd 662244 1100//2211//2222 22::4466 PPMM\n\nH I G H - Y I E L D F A C T S I N\nPULMONARY\nObstructive Lung Disease 626 Mycobacterial Infections 657\nAsthmA 626 tuBerculosis 657\nBronchiectAsis 628 nontuBerculous mycoBActeriA 658\nchronic oBstructive PulmonAry DiseAse 630\nPneumocystis jirovecii Pneumonia 659\nRestrictive Lung Disease 631\nAnthrax 660\ninterstitiAl lung DiseAse 632\ncryPtogenic orgAnizing PneumoniA 633 Acute Pharyngitis 661\nsystemic sArcoiDosis 633\nOral Infections 662\nhyPersensitivity Pneumonitis 634\nluDwig AnginA 662\nPneumoconiosis 634\nAcute lymPhADenitis 662\neosinoPhilic PulmonAry synDromes 635\nSinusitis 662\nAllergic BronchoPulmonAry AsPergillosis 636\nHemoptysis 663\nAcute Respiratory Failure 637\nhyPoxemiA 637 Pleural Disease 664\nAcute resPirAtory Distress synDrome 638 PleurAl effusion 664\nmechAnicAl ventilAtion 639 PneumothorAx 666\ncoronAviruses AnD coviD-19 641\nPulmonary Sleep Disorders 667\nPulmonary Vascular Disease 643 oBstructive sleeP APneA 667\nPulmonAry hyPertension/cor PulmonAle 643 oBesity hyPoventilAtion synDrome 668\nPulmonAry thromBoemBolism 644\nNose and Throat 669\nNeoplasms of the Lungs 646 rhinitis 669\nsolitAry PulmonAry noDules 646 nAsAl PolyPs 670\nlung cAncer 647 ePistAxis 671\nRespiratory Tract Infections 650\nADenotonsillAr hyPertroPhy 672\nPneumoniA 650 Acute AnD chronic lAryngitis 672\ninfluenzA 652\nlAryngoPhAryngeAl reflux 673\nAsPergillosis 654 Benign AnD mAlignAnt lAryngeAl lesions 673\nhistoPlAsmosis 654\ncocciDiomycosis 656\nBlAstomycosis 656\n625\n22002222__0022..1144__SStte",
      "char_start": 1754000,
      "char_end": 1756000
    },
    {
      "chunk_id": 878,
      "text": "epp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 662255 1100//2211//2222 44::2244 PPMM\n\n626 HIGH-YIELD FACTS IN PULMONARY\nKEY FACT\nOBSTRUCTIVE LUNG DISEASE\nFEV/FVC ratio <70% suggests\n1\nobstructive ventilatory defect (eg, Characterized by airway narrowing or collapse that causes impaired expira-\nasthma, bronchiectasis, COPD). tion and results in air trapping. Figure 2.14-1 illustrates the role of lung vol-\nFEV/FVC ratio â‰¥70% suggests restrictive ume measurements in the diagnosis of lung disease; Table 2.14-1 and\n1\nventilatory defect (eg, interstitial lung Figure 2.14-2 contrast obstructive lung disease with restrictive lung disease.\ndisease, neuromuscular diseases,\nobesity, scoliosis).\nASTHMA\nReversible airway obstruction secondary to bronchial hyperreactivity, airway\nMNEMONIC inflammation, mucus plugging, and smooth muscle hypertrophy. Most often\ndiagnosed in childhood or early adulthood but can present later.\nEtiologies of obstructive\npulmonary diseaseâ€”\nHistory/PE\nABCO\nâ–  Usually presents with dry cough, episodic wheezing, dyspnea, and/or chest\nAsthma\ntightness, often worsening at night or in early morning\nBronchiectasis\nChronic obstructive pulmonary disease â–  PE: Wheezing, prolonged expiration (â†“ inspiration/expiration ratio),\nincreased accessory muscle use, tachypnea, tachycardia, and hyperresonance.\n(COPD)/Cystic fibrosis\nObstruction (tracheal or bronchial) â–  Signs of severe disease: â†“ breath sounds, cyanosis, â†“ O 2 saturation, hyper-\ncapnia (â†‘ partial pressure of carbon dioxide in arterial blood [Paco ]), and\n2\npulsus paradoxus\nKEY FACT\nTABLE 2.14-1. Obstructive vs Restrictive Lung Disease\nBewareâ€”all that wheezes is not\nasthma! Other conditions that can TEST NORMAL OBSTRUCTIVE RESTRICTIVE\ncause wheezing are foreign body\nFEV/FVC (FEV %) >0.70 â†“ Normal/â†‘\ninhalation, left heart failure (cardiac 1 1\nwheezing), and COPD (ie, anything\nFEV (% of predicted) 80%â€“120% â†“ â†“\n1\ncausing airway constriction).\nFVC (% of predicted) 80%â€“120% Normal/â†“ â†“\nFRC (% of pr",
      "char_start": 1756000,
      "char_end": 1758000
    },
    {
      "chunk_id": 879,
      "text": "edicted) 80%â€“120% â†‘ â†“\nKEY FACT\nTLC (% of predicted) 80%â€“120% â†‘ â†“\nAsthma should be suspected in\nchildren with multiple episodes of FEV1: Forced expiratory volume in 1 second; FRC: functional residual capacity; FVC: forced vital\ncroup and upper respiratory tract capacity; TLC: total lung capacity.\ninfections associated with dyspnea.\nChildren with eczema are more likely to\nLung volumes Lung capacities\ndevelop asthma or allergic rhinitis than\n6.0\nthose without eczema.\nIRV Volume\n(L) IC VC TLC\n2.7\nTV\n2.2\nERV\n1.2 FRC\nKEY FACT\nRV\nAsthma triggers include allergens, 0\nupper respiratory infections (URIs), cold\nFIGURE 2.14-1. Lung volumes in the interpretation of pulmonary function tests (PFTs). Left\nair, exercise, drugs (eg, aspirin, NSAIDs, panel shows lung volumes, and right panel shows lung capacities. ERV, Expiratory reserve\nÎ²-blockers), and stress in both adults volume; FRC, functional residual capacity; IC, inspiratory capacity; IRV, inspiratory reserve\nand children. volume; RV, residual volume; TLC, total lung capacity; TV, total volume; VC, vital capacity.\n(Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 662266 1100//2211//2222 44::2244 PPMM\n\nâ–  Aspirin-exacerbated respiratory disease: Samter triad has three clinical fea- KEY FACT\ntures: asthma, chronic rhinosinusitis with nasal polyps, and intolerance to\naspirin or nonsteroidal anti-inflammatory drugs (NSAIDs; most commonly The physician should suspect\nupper and lower respiratory tract symptoms but occasionally also rash, impending respiratory failure\nabdominal pain, or vomiting). Pseudoallergic reaction (not IgE mediated) in a patient with severe asthma\nexacerbation and normal or\nDiagnosis normalizing Paco2 and pH.\nâ–  Best initial test: Spirometry/pulmonary function tests (PFTs); obstructive\npattern that is reversible with short-acting Î² -agonists (SABAs)\n2 KEY FACT\nâ–  Forced expiratory volume in 1 second/forced vital capacity (FE",
      "char_start": 1758000,
      "char_end": 1760000
    },
    {
      "chunk_id": 880,
      "text": "V /FVC)\n1\n<70%, â†“ FEV , normal/â†“ FVC, â†‘ residual volume (RV) and total lung Summary of asthma medications:\n1\ncapacity (TLC), normal/â†‘ diffusing capacity of the lung for carbon â–  PRN (as needed) medicationsâ€”\nmonoxide (DLCO). Increase in FEV â‰¥12% and >200 mL in FEV short-acting bronchodilators (eg,\n1 1\nwith SABA (albuterol). PFTs are often normal between exacerbations. albuterol)\nâ–  Methacholine challenge: Tests for bronchial hyperresponsiveness; useful â–  Long-term medicationsâ€”inhaled\nwhen PFTs are normal but asthma is still suspected. The methacholine corticosteroids, long-acting Î²-\n2\nchallenge is considered positive with â‰¥20% decrease in FEV . The test is agonists (eg, salmeterol), long-\n1\nsensitive but not specific. acting muscarinic antagonists\nâ–  Arterial blood gas (ABG): (LAMAs), leukotriene antagonists\nâ–  Early exacerbation: Respiratory alkalosis is caused by hyperventilation (eg, montelukast), and PO (by\n(â†“ Paco , â†‘ pH). mouth) corticosteroids.\n2\nâ–  Late/severe exacerbation (impending respiratory failure): Respiratory\nmuscle fatigue results in respiratory acidosis caused by inability to ven-\ntilate (normalizing Paco 2 , normalizing pH, â†“ partial pressure of oxygen MNEMONIC\nin arterial blood [Pao ]).\n2\nâ–  X-ray of the chest (CXR): Normal appearance to hyperinflation with flat- Medications for asthma\ntening of the diaphragm. exacerbationsâ€”\nASTHMA\nTreatment Albuterol (bronchodilator)\nIn general, avoidance of allergens or any potential triggers. See Tables 2.14-2 Steroids (anti-inflammatory)\nTheophylline (rarely used bronchodilator\nand 2.14-3 for asthma medications and management guidelines.\ndue to narrow therapeutic index)\nâ–  Acute exacerbation: Humidified O 2 (in hypoxemic patients)\nâ–  O , SABA (albuterol is first-line), systemic glucocorticoids. SABA/ Magnesium (bronchodilator used in severe\n2\nipratropium and magnesium can be used in severe exacerbations. exacerbations)\nIpratropium should not be used alone in asthma treatment. Anticholinergics (bronchodilator)\nOBSTRUC",
      "char_start": 1760000,
      "char_end": 1762000
    },
    {
      "chunk_id": 881,
      "text": "TIVE NORMAL RESTRICTIVE\nLoop shifts to the left\n8\n8 6 2\nFIGURE 2.14-2. Obstructive vs restrictive lung disease. Shown are typical alterations in lung volumes and capacities\nin restrictive and obstructive diseases. Normal flow-volume loops shown in center panel. Obstructive lung disease (left)\ncauses increased reserve volume and total lung capacity due to air trapping. Restrictive lung disease shows a reduction\nin all lung volumes due to reduced lung expansion (right). RV, Residual volume; TLC, total lung capacity; VC, vital\ncapacity. (Reproduced with permission from USMLE-Rx.com.)\n)ces/L(\nwolF\nnoitaripxE\nnoitaripsnI\nPULMONARY HIGH-YIELD FACTS IN 627\nLoop shifts to the right\n8 8\n4 4 4\nVolume (L)\n4 0 8 6 4 2 0 8 6 4 2 0\n4 4 4\nRV\nVC\n8 8 8\nTLC\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 662277 1100//2211//2222 44::2244 PPMM\n\n628 HIGH-YIELD FACTS IN PULMONARY\nTABLE 2.14-2. Common Asthma Medications and Their Mechanisms\nDRUG MECHANISM OF ACTION\nÎ²-agonists Albuterol: Short-acting (SABA); relaxes bronchial smooth muscle (Î²-adrenoceptors)\n2 2\nSalmeterol + inhaled corticosteroids (ICS): Long-acting (LABA) agent for maintenance therapy\nFormoterol + ICS: Maintenance and reliever therapy (MART) with both short-acting and long-acting effects\nCorticosteroids Inhaled corticosteroids: First-line treatment for long-term control of asthma\nBeclomethasone, prednisone: Inhibit the synthesis of cytokines\nMuscarinic antagonists Ipratropium: Short-acting muscarinic antagonist (SAMA); competitively blocks muscarinic receptors, preventing\nbronchoconstriction\nTiotropium: Long-acting muscarinic antagonist (LAMA)\nMethylxanthines Theophylline: Causes bronchodilation by inhibiting phosphodiesterase, thereby â†“ cAMP hydrolysis and cAMP\nlevels; limited usage because of narrow therapeutic-toxic index (cardiotoxicity, neurotoxicity)\nCromolyn Prevents the release of vasoactive mediators from mast cells\nUseful for exercise-induced bronchospasm\nEffective only",
      "char_start": 1762000,
      "char_end": 1764000
    },
    {
      "chunk_id": 882,
      "text": " for the maintenance of asthma; not effective during an acute attack; toxicity is rare\nAntileukotrienes Zileuton: A 5-lipoxygenase pathway inhibitor; blocks conversion of arachidonic acid to leukotrienes\nMontelukast, zafirlukast: Block leukotriene receptors\nAnti-IgE Omalizumab: Monoclonal antibody against IgE; inhibits IgE binding to IgE receptor (FcÎµRI) on mast cells; used in\npatients with allergic asthma and high baseline IgE level\nAnti-IL-5/anti-IL-5R Mepolizumab, reslizumab: Monoclonal antibody against interleukin (IL)-5 (potent chemoattractant for eosinophils)\nBenralizumab: Monoclonal antibody against IL-5 receptor, which blocks binding of IL-5, resulting in inhibition of\neosinophil differentiation and maturation in bone marrow; refer to Table 2.14-3\nAnti-IL-4R Dupilumab: Binds IL-4 receptor and inhibits IL-4 and IL-13 cytokine-induced responses, thus inhibiting release of\ninflammatory cytokines, chemokines, and IgE; refer to Table 2.14-3\nâ–  The physician should consider intubation in severe cases (cyanosis,\nKEY FACT\ninability to maintain respiratory effort, altered mental status) or in\nCorticosteroids inhaled in a rush can patients with a Paco >50 mm Hg or Pao <50 mm Hg.\n2 2\nlead to thrush! â–  Initiation and adjustment of maintenance therapy:\nâ–  Initiation of treatment is determined by asthma symptom severity at\nbaseline.\nKEY FACT\nâ–  Therapy may include a combination of controller medications (which\nprevent exacerbations, eg, salmeterol + ICS) and reliever medications\nAdults and adolescents diagnosed with\n(which treat exacerbations acutely, eg, albuterol). Certain medications\nasthma, even mild forms, should use\n(formoterol + ICS) have both controller and reliever effects.\nICSs to control airway inflammation.\nBenefits of low-dose ICSs include â–  Controller therapy may be stepped up or down in intensity according\nto patientâ€™s needs.\nimproved lung function and reductions\nin symptoms, severe exacerbations,\nmortality, and exercise-induced BRONCHIECTASIS\nbronchoconstrict",
      "char_start": 1764000,
      "char_end": 1766000
    },
    {
      "chunk_id": 883,
      "text": "ion.\nA disease caused by recurrent cycles of infection and inflammation in the\nbronchi/bronchioles that leads to fibrosis, remodeling, and permanent dila-\ntion of bronchi (see Fig. 2.14-3).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 662288 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 629\nTABLE 2.14-3. Initiation of Asthma Treatment in Adults and Adolescents Aged 12+ Based on Global Initiative for Asthma (GINA) Guidelines\nPREFERRED TRACKa\nSTEP 1 STEP 2 STEP 3 STEP 4 STEP 5\nAs-needed low-dose As-needed low-dose Low-dose maintenance Medium-/high-dose Addition of LAMA\nICS/formoterol ICS/formoterol ICS/LABA maintenance ICS/LABA Phenotypic assessment Â± anti-IgE,\nanti-IL-5/5R, anti-IL-4R\nConsideration of high-dose ICS/LABA\nReliever medication: Low-dose ICS/formoterol as needed for all steps\nCriteria for initiation of treatment at various steps:\nSTEP 1: Symptoms less than two times/month\nSTEP 2: Symptoms fewer than 4â€“5 days/week\nSTEP 3: Symptoms on most days OR on waking more than once a week\nSTEP 4: Symptoms daily OR on waking more than once a week with low lung function\nWhen to step up ongoing treatment:\nTreatment can be stepped up or down along one track or can be switched between tracksa according to an individual patientâ€™s need.\nBefore stepping up or down, the physician should check inhaler technique, patient adherence, and environmental exposures and confirm that\nsymptoms are due to asthma.\naAlternate track: As an alternative, SABA can be taken as needed as a reliever mediation. This can be combined with low-dose ICS as needed\n(step 1), or low-dose ICS maintenance therapy can be started (step 2). All other add-on medications (steps 3â€“5) are the same as the preferred track.\nHistory/PE\nâ–  Presents with chronic productive cough accompanied by frequent bouts of\nyellow or green sputum production, dyspnea, and possible hemoptysis and\nhalitosis\nâ–  Associated with a history of cystic fibrosis (CF), pulmonary infec",
      "char_start": 1766000,
      "char_end": 1768000
    },
    {
      "chunk_id": 884,
      "text": "tions (eg,\nPseudomonas, atypical mycobacteria), allergic bronchopulmonary asper-\ngillosis, hypersensitivity, immunodeficiency, localized airway obstruction,\naspiration, autoimmune disease, or inflammatory bowel disease (IBD)\nâ–  PE: Reveals rales, wheezes, rhonchi, purulent mucus, and occasional\nhemoptysis\nDiagnosis FIGURE 2.14-3. Bronchiectasis. CT of\nthe chest demonstrates markedly dilated\nâ–  CXR: Shows â†‘ bronchovascular markings and tram lines (parallel lines and thick-walled airways (arrows) con-\noutlining dilated bronchi as a result of peribronchial inflammation and sistent with bronchiectasis in this cystic\nfibrosis). fibrosis (CF) patient. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nâ–  Most accurate test: High-resolution CT. Dilated airways (ie, larger than\npulmonary arteries) and ballooned cysts are seen at the end of the bron-\nchus (mostly lower lobes).\nâ–  Spirometry/PFTs: Obstructive pattern with â†“ FEV /FVC ratio.\n1\nâ–  Additional tests to identify underlying etiology: Depends on clinical sus-\npicion. Sputum microscopy and culture may reveal chronic infection (eg,\nPseudomonas, Escherichia coli, tuberculosis) or suggest allergic broncho-\nA 10-year-old child with a history\npulmonary aspergillosis (ie, presence of eosinophils or hyphae).\nof asthma on daily fluticasone has\nÎ± -Antitrypsin levels can rule out deficiency. Sweat chloride and/or\n1 been using an albuterol inhaler once\ngenetic testing for CFTR mutations may suggest CF. Rheumatoid factor\na day as needed for several weeks.\n(RF), antinuclear antibody (ANA), or other screening tests for autoim- What changes should be made to the\nmune disease may also be considered. current regimen?\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 662299 1100//2211//2222 44::2244 PPMM\n\n630 HIGH-YIELD FACTS IN PULMONARY\nTreatment\nâ–  Medications: Antibiotics for exacerbations (â†“ bacterial load and airway/\nsystematic inflammatory mediators)\nâ–  Empiric therapy: Respiratory fluoroquinolon",
      "char_start": 1768000,
      "char_end": 1770000
    },
    {
      "chunk_id": 885,
      "text": "e (levofloxacin,\nmoxifloxacin)\nâ–  Tailoring of treatment to sputum culture results, if available\nâ–  Allergic bronchopulmonary aspergillosis (ABPA): Systemic glucocor-\nticoids and antifungals (voriconazole, itraconazole)\nâ–  Lifestyle: Bronchopulmonary hygiene (cough promotion, postural drain-\nage, chest physiotherapy).\nâ–  Surgery: Consideration of lobectomy for localized disease or lung trans-\nplantation for severe disease.\nCHRONIC OBSTRUCTIVE PULMONARY DISEASE\nKEY FACT A disease with â†“ lung function associated with airflow obstruction. Can be\ndivided into two major subtypes:\nIn patients with COPD and chronic\nhypercapnia, excess supplemental â–  Chronic bronchitis: Productive cough for >3 months per year for 2 con-\nsecutive years (clinical diagnosis)\noxygen can decrease ventilatory drive,\nresulting in worsening hypercapnia and â–  Emphysema: Destruction and dilation of structures distal to the terminal\nbronchioles (pathologic diagnosis) that may be secondary to smoking (cen-\nrespiratory acidosis.\ntrilobular) or to Î± -antitrypsin deficiency (panlobular)\n1\nKEY FACT History/PE\nConsider Î±-antitrypsin deficiency in a â–  Symptoms are minimal or nonspecific until the disease is advanced.\n1\npatient who is <60 years of age, has a â–  The clinical spectrum is shown in Table 2.14-4 (most patients are a combi-\nfamily history of COPD, has minimal or nation of the two phenotypes).\nno smoking history, has liver disease, â–  Symptoms: Classic barrel chest, use of accessory chest muscles, jugular\nand has basilar-predominant COPD. vein distention (JVD), end-expiratory wheezing, dyspnea on exertion, and\nmuffled breath sounds.\nâ–  ABGs: Hypoxemia with acute or chronic respiratory acidosis (â†‘ Paco ).\nKEY FACT 2\nâ–  Gram stain and sputum culture: Considered if bacterial infection is sus-\nSupplemental O and smoking pected (eg, fever, productive cough, new infiltrate on CXR).\n2\ncessation are the only interventions\nproven to improve survival in patients Diagnosis\nwith COPD. â–  Best initial test: Spirometry (P",
      "char_start": 1770000,
      "char_end": 1772000
    },
    {
      "chunk_id": 886,
      "text": "FTs); obstructive pattern that is nonrevers-\nible with SABA.\nâ–  FEV /FVC <70%, â†“ FEV , normal/â†“ FVC, â†‘ RV and TLC; minimal\n1 1\n(<12%) to no change in FEV with SABA (albuterol)\n1\nâ–  â†“ DLCO (emphysema or late-stage COPD); normal DLCO (chronic\nbronchitis)\nTABLE 2.14-4. COPD Subtypes: Emphysema and Chronic Bronchitis\nCOPD TYPE DEFINITION APPEARANCE ACID-BASE STATUS\nEmphysema Terminal airway Thin, wasted appear- Late hypercarbia/\nâ€œPink pufferâ€ destruction and ance with pursed hypoxia (hence pink)\ndilation lips, minimal cough\nThis child has moderate persistent\nasthma with daily symptoms. The\nChronic bronchitis Productive cough Overweight, Early hypercarbia/\npatient will benefit from an inhaled\ncorticosteroid and a long-acting â€œBlue bloaterâ€ >3 months for edematous hypoxia (hence blue)\nÎ²-agonist, such as salmeterol, for 2 years\n2\nprevention of symptoms.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663300 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 631\nTABLE 2.14-5. COPD Treatment A\nTREATMENT\nAcute Supplemental O (titrate saturation of peripheral oxygen [titrate O\n2 2]\nexacerbation saturation to 88%â€“92%)\nInhaled bronchodilators: SABA (albuterol) and anticholinergics\n(ipratropium)\nSystemic corticosteroids (prednisone)\nAddition of antibiotics if two or more cardinal symptoms:\nâ–  â†‘ dyspnea\nâ–  â†‘ cough\nâ–  Sputum production (change from baseline)\nSevere exacerbations (respiratory failure, severe hypoxemia or respira-\nB\ntory acidosis, altered mental status):\nâ–  Noninvasive positive-pressure ventilation (NPPV) with bilevel\npositive airway pressure (BiPAP) first. (Note: Increased secretions,\nfacial trauma/burns [poor mask seal], risk of aspiration [eg, due to\naltered mental status] are contraindications to NPPV.)\nâ–  If NPPV fails, next step: Endotracheal intubation.\nChronic COPD (see Lifestyle modifications: Smoking cessation\nFig. 2.14-5) Vaccines: Pneumococcal vaccine, influenza vaccine (PPSV23 = polysac-\ncharide; PCV13, 15, ",
      "char_start": 1772000,
      "char_end": 1774000
    },
    {
      "chunk_id": 887,
      "text": "20 = conjugate)\nâ–  19â€“64 years of age: PCV20 alone or PCV15 + PPSV23\nâ–  â‰¥65 years of age: PCV20 alone or PCV15 + PPSV23\nâ–  All ages: Influenza vaccine annually\nInhaled bronchodilators: SABA (albuterol), LABA (salmeterol), anticholin-\nergics (ipratropium, tiotropium) FIGURE 2.14-4. COPD. (A) Posteroan-\nIf two or more exacerbations per year, consideration for adding ICS terior (PA) and (B) lateral radiographs\nof a patient with emphysema show\nLong-term oxygen therapy (LTOT)\nhyperinflation with large lung volumes,\nâ–  LTOT is indicated if Spo2 â‰¤88% or Pao2 â‰¤55 mm Hg in most patients. flattening of the diaphragm, and minimal\nIn those with cor pulmonale, right heart failure, or polycythemia peripheral vascular markings. (Reproduced\nwith permission from USMLE-Rx.com.)\n(hematocrit [Hct] >55%), LTOT is indicated when Spo2 â‰¤89% or\nPao2 â‰¤59 mm Hg.\nKEY FACT\nâ–  Supplemental O 2 can worsen hypercapnia. The goal oxygen saturation\nis 90%â€“93%. Treatments for acute asthma and COPD\nexacerbations both involve Î²-agonists\n2\nand corticosteroids. During an acute\nâ–  CXR: Hyperinflated lungs, â†“ lung markings with flat diaphragms, and a COPD exacerbation, antibiotics may\nthin-appearing heart and mediastinum are sometimes seen. Parenchymal also be given. During an acute asthma\nbullae or subpleural blebs are also seen (see Fig. 2.14-4). exacerbation, magnesium can be given.\nTreatment\nMNEMONIC\nSee Table 2.14-5.\nTreatment for COPDâ€”\nCOPD\nRESTRICTIVE LUNG DISEASE Corticosteroids\nOxygen (if resting Spo2 <88% or <89%\nwith cor pulmonale)\nCharacterized by a loss of lung compliance, restrictive lung diseases result in\nPrevention (smoking cessation,\nâ†‘ lung stiffness and â†“ lung expansion. Table 2.14-1 and Figure 2.14-2 contrast\npneumococcal and influenza vaccines)\nobstructive with restrictive lung disease. The etiologies of restrictive lung dis-\nDilators (Î²-agonists, anticholinergics)\nease are shown in the AINâ€™T mnemonic. 2\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinnddd",
      "char_start": 1774000,
      "char_end": 1776000
    },
    {
      "chunk_id": 888,
      "text": "d 663311 1100//2211//2222 44::2244 PPMM\n\n632 HIGH-YIELD FACTS IN PULMONARY\nAll patients:\nSmoking cessation\nPneumococcal vaccine\nPneumococcal vaccine (19-64 years of age:\nPCV20 alone or PCV15+PPSV23; â‰¥65 years of\nage: PCV20 alone or PCV15+PPSV23)\nInfluenza vaccine\nIf chronic hypoxemia, oxygen therapy\nPulmonary rehabilitation\nManagement by\npatient group\nExacerbations â‰¤ 1 with no â‰¥ 2 or â‰¥ 1 with\nper year hospital admissions hospital admission\nMild Severe Mild Severe\nSymptoms\n(CAT < 10) (CAT â‰¥ 10) (CAT < 10) (CAT â‰¥ 10)\nGroup A Group B Group C Group D\nShort-acting SABA PRN SABA PRN SABA PRN\nbronchodilator + long acting + LAMA + LAMA\nInitial\n(SABA, SAMA, bronchodilator If severe symptoms\ntherapy\nor combination) (LABA or LAMA) (CAT > 20), LAMA and LABA\nIf overlapping asthma,\nLABA and ICS\nFIGURE 2.14-5. Initial COPD treatment based on severity assessed using COPD assessment test (CAT).\n(Reproduced with permission from USMLE-Rx.com.)\nMNEMONIC INTERSTITIAL LUNG DISEASE\nEtiology of restrictive lung\nA heterogeneous group of disorders characterized by inflammation and/or\ndiseaseâ€”\nfibrosis of the interstitium. In advanced disease, cystic spaces can develop in\nIf the lungs AINâ€™T compliant\nthe lung periphery, a development that leads to the characteristic â€œhoney-\nAlveolar (edema, hemorrhage, pus)\ncombâ€ pattern seen on CT (see Fig. 2.14-6A). Interstitial lung disease (ILD) is\nInterstitial lung disease (idiopathic\nalso called diffuse parenchymal lung disease (DPLD).\npulmonary fibrosis, usual insterstitial\npneumonia, nonspecific interstitial\nSubgroups of ILD:\npneumonia, chronic hypersensitivity\npneumonitis, sarcoidosis with interstitial â–  Exposure related: Asbestosis, silicosis, berylliosis, coal workerâ€™s pneumo-\npneumonia)\nconiosis, medications (eg, amiodarone, bleomycin), hypersensitivity pneu-\nNeuromuscular (myasthenia, phrenic nerve\nmonitis, radiation-induced injury\npalsy, myopathy)\nâ–  ILD associated with systemic disease or connective tissue diseases:\nThoracic wall (kyphoscoliosis",
      "char_start": 1776000,
      "char_end": 1778000
    },
    {
      "chunk_id": 889,
      "text": ", obesity,\nPolymyositis/dermatomyositis, sarcoidosis, amyloidosis, vasculitis, sclero-\nascites, pregnancy, ankylosing\nderma (CREST syndrome)\nspondylitis)\nâ–  Idiopathic: Idiopathic pulmonary fibrosis (IPF), cryptogenic organizing\npneumonia, acute interstitial pneumonia\nKEY FACT History/PE\nMedications and interventions that â–  Presents with shallow, rapid breathing; progressive dyspnea with exertion;\nand a chronic nonproductive cough\ncan cause or contribute to ILD include\namiodarone, busulfan, nitrofurantoin, â–  May have cyanosis, inspiratory squeaks, fine or â€œVelcro-likeâ€ crackles,\nclubbing, or right heart failure\nbleomycin, methotrexate, radiation, and\nlong-term high O concentration (eg,\n2\nDiagnosis\nventilators).\nâ–  Best initial test: CXR; reticular, nodular, or ground-glass pattern\nâ–  Next best step: If CXR is suspicious for ILD, then high-resolution CT;\nCT shows â€œhoneycombâ€ pattern in severe disease\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663322 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 633\nâ–  PFTs: Restrictive pattern. Normal/â†‘ FEV /FVC, â†“ FVC, â†“ FEV , â†“ TLC, A\n1 1\nâ†“ FVC, â†“ DLCO\nâ–  If systemic disease is suspected as the cause, the physician can consider\nserologic testing (eg, ANA, antiâ€“cyclic citrullinated peptide [anti-CCP],\ncreatine kinase [CK], aldolase, anti-Jo1, antineutrophil cytoplasmic anti-\nbody [ANCA], antitopoisomerase, antiâ€“double-stranded [ds]DNA).\nâ–  Most accurate test: Surgical biopsy. This is not recommended if CT find-\nings are characteristic (see Fig. 2.14-6A). In IPF and rheumatologic dis-\nease, a surgical biopsy is only performed when the diagnosis is uncertain.\nTreatment\nB\nâ–  Supportive: Avoidance of exposure to causative agents\nâ–  Medications: Anti-inflammatory/immunosuppressive agents for some dis-\nease (eg, corticosteroids), antifibrotic agents (pirfenidone, nintedanib) for\nIPF\nâ–  Surgery: Referral for lung transplantation indicated at late stages of IPF\nCRYPTOGENIC ORGANIZING PN",
      "char_start": 1778000,
      "char_end": 1780000
    },
    {
      "chunk_id": 890,
      "text": "EUMONIA\nCryptogenic organizing pneumonia is a form of diffuse ILD. â€œCryptogenicâ€\nrefers to the idiopathic nature of the condition. â€œOrganizing pneumoniaâ€\nFIGURE 2.14-6. Idiopathic pulmonary\nrefers to the typical pathologic appearance of the condition wherein buds of\nfibrosis. (A) Chest CT showing the char-\ngranulation tissue form in distal air spaces (alveoli and bronchiolar lumen acteristic â€œhoneycombâ€ lung that is seen\n[bronchiolitis obliterans]). These findings are not specific to a disease, but just in advanced disease. (B) Lung biopsy\na type of inflammatory process. specimen demonstrating increased inter-\nstitial fibrosis and nonspecific inflam-\nmation with alveolar thickening. (Image A\nHistory/PE\nreproduced with permission from Walsh SLF, Wells AU,\nTypically presents with subacute fever, dry cough, shortness of breath, weight Sverzellati N, et al. Relationship between fibroblastic\nloss, anorexia, and malaise that have failed to respond to antibiotic therapy. foci profusion and high-resolution CT morphology in\nfibrotic lung disease. BMC Med. 2015;13:241. Image B\nreproduced with permission from USMLE-Rx.com.)\nDiagnosis\nâ–  Other causes such as infection or autoimmune disease must be excluded.\nâ–  Radiographic findings on CXR or CT include bilateral, peripheral patchy\nopacities that may migrate.\nâ–  PFTs show a restrictive defect with diffusion impairment.\nâ–  Pathologic examination of biopsy specimens is diagnostic (generally surgi-\ncal biopsy is required, although transbronchial biopsy can be attempted).\nTreatment\nTreatment with corticosteroids results in dramatic clinical and radiologic\nresponse. Relapse is common on tapering steroids. Overall, prognosis is\nexcellent.\nSYSTEMIC SARCOIDOSIS\nA multisystem disease of unknown etiology characterized by infiltration of\nnoncaseating granulomas. In the United States, more commonly found in\nfemales (although it occurs in males too) of African or Northern European\ndescent. Most often arises in the third or fourth decade of life.",
      "char_start": 1780000,
      "char_end": 1782000
    },
    {
      "chunk_id": 891,
      "text": " A 25-year-old Black woman presents\nto the physicianâ€™s office with painful\nHistory/PE bumps on her shins, weight loss,\nand cough. Examination reveals a\nâ–  Systemic sarcoidosis can present with fever, cough, dyspnea, malaise,\nprominent 1-cm right axillary lymph\nweight loss, or arthritis.\nnode. What is the next best step for\nâ–  Lofgren syndrome: Erythema nodosum, bilateral hilar adenopathy, migra- diagnosis?\ntory polyarthralgia, and fever; associated with good prognosis\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663333 1100//2211//2222 44::2244 PPMM\n\n634 HIGH-YIELD FACTS IN PULMONARY\nâ–  Extrapulmonary manifestations can involve the following organs: liver,\neyes (uveitis), skin (erythema nodosum, violaceous skin plaques), central\nnervous system (CNS), heart (third-degree heart block, arrhythmias), and\nkidneys.\nDiagnosis\nâ–  Best initial test: CXR shows bilateral hilar adenopathy and reticular opaci-\nties (upper lobe predominant). Figure 2.14-7 illustrates CXR findings of\nsarcoidosis. High-resolution CT is usually done following suspicious CXR.\nâ–  Next best step: If CXR/CT is suspicious, then bronchoscopic biopsy. Non-\ncaseating granulomas are diagnostic in the presence of a compatible clini-\nFIGURE 2.14-7. Bilateral hilar lymph- cal picture with exclusion of other diseases.\nadenopathy (arrows) in a patient with\npulmonary sarcoidosis. (Reproduced with â–  PFTs: Restrictive pattern and â†“ DLCO.\npermission from USMLE-Rx.com.) â–  Other findings: â†‘ serum angiotensin-converting enzyme (ACE) levels\n(neither sensitive nor specific), hypercalcemia, hypercalciuria, â†‘ alkaline\nphosphatase (with liver involvement), lymphopenia, cranial nerve defects,\nMNEMONIC arrhythmias.\nLearning the features of sarcoid Treatment\ncan be GRUELINGâ€”\nâ–  Asymptomatic: Observation\nGranulomas\nâ–  Symptomatic: Systemic corticosteroids indicated for deteriorating respira-\naRthritis\ntory function, constitutional symptoms, hypercalcemia, and extrathoracic\nUveitis\norgan inv",
      "char_start": 1782000,
      "char_end": 1784000
    },
    {
      "chunk_id": 892,
      "text": "olvement\nErythema nodosum\nLymphadenopathy (particularly hilar, seen â–  Refractory disease: Immunosuppressants (eg, methotrexate, azathioprine,\non CXR) tumor necrosis factor [TNF]-Î± inhibitors)\nInterstitial fibrosis â–  Lofgren syndrome: NSAIDs and supportive therapy\nNegative tuberculosis (TB) test\nGammaglobulinemia\nHYPERSENSITIVITY PNEUMONITIS\nAlveolar thickening and noncaseating granulomas secondary to environmen-\nKEY FACT\ntal exposure (eg, farmerâ€™s lung seen in farmers and cattle workers due to\nLofgren syndrome is a type of chronic inhalation of mold that grows on hay and grain or pigeon breederâ€™s\nsarcoidosis with the following triad: disease due to chronic inhalation of particles from feathers or bird droppings)\narthritis, erythema nodosum, and\nHistory/PE\nbilateral hilar adenopathy. Associated\nwith a good prognosis. â–  Acute: Dyspnea, fever, malaise, shivering, and cough starting 4 to 6 hours\nafter exposure; the physician should gather a job/travel history to deter-\nmine exposure\nâ–  Chronic: Presents with progressive dyspnea; physical examination reveals\nfine bilateral rales\nDiagnosis\nAppearance on CXR/CT is variable, but upper lobe fibrosis is a common fea-\nture of chronic disease.\nTreatment\nThe patient should avoid ongoing exposure to inciting agents; the physician\nshould prescribe corticosteroids to â†“ chronic inflammation.\nPNEUMOCONIOSIS\nThis is presumed sarcoidosis. Biopsy\nof the right axillary lymph node is the\nPneumoconiosis refers to lung conditions caused by the inhalation of organic\nnext best step for diagnosis and is\nor nonorganic airborne dust and fibers. Risk factors include prolonged occu-\nless invasive than transbronchial lung\npational exposure and inhalation of small inorganic dust particles.\nbiopsy.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663344 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 635\nTABLE 2.14-6. Diagnoses of Pneumoconioses\nDISORDER HISTORY IMAGING FINDINGSa COMPLICATIONS\nAs",
      "char_start": 1784000,
      "char_end": 1786000
    },
    {
      "chunk_id": 893,
      "text": "bestosis Work involving the manufacture of tile Linear opacities at lung bases and inter- â†‘ risk for mesothelioma (rare) and\nor brake linings, insulation, construc- stitial fibrosis; calcified pleural plaques lung cancer; the risk for lung\ntion, demolition, or shipbuilding (Image A) indicative of benign pleural cancer is higher in smokers; the\nPresents 15â€“20 years after initial disease; Image B shows ferruginous most common malignancy associ-\nexposure bodies in alveolar septum ated with asbestos exposure is\nbronchogenic carcinoma\nCoal workersâ€™ Work in underground coal mines Small nodular opacities (<1 cm) in upper Progressive massive fibrosis\ndisease lung zones\nSilicosis Work in mines or quarries or with glass, Small (<1 cm) nodular opacities in upper â†‘ risk for TB; need annual TB test\npottery, or silica lung zones; eggshell calcifications Progressive massive fibrosis\nBerylliosis Work in high-technology fields such as Diffuse infiltrates; hilar adenopathy Requires chronic corticosteroid\naerospace, nuclear, and electronics treatment\nplants; ceramics industries; foundries;\nplating facilities; dental material sites;\nor dye manufacturing\nA B\naSpirometry, consistent with restrictive disease.\nImage A reproduced with permission from Miles SE, Sandrini A, Johnson AR, et al. Clinical consequences of asbestos-related diffuse pleural\nthickening: a review. J Occup Med Toxicol 2008;3:20. Image B reproduced with permission from Mizell KN, Morris CG, Carter JE. Antemortem\ndiagnosis of asbestosis by screening chest radiograph correlated with postmortem histologic features of asbestosis: a study of 273 cases. J Occup\nMed Toxicol. 2009 Jun 12;4:14. doi: 10.1186/1745-6673-4-14.\nHistory/PE/Diagnosis\nTable 2.14-6 outlines the findings and diagnostic criteria associated with com-\nmon pneumoconioses.\nTreatment\nAvoidance of triggers; supportive therapy and supplemental O .\n2\nEOSINOPHILIC PULMONARY SYNDROMES\nA diverse group of disorders characterized by eosinophilic pulmonary infil-\ntrates ",
      "char_start": 1786000,
      "char_end": 1788000
    },
    {
      "chunk_id": 894,
      "text": "and abnormal peripheral blood eosinophilia. Includes ABPA, Loffler\nsyndrome, acute and chronic eosinophilic pneumonia, eosinophilic granulo-\nmatosis polyangitis, and drug-induced disorders (eg, NSAIDs, nitrofurantoin,\nsulfonamides).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663355 1100//2211//2222 44::2244 PPMM\n\n636 HIGH-YIELD FACTS IN PULMONARY\nKEY FACT History/PE\nPresents with dyspnea, cough, potentially blood-tinged sputum, and/or fever.\nLoffler syndrome is a form of\neosinophilic pulmonary disease\nDiagnosis\ncharacterized by absent or mild\nrespiratory symptoms (most often dry â–  Complete blood cell count (CBC): May reveal peripheral eosinophilia\ncough), fleeting migratory pulmonary (â‰¥500 eosinophils/uL)\nopacities, and peripheral blood â–  CXR: Shows pulmonary infiltrates\neosinophilia. â–  Bronchoalveolar lavage: â†‘ eosinophils (>25%)\nTreatment\nRemoval of the extrinsic cause or treatment of underlying infection (eg, hel-\nminths) if identified. Corticosteroid treatment may be used.\nALLERGIC BRONCHOPULMONARY ASPERGILLOSIS\nABPA is a hypersensitivity reaction of airways to colonization by Aspergillus.\nAs a result of recurrent inflammation, obstruction, and mucous secretions,\nbronchiectasis and fibrosis develop. Early treatment may prevent progression\nto bronchiectasis or pulmonary fibrosis.\nHistory/PE\nPatients often have underlying asthma or CF, and they present with recurrent\nfever, bronchial obstruction, brownish expectoration, and hemoptysis.\nDiagnosis\nâ–  Initial tests look for evidence of Aspergillus sensitization (eg, Aspergillus-\nspecific IgE antibodies or positive Aspergillus skin prick test). Negative\nresults rule out aspergillosis.\nâ–  Patients sensitized to Aspergillus should undergo further laboratory testing\nfor total serum IgE, Aspergillus precipitins, and eosinophil counts (gener-\nally >500 cells/uL).\nâ–  Sputum may have eosinophil-rich plugs and Charcot-Leyden crystals.\nCulture of sputum may grow Aspergillus.\nâ–  Imagi",
      "char_start": 1788000,
      "char_end": 1790000
    },
    {
      "chunk_id": 895,
      "text": "ng with CT of chest or a CXR may show evidence of bronchiectasis.\nTreatment\nâ–  Systemic glucocorticoids (prednisone) and antifungal therapy (itracon-\nazole or voriconazole) may be used.\nâ–  Optimization of asthma treatment with possible addition of biologic agents\n(eg, omalizumab). Patients with CF may also benefit from omalizumab.\nâ–  Patients should reduce Aspergillus exposure at home or work.\nComplications\nComplications include acute/chronic invasive pulmonary aspergillosis and\naspergilloma.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663366 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 637\nACUTE RESPIRATORY FAILURE\nHYPOXEMIA\nHypoxemia is a below normal arterial oxygen level, normally defined as PaO\n2\n<60 mm Hg. Causes include ventilation-perfusion (V/Q) mismatch, right-to-\nleft shunt, hypoventilation, low inspired O content (high altitudes), and dif-\n2\nfusion impairment.\nHistory/PE\nFindings depend on the etiology. â†“ saturation of peripheral oxygen (Spo ),\n2\ncyanosis, tachypnea, shortness of breath, pleuritic chest pain (caused by\nwheezing, coughing), and altered mental status may be seen.\nDiagnosis\nâ–  Best initial test: ABGs; exhibition of â†“ Pao . Calculate the alveolar-\n2\narterial (A-a) oxygen gradient:150 âˆ’ (Paco /0.8) âˆ’ Pao . (Note: Presumes KEY FACT\n2 2\nP is 760 mm Hg at sea level, fraction of inspired oxygen [Fio ] is 0.21).\natm 2 If the problem is hypoventilation or low\nâ–  CXR: To evaluate for an infiltrative process (eg, pneumonia), atelectasis, a inspired oxygen, the A-a gradient will\nlarge pleural effusion, or pneumothorax and to assess for acute respiratory\nbe normal. If the problem is ventilation/\ndistress syndrome (ARDS). An â†‘ A-a gradient suggests shunt, V/Q mis-\nperfusion (V/Q) mismatch or shunting,\nmatch, or diffusion impairment. Figure 2.14-8 summarizes the approach\nthe A-a gradient will increase.\ntoward patients who have hypoxemia.\nTreatment\nâ–  Address the underlying etiology.\nâ–  Administer O",
      "char_start": 1790000,
      "char_end": 1792000
    },
    {
      "chunk_id": 896,
      "text": " before initiating evaluation.\n2\nHypoxemia (â†“ Paoâ‚‚)\nCheck A-a gradient\nRule out a\nsecond process\nNormal Increased\nIs Pacoâ‚‚ increased? Is Paoâ‚‚ correctable with Oâ‚‚?\nNo Yes No Yes\nHypoventilation Shunt (right-to-left) V/Q mismatch\nâ†“ Fioâ‚‚ (eg, high altitude)\nâ†“ respiratory drive Intracardiac shunt Airway disease (asthma, COPD)\nNeuromuscular disease Vascular shunt within lungs Interstitial lung disease\nCNS depression Alveolar disease (atelectasis,\nObesity hypoventilation pneumonia, pulmonary edema)\nPulmonary vascular disease\nFIGURE 2.14-8. Determination of the mechanism of hypoxemia. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663377 1100//2211//2222 44::2244 PPMM\n\n638 HIGH-YIELD FACTS IN PULMONARY\nTABLE 2.14-7. Mechanical Ventilator â–  â†‘ oxygenation parameters if the patient is on mechanical ventilation (see\nParameters Affecting Oxygenation and\nTable 2.14-7).\nVentilation\nâ–  In hypercapnic patients, â†‘ ventilation (â†‘ respiratory rate [RR] or â†‘ VT) to\nâ†‘ OXYGENATION â†‘ VENTILATION â†‘ CO exchange.\n2\nâ†‘ Fio â†‘ RR\n2\nâ†‘ Positive end- â†‘ VT ACUTE RESPIRATORY DISTRESS SYNDROME\nexpiratory pressure\n(PEEP) â–  Respiratory failure with refractory hypoxemia, â†“ lung compliance, and\nnoncardiogenic pulmonary edema with a Pao /Fio â‰¤300. Pathogenesis is\n2 2\nthought to be dependent on endothelial injury.\nâ–  Common triggers are as follows: Sepsis (most common), severe pulmonary\ninfection (pneumonias), aspiration, blood transfusions, inhaled/ingested\ntoxins, drowning, and trauma.\nâ–  Overall mortality is 30% to 40%.\nHistory/PE\nâ–  Presents with acute-onset (12â€“48 hours) tachypnea, dyspnea, and tachy-\ncardia Â± fever, cyanosis, labored breathing, diffuse high-pitched rales, and\nhypoxemia in the setting of one of the systemic inflammatory causes or\nexposure.\nâ–  Additional findings are as follows:\nâ–  Phase 1 (acute injury): Normal physical examination; possible respira-\ntory alkalosis\nâ–  Phase 2 (6â€“48 hours): Hyperventila",
      "char_start": 1792000,
      "char_end": 1794000
    },
    {
      "chunk_id": 897,
      "text": "tion, hypocapnia, widening A-a\ngradient\nFIGURE 2.14-9. Anteroposterior CXR â–  Phase 3: Acute respiratory failure, tachypnea, dyspnea, â†“ lung compli-\nshowing a diffuse alveolar filling pat- ance, scattered rales, diffuse chest opacities on CXR (see Fig. 2.14-9)\ntern secondary to ARDS. (Reproduced with â–  Phase 4: Severe hypoxemia unresponsive to therapy; â†‘ intrapulmonary\npermission from Kasper DL et al. Harrisonâ€™s Principles of\nshunting; metabolic and respiratory acidosis\nInternal Medicine, 16th ed. New York, NY: McGraw-Hill;\n2005.)\nDiagnosis\nThe criteria for an ARDS diagnosis (according to the Berlin definition) are as\nfollows:\nâ–  Acute onset (<1 week) of respiratory distress.\nâ–  CXR: Bilateral alveolar opacities consistent with pulmonary edema. Pul-\nmonary edema on CXR <24 hours after trauma may suggest pulmonary\ncontusion instead of ARDS; features of pulmonary contusions are shown\nin Figure 2.14-10.\nâ–  A Pao /Fio ratio â‰¤300 with positive end-expiratory pressure (PEEP)/\n2 2\ncontinuous positive airway pressure (CPAP) â‰¥5 cm H O.\n2\nâ–  Respiratory failure not completely explained by heart failure.\nTreatment\nFIGURE 2.14-10. Pulmonary contusion.\nRib fractures, subcutaneous emphysema, â–  Treat the underlying disease and maintain adequate perfusion to prevent\nand lung opacities on right correspond- end-organ damage.\ning to lung contusion. Pneumothorax of\nâ–  Prone positioning in select patients with severe ARDS (eg, severe ARDS\nleft lung. (Reproduced with permission from Ser-\nwith Pao /Fio ratio <150 mm Hg and Fio â‰¥0.6 and PEEP â‰¥5 cm H O)\ntaridou E, Papaioannou V, Kouliatsis G, et al. Traumatic 2 2 2 2\nasphyxia due to blunt chest trauma: a case report reduces mortality.\nand literature review. J Med Case Rep. 2012;6:257 â–  Use mechanical ventilation with low tidal volumes (6 cc/kg of ideal body\ndoi:10.1186/1752-1947-6-257.) weight) to minimize ventilator-induced lung injury by overdistention of\nalveoli.\nâ–  Use PEEP to recruit collapsed alveoli and titrate PEEP and Fio to\n2\nachieve ade",
      "char_start": 1794000,
      "char_end": 1796000
    },
    {
      "chunk_id": 898,
      "text": "quate oxygenation.\nâ–  To â†‘ Pao , â†‘ PEEP.\n2\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663388 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 639\nâ–  Keep Fio â‰¤60% (0.6), if possible, to prevent oxygen toxicity.\n2\nâ–  Goal oxygenation is Pao >55 mm Hg or Spo >88%.\n2 2\nâ–  Extubation may be attempted if:\nâ–  The cause of respiratory failure has improved.\nâ–  Ventilator support required is minimal (low PEEP, low pressure\nsupport).\nâ–  Oxygen supplementation is easily accomplished without the support of\nPEEP or other adjuvant treatments.\nâ–  Patient passes a spontaneous breathing trial.\nMECHANICAL VENTILATION\nMechanical ventilation is the process by which gas is moved to and from the\nlungs by an external device to artificially support their functions. It may be\ninvasive (via tracheostomy, endotracheal tube) or noninvasive (via mask). KEY FACT\nIndications For Invasive Mechanical Ventilation In flail chest, multiple rib fractures\nresult in a floppy segment that\nIndications for mechanical ventilation include but are not limited to:\nmoves paradoxically due to negative\nâ–  Inadequate oxygenation (acute hypoxemia, eg, atelectasis, small airway/ intrathoracic pressure on inspiration.\nparenchymal disease)\nBy increasing positive intrathoracic\nâ–  Inadequate ventilation (acute hypercapnia, eg, flail chest or inadequate pressure, positive-pressure ventilation\nventilation)\nimproves oxygenation and causes the\nâ–  Inability to maintain airway (eg, trauma, intoxication, postictal state) flail segment to move normally.\nâ–  Hemodynamic instability\nVentilator Mechanics\nTable 2.14-8 depicts changes in lung pressures during ventilation. Table 2.14-9\nshows abnormal ventilator waveforms and explains the significance.\nVentilator Settings\nKey initial settings for volume assist/control follow:\nâ–  Tidal volume is set at 6 to 8 mL/kg in obstructive lung disease (eg, chronic\nobstructive pulmonary disease [COPD]) or 6 mL/kg in ARDS (ie, restric-\ntive disease).\n",
      "char_start": 1796000,
      "char_end": 1798000
    },
    {
      "chunk_id": 899,
      "text": "â–  The rate is generally set lower for obstructive diseases as opposed to ARDS\n(eg, 10â€“14/min in obstructive lung disease and 14â€“18/min in ARDS; how-\never, specific settings vary based on disease process and ABG).\nâ–  Fio is initially started at 100% and titrated down to maintain arterial oxy-\n2\ngen saturation (SaO ) of 88% to 95% or Pao 55 to 80 mm Hg. Ideally,\n2 2\nFiO is reduced to â‰¤60% to prevent oxygen toxicity.\n2\nâ–  Use ARDSnet PEEP/FiO2 table for guidnace on PEEP for ARDS manage-\nment. This is to prevent barotrauma. For obstructive disease, start with\nPEEP of 0 to 5 cm H O.\n2\nâ–  I:E ratio: In obstructive lung disease, the inspiratory-to-expiratory time ratio\nis higher (I:E >1:3) than with ARDS (I:E > 1:1.5). This is needed because\nthe lungs take more time to effectively empty due to obstructed airways.\nâ–  After initiation of ventilation, changes in settings should be based on\nABGs. Refer to Table 2.14-10.\nComplications of Mechanical Ventilation\nVentilation is associated with multiple complications, including ventilator-\nassociated lung injury and hypotension.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 663399 1100//2211//2222 44::2244 PPMM\n\nTABLE 2.14-8. Respiratory Mechanics\nPeak pressure (P )\nPeak\nResistive pressure\nPlateau pressure (P )\nPlat\np D re r s iv su in r g e Elastic pressure\nAutoPEEP\nAIRWAY PRESSURE/TIME CURVE\nVentilator-Induced Lung Injury\nKEY FACT Acute lung injury inflicted by mechanical ventilation that may result in\nincreased mortality and morbidity. Some mechanisms are described next:\nIn left heart failure, PEEP is beneficial,\nas â†‘ intrathoracic pressure causes â†“ â–  Volutrauma: Caused by excessive stretch by high tidal volume. This can\npreload and â†“ afterload. On the other be prevented by using lower tidal volumes.\nhand, â†‘ PEEP worsens right heart â–  Barotrauma: Due to high pressures. In ARDS, a lung-protective strategy\nfailure (â†‘ increased intrathoracic and â†‘ (plateau pressure <30 cmH 2 O) minimizes bar",
      "char_start": 1798000,
      "char_end": 1800000
    },
    {
      "chunk_id": 900,
      "text": "otrauma.\npulmonary vascular pressures). â–  Atelectrauma: Due to cyclical opening and closing of alveoli. This can be\nminimized with â†‘ PEEP.\nâ–  Biotrauma: Due to inflammatory mediators possibly caused by other\nKEY FACT forms of trauma.\nâ–  Oxygen effect: Possibility for high Fio to cause lung damage. This is less\nFor acute brain injury (stroke) target an 2\nlikely at Fio <0.6.\nSpo of 94% to 98% or a Pao of 80 to 2\n2 2\n100 mm Hg to help the brain oxygenate.\nAcute Hypotension\nBoth very high PEEP and hypoxemia can\nincrease intracranial pressure (ICP) and â–  Tension pneumothorax: Acute hypotension with tachycardia and sudden\nincrease in peak inspiratory pressure is suggestive of tension pneumotho-\ncause cerebral ischemia.\nrax. CXR should be ordered.\n)OHmc(\nerusserp\nyawriA\n2\n640 HIGH-YIELD FACTS IN PULMONARY\nAirway\nresistance\n(Resistive\nPressure)\nPressure from lung compliance\nPEEP\nInspiration Expiration InspiratoryExpiratory\nhold hold\nTime\nDEFINITIONS\nPeak inspiratory pressure Total pressure required to push air into the lung\n(P ) P = Resistive pressure + elastic pressure + PEEP\nPeak Peak\nPlateau pressure (P ) Reflects lung compliance (â†‘ P = â†“ compliance)\nPlat Plat\nEnd-inspiratory hold maneuver allows measurement of P\nPlat\nResistive pressure Reflects resistance to airflow (P â€“ P )\nPeak Plat\nResistive pressure comprises ventilator circuit, endotracheal tube, and patient airway resistance\nPositive end-expiratory Pressure at end expiration; normally equals atmospheric pressure\npressure (PEEP) When there is incomplete emptying of air, an intrinsic positive end-expiratory pressure (auto-PEEP) may develop\nAuto PEEP can be measured in the passive patient through an end-expiratory hold maneuver\nPEEP may be applied by ventilator settings for therapeutic indications (prevent airway collapse)\nElastic pressure (also Due to elastic recoil of the lungs and chest wall and to the volume of gas delivered\nknown as driving May be derived from P and PEEP (Elastic pressure = P â€“ PEEP)\nPlat Plat\npre",
      "char_start": 1800000,
      "char_end": 1802000
    },
    {
      "chunk_id": 901,
      "text": "ssure) Elastic pressure is increased by increased lung stiffness (fibrosis) or reduced chest wall/diaphragm movement\n(obesity/ascites)\nIllustration reproduced with permission from USMLE-Rx.com.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664400 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 641\nTABLE 2.14-9. Pathologic Waveforms During Ventilation\nCAUSES AND\nWAVE FORM P P PATHOPHYSIOLOGY MANAGEMENT\nPEAK PLAT\nIncreased Resistive Airway Pressure â†‘â†‘ Normal Increased airway Think airway!\nresistance but Kinked endotracheal\nIncreased PIP\nResistive pressure normal lung (ET) tube: Untangle\nBaseline PIP Increases compliance Mucous plug: Suction\ndifference\nmucus\nBaseline plateau pressure Bronchospasm:\nBronchodilate\nNarrow ET tube\nDecreased compliance â†‘ â†‘ Normal airway Think lung!\nresistance but Mainstem intuba-\nIncreased PIP\nResistive pressure Maintains reduced lung tionâ€”Rx: Retract\nBaseline PIP difference compliance tube\nIncreased plateau pressure Atelectasisâ€”Rx:\nResistive pressure\nChest percussion,\nBaseline plateau pressure\nbronchoscopy\nPulmonary edemaâ€”\nRx: Diuretics\nARDSâ€”Rx: Low tidal\nvolume/high PEEP\nventilation strategy\nPneumothoraxâ€”Rx:\nChest tube\nPneumonia\nIllustrations reproduced with permission from USMLE-Rx.com\nâ–  Decreased venous return: High levels of PEEP cause increased intratho-\nracic pressure and decreased venous return. This may cause or exacerbate\nhypotension.\nâ–  Sedatives and opioids used in ventilated patients may cause hypotension.\nCORONAVIRUSES AND COVID-19\nRNA viruses that can infect animals and humans. Global outbreaks of severe\ndisease have been caused by coronaviruses, including the severe acute respira-\ntory syndrome coronavirus (SARS-CoV) outbreak of 2002 and the Middle\nEast respiratory syndrome coronavirus (MERS-CoV) outbreak of 2012. SARS-\nCoV-2 emerged in December 2019, and this led to the COVID-19 pandemic. A 25-year-old man in the intensive\nThe first cases were reported in Wuhan, China",
      "char_start": 1802000,
      "char_end": 1804000
    },
    {
      "chunk_id": 902,
      "text": ". A detailed discussion of care unit (ICU) is intubated, following\nan acute asthma exacerbation. A\nCOVID-19 follows.\nrepeat ABG is sent after intubation\nand shows a pH of 7.5, a Paco2 of\nPathogenesis 33 mm Hg, and an HCOâ€“ of 26 mEq/L.\n3\nThe pathogenesis of COVID-19 involves an exaggerated inflammatory What adjustments, if any, should\nthe physician make to the ventilator\nresponse to viral infection (cytokine storm syndrome [CSS]). CSS may result\nsettings?\nin fever, multiorgan dysfunction, cardiac and renal injury, and ARDS.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664411 1100//2211//2222 44::2244 PPMM\n\n642 HIGH-YIELD FACTS IN PULMONARY\nHistory/PE\nTABLE 2.14-10. Ventilator Setting\nAdjustments Based on ABG\nAbnormalities â–  The virus is spread by respiratory droplets and has an incubation period of\n2 to 14 days (average of 5 days).\nABG VENTILATOR\nâ–  Clinical presentation ranges from asymptomatic or mildly symptomatic to\nABNORMALITY ADJUSTMENT\nsevere and life-threatening disease.\nâ†“ Pao2 â†‘ PEEP or â†‘ Fio2 â–  Patients with mild infection may present with fever and upper respiratory\ntract symptoms such as cough, sore throat, and nasal congestion. Anosmia\nâ†“ Paco2 â†“ respiratory rate or and ageusia (loss of smell and taste, respectively) are common. Addition-\nally, GI symptoms, such as nausea, vomiting, and diarrhea, are also\nâ†“ tidal volume\nreported with COVID-19.\nâ†‘ Paco2 â†‘ respiratory rate or â–  More serious infections may result in dyspnea, respiratory failure, ARDS,\nshock, or multiorgan dysfunction syndrome.\nâ†‘ tidal volumea\nâ–  Thromboembolic events (such as pulmonary embolism) may occur.\naPreferable to adjust RR over tidal volume\nin situations where low tidal volume Diagnosis\nventilation is beneficial (ie, ARDS).\nâ–  Most sensitive test: Nucleic acid amplification test ([NAAT] also known\nas reverse transcription quantitative polymerase chain reaction [RT-PCR])\nof nasopharyngeal samples. Rapid antigen testing has lower sensitivity;\nh",
      "char_start": 1804000,
      "char_end": 1806000
    },
    {
      "chunk_id": 903,
      "text": "owever, point-of-care testing allows for immediate results and communi-\ncation of advice so patients can isolate and monitor sooner.\nâ–  CXR may show bilateral opacities. CT may show multifocal, bilateral,\nperipheral ground-glass opacities (often affecting the posterior portion of\nthe lower lobes), consolidation, and air bronchograms (Fig. 2.14-11).\nâ–  Laboratory findings: Abnormal blood counts (eg, lymphopenia [most com-\nmon laboratory finding], thrombocytopenia), coagulation studies (eg,\nâ†‘ d-dimer), inflammatory markers (eg, â†‘ C-reactive protein [CRP]), and\nother biochemical tests (eg, â†‘ lactate dehydrogenase [LDH], â†‘ alanine ami-\nnotransferase [ALT], â†‘ aspartate aminotransferase [AST], â†‘ creatinine) are\ncommonly seen in hospitalized patients.\nTreatment\nMild cases can be managed at home with isolation, monitoring, and symp-\nFIGURE 2.14-11. CT angiogram of chest tomatic treatment (eg, antipyretics, analgesics, antitussives, hydration).\nin COVID-19 pneumonia shows dense Patients with mild to moderate COVID-19 at high risk for progression to\nright lower lobe and left lower lobe severe disease may be treated with neutralizing antibodies or antivirals. For\nopacities and air bronchograms. (Repro-\nsevere cases, inpatient care is needed.\nduced with permission from USMLE-Rx.com, courtesy\nof Dr. Arjun Iyer.)\nPrevention\nâ–  Personal preventive strategies: Social distancing (maintaining distance of\n6 feet, avoiding crowds), mask wearing, handwashing, use of hand sani-\ntizer, reducing hand-to-face contact, good ventilation.\nâ–  Strategies by healthcare personnel: Personal protective equipment\n([PPE], gowns, gloves, eye protection) while caring for patients with\nCOVID-19. For aerosol-generating procedures, an N95 mask must be\nused.\nâ–  Vaccines: Reduce severity of illness.\nThis patient has an uncompensated\nrespiratory alkalosis caused by â†‘\nventilation. To â†“ ventilation, tidal\nvolume can be â†“ or respiratory rate\ncan be slowed; however, reducing\nthe tidal volume can trigger an â†‘ in\nventil",
      "char_start": 1806000,
      "char_end": 1808000
    },
    {
      "chunk_id": 904,
      "text": "atory rate, exacerbating the\nsituation.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664422 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 643\nPULMONARY VASCULAR DISEASE\nPULMONARY HYPERTENSION/COR PULMONALE\nâ–  Pulmonary hypertension (PH): Elevated mean pulmonary arterial pres-\nsure (>20 mm Hg) at rest\nâ–  Classified into the following groups:\nâ–  Group 1: Pulmonary arterial hypertension (PAH)\nâ–  Group 2: â†‘ pulmonary venous pressure from left-sided heart disease\nâ–  Group 3: Hypoxic vasoconstriction secondary to chronic lung disease\nâ–  Group 4: Chronic thromboembolic disease\nâ–  Group 5: Pulmonary hypertension with a multifactorial etiology\nâ–  Core pulmonale (group 3): Alteration in structure and function of the\nright ventricle (RV) of the heart caused by a primary disorder of the respi-\nratory system. Right-sided heart failure can occur in severe cases.\nHistory/PE KEY FACT\nâ–  Presents with dyspnea, syncope on exertion, fatigue, lethargy, chest pain, Other etiologies of embolic disease\nand/or symptoms of right-sided congestive heart failure (CHF) (edema,\ninclude postpartum status (amniotic\nabdominal distention, JVD)\nfluid emboli), fracture (fat emboli),\nâ–  Hx: COPD, ILD, heart disease, sickle cell anemia, emphysema, and pul- cardiac surgery (air emboli), and\nmonary embolism\nendovascular procedure (cholesterol\nâ–  PE: Loud, palpable S 2 (often split), a flow murmur, an S 4 , or a parasternal emboli).\nheave; patient may also be hypoxemic, especially on exertion\nDiagnosis\nâ–  Best initial test: Echocardiogram that estimates pulmonary artery (PA)\npressure and assesses RV function\nâ–  CXR: Shows enlargement of central pulmonary arteries with rapid taper-\ning of the distal vessels (pruning)\nâ–  ECG: Demonstrates right ventricular hypertrophy (RVH)\nâ–  Diagnostic test of choice: Right heart catheterization; mean pulmonary\nartery pressure >20 mm Hg (normal: 8â€“20 mm Hg)\nTreatment\nâ–  Treat underlying disease.\nâ–  Supportive therapy: Supplement",
      "char_start": 1808000,
      "char_end": 1810000
    },
    {
      "chunk_id": 905,
      "text": "al O , diuretics; some patients may also\n2\nbenefit from exercise therapy\nâ–  Consider digoxin and anticoagulation in patients with underlying left ven-\ntricle systolic dysfunction and atrial fibrillation\nâ–  Group 1 (primary PAH): Prostanoids (eg, beraprost, epoprostenol, ilo-\nprost, treprostinil), endothelin receptor antagonists (eg, ambrisentan,\nbosentan, and macitentan), and phosphodiesterase (PDE) inhibitors (eg,\nsildenafil, tadalafil, vardenafil) can be added to improve hemodynamics\nand increase exercise tolerance. Some patients have vasoreactivity and\nrespond well to calcium channel blockers\nâ–  Group 4 (thromboembolic disease): Surgical thromboendarterectomy;\nanticoagulation is recommended for everyone; balloon pulmonary angio-\nplasty and riociguat are the alternatives for chronic thromboembolic pul-\nmonary hypertension (CTEPH)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664433 1100//2211//2222 44::2244 PPMM\n\n644 HIGH-YIELD FACTS IN PULMONARY\nTABLE 2.14-11. Virchow Triad for Venous Thrombosis\nVENOUS STASIS ENDOTHELIAL INJURY HYPERCOAGULABILITY\nImmobility Trauma Pregnancy, postpartum\nCHF Surgery Cigarette smoking\nObesity Recent fracture Oral contraceptive pill (OCP) use\nâ†‘ central venous pressure Previous DVT Coagulation disorders (eg, protein C/\nMNEMONIC (eg, renal failure) protein S deficiency, factor V Leiden)\nMalignancy\nWells criteriaâ€”Consider when\nSevere burns\nthe history and physical exam are\nsuggestive of DVT to assess the risk\nof pulmonary embolism\nSHIT PMH\nPULMONARY THROMBOEMBOLISM\nSymptoms of DVT: 3 points\nHistory of DVT or PE: 1.5 points\nImmobilization (â‰¥3 days): 1.5 points An occlusion of the pulmonary vasculature by a blood clot. Ninety-five per-\nTachycardia (HR >100/min): 1.5 points cent of emboli originate from deep venous thrombosis (DVT) in the deep leg\nPostop (surgery within previous 4 weeks): veins (eg, femoral vein). May lead to pulmonary infarction, right heart failure,\n1.5 points and hypoxemia.\nMali",
      "char_start": 1810000,
      "char_end": 1812000
    },
    {
      "chunk_id": 906,
      "text": "gnancy: 1 point\nHemoptysis: 1 point History/PE\nTotal point value = 11\nâ–  Factors predisposing to thromboembolism are summarized by the Virchow\ntriad (see Table 2.14-11).\nâ–  Presents with sudden-onset or subacute dyspnea, pleuritic chest pain, low-\ngrade fever, cough, tachypnea, tachycardia, and rarely, hemoptysis (indi-\nMNEMONIC\ncates pulmonary infarction).\nVIRchow triadâ€”risk factors for â–  May have history of immobility (eg, long plane ride, bedbound)\nvenous thrombosis: â–  Examination that may reveal a loud P 2 and prominent jugular A waves\nwith right heart failure.\nVascular trauma\nIncreased coagulability â–  Acute massive pulmonary embolism: Presents with hypotension, JVD, and\nnew-onset right bundle branch block.\nReduced blood flow (stasis)\nDiagnosis\nâ–  Best initial step: Calculation of modified Wells score (Table 2.14-12)\nâ–  Pulmonary embolism unlikely (modified Wells score â‰¤4):\nâ–  Best initial test: d-dimer used to rule out pulmonary embolism; high\nnegative predictive value and sensitivity; not specific. If â†‘ d-dimer\n(â‰¥500 ng/mL) â†’ CT of chest with contrast (or V/Q scan if unable to\nobtain CT with contrast). If normal d-dimer â†’ pulmonary embolism\nexcluded.\nâ–  Pulmonary embolism likely (modified Wells score >4):\nâ–  Best initial test: CT of chest with contrast high sensitivity and specific-\nity (see Fig. 2.14-12)\nâ–  Ventilation/perfusion (V/Q) scan: Used when CT scan is contraindicated\n(â†‘ creatinine [(Cr) relative contraindication to contrast], pregnancy [con-\ntraindication to radiation]). May reveal areas of V/Q mismatch to predict\nFIGURE 2.14-12. Pulmonary embolus. low, indeterminate, or high probability of pulmonary embolism. A V/Q\nAxial slice from a CT pulmonary\nscan is sensitive for pulmonary embolism but not specific, especially if\nangiogram shows a filling defect of the\nangiogram dye that corresponds to a pul- there is underlying lung disease.\nmonary embolus (red arrow) extending â–  ABGs: Respiratory alkalosis caused by hyperventilation (â†“ Pao\n2\nfrom the main pulmonary ",
      "char_start": 1812000,
      "char_end": 1814000
    },
    {
      "chunk_id": 907,
      "text": "artery into the [<80 mm Hg], â†“ Paco ).\n2\nright and left pulmonary arteries, con-\nâ–  CXR: May appear normal or show atelectasis, pleural effusion, Hampton\nsistent with a saddle embolus. (Reproduced\nhump (a wedge-shaped infarct), or Westermark sign (oligemia/collapse of\nwith permission from Chen MY et al. Basic Radiology,\nvessels seen distal to pulmonary embolism).\n2nd ed. New York, NY: McGraw-Hill; 2011.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664444 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 645\nTABLE 2.14-12. Modified Wells Criteria for Pulmonary Embolism\nCRITERIA POINTS\nSigns/symptoms of DVT 3\nPulmonary embolism most likely clinical diagnosis 3\nTachycardia (heart rate >100/min) 1.5\nImmobilization (â‰¥3 days) or surgery in last month 1.5\nPrevious pulmonary embolism/DVT 1.5\nHemoptysis 1\nMalignancy 1\nTRADITIONAL CLINICAL PROBABILITY ASSESSMENT\nHigh >6\nModerate 2â€“6\nLow <2\nSIMPLIFIED CLINICAL PROBABILITY ASSESSMENT\nPulmonary embolism likely >4\nPulmonary embolism unlikely â‰¤4\nâ–  ECG: Most commonly reveals sinus tachycardia. The classic triad of\nKEY FACT\nS1Q3T3 is rare (acute right heart strain with an S wave in lead I, a Q wave\nin lead III, and an inverted T wave in lead III). Dyspnea, tachycardia, and a normal\nâ–  Lower extremity venous ultrasound: Specific and sensitive for DVT, CXR in a hospitalized and/or bedridden\nwhich may be the cause of the pulmonary embolism. patient should raise suspicion of PE.\nTreatment\nâ–  Anticoagulation: See Figure 2.14-13.\nâ–  Acute: Unfractionated heparin, subcutaneous low-molecular-weight hepa-\nrin (LMWH), subcutaneous fondaparinux, or direct oral anticoagulants\n(rivaroxaban, apixaban). In patients with high probability of pulmonary\nembolism, anticoagulation should be given before confirmatory testing.\nPatients with renal failure require unfractionated heparin or apixaban.\nâ–  Chronic: LMWH, direct oral anticoagulants (preferred), or warfarin (goal\nfor international normalized r",
      "char_start": 1814000,
      "char_end": 1816000
    },
    {
      "chunk_id": 908,
      "text": "atio [INR] = 2â€“3). Use LMWH in preg-\nnancy (warfarin is contraindicated).\nâ–  Inferior vena cava (IVC) filter: Indicated in patients with a documented\nlower extremity DVT/pulmonary embolism if anticoagulation is contrain-\ndicated or if patients experience recurrent emboli while on therapeutic\ndoses of anticoagulation.\nâ–  Thrombolysis: Indicated in cases of massive pulmonary embolism causing\nright heart failure and hemodynamic instability (saddle pulmonary\nembolism).\nâ–  DVT prophylaxis: Treatment for all immobile patients. The physician\nshould prescribe subcutaneous heparin or low-dose LMWH, early ambu-\nlation (most effective), and intermittent compression of the lower extremi-\nties (less effective).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664455 1100//2211//2222 44::2244 PPMM\n\n646 HIGH-YIELD FACTS IN PULMONARY\nAnticoagulation in suspected PE\nContraindication to anticoagulation? a\nYes No\nDiagnostic evaluation Clinical suspicion of PEb\nPE confirmed PE excluded High Moderate/low\nNo further Start emperic Diagnosticc\nIVC filter\nevaluation anticoagulation evaluation\nPE confirmed PE excluded\nNo anticoagulation\nStart/continue\n(discontinue if started\nanticoagulation\nempirically)\nKEY FACT\nFIGURE 2.14-13. Guide to anticoagulation in hemodynamically stable patients with a sus-\nLung nodule clues based on history: pected pulmonary embolism (PE). aContraindications to anticoagulation include recent\nâ–  Recent immigrantâ€”think TB surgery, hemorrhagic stroke, active bleeding (eg, GI bleed), and aortic dissection. bClinical\nâ–  From the Southwestern United suspicion of pulmonary embolism is determined using the modified Wells criteria: High >6,\nmoderate 2 to 6, low <2. cIf diagnostic evaluation cannot be completed within 4 hours, start\nStatesâ€”think coccidioidomycosis\nempiric anticoagulation. (Modified with permission from USMLE-Rx.com.)\nâ–  From the Ohio River Valleyâ€”think\nhistoplasmosis or blastomycosis\nNEOPLASMS OF THE LUNGS\nSOLITARY PULMONAR",
      "char_start": 1816000,
      "char_end": 1818000
    },
    {
      "chunk_id": 909,
      "text": "Y NODULES\nCommonly found on CXR. History, physical exam, and imaging features help\nguide treatment (see Table 2.14-13).\nHistory/PE\nâ–  Often asymptomatic; may present with chronic cough, dyspnea, and short-\nness of breath.\nâ–  Necessary to always inquire about smoking and exposure history, which\nare associated with â†‘ cancer risk.\nDiagnosis and Treatment\nBest initial test: CT of the chest. The physician should obtain a noncontrast\nCT of the chest if a nodule was discovered on another modality (Fig. 2.14-14).\nâ–  If a nodule has fat or calcifications characteristic of a benign lesion (eg,\nhamartoma, granuloma), no further evaluation is required.\nâ–  If a nodule does not have characteristics of a benign lesion, the next step is\nto review the medical record for a previous CT (if available).\nâ–  If the nodule is old and the size is stable (>2 years), no further evaluation\nis required.\nâ–  If the nodule is new, increasing in size, or no prior CT scans are available,\nthen determine risk for malignancy.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664466 1100//2211//2222 44::2244 PPMM\n\nTABLE 2.14-13. Risk for Malignancy in Patients With Solitary Pulmonary Nodules\nVARIABLE LOW INTERMEDIATE HIGH\nDiameter of nodule (mm) <8 8â€“20 â‰¥20\nAge (years) <45 45â€“60 >60\nSmoking history? Never Yes Yes\nYears since smoking cessation >15 5â€“15 <5\nNodule characteristics Smooth Scalloped Corona radiata or\nspiculated\nCalcification Central, uniform, â€“ Absent or irregular\nor popcorn calcification\ncalcification\nDetermine risk for malignancy\nBenign Low to\nHigh\nfeatures intermediate\nSurgical\nSerial CT scans\nresection\nDetermine\nnodule size\n5-7 mm\nMalignancy risk PET or biopsy\nMNEMONIC\nSquamous and Small cell cancers are\nSentral lesions\nNo further SSuurrggiiccaall\nSerial CT scans\nevaluation rreesseeccttiioonn\nFIGURE 2.14-14. Evaluation of solitary pulmonary nodule detected on CT scan. (Reproduced with\nMNEMONIC\npermission from USMLE-Rx.com.)\nLung cancer metastases are oft",
      "char_start": 1818000,
      "char_end": 1820000
    },
    {
      "chunk_id": 910,
      "text": "en\nâ–  Low risk: Serial CT scans. found in LABBsâ€”\nâ–  Intermediate risk: Further investigation required with biopsy or posi- Liver\ntron emission tomography (PET). Adrenals\nâ–  High risk: Surgical resection. Brain\nBone\nLUNG CANCER\nThe leading cause of cancer death in the United States. Risk factors include\ntobacco smoke (except for bronchioalveolar carcinoma) and radon or asbestos\nexposure. Types are as follows (see also Table 2.14-14):\nA 25-year-old woman presents with\ndyspnea, chest pain, and leg pain. She\nHistory/PE\ntakes birth control pills regularly. She\nâ–  Presentation: Cough, hemoptysis, dyspnea, wheezing, pneumonia, chest returned from Asia 3 days ago. What is\npain, weight loss, and possible abnormalities on respiratory exam (crackles, the next step?\natelectasis)\n>â€“\nPULMONARY HIGH-YIELD FACTS IN 647\n4 mm â€“ >8 mm\nNo suspicion Suspicion\nLow Intermediate for malignancy for malignancy\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664477 1100//2211//2222 44::2244 PPMM\n\n648 HIGH-YIELD FACTS IN PULMONARY\nTABLE 2.14-14. Small Cell and Nonâ€“Small Cell Lung Cancers\nTYPE LOCATION CHARACTERISTICS HISTOLOGY\nSMALL CELL\nSmall cell (oat cell) Central Central location (Fig. 2.14-15 A and B) Neoplasm of neuroendo-\ncarcinoma Highly correlated with cigarette exposure crine Kulchitsky cells â†’\nUndifferentiated and very aggressive; patients have low median survival small, dark blue cells\nrate and a poor prognosis (Fig. 2.14-15 C)\nMetastases often found on presentation in intrathoracic and extratho- Chromogranin A âŠ•\nracic sites such as brain, liver, and bone\nAssociated with paraneoplastic syndromes (see Table 2.14-15); may\nproduce ACTH (Cushing syndrome), syndrome of inappropriate\nsecretion of ADH (SIADH), or Antibodies against presynaptic Ca2+\nchannels (Lambert-Eaton myasthenic syndrome) or neurons (para-\nneoplastic myelitis/encephalitis)\nRarely operable; treat with radiotherapy (for primary tumour at early\nstage, and to prevent/palliate brain m",
      "char_start": 1820000,
      "char_end": 1822000
    },
    {
      "chunk_id": 911,
      "text": "etastasis), chemotherapy (for\nmetastatic disease)\nNONâ€“SMALL CELL (LESS LIKELY THAN SCLC TO METASTASIZE AT AN EARLY STAGE)\nAdenocarcinoma Peripheral Most common lung cancer in female patients, nonsmokers, and overall Glandular pattern on his-\n(except for metastases); activating mutations include KRAS, EGFR, and tology, often stains mucin\nALK translocation âŠ• (Fig. 2.14-15 D)\nAssociated with hypertrophic osteoarthropathy (clubbing) Bronchioloalveolar subtype:\nBronchioloalveolar subtype (adenocarcinoma in situ): CXR often shows It grows along alveolar\nmultiple nodules, interstitial infiltration, and prolific sputum produc- septa, showing apparent\ntion (often confused with pneumonia); good prognosis, â†“ association â€œthickeningâ€ of alveolar\nwith smoking; patients have favorable prognosis walls\nSquamous cell Central Hilar mass arising from bronchus; cavitation; cigarettes; hypercalcemia Keratin pearls and intercel-\ncarcinoma (produces PTHrP) strongly associated with smoking lular bridges\nLarge cell carcinoma Peripheral High-grade neuroendocrine tumors sharing hallmarks of both small cell Pleomorphic giant cells\nand non-small cell lung cancers; poor prognosis; less responsive to\nchemotherapy; surgical removal\nBronchial carcinoid â€” Favorable prognosis; metastasis rare Nests of neuroendocrine\ntumor Symptoms usually caused by mass effect; occasionally carcinoid syn- cells; chromogranin A âŠ•\ndrome (5-hydroxytryptamine [HT] secretion â†’ flushing, diarrhea,\nwheezing)\nâ–  Superior sulcus tumors (Pancoast tumors): Tumor at the apex of the\nlung, adjacent to the subclavian vessels; presentation is dependent on\nThe next step is to treat with a which of the following structures are compressed:\nheparin bolus or low-molecular- â–  Brachial plexus: Shoulder pain (most common initial symptom) and\nweight heparin (LMWH). When arm pain (C8â€“T2 radicular pain)\nthere is high clinical suspicion (birth\nâ–  Paravertebral sympathetic chain and inferior cervical (stellate) gan-\ncontrol, history of long flight",
      "char_start": 1822000,
      "char_end": 1824000
    },
    {
      "chunk_id": 912,
      "text": ", multiple\nglion: Horner syndrome (miosis, ptosis, anhidrosis)\nsymptoms) for a DVT/PE, one should\nâ–  Superior vena cava (SVC) syndrome: Obstruction of the SVC with\ntreat first and follow with imaging (CT\nsupraclavicular venous engorgement and facial swelling (see Fig. 2.14-16)\nangiogram). With patients who have\nlower clinical suspicion, imaging is â–  Hoarseness: Secondary to recurrent laryngeal nerve involvement\nwarranted first before treatment. â–  Many paraneoplastic syndromes (see Table 2.14-15)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 664488 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 649\nA B C\nFIGURE 2.14-15. Histopathology and imaging of lung cancers. A, B, C: Small cell lung cancer. D\nNote the central location of the tumor in the posteroanterior (A) and lateral (B) x-rays of the\nchest. Histopathology shows clusters of round/oval cells with scant cytoplasm that frequently\nmold to the neighboring cell (C). Adenocarcinoma of lung: Histopathology (D) shows histol-\nogy of squamous cell carcinoma with prominent nucleoli, mitoses, and necrosis. (Images A and B\nreproduced with permission from Kantarjian HM et al. MD Anderson Manual of Medical Oncology. New York, NY: McGraw-\nHill; 2006. Image C reproduced with permission from Kanchustambham V, Saladi S, Patolia S, Stoeckel D. Spontaneous tumor\nlysis syndrome in small cell lung cancer. Cureus. 2017;9[2]:e1017. Published 2017 Feb 8. doi:10.7759/cureus.1017. Image D\nreproduced with permission from Wang JF, Wang B, Jansen JA, et al. Primary squamous cell carcinoma of lung in a 13-year-\nold boy: a case report. Cases J. 2008 Aug 22;1(1):123. doi: 10.1186/1757-1626-1-123.)\nDiagnosis\nâ–  Best initial test: CXR or CT of the chest\nâ–  If initial test raises suspicion for malignancy, the physician should obtain a\ntissue sample next\nâ–  Most accurate tests: Fine-needle aspiration (CT guided) for peripheral\nlesions and bronchoscopy (biopsy or brushing) for central lesions\nâ– ",
      "char_start": 1824000,
      "char_end": 1826000
    },
    {
      "chunk_id": 913,
      "text": " Once diagnosis established, PET/CT is done for staging.\nTreatment\nTreatment of small cell lung cancer (SCLC) and nonâ€“small cell lung cancer\n(NSCLC) varies according to the stage. Early-stage diseases require surgery\nwith or without neoadjuvant/adjuvant therapy (chemotherapy, immunother-\napy, radiotherapy).\nGiven prior to surgery, neoadjuvant therapy aims to decrease the size of a\ntumor. Adjuvant therapy is given right after surgery to decrease chances for\nFIGURE 2.14-16. SVC syndrome. Promi-\nresidual disease. nent JVD is seen in SVC syndrome\nFor advanced-stage disease, systemic therapy is the best recommended secondary to obstruction of the SVC by a\napproach. For some inoperable tumours (Stage III) or in patients unfit for sur- central malignant lesion. (Reproduced with\ngery, chemotherapy and radiation alone may sometimes be curative. The regi- permission from Tintinalli JE et al. Tintinalliâ€™s Emergency\nMedicine: A Comprehensive Study Guide, 7th ed. New\nmens of systemic therapies differ according to the histology, but the principles\nYork, NY: McGraw-Hill; 2011.)\nremain the same.\nTypes of systemic therapies include:\nâ–  Chemotherapy: Aims to kill rapidly dividing cells. It is an imprecise way\nof preventing cancer growth. However, chemotherapy prevents growth of\nnot only cancer cells but also normal cells of the GI tract and others. It\nA 65-year-old patient with a 30-pack-\ncan therefore cause adverse events such as diarrhea, nausea, and hair loss.\nyear history presents with a 2-week\nâ–  Targeted therapy: Aims to block cancer cells harboring a driver mutation history of facial swelling. CT imaging\n(eg, EGFR mutation or ALK translocation).\nreveals a hilar mass and biopsy\nâ–  Immunotherapy: Aims to activate the immune system to fight cancer reveals SCLC. What is the next step in\ncells. Examples are immune checkpoint inhibitors (eg, anti-programmed treatment?\ndeath [PD]-1 inhibitors, antiâ€“programmed death-ligand 1 [PD-L1]\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarry",
      "char_start": 1826000,
      "char_end": 1828000
    },
    {
      "chunk_id": 914,
      "text": "y__1111ee__662255--667744..iinndddd 664499 1100//2211//2222 44::2244 PPMM\n\n650 HIGH-YIELD FACTS IN PULMONARY\nTABLE 2.14-15. Paraneoplastic Syndromes of Lung Cancer\nCLASSIFICATION SYNDROME HISTOLOGIC TYPE\nEndocrine/metabolic Cushing syndrome (ACTH) Small cell\nSIADH leading to hyponatremia Small cell\nHypercalcemia (parathyroid hormoneâ€“related Squamous cell\nprotein [PTHrP]) Large cell\nGynecomastia\nSkeletal Hypertrophic pulmonary osteoarthropathy Nonâ€“small cell\n(including digital clubbing)\nNeuromuscular Peripheral neuropathy Small cell\nSubacute cerebellar degeneration Small cell\nMyasthenia (Lambert-Eaton syndrome) Small cell\nDermatomyositis All\nCardiovascular Migratory thrombophlebitis Adenocarcinoma\nNonbacterial verrucous endocarditis Adenocarcinoma\nHematologic Anemia All\nDisseminated intravascular coagulation (DIC) All\nEosinophilia All\nThrombocytosis All\nHypercoagulability All\nCutaneous Acanthosis nigricans All\ninhibitors, and anti-cytotoxic T-lymphocyteâ€“associated antigen 4 [anti-\nCTLA-4]). PD-1 and CTLA4 are checkpoint regulators present on\nimmune cells. When PD-1 is bound to its ligands (present on the cancer\ncells), it prevents activation of the immune system.\nRESPIRATORY TRACT INFECTIONS\nNote: Epiglottitis, laryngotracheobronchitis, and bronchiolitis are mostly seen\nin infantsâ€”please refer to the Pediatrics chapter for a discussion of these\nentities.\nPNEUMONIA\nBacterial, fungal, or viral infection of the parenchyma of the lung.\nHistory/PE\nLiving conditions and social history in the weeks preceding presentation,\ncomorbidities, and history of hospitalizations can all give important clues to\ndetermine the most likely pathogens.\nâ–  Classic presentation: Acute onset of fever, productive cough (purulent\nyellow-green sputum or hemoptysis), dyspnea, night sweats, and pleuritic\nThe mainstay of therapy for SCLC is\nchest pain. Symptoms may be subtle in immunocompromised/older adult\nchemotherapy, which yields high\nrates of response. It is the next step in patients.\ntreatment.",
      "char_start": 1828000,
      "char_end": 1830000
    },
    {
      "chunk_id": 915,
      "text": " â–  Atypical presentations (gradual onset, dry cough, headaches, myalgias,\nsore throat, GI symptoms) can be seen with viral pneumonias and\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665500 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 651\nA B\nFIGURE 2.14-17. Lobar pneumonia.\nPosteroanterior (A) and lateral (B) CXRs\nof a 41-year-old man with cough and\nshortness of breath show a left lower lobe\nopacity consistent with lobar pneumonia.\nStreptococcus pneumoniae was confirmed\nby sputum Gram stain and culture. (Repro-\nduced with permission from USMLE-Rx.com.)\nTABLE 2.14-16. Causes of Pneumonia by Category\nCATEGORY ETIOLOGY\nTypical bacteria Streptococcus pneumoniae, H influenzae, Moraxella catarrhalis, Staphylo-\ncoccus aureus, group A Streptococcus\nAtypical bacteria Legionella, M pneumoniae, C pneumoniae, Chlamydia psittaci\nRespiratory viruses Influenza A and B, SARS-CoV-2 and other coronaviruses, rhinoviruses,\nparainfluenza viruses, adenoviruses\ninfections with fastidious organisms (Legionella pneumophila, Myco- MNEMONIC\nplasma pneumoniae, C pneumoniae).\nâ–  Lung examination may show â†“ or bronchial breath sounds, rales, wheez- CURB-65 score for pneumonia\nseverity\ning, dullness to percussion, egophony, and/or tactile fremitus.\nPneumonia hospitalization criteria: 3 to 4\nDiagnosis = consider inpatient treatment; >4 =\nconsider admission to ICU\nThe diagnosis of pneumonia is made in the setting of a suspicious clinical\nConfusion\ncontext and compatible chest imaging findings.\nUremia (blood urea nitrogen [BUN]\n>19 mg/dL)\nâ–  CXR is the best initial diagnostic test (see figure 2.14-17). If CXR does not\nRespiratory rate (>30 breaths/min)\nreveal clear infiltrate but suspicion for pneumonia is high, a noncontrast\nBlood pressure (systolic blood pressure\nCT of the chest can be obtained for more detailed visualization of the\n[SBP] <90 mm Hg or diastolic blood\nlung parenchyma.\npressure [DBP] <60 mm Hg)\nâ–  Severity of illness deter",
      "char_start": 1830000,
      "char_end": 1832000
    },
    {
      "chunk_id": 916,
      "text": "mines best management setting (inpatient vs outpa- Age >65 years\ntient) and recommended diagnostic workup. Routine bloodwork (CBC,\nmetabolic panel) should be obtained for all patients.\nâ–  For patients treated in the outpatient setting, influenza testing can be con-\nsidered if they are candidates for antiviral treatment with oseltamivir. Oth-\nerwise, no additional workup is needed unless there is failure to respond to\ninitial treatment or if there are risk factors for resistant organisms (recent\nA 70-year-old man presents to the\nhospitalization, structural lung disease).\nemergency department with 5 days\nâ–  For patients treated in the hospital, blood cultures and sputum Gram stain of fever, productive cough, and\n(see Fig. 2.14-18) and culture are indicated, as well as respiratory viral test- altered mental status. He is also found\ning, Legionella testing, and urine streptococcal antigen testing. to be hypotensive and tachypneic.\nâ–  Testing for â€œatypicalâ€ organismsâ€”those that are difficult to culture on Broad-spectrum antibiotics and\nstandard culture mediaâ€”can be considered if clinical suspicion is high. fluid resuscitation are promptly\nadministered, but the patient\nClinical and social context is important when trying to determine the most continues to be hypotensive. What is\nlikely pathogen in a patient with pneumonia. Common causes of pneumonia the next best step in treatment?\nare outlined in Tables 2.14-16 and 2.14-17 and illustrated in Figure 2.14-18.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665511 1100//2211//2222 44::2244 PPMM\n\n652 HIGH-YIELD FACTS IN PULMONARY\nA TABLE 2.14-17. Causes of Pneumonia by Risk Factors and Associated Conditions\nCONDITIONS ETIOLOGY\nAlcohol use disorder S pneumoniae, Klebsiella, Acinetobacter, oral anaerobes\nAspiration Enteric gram negatives and oral anaerobes\nCOPD H influenzae, Moraxella catarrhalis, S pneumoniae, Pseudomonas,\nLegionella\nExposure to animals Birds: Avian influenza, C psittac",
      "char_start": 1832000,
      "char_end": 1834000
    },
    {
      "chunk_id": 917,
      "text": "i. Birds or bats: Histoplasma cap-\nB\nsulatum. Rabbits: Francisella tularensis. Farm animals: Coxiella\nburnetiid\nHIV S pneumoniae, H influenzae, Mycobacterium tuberculosis (partic-\nularly in early infection), Pneumocystis jirovecii, Cryptococcus,\nHistoplasma, Aspergillus, atypical mycobacteria, Pseudomonas\nRecent travel Hotel or cruise: Legionella. Southwest United States: Hantavirus,\nCoccidioides. Southeast/East Asia: Burkholderia pseudomallei.\nFIGURE 2.14-18. Common pathogens Middle East: MERS coronavirus\ncausing pneumonia. (A) Staphylococ-\ncus aureus. These clusters of gram âŠ• Structural lung disease Pseudomonas, Burkholderia cepacia, S aureus\ncocci were isolated from the sputum of a\npatient who developed pneumonia while\nPostviral Staphylococcus, S pneumoniae, H influenzae\nhospitalized. (B) Streptococcus pneu-\nmoniae. Sputum sample from a patient\nwith pneumonia. Note the characteristic Injection drug use S aureus, anaerobes, Mycoplasma tuberculosis, S pneumoniae\nlancet-shaped gram âŠ• diplococci. Image A\nreproduced with permission from Dr. Richard Facklam, Endobronchial obstruction S pneumoniae, H influenzae, S aureus, anaerobes\nCenters for Disease Control and Prevention, Atlanta,\nGA. Image B reproduced with permission from Dr.\nMike Miller, Centers for Disease Control and Preven-\ntion, Atlanta, GA.\nTreatment\nKEY FACT\nEmpiric antibiotic choice is also determined by illness severity and local anti-\nThe pneumococcal vaccine should be biotic sensitivity. If a specific pathogen is identified in diagnostic testing, anti-\ngiven to all children and to patients biotic therapy should then be tailored to target it.\n>65 years of age. Other indications for Immunocompromised patients and those with structural lung disease (bron-\npneumococcal vaccine include chronic chiectasis, CF) have a higher risk of developing Pseudomonas pneumoniaâ€”con-\nheart/lung/liver disease, chronic renal sider activity against this pathogen by using an antipseudomonal Î²-lactam (eg,\nfailure, diabetes, cigar",
      "char_start": 1834000,
      "char_end": 1836000
    },
    {
      "chunk_id": 918,
      "text": "ette smoking, piperacillin-tazobactam) plus either a respiratory fluoroquinolone or a macrolide.\nasplenia, immunocompromise A summary of the recommended best initial treatment for pneumonia is\n(congenital immunodeficiency, given in Table 2.14-18.\nmalignancy), asplenia, cerebrospinal\nfluid (CSF) leaks, and cochlear implants. INFLUENZA\nA highly contagious orthomyxovirus transmitted by droplet nuclei. There are\nthree types of influenza: A, B, and C. Subtypes of influenza A (eg, H5N1,\nH1N1) are classified based on glycoproteins (hemagglutinin [H] and neur-\nThe next best step in treatment aminidase [N]). Relevant terms are as follows:\nentails administration of vasopressors\nâ–  Antigenic drift: Refers to small, gradual changes in surface proteins\nand ICU admission. This patient is in\nthrough point mutations. These small changes are sufficient to allow the\nseptic shock, probably secondary\nvirus to escape immune recognition, accounting for why individuals can\nto pneumonia. Patients with\nbe infected with influenza multiple times.\npneumonia who require vasopressors\nor mechanical ventilation warrant â–  Antigenic shift: Describes an acute, major change in the influenza A sub-\nadmission to an ICU. type (significant genetic reassortment) circulating among humans. Leads\nto pandemics.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665522 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 653\nTABLE 2.14-18. Treatment of Pneumonia\nPATIENT TYPE SUSPECTED PATHOGENS EMPIRIC COVERAGE\nThose with outpatient community-acquired S pneumoniae, M pneumoniae, C pneumoniae, Amoxicillin, doxycycline, or macrolide (if\npneumonia, â‰¤65 years of age, otherwise H influenzae, viral local pneumococcal resistance is <25%)\nhealthy, no antimicrobials within 3 months\n>65 years of age or comorbidity (COPD, heart S pneumoniae, H influenzae, aerobic Combination of amoxicillin/\nfailure, renal failure, diabetes, liver disease, gram-negative rods ([GNRs], eg, E co",
      "char_start": 1836000,
      "char_end": 1838000
    },
    {
      "chunk_id": 919,
      "text": "li, clavulanate or cephalosporin + mac-\nethanol [EtOH] abuse) or antimicrobial use Enterobacter, Klebsiella), S aureus, Legionella, rolide or doxycycline OR respiratory\nwithin 3 months viruses fluoroquinolone monotherapy\nPatients with community-acquired pneumonia S pneumoniae, H influenzae, anaerobes, Respiratory fluoroquinolone OR Î²-lactam\nrequiring hospitalization aerobic GNRs, Legionella, Chlamydia + macrolide\nCommunity-acquired pneumonia requiring ICU S pneumoniae, Legionella, H influenzae, Î²-Lactam + macrolide OR Î²-lactam +\ncare anaerobes, aerobic GNRs, Mycoplasma, fluoroquinolone\nPseudomonas\nPatients with hospital-acquired pneumonia GNRs (including Pseudomonas and Acineto- Antipseudomonal agent to start\nbacter), S aureus, Legionella, mixed flora If structural lung disease is present, addi-\ntion of second antipseudomonal agent\nIf patient is critically ill (in shock or\nrequiring ventilatory support due to\npneumonia), the physician should use\ntwo antipseudomonal agents plus an\nanti-MRSA agent\nIn the United States, the typical influenza season begins in November and\nlasts until April. Yearly vaccination with inactivated influenza virus is cur-\nrently recommended for all patients â‰¥6 months of age. Children 6 months to\n8 years of age require two doses of the seasonal vaccine if they are receiving\nthe vaccine for the first time. A high-dose flu vaccine is available for people\nâ‰¥65 years of age or those who are immunocompromised.\nHistory/PE\nPatients typically present with abrupt onset of fever, myalgia, chills, cough,\ncoryza, and weakness. Older adult patients may have atypical presentations\ncharacterized only by confusion.\nDiagnosis\nâ–  Best initial test: Rapid influenza test of viral antigens from nasopharyn-\ngeal swab.\nâ–  Most accurate test: Diagnosis can be made with direct fluorescent anti-\nbody (DFA) tests, viral culture, or PCR assays. Rapid influenza tests have\nlow sensitivity, and influenza is usually a clinical diagnosis. Leukopenia is\na common finding.\nTreatmen",
      "char_start": 1838000,
      "char_end": 1840000
    },
    {
      "chunk_id": 920,
      "text": "t\nâ–  Analgesics and hydration provide symptomatic care.\nâ–  Antivirals such as oseltamivir or zanamivir are most effective when used\nwithin 2 days of onset and may shorten the duration of infection by 1 to\n3 days.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665533 1100//2211//2222 44::2244 PPMM\n\n654 HIGH-YIELD FACTS IN PULMONARY\nComplications\nSevere primary viral pneumonia with ARDS, secondary bacterial pneumonia\n(see â€œPostviralâ€ in Table 2.14-20), sinusitis, bronchitis, and exacerbation of\nCOPD and asthma can occur.\nASPERGILLOSIS\nA group of diseases caused by Aspergillus, typically Aspergillus fumigatus,\nthrough infection by spores. Aspergillus can be seen on silver stain as acutely\n(<45 degrees) branched septate hyphae.\nAllergic Bronchopulmonary Aspergillosis\nFIGURE 2.14-19. Chronic aspergilloma.\nIntracavitary mass with surrounding â€œair Hypersensitivity reaction seen in people with asthma or CF. Refer to the\ncrescentâ€. The mass may move with\nRestrictive Lung Disease section of this chapter.\nchange in posture. (Reproduced with permis-\nsion from Farid S, Mohamed S, Devbhandari M, et al.\nResults of surgery for chronic pulmonary aspergillosis, Aspergilloma\noptimal antifungal therapy and proposed high risk\nTypically discovered as an incidental radiographic finding in patients with\nfactors for recurrence: a national centreâ€™s experi-\npreexisting lung disease (eg, TB, COPD).\nence. J Cardiothorac Surg. 2013;8[180]. https://doi.\norg/10.1186/1749-8090-8-180.)\nâ–  Hx/PE: May be asymptomatic or present with hemoptysis. Fever and\ncough are less common.\nâ–  Dx: CXR or CT reveals a solid mass within a preexisting lung cavity (Fig.\n2.14-19). Laboratory tests are typically normal.\nâ–  Tx: Antifungals are not very effective. If symptomatic, curative surgical\nresection or embolization for hemoptysis can be pursued.\nChronic Necrotizing Pulmonary Aspergillosis\nRare, antibiotic-resistant pneumonia that occurs in patients with immunosup-\npression (eg",
      "char_start": 1840000,
      "char_end": 1842000
    },
    {
      "chunk_id": 921,
      "text": ", alcohol use disorder, steroid-dependent COPD).\nâ–  Hx/PE: Fever, cough, hemoptysis, night sweats, fatigue.\nâ–  Tx: Voriconazole (or other triazole); rarely surgical resection can be per-\nformed if localized and severe disease.\nInvasive Pulmonary Aspergillosis\nSevere, rapidly progressive infection that occurs in profoundly immunosup-\npressed patients (eg, chemotherapy, transplant). Infection begins in the respi-\nratory tract and then disseminates hematogenously (angioinvasion leading to\nseptic emboli).\nâ–  Hx/PE: Fever, cough, pleuritic chest pain, tachypnea/hypoxemia.\nâ–  Dx: Serum galactomannan assay. If negative but degree of suspicion is\nhigh, bronchoscopy with bronchoalveolar lavage sent for galactomannan\nand Aspergillus PCR or lung biopsy can be considered.\nâ–  Tx: Voriconazole (or other triazole) in addition to decreasing\nimmunosuppression.\nHISTOPLASMOSIS\nRisk factors include HIV/AIDS, spelunking (exploring caves), and exposure to\nbird or bat excrement, especially in the Ohio and Mississippi river valleys (see\nFig. 2.14-20).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665544 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 655\nBlastomycosis\nHistoplasmosis\nCoccidiodomycosis\nFIGURE 2.14-20. Geographic distribution of systemic fungal infection in the United States.\n(Reproduced with permission from Ryan KJ, Ray CG. Sherris Medical Microbiology, 5th ed. New York, NY: McGraw-Hill; 2010.)\nTABLE 2.14-18. Differential Diagnosis of Opportunistic Pulmonary Fungal Infections\nHISTOPLASMOSIS COCCIDIOIDOMYCOSIS BLASTOMYCOSIS\nDisseminated Hepatosplenomegaly, Meningitis, bone Meningitis; bone,\ndisease lymphadenopathy, lesions, abscesses, prostate, and skin\nnonproductive cough erythema nodosum lesions; ARDS\nDiagnosis Urine and serum polysac- PCR assay of bron- Culture showing\ncharide antigens choalveolar lavage broad-based\nand tissue samples budding yeast\nHistory/PE\nâ–  Primary exposure is often asymptomatic or causes a flulike ",
      "char_start": 1842000,
      "char_end": 1844000
    },
    {
      "chunk_id": 922,
      "text": "illness.\nâ–  Presentation may range from no symptoms to fulminant disease with pul-\nmonary and/or extrapulmonary manifestations.\nâ–  Fever, weight loss, hepatosplenomegaly, lymphadenopathy, nonproductive\ncough, palatal or tongue ulcers, and pancytopenia indicate disseminated\ninfection (most often within 14 days).\nâ–  The differential diagnosis includes atypical bacterial pneumonia, blasto-\nmycosis, coccidioidomycosis, tuberculosis (TB), sarcoidosis, pneumoconi-\nosis, and lymphoma (see Table 2.14-18).\nDiagnosis\nâ–  CXR shows diffuse nodular densities, focal infiltrate, cavity, and/or hilar\nlymphadenopathy (chronic infection is usually cavitary).\nâ–  Urine and serum polysaccharide antigen tests are the most sensitive for\nmaking the initial diagnosis of disseminated disease, monitoring response\nFIGURE 2.14-21. Histiocyte macrophage\nto therapy, and diagnosing relapse. Culture is also diagnostic (blood, spu- containing numerous yeast cells of\ntum, bone marrow, cerebrospinal fluid [CSF]). Histoplasma capsulatum (Giemsa stain).\nâ–  The yeast form is seen with special stains on biopsy (bone marrow, lymph (Adapted with permission from Dr. J.T. McClellan\nand the Centers for Disease Control and Prevention,\nnode, liver) or bronchoalveolar lavage (see Fig. 2.14-21).\nLexington, KY.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665555 1100//2211//2222 44::2244 PPMM\n\n656 HIGH-YIELD FACTS IN PULMONARY\nKEY FACT Treatment\nNocardia is a partially acid-fast, gram â–  Mild pulmonary disease or stable nodules: Treat supportively in the\nimmunocompetent host. Consider itraconazole.\nâŠ•, branching rod found in soil that\nis a common cause of lung and CNS â–  Chronic cavitary lesions: Give itraconazole for >1 year.\ninfection in immunocompromised â–  Severe acute pulmonary disease or disseminated disease: Liposomal\namphotericin B or amphotericin B for 14 days, followed by itraconazole\nhosts. Trimethoprim-sulfamethoxazole\nfor 1 year or longer. Lifelong maintenance thera",
      "char_start": 1844000,
      "char_end": 1846000
    },
    {
      "chunk_id": 923,
      "text": "py with daily itraconazole\n(TMP-SMX) is the treatment of choice\nmay be necessary.\n(see Fig. 2.14-22).\nCOCCIDIOIDOMYCOSIS\nA pulmonary fungal infection endemic to the Southwestern United States\n(Fig. 2.14-20). Can present as an acute or subacute pneumonia or as a flulike\nillness and may involve extrapulmonary sites, including bone, CNS, and skin\n(manifestations include erythema multiforme or erythema nodosum). The\nincubation period is 1 to 4 weeks after exposure. Pregnant, HIV âŠ• patients,\nand those of Filipino or African descent are at â†‘ risk for disseminated disease.\nHistory/PE\nFIGURE 2.14-22. Nocardia. Branching Patients present with fever, anorexia, headache, chest pain, cough, dyspnea,\nfilaments on acid-fast stain. (Modified arthralgias, and night sweats. Disseminated infection can present with menin-\nwith permission from Leli C et al. Fatal Nocardia gitis, bone lesions, and soft tissue abscesses.\nfarcinica bacteremia is diagnosed by matrix-assisted\nlaser desorption-ionization time of flight mass\nDiagnosis\nspectrometry in a patient with myelodysplastic syn-\ndrome treated with corticosteroids. Case Rep Med. â–  Serology is specific but not sensitive during the first 1 to 2 weeks after\n2013;2013:368637.)\ninfection. Repeat testing can increase sensitivity, and the disease can be\nconfirmed with immunodiffusion testing.\nâ–  PCR assays of respiratory specimens have been developed that are highly\nsensitive and specific.\nâ–  The physician should obtain bronchoalveolar lavage and fungal cultures\nof sputum, wound exudate, or other affected tissue. Cultures are usually\nonly obtained in hospitalized patients or patients with severe disease, and\ngrowth can take days to weeks.\nKEY FACT â–  Identification of Coccidioides immitis spherules can occur with hematoxy-\nlin and eosin (H&E) stain or other special sputum or tissue stains.\nConsider coccidioidomycosis in a â–  CXR findings may be normal or show infiltrates, nodules, cavities, medias-\npatient from the Southwestern United tinal or hil",
      "char_start": 1846000,
      "char_end": 1848000
    },
    {
      "chunk_id": 924,
      "text": "ar adenopathy, or pleural effusion.\nStates who presents with respiratory\ninfection. Pregnant and HIV âŠ• patients Treatment\nand those of Filipino and African\nâ–  Acute: PO fluconazole or itraconazole for mild infection. IV amphoteri-\ndescent are at â†‘ risk for disseminated\ncin B is only for severe or protracted primary pulmonary infection and dis-\ndisease.\nseminated disease, followed by PO azole therapy once stable.\nâ–  Chronic: No treatment needed for asymptomatic chronic pulmonary nod-\nules or cavities. Progressive cavitary or symptomatic disease usually\nrequires surgery plus long-term azole therapy for 8 to12 months.\nBLASTOMYCOSIS\nA fungal infection endemic to the central and southeastern United States,\nparticularly the Mississippi and Ohio river valleys.\nâ–  Hx/PE: Presents similarly to coccidioidomycosis and typically has extra-\npulmonary involvement in the bone, prostate, and skin.\nâ–  Dx: Serologic tests not sensitive enough. Culture is the only way to defini-\ntively diagnose, and a sputum smear will show broad-based budding yeast.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665566 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 657\nâ–  Tx: Treat symptomatic patients with itraconazole and consider inpatient\ntreatment with amphotericin B and intensive care unit (ICU) admission if\nthe condition is complicated by ARDS, meningitis, or other systemic\ninvolvement.\nMYCOBACTERIAL INFECTIONS\nTUBERCULOSIS\nInfection caused by Mycobacterium tuberculosis. Roughly 2 billion people are\ninfected with TB (global prevalence). In the United States, close to 10,000\nnew TB disease cases are identified per year.\nHistory/PE\nâ–  The physician should identify risk factors for TB in a patientâ€™s history,\nincluding history of travel to and from high-risk nations (particularly preva- KEY FACT\nlent in Southeast Asia and sub-Saharan Africa), homelessness, incarcera-\nManagement of the Mantoux\ntion, alcohol use disorder, IV drug use, HIV positivi",
      "char_start": 1848000,
      "char_end": 1850000
    },
    {
      "chunk_id": 925,
      "text": "ty, and employment in\ntuberculin skin test is the same\nhealthcare. Pre-existing lung disease, immunosuppression, and advancing\nfor patients regardless of Bacillus\nage are also risk factors.\nCalmetteâ€“GuÃ©rin (BGC) vaccination\nâ–  Most people who become infected with TB are asymptomatic (latent TB). status, but testing with interferon-\nSymptomatic patients can present as primary or secondary (ie, reactivation\ngamma release assays is preferred\nof latent) TB.\nfor those who have received the BCG\nâ–  Most cases of TB are confined to the lungsâ€”presenting signs include vaccine.\ncough, hemoptysis, dyspnea, pleuritic chest pain, fever, weight loss, night\nsweats, and fatigue. Extrapulmonary TB (more common in patients with\nHIV) spreads hematogenously and can affect any organ system.\nDiagnosis\nâ–  Latent disease (asymptomatic and previous exposure): Diagnose with a\nâŠ• tuberculin skin test ([TST], see Fig. 2.14-23) or interferon-gamma\nrelease assay (IGRA).\nâ–  Immunocompromised individuals with latent TB infection may have a âŠ\nTST (anergy).\nâ–  All patients with a âŠ• purified protein derivative (PPD) require evaluation\nwith a CXR to rule out active disease.\nâ–  Active disease: Mycobacterial culture of sputum (or blood/tissue for extra-\npulmonary disease) is the most accurate test but can take weeks to obtain.\nTuberculin skin test\nA 41-year-old woman returns to\nthe emergency department a week\nafter she was discharged for diabetic\n5-9 mm 10-14 mm â‰¥ 15 mm ketoacidosis treatment. Today\nshe complains of low-grade fever,\nPositive test if: HIV risk factors IV drug use All other patients tenderness, and swelling over her\nClose tuberculosis Residents of developing (no known risk factors) face and a persistent nasal discharge\ncontacts nations with occasional blood. Physical\nEvidence of TB on CXR Chronic illness examination demonstrates necrosis in\nPeople who live or work the left nasal turbinates and left eye\nin high-risk congregate\nproptosis. Specimens from the sinuses\nsettings (eg, homeless\nshelters, ",
      "char_start": 1850000,
      "char_end": 1852000
    },
    {
      "chunk_id": 926,
      "text": "nursing homes show broad, nonseptate hyphae.\nor correctional facilities) What is the next most appropriate\nstep in management?\nFIGURE 2.14-23. Purified protein derivative (PPD) interpretation. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665577 1100//2211//2222 44::2244 PPMM\n\n658 HIGH-YIELD FACTS IN PULMONARY\nA sputum acid-fast stain (see Fig. 2.14-24) can yield rapid preliminary\nresults. It is the best initial test, but it lacks sensitivity. Testing of three spec-\nimens, obtained 8 hours apart, is recommended. If stains are positive,\nNAAT and culture are recommended. If extrapulmonary TB is suspected,\nsamples should be sent from affected sites.\nâ–  The most common finding among typical hosts is a cavitary infiltrate in\nthe upper lobe on CXR (see Fig. 2.14-25), which may be accompanied by\ncalcification of one or more nearby lymph nodes (Ghon complex).\nâ–  Patients with HIV or those with primary TB may show lower lobe infil-\ntrates with or without cavitation.\nâ–  Multiple fine nodular densities distributed throughout both lungs are typical\nof miliary TB, which represents hematologic or lymphatic dissemination.\nTreatment\nAll cases (both latent and active) must be reported to local and state health\ndepartments. Respiratory isolation in a negative-pressure room should be insti-\ntuted if active TB is suspected, and all healthcare workers in contact with the\npatient should wear N95 masks. Treatment measures are as follows:\nâ–  Latent disease: For a âŠ• PPD without signs or symptoms of active disease,\nFIGURE 2.14-24. Tuberculosis. Note the treatment with rifampin for 4 months or with isoniazid (isonicotinic acid\nred color (â€œred snappersâ€) of tubercle\nhydrazide [INH]) plus either rifampin or rifapentine for 3 months. Alter-\nbacilli on acid-fast staining. (Reproduced\nnative regimens include INH for 6 months.\nwith permission from Milikowski C. Color Atlas of Basic\nHistopathology. Stamford, CT:",
      "char_start": 1852000,
      "char_end": 1854000
    },
    {
      "chunk_id": 927,
      "text": " Appleton & Lange; â–  Active disease: Directly observed multidrug therapy with a four-drug regi-\n1997.) men (INH, pyrazinamide, rifampin, ethambutol) for 2 months, followed\nby INH and rifampin for 4 months.\nMNEMONIC â–  High-yield side effects of TB medications:\nâ–  Ethambutol can cause optic neuritis.\nPatients with TB are RIPE for â–  INH can cause hepatitis, peripheral neuropathy (consider administer-\ntreatmentâ€”\ning pyridoxine concurrently to prevent this), and a lupus-like\nRifampin syndrome.\nIsoniazid â–  Pyrazinamide can lead to hyperuricemia or hepatitis.\nPyrazinamide â–  Rifampin turns body fluids orange.\nEthambutol\nNONTUBERCULOUS MYCOBACTERIA\nThese organisms can cause a spectrum of disease, particularly in immuno-\ncompromised hosts.\nâ–  Mycobacterium avium complex (MAC): Can cause cavitary lung disease\nclassically in older patients with underlying chronic lung disease (COPD,\nCF). Disseminated disease is classically seen in people with HIV and a\nCD4+ cell count <50 ÂµL. Mycobacterium kansasii can also cause cavitary\nlung disease under similar conditions.\nâ–  Other mycobacteria (M marinum, M abscessus, M ulcerans, M chelonae)\ncan be isolated in chronic, nonhealing wounds.\nUbiquitous organisms cause pulmonary and disseminated infection in sev-\neral demographic groups. The primary pulmonary form occurs in apparently\nThe next most appropriate step healthy nonsmokers (Lady Windermere syndrome); a secondary pulmonary\nin management involves surgical form affects patients with preexisting pulmonary disease such as COPD, TB,\ndebridement and amphotericin B. or CF. Disseminated infection occurs in AIDS patients with a CD4+ cell\nThe patient has mucormycosis, a count <50/mm3 who are not on highly active antiretroviral therapy (HAART).\ndangerous and aggressive infection\nfound in patients who are diabetic History/PE\nand immunocompromised.\nAggressive surgical debridement is â–  Disseminated M. avium infection in AIDS is associated with fever, weight\nwarranted. loss, diarrhea, and severe anemia",
      "char_start": 1854000,
      "char_end": 1856000
    },
    {
      "chunk_id": 928,
      "text": " in patients who are not on HAART or\nchemoprophylaxis for MAC.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665588 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 659\nâ–  Hepatosplenomegaly and lymphadenopathy are occasionally seen. A\nâ–  Adrenal insufficiency is possible in the setting of adrenal infiltration.\nDiagnosis\nâ–  The physician should obtain mycobacterial blood cultures (âŠ• in 2â€“3 weeks).\nâ–  Labs show anemia, hypoalbuminemia, and â†‘ serum alkaline phosphatase\nand LDH.\nâ–  Biopsy of lung, bone marrow, intestine, or liver reveals foamy macro-\nphages with acid-fast bacilli (AFB). Typical granulomas may be absent in\nimmunocompromised patients.\nTreatment\nTreat with macrolide (clarithromycin or azithromycin) + ethambutol Â± rifab-\nB\nutin and consider HAART if the patient is drug-naive. Continue for\n>12 months and until CD4+ cell count >100/mm3 for >6 months.\nPrevention\nRoutine MAC prophylaxis is no longer recommended for HIV patients with\nCD4+ cell counts <50 and on HAART. Those not on HAART should\nreceive chemoprophylaxis with azithromycin.\nPNEUMOCYSTIS JIROVECII PNEUMONIA\nFormerly known as Pneumocystis carinii pneumonia (PCP). Risk factors\ninclude impaired cellular immunity and AIDS.\nHistory/PE\nFIGURE 2.14-25. Pulmonary TB. (A)\nPresents with dyspnea on exertion, fever, nonproductive cough, tachypnea,\nRight apical opacity with areas of cavita-\nweight loss, fatigue, and impaired oxygenation. Subacute (weeks) with AIDS. tion (arrow) is seen in an older adult\nAcute respiratory failure with immunosuppressive therapy. Can also present as patient with reactivation TB. (B) Coned-\ndisseminated disease or as local disease in other organ systems. The differential in view of CXR in a young man with\nmiliary TB shows innumerable 1- to\ndiagnosis includes TB, viral pneumonia, histoplasmosis, and coccidioidomycosis.\n2-mm pulmonary nodules. (Image A repro-\nduced with permission from Halter JB et al. Hazzardâ€™s\nDiagnosis\nGeriatric ",
      "char_start": 1856000,
      "char_end": 1858000
    },
    {
      "chunk_id": 929,
      "text": "Medicine and Gerontology, 6th ed. New York,\nâ–  Diagnosed by cytology of induced sputum or bronchoscopy specimen with NY: McGraw-Hill; 2009. Image B reproduced with\npermission from USMLE-Rx.com.)\nsilver stain and immunofluorescence (see Fig. 2.14-26A). Obtain an ABG\nto check Pao .\n2\nB\nA\nFIGURE 2.14-26. Pneumocystis pneumonia. (A) Lung tissue stained with silver uncovers folded\ncysts containing comma-shaped spores. (B) Frontal CXR shows diffuse â€œground-glassâ€ lung\nopacities characteristic of PCP in this patient with AIDS and a CD4+ cell count of 26. (Image\nA reproduced with permission from Ryan KJ, Ray CG. Sherris Medical Microbiology, 5th ed. New York, NY: McGraw-Hill; 2010.\nImage B reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 665599 1100//2211//2222 44::2244 PPMM\n\n660 HIGH-YIELD FACTS IN PULMONARY\nâ–  CXR most commonly shows diffuse, bilateral interstitial infiltrates with a\nground-glass appearance (see Fig. 2.14-26B, â€œbat wingâ€ or â€œbutterflyâ€ pat-\ntern), but any presentation is possible.\nâ–  â†‘ Î²-d-Glucan and â†‘ LDH can be useful but are nonspecific.\nTreatment\nThe preferred regimen is high-dose TMP-SMX for 21 days, PO if mild to\nKEY FACT moderate, and IV if severe. Alternative regimens:\nIn patients with Pneumocystis â–  Mild to moderate: trimethoprim + dapsone, or primaquine + clindamy-\npneumonia and moderate to severe cin, or atovaquone\nhypoxemia (Pao <70 mm Hg or an â–  Severe: pentamidine or primaquine + clindamycin\n2\nalveolar-arterial oxygen gradient â‰¥35),\nThe physician should use a prednisone taper in patients with moderate\nadd a prednisone taper to â†“ lung\nto severe hypoxemia (Pao <70 mm Hg or an alveolar-arterial oxygen gradi-\ninflammation and reduce mortality. 2\nent â‰¥35).\nANTHRAX\nCaused by the spore-forming, gram âŠ• bacterium Bacillus anthracis. Infection\nis an occupational hazard for veterinarians; farmers; and individuals who han-\ndle animal wool, hair, hides, or bone meal pro",
      "char_start": 1858000,
      "char_end": 1860000
    },
    {
      "chunk_id": 930,
      "text": "ducts. Has been used as a bio-\nlogic weapon. B anthracis can cause cutaneous (most common), inhalation\n(most deadly), or GI anthrax. There is no person-to-person spread of anthrax.\nHistory/PE\nâ–  Cutaneous: Presents 1 to 7 days after skin exposure and penetration of\nspores. The lesion begins as a pruritic papule that enlarges to form an ulcer\nsurrounded by a satellite bulbus/lesion with an edematous halo and a round,\nregular, raised edge. Regional lymphadenopathy is also characteristic. The\nlesion evolves into a black eschar within 7 to 10 days (see Fig. 2.14-27).\nâ–  Inhalational: Presents with fever, dyspnea, hypoxia, hypotension, or symp-\ntoms of pneumonia (1â€“3 days after exposure), classically caused by hemor-\nrhagic mediastinitis. Patients typically do not have pulmonary infiltrates.\nâ–  GI: Occurs after the ingestion of poorly cooked, contaminated meat. It\ncan present with dysphagia, nausea/vomiting, bloody diarrhea, and abdom-\ninal pain.\nDiagnosis\nFIGURE 2.14-27. Cutaneous anthrax.\nCriteria for diagnosis include culture isolation or two nonculture supportive\nBlack eschar is seen on the forearm.\n(Reproduced courtesy of James H. Steele, Centers for tests (PCR, immunohistochemical staining, or enzyme-linked immunosor-\nDisease Control and Prevention, Atlanta, GA.) bent assay [ELISA]). CXR is the most sensitive test for inhalational disease\n(shows a widened mediastinum and pleural effusions).\nTreatment\nâ–  Best initial treatment: Ciprofloxacin or doxycycline plus one to two addi-\ntional antibiotics for at least 14 days for inhalational disease or cutaneous\ndisease of the face, head, or neck.\nâ–  For other cutaneous disease, treat for 7 to 10 days. Postexposure prophy-\nlaxis (ciprofloxacin) to prevent inhalation anthrax should be continued for\n60 days.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666600 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 661\nACUTE PHARYNGITIS\nViral causes are more common (90% in adults)",
      "char_start": 1860000,
      "char_end": 1862000
    },
    {
      "chunk_id": 931,
      "text": ", but it is important to identify\nstreptococcal pharyngitis (group A Î²-hemolytic Streptococcus pyogenes). Etiol-\nogies are as follows:\nKEY FACT\nâ–  Bacterial: Group A Streptococcus (GAS), Neisseria gonorrhoeae, Coryne-\nbacterium diphtheriae, M pneumoniae Early antibiotic treatment of\nâ–  Viral: Rhinovirus, coronavirus, adenovirus, herpes simplex virus (HSV), streptococcal pharyngitis can\nEpstein-Barr virus (EBV), cytomegalovirus (CMV), influenza virus, cox- prevent rheumatic fever but not\nsackievirus, acute HIV infection glomerulonephritis.\nHistory/PE\nâ–  Typical of streptococcal pharyngitis: Fever, sore throat, pharyngeal ery-\nthema (see Fig. 2.14-28), tonsillar exudate, cervical lymphadenopathy, soft\npalate petechiae, headache, vomiting, scarlatiniform rash (indicates scarlet\nfever)\nâ–  Atypical of streptococcal pharyngitis: Coryza, hoarseness, rhinorrhea,\ncough, conjunctivitis, anterior stomatitis, ulcerative lesions, GI symptoms\nDiagnosis\nDiagnosed by clinical evaluation, rapid GAS antigen detection, and throat\nFIGURE 2.14-28. Pharyngeal erythema\nculture. If three out of four Centor criteria are met (see Table 2.14-19), the with palatal petechiae. Streptococcus\nsensitivity of rapid antigen testing is >90%. pyogenes is the most common bacterial\ncause of pharyngitis. (Reproduced courtesy of\nDr. Heinz F. Eichenwald from the Centers for Disease\nTreatment Control and Prevention, Atlanta, GA.)\nIf GAS is suspected, begin empiric antibiotic therapy with penicillin for 10\ndays. Cephalosporins, amoxicillin, and azithromycin are alternative options.\nSymptom relief can be attained with fluids, rest, antipyretics, and saltwater\ngargles.\nComplications\nâ–  Nonsuppurative: Acute rheumatic fever, poststreptococcal\nglom erulonephritis\nTABLE 2.14-19. Modified Centor Criteria (Centor Criteria + Age)\nCRITERIA POINTS\nFever 1\nTonsillar exudate 1\nTender anterior cervical lymphadenopathy 1\nLack of cough 1\n3â€“14 years of age 1\n15â€“45 years of age 0\n>45 years of age âˆ’1\nIf 4â€“5 points, treat empiricall",
      "char_start": 1862000,
      "char_end": 1864000
    },
    {
      "chunk_id": 932,
      "text": "y with antibiotics.\nIf 2â€“3 points, perform rapid antigen test. If âŠ• antigen test, treat with antibiotics; if âŠ– antigen\ntest, perform throat culture.\nIf 0â€“1 point, no testing or antibiotics are required (symptomatic treatment only).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666611 1100//2211//2222 44::2244 PPMM\n\n662 HIGH-YIELD FACTS IN PULMONARY\nKEY FACT â–  Suppurative: Cervical lymphadenitis, mastoiditis, sinusitis, otitis media,\nretropharyngeal or peritonsillar abscess, and, rarely, thrombophlebitis of\nAcute necrotizing mediastinitis is a life- the jugular vein (Lemierre syndrome) caused by Fusobacterium, an oral\nthreatening complication of untreated anaerobe\nretropharyngeal abscess that presents â–  Peritonsillar abscess may present with odynophagia, trismus (â€œlockjawâ€), a\nwith fever, chest pain, and dyspnea. muffled â€œhot potatoâ€ voice, unilateral tonsillar enlargement, and ery-\nIt requires urgent surgical drainage thema, with the uvula and soft palate deviated away from the affected side;\nto prevent spread to the posterior culture abscess fluid and localize the abscess via intraoral ultrasound or\nmediastinum, which may cause lethal CT; treat with antibiotics and surgical drainage\npleural and pericardial effusions.\nKEY FACT ORAL INFECTIONS\nAll patients with a history of rheumatic\nfever should be given routine penicillin LUDWIG ANGINA\nprophylaxis to prevent recurrent group\nA Streptococcus infection. Rapidly progressive cellulitis of the submandibular space that may cause air-\nway compromise from rapidly expanding edema. Usually caused by polymi-\ncrobial infection in the setting of poor oral hygiene. IV broad-spectrum\nantibiotics and diligent airway management are necessary; surgical drainage is\nperformed if there is abscess formation (uncommon).\nACUTE LYMPHADENITIS\nUnilateral and rapid onset (<1 week), commonly caused by S aureus and S\npyogenes, typically involving the submandibular lymph nodes. Antibiotics are\nrequired",
      "char_start": 1864000,
      "char_end": 1866000
    },
    {
      "chunk_id": 933,
      "text": " if symptoms (fluctuance, fever, cellulitis) are present to prevent\nabscess formation.\nSINUSITIS\nKEY FACT\nRefers to inflammation of the paranasal sinuses. The maxillary sinuses are\nLudwig angina is a bilateral cellulitis\nmost commonly affected. Subtypes include the following:\nof the submental, submaxillary, and\nsublingual spaces that usually results â–  Acute sinusitis (symptoms lasting <1 month): Most commonly associ-\nfrom an infected tooth. It presents with ated with viruses, S pneumoniae, H influenzae, and M catarrhalis. Bacte-\ndysphagia; drooling; fever; and a red, rial causes are rare and characterized by purulent nasal discharge, facial or\nwarm mouth, and it can lead to death tooth tenderness, hyposmia/anosmia, and symptoms lasting >10 days.\nfrom asphyxiation. â–  Chronic sinusitis (symptoms persisting >3 months): A chronic inflam-\nmatory process often caused by obstruction of sinus drainage and ongoing\nlow-grade anaerobic infections.\nKEY FACT\nHistory/PE\nPotential complications of sinusitis\ninclude meningitis, frontal bone â–  Presents with fever, facial pain/pressure, headache, nasal congestion, and\nosteomyelitis, cavernous sinus discharge. Examination may reveal tenderness, erythema, and swelling\nthrombosis, and abscess formation. over the affected area.\nâ–  High fever, leukocytosis, and a purulent nasal discharge are suggestive of\nacute bacterial sinusitis.\nKEY FACT\nDiagnosis\nBeware of invasive and life-threatening\nfungal sinusitis (caused by Mucor â–  A clinical diagnosis. Culture and imaging are generally not required for\nacute sinusitis but may guide the management of chronic cases.\nand Rhizopus) in patients with poorly\ncontrolled diabetes mellitus, immune\ncompromise, or neutropenia.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666622 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 663\nâ–  Transillumination shows opacification of the sinuses (low sensitivity).\nâ–  CT is the test of choice for sinus imaging (s",
      "char_start": 1866000,
      "char_end": 1868000
    },
    {
      "chunk_id": 934,
      "text": "ee Fig. 2.14-29) but is usually\nnecessary only if symptoms persist after treatment.\nTreatment\nMost cases of acute sinusitis are viral and/or self-limited and are treated with\nsymptomatic therapy (decongestants, antihistamines, nasal saline lavage, pain\nrelief).\nâ–  Acute bacterial sinusitis: The physician should consider either amoxicil-\nlin/clavulanate for 10 days or clarithromycin, azithromycin, trimethoprim-\nsulfamethoxazole (TMP-SMX), a fluoroquinolone, or a second-generation\ncephalosporin for 10 days. FIGURE 2.14-29. Sinusitis. Coronal CT\nimage shows an opacified left maxillary\nâ–  Chronic sinusitis: sinus and marked associated bony thick-\nâ–  Antibiotics like those used for acute disease may be prescribed for ening, consistent with chronic maxillary\nchronic sinusitis, although a longer course (3â€“6 weeks) may be sinusitis. (Reproduced with permission from Lal-\nnecessary. wani AK. Current Diagnosis & Treatment in Otolaryngol-\nâ–  Adjuvant therapy with intranasal corticosteroids, decongestants, and/or ogyâ€”Head and Neck Surgery, 2nd ed. New York, NY:\nMcGraw-Hill; 2008.)\nantihistamines may be useful in combating the allergic/inflammatory\ncomponent of the disease.\nâ–  Surgical intervention may be required.\nHEMOPTYSIS\nHemoptysis is the expectoration of blood from the lower respiratory tract, below\nthe vocal cords, which can be caused by various etiologies. These etiologies can\nbe divided into life-threatening and non-life-threatening hemoptysis. Bleeding\nfrom the pulmonary arteries (low-pressure system) is commonly non-life-\nthreatening, whereas bleeding from the bronchial arteries (high-pressure sys-\ntem) may be life-threatening. Hemoptysis is often classified as mild (<30 mL),\nmoderate (31â€“100 mL), severe (100â€“600 mL), or massive. Massive hemoptysis\nis defined by a number of criteria, often ranging from 100 mL to more than\n600 mL over 24 hours with respiratory or hemodynamic compromise.\nEtiologies of hemoptysis: Airway disease (bronchitis, bronchiectasis, bron-\nchial neoplas",
      "char_start": 1868000,
      "char_end": 1870000
    },
    {
      "chunk_id": 935,
      "text": "m, foreign bodies), pulmonary parenchymal disease (infection\nsuch as TB, rheumatic and immune disorders such as vasculitis, connective\ntissue disorders such as Ehlers-Danlos syndrome), pulmonary vascular disor-\nders (elevated pulmonary capillary pressure, pulmonary arteriovenous malfor-\nmation, pulmonary embolism), and bleeding disorders.\nHistory/PE\nAssess for risk factors for specific diseases such as lung cancer in patients with\nheavy smoking history. Rule out life-threatening hemoptysis, and observe for\nairway compromise.\nDiagnosis\nâ–  Order CXR first and consider CT imaging of the chest if needed to rule\nout specific etiologies.\nâ–  CBC, coagulation studies, urinalysis, rheumatologic workup should be\nperformed as needed.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666633 1100//2211//2222 44::2244 PPMM\n\n664 HIGH-YIELD FACTS IN PULMONARY\nLow suspicion for other\noropharyngeal or GI causes\nLife-threatening features\nMassive* (> 100 mL/hr or > 150 mL/24 hr)\nRespiratory distress\nHemodynamic instability\nNo Yes\nSecure airway,\nLabs, CXR, CT chest\nbreathing and\nÂ± contrast\ncirculation\nSource of\nbleeding\nBronchoscopy if Treat with bronchoscopy,\nidentified\nnormal imaging or if no IR embolization, or\nother etiologies identified resection\nOther etiologies *Most common causes of massive\nidentified hemoptysis: bronchiectasis, active\npulmonary TB, malignancy\nEvaluate and\ntreat findings\nFIGURE 2.14-30 Evaluation of hemoptysis. (Reproduced with permission from USMLE-Rx.com.)\nTreatment\nâ–  In the case of impending airway compromise due to massive hemoptysis,\nsecure the airway by placing an endotracheal tube while evaluating the\ncause.\nâ–  Management of hemoptysis includes hemodynamic stabilization and\ntreatment of the underlying cause. In the case of persistent bleeding, bron-\nchoscopic interventions and embolization can be performed to control the\nbleeding (Fig. 2.14-30).\nPLEURAL DISEASE\nPLEURAL EFFUSION\nAn abnormal accumulation of fluid in the",
      "char_start": 1870000,
      "char_end": 1872000
    },
    {
      "chunk_id": 936,
      "text": " pleural space. Classified as follows:\nâ–  Transudate: Secondary to â†‘ pulmonary capillary wedge pressure (PCWP)\nor â†“ oncotic pressure\nâ–  Exudate: Secondary to â†‘ pleural vascular permeability\nSee Figure 2.14-31 for an algorithm showing etiology of pleural effusion.\nTable 2.14-20 lists the possible causes of both transudates and exudates.\nHistory/PE\nPresents with dyspnea, pleuritic chest pain, and/or cough. Exam reveals dull-\nness to percussion and â†“ breath sounds over the effusion (see Table 2.14-21).\nA pleural friction rub may be present.\nDiagnosis\nâ–  Best initial test: CXR, blunting of the costophrenic angle. Lateral decubi-\ntus view is most sensitive; it also is used to assess for loculation.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666644 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 665\nDiagnostic thoracocentesis\nMeets no Light criteria Meets â‰¥ 1\ncriteria Pleural protein + serum protein >0.5 criteria\nTransudative Exudative\nPleural LDH + serum LDH >0.6\nPleural LDH > 2/3 ULN serum LDH\nhydrostatic pressure oncotic pressure Intrathoracic Extrathoracic\nCHF Cirrhosis Infection Right-sided\nESRD Nephrotic syndrome Neoplasm Meigs syndrome\nPulmonary embolism Autoimmune (eg, RA, SLE) Endometriosis\n(early) Drugs\nLeft-sided\nPulmonary embolism Pancreatitis\nChylothorax Esophageal rupture\nHemothorax\nTreat underlying cause\nFurther workup (eg, pleural fluid analysis,\nculture, AFB, TB antigen, RF, CCP, ANA)\nFIGURE 2.14-31. Etiology of pleural effusion based on pleural fluid analysis. (Reproduced with permission from USMLE-Rx.\ncom.)\nTABLE 2.14-20. Causes of Pleural Effusions\nTRANSUDATES EXUDATES\nCongestive heart failure Pneumonia (parapneumonic effusion)\nCirrhosis (hepatic hydrothorax) TB\nNephrotic syndrome Malignancy\nPulmonary embolism\nCollagen vascular disease (SLE)\nPancreatitis\nTrauma\nChylothorax (triglycerides)\nTABLE 2.14-21. Pulmonary Physical Exam Findings\nLUNG CONSOLIDATION\n(eg, LOBAR PNEUMONIA) PLEURAL EFFUSION P",
      "char_start": 1872000,
      "char_end": 1874000
    },
    {
      "chunk_id": 937,
      "text": "NEUMOTHORAX\nPercussion Dull Dull Hyperresonant\nTactile fremitus â†‘ â†“ â†“\nBreath sounds Bronchial â†“ â†“/Absent\nVoice transmission Bronchophony â†“ â†“\nEgophony\nCrackles Present (often) Absent Absent\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666655 1100//2211//2222 44::2244 PPMM\n\n666 HIGH-YIELD FACTS IN PULMONARY\nE TA ff B u L s E i o 2 n .1 s 4 a -22. Light Criteria for Pleural â–  Next step: Thoracentesis. It is indicated for new effusions >1 cm in the\ndecubitus view, except with bilateral effusions and other clinical evidence\nMEASURE VALUE of CHF.\nâ–  Using Light criteria can determine if the effusion is transudative or exuda-\nPleural protein/ >0.5\ntive (see Table 2.14-22).\nserum protein\nâ–  Transudative effusions: Typically have a pH of 7.4 to 7.55\nâ–  Exudative effusions: Typically have a pH of pH <7.4\nPleural LDH/ >0.6\nâ–  Effusion is an exudate if it meets any Light criteria.\nserum LDH\nâ–  Exudative effusions: Require further workup (eg, pleural fluid glucose,\namylase, cytology, cell count, culture, Gram stain, AFB, TB antigen,\nPleural fluid LDH More than 2/3 of\nRF, CCP, ANA)\nthe ULN serum\nâ–  Complications:\nLDH â–  Parapneumonic effusion and empyema: Pleural effusions that arise as\nresult of pneumonia, lung abscess, or bronchiectasis; see Table 2.14-23\naAn effusion is an exudate if any of the â–  Recurrent effusion\nprevious criteria are met.\nTreatment\nKEY FACT â–  Treat the underlying cause of the effusion.\nâ–  See Table 2.14-23 for treatment of parapneumonic effusions and empyemas.\nComplicated parapneumonic effusions\nâ–  Recurrent effusions: May require pleurodesis (procedure to obliterate\nnecessitate chest tube drainage.\npleural space).\nPNEUMOTHORAX\nCollection of air in the pleural space that can lead to pulmonary collapse. Eti-\nologies are the following:\nMNEMONIC\nâ–  Primary spontaneous pneumothorax: Due to rupture of subpleural apical\nPresentation of pneumothoraxâ€”\nblebs (usually found in tall, thin, young males).\nP-THORAX\nâ–  Secondary pneumoth",
      "char_start": 1874000,
      "char_end": 1876000
    },
    {
      "chunk_id": 938,
      "text": "orax: Due to COPD, trauma, infections (TB, P jir-\nPleuritic pain ovecii), and iatrogenic factors (thoracentesis, subclavian line placement,\nTracheal deviation positive-pressure mechanical ventilation, bronchoscopy with biopsy).\nHyperresonance â–  Tension pneumothorax: A pulmonary or chest wall defect acts as a one-\nOnset sudden\nway valve, causing air trapping in the pleural space. Buildup of air pushes\nReduced breath sounds (and dyspnea)\nthe mediastinum to the opposite side of the chest, which can obstruct\nAbsent fremitus (asymmetric chest wall)\nvenous return to the heart, leading to hemodynamic instability and even\nX-ray showing collapse\ncardiac arrest unless immediately treated.\nHistory/PE\nâ–  Pneumothorax presents with acute onset of unilateral pleuritic chest pain\nand dyspnea.\nâ–  Examination reveals tachypnea, diminished or absent breath sounds,\nhyperresonance, â†“ tactile fremitus, and JVD secondary to compression of\nthe SVC.\nâ–  Tension pneumothorax: Presents with respiratory distress, hypoxia, tra-\ncheal deviation, and hemodynamic instability.\nDiagnosis\nKEY FACT â–  The diagnosis of a tension pneumothorax should be made clinically.\nâ–  CXR shows the presence of a visceral pleural line and/or lung retraction\nTreatment of a tension pneumothorax from the chest wall (best seen in end-expiratory films; see Fig. 2.14-32). In\nrequires needle decompression first an emergency department (ED) or ICU setting, bedside ultrasound can be\nand then chest tube placement. used, and it has high sensitivity and specificity.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666666 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 667\nTABLE 2.14-23. Parapneumonic Effusions and Empyemas\nUNCOMPLICATED PARAPNEUMONIC EFFUSION COMPLICATED PARAPNEUMONIC EFFUSION EMPYEMA\nEtiology Fluid movement into pleural space (caused Persistent bacterial invasion into Bacterial colonization of\nby inflammation associated with pleural space pleural space\npneumoni",
      "char_start": 1876000,
      "char_end": 1878000
    },
    {
      "chunk_id": 939,
      "text": "a)\nAppearance Clear/cloudy Cloudy Purulent\nPleural fluid analysis pH >7.2 pH <7.2 pH <7.2\nGlucose: Normal/â†“ Glucose: â†“ Glucose: â†“\nLDH ratio >0.6 LDH ratio >0.6 LDH ratio >0.6\nPleural fluid Gram stain Negative Negative Positive\nand culture\nTreatment Antibiotics Antibiotics Antibiotics\nChest tube Chest tube\nTreatment A\nâ–  Tension pneumothorax: Requires immediate needle decompression (sec-\nond intercostal space at the midclavicular line) followed by chest tube\nplacement.\nâ–  Small pneumothorax (â‰¤2 cm): Observation Â± supplemental O . It may\n2\nresorb spontaneously.\nâ–  Large (>3 cm), symptomatic pneumothorax: Needle aspiration or small-\nbore chest tube placement.\nâ–  Patients who are unstable or who have recurrent pneumothorax: Chest\nA\ntube placement. B\nPULMONARY SLEEP DISORDERS\nOBSTRUCTIVE SLEEP APNEA\nObstructive sleep apnea (OSA) is a sleep disorder characterized by transient\nobstruction of the upper airway that causes hypoxemia. Etiology may be cen-\ntral (eg, stroke), secondary (eg, obesity), or mixed. Risk factors include male\nsex, older age, obesity, craniofacial abnormalities, upper airway abnormalities\n(adenotonsillar hypertrophy [children]), sedative use (eg, alcohol, benzodiaze-\npines), smoking, and many others. FIGURE 2.14-32. Pneumothorax. (A)\nPneumothorax. CT shows collapsed left\nHistory/PE lung. (B) Tension pneumothorax. (Image\nA reproduced with permission from Miura K, Kondo\nCardinal features:\nR, Kurai M, et al. Birt-Hogg-DubÃ© syndrome detected\nincidentally by asymptomatic bilateral pneumotho-\nâ–  Irregular respiratory pattern during sleep: Obstructive apneas, hypop-\nrax in health screening: a case of a young Japanese\nneas, or respiratory effortâ€“related arousals (RERAs)\nwoman. Surg Case Rep. 2015;1:17. doi:10.1186/s40792-\n015-0014-8.Image B reproduced with permission from\nRosat A, DÃ­az C. Reexpansion pulmonary edema after\ndrainage of tension pneumothorax. Pan Afr Med J.\n2015;22:143. doi:10.11604/pamj.2015.22.143.8097.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoo",
      "char_start": 1878000,
      "char_end": 1880000
    },
    {
      "chunk_id": 940,
      "text": "nnaarryy__1111ee__662255--667744..iinndddd 666677 1100//2211//2222 44::2244 PPMM\n\n668 HIGH-YIELD FACTS IN PULMONARY\nKEY FACT â–  Daytime symptoms related to poor sleep: Somnolence, fatigue, poor\nconcentration, morning headaches\nThe STOP-BANG survey is a clinical\nâ–  Signs of disturbed sleep: Snoring, gasping, choking, restlessness\nquestionnaire that can be used to\nassess the risk of OSA and direct further\nComplications:\nsleep testing: Snoring, Tiredness,\nObserved stop in breathing, increased â–  â†‘ cardiovascular morbidity (systemic hypertension, PAH, coronary artery\nblood Pressure, Body mass index (BMI) disease, arrhythmias, heart failure, polycythemia, and stroke)\n>35 kg/m2, Age >50 years, Neck â–  â†‘ risk for insulin resistance and type 2 diabetes mellitus\ncircumference >40 cm, male Gender. â–  â†‘ risk for motor vehicle collisions caused by impaired alertness\nThe presence of â‰¥3 positive items\nshould prompt sleep testing. Diagnosis\nâ–  Best initial test: Polysomnography (sleep study) based on apnea-hypopnea\nindex ([AHI] = apneas + hypopneas/total hours of sleep) and presence or\nabsence of related symptoms\nâ–  Diagnosis is confirmed with the following:\nâ–  AHI â‰¥5 PLUS symptoms\nâ–  AHI â‰¥15 regardless of symptoms\nTreatment\nâ–  Best initial therapy: Weight loss (if applicable) and CPAP\nâ–  Alternatives: Oral appliances, hypoglossal nerve stimulation, and maxillo-\nmandibular advancement (bones of upper and lower jaw surgically reposi-\ntioned to relieve obstruction)\nâ–  Last resort: Tracheostomy\nOBESITY HYPOVENTILATION SYNDROME\nObesity hypoventilation syndrome (OHS) is a sleep disorder defined as awake\nalveolar hypoventilation in an obese individual that cannot be attributed to\nother conditions associated with alveolar hypoventilation.\nHistory/PE\nPresents with hypersomnolence and obesity. OHS is further characterized by\ncoexisting sleep disturbances:\nâ–  OHS with OSA (90% of patients): Presents with symptoms of OSA (see\nearlier section)\nâ–  OHS with sleep-related hypoventilation (10%): Presents the s",
      "char_start": 1880000,
      "char_end": 1882000
    },
    {
      "chunk_id": 941,
      "text": "ame as\nOHS + OSA but witnessed apneas during sleep are uncommon\nDiagnosis\nDiagnosis of exclusion. Patient must meet all of the following criteria:\nâ–  Obesity (body mass index [BMI] >30 kg/m2)\nâ–  Awake alveolar hypoventilation (Paco >45 mm Hg)\n2\nâ–  Exclusion of alternative causes of hypercapnia and hypoventilation\nTreatment\nâ–  Best initial treatment: Weight loss and noninvasive positive airway pres-\nsure (PAP)\nâ–  OHS + OSA: CPAP\nâ–  Initiate bilevel positive airway pressure (BiPAP) if initial management\nwith CPAP fails\nâ–  OHS + hypoventilation: BiPAP\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666688 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 669\nâ–  Next best treatment:\nâ–  Bariatric surgery\nâ–  Tracheostomy (last resort)\nNOSE AND THROAT\nRHINITIS\nRhinitis is characterized by symptoms of rhinorrhea (posterior or anterior),\nnasal congestion, sneezing, and itching. Although most forms of rhinitis\ninvolve inflammation, some forms, such as vasomotor rhinitis, do not. It may\nbe further classified into allergic and nonallergic causes.\nAllergic Rhinitis\nPathogenesis\nâ–  Results from IgE-mediated type 1 hypersensitivity reaction of the nasal\nmucosa\nâ–  Commonly associated with atopic diseases such as asthma and eczema\nHistory/PE\nPresents with rhinitis in response to allergens. Based on temporal pattern, can\nbe further classified as follows:\nâ–  Intermittent/seasonal: Allergic reactions to grass/trees or pollen (hay\nfever); occurs in late spring/summer\nâ–  Persistent/perennial: Allergic reactions to house dust, dust mites, molds,\ndogs, cats\nâ–  Food allergens: May also be contributory; however, evidence is lacking\nDiagnosis\nâ–  Clinical diagnosis based on typical history and nasal examination\nâ–  Skin prick test involves introducing common allergens into the skin to\nobserve for hypersensitivity reactions; this can help identify allergens\nâ–  Serum total IgE is generally increased\nâ–  Serum radio-allergosorbent test (RAST) is a blood test that",
      "char_start": 1882000,
      "char_end": 1884000
    },
    {
      "chunk_id": 942,
      "text": " identifies IgE\nantibodies to specific allergens\nTreatment\nâ–  Allergen avoidance\nâ–  Medications:\nâ–  Second-generation oral nonsedating antihistamines such as loratadine,\ncetirizine, and fexofenadine\nâ–  Intranasal steroids such as fluticasone, beclomethasone, or mometa-\nsone nasal sprays titrated to minimum effective dose; sometimes these\ninternal steroids may be combined with intranasal antihistamines\nâ–  Leukotriene antagonists such as montelukast; this is also beneficial\nwith concomitant asthma\nâ–  Immunotherapy: Allergen exposure and desensitization\nNonallergic Rhinitis\nNonallergic rhinitis is a subtype of rhinitis without an allergic or infectious\ncause. It accounts for up to 50% of cases of rhinitis in adults.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 666699 1100//2211//2222 44::2244 PPMM\n\n670 HIGH-YIELD FACTS IN PULMONARY\nEtiology/Pathogenesis\nâ–  Irritants: Cigarette smoke (tobacco), pollutants, occupational (chemicals\nsuch as cleaning products)\nâ–  Vasomotor: Caused by increased blood flow to the nasal mucosa; it is\ninstigated by temperature changes or dry air and irritant odors\nâ–  Gustatory: Clear rhinorrhea after ingestion of food (most often spicy)\nâ–  Drug induced: Due to antihypertensives, NSAIDs, PDE-5 inhibitors, or\ncocaine\nâ–  Hormonal rhinitis: Onset during pregnancy; it resolves with end of\npregnancy\nâ–  Senile rhinitis (also called atrophic rhinitis): occurs in older adults when\nthe nasal glands that produce moisture fail to function adequately\nDiagnosis\nWorkup to exclude allergic rhinitis (see earlier information).\nTreatment\nâ–  Treatment is symptom driven.\nâ–  The patient should avoid any precipitating factors.\nâ–  Intranasal corticosteroids (eg, fluticasone) and intranasal antihistamines\n(eg, azelastine) alone or in combination treat nasal congestion, postnasal\ndrip, rhinorrhea, and sneezing.\nâ–  Intranasal anticholinergics (eg, ipratropium) treat rhinorrhea. Deconges-\ntants (eg, phenylephrine, oxymetazoline) help with nas",
      "char_start": 1884000,
      "char_end": 1886000
    },
    {
      "chunk_id": 943,
      "text": "al congestion.\nâ–  Nasal irrigation and intranasal capsaicin may help.\nNASAL POLYPS\nNasal polyps are benign outgrowths of nasal mucosa, and they represent the\nmost common tumors of the nasal cavity. They commonly occur in associa-\ntion with allergic rhinitis, acute and chronic infections, and CF.\nHistory/PE\nâ–  Patients present with nasal obstruction, postnasal discharge, congestion,\nsneezing, rhinorrhea, hyposmia, and anosmia.\nâ–  Important associations:\nâ–  Aspirin allergy\nâ–  Sinus infections\nâ–  Asthma\nDiagnosis\nâ–  Coronal sinus CT scanning is first-line imaging modality.\nâ–  Endoscopy can sometimes be helpful for evaluation in the clinic.\nâ–  Nasal masses that do not appear typical or respond to treatment should be\nbiopsied.\nTreatment\nâ–  Medical treatment:\nâ–  Oral corticosteroids are the most effective.\nâ–  Intranasal corticosteroids (mometasone, beclomethasone) are less\neffective. Other medical options include leukotriene antagonists (mon-\ntelukast) or IL inhibitors (dupilumab).\nâ–  Surgical removal is indicated in select cases due to severe symptoms of\nobstruction or infection refractory to medical treatment.\nâ–  The physician should concomitantly treat predisposing factors (eg, under-\nlying allergy).\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 667700 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 671\nEPISTAXIS\nIf conservative treatment ineffective,\nperform rhinoscopy to localize source\nto anterior vs posterior\nEpistaxis (bleeding from the nose) may either be anterior or posterior, based\nAnterior bleeding Posterior bleeding\non the location of bleeding.\nChemical or electrical Posterior packing (balloon,\nnasal cautery Foley catheter)\nâ–  Anterior epistaxis: This is the most common (90%) and tends to be self- Anterior packing (tampon, Consider admission and\nlimited. Bleeding is most often from the Kiesselbach plexus (eg, the area balloon, guaze) ENT consultation\nIf ineffective\nof anastomosis of the septal branch of the anterior",
      "char_start": 1886000,
      "char_end": 1888000
    },
    {
      "chunk_id": 944,
      "text": " ethmoidal artery, the\nPerform bilateral\nlateral nasal branch of the sphenopalatine artery, and the septal branch of nasal packing\nthe superior labial branch of the facial artery). If ineffective\nConsider and treat as\nâ–  Posterior epistaxis: This is less common (10%) and may result in signifi- posterior source\ncant hemorrhage. Bleeding occurs from the posterolateral branches of the\nsphenopalatine artery and, rarely, the carotid artery. FIGURE 2.14-33. Approach to treatment\nof active nosebleed. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nEtiology\nLocal causes of epistaxis include mucosal irritation (eg, nose picking, dry air,\nrhinitis, foreign body), facial trauma, intranasal drugs (cocaine, intranasal cor-\nticosteroids), or tumors (nasopharyngeal carcinomas).\nSystemic conditions or drugs may also cause epistaxis (eg, anticoagulation,\nantiplatelet medications, alcohol, bleeding disorders [eg, von Willebrand dis-\nease], vascular malformations [nasal hemangioma], or hypertension).\nTreatment\nFigure 2.14-33 outlines the approach to the management of epistaxis.\nâ–  Initial assessment and resuscitation:\nâ–  Assess and treat for airway, breathing, and cardiovascular (fluid resusci-\ntation, redundant large-bore IV lines as indicated) compromise.\nâ–  Target history to rule out conditions that predispose to bleeding\n(detailed earlier).\nâ–  Laboratory tests: Coagulation studies (for anticoagulated patients,\nCBC, type and cross).\nâ–  Initial conservative treatment:\nâ–  Position patient: Elevate body and bend forward.\nâ–  Administer topical vasoconstrictor (eg, oxymetazoline) and local anes-\nthetic (lidocaine) and pinch nostrils for 10 to 15 minutes.\nâ–  Apply cold compress.\nâ–  If conservative measures fail, examine nose to look for sources of bleed-\ning (rhinoscopy, speculum).\nâ–  Subsequent treatment of anterior bleeding:\nâ–  Cauterization: This is considered first line; either chemical (silver KEY FACT\nnitrate) or electrical cautery is possible.\nBrisk bleeding even after adequate\nâ–  Nasal pack",
      "char_start": 1888000,
      "char_end": 1890000
    },
    {
      "chunk_id": 945,
      "text": "ing: Nasal tampons, ribbon gauze, or nasal balloon cathe- nasal packing may indicate a posterior\nters can be used; if unilateral packing ineffective, bilateral nasal pack-\nsource of bleeding.\ning can be performed.\nâ–  Subsequent treatment of posterior bleeding:\nâ–  Balloon catheter is preferred; alternatively, a Foley catheter can be\nused.\nâ–  These patients may require hospitalization and urgent ear, nose, and\nthroat (ENT) consultation. KEY FACT\nComplications Consider toxic shock syndrome in\na patient with fever, hypotension,\nProlonged retention of nasal packing (>72 hours) increases the risk of com-\ndesquamation, and mucosal hyperemia\nplications, including necrosis, toxic shock syndrome, sinus or nasolacrimal\nafter receiving nasal packing.\ninfections, and dislodgment.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 667711 1100//2211//2222 44::2244 PPMM\n\n672 HIGH-YIELD FACTS IN PULMONARY\nADENOTONSILLAR HYPERTROPHY\nAdenoids develop at the posterior surface of the nasopharynx and grow to a\nfinal size at 6 to 7 years of age. Palatine tonsils are located toward the end of\nthe soft palate. Both structures are dense in B and T lymphocytes and play a\nrole in local immunity and in host immune defense. Adenotonsillar hypertro-\nphy is characterized by recurrent infections and hypertrophy of the lymphoid-\nrich structures.\nHistory/PE\nAdenotonsillar hypertrophy usually manifests in children as recurrent infec-\ntions and sleep-disordered breathing (SDB).\nâ–  Adenoid hypertrophy: History of mouth breathing, hyponasal voice, ade-\nnoid facies, rhinorrhea, and postnasal drip is commonly described.\nâ–  Tonsillar hypertrophy: History of recurrent infections (most commonly\nviral and then bacterial) and airway and feeding difficulties, such as dys-\nphagia and SDB with OSA. Voice changes and dental malocclusion may\nbe seen.\nâ–  SDB: History of excessive daytime somnolence, failure to thrive, enuresis,\npoor school performance, and/or behavioral disturbance d",
      "char_start": 1890000,
      "char_end": 1892000
    },
    {
      "chunk_id": 946,
      "text": "ue to chronic\nsleep deprivation.\nDiagnosis\nâ–  Adenoid hypertrophy: Rule out other causes of snoring and SDB such as\nanterior nasal obstruction.\nâ–  Best diagnostic test: Nasopharyngoscopy to visualize the hypertro-\nphied adenoid tissue\nâ–  Other: Lateral x-ray of the neck to visualize the adenoids\nâ–  Tonsillar hypertrophy: Tonsil grading by physical exam is informative.\nâ–  SDB: Best diagnostic test: Polysomnography.\nTreatment\nâ–  Infections should be first treated with supportive treatment as needed\n(pain control, adequate fluid intake, antibacterial if streptococcal infection\nis suspected).\nâ–  Use modified Centor criteria to decide on the use of antibiotics against\nS pyogenes (most common bacterial pathogen): Absence of cough, swol-\nlen/tender anterior cervical lymph nodes, temperature >38Â°C (100.4Â°F),\ntonsillar exudate, age of individual.\nâ–  Patients with recurrent infections (>7 episodes in the preceding year or\n>5 in the preceding 2 years or >4 in the preceding 3 years): Consider\ntonsillectomy.\nâ–  Patients with obstructive SDB diagnosed by polysomnography: Perform\nadenoidectomy and tonsillectomy.\nACUTE AND CHRONIC LARYNGITIS\nLaryngitis results from laryngeal inflammation due to several factors: excessive\ncoughing, infections, vocal abuse/strain, gastroesophageal reflux, irritants\nsuch as smoking. Chronic laryngitis usually results from multiple factors lead-\ning over time to persistent inflammation.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 667722 1100//2211//2222 44::2244 PPMM\n\nPULMONARY HIGH-YIELD FACTS IN 673\nHistory/PE\nâ–  Acute: Less than 3 weeks of hoarseness.\nâ–  Chronic: More than 3 weeks of hoarseness.\nâ–  History of the chief complaint reveals aforementioned inciting factors.\nDiagnosis\nâ–  Perform physical examination of the head and neck (lymph nodes can be\nsuggestive of malignancy).\nâ–  In select cases, perform nasopharyngoscopy to visualize the vocal cords\n(lesions on the vocal cord such as polyps or nodules, bilateral mot",
      "char_start": 1892000,
      "char_end": 1894000
    },
    {
      "chunk_id": 947,
      "text": "ion of the\nvocal cords, edema).\nTreatment\nâ–  Supportive management is often needed with vocal hygiene (absolute\nsilence is not required), hydration, cough suppression, and avoidance of\nprecipitating/irritating factors such as smoking.\nâ–  Proton pump inhibitors are needed if reflux is suspected or diagnosed.\nLARYNGOPHARYNGEAL REFLUX\nReflux of caustic gastric contents causing irritation of laryngeal tissue. Related\nto resting upper and lower esophageal sphincter tone and also to duration/\nmagnitude of increased intra-abdominal pressure (eg, obesity would cause\nchronic increased intra-abdominal pressure).\nHistory/PE\nâ–  Dysphonia\nâ–  Cough\nâ–  Globus\nâ–  Throat clearing\nâ–  Dysphagia\nDiagnosis\nLargely based on clinical signs/symptoms\nTreatment\nâ–  Dietary changes (avoidance of caffeine, chocolate, peppermint, alcohol,\nand acidic foods)\nâ–  Behavioral changes (avoidance of smoking, waiting 2 hours after eating for\nvigorous exercise, avoidance of eating/drinking 3 hours before sleep)\nâ–  Acid suppression (proton pump inhibitors [PPIs], H antagonist)\n2\nBENIGN AND MALIGNANT LARYNGEAL LESIONS\nVocal Cord Polyp\nMost common benign laryngeal lesion. Typically caused by vocal cord over-\nuse (eg, singers, teachers), smoking, and/or gastroesophageal reflux disease\n(GERD).\nâ–  Hx/PE: Presents with hoarseness and, in severe cases, dyspnea\nâ–  Dx: Laryngoscopy or stroboscopy\nâ–  Tx: Voice therapy, microsurgery\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 667733 1100//2211//2222 44::2244 PPMM\n\n674 HIGH-YIELD FACTS IN PULMONARY\nVocal Cord Nodule\nTypically caused by vocal cord overuse (eg, singers, teachers), smoking, and/\nor GERD. Presents with hoarseness.\nâ–  Dx: Laryngoscopy or stroboscopy\nâ–  Tx: Voice therapy, smoking cessation, PPI if GERD symptoms present, ste-\nroid injections, microsurgery\nRecurrent Respiratory Papillomatosis\nâ–  Recurrent respiratory papillomatosis is a rare disease caused by human pap-\nillomavirus (HPV) infection of the upper airway, resulting ",
      "char_start": 1894000,
      "char_end": 1896000
    },
    {
      "chunk_id": 948,
      "text": "in warty growths.\nâ–  In about 3% to 5% of patients, malignant transformation to squamous cell\ncarcinoma may occur.\nâ–  The juvenile form is due to peripartum transmission from an infected\nmother. Children may need up to 20 repeat procedures during their life-\ntime, causing significant morbidity; however, remission may occur after\nseveral years.\nâ–  The adult form is probably transmitted through oral sex.\nRisk Factors\nâ–  Juvenile form: Triad of being firstborn, vaginal delivery, and motherâ€™s age\n<20 years. Other risks include lower socioeconomic status. The physician\nshould consider sexual abuse in children older than 5 years.\nâ–  Adult form: More lifetime sexual partners and increased frequency of oral\nsex.\nHistory/PE\nHoarseness (most common), voice change, episodic choking, foreign body\nsensation, cough, dyspnea, inspiratory wheeze, and stridor.\nDiagnosis\nLaryngoscopy or bronchoscopy.\nTreatment\nâ–  there is no cure.\nâ–  repeated surgical debulking is mainstay of treatment. Cidofovir is injected\nin resection site in select patients.\nâ–  subcutaneous interferon therapy may be useful as second line.\nâ–  tracheostomy is used for significant airway obstruction.\nâ–  prevention is through quadrivalent HPV vaccination.\n22002222__0022..1144__SStteepp22CCKK__PPuullmmoonnaarryy__1111ee__662255--667744..iinndddd 667744 1100//2211//2222 44::2244 PPMM\n\nH I G H - Y I E L D F A C T S I N\nRENAL/GENITOURINARY\nElectrolyte Disorders 676 Scrotal Pain and Swelling 698\nHypernatremia 676\nUrinary Incontinence 700\nHyponatremia 676\nHyperkalemia 678 Interstitial Cystitis (Painful Bladder Syndrome) 701\nHypokalemia 679\nErectile Dysfunction 701\nHypercalcemia 680\nBenign Prostatic Hyperplasia 702\nHypocalcemia 681\nHypomagnesemia 682 Urologic Cancer 703\nAcid-Base Disorders 682\nprostate cancer 703\nUrine anion gap 683\nBladder cancer 704\nrenal cell carcinoma 705\nRenal Tubular Acidosis 684\ntesticUlar cancer 705\nAcute Kidney Injury 684\nGenitourinary Infections 706\nChronic Kidney Disease 684 Urinary tract infections 706\nUn",
      "char_start": 1896000,
      "char_end": 1898000
    },
    {
      "chunk_id": 949,
      "text": "complicated Uti/lower Uti/acUte simple cystitis 708\nDiuretics 687\npyelonepHritis/Upper Uti/one form of complicated Uti 708\nGlomerular Disease 688 prostatitis: one form of complicated Uti 710\nnepHritic syndrome 688\nSexually Transmitted Diseases 711\nnepHrotic syndrome 692\ncHlamydia 711\nNephrolithiasis 694 gonorrHea 712\nsypHilis 713\nPolycystic Kidney Disease 697\ngenital lesions 715\nHydronephrosis 698\n675\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 667755 1100//2211//2222 44::2277 PPMM\n\n676 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nKEY FACT\nELECTROLYTE DISORDERS\nCertain patients (eg, infants, intubated\npatients, immobilized patients, and\nHYPERNATREMIA\nthose with altered mental status) may\nnot drink enough free water to replace\nSerum sodium >145 mEq/L. Usually caused by free water loss rather than\ninsensible losses. This can cause or\nsodium gain.\nworsen hypernatremia.\nHistory/PE\nOften presents with thirst caused by hypertonicity. Patients can present with\nneurologic symptoms including altered mental status, weakness, focal neuro-\nlogic deficits, and seizures.\nDiagnosis\nThe etiology of hypernatremia can be determined by measuring urine\nosmolality.\nâ–  If urine osmolality is >600 mOsm/kg, hypernatremia most likely stems\nfrom extrarenal water loss (insensible losses, nasogastric tube suction, diar-\nrhea) or excess sodium intake. Measuring urine sodium through a frac-\ntional excretion of sodium can be helpful in distinguishing extrarenal\nlosses (<1%) from sodium gain (>2%).\nâ–  If urine osmolality is <300 mOsm/kg, diabetes insipidus (DI) is the most\nlikely cause of hypernatremia. A desmopressin challenge can differentiate\nbetween central and nephrogenic DI.\nâ–  Rise in urine osmolality with desmopressin = Central DI\nâ–  No rise in urine osmolality with desmopressin = Nephrogenic DI\nâ–  Intermediate values (300â€“600 mOsm/kg) are often seen in osmotic diure-\nsis or partial DI.\nTreatment\nâ–  Determine volume status. If the patient is hypovolemic with uns",
      "char_start": 1898000,
      "char_end": 1900000
    },
    {
      "chunk_id": 950,
      "text": "table vital\nsigns, use isotonic 0.9% NaCl before correcting free water deficits. Use iso-\ntonic 0.9% NaCl until the patient is approaching euvolemia.\nMNEMONIC â–  Determine free water deficit.\nâ–  Water deficit = Total body water Ã— ([serum Na/140] âˆ’ 1).\nCauses of hypernatremiaâ€”\nâ–  Total body water (TBW) is ~60% of lean body weight (in kg).\nThe 6 Ds\nâ–  Determine rate of correction. Correction of chronic hypernatremia (dura-\nDiuresis tion >48 hours) should be accomplished gradually over 48 to 72 hours\nDehydration (â‰¤0.5 mEq/L/hr) to prevent neurologic damage secondary to cerebral\nDiabetes insipidus\nedema. In acute hypernatremia (<48 hours), the entire free water deficit\nDocs (iatrogenic)\ncan be corrected within 24 hours.\nDiarrhea\nâ–  Free water deficit can then be corrected with dextrose 5% water (D W),\nDisease (eg, kidney, sickle cell) 5\n0.45% NaCl, or enteral fluids.\nHYPONATREMIA\nSerum sodium <135 mEq/L. Hyponatremia is most commonly caused by\nâ†‘ ADH, whether physiologic (eg, in decreased effective circulating volume) or\npathologic (as in syndrome of inappropriate secretion of antidiuretic hormone\n[SIADH]). There are some ADH-independent etiologies, such as primary\npolydipsia, starvation (solute deficiency), and the presence of a nonsodium\neffective osmole in the extracellular fluid (eg, glucose in hyperglycemia).\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 667766 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 677\nHyponatremia\nSerum osmolality\n280-295 mEq/L <280 mEq/L >295 mEq/L\nIsotonic Hypotonic Hypertonic\nClinically assess\nMeasure lipids,\nextracellular fluid Measure glucose\nprotein\nvolume\nHyperlipidemia Glucose\nHyperproteinemia Mannitol\nMannitol Contrast agents\nLow Normal Elevated\nHypovolemic Isovolemic Hypervolemic\nhypotonic hypotonic hypotonic\nUrine osmolality\nMeasure fractional Urine osmolality Measure fractional\n>100 mOsm/kg\nexcretion of Na+ <100 mOsm/kg excretion of Na+\n(often >300)\nFEN<1.0% FEN>2.0% FEN<",
      "char_start": 1900000,
      "char_end": 1902000
    },
    {
      "chunk_id": 951,
      "text": "1.0% FEN>2.0%\na a a a\nDiuretics\nGI losses (diarrhea, SIADH\nvomiting, NG suction) Urinary obstruction Hypothyroidism Primary polydipsia Cirrhosis Acute kidney injury\nAdrenal insufficiency Beer drinkers CHF\nSkin losses (burns) Bicarbonaturia (RTA, Glucocorticoid potomania Nephrotic syndrome Chronic renal failure\nThird spacing deficiency\nmetabolic alkalosis)\nFIGURE 2.15-1. Diagnostic algorithm for hyponatremia. Boxes highlighted in yellow represent key lab tests to perform. (Reproduced with permis-\nsion from USMLE-Rx.com.)\nHistory/PE\nâ–  May be asymptomatic, but can present with confusion, lethargy, muscle\ncramps, and nausea.\nâ–  Can progress to seizures, coma, or brainstem herniation. Severity of symp-\ntoms depends on rate and degree of hyponatremia.\nDiagnosis\nâ–  Measure serum osmolality (sOsm). Hypotonic hyponatremia (sOsm\n<280) is the most common type of hyponatremia and is further catego-\nrized by volume status. See Figure 2.15-1 for the full diagnostic algorithm.\nâ–  Hypertonic hyponatremia (sOsm >295) is secondary to increased concen-\ntration of effective osmotic solute. This is commonly seen in hyperglyce-\nmia. Be sure to â€œcorrectâ€ serum sodium for hyperglycemia by adding\n1.6 mEq/L to the sodium for every 100 mg/dL elevation in glucose above A 29-year-old woman with a history\n200 mg/dL. For example, a patient with a measured serum sodium con- of bipolar disorder presents to the\ncentration of 133 mEq/L and a blood glucose concentration of 400 mg/dL emergency department with altered\nmental status. On examination she\nactually has a serum sodium concentration closer to 136 mEq/L.\nseems hypovolemic, with vitals\nâ–  Isotonic hyponatremia (sOsm 280â€“295) is most commonly due to a labora-\nmeasured at blood pressure (BP) of\ntory measurement artifact. Conditions such as hyperlipidemia/hypertri-\n92/50 mm Hg and heart rate (HR)\nglyceridemia or hyperproteinemia (after intravenous [IV] immunoglobulin\nof 106 beats per minute (bpm). Her\ninfusion or in multiple myeloma) increase the solid",
      "char_start": 1902000,
      "char_end": 1904000
    },
    {
      "chunk_id": 952,
      "text": " phase of plasma,\nserum sodium level is 154 mEq/L.\nmeaning there is less water (where sodium is diluted) in the analyzed sam- What is the next best step in\nple, which is not corrected by the machine. management?\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 667777 1100//2211//2222 44::2277 PPMM\n\n678 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTreatment\nâ–  Treat the underlying disorder. Treat hyponatremia from hypervolemic and\neuvolemic etiologies with water restriction Â± diuretics. If hypovolemic,\nreplete volume with NaCl. If severe hyponatremia (Na <120 mEq/L),\nconsider 3% hypertonic saline, particularly if symptomatic (eg, seizures).\nâ–  Correct chronic hyponatremia (>72 hoursâ€™ duration) slowly (<10 mEq/L/\nday) to prevent osmotic demyelination syndrome (symptoms include para-\nparesis/quadriparesis, dysarthria, and coma). See Figure 2.15-2.\nHYPERKALEMIA\nSerum potassium (K+) >5 mEq/L. Etiologies include:\nâ–  Spurious: Hemolysis of blood samples, fist clenching during blood draws,\ndelays in sample analysis, extreme leukocytosis or thrombocytosis\nFIGURE 2.15-2. Osmotic demyelination â–  â†“ excretion: Renal insufficiency, drugs (eg, spironolactone, triamterene,\nsyndrome on MRI. (Adapted with permission\namiloride, angiotensin-converting enzyme [ACE] inhibitors, trime-\nfrom Chang KY, Lee IH, Kim GJ, et al. Plasma exchange\nthoprim, nonsteroidal anti-inflammatory drugs [NSAIDs], nonselective\nsuccessfully treats central pontine myelinolysis after\nacute hypernatremia from intravenous sodium Î²-blockers), hypoaldosteronism, type IV renal tubular acidosis (RTA), cal-\nbicarbonate therapy. BMC Nephrol. 2014;15:56. cineurin inhibitors\ndoi:10.1186/1471-2369-15-56.) â–  Cellular shifts: Cell lysis, tissue injury (rhabdomyolysis), tumor lysis syn-\ndrome, insulin deficiency, acidosis, drugs (eg, succinylcholine, digitalis,\narginine, nonselective Î²-blockers), hyperosmolality, exercise\nâ–  â†‘ intake: Food (most fruits, potatoes), iatrogenic, absorption of blood\n(from",
      "char_start": 1904000,
      "char_end": 1906000
    },
    {
      "chunk_id": 953,
      "text": " hematomas, gastrointestinal [GI] bleeding)\nHistory/PE\nKEY FACT\nMay be asymptomatic or may present with nausea, vomiting, intestinal colic,\nConsider using hypertonic saline\nareflexia, weakness, flaccid paralysis, arrhythmias, and/or paresthesia.\nonly if a patient has seizures or\nacute neurologic decline caused by\nDiagnosis\nhyponatremia and when serum Na+ is\n<120 mEq/L. â–  Confirmation of hyperkalemia with a repeat blood draw for suspected spu-\nrious results. In the setting of extreme leukocytosis or thrombocytosis, the\nphysician should check plasma K+ (as opposed to serum K+, since potas-\nsium can be released from cells in serum and falsely elevate the result).\nKEY FACT\nâ–  Other workup: ECG to evaluate for cardiac complications. ECG findings\nCorrecting hyponatremia too rapidly include tall, peaked T waves; a wide QRS; PR prolongation; and loss of P\ncan lead to osmotic demyelination waves (see Fig. 2.15-3). Can progress to sine waves, ventricular dysrhyth-\nsyndrome. mias, and cardiac arrest.\nTreatment\nâ–  Best initial treatment: It is critical to administer calcium gluconate for\ncardiac cell membrane stabilization if K+ >6.5 mEq/L or if ECG changes\nare present.\nâ–  Give insulin with glucose (to avoid hypoglycemia), Î²-agonists (eg, contin-\nuous inhaled albuterol), and/or alkali (eg, bicarbonate) to temporarily shift\nK+ into cells. This is the most rapid way to shift K+ into cells.\nThis patient probably has â–  Remove K+ from the body. If the patient has residual renal function (ie,\nthey are not anuric/oliguric), consider IV saline (in the setting of hypovo-\nnephrogenic diabetes insipidus\nfrom presumed lithium use. She is lemia) or loop diuretics (in normovolemia/hypervolemia) to enhance uri-\nhypovolemic with unstable vital nary excretion of potassium. Kayexalate (sodium polystyrene sulfonate) is a\nsigns; therefore, the next best step in medication that exchanges sodium for potassium in the bowel and can be\nmanagement calls for initial treatment used to excrete potassium in th",
      "char_start": 1906000,
      "char_end": 1908000
    },
    {
      "chunk_id": 954,
      "text": "e setting of a lack of residual renal func-\nwith normal saline (NS), followed by a tion. Contraindications to this include ileus, bowel obstruction, ischemic\nswitch to D 5 W once her volume status gut, or pancreatic transplants (can cause bowel necrosis).\nimproves.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 667788 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 679\nâ–  Eliminate K+ from the diet, medications (eg, penicillin has K+), and IV QRS\nPeaked\nfluids. widening T\nâ–  Dialysis is needed for patients with renal failure and hyperkalemia refrac-\nPR\ntory to the aforementioned medical management. prolongation\nLow P\nHYPOKALEMIA\nSerum K+ <3.6 mEq/L. Etiologies include:\nâ–  Transcellular shifts: Insulin, Î² -agonists, and alkalosis all cause K+ to shift\n2\nintracellularly (see Fig. 2.15-4).\nFIGURE 2.15-3. Hyperkalemia on ECG.\nâ–  GI losses: Diarrhea, chronic laxative abuse, vomiting, nasogastric tube Electrocardiographic manifestations\nsuction. include peaked T waves, PR prolonga-\nâ–  Renal losses: Diuretics (eg, loop or thiazide), primary mineralocorticoid tion, and a widened QRS complex. (Repro-\nduced with permission from USMLE-Rx.com.)\nexcess or secondary hyperaldosteronism, â†“ circulating volume (stimulates\nrenin-angiotensin-aldosterone system [RAAS]âˆ’ and mineralocorticoid-\nassociated K+ secretion), Bartter and Gitelman syndromes, drugs (eg, gen-\ntamicin, amphotericin), diabetic ketoacidosis, hypomagnesemia, type I\nand type II RTA.\nHistory/PE\nHypokalemia is usually asymptomatic, but it can present with fatigue, muscle\nweakness or cramps, ileus, hyporeflexia, paresthesias, rhabdomyolysis, and\nascending paralysis.\nDiagnosis\nOther workup: ECG may show T-wave flattening, U waves (an additional KEY FACT\nwave after the T wave), and ST-segment depression, leading to atrioventricu-\nlar (AV) block and subsequent cardiac arrest. See Figure 2.15-5. If a patient is on digitalis, K+ levels must\nbe carefully monitored. Hypokalem",
      "char_start": 1908000,
      "char_end": 1910000
    },
    {
      "chunk_id": 955,
      "text": "ia\nTreatment sensitizes the heart to digitalis toxicity,\nbecause K+ and digitalis compete for\nâ–  Treat the underlying disorder.\nthe same sites on the Na+/K+ pump.\nâ–  Oral and/or IV K+ repletion. Oral is the preferred route for safety pur-\nposes. If IV is necessary, a continuous rate of K+ as an additive is preferred\nover an IV K+ bolus. IV boluses should be reserved for symptomatic hypo- KEY FACT\nkalemia or ECG changes. Treatment should not exceed 20 mEq/L/hr.\nHypokalemia is usually caused by\nâ–  Replacement of magnesium. This deficiency makes K+ repletion more\nrenal Â± GI losses.\ndifficult.\nKEY FACT\nIf hypokalemia is not responding to K+\nICF ECF repletion, check magnesium levels.\nMNEMONIC\nK+ shift out K+ shift in\nTreatment of hyperkalemiaâ€”\nC BIG K\nHyperosmolarity Insulin\nExercise Î²-agonists Calcium chloride or gluconate\nCell lysis Alkalosis\n(intravenous)\nAcidosis\nBicarbonate, Î²-agonists\n2\nInsulin + Glucose\nKayexalate (sodium polystyrene sulfonate)\nFIGURE 2.15-4. Causes of transcellular K+ shifts. ECF, Extracellular fluid; ICF, intracellular\nfluid. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 667799 1100//2211//2222 44::2277 PPMM\n\n680 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nFIGURE 2.15-5. Hypokalemia on ECG. Prominent U wave indicated by arrow. (Reproduced with\npermission from Van Beers EJ, Stam J, van den Bergh WM. Licorice consumption as a cause of posterior reversible encepha-\nlopathy syndrome: a case report. Crit Care. 2011;15[1]:R64.)\nHYPERCALCEMIA\nMNEMONIC Serum calcium >10.2 mg/dL. The most common causes are the following:\nCauses of hypercalcemiaâ€” â–  Hyperparathyroidism\nâ–  Malignancy (eg, breast cancer, squamous cell carcinoma, multiple\nCHIMPANZEES\nmyeloma)\nCalcium supplementation\nâ–  Other causes in the mnemonic CHIMPANZEES. See Mnemonic box.\nHyperparathyroidism/Hyperthyroidism\nIatrogenic (eg, thiazides, parenteral\nHistory/PE\nnutrition)/Immobility (especially in the\nintensive care u",
      "char_start": 1910000,
      "char_end": 1912000
    },
    {
      "chunk_id": 956,
      "text": "nit [ICU] setting) Usually asymptomatic but can present with bones (osteopenia, fractures),\nMilk-alkali syndrome (excessive intake of stones (kidney stones), abdominal groans (anorexia, constipation), and psychi-\ncalcium and absorbable alkali) atric overtones (weakness, fatigue, irritability, altered mental status).\nPaget disease\nAdrenal insufficiency/Acromegaly Diagnosis\nNeoplasm\nZollinger-Ellison syndrome (eg, multiple â–  Best initial test: Check of total/ionized calcium and albumin. Reasoning:\nendocrine neoplasia [MEN] type 1) A large portion of serum calcium is albumin bound, and changes in albu-\nExcess vitamin A min concentration can lead to alterations in serum calcium concentration\nExcess vitamin D that do not necessarily affect ionized calcium (the physiologically active\nSarcoidosis and other granulomatous form.) In general, when correcting for serum albumin concentration, the\ndiseases physician can assume that serum calcium falls by 0.8 mg/dL for every\n1 g/dL decrease in serum albumin below 4 g/dL.\nâ–  Also consider: Phosphate, magnesium, parathyroid hormone (PTH), cre-\nKEY FACT atinine, alkaline phosphatase levels. The following tests apply: parathyroid\nhormoneâ€“related peptide (PTHrP) if malignancy is suspected; serum pro-\nSerum calcium levels may be\ntein electrophoresis for multiple myeloma; vitamin D (total 25 vitamin D\nincidentally low in hypoalbuminemia;\nand 1,25 vitamin D levels) if granulomatous disease (eg, sarcoidosis), iatro-\ncheck ionized calcium. Corrected Ca2+\ngenic vitamin D intake, or tuberculosis (TB) is suspected.\n= Total serum Ca2+ + 0.8 (4 âˆ’ serum\nalbumin). â–  Other workup: ECG may show shortened QT interval.\nâ–  See Figure 2.15-6 for diagnostic testing algorithm.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668800 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 681\nHypercalcemia (corrected calcium)\nSerum PTH\nHigh-normal or high Low\nPTH-dependent PTH-independent\nhypercalcemia hyperca",
      "char_start": 1912000,
      "char_end": 1914000
    },
    {
      "chunk_id": 957,
      "text": "lcemia\n25-OH vitamin D\n1,25-OH vitamin D\nUrinary calcium 2\nPTH-related protein\n(PTHrP)\nLow High\n25-OH vitamin D 1,25-OH vitamin D PTHrP Normal\n2\nFamilial hypercalcemic 1Ëš and 3Ëš Sarcoidosis Breast cancer Multiple myeloma\nVitamin D toxicity\nhypocalciuria hyperparathyroidism Lymphoma Squamous cell Immobilization\ntumors Hyperthyroidism\nOvarian cancer Vitamin A toxicity\nRenal cancer Acromegaly\nMilk-alkali syndrome\nFIGURE 2.15-6. Diagnostic testing algorithm for evaluation of hypercalcemia. (Reproduced with permission from USMLE-Rx.com.)\nTreatment\nâ–  The physician should treat the underlying disorder.\nâ–  Mild hypercalcemia (albumin-corrected calcium <12 mg/dL) does not\nrequire urgent treatment. Patients should be encouraged to maintain ade-\nquate hydration (to avoid nephrolithiasis) and to avoid factors that worsen\nhypercalcemia (thiazides, high calcium intake, inactivity).\nâ–  If serum calcium >14 mg/dL, a patient requires urgent treatment with iso-\ntonic IV fluids (Â± furosemide) and calcitonin; bisphosphonates (eg, zole-\ndronic acid, pamidronate) should be considered as well. High sodium\nintake (in isotonic fluids) facilitates renal calcium excretion and prevents\nrenal complications (stones). KEY FACT\nâ–  Asymptomatic patients with serum calcium between 12 and 14 mg/dL do Loop diuretics (furosemide) Lose\nnot require emergent treatmentâ€”they may follow the same precautions\ncalcium. Thiazide diuretics â†‘ Tubular\nnoted earlier for mild hypercalcemia, as well as some therapies (eg, iso-\nreabsorption of calcium.\ntonic fluids) to facilitate excretion of calcium before symptoms develop.\nHYPOCALCEMIA\nSerum calcium <8.5 mg/dL. Etiologies include the following:\nâ–  Parathyroid-related: Hypoparathyroidism (postsurgical, idiopathic), chronic\nkidney disease (causing secondary hyperparathyroidism), and pseudohypo-\nparathyroidism (PTH resistance). In infants, consider abnormal parathyroid\ndevelopment in DiGeorge syndrome.\nâ–  Malnutrition, vitamin D deficiency.\nâ–  Other: Hypomagnesemia, acute pan",
      "char_start": 1914000,
      "char_end": 1916000
    },
    {
      "chunk_id": 958,
      "text": "creatitis, and chelation from citrate\nfound in blood products.\nHistory/PE\nâ–  Hypocalcemia presents with abdominal muscle cramps, dyspnea, tetany,\nperioral and acral paresthesias, and convulsions.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668811 1100//2211//2222 44::2277 PPMM\n\n682 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nKEY FACT â–  Facial spasms elicited from tapping of the facial nerve (Chvostek sign) and\ncarpal spasms after arterial occlusion by a blood pressure (BP) cuff (Trous-\nA classic case of hypocalcemia is a seau sign) are classic findings most commonly seen in severe hypocalcemia.\npatient who develops cramps and\ntetany following thyroidectomy Diagnosis\nbecause of parathyroidectomy as a\nâ–  Most accurate test: Ionized Ca2+ and PTH. See the Endocrinology chap-\ncomplication.\nter for interpretation of PTH levels.\nâ–  Other labs: Mg2+ (low levels can induce PTH resistance); albumin;\n25-OH vitamin D; 1,25-OH vitamin D levels; and electrolytes. Blood urea\nnitrogen (BUN), creatinine, and alkaline phosphatase values may also be\nKEY FACT\nhelpful to assess, depending on the clinical situation.\nHypomagnesemia is very commonly â–  Other workup: ECG may show prolonged QT interval.\nseen in the setting of chronic excessive\nalcohol consumption.\nTreatment\nâ–  Treat the underlying disorder.\nâ–  In most cases, the physician will need to administer oral calcium supple-\nments; severe symptoms or signs call for oral and IV calcium.\nKEY FACT\nâ–  Ensure magnesium repletion.\nAcetylsalicylic acid ([ASA] salicylate)\noverdose can cause both metabolic\nHYPOMAGNESEMIA\nacidosis and respiratory alkalosis.\nSerum magnesium <1.5 mEq/L. Etiologies are as follows:\nâ–  â†“ intake: Malnutrition, malabsorption, short bowel syndrome, total paren-\nKEY FACT teral nutrition (TPN), proton pump inhibitors (PPIs)\nâ–  â†‘ loss: Diuretics, diarrhea, vomiting, hypercalcemia, excessive alcohol\nEthylene glycol presentation = Urine\nconsumption\ncalcium oxalate (envelope-shaped)\nâ–  Miscellaneous",
      "char_start": 1916000,
      "char_end": 1918000
    },
    {
      "chunk_id": 959,
      "text": ": Diabetic ketoacidosis, pancreatitis, extracellular fluid vol-\ncrystals\nume expansion\nMethanol presentation = Vision loss,\noptic disc hyperemia\nBoth present with â†‘ osmolal gap History/PE\n(measured osmolality âˆ’ calculated In severe cases, symptoms may include hyperactive reflexes, tetany, paresthe-\nosmolality >10 mOsmol/L)\nsias, irritability, confusion, lethargy, seizures, and arrhythmias.\nDiagnosis\nMNEMONIC â–  Lab results may show concurrent hypocalcemia and hypokalemia.\nâ–  ECG may reveal prolonged PR and QT intervals.\nSpecific treatments for anion gap\ncauses of metabolic acidosisâ€”\nTreatment\nMUDPILES\nâ–  Generally, most causes respond to IV and/or oral supplements, depending\nMethanol: Fomepizole\non severity.\nUremia: Dialysis\nDiabetic ketoacidosis: Insulin, isotonic IV â–  Hypokalemia and hypocalcemia will not correct without magnesium\nfluids, K+ repletion correction.\nParaldehyde, Phenformin\nIron, INH: GI lavage, charcoal (isoniazid\n[INH])\nLactic acidosis: Correct underlying cause; ACID-BASE DISORDERS\nif from ischemia, then responds to\nrepletion of circulating volume\nTable 2.15-1 lists expected compensation for acid-base disorders. See Fig-\nEthylene glycol: Fomepizole\nure 2.15-7 for a diagnostic algorithm of acid-base disorders.\nSalicylates: Isotonic IV fluids with added\nsodium bicarbonate to alkalinize urine\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668822 1100//2211//2222 44::2277 PPMM\n\nCheck arterial pH\npH <7.35 pH >7.45\nAcidemia Alkalemia\nPco >44 mm Hg HCOâ€“ <20 mEq/L Pco <36 mm Hg HCOâ€“ >28 mEq/L\n2 3 2 3\nRespiratory Respiratory\nMetabolic acidosis Metabolic alkalosis\nacidosis alkalosis\nHypoventilation Check anion gap Hyperventilation\n= Na+ â€“ (CIâ€“ + HCO_)\nAirway obstruction 3 Anxiety/panic attack\nAcute lung disease Hypoxemia (eg, high altitude)\nChronic lung disease Salicylates (early)\nOpioids, sedatives Tumor\nWeakening ofrespiratory Pulmonary embolism\nmuscles Pregnancy\nPco = 40 m2m Hg\nRespiratory\n(cid:31)Anion gap acidosis Mixed\nG",
      "char_start": 1918000,
      "char_end": 1920000
    },
    {
      "chunk_id": 960,
      "text": "OLDMARK: alkalosis\nGlycols (ethylene glycol, propylene glycol)\nOxoproline (chronic acetaminophen use)\nBuffer line\nL-lactate (lactic acidosis) Mixed\nD-lactate (exogenous lactic acid) acidosis\nMethanol (and other alcohols)\nAspirin (late effect) Respiratory\nRenal failure alkalosis\nKetones (diabetic, alcoholic, starvation)\n6.9 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 7.9\npH\nFIGURE 2.15-7. Diagnostic algorithm for acid-base disorders. (Adapted with permission from USMLE-Rx.com.)\nURINE ANION GAP\nâ–  Calculated for normal anion gap acidosis to distinguish renal vs GI bicar-\nbonate loss.\nâ–  Urine anion gap (UAG) = [Urine Na+] + [Urine K+] âˆ’ [Urine Clâˆ’].\nâ–  Urine NH + (which represents renal acid excretion but is difficult to mea-\n4\nsure) is excreted along with Clâ€“ in the urine. A negative UAG indicated\nincreased urine Clâ€“, which suggests that acid (NH +) is being excreted by the\n4\nkidneys. This can be seen in cases of GI HCO â€“ loss or proximal/type 2 RTA.\n3\n)L/lomm(\n]â€“OCH[\namsalP\n3\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 683\nCheck urine Clâ€“\n> 20 mEq/L < 20 mEq/L\nSaline-resistant Saline-responsive\nHyperaldosteronism Vomiting\nBartter syndrome Recent loop/\nGitelman syndrome thiazide diuretics\nAntacids\n> 12 mEq/L 8â€“12 mEq/L\n45 Metabolic\nalkalosis\n40\nNormal anion gap 35\nHARDASS 30\nHyperchloremia/hyperalimentation\nAddison disease 25\nRenal tubular acidosis 20\nDiarrhea\n15\nAcetazolamide\nSpironolactone 10\nSaline infusion Metabolic\n5 acidosis\n1\nA 26-year-old woman with a history\nof depression presents to the\nemergency department with altered\nmental status, tinnitus, nausea, and\nvomiting. An arterial blood gas (ABG)\nassessment shows a pH of 7.4, Paco2\nof 22, and a HCOâˆ’ of 13. What is the\n3\nmost likely diagnosis, and what is her\nacid-base disorder?\nTABLE 2.15-1. Compensation for Acid-Base Disorders\nPRIMARY DISORDER EXPECTED COMPENSATION\n2\nMetabolic acidosis PaCO = (1.5 Ã— HCOâˆ’) + 8 Â± 2 (Winters formula)\n2 3\nA 17-year-old boy with a history of\nMetabolic alkalosis 10 mEq/L â†‘ in [HCO 3 âˆ’] â†’ 7 mm Hg ",
      "char_start": 1920000,
      "char_end": 1922000
    },
    {
      "chunk_id": 961,
      "text": "â†‘ PaCO 2 asthma presents to the emergency\ndepartment with severe shortness\nRespiratory acidosis (chronic) 10 mm Hg â†‘ PaCO 2 â†’ 4 mEq/L â†‘ in [HCO 3 âˆ’] of breath. His arterial pH has gone\nfrom 7.49 to 7.38 and his Paco2 from\nRespiratory alkalosis (chronic) 10 mm Hg â†“ PaCO â†’ 4 mEq/L â†“ in [HCOâˆ’] 30 to 50 mm Hg since the time of\n2 3\nadmission. What is the next best step\nin management?\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668833 1100//2211//2222 44::2277 PPMM\n\n684 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nâ–  A âŠ• UAG suggests impaired NH + excretion, which is seen in cases of\n4\ndistal/type 1 RTA.\nâ–  GI bicarbonate loss (eg, diarrhea) â†’ âŠ UAG\nRENAL TUBULAR ACIDOSIS\nA net â†“ in either tubular H+ secretion or HCO âˆ’ reabsorption that leads to\n3\na nonâ€“anion gap metabolic acidosis. There are three main types of RTA;\ntype IV (aldosterone deficient/resistant) is the most common form (see\nKEY FACT Table 2.15-2).\nA history of AKI and nephrotoxin\nexposure should make the physician\nACUTE KIDNEY INJURY\nsuspect a diagnosis of acute tubular\nnecrosis (ATN).\nFormerly known as acute renal failure, acute kidney injury (AKI) is defined as\nâ†“ renal function, compared with a previous baseline within a period of\n<3 months, leading to the retention of creatinine. â†“ urine output (oliguria,\nMNEMONIC\ndefined as <0.5 mL/kg/hr) is not required for AKI, but if present can be part\nof the diagnostic criteria. Complications include metabolic acidosis, electro-\nIndications for urgent dialysis\nif refractory to medical lyte abnormalities, volume overload, and uremia. Many cases of AKI will\nmanagementâ€” recover with treatment and/or supportive care, but each episode of AKI can\nAEIOU lead to chronic effects and scarring and progressively develop into chronic\nkidney disease (especially with very severe or recurrent AKI). See Table 2.15-3\nAcidosis\nfor the workup of AKI.\nElectrolyte abnormalities (hyperkalemia)\nIngestions (salicylates, theophylline,\nmethanol, barbiturates, li",
      "char_start": 1922000,
      "char_end": 1924000
    },
    {
      "chunk_id": 962,
      "text": "thium,\nethylene glycol) CHRONIC KIDNEY DISEASE\nOverload (fluid)\nUremic symptoms (pericarditis,\nDefined as the presence of kidney damage or decreased kidney function (glo-\nencephalopathy, bleeding, nausea,\nmerular filtration rate [GFR] <60 mL/min in adults, <90 mL/min in chil-\npruritus, myoclonus)\ndren; persistent proteinuria, or structural damage) for 3 or more months,\nregardless of the cause. In adults, it is most commonly caused by poorly con-\ntrolled or long-standing diabetes mellitus (DM) and hypertension. Other\n1\ncauses (in all ages) include:\nThe most likely diagnosis is an â–  Analgesic use (chronic NSAIDs) and chronic use of other nephrotoxic\nmedications\naspirin overdose. Though her pH is\nnormal, she has a mixed metabolic â–  Renovascular disease, particularly in patients with peripheral arterial\nacidosis and respiratory alkalosis. disease\nHer bicarbonate is low, indicating a â–  History of prolonged, severe, and/or recurrent AKI\nmetabolic acidosis. Winters formula â–  Severe or recurrent urinary tract infections\npredicts that the patientâ€™s Paco2 under â–  Urinary tract obstruction\nnormal compensation should be 29 â–  Inherited kidney diseases (such as polycystic kidney disease)\n[Paco2 = 1.5 (HCO 3 âˆ’) + 8]. Her Paco2 is â–  Glomerular disease\nlower than this at 22, which indicates\nâ–  Congenital abnormalities in kidneys or urinary tract (most common cause\na concurrent respiratory alkalosis.\nin children)\nA subset of patients with chronic kidney disease (CKD) will go on to develop\n2 CKD stage 5 (GFR <15 mL/min/1.73m2), which is designated as end-stage\nrenal disease (ESRD) when requiring renal replacement therapy (dialysis).\nThe patientâ€™s symptoms and\nlab results indicate respiratory History/PE\nmuscle fatigue. The next best step CKD is generally asymptomatic until GFR is <30 mL/min/1.73m2, but\nin management may be urgent\npatients can gradually experience the signs and symptoms of disorders such as:\nintubation.\nâ–  Hyperkalemia\n22002222__0022..1155__SStteepp22CCKK__RReennaall__111",
      "char_start": 1924000,
      "char_end": 1926000
    },
    {
      "chunk_id": 963,
      "text": "1ee__667755--771166..iinndddd 668844 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 685\nTABLE 2.15-2. Types of Renal Tubular Acidosisw\nVARIABLE TYPE I (DISTAL) TYPE II (PROXIMAL) TYPE IV (IMPAIRED MINERALOCORTICOID EFFECT)\nDefect H+ secretion HCOâˆ’ reabsorption Aldosterone deficiency or resistance\n3\nSerum K+ Low Low High\nUrinary pH >5.5 â‰¥5.5 at onset, but can be <5.5 once Variable (not typically used to differentiate)\nserum is in its acidotic state\nEtiologies (most Autoimmune disorders, Multiple myeloma, amyloidosis, all â†“ aldosterone production (eg, diabetic hypore-\ncommon) hypercalciuria, ampho- other causes of Fanconi syndrome ninism, ACE inhibitors, ARBs, NSAIDs, heparin,\ntericin B, ifosfamide, (genetic and acquired), amino- cyclosporine, adrenal insufficiency) or aldo-\ngenetic disorders glycosides, ifosfamide, cisplatin, sterone resistance (eg, K+-sparing diuretics,\nacetazolamide nephropathy due to obstruction, TMP-SMX)\nTreatment K+ bicarbonate Treatment of underlying cause, often Depending on etiology, may need mineralo-\nsupplementation needs sodium and K+ bicarbonate corticoid replacement, sodium bicarbonate\nsupplementation supplementation, or K+ wasting diuretics\nAssociated Nephrolithiasis Rickets, osteomalacia\nconditions\nTABLE 2.15-3. Acute Kidney Injury\nPRERENAL INTRINSIC POSTRENAL\nPathophysiology â†“ renal perfusion Injury within the nephron Urinary outflow obstruction\nCommon etiologies Hypovolemia, decreased intravascular volume/ Acute tubular necrosis (ATN) from Prostatic disease, pelvic\nfluid displacement (eg, cirrhosis, nephrotic ischemia or nephrotoxins, glo- tumors, intratubular\nsyndrome, increased vascular permeability merulonephritis, embolic disease, obstruction from crys-\nas in pancreatitis, shock/sepsis), renal artery rhabdomyolysis talluria (acyclovir),\nstenosis, hepatorenal syndrome, drugs Interstitial nephritis (drugs: penicil- bilateral stones, congen-\n(NSAIDs, ACE inhibitors), congestive heart lins, cephalosporins, NS",
      "char_start": 1926000,
      "char_end": 1928000
    },
    {
      "chunk_id": 964,
      "text": "AIDs, sulfa ital obstructions\nfailure (especially with diuretic treatment) drugs, PPIs, allopurinol)\nHistory/PE Symptoms of hypovolemia (tachycardia, History of drug exposure (amino- Suprapubic and/or flank\nhypotension) or other underlying disease glycosides, NSAIDs, penicillins, pain, distended bladder;\nprocess (liver failure, nephrotic syndrome) IV contrast media), red- or dark- bladder scan showing\ncolored urine postvoid residual >50 mL\nLAB VALUES\nBUN/creatinine ratio >20:1 <15:1 Varies\nFractional excretion <1% >2% Varies\nof sodium (Fe )\nNa\nUrine sodium <20 mEq/L >40 mEq/L Varies\nUrine osmolality >500 mOsm/kg <350 mOsm/kg (isosthenuria; Varies\ndamaged tubules cannot reabsorb\nwater or concentrate urine)\n(continues)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668855 1100//2211//2222 44::2277 PPMM\n\n686 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-3. Acute Kidney Injury (continued) pressures and can decrease the rate of progression of proteinuria and CKD\n(and thus should be the first choice for antihypertensive agents in this\nLAB VALUES (continued)\npopulation).\nUrine sediment Hyaline casts as shown in Image A (normal RBC casts/dysmorphic RBCs as shown â–  Reduce cardiovascular risk by starting statin therapy for patients with CKD\nfinding, but in volume depletion) in Image B (glomerulonephritis), over the age of 50 years or for those 18 to 49 years of age with CKD plus a\nWBCs/eosinophils, WBC casts (AIN), history of coronary artery disease (CAD), DM, or prior stroke.\nâ€œmuddy-brown or granular castsâ€ â–  Manage anemiaâ€”recommend erythropoiesis-stimulating agents (ESAs) for\npatients with anemia in CKD with a hemoglobin concentration <10 g/dL\nas shown in Image C (ATN), WBC\ndespite adequate iron stores.\ncasts (pyelonephritis), fatty casts\nâ–  Monitor serum phosphorus, calcium, and PTH to assess risk for mineral\n(nephrotic syndrome)\nand bone disorders. Manage persistent hyperphosphatemia with oral phos-\nphate binders (calcium acetate, c",
      "char_start": 1928000,
      "char_end": 1930000
    },
    {
      "chunk_id": 965,
      "text": "alcium carbonate, sevelamer, lantha-\nTreatment For all etiologies, avoid nephrotic drugs (metformin, NSAIDs) For intrinsic and postrenal etiologies, dialize if meet\nnum). Consider calcitriol (1,25-OH vitamin D) for patients with persistent\nAEIOU criteria and refractory to medical management (see mnemonic) secondary hyperparathyroidism to reduce the risk of osteodystrophy.\nâ–  Manage persistent metabolic acidosis (serum bicarbonate <22 mEq/L)\nProvide fluids to replete circulating volume Prevent contrast nephropathy with Provide urgent bladder scan\nwith alkali salt therapy (most commonly oral sodium bicarbonate\nif hypovolemic; IV fluids will not help IV fluids or nonionic contrast and catheterization or supplementation).\nhepatorenal syndrome, nephrotic syn- agents; discontinue offending relief of obstruction, as â–  Ensure medications are dose adjusted, taking into account the patientâ€™s GFR.\ndrome, CHF, or other causes of increased medications; specific therapies as applicable â–  Patients with a GFR <30 mL/min/1.73m2 should start education regard-\ntotal body volume applicable (eg, corticosteroids) for ing renal replacement therapy (dialysis, transplant). Patients anticipating\ninitiation of hemodialysis should be referred to a vascular surgeon for cre-\nglomerulonephritis\nation of a fistula.\nA B C\nDIURETICS\nTable 2.15-4 summarizes the mechanisms of action and adverse effects of\ncommonly used diuretics. Figure 2.15-8 provides a review of nephron physiol-\nogy with diuretic sites of action.\nImage A reproduced with permission from USMLE-Rx.com. Images B and C reproduced with permission from USMLE-Rx.com, courtesy of Dr. Adam\nWeinstein.\nâ–  Metabolic acidosis\nâ–  Secondary hyperparathyroidism (impaired vitamin D activation, decreased\nphosphate excretion, hypocalcemia, renal osteodystrophy)\nâ–  Anemia of CKD\nâ–  Uremia (seen most commonly in very advanced CKDâ€”symptoms and\ncomplications include anorexia, nausea/vomiting, uremic pericarditis, ure-\nmic frost, delirium, impaired platelet aggr",
      "char_start": 1930000,
      "char_end": 1932000
    },
    {
      "chunk_id": 966,
      "text": "egation, seizures and coma)\nDepending on the etiology, patients can exhibit a varying degree of edema\nand hypertension because of their reduced ability to excrete salt and water\n(also seen frequently in those with nephrotic-range proteinuria.)\nDiagnosis\nKEY FACT A diagnosis of CKD requires persistently impaired renal function or proteinuria,\nconfirmed by repeating laboratory assessment 3 months after initially detected.\nCardiovascular disease is the most Kidney biopsy may need to be considered to determine the etiology of\ncommon cause of death in dialysis CKD when there is suspicion of glomerulonephritis or unexplained tubuloin-\nand renal transplant patients (>50%). terstitial disease.\nInfectious complications are the\nsecond most common cause (and most Management\ncommon cause of death in pediatric\nâ–  Ensure tight BP controlâ€”target <130/80 mm Hg in adults. ACE inhibitors\ndialysis and transplant patients).\nand angiotensin receptor blockers (ARBs) decrease glomerular filtration\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668866 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 687\npressures and can decrease the rate of progression of proteinuria and CKD\n(and thus should be the first choice for antihypertensive agents in this\npopulation).\nâ–  Reduce cardiovascular risk by starting statin therapy for patients with CKD\nover the age of 50 years or for those 18 to 49 years of age with CKD plus a\n1\nhistory of coronary artery disease (CAD), DM, or prior stroke.\nâ–  Manage anemiaâ€”recommend erythropoiesis-stimulating agents (ESAs) for\nA 68-year-old woman with a history of\npatients with anemia in CKD with a hemoglobin concentration <10 g/dL\nhepatitis and chronic kidney disease\ndespite adequate iron stores.\n(CKD) presents with right upper\nâ–  Monitor serum phosphorus, calcium, and PTH to assess risk for mineral quadrant (RUQ) abdominal pain. A\nand bone disorders. Manage persistent hyperphosphatemia with oral phos- CT scan iden",
      "char_start": 1932000,
      "char_end": 1934000
    },
    {
      "chunk_id": 967,
      "text": "tifies liver cirrhosis. Two\nphate binders (calcium acetate, calcium carbonate, sevelamer, lantha- days later, her creatinine levels have\nnum). Consider calcitriol (1,25-OH vitamin D) for patients with persistent doubled. What is the likely cause,\nRsEeNcAoLn TUdBaUrLyA hR yApCIeDrOpSaISrathyroidism to reduce the risk of osteodystrophy. and what could have prevented this\nâ–  Manage persistent metabolic acidosis (serum bicarbonate <22 mEq/L) outcome?\nwith alkali salt therapy (most commonly oral sodium bicarbonate\nsupplementation).\nâ–  Ensure medications are dose adjusted, taking into account the patientâ€™s GFR. 2\nâ–  Patients with a GFR <30 mL/min/1.73m2 should start education regard-\ning renal replacement therapy (dialysis, transplant). Patients anticipating A 37-year-old unhoused man was\ninitiation of hemodialysis should be referred to a vascular surgeon for cre- found unconscious on a park bench.\nation of a fistula. Upon waking, he complains of severe\nmuscle soreness and red urine. His\nurine dipstick is positive for blood,\nbut his urine microscopy has no RBCs.\nDIURETICS What is the likely cause of this finding,\nand what is the best next step?\nTable 2.15-4 summarizes the mechanisms of action and adverse effects of\ncommonly used diuretics. Figure 2.15-8 provides a review of nephron physiol-\nogy with diuretic sites of action.\nDistal\nGlomerulus H N C a+ O 3 â€“ 4 con tu v b o u lu le ted Ca2+\nProximal Na+\nAfferent 2 convoluted CIâ€“\ntubule\nEfferent\n1\n5\nSugars K+\nHO Amino acids H+\n2 Na+\n5\nCa2+ Na+\nMg2+\nCortex\nMedulla 3\nNa+\nK+\n2CIâ€“\n1 Mannitol\nDescending limb,\nloop of Henle Ascending limb,\n2 Acetazolamide\nKEY FACT (permeable to water) loop of Henle\n3 Loop diuretics (permeable to salts)\nCardiovascular disease is the most\n4 Thiazide diuretics\ncommon cause of death in dialysis\n5 K+ sparing diuretics\nand renal transplant patients (>50%). Collecting\nduct\nInfectious complications are the\nsecond most common cause (and most\ncommon cause of death in pediatric Loop of Henle\ndialysis and transp",
      "char_start": 1934000,
      "char_end": 1936000
    },
    {
      "chunk_id": 968,
      "text": "lant patients).\nFIGURE 2.15-8. Diuretics: Site of action. (Adapted with permission from USMLE-Rx.com.)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668877 1100//2211//2222 44::2277 PPMM\n\n688 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-4. Mechanisms of Action and Adverse Effects of Diuretics\nTYPE DRUGS SITE OF ACTION MECHANISM OF ACTION ADVERSE EFFECTS\nCarbonic Acetazolamide Proximal convo- Inhibit carbonic anhydrase â†’ Metabolic acidosis (due to loss of\nanhydrase luted tubule Na+/HCOâˆ’ loss HCOâˆ’); contraindicated in sulfa\n3 3\ninhibitors allergy\nOsmotic Mannitol, urea Entire tubule â†‘ tubular fluid osmolarity (nonre- No high-yield adverse effectsâ€”rarely\nagents absorbable sugar alcohol) used in clinical practice\nLoop agents Furosemide, ethacrynic Ascending loop Inhibit Na+/K+/2Clâˆ’ transporter Water loss, metabolic alkalosis, â†“ K+,\nacid, bumetanide, of Henle â†“ Ca2+, â†“ Mg2+, ototoxicity, sulfa\ntorsemide allergy (except ethacrynic acid),\nhyperuricemia\nThiazide Hydrochlorothiazide, Distal convoluted Inhibit Na+/Clâˆ’ transporter Metabolic alkalosis, â†“ Na+, â†“ K+, â†‘\nagents chlorothiazide, tubule glucose, â†‘ Ca2+, uric acid, sulfa allergy\nchlorthalidone\nK+-sparing Spironolactone, eplere- Cortical collecting Aldosterone receptor antagonist Metabolic acidosis; â†‘ K+; anti-\nagents none, triamterene, tubule (spironolactone, eplerenone); androgenic effects, including\namiloride block sodium channel gynecomastia (spironolactone)\n(triamterene, amiloride)\nKEY FACT\nPostinfectious glomerulonephritis will\npresent 2 to 6 weeks after an infection\nGLOMERULAR DISEASE\nand has a low C3; IgA nephropathy will\npresent concurrent with an infection\nand has a normal C3.\nNEPHRITIC SYNDROME\nKEY FACT\nA disorder of glomerular inflammation, also called glomerulonephritis. Pro-\nGranulomatosis with polyangiitis = teinuria may be present but is variable. If severe glomerular inflammation, it\nkidney + lung + sinus can exceed 2 g/day and lead to a concurrent nephrotic sy",
      "char_start": 1936000,
      "char_end": 1938000
    },
    {
      "chunk_id": 969,
      "text": "ndrome. Most cases\nMicroscopic polyangiitis = kidney + of glomerulonephritis are usually associated with less proteinuria, often\nlung <1.5 g/day. Causes are summarized in Table 2.15-5. Subtypes based on\nChurg-Strauss syndrome = kidney + serum complement levels are displayed in Figure 2.15-9.\nasthma\nNephritic syndrome\n1\nSerum C3 and C4\nThe patient probably has contrast-\nLow Normal\ninduced nephropathy and would have\nbenefited from isotonic saline hydration\nbefore and during the CT scan. Postinfectious IgA nephropathy\nglomerulonephritis Goodpasture syndrome\nMembranoproliferative Granulomatosis with polyangiitis\nglomerulonephritis\n2 Microscopic polyangiitis\nSystemic lupus erythematosus\nChurg-Strauss syndrome\nSubacute endocarditis\nHenoch-Schonlein purpura\nThis patient probably has Cryoglobulinemia\nAlport syndrome\nrhabdomyolysis, and the urine dipstick Cholesterol emboli Hypersensitivity vasculitis\nis detecting myoglobin. He should Hemolytic-uremic syndrome (HUS)/\nbe managed with saline hydration, thrombotic thrombocytopenic purpura (TTP)\nbicarbonate, and an ECG to rule out\nlife-threatening hyperkalemia. FIGURE 2.15-9. Serum complement levels in nephritic syndromes. (Reproduced with permission from\nUSMLE-Rx.com.)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668888 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 689\nTABLE 2.15-5. Causes of Nephritic Syndrome\nDISORDER DESCRIPTION HISTORY/PE LABS/HISTOLOGY TREATMENT/PROGNOSIS\nIMMUNE COMPLEX\nPostinfectious Classically associated Tea- or cola-colored urine, Low serum C3 that nor- Supportive with\nglomerulonephritis with recent group A HTN, edema, and occasional malizes 6â€“8 weeks diuretics to treat\nÎ²-hemolytic strep- oliguria after presentation; ASO fluid overload\ntococcal infection and/or anti-DNase B (if and/or HTN, most\nbut can be seen with Streptococcus associ- patients have a\nmany other infec- ated); lumpy-bumpy complete recovery\ntions (usually immunofluorescence",
      "char_start": 1938000,
      "char_end": 1940000
    },
    {
      "chunk_id": 970,
      "text": "\n2â€“4 weeks after the\ninfectious trigger)\nMost common cause in\nchildren\nIgA nephropathy Most common cause of Episodic gross hematuria with Normal C3; IgA deposits on ACE inhibitors in\n(Berger disease) glomerulonephritis respiratory and/or GI infec- immunofluorescence patients with persis-\nin adults; typically tions; often with persistent tent hypertension\noccurs concurrent microscopic hematuria and/or proteinuria;\nwith an upper respi- between infections; patient glucocorticoids\nratory or GI infection may also have chronic HTN in select severe\n(IgA-producing and low to moderate levels inflammatory\nmucosa); this is the of proteinuria presentations\nrenal manifestation HSP is diagnosed when there Nonresponsive\nof HSP (IgA vasculitis) is palpable purpura without patients have slow\nthrombocytopenia and one progression to ESRD\nof the following three: renal Treatment for HSP in\ndisease, arthralgia, abdom- the absence of renal\ninal pain involvement is gen-\nerally supportive\nMembranoproliferative Immune complexâ€“ May present with nephrotic â€œTram-track,â€ double-layered Prednisone Â± immu-\nnephropathy type I/ mediated MPGN syndrome; clinical features basement membrane; nosuppressive\nIII (nomenclature is either primary may include gross hema- subendothelial and therapy the main-\nchanging, but these (especially in chil- turia, HTN, and/or edema mesangial deposits are stays of treatment;\nare the classic terms, dren) or secondary present RAAS inhibition is\nbased on electron to HBV, HCV, SLE, or often given\nmicroscopy) cryoglobulinemia\nMembranoprolif- Complement-mediated This nephritis may also present Intramembranous dense Antihypertensive\nerative nephropathy MPGN (dense deposit with a nephrotic syndrome; deposits. â€œTram-track,â€ therapy and RAAS\ntype II (nomencla- disease) associated clinical features may include double-layered basement inhibition; severe\nture is changing, with C3 nephritic gross hematuria, hyperten- membrane may also be cases call for immu-\nbut this is the classic fa",
      "char_start": 1940000,
      "char_end": 1942000
    },
    {
      "chunk_id": 971,
      "text": "ctor and persistent sion, and/or edema present (arrows in image) nosuppressive\nterm based on elec- compliment activa- therapy\ntron microscopy) tion with â†“ C3 levels\n(continues)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 668899 1100//2211//2222 44::2277 PPMM\n\n690 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-5. Causes of Nephritic Syndrome (continued)\nDISORDER DESCRIPTION HISTORY/PE LABS/HISTOLOGY TREATMENT/PROGNOSIS\nLupus nephritis Classified as WHO types May present with gross Mesangial proliferation; Prednisone and\nIâ€“VI; the severity of hematuria, HTN, and/or subendothelial and/or immunosup-\nrenal disease often edema, or as microscopic subepithelial immune pressive therapy\ndetermines overall proteinuria/hematuria; complex deposition; (mycophenolate,\nprognosis renal disease may include there is typically a low cyclophosphamide)\nnephrotic (membranous), serum C3 and C4 level the mainstays of\nRPGN, nephritic (membra- treatment; RAAS\nnoproliferative), or mixed inhibition is also\npresentations often given\nPAUCI-IMMUNE (NO IG DEPOSITS ON IMMUNOFLUORESCENCE)\nGranulomatosis with Granulomatous Nasopharyngeal symptoms Presence of High-dose cor-\npolyangiitis ([GPA], inflammation of the that may include stridor; PR3-ANCA/c-ANCA (anti- ticosteroids,\nformerly Wegener respiratory tract (with cavitary pulmonary lesions proteinase 3); crescents cyclophospha-\ngranulomatosis) nasopharyngeal bleed and lead to hemop- may be apparent on light mide, or rituximab;\ninvolvement) and tysis; renal manifestations microscopy patients tend to\nkidney with necro- often include AKI/RPGN, have frequent\ntizing vasculitis of HTN, gross hematuria, and relapses; life-\nglomerular capillaries oliguria threatening cases\nare treated with\nplasmapheresis\nMicroscopic Small vessel vasculitis Similar to GPA but no naso- MPO-ANCA/p-ANCA Glucocorticoids,\npolyangiitis similar to GPA; no pharyngeal involvement; (antimyeloperoxidase); cyclophosphamide,\ngranulomas renal man",
      "char_start": 1942000,
      "char_end": 1944000
    },
    {
      "chunk_id": 972,
      "text": "ifestation often necrotizing glomerulone- or rituximab; life-\nAKI, HTN, sometimes gross phritis with crescents on threatening cases\nhematuria, oliguria light microscopy are treated with\nplasmapheresis\nEosinophilic granu- Small vessel vasculitis Asthma, sinusitis, skin nodules/ MPO-ANCA, eosinophils, Glucocorticoids,\nlomatosis with similar to GPA purpura, peripheral neu- IgE; necrotizing glomeru- cyclophosphamide,\npolyangiitis (Churg- ropathy; renal manifestation lonephritis with crescents or rituximab; life-\nStrauss syndrome) often AKI, HTN, sometimes on light microscopy threatening cases\ngross hematuria, oliguria are treated with\nplasmapheresis\nANTIâ€“GLOMERULAR BASEMENT MEMBRANE (GBM) DISEASE\nGoodpasture Rapidly progressing Hemoptysis, dyspnea, pos- Linear anti-GBM IgG Plasma exchange\nsyndrome glomerulonephritis sible respiratory failure; deposits on immunofluo- therapy; pulsed\nwith pulmonary no upper respiratory tract rescence; iron-deficiency steroids and\nhemorrhage; peak involvement; renal manifes- anemia; hemosiderin- cyclophosphamide\nincidence affects tations often include AKI/ filled macrophages in Anti-GBM disease\nmales in their RPGN, HTN, gross hematuria, sputum; pulmonary infil- is severe and life-\nmid-20s oliguria trates on CXR; necrotizing threatening; it may\nglomerulonephritis with not be responsive to\ncrescents apparent via treatment and may\nlight microscopy progress to ESRD\n(continues)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669900 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 691\nTABLE 2.15-5. Causes of Nephritic Syndrome (continued)\nDISORDER DESCRIPTION HISTORY/PE LABS/HISTOLOGY TREATMENT/PROGNOSIS\nAlport syndrome Hereditary glomeru- Ranges from asymptomatic Irregular thickness of GBM Progresses to CKD,\nlonephritis; 80% of but persistent microscopic with areas of thinning but ACE inhibitor\ncases are X-linked hematuria to gross hema- and areas of thickening; can slow progres-\nones; t",
      "char_start": 1944000,
      "char_end": 1946000
    },
    {
      "chunk_id": 973,
      "text": "hus, they are turia during systemic GBM may also have a sion by controlling\nmore often present stressors or illness â€œbasket-weaveâ€ appear- proteinuria and\nin males; Alport Progressive proteinuria and ance and have areas of hypertension\nsyndrome is typically [down] GFR is seen in splitting on electron Kidney transplant\ndiagnosed between patients microscopy is the definitive\n5 and 20 years of age Sensorineural deafness and treatment if there\neye disorders are also noted is progression to\nESRD; about 10%\nof patients develop\nanti-GBM disease\nafter transplant\nAKI, Acute kidney injury; ANCA, antineutrophil cytoplasmic antibody; Anti-DNase B, antiâ€“deoxyribonuclease B; ASO, antistreptolysin O; CXR, x-ray\nof the chest; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HSP, Henoch-Schonlein purpura; HTN, hypertension; MPGN, membranoproliferative\nglomerulonephritis; PR3, proteinase 3; RPGN, rapidly progressive glomerulonephritis; SLE, systemic lupus erythematosus; WHO, World Health\nOrganization. (Image reproduced with permission from USMLE-Rx.com; courtesy of Dr. Adam Weinstein.)\nHistory/PE\nThe classic findings of nephritic syndrome may include microscopic or mac-\nroscopic (if so, tea- or cola-colored urine), hypertension, and/or edema.\nDiagnosis\nâ–  Urinalysis (UA) shows hematuria and variable degrees of proteinuria.\nâ–  In most severe cases, patients may have a â†“ GFR with elevated BUN and\ncreatinine. See Table 2.15-5 for pertinent labs.\nâ–  Renal biopsy may be needed for histologic evaluation and treatment and\nprognosis considerations.\nâ–  Two specific examples of findings are shown in Figure 2.15-10.\nTreatment\nâ–  If present, treat hypertension, fluid overload with salt restriction, RAAS\nblockade, Â± diuretics.\nâ–  In some cases, depending on the etiology, corticosteroids Â± other immu-\nnosuppressant agents are a necessary treatment to reduce glomerular\ninflammation.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669911 1100//2211//2222 44::2277 PPMM\n\n69",
      "char_start": 1946000,
      "char_end": 1948000
    },
    {
      "chunk_id": 974,
      "text": "2 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nA NEPHROTIC SYNDROME\nNephrotic syndrome is defined as follows:\nâ–  Hyperproteinuria (â‰¥3.5 g/day)\nâ–  Hypoproteinemia/hypoalbuminemiaâ€”albumin levels fall because of pro-\ntein loss\nâ–  Hyperlipidemia (may result in accelerated atherosclerosis if chronic)\nâ–  Edema\nNephrotic syndrome can cause a hypercoagulable state with thrombosis\ndue to loss of antithrombin III, protein C, and protein S in urine.\nB\nApproximately one third of all cases result from systemic diseases such as\nDM, systemic lupus erythematosus (SLE), or amyloidosis. In children, the\nmost common cause is minimal change disease, a primary disease of the\nkidney and not a systemic disease. Causes and findings are summarized in\nTable 2.15-6.\nHistory/PE\nâ–  Presents with generalized edema. Sometimes patients will notice they\nhave foamy urine. In severe cases, dyspnea and ascites and other complica-\ntions from anasarca may develop.\nâ–  Patients have â†‘ susceptibility to infection (caused by loss of IgG protein in\nthe urine) and hypercoagulable states with an â†‘ risk for venous thrombosis\nand pulmonary embolism (caused by loss of antithrombin 3, increased\nFIGURE 2.15-10. Examples of immu- platelet aggregation, and changes in protein C and S levels). This\nnofluorescent findings in nephritic\nincreased risk of hypercoagulability commonly manifests as renal vein\nsyndrome. (A) Granular endocapillary\nthrombosis.\nimmune complex deposition, causing\nâ€œlumpy-bumpyâ€ texture, also known as\nâ€œstarry skyâ€ immunofluorescence, found Diagnosis\nin postinfectious glomerulonephritis.\nâ–  UA shows proteinuria (â‰¥3.5 g/day) and may show lipiduria (Maltese\n(B) Linear immunofluorescence seen in\ncrosses signifying lipids on microscopic urine exam). It is now more\nGoodpasture syndrome. (Image A reproduced\nwith permission from Oda T, Yoshizawa N, Yamakami common for clinicians to use a spot protein-to-creatinine ratio rather\nK, et al. The role of nephritis-associated plasmin than 24-hour urine. The cutoff for nephrot",
      "char_start": 1948000,
      "char_end": 1950000
    },
    {
      "chunk_id": 975,
      "text": "ic syndrome is 2.0 on this\nreceptor [NAPLR] in glomerulonephritis associated ratio.\nwith streptococcal infection, Biomed Biotechnol.\nâ–  Blood chemistry shows â†“ albumin (<3 g/dL) and hyperlipidemia.\n2012;2012:417675. Image B reproduced with permis-\nsion from Kasper D et al. Harrisonâ€™s Principles of Internal â–  Evaluation should include workup for secondary causes.\nMedicine, 19th ed. New York, NY: McGraw-Hill; 2015.) â–  Renal biopsy may also be needed to definitively diagnose the underlying\netiology.\nKEY FACT Treatment\nâ–  Treat with salt restriction and judicious diuretic therapy.\nDifferential diagnosis for nephritic/\nâ–  If the patient is hypertensive, the physician can use RAAS blockade and/or\nnephrotic syndrome with low C3:\ndiuretic therapy.\nPostinfectious, membranoproliferative\nâ–  If nephrotic syndrome is chronic, the physician may need to treat the\nglomerulonephritis (including mixed\npatient with statins. A history of or a suspicion for thrombosis calls for\ncryoglobulinemia) and lupus nephritis.\nanticoagulants.\nâ–  Steroids and/or other immunosuppressant medications may be useful for\ncertain etiologies.\nKEY FACT â–  ACE inhibitors/ARBs â†“ proteinuria and diminish the progression of renal\ndisease in patients with renal scarring (especially in patients with diabetes).\nMixed cryoglobulinemia presents with\nâ–  Vaccinate patients with 23-polyvalent pneumococcus vaccine (PPV23), as\npalpable purpura, arthralgias, nephritic/\npatients are at â†‘ risk for Streptococcus pneumoniae infection, based on\nnephrotic syndrome, low C3, and\nhypogammaglobulinemia from immunoglobulin losses in urine and\npositive hepatitis C virus (HCV).\nedema (pulmonary edema, ascites).\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669922 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 693\nTABLE 2.15-6. Causes of Nephrotic Syndrome\nDISORDER DESCRIPTION HISTORY/PE LABS/HISTOLOGY TREATMENT/PROGNOSIS\nMinimal change disease The most common Sudden onset of Biops",
      "char_start": 1950000,
      "char_end": 1952000
    },
    {
      "chunk_id": 976,
      "text": "y is recommended Steroids; favorable\nA cause of nephrotic edema in treatment-resistant prognosis\nsyndrome in children disease or with age >12\nIdiopathic etiology; years; otherwise diag-\nsecondary causes nosis is clinical; light\ninclude NSAIDs and microscopy appears\nhematologic malig- normal; electron\nnancies (eg, Hodgkin microscopy shows\nB\ndisease) diffuse effacement of\nepithelial foot processes\n(see Image A)\nImage B shows a normal\nglomerulus\nFocal segmental glomeruloscle- Idiopathic, but also can Presents with hyper- Biopsy shows focal For idiopathic FSGS,\nrosis (FSGS) be secondary to IV tension and often glomerular sclerosis treatment is predni-\nC drug use (heroin), with edema in capillary tufts (see sone and/or other\nHIV, sickle cell Image C) immunosuppressant\ndisease, and obesity; therapy; in addition,\nfocal segmental and for all other\nglomerulosclerosis cases, supportive\nis the most common treatments with ACE\ncause of nephrotic inhibitors/ARBs to â†“\nsyndromes in adults, proteinuria and treat\nespecially in people hypertension\nof African descent\nMembranous nephropathy Accounts for Â±30% of May be primary â€œSpike-and-domeâ€ RAAS inhibition is first\nD nephrotic syndromes (antibodies to appearance caused by line; prednisone\nin adults; membra- phospholipase granular deposits of and immunosup-\nnous nephropathy [PLA]2 receptors) or IgG and C3 at the sub- pressive therapy are\nis the most common secondary to solid epithelial side of the for severe disease\ncause of nephrotic tumor malignan- basement membrane; refractory to RAAS\nsyndrome in people cies, infections (HBV, on light microscopy, inhibition alone\nof European descent malaria), autoim- GBM thickening is seen\nmune diseases (SLE), (arrows in Image D)\ndrugs (NSAIDs, gold) Antiphospholipase A\n2\nPatients present with receptor (PLA2R) anti-\nanasarca bodies are associated\nMembranous nephrop- with primary membra-\nathy has the highest nous nephropathy\nrate of thrombosis,\nlikely related to\nseverity of protein\nlosses\n(continues)",
      "char_start": 1952000,
      "char_end": 1954000
    },
    {
      "chunk_id": 977,
      "text": "\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669933 1100//2211//2222 44::2277 PPMM\n\n694 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-6. Causes of Nephrotic Syndrome (continued)\nDISORDER DESCRIPTION HISTORY/PE LABS/HISTOLOGY TREATMENT/PROGNOSIS\n8P5.5\nDiabetic nephropathy Has two characteristic Patients generally Thickened GBM; Tight control of blood\nE forms: diffuse hyalin- have long-standing, mesangial matrix; Kim- sugar; adminis-\nization and nodular poorly controlled melstiel-Wilson lesions tration of ACE\nglomerulosclerosis DM with evidence of are seen (see Image E) inhibitors or ARBs\n(Kimmelstiel-Wilson other organ system The physician can\nlesions) complications (eg, screen for diabetic\nretinopathy, neu- nephropathy with\nropathy); rapidly random urine\nprogressing kidney microalbumin/cre-\ndisease is sugges- atinine ratio\ntive of a different\netiology\nRenal amyloidosis Primary (plasma cell Patients may have Nodular glomerulo- Prednisone and\ndyscrasia) and sec- multiple myeloma sclerosis; electron melphalan; bone\nondary (infectious or or a chronic inflam- microscope reveals marrow transplanta-\ninflammatory)â€”the matory disease (eg, amyloid fibrils, apple- tion may be used for\nmost common rheumatoid green birefringence multiple myeloma;\narthritis, TB) with Congo red stain AA amyloidosis\nis managed by\ntreating the under-\nlying inflammatory\ncondition\nImage A reproduced with permission from Teoh DC, El-Modir A. Managing a locally advanced malignant thymoma complicated by nephrotic\nsyndrome: a case report. J Med Case Rep. 2008;2:89 doi:10.1186/1752-1947-2-89. Image B and C reproduced with permission from Ramidi GB,\nKurukumbi MK, Sealy PL. Collapsing glomerulopathy in sickle cell disease: a case report. J Med Case Rep. 2011;5:71 doi:10.1186/1752-1947-5-71.\nImage C reproduced with permission from Ramidi GB, Kurukumbi MK, Sealy PL. Collapsing glomerulopathy in sickle cell disease: a case report.\nJ Med Case Rep. 2011;5:71 doi:10.1186",
      "char_start": 1954000,
      "char_end": 1956000
    },
    {
      "chunk_id": 978,
      "text": "/1752-1947-5-71. Image D reproduced with permission from USMLE-Rx.com. Image E reproduced with\npermission from the US Department of Health and Human Services and Dr. Edwin P. Ewing, Jr.\nNEPHROLITHIASIS\nRenal calculi. Stones are most commonly calcium oxalate, but many\nKEY FACT other types exist (see Table 2.15-7). Risk factors include a âŠ• family history,\nlow fluid intake, gout, medications (allopurinol, chemotherapy, loop\nThe bacteria associated with â€œstaghorn\ndiuretics), postcolectomy/postileostomy, specific enzyme deficiencies, type\ncalculiâ€ are urease-producing organisms,\nI RTA (caused by alkaline urinary pH and associated hypocitraturia), and\nsuch as Proteus and Klebsiella.\nhyperparathyroidism.\nHistory/PE\nâ–  Presents with acute onset of severe, colicky flank pain that may radiate to\nthe groin and is associated with nausea and vomiting.\nâ–  Patients are unable to get comfortable and shift position frequently (as\nopposed to those with peritonitis, who lie still).\nDiagnosis\nâ–  UA may show gross or microscopic hematuria (85%).\nâ–  Noncontrast abdominal CT scan is the gold standard for the diagnosis of\nkidney stones (see Fig. 2.15-11).\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669944 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 695\nTABLE 2.15-7. Types of Nephrolithiasis\nTYPE ETIOLOGY AND CHARACTERISTICS URINARY PH TREATMENT\n8P5.5\nCalcium oxalate Most common causes are idio- Calcium oxalate precipitates Hydration, dietary sodium\nA pathic hypercalciuria, but also with hypocitraturia, which is restriction, thiazide diuretic\nmay see in fat malabsorption often associated with â†“ pH Do not decrease calcium\n(eg, with Crohn disease or intake (can lead to hyp-\nbowel resection) eroxaluria and risk for\nStones are radiopaque osteoporosis)\nEnvelope- or dumbbell-shaped May also begin citrate supple-\nstones (Image A) ments, but pH must not be\nraised too high\nCalcium phosphate Most common causes are idio- Calcium phosphate ",
      "char_start": 1956000,
      "char_end": 1958000
    },
    {
      "chunk_id": 979,
      "text": "precipitates Hydration, dietary sodium\npathic hypercalciuria but also at â†‘ pH restriction\nmay see in primary hyper- Thiazide diuretic only for\nparathyroidism or immobility idiopathic etiology and not\nsyndromes that result in high when hyperparathyroidism\nbone loss is etiology\nStones are radiopaque Do not decrease calcium\nWedge-shaped prism stones intake (can lead to hyp-\neroxaluria and risk for\nosteoporosis)\nStruvite (MgNHPO) or â€œtriple Associated with urease-pro- â†‘ pH Hydration\n4 4\nphosphateâ€ ducing organisms (eg, Proteus) Treat UTI if present\nB Patients may have history of Surgically remove staghorn\nrecurrent UTIs stones (antibiotics alone are\nStones are radiopaque not enough)\nStaghorn-shaped stones (Image\nB)\nFrequency: 9%\nUric acid Associated with gout, xanthine â†“ pH Hydration\nC oxidase deficiency, and high Alkalize urine\npurine turnover states (eg, First-line management:\nchemotherapy) Restrict dietary purines\nStones are radiolucent on plain If stones recur despite dietary\nfilm, but can be detectable management, consider\nwith CT (not as bright as allopurinol\ncalcium stones on CT)\nRhomboid-shaped stones\n(Image C)\nFrequency: 7%\n(continues)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669955 1100//2211//2222 44::2277 PPMM\n\n696 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-7. Types of Nephrolithiasis (continued)\nTYPE ETIOLOGY AND CHARACTERISTICS URINARY PH TREATMENT\nCystine Caused by a defect in renal â†“ pH Hydration, dietary sodium\ntransport of certain amino restriction\nacids (COLA: Cystine, Orni- Alkanize urine\nthine, Lysine, and Arginine) If stones recur despite above\nStones are partially radiopaque treatments, consider peni-\n(may need CT to see; not cillamine or tiopronin\nalways seen on x-ray)\nHexagonal crystals\nFrequency: 1%\nImage A reproduced with permission from Nair S, George J, Kumar S, Gracious N. Acute oxalate nephropathy following Ingestion of Averrhoa\nbilimbi Juice. Case Rep Nephrol. 2014;2014:240936. doi: 10.115",
      "char_start": 1958000,
      "char_end": 1960000
    },
    {
      "chunk_id": 980,
      "text": "5/2014/240936. Image B reproduced with permission from USMLE-Rx.com. Image C\ncourtesy of Dr. Adam Weinstein.\nClinical suspicion of nephrolithiasis\nPregnant patient\nNo Yes\nCT scan of\nKidney ultrasound\nabdomen/pelvis\nAssess diameter of kidney stone\n<10 mm â‰¥10 mm\nMedical management Urological management\nFIGURE 2.15-11. Nephrolithiasis. CT\nâ‰¤20 mm >20 mm\nscan shows a dense 1-cm calcification\nAlpha blocker or Shock wave lithotripsy Percutaneous\n(arrow) in the left ureter, consistent with\nCa channel blocker or ureteroscopy nephrolithotomy\nnephrolithiasis. (Reproduced with permission\nAnalgesia\nfrom Tintinalli JE et al. Tintinalliâ€™s Emergency Medicine:\nHydration\nA Comprehensive Study Guide, 7th ed. New York, NY:\nMcGraw-Hill; 2011.)\nFIGURE 2.15-12. Nephrolithiasis treatment algorithm. (Reproduced with permission from USMLE-Rx.com.)\nKEY FACT\nâ–  Ultrasound is preferred for pregnant patients and children when there is a\nIn gout, urate crystals are needle\nlow likelihood for another pathology.\nshaped. In contrast, uric acid\nâ–  Plain x-rays of the abdomen are still useful for following the progression/\nnephroliths are pleomorphic.\ntreatment of larger stones.\nTreatment\nâ–  Best initial treatment: Hydration and analgesia (see Fig. 2.15-12).\nâ–  Î± -Receptor blockers (eg, tamsulosin) and calcium channel blockers (eg,\n1\nnifedipine) reduce ureteral spasms and facilitate passage of ureteral stone\n<10 mm, reducing the need for analgesics.\nâ–  Treatment varies according to the size and diameter of the stone:\nâ–  <5 mm: May pass spontaneously\nâ–  <10 mm: Higher rate of spontaneous passage with Î±-blocker or cal-\ncium channel blocker therapy\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669966 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 697\nA\nâ–  5 to 20 mm: May be treated with shock wave lithotripsy or ureteroscopy\nâ–  >20 mm: Percutaneous nephrolithotomy\nâ–  Dietary changes to prevent calcium stones include â†‘ fluid intake (most\nimportant), norma",
      "char_start": 1960000,
      "char_end": 1962000
    },
    {
      "chunk_id": 981,
      "text": "l calcium intake (recommended daily allowance\n[RDA]), and â†“ sodium intake. If caused by hyperoxaluria, then â†“ oxalate\nintake.\nâ–  Indications for a urologic consult: Stone size >9 mm, refractory pain/\nvomiting, signs of sepsis or complete obstruction\nPOLYCYSTIC KIDNEY DISEASE B\nCharacterized by the presence of progressive cystic dilation of the renal\ntubules. Polycystic kidney disease includes two main typesâ€”ADPKD and\nARPKD.\nâ–  Autosomal dominant polycystic kidney disease (ADPKD):\nâ–  Most common\nâ–  Usually asymptomatic until patients are >30 years of age (as cysts grad-\nually enlarge with time), although about 10% of these patients present\nin childhood\nâ–  Possible formation in other organs, especially the liver, pancreas,\nspleen, and epididymis\nâ–  In one half of ADPKD patients, ESRD to require dialysis by 60 years of\nage; other patients may simply have mildly reduced renal function and\nonly require supportive care and BP control\nâ–  Autosomal recessive polycystic kidney disease (ARPKD):\nâ–  Less common but more severe\nâ–  Presents in infants and young children with renal failure, liver fibrosis,\nand portal hypertension; ARPKD can lead to death in the first few days FIGURE 2.15-13. Autosomal dominant\npolycystic kidney disease. (A) Con-\nof life if associated with in utero oliguria (oligohydramnios) leading to\ntrast-enhanced CT scan demonstrates\nPotter sequence bilaterally enlarged kidneys that have\nbeen almost entirely replaced by cysts\nHistory/PE (arrows). (B) Gross specimen of a right\nkidney from a patient with ADPKD who\nâ–  ADPKD: underwent renal transplantation. (Image A\nâ–  Presenting symptoms are hypertension, bilateral palpable abdominal adapted with permission from Fauci AS et al. Harrisonâ€™s\nmasses, flank pain, history of UTI or gross hematuria. Polyuria and noc- Principles of Internal Medicine, 17th ed. New York, NY:\nturia can also be seen. Sharp, localized pain may result from cyst rup- McGraw-Hill; 2008. Image B reproduced with permis-\nsion from USMLE-Rx.com.)\nture, infecti",
      "char_start": 1962000,
      "char_end": 1964000
    },
    {
      "chunk_id": 982,
      "text": "on, or passage of renal calculi.\nâ–  Additional findings include hepatic/pancreatic cysts, cerebral berry KEY FACT\naneurysms (especially in patients with âŠ• family history; risk also\nincreases with age), valvular heart disease (mitral valve prolapse [MVP] If a patient with known ADPKD\nand aortic regurgitation [AR]), colonic diverticula, and abdominal and develops a sudden-onset, severe\ninguinal hernia. headache, rule out subarachnoid\nâ–  ARPKD: Hypertension, abdominal distention, and flank masses are the hemorrhage from a ruptured berry\nmost common presenting findings. It is most commonly identified aneurysm!\nprenatally.\nâ–  ADPKD and ARPKD:\nâ–  Patients may have large, palpable kidneys on abdominal examination.\nâ–  A single, simple renal cyst in an adult does not suggest ADPKD and\ndoes not require further evaluation. A 19-year-old man with a history of\nrecurrent kidney stones presents\nwith acute left flank pain. His father\nDiagnosis\nalso has a history of kidney stones. A\nBased on ultrasonography (most common) or CT scan (see Fig. 2.15-13). urinary cyanide nitroprusside test is\nMultiple bilateral cysts will be present throughout the renal parenchyma, and âŠ•. A CT scan confirms nephrolithiasis.\nrenal enlargement will be visualized. Genetic testing for ADPKD (PKD1 and What is the most likely diagnosis?\nPKD2 genes) and ARPKD (PKHD gene) is available but often not necessary.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669977 1100//2211//2222 44::2277 PPMM\n\n698 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nA Patients >18 years of age with + family history may be offered a screening\nultrasound.\nTreatment\nâ–  Prevent complications and â†“ the rate of progression to ESRD. Early man-\nagement of urinary tract infections (UTIs) is critical to prevent renal cyst\ninfection. BP control (ACE inhibitors, ARBs) is necessary to â†“ hyperten-\nsion-induced renal damage and control proteinuria. Sodium intake should\nalso be limited. Aggressive lipid control with statin to ",
      "char_start": 1964000,
      "char_end": 1966000
    },
    {
      "chunk_id": 983,
      "text": "decrease CV risk.\nB â–  Dialysis and renal transplantation are used to manage patients with ESRD.\nâ–  High fluid intake is helpful to prevent development of kidney stones and\nmay be helpful at slowing cyst progression too (ADH stimulates cyst\ngrowth). Vasopressin receptor antagonists have also been approved for use.\nHYDRONEPHROSIS\nDilation of the urinary tractâ€”often secondary to downstream obstruction of\nFIGURE 2.15-14. Hydronephrosis. (A) the urinary tract. In pediatric patients, the obstruction is often at the uretero-\nUltrasound of a renal transplant shows pelvic junction but may also be at the ureterovesicular junction (at the inser-\nsevere hydronephrosis, with dilation of tion into the bladder) or at the bladder outlet (eg from â€œposterior urethral\nthe renal pelvis (P) and the renal caly-\nvalvesâ€). In adults, it may be caused by benign prostatic hyperplasia (BPH)\nces (C). The overlying renal cortex is\nand aortic aneurysms. In both children and adults, it may be from neurogenic\nseverely thinned (arrows). (B) Normal\nrenal ultrasound for comparison. C, cor- bladder (spinal cord injuries), tumors, or renal calculi. Apart from obstruc-\ntex; S, sinus fat. (Reproduced with permission tion, hydronephrosis can also be caused by excessively high-output urinary\nfrom Tanagho EA, McAninch JW. Smithâ€™s General Urol- flow and vesicoureteral reflux.\nogy, 17th ed. New York, NY: McGraw-Hill; 2008.)\nHistory/PE\nMay be asymptomatic or may present with flank/back pain, abdominal pain,\nKEY FACT\nand/or UTIs.\nLeft untreated, hydronephrosis resulting\nfrom urinary obstruction poses a risk for Diagnosis\ninfection and sepsis, as well as kidney Ultrasonography or CT scan to detect dilation of the renal pelvis, calyces (see\ndamage with resulting hypertension, Fig. 2.15-14A), and/or ureter.\nacute kidney injury, and/or chronic\nkidney disease. Treatment\nâ–  Some pediatric cases will spontaneously resolve. Otherwise, the only treat-\nment is to surgically correct any anatomic obstruction or reflux; if th",
      "char_start": 1966000,
      "char_end": 1968000
    },
    {
      "chunk_id": 984,
      "text": "e\npatient has a neurogenic bladder, the physician can start a clean intermit-\ntent catheterization regimen for bladder emptying.\nâ–  Ureteral stent placement across the obstructed area of the urinary tract\nand/or percutaneous nephrostomy tube placement to relieve pressure may\nbe appropriate if the urinary outflow tract is not sufficiently cleared of\nobstruction. Foley or suprapubic catheters may be required for lower uri-\nnary tract obstruction (eg, BPH).\nSCROTAL PAIN AND SWELLING\nCystinuria is the most likely Scrotal wall swelling can be seen in generalized edematous states (nephrotic\ndiagnosis. It refers to decreased syndrome, liver disease, congestive heart failure) or in angioedema or allergic\ncystine reabsorption caused by a\nreactions.\ndefect in proximal tubular amino\nacid transport. Hexagonal crystals\nprobably would be visible on UA.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669988 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 699\nScrotal swelling\nPainful Painless\nScrotal US Flashlights test\nblood flow blood flow Transillumination No transillumination\nHydrocele Varicocele\nTesticular torsion Epididymitis\nSpermatocele Tumor\nFIGURE 2.15-15. Evaluation of scrotal swelling. (Reproduced with permission from USMLE-Rx.com.)\nEtiologies of a swollen/enlarged scrotum can be broken down as follows (see\nFig. 2.15-15):\nâ–  Painless etiologies â†’ hydrocele (remnant of processus vaginalis; may be\naccompanied by inguinal hernia), varicocele (dilatation of pampiniform\nplexus), tumors\nâ–  Painful etiologies â†’ epididymitis, orchitis, testicular torsion (twisting and\nsubsequent ischemia of the spermatic cord), incarcerated inguinal hernias\nProstatitis (both acute and chronic), distally migrated ureteral stones, and\nchronic pelvic pain syndrome can manifest as scrotal pain.\nHistory/PE\nDetailed history regarding preceding viral infections, UTIs, sexual activity,\nand acuity of onset of swelling and/or pain should be obtained",
      "char_start": 1968000,
      "char_end": 1970000
    },
    {
      "chunk_id": 985,
      "text": ". Testicular tor-\nsion tends to present very acutely with severe pain that can lead to nausea/\nemesis, whereas other etiologies present more gradually.\nPhysical examination can reveal a number of characteristic features:\nâ–  Hydrocele can present with a transilluminating scrotum. Increase of size\nduring Valsalva maneuver could indicate communicating hydrocele.\nâ–  Varicocele does not transilluminate. It is often described as having a â€œbag\nof wormsâ€ texture to palpation, and more commonly it is seen in the left\ntesticle (see Fig. 2.15-16). Varicoceles can also augment with the Valsalva FIGURE 2.16-16. Varicocele. Multiple\nmaneuver. tortuous tubular like structures are seen\nâ–  Epididymitis can present with a âŠ• Prehn sign (â†“ pain with scrotal eleva- in the left scrotum. (Reproduced with permis-\ntion); âŠ– Prehn sign is manifested in torsion. sion from Mak CW, Tzeng WS. Sonography of the\nscrotum. Available at https://www.intechopen.com/\nchapters/27883.)\nDiagnosis\nâ–  If the diagnosis is unclear after physical examination, an ultrasound should\nbe pursued. Doppler ultrasonography shows normal to â†‘ blood flow to tes-\ntes in epididymitis and â†“ blood flow in torsion.\nâ–  UA and culture may show Neisseria gonorrhoeae, Escherichia coli, or Chla-\nmydia in epididymitis. Culture is required to direct therapy in acute pros-\ntatitis, which may accompany epididymitis. Chronic prostatitis/chronic\npelvic pain syndrome will present with culture âŠ– irritation on voiding.\nKEY FACT\nTreatment\nA tender, boggy prostate on rectal\nâ–  Hydrocele: Typically resolves within 12 months. Hydroceles that do not\nexamination in the setting of fever is\nresolve should be removed surgically because of risk for inguinal hernia.\ndiagnostic for prostatitis.\nâ–  Varicocele: May need surgery if large or symptomatic.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 669999 1100//2211//2222 44::2277 PPMM\n\n700 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nâ–  Epididymitis and acute prostatitis: Antibioti",
      "char_start": 1970000,
      "char_end": 1972000
    },
    {
      "chunk_id": 986,
      "text": "cs (ceftriaxone, doxycycline,\nfluoroquinolones); NSAIDs; scrotal support for pain.\nâ–  Testicular torsion: Immediate surgery (<6 hours) to salvage testis. The phy-\nsician should attempt manual detorsion only if surgery is unavailable or if it\nwill not delay surgery. Orchiopexy of both testes to prevent future torsion.\nâ–  Chronic prostatitis/chronic pelvic pain syndrome: Î±-Blockers, 5-Î±-reductase\ninhibitors.\nMNEMONIC URINARY INCONTINENCE\nCauses of urinary incontinence\nwithout specific urogenital The involuntary loss of urine caused by either bladder or urethral sphincter\npathologyâ€” dysfunction.\nDIAPPERS\nHistory/PE\nDelirium/confusion\nInfection Table 2.15-8 outlines the types of incontinence along with their distinguishing\nAtrophic urethritis/vaginitis features and treatment (see also the DIAPPERS mnemonic).\nPharmaceutical\nPsychiatric disorders (especially Diagnosis/Treatment\ndepression)\nExcessive urinary output (hyperglycemia, â–  A UA can evaluate for pyuria that might suggest a UTI. Assessing serum\nhypercalcemia) creatinine can reveal signs of renal dysfunction if urinary obstruction lead-\nRestricted mobility ing to overflow is suspected.\nStool impaction â–  Voiding diaries may be helpful in better defining the type of incontinence.\nâ–  Urodynamic and radiographic testing is not routinely done for evaluation\nof incontinence. These measures merit consideration if plans exist for sur-\ngical management of incontinence.\nâ–  Table 2.15-8 outlines treatment options according to subtype.\nTABLE 2.15-8. Types of Incontinence\nTYPE HISTORY OF URINE LOSS MECHANISM TREATMENT\nTotal Uncontrolled loss at all times and Loss of sphincteric efficiency (previous surgery,\nin all positions nerve damage, cancer infiltration)\nAbnormal connection between the urinary tract Surgery\nand the skin (fistula)\nStress Loss following rise in intra- Urethral sphincteric insufficiency caused by Kegel exercises and pessary\nabdominal pressure (coughing, laxity of pelvic floor musculature Urethral sling procedure\nsn",
      "char_start": 1972000,
      "char_end": 1974000
    },
    {
      "chunk_id": 987,
      "text": "eezing, lifting) Common in multiparous women or after pelvic\nsurgery\nUrge Strong, unexpected urge to void Can be seen in bladder outlet obstruction (BPH, Pelvic floor exercises, bladder training\nthat is unrelated to position or drugs that increase sphincter tone) or detrusor Pharmacologic interventions: Anticho-\nactivity overactivity linergics (first line), Î²-agonists such as\nmirabegron (second line)\nOverflow Dribbling experienced after Chronically distended bladder with intravesical Placement of urethral catheter in acute\nincomplete emptying of pressure that just exceeds the outlet resis- settings\nbladder tance, allowing a small amount of urine to Treatment of underlying diseases\ndribble out Timed voiding/catheterization\nNeurologic injuries can lead to several/mixed types of incontinence (eg, detrusor overactivity after stroke, stress incontinence, or overflow\nincontinence after spinal cord injury).\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770000 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 701\nINTERSTITIAL CYSTITIS (PAINFUL BLADDER SYNDROME)\nChronic, painful bladder condition that is associated with psychiatric disor-\nders, other pain syndromes (eg, fibromyalgia, irritable bowel syndrome [IBS]),\nand a history of UTIs. The onset is gradual. Pain exacerbated by bladder fill-\ning, exercise, sexual intercourse, alcohol consumption, and prolonged sitting.\nPain is relieved with voiding. Interstitial cystitis is more common in females.\nHistory/PE\nâ–  Lower urinary tract symptoms\nâ–  UA normal\nâ–  Symptoms for >6 weeks\nDiagnosis\nPrimarily clinical.\nTreatment\nâ–  Avoiding triggers (behavioral modification) first line\nâ–  Physical therapy, analgesics\nâ–  Amitriptyline for refractory symptoms\nERECTILE DYSFUNCTION\nFound in 10% to 25% of middle-aged and older adult males. Classified as fail-\nure to initiate (eg, psychologic, endocrinologic, neurologic), failure to fill (eg,\narteriogenic), or failure to store (eg, veno-oc",
      "char_start": 1974000,
      "char_end": 1976000
    },
    {
      "chunk_id": 988,
      "text": "clusive dysfunction). Risk factors\ninclude DM, atherosclerosis, medications (eg, Î²-blockers, selective serotonin\nreuptake inhibitors [SSRIs], tricyclic antidepressants [TCAs], diuretics),\nhypertension, heart disease, surgery or radiation for prostate cancer, and spi-\nnal cord injury.\nHistory/PE\nâ–  Ask about risk factors (diabetes, peripheral vascular disease), medication KEY FACT\nuse, recent life changes, and psychologic stressors.\nâ€œPoint and Shootâ€: The Parasympathetic\nâ–  The distinction between psychologic and organic erectile dysfunction nervous system mediates erection; the\n(ED) is based on situational dependence (eg, occurring with only one\nSympathetic nervous system mediates\npartner) and the presence of nocturnal or early-morning erections with\nejaculation.\npenile tumescence testing (if present, it is nonorganic).\nDiagnosis\nClinical diagnosis.\nâ–  Evaluate for neurologic dysfunction (eg, anal tone, lower extremity sensa-\ntion) and for hypogonadism (eg, small testes, loss of secondary sexual\ncharacteristics).\nâ–  Other workup: Screening for diabetes and cardiovascular disease and mea-\nsurement of thyroid-stimulating hormone (TSH) and serum testosterone.\nElevated prolactin can result in â†“ in androgen activity.\nTreatment\nâ–  Best initial treatment: Patients with psychologic ED may benefit from\npsychotherapy involving discussion and exercises with the partner.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770011 1100//2211//2222 44::2277 PPMM\n\n702 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nâ–  Oral sildenafil, vardenafil, and tadalafil are phosphodiesterase-5 (PDE-5)\ninhibitors that result in prolonged action of cyclic guanosine monophos-\nphate (cGMP)â€“mediated smooth muscle relaxation and â†‘ blood flow in\nthe corpora cavernosa.\nâ–  Although sildenafil is useful for patients with ED secondary to cardiovas-\ncular disease, use with nitrates is contraindicated.\nâ–  Testosterone is a useful therapy for patients with hypogonadism of testicu-\nKEY FACT ",
      "char_start": 1976000,
      "char_end": 1978000
    },
    {
      "chunk_id": 989,
      "text": "lar or pituitary origin; it is discouraged for patients with normal testoster-\none levels.\nNitrates and PDE-5 inhibitors are a\ndangerous combination â†’ significant â–  Vacuum pumps, intracavernosal injections of prostaglandins or other vaso-\nactive agents, and surgical implantation of semirigid or inflatable penile\nâ†“ BP, which can lead to myocardial\nprostheses are alternatives for patients for whom PDE-5 therapy fails or is\nischemia.\ncontraindicated.\nBENIGN PROSTATIC HYPERPLASIA\nEnlargement of the prostate that is a normal part of the aging process and is\nseen in >80% of males by 80 years of age. Most commonly presents in males\n>50 years of age. BPH can coexist with prostate cancer, but BPH does not\ncause prostate cancer. See comparison between BPH and prostate cancer\n(Table 2.15-9).\nHistory/PE\nâ–  Obstructive symptoms: Hesitancy, weak stream, intermittent stream,\nincomplete emptying, urinary retention, bladder fullness, acute urinary\nretention following surgery.\nâ–  Irritative symptoms: Nocturia, daytime frequency, urge incontinence,\nopening hematuria.\nâ–  On digital rectal exam (DRE), the prostate is uniformly enlarged with a\nrubbery texture. The physician should suspect cancer if the prostate is\nhard or has irregular lesions.\nDiagnosis\nâ–  Obtain a UA and urine culture to rule out infection and hematuria.\nKEY FACT â–  Initial prostate-specific antigen (PSA) testing is controversial, although\noften â†‘ in BPH. Further workup is needed if â†‘ PSA correlates with other\nBPH most commonly occurs in the\nfindings suspicious for prostate cancer.\ncentral (periurethral) zone of the\nprostate and may not be detected on â–  Consider creatinine levels to rule out obstructive uropathy and renal insuf-\nficiency. Similarly, consider testing electrolytes for any signs of renal tubu-\nDRE.\nlar dysfunction from an obstruction.\nTABLE 2.15-9. Differences Between BPH and Prostate Cancer\nBPH PROSTATE CANCER\nRisk factor Age >50 years Age >40 years, family history\nZone affected Central Lateral lobe\nExaminati",
      "char_start": 1978000,
      "char_end": 1980000
    },
    {
      "chunk_id": 990,
      "text": "on Smooth and symmetrically Firms with nodules and asymmetrically\nenlarged enlarged\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770022 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 703\nTreatment\nâ–  Medical therapy:\nâ–  Initial treatment: Î±-Blockers (eg, tamsulosin, terazosin), which relax\nsmooth muscle in the prostate and bladder neck\nâ–  Second-line medical treatment: 5Î±-Reductase inhibitors (eg, finaste-\nride), which inhibit the production of dihydrotestosterone\nâ–  Transurethral resection of the prostate (TURP) or open, laparoscopic, or\nrobotic â€œsimple prostatectomyâ€ is appropriate for patients with moderate to\nsevere symptoms/complications (including renal insufficiency, recurrent\nUTIs, and bladder stones).\nâ–  In case of bladder obstruction, urgent catheterization is necessary while\nawaiting more definitive management.\nUROLOGIC CANCER\nKEY FACT\nLeading causes of cancer death in men:\nPROSTATE CANCER\n1. Lung cancer\n2. Prostate cancer\nThe most common nonskin cancer in men and the second leading cause of\n3. Colorectal cancer\ncancer death in males (after lung cancer). Risk factors include advanced age\n4. Pancreatic cancer\nand a âŠ• family history.\nHistory/PE\nâ–  Usually asymptomatic but may present with obstructive urinary symptoms.\nAdditional presentations include constitutional symptoms, lymphedema\n(from metastases obstructing lymphatic drainage), and/or back pain (from\nbone metastases).\nâ–  DRE that may reveal a palpable nodule or an area of induration (see\nFig. 2.15-17). Early carcinoma is usually not detectable on exam.\nDiagnosis\nâ–  Prostate cancer is suggested by clinical findings and/or a markedly â†‘ PSA\n(>10 ng/mL)\nâ–  Most accurate test: Transrectal ultrasound-guided biopsy\nâ–  The physician should look for metastases with CT of the abdomen/pelvis\nand a bone scan (metastatic lesions show an osteoblastic or â†‘ bone\ndensity)\nSeminal vesicle\nAmpulla of\nvas deferens\nPeripheral zone\nCentral zone\nTransition zone\nFibromusc",
      "char_start": 1980000,
      "char_end": 1982000
    },
    {
      "chunk_id": 991,
      "text": "ular zone\nUrethra\nFIGURE 2.15-17. Structure of the prostate. (Reproduced with permission from USMLE-Rx.com.)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770033 1100//2211//2222 44::2277 PPMM\n\n704 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTreatment\nâ–  Watchful waiting may be the best approach for older adult patients with\nKEY FACT low-grade tumors, as many cases of prostate cancer are slow to progress.\nâ–  Radical prostatectomy is associated with â†‘ risk for incontinence and/or\nAn â†‘ PSA can be caused by BPH, ED.\nprostatitis, prostatic trauma, or â–  Radiation therapy (eg, brachytherapy or external beam) is associated with\ncarcinoma. â†‘ risk for radiation proctitis and GI symptoms. Also associated with\nincreased risk for ED posttreatment.\nâ–  PSA, although controversial as a screening test, is used to follow a patient\nposttreatment to evaluate for disease recurrence.\nMNEMONIC\nâ–  The physician can treat metastatic disease with androgen ablation (eg,\ngonadotropin-releasing hormone agonists, orchiectomy, bicalutamide) and\nDifferential for hematuriaâ€”\nchemotherapy.\nI PEE RBCS\nâ–  Radiation therapy is useful to manage bone pain from metastases after\nInfection (UTI)\nandrogen ablation.\nPolycystic kidney disease\nExercise\nPrevention\nExternal trauma\nRenal glomerular disease Screening guidelines remain controversial. Males should discuss the pros and\nBenign prostatic hyperplasia cons of annual DRE and/or PSA testing starting at 50 years of age. Screening\nCancer, Congenital anomalies/obstruction, should begin earlier in Black males and in those with a first-degree relative\nCysts, HyperCalciuria, Crystals with prostate cancer.\nStones, Sickle cell\nBLADDER CANCER\nThe second most common urologic cancer and the most frequent malignant\ntumor of the urinary tract; usually a transitional cell carcinomaâ€”now called\nurothelial carcinoma (see Fig. 2.15-18). Most prevalent in males during the\nsixth and seventh decades. Risk factors include smoking, diets rich in meat\na",
      "char_start": 1982000,
      "char_end": 1984000
    },
    {
      "chunk_id": 992,
      "text": "nd fat, schistosomiasis (squamous cell carcinoma), past treatment with cyclo-\nphosphamide, and occupational exposure to aniline dye.\nHistory/PE\nâ–  Gross, painless hematuria is the most common presenting symptom. Ter-\nminal hematuria (end of voiding) suggests bleeding from the bladder.\nâ–  Other urinary symptoms, such as frequency, urgency, and dysuria, can also\nbe seen, but most patients are asymptomatic in the early stages of the\ndisease.\nDiagnosis\nâ–  Screening is not recommended.\nâ–  UA often shows hematuria (macroscopic or microscopic).\nâ–  Cystoscopy with biopsy is diagnostic and is recommended in the evalua-\ntion of adults >35 years of age with unexplained hematuria.\nâ–  Urine cytology may show dysplastic cells.\nFIGURE 2.15-18. Transitional cell carci- â–  MRI, CT, and bone scan are important tools with which to define muscle\nnoma of the bladder. Cystoscopic image invasion and metastases.\nof bladder wall mass. (Modified with permis-\nsion from Geavlete B, Stanescu F, Moldoveanu C, et al. Treatment\nNBI cystoscopy and bipolar electrosurgery in NMIBC\nTreatment depends on the extent of spread beyond the bladder mucosa.\nmanagementâ€”an overview of daily practice. J Med\nLife. 2013;6[2]:140â€“145.\nâ–  Carcinoma in situ: Intravesicular chemotherapy or transurethral resection\nâ–  Superficial cancers: Complete transurethral resection or intravesicular\nchemotherapy with mitomycin-C or Bacille Calmette-GuÃ©rin ([BCG], the\nTB vaccine)\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770044 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 705\nâ–  Large, high-grade recurrent lesions: Intravesicular chemotherapy\nâ–  Invasive cancers without metastases: Radical cystectomy or radiation ther-\nKEY FACT\napy for patients who are deemed poor candidates for radical cystectomy\nand for those with unresectable local disease. Neoadjuvant systemic ther-\nA key step for diagnosis in an adult\napy and radiosensitization is often considered.\npatient with unexplain",
      "char_start": 1984000,
      "char_end": 1986000
    },
    {
      "chunk_id": 993,
      "text": "ed hematuria\nâ–  Invasive cancers with distant metastases: Chemotherapy, immunother- is cystoscopy to evaluate for bladder\napy, and novel targeted agents are considered.\ncancer.\nRENAL CELL CARCINOMA\nAn adenocarcinoma from tubular epithelial cells (âˆ¼80%â€“90% of all KEY FACT\nmalignant tumors of the kidney). Tumors can spread along the renal vein\nto the inferior vena cava (IVC) and metastasize to other sites, eg, lung, The classic triad of renal cell carcinoma\nbone, brain, and liver. Risk factors include male sex, smoking, obesity, consists of hematuria, flank pain, and\nacquired cystic kidney disease in ESRD, and certain genetic conditions, a palpable flank mass, but only 5% to\nsuch as von Hippelâ€“Lindau disease. 10% present with all three components\nof the triad.\nHistory/PE\nPresenting signs include gross hematuria, flank pain, scrotal varicoceles, and\nKEY FACT\na palpable flank mass. Metastatic disease can present with weight loss and\nmalaise. Paraneoplastic symptoms include anemia, erythropoiesis, thrombocy- In a middle-aged individual with\ntosis, fever, cachexia, hypercalcemia, and polymyalgia rheumatica. a history of smoking and a left-\nsided varicocele, consider renal cell\nDiagnosis carcinoma!\nBest initial test: Diagnosed via CT (see Fig. 2.15-19) to characterize the renal\nmass and stage for lymph nodes/metastases. Ultrasonography rarely used.\nDiagnosis is then confirmed by histology on nephrectomy specimen.\nTreatment\nâ–  Surgical resection or thermal ablation may be curative in localized dis-\nease. Metastasectomy may improve survival in metastatic disease.\nâ–  Response rates from radiation or chemotherapy are only 15% to 30%.\nNewer tyrosine kinase inhibitors (axitinib, lenvatnib, cabozatonib), which\nâ†“ tumor angiogenesis and cell proliferation, have shown promising results.\nFIGURE 2.15-19. Renal cell carcinoma.\nTESTICULAR CANCER A contrast-enhanced CT through the\nabdomen demonstrates an enhancing\nexophytic mass (arrow) in the left kidney\nA heterogeneous group of neoplasms.",
      "char_start": 1986000,
      "char_end": 1988000
    },
    {
      "chunk_id": 994,
      "text": " About 95% of testicular tumors derive that proved on pathology to be renal cell\nfrom germ cells, and virtually all are malignant. Risk factors include cryptor- carcinoma. (Reproduced with permission from\nchidism, Klinefelter syndrome, and âŠ• family history. Testicular cancer is the Doherty GM. Current Diagnosis & Treatment: Surgery,\nmost common malignancy in males 15 to 34 years of age. 13th ed. New York, NY: McGraw-Hill; 2010.)\nHistory/PE\nâ–  Patients most often present with painless enlargement of the testes, a\nfirm ovoid mass with possible nodules, dull abdominal pain, and meta-\nstatic symptoms (lower back pain, dyspnea, cough and retroperitoneal\nlymphadenopathy).\nâ–  Most testicular cancers occur between 15 and 30 years of age, but semino-\nmas have a peak incidence between 40 and 50 years of age.\nDiagnosis\nâ–  Testicular ultrasonography\nâ–  CXR and CT of the abdomen/pelvis to evaluate for metastasis\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770055 1100//2211//2222 44::2277 PPMM\n\n706 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-10. Tumor Markers in Testicular Cancer\nTYPE TUMOR MARKER\nGERM CELL TUMORS (95% OF ALL TESTICULAR TUMORS)\nSeminoma (most common Usually âŠ–, Î²-human chorionic gonadotropin (Î²-hCG) in\ntesticular tumor) some cases\nYolk sac (endodermal sinus â†‘ Î±-fetoprotein (AFP)\ntumor)\nKEY FACT\nChoriocarcinoma â†‘ Î²-hCG\nÎ²-hCG in males = choriocarcinoma\nTeratoma AFP and/or Î²-hCG\nNONâ€“GERM CELL TUMORS (5% OF ALL TESTICULAR TUMORS)\nLeydig cell â†‘ testosterone and estrogen (causing â†“ luteinizing\nhormone and follicle-stimulating hormone)\nSertoli cell None\nTesticular lymphoma None; arises from metastasis to testes\nâ–  Tumor markers are useful for diagnosis and in monitoring treatment\nresponse (see Table 2.15-10)\nâ–  Biopsy is contraindicated due to the risk of spillage of cancer cells\nTreatment\nâ–  Radical orchiectomy and classification as seminoma or nonseminomatous\ngerm cell tumor (NSGCT)\nâ–  Seminoma: Chemotherapy or radiation therapy fo",
      "char_start": 1988000,
      "char_end": 1990000
    },
    {
      "chunk_id": 995,
      "text": "r low-stage disease\nâ–  NSGCT: Retroperitoneal lymph node dissection for low-stage disease\nâ–  Platinum-based chemotherapy used for advanced disease of either type\nGENITOURINARY INFECTIONS\nURINARY TRACT INFECTIONS\nTable 2.15-11 provides an overview/review of the types of UTIs, criteria, and\ntreatment. The rest of this section will further explore acute (uncomplicated)\nsimple cystitis, as well as pyelonephritis + prostatitis (both types of compli-\ncated UTIs).\nMicrobiology\nâ–  UTIs most commonly result from ascending infection from the urethra â†’\nprostate (prostatitis) â†’ bladder (cystitis) â†’ kidney (pyelonephritis) â†’ sys-\ntemic (urosepsis). Due to this â€œascension,â€ these infections share common\nmicrobiologic profiles, as captured in Table 2.15-12.\nâ–  Cystitis presents with dysuria, frequency, urgency, suprapubic pain, and\nWBCs (but not WBC casts) in urine. Primarily caused by ascension of\nmicrobes from urethra to bladder. Ascension to kidney results in pyelone-\nphritis, which presents with fever, chills, flank pain, costovertebral angle\n(CVA) tenderness, hematuria, and WBC casts.\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770066 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 707\nTABLE 2.15-11. Types of UTIs, Criteria, and Treatment\nTYPE CRITERIA TREATMENT\nUncomplicated UTI Lower UTI is acute, simple cystitis (classic symptoms: Trimethoprim-sulfamethoxazole (TMP-SMX) for 3 days\ndysuria, frequency, urgency, suprapubic pain) in an Nitrofurantoin (5â€“7 days), but only effective for cystitis;\notherwise healthy, nonpregnant female who has not if suspect a possibility for pyelonephritis or compli-\nfailed antibiotic therapy cated UTI, should not use nitrofurantoin\nInfection is confined to bladder (cystitis) Culturing is ONLY recommended if treatment fails\nPatient has no systemic symptoms of an acute, compli-\ncated UTI\nComplicated UTI Simply summarized: A complicated UTI is one that does For otherwise healthy patients wh",
      "char_start": 1990000,
      "char_end": 1992000
    },
    {
      "chunk_id": 996,
      "text": "o are hemody-\nnot meet criteria for uncomplicated namically stable and can tolerate oral antibiotics,\nThis may be a presentation similar to that of an uncom- treatment is given as outpatient, often with fluroqui-\nplicated UTI, but in a population at higher risk for nolones, third-/fourth-generation cephalosporins, or\ncomplexity, such as a pregnant woman, a patient with TMP-SMX\ncomorbidities (such as diabetes), infants and toddlers, For patients who are hemodynamically unstable, who\nand male sex; it would also include those with immu- have sepsis, or who cannot tolerate oral antibiotics, IV\nnocompromise or stents or urinary catheters, as well as third-/fourth-generation cephalosporins are typically\nthose with recurrent or refractory UTIs given, or fluroquinolones\nA complicated UTI would also be any patient with\nsystemic symptoms of UTI that might suggest pyelo-\nnephritis, such as fever, chills, vomiting, abdominal or\nflank pain, or costovertebral angle tenderness on exam\nPregnancy UTI In pregnant patients, urinalysis is routinely performed to Asymptomatic bacteria does not normally require\nscreen for asymptomatic bacteriuria treatment; however, due to increased risk for com-\nPregnant patients may also present with acute cystitis (as plications, pregnant women with asymptomatic\nnoted earlier) and would be considered a complicated bacteria are treated with either nitrofurantoin\nUTI and treated as such or amoxicillin with follow-up culture to confirm\nPregnant patients are at increased risk for pyelonephritis resolution\nand urosepsis Treatment of cystitis and pyelonephritis would be as for\ntreatment of complicated UTI\nProphylaxis of UTIs Suitable for a patient with recurrent UTIs (two or more If behavioral modifications are ineffective: Antibiotic\ninfections in 6 months or three or more infections prophylaxis (TMP-SMX or nitrofurantoin) after inter-\nin 1 year); behavioral modifications are first line and course, first sign(s) of symptoms; the physician can\ninclude â†‘ flui",
      "char_start": 1992000,
      "char_end": 1994000
    },
    {
      "chunk_id": 997,
      "text": "d intake (promoting urinary flow so that prescribe antibiotics at a low dose for 3â€“6 months or\nmicrobes cannot as easily ascend the urinary tract), continuously\npostcoital voiding/stoppage of spermicide use, and\nvaginal estrogen in postmenopausal females\nBladder pain Interstitial cystitis = bladder pain syndrome â†’ chronic First-line treatment: Avoid dietary triggers\nsyndrome + UTI suprapubic pain/discomfort, dysuria, frequency, dys- Amitriptyline, pain management (phenazopyridine or\nmimics pareunia, pelvic pain, relief after voiding that lasts methenamine), bladder hydrodistention\n>6 weeks without an underlying medical cause; classi-\ncally in women with psychiatric disease (analogous to\nfibromyalgia, IBS); notably, painful bladder syndrome\nis a UTI mimic; other UTI mimics include hemorrhagic\ncystitis (after cyclophosphamide) and bladder irritation\nfrom radiation therapy to pelvis\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770077 1100//2211//2222 44::2277 PPMM\n\n708 HIGH-YIELD FACTS IN RENAL/GENITOURINARY\nTABLE 2.15-12. Microbiology of UTIs\nSPECIES FEATURES COMMENTS\nEscherichia coli Leading cause of UTIs Diagnostic markers:\nâŠ• Leukocyte esterase =\nStaphylococcus Second leading cause of UTIs, particu-\nevidence of WBC activity\nsaprophyticus larly in young, sexually active females\nâŠ• Nitrite test = reduction\nof urinary nitrates by\nKlebsiella Third leading cause of UTIs\ngram âŠ bacterial species\npneumoniae\n(eg, E coli)\nSerratia marcescens Some strains revealed by red pigment\nOften health care associated and drug\nresistant\nEnterococcus Often health care associated and drug\nresistant\nProteus mirabilis Produces urease\nMNEMONIC Associated with struvite stones\nCommon UTI bugsâ€” Pseudomonas Usually health care associated and drug\nSEEKS PP aeruginosa resistant\nSerratia\nEscherichia coli\nEnterobacter â–  Ten times more common in females (shorter urethras colonized by fecal\nKlebsiella pneumoniae\nmicrobiota).\nStaphylococcus saprophyticus\nâ–  Risk fact",
      "char_start": 1994000,
      "char_end": 1996000
    },
    {
      "chunk_id": 998,
      "text": "ors: Obstruction (eg, kidney stones, enlarged prostate), kidney\nPseudomonas\nsurgery, catheterization, congenital genitourinary (GU) malformation (eg,\nProteus mirabilis\nvesicoureteral reflux), diabetes, pregnancy.\nUNCOMPLICATED UTI/LOWER UTI/ACUTE SIMPLE CYSTITIS\nHistory/PE\nClassic tetrad of frequent SUD: frequency (voiding a lot) + Suprapubic\npain + Urgency (feeling need to void) + Dysuria (burning, painful void-\ning). Fever + systemic signs are characteristically absent in simple cystitis\nâ†’ plasma WBC count being normal.\nDiagnosis\nClinical diagnosis is sufficient in symptomatic (frequent SUD), uncompli-\ncated lower UTIs in nonpregnant women â†’ begin treatment. Other patients\nâ†’ best initial test = UA.\nTreatment\nâ–  General guidelines: Treated on clinical diagnosis alone\nâ–  First-line antibiotics: TMP-SMX (3 days), nitrofurantoin (5â€“7 days)\nâ–  Pain: Pentosan (relieves cystitis pain) or phenazopyridine (relieves urinary\ntract pain)\nPYELONEPHRITIS/UPPER UTI/ONE FORM OF COMPLICATED UTI\nHistory/PE\nInfection ascends from urethra â†’ bladder (cystitis symptoms of frequency +\nsuprapubic pain + urgency + dysuria) â†’ kidney (pyelonephritis symptoms of\n22002222__0022..1155__SStteepp22CCKK__RReennaall__1111ee__667755--771166..iinndddd 770088 1100//2211//2222 44::2277 PPMM\n\nRENAL/GENITOURINARY HIGH-YIELD FACTS IN 709\nClinical suspicion A\nfor pyelonephritis\nCollect urine Â±\nblood cultures\nUrinalysis\nBenign WBCs\nUnlikely Likely\npyelonephritis pyelonephritis\nHigh Hemodynamically\ncomplication stable, can tolerate All other\nrisk PO regimen patients\nB\nImaging (CT, US) to assess for\nanatomic causes (abscess, etc.) Outpatient oral Inpatient IV\ntherapy therapy\nTreatment failure\nFIGURE 2.15-20. Pyelonephritis algorithm. (Reproduced with permission from USMLE-Rx.com.)\nCVA tenderness + flank pain) â†’ systemic infection (symptoms of fever +\nchills + tachycardia) â†’ eventually to urosepsis (10%â€“25% of cases). C\nDiagnosis\nClinical diagnosis supported by cultures (see Fig. 2.15-20).\nâ–  Cultures: All patien",
      "char_start": 1996000,
      "char_end": 1998000
    },
    {
      "chunk_id": 999,
      "text": "ts should have urine cultures collected prior to\nempiric antibiotic therapy. Therapy is tailored based on cultures.\nâ–  UA: Similar findings to uncomplicated simple cystitis (see earlier sec-\ntion) + WBC casts (infection in kidney â†’ casts form as WBCs infiltrate\ntubules).\nâ–  Imaging (CT, ultrasound): Reserved for patients at high risk for complica-\ntions (a complicated UTI = complicated pyelonephritis) and treatment\nfailure. Imaging examines anatomic causes + abscess formation + emphy-\nsematous pyelonephritis.\nFIGURE 2.15-21. Pyelonephritis find-\nings. (A) Emphysematous pyelonephritis.\nComplications (arrows indicate air pockets from gas-\nproducing bacteria) (B) Thyroidization of\nâ–  Abscesses can form in the renal parenchyma and/or in the perirenal fat the kidney in chronic pyelonephritis. (C)\n(perinephric abscess). Patients who have persistent fever + abdominal Bear paw sign in xanthogranulomatous\npain despite adequate antibiotic treatment â†’ CT/ultrasound imaging â†’ pyelonephritis. (Image A reproduced with per-\ndiagnose abscess â†’ drainage (all perinephric, >5 cm renal) + continued mission from ÃœnlÃ¼er EE, KaragÃ¶z A. Computed tomog-\nantibiotics. raphy in emphysematous pyelonephritis. Pan Afr Med\nJ. 2015;22:186. Published 2015 Oct 23. doi:10.11604/\nâ–  Emphysematous pyelonephritis â†’ caused by gas-producing bacteria (see\npamj.2015.22.186.7902. Image B reproduced with\nFig. 2.15-21A), classically in patients with diabetes or immunocompromise.\npermission from Bilgrami SM, Qureshi SA, Pervez\nâ–  Chronic pyelonephritis is caused by recurrent pyelonephritis (classically S, Abbas F. Promoter hypermethylation of tumor\nin children with with vesicoureteral reflux (VUR) + obstruction in adults suppressor genes correlates with tumor grade and\n(recurrent kidney stones, BPH, cervical carcinoma) â†’ blunted calyces + invasiveness in patients with urothelial bladder cancer.\nSpringerplus. 2014 Apr 5;3:178. doi: 10.1186/2193-\ncorticomedullary scarring of the kidneys (seen on imaging, upper/lower\n18",
      "char_start": 1998000,
      "char_end": 2000000
    }
  ]
}